<SEC-DOCUMENT>0001387131-15-000875.txt : 20150312
<SEC-HEADER>0001387131-15-000875.hdr.sgml : 20150312
<ACCEPTANCE-DATETIME>20150312163646
ACCESSION NUMBER:		0001387131-15-000875
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150312
DATE AS OF CHANGE:		20150312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		15696357

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>txmd-10k_123114.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 0; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">_______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><B>&#9746;</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 12pt"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><B>For the fiscal year ended December 31, 2014</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#9;<B>Commission File Number 001-001000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">_______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24 Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>TherapeuticsMD, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B><I>(Exact Name of Registrant as
Specified in Its Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>Nevada</b></td>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>87-0233535</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><i>(State or Other Jurisdiction of Incorporation or Organization)</i></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><i>(I.R.S. Employer Identification No.)</i></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>6800 Broken Sound Parkway NW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Third Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;Boca Raton, Florida 33487</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;(561) 961-1900</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B><I>(Address, including zip code,
and telephone number,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;including area code, of Principal
Executive Offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Title of
        Each Class</b></P></td>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Name of
        Each Exchange on Which Registered</b></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Common Stock, par value $0.001 per share</td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">NYSE MKT</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><B>Securities registered
pursuant to Section 12(g) of the Act: </B>None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings 2">&pound;</FONT>&nbsp;&nbsp;No
<FONT STYLE="font-family: Wingdings 2">&#83;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings 2">&pound;</FONT>&nbsp;&nbsp;No
<FONT STYLE="font-family: Wingdings 2">&#83;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings 2">&#83;</FONT>&nbsp;&nbsp;No
<FONT STYLE="font-family: Wingdings 2"></FONT><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings 2">&#83;</FONT>&nbsp;&nbsp;No
<FONT STYLE="font-family: Wingdings 2"></FONT><FONT STYLE="font-family: Wingdings 2">&pound;</Font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III
of this Form 10-K or any amendment to this Form 10-K. <FONT STYLE="font-family: Wingdings 2">&#83;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%"><font style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer&nbsp;&nbsp;</font><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: right; width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Accelerated filer </font><FONT STYLE="font-family: Times New Roman">&#9746;</FONT></td>
    <TD STYLE="width: 10%">&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Non-accelerated filer </font><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company </font><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></td>
    <TD>&nbsp;</TD></tr>
<tr>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Do not check if a smaller reporting company)</font></td>
    <TD STYLE="padding-bottom: 12pt; font-size: 12pt; text-align: justify"></td>
    <TD>&nbsp;</TD></tr>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &nbsp;<FONT STYLE="font-family: Wingdings 2">&pound;</FONT>&nbsp;&nbsp;No
<FONT STYLE="font-family: Wingdings 2">&#83;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The aggregate market
value of common stock held by non-affiliates of the registrant (90,410,979 shares) based on the closing price of the registrant&rsquo;s
common stock as reported on NYSE MKT on June 30, 2014, which was the last business day of the registrant&rsquo;s most recently
completed second fiscal quarter, was $399,616,527. For purposes of this computation, all officers, directors, and 10% beneficial
owners of the registrant are deemed to be affiliates. Such determination should not be deemed to be an admission that such officers,
directors, or 10% beneficial owners are, in fact, affiliates of the registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of March 6, 2015, there were outstanding
171,715,551 shares of the registrant&rsquo;s common stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Documents Incorporated by Reference</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Portions of the registrant&rsquo;s
definitive Proxy Statement for its 2015 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual
Report on Form 10- K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission no later than
120 days after the end of the registrant&rsquo;s fiscal year ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ANNUAL REPORT ON FORM 10-K</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fiscal Year Ended December 31, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_024">PART I</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_001">Item 1.</A></FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_001">Business</A></I></FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002">Item 1A.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_002">Risk Factors</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003">Item 1B.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_003">Unresolved Staff Comments</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">45</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004">Item 2.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_004">Properties</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">45</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005">Item 3.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_005">Legal Proceedings</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">45</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006">Item 4.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_006">Mine Safety Disclosures</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">45</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007">PART II</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008">Item 5.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_008">Market for the Registrant&rsquo;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">46</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009">Item 6.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_009">Selected Financial Data</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">48</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010">Item 7.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_010">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">49</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011">Item 7A.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_011">Quantitative and Qualitative Disclosures about Market Risk</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">61</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012">Item 8.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_012">Financial Statements and Supplementary Data</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013">Item 9.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_013">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_014">Item 9A.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_014">Controls and Procedures</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_015">Item 9B.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_015">Other Information</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">63</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_016">PART III</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_017">Item 10.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_017">Directors, Executive Officers, and Corporate Governance</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">63</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_018">Item 11.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_018">Executive Compensation</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">63</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019">Item 12.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_019">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">63</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020">Item 13.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_020">Certain Relationships and Related Transactions, and Director Independence</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">63</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_021">Item 14.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_021">Principal Accountant Fees and Services</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">63</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_022">PART IV</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_023">Item 15.</A></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><A HREF="#a_023">Exhibits and Financial Statement Schedules</A></I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">64</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">vitaMedMD<SUP>&reg;</SUP>,
TherapeuticsMD<SUP>&reg;</SUP>, and BocaGreenMD<SUP>&reg;</SUP> are registered trademarks of our company. This Annual Report also
contains trademarks and trade names of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report includes
market and industry data that we obtained from periodic industry publications, third-party studies and surveys, government agency
sources, filings of public companies in our industry, and internal company surveys. Industry publications and surveys generally
state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the foregoing
industry and market data to be reliable at the date of the report, this information could provide to be inaccurate as a result
of a variety of matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Statement Regarding Forward-Looking Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K contains forward-looking statements that involve substantial risks and uncertainties. For example, statements regarding our
operations, financial position, business strategy, product development, and other plans and objectives for future operations, and
assumptions and predictions about future product development and demand, research and development, marketing, expenses and sales
are all forward-looking statements. These statements may be found in the items of this Annual Report entitled &ldquo;Business&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; as well as in this
Annual Report generally. These statements are generally accompanied by words such as &ldquo;intend,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;potential(ly),&rdquo; &ldquo;continue,&rdquo; &ldquo;forecast,&rdquo; &ldquo;predict,&rdquo;
&ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
or the negative of such terms or other comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have based these forward-looking
statements on our current expectations and projections about future events. We believe that the assumptions and expectations reflected
in such forward-looking statements are reasonable, based on information available to us on the date hereof, but we cannot assure
you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently
be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results
or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause
or contribute to such differences include, but are not limited to, research and product development uncertainties, regulatory policies
and approval requirements, competition from other similar businesses, market and general economic factors, and the other risks
discussed in Item 1A of this Annual Report. This discussion should be read in conjunction with the consolidated financial statements
and notes thereto included in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have identified some
of the important factors that could cause future events to differ from our current expectations and they are described in this
Annual Report in the section entitled &ldquo;Risk Factors&rdquo; that you should review carefully. Please consider our forward-looking
statements in light of those risks as you read this Annual Report. If one or more of these or other risks or uncertainties materialize,
or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we project. We do not undertake
to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new
information or future events or developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_024"></A>PART I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><B>Item 1.</B></TD>
    <TD STYLE="width: 90%"><A NAME="a_001"><B><I>Business</I></B></A></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Overview</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Our Company</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I></I>We are a women&rsquo;s health
care product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused
on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical
products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health
risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are
developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim
of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing
products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with
high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal
vitamins, as well as over-the-counter, or OTC, vitamins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have obtained U.S. Food
and Drug Administration, or FDA, acceptance of our Investigational New Drug, or IND, applications to conduct clinical trials for
four of our hormone therapy drug candidates: TX-001HR, our oral combination of progesterone and estradiol; TX-002HR, our oral progesterone
alone; TX-003HR, our oral estradiol alone; and TX-004HR, our vaginal suppository estradiol alone. We are currently conducting phase
3 clinical trials for TX-001HR and TX-004HR. In July 2014, we temporarily suspended enrollment in the phase 3 clinical trial for
TX-002HR, and in October 2014 we temporarily stopped the trial in order to update the phase 3 protocol based on discussions with
the FDA. We have no current plans to conduct clinical trials for TX-003HR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Throughout this Annual
Report, the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;TherapeuticsMD,&rdquo; or &ldquo;our company&rdquo;
refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD,
LLC, a Delaware limited liability company, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation, or BocaGreen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Hormone Therapy Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The menopause hormone therapy
market includes two major components: an FDA-approved drug market and a non-FDA approved drug market supplied by compounding pharmacies.
On November 27, 2013, the Drug Quality and Security Act became law and the FDA was given additional oversight over compounding
pharmacies. We believe FDA-approved products are easily measured and monitored, while non-FDA approved hormone therapy drug products,
typically referred to as bioidenticals, when produced and sold by compounding pharmacies are not easily measured or monitored.
We estimate the non-FDA approved compounded bioidentical hormone therapy sales of estradiol and progesterone products
by compounding pharmacies approximate $1.5 billion per year and the FDA-approved market approximates $4.2 billion per year. Our
phase 3 clinical trials are intended to establish an indication of the safety and efficacy of our bioidentical drug candidates
at specific dosage levels. We intend our hormone therapy drug candidates, if approved, to provide hormone therapies with well characterized
safety and efficacy profiles that can be consistently manufactured to target specifications. This would provide an alternative
to the non-FDA approved compounded bioidentical market. This is based on our belief that our drug candidates will offer advantages
in terms of demonstrated safety and efficacy consistency in the hormone dose, lower patient cost as a result of insurance coverage,
and improved access as a result of availability from major retail pharmacy chains than custom order or formulation by individual
compounders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Pipeline of our Hormone Therapy Drug Candidates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX-001HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-001HR, our combination
estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms
due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal discomfort, for post-menopausal women with
an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&rsquo;s
body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen
and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time
a combination product of estradiol and progesterone biologically identical, or bioidentical, to the estradiol and progesterone
produced by the ovaries, would be approved for use in a single combined product. According to Symphony Health Solutions, the total
FDA-approved market for menopause-related combination estrogen/progestin was approximately $659 million in U.S. sales for the 12
months ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX-002HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-002HR is a natural progesterone
formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy
drug candidate is chemically identical to the hormones that naturally occur in a woman&rsquo;s body. If approved by the FDA, we
believe TX-002HR will be similarly effective to traditional treatments, but may be effective at lower dosages. According to Symphony
Health Solutions, the total FDA-approved market for oral progestin was approximately $400 million in U.S. sales for the 12 months
ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX-003HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-003HR is a natural estradiol
formulation. This hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&rsquo;s
body. We currently do not have plans to further develop this hormone therapy drug candidate. According to Symphony Health Solutions,
the total FDA-approved market for oral estradiol was approximately $131 million in U.S. sales for the 12 months ended December
31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX-004HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-004HR is a vaginal suppository
estradiol drug candidate for the treatment of vulvar and vaginal atrophy, or VVA, in post-menopausal women with vaginal linings
that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments
for VVA because of an early onset of action with less systemic exposure, inferring a greater probability of dose administration
to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments.
According to Symphony Health Solutions, the total FDA-approved market for VVA treatment was approximately $1.3 billion in U.S.
sales for the 12 months ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Preclinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based upon
leveraging our hormone platform technology, we have seven preclinical projects that include development of our
proposed progesterone-alone and combination estradiol and progesterone   products in a topical cream and
transdermal patch form, which we refer to as TX-005HR and TX-006HR, respectively, and transdermal patch form, which we refer
to as TX-007HR and TX-008HR, respectively. We recently completed a pilot pharmacokinetic, or PK, study of TX-005HR in
eight patients that tested the topical administration on the upper arm of 50 mcg of estradiol and 25 mg of progesterone.
The results of the PK study suggest that topical formulations of estradiol and progesterone may be possible using our
proprietary solubilized forms of the compounds. We intend to file an IND with respect to TX-005HR and TX-006HR during the
    second half of 2015 and then commence phase 1 clinical trials. We may in the future engage with a financing partner to
advance our topical cream and transdermal patch projects. We are also evaluating various other indications for our hormone
technology, including oral contraception, treatment of preterm birth, and premature ovarian failure. According to
Symphony Health Solutions, the total FDA-approved menopause-related market for estrogen alone and in combination was
approximately $3.7 billion in U.S. sales for the 12 months ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Current Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As we continue the clinical
development of our hormone therapy drug candidates, we continue to manufacture and distribute our prescription and OTC product
lines, consisting of prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under our
vitaMedMD<SUP>&reg;</SUP> brand name and duplicate formulations of some of our prescription prenatal vitamin products, also referred
to as &ldquo;generic&rdquo; formulations, under our BocaGreenMD<SUP>&reg;</SUP> Prena1&trade; name. All of our prenatal vitamins
are gluten-, sugar-, and lactose-free. We believe our product attributes result in greater consumer acceptance and satisfaction
than competitive products while offering the highest quality and patented ingredients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Industry and Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Health Care and Pharmaceutical
Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">According to EvaluatePharma<SUP>&reg;</SUP>
World Preview report, the pharmaceutical industry experienced an unprecedented decline in worldwide prescription drug sales in
2012. Worldwide prescription drug sales fell by 1.6% to $714 billion in 2012, with the United States representing about 36% of
the market. Loss of patent protection on a number of blockbuster brands and fiscal austerity affecting Eurozone countries (compounded
by a weak euro compared to the U.S. Dollar) contributed to this unprecedented contraction. In total, $38 billion of sales were
lost as a result of expired patent protection, including drugs such as Lipitor and Plavix. According to the report, this anomaly
is not expected to continue and sustained sales growth should start returning at the end of 2013 at an average rate of 3.8% per
annum between 2012 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In terms of numbers of
new drug approvals in the United States, 2012 was the best year since 1997 when the Pfizer drug, Lipitor, was approved. But perhaps
more important than the large number of approvals in 2012 (45 versus 35 in 2011), quality was also significantly better than in
previous years, as judged by analysts&rsquo; consensus expectations of sales five-year post launch. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Women&rsquo;s Health Care
Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">According to the GBI Research
(a provider of industry-leading business intelligence solutions on a global basis) report &ldquo;Women&rsquo;s Health Therapeutic
Market through 2018,&rdquo; the women&rsquo;s health therapeutics market is one of the most attractive markets in the global pharmaceutical
industry. Hormone therapy, gynecological disorders, and musculoskeletal disorders in women are the prime areas of focus in the
women&rsquo;s health therapeutics market. The women&rsquo;s health therapeutics market in the United States was valued at $12.5
billion in 2011. Revenues are projected to increase to $15.1 billion in 2018 at a compound and growth rate of 2.7%. This can be
attributed to the launch of new drug molecules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Hormone Therapy Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Menopause is the spontaneous
and permanent cessation of menstruation, which naturally occurs in most women between the ages of 40 and 58. It is defined as the
final menstrual period and is confirmed when a woman has not had her period for 12 consecutive months. These symptoms are caused by the
reduced levels of circulating estrogen as ovarian production shuts down. The symptoms include hot flashes, night sweats, sleep
disturbances, and vaginal dryness. According to Symphony Health Solutions, prescriptions for hormone therapy products for the treatment
of menopause symptoms or prevention of osteoporosis generated total sales of over $4.2 billion on over 35 million prescriptions
for the 12 months ended December 31, 2014. Oral hormone therapy accounted for $2.0 billion on 23 million prescriptions over the
same time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prescriptions for menopausal
hormone therapy in the United States dropped significantly following the Women&rsquo;s Health Initiative, or WHI, study in 2002,
which found that subjects using estrogen plus synthetic progestin had, among other things, a greater incidence of coronary heart
disease, breast cancer, stroke, and pulmonary embolism. A number of additional studies regarding the benefits and risks of hormone
therapy have been conducted over the last decade since the WHI results were first published. In general, recommendations for hormone
therapy use are to be judged on an individual basis, and the FDA recommends that women with moderate to severe menopausal symptoms
who want to try menopausal hormone therapy for relief use it for the shortest time needed and at the lowest effective dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were approximately
41.7 million women in the United States between the ages of 45 and 64 in 2010, projected to increase slightly (2.8%) to 42.9 million
in 2015 and to approximately 44.3 million in 2040, according to the 2010 National Census population figures. These women are the
target market for hormone therapy to treat menopausal related symptoms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Hormone Therapy Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Estrogen (with or
without a progestin) is the most effective treatment of vasomotor symptoms due to menopause according to the North American
Menopause Society, or NAMS. According to Symphony Health Solutions, sales of total FDA-approved oral, transdermal, and
suppository estrogen (with and without a progestin) hormone therapy products were approximately $3.7 billion for the 12
months ended December 31, 2014, an approximately 7% increase over the prior year. The three
primary hormone therapy products are estrogen, progestin, and combination of estrogen and progestin, which are produced in a
variety of forms, including oral tablets or capsules, skin patches, gels, emulsion, or vaginal suppositories and creams.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Estrogen-Only Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Estrogen therapies are
used to treat vasomotor symptoms due to menopause that are a direct result of the decline in estrogen levels associated with ovarian
shutdown at menopause. Estrogen therapy has been used to manage these symptoms for more than 50 years. Estrogen is a generic term
for any substance, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones, such as estradiol.
Based upon the age demographic for all women receiving prescriptions for estrogen therapy and the average age range during which
women experience vasomotor symptoms, we believe that estrogen is primarily used for the treatment of vasomotor symptoms, but also
prescribed for the prevention of osteoporosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Estrogen-only
therapy, or ET, is used primarily in women who have had a hysterectomy and have undergone a surgical menopause, as those
women do not require a progestin to protect the uterine endometrium from proliferation. Approximately 433,000 women undergo a
hysterectomy each year in the United States according to the United States Centers for Disease Control and Prevention. Sales
of FDA-approved ET were approximately $3.0 billion for the 12 months ended December 31, 2014, according to Symphony Health
Solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ET is also used for
the treatment of VVA, which has a variety of indications, including vaginal dryness, vaginal itching and irritation, painful
intercourse, painful urination, and other symptoms. Sales of FDA-approved ET for VVA were approximately $1.3 billion for the
12 months ended December 31, 2014, according to Symphony Health Solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ET is also approved for
the prevention of osteoporosis. Multiple studies conducted on various estrogen compositions, including studies published in the
Journal of the American Medical Association in 2002, Osteoporosis International in 2000, The Lancet in 2002, Maturitas in 2008,
and Climacteric in 2005, demonstrated efficacy based on increases in bone mineral density. Epidemiological and some fracture prevention
studies, such as the study published in the New England Journal of Medicine in 1980, also have demonstrated a decrease in bone
fractures as a result of ET.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Progestin-Only Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Progestins include the
naturally occurring hormone progesterone and a number of synthetic progestin compounds that have progestational activity. These
agents are used for a variety of indications and conditions, but most often, progestins are used either alone or in combination
with an estrogen for hormonal contraception and to prevent endometrial hyperplasia from unopposed estrogen in hormone therapy.
Progestins alone are also used to treat women with secondary amenorrhea in order to create withdrawal bleeding in these women who
have not had regular menses. Progestins are also used to treat dysfunctional uterine bleeding and endometriosis. Progesterone has
also been used to prevent threatened or recurrent pregnancy loss and for the prevention of preterm birth. Progestins have also
been used in fertility treatments. Progestins have also been used as a palliative measure for metastatic endometrial carcinoma
and in the treatment of renal and breast carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Estrogen/Progestin Combination
Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Progestins are used in
combination with estrogen in post-menopausal women with uteruses to avoid an increase in the incidence of endometrial hyperplasia,
which is a condition caused by chronic use of estrogen alone by a woman with a uterus and is associated with an increased incidence
of uterine, or endometrial, cancer. Studies have shown that, after one year, the incidence of endometrial hyperplasia is less than
1% in women taking estrogen/progestin combinations, in contrast to up to 20% in women taking estrogen alone. In accordance with
FDA recommendations, doctors typically recommend that a menopausal or post-menopausal woman who has a uterus take estrogen plus
a progestin, either as a combination drug or as two separate drugs. Symphony Health Solutions estimates that sales of FDA-approved
estrogen/progestin combinations were approximately $659 million in the United States for the 12 months ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Limitations of Existing
Estrogen/Progestin Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The most commonly prescribed
progestin is a synthetic progestin (medroxyprogesterone acetate), which can cause some women to experience painful vaginal bleeding,
breast tenderness, and bloating and may reduce cardio-protective benefits potentially associated with estrogen therapy by limiting
the estrogen&rsquo;s ability to raise high-density lipoprotein cholesterol, or good cholesterol, and low-density lipoprotein, or
bad cholesterol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A widely prescribed naturally
occurring progesterone is known as Prometrium<SUP>&reg;</SUP> (progesterone USP), sold by AbbVie Inc. Natural progesterone is used
in combination with estrogen for hormone therapy; however, we believe there are currently no FDA-approved hormone therapy combination
products with natural progesterone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Prenatal Vitamin Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">According to
the American Pregnancy Association, approximately six million women become pregnant each year, resulting in approximately
four million births. Of these women, over 75% receive prenatal care during the first trimester, and most doctors encourage
taking a prenatal vitamin as the recommended standard of care. Prenatal vitamins are usually dietary supplements intended to
be taken before and during pregnancy and during postnatal lactation that provide nutrients recognized by various health
organizations as helpful for a healthy pregnancy outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are hundreds of
prenatal vitamins available, with both prescription and OTC choices. According to Symphony Health Solutions&rsquo; PHAST 2.0
Report, during the 12 months ended November 30, 2014, approximately 8.2 million prescriptions for prenatal vitamins were
issued in the United States resulting in total sales of approximately $399 million, with sales between branded and generic
products split nearly evenly. According to the 2012 Gallup Target Market Report on Prenatal Vitamins, supplement use has been
fairly constant overall between 2008 and 2011. However, shifts have occurred in terms of types used, with the trend toward
OTC prenatal vitamins and away from prescription prenatal vitamins. During this same period, the use of OTC products
surpassed the use of prescription products, largely driven by increased use among women currently pregnant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Our Business Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a women&rsquo;s
health care product company focused on creating and commercializing products targeted exclusively for women, including products
specifically for pregnancy, childbirth, nursing, pre-menopause, menopause, and post-menopause. We intend to use our current prescription
and OTC product lines, consisting of prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products,
as the foundation of our business platform. If approved and commercialized, our hormone therapy drug candidates will allow us to
enter the $4.2 billion hormone therapy market, based on 2014 total sales of the hormone therapy market, according to Symphony Health
Solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our current product line
is marketed and sold by a direct national sales force that calls on health care providers in the OB/GYN market space, as well
as through our website to consumers who have been referred to our website by physicians. We market our prescription and OTC prenatal
vitamins and other products under our vitaMedMD brand name and duplicate formulations of our prescription prenatal vitamin products,
also referred to as &ldquo;generic&rdquo; formulations, under our BocaGreenMD brand name. We believe that our vitaMedMD brand
name has become a recognized name for high quality women&rsquo;s health care, while our BocaGreenMD products provide physicians,
women, and payors with a lower cost alternative for prenatal supplements. We intend to leverage our existing relationships and
distribution system to introduce our hormone therapy drug candidates, if approved, which we believe will enable us to provide
a comprehensive line of women&rsquo;s health care products all under one brand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our sales model focuses
on the &ldquo;4Ps&rdquo;: patient, provider, pharmacist, and payor. We market and sell our current products primarily through a
direct national sales force of approximately 34 full-time professionals that calls on health care providers in the OB/GYN market
space, as well as through our website directly to consumers. In addition, our products allow health care providers to offer an
alternative to patients to meet their individual nutritional and financial requirements related to co-payment and cost-of-care
considerations and help patients realize cost savings over competing products. We also believe that our combination of branded,
generic, and OTC lines offers physicians, women, and payors cost-effective alternatives for top-quality care. We supply our prescription
products to consumers through retail pharmacies. We market our OTC products either directly to consumers via our website and phone
sales followed by direct shipment to their homes or offices or through physicians who then re-sell them to their patients. Our
fully staffed customer care center uses current customer relationship management software to respond to health care providers,
pharmacies, and consumers via incoming and outgoing telephone calls, e-mails, and live-chat. We also facilitate repeat customer
orders for our non-prescription products through our website&rsquo;s auto-ship feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As health care becomes
increasingly consumer driven, patients are seeking more information, control, and convenience, which places additional time and
financial pressures on physicians, and as a result, physicians are looking for improved ways to provide better service to their
patients. A recent study by IMS Health Inc. concluded that physicians desire fewer but more encompassing relationships with companies
that can provide more valuable information, deliver more relevant services, and better respond to specific needs of their practice
and patients. Our goal is to meet this challenge by focusing on the opportunities in women&rsquo;s health, specifically the OB/GYN
market, to provide a better customer experience for physician, payor, and patient through the following means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We believe we will offer physicians a comprehensive product line of women&rsquo;s health care products,
including our hormone therapy drug candidates, if approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Our hormone therapy drug candidates are designed to use the lowest effective dose for the shortest
duration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We believe the attributes of
                                         our dietary supplements will result in greater consumer acceptance and satisfaction than
                                         competitive products while offering the highest quality products incorporating patented
                                         ingredients, such as Quatrefolic<SUP>&reg;</SUP>, FOLMAX<SUP>&reg;</SUP>, FePlus<SUP>&reg;</SUP>,
                                         and pur-DHA&trade;. All of our prenatal vitamins are gluten-, sugar-, and lactose-free.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We strive to improve our existing products and develop new products to generate additional revenue
through our existing sales channels.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We believe health care providers are able to offer alternatives to patients that meet the patient&rsquo;s
individual nutritional and financial requirements and help patients realize cost savings over competing products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Health care provider practices that choose to dispense our OTC products directly to their patients
through their offices could earn revenue from the sale of the products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Improved patient education, a high level of patient compliance, and reduced cost of products all
result in lower cost of care for payors and improved outcomes for patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our goal is to become the
women&rsquo;s health care company recommended by health care providers to all patients by becoming the new standard in women&rsquo;s
health with a complete line of products, all under one quality brand. Key elements of our strategy to achieve this goal are as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Exclusive Focus on Women&rsquo;s
Health Issues</I>. We plan to focus exclusively on women&rsquo;s health issues to enable us to build long-term relationships with
women as they move through their life cycles of birth control, pregnancy, child birth, and pre- and post- menopause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Focus on Hormone Therapy
Products</I>. We plan to focus on the development, clinical trials, and commercialization of hormone therapy products designed
to (1) alleviate the systems of and reduce the health effects resulting from menopause-related hormone deficiencies, including
hot flashes, osteoporosis, and vaginal dryness, and (2) demonstrate equivalent clinical efficacy at lower doses, enabling an enhanced
side effect profile compared with competing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Penetrate Bioidentical
Market with FDA-approved Products</I>. As we are not aware of any current FDA-approved bioidentical hormone therapy combination
products, we believe that our hormone therapy drug candidate for combined estradiol and progesterone, if approved by the FDA, will
provide a safer and more effective alternative to non-FDA approved compounded bioidentical hormone therapy products, at a lower
price to patients due to insurance coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Marketing Emphasis</I>.
We plan to maintain an emphasis on large group OB/GYN practices that provide opportunities to reach large patient bases and that
are receptive to the data and savings we provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Multiple Distribution
Channels</I>. We are pursuing multiple distribution channels, including physicians and pharmacies, through our sales force and
our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Geographical Expansion</I>.
We plan to expand our geographic market and sales team to cover the entire country by increasing our current 37 sales territories
to 60 sales territories by the end of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Introducing New
Products</I>. We continue to develop our hormone therapy drug candidates  which currently consist of a (1) bioidentical oral
combination of progesterone and estradiol product, and (2) a suppository VVA estradiol product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Current Product Lines</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We offer a wide range of
products targeted for women&rsquo;s health specifically associated with pregnancy, child birth, nursing, post-child birth, and
menopause, including prescription and OTC prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief
products under our vitaMedMD brand name and duplicate formulations of some of our prescription prenatal vitamin products, referred
to as &ldquo;generic&rdquo; formulations, under our BocaGreenMD Prena1 name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">For</FONT>
<FONT STYLE="letter-spacing: -0.05pt">the</FONT> <FONT STYLE="letter-spacing: -0.05pt">years</FONT> <FONT STYLE="letter-spacing: -0.05pt">ended</FONT>
<FONT STYLE="letter-spacing: -0.05pt">December 31,</FONT> <FONT STYLE="letter-spacing: -0.05pt">2014,</FONT> <FONT STYLE="letter-spacing: -0.05pt">2013</FONT>
<FONT STYLE="letter-spacing: -0.05pt">and</FONT> <FONT STYLE="letter-spacing: -0.05pt">2012,</FONT> <FONT STYLE="letter-spacing: -0.05pt">approximately</FONT>
<FONT STYLE="letter-spacing: -0.05pt">98%,</FONT> <FONT STYLE="letter-spacing: -0.05pt">98%,</FONT> <FONT STYLE="letter-spacing: -0.05pt">and</FONT>
<FONT STYLE="letter-spacing: -0.05pt">97%, respectively, of our consolidated revenue was generated by our prenatal vitamin products.
Our prenatal vitamin products are marketed as either OTC products or prescription products. Our OTC and prescription prenatal vitamin
products are generally variations of the same product with modifications in formulation and marketing. The primary significant
difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal
vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product
via third-party payor. For both our OTC and prescription prenatal vitamin products, we employ the same sales force and marketing
team to sell and market our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.05pt">In
March 2012, we launched our first prescription prenatal vitamin, vitaMedMD Plus Rx, with subsequent launches of our second
prescription prenatal vitamin, vitaMedMD One Rx, in April 2012 and our third prescription prenatal vitamin, vitaMedMD
RediChew&trade; Rx, in May 2012. In the fourth quarter of 2012, we launched our BocaGreenMD Prena1 line of prescription
prenatal vitamins, which included three prescription prenatal vitamins that were generic formulations of our
vitaMedMD-branded prescription prenatal vitamins. In the first quarter of 2014, we introduced a new prescription prenatal
vitamin product under our branded vitaMedMD name as vitaPearl and under our generic Prena1 name as Prena1 Pearl, which
features a unique, proprietary combination of FOLMAX&trade;, FePlus&trade;, and pur-DHA&trade;. Our product line is detailed
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaPearl&trade;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaPearl</I>
is our newest prescription product and a complete prenatal vitamin in one tiny pearl. vitaPearl provides 40% more folic acid
as Flowmax&trade;, our proprietary modified-release folic acid than the leading prescription prenatal vitamin.
vitaPearl delivers 14 key vitamins and minerals plus 200 mg of DHA, as par-DHA&trade;, providing comprehensive support for a
women and her body whether she is planning a pregnancy, pregnant, or nursing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD Plus</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD Plus </I>
is a once-daily, two pill combo pack that contains a complete multivitamin with 16 essential vitamins and minerals and 300 mg of
plant based docosohexaenoic acid, or DHA, and is vegan and Kosher certified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD One Prenatal
Multivitamin </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD One</I> is
a single-dose daily multivitamin that provides 14 vitamins and minerals and 200 mg of plant-based DHA. Each convenient, easy-to-swallow
softgel  features 975 mcg of folic acid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD Plus Rx Prenatal
Multivitamin </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD Plus Rx</I>
is a once-daily, two pill combo prescription product containing one prenatal vitamin tablet with Quatrefolic<SUP>&reg;</SUP>, the
fourth generation folate, and one plant-based DHA 300 mg capsule. Quatrefolic<SUP>&reg;</SUP> is a registered trademark of Gnosis
S.P.A. All minerals, including iron, zinc, and copper, are chelated to improve absorption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD One Rx Prenatal
Multivitamin</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD</I> <I>One
Rx</I> is a prescription product with a single-dose daily multivitamin that provides 14 vitamins and minerals, Quatrefolic<SUP>&reg;</SUP>,
and 200 mg of plant-based DHA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD RediChew<SUP>&reg;
</SUP>Rx Prenatal Multivitamin </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD</I> <I>RediChew<SUP>&reg;
</SUP>Rx</I> is a prescription, easy-to-chew, small, vanilla-flavored tablet containing Quatrefolic<SUP>&reg;</SUP>, vitamin D3,
vitamin B2, vitamin B6 and vitamin B12. We believe <I>vitaMedMD RediChew Rx</I> is an excellent option for women who have difficulty
swallowing tablets or softgels, or are experiencing nausea and morning sickness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Iron 21/7</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD Iron 21/7</I>
is an iron replacement supplement with a three weeks-on/one week-off dosing schedule intended to maximize absorption and enhance
tolerability. It is formulated with 150 mg of chelated iron to help improve tolerability and limit typical side effects associated
with iron replacements. Each easy-to-swallow single tablet serving also includes 800 mcg of folic acid, plus vitamins C and B12,
and succinic acid to aid in absorption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Menopause Relief
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD Menopause
Relief </I>offers a natural treatment for hot flashes, night sweats, and mood disturbances. Each single tablet dosage delivers
120 mg of Lifenol<SUP>&reg;</SUP>, a well-studied female hops extract recognized for its potency and support in alleviating hot
flashes, plus plant phytoestrogens. It also includes calcium and vitamin D3 for added bone support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD Vitamin D3
50,000 IU and Vitamin D3 2,000 IU</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>vitaMedMD Vitamin D3
50,000 IU and Vitamin D3 2,000 IU</I> are dietary supplements provided in a small, easy-to-swallow gel capsule that help replenish
and maintain beneficial levels of vitamin D in the body. Sustaining adequate levels of vitamin D in the body is essential to bone
health, enhancing the absorption of calcium and phosphorus. Vitamin D3, also known as cholecalciferol, is considered the most preferred
form of vitamin D as it is the most active form of the nutrient. We believe <I>vitaMedMD</I> <I>Vitamin D3 50,000 IU</I> and <I>Vitamin
D3 2,000 IU</I> are ideal for pregnant, breastfeeding, and menopausal women to sustain adequate levels of vitamin D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>BocaGreenMD Prena1 Pearl</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>BocaGreenMD
Prena1 Pearl</I> is our newest prescription product and a complete prenatal vitamin in one tiny pearl. vitaPearl provides 40%
more folic acid than the leading prescription prenatal vitamin. vitaPearl delivers 14 key vitamins and minerals plus 200 mg
of DHA, providing comprehensive support for a women and her body whether she is planning a pregnancy, pregnant, or
nursing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>BocaGreenMD Prena1 Chew</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>BocaGreenMD Prena1 Chew</I>
is a prescription, single daily easy-to-chew, vanilla-flavored tablet well-suited for women planning a pregnancy and
those with difficulty swallowing tablets or capsules or when nausea or morning sickness make taking tablets or capsules difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Hormone Therapy Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have obtained FDA acceptance
of our IND applications to conduct clinical trials for four of our proposed products: TX-001HR, our oral combination of progesterone
and estradiol; TX-002HR, our oral progesterone alone; TX-003HR, our oral estradiol alone; and TX-004HR, our estradiol alone vaginal
suppository.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>TX-001HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-001HR, our combination
estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms
due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal dryness, for post-menopausal women with
an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&rsquo;s
body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen
and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time
a combination product of estradiol and progesterone bioidentical to the estradiol and progesterone produced by the ovaries, would
be approved for use in a single combined product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 5,
2013, we initiated the REPLENISH trial, a multicenter, double-blind, placebo-controlled, phase 3 study of TX-001HR
in postmenopausal women with an intact uterus. The study is designed to evaluate the efficacy of TX-001HR for the treatment
of moderate to severe vasomotor symptoms due to menopause and the endometrial safety of TX-001HR. Patients are assigned to
one of five treatment arms, four active and one placebo, and receive study medication for 12 months. The primary endpoint for
the reduction of endometrial hyperplasia is an incidence of endometrial hyperplasia of less than 1% at 12 months, as
determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe vasomotor symptoms is the mean
change of frequency and severity of moderate to severe vasomotor symptoms at weeks four and 12 compared to placebo, as
measured by the number and severity of hot flushes. Only subjects experiencing a minimum daily frequency of seven moderate to
severe hot flushes at screening are included in the vasomotor symptoms analysis, while all subjects are included in the
endometrial hyperplasia analysis. The secondary endpoints include reduction in sleep disturbances and improvement in quality
of life measures, night sweats and vaginal dryness, measured at 12 weeks, six months and 12 months. We intend to enroll
approximately 1,750 patients at approximately 100 sites. We currently anticipate that enrollment in the REPLENISH Trial will
be completed in the first-half of 2015 and that results of the trial will be reported in the middle of 2016. Based on
such timeline and successful reports of the trial, we would anticipate filing a New Drug Application, or NDA, for TX-001HR
during the first-half of 2016 and that such NDA would be approved by the FDA during the first-half of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We previously conducted
a PK study of TX-001HR to demonstrate that our drug candidate is bioequivalent to the reference listed drug
based on the criterion that the 90% confidence interval on the test-to-reference ratio is contained entirely within the interval
80% to 125%. The study compared our combined capsule TX-001HR of 2 mg estradiol and 200 mg of progesterone to 2 mg of Estrace<SUP>&reg;
</SUP>and 200 mg of Prometrium<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The study compared the
mean plasma concentrations for free estradiol between TX-001HR and Estrace<SUP>&reg;</SUP> in 62 female test subjects. When the
results of a single dose-fed study were compared over 48 hours by the test drug versus reference drug, the ratio was 0.93 with
the standard deviation within the subject being 0.409 for an upper 95% confidence bound of -0.089. The maximum plasma concentration
levels of free estradiol showed that the drug -versus -reference drug ratio was 0.88 with the standard deviation within the subject
being 0.344 for an upper 95% confidence bound of -0.040 over 48 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The study also compared
the mean plasma concentrations for progesterone between TX-001HR and Prometrium<SUP>&reg;</SUP> in 62 female test subjects. When
the results were compared over 48 hours of the test that the drug-versus-reference drug, the ratio was 1.05 with the standard deviation
within the subject being 0.956 for an upper 95% confidence bound of -0.542. The maximum plasma concentration levels of progesterone
showed drug versus reference drug ratio as 1.16 with the standard deviation within the subject being 1.179 for an upper 95% confidence
bound of -0.785 over 48 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe these data
are sufficient to demonstrate the bioequivalence of TX-001HR to Estrace<SUP>&reg;</SUP> and Prometrium<SUP>&reg;</SUP> based
on the criteria for demonstrating bioequivalence established in connection with the study. On September 5, 2013, we began
enrollment of the REPLENISH trial, a multicenter, double-blind, placebo-controlled, phase 3 study of TX-001HR
in postmenopausal women with an intact uterus. The study is designed to evaluate the efficacy of TX-001HR for the treatment
of moderate to severe vasomotor symptoms due to menopause and the endometrial safety of TX-001HR. Patients are assigned to
one of five treatment arms, four active and one placebo, and receive study medication for 12 months. The primary endpoint
for the reduction of endometrial hyperplasia is an incidence of endometrial hyperplasia of less than 1% at 12 months, as
determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe vasomotor symptoms is the mean
change of frequency and severity of moderate to severe vasomotor symptoms at weeks four and 12 compared to placebo, as
measured by the number and severity of hot flushes. Only subjects experiencing a minimum daily frequency of seven moderate to
severe hot flushes at screening are included in the vasomotor symptoms analysis, while all subjects are included in the
endometrial hyperplasia analysis. The secondary endpoints include reduction in sleep disturbances and improvement in quality
of life measures, night sweats and vaginal dryness, measured at 12 weeks, six months and 12 months. We intend to enroll
approximately 1,750 patients at approximately 100 sites. We currently anticipate that enrollment in the REPLENISH Trial will
be complete in 2015 and that results of the trial will be reported in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX-002HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-002HR is a natural progesterone
formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy
drug candidate is chemically identical to the hormones that naturally occur in a woman&rsquo;s body. We believe it will be similarly
effective to traditional treatments, but may demonstrate efficacy at lower dosages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2014, we began
recruitment of patients in the SPRY trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR
in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY trial encountered enrollment challenges
because of Institutional Review Board, or IRB, approved clinical trial protocols and FDA inclusion and exclusion criteria. In July
2014, we temporarily suspended enrollment and in October 2014 we stopped the SPRY trial in order to update the phase 3 protocol
based on discussions with the FDA. We intend to update the phase 3 protocol to, among other things, target only those women with
secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated
phase 3 protocol, if approved by the FDA, will allow us to mitigate the enrollment challenges in, and shorten the duration of,
the SPRY trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol that we intend to propose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX-003HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-003HR is a natural estradiol
formulation. This hormone therapy drug candidate would be chemically identical to the hormones that naturally occur in a woman&rsquo;s
body. We currently do not have plans to further develop this hormone therapy drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX-004HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-004HR is a vaginal suppository
estradiol drug candidate for the treatment of VVA in post-menopausal women with vaginal linings that do not receive enough estrogen.
We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset
of action with less systemic exposure, inferring a greater probability of dose administration to the target tissue, and it will
have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We initiated the REJOICE
trial, a multicenter, double-blind, placebo-controlled phase 3 clinical trial during the third quarter of 2014 to assess the safety
and efficacy of TX-004HR for the treatment of moderate to severe dyspareunia, or painful intercourse, as a symptom of VVA due to
menopause. We are conducting a single 12 week study, evaluating three different doses of estradiol: 4 mcg, 10 mcg and 25 mcg versus
placebo. The FDA has to date noted that in order to approve a drug based on a single trial, the trial would need to show statistical
significance at a 0.01 level. The study has been designed to include four primary endpoints: the reduction of vaginal pH levels
to less than 5.0, an increase in superficial cells, a decrease in parabasal cells and the improvement of dyspareunia. If approved,
the 4 mcg formulation would represent a lower effective dose than the currently available VVA therapies approved by the FDA. The
trial is designed to enroll approximately 700 patients across approximately 100 sites. We currently anticipate that enrollment
in the REJOICE trial will be complete during the second quarter of 2015 and that results of the trial will be reported during the
third quarter of 2015. Based on such timeline and successful reports of the trial, we would anticipate filing an NDA for TX-004HR
during the fourth quarter of 2015 and that such NDA would be approved by the FDA during the fourth quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In August 2013, we
initiated a phase 2 clinical trial for VVA, designed to measure the effect of TX-004HR on certain clinical endpoints,
including a study candidate&rsquo;s pH levels, vaginal cytology, and most bothersome symptom of VVA, out of the symptoms
identified in FDA guidance. Based upon our phase 2  results, we believe we have a rapidly acting product that differs
substantially from the reference listed drug Vagifem<SUP>&reg;</SUP> sold by Novo Nordisk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Preclinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based upon
leveraging our hormone platform technology, we have seven preclinical projects that include development of our
proposed progesterone-alone and combination estradiol and progesterone  products in a topical cream and
transdermal patch form, which we refer to as TX-005HR and TX-006HR, respectively, and transdermal patch form, which we refer
to as TX-007HR and TX-008HR, respectively. We recently completed a pilot pharmacokinetic, or PK, study of TX-005HR in
eight patients that tested the topical administration on the upper arm of 50 mcg of estradiol and 25 mg of progesterone.
The results of the PK study suggest that topical formulations of estradiol and progesterone may be possible using our
proprietary solubilized forms of the compounds. We intend to file an IND with respect to TX-005HR and TX-006HR during the
second half of 2015 and then commence phase 1 clinical trials. We may in the future engage with a financing partner to
advance our topical cream and transdermal patch projects. We are also evaluating various other indications for our hormone
technology, including oral contraception, treatment of preterm birth, and premature ovarian failure. According to Symphony
Health Solutions, the total FDA-approved menopause-related market for estrogen alone and in combination was approximately
$3.7 billion in U.S. sales for the 12 months ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Sales and Marketing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although our direct national
sales force is similar to that of a traditional pharmaceutical company in that sales representatives call on OB/GYN practices to
provide education and sampling, we believe our sales representatives are more customer centric in their sales approach by offering
physicians more than just differences in our products from the competition; they are also able to offer an array of partnering
opportunities to promote efficiency and cost savings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our national rollout strategy
has been to focus first on the largest metropolitan areas in the United States. In order to accelerate the sales ramp-up in a new
territory, we employ a national sales/large practice sales effort to identify key practices in new or expanding markets. Concurrent
with our provider sales effort, we work with commercial insurance payors for partnerships in which the payor can support the prescription
and/or recommendation of our products for the benefit of the patient, physician, and payor, with an end result of providing better
outcomes for all three constituents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the forefront of our
sales approach is the philosophy that the physician should recommend or prescribe products based only on what is best for the patient.
In general, a better outcome is achieved by providing patients with the best products and care at the best value. We believe having
an assortment of high-quality product options that can be recommended or prescribed by both the physician and payor is the foundation
of providing valuable options to the patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe our sales force
has developed strong relationships and partnerships in the OB/GYN market to sell our current products. We have also established
relationships with some of the largest OB/GYN practices in their respective markets. By delivering additional products through
the same sales channel, we believe we can leverage our already deployed assets to increase our sales and achieve profitability.
We intend to leverage and grow our current marketing and sales organization to commercialize our drug candidates in the United
States assuming the successful completion of the FDA regulatory process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Online Commerce</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A vast majority of our
OTC product sales are completed online. The Internet has continued to increase its influence over communication, content, and commerce.
We believe several factors will contribute to this continuing increase, including convenience, expanded range of available products
and services, improved security and electronic payment technology, increased access to broadband Internet connections and widespread
consumer confidence and acceptance of the Internet as a means of commerce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Retail Commerce</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The vast majority of our
prescription product sales are completed through the traditional pharmacy distribution network. Although online and mail order
pharmacy commerce continues to grow, the majority of products are still purchased directly by the consumer locally at traditional
stores. As this division of our business expands, we will continue to employ strategies that help us reduce inefficiencies in this
channel and develop relationships that allow our products to be differentiated from the competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Pharmaceutical Industry</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The pharmaceutical industry
is subject to intense competition and is characterized by extensive research efforts and rapid technological change. Competition
in our industry occurs in a variety of areas, including developing and bringing new products to market before others, developing
new technologies to improve existing products, developing new products to provide the same benefits as existing products at lower
cost, and developing new products to provide benefits superior to those of existing products. Most major pharmaceutical companies,
as well as numerous specialty pharmaceutical companies, sell products in the women&rsquo;s health sector of the pharmaceutical
industry, which is comprised of products designed for post-pubescent females and is generally considered very fragmented. There
are many companies focused on the women&rsquo;s health sector of the pharmaceutical industry that have significantly greater financial
and other resources than we do, including generic manufacturers, drug compounding pharmacies, and large pharmaceutical companies.
In addition, academic and other research institutions could be engaged in research and development efforts for the indications
targeted by our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Hormone Therapy Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The menopause hormone therapy
market includes two major components: an FDA-approved drug market and a non-FDA approved drug market supplied by compounding pharmacies.
On November 27, 2013, the Drug Quality and Security Act became law and the FDA was given additional oversight over compounding
pharmacies. We believe FDA-approved products are easily measured and monitored, while non-FDA approved hormone therapy drug products,
typically referred to as bioidenticals, when produced and sold by compounding pharmacies, are not easily measured or monitored.
Our phase 3 clinical trials are intended to establish an indication of the safety and efficacy of our bioidentical drug candidates
at specific dosage levels. We intend our hormone therapy drug candidates, if approved by the FDA, to provide hormone therapies
with well characterized safety and efficacy profiles that can be consistently manufactured to target specifications. This would
provide an alternative to the non-FDA approved compounded bioidentical market. This aim is based on our belief that our drug candidates
will offer advantages in terms of demonstrated safety and efficacy consistency in the hormone dose, lower patient cost as a result
of insurance coverage and improved access as a result of availability from major retail pharmacy chains rather than custom order
or formulation by individual compounders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-001HR, our
combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe
vasomotor symptoms due to menopause. The combination of estradiol and progesterone for the treatment of moderate to severe
vasomotor symptoms due to menopause for postmenopausal women with an intact uterus is comprised of two components: the
FDA-approved drug market and the non-FDA-approved compounded drug market. According to the PHAST Prescription Monthly by
Symphony Health Solutions, the U.S. FDA-approved market for menopause-related combination estradiol and progesterone was
approximately $659 million for the 12 months ended December 31, 2014. The largest competitors in the FDA-approved
market are PREMARIN cream (Pfizer), generic estradiol and progestins (TEVA), FemHRT (Warner Chilcott), Angeliq (Bayer), and
Activella (Novo Nordisk), with sales of PREMARIN cream constituting a majority of such sales. None of the current
FDA-approved drugs for the treatment of moderate to severe vasomotor symptoms due to menopause is bioidentical to the
estradiol and progesterone produced by the ovaries. Based on various reports, included data recently presented at the North
American Menopause Society, including Knowledge, Use, and Prescribing of Custom-Compounded Bioidentical Hormones
for Menopausal Women: It&rsquo;s Not What You Think, by JoAnn V. Pinkerton, et al., we estimate that U.S. sales of non-FDA
-approved compounded combination estradiol and progesterone products approximate $1.5 billion per year. The market for
non-FDA -approved compounded hormone therapy products is generally considered very fragmented because the products are
prepared and sold by individual compounding pharmacies. We believe that TX-001HR, if approved by the FDA, would represent the
first time a bioidentical combination product of estradiol and progesterone would be approved for use in a single combined
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-002HR, our progesterone
only drug candidate, is  for the treatment of secondary amenorrhea. According to PHAST Prescription Monthly by Symphony
Health Solutions, the U.S. progesterone alone oral market for 2014 was approximately $400 million. The largest competitors in the
progestin alone oral market are Aygestin tablets (TEVA), Provera tablets (Pfizer), and Prometrium capsules (AbbVie). We believe
that TX-002HR, if approved by the FDA, would provide for treatment of secondary amenorrhea without the potentially allergenic component
of peanut oil found in existing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-004HR, our vaginal suppository
estradiol drug candidate, is undergoing clinical trials for the treatment of VVA in post-menopausal women with vaginal linings
that do not receive enough estrogen. According to the PHAST Prescription Monthly by Symphony Health Solutions, the U.S. market
for vaginal suppository estradiol for the treatment of VVA in post-menopausal women was approximately $1.3 billion for the 12 months
ended December 31, 2014. Approximately $1.15 billion of such sales were by three products currently on the market: PREMARIN cream
(Pfizer), ESTRACE cream (Warner Chilcott), and Vagifem tablets (Novo Nordisk). We believe that TX-004HR, if approved by the FDA,
will be at least as effective as the existing treatments for VVA because of an early onset of action with less systemic exposure
inferring a greater probability of dose administration to the target tissue, and it will have an added advantage of being a simple,
easier to use dosage form versus traditional VVA treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Prenatal Vitamin Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The prenatal vitamin market
is highly fragmented, with dozens of companies selling hundreds of competitive products. Prenatal vitamin products are marketed
as either OTC products or prescription products, with many companies marketing their products through both channels. According
to Symphony Health Solutions&rsquo; PHAST 2.0 Report, during the 12 months ended December 31, 2014, approximately 8.2 million prescriptions
for prenatal vitamins were issued in the United States resulting in total sales of approximately $399 million. According to the
2012 Gallup Target Market Report on Prenatal Vitamins, supplement use has been fairly constant overall between 2008 and 2011. However,
shifts have occurred in terms of types used, with the trend toward OTC prenatal vitamins and away from prescription prenatal vitamins.
We estimate that the U.S. OTC prenatal vitamin market is approximately $800 million a year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Seasonality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The specialty pharmaceutical
industry is not subject to seasonal sales fluctuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Products in Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We introduced our branded
prescription products in the first and second quarters of 2012 and introduced our first prescription generic product line in the
fourth quarter of 2012. Our market objective is to develop an entire suite of products that are condition-specific and geared to
the women&rsquo;s health sector. Our focus is to introduce products in which we use proprietary or patented molecules or ingredients
that will differentiate our products from the competition. We currently have numerous products in development, including our hormone
therapy drug candidates as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Raw Materials for Our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We acquire all raw materials
and ingredients for our proprietary products from a group of third-party suppliers specializing in raw material manufacturing,
processing, and specialty distribution. Our primary manufacturer maintains multiple supply and purchasing relationships throughout
the raw materials marketplace to provide an uninterrupted supply of product to meet our manufacturing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Availability of and Dependence Upon Suppliers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently obtain approximately
97% of our vitaMedMD and BocaGreenMD products from Lang Pharma Nutrition, or Lang, a full-service, private label and corporate brand
manufacturer specializing in premium health benefit driven products, including medical foods, nutritional supplements, beverages,
bars, and functional foods in the dietary supplement category. As a result, we are dependent on Lang and its subcontractors for
the manufacture of most of our products. We believe the terms of our agreements with Lang are competitive with other suppliers
and manufacturers. Although we anticipate continuing our relationship with Lang, we believe that we could obtain similar terms
with other suppliers to provide the same services. We have experienced no difficulties in obtaining the products we need in the
amounts we require and do not anticipate those issues in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Manufacturing of Our Products</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our vitamin products are
manufactured in accordance with the FDA&rsquo;s current Good Manufacturing Practice, or cGMPs, for dietary supplements. In addition,
we employ an outside third party to enforce rigorous quality audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our manufacturing
is performed by third-party manufacturers. In addition to manufacturing substantially all of our products, Lang also provides a
variety of additional services to us, including development processes, prototype development, raw materials sourcing, regulatory
review, and packaging production. At present, we believe our relationship with Lang is excellent, and we intend to continue to
use Lang as our third-party manufacturer for most of our products. In the event our relationship with Lang terminates for any reason,
there are a number of other manufacturers available to us. Accordingly, we do not believe that such termination would have a material
adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use third-party manufacturers
to source key raw materials and manufacture and package our products. The FDA must approve the manufacturing facility for compliance
with the FDA&rsquo;s cGMP regulations before an NDA for a new drug is approved. Accordingly, we intend
to engage only those third-party contract manufacturers that have consistently shown the ability to satisfy these requirements
for our hormone therapy drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Quality Control for our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A quality assurance team
establishes process controls and documents and tests every stage of the manufacturing process to ensure we meet product specifications
and that our finished products contain the correct ingredients, purity, strength, and composition in compliance with FDA regulations.
We test incoming raw materials and finished goods to ensure they meet or exceed FDA and U.S. Pharmacopeia standards, including
quantitative and qualitative assay and microbial and heavy metal contamination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our manufacturers&rsquo;
quality and production standards are designed to meet or exceed current FDA regulations. To ensure the highest quality, our manufacturing
operations are audited by AIB International, Inc., or AIB, among others, for independent cGMP certification. AIB is an independent,
not-for-profit organization that offers programs and services to augment and support the work of regulatory officials around the
country, including standards development, product testing and certification, and onsite audits and inspections. The manufacturing
facilities we primarily use are also ISO 9001 certified, which is a family of standards related to quality management systems and
are designed to help organizations ensure they meet the needs of customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Distribution of our Products</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use a variety of distribution
channels dependent upon product type. We sell our prescription prenatal vitamins to patients through their pharmacies. Since the
launch of our prescription products, in addition to third-party logistics providers, we use some of the same national and regional
distributors as other pharmaceutical companies, including Cardinal, McKesson, AmerisourceBergen, H.D. Smith, and Smith Drug. Wholesaler
product inventory is monitored daily and sales out is monitored weekly. National and regional retail chain pharmacies are also
an area of focus to make sure our products are purchased and dispensed properly. We sell our OTC products directly to consumers
via our website and phone sales and the products are shipped directly from us to the consumer&rsquo;s home or office. In a few
instances, we sell OTC product to physicians who then sell the products directly to their patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer Service</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our goal is 100% customer
satisfaction by consistently delivering superior customer experiences before, during, and after the sale. To achieve this goal,
we maintain a fully -staffed customer care center that uses current customer relationship management software to respond to health
care providers, pharmacies, and consumers and accept orders for non-prescription products via incoming and outgoing telephone calls,
e-mails, and live-chat. We believe our customer service initiatives allow us to establish and maintain long-term customer relationships
and facilitate repeat visits and purchases. We also facilitate repeat customer orders through our auto-ship feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our representatives receive
regular training so that they can effectively and efficiently field questions from current and prospective customers and are also
trained not to answer questions that should be directed to a customer&rsquo;s physician. Having a quality customer care center
allows our representatives to provide an array of valuable data in the areas of sales, market research, quality assurance, lead
generation, and customer retention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Return Policy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We sell our
prescription products through third-party logistics providers, major distributors, and pharmacies, all of whom may return a
product within six months prior to or up to 12 months after the expiration date of the product. Once customers buy a product
from the pharmacy, the product may not be returned. Customers may return or exchange our non-prescription products for any
reason by returning the product within 30 days of receipt. We will refund the entire purchase price, less shipping. The
customer is responsible for the cost of returning the products to us, except in cases in which the product is being returned
because of a defect or an error made in our order fulfillment. If the purchased product exceeded a 30-day supply, the unused
product must be returned to receive the full refund. All unopened OTC products may be exchanged for different products; the
customer will be responsible for the difference in price if the replacement product is more expensive or we will refund the
difference if the replacement product is less expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Quality Guarantee</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We proudly stand behind
the quality of our products. We believe our guarantee makes it easy, convenient, and safe for customers to purchase our products.
Under our quality guarantee, we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">ensure the potency and quality of our vitamin products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">help health care providers and payors by delivering information on patient compliance and satisfaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">provide a 30-day money back guarantee for all of our OTC products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">ensure a safe, secure online shopping experience through our encrypted website.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We value frequent communication
with and feedback from our customers in order to continue to improve our offerings and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and Development</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our
product development programs are concentrated in the area of advanced hormone therapy pharmaceutical products. We engage in
programs to provide alternatives to both the FDA-approved and the non-FDA -approved compounded bioidentical market for
hormone therapy. Our programs seek to bring new products to market in unique delivery systems or formats that enhance the
effectiveness, safety, and reliability of existing hormone therapy alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend our hormone therapy
drug candidates, if approved, to provide an alternative to the non-FDA -approved compounded bioidentical market based on our belief
that our drug candidates will offer advantages in terms of proven safety, efficacy, and stability, lower patient cost as a result
of insurance coverage, and improved access as a result of availability from major retail pharmacy chains rather than custom order
or formulation by individual compounders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 40.3pt">Our research and development
expenses were $43.2 million in 2014, $13.6 million in 2013, and $4.5 million in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 40.3pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intellectual Property</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success depends, in
part, on our ability to obtain patents, maintain trade secret protection, and operate without infringing the proprietary rights
of others. Our intellectual property portfolio is one of the means by which we attempt to protect our competitive position. We
rely primarily on a combination of know-how, trade secrets, patents, trademarks, and contractual restrictions to protect our products
and to maintain our competitive position. We are diligently seeking ways to protect our intellectual property through various legal
mechanisms in relevant jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have developed hormone
products using our SYMBODA<SUP>&reg;</SUP> platform, which is our advanced hormone therapy platform to enable delivery of bio-identical
hormones through a variety of dosage forms and administrative routes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to numerous
pending patent applications, as of December 31, 2014, we had four issued patents, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">one method patent that
relates to our OPERA<SUP>&reg;</SUP> information technology platform, which is owned by us &#9;and is a U.S. jurisdiction patent
with an expiration date in 2029; and</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">three utility patents that relate to our combination progesterone and estradiol formulations,
                                                                   which is&#9;owned by us and is a  U.S. jurisdiction patent with expiration date in 2032. We have pending patent
                                                                   &#9;applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, &#9;Japan, Mexico,
                                                                   Russia, South Africa and South Korea.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subsequent to December
31, 2014, one additional patent was issued related to our combination progesterone and estradiol formulations, which are owned
by us and are U.S. jurisdiction patents with an expiration date in 2032.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2014, we had filed 24 non-provisional
and 13 provisional patent applications with the U.S. Patent and Trademark Office, or the USPTO, with respect to our hormone therapy
drug candidates, and 55 international patent applications with respect to our hormone therapy drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We hold multiple U.S. trademark
registrations and have numerous pending trademark applications. Issuance of a federally registered trademark creates a rebuttable
presumption of ownership of the mark; however, it is subject to challenge by others claiming first use in the mark in some or all
of the areas in which it is used. Federally registered trademarks have a perpetual life as long as they are maintained and renewed
on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks
if they claim priority or confusion of usage. We believe our patents and trademarks are valuable and provide us certain benefits
in marketing our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to actively
protect our intellectual property with patents, trademarks, trade secrets, or other legal avenues for the protection of intellectual
property and to aggressively prosecute, enforce, and defend our patents, trademarks, and proprietary technology. The loss, by
expiration or otherwise, of any one patent may have a material effect on our business. Defense and enforcement of our intellectual
property rights can be expensive and time consuming, even if the outcome is favorable to us. It is possible that the patents issued
or licensed to us will be successfully challenged, that a court may find that we are infringing on validly issued patents of third
parties, or that we may have to alter or discontinue the development of our products or pay licensing fees to take into account
patent rights of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">OPERA&reg; is our patented
information technology platform used in our business. We believe the deployment of OPERA&reg; and the further development and
deployment of related technology creates a sustainable competitive advantage in clinical development and product improvement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As we continue to develop
proprietary intellectual property, we will expand our protection by applying for patents on future technologies. As we examine
our current product offerings and new product pipeline, we are in the process of modifying and developing new formulations that
will enable us to gain patent protection for these products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">While we seek broad coverage
under our patent applications, there is always a risk that an alteration to the process may provide sufficient basis for a competitor
to avoid infringement claims. In addition, patents expire and we cannot provide any assurance that any patents will be issued from
our pending application or that any potentially issued patents will adequately protect our intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceuticals, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and
its implementing regulations. These products are also subject to other federal, state, and local statutes and regulations, including
federal and state consumer protection laws, laws protecting the privacy of health-related information, and laws prohibiting unfair
and deceptive acts and trade practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Pharmaceutical Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The process required by
the FDA before a new drug product may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">completion or reference of extensive preclinical laboratory tests and preclinical animal studies,
all performed in accordance with the FDA&rsquo;s Good Laboratory Practice, or GLP, regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">submission to the FDA of an IND, which the FDA must allow to become effective before human clinical
trials may begin and must be updated annually;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy
of the drug candidate for each proposed indication; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">submission to the FDA of an NDA after completion of all pivotal clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An IND is a request for
authorization from the FDA to administer an investigational drug product to humans. We currently have effective INDs for all of
our hormone therapy drug candidates, although we have no current plans to conduct clinical trials for TX-003HR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical trials involve
the administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance
with current Good Clinical Practices, or cGCPs, which include the requirement that all research subjects provide their informed
consent for their participation in any clinical trial. A protocol for each clinical trial and any subsequent protocol amendments
must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical trial site&rsquo;s
IRB before the trials may be initiated, and the IRB must monitor the study until completed. There are also requirements governing
the reporting of ongoing clinical trials and clinical trial results to public registries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical trials are usually
conducted in three phases. Phase 1 clinical trials are normally conducted in small groups of healthy volunteers to assess safety
and find the potential dosing range. After a safe dose has been established, the drug is administered to small populations of sick
patients (phase 2) to look for initial signs of efficacy in treating the targeted disease or condition and to continue to assess
safety. Phase 3 clinical trials are usually multi-center, double-blind controlled trials in hundreds or even thousands of subjects
at various sites to assess as fully as possible both the safety and effectiveness of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA, the IRB, or the
clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research
subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group
of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This
group reviews unblinded data from clinical trials and provides authorization for whether or not a trial may move forward at designated
check points based on access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving
business objectives and/or competitive climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Assuming successful completion
of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information
is submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The application
includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as
well as positive findings, together with detailed information relating to the product&rsquo;s chemistry, manufacturing, controls
and proposed labeling, among other things.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Once the NDA submission
has been accepted for filing, the FDA&rsquo;s goal is to review applications within ten months of filing. However, the review process
is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application
to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. The FDA is
not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After the FDA evaluates
the NDA and conducts inspections of manufacturing facilities in which the drug product will be formulated and its active pharmaceutical
ingredient, or API, will be produced, it may issue an approval letter or, instead, a Complete Response Letter. An approval letter
authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response
Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete
Response Letter may require additional clinical data and/or an additional pivotal phase 3 clinical trial(s), and/or other significant,
expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such additional
information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could
also approve the NDA with a REMS plan to mitigate risks, which could include medication guides, physician communication plans,
or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and
specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include
phase 4 clinical trials and surveillance to further assess and monitor the product&rsquo;s safety and effectiveness after commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After regulatory approval
of a drug product is obtained, we are required to comply with a number of post-approval requirements. As a holder of an approved
NDA, we would be required to report, among other things, certain adverse reactions and production problems to the FDA, to provide
updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any
of our products. Also, quality control and manufacturing procedures must continue to conform to cGMP after approval to ensure and
preserve the long-term stability of the drug product. The FDA periodically inspects manufacturing facilities to assess compliance
with cGMP, which imposes extensive procedural, substantive, and record keeping requirements. In addition, changes to the manufacturing
process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented.
FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money
and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely, and expect to
continue to rely, on third parties for the production of clinical and commercial quantities of our drug candidates. Future FDA
and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that
may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of previously unknown
problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer,
or holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or
judicial action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may
require changes to a product&rsquo;s approved labeling, including the addition of new warnings and contraindications, and also
may require the implementation of other risk management measures. Also, new government requirements, including those resulting
from new legislation, may be established, or the FDA&rsquo;s policies may change, which could delay or prevent regulatory approval
of our products under development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our hormone therapy drug
candidates may compete with unapproved hormone therapy products supplied by compounding pharmacies. Pharmacy compounding is a practice
in which a licensed pharmacist combines, mixes, or alters ingredients in response to a prescription to create a medication tailored
to the medical needs of an individual patient. The medications created by the compounding pharmacy are technically &ldquo;new drugs&rdquo;
subject to the new drug approval requirements of the FDCA. However, FDA&rsquo;s 2002 Compliance Policy Guide 460.200 states that
FDA will exercise enforcement discretion to exclude compounded drugs from the new drug approval requirements except where compounding
pharmacies act more akin to traditional drug manufacturers. The FDA does not exercise the same authority to regulate compounding
pharmacies as pharmaceutical manufacturers. For example, compounding pharmacies are not required to report adverse events associated
with compounded drugs, while commercial drug manufacturers are subject to stringent regulatory reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>505(b)(2) Applications</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to submit NDAs
for our hormone therapy drug candidates, assuming that the clinical data justify submission, under section 505(b)(2) of the FDCA,
or Section 505(b)(2). Section 505(b)(2) permits the filing of an NDA when at least some of the information required for approval
comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The
applicant may rely upon published literature and the FDA&rsquo;s findings of safety and effectiveness based on certain pre-clinical
or clinical studies conducted for an approved product. The FDA may also require companies to perform additional studies or measurements
to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications
for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.
In regards to TX-001HR, we are required to conduct phase 3 studies for vasomotor symptoms versus placebo and an endometrial protection
study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Phase 3 clinical trials for
secondary amenorrhea versus placebo will be required for TX-002HR. TX-003HR would be required to undergo phase 3 studies of vasomotor
symptoms compared to placebo, though we currently do not have plans to continue development of this drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As part of our submission,
we intend to certify that all of the patents for approved products referenced in the NDA for each of the hormone therapy drug candidates
as listed in the FDA&rsquo;s Orange Book have expired and that we will not be compelled to certify that any patent is invalid,
unenforceable, or will not be infringed by the new product. If, in fact, this assessment is incorrect, it can have a serious and
significant adverse effect on our ability to obtain FDA approval or market our new product. If we are compelled to certify that
a patent is invalid, unenforceable, or not infringed, then the holder of that patent can initiate a patent infringement suit against
us and the FDA is precluded from approving our product for 30 months or until a court decision or settlement finding that the patent
is invalid, unenforceable or not infringed, whichever is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Marketing Exclusivity</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A 505(b)(2) NDA applicant
may be eligible for its own regulatory exclusivity period, such as three-year exclusivity. The first approved 505(b)(2) NDA applicant
for a particular condition of approval, or change to a marketed product, such as a new extended release formulation for a previously
approved product, may be granted three-year Hatch-Waxman exclusivity if one or more clinical studies, other than bioavailability
or bioequivalence studies, was essential to the approval of the application and was conducted/sponsored by the applicant. Should
this occur, the FDA would be precluded from making effective any other application for the same condition of use or for a change
to the drug product that was granted exclusivity until after that three-year exclusivity period has run. Additional exclusivities
may also apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, the 505(b)(2)
NDA applicant may have relevant patents in the Orange Book, and if it does, it can initiate patent infringement litigation against
those applicants that challenge such patents, which could result in a 30-month stay delaying those applicants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Dietary Supplement Regulation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our currently marketed
products are regulated as dietary supplements. The processing, formulation, safety, manufacturing, packaging, labeling, advertising,
and distribution of these products are subject to regulation by one or more federal agencies, including the FDA and the Federal
Trade Commission, or the FTC, and by various agencies of the states and localities in which our products are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Generally, our nutritional
product formulations are proprietary in that in designing them, we attempt to blend an optimal combination of nutrients that appear
to have beneficial impact based upon scientific literature and input from physicians; however, we are generally prohibited from
making disease treatment and prevention claims in the promotion of our products that use these formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Dietary Supplement
Health and Education Act of 1994, or DSHEA, amended the FDCA to establish a new framework governing the composition, safety, labeling,
manufacturing, and marketing of dietary supplements. Generally, under the FDCA, dietary ingredients that were marketed in the United
States prior to October 15, 1994 may be used in dietary supplements without notifying the FDA. &ldquo;New&rdquo; dietary ingredients
(<I>i.e.</I>, dietary ingredients that were &ldquo;not marketed in the United States before October 15, 1994&rdquo;) must be the
subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been &ldquo;present in the food
supply as an article used for food&rdquo; without being &ldquo;chemically altered.&rdquo; A new dietary ingredient notification
must provide the FDA evidence of a &ldquo;history of use or other evidence of safety&rdquo; establishing that use of the dietary
ingredient &ldquo;will reasonably be expected to be safe.&rdquo; A new dietary ingredient notification must be submitted to the
FDA at least 75 days before the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient
notification does not provide an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe. Such a
determination could prevent the marketing of such dietary ingredient. The FDA recently issued draft guidance governing the notification
of new dietary ingredients. FDA guidance is not mandatory and companies are free to use an alternative approach if the approach
satisfies the requirements of applicable laws and regulations. However, FDA guidance is a strong indication of the FDA&rsquo;s
&ldquo;current thinking&rdquo; on the topic discussed in the guidance, including its position on enforcement. The draft guidance
on new dietary ingredients is expected to be significantly revised when published in final form. Moreover, Congress can amend the
dietary supplement provisions of the FDCA to impose additional restrictions on labeling and marketing of dietary supplements. Such
action would have material adverse impact on our business and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA or other agencies
could take actions against products or product ingredients that in its determination present an unreasonable health risk to consumers
that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the
products or ingredients in such products. Such actions or warnings could be based on information received through FDCA-mandated
reporting of serious adverse events. The FDCA requires that reports of serious adverse events be submitted to the FDA, and based
in part on such reports, the FDA has issued public warnings to consumers to stop using certain third party dietary supplement products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDCA permits &ldquo;statements
of nutritional support&rdquo; to be included in labeling for dietary supplements without premarket approval. Such statements must
be submitted to the FDA within 30 days of marketing. Such statements may describe how a particular dietary ingredient affects the
structure, function, or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body
structure, function, or well-being, but may not expressly or implicitly represent that a dietary supplement will diagnose, cure,
mitigate, treat, or prevent a disease. A company that uses a statement of nutritional support in labeling must possess scientific
evidence substantiating that the statement is truthful and not misleading. If the FDA determines that a particular statement of
nutritional support is an unacceptable drug claim, conventional food claim, or an unauthorized version of a &ldquo;health claim,&rdquo;
or, if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading,
we would be prevented from using the claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, DSHEA provides
that so-called &ldquo;third-party literature,&rdquo; such as a reprint of a peer-reviewed scientific publication linking a particular
dietary ingredient with health benefits, may be used &ldquo;in connection with the sale of a dietary supplement to consumers&rdquo;
without the literature being subject to regulation as labeling. The literature : (1) must not be false or misleading; (2) may not
&ldquo;promote&rdquo; a particular manufacturer or brand dietary supplement; (3) must present a balanced view of the available
scientific information on the subject matter; (4) if displayed in establishment, must be physically separate from the dietary supplements;
and (5) should not have appended to it any information by sticker or another method. If the literature fails to satisfy each of
these requirements, we may be prevented from disseminating such literature with our products, and any dissemination could subject
our product to regulatory action as an illegal drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2007, pursuant
to the authority granted by the FDCA as amended by DSHEA, the FDA published detailed cGMP regulations that govern the manufacturing,
packaging, labeling, and holding operations of dietary supplement manufacturers. The cGMP regulations, among other things, impose
significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all manufacturers, and the FDA
is conducting inspections of dietary supplement manufacturers pursuant to these requirements. There remains considerable uncertainty
with respect to the FDA&rsquo;s interpretation of the regulations and their actual implementation in manufacturing facilities.
In addition, the FDA&rsquo;s interpretation of the regulations will likely change over time as the agency becomes more familiar
with the industry and the regulations. The failure of a manufacturing facility to comply with the cGMP regulations renders products
manufactured in such facility &ldquo;adulterated,&rdquo; and subjects such products and the manufacturer to a variety of potential
FDA enforcement actions. In addition, under the Food Safety Modernization Act, or FSMA, which was enacted on January 4, 2011, the
manufacturing of dietary ingredients contained in dietary supplements will be subject to similar or even more burdensome manufacturing
requirements, which will likely increase the costs of dietary ingredients and will subject suppliers of such ingredients to more
rigorous inspections and enforcement. The FSMA will also require importers of food, including dietary supplements and dietary ingredients,
to conduct verification activities to ensure that the food they might import meets applicable domestic requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA has broad authority
to enforce the provisions of federal law applicable to dietary supplements, including powers to issue public Warning Letters or
Untitled Letters to a company, publicize information about illegal products, detain products intended for import, require the reporting
of serious adverse events, request a recall of illegal or unsafe products from the market, and request that the Department of Justice
initiate a seizure action, an injunction action, or a criminal prosecution in the U.S. courts. The FSMA expands the reach and regulatory
powers of the FDA with respect to the production and importation of food, including dietary supplements. The expanded reach and
regulatory powers include the FDA&rsquo;s ability to order mandatory recalls, administratively detain domestic products, require
certification of compliance with domestic requirements for imported foods associated with safety issues and administratively revoke
manufacturing facility registrations, effectively enjoining manufacturing of dietary ingredients and dietary supplements without
judicial process. The regulation of dietary supplements may increase or become more restrictive in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FTC exercises jurisdiction
over the advertising of dietary supplements and cosmetics. In recent years, the FTC has instituted numerous enforcement actions
against companies for failure to have adequate substantiation for claims made in advertising or for the use of false or misleading
advertising claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In recent years, the FTC
has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims
and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in consent
decrees and the payment of civil penalties and/or restitution by the companies involved. The FTC also regulates other aspects of
consumer purchases, including promotional offers of savings compared policies, telemarketing, continuity plans, and &ldquo;free&rdquo;
offers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are also subject to
regulation under various state, local, and international laws that include provisions governing, among other things, the formulation,
manufacturing, packaging, labeling, advertising, and distribution of dietary supplements and drugs. For example, Proposition 65
in the state of California is a list of substances deemed to pose a risk of carcinogenicity or birth defects at or above certain
levels. If any such ingredient exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully
sold in California only if accompanied by a prominent warning label alerting consumers that the product contains an ingredient
linked to cancer or birth defect risk. Private attorney general actions as well as California attorney general actions may be brought
against non-compliant parties and can result in substantial costs and fines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other U.S. Health Care Laws and Compliance
Requirements</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are also subject to
additional health care regulation and enforcement by the federal government and the states in which we conduct our business. Applicable
federal and state health care laws and regulations include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">The federal health care anti-kickback statute prohibits, among other things, persons from knowingly
and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce
or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which
payment may be made under federal health care programs, such as Medicare and Medicaid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">The Ethics in Patient Referrals Act of 1989, commonly referred to as the Stark Law, and its
                                                                   corresponding regulations, prohibit physicians from referring patients for designated health services, including outpatient
                                                                   drugs, reimbursed under the Medicare or Medicaid programs to entities with which the physicians or their immediate family
                                                                   members have a financial relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those
                                                                   entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred
                                                                   beneficiary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">The federal False Claims Act imposes criminal and civil penalties, and authorizes civil
                                                                   actions by the government and also by whistleblowers or
                                                                   qui                                                                    tam
                                                                   relators, against individuals or entities for                                                                    knowingly
                                                                   presenting, or causing to be presented,  claims for payment that are false or fraudulent or making a false statement to
                                                                   avoid, decrease, or conceal an                                                                    obligation to pay money to
                                                                   the federal government.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, imposes
                                                                   criminal                                                                    and civil liability for executing a scheme to
                                                                   defraud any health care benefit program and also imposes obligations, including
                                                                   mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually
                                                                   identifiable health information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">The federal False Statement Act which prohibits knowingly making a material false statement in connection with a matter
within the jurisdiction of the federal government and the Health Care False Statements Act which prohibits false statements
in connection with the delivery of or payment for healthcare items or services, even if unconnected to the federal government.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply
to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party
payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Efforts to ensure that
our business arrangements with third parties comply with applicable health care laws and regulations could be costly. Although
we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities
will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable
fraud and abuse or other health care laws and regulations. If our past or present operations, including activities conducted by
our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply
to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from third party
payor programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians,
providers, or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to
criminal, civil, or administrative sanctions, including exclusion from government funded health care programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Many aspects of these laws
have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety
of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations
are subject to change. Any action against us for violation of these laws, even if we successfully defend against it, could cause
us to incur significant legal expenses, divert our management&rsquo;s attention from the operation of our business, and damage
our reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, from time
to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, or by other federal,
state, local, or foreign regulatory authorities, to the repeal of laws or regulations that we generally consider favorable, such
as DSHEA, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future
laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if and when
it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products
to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements,
increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation,
additional personnel, or other new requirements. Any such developments could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The growth and demand for
eCommerce could result in more stringent consumer protection laws that impose additional compliance burdens on online retailers.
These consumer protection laws could result in substantial compliance costs and could interfere with the conduct of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is currently great
uncertainty in many states whether or how existing laws governing issues such as property ownership, sales and other taxes, and
libel and personal privacy apply to the Internet and commercial online retailers. These issues may take years to resolve. For example,
tax authorities in a number of states, as well as a Congressional advisory commission, are currently reviewing the appropriate
tax treatment of companies engaged in online commerce and new state tax regulations may subject us to additional state sales and
income taxes. New legislation or regulation, the application of laws and regulations from jurisdictions whose laws do not currently
apply to our business, or a change in application of existing laws and regulations to the Internet and commercial online services
could result in significant additional taxes on our business. These taxes could have an adverse effect on our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Employees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
we had 100 full-time employees, five of whom are executive officers. Additionally, from time to time, we hire temporary contract
employees. None of our employees are covered by a collective bargaining agreement, and we are unaware of any union organizing efforts.
We have never experienced a major work stoppage, strike, or dispute. We consider our relationship with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our History</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 3, 2011, we
changed our name to TherapeuticsMD, Inc. On October 4, 2011, we closed a reverse merger with VitaMedMD, LLC, pursuant to which (1) all outstanding membership units of VitaMed were exchanged for shares of our
common stock, (2) all outstanding VitaMed options and warrants were exchanged and converted into options and warrants to purchase
shares of our common stock, and (3) VitaMed became our wholly owned subsidiary. As of December 31, 2011, we determined that VitaMed
would become the sole focus of our company and services previously performed relative to the licensing agreement discussed in the
following paragraph were discontinued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were incorporated in
Utah in 1907 under the name Croff Mining Company. Prior to 2008, Croff&rsquo;s operations consisted entirely of oil and natural
gas leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced
its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or
the Exchange Act. As a result of the spin-off, Croff was a &ldquo;shell company&rdquo; under the rules of the Securities and Exchange
Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America&rsquo;s Minority Health Network, Inc. as
a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders
of America&rsquo;s Minority Health Network, Inc. acquired control of our company. On June 11, 2010, we closed a transaction to
acquire Spectrum Health Network, Inc. as a wholly owned subsidiary. On July 20, 2010, we filed Articles of Conversion and Articles
of Incorporation to redomicile in the state of Nevada. On July 31, 2010, we transferred the assets of America&rsquo;s Minority
Health Network, Inc. to a secured noteholder in exchange for the satisfaction of certain associated debt. On February 15, 2011,
we transferred the assets of Spectrum Health Network, Inc. to a secured noteholder in exchange for the satisfaction of associated
debt and in exchange for a licensing agreement under which we subsequently sold subscription services and advertising on the Spectrum
Health Network for commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Available Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a Nevada corporation.
We maintain our principal executive offices at 6800 Broken Sound Parkway NW, Third Floor, Boca Raton, Florida 33487. Our telephone
number is (561) 961-1900. We maintain websites at <I>www.therapeuticsmd.com</I>, <I>www.vitamedmd.com</I>, <I>www.vitamedmdrx.com</I>,
and <I>www.bocagreenmd.com</I>. The information contained on our websites or that can be accessed through our websites is not incorporated
by reference into this Annual Report or in any other report or document we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We file reports with the
SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any other filings
required by the SEC. Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports, as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The public may read and
copy any materials we file with, or furnish to, the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Washington,
DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.
The SEC maintains an Internet site (<I>www.sec.gov</I>) that contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_002"></A>Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><B>Item 1A.</B></TD>
    <TD STYLE="width: 90%"><B>Risk Factors</B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Investing in our common stock involves a
high degree of risk. You should carefully consider the following risk factors, together with all of the information included in
this Annual Report before you decide to purchase shares of our common stock. We believe the risks and uncertainties described below
are the most significant we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial,
also may become important factors that affect us. If any of the following risks occur, our business, financial condition, or results
of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and
you may lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>Risks Related to Our Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have incurred significant operating losses since
inception and anticipate that we will incur continued losses for the foreseeable future.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have incurred recurring
net losses, including net losses of $54 million, $28 million, and $35 million for the years ended December 31, 2014, 2013, and
2012, respectively. As of December 31, 2014, we had an accumulated deficit of approximately $135 million. We have generated limited
revenue and have funded our operations to date primarily from public and private sales of equity and private sales of debt securities.
We expect to incur substantial additional losses over the next several years as our research, development, and clinical trial activities
increase, especially those related to our hormone therapy drug candidates. As a result, we may never achieve or maintain profitability
unless we successfully commercialize our products, in particular, our hormone therapy drug candidates. If we are unable to make
required payments under any of our obligations for any reason, our creditors may take actions to collect their debts, including
foreclosing on our property that collateralizes our obligations. If we continue to incur substantial losses and are unable to secure
additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices,
refinance existing debt obligations on terms unfavorable to us, or merge, consolidate, or combine with a company with greater financial
resources in a transaction that might be unfavorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently derive all of our
revenue from sales of our women&rsquo;s health care products, and our failure to maintain or increase sales of these products would
have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently derive all
of our revenue from sales of women&rsquo;s health care products, including prenatal and women&rsquo;s multi-vitamins, iron supplements,
vitamin D supplements, and natural menopause relief. While sales of our vitamin products grew from 2010 through 2014, we cannot
assure you that such sales will continue to grow. In addition to other risks described herein, our ability to maintain or increase
existing product sales is subject to a number of risks and uncertainties, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the presence of new or
existing competing products, including generic copies of our prescription prenatal &#9;vitamin products;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">any supply or distribution problems arising with any of our manufacturing and distribution strategic
partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">changed or increased regulatory restrictions or regulatory actions by the FDA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">changes in health care laws and policy, including changes in requirements for rebates, reimbursement,
and coverage by federal health care programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the impact or efficacy of any price increases we may implement in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">changes to our label and labeling, including new safety warnings or changes to our boxed warning,
that further restrict how we market and sell our products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">acceptance of our products as safe and effective by physicians and patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If revenue from sales of
our existing prescription and OTC prenatal vitamins does not continue or increase, we may be required to reduce our operating expenses
or to seek to raise additional funds, which could have a material adverse effect on our business, financial condition, results
of operations, and growth prospects, or we may not be able to commence or continue clinical trials to seek approval for and commercialize
our hormone therapy drug candidates or any other products we may choose to develop in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If our products do not have the effects intended or
cause undesirable side effects, our business may suffer.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although many of the ingredients
in our current dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human
consumption, they also contain innovative ingredients or combinations of ingredients. Although we believe all of these products
and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects
if not taken as directed or if taken by a consumer who has certain medical conditions, such as the potential effect of high doses
of folic acid masking pernicious anemia. In addition, these products may not have the effect intended if they are not taken in
accordance with certain instructions, which include certain dietary restrictions. Furthermore, there can be no assurance that any
of the products, even when used as directed, will have the effects intended or will not have harmful side effects in an unforeseen
way or on an unforeseen cohort. If any of our products or products we develop or commercialize in the future are shown to be harmful
or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations, and prospects
would be harmed significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future success will depend in large part on our
ability to commercialize our hormone therapy drug candidates designed to alleviate the symptoms of and reduce the health risks
resulting from menopause, including hot flashes, osteoporosis, and vaginal dryness.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future success will
depend in large part on our ability to successfully develop and commercialize our hormone therapy drug candidates designed to alleviate
the symptoms of and reduce the health risks resulting from menopause, including hot flashes, osteoporosis, and vaginal dryness.
We have submitted IND applications for our four hormone therapy drug candidates, which the FDA has made effective and which permit
us to conduct clinical testing on these proposed products. We currently intend to clinically test three of those drug candidates.
However, we may not be able to complete the development of these drug candidates, the results of the clinical trials may not be
sufficient to support NDA for any of them, and even if we believe the results of our clinical trials are sufficient to support
any NDA that we submit, the FDA may disagree and may not approve our NDA. In addition, even if the FDA approves one or more of
our NDAs, it may do so with restrictions on the intended uses that may make commercialization of the product or products financially
untenable. The failure to commercialize or obtain necessary approval for any one or more of these products would substantially
harm our prospects and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may not be able to complete the development and commercialization
of our hormone therapy drug candidates if we fail to obtain additional financing.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We need substantial amounts
of cash to complete the clinical development of our hormone therapy drug candidates. Our existing cash and cash equivalents will
not be sufficient to fund these requirements. In addition, changing circumstances may cause us to consume funds significantly faster
than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.
We do not currently have any committed external source of funds. We will attempt to raise additional capital from the issuance
of equity or debt securities, collaborations with third parties, licensing of rights to these products, or other means, or a combination
of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management
and may divert a disproportionate amount of their attention away from our day-to-day activities, which may adversely affect our
ability to conduct our day-to-day operations. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms,
we may be required to take one or more of the following actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">significantly delay, scale back, or discontinue our product development and commercialization efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">seek collaborators for our hormone therapy drug candidates at an earlier stage than otherwise would
be desirable or on terms that are less favorable than might otherwise be the case; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">license, potentially on unfavorable terms, our rights to our hormone therapy drug candidates that
we otherwise would seek to develop or commercialize ourselves.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Debt financing, if available,
may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional
debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new
securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise
additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs, or proposed products or grant licenses on terms
that may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we are unable to raise
additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing discovery, development,
and commercialization efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no experience as a company in bringing a drug
to regulatory approval.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never obtained
regulatory approval for, or commercialized, a drug. It is possible that the FDA may refuse to accept any or all of our planned
NDAs for substantive review or may conclude, after review of our data, that our applications are insufficient to obtain regulatory
approval of any of our hormone therapy drug candidates. We have recently begun to conduct validation and scale up of the manufacturing
processes for our proposed combination estradiol and progesterone drug candidate and our proposed suppository estradiol VVA product.
The FDA may also require that we conduct additional clinical or manufacturing validation studies, which may be costly and time-consuming,
and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA required studies,
approval of any NDA that we submit may be significantly delayed, possibly for years, or may require us to expend more resources
than we have available or can secure. Any delay or inability in obtaining regulatory approvals would delay or prevent us from commercializing
our hormone therapy drug candidates, generating revenue from these proposed products, and achieving and sustaining profitability.
It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve
any NDA we submit. If any of these outcomes occur, we may be forced to abandon our planned NDAs for one or more of our hormone
therapy drug candidates, which would materially adversely affect our business and could potentially cause us to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Three hormone therapy drug
candidates are currently in various stages of clinical testing. We have begun phase 3 clinical trial of our estradiol and progesterone
combination drug candidate, our progesterone alone drug candidate and our vaginal suppository estradiol drug candidate. Clinical
trials are expensive, can take many years to complete and have highly uncertain outcomes. For example, we recently temporarily
suspended enrollment in and subsequently stopped the SPRY trial for our progesterone alone drug candidate in order to update the
phase 3 protocol based on discussions with the FDA. Failure can occur at any time during the clinical trial process as a result
of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, or other factors.
New drugs in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed
through earlier clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in
advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials.
Our future clinical trials may not be successful or may be more expensive or time-consuming than we currently expect. Prior to
approving a new drug, the FDA generally requires that the safety and efficacy of the drug be demonstrated in two adequate and well-controlled
clinical trials. In some situations the FDA approves drugs on the basis of a single well-controlled clinical trial. We believe
we may be required to conduct only a single phase 3 clinical trial of each of our estradiol and progesterone combination drug candidate,
our progesterone alone drug candidate and our vaginal suppository estradiol drug candidate for the treatment of VVA. However, in
connection with our VVA drug candidate, the FDA has to date noted that in order to approve a drug based on a single trial, the
trial would need to show statistical significance at a 0.01 level, and that a trial that is merely statistically significant may
not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical
trial. If clinical trials for any of our hormone therapy drug candidates fail to demonstrate safety or efficacy to the satisfaction
of the FDA, the FDA will not approve that drug and we would not be able to commercialize it, which will have a material adverse
effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Delays in clinical trials are common
for many reasons, and any such delays could result in increased costs to us and jeopardize or delay our ability to obtain regulatory
approval and commence product sales as currently contemplated.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We may experience delays in
clinical trials for our hormone therapy drug candidates. Our planned clinical trials might not begin on time; may be interrupted,
delayed, suspended, or terminated once commenced; might need to be redesigned; might not enroll a sufficient number of patients;
or might not be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in obtaining regulatory approval to commence a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites
by the FDA or other regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">imposition of a clinical hold because of safety or efficacy concerns by DSMB, the FDA, or IRB, or
us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in reaching agreement on acceptable terms with prospective contract research organizations,
or CROs, and clinical trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in obtaining required
IRB approval at each site;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in identifying, recruiting, and training suitable clinical investigators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in recruiting suitable patients to participate in a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in having patients complete participation in a trial or return for post-treatment follow-up;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">clinical sites dropping out of a trial to the detriment of enrollment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">time required to add new sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in obtaining sufficient supplies of clinical trial materials, including suitable API; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays resulting from negative or equivocal findings of DSMB for a trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Patient enrollment, a significant
factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population,
the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing
clinical trials, and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the drug being studied
in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.
Any of these delays in completing our clinical trials could increase our costs, slow down our product development and approval
process, and jeopardize our ability to commence product sales and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may be required to suspend or
discontinue clinical trials because of adverse side effects or other safety risks that could preclude approval of our hormone therapy
drug candidates.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our clinical trials may
be suspended or terminated at any time for a number of reasons. A clinical trial may be suspended or terminated by us, our collaborators,
the FDA, or other regulatory authorities because of a failure to conduct the clinical trial in accordance with regulatory requirements
or our clinical protocols, presentation of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from
using the investigational drug, changes in governmental regulations or administrative actions, lack of adequate funding to continue
the clinical trial, or negative or equivocal findings of the DSMB or the IRB for a clinical trial. An IRB may also suspend or terminate
our clinical trials for failure to protect patient safety or patient rights. We may voluntarily suspend or terminate our clinical
trials if at any time we believe that they present an unacceptable risk to participants. In addition, regulatory agencies may order
the temporary or permanent discontinuation of our clinical trials at any time if they believe the clinical trials are not being
conducted in accordance with applicable regulatory requirements or present an unacceptable safety risk to participants. If we elect
or are forced to suspend or terminate any clinical trial of any proposed product that we develop, the commercial prospects of such
proposed product will be harmed and our ability to generate product revenue from any of these proposed products will be delayed
or eliminated. Any of these occurrences may harm our business, financial condition, results of operations, and prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely on third parties
to conduct our research and development activities, including our clinical trials, and we may experience delays in obtaining or
may be unsuccessful in obtaining regulatory approval for, or in commercializing, our hormone therapy drug candidates if these third
parties do not successfully carry out their contractual duties or meet expected deadlines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not have the resources
to independently conduct research and development activities. Therefore, we have relied, and plan to continue to rely, on various
third-party CROs to conduct our research and development activities and to recruit patients and monitor and manage data for our
on-going clinical programs for our hormone therapy drug candidates, as well as for the execution of our clinical studies. Although
we control only certain aspects of our CROs&rsquo; activities, we are responsible for ensuring that each of our studies is conducted
in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve
us of our regulatory responsibilities. We cannot assure you that the CROs will conduct the research properly or in a timely manner,
or that the results will be reproducible. We and our CROs are required to comply with the FDA&rsquo;s cGCPs, which are regulations
and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces these cGCPs through periodic
inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with applicable
cGCPs, the clinical data generated in our clinical trials may be deemed unreliable or invalid, and the FDA may require us to perform
additional clinical trials before approving our proposed products. We cannot assure you that, upon inspection, the FDA will determine
that any of our clinical trials comply with cGCPs. In addition, to evaluate the safety and effectiveness compared to placebo of
our hormone therapy drug candidates to a statistically significant degree, our clinical trials will require an adequately large
number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly,
if our CROs fail to comply with these regulations or recruit a sufficient number of patients, we may be required to repeat clinical
trials, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we do not
employ the personnel of our CROs, and, except for remedies available to us under our agreements with such organizations, we cannot
control whether or not they will devote sufficient time and resources to our on-going clinical and pre-clinical programs. Our CROs
may also have relationships with other commercial entities, including one or more of our competitors, for which they may also be
conducting clinical studies or other drug development activities, which could impede their ability to devote appropriate time to
our clinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines,
if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised because of the failure
to adhere to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed,
or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our hormone therapy drug
candidates that we seek to develop. As a result, our financial results and the commercial prospects for our hormone therapy drug
candidates that we seek to develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed
or ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We typically engage one
or more CROs on a project-by-project basis for each study or trial. While we have developed and plan to maintain our relationships
with CROs that we have previously engaged, we also expect to enter into agreements with other CROs to obtain additional resources
and expertise in an attempt to accelerate our progress with regard to on-going clinical programs and, specifically, the compilation
of clinical trial data for submission with an NDA for each of our hormone therapy drug candidates. If any of our relationships
with these third parties terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially
reasonable terms. Switching or entering into new relationships with CROs involves substantial cost and requires extensive management
time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which
can materially affect our ability to meet our desired clinical development timelines and can increase our costs significantly.
Although we try to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges
or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial
condition, results of operations, or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future legislation, regulations, and policies adopted
by the FDA or other regulatory authorities may increase the time and cost required for us to conduct and complete clinical trials
for our hormone therapy drug candidates.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA has established
regulations, guidelines, and policies to govern the drug development and approval process, as have foreign regulatory authorities.
Any change in regulatory requirements resulting from the adoption of new legislation, regulations, or policies may require us to
amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to existing protocols
or clinical trial applications or the need for new ones, may significantly and adversely affect the cost, timing, and completion
of the clinical trials for our hormone therapy drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the FDA&rsquo;s
policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval
of our drug candidates, or impose more stringent product labeling and post-marketing testing and other requirements. For example,
in the past the FDA has indicated it would regulate prenatal vitamins containing greater than 0.8 mg of folic acid as a drug under
the FDCA. More recently the FDA indicated that there is no specified upper limit on the amount of folic acid permitted in a dietary
supplement. If the FDA were to seek to regulate products with higher amounts of folic acid as drugs, it may require us to stop
selling certain of our dietary supplement products and otherwise adversely affect our business. If we are slow or unable to adapt
to any such changes, our business, prospects, and ability to achieve or sustain profitability would be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if we obtain regulatory approval
for our hormone therapy drug candidates, we will still face extensive, ongoing regulatory requirements and review, and our products
may face future development and regulatory difficulties.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if we obtain regulatory
approval for one or more of our hormone therapy drug candidates in the United States, the FDA may still impose significant restrictions
on a product&rsquo;s indicated uses or marketing or to the conditions for approval, or impose ongoing requirements for potentially
costly post-approval studies, including phase 4 clinical trials or post-market surveillance. As a condition to granting marketing
approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these post-approval
clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side
effects or efficacy of a product. For example, the labeling for our hormone therapy drug candidates, if approved, may include restrictions
on use or warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority,
including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information,
and compliance with FDA-approved Risk Evaluation and Mitigation Strategies, or REMS, programs. If approved, our hormone therapy
drug candidates will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution,
safety surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&rsquo;s
exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory
review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of
approved products. Foreign regulatory agencies often have similar authority and may impose comparable costs. Post-marketing studies,
whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed
products, such as adverse event reports, may also adversely affect sales of our hormone therapy drug candidates once approved,
and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our
products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our
approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects
or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information,
including information about product misuse, may lead government agencies, professional societies, and practice management groups
or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or
the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The holder of an approved
NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications
in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the
approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional
material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of clinical
trial results on publicly available databases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, manufacturers
of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory
authorities for compliance with the FDA&rsquo;s cGMPs regulations. If we or a regulatory agency discovers previously unknown problems
with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is
manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring
recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes
to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring
that we establish a REMS. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable
federal and state laws. The distribution of product samples to physicians must comply with the requirements of the Prescription
Drug Marketing Act. Sales, marketing, and scientific/educational grant programs must comply with the anti-fraud and abuse provisions
of the Social Security Act, the False Claims Act, and similar state laws. Pricing and rebate programs must comply with the Medicaid
rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. If products are made
available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements
apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.
If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take any
of the following actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">conduct an investigation into our practices and any alleged violation of law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">issue warning letters or untitled letters asserting that we are in violation of the law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">seek an injunction or impose civil or criminal penalties or monetary fines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">suspend or withdraw regulatory approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">require that we suspend or terminate any ongoing clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">refuse to approve pending applications or supplements to applications filed by us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">suspend or impose restrictions on operations, including costly new manufacturing requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">seize or detain products, refuse to permit the import or export of products, or require us to initiate
a product recall; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">exclude us from providing our products to those participating in government health care programs,
such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The occurrence of any of
the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our
ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our dependence upon third parties for the manufacture
and supply of our existing women&rsquo;s health care products and our hormone therapy drug candidates may cause delays in, or prevent
us from, successfully developing, commercializing, and marketing our products.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently have
nor do we plan to build the infrastructure or capability internally to manufacture our existing women&rsquo;s health care products.
For example, we depend on Lang, a full-service, private label and corporate brand manufacturer specializing in premium health benefit
driven products, including medical foods, nutritional supplements, beverages, bars and functional foods in the dietary supplement
category, to supply approximately 97% of our vitaMedMD and BocaGreen products. In certain circumstances, including our failure
to satisfy our production forecasts to Lang, we may be obligated to reimburse Lang for the costs of excess raw materials purchased
by Lang that it cannot use in another product category that it then sells. We also rely on third-party contract manufacturing organizations,
or CMOs to supply our hormone therapy drug candidates for use in the conduct of our clinical trials. We rely on these third parties
to manufacture these products in accordance with our specifications and in compliance with applicable regulatory requirements.
We do not have long-term contracts for the commercial supply of our products or our hormone therapy drug candidates. We intend
to pursue long-term manufacturing agreements, but we may not be able to negotiate such agreements on acceptable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, regulatory
requirements could pose barriers to the manufacture of our products, including our hormone therapy drug candidates. Our third-party
manufacturers are required to comply with cGMP regulations. As a result, the facilities used by any of our current or future manufacturers
must be approved by the FDA. Holders of NDAs, or other forms of FDA approvals or clearances, or those distributing a regulated
product under their own name, are responsible for manufacturing even though that manufacturing is conducted by a third-party CMO.
All of our existing products are, and our hormone therapy drug candidates, if approved, will be, manufactured by CMOs. These CMOs
are required by the terms of our contracts to manufacture our products in compliance with the applicable regulatory requirements.
If our manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements
of the FDA and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for their manufacturing
facilities. If these facilities are not approved for the commercial manufacture of our existing products or our hormone therapy
drug candidates, we may need to find alternative manufacturing facilities, which would result in disruptions of our sales and significant
delays of up to several years in obtaining approval for our hormone therapy drug candidates. In addition, our manufacturers will
be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with
cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMP regulations could
result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals,
operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any
of which could have a material adverse impact on our business, financial condition, results of operations, and prospects. Finally,
we also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products
and proposed products or otherwise do not satisfactorily perform according to the terms of their agreements with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any supplier of the
product for our hormone therapy drug candidates experiences any significant difficulties in its respective manufacturing processes,
does not comply with the terms of the agreement between us, or does not devote sufficient time, energy, and care to providing our
manufacturing needs, we could experience significant interruptions in the supply of our hormone therapy drug candidates, which
could impair our ability to supply our hormone therapy drug candidates at the levels required for our clinical trials and commercialization
and prevent or delay their successful development and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The commercial success of our existing
products and our hormone therapy drug candidates that we develop, if approved in the future, will depend upon gaining and retaining
significant market acceptance of these products among physicians and payors.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Physicians may not prescribe
our products, including any of our hormone therapy drug candidates, if approved by the appropriate regulatory authorities for marketing
and sale, which would prevent us from generating revenue or becoming profitable. Market acceptance of our products, including our
hormone therapy drug candidates, by physicians, patients, and payors, will depend on a number of factors, many of which are beyond
our control, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the clinical indications for which our hormone therapy drug candidates are approved, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">acceptance by physicians and payors of each product as safe and effective treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the cost of treatment in relation to alternative treatments, including numerous generic drug products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the relative convenience and ease of administration of our products in the treatment of the symptoms
for which they are intended;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the availability and efficacy of competitive drugs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the effectiveness of our sales force and marketing efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the extent to which the product is approved for inclusion on formularies of hospitals and managed
care organizations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the availability of coverage
and adequate reimbursement by third parties, such as insurance companies &#9;and other health care payors, or by government health
care programs, including Medicare and Medicaid;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">limitations or warnings contained in a product&rsquo;s FDA-approved labeling; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">prevalence and severity of adverse side effects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if the medical community
accepts that our products are safe and efficacious for their approved indications, physicians may not immediately be receptive
to the use or may be slow to adopt our products as an accepted treatment for the symptoms for which they are intended. We cannot
assure you that any labeling approved by the FDA will permit us to promote our products as being superior to competing products.
If our products, including, in particular our hormone therapy drug candidates, if approved, do not achieve an adequate level of
acceptance by physicians and payors, we may not generate sufficient or any revenue from these products and we may not become profitable.
In addition, our efforts to educate the medical community and third-party payors on the benefits of our products may require significant
resources and may never be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our products, including our hormone
therapy drug candidates if approved, face significant competition from branded and generic products, and our operating results
will suffer if we fail to compete effectively.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Development and awareness
of our brand will depend largely upon our success in increasing our customer base. The dietary supplement and pharmaceutical industries
are intensely competitive and subject to rapid and significant technological change. Our products, including any hormone therapy
drug candidates that are approved, face intense competition, including from major multinational pharmaceutical and dietary supplement
companies, established biotechnology companies, specialty pharmaceutical, and generic drug companies. A new non-hormonal product,
Brisdelle, produced by Noven Pharmaceuticals, was approved by the FDA for treatment of vasomotor symptoms in June 2013. Many of
these companies have greater financial and other resources, such as larger research and development staffs and more experienced
marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly and may be
more effective in selling and marketing their products. They also may invest heavily to accelerate discovery and development of
novel compounds or to in-license novel compounds that could make the products that we sell or develop obsolete. As a result, our
competitors may succeed in commercializing products before we do. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large, established companies. If we are unable to economically
promote or maintain our brand, our business, results of operations and financial condition could be severely harmed. In addition,
our efforts to provide an alternative to the non FDA-approved compound bioidentical market for estradiol and progesterone products
sold by compounding pharmacies may not be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Coverage and reimbursement
may not be available for our products, which could make it difficult for us to sell our products profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Market acceptance and sales
of our products, including any hormone therapy drug candidates, will depend on coverage and reimbursement policies and may be affected
by health care reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance
organizations, decide which products they will pay for and establish reimbursement levels. Third-party payors generally do not
cover OTC products, and coverage for vitamins and dietary supplements varies. We cannot be sure that coverage and reimbursement
will be available for our products, including any hormone therapy drug candidates, if approved. We also cannot be sure that the
amount of reimbursement available, if any, will not reduce the demand for, or the price of, our products. If reimbursement is not
available or is available only at limited levels, we may not be able to successfully compete through sales of our existing dietary
supplement products or successfully commercialize our hormone therapy drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Specifically, in both the
United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health
care system in ways that could affect our ability to sell our products profitably. In the United States, the Medicare Prescription
Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare
covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain
others and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition,
this legislation provided authority for limiting the number of certain outpatient drugs that will be covered in any therapeutic
class. As a result of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional
pressure to contain and reduce costs. These and future cost-reduction initiatives could decrease the coverage and price that we
receive for our products, including our hormone therapy drug candidates, if approved, and could seriously harm our business. While
the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policies and payment
limitations in setting their own reimbursement rates, and any reduction in reimbursement under Medicare may result in a similar
reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2010,
the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or
collectively, PPACA, became law in the United States. The goal of PPACA is to reduce the cost of health care and
substantially change the way health care is financed by both governmental and private insurers. Among other measures, PPACA
imposes increased rebates on manufacturers for certain covered drug products reimbursed by state Medicaid programs. While we
cannot predict the full effect PPACA will have on federal reimbursement policies in general or on our business specifically,
the PPACA may result in downward pressure on drug reimbursement, which could negatively affect market acceptance of our
products. In addition, we cannot predict whether new proposals will be made or adopted, when they may be adopted, or what
impact they may have on us if they are adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 4, 2015, the U.S. Supreme Court heard oral arguments in <I>King v. Burwell</I> where the Supreme
Court has been asked to decide the validity an IRS regulation paying subsidies, in the form of federal tax credits, to individuals
who meet certain income guidelines, but who reside in states that have elected to use the federal government&rsquo;s insurance
exchange rather than establishing one of their own.&nbsp; Those challenging the IRS regulation have argued that federal subsidies
are only available to those residing in states that have established their own insurance exchanges.&nbsp; Should the Supreme Court
rule against the government, that could have adverse implications for most health care providers, including companies manufacturing
prescription drugs and other products covered by health insurance under the PPACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The availability of generic
products at lower prices than branded products may also substantially reduce the likelihood of reimbursement for branded products,
such as our hormone therapy drug candidates, if approved. We expect to experience pricing pressures in connection with the sale
of our products generally due to the trend toward managed health care, the increasing influence of health maintenance organizations,
and additional legislative proposals. If we fail to successfully secure and maintain adequate coverage and reimbursement for our
products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and our
business will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product liability lawsuits could divert our resources,
result in substantial liabilities and reduce the commercial potential of our products.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We face an inherent risk
of product liability claims as a result of the marketing of our current products and the clinical testing of our hormone therapy
drug candidates despite obtaining appropriate informed consents from our clinical trial participants, and, in light of the history
of product liability claims related to other hormone replacement therapy products, we will face an even greater risk if we obtain
FDA approval and commercialize our hormone therapy drug candidates in the United States or other additional jurisdictions or if
we engage in the clinical testing of proposed new products or commercialize any additional products. For example, we may be sued
if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing,
marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failures
to warn of dangers inherent in the product, negligence, strict liability, or breaches of warranties. Claims could also be asserted
under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur
substantial liabilities or be required to limit commercialization of our existing products or hormone therapy drug candidates,
if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or
eventual outcome, product liability claims may result in any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the inability to commercialize our products or hormone therapy drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">difficulty recruiting subjects for clinical trials or withdrawal of these subjects before a trial
is completed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">labeling, marketing, or promotional restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">product recalls or withdrawals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">decreased demand for our products or products that we may develop in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">loss of revenue;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">injury to our reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">initiation of investigations by regulators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">costs to defend the related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">a diversion of management&rsquo;s time and our resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">substantial monetary awards to trial participants or patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">exhaustion of any available insurance and our capital resources; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">a decline in our stock price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we maintain general
liability insurance of up to $10 million in the aggregate and clinical trial liability insurance of $10 million in the aggregate
for our hormone therapy drug candidates, this insurance may not fully cover potential liabilities. The cost of any product liability
litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, our inability to obtain or maintain
sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims could prevent
or inhibit the development and commercial production and sale of our products, which could adversely affect our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">Our business may be affected by unfavorable publicity
or lack of consumer acceptance.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are highly dependent
upon consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies.
Consumer acceptance of a product can be significantly influenced by scientific research or findings, national media attention,
and other publicity about product use. A product may be received favorably, resulting in high sales associated with that product
that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our
industry or any of our particular products and may not be consistent with earlier favorable research or publicity. A future research
report or publicity that is perceived by our consumers as less than favorable or that may question earlier favorable research or
publicity could have a material adverse effect on our ability to generate revenue. Adverse publicity in the form of published scientific
research, statements by regulatory authorities or otherwise, whether or not accurate, that associates consumption of our product
or any other similar product with illness or other adverse effects, or that questions the benefits of our product or a similar
product, or that claims that such products do not have the effect intended could have a material adverse effect on our business,
reputation, financial condition, or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we use hazardous and biological materials in a manner
that causes injury or violates applicable law, we may be liable for damages.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our research and development
activities involve the controlled use of potentially hazardous substances, including chemical, biological, and radioactive materials.
In addition, our operations produce hazardous waste products. Federal, state, and local laws and regulations in the United States
govern the use, manufacture, storage, handling, and disposal of hazardous materials. Although we believe that our procedures for
use, handling, storing, and disposing of these materials (all of which only occur at third-party sites operated by our contractors)
comply with legally prescribed standards, we may incur significant additional costs to comply with applicable laws in the future.
We also cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way
existing and future laws and regulations are interpreted or enforced. Also, even if we are in compliance with applicable laws,
we cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur liability
as a result of any such contamination or injury. In the event of an accident, we could be held liable for damages or penalized
with fines, and the liability could exceed our resources, and we do not carry liability insurance covering the use of hazardous
materials. If we fail to comply with applicable requirements, we could incur substantial costs, including civil or criminal fines
and penalties, clean-up costs, or capital expenditures for control equipment or operational changes necessary to achieve or maintain
compliance. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations
may impair our research, development and production efforts, which adversely affect our business, financial condition, results
of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">We are subject to extensive and costly government regulation.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The products we currently
market, including the vitamins, and the pharmaceutical products we are developing and planning to develop in the future, are subject
to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare &amp; Medicaid
Services, or CMS, other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General,
the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our products are paid for directly
or indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates dietary
supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing, formulation,
safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement
and cosmetic authority, respectively. The FDA also regulates the research, development, pre-clinical and clinical testing, manufacture,
safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import,
and export of pharmaceutical products under various regulatory provisions. If any drug products we develop are tested or marketed
abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval
for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Government regulation substantially
increases the cost and risk of researching, developing, manufacturing, and selling products. Our failure to comply with these regulations
could result in, by way of example, significant fines, criminal and civil liability, product seizures, recalls, withdrawals, withdrawals
of approvals, and exclusion and debarment from government programs. Any of these actions, including the inability of our hormone
therapy drug candidates to obtain and maintain regulatory approval, would have a materially adverse effect on our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to additional federal and state laws
and regulations relating to our business, and our failure to comply with those laws could have a material adverse effect on our
results of operations and financial conditions.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to additional
health care regulation and enforcement by the federal government and the states in which we conduct our business. The laws that
may affect our ability to operate include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the federal health care program Anti-Kickback Statute, which prohibits, among other things, persons
from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, in exchange for or
to induce either the referral of an individual for, or the purchase, order, or recommendation of, any good or service for which
payment may be made under government health care programs such as the Medicare and Medicaid programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">federal false claims laws that prohibit, among other things, individuals or entities from knowingly
presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government health care programs that
are false or fraudulent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">federal criminal laws that prohibit executing a scheme to defraud any health care benefit program
or making false statements relating to health care matters; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">state law equivalents of each of the above federal laws, such as anti-kickback and false claims
laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, the recently enacted
PPACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes.
A person or entity can now be found guilty of fraud or false claims under PPACA without actual knowledge of the statute or specific
intent to violate it. In addition, PPACA provides that the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims
statutes. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties, exclusion
from Medicare, Medicaid and other government programs and forfeiture of amounts collected in violation of such prohibitions. Any
violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could
result in a material adverse effect on our reputation, business, results of operations, and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">PPACA also imposes new
reporting requirements on device and pharmaceutical manufacturers to make annual public disclosures of payments to health care
providers and ownership of their stock by health care providers. Failure to submit required information may result in civil monetary
penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for &ldquo;knowing failures&rdquo;),
for all payments, transfers of value, or ownership or investment interests that are not reported. Manufacturers were required to
begin data collection on August 1, 2013 and were required to report such data to CMS by March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, there has
been a recent trend of increased federal and state regulation of payments made to physicians for marketing. Some states, such as
California, Massachusetts and Vermont, mandate implementation of corporate compliance programs, along with the tracking and reporting
of gifts, compensation, and other remuneration to physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The scope and enforcement
of these laws is uncertain and subject to change in the current environment of health care reform, especially in light of the lack
of applicable precedent and regulations. We cannot predict the impact on our business of any changes in these laws. Federal or
state regulatory authorities may challenge our current or future activities under these laws. Any such challenge could have a material
adverse effect on our reputation, business, results of operations, and financial condition. Any state or federal regulatory review
of us, regardless of the outcome, would be costly and time-consuming.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are not successful in attracting and
retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ability to compete
in the highly competitive pharmaceutical industry depends in large part on our ability to attract and retain highly qualified managerial,
scientific, and medical personnel. In order to induce valuable employees to remain with us, we have, among other things, provided
stock-based compensation that vests over time. The value to employees of stock-based compensation will be significantly affected
by movements in our stock price that we cannot control and may at any time be insufficient to counteract more lucrative offers
from other companies. Despite our efforts to retain valuable employees, members of our management, scientific, and medical teams
may terminate their employment with us on short notice. We do not have employment agreements with a number of our key employees.
As a result, most employees are employed on an at-will basis, which means that any of these employees could leave our employment
at any time, with or without notice, and may go to work for a competitor. The loss of the services of any of our executive officers
or other key employees could potentially harm our business, operating results, and financial condition. Our success also depends
on our ability to continue to attract, retain, and motivate highly skilled scientific and medical personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Any failure to adequately expand a direct
sales force will impede our growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to be substantially
dependent on a direct sales force to attract new business and to manage customer relationships. We plan to expand our direct sales
force and believe that there is significant competition for qualified, productive direct sales personnel with advanced sales skills
and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend, in large part, on our
success in recruiting, training, and retaining sufficient direct sales personnel. New and future hires may not become as productive
as expected, and we may be unable to hire sufficient numbers of qualified individuals in the future in the markets in which we
do business. While there presently exists a high rate of unemployment, if we are unable to hire and develop sufficient numbers
of productive sales personnel our business prospects could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other pharmaceutical companies
with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and longer histories
than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics
may be more appealing to high-quality candidates than what we offer. If we are unable to continue to attract and retain high-quality
personnel, our ability to commercialize drug candidates will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our success is tied to our distribution
channels.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We sell our prescription
prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally
sell products to retail pharmacies, hospitals, and other institutional customers. However, over 75% of our product shipments since
inception were to only four customers. Our business would be harmed if any of these customers refused to distribute our products
or refused to purchase our products on commercially favorable terms to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A failure to maintain optimal inventory
levels to meet commercial demand for our products could harm our reputation and subject us to financial losses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ability to maintain
optimal inventory levels to meet commercial demand depends on the performance of third-party contract manufacturers. In some instances,
our products have unique ingredients used under license arrangements. If our manufacturers are unsuccessful in obtaining raw materials,
if we are unable to manufacture and release inventory on a timely and consistent basis, if we fail to maintain an adequate level
of product inventory, if inventory is destroyed or damaged, or if our inventory reaches its expiration date, patients might not
have access to our products, our reputation and brands could be harmed, and physicians may be less likely to recommend our products
in the future, each of which could have a material adverse effect on our business, financial condition, results of operations,
and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our ability to utilize net operating
loss carryforwards may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
we had net operating loss carryforwards, or NOLs, of approximately $105.5 million available to offset future taxable income through
2034. These NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce
or eliminate our future federal income taxes otherwise payable. Section 382 of the Internal Revenue Code of 1986, as amended, imposes
limitations on a corporation&rsquo;s ability to utilize NOLs if it experiences an ownership change as defined in Section 382. In
general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of
a corporation by more than 50 percent over a three-year period. In the event that an ownership change has occurred, or were to
occur, utilization of our NOLs would be subject to an annual limitation under Section 382 determined by multiplying the value of
our stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation may be
carried over to later years. We may be found to have experienced an ownership change under Section 382 as a result of events in
the past or the issuance of shares of our common stock in the future. If so, the use of our NOLs, or a portion thereof, against
our future taxable income may be subject to an annual limitation under Section 382, which may result in expiration of a portion
of our NOLs before utilization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our success depends on how efficiently
we respond to changing consumer preferences and demand.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success depends, in
part, on our ability to anticipate and respond to changing consumer trends and preferences. We may not be able to respond in a
timely or commercially appropriate manner to these changes. Our failure to accurately predict these trends could negatively impact
our inventory levels, sales, and consumer opinion of us as a source for the latest product. The success of our new product offerings
depends upon a number of factors, including our ability to achieve the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">accurately anticipate customer needs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">innovate and develop new products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">successfully commercialize new products in a timely manner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">competitively price our products in the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">procure and maintain products in sufficient volumes and in a timely manner; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">differentiate our product
offerings from those of our competitors.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we do not introduce
new products, make enhancements to existing products, or maintain the appropriate inventory levels to meet customers&rsquo; demand
in a timely manner, our business, results of operations, and financial condition could be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may initiate product recalls or withdrawals,
or may be subject to regulatory enforcement actions that could negatively affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may be subject to product
recalls, withdrawals, or seizures if any of the products we formulate, manufacture, or sell are believed to cause injury or illness
or if we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of
any of our products. A recall, withdrawal, or seizure of any of our products could materially and adversely affect consumer confidence
in our brands and lead to decreased demand for our products. In addition, a recall, withdrawal, or seizure of any of our products
would require significant management attention, would likely result in substantial and unexpected expenditures, and could materially
and adversely affect our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We will need to grow our organization, and
we may experience difficulties in managing this growth, which could disrupt our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
we had 100 employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base
for managerial, operational, financial, and other resources and, depending on our commercialization strategy, we may further expand
our employee base for sales and marketing resources. Future growth would impose significant added responsibilities on members of
management, including the need to identify, recruit, maintain, motivate, and integrate additional employees. Also, our management
may need to divert a disproportionate amount of its attention away from their day-to-day activities and devote a substantial amount
of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may
result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees
and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial
resources from other projects, such as the development of additional drug candidates. If we are unable to effectively manage our
expected growth, our expenses may increase more than expected, our ability to increase revenue could be reduced and we may not
be able to implement our business strategy. Our future financial performance and our ability to commercialize our hormone therapy
drug candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage any future growth
in our organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our employees may engage in misconduct or
other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are exposed to the risk
of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations,
to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations,
to report financial information or data accurately, or to disclose unauthorized activities to us. In particular, sales, marketing,
and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud,
misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range
of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements.
Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result
in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Conduct and Ethics, but it is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against
us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on
our business, including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>Risks Related to our Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Another party could develop hormone therapy
products and obtain FDA regulatory exclusivity in the United States before we do, potentially preventing our ability to commercialize
our hormone therapy drug candidates and other products in development.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We plan to seek to obtain
market exclusivity for our hormone therapy drug candidates and any other drug candidates we develop in the future. To the extent
that patent protection is not available or has expired, FDA marketing exclusivity may be the only available form of exclusivity
available for these proposed products. Marketing exclusivity can delay the submission or the approval of certain marketing applications.
Potentially competitive products may also be seeking marketing exclusivity and may be in various stages of development, including
some more advanced than us. We cannot predict with certainty the timing of FDA approval or whether FDA approval will be granted,
nor can we predict with certainty the timing of FDA approval for competing products or whether such approval will be granted. It
is possible that competing products may obtain FDA approval with marketing exclusivity before we do, which could delay our ability
to submit a marketing application or obtain necessary regulatory approvals, result in lost market opportunities with respect to
our hormone therapy drug candidates, and materially adversely affect our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If our efforts to protect the proprietary
nature of the intellectual property covering our hormone therapy drug candidates and other products are not adequate, we may not
be able to compete effectively in our market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our commercial success
will depend in part on our ability to obtain additional patents and protect our existing patent positions as well as our ability
to maintain adequate protection of other intellectual property for our hormone therapy drug candidates and other products. If we
do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive
advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical
companies are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and
legislative action, and we cannot be certain that the historical legal standards surrounding questions of validity will continue
to be applied or that current defenses relating to issued patents in these fields will be sufficient in the future. Changes in
patent laws in the United States, such as the America Invents Act of 2011, may affect the scope, strength, and enforceability of
our patent rights or the nature of proceedings that may be brought by us related to our patent rights. In addition, the laws of
some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and we may encounter
significant problems in protecting our proprietary rights in these countries. We will be able to protect our proprietary rights
from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable
patents or are effectively maintained as trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">These risks include the
possibility of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the patent applications that we have filed may fail to result in issued patents in the United States
or in foreign countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">patents issued or licensed to us or our partners may be challenged or discovered to have been issued
on the basis of insufficient, incomplete, or incorrect information, and thus held to be invalid or unenforceable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the scope of any patent protection may be too narrow to exclude competitors from developing or
designing around these patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we or our licensors were not the first to make the inventions covered by each of our issued patents
and pending patent applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we or our licensors were not the first inventors to file patent applications for these technologies
in the United States or were not the first to file patent applications directed to these technologies abroad;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we may fail to comply with procedural, documentary, fee payment, and other similar provisions during
the patent application process, which can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">future drug candidates may not be patentable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">others will claim rights or ownership with regard to patents and other proprietary rights that
we hold or license;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">delays in development, testing, clinical trials, and regulatory review may reduce the period of
time during which we could market our drug candidates under patent protection; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we may fail to timely apply for patents on our technologies or products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">While we apply for patents
covering our technologies and products, as we deem appropriate, many third parties may already have filed patent applications or
have received patents in our areas of product development. These entities&rsquo; applications, patents, and other intellectual
property rights may conflict with patent applications to which we have rights and could prevent us from obtaining patents or could
call into question the validity of any of our patents, if issued, or could otherwise adversely affect our ability to develop, manufacture,
or commercialize our hormone therapy drug candidates. In addition, if third parties file patent applications in the technologies
that also claim technology to which we have rights, we may have to participate in interference, derivation, or other proceedings
with the USPTO or foreign patent regulatory authorities to determine our rights in the technologies, which may be time-consuming
and expensive. Moreover, issued patents may be challenged during in the courts or in post-grant proceedings at the USPTO, or in
similar proceedings in foreign countries. These proceedings may result in loss of patent claims or adverse changes to the scope
of the claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we, our licensors, or
our strategic partners fail to obtain and maintain patent protection for our products, or our proprietary technologies and their
uses, companies may be dissuaded from collaborating with us. In such event, our ability to commercialize our hormone therapy drug
candidates or future drug candidates, if approved, may be threatened, we could lose our competitive advantage, and the competition
we face could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, mechanisms
exist in much of the world permitting some form of challenge by generic drug marketers to our patents prior to, or immediately
following, the expiration of any regulatory exclusivity, and generic companies are increasingly employing aggressive strategies,
such as &ldquo;at risk&rdquo; launches to challenge relevant patent rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business also may rely
on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached,
it could adversely impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are sued for infringing intellectual
property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing or
commercializing our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our commercial success
depends, in part, on our not infringing the patents and proprietary rights of other parties and not breaching any collaboration
or other agreements we have entered into with regard to our technologies and products. We are aware of numerous third-party U.S.
and non-U.S. issued patents and pending applications that exist in the areas of hormone therapy, including compounds, formulations,
treatment methods, and synthetic processes, which may be applied towards the synthesis of hormones. Patent applications are confidential
when filed and remain confidential until publication, approximately 18 months after initial filing, while some patent applications
remain unpublished until issuance. As such, there may be other third-party patents and pending applications of which we are currently
unaware with claims directed towards composition of matter, formulations, methods of manufacture, or methods for treatment related
to the use or manufacture of our products or drug candidates. Therefore, we cannot ever know with certainty the nature or existence
of every third-party patent filing. We cannot provide assurances that we or our partners will be free to manufacture or market
our drug candidates as planned or that we or our licensors&rsquo; and partners&rsquo; patents will not be opposed or litigated
by third parties. If any third-party patent was held by a court of competent jurisdiction to cover aspects of our materials, formulations,
methods of manufacture, or methods of treatment related to the use or manufacture of any of our drug candidates, the holders of
any such patent may be able to block our ability to develop and commercialize the applicable drug candidate unless we obtained
a license or until such patent expires or is finally determined to be held invalid or unenforceable. There can be no assurances
that we will be able to obtain a license to such patent on favorable terms or at all. Failure to obtain such license may have a
material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is a substantial
amount of litigation involving intellectual property in the pharmaceutical industry generally. If a third party asserts that we
infringe its patents or other proprietary rights, we could face a number of risks that could adversely affect our business, financial
condition, results of operations, and prospects, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">infringement and other intellectual property claims, which would be costly and time-consuming to
defend, whether or not we are ultimately successful, which in turn could delay the regulatory approval process, consume our capital,
and divert management&rsquo;s attention from our business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">substantial damages for past infringement, which we may have to pay if a court determines that
our products or technologies infringe a competitor&rsquo;s patent or other proprietary rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">a court prohibiting us from selling or licensing our technologies or future products unless the
third party licenses its patents or other proprietary rights to us on commercially reasonable terms, which it is not required to
do;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">if a license is available from a third party, we may have to pay substantial royalties or lump
sum payments or grant cross licenses to our patents or other proprietary rights to obtain that license; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">redesigning our products so they do not infringe, which may not be possible or may require substantial
monetary expenditures and time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are party from time
to time to legal proceedings relating to our intellectual property, and third parties in the future may file claims asserting that
our technologies, processes, or products infringe on their intellectual property. We cannot predict whether third parties will
assert these claims against us or our strategic partners or against the licensors of technology licensed to us, or whether those
claims will harm our business. In addition, the outcome of intellectual property litigation is subject to uncertainties that cannot
be adequately quantified in advance. If we or our partners were to face infringement claims or challenges by third parties relating
to our drug candidates, an adverse outcome could subject us to significant liabilities to such third parties, and force us or our
partners to curtail or cease the development of some or all of our drug candidates, which could adversely affect our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to submit NDAs
for our hormone therapy drug candidates, assuming that the clinical data justify submission, under Section 505(b)(2), which was
enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act.
Section 505(b)(2) permits the filing of an NDA when at least some of the information required for approval comes from studies not
conducted by or for the applicant and for which the applicant has not obtained a right of reference. To the extent that a Section
505(b)(2) NDA relies on clinical trials conducted for a previously approved drug product or the FDA&rsquo;s prior findings of safety
and effectiveness for a previously approved drug product, the Section 505(b)(2) applicant must submit patent certifications in
its Section 505(b)(2) NDA with respect to any patents for the approved product on which the application relies that are listed
in the FDA&rsquo;s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange
Book. Specifically, the applicant must certify for each listed patent that (i) the required patent information has not been filed;
(ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval
is not sought until after patent expiration; or (iv) the listed patent is invalid, unenforceable or will not be infringed by the
proposed new product. A certification that the new product will not infringe the previously approved product&rsquo;s listed patent
or that such patent is invalid or unenforceable is known as a Paragraph IV certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Section 505(b)(2)
NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification
to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section
505(b)(2) NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement suit
against the Section 505(b)(2) applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt
of the notification regarding a Paragraph IV certification automatically prevents the FDA from approving the Section 505(b)(2)
NDA for 30 months beginning on the date the patent holder receives notice, or until a court deems the patent unenforceable, invalid
or not infringed, whichever is earlier. The court also has the ability to shorten or lengthen the 30 month period if either party
is found not to be reasonably cooperating in expediting the litigation. Thus, the Section 505(b)(2) applicant may invest a significant
amount of time and expense in the development of its product only to be subject to significant delay and patent litigation before
its product may be commercialized. Alternatively, if the NDA or relevant patent holder does not file a patent infringement lawsuit
within the specified 45 day period, the FDA may approve the Section 505(b)(2) application at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we cannot certify that
all of the patents listed in the Orange Book for the approved products referenced in the NDAs for each of our hormone therapy drug
candidates have expired, we will be compelled to include a Paragraph IV certification in the NDA for such drug candidate. Our inability
to certify that all of the patents listed in the FDA&rsquo;s Orange Book for approved products referenced in the NDAs for each
of our hormone therapy drug candidates could have a serious and significant adverse effect on the timing for obtaining approval
of our hormone therapy drug candidates. For example, at least one approved product that may be referenced in our 505(b)(2) application
as a reference product for our vaginal suppository estradiol product currently lists unexpired patents in the Orange Book.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may be required to file lawsuits or take other actions
to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Competitors may infringe
our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement
claims, which can be expensive and time-consuming. Moreover, there can be no assurance that we will have sufficient financial or
other resources to file and pursue such infringement claims, which typically last for years before they are concluded. The legal
systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual
property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally.&#9;&#9;&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not
valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents,
or those of our licensors, do not cover the technology in question or on other grounds.&nbsp; An adverse result in any litigation
or defense proceedings could put one or more of our patents, or those of our licensors, at risk of being invalidated, held unenforceable,
or interpreted narrowly and could put our patent applications, or those of our licensors, at risk of not issuing.&nbsp; Moreover,
we may not be able to prevent, alone or with our licensors, misappropriation of our proprietary rights, particularly in countries
in which the laws may not protect those rights as fully as in the United States or in those countries in which we do not file national
phase patent applications.&nbsp; Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type
of litigation.&nbsp; In addition, if securities analysts or investors perceive public announcements of the results of hearings,
motions, or other interim proceedings or developments to be negative, the price of our common stock could be adversely affected.&nbsp;
The occurrence of any of the above could adversely affect our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are unable to protect the confidentiality of certain
information, the value of our products and technology could be materially adversely affected.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,
know-how, and continuing technological advancement to develop and maintain our competitive position. To protect this competitive
position, we regularly enter into confidentiality and proprietary information agreements with third parties, including employees,
independent contractors, suppliers, and collaborators. We cannot, however, ensure that these protective arrangements will be honored
by third parties, and we may not have adequate remedies if these arrangements are breached. In addition, enforcement of claims
that a third party has illegally obtained and is using trade secrets, know-how, or technological advancements is expensive, time-consuming,
and uncertain. Non-U.S. courts are sometimes less willing than U.S. courts to protect this information. Moreover, our trade secrets,
know-how, and technological advancements may otherwise become known or be independently developed by competitors in a manner providing
us with no practical recourse against the competing parties. If any such events were to occur, they could adversely affect our
business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may be subject to claims that
our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As is common in the pharmaceutical
industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise
used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend
against these claims. Such claims may lead to material costs for us, or an inability to protect or use valuable intellectual property
rights, which could adversely affect our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>Risks Related to Ownership of Our Common
Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">The market price of our common stock may be highly volatile,
and you could lose all or part of your investment.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The trading price of our
common stock on NYSE MKT is likely to be volatile. This volatility may prevent you from being able to sell your shares at or above
the price you paid for your shares. Our stock price could be subject to wide fluctuations in response to a variety of factors,
which include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">any delay of our phase 3 clinical trials for our hormone therapy drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">adverse results or delays in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">any delay in filing our NDAs for our hormone therapy drug candidates and any adverse development
or perceived adverse development with respect to the FDA&rsquo;s review of the NDAs, including the FDA&rsquo;s issuance of a &ldquo;refusal
to file&rdquo; letter or a request for additional information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">changes in laws or regulations applicable to our products or proposed products, including clinical
trial requirements for approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">unanticipated serious safety concerns related to the use of our hormone therapy drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">a decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing
clinical trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the inability to obtain adequate clinical supply for our hormone therapy drug candidates or the inability
to do so at acceptable prices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">adverse regulatory decisions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the introduction of new products or technologies offered by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the effectiveness of our or our potential strategic partners&rsquo; commercialization efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">developments concerning our sources of manufacturing supply and any commercialization strategic partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment
community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">disputes or other developments relating to proprietary rights, including patents, litigation matters,
and our ability to obtain patent protection for our technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the inability to effectively manage our growth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">actual or anticipated variations in quarterly operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the failure to meet or exceed the estimates and projections of the investment community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the overall performance of the U.S. equity markets and general political and economic conditions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments
by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">additions or departures of key scientific or management personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">adverse market reaction to any indebtedness we may incur or securities we may issue in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">sales of our common stock by us or our stockholders in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">significant lawsuits, including patent or stockholder litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">changes in the market valuations of similar companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the trading volume of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">increases in our common stock available for sale upon expiration of lock-up agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">effects of natural or man-made catastrophic events or other business interruptions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">other events or factors, many of which are beyond our control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the stock
market in general and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors
may negatively affect the market price of our common stock, regardless of our actual operating performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our principal stockholders and
management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder
approval.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At December 31, 2014, our
executive officers, directors, holders of 5% or more of our stock, and their affiliates beneficially owned approximately 61.1%
of our common stock on an as converted basis. These stockholders may be able to determine the outcome of all matters requiring
stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational
documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited
acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. In
addition, pursuant to a Securities Purchase Agreement dated September 26, 2012, we granted certain of our stockholders the right,
expiring in October 2015, if they elect, to purchase on the same terms as in any offering of our common stock, a number of shares
of common stock that is sufficient to maintain their respective pro rata ownership percentage of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to maintain proper internal controls, our
ability to produce accurate financial statements or comply with applicable regulations could be impaired.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to Section 404
of the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal
control over financial reporting and our independent registered public accounting firm is required annually to deliver an attestation
report on the effectiveness of our internal control over financial reporting. If we are unable to maintain effective internal control
over financial reporting or if our independent auditors are unwilling or unable to provide us with an attestation report on the
effectiveness of internal control over financial reporting for future periods as required by Section 404 of the Sarbanes-Oxley
Act, we may not be able to produce accurate financial statements, and investors may therefore lose confidence in our operating
results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If securities or industry analysts do not publish research
or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The trading market for
our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business.
If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business,
our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly,
we could lose visibility in the financial markets, which might cause our stock price and trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">We do not intend to pay dividends on our common stock
so any returns will be limited to the value of our stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never declared
or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development,
operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.
Any return to stockholders will be limited to the value of their stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some provisions of our charter
documents and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition
would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Provisions in our articles
of incorporation and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third party to acquire
us or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, and could also make it more difficult
to remove our current management. These provisions in our articles of incorporation and bylaws include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">authorizing the issuance of &ldquo;blank check&rdquo; preferred stock that could be issued by our
board of directors to increase the number of outstanding shares and thwart a takeover attempt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">prohibiting cumulative voting in the election of directors, which would otherwise allow less than
a majority of stockholders to elect director candidates; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">advance notice provisions in connection with stockholder proposals that may prevent or hinder any
attempt by our stockholders to bring business to be considered by our stockholders at a meeting or replace our board of directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we are subject
to Nevada&rsquo;s Combination with Interested Stockholders statute (Nevada Revised Statute Sections 78.411 - 78.444), which prohibits
an &ldquo;interested stockholder&rdquo; from entering into a &ldquo;combination&rdquo; with a company, unless certain conditions
are met. An &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, beneficially owns (or
within the prior two years, did beneficially own) 10% or more of the corporation&rsquo;s capital stock entitled to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: center">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; margin-left: -20pt"><B><A NAME="a_003"></A>Item
                           1B.</B></P>
</TD>
    <TD STYLE="width: 90%; text-align: left"><B>Unresolved Staff Comments</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_004"></A>Item 2.</P>
</TD>
    <TD STYLE="width: 90%"><B>Properties</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters
is located in Boca Raton, Florida, where we lease 17,686 square feet of office space pursuant to a 63 month non-cancelable operating
lease that commenced on July 1, 2013, was amended on February 18, 2015, and expires on September 30, 2018. The primary functions
performed at this location are executive, administrative, accounting, treasury, marketing, and human resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that our current
facility is in good working order and is capable of supporting our operations for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B><A NAME="a_005"></A>Item
                           3.</B></P>
</TD>
    <TD STYLE="width: 90%"><B>Legal Proceedings</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, we are
involved in litigation and proceedings in the ordinary course of our business. We are not currently involved in any legal proceeding
that we believe would have a material effect on our business or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B><A NAME="a_006"></A>Item
                           4.</B></P>
</TD>
    <TD STYLE="width: 90%"><B>Mine Safety Disclosures</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_007"></A>PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><B>Item 5.</B></TD>
    <TD STYLE="width: 90%; text-align: justify"><B><A NAME="a_008"></A>Market for the Registrant&rsquo;s Common Equity, Related Stockholder Matters, and Issuer Purchases
    of Equity Securities</B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">Market Information
on Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since April 23, 2013, our
common stock has been listed on the NYSE MKT under the symbol &ldquo;TXMD.&rdquo; Prior to that time, our common stock was quoted
on the OTCQB. The following table sets forth for the periods indicated the high and low bid or sales prices of our common stock
on the OTCQB and the NYSE MKT, as applicable. The below quotations reflect inter-dealer prices, without retail mark-up, mark-down
or commission, and may not represent actual transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; padding-left: 10; text-indent: -10">2014</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: justify; padding-left: 10; text-indent: -10">Fourth Quarter&#9;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4.95</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.44</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Third Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.88</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Second Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.42</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">First Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-left: 10; text-indent: -10">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Fourth Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Third Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Second Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.73</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">First Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On March
6, 2015, there were approximately 277 shareholders of record and on February 23, 2015, there were approximately 6,965 beneficial
owners of our common stock.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically, we have not
paid dividends on our common stock, and we currently do not intend to pay any dividends on our common stock in the foreseeable
future. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends. Payments
of any cash dividends in the future will depend on our financial condition, results of operations, and capital requirements as
well as other factors deemed relevant by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Performance Graph</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following line
graph compares cumulative total shareholder return for the five years ended December 31, 2014 for (i) our common stock; (ii)
NASDAQ Stock Market (US Companies); (iii) NASDAQ Pharmaceutical Index; and (iv) Peer Group (includes: Acorda Therapeutics,
Inc., AMAG Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Dendreon Corporation, Dyax Corporation, Exelixis, Inc.,
Halozyme Therapeutics, Inc., Orexigen Therapeutics, Ind., Spectrium Pharmaceuticals, Inc., and VIVUS Inc.) does not include
the following companies that were included in the prior year's performance graph: Amarillo Biosciences Inc., which filed for
bankruptcy protection in October 2013, Avanir Pharmaceuticals, Inc., which entered into an agreement and plan of merger to be
acquired in December 2014 and was acquired in January 2015, and Cadence Pharmaceuticals Inc., which was acquired in March
2014. The graph assumes $100 invested on December 31, 2009 and includes reinvestment of dividends. Measurement points are at
the last trading day of the fiscal years ended December 31, 2009, 2010, 2011, 2012, 2013 and 2014. The stock price
performance on the following graph is not necessarily indicative of future stock price performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="txmd-10k_3.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following line graph compares
cumulative total shareholder return for the period beginning when our common stock became listed on the NYSE MKT exchange
(April 23, 2013) and ended December 31, 2014 for (i) our common stock; (ii) NASDAQ Stock Market (US Companies); (iii) NASDAQ
Pharmaceutical Index; and (iv) our Peer Group (includes: Acorda Therapeutics, Inc., AMAG Pharmaceuticals, Inc., Arena
Pharmaceuticals, Inc., Dendreon Corporation, Dyax Corporation, Exelixis, Inc., Halozyme Therapeutics, Inc., Orexigen
Therapeutics, Ind., Spectrium Pharmaceuticals, Inc., and VIVUS Inc.) does not include the following companies that were included in the prior year&rsquo;s performance graph: Amarillo
Biosciences Inc., which filed for bankruptcy protection in October 2013, Avanir Pharmaceuticals, Inc., which entered into an agreement
and plan of merger to be acquired in December 2014 and was acquired in January 2015, and Cadence Pharmaceuticals Inc., which was
acquired in March 2014. The graph assumes $100 invested on April 23, 2013 and
includes reinvestment of dividends. Measurement points are April 23, 2013 and the last trading day of the fiscal years ended
December 31, 2014 and 2013 and each of the following quarters ended therein beginning with the quarter ended June 30, 2013. The
stock price performance on the following graph is not necessarily indicative of future stock price performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Sans-Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"><B>&nbsp;</B><IMG SRC="txmd-10k_2a.jpg" ALT=""></P>

<P STYLE="font: 9pt Sans-Serif; margin: 0; text-align: left; color: Red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The performance graphs
shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of
that section. The performance graphs will not be deemed incorporated by reference into any filing of our company under the Exchange
Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><B>Item 6.</B></TD>
    <TD STYLE="width: 90%"><B><A NAME="a_009"></A>Selected Financial Data</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth selected consolidated financial and other data as of and for the periods indicated. You should read the following information
together with the more detailed information contained in &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo; and our consolidated financial statements and the related notes included elsewhere in this Annual
Report. The consolidated statements of operations for the years ended December 31, 2014, 2013, and 2012, and the consolidated balance
sheet data as of December 31, 2014, and 2013 are derived from our audited consolidated financial statements included in this Annual
Report. The consolidated statements of operations for the years ended December 31, 2011 and 2010, and the consolidated balance
sheet data as of December 31, 2012, 2011, and 2010, are derived from our audited consolidated financial statements not included
in this Annual Report, as well as the audited consolidated financial statements of VitaMed, our predecessor, not included in this
Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>(in thousands, except per share data)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom"><TD STYLE="padding-left: 10; text-indent: -10"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Year Ended December 31,</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">(Restated)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10; text-indent: -10">Consolidated Statements of Operations Data:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left; text-indent: -10; padding-left: 10">Revenue, net</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">15,026</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,776</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,818</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,088</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,242</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Cost of goods sold</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,960</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,348</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">947</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,354</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,816</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,470</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,141</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">686</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Sales, general, and administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,406</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,551</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">55</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 20pt">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65,395</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,624</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,618</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,568</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,553</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(54,041</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,148</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,427</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,867</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Other (expense) income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,611</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,972</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,486</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(54,217</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,419</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,120</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,913</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,867</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Net loss per share, basic and diluted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.38</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.07</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10; padding-left: 10">Weighted average number of common shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">149,727</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,516</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,289</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10; padding-left: 10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Consolidated Balance Sheet Data (at end of period)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 30pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">59,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">62,016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,926</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 30pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,690</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,151</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">233</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 20pt">Total stockholder' surplus (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">48,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54,698</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,433</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,712</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">964</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Other Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Capital expenditures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10; padding-left: 10">Working Capital (deficit)(end of period)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">52,085</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,914</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">826</TD><TD STYLE="text-align: left">&nbsp;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><A NAME="a_010"></A>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>You should read the
following discussion and analysis in conjunction with the information set forth under &ldquo;Selected Consolidated Financial and
Other Data&rdquo; and our consolidated financial statements and the notes to those financial statements included elsewhere in this
Annual Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties.
See &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo; Our actual results may differ materially from those contained
in or implied by any forward-looking statements as a result of various factors, including the risks and uncertainties described
under &ldquo;Risk Factors&rdquo; elsewhere in this Annual Report.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Company Overview</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a women&rsquo;s
health care product company focused on creating and commercializing products targeted exclusively for women. Currently, we are
focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical
products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health
risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. We are developing
these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating
equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products.
Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability
alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well
as or OTC vitamins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Research and Development &ndash; Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have obtained FDA acceptance
of our IND applications to conduct clinical trials for four of our hormone therapy drug candidates: TX-001HR, our oral combination
of progesterone and estradiol; TX-002HR, our oral progesterone alone; TX-003HR, our oral estradiol alone; and TX-004HR, our vaginal
suppository estradiol alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently conducting
phase 3 clinical trials for TX-001HR and TX-004HR. In July 2014, we suspended enrollment in the phase 3 clinical trial for TX-002HR
and in October 2014 we temporarily stopped the trial in order to update the phase 3 protocol based on discussions with the FDA.
We have no current plans to conduct clinical trials for TX-003HR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-001HR, our
combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe
vasomotor symptoms due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal dryness for
post-menopausal women with an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones
that naturally occur in a woman&rsquo;s body, namely estradiol and progesterone, and is being studied as a
continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily.
If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone
(bioidentical to the estradiol and progesterone produced by the ovaries) would be approved for use
in a single combined product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 5, 2013,
we initiated the REPLENISH trial, a multicenter, double-blind, placebo-controlled, phase 3 study of TX-001HR in
postmenopausal women with an intact uterus. The study is designed to evaluate the efficacy of TX-001HR for the treatment of
moderate to severe vasomotor symptoms due to menopause and the endometrial safety of TX-001HR. Patients are assigned to one
of five treatment arms, four active and one placebo, and receive study medication for 12 months. The primary endpoint for the
reduction of endometrial hyperplasia is an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined
by endometrial biopsy. The primary endpoint for the treatment of moderate to severe vasomotor symptoms is the mean change of
frequency and severity of moderate to severe vasomotor symptoms at weeks four and 12 compared to placebo, as measured by the
number and severity of hot flushes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot
flushes at screening are included in the vasomotor symptoms analysis, while all subjects are included in the endometrial
hyperplasia analysis. The secondary endpoints include reduction in sleep disturbances and improvement in quality of life
measures, night sweats and vaginal dryness, measured at 12 weeks, six  months and 12 months. We intend to enroll
approximately 1,750 patients at approximately 100 sites. We currently anticipate that enrollment in the REPLENISH Trial will
be completed in the first half of 2015 and that results of the trial will be reported in the first half of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on such timeline and successful reports of the trial, we would anticipate filing an NDA for TX-001HR
during the first-half of 2016 and that such NDA would be approved by the FDA during the first-half of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic
component of peanut oil. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in
a woman's body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower
dosages. In January 2014, we began recruitment
of patients in the SPRY trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment
of secondary amenorrhea. During the first two quarters of 2014, the SPRY trial encountered enrollment challenges because of IRB
approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we temporarily suspended enrollment,
and in October 2014 we stopped the SPRY trial in order to update the phase 3 protocol based on discussions with the FDA. We intend
to update the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian
syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if approved by the FDA,
will allow us to mitigate the enrollment challenges in, and shorten the duration of, the SPRY trial. However, there can be no assurance
that the FDA will approve the updated phase 3 protocol that we intend to propose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-004HR is a vaginal
suppository estradiol drug candidate for the treatment of VVA in post-menopausal women with vaginal linings that do not
receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for
VVA because of an early onset of action with less systemic exposure inferring a greater probability of dose administration to
the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA
treatments. We initiated the REJOICE trial, a multicenter, double-blind, placebo-controlled phase 3 clinical trial during the
third quarter of 2014 to assess the safety and efficacy of TX-004HR for the treatment of moderate to severe dyspareunia, or
painful intercourse, as a symptom of VVA due to menopause. We are conducting a single 12 week study, evaluating three
different doses of estradiol: 4 mcg, 10 mcg and 25 mcg versus placebo. The FDA has to date noted that in order to approve a
drug based on a single trial, the trial would need to show statistical significance at a 0.01 level. The study has been
designed to include four primary endpoints: the reduction of vaginal pH levels to less than 5.0, an increase in superficial
cells, a decrease in parabasal cells and the improvement of dyspareunia. If approved, the 4 mcg formulation would represent a
lower effective dose than the currently available VVA therapies approved by the FDA. The trial is designed to enroll
approximately 700 patients across approximately 100 sites. We currently anticipate that enrollment in the REJOICE trial will be complete during the second quarter of 2015 and that results
of the trial will be reported during the third quarter of 2015. Based on such timeline and successful reports of the trial,
we would anticipate filing an NDA for TX-004HR during the fourth quarter of 2015 and that such NDA would be approved by the
FDA during the fourth quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">Research and Development Expenses</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A significant portion of
our operating expenses to date have been incurred in research and development activities. Research and development expenses relate
primarily to the discovery and development of our drug products. Our business model is dependent upon our company continuing to
conduct a significant amount of research and development. Until one of our drug products receives IND approval from the FDA, products
costs are listed as &ldquo;Other Research and Development&rdquo; costs in the accompanying condensed consolidated financial statements.
Our research and development expenses consist primarily of expenses incurred under agreements with CROs, investigative sites, and
consultants that conduct our clinical trials and a substantial portion of our preclinical studies; employee-related expenses, which
include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing and controls
capabilities, and acquiring clinical trial materials; and costs associated with other research activities and regulatory approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We make payments to the
CROs based on agreed upon terms that may include payments in advance of a study starting date. Nonrefundable advance payments for
goods and services that will be used in future research and development activities are expensed when the activity has been performed
or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future research and
development activities were $1,175,082 and $2,606,405, at December 31, 2014 and December 31, 2013, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following table indicates our research and development expense by project/category for the periods indicated (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,&nbsp; <BR>(000s)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; font-weight: bold; text-align: left">TX-001HR</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">26,123</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,809</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">TX-002HR</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,059</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">TX-004HR</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,984</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Other research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,669</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,683</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">&nbsp;<B>Total research and development</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,219</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,551</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Research
and development expenditures will continue to be significant as we continue development of our drug candidates and advance the
development of our proprietary pipeline of novel drug candidates. We expect to incur significant research and development costs
as we develop our drug pipeline, complete the ongoing clinical trials of our drug candidates, conduct our planned phase 3 clinical
trials, subject to receiving input from regulatory authorities, and prepare regulatory submissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The costs of clinical trials
may vary significantly over the life of a project owing to factors that include, but are not limited to, the following: per patient
trial costs, the number of patients that participate in the trials; the number of sites included in the trials; the length of time
each patient is enrolled in the trial; the number of doses that patients receive; the drop-out or discontinuation rates of patients;
the amount of time required to recruit patients for the trial, the duration of patient follow-up; and the efficacy and safety profile
of the drug candidate. We base our expenses related to clinical trials on estimates that are based on our experience and estimates
from CROs and other third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Results of Operations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">Comparison of Years Ended December 31, 2014, 2013, and
2012:</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Year ended December 31, 2014 compared
with year ended December 31, 2013</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center; border-bottom: Black 1pt solid">(000s)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%; text-align: justify; padding-left: 10; text-indent: -10">Revenue</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">15,026</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,776</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Cost of goods sold</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,672</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,712</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65,395</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,624</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,771</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt; text-indent: -10">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(54,041</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,233</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Financing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(260</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,504</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,244</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,166</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Other income (expense) net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">84</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(54,217</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(28,419</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(25,798</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Revenue for year ended
December 31, 2014 increased by approximately $6,250,000, or 71%, to approximately $15,026,000, compared with approximately $8,776,000
for the year ended December 31, 2013. Of this $6,250,000, approximately $2,003,494, or 32%, was attributable to an increase in
the average sales price of our existing products, and approximately $4,247,127, or 68%, was attributable to sales of new products
introduced during the year ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cost of goods sold increased
by approximately $1,712,000, or 87%, to approximately $3,672,000 for the year ended December 31, 2014, compared with approximately
$1,960,000 for the year ended December 31, 2013. Our gross margins decreased to approximately 76% for the year ended December 31,
2014, compared to approximately 78% for the year ended December 31, 2013. The gross margin change was primarily attributable to increases in distribution related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Operating Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our principal operating costs
included the following items as a percentage of total operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended &nbsp; <BR>December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: justify; padding-left: 10; text-indent: -10">Human resource related costs</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">16</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">33</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Sales and marketing costs, excluding human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Product research and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Professional fees and consulting costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Other operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Operating expenses increased
by approximately $32,771,000, or 100%, to approximately $65,395,000 for the year ended December 31, 2014, compared with approximately
$32,624,000 for year ended December 31, 2013, as a result of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 83%; text-align: justify; text-indent: -10; padding-left: 10">&nbsp;</TD><TD STYLE="width: 5%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center">(000s)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Increase in product research and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">29,668</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Increase in human resource related costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">509</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Increase in sales and marketing, excluding human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">702</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Increase in professional and consulting costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">852</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10; padding-left: 10">Increase in all other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,040</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10; padding-left: 10">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,771</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development
costs for the year ended December 31, 2014 increased by approximately $29,668,000, or 219%, to approximately $43,219,000, primarily
as a result of the continuing phase 3 clinical trial of TX-001HR, the partial year phase 3 clinical trial for TX-002HR, and phase
1 and partial year phase 3 clinical trial for TX-004HR. Research and developments costs during the year ended December 31, 2014
included the following research and development projects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2014 and the period February 2013 (project inception) through December 31, 2014, we have incurred
approximately $26,123,000 and $30,932,000, respectively, in research and development costs with respect to TX-001HR, our
combination estradiol and progesterone drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year
ended December 31, 2014 and the period April 2013 (project inception) through December 31, 2014, we have incurred approximately
$1,443,000 and $2,502,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only
drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year
ended December 31, 2014 and since the project&rsquo;s inception in August 2014, we have incurred approximately $3,984,000 in research
and development costs with respect to TX-004HR, our vaginal suppository estradiol drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For a discussion of the
nature of efforts and steps necessary to complete these projects, see &ldquo;Item 1. Business &mdash; Research and Development.&rdquo;
For a discussion of the risks and uncertainties associated with completing development of our products, see &ldquo;Item 1A. Risk
Factors &mdash; Risks Related to Our Business.&rdquo; For a discussion of the extent and nature of additional resources that we
may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &ldquo;&mdash; Liquidity
and Capital Resources.&rdquo; For a discussion as to whether a future milestone such as completion of a development phase, date
of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &ldquo;Item 1. Business
&mdash; Our Hormone Therapy Drug Candidates,&rdquo; &ldquo;Item 1. Business &mdash; Products in Development&rdquo; and &ldquo;Item
1. Business &mdash; Pharmaceutical Regulation.&rdquo; Future milestones, including NDA submission dates, are not easily determinable
as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment
efforts to find eligible subjects for the applicable trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Human resource related
costs, including salaries and benefits, increased by approximately $509,000, or 5%, to approximately $10,870,000, primarily as
a result of an increase in salary and wages and related cost of $1,060,000 associated with additional employees required for our
clinical trials, partially offset by a decrease in amortization of non-cash compensation totaling approximately $551,000 related
to employee stock options issued during 2014 as compared to 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales and marketing costs
increased approximately $702,000, or 14%, to approximately $5,717,000, primarily as a result of expanded marketing, advertising,
education, and training. Many of these incurred added costs were associated with our new prenatal products introduced in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Professional and consulting
costs increased approximately $852,000, or 67%, to approximately $2,368,000 as a result of additional costs incurred for legal,
consulting, and regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All other costs increased
approximately $1,040,000, or 48%, to approximately $3,221,000 as a result of additional costs incurred for rent, travel, corporate
communications, insurance, and contract labor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Operating Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
our operating loss increased approximately $28,233,000, or 109%, to approximately $54,041,000 for the year ended December 31, 2014,
compared with approximately $25,808,000 for the year ended December 31, 2013, primarily as a result increased research and development
costs associated with our continued development of our hormone therapy drug candidates, partially offset by increased revenue from
sales of our prenatal vitamin products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the continued
development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future
until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we
will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Financing Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financing costs decreased
approximately $1,244,000, or 83%, to approximately $260,000 for the year ended December 31, 2014, compared with approximately $1,504,000
for the year ended December 31, 2013, primarily as a result of the amortization of the costs associated with warrants granted in
2013 in connection with a $10,000,000 revolving line of credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We did not incur interest
expense for the year ended December 31, 2014, compared with approximately $1,166,000 in interest expense incurred for the year
ended December 31, 2013, as a result of the retirement of our debt during 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Net Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the net
effects of the foregoing, net loss increased approximately $25,798,000, or 91%, to approximately $54,217,000 for the year ended
December 31, 2014, compared with approximately $28,419,000 for the year ended December 31, 2013. Net loss per share of common stock,
basic and diluted, was ($0.36) for the year ended December 31, 2014, compared with ($0.22) per share of common stock for the year
ended December 31, 2013. Net loss per share of common stock was positively affected by our issuance of shares of common stock in
an underwritten public offering in August 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Year ended December 31, 2013 compared with
year ended December 31, 2012</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center; border-bottom: Black 1pt solid">(000s)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%; text-align: justify; padding-left: 10; text-indent: -10">Revenue</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,776</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,818</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,958</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Cost of goods sold</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10; padding-left: 10">Operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,624</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,618</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,006</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt; text-indent: -10">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,148</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,660</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Financing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,504</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,504</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,905</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">739</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Other income (expense) net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10; padding-bottom: 1pt">Beneficial conversion feature</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(6,717</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,717</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10; padding-left: 10">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(28,419</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(35,120</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,701</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Revenue for the year ended
December 31, 2013 increased by approximately $4,958,000, or 130%, to $8,776,000, compared with the year ended December 31, 2012.
Of this $4,958,000, approximately $713,000, or 14%, was attributable to an increase in the average sales price of our existing
products, and approximately $4,245,000, or 86%, was attributable to sales of new products introduced in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cost of goods sold increased
by approximately $612,000, or 45%, to $1,960,000 for the year ended December 31, 2013, compared with the year ended December 31,
2012. Our gross margins increased to 78% in 2013 compared to 65% in 2012. The gross margin change was primarily attributable to
the increase in average sales price of products sold and product mix of prescription and OTC products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Operating Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">Our
principal operating costs included the following items as a percentage of total operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended <BR>December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: justify; padding-left: 10; text-indent: -10">Human resource related costs</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">33</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">39</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Sales and marketing, excluding human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Production design and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Professional fees and consulting costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Other operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">Operating
expenses increased by approximately $14,006,000, or 75%, for the year ended December 31, 2013 from year ended December 31, 2012
as a result of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 83%; text-align: justify; text-indent: -10; padding-left: 10">&nbsp;</TD><TD STYLE="width: 5%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center">(000s)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Increase in product research and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,059</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Increase in human resource related costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,333</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Increase in sales and marketing costs, excluding human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">582</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Increase in professional and consulting costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10; padding-left: 10">Increase in all other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">953</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: -10; padding-left: 10">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,006</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development
costs increased by approximately $9,059,000, or 202%, to approximately $13,551,000, primarily as a result of the commencement of
phase 3 clinical trials for TX-001HR as well as the preparation of phase 3 clinical trials for TX-002HR, and phase 3 clinical trials
for TX-004HR. Research and developments costs during the year ended December 31, 2013 included the following research and development
projects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-001HR. Since the project&rsquo;s
inception in February 2013, we have incurred approximately $4,809,000 in research and development costs with respect to TX-001HR,
our combination estradiol and progesterone drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">TX-002HR. Since the project&rsquo;s
inception in April 2013, we have incurred approximately $1,059,000 in research and development costs with respect to TX-002HR, our
progesterone only drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For a discussion of the
nature of efforts and steps necessary to complete these projects, see &ldquo;Item 1. Business &mdash; Research and Development.&rdquo;
For a discussion of the risks and uncertainties associated with completing development of our products, see &ldquo;Item 1A. Risk
Factors &mdash; Risks Related to Our Business.&rdquo; For a discussion of the extent and nature of additional resources that we
may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &ldquo;&mdash; Liquidity
and Capital Resources.&rdquo; For a discussion as to whether a future milestone such as completion of a development phase, date
of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &ldquo;Item 1. Business
&mdash; Our Hormone Therapy Drug Candidates,&rdquo; &ldquo;Item 1. Business &mdash; Products in Development&rdquo; and &ldquo;Item
1. Business &mdash; Pharmaceutical Regulation.&rdquo; Future milestones, including NDA submission dates, are not easily determinable
as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment
efforts to find eligible subjects for the applicable trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Human resource related
costs, including salaries and benefits, increased by approximately $3,333,000, or 46%, to approximately $10,611,000, primarily
as a result of an increase in amortization of non-cash compensation totaling approximately $3,152,000 related to employee stock
options issued during 2013 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales and marketing costs
increased by approximately $582,000, or 13%, to approximately $5,015,000, primarily as a result of expanded marketing, advertising,
education, and training. In addition, we increased spending in the areas of travel, product samples, and commissions. We also incurred
added costs associated with our new product distribution channels introduced in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Operating Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
our operating loss increased approximately $9,660,000, or 60%, to approximately $25,808,000 for the year ended December 31, 2013,
compared with approximately $16,148,000 for the year ended December 31, 2012, primarily as a result increased research and development
costs associated with our continued development of our hormone therapy drug candidates, partially offset by increased revenue from
sales of our prenatal vitamin products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the continued
development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future
until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we
will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Financing Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financing costs increased
from $0, to approximately $1,504,000, resulting from the amortization of costs associated with warrants granted in 2013 in connection
with a $10,000,000 revolving line of credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Interest Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest expense decreased
approximately $739,000, or 39%, to approximately $1,166,000, primarily as a result of the retirement of debt issued during 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Net Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of
the net effects of the foregoing, including a lack of charges in 2013 for loss on extinguishment of debt and a beneficial
conversion feature of debt that were included in our 2012 results, net loss decreased approximately $6,701,000, or 19%, to
approximately $28,419,000 for the year ended December 31, 2013, compared with approximately $35,120,000 for the year ended
December 31, 2012. Net loss per share of common stock, basic and diluted, was ($0.22) for the year ended December 31, 2013,
compared with ($0.38) per share of common stock for the year ended December 31, 2012. Net loss per share of common stock was
positively affected by our issuance of shares of common stock in underwritten public offerings in March and September
2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Liquidity and Capital Resources</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have funded our operations
primarily through the private placement of equity and debt securities, and public offerings of our common stock. For the three
year period ending December 31, 2014, we received $9 million in net proceeds from the issuance of debt securities and $130 million
in net proceeds from the issuance of shares of our common stock. As of December 31, 2014, we had cash totaling
approximately $51.4 million: however, changing circumstances may cause us to consume funds significantly faster than we currently
anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe that our existing cash will allow us to fund our operating plan through at least the next 12 months.
If our available cash and cash equivalents is insufficient to satisfy our liquidity requirements, we may seek to sell additional
equity or debt securities or obtain a credit facility. Debt financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or
declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
the ownership interest of our existing shareholders will be diluted, and the terms of these new securities may include liquidation
or other preferences that adversely affect the rights of our existing shareholders. If we raise additional funds through collaborations,
strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs, or proposed products. Additionally, we may have to grant licenses on terms that may
not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
need substantial amounts of cash to complete the clinical development of our hormone therapy drug candidates. The following table
sets forth the primary sources and uses of cash for each of the periods set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Summary of (Uses) and Sources of
Cash</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%; text-align: justify; padding-left: 10; text-indent: -10">Net cash flows used in operating activities</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(45,520,996</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(20,768,069</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(12,737,326</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Net cash flows used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(606,756</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(583,561</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(272,506</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">Net cash flows provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43,298,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">73,989,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,436,885</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I></I></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
use of cash in all periods resulted primarily from our net loss adjusted for non-cash charges and changes in components of working
capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The increase of approximately
$25 million in cash used in operating activities for the year ended December 31, 2014 in comparison to the year ended December
31, 2013 was due primarily to research and development, sales, general and administrative costs. These were offset by an approximately
$6 million increase in sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The increase of approximately
$8 million in cash used in operating activities for the year ended December 31, 2013 in comparison to the year ended December 31,
2012 was due primarily to research and development, sales, general and administrative costs. These were offset by an approximately
$9 million increase in sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Investing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The increase of approximately
$23,000 in cash used in investing activities for the year ended December 31, 2014 compared with the prior year was due to patent
development costs and purchase of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The increase of approximately
$311,000 in cash used in investing activities for the year ended December 31, 2013 compared with the prior year was due to patent
development costs and purchase of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">Financing
activities represent the principal source of our cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
financing activities for the year ended December 31, 2014 provided net cash of approximately $43,298,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 29, 2014, we
entered into an underwriting agreement relating to the issuance and sale by us of 8,565,310 shares of our common stock. Under
the terms of the underwriting agreement, we granted the underwriters a 30-day option to purchase up to an additional
1,284,796 shares of our common stock, which was exercised in full on July 30, 2014. The offering closed on August 4, 2014.
The net proceeds to us from this offering were approximately $42.8 million, after deducting underwriting discounts and
commissions and other offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
financing activities for the year ended December 31, 2013 provided net cash of approximately $73,989,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 14, 2013, we entered
into an underwriting agreement relating to the issuance and sale by us of 29,411,765 shares of our common stock. Under the terms
of the underwriting agreement, we granted the underwriters a 30-day option to purchase up to an additional 4,411,765 shares of
our common stock. On April 12, 2013, the underwriters exercised their option to purchase 1,954,587 shares of our common stock.
The net proceeds to us from this offering were approximately $48 million, after deducting underwriting discounts and commissions
and other offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 25, 2013,
we entered into an underwriting agreement relating to the issuance and sale by us of 13,750,000 shares of our common stock. The
net proceeds to us from this offering were approximately $30 million, after deducting underwriting discounts and commissions and
other offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">In
March 2013, we repaid approximately $5 million in notes and credit lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
financing activities for the year ended December 31, 2012 provided net cash of approximately $14,437,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2012, we entered
into a securities purchase agreement with multiple investors, relating to the issuance and sale of
our common stock in a private placement that provided us with approximately $8 million in net proceeds. During 2012, we issued
notes in the aggregate principal amount of approximately $9 million to multiple parties, of which approximately $2 million was
repaid during 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Critical Accounting Estimates and New
Accounting Pronouncements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Critical Accounting Estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in accordance with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates
and assumptions that affect reported amounts and related disclosures in the financial statements. We consider an accounting estimate
to be critical if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">it requires assumptions to be made that were uncertain at the time the estimate was made, and</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">changes
in the estimate or different estimates that could have been selected could have a material &#9;impact on our results of operations
or financial condition.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
base our estimates and judgments on our experience, our current knowledge, our beliefs of what could occur in the future, our observation
of trends in the industry, information provided by our customers, and information available from other sources. Actual results
may differ from these estimates under different assumptions or conditions. We have identified the following accounting policies
and estimates as those that we believe are most critical to our financial condition and results of operations and that require
our most subjective and complex judgments in estimating the effect of inherent uncertainties: share-based compensation expense
and income taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Revenue
Recognition</I>. We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only
when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability
is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation
and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers
of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products
pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support
team utilizing similar marketing techniques.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white"><I><U>Over-the-Counter
Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when
the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in sales and
bill them upon shipment. We include shipping expenses in cost of sales. A majority of our customers pay for our products with credit
cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable
balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from
our retail and eCommerce customers. We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white"><I><U>Prescription
Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue
from prescription product sales, net of sales discounts, chargebacks, and rebates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We accept returns of
unsalable product from customers within a return period of six months prior to and up to 12 months following product
expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. Given the
limited history of our prescription products, we currently cannot reliably estimate expected returns of the prescription
products at the time of shipment. Accordingly, we defer recognition of revenue on prescription products until the right of
return no longer exists, which occurs at the earlier of the time the prescription products are dispensed through patient
prescriptions or expiration of the right of return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer
loyalty. The consumer rebate program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send
a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages, which
is reviewed, and adjusted if necessary, on a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Research and Development
Expense.</I> We rely on the services of external CRO&rsquo;s to facilitate our clinical studies. Certain of these CRO&rsquo;s require
us to make payments based on agreed-upon terms, which may include payments in advance of a study starting date. We capitalize these
advance payments into prepaid expense when paid. We expense these nonrefundable advance payments for goods and services that will
be used in future research and development activities when the activity has been performed rather than when the payment is made.
As a result, we amortize certain of these amounts based on factors relating to the progress of our clinical studies. These factors
include successful enrollment of patients, expected duration of studies, and completion of clinical trial milestones. On a quarterly
basis we re-assess the factors by which these advanced payments are expensed. If these factors change we adjust these prepaid balances
accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Share-Based Compensation.</I>
We periodically issue stock options and warrants to employees and non-employees in non-capital raising transactions for services
and for financing costs. We account for stock option and warrant grants issued and vesting to employees based on the authoritative
guidance provided by the Financial Accounting Standards Board, or FASB, whereas the value of the awards are measured on the date
of grant and recognized over the vesting period. We account for stock option and warrant grants issued and vesting to non-employees
in accordance with the authoritative guidance of the FASB whereas the value of the stock compensation is based upon the measurement
date as determined at either (a) the date at which a performance commitment is reached, or (b) at the date at which the necessary
performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over
the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the
non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the
measurement date. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating
the expected term that stock options and warrants will be outstanding prior to exercise and the associated volatility. We estimate
the fair value of options granted using the Black-Scholes-Merton valuation model. The expected life of the options used in this
calculation is the period the options are expected to be outstanding and has been determined based on the simplified method in
accordance with guidance provided by SEC Staff Accounting Bulletin 07 (ASC 718-10-S00). Expected stock price volatility is based
on the historical volatility of the stock of peer entities whose stock prices were publicly available for a period approximating
the expected life. We use the historical volatility of peer entities due to the lack of sufficient historical data on our stock
prices. The risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the
expected life. We believe that these assumptions are &ldquo;critical accounting estimates&rdquo; because significant changes in
the assumptions used to develop the estimates materially affect key financial measures including net income/(loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Income
Taxes.</I> As part of the process of preparing our consolidated financial statements, we are required to estimate income taxes
in each of the jurisdictions in which we operate. We determine provision for income taxes using the asset and liability approach
to account for income taxes. We record current liability for the estimated taxes payable for the current year. We record deferred
tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured
using the enacted tax rates in effect for the year in which the timing differences are expected to be recovered or settled. The
effect on deferred tax assets and liabilities of changes in tax rates or tax laws is recognized in the provision for income taxes
in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets
to the amount more-likely-than-not to be realized. Changes in valuation allowances will flow through the statement of operations
unless related to deferred tax assets that expire unutilized or are modified through translation, in which case both the deferred
tax asset and related valuation allowance are similarly adjusted. Where a valuation allowance was established through purchase
accounting for acquired deferred tax assets, any future change will be credited or charged to income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
determination of our provision for income taxes requires significant judgment, the use of estimates, and the interpretation and
application of complex tax laws. In the ordinary course of our business, there are transactions and calculations for which the
ultimate tax determination is uncertain. In spite of our belief that we have appropriate support for all the positions taken on
our tax returns, we acknowledge that certain positions may be successfully challenged by the taxing authorities. We determine the
tax benefits more likely than not to be recognized with respect to uncertain tax positions. Although we believe our recorded tax
assets and liabilities are reasonable, tax laws and regulations are subject to interpretation and inherent uncertainty; therefore,
our assessments can involve both a series of complex judgments about future events and rely on estimates and assumptions. Although
we believe these estimates and assumptions are reasonable, the final determination could be materially different than that which
is reflected in our provision for income taxes and recorded tax assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Segment Reporting. </I>We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to our president. We do not operate separate lines
of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products.
All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>New Accounting Pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2014, the FASB
issued Accounting Standards Update, or ASU, No. 2014-05, Presentation of Financial Statements-Going Concern (Subtopic 205-40):
Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to
evaluate whether there are conditions and events that raise substantial doubt about the entity&rsquo;s ability to continue as a
going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so,
disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual
periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial
statements have not previously been issued. We do not expect the adoption of the ASU 2014-15 to have a material effect on our consolidated
financial statements and disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2014, the FASB and
the International Accounting Standards Board (IASB) issued ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606).
The standard&rsquo;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.
In doing so, companies will need to use more judgment and make more estimates than under today&rsquo;s guidance. These may include
identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction
price and allocating the transaction price to each separate performance obligations. ASU 2014-09 is effective for public business
entities, certain not-for-profit entities and certain employee benefit plans, for annual periods beginning after December 15, 2016,
including interim periods within that period. Early adoption is not permitted under GAAP. We are currently evaluating the impact
of ASU 2014-09 on our consolidated financial statements and disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2013, the FASB
issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward,
a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The
amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating
loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in
the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a
tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial
statements as a liability. The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11
are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU
No. 2013-11 did not have a material impact on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In
December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities,
or ASU 2011-11. ASU 2011-11 enhances current disclosures about financial instruments and derivative instruments that are either
offset on the statement of financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective
of whether they are offset on the statement of financial position. Entities are required to provide both net and gross information
for these assets and liabilities in order to facilitate comparability between financial statements prepared in conformity with
GAAP and financial statements prepared on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for
annual reporting periods beginning on or after January 1, 2013, and interim periods within those years. ASU 2011-11 did not have
a material impact on our financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently
issued, but not yet effective, accounting standards been adopted in the current period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Off-Balance Sheet Arrangements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
2013, and 2012, we had no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect
on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures
or capital resources that are material to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the ordinary course
of business, we enter into agreements with third parties that include indemnification provisions, which, in our judgment, are normal
and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and
suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for
losses suffered or incurred by the indemnified parties with respect to our drug candidates, use of such drug candidates, or other
actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification
provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification
provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have
no liabilities recorded for these provisions as of December 31, 2014, 2013, or 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the normal course of
business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits,
claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts
to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by GAAP, an estimate is made of the loss
and the appropriate accounting entries are reflected in our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effects of Inflation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For each of the fiscal
years ended December 31, 2014, 2013, and 2012, our business and operations have not been materially affected by inflation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contractual Obligations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">A
summary of contractual cash obligations as of December 31, 2014 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Payments Due By Period</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center">(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Less than 1 Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1-3 Years</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">4-5 Years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 29%; text-align: left; text-indent: -10; padding-left: 10; padding-bottom: 2.5pt">Operating Lease Obligations</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right">1,450</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right; border-bottom: Black 2.5pt double">$</TD>
    <TD STYLE="width: 14%; text-align: right; border-bottom: Black 2.5pt double; padding-left: 5.4pt">371</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right">1,079</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right">0</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: yellow"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Seasonality</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
specialty pharmaceutical industry component of women&rsquo;s health is not subject to seasonal sales fluctuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7A.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><A NAME="a_011"></A>Quantitative and Qualitative Disclosures about Market Risk</B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
had cash and cash equivalents totaling $51.4 million as of December 31, 2014<FONT STYLE="color: #252525">. </FONT>We hold our
cash in money market funds and the primary objective of our investment policy is to preserve principal and maintain proper liquidity
to meet operating needs<FONT STYLE="color: #252525">. </FONT>Our investment policy specifies credit quality standards for our
investments and limits the amount of credit exposure to any single issue, issuer or type of investment<FONT STYLE="color: #252525">.
</FONT>Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of
U.S. interest rates<FONT STYLE="color: #252525">. </FONT>To minimize this risk, we intend to maintain a portfolio that may include
cash, cash equivalents and investment securities available-for-sale in a variety of securities which may include money market
funds, government and non-government debt securities and commercial paper, all with various maturity dates<FONT STYLE="color: #252525">.
</FONT>Due to the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a
material effect on the fair market value of our portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes.
Further, we do not believe our cash equivalents and investment securities have significant risk of default or illiquidity. We made
this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash equivalents
and investment securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments
will not be subject to adverse changes in market value. All of our investments are held at fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_012"></A>Financial Statements and Supplementary Data</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Reference
is made to the financial statements, the notes thereto, and the report thereon, commencing on page F-1 of this Annual Report, which
financial statements, notes, and report are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_013"></A>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9A.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_014"></A>Controls and Procedures</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Evaluation of Disclosure Controls and Procedures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We maintain disclosure
controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act is
recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated
to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding
required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management, with the
participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls
and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(f) or 15d-15(f)) as of the end of the period covered
by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded
that, as of December 31, 2014, our disclosure controls and procedures were effective to ensure that information required to be
disclosed by us in the reports we file or submit under the Exchange Act is (i) recorded, processed, summarized, and reported within
the time periods specified in the SEC rules and forms, and (ii) is accumulated and communicated to our management, including our
Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Management&rsquo;s Annual Report on Internal
Control over Financial Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f)
and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal
control over financial reporting includes those policies and procedures that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the
transactions and dispositions of our assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">provide reasonable assurance that transactions are recorded as necessary to permit preparation
of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are
being made only in accordance with authorizations of our management and directors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use, or disposition of our assets that could have a material effect on the financial statements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management assessed
the effectiveness of our internal control over financial reporting as of December 31, 2014. In making this assessment, our management
used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&mdash;Integrated
Framework (2013). Management&rsquo;s assessment included an evaluation of the design of our internal control over financial reporting
and testing of the operational effectiveness of its internal control over financial reporting. Based on management&rsquo;s assessment,
we believe that our internal controls over financial reporting were effective as of December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Rosenberg Rich Baker Berman
&amp; Company, an independent registered public accounting firm, has audited the consolidated financial statements included in
this Annual Report; and, as part of its audit, has issued an attestation report, included herein, on the effectiveness of our internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Changes in Internal Control over Financial
Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There was no change in
our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably
likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Inherent Limitations on Effectiveness of
Controls</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management, including
our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal
controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect
the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of
the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues,
misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further,
internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance
with policies or procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9B.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_015"></A>Other Information</I></B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_016"></A>PART III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 10.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_017"></A>Directors, Executive Officers, and Corporate
Governance</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required by this Item relating
to our directors and corporate governance is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant
to Regulation 14A of the Exchange Act for our 2015 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 11.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_018"></A>Executive Compensation</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the
Exchange Act for our 2015 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 12.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_019"></A>Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I></I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated by reference to the definitive Proxy Statement to be filed pursuant to Regulations 14A of the Exchange
Act for our 2015 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 13.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_020"></A>Certain Relationships and Related Transactions,
and Director Independence</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the
Exchange Act for our 2015 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 14.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_021"></A>Principal Accountant Fees and Services</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regular 14A of the Exchange
Act for our 2015 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_022"></A>PART IV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 15.</B></P>

</TD>
    <TD STYLE="width: 90%"><B><I><A NAME="a_023"></A>Exhibits and Financial Statement Schedules</I></B></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">(a)&#9;<B>Financial Statements and Financial Statements
Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">Financial Statements are listed in the Index to Consolidated Financial Statements on page F-1 of
this Annual Report.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">No financial statement schedules are included because such schedules are not applicable, are not
required, or because required information is included in the consolidated financial statements or notes thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b)&#9;<B>Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><B>Exhibit</B></P></TD>
    <TD STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><B>Date</B></P></TD>
    <TD STYLE="width: 68%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">2.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">July 6, 2009</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Agreement and Plan of Reorganization among Croff Enterprises, Inc., AMHN Acquisition Corp., America&rsquo;s Minority Health Network, Inc., and the Major Shareholders<SUP>(1)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">2.2</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">June 11, 2010</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Agreement and Plan of Reorganization among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health Network, Inc.<SUP>(2)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">2.3</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">October 25, 2007</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization<SUP>(3)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">2.4</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">July 18, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Agreement and Plan of Merger among VitaMedMD, LLC, AMHN, Inc., and VitaMed Acquisition, LLC<SUP>(4)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">3.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">September 15, 2009</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Articles of Amendment to Articles of Incorporation (to change name to AMHN, Inc.)<SUP>(5)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">3.2</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">July 27, 2009</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Certificate of Merger of AMHN Acquisition Corp., with and into America&rsquo;s Minority Health Network, Inc.<SUP>(6)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">3.3</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">December 27, 2007</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Articles of Amendment to Articles of Incorporation of Croff Enterprises, Inc. (to increase authorized common shares from 20,000,000 to 50,000,000)<SUP>(3)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">3.4</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">July 20, 2010</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Articles of Conversion of AMHN, Inc. filed in the State of Nevada<SUP>(7)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">3.5</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">July 20, 2010</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Articles of Incorporation of AMHN, Inc. filed in the State of Nevada<SUP>(7)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">3.6</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">August 29, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Certificate of Amendment and Restatement of Articles of Incorporation of AMHN, Inc. (to change name and increase authorized shares)<SUP>(8)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">3.7</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Bylaws of AMHN, Inc.<SUP>(9)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">4.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">September 26, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Securities Purchase Agreement<SUP> (10)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">4.2</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Certificate of Common Stock<SUP>(11)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">November 9, 2010</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Demand Promissory Note to Philip M. Cohen for $210,000<SUP>(12)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.2</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">April 18, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Convertible Promissory Note to First Conquest Investment Group, L.L.C. for $105,000<SUP>(12)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.3</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">April 18, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Convertible Promissory Note to Energy Capital, LLC for $105,000<SUP>(12)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.4</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">May 7, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Sales Representative Agreement between AMHN, Inc. and Mann Equity, LLC<SUP>(12)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.5</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">July 9, 2009</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Lease Agreement between Liberty Property Limited Partnership and VitaMedMD, LLC<SUP>(13)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.6</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">September 8, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Stock Purchase Agreement between AMHN, Inc. and Pernix Therapeutics, LLC<SUP>(14)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.7</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">September 8, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Lock-Up Agreement between AMHN, Inc. and Pernix Therapeutics, LLC<SUP>(14)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.8</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Common Stock Purchase Warrant<SUP> (13)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.9*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Non-Qualified Stock Option Agreement<SUP> (13)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.10</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">September 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Convertible Promissory Note<SUP>(15)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.11</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">September 20, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Financing Agreement between Lang Naturals, Inc. and VitaMedMD, LLC<SUP>(16)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.12</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">October 18, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Debt Conversion Agreement between the Company and Energy Capital, LLC<SUP>(17)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.13</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">October 18, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Debt Conversion Agreement between the Company and First Conquest Investment Group, LLC<SUP>(17)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.14</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">October 23, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Consulting Agreement among VitaMedMD, LLC, the Company, and Lang Naturals, Inc.<SUP>(17)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.15</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">October 23, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Common Stock Purchase Warrant to Lang Naturals, Inc.<SUP>(17)</SUP></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 11%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><B>Exhibit</B></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 21%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><B>Date</B></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><B>Description</B></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; width: 11%">10.16</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; width: 21%">October 23, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; width: 68%">Lock-Up Agreement between the Company and Lang Naturals, Inc. <SUP>(17)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.17</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">November 3, 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Software License Agreement between vitaMedMD, LLC and Pernix Therapeutics, LLC<SUP>(18)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.18</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">November 2011</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Promissory Note<SUP> (19)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.19</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">February 24, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Note Purchase Agreement among the Company, Plato &amp; Associates, Inc., and Steven G. Johnson<SUP>(20)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.20</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">February 24, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Secured Promissory Note<SUP>(20)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.21</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">February 24, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Security Agreement among the Company, Plato &amp; Associates, Inc., and Steven G. Johnson<SUP>(20)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.22</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">February 24, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Common Stock Purchase Warrant<SUP>(20)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.26</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">April 17, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Master Services Agreement between the Company and Sancilio and Company, Inc.<SUP>(21)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.27**</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">May 17, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Consulting Agreement between the Company and Sancilio and Company, Inc.<SUP> (21)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.28*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">November 8, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Form of Employment Agreement<SUP>(22)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.29</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">January 31, 2013</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Multiple Advance Revolving Credit Note, issued to Plato &amp; Associates, LLC<SUP>(23)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.30</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">January 31, 2013</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Common Stock Purchase Warrant, issued to Plato &amp; Associates, LLC<SUP>(23)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.31*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">May 8, 2013</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Agreement to Forfeit Non-Qualified Stock Options between the Company and Robert G. Finizio<SUP>(24)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.32</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">May 7, 2013</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Consulting Agreement between the Company and Sancilio and Company, Inc.<SUP> (24)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">10.33</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">May 16, 2013</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Lease between the Company and 6800 Broken Sound LLC<SUP>(25)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">10.34*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Amended and Restated 2012 Stock Incentive Plan<SUP>(26)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">10.35*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">2009 Long Term Incentive Compensation Plan, as amended<SUP>(27)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">10.36&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">February 18, 2015</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><A HREF="ex10-36.htm">First Amendment to Lease between the Company and 6800 Broken Sound, LLC</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">21.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">December 31, 2012</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Subsidiaries of the Company<SUP>(28)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">23.1&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">March 12, 2015</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex23-1.htm">Consent of Rosenberg Rich Baker Berman &amp; Company</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">31.1&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">March 12, 2015</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><BR CLEAR="ALL">
 31.2&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">March 12, 2015</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">32.1&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">March 12, 2015</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex32-1.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">32.2&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">March 12, 2015</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex32-2.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">101.INS&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">XBRL Instance Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">101.SCH&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">101.CAL&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">101.DEF&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">XBRL Taxonomy Extension Definition Linkbase Instance Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">101.LAB&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">XBRL Taxonomy Extension Label Linkbase Instance Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">101.PRE&dagger;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">n/a</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">XBRL Taxonomy Extension Presentation Linkbase Instance Document</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">*</TD><TD STYLE="text-align: justify; width: 95%">Indicates a contract with management or compensatory plan or arrangement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">**</TD><TD STYLE="text-align: justify; width: 95%">Certain information in this exhibit has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">&dagger;</TD><TD STYLE="text-align: justify; width: 95%">Filed herewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><SUP>&nbsp;&nbsp;</SUP></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"><SUP>(1)</SUP></TD><TD STYLE="text-align: justify; width: 95%">Filed as an exhibit to Form 8-K filed with the Commission on July 10, 2009 and incorporated herein by reference (SEC File
No. 000-16731).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"><SUP>(2)</SUP></TD><TD STYLE="text-align: justify; width: 95%">Filed as an exhibit to Form 8-K filed with the Commission on June 14, 2010 and incorporated herein by reference (SEC File
No. 000-16731).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"><SUP>(3)</SUP></TD><TD STYLE="text-align: justify; width: 95%">Filed as an exhibit to Form 10-K for the year ended December 31, 2007 filed with the Commission on May 1, 2008 and incorporated
herein by reference (SEC File No. 000-16731).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"><SUP>(4)</SUP></TD><TD STYLE="text-align: justify; width: 95%">Filed as an exhibit to Form 8-K filed with the Commission on July 21, 2011 and incorporated herein by reference (SEC File
No. 000-16731).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"><SUP>(5)</SUP></TD><TD STYLE="text-align: justify; width: 95%">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2009 filed with the Commission on November 16, 2009
and incorporated herein by reference (SEC File No. 000-16731).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(6)</SUP></FONT></TD>
    <TD STYLE="width: 95%; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-K for the year ended December 31, 2009 filed with the Commission on March 17, 2010 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(7)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2010 filed with the Commission on August 3, 2010 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(8)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on September 12, 2011 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(9)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on June 29, 2010 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(10)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on October 2, 2012 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(11)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form S-3 filed with the Commission on January 25, 2013 and incorporated hereby by reference (SEC File No. 333-186189).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(12)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for quarter ended March 31, 2011 filed with the Commission on May 19, 2011 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(13)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on October 11, 2011 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(14)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on September 14, 2011 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(15)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K/A filed with the Commission on November 22, 2011 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(16)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K/A filed with the Commission on February 2, 2012 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(17)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on October 24, 2011 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(18)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2011 filed with the Commission on November 7, 2011 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(19)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on November 23, 2011 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(20)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on February 24, 2012 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(21)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2012 filed with the Commission on August 9, 2012 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(22)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2012 filed with the Commission on November 13, 2012 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(23)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on February 6, 2013 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(24)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for quarter ended March 31, 2013 filed with the Commission on May 10, 2013 and incorporated herein by reference (SEC File No. 001-00100).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(25)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2013 filed with the Commission on August 7, 2013 and incorporated herein by reference (SEC File No. 001-00100).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(26)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on August 22, 2013 and incorporated herein by reference (SEC File No. 001-00100).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(27)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Registration Statement on Form S-8 filed with the Commission on October 15, 2013 and incorporated herein by reference (SEC File No. 333-191730).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(28)</SUP></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-K for the year ended December 31, 2012 filed with the Commission on March 12, 2013 and incorporated herein by reference (SEC File No. 000-16731).</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 45%">Date: March 12, 2015&#9;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 50%">THERAPEUTICSMD,
INC.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt"></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/<I>s</I>/<I> Robert G. Finizio</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Robert G. Finizio</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the date indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Signature</U></B></FONT></TD>
    <TD STYLE="width: 41%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Capacity</U></B></FONT></TD>
    <TD STYLE="width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Date</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Robert G. Finizio</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, Director</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
12, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert G. Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ John C.K. Milligan, IV</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President, Secretary, Director</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 12, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">John C.K. Milligan, IV</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Daniel A. Cartwright</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Chief Financial Officer, Treasurer&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Principal Financial and Accounting Officer)</P></TD>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 12, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Daniel A. Cartwright</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Tommy G. Thompson</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Chairman</P></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tommy G. Thompson</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 12, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Brian Bernick</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Director</P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 12, 2015</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Brian Bernick</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Cooper C. Collins</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Director</P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 12, 2015</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cooper C. Collins</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Robert V. LaPenta, Jr.</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Director</P></TD>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 12, 2015</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert V. LaPenta, Jr.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR><TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 35%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
                                                                                                                                     Nicholas Segal</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Director</P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; width: 24%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 12, 2015</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nicholas
    Segal</FONT></TD></TR></TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 35%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 41%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 24%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
                                                                                                                                     Jules Musing </I></FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Director</P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 12, 2015</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jules
Musing</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Randall Stanicky</I></FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Director</P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 12, 2015</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Randall Stanicky</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INDEX TO FINANCIAL STATEMENTS</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 85%; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Page</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="line-height: 107%">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ReportofPAF">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#CONSOLIDATED">Consolidated Balance Sheets as of December 31, 2014 and 2013</A></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#STATEMENTS">Consolidated Statements of Operations for the years ended December 31, 2014, 2013 and 2012</A></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%; padding-left: 10; text-indent: -10"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_0033">Consolidated
    Statements of Stockholders' (Deficit) Equity for the years ended December 31, 2014, 2013 and 2012</A></FONT></TD>
    <TD NOWRAP STYLE="background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#CASHFLOWS">Consolidated Statements of Cash Flows for the years ended December 31, 2014, 2013 and 2012</A></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#THERAPEUTICSMD">Notes
    to Consolidated Financial Statements</A></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-7</FONT></TD></TR>
</TABLE>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 71; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><A NAME="ReportofPAF" TITLE="Report of PAF"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">To
the Board of Directors and<BR>
Stockholders of TherapeuticsMD, Inc.</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">We
have audited the accompanying balance sheets of TherapeuticsMD, Inc. as of December 31, 2014 and 2013, and the related statements
of operations, stockholders&rsquo; equity, and cash flows for each of the years in the three year period ended December 31, 2014.
We also have audited TherapeuticsMD&rsquo;s internal control over financial reporting as of December 31, 2014, based on criteria
established in <I>Internal Control&mdash;Integrated Framework (2013)</I> issued by the Committee of Sponsoring Organizations of
the Treadway Commission (COSO). TherapeuticsMD&rsquo;s management is responsible for these financial statements, for maintaining
effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial
reporting, included in the accompanying Management&rsquo;s Annual Report on Internal Control over Financial Reporting. Our responsibility
is to express an opinion on these financial statements and an opinion on the company&rsquo;s internal control over financial reporting
based on our audits.</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are
free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating
the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding
of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the
design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other
procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">A
company&rsquo;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company&rsquo;s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&rsquo;s
assets that could have a material effect on the financial statements.</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of TherapeuticsMD,
Inc. as of December 31, 2014 and 2013, and the results of its operations and its cash flows for each of the years in the three
year period ended December 31, 2014, in conformity with accounting principles generally accepted in the United States of America.
Also in our opinion, TherapeuticsMD, Inc. maintained, in all material respects, effective internal control over financial reporting
as of December 31, 2014, based on criteria established in <I>Internal Control&mdash;Integrated Framework (2013)</I> issued by
the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">/s/
Rosenberg Rich Baker Berman &amp; Company</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Somerset,
New Jersey</FONT></P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">March
12, 2015</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="73" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><A NAME="CONSOLIDATED"></A>THERAPEUTICSMD, INC. AND SUBSIDIARIES</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="73" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">CONSOLIDATED BALANCE SHEETS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="73" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">ASSETS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Cash</TD><TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">51,361,607</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">54,191,260</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accounts receivable, net of allowance for doubtful accounts&nbsp;of $21,119 and $26,555, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,154,217</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,690,753</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,182,113</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,043,618</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,537,407</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,477,715</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">56,235,344</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">59,403,346</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Fixed assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,293</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">61,318</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Prepaid expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,427,263</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,750,455</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,228,588</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">665,588</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Security deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">125,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,686</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,780,851</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,551,729</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">59,079,488</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">62,016,393</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;LIABILITIES AND STOCKHOLDERS' EQUITY</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,327,129</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,114,217</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Deferred revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">522,613</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,602,580</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,840,639</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,601,189</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,690,381</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,317,986</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and Contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders' Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Common stock - par value $0.001; 250,000,000 shares authorized; 156,097,019 and 144,976,757 issued and outstanding, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">156,097</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">144,977</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Additional paid in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">182,982,846</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">135,086,056</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(134,749,836</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(80,532,626</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">48,389,107</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">54,698,407</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total liabilities and stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">59,079,488</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">62,016,393</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>








<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="29" STYLE="font-weight: bold; text-align: center"><A NAME="STATEMENTS"></A>THERAPEUTICSMD, INC. AND SUBSIDIARIES</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="29" STYLE="font-weight: bold; text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Revenues, net</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15,026,219</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8,775,598</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,818,013</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cost of goods sold</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,671,803</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,959,597</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,348,113</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Gross profit</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11,354,416</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,816,001</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,469,900</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Operating expenses:</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sales, general, and
    administrative</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22,124,072</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19,014,837</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14,069,701</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research and development</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">43,218,938</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13,551,263</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,492,362</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Depreciation and amortization</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">52,467</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">58,145</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">56,260</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
    operating expense</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65,395,477</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32,624,245</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18,618,323</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Operating loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(54,041,061</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(25,808,244</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(16,148,423</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other income and (expense)</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Miscellaneous income</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">46,569</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34,544</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,001</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interest income</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">37,309</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">27,234</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Financing costs</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(260,027</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1,503,922</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interest expense</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1,165,981</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1,905,409</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Loan guaranty costs</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2,944</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(45,036</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Loss on extinguishment
    of debt</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(10,307,864</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Beneficial conversion
    feature</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6,716,504</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
    other expense</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(176,149</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2,611,069</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(18,971,812</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Loss before taxes</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(54,217,210</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(28,419,313</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(35,120,235</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Provision for income
    taxes</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(54,217,210</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(28,419,313</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(35,120,235</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net loss per share,
    basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(0.36</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(0.38</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10; text-indent: -10"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Weighted average number
    of common shares outstanding</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">149,727,228</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">127,569,731</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">91,630,693</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>






<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font-weight: bold; text-align: center"><A NAME="a_0033"></A>THERAPEUTICSMD, INC. AND SUBSIDIARIES</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font-weight: bold; text-align: center">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font-weight: bold; text-align: center">FOR THE YEARS ENDED DECEMBER 31, 2014, 2013 AND 2012</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Additional</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Paid in</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10; text-indent: -10">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; font-weight: bold; padding-left: 10; text-indent: -10">Balance, December 31, 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">82,978,804</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">82,979</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">15,198,241</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(16,993,078</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(1,711,858</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Shares issued in private placement, net of cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,953,489</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,891,531</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,895,485</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Shares issued in exchange for debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,775,415</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,051,882</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,054,657</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10; text-indent: -10">Shares issued for exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,931,788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189,068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10; text-indent: -10">Shares issued for exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,145,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,093,855</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,102,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Employee share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,832,061</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,832,061</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Warrants issued for financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,014,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,014,784</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Warrants issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,563,620</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,563,620</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Warrants issued as compensation-related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,284</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,284</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Warrants issued for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Cancellation of warrants issued for loan guaranty costs-related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,830</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,830</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Beneficial ownership feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,716,504</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,716,504</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,120,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,120,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 10; text-indent: -10">Balance, December 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,784,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,785</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,580,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,113,313</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,433,128</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Shares issued in private placements, net of cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,116,352</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,117</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,605,236</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,650,353</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10; text-indent: -10">Shares issued for exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,835</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,910</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Employee share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,170,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,170,954</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10; text-indent: -10">Non-employee share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Warrants issued for financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,711,956</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,711,956</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Warrants issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">867,262</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">867,262</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Warrants issued as compensation-related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,284</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,284</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,419,313</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,419,313</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 10; text-indent: -10">Balance, December 31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,976,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,086,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(80,532,626</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,698,407</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Shares issued in private placements, net of cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,850,106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,761,503</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,771,353</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10; text-indent: -10">Shares issued for exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">854,573</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">855</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">344,891</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,746</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10; text-indent: -10">Shares issued for exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365,583</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,635</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">181,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Shares issued for exercise of restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Employee share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,239,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,239,358</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10; text-indent: -10">Non-employee share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,453</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,453</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10; text-indent: -10">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(54,217,210</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(54,217,210</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10; text-indent: -10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 10; text-indent: -10">Balance, December 31, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">156,097,019</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">156,097</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">182,982,846</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(134,749,836</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">48,389,107</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><A NAME="CASHFLOWS"></A>THERAPEUTICSMD, INC. AND SUBSIDIARIES</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended December, 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Net loss</TD><TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(54,217,210</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(28,419,313</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(35,120,235</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Adjustments to reconcile net loss to net cash flows used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10; padding-left: 30pt">Depreciation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,987</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">47,883</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,484</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Amortization of intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,262</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,776</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Provision for doubtful accounts</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,436</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(15,493</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,548</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Loss on extinguishment of debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,307,864</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Beneficial conversion feature</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,716,504</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Amortization of debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,102,680</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,604,240</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Stock based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,239,358</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,207,238</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,868,345</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Amortization of deferred financing costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">260,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,451,934</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Stock based expense for services</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">730,954</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">636,917</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">338,457</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Loan guaranty costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,944</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,036</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 30pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 40pt">Accounts receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(458,028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,068,619</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(728,253</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10; padding-left: 40pt">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(138,495</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">571,592</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,027,137</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 40pt">Other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">680,281</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,386,319</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42,281</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 40pt">Other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(37,309</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(565,706</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 40pt">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,212,912</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">472,851</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,334,855</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 40pt">Deferred revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,079,967</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">457,828</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,144,752</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 40pt">Accrued expenses and other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">239,450</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,875,320</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">639,157</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 40pt">Other liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(150,068</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10; padding-left: 10">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt">Net cash flows used in operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(45,520,996</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,768,069</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,737,326</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10; padding-left: 10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 10">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Patent costs, net of abandoned costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(586,480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(439,034</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(206,101</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Purchase of property and equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(30,962</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(40,790</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(66,405</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Refund (payment) of security deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,686</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(103,737</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10; padding-left: 10">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt">Net cash flows used in investing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(606,756</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(583,561</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(272,506</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10; padding-left: 10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 10">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Proceeds from sale of common stock, net of costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42,771,353</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">78,650,353</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,895,485</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10; padding-left: 20pt">Proceeds from exercise of options</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">345,746</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,910</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">191,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10; padding-left: 20pt">Proceeds from exercise of warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">181,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Proceeds from notes and loans payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,700,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Proceeds bank line of credit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Proceeds from sale of warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Repayment of bank line of credit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(300,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Repayment of notes payable-related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(200,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Repayment of notes payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,691,847</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,850,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -10; padding-left: 20pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt">Net cash flows provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">43,298,099</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">73,989,416</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,436,885</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10; padding-left: 20pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10; padding-left: 20pt">Increase in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,829,653</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">52,637,786</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,427,053</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt">Cash, beginning of period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">54,191,260</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,553,474</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">126,421</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -10; padding-left: 20pt">Cash, end of period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">51,361,607</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">54,191,260</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,553,474</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10; padding-left: 10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="13" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -10; padding-left: 20pt">Cash paid for interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">212,853</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,253</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10; padding-left: 20pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -10; padding-left: 20pt">Cash paid for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10; padding-left: 10">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="13" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10">SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="13" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 10">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -10; padding-left: 20pt">Warrants issued for financing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,711,956</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,509,537</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -10; padding-left: 20pt">Warrants issued for services</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">462,196</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,532,228</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -10; padding-left: 20pt">Warrants exercised in exchange for debt and accrued interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,102,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -10; padding-left: 20pt">Shares issued in exchange for debt and accrued interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,054,658</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -10; padding-left: 20pt">Notes payable issued for accrued interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,123</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>











<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="THERAPEUTICSMD"></A>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 1 &ndash; THE COMPANY&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc., a Nevada corporation,
or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed,
and BocaGreenMD, Inc., a Nevada corporation, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and
BocaGreen collectively are sometimes referred to as &ldquo;our company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Nature of Business</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a women&rsquo;s health care
product company focused on creating and commercializing products targeted exclusively for women. As of the date of these
consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and
commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials
are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies,
including hot flashes, osteoporosis, and vaginal dryness. We are developing these hormone therapy drug candidates, which
contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at
lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are
created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or
in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as
over-the-counter, or OTC, vitamins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Principles of Consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances
and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Cash</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal">We
maintain cash at financial institutions that at times may exceed the federally insured limit of $250,000 per financial institution.
We have never experienced any losses related to these funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Trade Accounts Receivable and Allowance
for Doubtful Accounts</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations
due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide
an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,
and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection
efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance
for doubtful accounts when received. <FONT STYLE="color: #252525">To the extent data we use to calculate these estimates does not
accurately reflect bad debts; adjustments to these reserves may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">&nbsp;</P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>Inventories&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">Inventories
represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or
market using the average-cost method. The costs of manufacturing the prescription products associated with the deferred
revenue (as discussed in Revenue Recognition) are recorded as deferred costs and are included in inventory, until such time
as the related deferred revenue is recognized. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><I><U>Pre-Launch
Inventory</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><I>&nbsp;&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="letter-spacing: -0.15pt">Inventory
costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe
there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic
benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as
research and development expenses during the period the costs are incurred. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Fixed Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Equipment</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We state equipment at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expense as incurred. <FONT STYLE="letter-spacing: -0.15pt">We compute depreciation using the straight-line method
over the estimated useful lives of the related assets, which range from three to seven years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><I><U>Leasehold
Improvements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">We state
improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining
term of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>Intangible
</U></FONT><U>Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><I><U>Patent
and Trademarks</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><I>&nbsp;&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">We have
adopted the provisions of </FONT>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <FONT STYLE="letter-spacing: -0.15pt">350,
<I>Intangible-Goodwill and Other</I>,<I> </I>or </FONT>ASC 350<FONT STYLE="letter-spacing: -0.15pt">. Capitalized patent costs,
net of accumulated amortization, include legal costs incurred for patent applications. </FONT>In accordance with ASC 350, <FONT STYLE="letter-spacing: -0.15pt">once
a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.
If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment
annually or when events or circumstances indicate that their carrying amount may not be recoverable. As of December 31, 2014, we
had 4 issued patents (See Note 7). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Impairment of Long-Lived Assets&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review the carrying values of property
and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their
carrying values may not be recoverable. Such events or circumstances include the following:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%">&bull;</TD><TD STYLE="text-align: justify; width: 92%">significant declines in an asset&rsquo;s market price;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%"><P STYLE="margin-top: 0; margin-bottom: 0">&bull;&nbsp;</P></TD><TD STYLE="text-align: justify; width: 92%">significant deterioration in an asset&rsquo;s physical condition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%">&bull;</TD><TD STYLE="text-align: justify; width: 92%">significant changes in the nature or extent of an asset&rsquo;s use or operation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%">&bull;</TD><TD STYLE="text-align: justify; width: 92%">significant adverse changes in the business climate that could impact an asset&rsquo;s value, including
adverse actions or assessments by regulators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%">&bull;</TD><TD STYLE="text-align: justify; width: 92%">accumulation of costs significantly in excess of original expectations related to the acquisition
or construction of an asset;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%">&bull;</TD><TD STYLE="text-align: justify; width: 92%">current-period operating or cash flow losses combined with a history of such losses or a forecast
that demonstrates continuing losses associated with an asset&rsquo;s use; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%">&bull;</TD><TD STYLE="text-align: justify; width: 92%">expectations that it is more likely than not that an asset will be sold or otherwise disposed of
significantly before the end of its previously estimated useful life.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If impairment indicators are present, we determine
whether an impairment loss should be recognized by testing the applicable asset or asset group&rsquo;s carrying value for recoverability.
This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent
of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted
future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective
carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment
in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.
In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected
timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record
a loss for the difference between the assets&rsquo; fair value and respective carrying values. We determine the fair value of
the assets using an &ldquo;income approach&rdquo; based upon a forecast of all the expected discounted future net cash flows associated
with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share,
projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial
relationships, market conditions, and available external information about future trends. We believe our current assumptions and
estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates,
resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets
during the years ended December 31, 2014, 2013 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Fair Value of Financial Instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and
accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level
1 assets under the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Fair Value of Financial Instruments (continued)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <I>Fair Value Measurements. </I>The fair value hierarchy gives the highest priority to quoted prices in active markets
for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top"><TD STYLE="width: 8%"></TD><TD STYLE="width: 12%"><B>Level
                                         1</B></TD><TD STYLE="text-align: justify; width: 80%">unadjusted
quoted prices in active markets for identical assets or liabilities;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top"><TD STYLE="width: 8%"></TD><TD STYLE="width: 12%"><B>Level
                                         2</B></TD><TD STYLE="text-align: justify; width: 80%">quoted
prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top"><TD STYLE="width: 8%"></TD><TD STYLE="width: 12%"><B>Level
                                         3</B></TD><TD STYLE="text-align: justify; width: 80%">unobservable
inputs for the asset or liability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, and 2013, we had no assets
or liabilities that were valued at fair value on a recurring basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of indefinite-lived assets is
measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with our impairment
test. There was no impairment of intangible assets during the years ended December 31, 2014, 2013, and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Income Taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon a change in our business model,
deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740, <I>Income Taxes</I>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur. At December 31, 2014, 2013, and 2012 we had no uncertain income tax positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize both interest and penalties related
to uncertain tax positions as part of the income tax provision. At December 31, 2014 and 2013, we had no tax positions relating
to open tax returns that were considered to be uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Income Taxes (continued)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our tax returns are subject to review by the
Internal Revenue Service three years after they are filed. Currently, years filed after 2011 are subject to review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Share-Based Compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation
cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective vesting
periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in
accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the
award and our expected stock price volatility over a period equal to or greater than the expected life of the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments (&ldquo;instruments&rdquo;)
issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, <I>Equity Based
Payments to Non-Employees</I>,<I> </I>or ASC 505<I>. </I>ASC 505<I> </I>defines the measurement date and recognition period for
such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the
earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments
is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize the compensation expense for all
share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize
the compensation expense on a straight-line basis over the employee&rsquo;s requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Debt Discounts</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred from parties that are providing
long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based
on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the
related debt using the effective interest rate method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Revenue Recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize revenue on arrangements in accordance
with ASC 605, <I>Revenue Recognition</I>. We recognize revenue only when the price is fixed or determinable, persuasive evidence
of an arrangement exists, the service is performed, and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Revenue Recognition (continued)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our OTC and prescription
prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing.
The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our
OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay
for the product via third-party payers.&nbsp;Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from
major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note
13.&nbsp;There are no major external customers for our OTC prenatal vitamin or other products.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Over-the-Counter Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We generate OTC revenue from product sales
primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of
loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include
shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive
the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. <FONT STYLE="color: #252525">We
provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.
</FONT>We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Prescription Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #252525">We sell our name
brand and generic prescription products </FONT>primarily through drug wholesalers and retail pharmacies. We recognize revenue from
prescription product sales, net of sales discounts, chargebacks, and rebates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable product
from customers within a return period of six months prior to and up to twelve months following product expiration. Our
prescription products currently have a shelf life of 24 months from the date of manufacture. Given the limited history of our
prescription products, we currently cannot reliably estimate expected returns of the prescription products at the time of
shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists,
which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration
of the right of return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain various rebate programs in an effort
to maintain<I> </I>a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program
is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We
estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary,
on a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Revenue Recognition (continued)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Segment Reporting&nbsp;</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are managed and operated
as one business, which is focused on creating and commercializing products targeted exclusively for women. Our
business operations are managed by a single management team that reports to the President of  our Company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with
respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our
business as one reportable operating segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Shipping and Handling Costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>Advertising
Costs</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $698,871, $11,739 and $65,944 during the years ended December 31, 2014, 2013 and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&amp;D, expenses
include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, and other activities. Internal R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based
compensation expenses. Advance payments to be expensed in future R&amp;D activities were $1,175,082 and $2,606,405 for the years
ended December 31, 2014 and 2013, respectively. CRO activity expenses include preclinical laboratory experiments and clinical trial
studies. Other activity expenses include regulatory consulting and legal counsel. The activities undertaken by our regulatory consultants
that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff with
respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols
and FDA submissions. Legal activities that were classified as research and development expenses related to designing experiments
to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel
also provided professional research regarding the legal landscape of potential patents. These consulting and legal expenses were
direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge
internal R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon
terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and
services that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received
rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject
to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise
to the revision become known.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Earnings Per Share&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculate earnings per share, or EPS,
in accordance with ASC 260, <I>Earnings Per Share</I>, which requires the computation and disclosure of two EPS amounts:
basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per
share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares
of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such
potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of
diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the potentially dilutive
securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they
were not antidilutive for the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center; border-bottom: Black 1pt solid">As of December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0pt">Stock options</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">16,792,443</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">15,632,742</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">13,733,488</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,927,916</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,293,499</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,193,499</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">30,720,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,926,241</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">25,926,987</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Use of Estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Recently Issued Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #252525">In August 2014,
the FASB issued Accounting Standards Update, or ASU, No. 2014-05, Presentation of Financial
Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going
Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about
</FONT>the entity&rsquo;s ability to continue as a going concern within one year after the financial statements are issued (or
available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after
December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for
annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption
of the ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Recently Issued Accounting Pronouncements
(continued)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB and the International
Accounting Standards Board (IASB) issued ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&rsquo;s
core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount
that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so,
companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance
obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating
the transaction price to each separate performance obligations. ASU 2014-09 is effective for public business entities, certain
not-for-profit entities and certain employee benefit plans, for annual periods beginning after December 15, 2016, including interim
periods within that period. Early adoption is not permitted under GAAP. We are currently evaluating the impact of ASU 2014-09 on
our consolidated financial statements and disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2013, the FASB issued ASU 2013-11,
Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss,
or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU
2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward,
a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements
as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward
with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability.
The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal
years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 did not have
a material impact on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, the FASB issued ASU No. 2011-11,
Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures
about financial instruments and derivative instruments that are either offset on the statement of financial position or subject
to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of
financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to
facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the
basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after
January 1, 2013, and interim periods within those years. ASU 2011-11 did not have a material impact on our financial position or
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe there would have been a material
effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards
been adopted in the current period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Reclassifications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain 2013 and 2012 amounts have been reclassified
to conform to current year presentation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 3 &ndash; INVENTORY&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventory consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left; padding-left: 0pt">Finished product</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">874,294</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">621,679</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Raw material</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,341</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,943</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Deferred costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">152,478</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">170,996</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">TOTAL INVENTORY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,182,113</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,043,618</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 4 &ndash; OTHER CURRENT ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left; padding-left: 0pt">Prepaid consulting</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">411,864</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">530,596</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Prepaid insurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">394,878</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Prepaid research and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">299,498</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,267,588</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Other receivables-related party (Note 12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,981</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,981</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Other prepaid costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">181,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,806</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Deferred financing costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">260,022</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">TOTAL OTHER CURRENT ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,537,407</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,477,715</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 5 &ndash; FIXED ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left; padding-left: 0pt">Equipment</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">132,150</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">108,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Furniture and fixtures</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,895</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,625</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186,045</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,083</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(122,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(93,765</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">TOTAL FIXED ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">63,293</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">61,318</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the years ended December
31, 2014, 2013, and 2012 was $28,987, $47,883, and $27,484, respectively. In December 2013, accumulated depreciation was reduced
by $11,980 associated with leasehold improvements of our previously leased office property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 6 &ndash;PREPAID EXPENSE&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expense consists of the following:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left; padding-left: 0pt">Prepaid manufacturing costs</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">899,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">899,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Prepaid research and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">463,720</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824,221</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Accreted prepaid costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,543</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">TOTAL PREPAID EXPENSE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,427,263</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,750,455</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 7 &ndash; INTANGIBLE ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">The following table sets forth
the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2014 and December 31, 2013:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, 2014</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Gross Carrying Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Accumulated Amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Net &nbsp; <BR>Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted- Average &nbsp; <BR>Remaining Amortization Period (yrs.)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Amortizing intangible assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OPERA<SUP>&reg;</SUP> software patent</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">31,951</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,496</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">29,455</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">14.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10">Development costs of corporate website</TD><TD></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(91,743</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 20pt">Approved hormone therapy drug&nbsp;candidate patents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">439,184</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,401</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">419,783</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Non-amortizing intangible assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10">Hormone therapy drug candidate patents (pending)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">675,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">675,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Multiple trademarks for vitamins/supplements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">103,368</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">103,368</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">n/a</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 20pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,342,228</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(113,640</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,228,588</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 7 &ndash; INTANGIBLE ASSETS&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, 2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Gross Carrying Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Accumulated Amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Net &nbsp; <BR>Amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted- Average Remaining Amortization Period (yrs.)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Amortizing intangible assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OPERA<SUP>&reg;</SUP> software patent</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">31,951</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(499</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">31,452</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">15.8</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 20pt">Development costs of&nbsp;corporate website</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(89,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 10">Non-amortizing intangible assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10; padding-left: 20pt">Hormone therapy drug candidate patents (pending)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">572,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">572,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt">Multiple trademarks for vitamins/supplements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">n/a</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 20pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">755,748</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(90,160</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">665,588</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">We amortized
the intangible asset related to development costs for corporate website over 36 months, which is the prescribed life for software
and website development costs. We amortize the intangible asset related to OPERA&reg; using the straight-line method over the estimated
useful life of approximately 20 years, which is the life of the intellectual property patents. We amortize the approved hormone
therapy drug candidate patents using straight-line method over the estimated useful life of approximately 20 years. During the
years ended December 31, 2014 and 2013, there was no impairment recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">In
addition to numerous pending patent applications, as of December 31, 2014, we had 4 issued patents, including: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%">&bull;</TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="background-color: white">one method patent that relates to our OPERA&reg; information
technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 3%"><P STYLE="margin-top: 0; margin-bottom: 0">&bull;</P>
                                                        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="background-color: white">3 utility patents that relate to our combination progesterone
and estradiol formulations, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending
patent applications with respect to certain of these patents in Argentina, Australia, Canada, the European Union, Mexico, Brazil,
Japan, Russia, South Africa and South Korea.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">Subsequent
to December 31, 2014, 1 additional patent was issued related to our combination progesterone and estradiol formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 7 &ndash; INTANGIBLE ASSETS<FONT STYLE="background-color: white">&nbsp;</FONT></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Amortization
expense was $23,480, $10,262 and $28,776 for the years ended December 31, 2014, 2013, and 2012, respectively.</FONT> As of December
31, 2014, the estimated amortization expense for the next five years is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ending December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Estimated Amortization</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: center">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: center">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: center">2017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: center">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: center">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: left; width: 66%"></TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%"></TD><TD STYLE="text-align: right; width: 25%"></TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;<U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 8 &ndash; OTHER CURRENT LIABILITIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other current liabilities consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left">Accrued clinical trial costs</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,706,542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">665,782</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued payroll, bonuses and commission costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">814,205</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">941,313</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued vacation costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">442,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256,920</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued legal and accounting expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276,470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other accrued expenses<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Allowance for wholesale distributor fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,503</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306,303</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued royalties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Allowance for coupons and returns</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,233</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued financing costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">850,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">TOTAL OTHER CURRENT LIABILITIES</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,840,639</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,601,189</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP>(1)</SUP> In June 2008, we declared and
paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359
remained unclaimed by certain stockholders at both December 31, 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 9 &ndash; NOTES PAYABLE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Payment of Multiple Advance
Revolving Credit Note</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2013, we entered into a business
loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the Revolving Credit
Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal amount, at a stated interest
rate of 6% per annum. Plato was able to make advances to us from time to time under the Revolving Credit Note at our request,
which advances were of a revolving nature and were able to be made, repaid, and made from time to time. Interest payments were
due and payable on the tenth day following the end of each calendar quarter in which any interest was accrued and unpaid, commencing
on April 10, 2013, and the principal balance outstanding under the Revolving Credit Note, together with all accrued interest and
other amounts payable under the Revolving Credit Note, if any, was due and payable on February 24, 2014. The Revolving Credit
Note was secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the
Revolving Credit Note. On March 21, 2013, we repaid $401,085, which included accrued interest, and there was no balance outstanding
under the Revolving Credit Note as of December 31, 2013 and February 24, 2014 when it expired. As additional consideration for
the Revolving Credit Note, we granted to Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price
of $3.20 per share (See Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Borrowing
under Business Loan Agreement and Promissory Note</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United Bank for a $300,000 bank line of credit for which personal guarantees and cash collateral were
required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers
of our Company, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of our Company.
The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012.
We negotiated a one-year extension with First United to the bank line of credit, which was executed on March 19, 2012. Under the
extension, borrowings bore interest at a rate of 2.35% and were due on March 1, 2013. On November 13, 2012, the outstanding balance
of $299,220 was repaid in full, and we amended the line of credit to reflect a $100,000 bank line of credit. In accordance with
the amended line of credit, the personal guarantee and cash collateral limited to $100,000 provided by the Reich Family Limited
Partnership remained in place, while the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan.
In February 2013, we borrowed $100,000 from First United Bank under the amended bank line of credit. On April 25, 2013, we re-paid
$100,735, which represented the principal and interest that was due under the amended bank line of credit. On May 1, 2013, the
amended bank line of credit expired and was not renewed. Accordingly, the personal guarantee was canceled, and the cash collateral
was refunded to the Reich Family Limited Partnership. During the years ended December 31, 2013 and 2012, we paid $735 and $7,366,
respectively, of interest expense, which are included in interest expense on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance of January and February 2012
Promissory Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January and February 2012, we issued
6% promissory notes in the aggregate principal amount of $900,000, due March 1, 2012, which were subsequently increased to an
aggregate principal amount of $1,700,000. As discussed below in Issuance and Settlement of February 2012 Notes, these promissory
notes were modified on February 24, 2012 through the issuance of secured promissory notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 9 &ndash; NOTES PAYABLE (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Settlement of February 2012
Promissory Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 24, 2012, we
issued promissory notes, the February 2012 Notes, to an individual and an entity, both of which were stockholders of our
company, in the principal amount of $1,358,014 and $1,357,110, respectively, and granted warrants to purchase an aggregate of
9,000,000 shares of our Common Stock pursuant to the terms of a Note Purchase Agreement, dated February 24, 2012. We received
an aggregate of $1,000,000 of new funding upon issuance of the February 2012 Notes and related warrants and surrender by
the holders of certain promissory notes, which we previously issued in the aggregate amount of $1,700,000 plus the
aggregate accrued interest of $15,124 (collectively, the &ldquo;Prior Notes&rdquo;). Under the February 2012 Notes, as
amended, we borrowed an additional $3,000,000 during March, April, and May 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We granted warrants to purchase an aggregate
of 5,685,300 shares of Common Stock in consideration of the modification of the Prior Notes and warrants to purchase an aggregate
of 3,314,700 shares of Common Stock in connection with the issuance of the February 2012 Notes. We determined that the resulting
modification of the Prior Notes was substantial in accordance with ASC 470-50,&nbsp;<I>Modifications and Extinguishments</I>. As
such the modification was accounted for as an extinguishment and restructuring of the debt, and the 5,685,300 warrants issued in
consideration of the modification were expensed (see Warrant Activity during 2012 in NOTE 10 for more details). The fair
value of the Prior Notes was estimated by calculating the present value of the future cash flows discounted at a market rate of
return for comparable debt instruments to be $1,517,741, resulting in a debt discount of $197,383 and recognized a loss on extinguishment
of debt of $10,307,864, which represented the fair value of the 5,685,300 warrants net of the difference between the carrying amount
of the Prior Notes and their fair value as of the date of the modification on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2012, we settled an aggregate amount
of $3,102,000 of principal and accrued interest of the February 2012 Notes in exchange for the exercise of warrants to purchase
8,145,486 shares of our Common Stock. As discussed below in Issuance and Payment of June 2012 Notes, the remaining balance of $2,691,847
of the February 2012 Notes was modified on June 19, 2012 through the issuance of the June 2012 Notes (as defined below) (see NOTE
10 for more details).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Payment of June 2012 Promissory
Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2012, we issued secured promissory
notes, or the June 2012 Notes, to the holders of the February 2012 Notes in the principal amounts of $2,347,128 and $2,344,719, pursuant to the terms of a Note Purchase Agreement. In connection with the June 2012 Notes, the holders of the February 2012 Notes
surrendered the remaining balance of such notes in the aggregate amount of $1,347,128 and $1,344,719,  which sums
included principal and accrued interest through June 19, 2012, and we received an aggregate of $2,000,000 of new funding, or the
June Funding, from the holders of the February 2012 Notes. The principal amount of each of the June 2012 Notes, plus any additional
advance made to us thereafter, together with accrued interest at the annual rate of 6%, was due in one lump sum payment on February
24, 2014. As security for our obligations under the June 2012 Notes, we entered into a security agreement and pledged all of our
assets, tangible and intangible, as further described therein. We also granted warrants to purchase an aggregate of 7,000,000 shares
of our Common Stock in connection with the June Funding. On March 21, 2013, we repaid $4,882,019 of the June 2012 Notes, including
accrued interest, leaving a balance of $21,595 in accrued interest as of March 31, 2013. On April 25, 2013, the balance of accrued
interest was paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 9 &ndash; NOTES PAYABLE (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Payment of Additional
Promissory Notes in 2012</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August and September 2012, we issued 6%
promissory notes in the amount of $1,600,000 due on October 1, 2012, which due date was subsequently extended. These notes were
paid in full in October 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2012, we issued a 6% promissory
note for $200,000 due on October 15, 2012. This note was paid in full in October 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Payment of Additional Promissory
Notes in 2011</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 4% promissory notes
to Mr. Finizio and Mr. Milligan for an aggregate of $100,000 due March 1, 2012. These promissory notes were subsequently extended
by mutual agreement to June 1, 2012. In June 2012, we paid the promissory note held by Mr.&nbsp;Finizio in full, including $888
in accrued interest. Mr. Milligan&rsquo;s promissory note was extended to October 15, 2012. On October 4, 2012, we paid Mr. Milligan&rsquo;s
promissory note in full, including $1,519 in accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Conversion of July 2011 Secured Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2011, VitaMed issued two
senior secured promissory notes, or the Secured Notes, each in the amount of $500,000 and also entered into a security
agreement under which VitaMed pledged all of its assets to secure the obligation. The Secured Notes were assumed by us upon
the merger with VitaMed in October 2011 and bore interest at the rate of 6% per annum, were due on the one year anniversary
thereof, and were convertible into shares of our Common Stock at our option. We were permitted to satisfy the obligations
underlying the Secured Notes by delivering such number of shares of our Common Stock calculated by dividing the
then-outstanding principal balance by the Share Price. For purposes of the Secured Notes, the &ldquo;Share Price&rdquo; meant
the lower of the most recent price at which we offered and sold shares of our Common Stock (not including any shares of our
Common Stock issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities) or the
five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we reached an agreement to
convert the outstanding amount of the Secured Notes, representing principal and accrued interest through June 19, 2012, of
$1,054,647 into an aggregate of 2,775,415 shares of our Common Stock at $0.38 per share. This resulted in a beneficial
conversion feature of $6,716,504 as recorded in other income and expense on the accompanying consolidated financial
statements. For the year ended December 31, 2012 we recorded an aggregate of $33,204 as interest expense on the accompanying
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance, Payment and Conversion of VitaMed
Promissory Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, VitaMed issued promissory
notes, or the VitaMed Notes, in the aggregate principal amount of $500,000. In connection with the VitaMed Notes, VitaMed
granted warrants to purchase equity interests in VitaMed that were equivalent to an aggregate of 613,718 shares of our Common
Stock when the VitaMed Notes were assumed by us upon the merger with VitaMed. The VitaMed Notes bore interest at a rate of 4%
per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed
received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding. Upon the
closing of the Funding in July 2011, as more fully described above in Conversion of July 2011 Secured Notes, two of the
VitaMed Notes in the aggregate principal amount of $200,000 were paid in full. By mutual agreement, the remaining
VitaMed Notes in the aggregate principal amount of $300,000 were extended. In October 2011, one of the VitaMed Notes in the
aggregate principal amount of $50,000 was paid in full, and, by mutual agreement, certain of the VitaMed Notes in the
aggregate principal amount of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share, which
represented the fair value of our Common Stock on the date of conversion. In June 2012, a VitaMed Note held by an
unaffiliated individual was paid in full, including $2,160 in accrued interest. The remaining VitaMed Notes, held by Mr.
Milligan and by BF Investment Enterprises, Ltd., which is owned by Brian Bernick, a director of our company, in the aggregate
principal amount of $100,000, were extended to October 15, 2012. On October 4, 2012, we re-paid the outstanding VitaMed Notes
in full, including $5,341 in accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 9 &ndash; NOTES PAYABLE (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance, Payment and Conversion of VitaMed
Promissory Notes (continued)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September and October 2011, VitaMed
issued convertible notes, or the VitaMed Convertible Notes, in the aggregate amount of $534,160. The VitaMed Convertible
Notes bore interest at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we entered into Debt
Conversion Agreements with the holders of the VitaMed Convertible Notes, pursuant to which we converted the principal and
accrued interest of the VitaMed Convertible Notes into 1,415,136 shares of our Common Stock at $0.38 per share, which
represented the fair value of the shares of our Common Stock on the date of conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December 31, 2012, we recorded
an aggregate of $6,344 as interest expense on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo; EQUITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">At December
31, 2014, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred
Stock were issued or outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Common Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">At
December 31, 2014, we had </FONT>250,000,000 shares of Common Stock, par value $0.001,<FONT STYLE="letter-spacing: -0.15pt"> authorized for
issuance, of which </FONT>156,097,019<FONT STYLE="letter-spacing: -0.15pt"> shares of our Common Stock were issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Issuances During 2014</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 29, 2014, we entered into an underwriting
agreement with Goldman Sachs &amp; Co,  as the representative of the underwriters named therein, or the Goldman
Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of our Common Stock. The price to the public
in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a
30-day option to purchase up to an additional 1,284,796 shares of our Common Stock. On July 30, 2014, the Goldman Sachs Underwriters
exercised their option to purchase the additional 1,284,796 shares of our Common Stock. Net proceeds from this offering were approximately
$42.8 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed
on August 4, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo;
EQUITY (Continued)</U>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014, certain
individuals exercised stock options to purchase 860,800 shares of our Common Stock. Stock options to purchase shares of our Common
Stock were exercised as follows: (i) 724,193 options for $345,746 in cash and (ii) <FONT STYLE="letter-spacing: -0.15pt">136,607
options, pursuant to the stock options&rsquo; cashless provision, wherein 130,380 shares of Common Stock were issued. In addition,
during 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were
granted in December 2013.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014, certain
individuals exercised warrants to purchase 365,583 shares of our Common Stock for $181,000 in cash.<FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Issuances During 2013&nbsp;</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 14, 2013, we entered into an underwriting
agreement with Jefferies LLC as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to
the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share. In
addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to
an additional 4,411,765 shares of our Common Stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters
exercised their option to purchase an additional 1,954,587 shares of our Common Stock, which were issued on April 18, 2013. The
net proceeds to us from this offering were approximately $48.5 million, after deducting underwriting discounts and commissions
and other offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2013, we entered into an underwriting
agreement with Stifel, Nicolaus &amp; Company, Incorporated, as the representative of the underwriters named therein, or the Stifel
Underwriters, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering
was $2.40 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts
and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2013 certain individuals exercised
stock options to purchase an aggregate of 75,423 shares of our Common Stock for approximately $31,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Issuances During 2012</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During June 2012, we settled $3,102,000 in
principal and accrued interest of the February 2012 Notes in exchange for the holders&rsquo; exercise of a portion of the related
warrants for an aggregate of 8,145,486 shares of Common Stock. During June 2012, we and the holders also agreed to convert
a portion of the February 2012 Notes, and principal and accrued interest through June 19, 2012 totaling $1,054,647, into 2,775,415
shares of Common Stock at $0.38 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo;
EQUITY (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Issuances During 2012 (continued)</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2012, we entered into a Securities
Purchase Agreement with multiple investors, relating to the issuance and sale of Common Stock in a private placement. The private
placement closed on October 2, 2012, through which we sold an aggregate of 3,953,489 shares of Common Stock at $2.15 per share,
for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies LLC served as our exclusive
placement agent. Jefferies&rsquo; compensation for the transaction was a cash fee of $552,500. We also paid legal fees and expenses
of the investors in the aggregate of $52,016, resulting in net proceeds to us from the private placement of $7,895,485. Pursuant
to the terms of the Securities Purchase Agreement, we agreed to file a registration statement covering the resale of these shares,
which was filed on November 27, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2012, certain
individuals exercised stock options to purchase 1,958,216 shares of Common Stock. Stock options to purchase shares of Common Stock
were exercised as follows: (i) 1,691,393 options for $191,000 in cash and (ii) <FONT STYLE="letter-spacing: -0.15pt">266,823 options,
pursuant to the stock options&rsquo; cashless provision, wherein 240,395 shares of Common Stock were issued. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Warrants to Purchase Common Stock </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, we had warrants outstanding
to purchase an aggregate of 13,927,916 shares of our Common Stock with a weighted-average contractual remaining life of 3.0 years,
and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.82 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation methodology used to determine
the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,
including volatility of the stock price, the risk-free interest rate and the term of the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrant Activity During 2014</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014, we
did not issue any warrants. As of December 31, 2014, unamortized costs associated with the Sancilio &amp; Company, Inc., or SCI
warrants issued in 2013 and 2012 totaled approximately $875,600.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrant Activity During 2013</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2013, we issued warrants to purchase
1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see
NOTE 10 above for more details). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October
31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately
$1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and
a dividend yield of 0%. During the years ended December 31, 2014 and 2013, $260,027 and $1,451,934, respectively, was recorded
as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo;
EQUITY (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrant Activity During 2013 (continued)</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2013, we entered into a consulting agreement
with SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our
efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal
capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights
to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting
agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares
of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6%"></TD><TD STYLE="width: 5%">1.</TD><TD STYLE="text-align: justify; width: 89%">283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application
by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the
terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested
on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of
45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June
30, 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6%"></TD><TD STYLE="width: 5%">2.</TD><TD STYLE="text-align: justify; width: 89%">283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined
by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.84%; risk free rate of
1.41%; and a dividend yield of 0%. As of December 31, 2014, we recorded $154,068 as prepaid expense-short term and $77,026 as prepaid
expense-long term in the accompanying consolidated financial statements. During the years ended December 31 2014 and 2013, we recorded
$154,068 and $77,034, respectively, as non-cash compensation in the accompanying consolidated financial statements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6%"></TD><TD STYLE="width: 5%">3.</TD><TD STYLE="text-align: justify; width: 89%">283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that
SCI helped us design. It is anticipated that this event will not occur before December 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrant Activity During 2012</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2012, we issued warrants for the
purchase of an aggregate of 5,685,300 shares of Common Stock in connection with the modification of certain existing promissory
notes, or the Modification Warrants, and warrants for the purchase of an aggregate of 3,314,700 shares of our Common Stock in connection
with the issuance of the February 2012 Notes, or the February 2012 Warrants (see NOTE 9). Both the Modification Warrants
and the February 2012 Warrants are exercisable at $0.38 per share. The Modification Warrants have a fair value of $10,505,247,
and the February 2012 Warrants have a fair value of $6,124,873. Fair value was determined on the date of the issuance using a term
of five years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification
Warrants as part of the loss on extinguishment of debt in the accompanying consolidated financial statements. The relative fair
value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012
Notes on June 19, 2012, we expensed the remaining unamortized debt discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo;
EQUITY (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrant Activity During 2012</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2012, we issued warrants to purchase
an aggregate of 31,000 shares of Common Stock to five unaffiliated individuals for services rendered. These warrants were valued
on the date of the issuance using a term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield
of 0%; we recorded $29,736 as consulting expense in the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2012, we issued warrants to
purchase an aggregate of 1,300,000 shares of Common Stock to an unaffiliated entity for services to be rendered over
approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug
development efforts, including services in support our ongoing and future drug development and commercialization efforts,
regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and
controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated
therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services
as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at
$1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk
free rate of 0.74%; and a dividend yield of 0%. At December 31, 2014, we had $257,796 reported as prepaid expense-short term
and $386,694 recorded as prepaid expense-long term. During the years ended December 31, 2014, 2013 and 2012, we recorded
$309,165, $360,528 and $218,045, respectively as non-cash compensation with respect to these warrants in the
accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product.
We have determined that the process will take approximately five years. As a result, we are amortizing the $1,532,228 over
five years.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, we issued warrant to purchase
aggregate of 7,000,000 shares of Common Stock in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants,
(see NOTE 9). Of the June 2012 Warrants issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable
at $3.00 per share. The fair value of the June 2012 Warrants of $9,424,982 was determined on the date of the issuance using a term
of five years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June
2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the issuance. $547,210
was amortized to interest expense in 2012 and as a result of the repayment of the associated debt on March 21, 2013, the remaining
unamortized debt discount of $1,102,680 was amortized to interest expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, we issued warrants to purchase
an aggregate of 1,500 shares of Common Stock to three unaffiliated individuals for services rendered. The warrants were valued
on the date of the issuance using a term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of
0%. A total of $1,656 was recorded as consulting expense in the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo;
EQUITY (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Summary of our Warrant activity and related information for
2012-2014&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares Under Warrants</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted &nbsp; <BR>Average&nbsp; <BR>Remaining &nbsp; <BR>Contractual&nbsp; <BR>Life in Years</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate&nbsp; <BR>Intrinsic Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-family: Times New Roman, Times, Serif">Balance at December 31, 2011</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">3,057,627</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">0.36</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7.9</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">3,483,691</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">17,332,500</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.26</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(8,145,486</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">0.38</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(51,142</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">0.24</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Balance at December 31, 2012</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">12,193,499</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.63</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4.8</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">17,971,994</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2,100,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2.72</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Balance at December 31, 2013</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">14,293,499</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.79</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">3.9</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">48,932,777</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(365,583</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">0.50</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Balance at December 31, 2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">13,927,916</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.82</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">3.0</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">36,623,875</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10; text-indent: -10">Vested and Exercisable at December 31, 2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">13,562,764</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.83</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2.9</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">35,599,540</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average fair value per share of
warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are
set forth in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Weighted average fair value</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2.83</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&mdash;</TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.88-1.12</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.72-1.04</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">44.29-45.89</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">44.64-44.81</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5-6</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated volatility is a measure of the amount
by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average
of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation
of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical
volatility of peer entities due to the lack of sufficient historical data of our stock price during 2011-2014.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo;
EQUITY (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Options to Purchase Common Stock of the
Company</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2009, we adopted the 2009 Long Term Incentive
Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our
company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options
and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the merger with VitaMed, no Awards
had been issued under the 2009 Plan. As of December 31, 2014, there were Awards for 18,246,625 shares of our Common Stock issued
under the 2009 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 23, 2012, we adopted the 2012
Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve
as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors
of our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2014, there
were awards for 2,600,000 shares issued under the 2012 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions
used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are set forth in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.07-1.77</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.65-1.71</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.61-2.23</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">68.05-82.29</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33.35-45.76</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">40.77-46.01</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.5-6.25</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5-6.25</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5-6.25</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left">Dividend yield</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated
volatility is a measure of the amount by which the price of Common Stock is expected to fluctuate each year during the term of
the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock
prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal
to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data
on our stock price. The average expected life is based on the contractual term of the option using the simplified method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo;
EQUITY (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Options to Purchase Common Stock of the
Company (continued)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of activity under the 2009 and 2012
Plans and related information for 2012-2014 follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares Under Options</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted &nbsp; <BR>Average &nbsp; <BR>Remaining &nbsp; <BR>Contractual&nbsp; <BR>Life in Years</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate&nbsp; <BR>Intrinsic Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; font-family: Times New Roman, Times, Serif">Balance at December 31, 2011</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">10,590,161</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">0.16</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7.6</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 3%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">14,067,649</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5,121,250</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2.80</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(1,931,788</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(46,135</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Balance at December 31, 2012</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">13,733,488</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.16</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">7.7</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">26,804,117</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2,583,677</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">3.31</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(75,423</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(250</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(608,750</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Balance at December 31, 2013</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">15,632,742</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.44</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">7.2</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">58,878,132</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">2,442,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4.71</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(854,573</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(250</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(427,476</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif">Balance at December 31, 2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">16,792,443</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.88</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">6.9</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">43,996,311</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">Vested and Exercisable at December 31, 2014</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">13,276,462</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1.39</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5.5</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">40,720,977</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, our outstanding options
had exercise prices ranging from $0.10 to $5.21 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Share-based compensation expense for options
recognized in our results for the years ended December 31, 2014, 2013, and 2012&nbsp; ($4,393,455, $3,200,655 and $1,832,061, respectively)
is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant
and revised in subsequent periods if actual forfeitures differ from the estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, total unrecognized estimated
compensation expense related to unvested options granted prior to that date was approximately $5,160,000, which is expected to
be recognized over a weighted-average period of 2.9 years. No tax benefit was realized due to a continued pattern of operating
losses. At December 31, 2013 and 2012, total unrecognized estimated compensation expense related to unvested options granted prior
to that date was approximately $3,921,000 and $4,391,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2013, we granted a restricted
stock unit, or the RSU, under our 2012 Plan to an employee of 50,000 shares of our Common Stock having a fair value of
$233,500. During the years ended December 31, 2014 and 2013, we recorded $53,428 and $180,072, respectively, of non-cash
compensation related to the RSU on the accompanying consolidated financial statements. The RSU vested and the shares
of Common Stock underlying the RSU were  issued in June 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE</U></B><U>&nbsp;<B> 11 &ndash;
INCOME TAXES<FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></B></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">For
the years ended December 31, 2014, 2013 and 2012, there was no provision for income taxes, current or deferred.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, we have a federal net
operating loss carry forward of approximately $105,529,416 available to offset future taxable income through 2034.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation between taxes computed at
the federal statutory rate and the consolidated effective tax rate is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Federal statutory tax rate</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">34.0</TD><TD STYLE="width: 1%; text-align: left; vertical-align: middle">%</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">35.0</TD><TD STYLE="width: 1%; text-align: left; vertical-align: middle">%</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">35.0</TD><TD STYLE="width: 1%; text-align: left; vertical-align: middle">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State tax rate, net of federal tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.8</TD><TD STYLE="text-align: left; vertical-align: middle">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.5</TD><TD STYLE="text-align: left; vertical-align: middle">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustment in valuation allowances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50.9</TD><TD STYLE="text-align: left; vertical-align: middle">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32.4</TD><TD STYLE="text-align: right; vertical-align: middle">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18.2</TD><TD STYLE="text-align: right; vertical-align: middle">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Permanent and other differences</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11.1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8.4</TD><TD STYLE="padding-bottom: 1pt; text-align: right; vertical-align: middle">)%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22.3</TD><TD STYLE="padding-bottom: 1pt; text-align: right; vertical-align: middle">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Provision (Benefit) for Income Taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our deferred tax asset and liability
as presented in the accompanying consolidated financial statements consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Deferred Income Tax Assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 10pt">Net operating losses</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">43,091,437</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">14,773,537</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,920,861</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">R&amp;D Credit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">547,511</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">186,346</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Total deferred income tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,091,437</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,321,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,107,207</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(43,091,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,321,048</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,107,207</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred Income Tax Assets, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that it is more likely than
not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets
on our balance sheet and as such, a valuation allowance has been established against the deferred tax
assets for the period ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Unrecognized Tax Benefits&#9;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the period ended December 31, 2014,
we had no unrecognized tax benefits.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 12 &ndash; RELATED PARTIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Loan Guaranty&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.
Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family
Limited Partnership. See NOTES 9 and 10 &nbsp;for more details.&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 12 &ndash; RELATED PARTIES (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Loans from Affiliates&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, VitaMed issued the VitaMed Notes
in the aggregate principal amount of $500,000, of which $100,000 was sold to affiliates. In June 2012, the affiliate notes were
extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments, LLC, which is owned
by Brian Bernick, a member of the board of directors of our company. On October 4, 2012 these VitaMed Notes were paid in full
including $5,341 in accrued interest.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 4% promissory
notes to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012.
These promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the promissory note held by Mr. Finizio
was paid in full, including $888 in accrued interest. Mr. Milligan&rsquo;s promissory note was extended to October 15, 2012. On
October 4, 2012 this promissory note was paid in full including $1,519 in accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Purchases by Related Parties&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2012, we sold our products to Dr. Brian
Bernick, a director of our company, in the amount of $2,632, and $1,272 of receivables related thereto remained outstanding at
December 31, 2012. No products were sold to Dr. Bernick during 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Agreements with Pernix Therapeutics, LLC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 29, 2012, Cooper C.
Collins, president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of
directors. From time to time, we have entered into agreements with Pernix in the normal course of business. All such
agreements are reviewed by independent directors of our company or a committee consisting of independent directors of our company.
During the years ended December 31, 2014, 2013, and 2012, we made purchases of $0, $0 and $404,000, respectively, from
Pernix. At December 31, 2014, 2013, and 2012, there were amounts due Pernix of approximately $46,000, $46,000, and
$308,000 outstanding, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, there were amounts due to us
from Pernix for legal fee reimbursement relating to a litigation matter pursuant to a license and supply agreement in the amount
of $249,981 for each of the years ended December 31, 2014 and 2013.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Warrants assigned to Related Party&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, a warrant to purchase 100,000
shares of our Common Stock was assigned by a non-affiliated third party to the son of the Chairman of our board of directors.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 13 - BUSINESS CONCENTRATIONS&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We purchase our products
from several suppliers with approximately 82%, 98%, and 76% of our purchases supplied from one vendor for the years ended December
31, 2014, 2013, and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 13 - BUSINESS CONCENTRATIONS (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We sell our vitamins,
prenatal dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug
stores that generally sell products to retail pharmacies, hospitals, other institutions and directly to retail customers.
Revenue generated from four customers accounted for approximately 75%, 79%, and 28% of our recognized revenue and 97%, 97%,
and 98% of our deferred revenue for the years ended December 31, 2014, 2013, and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">For the years
ended December 31, 2014, 2013 and 2012, we had four customers that generated more than 10% of our sales &ndash; these
customers are designated as customers &ldquo;A&rdquo;, &ldquo;B&rdquo;, &ldquo;C&rdquo; and &ldquo;D&rdquo;. Customers A, B,
C and D generated $1,609,950, $1,586,903, $1,804,018 and $4,053,838, respectively, in sales in 2014; $1,221,212, $1,711,417,
$2,588,626, and $1,312,192, respectively, in sales in 2013; and $67,599, $490,092, $830,902, and $0, respectively,
in sales in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 14 &ndash; COMMITMENTS AND CONTINGENCIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Operating Lease</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We lease administrative office space in Boca
Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30,
2018. The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses)
and sales tax, for a total future minimum payments over the life of the lease of $1,899,414.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The straight line rental expense related
to our current lease totaled&nbsp; $361,793 for the year ended December 31, 2014, partially offset by the rent income of
$41,613 for sublet space. The straight line rental expense related to our current lease totaled&nbsp; $180,894 for the six
months ended December 31, 2013, partially offset by rent income of $32,963 for sublet space. The rental expense related to our
prior lease which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013, and $106,315 for the year
ended December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, future minimum rental
payments under our office lease are as follows:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Years Ending December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">371,240</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">382,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left">2017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">393,848</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">302,748</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-cancellable sub-lease income</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left; padding-bottom: 2.5pt">Net minimum lease payments</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,450,213</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: left; width: 66%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%"></TD><TD STYLE="text-align: right; width: 25%"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; width: 1%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Legal Proceedings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we are involved in litigation and proceedings
in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material
effect on our consolidated financial condition, results of operations, or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Off-Balance Sheet Arrangements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, 2013 and 2012, we had no
off-balance sheet arrangements that have had or are reasonably likely to have current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or
capital resources that are material to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 15 &ndash; SELECTED QUARTERLY FINANCIAL
DATA (UNAUDITED)</U></B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Summarized quarterly financial data for fiscal years 2014, 2013,
and 2012 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="text-align: center; border-bottom: Black 1pt solid">2014 Quarters</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; text-align: left">(In thousands, except per share)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1<SUP>st</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2<SUP>nd</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3<SUP>rd</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">4th</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,831</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,752</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,186</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,257</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,859</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,118</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(9,183</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(10,899</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(17,832</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(16,303</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss per common share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.07</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.10</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="text-align: center; border-bottom: Black 1pt solid">2013 Quarters</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; text-align: left">(In thousands, except per share)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1<SUP>st</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2<SUP>nd</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3<SUP>rd</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">4th</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,537</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,081</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,295</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,863</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,646</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,376</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,009</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,673</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(8,361</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss per common share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="text-align: center; border-bottom: Black 1pt solid">2012 Quarters</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; text-align: left">(In thousands, except per share)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1<SUP>st</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2<SUP>nd</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3<SUP>rd</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">4th</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">722</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">819</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,036</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,241</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">386</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">447</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">908</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(13,290</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(11,850</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,253</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,727</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss per common share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.16</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.04</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 16 &ndash; SUBSEQUENT EVENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February&nbsp;10, 2015, we
entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the
several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246
shares of the  our Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen
Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional
shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were
approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses
payable by us. The offering closed on February&nbsp;17, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 18, 2015, we entered into an agreement
to lease administrative office space in Boca Raton, Florida, pursuant to an addendum to our existing 63 month non-cancelable operating
lease commencing on July 1, 2013 and expiring on September 30, 2018. This addendum will be effective beginning April 1, 2015 and
will expire with the original lease term on September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 104; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>ex10-36.htm
<DESCRIPTION>FIRST AMENDMENT TO LEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 0; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: left"><A HREF="txmd-10k_123114.htm">TherapeuticsMD, Inc. 10-K</A><B></B></P>

<P STYLE="margin: 0; text-align: right"><B><U>Exhibit 10.36</U></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>FIRST AMENDMENT TO LEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">THIS FIRST AMENDMENT TO
LEASE (the &ldquo;First Amendment&rdquo;) is made and entered into as of the Effective Date hereof, by and between, <FONT STYLE="letter-spacing: -0.25pt">6800
BROKEN SOUND LLC, a Florida limited liability company and its successors or assigns (&ldquo;Landlord&rdquo;), and THERAPEUTICSMD,
INC., a Nevada corporation authorized to do business in Florida</FONT><FONT STYLE="letter-spacing: -0.3pt"> (&ldquo;Tenant</FONT>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RECITALS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord and Tenant have entered into
that certain Lease with the Effective Date of May 13, 2013 (the &ldquo;Lease&rdquo;) for the Lease of that certain Premises described
within the Lease as the entire third floor of the Building located at 6800 Broken Sound Parkway, Boca Raton, Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord and Tenant desire to modify
and amend the Lease to increase the size of the Premises to include Suite 100 of the Building which consists of approximately 3,533
rentable square feet and to modify such other terms and conditions of the Lease consistent with the addition of the additional
rentable square footage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord and Tenant desire to enter into
such other terms, conditions, and amendments to the Lease as are more specifically set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">NOW, THEREFORE, in consideration
of the mutual terms, covenants and conditions contained herein, and for separate consideration, the receipt and sufficiency of
which is hereby acknowledged and agreed to by the parties hereto, the Landlord and Tenant do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recitals</U>. The above recitals are
hereby ratified and confirmed as being true and correct and are incorporated herein in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. All terms defined herein
shall have the identical definitions as ascribed to within the Lease, except where such definition is expressly modified herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective Date</U>. The Effective Date
of this First Amendment to Lease shall be the date and time of the last party to fully execute this First Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Premises</U>. Commencing upon the Additional
Premises Commencement Date (hereafter defined) the Premises as defined in Article 1 BASIC PROVISIONS of the Lease shall be amended
to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify"><U>Premises</U>: The entire third
floor of the Building as outlined on the floor plan attached to the Lease as Exhibit &ldquo;A&rdquo; and that certain Premises
designated as Suite 100 located at the Building. For all purposes of the Lease and this First Amendment, commencing upon the Additional
Premises Commencement Date, where the defined term &ldquo;Premises&rdquo; is used the same shall be defined as the entire third
floor of the Building as outlined on Exhibit &ldquo;A&rdquo; to the Lease and Suite 100. Where the defined term &ldquo;Additional
Premises&rdquo; is used the same shall be defined solely as Suite 100 at the Building, and where the defined term &ldquo;Original
Premises&rdquo; is used herein the same shall be defined solely as the entire third floor of the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Premises Occupancy Date</U>.
The date in which Landlord shall allow Tenant occupancy of the Additional Premises shall be defined herein as the Additional Premises
Occupancy Date, which shall be forty five (45) days subsequent to the Effective Date of this First Amendment to Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Premises Rent Commencement
Date</U>. The Rent Commencement Date for the Additional Premises shall be upon the Additional Premises Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The Lease Term for the Additional
Premises shall commence upon the Additional Premises Commencement Date and be coterminous with the Lease Term for the Original
Premises set forth within the Lease and shall expire September 30, 2018 or such earlier date in which the term of the Lease for
the Original Premises shall expire or be terminated pursuant to the terms and conditions of the Lease. The Renewal Option set
forth in Article 33 of the Lease shall also apply to the Additional Premises, and in the event Tenant should exercise the Renewal
Option, it must be exercised for both the Original Premises and the Additional Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Premises Commencement
Date</U>. The Additional Premises Commencement Date shall be the same date as the Additional Premises Occupancy Date, which shall
be forty five (45) days subsequent to the Effective Date of this First Amendment to Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Premises Rentable Area</U>.
<FONT STYLE="letter-spacing: -0.35pt">T</FONT>he Additional Premises Rentable Area is designated as Suite 100, located at 6800
Broken Sound Parkway<FONT STYLE="letter-spacing: -0.15pt">, Boca Raton, Florida 33487. The </FONT>Additional Premises Rentable
Area<FONT STYLE="letter-spacing: -0.15pt"> consists of approximately 3,533 rentable square feet and constitutes </FONT>6.95% percentage
of the gross rentable square footage of the Building which is 50,809 rentable square feet. Commencing upon the Additional Premises
Commencement Date, the Premises shall consists of approximately 21,219 rentable square feet and constitute collectively for both
the Original Premises and Additional Premises 41.75% of the Gross Rentable square footage of the Building. The square footage
and <FONT STYLE="letter-spacing: -0.25pt">percentages set forth in herein shall be deemed conclusive, with the Landlord and Tenant
agreeing upon the square footage and percentages to be paid which may take into account any loss factor, area located between
demising walls, or may include exterior wall structures. The parties acknowledge and agree that the Tenant is satisfied with the
square footage calculation and the percentage calculation and accepts the same, thereby waiving any right to object to the square
footage or percentage calculation in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&rsquo;s Share of Taxes</U>.
The Lease, Article 1: BASIC PROVISIONS (I) Tenant&rsquo;s Share of Taxes is hereby amended to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">I. Tenant&rsquo;s Share
of Taxes: Commencing on the Additional Premises Commencement Date, Tenants share of Taxes shall be 41.75% subject to Articles 4
and 32. To the extent required for any calculation the Tenants share attributable to the Additional Premises shall be 6.95%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&rsquo;s
Share of Expenses</U>. The Lease, Article 1: BASIC PROVISIONS (J) Tenant&rsquo;s Share of Expenses are hereby amended to read
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify">J. Tenant&rsquo;s Share of Expenses:
Commencing on the Additional Premises Commencement Date, Tenants share of Expenses shall be 41.75% subject to Articles 4 and 32.
To the extent required for any calculation the Tenants share attributable to the Additional Premises shall be 6.95%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Premises Base Rent:</U>
<FONT STYLE="letter-spacing: -0.15pt">The Base Rent for the Additional Premises (in addition to all Rent due for the Original
Premises pursuant to the Lease) set forth hereinafter shall increase yearly by an amount equal to 3.0% over each </FONT>prior
Lease Year (defined below) (plus all applicable sales tax legally required):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="letter-spacing: -0.35pt">&#9;Annual
Base Rent</FONT>&#9;<FONT STYLE="letter-spacing: -0.3pt">Annual Base</FONT>&#9;<FONT STYLE="letter-spacing: -0.2pt">Monthly Base&#9;Monthly&#9;Sales
Monthly</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; width: 21%">Lease Term<SUP>(1)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; width: 10%">Annual Base Rent per Square Foot<SUP>(2)</SUP></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; width: 10%">Annual Base Rent</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; width: 10%">Monthly Base Rent</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; width: 10%">Monthly CAM</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; width: 10%">Sales Tax</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid; width: 1%">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; width: 10%">Monthly Total</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/1/15-3/31/16</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">16.00</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">56,528.00</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,710.67</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">3,942.24</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">519.18</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">9,172.09</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/1/16-3/31/17</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">16.48</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">58,223.84</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,851.98</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/1/17-3/31/18</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">16.97</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">59,955.01</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">4,996.25</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/1/18-9/30/18</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">17.48</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">61,756.84</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5,146.40</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TBD</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(1) In the event the
Additional Premises Rent Commencement Date is a date other than April 1, 2015, upon Landlord and Tenant learning of the actual
Additional Premises Rent Commencement Date, Landlord and Tenant shall enter into a Second Amendment to the Lease which shall set
forth the actual Lease Term and Lease Years for the Additional Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(2) The foregoing
Base Rent for the Additional Premises shall be in addition to all Rent due for the Original Premises set forth in the Lease and
nothing contained in this First Amendment shall diminish or reduce in any manner all amounts due and owing pursuant to the Lease
for the Original Premises. Notwithstanding any term or condition of the Lease, the Additional Premises Base Rent, Taxes, Expenses
and/or other amounts due shall not be subject to, or used in any manner in calculating the Rent Maximum Payment Ceiling pursuant
to the Lease. The Rent Maximum Payment Ceiling shall only apply to the Rent due for the Original Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Rent</U>. For all purposes as set forth within the Lease and for the Additional Premises, this Lease shall be deemed a triple
net lease and Tenant shall be responsible for payment of its share of all Expenses, Taxes and other amounts as defined and
allowed pursuant to the Lease and Landlord shall be entitled to pass through Tenant&rsquo;s share of all Expenses, Taxes and
other amounts necessary to operate the Building, the Premises and Common Areas as set forth within the Lease and this First
Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">14.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Security
Deposit</U>. One (1) months Gross Rent for the Additional Premises in the total amount of Nine Thousand One Hundred Seventy
Two and 09/100 ($9,172.09) Dollars shall be paid by Tenant to Landlord upon Tenants execution of this First Amendment to
Lease. This amount shall be held as Security Deposit pursuant to all terms and conditions of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">15.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furniture</U>.
<FONT STYLE="letter-spacing: -0.15pt">Tenant shall have the right to use any office furniture located within the Additional Premises
during the Term of this Lease at no additional cost to Tenant. The foregoing shall not grant any rights of ownership to any such
office furniture to Tenant. All such furniture shall remain at the Additional Premises upon Tenants vacating of the Additional
Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">16.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Premises Tenant Improvements</U>. Tenant has performed such inspections of the Additional Premises as it deemed necessary in its
sole and absolute discretion and understands the Tenant acceptance of the Additional Premises in accordance with the terms and
conditions contained herein is a material inducement to Landlord entering into this First Amendment to Lease. Tenant hereby accepts
the Additional Premises in its &ldquo;AS IS, Where Is&rdquo; condition with any and all faults. Landlord shall have no responsibility
or obligation whatsoever to perform any repairs, improvements or alterations to the Additional Premises in any manner and all
alterations or improvements which Tenant may desire to the Additional Premises shall be at Tenant&rsquo;s sole cost and expense
and shall be performed in accordance with all other terms and conditions required pursuant to Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">17.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lease
Terms.</U> Commencing upon the Additional Premises Commencement Date, other than as specifically provided for herein with
respect to the Additional Premises, all the terms and conditions of the Lease shall also apply to and govern the Additional
Premises. Tenant agrees that upon the Additional Premises Commencement Date, Tenant shall continue to be responsible for
compliance with and satisfying all terms and conditions of the Lease with respect to the Premises, and specifically with
those terms and conditions as are specifically set forth with respect to the Additional Premises herein which Tenant shall
also be responsible for commencing upon the Additional Premises Commencement Date. Except to the extent any terms and
conditions specifically provided for in this First Amendment being specifically applicable to the Additional Premises, all
terms and conditions of the Lease shall apply to and bind both the Additional Premises, in addition to the Original Premises.
Notwithstanding the foregoing, this shall in no way diminish or reduce any responsibility, obligation or liability of Tenant
pursuant to the Lease with respect to the Original Premises, but all such terms, conditions, obligations and responsibilities
of Tenant with respect to the Original Premises shall continue for the full Term of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Estoppel</U>.
Tenant hereby represents and warrants that Tenant is not in default of any term or condition of the Lease and that the Lease is
in full force and effect and is the binding obligation of the Tenant in accordance with all terms and conditions of the Lease,
as supplemented or amended herein. Tenant further acknowledges and represents that the Landlord is not in default of any term
or condition of the Lease, and the Lease is in full force and effect in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">19.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="letter-spacing: -0.15pt"><U>Bankruptcy
or Insolvency</U>. Tenant shall not assign, mortgage or encumber this Lease, </FONT><FONT STYLE="letter-spacing: -0.2pt">nor sublet,
nor suffer or permit the Premises or any part thereof to be used by others, except as allowed </FONT><FONT STYLE="letter-spacing: -0.3pt">herein;
provided, however, that if this Lease is assigned to any person or entity pursuant to the provisions </FONT><FONT STYLE="letter-spacing: -0.2pt">of
the Bankruptcy Code, 11 U.S.C. &sect;101 et seq. (the &ldquo;Bankruptcy Code&rdquo;), any and all monies or other considerations
payable or otherwise to be delivered in connection with such assignment shall be paid or delivered
to Landlord, shall be and remain the exclusive property of Landlord and shall not constitute property of Tenant or of the estate
of Tenant within the meaning of the Bankruptcy Code. Any and all </FONT><FONT STYLE="letter-spacing: -0.3pt">monies or other consideration
constituting Landlord&rsquo;s property under the preceding sentence not paid or delivered to Landlord shall be held in trust for
the benefit of Landlord and be promptly paid to or turned over to Landlord. In the event that Tenant shall become a Debtor under
the Bankruptcy Code, and the </FONT><FONT STYLE="letter-spacing: -0.15pt">Trustee or Tenant shall elect to assume this Lease for
the purpose of assigning the same or otherwise, </FONT><FONT STYLE="letter-spacing: -0.1pt">such election and assignment may only
be made if all the terms and conditions herein are satisfied. If </FONT><FONT STYLE="letter-spacing: -0.15pt">such Trustee shall
fail to elect to assume this Lease within sixty (60) days after the filing of the Petition or such shorter period as imposed by
law, this Lease shall, at Landlord&rsquo;s sole option, be deemed to have been rejected. Landlord </FONT><FONT STYLE="letter-spacing: -0.05pt">shall
thereupon be immediately entitled to possession of the Premises without further obligation to </FONT><FONT STYLE="letter-spacing: -0.25pt">Tenant
or the Trustee, and this Lease shall be terminated, but Landlord&rsquo;s right to be compensated for </FONT>damages both at law
and as provided herein in such case shall survive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">20.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="letter-spacing: -0.1pt"><U>Notices</U>.
All notices, communications and statements required or permitted under this Lease </FONT><FONT STYLE="letter-spacing: -0.3pt">shall
be in writing, delivered in person or sent by United State Registered or Certified Mail, return receipt </FONT><FONT STYLE="letter-spacing: -0.2pt">requested,
with postage prepaid, or Express Mail or Federal Express (or other similar courier service </FONT><FONT STYLE="letter-spacing: -0.05pt">having
a delivery system which provides for or makes available a signed receipt of delivery) or by </FONT><FONT STYLE="letter-spacing: -0.15pt">facsimile
transmission (provided an original copy is thereafter provided by Express Mail or Federal </FONT>Express overnight carrier service,
addressed to the parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 45%">AS
TO TENANT:</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%">AS TO LANDLORD:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="letter-spacing: -0.25pt">TherapeuticsMD,
Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>6800 Broken Sound, LLC</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Attention:
Mitchell Krassan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Attention: Marc Bell</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>6800
Broken Sound Parkway</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="letter-spacing: -0.15pt">6800 Broken Sound Parkway</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>3<SUP>rd</SUP>
Floor</TD>
    <TD>&nbsp;</TD>
    <TD>Boca
Raton, FL 33487</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="letter-spacing: -0.25pt">Boca
Raton, FL 33487</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Phone: (561) 988-1700</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Phone:____________________________</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>With
Copy to:&#9;</TD>
    <TD>&nbsp;</TD>
    <TD>With
Copy to:&#9;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>TheapeuticsMD,
Inc.&#9;</TD>
    <TD>&nbsp;</TD>
    <TD>Scott A. Elk, Esq.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Attention:
Legal Dept.</TD>
    <TD>&nbsp;</TD>
    <TD>Scott A. Elk, P.A</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>6800
Broken Sound Parkway NW</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">750 Park of Commerce Blvd.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>3<SUP>rd</SUP>
Floor&#9;</TD>
    <TD>&nbsp;</TD>
    <TD>Suite
400</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="letter-spacing: -0.25pt">Boca
Raton, FL 33487</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="letter-spacing: -0.25pt">Boca
Raton, FL 33487</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Phone:____________________________</TD>
    <TD>&nbsp;</TD>
    <TD>Phone: (561) 368-5551</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.2pt 0 0.2pt; text-align: justify; text-indent: -0.2pt; background-color: white"><FONT STYLE="letter-spacing: -0.25pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.1pt">Mail service
shall be deemed effective upon the earlier of either seventy two (72) hours after </FONT><FONT STYLE="letter-spacing: -0.3pt">deposit
in the U.S. mail, in accordance herewith, or upon receipt or refusal to accept receipt by a reputable </FONT>courier service. Notices
sent by facsimile transmission which are received by 4:00&nbsp;p.m. (in the <FONT STYLE="letter-spacing: -0.15pt">addressee&rsquo;s
time zone), shall be deemed delivered as of the date of such transmission, provided that an </FONT><FONT STYLE="letter-spacing: -0.25pt">original
copy of such transmission is delivered to the addressee by a nationally utilized overnight courier service on the day following
such transmission. Either party by written notice to the other may designate </FONT>additional parties to receive copies of notices
sent to it. Such designees may be changed by written <FONT STYLE="letter-spacing: -0.2pt">notice. Either party may at any time,
in the manner set forth for giving notice to the other, designate a </FONT><FONT STYLE="letter-spacing: -0.25pt">different address
to which notices, communication and statements to it shall be sent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.25pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">21.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="letter-spacing: -0.25pt"><U>RADON
GAS</U>. Radon is a naturally occurring radioactive gas that, when it has accumulated in a </FONT><FONT STYLE="letter-spacing: -0.15pt">building
in sufficient quantities, may present health risks to persons who are exposed to it over time. </FONT><FONT STYLE="letter-spacing: -0.05pt">Levels
of radon that exceed federal and state guidelines have been found in buildings in Florida. </FONT><FONT STYLE="letter-spacing: -0.15pt">Additional
information regarding radon and radon testing may be obtained from your county public </FONT>health unit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">22.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Duplicate Counterparts</U>. This First
Amendment may be executed by the parties in duplicate counterparts and when taken together the same shall make one complete and
binding document. This First Amendment may be executed in full via facsimile transfer or electronic transmission, which facsimile
copy or electronic transfer shall be deemed as binding as an original. All parties hereto may rely upon such facsimile copy or
electronic transfer as though it were an original</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">23.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Superseding Clause</U>. The terms
and conditions of this First Amendment shall supersede, amend and modify all terms and conditions of the Lease. In the event of
any conflict between the terms and conditions contained herein and the terms and conditions contained in the Lease, all terms and
conditions contained in this First Amendment shall control. In all other respects, all terms and conditions of the Lease shall
remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Signature Page to Follow]</I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
respective parties have signed, sealed and delivered this Second Amendment on the date and year written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">WITNESSES:</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">LANDLORD:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Signed, sealed and delivered&#9;in the presence of:</P>

</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">6800 BROKEN SOUND LLC, a Florida
limited liability company</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Marc Bell</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt">Print Name: </TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Marc Bell</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Print Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">STATE OF <U>FLORIDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</U>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) ss:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">COUNTY OF<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">I HEREBY CERTIFY that on
this day, before me, an officer duly authorized in the State aforesaid and in the County aforesaid to take acknowledgments, the
foregoing instrument was acknowledged before me by MARC BELL as Manager of 6800 BROKEN SOUND LLC, a Florida limited liability company,
on behalf of the Company, who</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.4in">&#9744;&nbsp;&nbsp;is personally known to me or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.4in">&#9744;&nbsp;&nbsp;has produced ___________________________
as identification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in">WITNESS my hand and official seal in the County and State last
aforesaid this __________&nbsp;day of ____________, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black">(NOTARY SEAL)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><U></U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid">NOTARY PUBLIC</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">(Name of Notary Typed, Printed, or Stamped)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 25%">My Commission E&#9;xpires:</TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
<TD COLSPAN="2">WITNESSES:</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">TENANT:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Signed, sealed and delivered&#9;in the presence of:</P>

</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">THERAPEUTICSMD, INC., a Nevada corporation</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid">/s/ John Milligan</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Robert G. Finizio</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt">Print Name: </TD>
    <TD STYLE="border-bottom: Black 1pt solid">John Milligan</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Robert G. Finizio</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Daniel A. Carwright</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Chief Executive
Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Print Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Daniel A. Cartwright</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">February
18, 2005&#9;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">STATE OF <U>FLORIDA
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</U>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) ss:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">COUNTY OF<U> </U> <U>PALM BEACH&nbsp;</U>)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">I HEREBY CERTIFY that on
this day, before me, an officer duly authorized in the State aforesaid and in the County aforesaid to take acknowledgments, the
foregoing instrument was acknowledged before me by <U>Robert G. Finizio</U> as authorized representative of THERAPEUTICSMD, INC.
a Nevada corporation, on behalf of the Company, who</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.4in">&#9746; &nbsp;is personally known
to me or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.4in">&#9744; &nbsp;has produced ___________________________
as identification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.4in">WITNESS my hand and official seal in the County
and State last aforesaid this18th day of February, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: black">(NOTARY SEAL)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">                                                                                                                                <TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD COLSPAN="2">/s/ Giuseppina N. Gamby</TD></TR>
<TR STYLE="vertical-align: top; text-align: left"><TD></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid">NOTARY PUBLIC</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">Giuseppina N. Gamby</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">(Name of Notary Typed, Printed, or Stamped)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 25%">My Commission Expires:</TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid">January 27, 2017&#9;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">7</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-10k_123114.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U><A NAME="Exhibits"></A>Exhibit
23.1</U></B></FONT></P>

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B>&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We consent to the incorporation by reference in the registration
statements (Nos. 333-185156, 333-186189, 333-193558, 333-197699, 333-201171) on Form S-3 and (No. 333-191730) on Form S-8 of TherapeuticsMD,
Inc. of our report dated March 12, 2015, relating to our audits of the consolidated financial statements as of December 31, 2014
and 2013 and for each of the three years in the period ended December 31, 2014, and the effectiveness of internal control over
financial reporting as of December&nbsp;31, 2014, which appear in the Annual Report on Form 10-K of TherapeuticsMD, Inc. for the
year ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>/s/ Rosenberg Rich Baker Berman &amp; Company</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Somerset, NJ</P>

<P STYLE="margin: 0">March 12, 2015</P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATE OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;<A HREF="txmd-10k_123114.htm">TherapeuticsMD, Inc. 10-K</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><U>Exhibit 31.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Certification of Chief Executive Officer
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Robert G. Finizio, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">1. I have reviewed this annual report
on Form 10-K of TherapeuticsMD, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">2. Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">d) Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most
recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top; width: 42%; padding: 0; font-size: 9pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 12, 2015</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 58%; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; font-size: 12pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font-size: 12pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding: 0; font-size: 9pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    <I>Robert G. Finizio</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 9pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert
    G. Finizio</FONT></TD>
    <TD STYLE="padding: 0; font-size: 9pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
                                         Executive Officer</FONT></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
        Executive Officer)</FONT></P></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATE OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="txmd-10k_123114.htm">TherapeuticsMD,
Inc. 10-K</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><A NAME="ex31-2"></A><B><U>Exhibit 31.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Certification of Chief Financial Officer
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Daniel A. Cartwright, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">1. I have reviewed this annual report
on Form 10-K of TherapeuticsMD, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">2. Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">d) Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most
recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top; width: 42%; padding: 0; font-size: 9pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 12, 2015</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 58%; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; font-size: 12pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font-size: 12pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding: 0; font-size: 9pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    <I>Daniel A. Cartwright</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 9pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Daniel
    A. Cartwright</FONT></TD>
    <TD STYLE="padding: 0; font-size: 9pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
                                         Financial Officer</FONT></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
        Financial Officer and Principal Accounting Officer)</FONT></P></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATE OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="txmd-10k_123114.htm">TherapeuticsMD,
Inc. 10-K</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><A NAME="ex32-1"></A><B><U>Exhibit 32.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Section 1350 Certification of Chief
Executive Officer </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">In connection with the Annual Report of TherapeuticsMD, Inc. (the "Company") on Form 10-K for the year ended December 31,
2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Robert G. Finizio, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">(1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">(2) The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; font: 9pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 12, 2015</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    <I>Robert G. Finizio</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 9pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:
                                         &#9;Robert G. Finizio</FONT></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:
        &#9;Chief Executive Officer</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATE OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="txmd-10k_123114.htm">TherapeuticsMD, Inc. 10-K</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><A NAME="ex32-2"></A><B><U>Exhibit 32.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Section 1350 Certification of Chief
Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">In connection with the Annual Report of TherapeuticsMD, Inc. (the "Company") on Form 10-K for the year ended December 31,
2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Daniel A. Cartwright, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">(1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">(2) The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; font: 9pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 12, 2015</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    <I>Daniel A. Cartwright</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 9pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:
                                         &#9;Daniel A. Cartwright</FONT></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:
        &#9;Chief Financial Officer</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>txmd-20141231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20141231\txmd_123114.xfr; Date: 2015%2D03%2D10T21:08:48 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:txmd="http://therapeuticsmd.com/20141231">
    <link:schemaRef xlink:href="txmd-20141231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-11_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-08</xbrli:startDate>
        <xbrli:endDate>2013-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_SancilioAndCompanyWarrants3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-30to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-30</xbrli:startDate>
        <xbrli:endDate>2013-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-24to2013-02-25_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-24</xbrli:startDate>
        <xbrli:endDate>2013-02-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-12to2013-03-13_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-12</xbrli:startDate>
        <xbrli:endDate>2013-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-19to2013-03-21_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-19</xbrli:startDate>
        <xbrli:endDate>2013-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_DeferredRevenueConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:DeferredRevenueConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_DeferredRevenueConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:DeferredRevenueConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_InternalRevenueServiceIRSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_EquipmentMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_EquipmentMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_WarrantMember278504544">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-06-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-03to2012-10-04_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-03</xbrli:startDate>
        <xbrli:endDate>2012-10-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_NotesIssuedToPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_custom_NotesIssuedToParty1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToParty1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-03to2012-10-04_custom_NotesIssuedToParty2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToParty2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-03</xbrli:startDate>
        <xbrli:endDate>2012-10-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_custom_NonAffiliatedThirdPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:NonAffiliatedThirdPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_DeferredRevenueConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:DeferredRevenueConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-03-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-18to2012-03-19_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-18</xbrli:startDate>
        <xbrli:endDate>2012-03-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-13_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-11-12to2012-11-13_custom_VitaMedPromissoryNotesMember_custom_ReichFamilyLimitedLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:ReichFamilyLimitedLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-11-12</xbrli:startDate>
        <xbrli:endDate>2012-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-11-12to2012-11-13_custom_MrMilliganMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:MrMilliganMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-11-12</xbrli:startDate>
        <xbrli:endDate>2012-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-01to2013-02-28_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-01</xbrli:startDate>
        <xbrli:endDate>2013-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-24to2013-04-25_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-24</xbrli:startDate>
        <xbrli:endDate>2013-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_custom_IssuanceOfPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:IssuanceOfPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_custom_February2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-23to2012-02-24_custom_February2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-23</xbrli:startDate>
        <xbrli:endDate>2012-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_custom_February2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-23to2012-02-24_custom_February2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-23</xbrli:startDate>
        <xbrli:endDate>2012-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-05-31_custom_February2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_June2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_February2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_February2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-21_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-24to2013-04-25_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-24</xbrli:startDate>
        <xbrli:endDate>2013-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-18to2013-03-21_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-18</xbrli:startDate>
        <xbrli:endDate>2013-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_custom_NotesIssuedInAugustAndSeptember2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedInAugustAndSeptember2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-10-31_custom_NotesIssuedInAugustAndSeptember2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedInAugustAndSeptember2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_custom_NotesIssuedInSeptember2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedInSeptember2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-10-31_custom_NotesIssuedInSeptember2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedInSeptember2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-31_custom_July2011SecuredNotes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-31_custom_July2011SecuredNotes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-06-01</xbrli:startDate>
        <xbrli:endDate>2011-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-10-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-10-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-09-30to2011-10-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-30</xbrli:startDate>
        <xbrli:endDate>2011-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_custom_NotesIssuedToVariousPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToVariousPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_NotesIssuedToVariousPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToVariousPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-31_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-19to2013-03-20_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-19</xbrli:startDate>
        <xbrli:endDate>2013-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-25_custom_StifelNicolausAndCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelNicolausAndCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-19to2013-04-20_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-19</xbrli:startDate>
        <xbrli:endDate>2013-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelNicolausAndCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-24</xbrli:startDate>
        <xbrli:endDate>2013-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-01to2013-06-30_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:PrivatePlacementAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:PrivatePlacementAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-01to2012-02-29_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_custom_ModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedIndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedIndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-05-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012NotesWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012NotesWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012NotesWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_June2012NotesWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedIndividuals1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedIndividuals1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-28to2014-07-29_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-28</xbrli:startDate>
        <xbrli:endDate>2014-07-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-07-29_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-07-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-10_us-gaap_SubsequentEventMember_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-02-10_us-gaap_SubsequentEventMember_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-02-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-06-30_custom_NonaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:NonaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-11to2015-02-17_us-gaap_SubsequentEventMember_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-11</xbrli:startDate>
        <xbrli:endDate>2015-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPUnit">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>txmd:Unit</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>txmd:Number</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2014-01-01to2014-12-31">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2014-01-01to2014-12-31">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2014-01-01to2014-12-31">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2014-01-01to2014-12-31">2014-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2014-01-01to2014-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2014-01-01to2014-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2014-01-01to2014-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2014-01-01to2014-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2014-01-01to2014-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2014-01-01to2014-12-31">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2014-01-01to2014-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2014-01-01to2014-12-31">2014</dei:DocumentFiscalYearFocus>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">62016393</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">59079488</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-80532626</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-134749836</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">135086056</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">182982846</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">144977</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">156097</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">7317986</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10690381</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3601189</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">3840639</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1602580</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">522613</us-gaap:DeferredRevenue>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2114217</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">6327129</us-gaap:AccountsPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">62016393</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">59079488</us-gaap:Assets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2551729</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2780851</us-gaap:AssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">135686</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">125000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">665588</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1228588</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1750455</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1427263</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2014-12-31_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">77026</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2014-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">386694</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">61318</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">63293</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">59403346</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">56235344</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2477715</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1537407</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1043618</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1182113</us-gaap:InventoryNet>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1690753</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2154217</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Cash contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">54191260</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1553474</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">51361607</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">126421</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">26555</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">21119</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">144976757</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesIssued>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">149727228</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">127569731</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">91630693</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-07-01to2014-09-30" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-07-01to2013-09-30" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-01-01to2012-12-31" unitRef="USDPShares" decimals="INF">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-04-01to2013-06-30" unitRef="USDPShares" decimals="INF">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-10-01to2013-12-31" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-04-01to2012-06-30" unitRef="USDPShares" decimals="INF">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-07-01to2012-09-30" unitRef="USDPShares" decimals="INF">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-10-01to2012-12-31" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-03-31" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-04-01to2014-06-30" unitRef="USDPShares" decimals="INF">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-10-01to2014-12-31" unitRef="USDPShares" decimals="INF">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-54217210</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-28419313</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-35120235</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-176149</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-2611069</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-18971812</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-6716504</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2012-06-18to2012-06-19_custom_July2011SecuredNotesMember" unitRef="USD" decimals="0">6716504</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2011-10-01to2011-10-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">100000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2013-06-01to2013-06-30_custom_February2012NotesMember" unitRef="USD" decimals="0">1054647</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-10307864</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-7390000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-02-23to2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">10307864</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2944</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">45036</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:InterestExpenseDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestExpenseDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1165981</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1905409</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1503922</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeInterest contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">37309</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">27234</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNonoperatingIncome contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">46569</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">34544</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">3001</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-54041061</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-25808244</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-16148423</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">65395477</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">32624245</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">18618323</us-gaap:OperatingExpenses>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">52467</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">58145</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">56260</us-gaap:DepreciationAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">43218938</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">13551263</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">4492362</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">22124072</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">19014837</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">14069701</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GrossProfit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">11354416</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">3118</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">1646</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">6816001</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">2469900</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1157</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">1617</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-10-01to2013-12-31" unitRef="USD" decimals="0">2396</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">386</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">447</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">729</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">908</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">2000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">2859</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">3377</us-gaap:GrossProfit>
    <us-gaap:CostOfGoodsSold contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">3671803</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1959597</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1348113</us-gaap:CostOfGoodsSold>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">15026219</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">4186</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">2295</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">8775598</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">3818013</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1537</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">2081</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-10-01to2013-12-31" unitRef="USD" decimals="0">2863</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">722</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">819</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">1036</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">1241</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">1609950</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">1586903</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">1804018</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">4053838</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">1221212</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">1711417</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member" unitRef="USD" decimals="0">2588626</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member" unitRef="USD" decimals="0">1312192</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member" unitRef="USD" decimals="0">67599</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member" unitRef="USD" decimals="0">490092</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member" unitRef="USD" decimals="0">830902</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member" unitRef="USD" decimals="0">0</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">2831</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">3752</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">4257</us-gaap:SalesRevenueNet>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">8145486</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">365583</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2012-06-18to2012-06-19_custom_February2012NotesMember" unitRef="Shares" decimals="INF">8145486</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2013-06-01to2013-06-30_custom_February2012NotesMember" unitRef="Shares" decimals="INF">8145486</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">181000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="USD" decimals="0">8145</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3093855</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">3102000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">365</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">180635</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2013-06-01to2013-06-30_custom_February2012NotesMember" unitRef="USD" decimals="0">3102000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-854573</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-75423</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">75423</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">1931788</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">75423</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">854573</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-1931788</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">345746</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">30910</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="USD" decimals="0">1932</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">189068</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">191000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">75</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">30835</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">855</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">344891</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">2775415</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="USD" decimals="0">2775</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1051882</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1054657</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">3953489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">45116352</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9850106</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-01-01to2013-12-31_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">29411765</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF">13750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">3953489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">8565310</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-09to2015-02-10_us-gaap_SubsequentEventMember_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">13580246</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-11to2015-02-17_us-gaap_SubsequentEventMember_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">2037036</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">42771353</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">78650353</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="USD" decimals="0">3954</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7891531</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">7895485</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">45117</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">78605236</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9850</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">42761503</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="USD" decimals="0">30200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">7895485</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="USD" decimals="0">42771353</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-02-09to2015-02-10_us-gaap_SubsequentEventMember_custom_CowenAndCompanyLLCMember" unitRef="USD" decimals="-3">59100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">144976757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">99784982</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">144976757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">82978804</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">54698407</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-1433128</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">48389107</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_CommonStockMember" unitRef="USD" decimals="0">99785</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">50580400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-52113313</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">144977</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">135086056</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-80532626</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">156097</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">182982846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-134749836</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">82979</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">15198241</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-16993078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-1711858</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6716504</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">6716504</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <txmd:AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-7830</txmd:AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued>
    <txmd:AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-7830</txmd:AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">400</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">400</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">36284</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36284</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">36284</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36284</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">867262</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1563620</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1563620</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">867262</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1711956</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">13014784</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">13014784</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1711956</txmd:WarrantsIssuedForFinancingCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4239358</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3170954</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1832061</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1832061</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3170954</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4239358</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-54217210</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-17832</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-7673</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-28419313</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-35120235</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-35120235</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-28419313</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-54217210</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-6376</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">-6009</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-10-01to2013-12-31" unitRef="USD" decimals="0">-8361</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-13290</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-11850</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-4253</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">-5727</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-9183</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="0">-10899</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="0">-16303</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">370453</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">83129</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">83129</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">370453</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">50</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-50</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-45520996</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-20768069</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-12737326</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-150068</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">239450</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2875320</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">639157</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-1079967</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">457828</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1144752</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4212912</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">472851</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1334855</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">37309</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">565706</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-680281</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1386319</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-42281</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">138495</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-571592</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1027137</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">458028</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1068619</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">728253</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">730954</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">636917</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">338457</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfDeferredCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1451934</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4239358</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3207238</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1868345</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1102680</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1604240</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-5436</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-15493</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">40548</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">23480</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">10262</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">28776</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">28776</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">28987</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">47883</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">27484</us-gaap:Depreciation>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-606756</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-583561</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-272506</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherDeposits contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10686</us-gaap:PaymentsForProceedsFromOtherDeposits>
    <us-gaap:PaymentsForProceedsFromOtherDeposits contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">103737</us-gaap:PaymentsForProceedsFromOtherDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">30962</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">40790</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">66405</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">586480</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">439034</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">206101</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">43298099</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">73989416</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">14436885</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">4691847</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1850000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-10-03to2012-10-04_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember" unitRef="USD" decimals="0">100000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-02-23to2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">1700000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-03-18to2013-03-21_custom_June2012NotesMember" unitRef="USD" decimals="0">4882019</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-10-01to2012-10-31_custom_NotesIssuedInAugustAndSeptember2012Member" unitRef="USD" decimals="0">1600000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-10-01to2012-10-31_custom_NotesIssuedInSeptember2012Member" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-10-01to2011-10-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">50000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">300000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2012-11-12to2012-11-13_custom_VitaMedPromissoryNotesMember_custom_ReichFamilyLimitedLPMember" unitRef="USD" decimals="0">299220</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2013-04-24to2013-04-25_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">100735</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">400</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2012-11-12to2012-11-13_custom_VitaMedPromissoryNotesMember_custom_ReichFamilyLimitedLPMember" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2013-02-01to2013-02-28_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">8700000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-02-23to2012-02-24_custom_February2012Notes1Member" unitRef="USD" decimals="0">1000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-02-23to2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">1700000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-03-01to2012-05-31_custom_February2012Notes1Member" unitRef="USD" decimals="0">3000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-06-18to2012-06-19_custom_June2012Notes2Member" unitRef="USD" decimals="0">2000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">181000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">345746</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">30910</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">191000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">42771353</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">78650353</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">7895485</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-2829653</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">52637786</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1427053</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:InterestPaid contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">212853</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">17253</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">696</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-10-03to2012-10-04_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember" unitRef="USD" decimals="0">5341</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-06-01to2012-06-30_custom_NotesIssuedToParty1Member" unitRef="USD" decimals="0">888</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-10-03to2012-10-04_custom_NotesIssuedToParty2Member" unitRef="USD" decimals="0">1519</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2013-04-24to2013-04-25_custom_June2012NotesMember" unitRef="USD" decimals="0">21595</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-06-01to2012-06-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">2160</us-gaap:InterestPaid>
    <us-gaap:NotesIssued1 contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">15123</us-gaap:NotesIssued1>
    <txmd:DebtConversionConvertedInstrumentNonCash contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1054658</txmd:DebtConversionConvertedInstrumentNonCash>
    <txmd:WarrantsExercisedInExchangeForDebtAndAccruedInterest contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">3102000</txmd:WarrantsExercisedInExchangeForDebtAndAccruedInterest>
    <txmd:WarrantsIssuedForServices contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">462196</txmd:WarrantsIssuedForServices>
    <txmd:WarrantsIssuedForServices contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1532228</txmd:WarrantsIssuedForServices>
    <txmd:WarrantsIssuedForFinancing contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1711956</txmd:WarrantsIssuedForFinancing>
    <txmd:WarrantsIssuedForFinancing contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">2509537</txmd:WarrantsIssuedForFinancing>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_EquipmentMember_us-gaap_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_EquipmentMember_us-gaap_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AdvertisingExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">698871</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">11739</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">65944</us-gaap:AdvertisingExpense>
    <txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2606405</txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities>
    <txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1175082</txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">30720359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">16792443</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">15632742</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13927916</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">14293499</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">29926241</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">25926987</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-01-01to2012-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">13733488</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember278504544" unitRef="Shares" decimals="INF">12193499</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">170996</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">152478</us-gaap:DeferredCostsCurrent>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">250943</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">155341</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">621679</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">874294</us-gaap:InventoryFinishedGoods>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">260022</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">23806</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">181186</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">249981</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">249981</us-gaap:DueFromRelatedPartiesCurrent>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1267588</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">299498</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <us-gaap:PrepaidInsurance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">145722</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">394878</us-gaap:PrepaidInsurance>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">530596</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">411864</txmd:PrepaidConsultingCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">155083</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_EquipmentMember" unitRef="USD" decimals="0">132150</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-12-31_EquipmentMember" unitRef="USD" decimals="0">108458</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">53895</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">46625</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">186045</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">93765</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">122752</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <txmd:PrepaidAccreditedCostsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">27234</txmd:PrepaidAccreditedCostsNoncurrent>
    <txmd:PrepaidAccreditedCostsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">64543</txmd:PrepaidAccreditedCostsNoncurrent>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">824221</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">463720</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">899000</txmd:PrepaidManufacturingCostsNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">899000</txmd:PrepaidManufacturingCostsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_InternetDomainNamesMember">P36M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2014-01-01to2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31452</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">2082</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">29455</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">419783</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-90160</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-113640</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">-499</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">-89661</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">-2496</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">-91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">-19401</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">439184</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P14Y9M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2013-01-01to2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P15Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2013-01-01to2013-12-31_us-gaap_InternetDomainNamesMember">P3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P18Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">572726</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">59328</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">675982</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">103368</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">572726</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">59328</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">675982</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">103368</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">755748</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1342228</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">25138</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">25138</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">25138</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">25138</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">25138</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:DividendsPayableAmountPerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.40</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">41359</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">41359</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <txmd:AccruedFinancingCostsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">850000</txmd:AccruedFinancingCostsCurrent>
    <txmd:AccruedFinancingCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedRentCurrent contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedRentCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">91368</us-gaap:AccruedRentCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">126233</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">90446</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">52188</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">72710</us-gaap:AccruedRoyaltiesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">306303</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">160503</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" id="Foot-00-0" decimals="0">177900</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" id="Foot-00-1" decimals="0">185965</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">224550</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">276470</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">256920</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">442430</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">941313</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">814205</us-gaap:AccruedSalariesCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">665782</txmd:AccruedClinicalTrialCostsCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1706542</txmd:AccruedClinicalTrialCostsCurrent>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2014-12-31_us-gaap_InternalRevenueServiceIRSMember" unitRef="USD" decimals="0">105529416</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">-.509</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">-0.324</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">-0.182</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">.111</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">-0.084</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">-.223</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2014-01-01to2014-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2013-01-01to2013-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2012-01-01to2012-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15321048</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6107207</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">43091437</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15321048</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6107207</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">43091437</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">547511</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">186346</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">14773537</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5920861</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">43091437</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:LineOfCredit contextRef="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2014-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2012-11-13_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">299220</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-12-31_custom_NotesIssuedToPartiesMember" unitRef="USD" decimals="0">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-02-29_custom_IssuanceOfPromissoryNotesMember" unitRef="USD" decimals="0">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-02-24_custom_February2012Notes1Member" unitRef="USD" decimals="0">1358014</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">1357110</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-06-19_custom_June2012Notes1Member" unitRef="USD" decimals="0">2347128</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-06-19_custom_June2012Notes2Member" unitRef="USD" decimals="0">2344719</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-09-30_custom_NotesIssuedInAugustAndSeptember2012Member" unitRef="USD" decimals="0">1600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-09-30_custom_NotesIssuedInSeptember2012Member" unitRef="USD" decimals="0">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-07-31_custom_July2011SecuredNotes1Member" unitRef="USD" decimals="0">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-07-31_custom_July2011SecuredNotes2Member" unitRef="USD" decimals="0">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-10-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">534160</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-12-31_custom_NotesIssuedToVariousPartiesMember" unitRef="USD" decimals="0">100000</us-gaap:DebtInstrumentFaceAmount>
    <txmd:DebtInstrumentRemainingFaceAmount contextRef="AsOf2012-06-30_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember" unitRef="USD" decimals="0">100000</txmd:DebtInstrumentRemainingFaceAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2012-01-01to2012-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">2632</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2014-01-01to2014-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2013-01-01to2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2012-01-01to2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">404000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">46000</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2014-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">46000</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2012-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">1272</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">308000</us-gaap:DueFromOfficersOrStockholders>
    <txmd:LegalFeeReimbursement contextRef="From2014-01-01to2014-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">249981</txmd:LegalFeeReimbursement>
    <txmd:LegalFeeReimbursement contextRef="From2013-01-01to2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">249981</txmd:LegalFeeReimbursement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">850000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-05-11_custom_SancilioAndCompanyWarrants1Member" unitRef="Shares" decimals="INF">283333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Shares" decimals="INF">283333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2014-12-31_custom_SancilioAndCompanyWarrants3Member" unitRef="Shares" decimals="INF">283334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_custom_NonAffiliatedThirdPartyMember" unitRef="Shares" decimals="INF">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Shares" decimals="INF">1250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-02-24_custom_February2012NotesMember" unitRef="Shares" decimals="INF">3314700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="Shares" decimals="INF">5685300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesMember" unitRef="Shares" decimals="INF">7000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-02-29_custom_February2012NotesMember" unitRef="Shares" decimals="INF">5685300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-02-29_custom_ModificationWarrantsMember" unitRef="Shares" decimals="INF">3314700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="Shares" decimals="INF">31000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="Shares" decimals="INF">1300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrantsMember" unitRef="Shares" decimals="INF">7000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrants1Member" unitRef="Shares" decimals="INF">6000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrants2Member" unitRef="Shares" decimals="INF">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="Shares" decimals="INF">1500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-12-31_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.79</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-12-31_custom_DeferredRevenueConcentrationRiskMember" unitRef="Pure" decimals="INF">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_custom_DeferredRevenueConcentrationRiskMember" unitRef="Pure" decimals="INF">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-01-01to2012-12-31_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-01-01to2012-12-31_custom_DeferredRevenueConcentrationRiskMember" unitRef="Pure" decimals="INF">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2014-01-01to2014-12-31">P63M</txmd:CapitalLeaseObligationsTerm>
    <txmd:MonthlyBaseRentOfLeases contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">30149</txmd:MonthlyBaseRentOfLeases>
    <txmd:FutureMinimumLeasePaymentsOverLifeOfLease contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1899414</txmd:FutureMinimumLeasePaymentsOverLifeOfLease>
    <us-gaap:LeaseAndRentalExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">361793</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">106315</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-07-01to2013-12-31" unitRef="USD" decimals="0">180894</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">60168</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">41613</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="From2013-07-01to2013-12-31" unitRef="USD" decimals="0">32963</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">371240</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">382377</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">393848</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">302748</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <txmd:OperatingLeasesFutureMinimumPaymentsNetDue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1450213</txmd:OperatingLeasesFutureMinimumPaymentsNetDue>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="From2013-01-30to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.06</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="From2011-03-01to2011-03-31_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.0302</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="From2012-03-18to2012-03-19_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.0235</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="From2013-01-30to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">Interest payments were due and payable on the tenth day following the end of each calendar quarter</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="From2011-03-01to2011-03-31_custom_VitaMedPromissoryNotesMember">The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="From2012-03-18to2012-03-19_custom_VitaMedPromissoryNotesMember">Under the extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013.</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-02-24to2013-02-25_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-03-12to2013-03-13_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:RepaymentsOfDebt contextRef="From2013-03-19to2013-03-21_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">401085</us-gaap:RepaymentsOfDebt>
    <us-gaap:LineOfCreditFacilityDecreaseForgiveness1 contextRef="From2012-11-12to2012-11-13_custom_MrMilliganMember" unitRef="USD" decimals="0">100000</us-gaap:LineOfCreditFacilityDecreaseForgiveness1>
    <us-gaap:InterestExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1165981</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1905409</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">64380</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-01-01to2013-12-31_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">735</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-12-31_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">7366</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-12-31_custom_July2011SecuredNotesMember" unitRef="USD" decimals="0">33204</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-12-31_custom_NotesIssuedToVariousPartiesMember" unitRef="USD" decimals="0">6344</us-gaap:InterestExpense>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">15124</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2013-03-21_custom_June2012NotesMember" unitRef="USD" decimals="0">21595</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFairValue contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">1517741</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">197383</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="AsOf2012-02-29_custom_February2012NotesMember" unitRef="USD" decimals="0">859647</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:LongTermDebt contextRef="AsOf2012-06-19_custom_February2012NotesMember" unitRef="USD" decimals="0">3102000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2012-06-19_custom_July2011SecuredNotesMember" unitRef="USD" decimals="0">1054647</us-gaap:LongTermDebt>
    <txmd:RemainingSurrenderValueOfNotes contextRef="AsOf2012-06-19_custom_February2012NotesMember" unitRef="USD" decimals="0">2691847</txmd:RemainingSurrenderValueOfNotes>
    <txmd:RemainingSurrenderValueOfNotes contextRef="AsOf2012-06-19_custom_February2012Notes1Member" unitRef="USD" decimals="0">1347128</txmd:RemainingSurrenderValueOfNotes>
    <txmd:RemainingSurrenderValueOfNotes contextRef="AsOf2012-06-19_custom_February2012Notes2Member" unitRef="USD" decimals="0">1344719</txmd:RemainingSurrenderValueOfNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2012-06-19_custom_June2012NotesMember" unitRef="Pure" decimals="INF">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2011-10-31_us-gaap_ConvertibleNotesPayableMember" unitRef="Pure" decimals="INF">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2011-07-31_custom_July2011SecuredNotesMember" unitRef="Pure" decimals="INF">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2012-06-18to2012-06-19_custom_June2012NotesMember">Accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember">The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier&#13;of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory&#13;note(s) issued in an amount of not less than $1,000,000, or the Funding.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2012-06-18to2012-06-19_custom_July2011SecuredNotesMember" unitRef="N" decimals="INF">2775415</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2011-10-01to2011-10-30_custom_VitaMedPromissoryNotesMember" unitRef="N" decimals="INF">266822</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2011-09-30to2011-10-31_us-gaap_ConvertibleNotesPayableMember" unitRef="N" decimals="INF">1415136</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2013-06-01to2013-06-30_custom_February2012NotesMember" unitRef="N" decimals="INF">2775415</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2012-06-19_custom_July2011SecuredNotesMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2011-10-30_custom_VitaMedPromissoryNotesMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2011-10-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2013-06-30_custom_February2012NotesMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SharePrice contextRef="AsOf2013-12-31_custom_JefferiesLLCMember" unitRef="USDPShares" decimals="INF">1.70</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="USDPShares" decimals="INF">2.40</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">2.15</us-gaap:SharePrice>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2013-01-01to2013-12-31_custom_JefferiesLLCMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:StockExpectedToIssuedDuringPeriodShares contextRef="From2013-03-19to2013-03-20_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">4411765</txmd:StockExpectedToIssuedDuringPeriodShares>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2013-04-19to2013-04-20_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">1954587</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">1284796</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodValueNewIssues1 contextRef="From2013-04-19to2013-04-20_custom_JefferiesLLCMember" unitRef="USD" decimals="0">48500000</txmd:StockIssuedDuringPeriodValueNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesStockOptionsExercised1 contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">136607</txmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <txmd:StockIssuedDuringPeriodSharesStockOptionsExercised1 contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">266823</txmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <txmd:PrivatePlacementFees contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">552500</txmd:PrivatePlacementFees>
    <us-gaap:LegalFees contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">52016</us-gaap:LegalFees>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">8500001</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">2019-01-31</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrants1Member">2013-06-30</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">2013-10-31</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="USD" decimals="0">405066</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">462196</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">1711956</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2012-02-29_custom_February2012NotesMember" unitRef="USD" decimals="0">10505247</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2012-02-29_custom_ModificationWarrantsMember" unitRef="USD" decimals="0">6124873</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">1532228</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrantsMember" unitRef="USD" decimals="0">9424982</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-02-01to2012-02-29_custom_February2012NotesMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.3335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.6805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.4576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.8229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.4589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.4584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.4429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-02-01to2012-02-29_custom_February2012NotesMember" unitRef="Pure" decimals="INF">0.4450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember" unitRef="Pure" decimals="INF">0.4450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="Pure" decimals="INF">0.4481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="Pure" decimals="INF">0.4471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember" unitRef="Pure" decimals="INF">0.4464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="Pure" decimals="INF">0.4478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.4077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.4600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.0065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-02-01to2012-02-29_custom_February2012NotesMember" unitRef="Pure" decimals="INF">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember" unitRef="Pure" decimals="INF">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="Pure" decimals="INF">0.0104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="Pure" decimals="INF">0.0074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember" unitRef="Pure" decimals="INF">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="Pure" decimals="INF">0.0072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-02-01to2012-02-29_custom_February2012NotesMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2014-01-01to2014-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">1451934</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">1532228</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2012-01-01to2012-12-31_custom_June2012NotesWarrantsMember" unitRef="USD" decimals="0">547210</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2013-01-01to2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">833000</txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">Black-Scholes Model</txmd:ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="USD" decimals="0">405066</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2014-01-01to2014-12-31_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">154068</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">309165</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2013-01-01to2013-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">360528</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2013-01-01to2013-12-31_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">77034</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2012-01-01to2012-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">218045</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2014-12-31_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">154068</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2014-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">257796</us-gaap:PrepaidExpenseCurrent>
    <txmd:FairValueOfWarrantsByRelativeFairValueCalculationMethod contextRef="AsOf2012-06-19_custom_June2012NotesWarrantsMember" unitRef="USD" decimals="0">1649890</txmd:FairValueOfWarrantsByRelativeFairValueCalculationMethod>
    <txmd:RemainingAmortizationOfFinancingCostsAndDiscounts contextRef="From2012-01-01to2012-12-31_custom_June2012NotesWarrantsMember" unitRef="USD" decimals="0">1102680</txmd:RemainingAmortizationOfFinancingCostsAndDiscounts>
    <txmd:NumbersOfUnaffiliatedIndividuals contextRef="AsOf2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="N" decimals="INF">5</txmd:NumbersOfUnaffiliatedIndividuals>
    <txmd:NumbersOfUnaffiliatedIndividuals contextRef="AsOf2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="N" decimals="INF">3</txmd:NumbersOfUnaffiliatedIndividuals>
    <us-gaap:ProfessionalFees contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="USD" decimals="0">29736</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="USD" decimals="0">1656</us-gaap:ProfessionalFees>
    <txmd:LoanGuarantyCosts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2944</txmd:LoanGuarantyCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2014-01-01to2014-12-31_custom_LongTermIncentiveCompensationPlan2009Member">To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember">Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2014-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2014-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2014-01-01to2014-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">18246625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">15632742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">16792443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">13733488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">10590161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">5.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3921000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4391000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">5160000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate contextRef="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember">2014-04-01</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate>
    <us-gaap:DividendsPayableDateDeclaredMonthAndYear contextRef="AsOf2014-12-31">2008-06</us-gaap:DividendsPayableDateDeclaredMonthAndYear>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2014-01-01to2014-12-31">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue contextRef="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">180072</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13927916</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2012-12-31_WarrantMember" unitRef="Shares" decimals="INF">12193499</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2013-12-31_WarrantMember" unitRef="Shares" decimals="INF">14293499</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2011-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3057627</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">17332500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" decimals="INF">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-8145486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593" unitRef="Shares" decimals="INF">-365583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-51142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593" unitRef="Shares" xsi:nil="true" />
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13562764</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">1.26</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="USDPUnit" decimals="INF">2.72</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">0.38</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593" unitRef="USDPUnit" decimals="INF">0.5</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">0.24</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">1.83</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">36623875</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2012-12-31_WarrantMember" unitRef="USD" decimals="0">17971994</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2013-12-31_WarrantMember" unitRef="USD" decimals="0">48932777</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2011-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">3483691</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">35599540</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2012-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">2.05</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2013-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">2.83</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0112</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0072</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0104</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.4429</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.4589</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.4464</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.4481</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">2442000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">2583677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">5121250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-427476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-608750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-46135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">13276462</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">4.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="USD" decimals="0">58878132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">43996311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2012-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">26804117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">14067649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">40720977</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember">P7Y2M12D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember">P7Y8M12D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember">P7Y7M6D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2 contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember">P6Y10M24D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2 contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember">P7Y2M12D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2 contextRef="From2012-01-01to2012-12-31_us-gaap_EmployeeStockOptionMember">P7Y8M12D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2>
    <txmd:ClassOfWarrantOrRighstContractualLifeBeginningOustanding contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember">P7Y10M24D</txmd:ClassOfWarrantOrRighstContractualLifeBeginningOustanding>
    <txmd:ClassOfWarrantOrRighstContractualLifeBeginningOustanding contextRef="From2013-01-01to2013-12-31_WarrantMember">P4Y9M18D</txmd:ClassOfWarrantOrRighstContractualLifeBeginningOustanding>
    <txmd:ClassOfWarrantOrRighstContractualLifeBeginningOustanding contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593">P3Y10M24D</txmd:ClassOfWarrantOrRighstContractualLifeBeginningOustanding>
    <txmd:ClassOfWarrantOrRighstContractualLifeClosingOustanding contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember">P4Y9M18D</txmd:ClassOfWarrantOrRighstContractualLifeClosingOustanding>
    <txmd:ClassOfWarrantOrRighstContractualLifeClosingOustanding contextRef="From2013-01-01to2013-12-31_WarrantMember">P3Y10M24D</txmd:ClassOfWarrantOrRighstContractualLifeClosingOustanding>
    <txmd:ClassOfWarrantOrRighstContractualLifeClosingOustanding contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593">P3Y</txmd:ClassOfWarrantOrRighstContractualLifeClosingOustanding>
    <txmd:ClassOfWarrantOrRighstContractualLifeVestedAndExercisable contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember102288593">P2Y10M24D</txmd:ClassOfWarrantOrRighstContractualLifeVestedAndExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2014-12-31_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2014-12-31_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">1.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USDPShares" decimals="INF">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2014-12-31_us-gaap_WeightedAverageMember" unitRef="USDPShares" decimals="INF">1.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-02-29_custom_February2012NotesMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-02-29_custom_ModificationWarrantsMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USDPShares" decimals="INF">2.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-19_custom_June2012NotesWarrants1Member" unitRef="USDPShares" decimals="INF">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-19_custom_June2012NotesWarrants2Member" unitRef="USDPShares" decimals="INF">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2011-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:SharePrice1 contextRef="AsOf2014-07-29_custom_GoldmanSachsMember" unitRef="USDPShares" decimals="INF">4.67</txmd:SharePrice1>
    <txmd:SharePrice1 contextRef="AsOf2015-02-10_us-gaap_SubsequentEventMember_custom_CowenAndCompanyLLCMember" unitRef="USDPShares" decimals="INF">4.05</txmd:SharePrice1>
    <txmd:StockIssuedDuringPeriodSharesStockOptionsExercised3 contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">724193</txmd:StockIssuedDuringPeriodSharesStockOptionsExercised3>
    <txmd:StockIssuedDuringPeriodSharesStockOptionsExercised3 contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">1691393</txmd:StockIssuedDuringPeriodSharesStockOptionsExercised3>
    <txmd:StockIssuedDuringPeriodSharesStockOptionsExercised2 contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">130380</txmd:StockIssuedDuringPeriodSharesStockOptionsExercised2>
    <txmd:StockIssuedDuringPeriodSharesStockOptionsExercised2 contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">240395</txmd:StockIssuedDuringPeriodSharesStockOptionsExercised2>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">13927916</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2014-01-01to2014-12-31">P3Y</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <txmd:UnamortizedCostsOfWarrants contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">875600</txmd:UnamortizedCostsOfWarrants>
    <txmd:PrepaidExpensesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 6 &amp;#150;PREPAID EXPENSE&amp;#160;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expense consists of the following:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&#13;    &lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;899,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;899,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;463,720&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;824,221&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Accreted prepaid costs&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;64,543&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;27,234&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;TOTAL PREPAID EXPENSE&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,427,263&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,750,455&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</txmd:PrepaidExpensesDisclosureTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 15 &amp;#150; SELECTED QUARTERLY FINANCIAL&#13;DATA (UNAUDITED)&lt;/u&gt;&lt;/b&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Summarized quarterly financial data for fiscal years 2014, 2013,&#13;and 2012 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014 Quarters&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif"&gt;(In thousands, except per share)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;4th&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,831&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;3,752&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;4,186&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;4,257&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,859&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;3,118&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;3,377&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(9,183&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(10,899&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(17,832&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(16,303&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.07&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.12&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013 Quarters&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif"&gt;(In thousands, except per share)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;4th&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,537&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,081&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,295&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,863&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,157&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,617&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,646&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,396&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(6,376&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(6,009&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(7,673&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(8,361&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.05&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012 Quarters&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif"&gt;(In thousands, except per share)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;4th&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;722&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;819&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,036&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,241&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;386&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;447&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;729&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;908&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(13,290&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(11,850&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(4,253&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(5,727&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.16&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.14&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.04&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements&#13;include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances&#13;and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Trade Accounts Receivable and Allowance&#13;for Doubtful Accounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade accounts receivable are customer obligations&#13;due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide&#13;an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,&#13;and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write&#13;off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection&#13;efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance&#13;for doubtful accounts when received. &lt;font style="color: #252525"&gt;To the extent data we use to calculate these estimates does not&#13;accurately reflect bad debts; adjustments to these reserves may be required.&lt;/font&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Fixed Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Equipment&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We state equipment at cost, net of accumulated&#13;depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair&#13;costs to operating expense as incurred. &lt;font style="letter-spacing: -0.15pt"&gt;We compute depreciation using the straight-line method&#13;over the estimated useful lives of the related assets, which range from three to seven years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Leasehold&#13;Improvements&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We state&#13;improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining&#13;term of the lease.&lt;/font&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Intangible&#13;&lt;/u&gt;&lt;/font&gt;&lt;u&gt;Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Patent&#13;and Trademarks&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We have&#13;adopted the provisions of &lt;/font&gt;Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, &lt;font style="letter-spacing: -0.15pt"&gt;350,&#13;&lt;i&gt;Intangible-Goodwill and Other&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or &lt;/font&gt;ASC 350&lt;font style="letter-spacing: -0.15pt"&gt;. Capitalized patent costs,&#13;net of accumulated amortization, include legal costs incurred for patent applications. &lt;/font&gt;In accordance with ASC 350, &lt;font style="letter-spacing: -0.15pt"&gt;once&#13;a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.&#13;If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment&#13;annually or when events or circumstances indicate that their carrying amount may not be recoverable. As of December 31, 2014, we&#13;had 4 issued patents (See Note 7). &lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Impairment of Long-Lived Assets&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review the carrying values of property and&#13;equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying&#13;values may not be recoverable. Such events or circumstances include the following:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; width: 93%"&gt;significant declines in an asset&amp;#146;s market price;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#149;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; width: 93%"&gt;significant deterioration in an asset&amp;#146;s physical condition;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; width: 93%"&gt;significant changes in the nature or extent of an asset&amp;#146;s use or operation;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; width: 93%"&gt;significant adverse changes in the business climate that could impact an asset&amp;#146;s value, including adverse actions or assessments by regulators;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; width: 93%"&gt;accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; width: 93%"&gt;current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&amp;#146;s use; and&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#149;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; width: 93%"&gt;expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If impairment indicators are present, we determine&#13;whether an impairment loss should be recognized by testing the applicable asset or asset group&amp;#146;s carrying value for recoverability.&#13;This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent&#13;of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted&#13;future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective&#13;carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment&#13;in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.&#13;In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected&#13;timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record&#13;a loss for the difference between the assets&amp;#146; fair value and respective carrying values. We determine the fair value of&#13;the assets using an &amp;#147;income approach&amp;#148; based upon a forecast of all the expected discounted future net cash flows associated&#13;with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share,&#13;projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial&#13;relationships, market conditions, and available external information about future trends. We believe our current assumptions and&#13;estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates,&#13;resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets&#13;during the years ended December 31, 2014, 2013 and 2012.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based upon a change in our business model,&#13;deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We account for income taxes under the asset&#13;and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to&#13;differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.&#13;We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which&#13;the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities&#13;of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the&#13;amount that will more likely than not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;,&#13;we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in&#13;an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest&#13;amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in&#13;the period in which those changes in judgment occur. At December 31, 2014, 2013, and 2012 we had no uncertain income tax positions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize both interest and penalties related&#13;to uncertain tax positions as part of the income tax provision. At December 31, 2014 and 2013, we had no tax positions relating&#13;to open tax returns that were considered to be uncertain.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our tax returns are subject to review by the&#13;Internal Revenue Service three years after they are filed. Currently, years filed after 2011 are subject to review.&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We measure the compensation costs of share-based&#13;compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period&#13;during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,&#13;restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation&#13;cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective vesting&#13;periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in&#13;accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the&#13;award and our expected stock price volatility over a period equal to or greater than the expected life of the award.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity instruments (&amp;#147;instruments&amp;#148;)&#13;issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, &lt;i&gt;Equity Based&#13;Payments to Non-Employees&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASC 505&lt;i&gt;. &lt;/i&gt;ASC 505&lt;i&gt; &lt;/i&gt;defines the measurement date and recognition period for&#13;such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the&#13;earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments&#13;is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize the compensation expense for all&#13;share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize&#13;the compensation expense on a straight-line basis over the employee&amp;#146;s requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Debt Discounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs incurred from parties that are providing&#13;long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based&#13;on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the&#13;related debt using the effective interest rate method.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Shipping and Handling Costs&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We expense all shipping and handling costs&#13;as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Advertising&#13;Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We expense advertising costs when incurred.&#13;Advertising costs were $698,871, $11,739 and $65,944 during the years ended December 31, 2014, 2013 and 2012, respectively.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development, or R&amp;#38;D, expenses&#13;include internal R&amp;#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research&#13;sites, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash&#13;share-based compensation expenses. Advance payments to be expensed in future R&amp;#38;D activities were $1,175,082 and $2,606,405&#13;for the years ended December 31, 2014 and 2013, respectively. CRO activity expenses include preclinical laboratory experiments&#13;and clinical trial studies. Other activity expenses include regulatory consulting and legal counsel. The activities undertaken&#13;by our regulatory consultants that were classified as research and development expenses include assisting, consulting with, and&#13;advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing&#13;matters, including preparing protocols and FDA submissions. Legal activities that were classified as research and development&#13;expenses related to designing experiments to generate data for patents and to further the formulation development process for&#13;our pipeline technologies. Outside legal counsel also provided professional research regarding the legal landscape of potential&#13;patents. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for&#13;our clinical trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity expenses to operations as&#13;incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date.&#13;We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D activities when the activity&#13;has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses&#13;and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion&#13;stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies progress to completion. We charge&#13;revisions expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:UseOfEstimates contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our consolidated financial statements have&#13;been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation&#13;of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,&#13;liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including&#13;those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions&#13;that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying&#13;values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material&#13;amounts, from these estimates under different assumptions or conditions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Reclassifications&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain 2013 and 2012 amounts have been reclassified&#13;to conform to current year presentation.&amp;#160;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Summarized quarterly financial data for fiscal years 2014, 2013,&#13;and 2012 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014 Quarters&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif"&gt;(In thousands, except per share)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;4th&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,831&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;3,752&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;4,186&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;4,257&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,859&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;3,118&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;3,377&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(9,183&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(10,899&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(17,832&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(16,303&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.07&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.12&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013 Quarters&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif"&gt;(In thousands, except per share)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;4th&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,537&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,081&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,295&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,863&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,157&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,617&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,646&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,396&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(6,376&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(6,009&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(7,673&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(8,361&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.05&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012 Quarters&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif"&gt;(In thousands, except per share)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;4th&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;722&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;819&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,036&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,241&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;386&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;447&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;729&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;908&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(13,290&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(11,850&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(4,253&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(5,727&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.16&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.14&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.04&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1450213</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below presents the potentially dilutive&#13;securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they&#13;were not antidilutive for the periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;As of December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;15,632,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;13,733,488&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;14,293,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;12,193,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;30,720,359&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;29,926,241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,926,987&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 3 &amp;#150; INVENTORY&amp;#160;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventory consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;874,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;621,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;155,341&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;250,943&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Deferred costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;152,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;170,996&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,182,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,043,618&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventory consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;874,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;621,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;155,341&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;250,943&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Deferred costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;152,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;170,996&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,182,113&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,043,618&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 4 &amp;#150; OTHER CURRENT ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;411,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;530,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;394,878&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;145,722&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;299,498&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,267,588&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Other receivables-related party (Note 12)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;181,186&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;23,806&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Deferred financing costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;260,022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,537,407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,477,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;411,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;530,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;394,878&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;145,722&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;299,498&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,267,588&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Other receivables-related party (Note 12)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;181,186&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;23,806&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Deferred financing costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;260,022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,537,407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,477,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fixed assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;108,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;53,895&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;46,625&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;186,045&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;155,083&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(122,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(93,765&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;63,293&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;61,318&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 5 &amp;#150; FIXED ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fixed assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;108,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;53,895&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;46,625&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;186,045&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;155,083&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(122,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(93,765&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;63,293&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;61,318&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense for the years ended December&#13;31, 2014, 2013, and 2012 was $28,987, $47,883, and $27,484, respectively. In December 2013, accumulated depreciation was reduced&#13;by $11,980 associated with leasehold improvements of our previously leased office property.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expense consists of the following:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;899,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;899,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;463,720&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;824,221&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Accreted prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;64,543&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;27,234&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;TOTAL PREPAID EXPENSE&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,427,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,750,455&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 7 &amp;#150; INTANGIBLE ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;The following table sets forth&#13;the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2014 and December 31, 2013:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Gross Carrying Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Net &amp;#160; &lt;br /&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Weighted- Average &amp;#160; &lt;br /&gt;Remaining Amortization Period (yrs.)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; software patent&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(2,496&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;29,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;14.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 20pt; text-indent: -10; font-family: Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Approved hormone therapy drug&amp;#160;candidate patents&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;439,184&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(19,401&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;419,783&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;18&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 10; font-family: Times New Roman, Times, Serif"&gt;Non-amortizing intangible assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 20pt; text-indent: -10; font-family: Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;103,368&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;103,368&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,342,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(113,640&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,228,588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Gross Carrying Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Net &amp;#160; &lt;br /&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Weighted- Average Remaining Amortization Period (yrs.)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; software patent&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(499&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;31,452&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;15.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Development costs of&amp;#160;corporate website&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(89,661&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,082&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.3&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 10; font-family: Times New Roman, Times, Serif"&gt;Non-amortizing intangible assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;572,726&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;572,726&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;59,328&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;59,328&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;755,748&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(90,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;665,588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;We amortized&#13;the intangible asset related to development costs for corporate website over 36 months, which is the prescribed life for software&#13;and website development costs. We amortize the intangible asset related to OPERA&amp;#174; using the straight-line method over the estimated&#13;useful life of approximately 20 years, which is the life of the intellectual property patents. We amortize the approved hormone&#13;therapy drug candidate patents using straight-line method over the estimated useful life of approximately 20 years. During the&#13;years ended December 31, 2014 and 2013, there was no impairment recognized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;font style="background-color: white"&gt;In&#13;addition to numerous pending patent applications, as of December 31, 2014, we had 4 issued patents, including: &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white"&gt;one method patent that relates to our OPERA&amp;#174; information&#13;technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/p&gt;&#13;                                                        &lt;p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white"&gt;3 utility patents that relate to our combination progesterone&#13;and estradiol formulations, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending&#13;patent applications with respect to certain of these patents in Argentina, Australia, Canada, the European Union, Mexico, Brazil,&#13;Japan, Russia, South Africa and South Korea.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;font style="background-color: white"&gt;Subsequent&#13;to December 31, 2014, 1 additional patent was issued related to our combination progesterone and estradiol formulations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;Amortization&#13;expense was $23,480, $10,262 and $28,776 for the years ended December 31, 2014, 2013, and 2012, respectively.&lt;/font&gt; As of December&#13;31, 2014, the estimated amortization expense for the next five years is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Estimated Amortization&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 46%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 45%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;The following table sets forth&#13;the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2014 and December 31, 2013:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Gross Carrying Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Net &amp;#160; &lt;br /&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Weighted- Average &amp;#160; &lt;br /&gt;Remaining Amortization Period (yrs.)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; software patent&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(2,496&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;29,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;14.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 20pt; text-indent: -10; font-family: Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Approved hormone therapy drug&amp;#160;candidate patents&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;439,184&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(19,401&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;419,783&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;18&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 10; font-family: Times New Roman, Times, Serif"&gt;Non-amortizing intangible assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 20pt; text-indent: -10; font-family: Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;103,368&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;103,368&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,342,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(113,640&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;1,228,588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Gross Carrying Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Net &amp;#160; &lt;br /&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Weighted- Average Remaining Amortization Period (yrs.)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#174;&lt;/sup&gt; software patent&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(499&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;31,452&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;15.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Development costs of&amp;#160;corporate website&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(89,661&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;2,082&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.3&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 10; font-family: Times New Roman, Times, Serif"&gt;Non-amortizing intangible assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;572,726&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;572,726&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;59,328&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;59,328&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;755,748&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(90,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;665,588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December&#13;31, 2014, the estimated amortization expense for the next five years is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Estimated Amortization&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,138&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 46%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <txmd:ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average fair value per share of&#13;warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are&#13;set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Weighted average fair value&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.88-1.12&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.72-1.04&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.29-45.89&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.64-44.81&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;5&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</txmd:ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The assumptions&#13;used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.07-1.77&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.65-1.71&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.61-2.23&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68.05-82.29&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33.35-45.76&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.77-46.01&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <dei:EntityPublicFloat contextRef="AsOf2014-06-30" unitRef="USD" decimals="0">399616527</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2015-03-06" unitRef="Shares" decimals="INF">171715551</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2014-06-30_custom_NonaffiliatedEntityMember" unitRef="Shares" decimals="INF">90410979</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 1 &amp;#150; THE COMPANY&amp;#160;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;TherapeuticsMD, Inc., a Nevada corporation,&#13;or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed,&#13;and BocaGreenMD, Inc., a Nevada corporation, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and&#13;BocaGreen collectively are sometimes referred to as &amp;#147;our company,&amp;#148; &amp;#147;we,&amp;#148; &amp;#147;our,&amp;#148; or &amp;#147;us.&amp;#148;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Nature of Business&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are a women&amp;#146;s health care&#13;product company focused on creating and commercializing products targeted exclusively for women. As of the date of these&#13;consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and&#13;commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials&#13;are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies,&#13;including hot flashes, osteoporosis, and vaginal dryness. We are developing these hormone therapy drug candidates, which&#13;contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at&#13;lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are&#13;created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or&#13;in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as&#13;over-the-counter, or OTC, vitamins.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;NOTE&#13;2 &amp;#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements&#13;include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances&#13;and transactions have been eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Cash&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;We&#13;maintain cash at financial institutions that at times may exceed the federally insured limit of $250,000 per financial institution.&#13;We have never experienced any losses related to these funds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Trade Accounts Receivable and Allowance&#13;for Doubtful Accounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade accounts receivable are customer obligations&#13;due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide&#13;an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,&#13;and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write&#13;off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection&#13;efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance&#13;for doubtful accounts when received. &lt;font style="color: #252525"&gt;To the extent data we use to calculate these estimates does not&#13;accurately reflect bad debts; adjustments to these reserves may be required.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Inventories&amp;#160;&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventories&#13;represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or&#13;market using the average-cost method. The costs of manufacturing the prescription products associated with the deferred&#13;revenue (as discussed in Revenue Recognition) are recorded as deferred costs and are included in inventory, until such time&#13;as the related deferred revenue is recognized. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Pre-Launch&#13;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventory&#13;costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe&#13;there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic&#13;benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as&#13;research and development expenses during the period the costs are incurred. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Fixed Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Equipment&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We state equipment at cost, net of accumulated&#13;depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair&#13;costs to operating expense as incurred. &lt;font style="letter-spacing: -0.15pt"&gt;We compute depreciation using the straight-line method&#13;over the estimated useful lives of the related assets, which range from three to seven years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Leasehold&#13;Improvements&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We state&#13;improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining&#13;term of the lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Intangible&#13;&lt;/u&gt;&lt;/font&gt;&lt;u&gt;Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Patent&#13;and Trademarks&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We have&#13;adopted the provisions of &lt;/font&gt;Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, &lt;font style="letter-spacing: -0.15pt"&gt;350,&#13;&lt;i&gt;Intangible-Goodwill and Other&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or &lt;/font&gt;ASC 350&lt;font style="letter-spacing: -0.15pt"&gt;. Capitalized patent costs,&#13;net of accumulated amortization, include legal costs incurred for patent applications. &lt;/font&gt;In accordance with ASC 350, &lt;font style="letter-spacing: -0.15pt"&gt;once&#13;a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.&#13;If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment&#13;annually or when events or circumstances indicate that their carrying amount may not be recoverable. As of December 31, 2014, we&#13;had 4 issued patents (See Note 7). &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Impairment of Long-Lived Assets&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review the carrying values of property&#13;and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their&#13;carrying values may not be recoverable. Such events or circumstances include the following:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;significant declines in an asset&amp;#146;s market price;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;significant deterioration in an asset&amp;#146;s physical condition;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;significant changes in the nature or extent of an asset&amp;#146;s use or operation;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;significant adverse changes in the business climate that could impact an asset&amp;#146;s value, including&#13;adverse actions or assessments by regulators;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;accumulation of costs significantly in excess of original expectations related to the acquisition&#13;or construction of an asset;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;current-period operating or cash flow losses combined with a history of such losses or a forecast&#13;that demonstrates continuing losses associated with an asset&amp;#146;s use; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&amp;#149;&lt;/td&gt;&lt;td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"&gt;expectations that it is more likely than not that an asset will be sold or otherwise disposed of&#13;significantly before the end of its previously estimated useful life.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If impairment indicators are present, we determine&#13;whether an impairment loss should be recognized by testing the applicable asset or asset group&amp;#146;s carrying value for recoverability.&#13;This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent&#13;of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted&#13;future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective&#13;carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment&#13;in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.&#13;In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected&#13;timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record&#13;a loss for the difference between the assets&amp;#146; fair value and respective carrying values. We determine the fair value of&#13;the assets using an &amp;#147;income approach&amp;#148; based upon a forecast of all the expected discounted future net cash flows associated&#13;with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share,&#13;projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial&#13;relationships, market conditions, and available external information about future trends. We believe our current assumptions and&#13;estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates,&#13;resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets&#13;during the years ended December 31, 2014, 2013 and 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our financial instruments consist primarily&#13;of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and&#13;accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level&#13;1 assets under the fair value hierarchy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We categorize our assets and liabilities&#13;that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, &lt;i&gt;Fair&#13;Value Measurements. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical&#13;assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the&#13;consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&lt;td style="width: 8%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;                                         1&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif"&gt;unadjusted&#13;quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&lt;td style="width: 8%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;                                         2&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif"&gt;quoted&#13;prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly&#13;or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&lt;td style="width: 8%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;                                         3&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif"&gt;unobservable&#13;inputs for the asset or liability.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014, and 2013, we had no assets&#13;or liabilities that were valued at fair value on a recurring basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of indefinite-lived assets is&#13;measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with our impairment&#13;test. There was no impairment of intangible assets during the years ended December 31, 2014, 2013, and 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based upon a change in our business model,&#13;deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We account for income taxes under the asset&#13;and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to&#13;differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.&#13;We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which&#13;the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities&#13;of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the&#13;amount that will more likely than not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;,&#13;we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in&#13;an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest&#13;amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in&#13;the period in which those changes in judgment occur. At December 31, 2014, 2013, and 2012 we had no uncertain income tax positions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize both interest and penalties related&#13;to uncertain tax positions as part of the income tax provision. At December 31, 2014 and 2013, we had no tax positions relating&#13;to open tax returns that were considered to be uncertain.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our tax returns are subject to review by the&#13;Internal Revenue Service three years after they are filed. Currently, years filed after 2011 are subject to review.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We measure the compensation costs of share-based&#13;compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period&#13;during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,&#13;restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation&#13;cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective vesting&#13;periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in&#13;accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the&#13;award and our expected stock price volatility over a period equal to or greater than the expected life of the award.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity instruments (&amp;#147;instruments&amp;#148;)&#13;issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, &lt;i&gt;Equity Based&#13;Payments to Non-Employees&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASC 505&lt;i&gt;. &lt;/i&gt;ASC 505&lt;i&gt; &lt;/i&gt;defines the measurement date and recognition period for&#13;such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the&#13;earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments&#13;is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize the compensation expense for all&#13;share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize&#13;the compensation expense on a straight-line basis over the employee&amp;#146;s requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Debt Discounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs incurred from parties that are providing&#13;long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based&#13;on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the&#13;related debt using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize revenue on arrangements in accordance&#13;with ASC 605, &lt;i&gt;Revenue Recognition&lt;/i&gt;. We recognize revenue only when the price is fixed or determinable, persuasive evidence&#13;of an arrangement exists, the service is performed, and collectability is reasonably assured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our OTC and prescription&#13;prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing.&#13;The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our&#13;OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay&#13;for the product via third-party payers.&amp;#160;Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from&#13;major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note&#13;13.&amp;#160;There are no major external customers for our OTC prenatal vitamin or other products.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We generate OTC revenue from product sales&#13;primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of&#13;loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include&#13;shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive&#13;the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. &lt;font style="color: #252525"&gt;We&#13;provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.&#13;&lt;/font&gt;We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Prescription Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="color: #252525"&gt;We sell our name&#13;brand and generic prescription products &lt;/font&gt;primarily through drug wholesalers and retail pharmacies. We recognize revenue from&#13;prescription product sales, net of sales discounts, chargebacks, and rebates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We accept returns of unsalable product&#13;from customers within a return period of six months prior to and up to twelve months following product expiration. Our&#13;prescription products currently have a shelf life of 24 months from the date of manufacture. Given the limited history of our&#13;prescription products, we currently cannot reliably estimate expected returns of the prescription products at the time of&#13;shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists,&#13;which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration&#13;of the right of return.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We maintain various rebate programs in an effort&#13;to maintain&lt;i&gt; &lt;/i&gt;a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program&#13;is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We&#13;estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary,&#13;on a quarterly basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Segment Reporting&amp;#160;&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are managed and operated&#13;as one business, which is focused on creating and commercializing products targeted exclusively for women. Our&#13;business operations are managed by a single management team that reports to the President of  our Company. We do not operate&#13;separate lines of business with respect to any of our products and we do not prepare discrete financial information with&#13;respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our&#13;business as one reportable operating segment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Shipping and Handling Costs&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We expense all shipping and handling costs&#13;as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Advertising&#13;Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We expense advertising costs when incurred.&#13;Advertising costs were $698,871, $11,739 and $65,944 during the years ended December 31, 2014, 2013 and 2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development, or R&amp;#38;D, expenses&#13;include internal R&amp;#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research&#13;sites, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based&#13;compensation expenses. Advance payments to be expensed in future R&amp;#38;D activities were $1,175,082 and $2,606,405 for the years&#13;ended December 31, 2014 and 2013, respectively. CRO activity expenses include preclinical laboratory experiments and clinical trial&#13;studies. Other activity expenses include regulatory consulting and legal counsel. The activities undertaken by our regulatory consultants&#13;that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff with&#13;respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols&#13;and FDA submissions. Legal activities that were classified as research and development expenses related to designing experiments&#13;to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel&#13;also provided professional research regarding the legal landscape of potential patents. These consulting and legal expenses were&#13;direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge&#13;internal R&amp;#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon&#13;terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and&#13;services that will be used in future R&amp;#38;D activities when the activity has been performed or when the goods have been received&#13;rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed&#13;and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject&#13;to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise&#13;to the revision become known.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Earnings Per Share&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We calculate earnings per share, or EPS,&#13;in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts:&#13;basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per&#13;share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares&#13;of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such&#13;potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of&#13;diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below presents the potentially dilutive&#13;securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they&#13;were not antidilutive for the periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;As of December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;15,632,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;13,733,488&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;14,293,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;12,193,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;30,720,359&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;29,926,241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,926,987&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our consolidated financial statements have&#13;been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation&#13;of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,&#13;liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including&#13;those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions&#13;that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying&#13;values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material&#13;amounts, from these estimates under different assumptions or conditions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="color: #252525"&gt;In August&#13;2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-05, Presentation of Financial Statements-Going Concern&#13;(Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#146;s Ability to Continue as a Going Concern. ASU 2014-15&#13;requires management to evaluate whether there are conditions and events that raise substantial doubt about &lt;/font&gt;the&#13;entity&amp;#146;s ability to continue as a going concern within one year after the financial statements are issued (or available&#13;to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending&#13;after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is&#13;permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do&#13;not expect the adoption of the ASU 2014-15 to have a material effect on our consolidated financial statements and&#13;disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the FASB and the International&#13;Accounting Standards Board (IASB) issued ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&amp;#146;s&#13;core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount&#13;that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so,&#13;companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance&#13;obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating&#13;the transaction price to each separate performance obligations. ASU 2014-09 is effective for public business entities, certain&#13;not-for-profit entities and certain employee benefit plans, for annual periods beginning after December 15, 2016, including interim&#13;periods within that period. Early adoption is not permitted under GAAP. We are currently evaluating the impact of ASU 2014-09 on&#13;our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2013, the FASB issued ASU 2013-11,&#13;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss,&#13;or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU&#13;2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward,&#13;a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements&#13;as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward&#13;with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability.&#13;The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal&#13;years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 did not have&#13;a material impact on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, the FASB issued ASU No. 2011-11,&#13;Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures&#13;about financial instruments and derivative instruments that are either offset on the statement of financial position or subject&#13;to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of&#13;financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to&#13;facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the&#13;basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after&#13;January 1, 2013, and interim periods within those years. ASU 2011-11 did not have a material impact on our financial position or&#13;results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We do not believe there would have been a material&#13;effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards&#13;been adopted in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Reclassifications&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain 2013 and 2012 amounts have been reclassified&#13;to conform to current year presentation.&amp;#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Cash&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;We&#13;maintain cash at financial institutions that at times may exceed the federally insured limit of $250,000 per financial institution.&#13;We have never experienced any losses related to these funds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Inventories&amp;#160;&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventories&#13;represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or&#13;market using the average-cost method. The costs of manufacturing the prescription products associated with the deferred&#13;revenue (as discussed in Revenue Recognition) are recorded as deferred costs and are included in inventory, until such time&#13;as the related deferred revenue is recognized. &lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize revenue on arrangements in accordance&#13;with ASC 605, &lt;i&gt;Revenue Recognition&lt;/i&gt;. We recognize revenue only when the price is fixed or determinable, persuasive evidence&#13;of an arrangement exists, the service is performed, and collectability is reasonably assured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our OTC and prescription&#13;prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing.&#13;The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our&#13;OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay&#13;for the product via third-party payers.&amp;#160;Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from&#13;major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note&#13;13.&amp;#160;There are no major external customers for our OTC prenatal vitamin or other products.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We generate OTC revenue from product sales&#13;primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of&#13;loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include&#13;shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive&#13;the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. &lt;font style="color: #252525"&gt;We&#13;provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.&#13;&lt;/font&gt;We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Prescription Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="color: #252525"&gt;We sell our name&#13;brand and generic prescription products &lt;/font&gt;primarily through drug wholesalers and retail pharmacies. We recognize revenue from&#13;prescription product sales, net of sales discounts, chargebacks, and rebates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We accept returns of unsalable product&#13;from customers within a return period of six months prior to and up to twelve months following product expiration. Our&#13;prescription products currently have a shelf life of 24 months from the date of manufacture. Given the limited history of our&#13;prescription products, we currently cannot reliably estimate expected returns of the prescription products at the time of&#13;shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists,&#13;which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration&#13;of the right of return.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We maintain various rebate programs in an effort&#13;to maintain&lt;i&gt; &lt;/i&gt;a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program&#13;is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We&#13;estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary,&#13;on a quarterly basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Segment Reporting&amp;#160;&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are managed and operated&#13;as one business, which is focused on creating and commercializing products targeted exclusively for women. Our&#13;business operations are managed by a single management team that reports to the President of  our Company. We do not operate&#13;separate lines of business with respect to any of our products and we do not prepare discrete financial information with&#13;respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our&#13;business as one reportable operating segment.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Earnings Per Share&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We calculate earnings per share, or EPS,&#13;in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts:&#13;basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per&#13;share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares&#13;of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such&#13;potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of&#13;diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below presents the potentially dilutive&#13;securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they&#13;were not antidilutive for the periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;As of December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;15,632,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;13,733,488&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;14,293,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;12,193,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;30,720,359&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;29,926,241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;25,926,987&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="color: #252525"&gt;In August&#13;2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-05, Presentation of Financial Statements-Going Concern&#13;(Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#146;s Ability to Continue as a Going Concern. ASU 2014-15&#13;requires management to evaluate whether there are conditions and events that raise substantial doubt about &lt;/font&gt;the&#13;entity&amp;#146;s ability to continue as a going concern within one year after the financial statements are issued (or available&#13;to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending&#13;after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is&#13;permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do&#13;not expect the adoption of the ASU 2014-15 to have a material effect on our consolidated financial statements and&#13;disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the FASB and the International&#13;Accounting Standards Board (IASB) issued ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&amp;#146;s&#13;core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount&#13;that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so,&#13;companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance&#13;obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating&#13;the transaction price to each separate performance obligations. ASU 2014-09 is effective for public business entities, certain&#13;not-for-profit entities and certain employee benefit plans, for annual periods beginning after December 15, 2016, including interim&#13;periods within that period. Early adoption is not permitted under GAAP. We are currently evaluating the impact of ASU 2014-09 on&#13;our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2013, the FASB issued ASU 2013-11,&#13;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss,&#13;or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU&#13;2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward,&#13;a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements&#13;as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward&#13;with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability.&#13;The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal&#13;years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 did not have&#13;a material impact on our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, the FASB issued ASU No. 2011-11,&#13;Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures&#13;about financial instruments and derivative instruments that are either offset on the statement of financial position or subject&#13;to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of&#13;financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to&#13;facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the&#13;basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after&#13;January 1, 2013, and interim periods within those years. ASU 2011-11 did not have a material impact on our financial position or&#13;results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We do not believe there would have been a material&#13;effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards&#13;been adopted in the current period.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 8 &amp;#150; OTHER CURRENT LIABILITIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other current liabilities consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: left"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td style="width: 4%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,706,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;665,782&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;814,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;941,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued vacation costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;442,430&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;185,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;306,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued royalties&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued rent&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued financing costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;850,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,840,639&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,601,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;_________________&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;sup&gt;(1)&lt;/sup&gt; In June 2008, we declared and&#13;paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359&#13;remained unclaimed by certain stockholders at both December 31, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other current liabilities consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 68%; text-align: left"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td style="width: 4%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,706,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;665,782&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;814,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;941,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued vacation costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;442,430&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;185,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;306,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued royalties&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued rent&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued financing costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;850,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,840,639&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,601,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;_________________&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;sup&gt;(1)&lt;/sup&gt; In June 2008, we declared and&#13;paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359&#13;remained unclaimed by certain stockholders at both December 31, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 9 &amp;#150; NOTES PAYABLE&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Payment of Multiple Advance&#13;Revolving Credit Note&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 31, 2013, we entered into a business&#13;loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the Revolving Credit&#13;Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal amount, at a stated interest&#13;rate of 6% per annum. Plato was able to make advances to us from time to time under the Revolving Credit Note at our request,&#13;which advances were of a revolving nature and were able to be made, repaid, and made from time to time. Interest payments were&#13;due and payable on the tenth day following the end of each calendar quarter in which any interest was accrued and unpaid, commencing&#13;on April 10, 2013, and the principal balance outstanding under the Revolving Credit Note, together with all accrued interest and&#13;other amounts payable under the Revolving Credit Note, if any, was due and payable on February 24, 2014. The Revolving Credit&#13;Note was secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the&#13;Revolving Credit Note. On March 21, 2013, we repaid $401,085, which included accrued interest, and there was no balance outstanding&#13;under the Revolving Credit Note as of December 31, 2013 and February 24, 2014 when it expired. As additional consideration for&#13;the Revolving Credit Note, we granted to Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price&#13;of $3.20 per share (See Note 10).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Borrowing&#13;under Business Loan Agreement and Promissory Note&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2011, VitaMed entered into a business&#13;loan agreement with First United Bank for a $300,000 bank line of credit for which personal guarantees and cash collateral were&#13;required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers&#13;of our Company, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of our Company.&#13;The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012.&#13;We negotiated a one-year extension with First United to the bank line of credit, which was executed on March 19, 2012. Under the&#13;extension, borrowings bore interest at a rate of 2.35% and were due on March 1, 2013. On November 13, 2012, the outstanding balance&#13;of $299,220 was repaid in full, and we amended the line of credit to reflect a $100,000 bank line of credit. In accordance with&#13;the amended line of credit, the personal guarantee and cash collateral limited to $100,000 provided by the Reich Family Limited&#13;Partnership remained in place, while the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan.&#13;In February 2013, we borrowed $100,000 from First United Bank under the amended bank line of credit. On April 25, 2013, we re-paid&#13;$100,735, which represented the principal and interest that was due under the amended bank line of credit. On May 1, 2013, the&#13;amended bank line of credit expired and was not renewed. Accordingly, the personal guarantee was canceled, and the cash collateral&#13;was refunded to the Reich Family Limited Partnership. During the years ended December 31, 2013 and 2012, we paid $735 and $7,366,&#13;respectively, of interest expense, which are included in interest expense on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance of January and February 2012&#13;Promissory Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January and February 2012, we issued&#13;6% promissory notes in the aggregate principal amount of $900,000, due March 1, 2012, which were subsequently increased to an&#13;aggregate principal amount of $1,700,000. As discussed below in Issuance and Settlement of February 2012 Notes, these promissory&#13;notes were modified on February 24, 2012 through the issuance of secured promissory notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Settlement of February 2012&#13;Promissory Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 24, 2012, we&#13;issued promissory notes, the February 2012 Notes, to an individual and an entity, both of which were stockholders of our&#13;company, in the principal amount of $1,358,014 and $1,357,110, respectively, and granted warrants to purchase an aggregate of&#13;9,000,000 shares of our Common Stock pursuant to the terms of a Note Purchase Agreement, dated February 24, 2012. We received&#13;an aggregate of $1,000,000 of new funding upon issuance of the February 2012 Notes and related warrants and surrender by&#13;the holders of certain promissory notes, which we previously issued in the aggregate amount of $1,700,000 plus the&#13;aggregate accrued interest of $15,124 (collectively, the &amp;#147;Prior Notes&amp;#148;). Under the February 2012 Notes, as&#13;amended, we borrowed an additional $3,000,000 during March, April, and May 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We granted warrants to purchase an aggregate&#13;of 5,685,300 shares of Common Stock in consideration of the modification of the Prior Notes and warrants to purchase an aggregate&#13;of 3,314,700 shares of Common Stock in connection with the issuance of the February 2012 Notes. We determined that the resulting&#13;modification of the Prior Notes was substantial in accordance with ASC 470-50,&amp;#160;&lt;i&gt;Modifications and Extinguishments&lt;/i&gt;. As&#13;such the modification was accounted for as an extinguishment and restructuring of the debt, and the 5,685,300 warrants issued in&#13;consideration of the modification were expensed (see Warrant Activity during 2012 in NOTE 10 for more details). The fair&#13;value of the Prior Notes was estimated by calculating the present value of the future cash flows discounted at a market rate of&#13;return for comparable debt instruments to be $1,517,741, resulting in a debt discount of $197,383 and recognized a loss on extinguishment&#13;of debt of $10,307,864, which represented the fair value of the 5,685,300 warrants net of the difference between the carrying amount&#13;of the Prior Notes and their fair value as of the date of the modification on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 19, 2012, we settled an aggregate amount&#13;of $3,102,000 of principal and accrued interest of the February 2012 Notes in exchange for the exercise of warrants to purchase&#13;8,145,486 shares of our Common Stock. As discussed below in Issuance and Payment of June 2012 Notes, the remaining balance of $2,691,847&#13;of the February 2012 Notes was modified on June 19, 2012 through the issuance of the June 2012 Notes (as defined below) (see NOTE&#13;10 for more details).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Payment of June 2012 Promissory&#13;Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 19, 2012, we issued secured promissory&#13;notes, or the June 2012 Notes, to the holders of the February 2012 Notes in the principal amounts of $2,347,128 and $2,344,719, pursuant to the terms of a Note Purchase Agreement. In connection with the June 2012 Notes, the holders of the February 2012 Notes&#13;surrendered the remaining balance of such notes in the aggregate amount of $1,347,128 and $1,344,719,  which sums&#13;included principal and accrued interest through June 19, 2012, and we received an aggregate of $2,000,000 of new funding, or the&#13;June Funding, from the holders of the February 2012 Notes. The principal amount of each of the June 2012 Notes, plus any additional&#13;advance made to us thereafter, together with accrued interest at the annual rate of 6%, was due in one lump sum payment on February&#13;24, 2014. As security for our obligations under the June 2012 Notes, we entered into a security agreement and pledged all of our&#13;assets, tangible and intangible, as further described therein. We also granted warrants to purchase an aggregate of 7,000,000 shares&#13;of our Common Stock in connection with the June Funding. On March 21, 2013, we repaid $4,882,019 of the June 2012 Notes, including&#13;accrued interest, leaving a balance of $21,595 in accrued interest as of March 31, 2013. On April 25, 2013, the balance of accrued&#13;interest was paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Payment of Additional&#13;Promissory Notes in 2012&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August and September 2012, we issued 6%&#13;promissory notes in the amount of $1,600,000 due on October 1, 2012, which due date was subsequently extended. These notes were&#13;paid in full in October 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2012, we issued a 6% promissory&#13;note for $200,000 due on October 15, 2012. This note was paid in full in October 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Payment of Additional Promissory&#13;Notes in 2011&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, we issued 4% promissory notes&#13;to Mr. Finizio and Mr. Milligan for an aggregate of $100,000 due March 1, 2012. These promissory notes were subsequently extended&#13;by mutual agreement to June 1, 2012. In June 2012, we paid the promissory note held by Mr.&amp;#160;Finizio in full, including $888&#13;in accrued interest. Mr. Milligan&amp;#146;s promissory note was extended to October 15, 2012. On October 4, 2012, we paid Mr. Milligan&amp;#146;s&#13;promissory note in full, including $1,519 in accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Conversion of July 2011 Secured Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2011, VitaMed issued two&#13;senior secured promissory notes, or the Secured Notes, each in the amount of $500,000 and also entered into a security&#13;agreement under which VitaMed pledged all of its assets to secure the obligation. The Secured Notes were assumed by us upon&#13;the merger with VitaMed in October 2011 and bore interest at the rate of 6% per annum, were due on the one year anniversary&#13;thereof, and were convertible into shares of our Common Stock at our option. We were permitted to satisfy the obligations&#13;underlying the Secured Notes by delivering such number of shares of our Common Stock calculated by dividing the&#13;then-outstanding principal balance by the Share Price. For purposes of the Secured Notes, the &amp;#147;Share Price&amp;#148; meant&#13;the lower of the most recent price at which we offered and sold shares of our Common Stock (not including any shares of our&#13;Common Stock issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities) or the&#13;five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we reached an agreement to&#13;convert the outstanding amount of the Secured Notes, representing principal and accrued interest through June 19, 2012, of&#13;$1,054,647 into an aggregate of 2,775,415 shares of our Common Stock at $0.38 per share. This resulted in a beneficial&#13;conversion feature of $6,716,504 as recorded in other income and expense on the accompanying consolidated financial&#13;statements. For the year ended December 31, 2012 we recorded an aggregate of $33,204 as interest expense on the accompanying&#13;consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance, Payment and Conversion of VitaMed&#13;Promissory Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2011, VitaMed issued promissory&#13;notes, or the VitaMed Notes, in the aggregate principal amount of $500,000. In connection with the VitaMed Notes, VitaMed&#13;granted warrants to purchase equity interests in VitaMed that were equivalent to an aggregate of 613,718 shares of our Common&#13;Stock when the VitaMed Notes were assumed by us upon the merger with VitaMed. The VitaMed Notes bore interest at a rate of 4%&#13;per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed&#13;received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding. Upon the&#13;closing of the Funding in July 2011, as more fully described above in Conversion of July 2011 Secured Notes, two of the&#13;VitaMed Notes in the aggregate principal amount of $200,000 were paid in full. By mutual agreement, the remaining&#13;VitaMed Notes in the aggregate principal amount of $300,000 were extended. In October 2011, one of the VitaMed Notes in the&#13;aggregate principal amount of $50,000 was paid in full, and, by mutual agreement, certain of the VitaMed Notes in the&#13;aggregate principal amount of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share, which&#13;represented the fair value of our Common Stock on the date of conversion. In June 2012, a VitaMed Note held by an&#13;unaffiliated individual was paid in full, including $2,160 in accrued interest. The remaining VitaMed Notes, held by Mr.&#13;Milligan and by BF Investment Enterprises, Ltd., which is owned by Brian Bernick, a director of our company, in the aggregate&#13;principal amount of $100,000, were extended to October 15, 2012. On October 4, 2012, we re-paid the outstanding VitaMed Notes&#13;in full, including $5,341 in accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September and October 2011, VitaMed&#13;issued convertible notes, or the VitaMed Convertible Notes, in the aggregate amount of $534,160. The VitaMed Convertible&#13;Notes bore interest at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we entered into Debt&#13;Conversion Agreements with the holders of the VitaMed Convertible Notes, pursuant to which we converted the principal and&#13;accrued interest of the VitaMed Convertible Notes into 1,415,136 shares of our Common Stock at $0.38 per share, which&#13;represented the fair value of the shares of our Common Stock on the date of conversion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the year ended December 31, 2012, we recorded&#13;an aggregate of $6,344 as interest expense on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 12 &amp;#150; RELATED PARTIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Loan Guaranty&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2011, VitaMed entered into a business&#13;loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.&#13;Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family&#13;Limited Partnership. See NOTES 9 and 10 &amp;#160;for more details.&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Loans from Affiliates&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2011, VitaMed issued the VitaMed Notes&#13;in the aggregate principal amount of $500,000, of which $100,000 was sold to affiliates. In June 2012, the affiliate notes were&#13;extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments, LLC, which is owned&#13;by Brian Bernick, a member of the board of directors of our company. On October 4, 2012 these VitaMed Notes were paid in full&#13;including $5,341 in accrued interest.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, we issued 4% promissory&#13;notes to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012.&#13;These promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the promissory note held by Mr. Finizio&#13;was paid in full, including $888 in accrued interest. Mr. Milligan&amp;#146;s promissory note was extended to October 15, 2012. On&#13;October 4, 2012 this promissory note was paid in full including $1,519 in accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Purchases by Related Parties&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2012, we sold our products to Dr. Brian&#13;Bernick, a director of our company, in the amount of $2,632, and $1,272 of receivables related thereto remained outstanding at&#13;December 31, 2012. No products were sold to Dr. Bernick during 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Agreements with Pernix Therapeutics, LLC&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 29, 2012, Cooper C.&#13;Collins, president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of&#13;directors. From time to time, we have entered into agreements with Pernix in the normal course of business. All such&#13;agreements are reviewed by independent directors of our company or a committee consisting of independent directors of our company.&#13;During the years ended December 31, 2014, 2013, and 2012, we made purchases of $0, $0 and $404,000, respectively, from&#13;Pernix. At December 31, 2014, 2013, and 2012, there were amounts due Pernix of approximately $46,000, $46,000, and&#13;$308,000 outstanding, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, there were amounts due to us&#13;from Pernix for legal fee reimbursement relating to a litigation matter pursuant to a license and supply agreement in the amount&#13;of $249,981 for each of the years ended December 31, 2014 and 2013.&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Warrants assigned to Related Party&amp;#160;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2012, a warrant to purchase 100,000&#13;shares of our Common Stock was assigned by a non-affiliated third party to the son of the Chairman of our board of directors.&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2014, future minimum rental&#13;payments under our office lease are as follows:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;2015&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;371,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;2016&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;382,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;2017&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;2018&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;302,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;2019&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-cancellable sub-lease income&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td colspan="2" style="text-align: left; padding-bottom: 2.5pt"&gt;Net minimum lease payments&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;1,450,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 66%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 16 &amp;#150; SUBSEQUENT EVENTS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February&amp;#160;10, 2015, we&#13;entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the&#13;several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246&#13;shares of the  our Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen&#13;Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional&#13;shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were&#13;approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses&#13;payable by us. The offering closed on February&amp;#160;17, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 18, 2015, we entered into an agreement&#13;to lease administrative office space in Boca Raton, Florida, pursuant to an addendum to our existing 63 month non-cancelable operating&#13;lease commencing on July 1, 2013 and expiring on September 30, 2018. This addendum will be effective beginning April 1, 2015 and&#13;will expire with the original lease term on September 30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Summary of our Warrant activity and related information for&#13;2012-2014&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Number of Shares Under Warrants&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &amp;#160; &lt;br /&gt;Average&amp;#160; &lt;br /&gt;Remaining &amp;#160; &lt;br /&gt;Contractual&amp;#160; &lt;br /&gt;Life in Years&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Aggregate&amp;#160; &lt;br /&gt;Intrinsic Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2011&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,057,627&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;7.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,483,691&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;17,332,500&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.26&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(8,145,486&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;(51,142&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2012&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;12,193,499&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.63&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;17,971,994&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,100,000&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2.72&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2013&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;14,293,499&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.79&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3.9&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;48,932,777&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(365,583&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.82&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;36,623,875&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10; text-indent: -10"&gt;Vested and Exercisable at December 31, 2014&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,562,764&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2.9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;35,599,540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of activity under the 2009 and 2012&#13;Plans and related information for 2012-2014 follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Number of Shares Under Options&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &amp;#160; &lt;br /&gt;Average &amp;#160; &lt;br /&gt;Remaining &amp;#160; &lt;br /&gt;Contractual&amp;#160; &lt;br /&gt;Life in Years&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Aggregate&amp;#160; &lt;br /&gt;Intrinsic Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 50%; font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2011&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;10,590,161&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;7.6&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;14,067,649&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,121,250&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2.80&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(1,931,788&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;(46,135&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2012&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,733,488&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.16&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7.7&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;26,804,117&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,583,677&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3.31&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(75,423&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(250&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;(608,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2013&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;15,632,742&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.44&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;58,878,132&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,442,000&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4.71&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(854,573&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(250&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;(427,476&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;16,792,443&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.88&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;6.9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;43,996,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;Vested and Exercisable at December 31, 2014&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"&gt;13,276,462&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.39&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5.5&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;40,720,977&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 10 &amp;#150; STOCKHOLDERS&amp;#146; EQUITY&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;At December&#13;31, 2014, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred&#13;Stock were issued or outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Common Stock&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;At&#13;December 31, 2014, we had &lt;/font&gt;250,000,000 shares of Common Stock, par value $0.001,&lt;font style="letter-spacing: -0.15pt"&gt; authorized for&#13;issuance, of which &lt;/font&gt;156,097,019&lt;font style="letter-spacing: -0.15pt"&gt; shares of our Common Stock were issued and outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2014&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 29, 2014, we entered into an underwriting&#13;agreement with Goldman Sachs &amp;#38; Co,  as the representative of the underwriters named therein, or the Goldman&#13;Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of our Common Stock. The price to the public&#13;in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a&#13;30-day option to purchase up to an additional 1,284,796 shares of our Common Stock. On July 30, 2014, the Goldman Sachs Underwriters&#13;exercised their option to purchase the additional 1,284,796 shares of our Common Stock. Net proceeds from this offering were approximately&#13;$42.8 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed&#13;on August 4, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2014, certain&#13;individuals exercised stock options to purchase 860,800 shares of our Common Stock. Stock options to purchase shares of our Common&#13;Stock were exercised as follows: (i) 724,193 options for $345,746 in cash and (ii) &lt;font style="letter-spacing: -0.15pt"&gt;136,607&#13;options, pursuant to the stock options&amp;#146; cashless provision, wherein 130,380 shares of Common Stock were issued. In addition,&#13;during 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were&#13;granted in December 2013.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2014, certain&#13;individuals exercised warrants to purchase 365,583 shares of our Common Stock for $181,000 in cash.&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2013&amp;#160;&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 14, 2013, we entered into an underwriting&#13;agreement with Jefferies LLC as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to&#13;the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share. In&#13;addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to&#13;an additional 4,411,765 shares of our Common Stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters&#13;exercised their option to purchase an additional 1,954,587 shares of our Common Stock, which were issued on April 18, 2013. The&#13;net proceeds to us from this offering were approximately $48.5 million, after deducting underwriting discounts and commissions&#13;and other offering expenses payable by us.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 25, 2013, we entered into an underwriting&#13;agreement with Stifel, Nicolaus &amp;#38; Company, Incorporated, as the representative of the underwriters named therein, or the Stifel&#13;Underwriters, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering&#13;was $2.40 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts&#13;and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2013 certain individuals exercised&#13;stock options to purchase an aggregate of 75,423 shares of our Common Stock for approximately $31,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2012&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During June 2012, we settled $3,102,000 in&#13;principal and accrued interest of the February 2012 Notes in exchange for the holders&amp;#146; exercise of a portion of the related&#13;warrants for an aggregate of 8,145,486 shares of Common Stock. During June 2012, we and the holders also agreed to convert&#13;a portion of the February 2012 Notes, and principal and accrued interest through June 19, 2012 totaling $1,054,647, into 2,775,415&#13;shares of Common Stock at $0.38 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2012, we entered into a Securities&#13;Purchase Agreement with multiple investors, relating to the issuance and sale of Common Stock in a private placement. The private&#13;placement closed on October 2, 2012, through which we sold an aggregate of 3,953,489 shares of Common Stock at $2.15 per share,&#13;for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies LLC served as our exclusive&#13;placement agent. Jefferies&amp;#146; compensation for the transaction was a cash fee of $552,500. We also paid legal fees and expenses&#13;of the investors in the aggregate of $52,016, resulting in net proceeds to us from the private placement of $7,895,485. Pursuant&#13;to the terms of the Securities Purchase Agreement, we agreed to file a registration statement covering the resale of these shares,&#13;which was filed on November 27, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2012, certain&#13;individuals exercised stock options to purchase 1,958,216 shares of Common Stock. Stock options to purchase shares of Common Stock&#13;were exercised as follows: (i) 1,691,393 options for $191,000 in cash and (ii) &lt;font style="letter-spacing: -0.15pt"&gt;266,823 options,&#13;pursuant to the stock options&amp;#146; cashless provision, wherein 240,395 shares of Common Stock were issued. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Warrants to Purchase Common Stock &lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2014, we had warrants outstanding&#13;to purchase an aggregate of 13,927,916 shares of our Common Stock with a weighted-average contractual remaining life of 3.0 years,&#13;and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.82 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The valuation methodology used to determine&#13;the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,&#13;including volatility of the stock price, the risk-free interest rate and the term of the warrant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Warrant Activity During 2014&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2014, we&#13;did not issue any warrants. As of December 31, 2014, unamortized costs associated with the Sancilio &amp;#38; Company, Inc., or SCI&#13;warrants issued in 2013 and 2012 totaled approximately $875,600.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Warrant Activity During 2013&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2013, we issued warrants to purchase&#13;1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see&#13;NOTE 10 above for more details). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October&#13;31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately&#13;$1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and&#13;a dividend yield of 0%. During the years ended December 31, 2014 and 2013, $260,027 and $1,451,934, respectively, was recorded&#13;as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2013, we entered into a consulting agreement&#13;with SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our&#13;efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal&#13;capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights&#13;to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting&#13;agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares&#13;of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 6%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify; width: 89%; font-family: Times New Roman, Times, Serif"&gt;283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application&#13;by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the&#13;terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested&#13;on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of&#13;45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June&#13;30, 2013;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 6%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify; width: 89%; font-family: Times New Roman, Times, Serif"&gt;283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined&#13;by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.84%; risk free rate of&#13;1.41%; and a dividend yield of 0%. As of December 31, 2014, we recorded $154,068 as prepaid expense-short term and $77,026 as prepaid&#13;expense-long term in the accompanying consolidated financial statements. During the years ended December 31 2014 and 2013, we recorded&#13;$154,068 and $77,034, respectively, as non-cash compensation in the accompanying consolidated financial statements; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 6%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify; width: 89%; font-family: Times New Roman, Times, Serif"&gt;283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that&#13;SCI helped us design. It is anticipated that this event will not occur before December 2015.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Warrant Activity During 2012&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2012, we issued warrants for the&#13;purchase of an aggregate of 5,685,300 shares of Common Stock in connection with the modification of certain existing promissory&#13;notes, or the Modification Warrants, and warrants for the purchase of an aggregate of 3,314,700 shares of our Common Stock in connection&#13;with the issuance of the February 2012 Notes, or the February 2012 Warrants (see NOTE 9). Both the Modification Warrants&#13;and the February 2012 Warrants are exercisable at $0.38 per share. The Modification Warrants have a fair value of $10,505,247,&#13;and the February 2012 Warrants have a fair value of $6,124,873. Fair value was determined on the date of the issuance using a term&#13;of five years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification&#13;Warrants as part of the loss on extinguishment of debt in the accompanying consolidated financial statements. The relative fair&#13;value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012&#13;Notes on June 19, 2012, we expensed the remaining unamortized debt discount.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Warrant Activity During 2012&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2012, we issued warrants to purchase&#13;an aggregate of 31,000 shares of Common Stock to five unaffiliated individuals for services rendered. These warrants were valued&#13;on the date of the issuance using a term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield&#13;of 0%; we recorded $29,736 as consulting expense in the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2012, we issued warrants to&#13;purchase an aggregate of 1,300,000 shares of Common Stock to an unaffiliated entity for services to be rendered over&#13;approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug&#13;development efforts, including services in support our ongoing and future drug development and commercialization efforts,&#13;regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and&#13;controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated&#13;therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services&#13;as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at&#13;$1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk&#13;free rate of 0.74%; and a dividend yield of 0%. At December 31, 2014, we had $257,796 reported as prepaid expense-short term&#13;and $386,694 recorded as prepaid expense-long term. During the years ended December 31, 2014, 2013 and 2012, we recorded&#13;$309,165, $360,528 and $218,045, respectively as non-cash compensation with respect to these warrants in the&#13;accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product.&#13;We have determined that the process will take approximately five years. As a result, we are amortizing the $1,532,228 over&#13;five years.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2012, we issued warrant to purchase&#13;aggregate of 7,000,000 shares of Common Stock in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants,&#13;(see NOTE 9). Of the June 2012 Warrants issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable&#13;at $3.00 per share. The fair value of the June 2012 Warrants of $9,424,982 was determined on the date of the issuance using a term&#13;of five years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June&#13;2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the issuance. $547,210&#13;was amortized to interest expense in 2012 and as a result of the repayment of the associated debt on March 21, 2013, the remaining&#13;unamortized debt discount of $1,102,680 was amortized to interest expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2012, we issued warrants to purchase&#13;an aggregate of 1,500 shares of Common Stock to three unaffiliated individuals for services rendered. The warrants were valued&#13;on the date of the issuance using a term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of&#13;0%. A total of $1,656 was recorded as consulting expense in the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Summary of our Warrant activity and related information for&#13;2012-2014&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Number of Shares Under Warrants&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &amp;#160; &lt;br /&gt;Average&amp;#160; &lt;br /&gt;Remaining &amp;#160; &lt;br /&gt;Contractual&amp;#160; &lt;br /&gt;Life in Years&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Aggregate&amp;#160; &lt;br /&gt;Intrinsic Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2011&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,057,627&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;7.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,483,691&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;17,332,500&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.26&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(8,145,486&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;(51,142&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2012&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;12,193,499&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.63&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;17,971,994&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,100,000&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2.72&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2013&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;14,293,499&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.79&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3.9&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;48,932,777&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(365,583&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.82&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;36,623,875&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10; text-indent: -10"&gt;Vested and Exercisable at December 31, 2014&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,562,764&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2.9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;35,599,540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average fair value per share of&#13;warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are&#13;set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; font-family: Times New Roman, Times, Serif"&gt;Weighted average fair value&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;2.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.88-1.12&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.72-1.04&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.29-45.89&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.64-44.81&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;5&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The risk-free interest rate assumption is based&#13;upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Estimated volatility is a measure of the amount&#13;by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average&#13;of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation&#13;of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical&#13;volatility of peer entities due to the lack of sufficient historical data of our stock price during 2011-2014.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Options to Purchase Common Stock of the&#13;Company&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2009, we adopted the 2009 Long Term Incentive&#13;Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our&#13;company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options&#13;and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation&#13;rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described&#13;in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the merger with VitaMed, no Awards&#13;had been issued under the 2009 Plan. As of December 31, 2014, there were Awards for 18,246,625 shares of our Common Stock issued&#13;under the 2009 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 23, 2012, we adopted the 2012&#13;Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve&#13;as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors&#13;of our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2014, there&#13;were awards for 2,600,000 shares issued under the 2012 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The valuation methodology used to determine&#13;the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions&#13;including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions&#13;used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.07-1.77&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.65-1.71&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.61-2.23&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68.05-82.29&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33.35-45.76&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.77-46.01&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 2%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The risk-free interest rate assumption is based&#13;upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated&#13;volatility is a measure of the amount by which the price of Common Stock is expected to fluctuate each year during the term of&#13;the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock&#13;prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal&#13;to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data&#13;on our stock price. The average expected life is based on the contractual term of the option using the simplified method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of activity under the 2009 and 2012&#13;Plans and related information for 2012-2014 follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Number of Shares Under Options&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &amp;#160; &lt;br /&gt;Average &amp;#160; &lt;br /&gt;Remaining &amp;#160; &lt;br /&gt;Contractual&amp;#160; &lt;br /&gt;Life in Years&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"&gt;Aggregate&amp;#160; &lt;br /&gt;Intrinsic Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 50%; font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2011&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;10,590,161&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;0.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;7.6&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;14,067,649&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,121,250&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2.80&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(1,931,788&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;(46,135&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2012&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,733,488&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.16&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7.7&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;26,804,117&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,583,677&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3.31&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(75,423&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(250&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;(608,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2013&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;15,632,742&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.44&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;58,878,132&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,442,000&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4.71&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(854,573&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(250&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;(427,476&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;16,792,443&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.88&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;6.9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;43,996,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;Vested and Exercisable at December 31, 2014&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"&gt;13,276,462&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1.39&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5.5&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;40,720,977&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014, our outstanding options&#13;had exercise prices ranging from $0.10 to $5.21 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Share-based compensation expense for options&#13;recognized in our results for the years ended December 31, 2014, 2013, and 2012&amp;#160; ($4,393,455, $3,200,655 and $1,832,061, respectively)&#13;is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant&#13;and revised in subsequent periods if actual forfeitures differ from the estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014, total unrecognized estimated&#13;compensation expense related to unvested options granted prior to that date was approximately $5,160,000, which is expected to&#13;be recognized over a weighted-average period of 2.9 years. No tax benefit was realized due to a continued pattern of operating&#13;losses. At December 31, 2013 and 2012, total unrecognized estimated compensation expense related to unvested options granted prior&#13;to that date was approximately $3,921,000 and $4,391,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2013, we granted a restricted&#13;stock unit, or the RSU, under our 2012 Plan to an employee of 50,000 shares of our Common Stock having a fair value of&#13;$233,500. During the years ended December 31, 2014 and 2013, we recorded $53,428 and $180,072, respectively, of non-cash&#13;compensation related to the RSU on the accompanying consolidated financial statements. The RSU vested and the shares&#13;of Common Stock underlying the RSU were  issued in June 2014.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE&lt;/u&gt;&lt;/b&gt;&lt;u&gt;&amp;#160;&lt;b&gt; 11 &amp;#150;&#13;INCOME TAXES&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;For&#13;the years ended December 31, 2014, 2013 and 2012, there was no provision for income taxes, current or deferred.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014, we have a federal net&#13;operating loss carry forward of approximately $105,529,416 available to offset future taxable income through 2034.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation between taxes computed at&#13;the federal statutory rate and the consolidated effective tax rate is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&lt;td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(50.9&lt;/td&gt;&lt;td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(32.4&lt;/td&gt;&lt;td style="text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(18.2&lt;/td&gt;&lt;td style="text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;11.1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(8.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(22.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Provision (Benefit) for Income Taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt; Our deferred tax asset and liability&#13;as presented in the accompanying consolidated financial statements consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Deferred Income Tax Assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;43,091,437&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;14,773,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;5,920,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;R&amp;#38;D Credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;547,511&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;186,346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;43,091,437&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;15,321,048&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;6,107,207&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(43,091,437&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(15,321,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(6,107,207&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Deferred Income Tax Assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We believe that it is more likely than&#13;not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets&#13;on our balance sheet and as such, a valuation allowance has been established against the deferred tax&#13;assets for the period ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Unrecognized Tax Benefits&amp;#9;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of the period ended December 31, 2014,&#13;we had no unrecognized tax benefits.&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation between taxes computed at&#13;the federal statutory rate and the consolidated effective tax rate is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&lt;td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(50.9&lt;/td&gt;&lt;td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(32.4&lt;/td&gt;&lt;td style="text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;(18.2&lt;/td&gt;&lt;td style="text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;11.1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(8.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(22.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Provision (Benefit) for Income Taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our deferred tax asset and liability&#13;as presented in the accompanying consolidated financial statements consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Deferred Income Tax Assets:&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;43,091,437&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;14,773,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"&gt;5,920,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;R&amp;#38;D Credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;547,511&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;186,346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;43,091,437&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;15,321,048&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;6,107,207&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(43,091,437&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(15,321,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;(6,107,207&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;Deferred Income Tax Assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 13 - BUSINESS CONCENTRATIONS&amp;#160;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;We purchase our products&#13;from several suppliers with approximately 82%, 98%, and 76% of our purchases supplied from one vendor for the years ended December&#13;31, 2014, 2013, and 2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;We sell our vitamins,&#13;prenatal dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug&#13;stores that generally sell products to retail pharmacies, hospitals, other institutions and directly to retail customers.&#13;Revenue generated from four customers accounted for approximately 75%, 79%, and 28% of our recognized revenue and 97%, 97%,&#13;and 98% of our deferred revenue for the years ended December 31, 2014, 2013, and 2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;For the years&#13;ended December 31, 2014, 2013 and 2012, we had four customers that generated more than 10% of our sales &amp;#150; these&#13;customers are designated as customers &amp;#147;A&amp;#148;, &amp;#147;B&amp;#148;, &amp;#147;C&amp;#148; and &amp;#147;D&amp;#148;. Customers A, B,&#13;C and D generated $1,609,950, $1,586,903, $1,804,018 and $4,053,838, respectively, in sales in 2014; $1,221,212, $1,711,417,&#13;$2,588,626, and $1,312,192, respectively, in sales in 2013; and $67,599, $490,092, $830,902, and $0, respectively,&#13;in sales in 2012.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 14 &amp;#150; COMMITMENTS AND CONTINGENCIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Operating Lease&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We lease administrative office space in Boca&#13;Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30,&#13;2018. The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses)&#13;and sales tax, for a total future minimum payments over the life of the lease of $1,899,414.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The straight line rental expense related&#13;to our current lease totaled&amp;#160; $361,793 for the year ended December 31, 2014, partially offset by the rent income of&#13;$41,613 for sublet space. The straight line rental expense related to our current lease totaled&amp;#160; $180,894 for the six&#13;months ended December 31, 2013, partially offset by rent income of $32,963 for sublet space. The rental expense related to our&#13;prior lease which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013, and $106,315 for the year&#13;ended December 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2014, future minimum rental&#13;payments under our office lease are as follows:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;371,240&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;382,377&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;393,848&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;302,748&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-cancellable sub-lease income&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;Net minimum lease payments&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"&gt;1,450,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 66%; font-family: Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 5%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 25%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Legal Proceedings&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, we are involved in litigation and proceedings&#13;in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material&#13;effect on our consolidated financial condition, results of operations, or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Off-Balance Sheet Arrangements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2014, 2013 and 2012, we had no&#13;off-balance sheet arrangements that have had or are reasonably likely to have current or future effect on our financial&#13;condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or&#13;capital resources that are material to investors.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our financial instruments consist primarily&#13;of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and&#13;accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level&#13;1 assets under the fair value hierarchy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We categorize our assets and liabilities&#13;that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, &lt;i&gt;Fair&#13;Value Measurements. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical&#13;assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the&#13;consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&lt;td style="width: 8%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;                                         1&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif"&gt;unadjusted&#13;quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&lt;td style="width: 8%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;                                         2&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif"&gt;quoted&#13;prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly&#13;or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"&gt;&lt;td style="width: 8%; font-family: Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 12%; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;                                         3&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif"&gt;unobservable&#13;inputs for the asset or liability.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014, and 2013, we had no assets&#13;or liabilities that were valued at fair value on a recurring basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of indefinite-lived assets is&#13;measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with our impairment&#13;test. There was no impairment of intangible assets during the years ended December 31, 2014, 2013, and 2012.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4393455</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3200655</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1832061</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">53428</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">180072</us-gaap:AllocatedShareBasedCompensationExpense>
    <txmd:NumberOfDaysForOptionToPurchaseShares contextRef="From2015-02-11to2015-02-17_us-gaap_SubsequentEventMember_custom_CowenAndCompanyLLCMember">P30D</txmd:NumberOfDaysForOptionToPurchaseShares>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain stockholders at both December 31, 2014 and 2013.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>txmd-20141231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20141231\txmd_123114.xfr; Date: 2015%2D03%2D10T21:08:48 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaaMCbP9w5dzqelBtm95HekanyYg9rdQ1CeA/VxW8SoJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:txmd="http://therapeuticsmd.com/20141231" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20141231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" id="ConsolidatedStatementsOfStockholdersDeficitEquity">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000007 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssets" id="FixedAssets">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpense" id="PrepaidExpense">
	  <link:definition>00000012 - Disclosure - PREPAID EXPENSE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000013 - Disclosure - INTANGIBLE ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000015 - Disclosure - NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000016 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000018 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000019 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" id="SelectedQuarterlyFinancialData">
	  <link:definition>00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000025 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" id="FixedAssetsTables">
	  <link:definition>00000027 - Disclosure - FIXED ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" id="PrepaidExpenseTables">
	  <link:definition>00000028 - Disclosure - PREPAID EXPENSE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000029 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000032 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" id="SelectedQuarterlyFinancialDataTables">
	  <link:definition>00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryDetails" id="InventoryDetails">
	  <link:definition>00000037 - Disclosure - INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
	  <link:definition>00000038 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" id="FixedAssetsDetailsNarrative">
	  <link:definition>00000039 - Disclosure - FIXED ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" id="FixedAssetsDetails">
	  <link:definition>00000040 - Disclosure - FIXED ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" id="PrepaidExpenseDetails">
	  <link:definition>00000041 - Disclosure - PREPAID EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000043 - Disclosure - INTANGIBLE ASSETS (Details )</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
	  <link:definition>00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" id="OtherCurrentLiabilitiesDetailsNarrative">
	  <link:definition>00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000046 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000047 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" id="NotesPayableDetailsNarrative1">
	  <link:definition>00000048 - Disclosure - NOTES PAYABLE (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" id="StockholdersEquityDetailsNarrative1">
	  <link:definition>00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" id="StockholdersEquityDetailsNarrative2">
	  <link:definition>00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
	  <link:definition>00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
	  <link:definition>00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000056 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000057 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000058 - Disclosure - INCOME TAXES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000059 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" id="SelectedQuarterlyFinancialDataDetails">
	  <link:definition>00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20141231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20141231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20141231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20141231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" name="AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedAsCompensationRelatedParty" name="WarrantsIssuedAsCompensationRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" name="AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForFinancingCosts" name="WarrantsIssuedForFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtConversionConvertedInstrumentNonCash" name="DebtConversionConvertedInstrumentNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" name="WarrantsExercisedInExchangeForDebtAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForServices" name="WarrantsIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForFinancing" name="WarrantsIssuedForFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" name="AdvancePaymentsForFutureResearchAndDevelopmentActivities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidConsultingCurrent" name="PrepaidConsultingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidAccreditedCostsNoncurrent" name="PrepaidAccreditedCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchDevelopmentCostsNoncurrent" name="PrepaidResearchDevelopmentCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturingCostsNoncurrent" name="PrepaidManufacturingCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedFinancingCostsCurrent" name="AccruedFinancingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtInstrumentRemainingFaceAmount" name="DebtInstrumentRemainingFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LegalFeeReimbursement" name="LegalFeeReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MonthlyBaseRentOfLeases" name="MonthlyBaseRentOfLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FutureMinimumLeasePaymentsOverLifeOfLease" name="FutureMinimumLeasePaymentsOverLifeOfLease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OperatingLeasesFutureMinimumPaymentsNetDue" name="OperatingLeasesFutureMinimumPaymentsNetDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RemainingSurrenderValueOfNotes" name="RemainingSurrenderValueOfNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalPeriodForPurchaseShare" name="AdditionalPeriodForPurchaseShare" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockExpectedToIssuedDuringPeriodShares" name="StockExpectedToIssuedDuringPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" name="StockIssuedDuringPeriodSharesStockOptionsExercised1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrivatePlacementFees" name="PrivatePlacementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" name="ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" name="ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" name="ClassOfWarrantOrRightFairValueOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" name="ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExpenseRecognized" name="ClassOfWarrantOrRightExpenseRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" name="FairValueOfWarrantsByRelativeFairValueCalculationMethod" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" name="RemainingAmortizationOfFinancingCostsAndDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumbersOfUnaffiliatedIndividuals" name="NumbersOfUnaffiliatedIndividuals" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LoanGuarantyCosts" name="LoanGuarantyCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateTimeItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" nillable="true" xbrli:periodType="duration" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" nillable="true" xbrli:periodType="duration" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" nillable="true" xbrli:periodType="duration" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" nillable="true" xbrli:periodType="instant" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" name="ClassOfWarrantOrRighstContractualLifeBeginningOustanding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" name="ClassOfWarrantOrRighstContractualLifeClosingOustanding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" name="ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SharePrice1" name="SharePrice1" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" name="StockIssuedDuringPeriodSharesStockOptionsExercised3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" name="StockIssuedDuringPeriodSharesStockOptionsExercised2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnamortizedCostsOfWarrants" name="UnamortizedCostsOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidExpensesDisclosureTextBlock" name="PrepaidExpensesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" name="ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfDaysForOptionToPurchaseShares" name="NumberOfDaysForOptionToPurchaseShares" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrantsMember" name="SancilioAndCompanyWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants1Member" name="SancilioAndCompanyWarrants1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants2Member" name="SancilioAndCompanyWarrants2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants3Member" name="SancilioAndCompanyWarrants3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleAdvanceRevolvingCreditNoteMember" name="MultipleAdvanceRevolvingCreditNoteMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredRevenueConcentrationRiskMember" name="DeferredRevenueConcentrationRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" name="StockPurchaseAgreementWithPernixTherapeuticsLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_VitaMedPromissoryNotesMember" name="VitaMedPromissoryNotesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedToPartiesMember" name="NotesIssuedToPartiesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedToParty1Member" name="NotesIssuedToParty1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedToParty2Member" name="NotesIssuedToParty2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonAffiliatedThirdPartyMember" name="NonAffiliatedThirdPartyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk1Member" name="CustomerConcentrationRisk1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk2Member" name="CustomerConcentrationRisk2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk3Member" name="CustomerConcentrationRisk3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk4Member" name="CustomerConcentrationRisk4Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReichFamilyLimitedLPMember" name="ReichFamilyLimitedLPMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MrMilliganMember" name="MrMilliganMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IssuanceOfPromissoryNotesMember" name="IssuanceOfPromissoryNotesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_February2012Notes1Member" name="February2012Notes1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_February2012NotesMember" name="February2012NotesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_February2012Notes2Member" name="February2012Notes2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012Notes1Member" name="June2012Notes1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012Notes2Member" name="June2012Notes2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012NotesMember" name="June2012NotesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedInAugustAndSeptember2012Member" name="NotesIssuedInAugustAndSeptember2012Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedInSeptember2012Member" name="NotesIssuedInSeptember2012Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_July2011SecuredNotesMember" name="July2011SecuredNotesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_July2011SecuredNotes1Member" name="July2011SecuredNotes1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_July2011SecuredNotes2Member" name="July2011SecuredNotes2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedToVariousPartiesMember" name="NotesIssuedToVariousPartiesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_JefferiesLLCMember" name="JefferiesLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StifelNicolausAndCompanyMember" name="StifelNicolausAndCompanyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ModificationWarrantsMember" name="ModificationWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" name="WarrantsIssuedToUnaffiliatedIndividualsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToUnaffiliatedEntityMember" name="WarrantsIssuedToUnaffiliatedEntityMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012NotesWarrantsMember" name="June2012NotesWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012NotesWarrants1Member" name="June2012NotesWarrants1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012NotesWarrants2Member" name="June2012NotesWarrants2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" name="WarrantsIssuedToUnaffiliatedIndividuals1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_GoldmanSachsMember" name="GoldmanSachsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonaffiliatedEntityMember" name="NonaffiliatedEntityMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedAsFinancingCostRelatedParties" name="WarrantsIssuedAsFinancingCostRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CommitmentsAndContingenciesTablesAbstract" name="CommitmentsAndContingenciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrivatePlacementAxis" name="PrivatePlacementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_PrivatePlacementDomain" name="PrivatePlacementDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAbstract" name="WarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" name="DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AgreementCoverPeriod" name="AgreementCoverPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingExpense" name="FinancingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmortizationResearchAndDevelopmentExpense" name="AmortizationResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedDuringPeriodShares" name="WarrantsIssuedDuringPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfWarrantsVested" name="NumberOfWarrantsVested" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsActivityAndRelatedInformationAbstract" name="WarrantsActivityAndRelatedInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSharesUnderWarrantAbstract" name="NumberOfSharesUnderWarrantAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceAbstract" name="WeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" nillable="true" xbrli:periodType="duration" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageRemainingContractualLifeAbstract" name="WeightedAverageRemainingContractualLifeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeGrants" name="ClassOfWarrantOrRighstContractualLifeGrants" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeExercises" name="ClassOfWarrantOrRighstContractualLifeExercises" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" name="ClassOfWarrantOrRighstContractualLifeExpirations" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" name="ClassOfWarrantOrRighstContractualLifeForfeitures" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ActivityUnderLtipAbstract" name="ActivityUnderLtipAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOptionsAbstract" name="NumberOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredIncomeTaxAssetsAbstract" name="DeferredIncomeTaxAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OperatingLeasesNonCancellableSubleaseIncome" name="OperatingLeasesNonCancellableSubleaseIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>txmd-20141231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20141231\txmd_123114.xfr; Date: 2015%2D03%2D10T21:08:48 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20141231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20141231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20141231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20141231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20141231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20141231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20141231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20141231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20141231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20141231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20141231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20141231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20141231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20141231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20141231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20141231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20141231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20141231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20141231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20141231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20141231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20141231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20141231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20141231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20141231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20141231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20141231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:href="txmd-20141231.xsd#NotesPayableDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20141231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20141231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20141231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20141231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20141231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20141231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="loc_us-gaapAmortizationOfDeferredCharges" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDeferredCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:label="loc_us-gaapPaymentsForProceedsFromOtherDeposits" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromOtherDeposits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000027 - Disclosure - FIXED ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000028 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000029 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000037 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - FIXED ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000040 - Disclosure - FIXED ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000041 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidAccreditedCostsNoncurrent" xlink:label="loc_txmdPrepaidAccreditedCostsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidAccreditedCostsNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details )" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000046 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AccruedFinancingCostsCurrent" xlink:label="loc_txmdAccruedFinancingCostsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedFinancingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000047 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:title="00000048 - Disclosure - NOTES PAYABLE (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000057 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000058 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000059 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_OperatingLeasesFutureMinimumPaymentsNetDue" xlink:label="loc_txmdOperatingLeasesFutureMinimumPaymentsNetDue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txmdOperatingLeasesFutureMinimumPaymentsNetDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_OperatingLeasesNonCancellableSubleaseIncome" xlink:label="loc_txmdOperatingLeasesNonCancellableSubleaseIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txmdOperatingLeasesFutureMinimumPaymentsNetDue" xlink:to="loc_txmdOperatingLeasesNonCancellableSubleaseIncome" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>txmd-20141231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20141231\txmd_123114.xfr; Date: 2015%2D03%2D10T21:08:48 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20141231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20141231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20141231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20141231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20141231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20141231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20141231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20141231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20141231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20141231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20141231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20141231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20141231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20141231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20141231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20141231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20141231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20141231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20141231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20141231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20141231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20141231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20141231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20141231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20141231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20141231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20141231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:href="txmd-20141231.xsd#NotesPayableDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20141231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20141231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20141231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20141231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20141231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20141231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonaffiliatedEntityMember" xlink:label="loc_txmdNonaffiliatedEntityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdNonaffiliatedEntityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedForFinancingCosts" xlink:label="loc_txmdWarrantsIssuedForFinancingCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedForFinancingCosts_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:label="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:label="loc_txmdWarrantsIssuedAsCompensationRelatedParty_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedAsCompensationRelatedParty_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" xlink:label="loc_txmdAdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:label="loc_txmdWarrantsIssuedAsFinancingCostRelatedParties_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedAsFinancingCostRelatedParties_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000027 - Disclosure - FIXED ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000028 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000029 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAdvertisingExpense_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:label="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities_80" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000037 - Disclosure - INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - FIXED ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000040 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000041 - Disclosure - PREPAID EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_160" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_160" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_160" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_160" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_160" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_160" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_160" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_160" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_160" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000046 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000047 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_IssuanceOfPromissoryNotesMember" xlink:label="loc_txmdIssuanceOfPromissoryNotesMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdIssuanceOfPromissoryNotesMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012Notes1Member" xlink:label="loc_txmdFebruary2012Notes1Member_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012Notes1Member_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012Notes2Member" xlink:label="loc_txmdFebruary2012Notes2Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012Notes2Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012Notes1Member" xlink:label="loc_txmdJune2012Notes1Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012Notes1Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012Notes2Member" xlink:label="loc_txmdJune2012Notes2Member_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012Notes2Member_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesMember" xlink:label="loc_txmdJune2012NotesMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012NotesMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="loc_txmdReichFamilyLimitedLPMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdReichFamilyLimitedLPMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MrMilliganMember" xlink:label="loc_txmdMrMilliganMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrMilliganMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_400" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_400" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDescription_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDescription_400" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_400" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt_400" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCredit_400" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_400" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_400" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit_400" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_400" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:label="loc_us-gaapLineOfCreditFacilityDecreaseForgiveness1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityDecreaseForgiveness1_400" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense_400" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_400" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_400" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_400" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_400" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue_400" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_400" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_400" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt_400" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_400" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_RemainingSurrenderValueOfNotes" xlink:label="loc_txmdRemainingSurrenderValueOfNotes_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRemainingSurrenderValueOfNotes_400" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_400" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_400" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid_400" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:title="00000048 - Disclosure - NOTES PAYABLE (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:label="loc_txmdNotesIssuedInAugustAndSeptember2012Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedInAugustAndSeptember2012Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedInSeptember2012Member" xlink:label="loc_txmdNotesIssuedInSeptember2012Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedInSeptember2012Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotesMember" xlink:label="loc_txmdJuly2011SecuredNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotes1Member" xlink:label="loc_txmdJuly2011SecuredNotes1Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotes1Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotes2Member" xlink:label="loc_txmdJuly2011SecuredNotes2Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotes2Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToVariousPartiesMember" xlink:label="loc_txmdNotesIssuedToVariousPartiesMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToVariousPartiesMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="loc_txmdNotesIssuedToParty1Member_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty1Member_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="loc_txmdNotesIssuedToParty2Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty2Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="loc_txmdDebtInstrumentRemainingFaceAmount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdDebtInstrumentRemainingFaceAmount_240" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdGoldmanSachsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_JefferiesLLCMember" xlink:label="loc_txmdJefferiesLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdJefferiesLLCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="loc_txmdStifelNicolausAndCompanyMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelNicolausAndCompanyMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementAxis" xlink:label="loc_txmdPrivatePlacementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_txmdPrivatePlacementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementDomain" xlink:label="loc_txmdPrivatePlacementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmdPrivatePlacementAxis" xlink:to="loc_txmdPrivatePlacementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementDomain" xlink:label="loc_txmdPrivatePlacementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_txmdPrivatePlacementAxis" xlink:to="loc_txmdPrivatePlacementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdPrivatePlacementDomain" xlink:to="loc_us-gaapPrivatePlacementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SharePrice1" xlink:label="loc_txmdSharePrice1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdSharePrice1_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="loc_txmdStockExpectedToIssuedDuringPeriodShares_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockExpectedToIssuedDuringPeriodShares_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodValueNewIssues1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodValueNewIssues1_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised3_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised3_180" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_180" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised1_180" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised2_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised2_180" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_180" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_180" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_180" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments_180" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_180" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementFees" xlink:label="loc_txmdPrivatePlacementFees_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdPrivatePlacementFees_180" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees_180" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForCash_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForCash_180" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_180" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaapWeightedAverageMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapWeightedAverageMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="loc_txmdSancilioAndCompanyWarrants1Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants1Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="loc_txmdSancilioAndCompanyWarrants2Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants2Member_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="loc_txmdSancilioAndCompanyWarrants3Member_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants3Member_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ModificationWarrantsMember" xlink:label="loc_txmdModificationWarrantsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdModificationWarrantsMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedIndividualsMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedIndividualsMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedEntityMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedEntityMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrantsMember" xlink:label="loc_txmdJune2012NotesWarrantsMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrantsMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrants1Member" xlink:label="loc_txmdJune2012NotesWarrants1Member_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrants1Member_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrants2Member" xlink:label="loc_txmdJune2012NotesWarrants2Member_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrants2Member_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedIndividuals1Member_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedIndividuals1Member_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract_420" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_420" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_420" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_420" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="loc_txmdUnamortizedCostsOfWarrants_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdUnamortizedCostsOfWarrants_420" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_420" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_420" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_420" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights_420" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_420" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_420" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_420" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_420" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_420" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet_420" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_420" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_420" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="loc_txmdClassOfWarrantOrRightExpenseRecognized_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdClassOfWarrantOrRightExpenseRecognized_420" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapPrepaidExpenseCurrent_420" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent_420" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_420" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:label="loc_txmdFairValueOfWarrantsByRelativeFairValueCalculationMethod_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdFairValueOfWarrantsByRelativeFairValueCalculationMethod_420" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_txmdRemainingAmortizationOfFinancingCostsAndDiscounts_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdRemainingAmortizationOfFinancingCostsAndDiscounts_420" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_420" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumbersOfUnaffiliatedIndividuals" xlink:label="loc_txmdNumbersOfUnaffiliatedIndividuals_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdNumbersOfUnaffiliatedIndividuals_420" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapProfessionalFees_420" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:label="loc_txmdDescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdDescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_420" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AgreementCoverPeriod" xlink:label="loc_txmdAgreementCoverPeriod_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdAgreementCoverPeriod_420" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_FinancingExpense" xlink:label="loc_txmdFinancingExpense_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdFinancingExpense_420" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AmortizationResearchAndDevelopmentExpense" xlink:label="loc_txmdAmortizationResearchAndDevelopmentExpense_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdAmortizationResearchAndDevelopmentExpense_420" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_420" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_420" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_420" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_420" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_420" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_420" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_us-gaapLineOfCredit_420" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedDuringPeriodShares" xlink:label="loc_txmdWarrantsIssuedDuringPeriodShares_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdWarrantsIssuedDuringPeriodShares_420" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfWarrantsVested" xlink:label="loc_txmdNumberOfWarrantsVested_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdNumberOfWarrantsVested_420" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LoanGuarantyCosts" xlink:label="loc_txmdLoanGuarantyCosts_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_420" xlink:to="loc_txmdLoanGuarantyCosts_420" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_150" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsActivityAndRelatedInformationAbstract" xlink:label="loc_txmdWarrantsActivityAndRelatedInformationAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsActivityAndRelatedInformationAbstract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="loc_txmdNumberOfSharesUnderWarrantAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeBeginningOustanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeBeginningOustanding_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeGrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeGrants_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExercises_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExercises_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeClosingOustanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeClosingOustanding_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_40" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ActivityUnderLtipAbstract" xlink:label="loc_txmdActivityUnderLtipAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdActivityUnderLtipAbstract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdNumberOptionsAbstract_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000057 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000058 - Disclosure - INCOME TAXES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000059 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToPartiesMember" xlink:label="loc_txmdNotesIssuedToPartiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToPartiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="loc_txmdNotesIssuedToParty1Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty1Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="loc_txmdNotesIssuedToParty2Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty2Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonAffiliatedThirdPartyMember" xlink:label="loc_txmdNonAffiliatedThirdPartyMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdNonAffiliatedThirdPartyMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaapRestructuringPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRestructuringPlanAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCredit_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="loc_txmdDebtInstrumentRemainingFaceAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdDebtInstrumentRemainingFaceAmount_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPaid_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueFromOfficersOrStockholders" xlink:label="loc_us-gaapDueFromOfficersOrStockholders_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueFromOfficersOrStockholders_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LegalFeeReimbursement" xlink:label="loc_txmdLegalFeeReimbursement_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdLegalFeeReimbursement_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="loc_txmdDeferredRevenueConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdDeferredRevenueConcentrationRiskMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet_200" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SharePrice1" xlink:label="loc_txmdSharePrice1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdSharePrice1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfDaysForOptionToPurchaseShares" xlink:label="loc_txmdNumberOfDaysForOptionToPurchaseShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdNumberOfDaysForOptionToPurchaseShares_40" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>txmd-20141231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20141231\txmd_123114.xfr; Date: 2015%2D03%2D10T21:08:48 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="txmd_SancilioAndCompanyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrantsMember_lbl" xml:lang="en-US">Sancilio and Company Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="txmd_SancilioAndCompanyWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants1Member" xlink:to="txmd_SancilioAndCompanyWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants1Member_lbl" xml:lang="en-US">Sancilio &amp;amp;amp; Company Warrants 1st Installments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="txmd_SancilioAndCompanyWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants2Member" xlink:to="txmd_SancilioAndCompanyWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants2Member_lbl" xml:lang="en-US">Sancilio and Company Warrants 2nd Installments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="txmd_SancilioAndCompanyWarrants3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants3Member" xlink:to="txmd_SancilioAndCompanyWarrants3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants3Member_lbl" xml:lang="en-US">Sancilio and Company Warrants 3rd Installments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="txmd_DeferredRevenueConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_lbl" xml:lang="en-US">Deferred revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:to="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_lbl" xml:lang="en-US">Stock Purchase Agreement With Pernix Therapeutics LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">OPERA software patent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Development costs for corporate website [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone therapy drug candidate patents - Pending [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple trademarks for vitamins/supplements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents (Member)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="txmd_VitaMedPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaMedPromissoryNotesMember" xlink:to="txmd_VitaMedPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_VitaMedPromissoryNotesMember_lbl" xml:lang="en-US">VitaMed Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Brian Bernick [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToPartiesMember" xlink:label="txmd_NotesIssuedToPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToPartiesMember" xlink:to="txmd_NotesIssuedToPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedToPartiesMember_lbl" xml:lang="en-US">Notes Issued to Mr. Finizio And Mr. Milligan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="txmd_NotesIssuedToParty1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToParty1Member" xlink:to="txmd_NotesIssuedToParty1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedToParty1Member_lbl" xml:lang="en-US">Notes Issued to Mr. Finizio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="txmd_NotesIssuedToParty2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToParty2Member" xlink:to="txmd_NotesIssuedToParty2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedToParty2Member_lbl" xml:lang="en-US">Notes Issued to Mr. Milligan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonAffiliatedThirdPartyMember" xlink:label="txmd_NonAffiliatedThirdPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonAffiliatedThirdPartyMember" xlink:to="txmd_NonAffiliatedThirdPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonAffiliatedThirdPartyMember_lbl" xml:lang="en-US">Non-affiliated third party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_2_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="txmd_CustomerConcentrationRisk1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_CustomerConcentrationRisk1Member_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="txmd_CustomerConcentrationRisk2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk2Member_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="txmd_CustomerConcentrationRisk3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk3Member_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="txmd_CustomerConcentrationRisk4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk4Member_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="txmd_ReichFamilyLimitedLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReichFamilyLimitedLPMember" xlink:to="txmd_ReichFamilyLimitedLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReichFamilyLimitedLPMember_lbl" xml:lang="en-US">Reich Family Limited LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MrMilliganMember" xlink:label="txmd_MrMilliganMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MrMilliganMember" xlink:to="txmd_MrMilliganMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MrMilliganMember_lbl" xml:lang="en-US">Mr. Milligan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_IssuanceOfPromissoryNotesMember" xlink:label="txmd_IssuanceOfPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IssuanceOfPromissoryNotesMember" xlink:to="txmd_IssuanceOfPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IssuanceOfPromissoryNotesMember_lbl" xml:lang="en-US">Issuance of 6% Promissory Notes (January and February 2012) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012Notes1Member" xlink:label="txmd_February2012Notes1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012Notes1Member" xlink:to="txmd_February2012Notes1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_February2012Notes1Member_lbl" xml:lang="en-US">February 2012 Notes Issued To Individual And Entity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012NotesMember" xlink:label="txmd_February2012NotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012NotesMember" xlink:to="txmd_February2012NotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_February2012NotesMember_lbl" xml:lang="en-US">February 2012 Notes/ Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012Notes2Member" xlink:label="txmd_February2012Notes2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012Notes2Member" xlink:to="txmd_February2012Notes2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_February2012Notes2Member_lbl" xml:lang="en-US">February 2012 Notes Issued To Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012Notes1Member" xlink:label="txmd_June2012Notes1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012Notes1Member" xlink:to="txmd_June2012Notes1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012Notes1Member_lbl" xml:lang="en-US">June 2012 Notes Issued To Individual And Entity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012Notes2Member" xlink:label="txmd_June2012Notes2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012Notes2Member" xlink:to="txmd_June2012Notes2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012Notes2Member_lbl" xml:lang="en-US">June 2012 Notes Issued To Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesMember" xlink:label="txmd_June2012NotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesMember" xlink:to="txmd_June2012NotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012NotesMember_lbl" xml:lang="en-US">June 2012 Notes (secured promissory notes) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:label="txmd_NotesIssuedInAugustAndSeptember2012Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:to="txmd_NotesIssuedInAugustAndSeptember2012Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedInAugustAndSeptember2012Member_lbl" xml:lang="en-US">6% Notes issued in August and September 2012 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedInSeptember2012Member" xlink:label="txmd_NotesIssuedInSeptember2012Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedInSeptember2012Member" xlink:to="txmd_NotesIssuedInSeptember2012Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedInSeptember2012Member_lbl" xml:lang="en-US">6% Notes issued in September 2012 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotesMember" xlink:label="txmd_July2011SecuredNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotesMember" xlink:to="txmd_July2011SecuredNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_July2011SecuredNotesMember_lbl" xml:lang="en-US">VitaMed July 2011 Secured Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotes1Member" xlink:label="txmd_July2011SecuredNotes1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotes1Member" xlink:to="txmd_July2011SecuredNotes1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_July2011SecuredNotes1Member_lbl" xml:lang="en-US">VitaMed July 2011 First Secured Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotes2Member" xlink:label="txmd_July2011SecuredNotes2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotes2Member" xlink:to="txmd_July2011SecuredNotes2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_July2011SecuredNotes2Member_lbl" xml:lang="en-US">VitaMed July 2011 Second Secured Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">VitaMed Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToVariousPartiesMember" xlink:label="txmd_NotesIssuedToVariousPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToVariousPartiesMember" xlink:to="txmd_NotesIssuedToVariousPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_NotesIssuedToVariousPartiesMember_lbl" xml:lang="en-US">Notes Issued to Mr. Finizio And Mr. Milligan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_JefferiesLLCMember" xlink:label="txmd_JefferiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_JefferiesLLCMember" xlink:to="txmd_JefferiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_JefferiesLLCMember_lbl" xml:lang="en-US">Jefferies LLC (Underwriters) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="txmd_StifelNicolausAndCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelNicolausAndCompanyMember" xlink:to="txmd_StifelNicolausAndCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StifelNicolausAndCompanyMember_lbl" xml:lang="en-US">Stifel, Nicolaus &amp; Company (Underwriters) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementAxis" xlink:label="txmd_PrivatePlacementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementAxis" xlink:to="txmd_PrivatePlacementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrivatePlacementAxis_lbl" xml:lang="en-US">Private Placement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageMember" xlink:to="us-gaap_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ModificationWarrantsMember" xlink:label="txmd_ModificationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ModificationWarrantsMember" xlink:to="txmd_ModificationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ModificationWarrantsMember_lbl" xml:lang="en-US">Modification Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember_lbl" xml:lang="en-US">Warrants Issued to Unaffiliated Individuals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:label="txmd_WarrantsIssuedToUnaffiliatedEntityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:to="txmd_WarrantsIssuedToUnaffiliatedEntityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToUnaffiliatedEntityMember_lbl" xml:lang="en-US">Warrants Issued to Unaffiliated Entity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrantsMember" xlink:label="txmd_June2012NotesWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrantsMember" xlink:to="txmd_June2012NotesWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012NotesWarrantsMember_lbl" xml:lang="en-US">June 2012 Notes/Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrants1Member" xlink:label="txmd_June2012NotesWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrants1Member" xlink:to="txmd_June2012NotesWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012NotesWarrants1Member_lbl" xml:lang="en-US">June 2012 Notes/Warrants 1st Issue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrants2Member" xlink:label="txmd_June2012NotesWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrants2Member" xlink:to="txmd_June2012NotesWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012NotesWarrants2Member_lbl" xml:lang="en-US">June 2012 Notes/Warrants 2nd Issue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_lbl" xml:lang="en-US">Warrants Issued to Unaffiliated Individuals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock unit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_GoldmanSachsMember" xlink:label="txmd_GoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_GoldmanSachsMember_lbl" xml:lang="en-US">Goldman Sachs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="txmd_CowenAndCompanyLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CowenAndCompanyLLCMember_lbl" xml:lang="en-US">Cowen and Company, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonaffiliatedEntityMember" xlink:label="txmd_NonaffiliatedEntityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonaffiliatedEntityMember" xlink:to="txmd_NonaffiliatedEntityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonaffiliatedEntityMember_lbl" xml:lang="en-US">Non-Affiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity a Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity a Voluntary Filer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $21,119 and $26,555, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 250,000,000 shares authorized; 156,097,019 and 144,976,757 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other income and (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xml:lang="en-US">Loan guaranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares outstanding (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in private placement, net of cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in private placement, net of cost, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Shares issued in exchange for debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Shares issued in exchange for debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued in exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued in exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Shares issued for exercise of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Shares issued for exercise of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Employee Share Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedForFinancingCosts" xlink:label="txmd_WarrantsIssuedForFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancingCosts" xlink:to="txmd_WarrantsIssuedForFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForFinancingCosts_lbl" xml:lang="en-US">Warrants issued for financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:label="txmd_WarrantsIssuedAsCompensationRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:to="txmd_WarrantsIssuedAsCompensationRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedAsCompensationRelatedParty_lbl" xml:lang="en-US">Warrants issued as compensation-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued_lbl" xml:lang="en-US">Cancellation of warrants issued for loan guaranty costs-related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:label="txmd_WarrantsIssuedAsFinancingCostRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:to="txmd_WarrantsIssuedAsFinancingCostRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedAsFinancingCostRelatedParties_lbl" xml:lang="en-US">Warrants issued as financing costs-related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Non-employee share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_2_lbl" xml:lang="en-US">Beneficial conversion feature</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="us-gaap_AmortizationOfDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Stock based expense for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2_lbl" xml:lang="en-US">Loan guaranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs, net of abandoned costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:label="us-gaap_PaymentsForProceedsFromOtherDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:to="us-gaap_PaymentsForProceedsFromOtherDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherDeposits_lbl" xml:lang="en-US">Refund (payment) of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes and loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from bank line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from sale of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayment of bank line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of notes payable-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedForFinancing" xlink:label="txmd_WarrantsIssuedForFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancing" xlink:to="txmd_WarrantsIssuedForFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForFinancing_lbl" xml:lang="en-US">Warrants issued for financing</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedForServices" xlink:label="txmd_WarrantsIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_WarrantsIssuedForServices_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:label="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:to="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest_lbl" xml:lang="en-US">Warrants exercised in exchange for debt and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DebtConversionConvertedInstrumentNonCash" xlink:label="txmd_DebtConversionConvertedInstrumentNonCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtConversionConvertedInstrumentNonCash" xlink:to="txmd_DebtConversionConvertedInstrumentNonCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtConversionConvertedInstrumentNonCash_lbl" xml:lang="en-US">Shares issued in exchange for debt and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Notes payable issued for accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued and Newly Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities in our calculation of diluted net loss per share allocable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:label="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:to="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average fair value per share and assumptions used in the Black-Scholes Model of warants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of tax rate reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CommitmentsAndContingenciesTablesAbstract" xlink:to="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum rental payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of quarterly unaudited summary information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:to="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_lbl" xml:lang="en-US">Advance payments for future research and development activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares excluded from earnings per share calculation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw material</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="txmd_OtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherCurrentAssetsAbstract" xlink:to="txmd_OtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="txmd_PrepaidConsultingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidConsultingCurrent_lbl" xml:lang="en-US">Prepaid consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Other receivables-related party (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Fixed Assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsAbstract_2_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xml:lang="en-US">Prepaid manufacturing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidAccreditedCostsNoncurrent" xlink:label="txmd_PrepaidAccreditedCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidAccreditedCostsNoncurrent" xlink:to="txmd_PrepaidAccreditedCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidAccreditedCostsNoncurrent_lbl" xml:lang="en-US">Accreted prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xml:lang="en-US">TOTAL PREPAID EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Amortization period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US">Weighted Average Amortization Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Estimated amortization expense for the year:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPayableDateDeclaredMonthAndYear" xlink:label="us-gaap_DividendsPayableDateDeclaredMonthAndYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableDateDeclaredMonthAndYear" xlink:to="us-gaap_DividendsPayableDateDeclaredMonthAndYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableDateDeclaredMonthAndYear_lbl" xml:lang="en-US">Date dividend declared</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends Payable, amount per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Unclaimed dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="txmd_AccruedClinicalTrialCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued vacation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US">Accrued rent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AccruedFinancingCostsCurrent" xlink:label="txmd_AccruedFinancingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedFinancingCostsCurrent" xlink:to="txmd_AccruedFinancingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedFinancingCostsCurrent_lbl" xml:lang="en-US">Accrued financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Stated interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xml:lang="en-US">Description of interest payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from revolving credit note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of revolving credit note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Revolving credit outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per unit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCredit_2_lbl" xml:lang="en-US">Line of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of lines of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_2_lbl" xml:lang="en-US">Proceeds from lines of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:label="us-gaap_LineOfCreditFacilityDecreaseForgiveness1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:to="us-gaap_LineOfCreditFacilityDecreaseForgiveness1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityDecreaseForgiveness1_lbl" xml:lang="en-US">Line of credit facility decrease forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_2_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Acrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Fair value of notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Recognized loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Aggregate principal and accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Amount of shares issued in exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_RemainingSurrenderValueOfNotes" xlink:label="txmd_RemainingSurrenderValueOfNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RemainingSurrenderValueOfNotes" xlink:to="txmd_RemainingSurrenderValueOfNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RemainingSurrenderValueOfNotes_lbl" xml:lang="en-US">Remaining balance of notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Description of interest rate terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_2_lbl" xml:lang="en-US">Acrued interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xml:lang="en-US">Numbers of shares converted for debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_3_lbl" xml:lang="en-US">Value of debt converted to shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Numbers of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="txmd_DebtInstrumentRemainingFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtInstrumentRemainingFaceAmount" xlink:to="txmd_DebtInstrumentRemainingFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtInstrumentRemainingFaceAmount_lbl" xml:lang="en-US">Aggregate remaining principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementAxis" xlink:to="txmd_PrivatePlacementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_PrivatePlacementAxis_2_lbl" xml:lang="en-US">PrivatePlacementAxis [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SharePrice1" xlink:label="txmd_SharePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharePrice1" xlink:to="txmd_SharePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SharePrice1_lbl" xml:lang="en-US">Share price to underwritters (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Number of shares issued during the period,value</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="txmd_AdditionalPeriodForPurchaseShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalPeriodForPurchaseShare_lbl" xml:lang="en-US">Additional period for purchase share</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockExpectedToIssuedDuringPeriodShares" xlink:to="txmd_StockExpectedToIssuedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares_lbl" xml:lang="en-US">Total Additional common stock issued under shelf registration statement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Additional common stock issued under shelf registration statement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:label="txmd_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Additional common stock issued under shelf registration statement,value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Numbers of options to purchase shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3_lbl" xml:lang="en-US">Numbers of portions shares issued for exercise of options, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Options to purchase shares of common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xml:lang="en-US">Numbers of options to purchase shares of common stock using cashless exercise feature</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_lbl" xml:lang="en-US">Numbers of balance shares issued for exercise of options, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Number of shares issued in exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementFees" xlink:label="txmd_PrivatePlacementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementFees" xlink:to="txmd_PrivatePlacementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrivatePlacementFees_lbl" xml:lang="en-US">Transaction cash fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees and expenses paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForCash_lbl" xml:lang="en-US">Aggregate purchase price of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsAbstract" xlink:label="txmd_WarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAbstract" xlink:to="txmd_WarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAbstract_lbl" xml:lang="en-US">Warrants:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="txmd_UnamortizedCostsOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnamortizedCostsOfWarrants" xlink:to="txmd_UnamortizedCostsOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnamortizedCostsOfWarrants_lbl" xml:lang="en-US">Unamortized costs of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xml:lang="en-US">Expiration date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xml:lang="en-US">Vesting date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares purchased forfeit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_lbl" xml:lang="en-US">Valuation method of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:to="txmd_ClassOfWarrantOrRightExpenseRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized_lbl" xml:lang="en-US">Non-cash compensation recongised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expense-short term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_3_lbl" xml:lang="en-US">Prepaid expense-long term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:label="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:to="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod_lbl" xml:lang="en-US">Fair value of warrants by relative fair value calculation method</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:label="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:to="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Remaining amortization deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumbersOfUnaffiliatedIndividuals" xlink:label="txmd_NumbersOfUnaffiliatedIndividuals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumbersOfUnaffiliatedIndividuals" xlink:to="txmd_NumbersOfUnaffiliatedIndividuals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumbersOfUnaffiliatedIndividuals_lbl" xml:lang="en-US">Number of unaffiliated individuals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:label="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:to="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_lbl" xml:lang="en-US">Description of vesting period of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AgreementCoverPeriod" xlink:label="txmd_AgreementCoverPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AgreementCoverPeriod" xlink:to="txmd_AgreementCoverPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AgreementCoverPeriod_lbl" xml:lang="en-US">Agreement covering period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_FinancingExpense" xlink:label="txmd_FinancingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingExpense" xlink:to="txmd_FinancingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingExpense_lbl" xml:lang="en-US">Financing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AmortizationResearchAndDevelopmentExpense" xlink:label="txmd_AmortizationResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmortizationResearchAndDevelopmentExpense" xlink:to="txmd_AmortizationResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmortizationResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Amortization research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Minimum volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Maximum volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Minimum risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Maximum risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedDuringPeriodShares" xlink:label="txmd_WarrantsIssuedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedDuringPeriodShares" xlink:to="txmd_WarrantsIssuedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedDuringPeriodShares_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfWarrantsVested" xlink:label="txmd_NumberOfWarrantsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfWarrantsVested" xlink:to="txmd_NumberOfWarrantsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfWarrantsVested_lbl" xml:lang="en-US">Number of warrants vested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LoanGuarantyCosts" xlink:label="txmd_LoanGuarantyCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LoanGuarantyCosts" xlink:to="txmd_LoanGuarantyCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_LoanGuarantyCosts_lbl" xml:lang="en-US">Loan guaranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Numbers of options oustanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Option exercise prices (in dollars per shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized estimated compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognized weighted-average period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_lbl" xml:lang="en-US">Vesting date</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsActivityAndRelatedInformationAbstract" xlink:label="txmd_WarrantsActivityAndRelatedInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsActivityAndRelatedInformationAbstract" xlink:to="txmd_WarrantsActivityAndRelatedInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsActivityAndRelatedInformationAbstract_lbl" xml:lang="en-US">Warrant activity and related information</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="txmd_NumberOfSharesUnderWarrantAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSharesUnderWarrantAbstract" xlink:to="txmd_NumberOfSharesUnderWarrantAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSharesUnderWarrantAbstract_lbl" xml:lang="en-US">Number of shares under warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="txmd_WeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceAbstract" xlink:to="txmd_WeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:to="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="txmd_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateIntrinsicValueAbstract" xlink:to="txmd_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExercisePrice" xlink:to="us-gaap_FairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Weighted average fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected Volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ActivityUnderLtipAbstract" xlink:label="txmd_ActivityUnderLtipAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ActivityUnderLtipAbstract" xlink:to="txmd_ActivityUnderLtipAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ActivityUnderLtipAbstract_lbl" xml:lang="en-US">Activity under the LTIP</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOptionsAbstract" xlink:label="txmd_NumberOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOptionsAbstract" xlink:to="txmd_NumberOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOptionsAbstract_lbl" xml:lang="en-US">Number Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Adjustment in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent and other differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision (Benefit) for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DeferredIncomeTaxAssetsAbstract" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Transaction amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueFromOfficersOrStockholders" xlink:label="us-gaap_DueFromOfficersOrStockholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOfficersOrStockholders" xlink:to="us-gaap_DueFromOfficersOrStockholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOfficersOrStockholders_lbl" xml:lang="en-US">Receivables outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LegalFeeReimbursement" xlink:label="txmd_LegalFeeReimbursement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LegalFeeReimbursement" xlink:to="txmd_LegalFeeReimbursement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LegalFeeReimbursement_lbl" xml:lang="en-US">Legal fee reimbursement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MonthlyBaseRentOfLeases" xlink:label="txmd_MonthlyBaseRentOfLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MonthlyBaseRentOfLeases" xlink:to="txmd_MonthlyBaseRentOfLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MonthlyBaseRentOfLeases_lbl" xml:lang="en-US">Monthly Base rent of leases</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_FutureMinimumLeasePaymentsOverLifeOfLease" xlink:label="txmd_FutureMinimumLeasePaymentsOverLifeOfLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FutureMinimumLeasePaymentsOverLifeOfLease" xlink:to="txmd_FutureMinimumLeasePaymentsOverLifeOfLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FutureMinimumLeasePaymentsOverLifeOfLease_lbl" xml:lang="en-US">Future minimum lease payments over life of lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xml:lang="en-US">Rental income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xml:lang="en-US">Future minimum rental payments, year ending December 31,</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_OperatingLeasesNonCancellableSubleaseIncome" xlink:label="txmd_OperatingLeasesNonCancellableSubleaseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesNonCancellableSubleaseIncome" xlink:to="txmd_OperatingLeasesNonCancellableSubleaseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OperatingLeasesNonCancellableSubleaseIncome_lbl" xml:lang="en-US">Non-cancellable sub-lease income</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_OperatingLeasesFutureMinimumPaymentsNetDue" xlink:label="txmd_OperatingLeasesFutureMinimumPaymentsNetDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesFutureMinimumPaymentsNetDue" xlink:to="txmd_OperatingLeasesFutureMinimumPaymentsNetDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="txmd_OperatingLeasesFutureMinimumPaymentsNetDue_lbl" xml:lang="en-US">Net minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Loss per common share, basic and diluted (in dollars per shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfDaysForOptionToPurchaseShares" xlink:label="txmd_NumberOfDaysForOptionToPurchaseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfDaysForOptionToPurchaseShares" xlink:to="txmd_NumberOfDaysForOptionToPurchaseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfDaysForOptionToPurchaseShares_lbl" xml:lang="en-US">Number of days granted for option to purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedFinancingCostsCurrent" xlink:to="txmd_AccruedFinancingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedFinancingCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for financing costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalPeriodForPurchaseShare_doc" xml:lang="en-US">Refers to additonal period for purchase of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are expired in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_doc" xml:lang="en-US">Refers to fair value of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xml:lang="en-US">Refer to numbers of shares forfeit during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_doc" xml:lang="en-US">Refers to valuation method of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are vesting in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_doc" xml:lang="en-US">Deferred Revenue Concentration Risk Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xml:lang="en-US">Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MonthlyBaseRentOfLeases" xlink:to="txmd_MonthlyBaseRentOfLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MonthlyBaseRentOfLeases_doc" xml:lang="en-US">Base monthly rent of operating leases, as stipulated in leasing agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xml:lang="en-US">Multiple Advance Revolving Credit Note Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidAccreditedCostsNoncurrent" xlink:to="txmd_PrepaidAccreditedCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidAccreditedCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of accredited contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidConsultingCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_doc" xml:lang="en-US">Disclosure of prepaid expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants1Member" xlink:to="txmd_SancilioAndCompanyWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants1Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants2Member" xlink:to="txmd_SancilioAndCompanyWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants2Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants3Member" xlink:to="txmd_SancilioAndCompanyWarrants3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants3Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrantsMember_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xml:lang="en-US">Number of shares issued during the period as a result of an cashless exercise feature.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:to="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_doc" xml:lang="en-US">Stock Purchase Agreement With Pernix Therapeutics LLC Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancing" xlink:to="txmd_WarrantsIssuedForFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForFinancing_doc" xml:lang="en-US">Warrants issued in the period for financing in a noncash transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForServices_doc" xml:lang="en-US">Warrants issued in the period for servcies in a noncash transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_GoldmanSachsMember_doc" xml:lang="en-US">Information pertaining to Goldman Sachs, underwrite of Public Offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FutureMinimumLeasePaymentsOverLifeOfLease" xlink:to="txmd_FutureMinimumLeasePaymentsOverLifeOfLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FutureMinimumLeasePaymentsOverLifeOfLease_doc" xml:lang="en-US">Amount of minimum rental payments for leases required over the life of lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which fully or partially vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_doc" xml:lang="en-US">The exercise price of each class of warrants granted in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_doc" xml:lang="en-US">The exercise price of each class of warrants exercised in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_doc" xml:lang="en-US">The exercise price of each class of warrants expired in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_doc" xml:lang="en-US">The exercise price of each class of warrants cancelled or forfeited in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_doc" xml:lang="en-US">The exercise price of each class of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants granted in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants exercised in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants expired in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants cancelled or forfeited in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants granted during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:to="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock_doc" xml:lang="en-US">Disclosure of schedule of weighted average fair value per share and valuation assumptions of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_doc" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants for services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancingCosts" xlink:to="txmd_WarrantsIssuedForFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForFinancingCosts_doc" xml:lang="en-US">Increase in additional paid in capital due to warrants issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:to="txmd_WarrantsIssuedAsFinancingCostRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedAsFinancingCostRelatedParties_doc" xml:lang="en-US">Increase in additional paid in capital due to warrants issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:to="txmd_WarrantsIssuedAsCompensationRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedAsCompensationRelatedParty_doc" xml:lang="en-US">Increase in additional paid in capital due to warrants issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract_doc" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued_doc" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from the cancellation of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:to="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest_doc" xml:lang="en-US">Refers to amount of warrants ecercised in exchange for debt and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtConversionConvertedInstrumentNonCash" xlink:to="txmd_DebtConversionConvertedInstrumentNonCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtConversionConvertedInstrumentNonCash_doc" xml:lang="en-US">The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:to="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_doc" xml:lang="en-US">Carrying amount of advance payments made for future research and development activiites to be expensed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaMedPromissoryNotesMember" xlink:to="txmd_VitaMedPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_VitaMedPromissoryNotesMember_doc" xml:lang="en-US">VitaMed Promissory Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MrMilliganMember" xlink:to="txmd_MrMilliganMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MrMilliganMember_doc" xml:lang="en-US">MrMilligan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReichFamilyLimitedLPMember" xlink:to="txmd_ReichFamilyLimitedLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReichFamilyLimitedLPMember_doc" xml:lang="en-US">ReichFamily Limited LP Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToPartiesMember" xlink:to="txmd_NotesIssuedToPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedToPartiesMember_doc" xml:lang="en-US">Notes Issued To Parties Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToParty1Member" xlink:to="txmd_NotesIssuedToParty1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedToParty1Member_doc" xml:lang="en-US">Notes Issued To Party 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToParty2Member" xlink:to="txmd_NotesIssuedToParty2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedToParty2Member_doc" xml:lang="en-US">Notes Issued To Party 2 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonAffiliatedThirdPartyMember" xlink:to="txmd_NonAffiliatedThirdPartyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonAffiliatedThirdPartyMember_doc" xml:lang="en-US">Non Affiliated Third Party Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtInstrumentRemainingFaceAmount" xlink:to="txmd_DebtInstrumentRemainingFaceAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtInstrumentRemainingFaceAmount_doc" xml:lang="en-US">Refers to balance amount of debt instrument at time of issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LegalFeeReimbursement" xlink:to="txmd_LegalFeeReimbursement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LegalFeeReimbursement_doc" xml:lang="en-US">Refers to reimbursment of legal fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk1Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk2Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk3Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk4Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesFutureMinimumPaymentsNetDue" xlink:to="txmd_OperatingLeasesFutureMinimumPaymentsNetDue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OperatingLeasesFutureMinimumPaymentsNetDue_doc" xml:lang="en-US">Refers to operating leases future minimum payments net due.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesNonCancellableSubleaseIncome" xlink:to="txmd_OperatingLeasesNonCancellableSubleaseIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OperatingLeasesNonCancellableSubleaseIncome_doc" xml:lang="en-US">Refers to operating leases non cancellable sublease income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IssuanceOfPromissoryNotesMember" xlink:to="txmd_IssuanceOfPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IssuanceOfPromissoryNotesMember_doc" xml:lang="en-US">Issuance Of Promissory Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012Notes1Member" xlink:to="txmd_February2012Notes1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_February2012Notes1Member_doc" xml:lang="en-US">Refers to amount of remaining surrender value of notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012NotesMember" xlink:to="txmd_February2012NotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_February2012NotesMember_doc" xml:lang="en-US">February 2012 Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012Notes2Member" xlink:to="txmd_February2012Notes2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_February2012Notes2Member_doc" xml:lang="en-US">February 2012 Notes 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012Notes1Member" xlink:to="txmd_June2012Notes1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012Notes1Member_doc" xml:lang="en-US">June 2012 Notes 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012Notes2Member" xlink:to="txmd_June2012Notes2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012Notes2Member_doc" xml:lang="en-US">June 2012 Notes 2 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesMember" xlink:to="txmd_June2012NotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012NotesMember_doc" xml:lang="en-US">June 2012 Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RemainingSurrenderValueOfNotes" xlink:to="txmd_RemainingSurrenderValueOfNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RemainingSurrenderValueOfNotes_doc" xml:lang="en-US">Refers to amount of remaining surrender value of notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:to="txmd_NotesIssuedInAugustAndSeptember2012Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedInAugustAndSeptember2012Member_doc" xml:lang="en-US">Notes Issued In August And September 2012 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedInSeptember2012Member" xlink:to="txmd_NotesIssuedInSeptember2012Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedInSeptember2012Member_doc" xml:lang="en-US">Notes Issued In September 2012 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotesMember" xlink:to="txmd_July2011SecuredNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_July2011SecuredNotesMember_doc" xml:lang="en-US">July 2011 Secured Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotes1Member" xlink:to="txmd_July2011SecuredNotes1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_July2011SecuredNotes1Member_doc" xml:lang="en-US">July 2011 Secured Notes 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotes2Member" xlink:to="txmd_July2011SecuredNotes2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_July2011SecuredNotes2Member_doc" xml:lang="en-US">July 2011 Secured Notes 2 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToVariousPartiesMember" xlink:to="txmd_NotesIssuedToVariousPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedToVariousPartiesMember_doc" xml:lang="en-US">Notes Issued to Various Parties Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementAxis" xlink:to="txmd_PrivatePlacementAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrivatePlacementAxis_doc" xml:lang="en-US">A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_JefferiesLLCMember" xlink:to="txmd_JefferiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_JefferiesLLCMember_doc" xml:lang="en-US">Jefferies LLC Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelNicolausAndCompanyMember" xlink:to="txmd_StifelNicolausAndCompanyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StifelNicolausAndCompanyMember_doc" xml:lang="en-US">Stifel Nicolaus And company Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharePrice1" xlink:to="txmd_SharePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SharePrice1_doc" xml:lang="en-US">Price of a single share of a number of saleable stocks of a company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockExpectedToIssuedDuringPeriodShares" xlink:to="txmd_StockExpectedToIssuedDuringPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares_doc" xml:lang="en-US">Refers to numbers of share expected to be issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodValueNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodValueNewIssues1_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementFees" xlink:to="txmd_PrivatePlacementFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrivatePlacementFees_doc" xml:lang="en-US">Refers to fees and expense regarding private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ModificationWarrantsMember" xlink:to="txmd_ModificationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ModificationWarrantsMember_doc" xml:lang="en-US">Modification Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember_doc" xml:lang="en-US">Warrants Issued To Unaffiliated Individuals Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:to="txmd_WarrantsIssuedToUnaffiliatedEntityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToUnaffiliatedEntityMember_doc" xml:lang="en-US">Warrants Issued To Unaffiliated Entity Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrantsMember" xlink:to="txmd_June2012NotesWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012NotesWarrantsMember_doc" xml:lang="en-US">June 2012 Notes Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrants1Member" xlink:to="txmd_June2012NotesWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012NotesWarrants1Member_doc" xml:lang="en-US">June 2012 Notes Warrants 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrants2Member" xlink:to="txmd_June2012NotesWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012NotesWarrants2Member_doc" xml:lang="en-US">June 2012 Notes Warrants 2 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_doc" xml:lang="en-US">Warrants Issued To Unaffiliated Individuals 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnamortizedCostsOfWarrants" xlink:to="txmd_UnamortizedCostsOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnamortizedCostsOfWarrants_doc" xml:lang="en-US">Refers to unamortized costs associated with warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:to="txmd_ClassOfWarrantOrRightExpenseRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized_doc" xml:lang="en-US">Refers to non cash compensation expenses of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:to="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod_doc" xml:lang="en-US">Refers to fair value of awards by a calculation method.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:to="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts_doc" xml:lang="en-US">Refers to remaining amortization deferred financing costs during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumbersOfUnaffiliatedIndividuals" xlink:to="txmd_NumbersOfUnaffiliatedIndividuals_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumbersOfUnaffiliatedIndividuals_doc" xml:lang="en-US">Refers to numbers of entities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:to="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_doc" xml:lang="en-US">Refers to description of warrants and rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AgreementCoverPeriod" xlink:to="txmd_AgreementCoverPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AgreementCoverPeriod_doc" xml:lang="en-US">This item provides the agreement covering period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingExpense" xlink:to="txmd_FinancingExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingExpense_doc" xml:lang="en-US">Refers to financing expense related to debt during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmortizationResearchAndDevelopmentExpense" xlink:to="txmd_AmortizationResearchAndDevelopmentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmortizationResearchAndDevelopmentExpense_doc" xml:lang="en-US">Refers to amortization research and development expenseduring the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedDuringPeriodShares" xlink:to="txmd_WarrantsIssuedDuringPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedDuringPeriodShares_doc" xml:lang="en-US">Numbers of shares warrants for common stock issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfWarrantsVested" xlink:to="txmd_NumberOfWarrantsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfWarrantsVested_doc" xml:lang="en-US">Refers to numbers of warrants vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LoanGuarantyCosts" xlink:to="txmd_LoanGuarantyCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LoanGuarantyCosts_doc" xml:lang="en-US">The expense incurred for loan guaranty costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_doc" xml:lang="en-US">Date which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_doc" xml:lang="en-US">Refers to fair value of awards on equity-based plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards granted in the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xml:lang="en-US">Refers to share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_doc" xml:lang="en-US">Refers to share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding_doc" xml:lang="en-US">Refers to class of warrant or righst contractual life beginning oustanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding_doc" xml:lang="en-US">Refers to class of warrant or righst contractual life closing oustanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3_doc" xml:lang="en-US">Refers to stock issued during period shares stock options exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_doc" xml:lang="en-US">Refers to stock issued during period shares stock options exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CowenAndCompanyLLCMember_doc" xml:lang="en-US">Refers to cowen and company llc member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonaffiliatedEntityMember" xlink:to="txmd_NonaffiliatedEntityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonaffiliatedEntityMember_doc" xml:lang="en-US">An nonaffiliate is a party that is not directly or indirectly controlled by, or is under common control with the entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfDaysForOptionToPurchaseShares" xlink:to="txmd_NumberOfDaysForOptionToPurchaseShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfDaysForOptionToPurchaseShares_doc" xml:lang="en-US">The number of days granted to underwriter for the option to purchase additional share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk1Member_3_lbl" xml:lang="en-US">CustomerConcentrationRisk1Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToVariousPartiesMember" xlink:to="txmd_NotesIssuedToVariousPartiesMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedToVariousPartiesMember_3_lbl" xml:lang="en-US">NotesIssuedToVariousPartiesMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_3_lbl" xml:lang="en-US">WarrantsIssuedToUnaffiliatedIndividuals1Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_2_lbl" xml:lang="en-US">Amortization of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_2_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:to="us-gaap_PaymentsForProceedsFromOtherDeposits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherDeposits_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForServices_3_lbl" xml:lang="en-US">WarrantsIssuedForServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_2_lbl" xml:lang="en-US">Advertising Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_2_lbl" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xml:lang="en-US">PrepaidResearchDevelopmentCostsNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_3_lbl" xml:lang="en-US">IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LoanGuarantyCosts" xlink:to="txmd_LoanGuarantyCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LoanGuarantyCosts_3_lbl" xml:lang="en-US">LoanGuarantyCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeGrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeExercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeExpirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeForfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesFutureMinimumPaymentsNetDue" xlink:to="txmd_OperatingLeasesFutureMinimumPaymentsNetDue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OperatingLeasesFutureMinimumPaymentsNetDue_3_lbl" xml:lang="en-US">OperatingLeasesFutureMinimumPaymentsNetDue</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>txmd-20141231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20141231\txmd_123114.xfr; Date: 2015%2D03%2D10T21:08:48 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20141231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20141231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20141231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20141231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20141231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20141231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20141231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20141231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20141231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20141231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20141231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20141231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20141231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20141231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20141231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20141231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20141231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20141231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20141231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20141231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20141231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20141231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20141231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20141231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20141231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20141231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20141231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20141231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20141231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20141231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20141231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:href="txmd-20141231.xsd#NotesPayableDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20141231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20141231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20141231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20141231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20141231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20141231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20141231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20141231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20141231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20141231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmdDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonaffiliatedEntityMember" xlink:label="loc_txmdNonaffiliatedEntityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdNonaffiliatedEntityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedForFinancingCosts" xlink:label="loc_txmdWarrantsIssuedForFinancingCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedForFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:label="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:label="loc_txmdWarrantsIssuedAsCompensationRelatedParty" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedAsCompensationRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" xlink:label="loc_txmdAdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:label="loc_txmdWarrantsIssuedAsFinancingCostRelatedParties" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedAsFinancingCostRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="loc_us-gaapAmortizationOfDeferredCharges" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:label="loc_us-gaapPaymentsForProceedsFromOtherDeposits" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromOtherDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedForFinancing" xlink:label="loc_txmdWarrantsIssuedForFinancing" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantsIssuedForFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedForServices" xlink:label="loc_txmdWarrantsIssuedForServices" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantsIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:label="loc_txmdWarrantsExercisedInExchangeForDebtAndAccruedInterest" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DebtConversionConvertedInstrumentNonCash" xlink:label="loc_txmdDebtConversionConvertedInstrumentNonCash" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdDebtConversionConvertedInstrumentNonCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="loc_txmdPrepaidExpensesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_txmdPrepaidExpensesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000027 - Disclosure - FIXED ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000028 - Disclosure - PREPAID EXPENSE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000029 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:label="loc_txmdScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_txmdScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="loc_txmdCommitmentsAndContingenciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:label="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000037 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaapInventoryNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNetAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmdOtherCurrentAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdOtherCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000039 - Disclosure - FIXED ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000040 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000041 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrepaidAccreditedCostsNoncurrent" xlink:label="loc_txmdPrepaidAccreditedCostsNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdPrepaidAccreditedCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPayableDateDeclaredMonthAndYear" xlink:label="loc_us-gaapDividendsPayableDateDeclaredMonthAndYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapDividendsPayableDateDeclaredMonthAndYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapDividendsPayableAmountPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapDividendsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapDividendsPayableCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000046 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AccruedFinancingCostsCurrent" xlink:label="loc_txmdAccruedFinancingCostsCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAccruedFinancingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000047 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_IssuanceOfPromissoryNotesMember" xlink:label="loc_txmdIssuanceOfPromissoryNotesMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdIssuanceOfPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012Notes1Member" xlink:label="loc_txmdFebruary2012Notes1Member" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012Notes1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012Notes2Member" xlink:label="loc_txmdFebruary2012Notes2Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012Notes2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012Notes1Member" xlink:label="loc_txmdJune2012Notes1Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012Notes1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012Notes2Member" xlink:label="loc_txmdJune2012Notes2Member" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012Notes2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesMember" xlink:label="loc_txmdJune2012NotesMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="loc_txmdReichFamilyLimitedLPMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdReichFamilyLimitedLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MrMilliganMember" xlink:label="loc_txmdMrMilliganMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrMilliganMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCredit_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:label="loc_us-gaapLineOfCreditFacilityDecreaseForgiveness1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityDecreaseForgiveness1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_RemainingSurrenderValueOfNotes" xlink:label="loc_txmdRemainingSurrenderValueOfNotes" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRemainingSurrenderValueOfNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:title="00000048 - Disclosure - NOTES PAYABLE (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:label="loc_txmdNotesIssuedInAugustAndSeptember2012Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedInAugustAndSeptember2012Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedInSeptember2012Member" xlink:label="loc_txmdNotesIssuedInSeptember2012Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedInSeptember2012Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotesMember" xlink:label="loc_txmdJuly2011SecuredNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotes1Member" xlink:label="loc_txmdJuly2011SecuredNotes1Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotes1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_July2011SecuredNotes2Member" xlink:label="loc_txmdJuly2011SecuredNotes2Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotes2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToVariousPartiesMember" xlink:label="loc_txmdNotesIssuedToVariousPartiesMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToVariousPartiesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="loc_txmdNotesIssuedToParty1Member" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="loc_txmdNotesIssuedToParty2Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="loc_txmdDebtInstrumentRemainingFaceAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdDebtInstrumentRemainingFaceAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_JefferiesLLCMember" xlink:label="loc_txmdJefferiesLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdJefferiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="loc_txmdStifelNicolausAndCompanyMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelNicolausAndCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementAxis" xlink:label="loc_txmdPrivatePlacementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_txmdPrivatePlacementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementDomain" xlink:label="loc_txmdPrivatePlacementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrivatePlacementAxis" xlink:to="loc_txmdPrivatePlacementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrivatePlacementDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SharePrice1" xlink:label="loc_txmdSharePrice1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdSharePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="loc_txmdStockExpectedToIssuedDuringPeriodShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockExpectedToIssuedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised3" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_PrivatePlacementFees" xlink:label="loc_txmdPrivatePlacementFees" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdPrivatePlacementFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForCash" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaapWeightedAverageMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapWeightedAverageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="loc_txmdSancilioAndCompanyWarrants1Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="loc_txmdSancilioAndCompanyWarrants2Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="loc_txmdSancilioAndCompanyWarrants3Member" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ModificationWarrantsMember" xlink:label="loc_txmdModificationWarrantsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdModificationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedIndividualsMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedIndividualsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedEntityMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedEntityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrantsMember" xlink:label="loc_txmdJune2012NotesWarrantsMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrants1Member" xlink:label="loc_txmdJune2012NotesWarrants1Member" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_June2012NotesWarrants2Member" xlink:label="loc_txmdJune2012NotesWarrants2Member" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedIndividuals1Member" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="loc_txmdUnamortizedCostsOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdUnamortizedCostsOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="loc_txmdClassOfWarrantOrRightExpenseRecognized" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpenseRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:label="loc_txmdFairValueOfWarrantsByRelativeFairValueCalculationMethod" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdFairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_txmdRemainingAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdRemainingAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumbersOfUnaffiliatedIndividuals" xlink:label="loc_txmdNumbersOfUnaffiliatedIndividuals" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdNumbersOfUnaffiliatedIndividuals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:label="loc_txmdDescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdDescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AgreementCoverPeriod" xlink:label="loc_txmdAgreementCoverPeriod" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdAgreementCoverPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_FinancingExpense" xlink:label="loc_txmdFinancingExpense" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdFinancingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AmortizationResearchAndDevelopmentExpense" xlink:label="loc_txmdAmortizationResearchAndDevelopmentExpense" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdAmortizationResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsIssuedDuringPeriodShares" xlink:label="loc_txmdWarrantsIssuedDuringPeriodShares" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsIssuedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfWarrantsVested" xlink:label="loc_txmdNumberOfWarrantsVested" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdNumberOfWarrantsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LoanGuarantyCosts" xlink:label="loc_txmdLoanGuarantyCosts" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdLoanGuarantyCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WarrantsActivityAndRelatedInformationAbstract" xlink:label="loc_txmdWarrantsActivityAndRelatedInformationAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsActivityAndRelatedInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="loc_txmdNumberOfSharesUnderWarrantAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeBeginningOustanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeGrants" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExercises" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeClosingOustanding" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ActivityUnderLtipAbstract" xlink:label="loc_txmdActivityUnderLtipAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdActivityUnderLtipAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdNumberOptionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000057 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000058 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DeferredIncomeTaxAssetsAbstract" xlink:label="loc_txmdDeferredIncomeTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000059 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToPartiesMember" xlink:label="loc_txmdNotesIssuedToPartiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="loc_txmdNotesIssuedToParty1Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="loc_txmdNotesIssuedToParty2Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NonAffiliatedThirdPartyMember" xlink:label="loc_txmdNonAffiliatedThirdPartyMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdNonAffiliatedThirdPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaapRestructuringPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRestructuringPlanAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="loc_txmdDebtInstrumentRemainingFaceAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdDebtInstrumentRemainingFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueFromOfficersOrStockholders" xlink:label="loc_us-gaapDueFromOfficersOrStockholders" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueFromOfficersOrStockholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_LegalFeeReimbursement" xlink:label="loc_txmdLegalFeeReimbursement" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdLegalFeeReimbursement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="loc_txmdDeferredRevenueConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdDeferredRevenueConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_MonthlyBaseRentOfLeases" xlink:label="loc_txmdMonthlyBaseRentOfLeases" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdMonthlyBaseRentOfLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_FutureMinimumLeasePaymentsOverLifeOfLease" xlink:label="loc_txmdFutureMinimumLeasePaymentsOverLifeOfLease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdFutureMinimumLeasePaymentsOverLifeOfLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_OperatingLeasesNonCancellableSubleaseIncome" xlink:label="loc_txmdOperatingLeasesNonCancellableSubleaseIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_txmdOperatingLeasesNonCancellableSubleaseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_OperatingLeasesFutureMinimumPaymentsNetDue" xlink:label="loc_txmdOperatingLeasesFutureMinimumPaymentsNetDue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_txmdOperatingLeasesFutureMinimumPaymentsNetDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_SharePrice1" xlink:label="loc_txmdSharePrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdSharePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20141231.xsd#txmd_NumberOfDaysForOptionToPurchaseShares" xlink:label="loc_txmdNumberOfDaysForOptionToPurchaseShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdNumberOfDaysForOptionToPurchaseShares" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>txmd-10k_2a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd-10k_2a.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`%$`G`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^AO\`X)J?
M\$U/^"<OQ(_X)R?L!_$3XB?L!_L4>/O'_C[]BC]E7QIXX\<>-?V5/@3XH\8^
M,O&/BOX%>`M<\4>*_%?BC5_`%WKGB'Q/X@UF]O=6UO7]6O+S5=6U>^N;_4+R
MZO;EWK[=_P"'3G_!++_I&I^P#_XAM^SI_P#.WI?^"3O_`"BR_P"":?\`V8!^
MQO\`^LZ_#FOO^@#\_P#_`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1
MJ?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_AT
MY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$LO^D:G[`/_B&W[.G_
M`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$LO^D:G[`/
M_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$L
MO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_
M`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"
MB@#\_P#_`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.
MG_SMZ_0"B@#\_P#_`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`
M_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2
MR_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$LO^D:G[`/_B&W[.G_`,[>
MC_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$LO^D:G[`/_B&W
M[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$LO^D:
MG[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.
M?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\
M_P#_`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SM
MZ_0"B@#\_P#_`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B
M&W[.G_SMZ^EOC3^T1\`?V;/#5AXU_:)^.7P?^`G@_6-:A\-Z7XL^-?Q.\%?"
MSPUJ/B&:SO;^+0M/UWQQK>@Z9=:S<6&EW]Y'I=M=/>-:6%W>+:%+6Z*>FZ#K
MVB^*M#T7Q1X7UO2?$?AKQ'I=AK_A[Q!H&I6>KZ%KVA:M;0WVDZSHNKZ=<W6G
MZEI&JZ=<07ECJ%E<W-G>VDT%Y9NR2*Q`/AS_`(=.?\$LO^D:G[`/_B&W[.G_
M`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"B@#\_P#_`(=.?\$LO^D:G[`/
M_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ_0"JTT\=M%)--)'%!$C
MRRRRN(XXHH1F6264G``'))Q@`D\`F@#X(_X=.?\`!++_`*1J?L`_^(;?LZ?_
M`#MZ/^'3G_!++_I&I^P#_P"(;?LZ?_.WK[:\+>*_#'CSPUH'C3P3XDT+QAX,
M\6Z+I?B/PKXN\)ZQIWB#PYXG\.ZU9P:AI.O>'=>T>YN]-U?1]4L+B"[L=4TR
MZNK&]L[BWN[&[=&!KIJ`/S__`.'3G_!++_I&I^P#_P"(;?LZ?_.WH_X=.?\`
M!++_`*1J?L`_^(;?LZ?_`#MZ_0"B@#\__P#ATY_P2R_Z1J?L`_\`B&W[.G_S
MMZ/^'3G_``2R_P"D:G[`/_B&W[.G_P`[>OLCX@_$7P!\)?!GB#XC?%3QUX/^
M&GP]\)67]K>*O'OQ`\3:/X,\%^&--$T5N=1\1^*?$-_I>B:/IXN9X;<W>IWE
MI:[YX$W=CRGBS]H#X$^`?A-#\??'?QL^$G@GX%W&E>'=>MOC/XM^(_@_P[\*
M)M"\8RZ?!X4UF'XCZQK5GX1GT?Q3-JVE+X;U-=6-CK)U731ISW1O+8,`?,7_
M``Z<_P""67_2-3]@'_Q#;]G3_P"=O1_PZ<_X)9?](U/V`?\`Q#;]G3_YV]?5
MMG\:?@_J/PI7X\:?\6/AK?\`P/;PG+X_B^,UEX[\+7/PH?P)!9RZG<>-1\1(
M-3/A#_A$;;3X)[VZ\0G5SHZ6,#7C7BJK&O1S=6Z6K7CSQ+9+";A[EI(Q;I;"
M/SO/\[/D_9_)&=X^7:=V[!W4`?!?_#IS_@EE_P!(U/V`?_$-OV=/_G;T?\.G
M/^"67_2-3]@'_P`0V_9T_P#G;U].>&/C_P#`?QO\);KX_>#?C5\)?%WP)L=%
M\4^(;OXU^&/B1X/U_P"$MGH'@F;5+?QGKUQ\1M(UJ[\(6^C^#[C0];M_$^J/
MK'V+P\VDZFNI75F;&\V=WX4\6>%?B!X6\/\`C;P-XF\/^-/!'C'1-+\3^$O&
M/A+6].\2>&/%7AS6[2WU31-?\-^(='N;K2]8T;5;"XAO-(U72[J[LKZRGMKR
MQNW1P2`?%'_#IS_@EE_TC4_8!_\`$-OV=/\`YV]'_#IS_@EE_P!(U/V`?_$-
MOV=/_G;U^@%<KK?C'PGX:U3PIHWB'Q1X>T'6/'>MW?AOP1H^M:WIFE:IXS\1
M6.@ZWXJO=`\*V&H7-M=>(=9L_"WAWQ'XHO-*TI+V]MO#F@:UK+6JZ?I5[=VP
M!\4_\.G/^"67_2-3]@'_`,0V_9T_^=O1_P`.G/\`@EE_TC4_8!_\0V_9T_\`
MG;U^@%>`>+_VH_V9/AY\6?"/P&\?_M%_`KP/\<O'Z:9+X#^"WC'XN?#[PS\6
M/&T>MWU[I6B2^#_AUK'B*R\7^(5UC4M/OM-TAM*T>]%_>V-U96>^ZM;I%`/G
M[_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ/\`ATY_P2R_Z1J?L`_^(;?LZ?\`SMZ_
M0"B@#\__`/ATY_P2R_Z1J?L`_P#B&W[.G_SMZ/\`ATY_P2R_Z1J?L`_^(;?L
MZ?\`SMZ_0"N4M?&'A.^\5ZWX&L?%/AV[\<>'-$T'Q)XA\&VNN:;<>*]`\.>*
MKS7;#PKK^M>'(+DZQINC>)K_`,*^*+70]4N[2ULM9O?#>N6=A<W;Z1?"V`/B
MK_ATY_P2R_Z1J?L`_P#B&W[.G_SMZ/\`ATY_P2R_Z1J?L`_^(;?LZ?\`SMZ_
M0"N5\+>,/"7CC3)M:\%>*?#WC+1K?6_$?AJXU?PKKFF^(-+M_$G@W7M4\*^+
M]!GOM(N;NU@UCPMXIT/5O"_B72V=;W1?$>E:EHNI6=IJ%G>6J`'Q3_PZ<_X)
M9?\`2-3]@'_Q#;]G3_YV]'_#IS_@EE_TC4_8!_\`$-OV=/\`YV]?H!7FWQ2^
M+?PJ^!W@G5_B;\:OB;\/_@]\-_#TFG)K_P`0?BEXR\-_#_P-HLFJZC;Z5I:Z
MKXK\7:EI&AZ:VJ:O?6.E6'VN^0W=_?6ME9;[NY5:`/DC_ATY_P`$LO\`I&I^
MP#_XAM^SI_\`.WH_X=.?\$LO^D:G[`/_`(AM^SI_\[>O4_@Q^W)^Q5^T=XKG
M\!_L^_M@_LN?'?QU;Z1=^(;GP7\&?V@?A+\3_%UKH-A/96=]KDWAWP/XMU[6
MH-&M+J_L+6\U5K065K<W]LDETK75MGZMH`_/_P#X=.?\$LO^D:G[`/\`XAM^
MSI_\[>C_`(=.?\$LO^D:G[`/_B&W[.G_`,[>OO>:>.VBDFFDCB@B1Y9997$<
M<44(S+)+*3@`#DDXP`2>`37/>&_%_A+QGX5T+QYX0\5>'O%?@7Q/H5CXK\->
M,_#>M:;KOA/Q!X8U:RM]5TGQ)H7B33KFZT;5=`U/39H=2T[5K*[NK&^L;B&]
ML[MK5@Y`/BG_`(=.?\$LO^D:G[`/_B&W[.G_`,[>C_ATY_P2R_Z1J?L`_P#B
M&W[.G_SMZ[OX:?\`!0;]@KXU>.]%^%GP;_;A_9"^+7Q/\0O?1>'_`(>?#']I
M3X,>//'FO2Z1IM[K6L0Z+X/\+^-M4\0ZD=-T?3+_`%6_%G971L["QN[V\"V=
MG<N/L6@#\_\`_ATY_P`$LO\`I&I^P#_XAM^SI_\`.WH_X=.?\$LO^D:G[`/_
M`(AM^SI_\[>OT`HH`_/_`/X=.?\`!++_`*1J?L`_^(;?LZ?_`#MZ/^'3G_!+
M+_I&I^P#_P"(;?LZ?_.WK]`**`/S_P#^'3G_``2R_P"D:G[`/_B&W[.G_P`[
M>C_ATY_P2R_Z1J?L`_\`B&W[.G_SMZ_0"B@#\_\`_ATY_P`$LO\`I&I^P#_X
MAM^SI_\`.WH_X=.?\$LO^D:G[`/_`(AM^SI_\[>OT`HH`_/_`/X=.?\`!++_
M`*1J?L`_^(;?LZ?_`#MZ/^'3G_!++_I&I^P#_P"(;?LZ?_.WK]`**`/S_P#^
M'3G_``2R_P"D:G[`/_B&W[.G_P`[>C_ATY_P2R_Z1J?L`_\`B&W[.G_SMZ_0
M"B@#\_\`_ATY_P`$LO\`I&I^P#_XAM^SI_\`.WKXB_X*5_\`!-3_`()R_#?_
M`()R?M^?$3X=_L!_L4>`?'_@']BC]JKQIX'\<>"OV5/@3X7\8^#?&/A3X%>/
M=<\+^*_"GBC2/`%IKGA[Q/X?UFRLM6T37])O+/5=)U>QMK_3[RUO;9'K]W:^
M`/\`@K%_RBR_X*6?]F`?MD?^LZ_$:@`_X)._\HLO^":?_9@'[&__`*SK\.:^
M_P"O@#_@D[_RBR_X)I_]F`?L;_\`K.OPYK[_`*`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_+GPG?
MZ$/^"P'QLL_B%=%?%K?L(_`=OV9+3Q#-8B!O`DWQB^-1_:G/PR@8_:?MY\56
M'[/'_"Y3:`WC65G\&FUT?V=:^&B/FK2/'_P^\3>,?V>OV6?^">?[26K?LK?L
MP^+_``I^W_\`&A_BY\)/"W@KQ8_B#XA_`GXW?#CPUXO^'GP>O?VKOAS\8_A?
M!\$+/Q_\8_B-XSUH_#OP2WAJ[TGPKX=L_@MXS\-^!+36$O/UM^-O[./[//[2
MN@:3X3_:-^!'P9^/WA?0=97Q%HGAKXU_"[P5\5?#^D:^ME>Z8=;TK1/'.AZ_
MING:P-.U"_TX:E:VJ7OV*\N;,76RZ<'/^)7[+/[,WQG^'OA3X2?&']G7X$_%
MCX5^!IM'G\%?#7XE?"+X?>._A_X,F\.Z//X<T&7PKX,\4>'-5\-Z!-H>@W-Q
MH6CMI>EV1TK1I[C3[$VUD[6M`'X0S_M@?MK_`!\^#5O\7_#/[2VH?L_7/A?_
M`((V^`_V]+S1/A5\)_@IK_A_Q_\`'B^E^+<T%Y/<?'#P#\6-;T_X'^,M/\'6
M-W>^"]+N]'\=WFD3^'&T'XG>`[^T\2?\))O_`!L_:M_;+^`/@[X_FZ_:WM=7
MUKQ!^R[^PQ^TQX/\?_$7X/\`P8T_P?\`LZ^*/CM^U1??"KXM:!X<\.>'_#?@
MG_A(/@-:^%KBR_L72OBWXW\>?%/PWH^E7/V_XZ:QKUW_`,)+9_OQJ7PH^%NM
MS:W/K/PU\`ZM+XF\!_\`"JO$DVI^#?#M_+XA^%^W4R/AOKLMSISG5_``.N:T
M/^$.O?M?AT'5M3(L0;V[W>!_M/\`['OP\_:-^%.N?#NUTSP9X"UCQ!%\%]!N
M?&\'PZT'7=3_`.%<_!?XP^%_BYI/PRG@6XT"YG\&W5QH6JZ7I^A-JZZ-X;NO
M$FHZW9:->.;NRO@#\IOB!^T9^TO\,?B#\8_V.8?VP_C_`/&/QUIWQR_9N\/?
M!GX@_"SX&?L4:I^V+\0[KXC_``,^(WQI^*G[,>E7WC[1?@G^PKX(\8^#?"'P
MRM_CP?B?\6?A3966C_`?QB?!(T;Q+\2/$'@+QB>%_8X_:Z_;%_:8\0_LK>$]
M8_:6\=>&M'BT;_@IUXP^)FMQ>"/V0=1^(_Q>L/V-?VP_A5\)?@]X;^(VK>`/
M!7Q9^!EA<ZIX/\8WV@?%G4_V:KO2/#?B,#4=9^&GC31[S^QO$=?M7)^PW^Q1
M-\'[?]GJ7]CW]EJ;X!6OB8^-;3X'2_L^_":3X/VGC(K,K>*K?X9GPB?!4'B8
M_:)\ZZNCC5F^T7`-WAV!])\*?`?X%^`;NRU#P1\%_A-X+O-(T[QCI&DWOA7X
M>>#_``W<:=I'Q!U+0M;\?:98SZ/HME-8:?XTUGPOX;U3QE9VS+:>)+[PYH=_
MKJ7MYI%BUH`?SW>(_P!MK]K^+]G#]E?]I+7?VB?'^E^`]#_X)T?LY?M/_M&Z
MQ^SGX3_87\>>)_!OCOQA93^(_B+\9OVT/V>OCO=?#WXLWW[+WBCP_I,O_"OM
M)_89\0>#_BGK&L>'/CMHM@+34+/X:FS^COC)^U3^T=I?Q6_:-^+7AG]H>Y\+
M>%OV8_VXOV*?V3?#?[),/@3X27?@?XT>"/VC8?V5O^$C\5>.=;\0>`=7^/D'
MQ1\8G]I3Q7=?"*Z^'/QA\">`M%_X5SX*'BWP5XD%M\2!K/W+\*/!?_!-_P#;
M0\)?#'XD?#7X,_LQ_&[PK^S#XGU3X:_!/Q#J/P$\'7?_``H37?AOJ6AP#1O@
M[!XP\$6FH?#?3=-_L+P?KW@S5/`EKI'AWQ%X;B\$^./`E_JWA:]\,ZS=?2&O
M?LW_`+/7BGXP>%_V@O$WP&^#'B3X]^!M+&B>"OCCKWPO\$:O\8/!VBF/6(/[
M'\*_$W4-%NO&V@:<(/$6N#[%I6L6MGMUS65*8U6]#@'XZ?`/]H']L#4OB[^R
M]X_\<_M,Z_XR\`_'[_@HM_P4$_9*U3X%W'PV^!VE>`-%^$WP(G_;;U7X6:[I
MGB+P_P#"[2/C$?B=H,_[/7A/0;W7;OXG7O@[6_"!(U'P3>>*KJ\\8WOZI?ML
M?&;Q;^SM^QY^U'\>?`>FZ7JWC/X-?`3XK_$SPM:>(+6\OO#TFO>#?!.MZ[I4
MWB"QTV[TS4[_`,/V5Y8P76MVNG7MI?7.D6]TEA=+>M&1ZY8_![X3:5_PC7]F
M_"[X=Z?_`,(;XV\6_$OP?]@\$^&K/_A$_B+X^/BD>./'OAOR-,7^P?&WC,>/
M?'!\5>*-+^R:UXD'C+Q9_;=]=_\`"1:P;ST*:".YBDAFCCE@E1XI8I4$D<L4
MPQ+'+$1@@C@@YR"0>"10!_+Q^V1>_M#ZNVI?LG>(OVZ_BY\7?#VD_$K_`((U
M?'RS^,MEX`_9'TSXAZ/K/[0G[>%Q\,;WP5JL'AC]G"S^$NH?#BUN?ASX5^./
MP8M+KX97GBX>)O#NIV'Q*\9_$CX;7?\`PAUY^U'[8GBGX-?"CPO\#/B!\4?`
MOBOX^_%_P)\5]/B_9*^&>@7`7X@?%3]IO7OAYXX\$:)#HFA6-UX5^'7]M'P3
MKWQ`U?7/&7C2RL/AO\(/"*^+?BGJ-WX.T3PF^M:5ZW\/?V1_V4/A+X/O?`'P
MK_9B_9[^&G@/4/'.A?$Z_P#!/P]^"WPY\%^$+_XE>%-2T36_"WQ!O?#7A[PU
MI>BW/CCPSK/AKPYJFA>*[BS;6]'U;P]HE]IU]:7NDV+6NK\</V9/V;?VF],T
M31/VD/V>_@A^T%I'AB_N]5\,:3\;OA+X$^+&E^&M3OH5LKW4M`L?'>A:_:Z/
MJ-U:Q0VU[=::+2ZNK>'8S84``'XE?MD_L$Z7X9_X(R?M>Z3\?WGU#QS9>!/V
MT?VQ?$7PW^&/C?QAX3^!?A?XV_%J[\9?'*W\+0^&_#%SX2TSXO\`@?X(^,+^
M`^"[GXG^';S2?$OC#1%^,>H>"M&\<76D?\(S^^NH?\DZO_\`L2;K_P!,)KA?
M"/[-O[.OP_\`A'J7[/\`X#^`7P4\$_`?6['Q%IVL?!/PE\*_`OAOX2ZKI_BS
M[0?%EEJOPWT;0[+P7J%AXG%[<CQ):W6CM;:R;FY^WK=_:CNW_A?\3_AQ\:_"
M-_XE^&^KP^)_"5AXO^)'PQOY9-$U?1[9?%/PF\>>(_A7\1-!.F>(-+TJZGM]
M`\;^$_$7A_[4MFVD:NMA]OT.\O\`1+NROKL`_E3_`&/+C2=%_9!_9A_X)G6Y
MCM]/_;2^#'[%'[4]MI4-M#';O^S]JWP"F\?_`+8>@SP'_D(:/XH^('[,NJ^#
M?B#=6OVPZ/>_M?>&OMYL_P"U;.O2_A'^T9^T+X3_`&%O`K?#;]I:3]G/0?V%
MO^"'7[''[8?ACPE%X&^$OBC0_P!H3QGXC^'OQ;GO]'^-%]\2/`/C?Q;_`,*7
MTP?`'PYX"_LOX#^(/A!\2/[7^('B:]_X6#]M;P)_8_\`0Q+I'[+'PS\2>&++
M4?`/PP^&-[\)?`G@GX/?#?Q5K7PLTWX?>#_"'@?XT^);'P/X3^!OPC^)^K>&
MM'\!_9_&7BGP-X4\/WGP2^'/BJZOH[VW^&-GKW@ZT/B#P`=8S+C]F[]C[XI7
M_@G2=?\`V6?@]XBG_9'US1O#'P7/Q`_9HT:VTKX,W>EZ!X(\2Z'+^SGJOCCP
M#::+IWA_2=/@\&V]EXG^"5X_AG1_$/AL^%5U>T\5^!]6T?10#\E_%7[2O[9<
M_P`1/CI\7[+]HGQ-X,\`_!__`(*1_L%?LS>'OV;$^&GP(N_!VJ?#C]IKPU^P
M];_%O0?B-XKU?X7:K\6;C6-`O_VA/%6N_#[7?!WQ-\'WFC>(_M/_``EG_"8>
M%AHWAS1OE_X.?#+XI2?#[]@[P?X9_:@^)#>+_$'_``6R_P""F.E6WQ1\1>%?
M@-JOBSX:6-AH_P#P4MT3QC>>!M#T#X.^'?`'_"<>*=/L=<\>6-U\4/!/Q'\-
MZ/\`$CQC=7Q\&7?PKM-'^%=G_1-KT'[,L?Q8L_@AKW@WX=3?$[XR_P!H?M/'
MPO>?#2TU#_A.M9_9[UWX+>'?^%O^(=;/AJZ\-W/CKX;:UJGP-M/#&N^(-6'C
MNR&E^$[WPD39^"#=:+S_`(.\'?L>V7Q[^(?@CP1\*O@WH_Q_\*:CX1_:E^(<
MN@?!W0M#\30^*?C3IWQ3^%?AWXUZCXXM?"-I:ZQ\2/&6@^#OBIX*OO$]IX@O
M?':^&%U31O$#VFA>([1=7`.+_P"">OQ2^)?Q8_9IBUGXO>+7^('CKP=\;OVI
MO@M?^/;G0?#OAS5_&VE?`']ISXM_!7PKXJ\2:)X.TO0?"-KXOUWPQX!TG5/%
M/_"'>'?#7AJ[\0SZG>Z#X8\.:?<VFBV7P)^SS??LEW'[!G[?W_#;-_HA\/6'
M[7'[:LW[>#^.]1U.+QG::S9_'GQ(/A*=<F\$7(\?0>($^`UE^SS;?LX#P&W_
M``F'_"'67P>L_A(KZBOAA3^VWA?PAX2\$:9-HO@OPOX>\&Z/<ZWXC\2W&D>%
M=#TWP]I=QXD\9:]JGBKQ?KT]CH]M:6L^L>*/%.N:OXH\2:HT;7NL^(M5U+6M
M2O+O4+R\NG\D\5_LI?LN^/OBYX8^/_CO]FWX!^-?CQX)&C)X+^-?BWX.?#[Q
M'\7/!\?AV\O+_0AX5^(^L>'+OQGH(T+4=0OKO1_[)UBS_LF[OKN\L?LS74A8
M`_+OQS^V=\8O#5M^U#9Z1\3SI,O@#_@J?_P3L_9P^&&F^(O#GAJW\3:5\!/V
MA=-_8(OO&'@F_P!*\7>&SXDU#4O&6G_%OXQ77]O>,+6\^(UE_:NI#3M9T>]\
M)V/]C>8WWQ;_`&W?$_C/1/$^D?MI^,?"6A_$;_@J9\?/V%K+X=:=\$OV<-2\
M)>"O@EH4'QR&C^+_``]?Z_\`"Z\\?ZA\?O!EQX(LCX*\9>*?&NM?"I;6QT2T
M^)7P(^*CVGB2\\8?LEXL_9=_9;\6_$N#X\>./V=?@%XG^,6DV.A6MM\9_%OP
MC^'FL_$O3=+\&ZU9>*/"]O#\1M8\/7?BRUL/"_B+2K#Q-H:#5A:Z)K.F6FMV
M`M+RSMKI-WPAX,^`'C3PSX0\:>`/"GP=\6>#=;\4#X^^!?%OA'0_!6N>&]6\
M9>,;/4+_`/X77X/US1[:[TN^\4^*+#Q+JMW_`,+&TBZ;5]:L_$6I7?\`;5VF
MJW370!^1'[-'[77[0Z_'KPC\%?B_\<#XUT#PGX1_X*P^'-:\<^+/"7PL\'ZS
M\4-?_9)_:7^`'A7X2>-_%0\'^$_"7AO3O%_A?X3>.?%=KXITKP%I/@[P?K(^
MU>*M0\%6@M;,:/\`(_P<_:J^)%_X1\=_M%>*/C5KWA+XZ_'7_@E9_P`$3(;;
MXI>"OA+\/?B!X\\6?&[]H7XI_M4:'8Z/\,OAEX@U+P1\$X/B1\4/%_C'_A%_
MA]J?CS^Q_@GX#\7^(]%\5>/-%O/AQX>UC1KW^A#QM^RE^RU\2K/2M-^(_P"S
M7\`?B#IV@_$/5/B[H=CXU^#GP]\5V6C_`!9UZ]GOM<^)FEV^O>&[ZWL/B#JM
M_-<7FK^,[14\27UY<2W=]?ER6-G5/V7/V:-<\'ZS\/\`6_V<_@3K'@3Q)X#\
M#_"OQ!X(U7X0_#[4O"&O?##X9W5]>_#GX;ZYX;N/#D^B:CX$^'^HZMJUWX+\
M'WEG=>'?"5WJFI7F@Z?927=T7`/YN?AU\5/VCOVA/VIOV8?!OQ>_:(_:2\.W
M7[,__!7WQE\)=!A^)VB?\$\9?C0^EZK_`,$N_''Q;OO!/QIU3]E[P3\3?V>-
M0\0:7X@O?'_PZLA\+[OPWK%GX#^)NMV'BVRL_C%X>\'^)/AO])Z3^W%^UWHN
MC>()=>^*5KK5_P#M/?$7]K[]D[]DRYOO!_PXLI/A]^U!\*_^"AWQ;^!'PRAL
M;'3O"=F/&$`_9W\1:%X\UG3?%(\2V@\-?LH>+_%%_97=]K'C&\UC]=;S]F3]
MA/P3H_@#X5ZA^SW^R7X0T'7_`(@^%-0^%?PVO?A3\'_#^D:U\5?A9X5U77?!
M-YX`\'3:%:6FH?$#X<^!/"NMZIX9NO#VF2>(_"/A'PYJE]IIL=$T>\>U]TTW
MX3?"O2(M`BTGX:_#_2X/"7C7Q1\3/"L6G>#/#=G'X9^(WC@^,?\`A,OB#X=A
MMM-4:1XW\8'X@>/AXG\5:8MKK?B$>-_%W]I7UY_PD>L?;`#\//V<?VM_VW_'
M'[6_@^;Q%9_%^3X*^*OVM_VI/V4O%&A?$[4?^">?@S]G^W\+_`./XMZ%X/\`
M&'P/B\/_`!'\/_M^>*/VF-5NO@II/C3XB^#O&/P^UCX;ZMX:\<?%G7_`WP_\
M&_#GPGX#\367]!=?,WBWX8_LH?!7Q7\4?VU_%'PI^"?@3XCZ-\.->U+XN_M-
MQ_##PC9?%>3X8^#?#]E?:[#XK^)ND>'/^$^UGP[H?AWP=I1_L>YU6^46?AS3
M+2RLF_LNRM5ZG0OVA/A1KGP/D_:/N];UGP+\';7PIKWCK5O$_P`9/`GQ!^!-
M_P"&_!OAT7]QJ_B/Q7X/^-'A3P!XX\'Z=:VNFW&J+/XH\.:/]LT<6VMV!N],
MO+&]N@#\>OA[\7_'_P`%?^":_CCQ#\,_%%GX`\4^,_\`@IS^T/\`!-/BE?Z/
MH^N1?"C1?C]_P5\^(GP6\1?$Z'2?$%M=^&M1\0^#-`\<7VJ^%SXHTC6?""^,
M(-$O?%OAGQ%X5MM8T:^\6\6ZQ\;O''[:7[*WP8\<?M<_%#QG;?LH?\%7=>^%
MWA[XNQ>$/V9-&\8?$?2_&/\`P2U\<?M#3^%?BW#HOP"M?A_/XY\&W'BKQ7\)
M#=_"[P1\+;*\^%7Q'_T_16^,>D:-\2?#7ZU?LX?'+]AW]K_P%\6OA7\%_#&D
M:QX`@G\2?\+B^"WQ+_9F^(7P+M]9MOBYXD\;3^,=8\5?!CX__"?X:ZEXN\/?
M$_QSI?Q/M/%/BE_">L>&_%_CK2?B/IVM:Q?>*M)\36=IY1I/CG_@D_%^QOX#
M\=>"OA]^S;XA_8Q\-_&V\T_X*>%/A7^S-:>./!&H_M`^%?BUXD\#V]Y^SU\"
MOA]\+]?UKQQ\23\5]+\57/@W7?@U\/\`Q%K'B1H=2\<^$;[5]"N3XCD`/S^U
MS]M;]H2?]L[X-VOA7X[_`!U^(7[.OQ__`&N/VI/V=8[+Q+\*_P!AOP!^RAK'
MA7X-_!_X^1>)/!_P1L+'QIJ__!1[5_B=\$_BS\*K+P]\0/BUX[LO^%*^._$=
MAXOO]`T;PSX(\1?#;1[O],_^";7_`"BB_8C_`.S$/@'_`.J/\.5YAKGQ-_X)
M&?"SPMX3_;C7X6?`F.\_:0U75/B'HGQ4^&O['FL^.OV@_B/KWA/0O%.N^-_&
M'B+P=\,/@IXB_:&_M_X8Z.OC(_%O7/&/A2SU;X0L?$FG?$R[\):@U]9G])OA
MU8?#./X9^!M/^$VG>"K?X/\`_"$^';;X;Z;X!L=&M_AVGP[GT>Q7PI:^#K#P
M_`GAV#P>?#S6"Z);:3;#1QH[6JV(%DJ@`'\S/P!\7_'GQC^R'_P14^`O[1OP
M@^"'P8_9M\9)^PSXO^%?[5_@_P"-GC#XS^)/^%C?`'1OAO\`%OX+?!_Q9\-/
M$'[/'P>T[X$?$']I^W\*7_@ZQ\8VGQ7^*7@[1]WBWX5'6O$GBKQQX#M/$GN/
M@_\`:L_;G^+_`,>_$$$L_P`;O`'P;^)7[17[;G[)%_#K]_\`\$X/#?P0^'OA
MWX+:#\<=#\`_$/\`9EM_$'C75OVZ/&_[4&F:A\&]"\>^*?!OQB^$_P`1OA5K
M7ASQ7\4-=L/AAI'PY\)^$/$@_=W5_@A\%M>^%VG?`_7/@_\`"[6?@OI.F^%M
M'TGX/ZMX`\*ZC\+M,T;P3>:5>^#=(L?A_<Z-<^$['3?!VHZ)HEYX9L[72EM/
M#MWI&F7FFI9O8VA3.TW]G7]G_1OC)K_[16D_`SX.Z9^T#XJT.'POXG^.NF?#
M#P59_&7Q)X=M[32=/BT'7OB=;Z(GC;6=&@L?#N@VB:5J6O7=DMEH6C68M-FF
M6*H`?B7_`,$YOB[\1?A/\%/^"3?PCO?C;JGB#X9>//\`@DA\8OC/JK^.=+^$
MUE(WC?X80_L=3^!](L-=\+>`?"9&D?!OP;\1_'^@6>F#[7K-[X:@_MKXFWOC
M'Q1I/_"25X38_MK?MQ^-?V8/BA\?+']J37_#.I?!#_@AE^S+^VG;:5X?^&/[
M/ESH_P`1/VEOCO\`"O\`:AGU7QMXX_X2'X.^(;G_`(1[2]8^&7ASQCHG@WP%
MJW@/1O\`A)-*M;"_L;OPG=:QX;U?]\+[]B7]C+4?"'A/X?ZA^R-^S%?^`O`/
MC:_^)G@?P3=_`3X5W/A'P9\1M6NYK[5O'_A7PU/X2.B>'O&^IW\]Q=W_`(IT
MJTLM:O+N>:\O+V21F)[V+]GOX`VWA_7/"5O\#O@_#X3\3_#/P_\`!?Q'X8A^
M&7@N/P_X@^#7A.UUVP\+_"77=%&C#3=6^&WAFV\5>*+30O`EW9W/AG1K/Q'K
MEII^CVZ:O>K=`'QC^R1XO_:#T3]K/]I+]GSXQ_'SQ'^T!H?A?]GW]DOX\^&]
M7\7>!_A/X0U+P9XI^.'B;]I3PYX_\%^%9OA-\/OAK;7_`,,+/_A3OAVY\%6G
MCRT\7?$;1Q/J2Z_\0O%QNE:Q_3:N3L/!?A'3?%&K^-=.\)>&=-\9:]H7ASPK
MKOBVRT'3+3Q-K?A?P?=Z_?>$_#FJ:[;VT>J:AH/A>^\5^*+SPYI=W=M8Z->>
M)-=N].M+5]5OVN^LH`****`"BBB@`HHHH`****`"O@#_`(*Q?\HLO^"EG_9@
M'[9'_K.OQ&K[_KX`_P""L7_*++_@I9_V8!^V1_ZSK\1J`#_@D[_RBR_X)I_]
MF`?L;_\`K.OPYK[_`*^`/^"3O_*++_@FG_V8!^QO_P"LZ_#FOO\`H`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"O@?_`(*._%7XC?#W]F77/!?P.:S/[2?[27B#1/V8
M?V<$OK^\TRQL?BM\8(;[3!XVU74M/\.>+KG3M!^$?@FQ\<?&;Q-J8\*:U]D\
M-?#K66_L>^.VTNOOBB@#^;WP5I'Q_P#V'/'?Q0^#_C7PG\(/V)?A'^U+^QQ?
M^"_V>/%7[,7Q"^*O[;MS\,?VH/V1/@;J'AN'QJO@'Q#^S/\`LX^+/''Q!\3?
MLT:)X5U[1?ASX6\$^/=8\>)^RAJ2WVLB[O5LQY%\$?C]'XC_`&0_VZM!\%_M
M2:GX9T#P#X?_`&8-;U']J+P)_P`%#?VI_P#@HI^RI'/XJU^\'Q&\-:7^V3XA
M^&VD_M1?LH>*/&7A;PT-`_:>NM"U?Q)X<_8G^&_Q$^'W[3/A*\\.:X?&%WJ_
M]3]%`'\R'P<_;&TKP;\/_P!EGXK:[\;O%'P^_9>^'7_!37XC?#'XM?&WQ'^W
M9XU_:Z_9/UOX=>(_V+?BW/X4/@[]N;XK^&OAIXL^-_[-X^//B3P?X8&N_'@:
MT/`/[3>EZW\.+#Q,;#P/X$L](Z+X&^(O%7[6OB+]CGPGXJ_:$_:5D^%_Q.^,
MG_!:/6-??X;_`+0WQK^$&N?$/P;\*_VP)])^!^CW_C[X?^+?"?Q1T_POX#\/
M3Z2OP]M?"_BSPY>:-X:L;;PK87I\#:KXD\-:Q_2;10!_*?\`#[QS^UK\._@'
M^S-\9_@U\;?VE/C7^TS^T1_P31_;EU^\\/?$GXG^+_BYX>\<?&3X(>%/A5??
M`'7O"GP/UBZO/A=X7^('ABZ/_"/C4_AU\/=&UGXJG5-3OOBT/B1XW\0ZMXEO
M7?!CXO?$#7OV7?VX=4\,?MM_#C0O@;I?@;]F35+7XA_#_P#;W_;A_P""AVG?
M"_XC7WC35/\`A>&F^/\`]N7Q!^SC\//B!^RQX>^+?PWTKPIX5^+5M\.?%?C'
M6/V$=(US6OVG#X8^%6GZMH[>)/ZKJ*`/RP_X)-_%>T^*WP(^)TFCZQXH\3>&
M?!?Q^\9>#_#'C&3]KGQ?^WO\(O%6F1>%O`_B&XO?V;OVR?B5X+\$_%;X\?"6
MPU;7M5T*^U7XCVFM>(_`WQ6TKXH_"W3_`!'<^%?`_AK3])_,/X#>$M=^+GQ+
M^%'P8O/B[\?/`'PMU*?_`(+X_$OQ5X4^"'QY^+_P'N/%GBSP%_P5`\*:3X(U
M/5O%7P8\;>"/%D$_A6X\8ZM=Z+<Z7XAL\V=[J6@WPO/"OB+Q)HVL_O[^U%^T
M7H7[+/PI;XK:[X$^(/Q-%SX^^%'PQ\/>`OA<O@,>-O%/C7XT_$[PK\)/`VD:
M3/\`$_QY\-/`-@+OQAXRT47VI^*?''AS2+"P-S?7EZ!;8/`_!7]L.P^*/Q9O
M_@)\1/@1\=/V7/C7%X!E^+'AGX<?'L?!/4+[XA_#&PU^Q\*^(?&O@'Q?^SQ\
M:_CU\-M8MO!OBC5M#T/QIX9N?&]AX[\,-XH\(:EKGA:ST#Q=X;U?5@#^:#XB
M?$CQ'\=?V9/AKXH_:=^./Q@G\"^%_P!EK_@W`_:*^)'BJ/X[_%3X3Z/X8U3Q
M_P#M7?%.P^/OQK\1ZW\-O&W@BW\+W&J>#K<:[XS\=B[LQH^K^#?"/Q&%[HWB
MGX>>#_$GAO[*_:1_:=L/"]E^UCX?\>_'+XC:9X`UO_@I]\*OA=\+_%.I_MT>
M-?V,/@/X?\&6_P#P3K^`'QKB\'_%K]MWPSHWQ!^(_P"S_P#`_P`47]OXD\4V
M(^";67B[XJ?&W7/#7A5K_P#L+XF^/3>?TPT4`?S&_P#!*[XD>./B=^T#^R!J
MGCWQ9XC\9:MH'P4_X+'^"M'U/Q9\2OB'\9-=M/`?A3]O?]DZP^'.@W/Q;^+_
M`(2^'WQ;^*&G:%X&&A6GAKQW\4?!'AKQYXD\,P:+K>OZ/97MV;0>A?MWZKXT
MT[]KC]J>S\!?$7QU\+-?\6>'O^"#_P`/9_&_PW\2:EX7\6:;X>^(_P#P4A_:
M&\#^*[*PU32+JUNEMM=\,:YJVEZS9Y-GJVCWUSI]_9WMC=7=I7]&%>9_%WXE
MZ!\%OA3\3OC#XHM=7OO#7PH^'GC+XD^(K'0;>TN-<O-"\$>'=0\2:M9:'!J.
MH:3IUQJ]S8:5/;V%M=ZK8637AMEO+ZSC9KH`'\]UW\1/C=^Q]XL_:@^(/P[^
M(_[17Q?^&7[,G[9GC']ECPM\'?B/\6_C5^T-K.K6W[5'['/[)'BOX!:/<:W\
M2/%?Q!\?^,-1TO\`;8\4^#O"WAGQ1X[U_P`17G@/P?\`'#Q_8Z?K.B^!_MEE
M9^4ZEXL_:P^%/[:OA7X"^(?VD]$T[XL?"_XN_L9>`_@:_P`8OV]OVI]+^)GQ
M^^`5_P"`_A*?VA?$FA_\$[O!'P+^,7@#]L#1_B/XPUS]I.U\3_M&>//&]GK'
MP'UC0_MVH>*/@_X'_9[L]9']17A'Q)8^,_"OAKQ?I4=Y;Z;XJ\/Z/XCTR/4$
M@2\BT_7-.M]5LH[V*WN;NV6Y6VN8A=+;W=TH<,!=,H5JZF@#^9[PK\38=?\`
M^"A'Q(^!>I?'_P")?QS\1_%KX@_M>^!_$^A?"#]M_P#:;\(?%?X/_#J?X;^,
M=;\+^%?C]_P32\7^"M)\)?LO_"'X<VMCX<\!?!?]MW]G/XA>`_'GQ?\`'EQ\
M$OB-H6M7MC^T)XE&L<O^Q)X<\&_%O]GW_@B;\"/!7[0/Q]M_A)K?[(/Q\/QP
MT#X/?M=_'?PIK^K?%KX9>"/V>(=<^''C#XB^#OBA9_%GP1<?"3XD:KXCM;'X
M<^%?&W@\?#8V%Q\-]/LM&^'-SK'@/6/Z0?BQ\4_`_P`#OAA\0OC)\3-8_P"$
M?^'OPO\`!_B/QYXTUM;.^U233?#GA73+C5M5N+72M*MKO5-7OQ:V<XLM)TJT
MO=7U:]-OIVG65U?75M:'X<L/^"F7PVTOP_\`&"_^,OP'_:7_`&<?&WPA\#?#
M+XC?\*@^+/A7X8ZQ\2/B7X7^-/BN]^'7P>F^%G_"D/BS\8O`/B#Q!X]^*%D_
MPOL_!6J>./#WCKPYXRGTRT\=^&O#.C:OI&LW@!^/7P^\<_M:_#OX!_LS?&?X
M-?&W]I3XU_M,_M$?\$T?VY=?O/#WQ)^)_B_XN>'O''QD^"'A3X57WP!U[PI\
M#]8NKSX7>%_B!X8NC_PCXU/X=?#W1M9^*IU34[[XM#XD>-_$.K>);WB_A_\`
M%KXS>*O@7\5[+X5_M=Z=??"CQ%^T%_P2L\%Z;XE_9X_X*)_M3_M_^+_AU\1/
MBW^V#X-\`_'6"?\`:T^.'P,^#MUX0G\>_#6X\*6OC3]E;0O&WB\?#?%WKFN^
M"O`6A?&2RLO$W[X:-_P41_9]M_@5\6/CK\:3XF_9=L_@/X_U[X4?&;X<_'EO
M!-G\3/`GQ-TO3M*US0O`4-G\,/&WQ-\(_$'Q3\2?#'BCP;XH^$VD_"/QKX^N
M_B18^-_#.G>%A>^*+RZ\/6B^-?\`@HE^SY\.?V!-*_X*.^-SXST#X$Z[\$/!
M'QTT?P_?Z5HL7Q/U'2?B)H.DZWX-\#V/AP^(_P"Q+GXD:_/KNEZ%9Z$OBO\`
MLC^VIL'75TZVNM54`_$[Q?X;\%^#?VJ_@SX=^+OQQ^/47P:_9?\`^"V5U\+?
MAEXJ^*_[8?[2%[)X)T;XJ?\`!*G0_B;X5\$^*?BWXI^+7_"7>+[?Q3^T!XIA
MT'PQ:_%KQ;XPO+RR^(&M_!S0KX?#CXA^)/`?B3^HW6)=2ATC4Y]'A2ZU6+3K
MZ72K6X<);W.H16LWV*&>49VPW%QY(8]0"6R.<7+2Y2\M;>[0%8[JWBN45OOB
M.>(2@''?GGZ'VJW0!_%3\3?']O\`&/\`8H^+?AW1/VG_`-H3XV?$3Q9_P25_
M:T^*/_!3KX=ZY^TI\9]?_P"%"_M<^!['X2:YX'\.>,/`$/CZZM?V./%'_"R;
M[X\>`C^ROX+TGX0^`OB1\-]!\7:#XM^&7C#PM\/+6RLOZ>OCU\/OA7X8_8)^
M*?PT\;>#?C=\6_@WI_[/7B7PSXM\'>%?%'C?XN?'_P`4^!6\*W,.NP^'/%/C
M_P`:ZM\1O''C^WTB:YO=&O-5\7ZSXPO;^RMQ8W>KZD;*SNOMRB@#^?3_`()C
M?%/P=^UG;?M0?LI:K\4?`'_!0C]CO2'\5^)KGXNZ[X/\!^(+?Q)XL^(_[4/[
M0E]KGPG^,?B/X8Z;X?\`V>?BA<>*O`VA^`/BW_PAGA;X8^!+KPWX0\<VUGX\
MT3Q%H7C;PRR>3_#K4_`OP*_9\_8C^+_BZZ\,_#/]F[]G/_@LK_P4'F^)OB>^
M_LSPO\-/@_X-\8_%7_@HU\"/ASXD\53XL_#?@[P1I?Q0^(_PX\&KKVK-9Z-X
M0/B/3KZ]O+&Q5KVT_I'TC1]'T*VFLM$TC3M'M+C4=7UBYMM*T^UTVVGUCQ%J
ME[K>NZG/#;06]O/J&NZU?7^K:S=N/M=_JU]<W]ZS7=T\E;E`'\N'P5^-'PI_
M9O\`&'[-O[9_[0/B_1/AE^R+\6'_`."UFH?"[XH^/)CH7@.YM/VE/VQ_`_[2
M7P!B@N-8%IIEA<?M`_`[X<>.?&?PEL_^/WXDV7V:QT*QO-<\165G>_M;_P`$
MU/`_C#X:_P#!/?\`8I\`_$+1=2\-^-?"?[,'P6T7Q)X;UJ&>VUCPWJMEX"T,
M3^'-5L;C_2+#4M!`72KW3&R;"ZL9[#@6P)^XJ*`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`KX`_P""L7_*++_@I9_V8!^V1_ZSK\1J^_Z^`/\`@K%_
MRBR_X*6?]F`?MD?^LZ_$:@`_X)._\HLO^":?_9@'[&__`*SK\.:^_P"OPI_9
MH_;-\,_L@_\`!*O_`((PVE[X1U;X@>+?CY\!_P#@F?\`!'PSX6T>\GL#HFB_
M$WP=^SW\,O%/Q4\1ZK!H^L6^C^#_`(<M\0-#-Y<WMK:6/B'QAXA\$>!1K&CW
MWC6QO[3Z<^)__!0?7/A_\>O$G@W2/@7;^)OV>?A+\=?@#^S1^T)\?KGXI_V#
MXC\`?&7]I2R\&S?#ZR\$?!\>`-9M?B/X(\/7WQ;^!MG\6_%>J_%;X<WOA!?B
M:;[P_P"%O'B^$O$B@`_3JBOS%^)__!0?7/A_\>O$G@W2/@7;^)OV>?A+\=?@
M#^S1^T)\?KGXI_V#XC\`?&7]I2R\&S?#ZR\$?!\>`-9M?B/X(\/7WQ;^!MG\
M6_%>J_%;X<WOA!?B:;[P_P"%O'B^$O$BCZ0_:B_:'USX"Z/\+='\`_#VP^*_
MQG^/?Q;TCX+?!KX?ZWXVE^&_A75O%ESX6\8_$7Q#K'CGX@6_A+XA:IX/\$>#
M?AM\/O''C#6]6T/X>^/-:;^R+71-#\+ZMJ&K6BJ`?55%?DG'_P`%(_B5XU\`
M?!G3O@9^RYIOC_\`:M^(UK^U`WC;X`>,_CO%\.O!_P`+K_\`8M\8P?"S]HK3
M+[XT:9\)OB#=>()D^,&K>%O`7PBNK;X3Z1:?$A?%FC>*?$#?#?0[76FTG]"_
M@-\9_"/[1'P2^$WQY\!_;X_!7QC^''@SXE^%X=6AB@UBTT7QOH%AXBL++6X+
M:ZNK6VUG38+X6FL6D%Y=K9WMM<H+IP`S`'L-%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`?G/\`\%0++79_V9O"^KZ'X-^(/CG_`(0G]K/]AKXE>(=!^%_P
MZ\>?%CQPO@GX:?MC_`_QSXXUG2/AY\,/#GBSQ[XG7PSX/T'6_$%]9^%O#VL:
MQ]BTNX>RL;HY%?'/[2=Y\>OVX?&WBGXA?L9>`OCO\-KOX*_L'?MN?#OX>_%K
MXR_"+XO_`+(GC#Q!^TY^T9IOPJL/A7X!^'7A;]H_P3\)_B?_`&?X6M_AQ?>,
M?$OQ1/AVQ^'&D>(K[X>V.A>,KS7M*\8VOA']WJ*`/Y,?A?\`LS?$?3_V>_VD
MG^'/PU\66_[/7B#Q-^PS<_'3]E[X+?\`!,CX^_\`!/3PA\2/`?PY^+=QJW[7
MMEX(^`/QO_:&^)GQC^._Q?\`'?P&&D>%_CKJO@/P1H_@_P#:&\">&_#GPJ\)
MZU\=_'%WXD\-:1]#_M%?!WP1XJ_9;\&:;^QA^R5XK^!?['^D_MKZ?XS^/OP3
M^,G_``3Y^/GQ%^%'Q*^'S?!/Q)X<'BOPY_P2O\/^+/@Y\?O$_P`']+_:`G^%
M&JZW\+M"^'OP@^V?$GPKKG[3)^&'Q(\+6>L^,?&/](]%`'\X7P4_8@@^(T?_
M``3<^'?[1'P?USX\?`GP=X8_X*$ZE/X3^,?[+NO_``J^$W@SP1XP\>?#G5OV
M<_AOXC_9S^(/Q(^/%SX`^&V@>%X(+7]G[X-_M!>.+SQYX.\.>#O!0U[P7X#^
M(WP\_P"$:\'^`^$?V*?%OPT_9I^`OB#P'^S7\2M$^-7Q'_X)8?\`!03X0_M(
M^(8?AYX]OOBOX]U\_#SX;P?`?X;_`!HUW4=-N_&WB'Q!I=QH@\+?`KPQXZN[
MW5_#?AS2O^$%^&ME9^%[,Z,/ZNZ*`/Y';G]G7QYJ_P`*/B[;_L+_`+,'QC_9
MF^&L'[)W[)?A+]J_P!\2/V5?BGX+TOX^_%CPO^TAX4\6?M&+JGP)U"Y^%'Q'
M_;(^(%K^S?I?Q<\&_&CQE\./%>KG]K3PYX_TWX5>%/CIXPUX:1]C]2^#W[%=
MSX^TG]E3P'XO^$5Y\0?V5-8_X*:?$'XCW'P6D_X)\?$;]C7]F?X=_"R']@GX
MQZ5JD&B?L??'3XH_'#QY\,/@-XI_:)@&J7FG_&O2OA;HOB;XV^*]<O\`P?\`
M#T^%/&_@[Q)XQ_J0HH`\7^/7Q4D^`WP2^)OQ;L/AQ\1?BQ=?#GP3K'B31OA1
M\(/"&L^./B1X_P!2TFR9M)\'>"/"?AG3M5U/4-9U^_\`L>F62VUFUI8_:#?7
MYL]/M+RZ3\#Y]$\5?'SX#?&7]H[6/!?[1?Q3_;7L_B9^Q%^T)\5/".I?L3?M
M??L\:)X5^!'[*_[3G@CX_0_LC?LE0?M+_!7X477QAN/`FCZ3\5=5LKO0AJWQ
M)^-GQ5\1W&NZ[X8\)6'B/X<?#CP9_2Q10!^7O['6BZUX_P!5_;V_:+OOAS\0
M?!OA7]HO]HJ+Q;\%-!^+WPP\8?"_XGWGA;X9?LO?!W]GH^-K_P"%OQ)\.>'/
MB1X`_P"$R\7_``_\='PSI7C'PGX<\3WGA"?3=>-C_9_BNSS^4'QT_9M_;W\2
M?\$E?@%X,\&?L[^!/'_ASX9?\$B!X'O/@_XX^)GQK^&'[2?A']I?QC^SI-\.
M?%6I:5\`?#_[+WQ7M_BAXX\&_#Z?5?`GP_\``>N^-OA9K'_"2?$#XD:'KX%\
MWAK6M'_JAHH`\_\`AC<^.+OX>>#)OB5X<\,>$?'LGAO2O^$M\,^#O%NK^//"
M^B:U]EA%[INA>,M?\$?#+6_$.GVI`"ZGJGP^\(7EUG+:+9L`M>@444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7P!_P`%8O\`
ME%E_P4L_[,`_;(_]9U^(U??]?`'_``5B_P"467_!2S_LP#]LC_UG7XC4`?B#
M\(_V(OVY?B__`,$]O^"='Q3^`?QE^`&N6>K_`+,__!$Z?PS\.OB)^S)XB\0>
M-?A-\/\`X!S_`+-GQ6\5:CI7Q:@_;.^#WA;7_"-IXHTKQ'\9_B#X.M_AI9>/
M/B5HNC:;\*]"\9VFH:3X$UG1/NGXM?LO_M4ZM\9OC;\%-)^$+^+?@_\`M8?M
ME?L2_M@>)_VI]*\7?#?PYX$^$NF?L\Z?^SQ-\8/AYXC^&>O^/Q\:;CQCK^H?
MLA>&[3X3#P;X(^)'@^\M?C3;#QUXU\.CP/K-[>?:O_!)W_E%E_P33_[,`_8W
M_P#6=?AS7W_0!^&_QI_9C_:9UKXZ?'OX,^%?@Q?^(O@;^UK^VK^Q9^V'JO[3
M4/CKX9:?X3^#FA?L]VG[/,WQ5^''C'P/J_C72OC'K'C_`%VY_9"\*VGPQO/`
M?PT\8>#;Q?C);-XM\4>$5\#ZPUW]8_M?^%OC+XRNOV</CA\,/@7XV\<>+/V0
M?VMYO'\WP<3Q3\&M`\8?&GX:^(?@]\6O@!XK\1_"K6_$'Q1TGX<V.H6FD_&N
M;XB^&-)^+/CGX6WNL6O@C4]!UZS\.:AJND"[_1>B@#\`/`_[/?[8O[-Q^`W[
M6'AS]F36OC7\7=7/_!2&Z^+W[,'@GXI?!30O%GPRO_V]?CUX>_:H\`0CQQ\2
MOB-X(^$OBFW^$_B#X;^%_A+\6[KP_P#$+63]J\5ZCXL^&5EX\T/0%M+S]7/V
M*_@=K7[,_P"R)^S/^S]XCU33];\2_!SX'_#3X=>)M4T8S?V+?^)/"OA32]+\
M17&B>?:V=U_8SZQ;WPT;[5:6MX;$6WV]?MA<U]1T4`?D+_P4V_9Z\,3^#_#O
MQKTGXG?M:^!?'GBK]K;_`()T_";6_P#A5'[<_P"VK\'?!+_#_P"+?[=/[,OP
M#^(VBZ9\*OA3\?O!?PKT"Y\5?"KQQXIT#4-?T'P38>)!>ZM/XJL-9M?&MO9^
M([7[(\&?L<?"3P)I1T31?%G[55]:-=S7YG\9?MV_MO?$76!/.;>)D/B+X@?M
M"^*-;%H%@7R].&J_8;7_`$C['9JUW=F3S'_@I7_R;K\.O^T@'_!)W_UZ9^QK
M7Z`4`?/_`/PS5\//^AB^/W_B6/[4_P#\^*C_`(9J^'G_`$,7Q^_\2Q_:G_\`
MGQ5]`44`?/\`_P`,U?#S_H8OC]_XEC^U/_\`/BH_X9J^'G_0Q?'[_P`2Q_:G
M_P#GQ5]`44`?/_\`PS5\//\`H8OC]_XEC^U/_P#/BH_X9J^'G_0Q?'[_`,2Q
M_:G_`/GQ5]`44`?/_P#PS5\//^AB^/W_`(EC^U/_`//BH_X9J^'G_0Q?'[_Q
M+']J?_Y\5?0%%`'S_P#\,U?#S_H8OC]_XEC^U/\`_/BH_P"&:OAY_P!#%\?O
M_$L?VI__`)\5?0%%`'S_`/\`#-7P\_Z&+X_?^)8_M3__`#XJ/^&:OAY_T,7Q
M^_\`$L?VI_\`Y\5?0%%`'S__`,,U?#S_`*&+X_?^)8_M3_\`SXJ/^&:OAY_T
M,7Q^_P#$L?VI_P#Y\5?0%%`'S_\`\,U?#S_H8OC]_P")8_M3_P#SXJ/^&:OA
MY_T,7Q^_\2Q_:G_^?%7T!10!\_\`_#-7P\_Z&+X_?^)8_M3_`/SXJ/\`AFKX
M>?\`0Q?'[_Q+']J?_P"?%7T!10!\_P#_``S5\//^AB^/W_B6/[4__P`^*C_A
MFKX>?]#%\?O_`!+']J?_`.?%7T!10!\__P##-7P\_P"AB^/W_B6/[4__`,^*
MC_AFKX>?]#%\?O\`Q+']J?\`^?%7T!10!\__`/#-7P\_Z&+X_?\`B6/[4_\`
M\^*C_AFKX>?]#%\?O_$L?VI__GQ5]`44`?/_`/PS5\//^AB^/W_B6/[4_P#\
M^*C_`(9J^'G_`$,7Q^_\2Q_:G_\`GQ5]`44`?/\`_P`,U?#S_H8OC]_XEC^U
M/_\`/BH_X9J^'G_0Q?'[_P`2Q_:G_P#GQ5]`44`?/_\`PS5\//\`H8OC]_XE
MC^U/_P#/BH_X9J^'G_0Q?'[_`,2Q_:G_`/GQ5]`44`?/_P#PS5\//^AB^/W_
M`(EC^U/_`//BH_X9J^'G_0Q?'[_Q+']J?_Y\5?0%%`'S_P#\,U?#S_H8OC]_
MXEC^U/\`_/BH_P"&:OAY_P!#%\?O_$L?VI__`)\5?0%%`'S_`/\`#-7P\_Z&
M+X_?^)8_M3__`#XJ/^&:OAY_T,7Q^_\`$L?VI_\`Y\5?0%%`'S__`,,U?#S_
M`*&+X_?^)8_M3_\`SXJ/^&:OAY_T,7Q^_P#$L?VI_P#Y\5?0%%`'S_\`\,U?
M#S_H8OC]_P")8_M3_P#SXJ/^&:OAY_T,7Q^_\2Q_:G_^?%7T!10!\_\`_#-7
MP\_Z&+X_?^)8_M3_`/SXJ/\`AFKX>?\`0Q?'[_Q+']J?_P"?%7T!10!\_P#_
M``S5\//^AB^/W_B6/[4__P`^*C_AFKX>?]#%\?O_`!+']J?_`.?%7T!10!\_
M_P##-7P\_P"AB^/W_B6/[4__`,^*C_AFKX>?]#%\?O\`Q+']J?\`^?%7T!10
M!\__`/#-7P\_Z&+X_?\`B6/[4_\`\^*C_AFKX>?]#%\?O_$L?VI__GQ5]`44
M`?/_`/PS5\//^AB^/W_B6/[4_P#\^*C_`(9J^'G_`$,7Q^_\2Q_:G_\`GQ5]
M`44`?/\`_P`,U?#S_H8OC]_XEC^U/_\`/BH_X9J^'G_0Q?'[_P`2Q_:G_P#G
MQ5]`44`?/_\`PS5\//\`H8OC]_XEC^U/_P#/BH_X9J^'G_0Q?'[_`,2Q_:G_
M`/GQ5]`44`?/_P#PS5\//^AB^/W_`(EC^U/_`//BH_X9J^'G_0Q?'[_Q+']J
M?_Y\5?0%%`'S_P#\,U?#S_H8OC]_XEC^U/\`_/BH_P"&:OAY_P!#%\?O_$L?
MVI__`)\5?0%%`'S_`/\`#-7P\_Z&+X_?^)8_M3__`#XJ/^&:OAY_T,7Q^_\`
M$L?VI_\`Y\5?0%%`'S__`,,U?#S_`*&+X_?^)8_M3_\`SXJ/^&:OAY_T,7Q^
M_P#$L?VI_P#Y\5?0%%`'S_\`\,U?#S_H8OC]_P")8_M3_P#SXJ/^&:OAY_T,
M7Q^_\2Q_:G_^?%7T!10!\_\`_#-7P\_Z&+X_?^)8_M3_`/SXJ/\`AFKX>?\`
M0Q?'[_Q+']J?_P"?%7T!10!\DZ+X)L?AM^TG\/-%\.>)/BA=:+XH^"'QWU?6
MM&\9_&7XO_$O1[C5/"_CW]FVST+4;?2OB/XW\6:;I^HZ9;>*_$5M:WFF6ME=
MFTU>[LRQB8J/K:OG_P`2?\G3_!K_`+(#^TM_ZL3]E"OH"@`KX`_X*Q?\HLO^
M"EG_`&8!^V1_ZSK\1J^_Z^`/^"L7_*++_@I9_P!F`?MD?^LZ_$:@#X__`&%O
MV[?V8?V:_P#@G+_P3-\#_%[QUKVAZ[%_P3;_`&*O''BB;PY\)OC+\3/#/PJ\
M!:I\#O`>A:7\0OCOXV^%_P`/_&O@O]GGX<ZGJ6GZVME\1/CAX@\`^#KJT\,>
M+K]-;;3_``CXDN](_1SQ-^UY\$_"OQPTG]G*[?XM^(?BGJFF^!]7GM?AU^S;
M^TA\6/`_A?1_B-J>NZ3X-U+XC?%SX8?";Q;\'_A=8:[=^%O$3I=_$?QSX2MK
M/2M*NM<U!K/11]N/X#:[\;OA!J'_``0V_8]_98D_:8/P?_:(\2?\$I/V3/%'
MPT_9^U!-"\-R?MQS>(_V7-*\-^'?V6/"DOCCPU:>(_C/H_Q;\4V5GX"^(7@W
M]DKXA>&?V@_#?_"1^$K'_A,_`G_"<>'/^$E^B?%OQ&M?@G^UU\3M2^#_`.V<
M9?VLOBK^T5^QYX>OO^"8\W@3X,^#)?$/PJG\*_`'X9?$:\L+'Q_X`U7]I?XP
M>!OA-\'I_BU\<-&^-W[/OQ,\(?!/P=K6A>++'Q99>)+#X>?$C1[T`_67QC^V
MM^S7X!^/7AG]FGQ3\0[BR^+GBJ^\+:-9Z=:^!/B/K'@W1/$GCJT\1W_@#PAX
M^^+>C^$M2^$OPR\;_$:V\+:V_P`-?`GQ$\<>&?&'CWR+9?"&BZTVK:0+STGX
MW_'7X7_LZ^!_^%A?%G7K_1O#T_B#0/"FD66@>$_&'Q"\:>*_%GBK4X-)\.>#
M_`7PX^&_AWQ9\2/B%XPUS4)@-)\*^!?"GB+Q'>I!=7J6)LK.]N;7\$?VA_%G
MAO1_CK^V+^R5J>M65K^U'^TK_P`%/?\`@FO\??V>/AO=38\<?$CX(^#;/]B6
M^\4_%3P/8`#6]8^'_P`);;]E[]H8_$'Q1I5I=Z/\-CX'U(:]>6?]K:/_`&O]
M[?M[_%CX8>&/%7[#OQ]\1?$/P1:?`S]FK]O*^T[]HGXAS^*M&D\#?!:_\2?L
MT?M&_!#1+WXJ:T+K^Q?`T&@?%KXJ_#KPQKFI^*;S2%\'WGBO3+_7#963-=*`
M>_\`C'_@HA^R'X'^"?PT_:$U?XHZKJ/PS^,=AJ^I?#B3P-\*/C+\3?'_`(BL
M?"VC:KXA\<S'X.?#?X?^*_C'HX^&.D:%K5Q\6QK_`(`TH_""ZTO4;#XE?\(S
MJ%G=VB_7WAWQ#H7C#P_HGBSPKK&G>(O#/B?2-,\0>&_$&BWD.I:/KF@ZW9V^
MJ:7J^DZG;-<6VHZ;J5A/!>V%Y;.UK=VEQ`8V965A_,A\%?C1\*?V;_&'[-O[
M9_[0/B_1/AE^R+\6'_X+6:A\+OBCX\F.A>`[FT_:4_;'\#_M)?`&*"XU@6FF
M6%Q^T#\#OAQXY\9_"6S_`./WXDV7V:QT*QO-<\165G>_M;_P34\#^,/AK_P3
MW_8I\`_$+1=2\-^-?"?[,'P6T7Q)X;UJ&>VUCPWJMEX"T,3^'-5L;C_2+#4M
M!`72KW3&R;"ZL9[#@6P)`,'_`(*5_P#)NOPZ_P"T@'_!)W_UZ9^QK7Z`5^,O
M_!5SPK^V+>_#SPIJ?P]^.W[-7ACX03_MK_\`!+RT\/>!O&?[*'Q3\>?$G2_&
M5Q_P42_9*L/#NO:W\5-&_;0^'GAG7_#&E_$>?2?%.M^#K+X.>&M7\1^!K+4O
MAWI_C7PWKNK6?Q*T;Z;_`.%=?\%2_P#H\?\`8"_\5I_M%_\`TV"@#[_HKX`_
MX5U_P5+_`.CQ_P!@+_Q6G^T7_P#38*/^%=?\%2_^CQ_V`O\`Q6G^T7_]-@H`
M^_Z*^`/^%=?\%2_^CQ_V`O\`Q6G^T7_]-@H_X5U_P5+_`.CQ_P!@+_Q6G^T7
M_P#38*`/O^BO@#_A77_!4O\`Z/'_`&`O_%:?[1?_`--@H_X5U_P5+_Z/'_8"
M_P#%:?[1?_TV"@#[_HKX`_X5U_P5+_Z/'_8"_P#%:?[1?_TV"C_A77_!4O\`
MZ/'_`&`O_%:?[1?_`--@H`^_Z*^`/^%=?\%2_P#H\?\`8"_\5I_M%_\`TV"C
M_A77_!4O_H\?]@+_`,5I_M%__38*`/O^BO@#_A77_!4O_H\?]@+_`,5I_M%_
M_38*/^%=?\%2_P#H\?\`8"_\5I_M%_\`TV"@#[_HKX`_X5U_P5+_`.CQ_P!@
M+_Q6G^T7_P#38*/^%=?\%2_^CQ_V`O\`Q6G^T7_]-@H`^_Z*^`/^%=?\%2_^
MCQ_V`O\`Q6G^T7_]-@H_X5U_P5+_`.CQ_P!@+_Q6G^T7_P#38*`/O^BO@#_A
M77_!4O\`Z/'_`&`O_%:?[1?_`--@H_X5U_P5+_Z/'_8"_P#%:?[1?_TV"@#[
M_HKX`_X5U_P5+_Z/'_8"_P#%:?[1?_TV"C_A77_!4O\`Z/'_`&`O_%:?[1?_
M`--@H`^_Z*^`/^%=?\%2_P#H\?\`8"_\5I_M%_\`TV"C_A77_!4O_H\?]@+_
M`,5I_M%__38*`/O^BO@#_A77_!4O_H\?]@+_`,5I_M%__38*/^%=?\%2_P#H
M\?\`8"_\5I_M%_\`TV"@#[_HKX`_X5U_P5+_`.CQ_P!@+_Q6G^T7_P#38*/^
M%=?\%2_^CQ_V`O\`Q6G^T7_]-@H`^_Z*^`/^%=?\%2_^CQ_V`O\`Q6G^T7_]
M-@H_X5U_P5+_`.CQ_P!@+_Q6G^T7_P#38*`/O^BO@#_A77_!4O\`Z/'_`&`O
M_%:?[1?_`--@H_X5U_P5+_Z/'_8"_P#%:?[1?_TV"@#[_HKX`_X5U_P5+_Z/
M'_8"_P#%:?[1?_TV"C_A77_!4O\`Z/'_`&`O_%:?[1?_`--@H`^_Z*^`/^%=
M?\%2_P#H\?\`8"_\5I_M%_\`TV"F/\.O^"IBKN;]LG]@!54;F9O^":G[1/R@
M=Q_QM?`XYSG!`YH`_0#.!A>1['./P[T*3T/7KZ9'^/\`A7Y>_#K4/^"@OQ:T
M6\\1?#/]OC_@G#XVT+3];U;PW>ZKX;_X)T_M!:K9VVN:)=?8M4TZ>:W_`."L
M9"7"/Y-Q;9)6\L+BTU"Q>ZL+RRN[GT,?#O\`X*EMP?VQOV`?_%:G[11_E_P5
M@R*4H3I3=.K3]C5U3BU9IZ/6\4T_)JX-.'NRW6]S]`:*^`/^%=?\%2_^CQ_V
M`O\`Q6G^T7_]-@H_X5U_P5+_`.CQ_P!@+_Q6G^T7_P#38*8'W_17P!_PKK_@
MJ7_T>/\`L!?^*T_VB_\`Z;!1_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP4`??\`
M17P!_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP4?\*Z_X*E_]'C_`+`7_BM/]HO_
M`.FP4`??]%?`'_"NO^"I?_1X_P"P%_XK3_:+_P#IL%'_``KK_@J7_P!'C_L!
M?^*T_P!HO_Z;!0!]_P!%?`'_``KK_@J7_P!'C_L!?^*T_P!HO_Z;!1_PKK_@
MJ7_T>/\`L!?^*T_VB_\`Z;!0!]_T5\`?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP
M4?\`"NO^"I?_`$>/^P%_XK3_`&B__IL%`'W_`$5\`?\`"NO^"I?_`$>/^P%_
MXK3_`&B__IL%'_"NO^"I?_1X_P"P%_XK3_:+_P#IL%`'W_17P!_PKK_@J7_T
M>/\`L!?^*T_VB_\`Z;!1_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP4`??\`17P!
M_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP4?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP
M4`??]%?`'_"NO^"I?_1X_P"P%_XK3_:+_P#IL%'_``KK_@J7_P!'C_L!?^*T
M_P!HO_Z;!0!]_P!%?`'_``KK_@J7_P!'C_L!?^*T_P!HO_Z;!1_PKK_@J7_T
M>/\`L!?^*T_VB_\`Z;!0!]_T5\`?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP4?\`
M"NO^"I?_`$>/^P%_XK3_`&B__IL%`'W_`$5\`?\`"NO^"I?_`$>/^P%_XK3_
M`&B__IL%'_"NO^"I?_1X_P"P%_XK3_:+_P#IL%`'W_17P!_PKK_@J7_T>/\`
ML!?^*T_VB_\`Z;!1_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP4`??\`17P!_P`*
MZ_X*E_\`1X_[`7_BM/\`:+_^FP4?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP4`>_
M^)/^3I_@U_V0']I;_P!6)^RA7T!7Y^_"_P`._M3>'_VI?`O_``TO\9/@%\61
M=?`/X\_\(4?@7^S3\0_V=QH!@^(G[,W_``D?_"4_\)_^UC^U%_PF`U7SM#&B
M?V4?`O\`PCO]E:U]N'B4:Q9'P[^@5`!7P!_P5B_Y19?\%+/^S`/VR/\`UG7X
MC5]_U\`?\%8O^467_!2S_LP#]LC_`-9U^(U`!_P2=_Y19?\`!-/_`+,`_8W_
M`/6=?AS7W_7P!_P2=_Y19?\`!-/_`+,`_8W_`/6=?AS7W_0`4444`%%%%`'Y
M_P#_``4K_P"3=?AU_P!I`/\`@D[_`.O3/V-:_0"OS_\`^"E?_)NOPZ_[2`?\
M$G?_`%Z9^QK7Z`4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`02,L:AGPJJ-[,?X<#KCVQSTP
M/K7GGP^^*OP[^+.B7WB+X9>,_#?CC0]/UK5?#EWJOAS4X-3LK;7-#O#9ZGIM
MQ-`[!;B,^3/;X^2^LKFTU&Q:ZTZ\LKJY_.O_`(*]^(OBOX?_`&7/*^&GCG3O
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MKX2T8:EXDFR.Z:2^.>:_)O\`;6_:G^-O[5OPDU/P+^Q5\,_V@+[P1=VNJ7/Q
M*^(P^%FI>%M$\8>#;>R$KZ%X'\4ZQK5CK-R;K]Z-:T*S\.+K'B.RGMK"PO/L
M7]L:1K/ZE?"?]BS]EKX)-;7/PX^"'@31=6M#FW\2:AI9\3>+(.,9A\5>*9]8
M\1P_2'5%&<';P*^HLXZ'`'H%Q^A//%>3A,QR?*<50QF#P.*S*M0DIQ6;N,<'
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MW3[7MJO770_1#DX)7GIG(4D_0TXA\>GMGGZD\?I^76OSH\(?MS7WP_\`$&F_
M#/\`;7^'K_L[>.+Z<:=H7Q$2>XUC]GSXAW2X/F^'/'IWVWA>ZN8"UZV@>,+J
M-](M%5=0UDWQ-I7OWP:_:X^`/[0'C#X@^`_A5\0=,\5>)/AOJ'V76[6V?RX=
M4L%^S0S>(_"MP2(/$WABVU&?^P[K7=,:6S34(>OV#5-%O-6^<KY1F6'A6JU,
M+-T(Z_6\*GB\&U?E4HXR">$DF]%[Z?\`-%:G)/#UHKG]FW'OTMY-7/IRBBBN
M(Q"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@#Y_\`$G_)T_P:_P"R`_M+?^K$_90KZ`KY_P#$G_)T_P`&O^R`
M_M+?^K$_90KZ`H`*^`/^"L7_`"BR_P""EG_9@'[9'_K.OQ&K[_KX`_X*Q?\`
M*++_`(*6?]F`?MD?^LZ_$:@#\=;_`,(^,O!__!$3]AS]I[P1XT_;(C\9_#+_
M`();_LEIX%D^!W[0.I?"?X(?LR:CH7[-_ACQAJO[5WQN^%G@_P`6>"=9_:1\
M#^#18:)=_$'X7^)O!7[6E[K7AGPO;>%OAI^SX!XK^(UYK?MOQ?\`B;\6+[XF
M?M$?M2VGQR^+$&J_LF?M]_L`_LP?#3X>^#_B/XP\-_L_^*OA!\:=(_9!LOC1
M_P`)_P#!C3=:_P"%;_$?6/B:/VOO'&IV'C+QWX>\2>,?AO>>#OAN?`>M^'#X
M=O6UCTO]B3]C6P_:(_X)K?\`!.ZZUK]H?]I3P+\.O'W_``3-_8N^&/QK^`O@
MKQ5\/-1^"_QN^'T/[/WA5-4\*^(O#OQ0^%OQ*\1_#?\`X2G1O$GB+PMXR\8?
MLY>*_@CX_P#%_AJ_M5UWQC>WWA+P)JWAG[/\:?\`!.[X3>,_C[:_&YO'WQC\
M.^'+KQM\%?BA\0/V<O"^K^`K']G_`.+7Q:_9UT[^S_@K\3_'VDZE\.-6^*$/
MB+P#;Z3\/VM--\"?%;P;X-\2W7PE^%I\<^%?$H\*$78!^?/QY^(GQ5/QG_:?
M_:9L/C)\7]#U+]D+_@H;^PC^RQ\-?A3X>^)_C'0_@;K'P@^,5I^R18_&C3/B
M-\'-'UJT^&_Q*\3^/!^UOXYNK/QGX]\*^(_&/@&\\'?#6]\!:SX<_P"$?O#J
M_P![?MY:MXFUOQ#^Q9^S[I'C3QWX`\*?M-_M62_#GXK>(/AAXU\2_#3XB7?P
MY\#?L]?'WX^WOA3PK\1O!.J>'_'_`(!_X3'Q1\(_"F@ZYXI\!^(_#?C"T\)7
M&O6&AZW9-JINUV?'O_!/GX7_`!"_:('Q\U#XD?&72-)UCQ[\'_BY\2/V>]!U
MOP);?`3XP?&/X`6K6'P=^*OQ`TO4?AQJOQ1_X2?P*+#P-=+IO@SXK>#O!OB:
M\^%7PO;QUX7\3+X65;OTKXY?LL6/Q[\(Z?H/B7XQ_&+PQXM\(?&C2OCG\'/B
M]X*_X5)IGQ(^!GC'1!?6.EV7@`:Q\)O$'@#6/#*>%]<\6>!+_2OBQX`^)=SX
MD\&^-O$NB>*[W6FO+2ZL0#\;_A/JWQ4_:;UKX$_L0^._VA?VC-$\$^`U_P""
ML6E:Q\4?AQ\;_B'\-/CY\2/^&+?VJ?`W[+O[.>I>-_C3X&UOP_\`$C5]0\+>
M#_B;/XH\9FZ\67@^+_CWPKHFO?$RR\26']LZ1K'Z\_\`!/WXO^,OC_\`L/?L
ME?&?XBWD.I>/_B7^SW\*?%_C?5;>UALX=8\6ZMX.TJX\1:Q!96UM9VUA_:FL
M?:-3-G:VJ6ED;DV5FICMU:O&-=_X)D?"ZY^$_P`%_AWX`^-_[2?P7\9_!.'X
MOVVF_M%_#3Q3\,G^._C:+]HM]5U/]H[_`(6+JGQ"^$GQ`^'.LW'QO\<7T'Q/
M\97FE?#/PY=^'OB/H?AK7_AE=^`AH%A96_W;\,OASX-^#WPZ\!_"CX=:'%X<
M\`_#+P9X7\`^"?#UO/<3PZ'X3\':-8^'/#>EPW%U<75W.+/2-/@MA=7=Q=7=
MYY6^]NWD+,0#\I/^"K?[5_PO\"?#WPI\*M:\+_M+WWB;P_\`MK?\$O/%][JO
M@[]B_P#;%^(GPXFTOP[_`,%$OV2OB!?VFB?&+X??`GQ5\)?%'BBXT'2[BRT/
MP7H'C?5_&/B7QU-IWPU\/:'JWQ'UC1O"-Y]-?\/+?V=O^B<_M^_^*G_^"I?_
M`-!U2_\`!2O_`)-U^'7_`&D`_P""3O\`Z],_8UK]`*`/S^_X>6_L[?\`1.?V
M_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\5/\`_!4O_P"@ZK]`:*`/S^_X
M>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\5/\`_!4O_P"@
MZK]`:*`/S^_X>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\
M5/\`_!4O_P"@ZK]`:*`/S^_X>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6
M_L[?]$Y_;]_\5/\`_!4O_P"@ZK]`:*`/S^_X>6_L[?\`1.?V_?\`Q4__`,%2
M_P#Z#JC_`(>6_L[?]$Y_;]_\5/\`_!4O_P"@ZK]`:*`/S^_X>6_L[?\`1.?V
M_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\5/\`_!4O_P"@ZK]`:*`/S^_X
M>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\5/\`_!4O_P"@
MZK]`:*`/S^_X>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\
M5/\`_!4O_P"@ZK]`:*`/S^_X>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6
M_L[?]$Y_;]_\5/\`_!4O_P"@ZK]`:*`/S^_X>6_L[?\`1.?V_?\`Q4__`,%2
M_P#Z#JC_`(>6_L[?]$Y_;]_\5/\`_!4O_P"@ZK]`:*`/S^_X>6_L[?\`1.?V
M_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\5/\`_!4O_P"@ZK]`:*`/S^_X
M>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\5/\`_!4O_P"@
MZK]`:*`/S^_X>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6_L[?]$Y_;]_\
M5/\`_!4O_P"@ZK]`:*`/S^_X>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JC_`(>6
M_L[?]$Y_;]_\5/\`_!4O_P"@ZK]`:*`/S\_X>5?LZ\_\6Z_;^Y_ZQ/\`_!4K
MUS_T9U5>X_X*9_LW6=O-=77@']O:UM[>*6XN+BZ_X)3?\%1K>WM[>!3--///
M/^QTJ0P0("2Q8*H`!P`2/T*)Q_7Z9QQ]._7\,U^:/[8?C/Q'\;O'_AS]A'X3
M:M=Z;J_CZPC\3_M&>-=+D*R_#?X%02PB_P!&$PR8/$_Q'\V'0K"W);9I]Z3?
MV8T[7OMUGT8#!O'8E44U0H)/$XS%;K"8.-GB\7*R?PIVBM.:<H15W)&E.'M9
M\K>FKDWLDM>I\7Z/^V1\)OCI^U/;_M"?$WP3^UMK?P,^$-A-:_LI:=\./V!/
MV[?CGX1\8Z[?SW%CXF^-.J>(_@U^SC\0?"6GZS:W.F3:1H/A?5M5M?%WAPP6
MUWKNA^&]<TO%Y]PZ)_P4+_9;\-VLNG^'_A!^W-H-A-?:IJL]EHG_``20_P""
MGFFVDNIZU?3ZKJNI3V^G_L9V\!U#5-1O;C4]0NG4W5]>W-S>7CO>7#L?NSP7
MX-\.?#[PGX=\$>$-(M="\+>$]'T[0M`TBS0?9[#3-,@CM;.*(EB\I5(@7NKA
MFNKFY9KNY=I"SGK@HP<GV^F#DCIZ]>M:9ECUC*ZA0BZ&"PZ>$P>%YDHQPD;V
MYM=<7-MXS%M*SQ>*D[Z*SJSYI>Y_!Z*[\OEYM]SX"_X>6_L[?]$Y_;]_\5/_
M`/!4O_Z#JC_AY;^SM_T3G]OW_P`5/_\`!4O_`.@ZK]`:*XS(_/[_`(>6_L[?
M]$Y_;]_\5/\`_!4O_P"@ZH_X>6_L[?\`1.?V_?\`Q4__`,%2_P#Z#JOT!HH`
M_$_]M3]J[X/_`+2_[.WCGX2^#])_;Z\&Z]KR6=U9W5S_`,$E?^"GMQI>M2:5
M-]N@\.:]-<?L4W>H:?HVJW4$"WFJZ`;36+(P0%6O;`W^CZM^`_[,>E>,OA)^
MT!\+O%_CU?VC?@#9Z3XLM89M9\,_LU_'SQE\6SJG]CV.N?\`"!:+\&/#7PO\
M5?$;5_$^OZ/KFE6FM^#KSX?ZO=Z-X:\1?V[XN\,_V$+PWG]T093L.1@@^N,9
M/3OGG^HXYKXP_;M^#^M_%?\`9_UJ]\"^;!\6?A'K.C_&KX1WULGFWMOX[^'4
M\NKVUI9*!FXN=>TA]7T"UMI/]&%[J-LTG%L,?9<*\55\NPN(R"<<&L!G+<?K
M4M7@L5C(K!_6Y147]:PJYHJ4)WTNU?1'IX+'5*,)87_ES7TVVOL[=5M=6_4Y
M'_AY7^SH?^:<?M^_^*G_`/@J6/Y?L=4[_AY9^SM_T3G]OW_Q4]_P5+_^@ZKZ
M6_9\^,6B?M`?!CX=?&#0/*2P\<^&-/UF6UA?S?[)UD9LO$.@O,?OSZ!X@L]4
MT.[SDF:P;GH3[5T'/X_UKXVI3J4*M7#U5:M1DXM.VC3E%I^:E%J^VW<\V490
MFXR6WX;'Y_\`_#RW]G;_`*)S^W[_`.*G_P#@J7_]!U1_P\M_9V_Z)S^W[_XJ
M?_X*E_\`T'5?H#10(_/[_AY;^SM_T3G]OW_Q4_\`\%2__H.J/^'EO[.W_1.?
MV_?_`!4__P`%2_\`Z#JOT!HH`_/[_AY;^SM_T3G]OW_Q4_\`\%2__H.J/^'E
MO[.W_1.?V_?_`!4__P`%2_\`Z#JOT!HH`_/[_AY;^SM_T3G]OW_Q4_\`\%2_
M_H.J/^'EO[.W_1.?V_?_`!4__P`%2_\`Z#JOT!HH`_/[_AY;^SM_T3G]OW_Q
M4_\`\%2__H.J/^'EO[.W_1.?V_?_`!4__P`%2_\`Z#JOT!HH`_/[_AY;^SM_
MT3G]OW_Q4_\`\%2__H.J/^'EO[.W_1.?V_?_`!4__P`%2_\`Z#JOT!HH`_/[
M_AY;^SM_T3G]OW_Q4_\`\%2__H.J/^'EO[.W_1.?V_?_`!4__P`%2_\`Z#JO
MT!HH`_/[_AY;^SM_T3G]OW_Q4_\`\%2__H.J/^'EO[.W_1.?V_?_`!4__P`%
M2_\`Z#JOT!HH`_/[_AY;^SM_T3G]OW_Q4_\`\%2__H.J/^'EO[.W_1.?V_?_
M`!4__P`%2_\`Z#JOT!HH`_/[_AY;^SM_T3G]OW_Q4_\`\%2__H.J/^'EO[.W
M_1.?V_?_`!4__P`%2_\`Z#JOT!HH`_/[_AY;^SM_T3G]OW_Q4_\`\%2__H.J
M/^'EO[.W_1.?V_?_`!4__P`%2_\`Z#JOT!HH`_/[_AY;^SM_T3G]OW_Q4_\`
M\%2__H.J/^'EO[.W_1.?V_?_`!4__P`%2_\`Z#JOT!HH`_/[_AY;^SM_T3G]
MOW_Q4_\`\%2__H.J/^'EO[.W_1.?V_?_`!4__P`%2_\`Z#JOT!HH`_/WX7?M
M*_#S]H?]J;P+_P`(#X=^/_A\>#_@%\>!JO\`PO3]E#]JC]E_[8/$7Q$_9H^P
MGPK_`,-+_!OX2CQN;8Z'>_VX/!O_``D7_"-^?HO]OG2AX@T;[=^@5?/_`(D_
MY.G^#7_9`?VEO_5B?LH5]`4`%?`'_!6+_E%E_P`%+/\`LP#]LC_UG7XC5]_U
M\`?\%8O^467_``4L_P"S`/VR/_6=?B-0`?\`!)W_`)19?\$T_P#LP#]C?_UG
M7X<U]_U_.+\#_CS^VA\"/^"2O['?QA^$6G?L[>"O@%^S7_P2'_8^^-7B3Q!\
M>M"\5>-]8_:-\7Z=^S[H>J:W\#OAS<?#?XQ^"-4^`]UI'AWPKI-C:_%#QC\/
MOC6OB;QA\5?#NG>%?A?>KX(UA?$?V)H_[<GC+XD_MRS?LY:!^T9^QQ\`;#PE
MI7P06_\`V<_C?X0O/%7[77QJ\7^-_A[_`,+I^)GAOX5P6O[6?P>N?"UOX%^&
MOB+P#:C6[GX"_%1;3Q'>^)KW4;&\L?#QL6`/UVHK\@OBY^W-\??"'QR^)NL>
M$M%^#_\`PRG^S9^U/^RW^R-\;=&\0^'O&NH_'/QSXR_::L_@]Y_Q"^''C?3_
M`!]H_@GP1X>^$FH?M*_!47G@W7OAC\1]8^)-EI7Q)-CXG\"-:^'#>?5_[7_Q
MO^)?PL3X`_#CX(1>!H/C+^T[\=;#X)^!O%'Q0T'7_%OP[^'UO8_#?XD?&CQQ
MX\\4^"_"_BWX?>(_&XTGX??"/Q3::'X.TKX@^`VUGQ=JN@I?>*-'TY+R[8`^
MSJ*_$SP_^W1^U]\:_#_P5^"WP8TO]G7P;^UYKEO^W!#\9O%GQ'\'_$GQO\`]
M*U7]@OXM:1^SSXQB\$>`?#WQ1^'OC;^SOC?\6?&/@?5?!EQJ?Q8U:Y^%?@.^
MULZ^OQ(UW2;.TUC],?V5_CI8_M.?LU_`7]HG3M$F\,VOQL^$O@3XG?\`",7-
MV+^7PY=>,?#>FZY?:!+?_9K/^T/["OKRXTO^TQ9V@O?LWVT6L8N`J@'@/_!2
MO_DW7X=?]I`/^"3O_KTS]C6OT`K\_P#_`(*5_P#)NOPZ_P"T@'_!)W_UZ9^Q
MK7Z`4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`#0P.<<>N?YT%NR@D_I_G\OK2,...YZ>O^?\^_Y8_\%+?V
M];[]D+P7IGA'P)I5W=?%[XB:=J$OAG7=1TF67PKX0TB&;[%?>))Y[BU;3-?\
M06DS[='\,(UVMI^XUKQ4BZ=]BTCQ+U9;EV,S;'4,!@*#GB,3*T5HKOJV[V2B
MKN3U:6R;:1I0HSQ%54J6LGTVM;\?N/L/]J#]H#0_V;?A'KGQ"U.UEUO7I9+7
MPY\/O!MFCRZKXX^(.NDVOA;PMI=M;XN;A[R^!N;XVP>>TTBVU&_`86A!\^_8
MW_9]UOX.^"-=\8_%"Z37OVA?C=JY^(/QN\2CR)-NO7X)TOP7I<D&4@\.^!=.
MF&DV%M;W+V?VTZG>Z?LL;NTM+/\`'+_@G!\?]>_;"_:4^'5C^TOXAU_QSXD^
M`?P[U>]^#%G'X9FO=`O?$[7H76_B#\1M5M?M=M;^,-+T!M)TOPQJNJVEG8W=
MW!;7QO;+QQ]C/B3^E;*D'G(X4CH0#G`[CDC^?<U[>?8&MPU#^P)I?7:[CB\=
MBXMI8J%O]BPF$OO@TD\7BM/>QK46K8/7IQ5*>$?U9K]ZM9/YZ+TMOMK\B:BB
MBOFCB"BBB@`HHHH`****`/S&_9>_XQT_:F^/?[)5X3:^"_'#R_M,?L_K(RBV
MAT/Q5>FP^)G@JRP=EM!X9\56XN-%TD9NVTA]1UA_ENF"_IIV(QSU'MG"D>N1
M_GMG\ZO^"A'AS6O"OAGX9?M:^!K&XN_'/[)_C.+QK>V5GQ>>(/A!X@%OH?Q;
M\-`J`HCN?#QAU1KJX)6RL].U,J`;IZ^]O"OB71?&7AGP]XN\.7T&J>'O%.B:
M5XCT+4;8Y@U#2-;LX=3TV\@)P62ZL9X+E3UPX/'(KULTOBZ.!S96YL5'ZIC>
MO^WX-1YI7T;>+PCPF+N]7B?K3UUOT5_?A3Q&Z>C?:45:_P`U9^>NYTE%%%>2
M<X4444`%%%%`!1110`4444`,+=AQP,^WL/?_`#ZD("!R!Q_X]Z9],9__`%4$
M=`2,`>O&[KS_`#__`%\_$O[3'[5=U\.M>TKX'?!#P[%\5/VH?'-D[^&/!$4Y
M_L3P/I<P$)^(7Q4OX"W_``C_`(/TMIENA;7#6U[K11;&P>U^U"\6\)A,1CJR
MH8=+FLVY2:4817Q8G$RNE##17O3E*RLGK?EB73IRJR4(;]7V[Z]+=7TT/Y^/
MV\/^"@W[3^H_M.+9Z0?&'P"LO@-XME?P;X%N9(;?59]4AAG@_P"$J\<0V]U=
MZ+XHG\3Z//-]@TPG6?"`\':K<V5BVL66K:SK.L?T>_L>?'/Q3^T9^S[X$^+/
MC'P!J/P\U[Q'92-=:9=%#I6M"VVPCQ5X71KJZU*W\+:Z<W6CV^N"TU!09PIU
M73EL/$6K_,?A;_@F#\'M?O/#7Q'_`&E=1UKXZ?'<^*SXZ\?^,]6U.]M_#?BO
M4SIIL+3P5_PBNW^S?^%;>&MME_8NAFSL[F[_`+)M[&]-OX4N[SP>>?U7P[X_
M_P""<6N7WBKP!I^O_$;]A_6-1FU3QG\.+:6?6O&'[-MW?S--?^*/`*3DW.L_
M"\3R_;-;T!KE[K10USJ,6<7MY=_?YOBN'L[RK+,DR/!87#9ME\9*.-DGAOKS
M47];P>$Q3<7-XR26,P?UWD;?N*4<7-)^IB*N#Q%&AA\.OW]#KHD^Z3WNW=J^
M_J?K)17'^"/&OA;XD>%]"\<^!]>TWQ-X2\2Z=;ZKH.OZ1<"YL-1L9MXWQ'`:
M"9'W6]Y:W*QW=G>07%E>VUK=VTB+V%?GK4HR<9+_`#3[,\@****`"BBB@`HH
MHH`****`"BBB@#Y_\2?\G3_!K_L@/[2W_JQ/V4*^@*^?_$G_`"=/\&O^R`_M
M+?\`JQ/V4*^@*`"O@#_@K%_RBR_X*6?]F`?MD?\`K.OQ&K[_`*^`/^"L7_*+
M+_@I9_V8!^V1_P"LZ_$:@#\EOV3?@/\`MM_%?]F'_@DOX\T/X5_LM?'?]E[X
M+?\`!.W]@[QE\)?@W\6?VMOC#^S^&_:5TOX(>`=6/QL^*7AOP/\`L3_M"Z)\
M1[CX<P0:':_`GP_J?BL>&_`?B0:W\5+W0]7^(J_#?5OAK^C?Q<_9H_:;^+?C
M;Q+X#F\`?LB^`_@7\2?C]^S5^T3XX^-WPR\5?$+PE^T?;:S^SWXE^#OQ&@\'
M^*?AQ_PIW5?"/QY\4:IXH^"NE>`[#X\ZK\;OA!>:-\*=<T2Q'P8O+[X9VMGX
M]]._X)._\HLO^":?_9@'[&__`*SK\.:^_P"@#\?/BW^PU^T+XO\`CW\4M#\*
MZM\&5_9'_:3_`&H?V5?VO/C+K^O^)O&UG\?/!OC?]F:S^%/]J?#CX?\`@*P^
M'&K>"O&7A;XLZA^S9\#MWC37?BUX#U;X<VFK?%$6'@SQBX\-J/HW]J7X-_M`
M_%BW^#/Q)^&FC?!VT^-7[+7[3H^,'PD\*^-OB5XVLOAO\4_`E_X"^('P6\5:
M%\0/'&C?!SQ!XC^%'B?Q!\,?BWXRU.P?0/AU\7;'PCXRT/PTOVWQ+HMYJYM?
MO:B@#\1=$_89_;%^"FA?`OXU?!'4/V;O&G[7&BC]N!_C?X6^)/C;XF^!/@1=
MWW[>GQ.L/VA?&,_P[\;^&_A+\2_&MQ;_``1^,7@[P#I'@VUUSX9>'6^*?PWM
M_$G]NWGPWU_5;,6/Z<?LK_`NQ_9C_9K^`O[.VG:W-XFM?@G\)?`GPQ_X2>YM
M!82^([KP=X;TW0[[7Y;#[3>?V?\`V[?6=QJG]F"\NQ9?:?L0NI!;AF^@J*`/
MQD_X*M_L7?L=?$;X?>$_C'\0OV3?V:O'7Q>\2?MK_P#!+SP3XA^*GC/X#_"W
MQ/\`$G7_``9XF_X*)_LE?#/Q'X0UOQQK'A6\\2ZMX7UWX;ZUJWP_UK0+[5;K
M2-7\#:IJ?A2_L[G0[R[L7^F_^'3G_!++_I&I^P#_`.(;?LZ?_.WH_P""E?\`
MR;K\.O\`M(!_P2=_]>F?L:U^@%`'Y_\`_#IS_@EE_P!(U/V`?_$-OV=/_G;T
M?\.G/^"67_2-3]@'_P`0V_9T_P#G;U^@%%`'Y_\`_#IS_@EE_P!(U/V`?_$-
MOV=/_G;T?\.G/^"67_2-3]@'_P`0V_9T_P#G;U^@%%`'Y_\`_#IS_@EE_P!(
MU/V`?_$-OV=/_G;T?\.G/^"67_2-3]@'_P`0V_9T_P#G;U^@%%`'Y_\`_#IS
M_@EE_P!(U/V`?_$-OV=/_G;T?\.G/^"67_2-3]@'_P`0V_9T_P#G;U^@%%`'
MY_\`_#IS_@EE_P!(U/V`?_$-OV=/_G;T?\.G/^"67_2-3]@'_P`0V_9T_P#G
M;U^@%%`'Y_\`_#IS_@EE_P!(U/V`?_$-OV=/_G;T?\.G/^"67_2-3]@'_P`0
MV_9T_P#G;U^@%%`'Y_\`_#IS_@EE_P!(U/V`?_$-OV=/_G;T?\.G/^"67_2-
M3]@'_P`0V_9T_P#G;U^@%%`'Y_\`_#IS_@EE_P!(U/V`?_$-OV=/_G;T?\.G
M/^"67_2-3]@'_P`0V_9T_P#G;U^@%%`'Y_\`_#IS_@EE_P!(U/V`?_$-OV=/
M_G;T?\.G/^"67_2-3]@'_P`0V_9T_P#G;U^@%%`'Y_\`_#IS_@EE_P!(U/V`
M?_$-OV=/_G;T?\.G/^"67_2-3]@'_P`0V_9T_P#G;U^@%%`'Y_\`_#IS_@EE
M_P!(U/V`?_$-OV=/_G;T?\.G/^"67_2-3]@'_P`0V_9T_P#G;U^@%%`'Y_\`
M_#IW_@EE_P!(U?V`?_$-OV=/_G;T?\.G?^"67_2-7]@'_P`0V_9T_P#G;U^@
M%?$/[07[:?A'X4^)(?A)\-O#^J_'?]HS6(9/["^#?@.6&:[TS(3.J?$371Y^
MF^!/#]L)X+B]N]6_TT6D]O>BQ&GLVJVNV&PV(QE7V.%INM5LV];))*[E.3:C
M&,5K*4I1BEO(NG3G5FH05VS\>?\`@HUX`_X).?LI:3-\,?AE_P`$V_\`@GAX
MB_:"UJRCF\BY_8T_9VO]&^&FE7T!GM]>\20+\.F%WK]U:LMUX:\,-@&WEMO$
M&NJNA_8++Q%YU\#%_P""<_[0WA_1_"/P>_X(:_L6?$C]H&V\/C4/&NA6_P"S
M)^R;X,^&>CBWNHM*G\1V_BG7_!=SK)T>YN+BRO1I-WH]O=V;WUOHW]L7K!=9
MNOM[XO\`_!+_`.,'[5_AKQ'\5_VAOB]HMM^TWJ>E65KX%\/^%-.AL_@[\.]'
ML;B]O;+P+JD\&FW?BSQ#;W37UR+[Q,;N[O=)O)RR#QA862KJ'Z%?L??L>_#;
M]CSX;1>#_!T*ZOXIU:.TN_'WCZYMH8]9\5ZU!'@EB"6T_0--:6X30]"2=K73
M[25VW75_=WMY=?:UI\%8#AVA2C3EF_$%#&-R:EC%@Y:>]?%0>$Y\#&]L*H<O
M--.[2E]:?IR>6TL'R6^L8V]NJ7WZ:?U;0_)7_AR!\//C8/,^+/[,'_!,[]G#
MPO=)^\\$?LW_`+"G[/FK^+I;9L?NKWXF^+_`!U#1-8M\@?:_"R75FQ/RA@>?
ML[P=_P`$9?V#/`/POU7X9>&/A9=6/]H:5-IMGXO&L26WB/0)2H:VU'P[8Z3;
MZ5X+T6ZM+C_2@NE>%+.SO/\`CRU&TO+#_0Q^K`&!QC';:<'/7T&?H<D=J0DX
MR<?1OEY^O'';.?PZ5\TN(LUIM+!XAY;2U?+E*^I1>[]]POBL79VM]<J8IV6J
M=VGP_6JT-:+^KZI6PWN[>>[^?Y[_`)E?#'_@DC^PGX7^&WAOP3\8/V:O@)^T
MWX@T=[F^O_'GQ^^"7PX^)NLW6L:@D/\`:<VB0>.M"\5#PCH["UM[>ST#2KO[
M-%9V]M]NO-7OS=ZA>=V/^"3O_!+/`_XUJ_L`^N/^&-_V=./_`#''45]_X'7_
M`"/IZ?A2DXY->=B<5B<;B:V+Q=>6(KUWS2E)ZM]?TV226B2ZXU*DZL^>>_\`
MP+)6UT1^?_\`PZ<_X)9?](U/V`?_`!#;]G3_`.=O1_PZ<_X)9?\`2-3]@'_Q
M#;]G3_YV]?H!161)^?\`_P`.G/\`@EE_TC4_8!_\0V_9T_\`G;T?\.G/^"67
M_2-3]@'_`,0V_9T_^=O7Z`44`?G_`/\`#IS_`()9?](U/V`?_$-OV=/_`)V]
M'_#IS_@EE_TC4_8!_P#$-OV=/_G;U^@%%`'Y_P#_``Z<_P""67_2-3]@'_Q#
M;]G3_P"=O1_PZ<_X)9?](U/V`?\`Q#;]G3_YV]?H!10!^?<'_!*G_@F';3PW
M6G?\$YOV%M*O[25+BRU/2OV2O@%I>J6%Y`PEM[[3-4L/A_:ZEIVH6DZK=66I
MV=U:7MI=1PW=I<I(J,/@_P#8]_X)[_L#7GBW]H+]GCX^_L-?L<_%'XP?!#XC
M7=]9_$?XE_LO_!#QCXZ^)'PG^('G>(_A_P"+_$/BK7_`5YK7B#68+>XN-+UF
MXN-1OO[+^SZ=IS7I-NHK]\!M/.<';Z\#C'?H>V,FOS-_:^3_`(9\^/\`^S_^
MVA8(UKX8COH?V>_VA9H5VQ?\*V\?:BK>#_%&ILMNVRS\&^.3;W-[<@F[NQ<Z
M-IZ90`#V,IOBZ>-RB4I?[?'ZS@TF_P#D;8)2E@U97;>,C];P5K.[Q4$T]+=&
M'?M%5PW_`#_UBEK_`+4MM^^JW6_0[;_ATY_P2R_Z1J?L`_\`B&W[.G_SMZ/^
M'3G_``2R_P"D:G[`/_B&W[.G_P`[>OO\'(R.]+7CG.?G_P#\.G/^"67_`$C4
M_8!_\0V_9T_^=O1_PZ<_X)9?](U/V`?_`!#;]G3_`.=O7Z`44`?G_P#\.G/^
M"67_`$C4_8!_\0V_9T_^=O1_PZ<_X)9?](U/V`?_`!#;]G3_`.=O7Z`44`?G
M\/\`@D[_`,$LCR/^":O[`/\`XAM^SI_\[>E_X=._\$LCT_X)J_L`'_NS?]G/
M_P"=Q7UOJ7Q5^'6E_$/0?A3J7C3P_9_$GQ-HNI^(_#O@JZU&&'Q!JFBZ5*(+
M^]L[$D,P4F<VBG%U>6VGZU>6"W=IHVLO9=MJ6IZ?I%C<:EJM]9Z9I]I&9[J^
MU&Y@L[.UB!VM-/>7#+;0*">2[!<L`",C)*-6/LN:G).KZKINKKWE?2ZOKY[G
M++[]M/\`@GP@/^"3_P#P2TP#_P`.UOV`1D_]&;?LZY/KC'PX/L.?TXH;_@D]
M_P`$M!_SC6_8!^@_8X_9U4CWQ_PKC!_*NC^('_!1']C[X=7*Z9>_&KP[XK\0
MR2-;6GAOX:Q:A\3-7O+[`_XEL2^"+76;&UOR>1%J5Y98&0Q5C7\Z_P"VU_P4
M:_:-^)/QQT^Z\)S?$/\`9^\-_#'4C?\`@#P9>QWGACQ>TVH:;]GB\7^.=/.1
M<ZOKVCW\ZV6E78O='T?PSJMQ86'VP:MK&L:Q]3D'!N=Y[64(TI8##N-_KN.C
M.--Z67*G:6*;=G:*>EVVG9/T,+EN)Q,[6]BENY?A9*WWJRM]Q^A_[1'[(/\`
MP3D;QJG[,?[*O_!,3_@GGXW_`&D-9M8Y_$6LWG[&_P"SO<>!/@!X8NS"LOC?
MXBWW_"N&MVU5;68W.@^%P+J\O+K[*U]8W?VO1M&\1_6'P;_X(_\`[`/P\^$W
MA;X:?$']E+]F[X[S^'S-?OK7Q=^`/PF\96=GJ]_@W\?@CPQXA\*ZIHGPZ\,*
M0+?2/"_A2ULK&SL88%O&O]0^U:A>=;_P3`T+0H/V5/!WBVU^&'B3X?>+/'#W
M&N^.]<\8W@U?Q/\`%;Q$XQ/\3+K7+E_[;U'2/$YGFO\`1;?6[2PDL5EN1I]I
M>:<]GXAUO]%R>,$=.I[GT(Z\GH>M>?F]=X"=?)<&I4*&&Q7+C,5_S%X[%X1N
M-YR3ERX123>$P<6E"_-/FQEW3PJOV5\/#9-\WFU;\%IIZ71\!_\`#IS_`()9
M?](U/V`?_$-OV=/_`)V].3_@E#_P2WC=7B_X)L?L!QNC;TDC_8Y_9V21''&0
M5^'`QQ_$"#Z=C7W]17C',?@/^TI_P3$_9H^#/Q4U;]J'2OV'/V:OVI?A1K$%
MK%\:/@O\2?V>OA+\3_''@?1K&>XG_P"$O^`>J>-O">L:A8:?I7VV\N[_`.'%
MO=6FA_9?M"V(L[(V-WX1^K/A1_P3Y_X([?&OP'H7Q*^&G_!/G_@GIXF\(^(K
M87-AJ5E^QW^SKYD,@^6YT[4(/^%<B?3M6TZ?-K?Z;=!+JTN8RCJ"!G]1RH(Y
MY!XP>N/3'J#Q@<'V/-?R%_\`!1OXC>,_@A^U-\2_!GP5TCXC_LY>%M;U+PGX
MRU_2='\076A^'_B=XRT2^N-5LOB_X<TK1KDZ9I^G7.H"!;(:7>$WFL:%]N\0
M6FDZ]]LTG2/L,EP%7C.LLNJU5ALVHQ<EFTG=8O"JRMCE%IRQ2=E''16L;K&O
MX<8>CAJ#S&HJ*_C:>]OS+S6FO9_>?OP/^"3O_!+/&?\`AVK^P"1[?L;?LZ?R
M_P"%<'G^7YT-_P`$GO\`@EF#_P`HU/V`R3TQ^QO^SH#^8^'&?YU\K_LI?\%7
M_#&K?"?PM?\`[6>C>,OAMKC%=+MOB]_PKKQ3=_"OXCQP3&PBUFRU;0-$O+72
M=8%[!+9>)[.UM$\-V>JPM?6%_9V5U/H^A_J'\-?C[\$_C%`)/A=\5O`/CURG
MG26?AGQ7HVJ:G;#;YG^G:1;73:E82]6:"\M+9UY+*.,>#F61YME4ZL,;@\9"
ME1;C]<Y92P;:;^'&1YHNZ5U>2TWLU8YJ^%Q.'FU4I->=G_PW]>A\R#_@D]_P
M2TZC_@FM^P%MP<'_`(8X_9V_7_BW'U_(<CB@_P#!)[_@EIU/_!-;]@+;@9/_
M``QQ^SM^G_%N/I^9Y/-?2WQR^._PS_9Q^'.K?$_XK^(8]"\-Z68K>$1H+C5]
M=U:X$KV.@^']+1A<:MK%[Y$IMK1-HM[6*ZU"_N;/3[2^O;3K_A]\0_!WQ5\&
M:!\0OA_XAT[Q1X/\4Z?#J>B:WILOF6MW:2D]01Y]O>6TXDM;_3;M+:]TZ]BN
M;"^M;2^M;FW7SGA\2L.L7[*7L&WAEBK2^JN27,XJ5[7Z\M[]+[VQY)\OM+?N
M=KV_K\O+R/CO_ATY_P`$LO\`I&I^P#_XAM^SI_\`.WH_X=.?\$LO^D:G[`/_
M`(AM^SI_\[>OT`HI$GY__P##IS_@EE_TC4_8!_\`$-OV=/\`YV]'_#IS_@EE
M_P!(U/V`?_$-OV=/_G;U^@%%`'Y^_P##I[_@EGU_X=K?L`[>V/V-_P!G7@^X
M_P"%<<=^>#[\T?\`#I[_`()9]?\`AVM^P#M[Y_8W_9UY/L/^%<<]N>3[\5]C
M?$+XA>#OA5X-U_X@_$#Q!IWA;P?X6T^74];UO4I3':VEI'@?*`#<3WES/Y=K
M8:;:+<WNH7LMM86-K=WUU;6[<C\#?CO\,_VCOAUI'Q/^%'B"/7?#>IF2WF61
M!;ZOH6JVXB>^T'Q#I3,;C2M8LO/B:YLWR+BVEM=0L+J[T^[L;VZ:H8AX=XM4
MY_5U)8=XKWOJRDUS).5^6]M;7OTO:UZY)<O/;3;YK_@Z;'S/\+OV3OV6OV8/
MVI?`H_9I_9K^`/[._P#PG'P"^/`\:_\`"B_@W\//A'_PF`\-_$/]F;_A'/\`
MA*AX`\-^'O\`A(3X?_X2'7/[$;5?MG]C_P!MZR;`VQU6\W?H%7S_`.)/^3I_
M@U_V0']I;_U8G[*%?0%(D*^`/^"L7_*++_@I9_V8!^V1_P"LZ_$:OO\`KX`_
MX*Q?\HLO^"EG_9@'[9'_`*SK\1J`/D#]B+]NS]E[]EO_`()L?\$S/"?QJ\?:
M]H.L/_P39_8U^(/B$>&/A-\8?BAI'PT^'-Q\$/`'A^#XF?&WQ'\*/`'C7PW\
M!OA?=:M9:M9V7Q'^,VK>`_`UX?#?BQK/77M/"/B5](_0KQ1^V[^S%X/^.'A#
M]G77/B;(OQ2\;7/A.PTBWTWP3\0M?\":;K/Q`TW7]5^'/AKQO\8?#WA'5?@[
M\-O&'Q.T_P`+:W<_#'P;\1?''AGQ1\2%M[4>!M'UMM5T@7O\Y_PZ_:X_94@_
M8<_8(_8,U/X^?LH_LK>-?CM_P2<_86@_;2_:0^-GQ8^$'P<\8>&_V8=>_9]T
M7PYH7PP^&5QXQUO1_$7Q(^._C/1];^(-M\._M?VWP'^S[X:\1ZY\5O%/VK6M
M?\!>`_B3[?\`%C7_`(<^%/B1^T]^QQHNNZ1'\=_VA/\`@HU_P2[^-_[*/P^B
MU0ZIXL^)O[-W@#0OV'Y[[XL_#FX^TW>M>*/AM\)O#_[*WQX/C3QEI9O-'\"#
MP;<G7;VT'B'2#K`!^X_C']M;]FOP#\>O#/[-/BGXAW%E\7/%5]X6T:STZU\"
M?$?6/!NB>)/'5IXCO_`'A#Q]\6]'\):E\)?AEXW^(UMX6UM_AKX$^(GCCPSX
MP\>^1;+X0T76FU;2!>>D_&_XZ_"_]G7P/_PL+XLZ]?Z-X>G\0:!X4TBRT#PG
MXP^(7C3Q7XL\5:G!I/ASP?X"^''PW\.^+/B1\0O&&N:A,!I/A7P+X4\1>([U
M(+J]2Q-E9WMS:_@C^T/XL\-Z/\=?VQ?V2M3UJRM?VH_VE?\`@I[_`,$U_C[^
MSQ\-[J;'CCXD?!'P;9_L2WWBGXJ>![``:WK'P_\`A+;?LO?M#'X@^*-*M+O1
M_AL?`^I#7KRS_M;1_P"U_O;]O?XL?##PQXJ_8=^/OB+XA^"+3X&?LU?MY7VG
M?M$_$.?Q5HTG@;X+7_B3]FC]HWX(:)>_%36A=?V+X&@T#XM?%7X=>&-<U/Q3
M>:0O@^\\5Z9?ZX;*R9KI0#W_`,8_\%$/V0_`_P`$_AI^T)J_Q1U74?AG\8[#
M5]2^'$G@;X4?&7XF^/\`Q%8^%M&U7Q#XYF/P<^&_P_\`%?QCT<?#'2-"UJX^
M+8U_P!I1^$%UI>HV'Q*_X1G4+.[M%^OO#OB'0O&'A_1/%GA76-.\1>&?$^D:
M9X@\-^(-%O(=2T?7-!UNSM]4TO5])U.V:XMM1TW4K">"]L+RV=K6[M+B`QLR
MLK#^9#X*_&CX4_LW^,/V;?VS_P!H'Q?HGPR_9%^+#_\`!:S4/A=\4?'DQT+P
M'<VG[2G[8_@?]I+X`Q07&L"TTRPN/V@?@=\./'/C/X2V?_'[\2;+[-8Z%8WF
MN>(K*SO?VM_X)J>!_&'PU_X)[_L4^`?B%HNI>&_&OA/]F#X+:+XD\-ZU#/;:
MQX;U6R\!:&)_#FJV-Q_I%AJ6@@+I5[IC9-A=6,]AP+8$@&#_`,%*_P#DW7X=
M?]I`/^"3O_KTS]C6OT`K\9?^"KGA7]L6]^'GA34_A[\=OV:O#'P@G_;7_P""
M7EIX>\#>,_V4/BGX\^).E^,KC_@HE^R58>'=>UOXJ:-^VA\//#.O^&-+^(\^
MD^*=;\'67P<\-:OXC\#66I?#O3_&OAO7=6L_B5HWTW_PKK_@J7_T>/\`L!?^
M*T_VB_\`Z;!0!]_T5\`?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP4?\`"NO^"I?_
M`$>/^P%_XK3_`&B__IL%`'W_`$5\`?\`"NO^"I?_`$>/^P%_XK3_`&B__IL%
M'_"NO^"I?_1X_P"P%_XK3_:+_P#IL%`'W_17P!_PKK_@J7_T>/\`L!?^*T_V
MB_\`Z;!1_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP4`??\`17P!_P`*Z_X*E_\`
M1X_[`7_BM/\`:+_^FP4?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP4`??]%?`'_"N
MO^"I?_1X_P"P%_XK3_:+_P#IL%'_``KK_@J7_P!'C_L!?^*T_P!HO_Z;!0!]
M_P!%?`'_``KK_@J7_P!'C_L!?^*T_P!HO_Z;!1_PKK_@J7_T>/\`L!?^*T_V
MB_\`Z;!0!]_T5\`?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP4?\`"NO^"I?_`$>/
M^P%_XK3_`&B__IL%`'W_`$5\`?\`"NO^"I?_`$>/^P%_XK3_`&B__IL%'_"N
MO^"I?_1X_P"P%_XK3_:+_P#IL%`'W_17P!_PKK_@J7_T>/\`L!?^*T_VB_\`
MZ;!1_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP4`??\`17P!_P`*Z_X*E_\`1X_[
M`7_BM/\`:+_^FP4?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP4`??8&>J@\<<X)'3
MIG]?RK\__P!NO]O#P%^QGX,B0Q67B[XO>)+65_`OP]^UF,_9S,T#^*O%4T!-
MQIWA>TFBF5"H%[X@O('T[3<);:QJVCN'PZ_X*E9)_P"&R/V`AP`1_P`.U/VB
M\`'IC/\`P5@'.!D_UK\3OC#^RO\`M1?MX?&OXZ:Q8^*_V</BKK_P+T>Q\+:A
M\6/@[\#O'?[-WAKXJ_$*Q^PF?X8"Q\?_`+3_`.TQIWB#7O"^CP36@\<GQ!X1
MM;)CIFA:[9G0;OPWXD7W^$\ORO'9JI9S+V&4X9/%8V=W]6NVEA88J44G%8N=
MH:/F>MK)2FNS!4Z-2NOK-_8)7;V^_7;MI]RW_0_P#^UI\>?^"C4;^$OV9_)_
M9Q^'>C:=I$?QK^+&MZKH_B#XGZ7JFK6@GG\*?"SPW87(F@@N%@OK2Q\>ZM9Z
M.;M(+J]T_P#X1W7=(;2+W]&/V?/V8_A'^S3X=NM%^&NA2+JFMR?;/%_C?Q!=
M-K?COQQJ@:66;4_%?B2<"XO[A[J>XN1:6XL](M+JXN3I]A9BYD!_+O\`95_X
M)K?MD_LG'6=<^$?[2_['>A>(?&FE:5%XAF^)G[$GQF^,7BG08HK>SFOO"&E^
M//"__!0#X$Z)J/AY=8AGO$N+?X9>&[R^?[*=1^U?8;(VGV:?AS_P5+`P?VR/
MV`SCG)_X)J_M$Y_`_P##U\8![YZ8ZD]7Q#F&#6)Q&79#+V&1*22C9IXQK5O&
M2?\`M6,2:E]5<^6,8VM@XO5K$U:?.Z6&_@75M-_-OK9[7?H?H'17P!_PKK_@
MJ7_T>/\`L!?^*T_VB_\`Z;!1_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP5\^<A]
M_P!%?`'_``KK_@J7_P!'C_L!?^*T_P!HO_Z;!1_PKK_@J7_T>/\`L!?^*T_V
MB_\`Z;!0!]_T5\`?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP4?\`"NO^"I?_`$>/
M^P%_XK3_`&B__IL%`'W_`$5\`?\`"NO^"I?_`$>/^P%_XK3_`&B__IL%'_"N
MO^"I?_1X_P"P%_XK3_:+_P#IL%`'W_17P!_PKK_@J7_T>/\`L!?^*T_VB_\`
MZ;!1_P`*Z_X*E_\`1X_[`7_BM/\`:+_^FP4`??\`17P!_P`*Z_X*E_\`1X_[
M`7_BM/\`:+_^FP4?\*Z_X*E_]'C_`+`7_BM/]HO_`.FP4`??]%?`'_"NO^"I
M?_1X_P"P%_XK3_:+_P#IL%'_``KK_@J7_P!'C_L!?^*T_P!HO_Z;!0!]_+G`
MSZ5XM^T%X"\$_$[X*_%'P%\1KVQTKP5XD\%Z]8^(-=U22UAL_#EK%9S7L/BB
M2XU`"RMCX8NX(?$%K=7;"TL[K3+>5R$C)KYH_P"%=?\`!4P_\WC_`+`7(_Z1
MJ?M%=>__`#E?]^O/T]>#^)'[.W_!1KXL>!?$WPY^('[5/_!/KQ'X.\6Z=)I>
MNZ-=_P#!-7]HL0W=JS1312PS0_\`!6'S[:ZM+B"VO+&\M#'=V5[!;W=FT=W;
MJX>'G[.O1J^U=#V.)B^9;IIQ::OU7Q*W:W4<'R34^JM^!\6?L2?\%;_#[:M\
M/?V?_CS;Z9HVF:/X7T7P%I?QMCUF:?2M<\3Z'=WVD66K^*H-0TO2SHWA_P`3
MZ/#HD*Z[<;?[(UN"YO->8:=K#W?AS^@E)%==RE2&`964G##Z'OU'H37\L5O_
M`,$(_P!H2Y\7:[X7;X^?"[1O#VF^'M`O]"^,-W\)-?\`$>C^)_$4]P%UW0IO
M@AIWQR\*>)O#]K:F"^P]S\:[P6EE?Z$;'6O$=X=9M-&^P/AO_P`$S?\`@I#\
M.A9Z?I__``5Q@A\/Z7%;V>C>&],_92^(\VD:+IME%906&CZ59>-OVY?B!:6V
MDZ9;65O:6=G]E:UMK0?9E&R2\%S]QQ5AN#L1C:-;(LTCAOK$/K6+C]5QN*PG
MO-M-.-Y83%ZOZW@[2479P:NXGJ8Z.73J*>%JNS5W>+:L]?D^_?KK8_>$$`#/
M7&1D<]_7],GGVK*BU2PDU.YT=;^REU6QL['4+O3([N&6_M+'4Y;^&PN[JS4B
MXM[6\GTS4+>RN70)<R6-XJLQMI\?F3XA^#W_``4V^''@G5-7\'_MC^"/CSXH
MT72YKNQ\'>+OV=_"/@!=?DMC"1IUGKNC>)=4N5U"YMEG%HVJ702ZOO(COM0M
M!=F]M/YP_AW\9/VVM3_:OU+Q%X"\3>/V_:C\<ZOJG@_6[:2PLI-4N;F?_0;_
M`$+7?#FLZ;_PC6GZ/X8%B<Z7JNDV>C^$/[#MKZP_L<:59W=GGD?!+SVAC*V%
MS_)_8X9=\6FFW\6,6+P>$^HX-J[^M-22:2MO:</EJQ$*LX8S"67F_5;I;>?X
M']K_`(K\9>$/`FB77B3QOXJ\.>#_``]8`F\UWQ1K>GZ!H]J,&4&XU35[FTM8
M"1%(5#W`&!G!`^7\]_&/_!1SP?XI.O>$/V1?`7Q#_:>^(\-O?6%AJ7@?P=J7
M_"K/#FO"+%A)XQ\;ZS<^'=,&D6\\\%R[:9>/:7]M_H@UJP-TMVOQCHG_``2D
M_;)U?Q);?$3XP?M>_LL_'+QA-%;:A%8?M#_L9_M$?&6Q\(75Q%#/?Z#8)H__
M``4D^$_A'7M'M+HS6EJ;OX:Z3:7EI!`?[$L%_P!%'W-H?P8_X*6^%])L]#\.
M?M5_\$Z]`T33X1!8Z1H?_!,3X_:3I5A".?)L["P_X*M6UO!$"?E6WMT7)SC-
M>%_PAX&7_,3G%?35MX'`7]%S8[%QTZO!Q=^S.7_9J??$6?I'3[VS^9'XI?#7
M]M?4/VN;;0_B#H_CW_AJGQ9XBTOQ!HMS8ZE!_:\U]-^^T35_"WB+0+G^Q-.\
M/:!;V&+34]"U8>&_!UGI-U8$6?\`9-[]B_HY^&'_``3*\`:MX;\,Z[^UYXJ^
M('[2OQ92WCO]?N/&WQ-\;:KX(TC6)GEF:Q\*Z$NI::C:1IL$Z:8%U,75O?"*
MXN_L%A:W?]E6G93_``<_X*6W.N6'B.X_:K_X)W3>(M-L+_3--\03_P#!,3X^
MRZUIVFZK<6$^JZ;9:JW_``5:^WVNGZI<:5I=S?VEO<K:WDFG6+7D;-:6NW=7
MX=?\%3,'_C,?]@/CM_P[4_:*)QVY_P"'KY`SVXKW<[XZS'-,/@:6#HQR=X;"
M.#E@FXRL]'#"/E4\'@6[26!C-+G2D[VB=6(S2O6A1A"V'LNEO_)>J6GX+LCZ
MM^'?P8^$GPFM6M/AA\,O`W@&$HL4W_")^%M'T.XNE`R?MEUI]I;W-\V,9GNK
MBX8G.68BO)?C?^QI^SY^T/XY^'GQ#^*/@BVUKQ+\/-1^V:?<HT=M!XCL(5G^
MS^&O&UO]G<>(O#-KJ,T6K6NFW)55O+<V9NCHNK:WI.M>5?\`"N?^"I>"!^V/
M^P$P_P"T:O[1>?\`UZ_C^?\`@J_#G_@J8,Y_;&_8"YZY_P"":G[11_\`@K^*
M^0I8_'T<1]:I8O%K$M2OC%BY_6O>33]YOFUN[ZKRLTFO/C4JPGSQJM/;SMZ[
M_IU/OF&&*"-(856**-(XXHHE"(D<0P(XP,<`#`'3''')%FO@#_A77_!4O_H\
M?]@+_P`5I_M%_P#TV"C_`(5U_P`%2_\`H\?]@+_Q6G^T7_\`38*Q(/O^BO@#
M_A77_!4O_H\?]@+_`,5I_M%__38*/^%=?\%2_P#H\?\`8"_\5I_M%_\`TV"@
M#[^!//![X_#C'U)S_C7S)^T?^RA\%?VJM&\/:+\7O#+ZM_PBVO6>MZ)J^GW)
MTK7;2.WO;>XU/0AJL$1NO^$>\3VUN=*UW2UQ]JM&2\L;JQURRTG5[#QS_A77
M_!4O_H\?]@+_`,5I_M%__38*3_A7/_!4K.?^&Q_V`L^W_!-/]HL?R_X*P55"
MOB<)6I8C"5WAZU!WC*+:E'2VC6S71ZKNF.,YTY*4-ULU:]_GHS[<TGPOX=\/
M^'M/\):+HFEZ9X8TK2X=$T[0+&Q@M](M-(@@^Q0:9!8QJ+5;%;8"W%ML*LF0
M5P37RW\2?V!?V0_BM,U_XE^!/@K3]8,OVE=?\&6<WP]\0"^#>;%J3:KX'N/#
M]W<7]O,%DCN=1>[8-&H(*9!X4?#K_@J9T'[8W[`(]?\`C6K^T4?_`(*^>M._
MX5W_`,%3,<_MC_L!+_WC4_:*/_P5_'\ZO#XS&X2I[?"XO%8:NG=RPF*G!_>N
M6]^MT^VS*C4K0GS0JM???[]3\C/^"F/_``3T^*/@/P=IGQ)^&GQ%^+WQA^$/
M@.VOI=6\!_$3QCK'CO5OA9:S^2M[KWA0W)W'PC-;6UNNMVMO9B]T=;)=0OKV
M[T]KN\T;L?\`@F?XGU[]B'4M2\'_`+6NH_$KX*>&OC/;:!J_POTWQQH]G;?!
MBXU2]M1<SZA?>,!/>?\`"(>/[JP^SVVHZ!JA\-6EE80'_A+4DOK;PW'I/Z?G
MX>?\%2@/^3R/V`\9[?\`!-3]HG(&,\X_X*O@#KR,<>O3/(^,O@#_`,%%_B-X
M<U7PAX[_`&H/^"='C#PMK<!M=5T+7_\`@F-\?=3TR\B^\/,M;K_@JU(GFP.%
MN+6Y4"[M+D+<V<BRJC)]A_KMB<5DD>'LUPD,3@N;F>,BW'&)\R:G!./U5XKF
M;YI.*EC$[2:FY8M^A_:,YX;ZKB*=Z"ZJREW\U?KM^.I^D5M<V]];PW-K-%<V
MUQ%'<P7-M(L\$\$R^;%+!-#N66&9"K*4)5U;(W*P+7,<;0"/?J/Q./Z=:_#K
MPA^R3_P4Q_8W^'OC.\_9Y_:-_9_^.<\TVIW_`(:^`FO?`7XG>!/A1X1AFBS!
M;^`M-\7_`+77Q5\;3W%M?^==_P!A77QL\':/?"YN6O+W[:+-AYIIG[=O[65O
MX&\7:]\2OVV/V(O@[XZ^'\$2>-?@I\0O^"8'[1^D?%6RU2<0QV^G>'O#T_\`
MP5=4^+Q>3SP+:7FDEK6TL[BUU#Q`/#UDS%/!EDE:LO;90_[7P^S^JP;QF$5T
ME'&X+6>$=W%<_O8.3;MBTM%R?5ISN\-_M"=K<N_S6Z]=O,_H.R.<D9`P",D^
MQSG&?Q[D&N9\7>,?"_@/P[JGBOQIK^D^%O#.AVKWFL:_KM_!IFF:;:@9:XN+
MRZQ`B+ZEN20N"3@_AOX^_;`_;=TC2?!]M\'/VROV$/VC_B;\2M+BU7X=?"GX
M4_\`!-S]HC4->U:TF4'[;XKO_P#AZE=6WPYT:S.1KEUXHM%U;21;ZB?[$NSI
M.H1VG;^,OV'/V_\`]I+6OA[\5/CG^TG^RYI&IZ%"-2E_9N\:_LM_%3XW?`CP
MWK_E6QL=1MK#PA^V7^S[<:QJ]J#?"^MO&5U\1[,F_GTY-;UC1;:R*Q2RGV4/
MK.;S>`PS?NQM_MV-LVFL)A)I.UU;ZYBU'!IIZSE_L[2H<B4L1>@NSUD_1:?>
M]+]]+_._[>;?'C_@H=X</C+]FSP;\2=2_9P^$6EZAJT=QKS1>&]*^-'B.&]%
MO/XC^&?@F?3;;Q9XGN-#TDWPL=4U>\^R/:PZEI^@:/I6O7=[:>)>P_X(Q_LL
M_'+P,-3_`&@?%'B/7O`WPS\<Z)]CT+X:ND6/B5``6TKQMKEC?6V[1](TWSI[
MCPM=67V36]7-Q<NMW:>$[DV?B3]"+?X7_P#!4&PMK>TM/VO_`/@GY:VEM$EO
M;6UO_P`$T/VA(;>VMXHQ'#!!!#_P5=$,$$$0`1``JH`J@`*M6?\`A7?_``5*
MQ_R>-^P#G'3_`(=J?M$COZ_\/7BO7DC%>U5XQKQR"MPW@\OP.'P+>DI7Q6,^
MK7NW.35GC925_KD8QDD^6*M&+75+,*GU/ZE"DE0O]R[7_KT/H/Q)_P`G3_!K
M_L@/[2W_`*L3]E"OH"OS]^%_AW]J;P_^U+X%_P"&E_C)\`OBR+KX!_'G_A"C
M\"_V:?B'^SN-`,'Q$_9F_P"$C_X2G_A/_P!K']J+_A,!JOG:&-$_LH^!?^$=
M_LK6OMP\2C6+(^'?T"KY$\X*^`/^"L7_`"BR_P""EG_9@'[9'_K.OQ&K[_KX
M`_X*Q?\`*++_`(*6?]F`?MD?^LZ_$:@`_P""3O\`RBR_X)I_]F`?L;_^LZ_#
MFOO^O@#_`()._P#*++_@FG_V8!^QO_ZSK\.:^_Z`"BBB@`HHHH`_/_\`X*5_
M\FZ_#K_M(!_P2=_]>F?L:U^@%?G_`/\`!2O_`)-U^'7_`&D`_P""3O\`Z],_
M8UK]`*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****```#@4
M@ZD?IG/'T[4<X/KSC^E>$?M$_'?P;^S=\)O%/Q7\:RO+8:!;^7IFCVKK_:GB
MCQ%>,8-#\+Z+#P9]2U>^*VJ_*5L[5;J_N]MC:7CJ4J57$5J.'HTG6K5VHQBE
MNVTDK6>[>B\FVTDVG&,IR48J[?X_U_6A\W_MI?&WQI:S^#_V5O@!<_\`&0_Q
M\2YL+;5XF+Q?"7X8@S6_B_XJ:W-`1/IYM+9;NT\,A<7-S?PW=WIQ:_TJWLKO
MZ<^`GP2\%_LZ_"GPE\)_`-IY&B>&+%(9[Z9$;4?$.L3GSM;\1ZW.H_?ZMKE^
M9KR[8-Y=MOBL;18[&TM+9/F[]BKX#>,/#4/B[]H_X[Q"X_:0_:!EAUKQ7#+$
MP'PS\%@Q3^$OA-HL=R#<6%OH-A%9OK5OE6;4K>VL=0>^.@6M[=??/3!!!Z`=
M<D8/;ZY([]L]J];-*U'#4:.48*HI4,.^;&8R-K8W'/24ELGA,'KA,%OS)3Q;
M][%JVM6480]A2:LM_-_Y+6WS)****\DQ"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`&<`;3WZG./H?T_#O7E6E?!CX6Z+\3?$7QGTGP-X?
ML/BAXJT73_#?B+QK;VA36=2T72II9K>"9O\`41SMN@2]O;>V2]U:VL=%L]1N
M[RRT?2$LO5L@G!'/H0/TZC_]5*0#P:495(*KR5&O:JVC:TML[/WEI>SOW%S.
M*TVZV_R_X(M%%%,84444`%%%%`!1110!"K`8!&<CC'./^!'`QC)/UY[TXJ.N
M01D]-HQZ#.??W_E7\X;_`/!?MU<B+]E/?'NPC2_'$HSQ\99;?_A4((/;DG'U
MQ7[T_!KXB'XM_";X9_%*/26T&/XD?#_P=XYBT22\-^=(3Q7X=TSQ`=/-_P#9
MK3[=]@74#;"Z%G:?:C#O%K;!MB^3E^<Y5FLJRR_&1Q+P[7/RK%*U[[WC&ZNF
MM+^=M+_<<8^&?''`%'`XCB_()Y-2S+$3PV"<L9E&+]I*E%2FE]1QV-2Y8RBW
MS<M[Z7=SU$\9.,^ZE1QTP<9`ZGN,TUNXQ@[>2<9QU^]CC^?KF@9",=S;@,E0
M%WX';@XR>F."2>G2OP+^,7_!;YOA9\6_B=\,(_V9_P#A(8OAU\0?&'@,:[)\
M86T>769/"/B+4O#\VH?V:/A5JJ:?]I:P%R;3^T;Q;9)@DEXV"QUS',\!EL*4
M\?7^K1JRY4W'$RO+E3M_LT96TVZ/N<7!_`G%G'V+Q>`X1R>6<8K`8)X_%TXX
MO`X-PP2GR.;EFN,P47%2?*TIREKI&VW[[':0=V"3U/(R!Z9&`<_U[T#"EB!@
M9Y(')&.N>.PSD']!Q^>GP:_X*._L]>//@5X&^,GQ.\=_#WX*:IXOB\123_#K
M7_B'I.L>(],/A[Q1K?AAY(+2&TTOQ#J=G=C1X]165?"UJ5M]2MU(.5,V+=?\
M%./@AKS-:?!/P)\?OVC)S)]ECG^$'P<\67NC"YY\X3ZMXJM?"MM%;VW!N[H/
M-:H<`,><K^ULL<:,EC,*WB$G&*G;$R35TEA$GBWHMG!./9]*_P"(?<;+$8[#
MOA;.5'+,9C,#C\9]3DLIP6,P.+^IXR$\YDZ>3KV<])2_M!PMJIN+4G]8^+_V
ME/V=?AUK]YX3\>?';X.^"?%.G):M?^&_%7Q+\&^'M?LHKVTAOK$WFCZOK%E?
MVRW=A<0W=J+BV4W-K+!=H61U)[?P/\2?AY\4M#E\1?#+QWX/^(/A^"^ETF;6
M_!?B/2/%&CPZG##!//ITVIZ%?7ML+Z"&]LYY+7[0ETD=Q;N0%N$W?Q/_`/!0
MCQAXG\??M>_%SQ=XP^'NN_"K7]:;P%<77@3Q->66H:WH=I9_#3P3INE?;KC3
MF-J;G4]/L['7#;#BT.J&RO@M[:8'Z<?\$H?$W[8_AS]G[QBW[/\`\-?@YX\\
M`S?&/7_[67Q[XN\0>&/%`\6GP9\/5NTL?LEI>:.=$M])CT7@'[9]LFOUX-LJ
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MI!"SKK.D>=<;0!^]MU(`Q\U?S%_\%"==^(WB;]K_`.+NN?%?P+8_#;Q]J#^`
MGUSP9I7B:T\7Z?I'E?#7P39Z7]G\1V%K9VVHC5-(ALM3#$'[,+W['EOLN6^A
M_P!?\7P77P><Y?@/;UHXSZHL+F^#QF"P<L--.,[XJSM914D^9.6JVB[^3X1>
M#=3B_BC%9?C^)<EP^'P^3XW&SEPWQ#P[Q)CGRXO!8.SP>$Q6(Q6$PLOKC?UZ
M.%ER6PB46L;=?N;_`,$5?V>[[P)\.O&/QLNO'WA77H_B6NGZ)%X*\)7WA/Q0
M?#8T01ZG!/XO\0Z4^IZAI'B<VVJQ$^!K75;5-'L;V*\\66=YKUW9V?AK]S%&
MT':0<]\`$=!C:H&#C@Y/KCW_`)E_^"4_Q@_:?^'7[/?C/2O@M^R*WQX\+7OQ
MBUW4K_QJ/CMX$^%?]FZ[)X-\`V=YX:_L7Q9IEW?ZA]FL+/3=4.L6Q^RW?]J"
MSQ]MTZ[#?IU_PU%^W]MX_P"":P4GJP_;!^#:L>W.-"#'GN,>V,5UU>,JO$\U
MGF84L7]<S)*<UA<GS?ZHG9)67U-6BK:2W?5O2WQ_'/AMF>3\7<0Y7ALVX;Q&
M$RW,JN`P<LTXXX%RG'.G3<5!XS*L7Q%A<9@I6E[T<5A8\K6MF[+]*WD1"`YC
M&X+@';E3P.200#]!GH?H(T;[F1E9@I#D$,>G&Y@2P&`3@A2>P]/XT/\`@JMX
M_P#C)\0_VA/!VK?&SX*GX#>)K/X.:#I^G>#1\1]`^*,5_H2^,/B!/;^*5USP
MK;V^G6BZG?3WNE_8+BW>Z)T-KMF:VN+<U]\?\$!Y9/,_:JC#-Y:CX'R(F[*)
M/.WQ:\T@=,YAA4YSQ#Z$U\]AN*J6*S^604\')<L7_MCFXW:P2QNN%GA5):.U
MG):^]NTG]3GG@+B,C\*(^*&)XIP6(J0PV#Q+R3!X/"XW#6QF>4<D2PG$F"SG
M%X#&\OMUBWB,)A)*UZ>DDV?N)XD_Y.G^#7_9`?VEO_5B?LH5]`5\_P#B3_DZ
M?X-?]D!_:6_]6)^RA7T!7UA^`A7P!_P5B_Y19?\`!2S_`+,`_;(_]9U^(U??
M]?`'_!6+_E%E_P`%+/\`LP#]LC_UG7XC4`?D)+\+=<\3_P#!(O\`X(?_`!&?
MXP_$_0?"?PZT7_@AA/#\%O"MSX;T/X=^//$^M_%7]E#0O^$D^)U^/#5UX^\4
MP:#HVN3#PMX.MO&VC>!+7Q$MKXJUWPSXF\4Z1X/OO#?TQ\:O`%W\-?VY/BC^
MVG^T]^PQ^SA\5OA'IGQI_8X^"'P'_:-^(OBSP5XI_:+^$6A:]>_#GP%X(\8?
M`'X5M\"O&XTC3[3]JKX[^*KGQ_KVO?M!?!3QU8^&]"/BC0/"_BX>'?!]AXD^
ME_\`@GA\)_`'QF_X))?\$P?"OQ(\/?\`"2Z#HG['G_!/'XF:9I_]JZSH_P!G
M\<?"3X8_!?XG?#O6/M/A_4]*N[@>'_&_A70M=.F75RVCZM]@.GZ[8WVBW=Y8
M77TG?_L0_LUZK\;KKX_S^#?%$/C[4?%F@>/_`!'H^F?%[XS:/\&O&/Q&\*:/
MI6A^%/B=X^_9TTGQ_9_L\^/_`(H>%].\.^%#X;^)'C+X8:WXZT6\\&^`]7T[
M7+74O`_@^]T8`_&G]HCPUHFL_&S]K_\`:IU?3;>]_::_9C_X*?\`_!-SX$_L
MY^/[I#)XO^&7P<^(%G^P_I7C'X8^`)RS:IH_@?XR:?\`M-?'?_A9N@Z"UK9?
M$?\`X2NY&O65[_PCVC'1_P!&_P#@HEX?T/XD^+?V!?@-\1=)L?%/P/\`CG^V
M7+X9^-/@'7+:'4/!GQ+\-^!_V7?VE?C'X4\!>/M'O]VB>*/!^I_$_P"'/@;7
MM9\&Z[:7ND>)CX;M["_LKVQ%Y97GO_B[]B/]F;QU^T%X?_:?\4?#^_O_`(P>
M&[KPCJ=KJ%M\1/B=I?@?6=?^'5IXJL_AUXO\<?!G1_&EE\&OB3X_^'4'C+Q$
MOP\\>^/?A[XD\9^!//T__A$]<TA]!T5K'J?BK^RU\&?C9X$UCX=_$S2?&_B+
MP_JWQ%TKXL6][#\8_C/X?\<>#/B)HFM6/B+0_$OPK^)OA?X@:1\1_@U<:!J5
MA"=#M/A-XL\':3H]A<ZIHFFV5GHFL:Q8WP!^`/P/^$/PQ_:*\5_L\?L5?'GP
MOI7Q(_9"^&B?\%J-)^&_PK\=9UGX?R6'[-?[9O@#]GKX`_Z/JYN],U@_L^_!
M?X@>,?"_PENQ_IGPXLX-,US0OL>N>'='U>S_`&G_`.":?CCQA\2_^">_[%/C
M[XA:SJ7B3QMXM_9@^"VM>)?$FM33W.L>)-5O/`6AM/XCU6^N/W]_J6O`KJM]
MJ9'^G7=[/?\`(N1AOC7_`()T?L?^/_@O\*?@!K/PQUW2OAK\$K;6K/X:Q^!/
MB_\`&SX7>//#]IXJ\.ZYX5\<VD_Q@^&WQ&\*?%SQ#;_$[1?$6NK\6;;Q/XXU
MA?BM?:I<ZY\2AXEUMEOJ^Q/#OA[0O"'A_1/"?A71].\.^&?#&CZ9X?\`#?A_
M1;*'3='T/0=$L[?2]+TC2=,MEMK;3]-TVP@@LK"SMD6UM+2"W6-514!`/R$_
MX*N?';XI>%_A_P"$_!&B?L7?M+_$;PQI7[:W_!+W7;#XQ^#?%7['5E\./$NJ
MZ5_P43_9+\567@K1-*^(/[67@;XMVWBGQ+KUA:_#'0[OQ#\*?#O@ZU\=:UIN
MH>(/&/AWX<KK'C_2/IO_`(;)_:*_Z1/?M_?^'&_X):__`$RFC_@I7_R;K\.O
M^T@'_!)W_P!>F?L:U^@%`'Y__P##9/[17_2)[]O[_P`.-_P2U_\`IE-'_#9/
M[17_`$B>_;^_\.-_P2U_^F4U^@%%`'Y__P##9/[17_2)[]O[_P`.-_P2U_\`
MIE-'_#9/[17_`$B>_;^_\.-_P2U_^F4U]_D@<FO.-.^*GPYU3XAZ]\*--\:^
M'[WXE>&=%TSQ'XB\%VFHPSZ_I>BZK*8+"^O+$,S*&(@-V@S=V=KJ&BWM^MI:
M:SHSWJ47*_+3VU?DN[LG9>;`^1O^&ROVB?\`I$_^W[_X<?\`X):?_3*:#^V3
M^T5W_P""3W[?V/?XC?\`!+3'_KRBOO"\N[6PMI[R]N[>SL[:*2:YO+J6*WM[
M>&(9EEN)YB(H80`"69@`N6.`&(^#?CK_`,%'_P!F3X-:5JUMH?CO1OB_\2H[
M>>'PU\,OA?J'_"7ZOXAUT`BWTN[U3P_!JVB^'D7FZU:ZU6Y6[L[&"Y:QT_5]
M0^QZ5>]&$P.-S"JJ&!P>*Q-:3LHTX2ENTKOE326J;;LENVEJ:4Z56M-0I4K^
ME_UM8:/VR/VBL;O^'3_[?@S_`!#XB_\`!+7G\?\`AY2,?A^-._X;'_:)S@_\
M$GOV_<=P?B+_`,$M`3],?\%*`?R!S7\YGP__`."EG[8,'[3.I?%O2M4F\9^(
MOB%+:^$G^#\UIK&H^"K_`$W[9/#X5\(^'/"UA<'4;"ZT'4;Z=M$N],NCXCO+
MV^U(W]YK'_"0ZN-8_?[2OA#_`,%$?C#I.F:G\5_VH/"'[/UEK&GVUYJ7P]^!
M'PSL]5UW3EO889SI,_Q`\7ZE?ZEH^L:;YWV:]NM"NM6LC=PW`L;V\L]ERWT^
M<<%XK()8?^U,RR?"T<1%-RE4Q<VI*WUN/U3!X3$XN3@Y;I*,^BZ';B<MGAG^
M^K86VMK2;=_1)O3?L;6N_MS?&OPMH^H>(?$W_!+K]NGP_H6CVDM_JVMZU\5_
M^"5>F:5IMC`#+/>7U]??\%+K>VM;:W`W-<W!15').3EOS1U;_@NS=7?QE\)Z
MSH'P<\2Z3^S_`!:)%!XQ\&>+/^$.?XSSZKJH@FO=2M[WPKXU\5_#^VU#PO<0
MG2]&T/2_&NL^'?$F=2^W^*+0:IHUWX9_333/^"9G[.U[>6^M?&76/B]^T?X@
MMY!-!J_QR^*WBKQ*L%QG][)!I&DW/A[1A`V"@L[FPN[46_RA6QD_*WC_`/X(
MK_![Q3^T1IGCG0=:E\'_``*O[:ZU'QA\+=(>\BU-/$4'DBPT_P`'ZH1<V^C^
M$M6\Z>ZUF*<-?:,UF+#01]AU6U/AGHX>_P!1</6Q<,ZK8[,%]3EROZF\)@[R
M3C)81+%RQDL8O^8-S6%A>S>MT5A'EL)UOK-\0K::65^MEO=^>MNQ]&>`?^"@
M?Q7^*'@[P_X_^'G_``3!_;L\5^#?%-A%J>@Z_IGQ(_X)=&TO[1BT3'RI_P#@
MI+;7%K=6UQ#/:7^G7=K9W^EW\%UI^HV=I?6EW;)V0_;)_:)Q@_\`!)[]OTYS
MS_PL;_@EKS]?^-E/7\<]/K7C?ASQK\6/^"=<FC^`OC"=5^*G[&UM+::)X$^.
M>EZ8+GQE\$=/FD6STGPM\7]$T>WW:OX6LV\FSL?&>EV2_9<P631DW>G>'[#]
M1O#^OZ'XKT/2_$GAK5=/U[0=<L;74]'UO2+V"_TS5=/NXA/;WMA>VS26US;W
M$)#)/;L5(;C&,#Y?,<!]4G[:A_M&6UY2^IXQ-M25](RLDHXQ+E^M825I1D[K
MFBXR?#5I<GOP_@OX7I]S\UK?3]3X@_X;)_:*_P"D3W[?W_AQO^"6O_TRFC_A
MLG]HK_I$]^W]_P"'&_X):_\`TRFOT`HKA,C\_P#_`(;)_:*_Z1/?M_?^'&_X
M):__`$RFC_ALG]HK_I$]^W]_X<;_`():_P#TRFOT`HH`_/\`_P"&R?VBO^D3
MW[?W_AQO^"6O_P!,IH_X;)_:*_Z1/?M_?^'&_P""6O\`],IK]`*S;Z\L],L[
MJ_U"ZM['3[&VFN[Z_O)H;>UL[6WB,]Q=WMQ<,L%M;VUO"UQ<W-R0L:`MN`&V
M@#\B_B[_`,%<++X!ZSHOAWXW_L._M;?!S6-=L?[8TN+QSXP_8=\0B\T:WUFP
ML-6E%A\#_P!LSXT>)=/N6MI]1N?#1U_P[HWASQ!J&E7.B?\`"2Z3MN;VS^;=
M(_:(^+_[:/QH^&O[3-C^P7^UK\7/V8OA7!<7GP@\`^#_`!'^Q1H&K1_&:#['
M_;7BGXIV?QA_;%^%.C:C?^%IYC9^&6^'>L?$CPB;[3&D3Q-97]KK-EJWQS^U
MW^SOXR_;'^._Q*^.W[(7@KXD_%CX:W?B7P[X5U_QIJ]]]JT?6_']Y??V%>M\
M,_[8N!K5_P##C05_LBVU#4QG1?!MJ;J\5M)\"V=D]I^]_P"P+^R`?V._@T?!
MFH^*=1\4>,/%&H1>)?&VW4;Y_!^EZZ;06YT[P?HDY%M86EI;B&UOM;^R6NK^
M)WMK:[U$QV5IH^CZ1^@X_`Y)P[P]0Q6%Q:_UGQ,7@\73<I?6L%];C_MD?JND
ML%BHX5K!.4FW;%R:7/*V$]>I3PV%P:G"L_KST:[)[]=&E==+7[LSO^&R?VBO
M^D3W[?W_`(<;_@EK_P#3*:/^&R?VBO\`I$]^W]_X<;_@EK_],IK]`**_/CR#
M\_\`_ALG]HK_`*1/?M_?^'&_X):__3*:/^&R?VBO^D3W[?W_`(<;_@EK_P#3
M*:_0"B@#\]Q^V-^T25&?^"4/[?C,5"D_\+%_X):E2,\DY_X*3D$8P/;'3(S2
MC]L;]HE2%_X=0?M^Y^;('Q$_X):CCT&W_@I.%`]<X[<5YW^T+_P59^`?[-_Q
MB\6?!/Q9X'^,.M^*/!2:$=6U#PEH/@ZZT%F\0^'M*\46<5E=ZO\`$'0M0G9-
M/UJQ6[!TN`+="XC0W"KO;Z?_`&4_VK?A_P#M??#W5_B+\.](\8:!I>A>+[_P
M7J&G^-[#2-/UD:GI^D:'KEQ/#%H7B#7K%[&XL?$%DMI<_P!IEFN8KE#`IMB6
M<*5>MA?KL*&)E@?K<L%]<^JXGZHL7AKN6$>*<5A5BENXJ5[/JEIV8K*\9EZH
MK&TZ6'K5\#@\VC0EB,,L3+`YK?ZEC8Y=]<>,>#QO))X7%O!J,K/WD]_*!^V/
M^T1QC_@D]^W]@#@'XC?\$M<8'4G/_!2CMGU_#K1_PV/^T41D_P#!)_\`;]`Q
MQGXC?\$M@!G'<?\`!2C)_&OOL.<YZ+MSZ<_0<>Y`%?G5^U]_P4@^%7[(?B^U
M^''BCP5\0?%_C?5?!5EXXT:+0(-!M_"\EGJ6NZWH=I::KXAOM:34M/N3=>'=
M48BS\+:P%MA;'):Y*CIP&`QN:X[#9=EN'EBL=C6HX7!P5Y2EHK+6.SEJW)):
MW:29Y>)KT,'A,7C<55CA\'@<+/%XO%2=HX;"TU>4G:[LE9MV;U6E]MD?MD?M
M#E<C_@E!^WX1S@CXC_\`!+8__!)U]^I^E!_;*_:)`.[_`()/_M^X./\`FHO_
M``2V(X^G_!2G^OH>]<]^QQ_P4B^$_P"UKJVL>#UT+5/AGX^TG2[G74T#Q!JN
MFZGI>MZ':,WVZ]\/>(;>/3!=7.E0&WNM9TR]TG2;NUM;C[=8#5K&SU>\TKW;
MXA_MM?LH_"UYX/&OQ^^&NEWMM@3Z18^);/7]>B)&"9-`\--J^M)]38`'&>#5
M9[E^,X;QF(P&?X>648C"N//#'.,)14E=.[ERZ]'"4D];.Z:6G#_M.+J5"KPO
M1Q>?^TNHK)\'C<;*32N_]EITI8E6[24?F]#R)OVR?VAXL@_\$I/V^DR0`K?$
M+_@ER-HS@[?+_P""DS%R<$[AE5P=^#BG+^V7^T(Q^7_@E-^WS,0#@1_$7_@E
MN60E<'G_`(>3@,<<G^+..G-?A[_P5Q_:A^''[3[_`+/S?",>-]0\.^&O^%GW
M,GB3Q%X+U_PCX;\0R:Z?AO\`9)?#$_B&'3+C65TL:5(FK$6UK]C&I:=&"5U-
M"?#?^"7M[\?-`_:+UC3_`-GZ\^#UI\0/%7PP\0Z)"OQGU+Q!;^&9M*B\1>$M
M>U!=&L?#?_$ZUGQ7;6VCFZM=+5EM1H]OK6H7K#[&:\##U.(,>\7CLJX6S?-N
M',N26*XEP26*P46\&\7)+EPJ7^R64<4UC%RW4KN[O^Q5O#3AO*^&\OQ7%'B9
MPUPCQ[FV%QN,P?AKQ)]7R_.G#!9QB,!?%8G%9N\5@_K=/#5,=A(SR1RJ<OU+
M"PQ-1^[_`$:C]L7]H4,=O_!*#]OHD!0Z_P#"QO\`@EOPJ\8)_P"'DVP-P"!N
M)/4X()KX:_;+_P""IW[3?P'_`.%<G2?V-/'7P!?Q4WBPW'_#5]]^S_XT3Q:F
MB?\`".C_`(H:+]DK]KSXPFQ&A#63_P`)*?'4GAUKW^UM`'A8:PMIX@.D_7$G
M[-_[;GCC?+\5OVZ)?!NF3Q[]1\+_``#^%OAOPHEDAWF5K7X@>(;B_P#$FUH.
M?-GM";?.1N&&/XZ_\%/_`-GKX)?##0OAC>>&?VDOB5\8OB4^L^)--U_2_B+\
M0[;XKZ[<:<T6C7%UJ5WJD.I6:^"$TNX@%K]C'AVZ;Q"=4W->VG]A`7.E++.*
MN*:D,FX7RC%QS;,WAHX+$XO%8+"_59O6I)V6.Y7'#*;O+E33UDY;^;PY4\)N
M"\\P>>>)/%N49QP]E^%QT\PRG)\HXGQ>%QDUE6,^IX'Z]B</DG^U2QCP?U;Z
MI'%89XR,8RQ.%P7/C%]+_LA?\%</VHOC9\2-:\):Q^RQ/\=HK/P;?Z_!X2_9
M>_X5;X-\>:?+9:YH&F'Q!JU]^U%^U%\*/`%UX4MO[4.GWMGHWB*[\6MJ^I:.
M;#1K[2;7Q#=:5^D/_#8_[1>X_P#&I_\`;Z.5(W?\+%_X)<#.?K_P4H``QP1M
M!'H*_ED_9`/P;TSXW:'#\9->\=>"/"NO6-WX=M?B/\/?&E[X(\1_#7Q'?7=C
M/HGC6'5+>WNA<Z=;"QGTJ]M+IA96=GJMSKF;L:59V=Y^[^B_%;XQ?"YXQ\#/
M^"BW[+_[2OAVW>6.T^'7[2?BSPKH?C=;"V'GSI8?$3POK-IJNOZD8,C^T/$E
ME;:;C:0I7./=S/@;C_@:HLOXGRC%YO-Q>*_MCAU2S?`SC)Z)<N!P6*NK-6^J
M)VU:::;\K.N)O!?Q*S2>;^&?$.#X*PDL)@<,N$>,<)4X>G2QBARRMF&'Q^>Y
M.GC9-5$\9C,%@U\*QED[?7;_`+8W[16S_E$_^W[NR&X^(O\`P2X`8\8+;?\`
M@I09,`'H`#Z]Z1?VQ_VB'Q_QJC_;ZW9)8K\1O^"6S8)`)#+_`,/)')QQA202
M3USD5^;W[6W_``4Y_:2T+X7:#I7A'X=ZI\`?B>_C'17U/Q]H.K?#'XX_"K6?
M"3:!XG:[TW0_%Z0>(-#@U?5]5AT?5-,TY]*2_P#[+L-0VZN%@D%W\Y?LM?\`
M!4W]HR'X]_#B/]HKXUW&N_!R^U2[TKQK:)\/OAAI`MHM6TF_TS1=8N+[P_X6
M\/:W;V&A^(+C2]=UM[6[+KHUCJ)%G>%5L[OT,CX2XKXFP6-S+)>&\TQ6`RU<
MV)QG^S82[LUC5AL)C,7A,;BOJ27^U*&";3:6'Y\1[A\=Q&LBX2G@,-Q'QCPG
ME^:9AA<5BL'E.&QV,S^<\%'D6#QRQW#F59UP[A:><8F?U7`3Q6=4^::F\9'`
MX6/UM_MB/VR?VBE('_#I_P#;[PQR<?$?_@EN2<?]Y)PHX//KWI?^&Q_VB6!)
M_P""4'[?8!&!GXD?\$MBH`/.[_C9.2#ZD9/7\?K*R^,_PBU$6@T[XH_#R_-X
M(C9_9?&GAVX%WYP_<>08M0Q,9S]T1@[NHS7D7[4G[3>A_LZ?`;Q]\;-,L-.^
M)%SX'B\-2_\`"(:?XKMM(EU/_A(_&7ASP<ADU2'3]=>QM+2Y\0P7!G&E78D=
M%M`5>X#+\[*M1A&K5]JDEU>VGEJ]EZZ:(Z,+E&9XS'8/+:&"Q3QN/QF$P.#A
MB5+")XS&XJ.$PL98K&1P>%PW-4DE?%3A%7NY)*3CY7_PV1^T/QM_X)1?M^CH
M<CXB?\$MB&QCC</^"D^W\SQ3?^&R?VASO!_X)0_M^D=_^+B_\$ME`''!!_X*
M3A3^!)R*^"?AM_P6^M/&7CWP)X1\0?LZV'@?0_%7B_PUX=UKQC>_'"VN+/PG
MIFN:O9Z9>^)]0@G^%^CV=QIVAP7/]I7N[5K-#9V\Y>\M",U^MOB7]K#]F/P>
M[0>*/V@/@WHDX4L+2_\`B3X0AO#D1<16;:NUU.X,T(S';N!YJ'^-:[LRR_'Y
M.J3SC+<;E"KKFPO]KX/%Y3)J*N],:L&V[:-)7P[TM=V,J&!KXVO4PF55<#GN
M(I-*4>&\VROB58>4I-16(EPYB\ZC%R?^[<\H?6DU+#.47<\'_P"&R/VB=H+?
M\$H?V^R-H;/_``L7_@EOVQAN/^"DW`(89'/)],E4/[9?[0:Y(_X)2_M[@HIR
M%^(O_!+AB%Q_%_QLE!4`Y8C'/1"Q(KY0_;R_X*+?`+6_V;?B1X+_`&?_`-HV
M5/C-JX\'1^#[OX>+XZT_588X/'7A2^\2&P\;:3HUIIFC[O"*:W\]SKMA)>!+
MG3[1I+P_9:_"KX:?MD?M&^!?B'X%\9ZS\=/CGXQTGPKXN\,>(M<\):U\9?'D
MNE>,-+T36+*_U7PMJL-_K&K:<;#7;&&XTR]^UZ3>_P"BSY^PDYKW^$^">)>.
M:&,QG#V$PM?!8!*^)Q.,AA:>+Q;][ZCA-,3_`+8L)_M5\4L)@^7%8-?6TY67
M'Q5B\EX#I9;3XRQV8Y#G6;8O%+"<.XCA[-5F']E0AAE'.L0\1#!PPV48O&/%
M8#"RH?6\5+&8/'?[*X81L_J&/[9'[1*D+_PZ@_;\&[N?B-_P2U!/;@#_`(*4
M8X'IR1UZ\<SXQ_;O^,O@3PKXD\;^,/\`@EK^WWI'A;PAH&L^)_$>JS>/?^"8
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M<2?`>65!'^Q5^WFNYBJI+9_L41C/'R^9+^VTL))Z9#A?7W_1,?MC_M"N5V?\
M$H_V_",$[1\1/^"6VW`8C)S_`,%)MP8GT.X`#Y3W_C46WB1/+\M?+S]S9VXY
M]^GU_"OW-^%7CS]OOXQ^`/#WCG7?$'[:/B/0O%$&J7.EZG\&A\%O#6C:EI4-
M]?:9YUE>G1+34H+@ZE8SG-U:8-K#FPS97=G>#[7B7PAXRX4P&"QE?&9-G^)Q
M,_JN,P>$EAN&E@<59\Z6*XBSB$<=A;:IX=8;&*S<L)U/GLL\0/"7B_-,;@\C
MEQ)P;A\O>,E]<XP^N<6_VSA4\)]1^J87@[A/FR?&?[VL9@\8\9A-,)]3S9W:
M?ZOM^V1^T)&C%_\`@E%^WTJHA)=_B'_P2X55&"68%?\`@I(QVCJ2BL.R@G"G
M\QV_X+\;7;;^REYJ%SLED^./ES-&>-RQ'X0%@1G')..V#6HOA#Q.7:;XA>#O
M^"T?BMXC!)K%E%\1+&]TJ.6P`AU)=%T[PK)I/VBUN%6?[,+6<_;AM;3[Q1<_
M:V_G]?2I-)EFTVZLY+6\LYI;._MKRV^SWD-U!^XGAOX+C-S;W`N!/_HOXUXW
M#GA-QSQGF,L/ALSP/"6#R_"^UQV-ODO$[Q4JEE@\)]3P6.;@VX8M_P"]QNE]
MKK]1'Q-\#O#W*L9BN(\DSCQ5S3,,9@<%D^!P3XFX$P>4X6#QKS?'RQU1.6/?
M*\$E@W@DXW;OA.9V_IO^'G_!;'P#\0O$.G^"M)_8T_;#U3Q;>:'9ZDC>`;3]
MF_XJ>%KNYOH1+ML+CX>_M$:[X_@L!,2<>+OAKX3\5V-JZ#Q1X/\`#NK_`&K1
M[1?C-^T[_P`%:->ETZU^"/\`P3V\8^&O"&L1RM/XNL?B!^ROXP^(VDVS%Q;W
M4?@_XQ_M,?L_Z-IVH?=9M*U"#5XL9\R\`XK@O^">7Q^_:HO_`-G#P_X7^#7[
M*/@7Q;I7A#5-4\(_\+5U#Q[X6^&&A:A+I<5C/:6FJ>%].T(ZYXGU[3=/U.UM
M=1\36Q":O]E#7][=ZX]_>/\`=+^'O^"F7C`'^U?B#^RK\&[.49B;P;X4\=_$
M/Q!;*.U\/%]W9:+--G<?]%4)\MN`1FY!\G'<!YUEF.K9;GW%/#F`EAYSP<W@
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MC>Z/I-Y9M8VOYN?M'_`KXM_!#XP>*/!'Q0TS5[GQ'<:]JESIGB26QNS9_$&U
MO=2G\GQ3X<N`2+^#7?/^TD6A-Y97LUS8W_V.^L[RSK]VOV&/V-?VN?"GP`T&
M[M?VE?''[.M[XCUK5O$]G\-)?AYX5\;6NCV-W!8VVEWFN:=XP'VG1=8U/['<
M:E?:$K?9%M+FP%_8V>N+?X^ZXD\"_#+A;AG*,YR_/<$\1F2PG^UYNGG&%SBT
M9/ZY@<)A,'C,;@$I<JDY)\JTQRYTD^"?TM?'?CS.<3E&:RQ^7T<LEC,6O]3Y
M3X9Q6$E4Y8+!X_%4\XP2QS5O=37+&3;P=DVUY</V7/@,RY'_``0F_;^Y'WE_
M:7_8@`';@M_P5M(&",_,,=1VK\&?VJO@U^T1\$/B-XHFU3]B;XN?"SP3XE\7
M>)M3^%W@GQ+\=/V'-6\9:;X!O=;U,^%[75-*T;]M#QKJV--TB"#2[S5+B\U:
MRN[ZQNA_;-U>_P"F5_7JGP8_X*$Z&A%A^VA\.O&CK#M0^,?V<]`T`/)+,)))
MI/\`A%=<N3'Y$>V"T"HH/+2$D[F_FD_;N\-_''PY^T[\1T_:`N(M1\=ZE?6N
MI0Z[I=I>6GAG7?#L]G!!X=O/"$6H%BV@VUA!#IEG;F]OCI-[976B:@QO[6\)
M\'A'P6X.XYS6.7XK.<D5"AA)8VW#:Q6#Q^*Y4ER/^ULFP7^S+F4JBFL5**<4
MJ2OSKMK_`$I_&#PWPU?-,#B>),PQ&/C'`O\`UZQL^)<EPJ<N9R]G4SO'16+N
MK1E#ZI+EO%U+>Z?I?_P3_@U#X>_L\_#?4M5_X(^?'GXP?$5AXCO=5^,?@SQ?
M_P`$IO'&G:ZE]XO\07NF0:1XJ\0_\%![#7HO[*T.72]"U"UDL-):TU72[NRN
M+1?LH+?II'^V!^T+;Q)##_P2=_;XC@BBCAAAA^(7_!+2.*)(N(TCB_X>3KA5
M`P@"@`#"X"U^6W_!+/X8_MF^(OA5XXOOA5\8=/\`@G\+-5\6VK6&I>)?A[:>
M/;C6]>ALFLO$.I^$=)U>\LM,@M[6!=*M-6U5@;35[^QMK%,'2KTU^H@_8^_:
M!\2`)\2?V^_CUJOF<73?#+0/`?P>#$"`N;;^P-*U4V@.+G.TD@S6_.;5C=9Y
MSP1D/".9XS(J?%62NAEU\)!1P>;XO&RM]G&1P64QPBQVRQ5\;)2J=5S/E^6J
M>(G$_'M^)\WR?.,1C\ZEBL?.4L;AOJCEB\7)_P"Q_7<:\3A,%UP<5@XJ.#45
M&/NQ3^>OB[_P5ZL_@MJUQX,^)/[%?[3/PG^(7]F:;K6F^'/BEXR_9&N=/U32
M+^>^@,_]M?L\_M+?M&3:5=6WV+>--UW2-)O+NVGM[RS#61:Y2CX)_P""R7A3
MQ['=IX3_`&0_VC?&5[HFF:7>^*;SP[\3?V$O!GA?2+G5;N^MK:RTW4_VCOVQ
M/V??$OB$(UBIO+O3?!GV:S-_86=ZZ7=Y;1GX0_X*!?\`!-SXV>$/&=E\1?A6
M?C!^T=X8U_3-+L]?U?7[^\^)OQ<TWQ#8P"R!UL6.GG7-=T:ZM8;>YLM3TW2O
MLFCD75E?"S6TT8WOM7_!,S_@G)JR7OB;XL_M2_"?3?["N]#_`.$?\#_#7XF>
M&[>ZU.2\FU*RO;_Q=JWA[6+;[1HHM8M*&EZ1:ZG:B^O5U/5+Q;.QLC9M=_H-
M?A3PQH^'=#.5G,L1G5HN5?"8R/U[$XJ4HIX'^PL;BTX1BKI2:T2>,^NS;5,_
M-Z/$7'M;C.MEG]F*AE[;2PN*PC^IX7"6TQJSF.DF]^5*S;^J<JUD>U>(O^"V
MW@+PLNW4/V,/VI+G'WCX=^-'_!*_Q@HYAR0/!_\`P4DUXDDSCJIX2XXS:7.S
MX`_:D_X*^_%+X\6V@VG[/^E_%G]FKP<EG*^N:=XQ;P!8?%O4M8AU"4&6XUWX
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MV*Q5HIZ-KZKAF[66*2O?\R_V,O\`@K/\2_"'A[Q'X1^./@3XV?M*'1[.QU+P
MOJ?PE\.>%?$?Q#TZP^U0V&J0^,)O$_BWP3IFH:.+F^TG['KMWJW]KVMW??8-
M0-X+NT&D_5^O?\%LOA]X?^S&Z_8<_P""@3?:Q*8\^`OV<K`+Y'D[\?VQ^U%I
M7GY\\`?8S=9&:^N_V+/V$OAW^QMHNN2:-K5YXZ\?>*X[>U\2>/-5TF#2)9=-
ML9&FL]'T/1;>\U4:+I`F9;NZMSJU]=WUW%;O>7CQV=C;V?W6P4C`P3[<MD]<
MXDSGT^7^M<_%^<<`XWB+'8K*,@QCR^=FL1A<?+)EBTHI2Q,,`LGQ:P//+7DC
M*S=Y?5:;;B]N'<LXPP>382AF6<X3Z]%._P!:PCS9Q=]GC/[4POUM]>:Q_+A^
MU+_P5-^#7QXT]F\*_L.7N@?%33TAT&;QO^V)\)_V?/%>KZ1X6\B?5+&#P3I_
M@SXE_&&6Y_XF&J7EV+;QA<:)I%F)KB\L=&UD:LUY:=)_P3[_`."A6L^#O$&I
M_"VP_8]LOB?XU\>QK/X?T_\`9-\%_LW?!OQ_XKO?#MKJNN7%IXIA^(?Q)_9_
M^$U]I.@Z#_PD.J6-[=^+-&UBR-OJ%C9Z/XBO-?S9?IW_`,%!O^"?D'[8FG^&
MO$_A#Q#IO@[XL^#K&XTG3M0UR.[?PWXF\/7%U]M_L+7;FPM[W4=);2K^:\U+
M2-5TW3;ULWFHV5_8WBWEE>:1X_\`L!?\$P-3_9D\?2_&+XN>*O#?BGQ]IEEJ
MFE>"-(\%MJ]QX;\.IK-G+INJ:]/JVKZ;H&H:AJ]SI%Q?:5:6ITBUL[&SO;LF
MYO[JYMC9?3T\1X02\.\<UEF&PW%BP>,E@UBU/'<0_P!J\R6"<<Z6`PD98%QW
MBI87"_5.=8N$L9&,WYE2OXJ_ZW83"5<ZQ>)X6B\&Y818S%X/AU817>,_X1WC
ML6EC;ZQ?*E];LTTKL^F/A?\`&/XB?%O]J;P*WC[]E#X__LO_`/"/_`+X[_V3
M_P`+T\1_LL:__P`)S_:OQ$_9G-]_PBW_``S1^TO^T,UJ?#']F60US_A,_P#A
M$!=#Q%HO]@?\)$;76?[&_0.OG_Q)_P`G3_!K_L@/[2W_`*L3]E"OH"OQ0_3P
MKX`_X*Q?\HLO^"EG_9@'[9'_`*SK\1J^_P"O@#_@K%_RBR_X*6?]F`?MD?\`
MK.OQ&H`/^"3O_*++_@FG_P!F`?L;_P#K.OPYK[_K^>SX&?M;?&O]FC_@EY_P
M1=L?A)\!+CQ]HWQ#^!G_``2>^&?Q4^,/B[6/#>F?"[X5^`OC3!\`/@YJL5GI
M$/C72?B3XV^+.J#Q41X*TGP_X4O/!GAM6N?%GCWQ1:_V7H_@3QY]+?%S]N;X
M^^$/CE\3=8\):+\'_P#AE/\`9L_:G_9;_9&^-NC>(?#WC74?CGXY\9?M-6?P
M>\_XA?#CQOI_C[1_!/@CP]\)-0_:5^"HO/!NO?#'XCZQ\2;+2OB2;'Q/X$:U
M\.&\`/U]HK\@OBY^W-\??"'QR^)NL>$M%^#_`/PRG^S9^U/^RW^R-\;=&\0^
M'O&NH_'/QSXR_::L_@]Y_P`0OAQXWT_Q]H_@GP1X>^$FH?M*_!47G@W7OAC\
M1]8^)-EI7Q)-CXG\"-:^'#>?5_[7_P`;_B7\+$^`/PX^"$7@:#XR_M._'6P^
M"?@;Q1\4-!U_Q;\._A];V/PW^)'QH\<>//%/@OPOXM^'WB/QN-)^'WPC\4VF
MA^#M*^(/@-M9\7:KH*7WBC1].2\NV`/LZBOQ,\/_`+='[7WQK\/_``5^"WP8
MTO\`9U\&_M>:Y;_MP0_&;Q9\1_!_Q)\;_`/2M5_8+^+6D?L\^,8O!'@'P]\4
M?A[XV_L[XW_%GQCX'U7P9<:G\6-6N?A7X#OM;.OK\2-=TFSM-8_3']E?XZ6/
M[3G[-?P%_:)T[1)O#-K\;/A+X$^)W_",7-V+^7PY=>,?#>FZY?:!+?\`V:S_
M`+0_L*^O+C2_[3%G:"]^S?;1:QBX"J`?//\`P4H`3]G?X<YPSG]OS_@D^&<`
MC('_``5*_8XYR<8QUX'."">!G]`5())PIROR@X!QWSZ#KSCZ=:_/_P#X*5;3
M^SK\.L\D_M^?\$H3U!`(_P""I/[&X..3CD@\=_KQ1_X*.?M4?$?]D?X*^%?B
M'\,M(\(ZQKNO_%71?`UU!XVL]:U#2+?2]1\+^,]?FN(;?0M?\/7AOQ-X8M;6
MU)U0VV+F;=;L0FV\-AL3C<10P>#H2Q&.Q.)6%PF%P^^*Q6*LHQ25G?FUM?1W
M>]K).E>]?$X7!T$L1B<3BL9..$PF$PV&P\L3B)XJI).,(QC&3<I:=]U?]#R%
MP"#U[;E'ZXP<\_IT/1I)"$D`$]CD@XXSE1CIU)_7G/\`-!\+O^"WOQ>C\;:,
MWQH^'GPZN?AP(M4_X21?AEX=\20^.'E_L>__`+$&A3>*/BA=Z$H;7SI?V[^T
ME&_1_P"T?L6;[[(:^G6_:,\<_M8?O/B!^U[^S[^Q7\%KX?\`(C_#WX[_``UU
M_P#:$\3Z9(5/E:WX^7Q"=+\`&Y@&^+^PK0ZS9/\`:M/UW2;D'(^RS'P[XGR:
MK&&>8)Y=1::CB[O&*3:;<<)'+XXS$U)Z;<L(J\6YQ3NO$RCB7AW/*,L3@,\P
M:H4?B^M2>#FNW^R8Q83%/?2T5Z'V5^V5^V#X2^#W@SQ5\//AUX[L[_\`:@\0
MZ/<:;\,OA]X5\,W7Q/\`&`\27D)-A)?>#=&G(T\/`9FT^Z\3,+-;LV]^=%\1
MVEJ^BWO\O/P2^&?[9FM?M=V>A^!X_'_A?]IFV\17.O\`B/Q#XC&I6NK^&GOQ
M]HUOQ5X^OM7MKO=X?N[?5A_;/]I6E[9^);2_M;!;+6?[7LK*\_H*N?B_^P5^
MPG\$?&?C;]G'4?@C\3/'FG+HYFT;1/C+X0UGXK_$B?7/%6CZ5J<U_P",3/XM
M\67UOI@U6\\4W]K;:;=Z7:6MAJ'V+3]/1FG@_*?PS_P5Z_:*TSXPW7Q,UGPW
M\,-3TC6?[,TGQ!X2L/!VG:1>7/AC2[R>XL])@\?6]M=^--VF?VKJUUHK:[JN
MKZ397FK75\NC78O+VS/W_`61Y[5P&?T^&\@6+H_5%&>-XDE]2EC,6DFL'A,(
M\#RO"<K4OJ.*Q<4V[RQJDW&-9IXC\,\**C1K5_K#Q_3"?5,9KIKC,(F_]BO?
M35XO9729^T>E_P#!-OX?^+?[/U/]IWXL_&W]J'7XA:W=Y9>.OB#KNC_#JVU6
M(+YLGAWP3X6N=*&DZ<;G]^-+N=5O[5F"_;%D`./M?X<?!?X0_!^P-I\+OAIX
M&\`VY@6&8^%/"^D:/=7D:G(^W7EE:I?W[=/WUW<W+]R3@`?'<_\`P5._8@M-
M*T^\?XMW,U]J&FV&HC0-/\"^.]1U:Q-_#!.;*_ETWP[>:+;ZA:&8V]W;'5CM
MNH;A$-SMKXQ_:8_X+*?"B_\`A;XJ\/?LUZG\0=*^+NH?V,GA'QGJ7@OPA)X<
MT<VWB30KCQ"U_8^)]7U2X<W?AD:WIME_Q2>J!;ZXMSBVPEXGY[7R3CG,,1AL
M%CL!G5".(QGU3"83&4YY3@N:4K/EPF+^H8."3E)MX:G90?,N9\S?3'B/+L91
MQ%:CF4,?0PT?K>*^HOZ['"83J^7*5BTO)==FM3].?"_[&?[/'@WX_P#B3]I3
M0/`EE:_$[Q)9PQ33@QMH6D:I.]X-;\3^']$%N;?2?%'B>WN(;37]5M2&NUMB
M]HEG>ZQXDNM:^K"5P`H`P#QSD#KT`)&?3&?PQG^#_P`/_M'?'3PQ\18OBQI/
MQ7\=1?$!+\7]SXEN?$.I7EWJ,@FMYYH-4&H7-W;:QI]S]G^RWFEZI9WEG=V8
M%C?67V$8K]__``E_P69\-ZEHFCOX@^$%E#X@ETS3I]4CL/CI\'K#3VOIH8//
M$$'B'Q)I6IZ>3<%LZ9J>V]LR?L5]A_G/TW'7AGGW#O\`9E;$YY@LZ5?"?5$\
M7C,+E/U+ZFFG@L(LYQT?KF$2?[N6#?=/!Q=F_F>$N.9\;3QD,+D^<NME^C6$
MP>+SC_9%>TW_`&1A,7]4MU6+MO=,_<0L`,`8'T!!Q^.#]>:81C/"G';"=1^'
MZXXY]*_(?4/^"LGAU/#.O:WI7[-_QDU670M)UC4)#!J/@270DN=)TV?4[C^T
M-;TGQ/J]Q9:1;I`;B_U:#2;[['I/_$P6QN6'V.OP_P#%7_!2O]L?Q+\1I/B'
M:_&'Q!X99=0FN]*\':"\-MX%TVT:>8V6F3^%YK:ZT[5[>U@F^S?:M=M-7O+L
MVX-]>W=^!CSN%O"SB?BAXR6'J97AL/AHW>+GC(8R$Y.]H+^R'F$ULN:5DHIK
MXM4CB3CC*N&/JL,;@\V>(Q#M'"_4<5A9)=_]NCA%UT76W0_LFU'3].UBPO-*
MU*QL]0TO4K.YL+_3K^WANK&_L;R(V]W97=G<*T%S:75O+/;W5M<JT<D;,KQL
MK$5^9.O_``0^+W[$6MZG\2/V2=+O_B+\!M3O[K6OB3^R;->3W%YX?,\AGU3Q
M3\`KVX^TW-A?Y+75WX";_0K\@V>G"[/]C6>C?(EE_P`%N9O^$6\'I_PH!O$W
MCK5;&UL-3M=(^)VG6=O<>(+>$PW]U9^%=*\/>+_&=A875U$;NQTW4[$78L)D
M3[7>;$O;Q\__``4O_;;\7,[>%/V=OA9\,[)FYO/B[KFH:5=PVA!Q>0:)X@\5
M_#[Q+JV"T+!M&\*:J<DYLST/R]:"X5J8W"Y[GG".7T:&+^IYSE^<\7Y)%.>#
M;YOK>$PN-QF+P>+PR<GS/"83'8.]VDVXO[C"5,UJ9=A,WI9!Q''),PP?UW!8
M[&\.YOE.3X_!_P`V#S?-L'@LJQ7+M?"8QN]M;:'J+?\`!<7]FEVLVL?A=\=I
M;:2[DCU">XT7X?V=Q;:<+&]FAN].@@^(ET+^=]06QM39W-QI*K9W%SJ`NR;(
M65Y^L7PH^)WACXS_``S\%_%3P9=F[\,^.-"L=>TXR26C75DMY"!>:1J<=A<W
MEK#KFB7RW.E:W9PWMRMCK-E?V37+-;L3_"'X@\)^(O"FH+I.O:/=:;?%(O)A
M?R;B.>'_`*<9[?[7;:ACUM;N\Z]>M?J]^RQ)^V[\./@O9:?\"_VBO@AX)T[6
M]9U7Q++\(OB)?^&],\8V.J79M]*40W/C_P`!W?AZ%]6@TRRO(],LO&5M9J92
MS6BW]UJI/WO%?!GAUD/!_"F<87Q&R6-?/U@U@\WS?.,)')N(X?4^;&8K)5@\
M-C,6HJ24E!+%_P"R.V*Y<2OK#_,,GX]S+B#B_/LKH\-4,!E6&Q>.6#P<L?A/
MKF4X7#2O@\+C\YS3,L%E.,E]CVEL%]:Q6N$7U7]POZIF9$4E@#A?FX)PHXW-
MD`A5XRQ``QT]?SMC_P""J_[!),C+\>F.TLF$^%WQC>)F[&"5/AULG`Z_Z.\G
M(Y)Z'\M=9_:3_P""M7@DI)\0+CQ'HFBOYD<OCC0/@GX`^)_@:T0#'FWWB+X8
M:-XKAMK;`PWV6SNSQ@V7I^&<)7RE\O"KL^1!_!_];\_6GP)X6X7BO,,0L1Q)
M@JV5X7#3YEDE#$U,5BJDE%X58;$YM@L'@?J\=)8MX=8J=JF$;CA%)2E]#QMQ
M)C>#<BCC<7P[C'C,=C<'AL#C%G'#V+R?"83_`&OZV\=_8^-S;%/%XQ?5%DZ6
M)P<7_M;?UNR4?[WF^+WPX3X6VGQLN?&.E6'PLNO"=AXWA\9ZH\VEZ4?#.JV5
MO?Z7J4_]IP6MW;?:[:\@$>GW5K'J9NYX;!K(7["U/YP2OX]_X*+7!UGQ#-KO
MP9_8'T>[^V0VEW<S^%_'/[3_`-AE!BO-;F)M;GPM\'R%!^R%A>:S@MDW_P!D
MO?!_YU_L0?L0_$K]LOX`:6WQ"_:-\3^'?V?O"WC75+'PI\*/#MW!XD#ZO83_
M`&[7M2O[.?6SHG@^X6?59SHUIJWA[5]8(U74M<2QTBRU6TN_$?ZB6'_!)S]F
M*>]34?B-KGQL^--S%'"L9^)_Q2U.\$?DY`\FX\+6'A74<@GI]K(/KC->+C<K
MX=X2S+,\OJ9_]8S;+\;/!_7<#DTL8L%3@TKX-8S&8+"_VC*ZBJBQ%2&#G?ZH
MWBDL6O4RG.\?B\LP>98;)U0KX[!K%)8O-4G@Y--J*M@W>ZM;%O"K3_F$39^(
M7Q1_X*#?M9?"_P"*_P`4OAS\(_BWHW@_X3>`?B/X\\%?#3PMX7^&WP@O/#VA
M^"/#OBO5=)\,66CW5SX#U6:ZB72+2T'VR:XN6N_^/X7UW]K`'Z?_`+*G_!6C
MX+V_P'\*P?M/?$_7'^-VGZEK^F^*IX/AQJDB:[:MK%_?>'==L&\">''\*VUC
M'H5]I6BW-L3I6K?VSI>IW9T-;"XBOKKX1_;I_P""8/B/X,>*F\;_``/;3M4^
M#_BW7+2RT;P]K?BW3-/\0>!]8U7SYO\`A'A>^)]3TK_A(/#Q(G_L75/[6O-8
MLM'AN1XN^V?V5=^)=9_57_@GG_P3[T_]G'X>:]J?QGT7P?XM^)WCZXTRZU.P
MN=,TGQ+I_@G1M,@N?L>@Z;JFHVMP9M1GGO+VZ\2W6ENNE731:;968N4TI;^]
M^@SC`^#&&X.P53*\WQF8<4TW@IXJ$,W7^L<HXUN6+6;Y/B\3C,)E$%['%/!S
MC@WA+818;!XW&7G(^<H<7>(F=\8X_!9KE&3X'AZG%1]A@^'<GRC#87#8/`U\
M%E4\+G&"RS"YKF]2K**GC_K>*MC)5'C,4EC,+%866^_X*]_L;17$<6GZ_P".
MM>8VY=?[*\`:[&WG`3`01P:S!I<_G_N&_>8%H`1_I)P:_!G]M_\`:W\8?&[X
M[_$K4O!'Q`^+^D?!G7Y/!T_ASX=>(=>US0=(LTTOP5X=LKZ^?P3;:U=:+9-J
MGB"'5M>M+QK07E[::K;WX55O`H_L>L-,TW3H_)TRQTZPBW^;-#96D-I%([KR
MZQ6PC0A\9.XD'.`-N,_!W[1W_!.3]E?]H37/%'Q*\>:9XD\)>.=;?3+_`,3?
M$;POXSO-/NI+'PWX?M-"MUFTSQ-)X@\`Z?I]MH6E6-M>7,'A>SO`MBMRUZCO
M=O=>)P3Q+P7PUQ#A,TQF1YO7PV'^L_[7B<WPV,GA+N\<7AL#ALJP4>>-GA;?
M7+J.+Q6,4N96CT\397Q#F_#V;9?@\SPF#Q&(PN&Y<-AL'B,,LS<<5A,1/!XK
M'8K.L3/`8648RQ3Q6"P[G]:P>%P4O]BQF,Q"_'/_`()N_MC?M7Z"GB_X/^`?
MAEXD_:@M$TB'7_#_`(>U7XA6_AYOAK#;3V^ESRV/B/Q':ZQ:6_A>[FO+%6\,
M&ZM+3[3`U]H'V(W6KM=?IC+XS_X*W^,FGCT3X-_LX?!RUFSY$OC#Q3+XMUFT
MS&3D7_A/Q1KFD3G<&(W:`?O6V01]IQ]B?LR?LE?!G]DOPOJ7ASX5:9J)NM>N
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M$UGQX/`OQL^*/[/_`,/=$M-*D\0>+?A_J/B'3X/$_BJ&4IHGAEK;0O%7A:VO
M[JST[4-<U1KRYN]5&BQF&T-H!X@M+P_J#^VY^TQX,^-7A#3?ACH'A2ZU#P])
MJUMXCO=;\8^';.&WU:"QBN(=)?P_I>L1W%V+*\-S<7+:E=6VE7(%L+%=NZ^`
M[K]CWX^?$6Q^&UM\,_`GP1T?QEI?P]B\N4^%O$_A[P/J-OI>JW=Y<64G_".7
MMC%;:PPG6XMKJ[TJ0,,P_;MUYNNKWY"?TP>$,3EB\+\%D?M\7'!+"?VU@LKA
MGW#F+>#MC']3X?6"QV)Q.,^IOZU+&K!8S!/%.6+CC%)Q2^9CPCS<=2X@J<0Y
MI.$DL9*&'AB:&:/_`&1818.6)P\,/B<-@HX5*2^JPPK^J*.$M]528:?_`,$U
M?C%`V=0_X**?M8W,6S]VFG^,?&.G['SU#R_$/6!GG[H`ZG)`S7YN?MP?\$XO
MVJ=*\9VGB;P?>_&;]J?PGI?@#3$U'QYXR\4V7B[QUINJ?\)'XB$W@W1/"]]X
MBU7QYJ&D:;;36&NV(T+2[VU%WXAUH''^E@?O(O[5-MHQ$?COX*?'7P7L^:XU
M*Y\!W&K^'XCR!LUC1KJ\\U3@9_T<=8P/O<9_B7]MGX%6'@[Q-KOA_P`96^K^
M(=(TRZ;3?"E]I7B'2-3O]<V-#8:;/!J&FV953?&$7TUMO%G:">ZSY:ACAE/C
MUE_#>/HYQ'.N'<"\`L9BL5@\?E.4Y!C,5A5AG]<P[PBRC+\W494[*7U-<R=K
M)ZI_8YID639ME^+R['8G,:BKX.6E?/,ZK/"P:6*6*>%KYG!W@US)8I8J+6DH
MM6Y?Y]_V/?\`@E=\6/CMJVL:G\<-!\<_!+X>Z98SI92Z]X=72/&'B'Q"S0+9
M6MAX5\46_P!H@T:T`:[UK5-4TK[)?;;?3]-#/=W=WI'ZE>"?^"4\OPKF&H?"
MK]HF_P#!NM*-@U<_`OX,ZI>M$.3NN)M!MK];@S%72Z^W;K<&YP/])8CZR^!G
M[77PZ\8_##0];^(WCOP=X6\9VWF:1XCT[5-8TS1IKB]L2/\`B;6.E7%PERUE
MJ=O)!<K<VUO]A^UO<V5IE;8`=GJ7[8G[-NE\3_%31I4PN1IVF>)-8ZC'_,(T
M6]R2.XP!Z#MMG7CWEG%M;"<3XS.>#\MH8G`X3ZEA,RPG#C^IX.WUSZJEG4<;
MC(RUOB8RD_>3OIHUP_D^#X<R3^R,%GV<T,!B9+%XM+B/-LIPF,Q3>DG@\'CL
M%A%;LEZ]S\<_^"D7[&/[5-U\,O#/Q`U?XW>(?VH-,^'6HZQ-=Z#+\,?#7AWQ
M/X.TOQ#9V)UWQ'83^%C>:CK'A\'P]H8UG2^&TG[-;ZX<6":O>6?YH?L+?LZ?
M%/X_?'GP;:^!+CQ?X2T7PQKMAJ_C+XG^%[F;1[OP-H]G^^FDTOQ$;6[MK#Q1
MJT$$UIX8M`+W-Y<&^O[+[#:WE?U(Z_\`ML?!K1M'U'5M/3QQK\-A#.R36_@3
MQ+8Z?-<C:+2SGU;6M.TJVL&O)Y;=%>ZP0)@>>0?GC]G/]M[6M6TW6/#WC+P7
M\2_B5XP.M:OKMF_PY\+VNNR6GAS4[R&<0W]F=<M9[&PTN^OS9V=TRBUM;&?3
MK#<#:HUSZ>`^EADF0Y?3X)5?)<RQN=8/'_4LXRGZHL)@^=2O'&8+)L#+!XW&
M8R^+6$NK_P"RR^N1DHQ4OD\R\/\`)<QXAP.9?VOC525KX)O%8R[P6NF-Q.+>
M+PGHEB[O:U[GHD/_``33_9VU4K)\3]9^-WQSN4*.]Q\7?C1XYUQKB56$OFW$
M.C:EX?M+@^>3=;/LHMC=C<$&"J\-^T5_P2S_`&>OBE\*O^$3^$OA+PK\&?&^
MC7L>J>'?%^DZ3->&]EBAFBET+Q5/<SW&J:AHVI"?:;DW-W?:1=Q6NH62W2K>
M:7?_`$E_PTEXQN"8[+]F;X[R2G_4?;M$TC2K>0$=9KBYU=E@P>>0>O2O-/BM
M^UQ\1O`/@W4M<O/@%XI\(B>.72-,UOQ9KWA^WM+77K^TN&TDQ:7:O=W.L&U>
M"XO+RUM%"FSLI/\`2R6ROR,O'&ODT(9M/B?B:GA\L4<7%QROB/ZG!0^&V"6`
MA@)*WN\KI*-K1LDDH_7XC(.%YX:O2KY1@_8XA?[6_J3^MN]M98KE^N)]FI_F
M?`O[''_!(?5/A[\4-*^)_P`>/&7P]\:Z5X-U26\\->$/`ESJ^OZ1JGB+2Y[B
MW^T^*;_7M%T+;!H.K6^\:#;V5Y]JUBQ4:C>BTMKJQO?UTU;]E3]F/7U<ZW^S
MM\$]0;R_)%Q=?"[P8]XB$<K#>#1EN8#GO!.I&3AA7YI_L<?M7?\`"N4\0>!O
M&6E^,O%EEKNJW/B/19O#-D_B/6+#4I8KBY\1RWMA-=C4I]/NX8%U-OLGVLVM
MW!J5ZUFRW-Y=6GZ7>$_VI?@'XPD^S:9\2-`L+\.(6T[Q-)/X3U!;@_\`+!+?
MQ+!I;7$ZG@BU$_3(RH)KSLM^D##Q,I8'/\RXCPF69O72P2RIXN.3/!O!MOZI
M@Z<)X&&*:;CBN:,9MK%<S4=;YY%D?#.6X!8/`X3"*.(U<<6UC)-[6;QB;:[*
M_F?'/[4'_!+GX!?%GX9ZUI/PA\$^$/@]\3K>\@UOPQXCT/3_`.S=&O[VR@N(
M#X=\4V,%M>;?#.JPW&;R70[>UOK/5+;3=04W]I:7NBZO^1WP4_X(_P#[3'B3
MXFZ;IOQF\/Z=\._AI8:C%<^(O$=OXP\+ZW?ZYI$%X1/IGA6R\/:SJ^I6^H:E
M`/\`1KK7;/2;73UN/[0=;N]M!I%Y_5?;W5O=V\=Q;3Q7-O,@>*>WE6:&2-OE
M#0S1$J5!!`93UX[''"^$_B3X.\<:QXX\/>&M46^U3X>Z[%H'B:V7*_9;^:W6
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MVR#]WL`#/4`G.22?7Y>,\CG(]NU0EQ@'G&QCMQ\QQGD'/`!YXQCG@G->/1XL
MXBHXG#XN.:UJ\L-B\+C%'%S^LPE+"24ESQE%W^'EUDERN76S7TT\NPLL-6PL
M?K6'HXB$\-+ZIC,7A7;$W4K<N+7KL[/97T7\$&@?![XH^)OB)#\)-%\!>*KK
MXD3:I_9#^"FT6[M]?L[Z#F>+5;*XMK2YT>VM0!]MN]4^QV5I9_Z??FSZU_3O
M\,_^"/W[*.@^$_"Q\?\`AKQ#XC\<0^'-"B\7WMMXZ\4:?H]YXGBT^#_A(;S2
MX-'N-(N(-/N]5-X]I;AEV6AMU(RIQ^M2A%*YV\]#A5'H>`.?8\9[TYB"&PY!
M!['D=<]<8Z?GD'C!K[3C'Q<S_B;^S%@Z/^KRRV,KO+\;4>)QDI)1YGB7#"RP
M\4[\D5JF[N39\7PKX>9?PXL=[;%RSAX]ZQQF%@L*NMGA4Y1Q-^K?1'YU:M_P
M2L_8@U#PUK7AW3?@\=`N-5T^^M[/Q'9>-?B!?Z[H&H7$06VU?2Y]?\3ZM;BX
MTVX2&[M;6\M;S2;DQ&SO[&[TZZN[.Z_+_0?^"&_Q1'Q%AMO$WQ@\!'X40ZKO
MN-8T6'Q&?B'J&CP#(B@\.7VBGP[HU_>?-:C_`(JO5[32/-:]VZP1]B/]*R[A
MCD'/J0,_09]CSSP!@4-D@C('/!P"!GU`Y'3\^#7A95XE\;Y/#&4\/Q#CL1]:
M7+)YM+^V''1I2PBS!U73DKZ<G5)N,FDSU<PX%X5S*>%G6R;"4/JSNOJ:^I7T
MVQ/U3EYEIU\]3AO`GP]\&?#3P]I/AGP7X=TKP[HNB:7I^B6%IIMG%`RV&EVD
M%C913S@?:+V=(((4:ZN7DN;C:&=F8DGO"HP?3'N>3CGU/04T#C*MGVQ_B>.G
MY4\$'UXZYZU\1.=6I.52K4=6KJW)MZMZ]92>[>[ZZ)*R7UM.$*45"FDJ:3LO
MZMH?EAXL_P""0O[(/BKXB2^/O[-\>>'[*[U4:MJ'P[\.>)=.TWX?W<IF\^\M
MX;.3P]=^)=,L+RX(=M.T+Q1I%GIZ?Z'H::18#[(?TP\/>'M$\*:#H_AGP]IM
MIHV@>']-L='T32-/B6WLM-TO2X(K.RL;.W7Y8;>TMXHK9$4855&?6MH#``7*
MCMENN?RX]_UZ"E`!)R"/7GC_`#W')_&O2S3/\\SBEA*.:9GF&8T<!'EP2QN-
MG4C!62M%2O9-+5N4V[:NS9Y^`R;*LKG7JY=EV$P%;$6^M/"4U%R?G;S[)>FB
M'8!4\#)&"`0.X[C\Z_-;XY_\$K?V7?CQ\1=1^)NLP>.O!GB'7+R34?%%M\/]
M=T?1](\4:Q<3"6]UC5;'5_#OB!H-1U'`;4+K09]&-[<M<7MYYFH7=Y>/^E(4
M+G)X/'I^N?K2,N.@'XGG]2/ZU&5YSFN1XKZYD^98W+<3R\OM,#-TY\M[VYHZ
MVOJDT[/56=RLQRK+LWH?5LRP6$Q]#?EQ<5)7[KL_1GGGPU^&O@OX0>"?#WPX
M^'6@VOAOP?X8M&LM(T>R\]XH899YKB:::>Y:YNKR^NKJ6:[OKR[N9+J\N[BX
MO+MV>0D^B\'(XP`/Y'^5'4<$`8]!Q^O%``Q@8V\Y.><_Y_SCKP5*E2M4JU:M
M5UJU9N3<FVVVVY2DVVVY-N[UO]R7;"$*4*5&C25&C15DE:UK6226UM];?B.H
MHHH-1K+N[_2O./'GPI^&'Q0AL;?XE_#KP-\0;;2Y)9M+MO&_A'0/%D&G32E?
M.GL(?$&G7JVD\ZPQ+(UNJ%O*0Y(49](/3GCMG^O3CU]!2#'3<&ST'&?_`*]*
M$ZE)^TIU'1JVW4FG\I1E%KMHU\]C.I"%6/LJM+VU)K9V:^9E:7I.F:%IMEHV
MB:=8Z1I6FVT5EINEZ7:06&GV%E`OE6]K9V=LMM;6MM;*`!;VZA44!54`JM:N
M"1@G/L/ZGJ?T^E.HHYN;WI;ZN[_,K2-HQ7GKLEW84444R@HHHH`****`"BBB
M@#Y_\2?\G3_!K_L@/[2W_JQ/V4*^@*^?_$G_`"=/\&O^R`_M+?\`JQ/V4*^@
M*`"O@#_@K%_RBR_X*6?]F`?MD?\`K.OQ&K[_`*^`/^"L7_*++_@I9_V8!^V1
M_P"LZ_$:@#Y,_9E^!GB[]H7_`((Q_P#!*'P/X,U'P[IFK^'?@O\`\$A?C)J%
MSXFN]3LM.G\*_`>^_9F^,7B^RMI](T;6;IO$&I>%?`^IV7AJUGM;2SO-;GTZ
MSU#6-%L9+S5[+K_BW^PU^T+XO^/?Q2T/PKJWP97]D?\`:3_:A_95_:\^,NOZ
M_P")O&UG\?/!OC?]F:S^%/\`:GPX^'_@*P^'&K>"O&7A;XLZA^S9\#MWC37?
MBUX#U;X<VFK?%$6'@SQBX\-J/H3_`()._P#*++_@FG_V8!^QO_ZSK\.:^_Z`
M/Q\^+?[#7[0OB_X]_%+0_"NK?!E?V1_VD_VH?V5?VO/C+K^O^)O&UG\?/!OC
M?]F:S^%/]J?#CX?^`K#X<:MX*\9>%OBSJ'[-GP.W>--=^+7@/5OAS::M\418
M>#/&+CPVH^C?VI?@W^T#\6+?X,_$GX::-\';3XU?LM?M.CXP?"3PKXV^)7C:
MR^&_Q3\"7_@+X@?!;Q5H7Q`\<:-\'/$'B/X4>)_$'PQ^+?C+4[!]`^'7Q=L?
M"/C+0_#2_;?$NBWFKFU^]J*`/Q%T3]AG]L7X*:%\"_C5\$=0_9N\:?M<:*/V
MX'^-_A;XD^-OB;X$^!%W??MZ?$ZP_:%\8S_#OQOX;^$OQ+\:W%O\$?C%X.\`
MZ1X-M=<^&7AUOBG\-[?Q)_;MY\-]?U6S%C^G'[*_P+L?V8_V:_@+^SMIVMS>
M)K7X)_"7P)\,?^$GN;06$OB.Z\'>&]-T.^U^6P^TWG]G_P!NWUG<:I_9@O+L
M67VG[$+J06X9OH*B@#\8?^"K/[%_['?Q%^'WA+XQ?$+]DW]FOQU\7O$?[:W_
M``2\\$^(OBGXS^!'PN\3_$?7_!GB7_@HC^R7\,O$?A#6_'&L^%KSQ+JWA?7O
MAOK6K?#[6M`OM5N=(U?P-JFI>%+^TN="O;NQ?*_;!_X))_LV7WPLME_8Q_9!
M_9E^!OQ<M_%.GW5QXA^"_P`"?@E\(==\0>$UTC78-0\(:UXO\/:9X(U*#PS=
MZS/X=UZ]M([K65NM7T#1BVAW/D?;M+^L/^"E9S^SO\.2/^C_`+_@E!C.,\_\
M%2OV-P>,Y.1D?4CG-??AZ=1D9P>.AZ>O3/?U/'4!T,9C\!B*&/RW'8O`8["X
MN.+P>,PJPM\+4PG*XNV*AB\(^O\`O&%E>[]WW3EQF$HX_!8O`8E7H8["8G"8
MJ*=FX8N+BTG;7?1;;;Z'\C'P^_X)/_M>W'C;P^OQ"^$$NG>![?7-+F\3S:=\
M1OA:^J7V@PWD`U6RT0VWC6[^S7]W8"X^Q7=W:`6G8_\`+G7]!\O_``3N_8LN
MVE:7]GCP.LDYD:3[,^MVD:O*,OY*6FLVR6V2"/\`150<9&,@C[8*D]"#V/S'
MZXXY/`XX/Z8IY`4'G![<]LGDXY]_3@?2OI^*N.>).,,90Q6<XVU'"X/ZIA,%
M@8QPF#PMT_K>*^*6+EB\;[DL7]9QF*PR>&C]4PV$BG&7SG#W!F1\.4*U#!4'
M76(:<GCEA<4]-K/ZJM'UO=6/R;_:4_X)D_`;6O@MXQTOX#?!+P_H/Q3N7\*_
M\([J]MJNI?:[>UC\7^&I_%,5E-XG\0G1[>\N/",&NVEG<73!+.XN?-LE6\V9
M_(6S_P""0W[70UJ-+[PGIA\/K<`S2V_C'P6-8FL\\$V)\1?9K><=6)U:\`[_
M`&O-?ULM]]5(4Y!))8#@88`#@XSW^[SVI-B@EOE#`$;@/J0,Y/`()QR3SCIB
MO*RGBCC#AW^TH<.\5YKD^'S+`RPOU+#X;)\7A:>,L^7-\)'-<HQOU7-%[BYN
M9X9_5<(WA6\+&SSK@SA[/G@_KF#='ZA*]\&U@_K46\*^3&<L?]LPR6$CR*6N
M%YL6L*X_6\5S?%WA;]A3]EVT\.:+"?@P=`F32M-%QI!\<>-IYM.N%LX%ET^>
M_L?%C6U]):D&U>YMLVUV8-RDQLK5Q/QN_80^"VI?"OQCIWPZ^&VL0^-;O2HX
MO#[Z)XRO9+Z2]^V68,,X^(>M:KX2FTZYA\VUUJ'5+-KNYT:;45T6[LM>>PO[
M7]"U0!"`,#&.0%';/?//&,]^_6@JI4#&>G3YLCD>O;H??VK\]Q?!'"V.E6JU
M\AR=X[$)MYQ_9&4O-5BVK_78XQX%M8WG7UN.*NW]9]X^BIX/!TER0PF#T=^5
M83"<NCW>'Y/J_35<MNFS/Y?]/_X)1?%JRUVWU63X2ZM?VL-Y'<_V#=?$#X>3
M:,\0/^HN,>(;349X/1?[6#'L#7Z?Q?\`!*/]D;5[&QOI_AS=^$=5O=/LKF^T
MVTA\"W\^E7<]G$;O3IK^X\+:Q;W)M9@+8S6UU=VA,!%@ZV.T']0,`#.!D'[Q
M()('4$KCG'?\":,#;CKC/7GJ>,-G(QVQSUZC-5C.'*V?5*-7C3B/B3CYX;"+
M"X-\79IALP64P3;:P7U;!X)1GC%RK&XJ[EC/JF$^M<WU6-N;(<IP7#$ZU3(X
M_P!GUL1N\(UA-E_U#*%EJF^^W>_X]_$S_@E1\";'P1XOU3P[)H.GWVF^%_$.
MHZ>WB;PCX(TW2$O[/2;B:R;7/$?A;PC:ZWI&CI+;P-J.JZ5;7NJV-J;J]TZT
M>[Q`?PBN?V9=+FU%;B/Q%-8V+/$]SI5M9_;-@_Y;PV.JW%S:7(M_^?+[5I7V
MSK]OK^UU63'S;5(0$*&R,'`.0,C`8E0<\X!(.:8RHH8%4"@Y#,J#).[@G;\N
M#@>WZU&#ROC'@[$U:WA1QWC?#E9AA'@\YPL<%'B+!YO'FM@Y/!9WC,7@L)C,
M"I8MX;&8/"QQJ^MR?UJR:2XIRZ'&='+\/Q'7QF;QRY8OZC]=QN:XOZG];4;_
M`%:^-7+AF\-%RCJL3HM.OY2?L_\`_!-G]BW5_"O@KXI6'@L^*+[5=$TR\@U7
M4H-`TW5+:XMX?L,]G-JWA?1M)UO^TM+G@FTV]N6UZ[O!=P7(^W-UK[5O?V0?
MV6M6T&3PWXC_`&?/A#XR\/SX-SI/COP#X:\=6=T<?\O">+].US[0!CI(6&<<
M=Z^B$<D;<;5"(P)QD'C<I&1QDY`'U.,U9ZC`Q@'GKSQZ+U/Z$C(]NC`\+Y/A
M)+&XC+L#CL[MS8S-\5@U/'8O&2Y98O%2QF,^N8S_`&O%<V*:EB\2U*5TVT=U
M.C2IPHTTE:A&.&BU:_+ADDK[VMOOU^9^1EG_`,$JO#F@Q2:=X-\>^$/A_P"&
M4N[ZXTCP9X`^"FD^$/"/ARVOKR:^.F>'_#F@^,K/1M&T^UGN)38VNF6=K;6N
M20OK]'_`S]@;]GGX/Z)?0ZE\)/@7XP\::IJ>JZCJ_P`2(?@7X$\-^,M?;5&$
M\[>(];@M=4UO7]0$YG7^U+S5OM36AM;/:!9H[_<*X`QTZ#CE03GIG.0,`9SG
MKR:>#@<],<-UY]`.V/Z<CFO)RCPYX,R7,,;F>79.HXS,5/Z[+%8W-,;'%?6I
M/$R6+PV-QF+PK;EK?D5FK7Z.88/#4)<].BD]4WO=>C;_``U[6/@_XK_\$VOV
M.?C+IKZ5XV^#F@7UJYEVP7$::QIT9G'[[RM"\3Q:_P"'(2>,%=(ZDYQ@5^''
MQ7^`/[/7PY\>>)?A_P#"KP=X?_X03PN\7A;2Q_PC_AO3XXX]$L[?2IX-+A\/
MZ'I.FZ?86MQ!/:6=UI5I:?:[."WO06%WN/\`5J,@8)&<'/?)(P3GG&,\CO@<
M<UY%)\`_@8Y9G^#GPM+.V]V;P!X4+/CJ3C21D_X'KFO$XNX"QV,PE"AP'F6$
MX%KK%<^-Q>4+&Y0\7&,?]DPLEDT\&M,7_M4I-7<H89)M*QRXW+:>*H>RC[NN
MZ5_NM;1]OUN?C1\+_P#@E-^S%\=?`'A;XC3_``X_8V\37FJZ)9:?>ZEX\_X)
M]?LO_$CQE!?:)$NE3:=XE\;^-/#6I^+/$M[IILA:_P!KZY=-?:M9+:W^\"Y6
MN^'_``1%_9<&<?!7]@<=CG_@F#^QV/R_XHOD=\C^8K]D?#?A'PKX-T]M)\(>
M'=!\+Z7)</>/IOAW2=/T6P>YD2&&:Z:ST^WMK8SO##`CW&W>Z6\"EF4!1TH&
M1TR.0`2".?;J,=>![\"O?P?!M-X3"/-LVXCQ^9_5E]=QG^NW&[>,Q<HI8O%_
MO.(W)_6W[SDVV^:S:BD=4:*Y5[6IBG5T3?UO%[]'JWYO5Z:NY_*M\1/V</@)
M^SY\4/$?A;X1?##]G;PQ?:,AT#Q!XL^"7[,?P0_9YGUB<F&XO-#UH_"KPWI-
MSKUMH=]"+<KKEU=BSOH=3%A9VGVLM>^W?LX_\$^?V8OCAX5U'5]*_8M_X)E>
M(-=T+4H].\0)\3?V(/@IJGB6[^V0"^A\1ZKXAL?`HU'5]0U;%VAU/4U^UWUW
M!J%YJ/VR['VN[_HW$0/)49XSN''N<D9_7_ZRA0.%4+ZXV@'\@,\^N3_.OB\G
M\*,PR[BK,N(:_&><5Z&9N2Q6"4\WPV+>$C?ZEA'G&(X@QF-Q:P7?&_6NMK-H
MYX8"4,0ZZQ<Y;^[9+TN[O16T26OD?BC'_P`$N/@5IR[K[_@E7_P1_P#$)*;A
M%H7[*OPOT@DYQY6==^%\B`_\ML[L84KU.3\S_M"?LS?LI?!W^Q=&T7_@FA^P
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M3\+0^&;BWTOQ/)X>_8O_`&?KOXJ^+7O(!/#XE\1>-]8\%7FHV^HZV?MN-?MK
MFZNM6NK.[OKVU%\6NF_7KP)^P1^R1X"\$M\/+;X&?#[Q/X2;3CI%SH'C;PMH
M/BOP_=6`82BT_P"$6U;39/"=K;$G_CVTS0K&U(!!C!#9]:^&/[/WPE^#VH:C
MJWPZ\+2>'K_5;+^SM1<>(_%.JP7-L)H;D*;'6=9U*T6<36X;[6+<7FYK@>9B
M\NM_MI``R/E)QD\Y/7`."2!_A7?PAP;+!95E<^+*>$SCB+`7;QDL9C<XPL6O
M=PLL"LXYOJ4OJG)&2PF#PFD4KM62*&&Y()8EJO66\WKMM9/9?(^=?!/[(O[*
MGPW\-67@[X=?LR_L_P#P^\(Z7)>2Z7X4\#_!KX=>$O#NG/>WEQJ5[)9:%X?\
M/6>F6KW=_=W%W>-;6J&ZOKBXO'S)<NQR?B-^Q3^QQ\7=&L_#_P`6OV3OV:OB
MEH6FZBFLV&B?$?X%?"[QUI%AJ\-K/8PZC8Z7XH\*:K:6VI?8;Z\LTO+>V6[2
MSO;JU5Q'<NI^HB-H^4<Y]_\`]9'MT[T<D<@#V(S_`(5]NLNR^.(^NQP&$6.U
M_P!L6%POUK6ZOS\JE=IO[7>]SIY8[]-_+\K[>9^?Q_X)/_\`!+3`/_#M;]@(
M\C_FS?\`9U!Z'/3X<?RXKP_XK?\`!,'X2Z5J.B#]D/\`9Q_8^_9OTZ"PO5\2
M:E\-_A'X-^$>O^(;F^NH#]BOI_AQ\,%>YT:UM[&"Y6VN=4VWMW<3+>V0^R65
MV/UPZX.-WODC]"?I[>M+\I)&!Q_+V/MWZ5P<0Y#@.*<GQ61YJ\4\#BDHXE8:
MI+"RDEK925W;TOZDU:4*T'3FKQ=M.NC[K4_)_P"!W[`.I>&O&,LOQQ\'_`'X
MM>!+[2-2T^\T7Q+H2^.KC3YKDQO;W>BV7B[P&;.(7`@_L_4(S>6JW5E/-YBW
MC6=FH^@=>_X)I?\`!.7Q4SMXI_8"_8H\2.TD<KMKW[*OP-UDM)#$(8)/^)CX
M$NANM[<&!">47Y5P,`_;Q!/7Y0/H?\/\YI5&!P2?PQ^7M7'PQPADW".`CEN3
MT91P_P!9EB[XN3Q>*YI;OZU)*;=TN5MZ:Z$T:-+#PY*:Y4MKOOOJ_P`OF?EY
MXV_X)+?L9FXT#5?V?OV;_P!E#]E[Q5H]Q?RW?C?X0_LH_"#PMXSU*TO+/[&-
M*A\4>#M,\%ZU8:2RR3G4=-^UW=GJX^RB\0"U&_F(/^"4GPNU_5M#C^,<_P`,
M/CWX$TW5K?5-4^&?Q?\`@!X6\=^"]=\A9H3]HT/QAXA\1:)]NMK>YG&CZK=Z
M1?76CW7V:]LP3;"-OUH)SQN[\GA>/;/)Q_G/%*RC'&`,>@Y''?\`SFN3,^`>
M%LXS^AQ1CLNE7SS"?5'A,8LUS?#/#/!ZX3EPV&QT<(N63;_W2\KN]]6)X7#2
MK*O.C%UDM)MNZMVZ.W8_/\?\$G_^"6>,C_@FK^P!C."1^QO^SI]#C_BW`(Q]
M/2M?0_\`@F?_`,$_?!=Y)J7PU_8V_9U^$.HSV\MI>ZC\$?A9X6^".H:O9--!
M<?8];OOA/IG@R?7K:WN+=)[*VUN>^M[-C.UDMO\`:[LO]T@9[\>F%Y_[Y/4<
M<_E2D`]>,=_Z_P#ZZ^HQ>"PF8X2M@LQPN&Q^#Q*Y<7@\9AUBL)52L[3PN)4H
M23:3LXM72E:Z36LHQDN65K.V]KZ>NY\8:O\`\$__`-CKQ/ITNC>+_@3X3\;>
M';T0MJ/A7QU=>(O&_A#6HH9XIQ:>(?!_B[6-7\.>(-/:>"%KO3=<TN]L;QDQ
M>6LG?=\"_L(?L2?"ZUO+3X7?L?\`[,/POMKY)%NT^&OP&^%G@%I_./S^9-X1
M\*:1.6/=R=Q^\3D5]8#'`.#[DJ3]`,G^?>GY`ZX'ISV^G']:X<'P_D&`P=7+
M\!DF4X'`8A\V+P6$RK!X7!8J3CRMU,)#"QIR=K+F<.:VE]"52I0CRQI12[))
M?HC\;?VZ/^"??["%W\,=7\??$3X'>"_$NJ:<]O9>%-*\4^'_``UXZTJ_\1WL
MN-,LCI7Q$T7Q7:BPMC%+JEY:6:V8%C8W8L]K8!_,3PO\-O@;KNN^#](^)O[.
M'[,_QP\*Z3Y6@^'?!7[0/P@\!_$+P!X7COOL-C;WFAZ5XHT35[7PA/:V\$%J
M=2T*SM$M+,_8&4Z>39'^LAPIR"`03SGGD=<`Y''N,\D#BF;$&=JH/0!1G''7
MD9]3CUP<<5^7<2>$TLRSW*\YX<SY\'T,GO+!8+)\I]U8V4KXW&<O]JX7!*6,
MIJ.$DU@E=)1;E9,XJV`YZU*M1K/#N/2*3O?Y[]'HM+;K0_$D?L<_\$W/!Y\K
MXU_\$8?V1O`D:!7N?$OAG]C/]G+XC>#X(R"#<7.JZ!\.?M5CN8'%J;&ZNL<$
M-C->R>!?V$O^"+'Q*6-?!G["W_!-[6[J4?N],C_9&_9UL];PO7.AZA\.;36%
M]]UF!P<`D5^JA`(Y'&./0]<[L\'C)]!^''S)\?\`X;?`-?!/BKQ[\2?A[X<O
MXO#^F76JW6IV<"Z%K]Y=8,5A90Z[I)LM1\_4]0EBLK03W36_VRX1F&"37VF(
MAQ3D="KBJ>?97F^!PN%>)Q7^L.&EE>+^KX=.4I3S;*+X5<FLN:ID&E];N7*N
MM+$4US^T]OOHTDU;:SCOIY>NEV?+]A_P3M_X)":G\0M?^%]G_P`$[/\`@G]/
MXQ\-:+IOB#5=,7]CC]G?]U8ZI(PBQ+_PKI@]Q;))83WB*/\`1;76M,<D_:QM
M[\?\$G_^"677_AVK^P".N?\`C#C]G3C\!\-_0]\'J>@S7X[>%O&NIZ+XTL_$
M2^(?&.@QSW\4.KZEX.\1WFD^)O["GF@^V6>EZU<W5U<F=;#%M9"Z-W9\6WVX
MW?4?MWI?[,5GK6E:=K&F?M,_M27FF:M86FHV-W!\7?W5W97L,=S:3P$^'URM
MS#-&P+!20<@`\GXK@'Q5S/CBCF<L)PZZU;+\8[K^U\'A;X/%^]@VGBU*6+:B
MFL7BHJU]KO1\>$QSQ?M>2DTT]-5L]NF_3IKY'&?\.H/^"68/_*-;]@+\/V./
MV=AP>O\`S3D?RQS7BNB_L*_\$@=;^,7BKX*VG_!-S]@4^(O"^AV&L373?L>?
MLX_8KRYN#_Q,M)LB/AT2U]I5M/I5S<(,Y^TWR`)_9-X5]Y^(O[.NH^#O!'B;
MQ1I/QP_:[\4:OI&E7-WIF@Z-\3;W5-0UC4VVV^G64%G8>&[J_P#(:\N(/MKV
MULWV*S\^]=2+48_*C2?AO^T-8^*XO%LOPW^.C:K)J4E]JFKV/ASQ_9^)+\7T
MV-4E'B,:=_:7V_5+>:<7ET.\]SCIFIXS\2N)^&,?D6$I\)8VHL3C%BL<X8K^
MUDLH7^RO7`X1_5,9+%S32=URX5N[4AXO%U:,Z,8X>4KN\FE=+RNHNW=7OHC]
M09/^"5?_``2OB1I9?^";O_!/Y$12S/)^QW^SHB*!W.?AR!CWY(XK@-9_X)^_
M\$8?#I9=>_8?_P""8VD/']]-2_9D_9:LI`0)?W92X\$)*9,0RG&"Q,+``[7`
M^AM'_9`^`>M:?IFLZYX6\8^(9KVTMM1A3Q]XO\;G5;0WL)G\C5-,.LVD=O?6
MRSK;7EK<VQ-J\13Y61J[U/V:/@KIFFWL'AKX9_#_`$O5&L[B'2=7U+PAIGB9
MM*U`0E;._>'5LSW2VMR(;IK9;ZT^UB(AKN,S^97WZQO&=>DYT\JX>P[M?7.<
M;C9)6O=+^R\LP[_\*>[O8ZU]9_Y]X5;[RE?9_P`J2L]K?>?B%XR^`7_!*'3O
MVEO"^GZ-_P`$]?\`@GY??!C2[/\`X1SQ-J%G^QQ^SK/I^HW^N?9YKCQ/;SK\
M.?\`2K7PS<V]C;'[/`[?98M;-@UV-554_0'P[_P3T_X(V>+1&GA?]A7_`()H
M>()I"42+1OV7?V7K^8R<'RA#:^"7F$^<Y4@-D`D9YKF)?^"8\DCM*WQO4M(^
M]W'PX'7T);Q\",_GQTZX^NM!_9%^#R^"]"\-^.?!OA+Q;KFDZ='I]]XNT_PT
MG@O4==$&1!>7;:%J3ZB;[[,((+JYN=6NKJ\NX[B])0W+(/S[@O$^,4<?G\N(
M,KRI4,=BGFN#^N9Q04<&Y..%648;^RL3F>)P^%CA81E&4L*USO%WUD<F'_M'
MFK>WHQLW>.MUZ+E;T_K3KY5_PZB_X)9-G;_P39_8`/);!_8Z_9TSR.H`^'/U
MY/'ZUP/BW_@G7_P2$\$:SX'\/>)?^"=?_!/VPU3XA:[)X?\`#-N?V./V=R;J
M_AM_M!,KCX<@0VQG:QTM78D&_P!5TVSP#<C;]$M^R%X&TI0?`/CSXQ?#-8Q^
M[M/!WQ(UB/3E`&(HIK36/[7\^W4D$VS38(`'<$?C%\</B#K_`(A^)%X$^(?B
M3QOI_@B_N=(\(^)M9ELH[][>QNYICJ4!TY;.V;[5?B:YL;S:+TV0M0<?9,5U
M<=^)F<<#99A\1F608:GCL?BG'"+"YRL9@VL-+"SQEU]5PN-BU@Y3Y;85Q^MR
MPJ=[L>+QTL'3YIT=[6U3_&R=[>5OF?JI_P`.G_\`@EH/^<:O[`.>O_)F_P"S
MJ!]`?^%<\^XZ9SU/4/\`P2@_X)98_P"4:W[`(..`W['/[.G/U'_"N?KUK+^!
MFC_$KX__``[TCQQ=_M-_$2V:ZNK[3M;T;P_I'A#1)='U.':EYIYO;#23\[1O
M::E87+6Y:VLKZW*VEJS.B>P#]E..Z9CK/Q^_:1U<ND/F13_$[['8F6+!$L%I
MINCV:PLQYQS^.,U]AEW%&;9S@<'F.6<,8SZEF&#AC,+BL9F^482+PN+2DO\`
M=,5C6M'>]Y>J=T=$*\JL.>%+I=7<6G^'X6O\M5\D_$K]A3_@D%\+?%'PX\)^
M(?\`@FW^P,U]\1M>DT>T>/\`8\_9Q\G2+<1-#!J^IY^'*D6%QK%QI>EH21Q=
M7%\"4TJ\`]I'_!)__@EB06'_``36_P""?^,9_P"3./V=#U/!P/AP>,>P[XXK
M\T?BK\*?BMKWCWQ%>^'?A1\;KKPS!J-U9^&I_$/A?Q_K>IOH\$TXLII[[4=/
M-R!=$SZH+0DFSO-0N`3TS^BGP$^!&L^,OAGH>O:MX^_::^$GB^W>XTO7/#\O
MB_7=)T^6^LP"=3M]'\4:*T]QI^J6\ZWORJ+*SU6?4;*Q(^Q[J^%X5\3.*,\X
MAS[*ZO"\EAL,GB\H?UJ6#<L'A+8/%_[;C<%A<+C)8O&?[9@K/"WP3O+9'+A\
M96K5JT'AY12V;36W2[BD[_)HVC_P2@_X):``#_@FM^P#[_\`&&_[.OZ$?#G_
M`#^E4[K_`()5_P#!*RSB2>[_`.";_P#P3ZM8C/;6HEN/V/OV<;=6N;Z>"QLX
M0\_PZVBXN+F>"VM+?[US=301(K/(*]8/P8_:!TM5'AO]J?7C$OS&S\6?#CP?
MXH:<\_NYKU?L-W"G4,;<KZX/%?G?^V%\6/C'HVKV/P@\6^/O#/B)]%NM'\77
ME_X.T6]\-WEIJ@,TVBV>JK_:A_TBTAE@UO[-;#D7FFWRDW5JIM/H.)_$B?"F
M58C-,SX9S?#QC;"X..+QF0K"8K&2OR87ZYA<VQ.(N[2UCA&[*[2-Z^*^K4?:
M5*4K[Z--??>ZOZ/OKT^Q?^'4'_!+/.?^':W[`()_ZLV_9T)QQUQ\.<\<=OPI
M/^'3_P#P2T!R/^":W[`&3V'[''[.N>>Y'_"N/K^=5O@Q\0/VI/CQX$M?&'A_
MQM\%="LVGN=(O$3POXCOM;L-3TR=4GAU.*75+C3EN+^VEMM4#6V+?[%?6NRU
MMF)SZK)\+?VGKUP;W]J"STV)C*DEKH'P;\*@,DOW!%?:GJ=[=0-!_>P2<9)/
M!KV,)QG4S/!X+,<LX8XBQ^"Q^$CC,)BU_8.$@XR6EUBL_P`//F=GK9Q[V14*
MRG'FA2Q>NJT2NM]W+1?*^FGGX+XZ_P"":_\`P24^'/A'7?&OBK_@G#^P)9Z%
MX?LC>ZA.G[&O[/$\[JTD4%M:00CX<YN+J\N)K>ULX"1YEW+;ID9##;TC_@EO
M_P`$I-=TO3M8TK_@G#_P3ZO],U>QMM3TV]@_8[_9V,%W8WT,=S9W<(_X5P"5
MN;>:%U)P>A`'!/QU^VAK/C'PKX@M/A7JOQF\7_$=TL;#7?%-IJ=OIFDZ3:7L
MW_(*LX]+T=5`NA8[M39;DO9`WNFD,U^>.\_8KT"V^,NF^(O"/B'XP?''0M5\
M*P6MQI7ASPS\2KS2/#<OA6X$%LK6.F"WNKJ&;2[_`&K>K]L6TQJ>G!;4EKI:
M^$POB]B<9QW6X-P^2/VZ@\''ZWF^#6)_M?"QQ&,QD7BL(\9A'%8)/E3:E];P
MSC+9G,L?*6,>%]C:RWNMU]ZVTT['TT?^"4'_``2Q/'_#MC]@`GC)_P"&.?V<
M^PP2?^+<^Y[`>_%>+?'_`/8"_P""4GP2^&6N^-I_^":7_!/J]U&%8=.\.Z7/
M^Q_^SM$-4UR^W+:6F1\-]P@MX8KC4KT@KML;"Z*$,./KK_AD'P+(H75/'WQK
MU@JY:$ZC\4M??R#P<0BW:U(ZCOWKX8_:+_8^^)VI>,XK+X0^`O$&M^$]-TVV
M-QXA\0_$?1M2NM>U>8^=-.(/$_BVWN-/M].MYX-,11I5H3]BNKP"^-Q:FO>X
MRXFXZRCA_&5\NX5^L8[$6P>#64X_%9OC,)BL7%_[4\'ALK5U@W>;D\4L-HFV
M]<,]L15Q<:+G3H7:71I[];<J=K[^JV/6/`?_``3B_P""2_Q#\">&_'VD_P#!
M.#_@GY#I/B'2K;42)OV0_P!G`_V?<,?)O=.NIA\.!"MWIFHK<:9='@?:K=U`
M.!6_=?\`!,S_`()&6`1;S_@G[_P3CM%D)V?:_P!E/]F2W,F,?=\[P`N[&.O7
MGIV/FG[,'[&MS!?>(K/]HCX+(\0@M[SPSX@?QK!-!',=L%]I%]IOA7QI<K<F
M>WF@N;&YGTT+:-97:M=LUS9A?M:U_9%_9OL]XB^%GAR0N?WGVB?4[]B/I?:E
M=8]\C!_GU\-<0<?YSD^$QV)X<RK`8B47#%X3-<VSC"8N.)PUH^W>$_L-K"K$
MM.?*\3B[*2_VF25BJ4\55HQFZ4(NU[.33OWM]5V[>N^Y\-?%;]B/_@CA\./`
M_BCQ''^P'_P36U;6M&TN9],\/6G[*_[,MWJ.I:O.!#I-E]BM/`;:@;>YNIH/
MMK06K-:67VJ[`9;=FK+_`&6OV"_^"6WQQ^%6E^(]1_X)M?\`!/L^*]*N)-#\
M76MM^QI^SO;Q#5+3$L.H6\'_``KD8M]4L)K:ZS&%M%O3?V=GN%F:]F_:'_8F
MO?&\OAFP^"?A_P"%/@/0=,MKR?6+F_;5-/UO5M4O9Q]G@GFT_P`-:X\^GZ9;
M0J;(OJ>!=WURQLPMI9L=']D_]F'XV_L_^-]3U#7]?\`ZAX.\1Z4+/7=,T;6?
M$-QJ`O[(2SZ-J%G!?^%M)M;F>UE:>V;[1=VP6TU/46"LX17\.EGOB0O$+!T,
M;P[)<*+!+*L5B\HJ?6L']=Q26,6:OZY+"8U1PDE'!./U1IX9XJ5VT9<^,^N<
MDZ*^KV^)-;]][Z6L^OD;7PN_9._9:_9@_:E\"C]FG]FOX`_L[_\`"<?`+X\#
MQK_PHOX-_#SX1_\`"8#PW\0_V9O^$<_X2H>`/#?A[_A(3X?_`.$AUS^Q&U7[
M9_8_]MZR;`VQU6\W?H%7S_XD_P"3I_@U_P!D!_:6_P#5B?LH5]`5^TG>%?`'
M_!6+_E%E_P`%+/\`LP#]LC_UG7XC5]_U\`?\%8O^467_``4L_P"S`/VR/_6=
M?B-0`?\`!)W_`)19?\$T_P#LP#]C?_UG7X<UWNK_`+6=Q'^TEJ?[-_@/]G7X
M\_%R]\(V/PTU'XK_`!9\":G^SCIWPI^#L/Q4N/$3>'8/'"_$W]H3X>_%+5]1
ML]%\-W'BC6M*^&?PP\>WUIX;U30[NRM;V_U>SL6X+_@D[_RBR_X)I_\`9@'[
M&_\`ZSK\.:^(_C%X(?1/VOOB1K7P$T/_`(*(Z#^V%\1/VH_V:O%EAK&OI^T?
M'^PAKOP8T+3?@/X.^.&KP:I\*#=_L/W/@]OV=O`_Q-T)="_:JNO^&C[3XO6^
MI-\,]&TC6]8^"-[?`'W1X2_X*`?"KQC^T7;_```T[P%\7[+1]:^(7Q4^"_@;
M]H/5-!\(6WP#^(OQY^".A7/B3XK_``4\'ZK;^/;KXGMXW\':/HGC@OJNO_"K
MP]\.-:O?AE\2=#\)^/O$.O>%+K2F]L_:)_:)\.?LX^%?"^M:OX2\=_$KQ7\1
M/'^@?"OX3_"?X7V?AJ\^(GQ3^(_B*TU;5;/PKX6_X3;Q7X'\!:;]D\+^'?%7
MC+7->\>>.?!OA#PYX2\*:]K>N^)+);/#?CQ\(?`?Q3_X7C^SU^RM>?!KXS:/
MK/[-/_!3?]MO]LGQY\7=9^%'CO3/V?\`4?@3\5;/]J_Q7\*]7\$?&^_T6U^%
MWCGQAXQU#]KWP-X-/PX\+>+=9\>>$=8\'?%&^\5^&-(T/PG]MO/M3]MG6=1?
M7?V1/VA?#G@#XP^./"7[(O[:5_JOQC\/>"?@E\6_%'Q'3P=XJ^`'QQ_9ZU3Q
MM\/_`(9:1X)N_'_Q@\,>#_%/QG\+^(;[4OA-X5\9VVK^#[+Q)KOA1M9'A^Z`
M`-36O^"F?PKC^$7P@^(_@/X+?M&?&+QK\8[3XO7ND?LW_#CPI\/3\?/"W_#.
M=Q?:-^T99^-]+\<?%+P3\.-&U#X'^,K*+X<^,;6U^)VK-XA\?:IH?A;X9CQ[
M>>(-&^W?<_PR^(_@[XP?#KP'\5_AUKD7B3P!\3/!OA?Q]X)\16T%Q!!K?A/Q
MEH]CK_AS5((+JWM;JW%[I%_;W/V:[M[6[L_-V7MHD@9:_GZ^%=C\4?V7]>^`
M/[;7CW]G?]I+7?!7Q&?_`(*Q:AJ/PN^&GP'^)OQ0^/'PWE_;2_:B\&_M4_LY
MV?Q&^#OP_P##?B'XD>%KCQ3X&^%<WA?QI_:GAZSL_A7\1_%7AOPK\2[WPW_I
MEY9_K]_P3]^$/C+X`?L/?LE_!CXBVD.F^/\`X:?L]_"GPAXXTJWNH;R'1_%N
MD^#M)@\1:-#>V]S>6U__`&7K'VC3#>6MTUI>FW-[9L([A5H`X7_@I7_R;K\.
MO^T@'_!)W_UZ9^QK7Z`5^,G_``5<^!/Q2\4?#_PGXWT3]M']I?X<^&-5_;6_
MX)>Z%8?!SP;X5_8ZO?AQX:U75?\`@HG^R7X5LO&NB:K\0?V3?'/Q;N?%/AK7
MK^U^)VAVGB'XK>(O!UUXZT73=/\`$'@[Q%\.6UCP!J_TW_PQM^T5_P!)8?V_
MO_#<_P#!+7_Z6M0!^@%%?G__`,,;?M%?])8?V_O_``W/_!+7_P"EK4?\,;?M
M%?\`26']O[_PW/\`P2U_^EK4`?H!17Y__P##&W[17_26']O[_P`-S_P2U_\`
MI:U'_#&W[17_`$EA_;^_\-S_`,$M?_I:U`'Z`45^?_\`PQM^T5_TEA_;^_\`
M#<_\$M?_`*6M1_PQM^T5_P!)8?V_O_#<_P#!+7_Z6M0!^@%%?G__`,,;?M%?
M])8?V_O_``W/_!+7_P"EK4?\,;?M%?\`26']O[_PW/\`P2U_^EK4`?H!17Y_
M_P##&W[17_26']O[_P`-S_P2U_\`I:U'_#&W[17_`$EA_;^_\-S_`,$M?_I:
MU`'Z`45^?_\`PQM^T5_TEA_;^_\`#<_\$M?_`*6M1_PQM^T5_P!)8?V_O_#<
M_P#!+7_Z6M0!^@%%?G__`,,;?M%?])8?V_O_``W/_!+7_P"EK4?\,;?M%?\`
M26']O[_PW/\`P2U_^EK4`?H!17Y__P##&W[17_26']O[_P`-S_P2U_\`I:U'
M_#&W[17_`$EA_;^_\-S_`,$M?_I:U`'Z`45^?_\`PQM^T5_TEA_;^_\`#<_\
M$M?_`*6M1_PQM^T5_P!)8?V_O_#<_P#!+7_Z6M0!^@%%?G__`,,;?M%?])8?
MV_O_``W/_!+7_P"EK4?\,;?M%?\`26']O[_PW/\`P2U_^EK4`?H!17Y__P##
M&W[17_26']O[_P`-S_P2U_\`I:U'_#&W[17_`$EA_;^_\-S_`,$M?_I:U`'Z
M`45^?_\`PQM^T5_TEA_;^_\`#<_\$M?_`*6M1_PQM^T5_P!)8?V_O_#<_P#!
M+7_Z6M0!^@%%?G__`,,;?M%?])8?V_O_``W/_!+7_P"EK4?\,;?M%?\`26']
MO[_PW/\`P2U_^EK4`?H!17Y__P##&W[17_26']O[_P`-S_P2U_\`I:U'_#&W
M[17_`$EA_;^_\-S_`,$M?_I:U`'Z`45^?_\`PQM^T5_TEA_;^_\`#<_\$M?_
M`*6M1_PQM^T5_P!)8?V_O_#<_P#!+7_Z6M0!^@%%?G__`,,;?M%?])8?V_O_
M``W/_!+7_P"EK4?\,;?M%?\`26']O[_PW/\`P2U_^EK4`?H!17Y__P##&W[1
M7_26']O[_P`-S_P2U_\`I:U'_#&W[17_`$EA_;^_\-S_`,$M?_I:U`'Z`45^
M?_\`PQM^T5_TEA_;^_\`#<_\$M?_`*6M1_PQM^T5_P!)8?V_O_#<_P#!+7_Z
M6M0!^@%%?G__`,,;?M%?])8?V_O_``W/_!+7_P"EK4?\,;?M%?\`26']O[_P
MW/\`P2U_^EK4`?H!17Y__P##&W[17_26']O[_P`-S_P2U_\`I:U'_#&W[17_
M`$EA_;^_\-S_`,$M?_I:U`'Z`45^?_\`PQM^T5_TEA_;^_\`#<_\$M?_`*6M
M1_PQM^T5_P!)8?V_O_#<_P#!+7_Z6M0!^@%%?G__`,,;?M%?])8?V_O_``W/
M_!+7_P"EK4?\,;?M%?\`26']O[_PW/\`P2U_^EK4`?H!17Y__P##&W[17_26
M']O[_P`-S_P2U_\`I:U'_#&W[17_`$EA_;^_\-S_`,$M?_I:U`'Z`45^?_\`
MPQM^T5_TEA_;^_\`#<_\$M?_`*6M1_PQM^T5_P!)8?V_O_#<_P#!+7_Z6M0!
M^@%%?G__`,,;?M%?])8?V_O_``W/_!+7_P"EK4?\,;?M%?\`26']O[_PW/\`
MP2U_^EK4`?H!17Y__P##&W[17_26']O[_P`-S_P2U_\`I:U'_#&W[17_`$EA
M_;^_\-S_`,$M?_I:U`'Z`45^?_\`PQM^T5_TEA_;^_\`#<_\$M?_`*6M1_PQ
MM^T5_P!)8?V_O_#<_P#!+7_Z6M0!]\D<8(!R,$=0>>.AZY]#Z>]?-'BC]D/]
MGSQGK^K>*?$W@.74]=UR]GU#5+^3QCXXC^T7-P6$I6WM_$=O:V\"J%\NTMK:
MVL[7.+2-*\:_X8Y_:)[_`/!6+]OWZ_\`"N?^"6W\O^':OK1_PQQ^T03_`,I8
M/V_O_#<?\$M/YG_@FO\`S->1F.39/G-&G0SC*L%FU"B[QCFN"PV,BG:SDEBX
MS2;ZNROH1*$:NE6FFNSU7W=^GII>Q]3?#'X+_#KX.6VJ67PZ\/R^'K36)K>Y
MU"WDU[Q'K,4UQ912P0S0PZ_J^II;.5G*N;3[*;E1!]J+FUMMOK.=HSD8R<9P
M`/0^I_GUSZU\!#]C7]HD=/\`@K#^W]SZ?#G_`():_GS_`,$U^E!_8V_:)`_Y
M2P?M_8_[)S_P2TQ^O_!-<5T8/`8++L+2P>787"9=@\.K87"X/"K"86">MHX7
M"PBDM6[<J5]6KCC&,8\L=ETT_P"&^Y(_0&BOS_\`^&-OVBO^DL/[?W_AN?\`
M@EK_`/2UJ/\`AC;]HK_I+#^W]_X;G_@EK_\`2UJ[RC]`**_/_P#X8V_:*_Z2
MP_M_?^&Y_P""6O\`]+6H_P"&-OVBO^DL/[?W_AN?^"6O_P!+6H`_0"BOS_\`
M^&-OVBO^DL/[?W_AN?\`@EK_`/2UJ/\`AC;]HK_I+#^W]_X;G_@EK_\`2UJ`
M/T`HK\__`/AC;]HK_I+#^W]_X;G_`():_P#TM:C_`(8V_:*_Z2P_M_?^&Y_X
M):__`$M:@#Z`\2?\G3_!K_L@/[2W_JQ/V4*^@*_/SX7_``<^(GPD_:F\"KX^
M_:O^/_[4'_"0?`+X[_V3_P`+T\.?LL:!_P`(-_97Q$_9G%]_PBW_``S1^S1^
MSRUT?$_]IV1US_A,_P#A+Q:CP[HO]@?\(Z;K6?[9_0.@`KX`_P""L7_*++_@
MI9_V8!^V1_ZSK\1J^_Z^`/\`@K%_RBR_X*6?]F`?MD?^LZ_$:@`_X)._\HLO
M^":?_9@'[&__`*SK\.:^_P"O@#_@D[_RBR_X)I_]F`?L;_\`K.OPYK[_`*`"
MBBB@`HHHH`_/_P#X*5_\FZ_#K_M(!_P2=_\`7IG[&M?H!7Y__P#!2O\`Y-U^
M'7_:0#_@D[_Z],_8UK]`*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`/G_P`2?\G3_!K_`+(#^TM_ZL3]E"OH"OG_`,2?\G3_
M``:_[(#^TM_ZL3]E"OH"@`KX`_X*Q?\`*++_`(*6?]F`?MD?^LZ_$:OO^O@#
M_@K%_P`HLO\`@I9_V8!^V1_ZSK\1J`#_`()._P#*++_@FG_V8!^QO_ZSK\.:
M^_Z^`/\`@D[_`,HLO^":?_9@'[&__K.OPYK[_H`_FQ_:(\-:)K/QL_:__:IU
M?3;>]_::_9C_`."G_P#P3<^!/[.?C^Z0R>+_`(9?!SX@6?[#^E>,?ACX`G+-
MJFC^!_C)I_[37QW_`.%FZ#H+6ME\1_\`A*[D:]97O_"/:,='_1O_`(*)>']#
M^)/BW]@7X#?$72;'Q3\#_CG^V7+X9^-/@'7+:'4/!GQ+\-^!_P!EW]I7XQ^%
M/`7C[1[_`':)XH\'ZG\3_ASX&U[6?!NNVE[I'B8^&[>PO[*]L1>65Y[_`.+O
MV(_V9O'7[07A_P#:?\4?#^_O_C!X;NO".IVNH6WQ$^)VE^!]9U_X=6GBJS^'
M7B_QQ\&='\:67P:^)/C_`.'4'C+Q$OP\\>^/?A[XD\9^!//T_P#X1/7-(?0=
M%:QZGXJ_LM?!GXV>!-8^'?Q,TGQOXB\/ZM\1=*^+%O>P_&/XS^'_`!QX,^(F
MB:U8^(M#\2_"OXF^%_B!I'Q'^#5QH&I6$)T.T^$WBSP=I.CV%SJFB:;96>B:
MQK%C?`'X?>!_#FA^-O@3^P]^R/XRTVW\4?LLW_\`P5N_;2_9FU#X;^(T_MOP
M1XP_9X_9EO/V]?$?P!^"?BJQU`W>B>,/AAX6UCX*_#+0;+P;JEK>>&]8T?X<
MZ)X5O[*\L;2\L[S]+/\`@EI'_9/[+FM^`=/>X_X0GX.?M0_MF_`[X36LUS<7
ML>B?!OX/?M7?&+X?_"OP?I-[<'%SX>\!^#]!TGP)X8$8%O8^'?#>FZ)@_P!F
M'/MFL?L2_LSZO^SQX+_98D^'U]I/P;^'%[X3UGP#IWA3XA_$_P`&>/?!WBCP
M9KR^*-"\=^&_C3X/\:^'_C7HOQ*;Q%]LUW6?B?IGQ"MO'OB;5=6\27OBKQ+K
M+>(_$9U7V3X0?"/X=_`/X9^#/@_\)O#,?A'X>>`M(CT/POH,-_J^LR6UMY\]
MY>WNK:[X@U'5?$7B;Q!J^H7%YKGB7Q3XHU;6/$WB7Q#J&I:[X@UG5]=U2^O;
MD`_//_@HEXE_:,\;Z!HOP;^$'["7[2WQG@\*?M+_`+"7QP?XJ^#/'G[$/AOX
M;Z_X:_9Z_:__`&>_VD_B)HVB6_Q>_;#^&/Q0_P"$G'A'X9>(O"NB6NO?#/1M
M&U;QS_9UH==M?"UV?%UKZY_PV3^T5_TB>_;^_P##C?\`!+7_`.F4U^@%%`'Y
M_P#_``V3^T5_TB>_;^_\.-_P2U_^F4T?\-D_M%?](GOV_O\`PXW_``2U_P#I
ME-?H!10!^?\`_P`-D_M%?](GOV_O_#C?\$M?_IE-'_#9/[17_2)[]O[_`,.-
M_P`$M?\`Z937Z`44`?G_`/\`#9/[17_2)[]O[_PXW_!+7_Z931_PV3^T5_TB
M>_;^_P##C?\`!+7_`.F4U^@%%`'Y_P#_``V3^T5_TB>_;^_\.-_P2U_^F4T?
M\-D_M%?](GOV_O\`PXW_``2U_P#IE-?H!10!^1'[,/[2W[<?P\_9G_9X\`?'
MW_@FE^WA\0_CIX'^!WPE\'_&CX@:?\6?^"9.M:?XY^+/AOP%X>T3XC^,;+6M
M7_X**^'];U>V\4>,;+6];M=4U30='U6]6_CO+[1K&\9K1/=_^&R?VBO^D3W[
M?W_AQO\`@EK_`/3*:_0"B@#\_P#_`(;)_:*_Z1/?M_?^'&_X):__`$RFC_AL
MG]HK_I$]^W]_X<;_`():_P#TRFOT`HH`_/\`_P"&R?VBO^D3W[?W_AQO^"6O
M_P!,IH_X;)_:*_Z1/?M_?^'&_P""6O\`],IK]`**`/S_`/\`ALG]HK_I$]^W
M]_X<;_@EK_\`3*:/^&R?VBO^D3W[?W_AQO\`@EK_`/3*:_0"B@#\_P#_`(;)
M_:*_Z1/?M_?^'&_X):__`$RFO!_A+^TO^W'X:\??M0ZU\1O^":7[>'B?PA\0
M_CIH/C#X!Z):_%K_`()E7\_PZ^$UC^S3^SSX`UOP?J%KJ/\`P45TJUT:[NOC
MKX'^,WCT:7H5YK>D/9>.-/UIM776M6U?1]'_`%XHH`_/_P#X;)_:*_Z1/?M_
M?^'&_P""6O\`],IH_P"&R?VBO^D3W[?W_AQO^"6O_P!,IK]`**`/S_\`^&R?
MVBO^D3W[?W_AQO\`@EK_`/3*:/\`ALG]HK_I$]^W]_X<;_@EK_\`3*:_0"B@
M#\__`/ALG]HK_I$]^W]_X<;_`():_P#TRFC_`(;)_:*_Z1/?M_?^'&_X):__
M`$RFOT`HH`_/_P#X;)_:*_Z1/?M_?^'&_P""6O\`],IH_P"&R?VBO^D3W[?W
M_AQO^"6O_P!,IK]`**`/R'U_]I?]N.]_:8^$_P`0-'_X)H_MX67P+\-?`W]H
M;P?\1OA\_P`6?^"94.H>)_BUXX\>_LOZW\%_&-OHL'_!16XT34+7P-X/^'7Q
M]T.\U.\U^PU;2'^(NG6>G:-K-EK&KWNC>\?\-D_M%?\`2)[]O[_PXW_!+7_Z
M937Z`44`?G__`,-D_M%?](GOV_O_``XW_!+7_P"F4T?\-D_M%?\`2)[]O[_P
MXW_!+7_Z937Z`44`?G__`,-D_M%?](GOV_O_``XW_!+7_P"F4T?\-D_M%?\`
M2)[]O[_PXW_!+7_Z937Z`44`?G__`,-D_M%?](GOV_O_``XW_!+7_P"F4T?\
M-D_M%?\`2)[]O[_PXW_!+7_Z937Z`44`?G__`,-D_M%?](GOV_O_``XW_!+7
M_P"F4UX1^T-^TQ^W%XZ\`^']$^#/_!-+]O'P+XPM/CG^S!XPUG6K[XM?\$R=
M*AOOA-\.OVE_A+X_^/?@];C2/^"BFK74]U\1O@5X:^(G@&QTQK1-)UJ^\4VV
MB:YJ^B:)>7VLV'Z[T4`?G_\`\-D_M%?](GOV_O\`PXW_``2U_P#IE-'_``V3
M^T5_TB>_;^_\.-_P2U_^F4U^@%%`'Y__`/#9/[17_2)[]O[_`,.-_P`$M?\`
MZ931_P`-D_M%?](GOV_O_#C?\$M?_IE-?H!10!^?_P#PV3^T5_TB>_;^_P##
MC?\`!+7_`.F4T?\`#9/[17_2)[]O[_PXW_!+7_Z937Z`44`?G_\`\-D_M%?]
M(GOV_O\`PXW_``2U_P#IE-'_``V3^T5_TB>_;^_\.-_P2U_^F4U^@%%`'Y__
M`/#9/[17_2)[]O[_`,.-_P`$M?\`Z937A'[,/[2W[<?P\_9G_9X\`?'W_@FE
M^WA\0_CIX'^!WPE\'_&CX@:?\6?^"9.M:?XY^+/AOP%X>T3XC^,;+6M7_P""
MBOA_6]7MO%'C&RUO6[75-4T'1]5O5OX[R^T:QO&:T3]=Z*`/S_\`^&R?VBO^
MD3W[?W_AQO\`@EK_`/3*:/\`ALG]HK_I$]^W]_X<;_@EK_\`3*:_0"B@#\__
M`/ALG]HK_I$]^W]_X<;_`():_P#TRFC_`(;)_:*_Z1/?M_?^'&_X):__`$RF
MOT`HH`_/_P#X;)_:*_Z1/?M_?^'&_P""6O\`],IH_P"&R?VBO^D3W[?W_AQO
M^"6O_P!,IK]`**`/S_\`^&R?VBO^D3W[?W_AQO\`@EK_`/3*:/\`ALG]HK_I
M$]^W]_X<;_@EK_\`3*:_0"B@#\A_A+^TO^W'X:\??M0ZU\1O^":7[>'B?PA\
M0_CIH/C#X!Z):_%K_@F5?S_#KX36/[-/[//@#6_!^H6NH_\`!172K71KNZ^.
MO@?XS>/1I>A7FMZ0]EXXT_6FU==:U;5]'T?WC_ALG]HK_I$]^W]_X<;_`():
M_P#TRFOT`HH`_/\`_P"&R?VBO^D3W[?W_AQO^"6O_P!,IH_X;)_:*_Z1/?M_
M?^'&_P""6O\`],IK]`**`/S_`/\`ALG]HK_I$]^W]_X<;_@EK_\`3*:/^&R?
MVBO^D3W[?W_AQO\`@EK_`/3*:_0"B@#\_P#_`(;)_:*_Z1/?M_?^'&_X):__
M`$RFC_ALG]HK_I$]^W]_X<;_`():_P#TRFOT`HH`_/\`_P"&R?VBO^D3W[?W
M_AQO^"6O_P!,IKP?7_VE_P!N.]_:8^$_Q`T?_@FC^WA9?`OPU\#?VAO!_P`1
MOA\_Q9_X)E0ZAXG^+7CCQ[^R_K?P7\8V^BP?\%%;C1-0M?`W@_X=?'W0[S4[
MS7[#5M(?XBZ=9Z=HVLV6L:O>Z-^O%%`'Y_\`_#9/[17_`$B>_;^_\.-_P2U_
M^F4T?\-D_M%?](GOV_O_``XW_!+7_P"F4U^@%%`'P?\`"OXB?&CXR_M&>$O%
M'C7]C']HK]FGPCX&^"WQAT&7Q/\`&_Q=^Q_KEAX@\2>.?'?P"O\`1=!T"Q_9
MP_:J_:"\2?:1IO@/Q'J=[=Z]H'A[1K5+"W3^V'O[RULW^\***`"O@#_@K%_R
MBR_X*6?]F`?MD?\`K.OQ&K[_`*^`/^"L7_*++_@I9_V8!^V1_P"LZ_$:@`_X
M)._\HLO^":?_`&8!^QO_`.LZ_#FOO^O@#_@D[_RBR_X)I_\`9@'[&_\`ZSK\
M.:^_Z`"BBB@#XO\`VZ?VK_`_['_P,D\<>*_B-\+/A9KWCWQ;H/P=^%GB[XT^
M+M'\$?##2OB9XY^WC2==\;^*?$-WI6BZ?X8\&:)I?B/XB^)K:ZU6RO-8T3P=
MJ.@Z`;OQ/JVC6%Y^,/[%/Q%^$OQ8_P""=G@C]DSX5_'?0OVC[[XW?\%'/VF_
M@/XS\5:)\3/!_P`0/$?B'X83?M@?'_\`:,^+7B3XBZIX/^V:;;GXM_LK>"?%
M>O66JBSTC2/$O_"S/"-]H/V/0_%FB@_O=\<?VI_V8/V88O#5Y^TE^T;\!_V>
M;7QE+JEMX0N?CC\8/A]\)[;Q5/H0L9M<@\.3^/O$?A]-9GTH:KI;ZNNEF[:R
M74=.-]M^V6N[X`\"?MB_\$1_AIJ7AW4O!7[>_P"P1HESX/\`$OQQ\8>'0?V\
MOA7J5OI_B?\`:2\=WGQ(^,^L_8=7^-5[IUS>^+/&-_?ZE9O>VMT/"%G?:AH?
M@Y?#F@WUUI+@'BVA?LU_!'5_^"@W@2Y_97\/7WB/XX_`GX__`!+^-/[>/[<^
MOVUG<>+;S1?B-X(\<0:%^P?KGQ8\-:;X<N/B/J0@^(/PQU/PS\!KL:OX#_9P
M^!'PK^'^N>(+/1O&]Y\'E\7;_P`;_P!GSX:_LW_\%#OV+_C1X2^#GPY^%6B_
M%WX\_%J+XH_M8>&_&&O>(OVH/C-\2_&/[/G[0OC$?`?X[7OC'3;/4I_V3[31
MO!UOXQT.YN_BQ\5+3P?XP^&_PE\#>!?@7\*_!/A+2/'OAO`^$'Q-_P""#OP)
M\;+X]^%?_!2[X+>%]0_X3GQC\1[CPQ+_`,%JOBMK_P`)M3\;^/\`6=:\1^.-
M?USX(^*/VS-8^#7B&X\3>(/$6KZ[J]KK?P_OK)];O6UHV:W\=K=KH:;\5O\`
M@@+I'BKQIXKTW]N[]C2TD\;K\3WO_":_\%/+,?"7PMJWQI@UR#XJ>,?A+\$6
M_:7/P>^"'Q(\>0>*?&/]N?$[X->!_`7Q`NY/'/CV];Q.+OQQXO;6@#R[Q=\/
M?V3O'?[//PT_:?\`VL?A#X@_:H\7_M7>._CG\5/V=OV&M<T'PK\0;+X^^//V
MBY=*OO@1K$'PE\4^'+2V/Q9^$O[)W@#P#X7_`.%H>*=7T?PC^S=\-Y_BSXL\
M0:SX;L#J_B6T^9OC;^SOK/AOX/?M)>`OVI_$EG\4OC7_`,$X/^"+'P'^+7[.
M_P`1;S6]>UB3X1_M-V.I_M7^*M<^.?P<\1^.+BZ\6V_Q`TOQC^SU\%O"]C\6
M[K[)X[O?#7@ZUT2_O;,>+?$>D7GWG\8OC5_P0@^./B[X:^/O&/\`P49_9F\/
M^,_@]X"UGX7?#?Q%\%_^"N&O_LY:EX7\!>(KC0KS7_#EO-^SU^UE\,!J&GZ[
M<>%/"KZNVJ_;;N_'AW0Q>73II-B+6G\0?BG_`,$!/BT?A,_Q,_;R_8\\<77P
M;\/6GA#P_J7B7_@J,NIZQXR\&V/BKPWXYA\#_'W7+G]I@ZU^U!X(/C#P?H?B
M6]\'?M*7GQ6\-7NKV]U>W^DW3:MK!O0#OOVFOAWXNU']MW_@DI\<_%7Q>^*&
MHPZE^T!XT\,:/\"S)X;\/_"#P??ZY_P3]_:IUOQ3XPGT71O#EGXM\4_$'4]7
MT*"ULM4\>>+O$FD^#]&_M'0_`GAKPV?$7C"]\2<U_P`%)?V</`'@CXD?!']K
M;P_\$_`-OXQO?VM_V0[;XN_MC2>+?$>L?M:?!KP[<?'3X2?#'P?\/OV>M*U_
M1;JTT_X/_%"X\13^`OCGX-T'XP_#;P)I'@'QQ\4/%?\`PICXV^*_&_B;1]7]
MW\:_\%!O^".7Q$\4?"KQAXQ_X*%_L":QXD^"?C74OB)\+]37]MWX):>/#'C+
M5?`7C+X8W^LBSTSXL6=CJ_VGP/\`$#QAH1TW7[75]'7^U?[0%BNM66DWEEXI
MJ'[0/_!"#5/C;=?'^X_;W_8K@\?:EXKT#X@>(=(TW_@I/H&C_!GQE\1?"ND:
M7H7A7XF^/?V=-)_:&LOV>?B!\3_#&G^'/"A\-_$CQE\,=<\=:+>>#/`>L:=K
MEGJ7@?P?>Z,`?MM7.>*]4N="\+^)=:L;<7EYI'A_6=6L[0+S<W5AIUQ>00?6
MXGA53ZD^M?$7_#V/_@EE_P!)*_V`?_$R?V=/_GD4?\/8_P#@EE_TDK_8!_\`
M$R?V=/\`YY%`'XQ?L`?$WX=?LL?#KX)_M/\`QP_9&T#P#\4OCO\`\$]?BI^U
M1>?M=>!?CG>>//C#^U/JFA:%\,?C'\<(/VK_``!H_AKP]IEQX_\`%7BCQCI6
MN_LY"Z\;_M.'PAX9N=4\#Z!K?P?OKR[\!ZQ[-^VW^PKH'@+_`()KS_%OQ%\`
M_AC\3OVF_A!^S5K_`(F^)WQK\?>-?$=Q\1_V9M3ELO&/QX_:&_:+_8UTNXT6
M[\-Z?^U!I?Q2USQ)X[\,7/ACQ9^S%??$GQ+I/@K_`(3OXYV5AX&\(:3:^IZ)
M\1O^#?/P[XG\3>+=-_;<_8@75/$]M_9GV/4_^"E6CZWX6\%^';CXD>'?B[JG
M@_X/>!M9_:.O?!?P-\`>)_B/X3\+>)_&G@3X-^'_``'X-\=MH6FV'B[0];T6
MSM;%>O\`B]^T%_P0B^.7Q%A^*OQ#_;X_8KN/&$F@Z#X3\4MX2_X*4:!\,?"W
MQ7\&^%=7U36O#G@CX^^`?AC^T/X0^'_[1/@/2KK7?$JV/@3X[^%?B/X/&D^*
M?%VA?V+_`&%XM\2V&K`'S7_P42\,>#/B]XJ_;Y\9?$$GQ-JO[&W_``29^$_[
M2W['/BKQ!((-<^#OQPU37_VL/'%Q\?/AP<D^&/BS<>*/V?\`X+V8\=Z#:66L
M65EH/_"*"[70O$&KV.K_`$_\4-#^#?[3OB7]JSXE?M4>-[_X<_LY_LX_"#X$
M_!GXH^()/$.F^#_"]Y()_"O[6O[4_@3Q3<:OHMX)_A-\4/"^K?LY?##XLZ!:
M79O/%^C:)XV^')N[(W=]9W<'QZ_:#_X(,_M,^+_!7CGXS_MR_L)>*/$7@2RC
MT73I-+_X*%>!?`FD>)O"T7BOPYXZA\!_%7PO\/OCYX3\-?&[X:KXP\(:'KZ_
M##XR:1X[\`#5[>YNO^$8']JZN;U?BS^T1_P0H^-OPO\`$'P=^('_``4`_8QN
M/`?BGXOP?'S7+3PM_P`%+="^&_B.Z^+-AXQ@^(&E>+H/'OPY_:)\)^/]-;0O
M&%EI6O>&M*TOQ39>'?#EUH7AM-!T>QLO#NBVMB`?'WA7]GO0R/@!X"U+X#V_
MP'_8+_;K_P""F0\0^%?V%O$_@G_A!O"VC_!'X?\`[#7QC\8>'/#?Q-^!]Q_Q
M1/P^T;]H+]H#X':7^T#K?[.9\/:19C[=HEC\3/#%I\1M5^)'ANSSOC1\*M>\
M;?\`!#;]M+P-H?QE^*WPT^$W[,^K?\%//`?@SPA\-]3T'3XO'?P;_9Z^./QQ
M\*_`_P"#WB+QQK/ASQ#XNM?@]X#\/>#-)\&_V!\-_$/@^\\2^$/#NF_#K7O$
MUYX'_P"$G\(^(_K&X^,O_!"C4OA7JOP;\1?\%*_@#XV\'ZGXY\+_`!+L]4^(
M_P#P6.\=?$SXH>#?'G@F\L+[PMXJ^%OQP^(/[7GB3XU?!_5M)N;"%[2Z^%OQ
M"\'+BXU,%2->UG[=Z'#^UA_P0SM/V9[[]CRV_;G_`."?D/[.FK?#?7?A+JWP
M^A_;I^$L<FJ^"/%-E?V/BJ'5?&P^,?\`PL#4O$/BC^U=6U3Q1X[N_%=UX[\1
M^(]5U/Q3KGB:\\07M[K#@'T1^VI^RAX(_:3^"^GZGJG[,?P$_:U^)7P]\':J
M?A'\*?VK/&'B/1_V?XM=\5V6DV&J^*-;T2V\%?%CPS_PF^A:-87`\%^,KKX8
MWGC'1EO=;\*^%/B!\-]$\<^+];/8?\$Y/$%OXK_8%_8Q\1VGC#QY\0(=6_9D
M^"MY_P`)M\4%B3XB^)Y3X!T(7&K^./(\1>+@OB>ZN%F;60/%OBT&^^T;O$_B
M0L=9OOC7XZ?M/_\`!#S]HC4/!NM?$?\`X*(_L@V'B?P'I&O>&_"GCGX1?\%.
MM,_9W^(FG^$_%1T2;Q+X*N/B-^S_`/M&_#'QQJ_@77[KPWX;U/7/`NN^(;_P
MAJ^M>'?#NN:AHMSK.CZ3>V?T#X8_X*=_\$E/!GAW0O"'A+_@H=_P3L\->%?"
M^D:;X?\`#/A[0OVN/V:],T+0=!T6TAL-*T;2=+L/B!;6NGZ;I>GPP6=C:6MN
MEK:6=O`L:JB```_1^OYJ_P!N'X3_`!7^#'[1WQ:_:>;]G:;QK\3O&'[7_P"P
M!<?LR?MQ0>.?AQ%??`WX(ZMX\_9S^`_C_P#9`TG2]7\2W?QM\/3_`!&\4:K\
M:3K'@3P%\,M8^`_Q(T;X\:AXL^)/C6R\4VFL:/:?JI_P]C_X)9?])*_V`?\`
MQ,G]G3_YY%?)^O\`[0__``0?\4?'FT_:2UW]NW]AJ\^*%GK_`(<\8.@_X*+>
M#[+X8:Q\0/!WA\^%/!WQ/\1_`>Q^/MK\"?&'Q8\'^&19:'X6^+/B?X:ZQ\1_
M#5CH7AFST/Q39CPGX<&D@'<Z1^S[\,_VU[#]KGXR_$;X,^!/VA]+\1?'W5?"
M/P1^%GQL\5:YH_P4^(.C?L>:+KOP6\*Z+\5=*T[PIXWT77_AO_PT?/\`'_QW
MHH\8_#'XP:-I%WKWAKXIZ!X+UGQ3X>\(7=E\+?"?PQI7C?\`9A_X)W_LM?%#
M0;*\^$OC#_@J!^U?\$/VA/@%?H-8^"FEVOP/A_;I\?\`AS]E;PW;W]S>:=XY
M_98^''Q0^$?@?0?A)X7\46=G9>,?AOX!\$6&N_#[P)9"]^%?AKZT\:_M'_\`
M!"KQ]\+_`(;_``BUO]OS]BK3_"OP>U>/7OA7K7@K_@I)X;^&7Q6^'FN_V9K6
MAWVN^#?CO\-_VAO"GQL\/ZQKV@>(O$>@>*=6TSX@VM]XPT;Q%KVB>*[O6-/U
MG5K.ZF\3?M*?\$*?%WP*\/?LY:Q^WI^PZOPQ\(:[H/C#PP^A_P#!1/P5X7^)
MF@^/?#GB7_A,K'XG:5\>/#/Q^TCXZ6OQ9O/%\U_XG\2_%FW^(B_$CQCK.N>)
M;_Q=XFUN\\5>)&U8`\=_96B3QWX6_9@_8ST>ZU'_`(0+X3?MI?M_>+]$MK>]
M^UVWA7]E_P#80_:7^)WPQ_9X\*6-QJ-MJUM<:?\`#KXL^,_V<])^'NE76;+_
M`(1SX27-B%O++PI>V9^8/&?PN\"?!CP/^V+^T1_P3CTS6/!7A']DO]@']L[X
M:_&G]LNV@\GQQ^W3^U<-!L-5L?&VJ^/M`M_#]O\`M$?$#]G/QAX&^(VO_$[]
MHS7])UBTT?XP>.-:^'/PTUE;[2/C!HWAO]$?AS^U/_P0S^$GAFU\(_#C]O+]
M@WPCH=A\((O@59Q:=_P4`^'']H6_P[75?$6NWD4&N7/QSNM<'C#7O$'BG7/$
M_BCXI?VI_P`+4\8>)+X:_P"*_&FKZW9V=[:>8?`?XH?\$%/V;-.M?#GPM_X*
M-_L[_P#""V7@*^^%VG_";XD?\%B/''QS^!UA\/K^RBTN?PI9_`_XX_M>_$3X
M/6VGKID"Z79?9O!"7.DZ5/<:?8/9V=[>QW(!UO[-'[/7A'X+?M0?M5?LK?LE
M:U=_LT?#'Q;^Q9^Q=\7WU7X0Z-X)U:?PK\:/%7C?]I7X9>*OC+HFE>-_#7C;
MX;W_`,5_B?\`#?X5>!U\4>,?&7A/QA_PGFL^%=,\:^+K+Q-J%I>F^WO^"<_[
M./PX^(/_``3G\3_LW_$^W\3?&#X<P_M6_MU^&/$5G\2/'?C&^UGXH6'@_P#;
M[^/5Q;VGQ:\4Z=J-MJ?C_3O&=QHT"_%#2_$']K>&OB5H^H:UH7CGPWXC\,>(
M-9T6]A_9G_:>_P""&7[(FC^)-$^`W[?G[$>A0^+IO#9\0:KXT_X*,>#_`(R>
M+;S3_!/ANS\'>"/#4/CCXT?'[X@^-+#P-X#\+V2Z1X)\!:9KUIX&\&V<^I?\
M(KH>D-J^KM>.U;]IO_@A3K?P:\0?L_W_`.W-^P-_PJWQ'\1O%7Q?N=(L?V^?
MAEIGB'2?BIXP^+>K?'C4_B1X.^(.D?&RT^(_P_\`&]G\7]<OO'G@WQ/X#\5^
M'-8\`ZT=.?P'>>&H])TBTL@#KO\`@E3X6D^&;_MP_"*Z^'/@/X#WOPY_:Z2U
M'[-GP.U$ZO\`LT?`W1_%G[._P(\;^'M(_9[U0^&/A]<7'ACQWIOB.#XH>/P?
MA/\`!^SMOC'XS^)"6'P^2R`\9>,?UPK\G/@I^W7_`,$;?V?_``E<>#OAK_P4
M;_8G6RU'7+_Q-KVO^._^"A/P[^+_`,1/&'B.^AMK&XU[Q[\6OC#\<O''Q1\?
MZQ:Z18:5H.G:GXR\7:U=Z1X0T/PYX3T-[+PQX=T72+'V/_A['_P2R_Z25_L`
M_P#B9/[.G_SR*`/C3X:_L^7=A^W!_P`%2/`7Q"_:B^/>JW7QC_8B_9`U+Q?\
M<=1\7^"/`_C3X4:-XC\7_MW>&Y[;X+3^%_!/A[P5\'?"_@/P]I4-SX8O+/P_
M>:Q8ZS_:/CKQ;XG\3_$35=:\77V!^Q_:_`;]G2T_;+_;K_9J^#ND_L]_\$]]
M)_9Y\)V_PT\#>!_"$_@'2OVF_%'P/L_B-XK\5?M:>#OAW8"ST3^Q_BCX>UWP
M=\+OAC\1KKP]_P`)[^T)9>#[?QQ>WFK^![KX5ZQXC].^+7[4'_!"_P".$/QT
MA^)/[>/["6L+^TM\(O"7P(^-EQI7_!0;X?>#[SQK\)O`VI^/M5\.^#6O?!/Q
MS\/77A^WMKKXG^/4OM1\+W&BZUXAL/$5WHNOZCJVBVMC96?)^!OCI_P0U\`>
M'/$7A#3_`/@II\"O%GA7Q2?!B:KX?^,7_!97X@?'S1X8?A_XCL?%?A>'P]9?
M'#]K_P"(5OX0M5UC2[$:S:^%1HUIXMTB#_A%_%J:UX?+:20#Q#]MO]A70/`7
M_!->?XM^(O@'\,?B=^TW\(/V:M?\3?$[XU^/O&OB.X^(_P"S-J<MEXQ^/'[0
MW[1?[&NEW&BW?AO3_P!J#2_BEKGB3QWX8N?#'BS]F*^^)/B72?!7_"=_'.RL
M/`WA#2;7ZA_:B^&^K7G[<G_!)[XW77QP^+/BCPY>_M#^./"O@SX0WUQX7T3X
M5Z):ZK^P%^U1JNM_$*_T/P_X0TKQ+XN^)&O7&B6)_MWQUXKUG1_!VCW&I:'X
M"\,>$/\`A(?&-YXEP/B]^T%_P0B^.7Q%A^*OQ#_;X_8KN/&$F@Z#X3\4MX2_
MX*4:!\,?"WQ7\&^%=7U36O#G@CX^^`?AC^T/X0^'_P"T3X#TJZUWQ*MCX$^.
M_A7XC^#QI/BGQ=H7]B_V%XM\2V&K>T^,_P#@H+_P1T^(/B3X3^+O%_\`P4(_
M8"U7Q#\#_&>H?$3X77T?[;OP2T\>%?&&J^`O&7PNO]7^PZ1\6++3=86?P+\0
M/%^@C3=>M=7TFU.J_P!H6EDNLVFDWUD`?.?Q,\-?LJ_&#PU^T;^US^V*=7\5
M?`(_M:VO@3P7\&9M*M/'_AW]IW2/V9]'\1_LV_#+X&ZY\%_^$4UG4_CM;:_^
MUCKGQJ^(OP6^#FD6]\/''Q)O?AMXI6RUD6=G:#YW^''['FD^)_%'['W[&_[8
M'PNT(?L\>,/@O_P4P_:@\,_LA^+;V'Q)\/\`X'?VK\9_@!8_`+X2WUO<ZGJO
MA*_\4?LK_!;X\>,M`\+V_A:[N_"'P@\7W^HM\)+RVT#PGX,\26GTA\3?C+_P
M06^+/@GX)?#[Q3_P4'_90T[P]^SIK]WXJ^#5U\-_^"K5]\&_%G@OQ/?Z#J_A
M6]\1P^/_`(/_`+47@?Q]K_B"X\/^(O$6E/JWB?Q'K-Z;3Q%XB7[5G6M6-WF>
M.OB;_P`$$?B;\+/!WPB^(/\`P45_9N\:>'?`.N>+-<\)>*/$G_!8#QCJ?QHT
MM_'VA:UX5\=:,?VB[C]KIOC_`*AX)\8>%]=U70/$O@#5/B9>^!=9T<V>GW_A
MF[L]*TBUL@#Q[]H;1?BA^TM_P;IZ'\0O&OQ\^,7A?4K;_@FM)\4?B4?!>IZ%
MI^M_'[4])^`T&NZ5IGQ-\;ZSX;\0^-O^$0U[4;"+7O&MKX!\0>#]8^)`O9]#
M\0>)[SP/JWB/PWXD^A_^"O/[,_@3Q5^RC\4/VF+3X"_#;XF_%[X5_`75KF+X
MP_$+QAXC/Q(_92^&7@C0M=\>^*?CE^QKX=N-,U?PWHW[3_@^X@@\4^%1X8\6
M_LW7WCWQ)X:\%#QU\=;.P\"^$K!/7_&W[=G_``1<^(?P1\1?LX^*?V]?^"=T
MOP0\5?#F_P#A!K'PZT3]L[X$>$](/PTU#0/^$5G\(:3-X0^*>@ZEX=TZ/P\?
M[*LCX?O=(NM)M/)_LZZLS;*:\C^*OQ\_X(._&KQ_:?$SQ_\`M[_L52>*AX=\
M.>#/$:^$O^"E.@_#/PS\4_!7@[4M5U7PYX$^/WP_^&O[1/A+P#^T3X%T2XUW
MQ%;V7@OX[^'/B/X2&D^*O%^A_P!C'0_%WB.QU8`_9CPU=17_`(=T&]M;R[U&
MVO-%TR[M=1OD,-W?PSV<$T-[>1;;;;<W*D7-T!;1Y:8@``$5Q'QH^#?P^^/O
MPW\0_"CXK>&4\<?#_P`5)8)XF\%WNNZ_H6A>+K32]2L]7'AKQ?\`\([J%G<>
M(/`^NW-C#I7C3P;JXU?PCXQ\-7&H^%?&'AOQ)X7U75M%O?E9?^"L'_!+)%"K
M_P`%*O\`@G^JCY55?VQOV=1MZX'_`"4C'Z"O)_C-^WI_P1I_:#\`:E\,/BS_
M`,%!_P!@?Q)X2U'4-"UL0V?[<GP:\)>(-$\1^%-9L/$OA#QCX,\;^#OBUX>\
M;>"/''@_Q/I>EZ_X.\;^#/$7ASQ;X9UK3[#7-!UFQU"UM;H`'P5\%O#B:!X#
M_:0_82D^&W@GX(Z[\:/^"E?P^^"^I?LN_`?5?[3_`&9/@M\%M4_9[^"W[37Q
MBT#X$ZX?"7@>YN/A_P#%#]F_P=\0/%'Q!W?!WX)V8^//Q;\6Z'8_#ZS_`+6L
M_'OCSZ,^,7[.'P]_9^_X*,_L1_%;P+\$OA_\--/^-/[0/Q6TSX@_M1>$O%>O
M^*_VI_C7\5/&W[/O[0'BJ#X`_'";Q5HMMJ5Q^RM_9'@Z#Q3X8-S\6?BI9>$?
M&'PY^#GP[\!?`OX6>$_"FB^//#76_"W]JW_@A_\`!RZ\+ZEX)_X*#?L52Z_X
M0O/'>I6'B_QU_P`%'_"GQ7\=ZSK7Q'L_#>E^*M?\?>/?BM\??&GC3XG>)KG0
M/!_A;PMHOB;XC:]XL\1>#_!VA:;X(\(WVB>$[/\`L<8'P^_:`_X(0?"[XK7O
MQD\#_M\_L5:1XGN-=\;>+=,\-W'_``4H\/Z_\&_!OC3XCW=_?>/_`!W\,OV>
M?$/[0VK?`+X3>/\`QG<:YXI;Q+X[^&'PT\(^+]9_X3?Q^NH:U=?\+!\8_P!M
M@'8:K\.=4\!?\%D?A/\`%'QA\:?B1XZM_'/["W[:TVG^%?&=]X6TKX8?!KP;
MX/\`CE^Q7>V.A?#OPWX7\->';:V^T_V[?ZGXU\>>/-6\8^//$EU;Z997_B>T
M\*>'O!WAGPW\M^+OA[^R=X[_`&>?AI^T_P#M8_"'Q!^U1XO_`&KO'?QS^*G[
M.W[#6N:#X5^(-E\??'G[1<NE7WP(UB#X2^*?#EI;'XL_"7]D[P!X!\+_`/"T
M/%.KZ/X1_9N^&\_Q9\6>(-9\-V!U?Q+:?7OQ!_;<_P""+7Q2\5Q>.?&O_!0'
M]@W4_%D'PA^*?P,MM:L?V\_A-X>O;3X6_&N[\%WWQ-\-V@\-?&32+>UN-?N?
MAUX.N5\46JCQ?X<;1%_X177-&^VWQO/'/C%\:O\`@A!\<?%WPU\?>,?^"C/[
M,WA_QG\'O`6L_"[X;^(O@O\`\%<-?_9RU+POX"\17&A7FO\`ARWF_9Z_:R^&
M`U#3]=N/"GA5]7;5?MMW?CP[H8O+ITTFQ%J`?!GQM_9WUGPW\'OVDO`7[4_B
M2S^*7QK_`."<'_!%CX#_`!:_9W^(MYK>O:Q)\(_VF['4_P!J_P`5:Y\<_@YX
MC\<7%UXMM_B!I?C']GKX+>%['XMW7V3QW>^&O!UKHE_>V8\6^(](O/TE_::^
M'?B[4?VW?^"2GQS\5?%[XH:C#J7[0'C3PQH_P+,GAOP_\(/!]_KG_!/W]JG6
M_%/C"?1=&\.6?BWQ3\0=3U?0H+6RU3QYXN\2:3X/T;^T=#\">&O#9\1>,+WQ
M)P/Q!^*?_!`3XM'X3/\`$S]O+]CSQQ=?!OP]:>$/#^I>)?\`@J,NIZQXR\&V
M/BKPWXYA\#_'W7+G]I@ZU^U!X(/C#P?H?B6]\'?M*7GQ6\-7NKV]U>W^DW3:
MMK!O?I#QK_P4&_X(Y?$3Q1\*O&'C'_@H7^P)K'B3X)^-=2^(GPOU-?VW?@EI
MX\,>,M5\!>,OAC?ZR+/3/BQ9V.K_`&GP/\0/&&A'3=?M=7T=?[5_M`6*ZU9:
M3>60!^>O[2'[=W[.?Q*_X*E?L1Z3<?M@_`KPSH7[-'[:_P`1O@-/\%KOXX?#
M?1_%.I?$O5?V0_VFO"WQ`^)/Q&\#:CJ-IXNT?3])^)^J>`/V=/@Q_:O]D6FK
M^/-5\?BQLO$H^(/PVNQ_2K7Y:>-?^"@W_!'+XB>*/A5XP\8_\%"_V!-8\2?!
M/QKJ7Q$^%^IK^V[\$M/'ACQEJO@+QE\,;_619Z9\6+.QU?[3X'^('C#0CINO
MVNKZ.O\`:O\`:`L5UJRTF\LO2_\`A['_`,$LO^DE?[`/_B9/[.G_`,\B@#[=
M\5ZI<Z%X7\2ZU8VXO+S2/#^LZM9V@7FYNK#3KB\@@^MQ/"JGU)]:_F%_8`^)
MOPZ_98^'7P3_`&G_`(X?LC:!X!^*7QW_`.">OQ4_:HO/VNO`OQSO/'GQA_:G
MU30M"^&/QC^.$'[5_@#1_#7A[3+CQ_XJ\4>,=*UW]G(77C?]IP^$/#-SJG@?
M0-;^#]]>7?@/6/V=_P"'L?\`P2R_Z25_L`_^)D_LZ?\`SR*^&]$^(W_!OGX=
M\3^)O%NF_MN?L0+JGB>V_LS['J?_``4JT?6_"W@OP[<?$CP[\7=4\'_![P-K
M/[1U[X+^!O@#Q/\`$?PGX6\3^-/`GP;\/^`_!OCMM"TVP\7:'K>BV=K8J`>6
M?MM_L*Z!X"_X)KS_`!;\1?`/X8_$[]IOX0?LU:_XF^)WQK\?>-?$=Q\1_P!F
M;4Y;+QC\>/VAOVB_V-=+N-%N_#>G_M0:7\4M<\2>._#%SX8\6?LQ7WQ)\2Z3
MX*_X3OXYV5AX&\(:3:YO_!1+PQX,^+WBK]OGQE\02?$VJ_L;?\$F?A/^TM^Q
MSXJ\02"#7/@[\<-4U_\`:P\<7'Q\^'!R3X8^+-QXH_9_^"]F/'>@VEEK%E9:
M#_PB@NUT+Q!J]CJ_TI\7OV@O^"$7QR^(L/Q5^(?[?'[%=QXPDT'0?"?BEO"7
M_!2C0/ACX6^*_@WPKJ^J:UX<\$?'WP#\,?VA_"'P_P#VB?`>E76N^)5L?`GQ
MW\*_$?P>-)\4^+M"_L7^PO%OB6PU:3X]?M!_\$&?VF?%_@KQS\9_VY?V$O%'
MB+P)91Z+ITFE_P#!0KP+X$TCQ-X6B\5^'/'4/@/XJ^%_A]\?/"?AKXW?#5?&
M'A#0]?7X8?&32/'?@`:O;W-U_P`(P/[5U<WH!/\`%#0_@W^T[XE_:L^)7[5'
MC>_^'/[.?[./P@^!/P9^*/B"3Q#IO@_PO>2"?PK^UK^U/X$\4W&KZ+>"?X3?
M%#POJW[.7PP^+.@6EV;SQ?HVB>-OAR;NR-W?6=W\<>%?V>]#(^`'@+4O@/;_
M``'_`&"_VZ_^"F0\0^%?V%O$_@G_`(0;PMH_P1^'_P"PU\8_&'ASPW\3?@?<
M?\43\/M&_:"_:`^!VE_M`ZW^SF?#VD68^W:)8_$SPQ:?$;5?B1X;L_L'XL_M
M$?\`!"CXV_"_Q!\'?B!_P4`_8QN/`?BGXOP?'S7+3PM_P4MT+X;^([KXLV'C
M&#X@:5XN@\>_#G]HGPGX_P!-;0O&%EI6O>&M*TOQ39>'?#EUH7AM-!T>QLO#
MNBVMCSUQ\9?^"%&I?"O5?@WXB_X*5_`'QMX/U/QSX7^)=GJGQ'_X+'>.OB9\
M4/!OCSP3>6%]X6\5?"WXX?$']KSQ)\:O@_JVDW-A"]I=?"WXA>#EQ<:F"I&O
M:S]N`/D[XT?"K7O&W_!#;]M+P-H?QE^*WPT^$W[,^K?\%//`?@SPA\-]3T'3
MXO'?P;_9Z^./QQ\*_`_X/>(O'&L^'/$/BZU^#W@/P]X,TGP;_8'PW\0^#[SQ
M+X0\.Z;\.M>\37G@?_A)_"/B/U3_`(+N_M;_``G\+?LF_%K]CS6/VE/AC\"O
M''C[]CGXK?&'Q)9^*OBIX*^'?CSQSX)T/PKKNA_#KX/_``RTGQ1<V>H^,/$/
MQW^)]B-!UG3?"]G>7O\`PK7P=\2="/\`8^N>+/"%ZWU!#^UA_P`$,[3]F>^_
M8\MOVY_^"?D/[.FK?#?7?A+JWP^A_;I^$L<FJ^"/%-E?V/BJ'5?&P^,?_"P-
M2\0^*/[5U;5/%'CN[\5W7COQ'XCU74_%.N>)KSQ!>WNL/Z'\4/\`@H-_P1R^
M,WPK\<_!3XE?\%"_V!/$?PQ^)7@G7OASXW\,#]MWX)Z.=;\&^)=(GT/7-)_M
MOP_\6=*\1:>;S2+B>U&J:5JMEJUH&\RQOK6\4,`#]"/A;XY\&?$KX<>!_'OP
MY\7>%_'W@7Q5X8T;6/"WC3P5KVC^*/"7B31[RSA-MJ>A>(=`NKS1-7TZY`;[
M+>:7=W-FXP58@`5Z'7Y\V_\`P59_X)76T$,$/_!2C]@%8;>&*"%!^V1^SJ=L
M4`$40'_%Q^@4``GZ'GBIO^'L?_!++_I)7^P#_P")D_LZ?_/(H`_*O]N'X3_%
M?X,?M'?%K]IYOV=IO&OQ.\8?M?\`[`%Q^S)^W%!XY^'$5]\#?@CJWCS]G/X#
M^/\`]D#2=+U?Q+=_&WP]/\1O%&J_&DZQX$\!?#+6/@/\2-&^/&H>+/B3XULO
M%-IK&CVGV[I'[/OPS_;7L/VN?C+\1O@SX$_:'TOQ%\?=5\(_!'X6?&SQ5KFC
M_!3X@Z-^QYHNN_!;PKHOQ5TK3O"GC?1=?^&__#1\_P`?_'>BCQC\,?C!HVD7
M>O>&OBGH'@O6?%/A[PA=V7#:_P#M#_\`!!_Q1\>;3]I+7?V[?V&KSXH6>O\`
MASQ@Z#_@HMX/LOAAK'Q`\'>'SX4\'?$_Q'\!['X^VOP)\8?%CP?X9%EH?A;X
ML^)_AKK'Q'\-6.A>&;/0_%-F/"?AP:3)XU_:/_X(5>/OA?\`#?X1:W^WY^Q5
MI_A7X/:O'KWPKUKP5_P4D\-_#+XK?#S7?[,UK0[[7?!OQW^&_P"T-X4^-GA_
M6->T#Q%XCT#Q3JVF?$&UOO&&C>(M>T3Q7=ZQI^LZM9W0!\E_"?PQI7C?]F'_
M`()W_LM?%#0;*\^$OC#_`(*@?M7_``0_:$^`5^@UCX*:7:_`^']NGQ_X<_96
M\-V]_<WFG>.?V6/AQ\4/A'X'T'X2>%_%%G9V7C'X;^`?!%AKOP^\"60O?A7X
M:]8_96B3QWX6_9@_8ST>ZU'_`(0+X3?MI?M_>+]$MK>]^UVWA7]E_P#80_:7
M^)WPQ_9X\*6-QJ-MJUM<:?\`#KXL^,_V<])^'NE76;+_`(1SX27-B%O++PI>
MV9]B\3?M*?\`!"GQ=\"O#W[.6L?MZ?L.K\,?"&NZ#XP\,/H?_!1/P5X7^)F@
M^/?#GB7_`(3*Q^)VE?'CPS\?M(^.EK\6;SQ?-?\`B?Q+\6;?XB+\2/&.LZYX
MEO\`Q=XFUN\\5>)&U;0^'/[4_P#P0S^$GAFU\(_#C]O+]@WPCH=A\((O@59Q
M:=_P4`^'']H6_P`.UU7Q%KMY%!KES\<[K7!XPU[Q!XIUSQ/XH^*7]J?\+4\8
M>)+X:_XK\::OK=G9WMH`?G=XS^%W@3X,>!_VQ?VB/^"<>F:QX*\(_LE_L`_M
MG?#7XT_MEVT'D^./VZ?VKAH-AJMCXVU7Q]H%OX?M_P!HCX@?LY^,/`WQ&U_X
MG?M&:_I.L6FC_&#QQK7PY^&FLK?:1\8-&\-_=_[-'[/7A'X+?M0?M5?LK?LE
M:U=_LT?#'Q;^Q9^Q=\7WU7X0Z-X)U:?PK\:/%7C?]I7X9>*OC+HFE>-_#7C;
MX;W_`,5_B?\`#?X5>!U\4>,?&7A/QA_PGFL^%=,\:^+K+Q-J%I>F^Y+X#_%#
M_@@I^S9IUKX<^%O_``4;_9W_`.$%LO`5]\+M/^$WQ(_X+$>./CG\#K#X?7]E
M%I<_A2S^!_QQ_:]^(GP>MM/73(%TNR^S>"$N=)TJ>XT^P>SL[V]CN?1?V9_V
MGO\`@AE^R)H_B31/@-^WY^Q'H4/BZ;PV?$&J^-/^"C'@_P",GBV\T_P3X;L_
M!W@CPU#XX^-'Q^^(/C2P\#>`_"]DND>"?`6F:]:>!O!MG/J7_"*Z'I#:OJ[7
M@!X=^S1^T)X$_8%_X)>W3>)?C/X:\*ZO>_MN_MM_LZ_"CXJ_M1_$VST_1[[X
MCZY^W+^TKI6E>._C'\3O'&I:7:ZD-!\/Z'XB^*/Q!U+4M6L;WQ=9^%-;L-"+
M>*-:TBQO/H3_`((>>/OA7XK_`&*=8\.?#'X]>'/VA?\`A7_[57[:VC^(?'FE
M?$3PA\2/$FLG7?VN_C=XK\)^*?'&J^#[@Z>-8^(_@[6]#^(UE>+9Z19^(M%\
M2Z=X@T.R&B:I8Y]#^%G_``4'_P"".?P6\,WG@_X:_P#!0O\`8#\->&]0\;?$
M7XB7FG_\-O?!/63-XR^+7C[Q)\3?B!K#7NO_`!8U:_4>(/''C#Q%KW]G"[72
M=)^W_P!GZ%96&C6=C96A\+/^"@__``1S^"WAF\\'_#7_`(*%_L!^&O#>H>-O
MB+\1+S3_`/AM[X)ZR9O&7Q:\?>)/B;\0-8:]U_XL:M?J/$'CCQAXBU[^SA=K
MI.D_;_[/T*RL-&L[&RM`#]2J_#3X:_L^7=A^W!_P5(\!?$+]J+X]ZK=?&/\`
M8B_9`U+Q?\<=1\7^"/`_C3X4:-XC\7_MW>&Y[;X+3^%_!/A[P5\'?"_@/P]I
M4-SX8O+/P_>:Q8ZS_:/CKQ;XG\3_`!$U76O%U]]E_P##V/\`X)9?])*_V`?_
M`!,G]G3_`.>17S'\6OVH/^"%_P`<(?CI#\2?V\?V$M87]I;X1>$O@1\;+C2O
M^"@WP^\'WGC7X3>!M3\?:KX=\&M>^"?CGX>NO#]O;77Q/\>I?:CX7N-%UKQ#
M8>(KO1=?U'5M%M;&RLP#S']C^U^`W[.EI^V7^W7^S5\'=)_9[_X)[Z3^SSX3
MM_AIX&\#^$)_`.E?M-^*/@?9_$;Q7XJ_:T\'?#NP%GHG]C_%'P]KO@[X7?#'
MXC77A[_A/?VA++P?;^.+V\U?P/=?"O6/$?F7[;?["N@>`O\`@FO/\6_$7P#^
M&/Q._:;^$'[-6O\`B;XG?&OQ]XU\1W'Q'_9FU.6R\8_'C]H;]HO]C72[C1;O
MPWI_[4&E_%+7/$GCOPQ<^&/%G[,5]\2?$ND^"O\`A._CG96'@;PAI-K[?X&^
M.G_!#7P!X<\1>$-/_P""FGP*\6>%?%)\&)JOA_XQ?\%E?B!\?-'AA^'_`(CL
M?%?A>'P]9?'#]K_XA6_A"U76-+L1K-KX5&C6GBW2(/\`A%_%J:UX?+:2=/XO
M?M!?\$(OCE\18?BK\0_V^/V*[CQA)H.@^$_%+>$O^"E&@?#'PM\5_!OA75]4
MUKPYX(^/O@'X8_M#^$/A_P#M$^`]*NM=\2K8^!/COX5^(_@\:3XI\7:%_8O]
MA>+?$MAJP!O_`+47PWU:\_;D_P""3WQNNOCA\6?%'AR]_:'\<>%?!GPAOKCP
MOHGPKT2UU7]@+]JC5=;^(5_H?A_PAI7B7Q=\2->N-$L3_;OCKQ7K.C^#M'N-
M2T/P%X8\(?\`"0^,;SQ+Y[\3/#7[*OQ@\-?M&_M<_MBG5_%7P"/[6MKX$\%_
M!F;2K3Q_X=_:=TC]F?1_$?[-OPR^!NN?!?\`X136=3^.UMK_`.UCKGQJ^(OP
M6^#FD6]\/''Q)O?AMXI6RUD6=G:#Z,\9_P#!07_@CI\0?$GPG\7>+_\`@H1^
MP%JOB'X'^,]0^(GPNOH_VW?@EIX\*^,-5\!>,OA=?ZO]ATCXL66FZPL_@7X@
M>+]!&FZ]:ZOI-J=5_M"TLEUFTTF^LOGOXF_&7_@@M\6?!/P2^'WBG_@H/^RA
MIWA[]G37[OQ5\&KKX;_\%6K[X-^+/!?B>_T'5_"M[XCA\?\`P?\`VHO`_C[7
M_$%QX?\`$7B+2GU;Q/XCUF]-IXB\1+]JSK6K&[`/F_X<?L>:3XG\4?L??L;_
M`+8'PNT(?L\>,/@O_P`%,/VH/#/[(?BV]A\2?#_X'?VK\9_@!8_`+X2WUO<Z
MGJOA*_\`%'[*_P`%OCQXRT#PO;^%KN[\(?"#Q??ZBWPDO+;0/"?@SQ):;G[0
MVB_%#]I;_@W3T/XA>-?CY\8O"^I6W_!-:3XH_$H^"]3T+3];^/VIZ3\!H-=T
MK3/B;XWUGPWXA\;?\(AKVHV$6O>-;7P#X@\'ZQ\2!>SZ'X@\3WG@?5O$?AOQ
M)[#XZ^)O_!!'XF_"SP=\(OB#_P`%%?V;O&GAWP#KGBS7/"7BCQ)_P6`\8ZG\
M:-+?Q]H6M>%?'6C']HNX_:Z;X_ZAX)\8>%]=U70/$O@#5/B9>^!=9T<V>GW_
M`(9N[/2M(M;+Z%\;?MV?\$7/B'\$?$7[./BG]O7_`()W2_!#Q5\.;_X0:Q\.
MM$_;.^!'A/2#\--0T#_A%9_"&DS>$/BGH.I>'=.C\/'^RK(^'[W2+K2;3R?[
M.NK,VRF@#\_?^"L/[<'P"'C[X-?L_>)/VM?@M\&Q^S'^TU_P3D^*WQ=^'_BK
MXT_#[P'XX^('B+Q%^T[\$/%5AI&J^%?%&HV?B.Y^#_P;^"PUSXW_`!-U^U%G
MHXU?5?A=?_VV;#P1X]T@_JA_P5.U"RU7_@E)_P`%'-5TN]M=0TW4O^">W[7M
M_IVI6-S#=V>H65[^SA\19[.\LKNWW6US:W<$\-Q9W5N[I=)*K(=IR?9=!UO]
MD;]NGX5Z9=?#WXD?"?\`:9^$/A3XI?#_`,1Z?XC^#/Q<TWQQX3TGXJ?!'QEX
M.^*_@F&?QA\+?%MQ:'6?!OBG1/!WB>[\,7>K-:WEI_9UGK^C7VAZJUG>^5_\
M%8O^467_``4L_P"S`/VR/_6=?B-0`?\`!)W_`)19?\$T_P#LP#]C?_UG7X<U
M]_U\`?\`!)W_`)19?\$T_P#LP#]C?_UG7X<U]_T`%%%%`'Y^?$8L/^"IG['&
M%R1^P#_P4K[_`/5Q/_!)SZ]L?G[5DZI^TC^WK#J-_#IO_!.!]0TZ"]N8M.OI
MOVNO@U8S7MA!,4MKR>Q&D79L)+N+9<FT%U=FVW;&NF8?-VO[1G[./QY\?_'G
MX'?M%?L[?'+X1_"'QU\(?A'^T/\`!;4M-^-/[._C+]H+PGXK\)?M!^,_V9O'
M-_?6.G^!_P!IG]F;6?#'B#POK/[,VAV]G=W.O>)+'4+'Q)K,<FC6EW:65[6"
M?AU_P5*.1_PV/^P%@\Y'_!-;]HH`GZ?\/7V_D.E;X:O2H.I[;`87'7226+EC
M(J-KZIX+%X23O=)W;T6EM;W"48?%1C6]=E^*^7H>#_%[]NG]MCX0>'-.\0^+
M/^"==]HUCJ7BGPOX;MKVP_:`\*_$H3WVN:S964&C_P!E>`/"=YJ5C>Z]O.@Z
M+JET#96OB+4-+)L]9)72;WU*/]I;_@H!(J./^":C!77='YG[8/P=A8$\8EAG
M\/++"1Z$,?K72'X<?\%2CS_PV3^P&#G^'_@FK^T4/_@KX'X?2E_X5Q_P5*/_
M`#>1^P$WKG_@FI^T2>GL?^"KQ!_'`KOGF67.C2A'AO)U73=Y_6^(7S7Z./\`
M:ZY;:=9==-7;H^LTN7_<L+9>>+3^_P"M6_K<[3PIK'[3/QX^&OQ&\-_$3P%X
M^_8.\6`Z$O@WXA_#/XE?L^_&[QB\(O/[5U>\T*#QA\+_`(G_``XTZ8#3!H&K
MVOC+X9^)%N]%\137F@-9:Y;)?:/^>_ASX_?MC_!O]E;]AWXJ:?\`$?7_`-LG
MXC?'SPEK'QB^).E_M`ZW\"?@)X?CT&']DO5/B[K'A32O&/[/7[)EM/X8\+>&
MM:\.7NJ^#;>S^%'COQUK/B35K;0/%GC-?!$UUK/AK[4/PU_X*ED;3^V/^P"5
M;.5/_!-;]HKD=>__``5?Z^N0<5P7_#-7[?W]A^&/#0_:#_X)CMX>\$Z/<^'?
M!F@?\.JOC6NB^$=`G\.S^#Y]!\,:6/\`@J6VGZ!H]QX5GN/"]UI6DVMG9R>'
M)Y]#:V_LYFM3Y565.I4=6%&.&A>_U/"2Q3@E9*R>+Q&)Q=KJ_O8IN[>MK)<T
MI<\^:/X=?OZIG@MW_P`%>_%%SXM^.-MX2_8\^)7B;X=_#/P?XGU+PGX_FTG]
MI#P_I'B'QOX/\$Z%XQOO#GQ`^(VK_LB+^RKX`\,:K?:GJ'A;PSX@\&_M2?&'
MQA>ZS#H?V_X8Z.-?O%\.^O\`A;_@H?\`$IOVI+S]FWXA?`GX?Z7'9_"7X@>,
MG\>_#+XH_M$^/_#'_"QOA-X6\*ZM\3/AQ!XW\<?L/_!OX">(;70/$^N:MX6:
MZ\!_'CQA\4M'_LO2[[Q]\%_`5_J^L^'/"/$2_P#!/3]I*?XB:I\7)]?_`.".
MLWQ7UOPQ:^"M:^)\O_!&3QX_Q"UCP=8Z/IGAVQ\*:IXV/_!3AO$FH>&+7P]H
M>DZ%:Z!=:H=)MM&TO3--2T2RL;.V2]/^P;^UO_PG?COXM:;\3?\`@D_X=^,_
MQ+TZXTSQS\;/#G_!(3XG:/\`%_Q+#/X<O/!T<^M_$>U_X*=GQ9K%S:>&+ZYT
M&RN-4U6\^R:1*U@`;%C:LB3RCQ#_`,%?_B]X;\'?#PW/[&,6L?%KXJ:5\/?B
M?X-^'WPT^('[2G[0FA_\*(^)'PSU7XB:'KWB+Q%^S%^P;\;?'^D?&&VN=%OM
M`UGX<VGP<UGX5V(N-,UX_M&MI^J6H/V]\._VW+CXF>*O#_A#2?A+JGA77?%^
MM_$_1=%TCXBZ_>>$_$VF3?#OX,_"SXM6\7C7PH?"-[K'A;4KB[^*EEX0\4:$
MRW][X.N]+N+U_P"V+R[31T^(?#?_``2=^+OAWX':/^SE=7G_``1M\7?"+3=?
MTOQQJ7@WQE_P19\2Z_H7C#XH:5X9M_!TOQE\8^'#_P`%);;PQX@^,&JZ!!]C
MUOXB7/A\>)+Y+J[M!?+97/V2O9/#'[#W[7/@KXDW?QD\&_$/_@DGX2^+^H>'
M]&\(WWQ5\,_\$>_B=H/Q)U#PIX<T*Q\+:#X:OO'&D?\`!4&T\2W'AW0?#&DZ
M7X?T71+C56L-)T33M.T6QM+6PM+2U4`\._9>_P""F_[2_P`0_@WX6\8^+_@7
M\)M<\8VWAJY^-'[0(U?]J?2/AGX&^'OP<L?"GP6UN^U+X%:WXG_9P\)Z)XJU
M?[!\1[GQ!_PKGXW^-O`>B^#;R"?1?%O[4^KZ+JOAS7*3X[?\%'?VE;S1_C'X
M9\*_"N[_`&=_B'\'_C]\&G\(Z9J_A[XU^(_%OQQ^".D_'\>'?BGHXTOXW_LA
M_"?X.Z@/B-X(TBW\+V7C#]E;XQ_M3^'/#=[\1M/O[+XG:1>6W@W5_%_H\?\`
MP3@^/\&D>"-`COO^",T&A?#?Q_??%CX<Z)!_P1:\:1Z3X`^*VJWMOJFJ?$OP
M3I@_X*9?9?"WC_4M0L;+4;[QEH-M9>)+N]LK6\O+\R6JD;'@#]@#]IWX5ZKX
MOUWX7^*_^"/WPXUOQ_XLT7QQX\UGP'_P1M^(/@_5?&_C?PUJVIZ]X<\8>+[_
M`,/_`/!3K3;KQ-XGT#7M<UO7-%U_5[B\UC2-8U74;^PN[>]O;MF`.'D_:?\`
MC_\`&K3/VFKCP5\=M6^&_@WQ%^U]^QY\+_V>/''PT\)_"#6?%G@#X(_%'XA_
M#[X6^,-9T*\^)'P_^)W@GQ1K/Q$N;+QCX\T75O'?A+Q?::-H_C'2K&QL+3^R
M$V_>O[*_B#XB6'B[]H/X(^/?C%XB_:('P.\9>"=,TKXQ>,]`^&7A[X@W+>/O
MAUH?CZ_^'OQ,L_@QX)^&/PPN/&O@TZO9:]8WGA7X9>`T;X:>/OAK::WH^K>)
MK36/&/B;Y2U[]A?]K'Q3\.=3^#GB?QW_`,$CO$7PCUK2_!N@ZQ\+->_X(\?$
MG5_AOJNB_#F'3X?A_HVJ>!K_`/X*@7?AK4-(\"6^E:9;>#-,N]+:R\,K8:<-
M"2S6TM0)OAM^Q%^V/\%?^$,A^#?Q>_X);_"'3/AWX>\=>%?`_AOX6?\`!*7X
MX_#OPAX7T'XG>(/"_BKQ_9:3X-\&_P#!5/1_"=O_`,)3XG\&^&];UBY&D&\>
M_L#>?;$:[OOM@!B>.?V^_CS\+OVH_CU\*M-^$W@WXM?#'X=_$S0M1\3^*O$W
MQ?F^%FO_``I^$UQ\._V(+&^TCX=^#_#WP+^(`^,OC"Z\;_M">,O&=EIGCKQO
M\-[(VMC<:#_PL"SLGT:UL?K+PK^U)X]\0_M&ZO\`#2[^%/@#2?@E%\1/%?P5
M\.?%2Y^/NFV/Q;UCXR^#?AO8_$[6]'G_`&=/$/@#PY'<>"+GP^/$8T;7O`?Q
M@^(_CZ[&DVGBK4?A+H_PXO-6\=^&O$;S]E;]N[4M8\1:_J'QT_X)=ZAKWB_9
M_P`)9K=Y_P`$G?C+>:MXH\J+PK%#_P`)%J<__!4UKO6ML'@7P.J_VI<W6U?!
MWA15X\/:.+/EM3_8@_:\UKXI77QSUGXB?\$D]7^-E]I_A[1[SXP:C_P1^^)V
MH?%.[TGPGKNA^*/"FF7'Q!N?^"H!\6SZ?X7\3^&O#OB#PW:OJS6NBZWX=T/6
MK`6M_I-C=6H!];?M`_%;]I7P!K^AV'P1_9/D^/VC7ND->:SXB'QK^'_PO&B:
MF;J6*/2$TSQ3:W>HZL6MX4NI+RV6VM%\^UMT,[?:VL_SL_:J_:;_`."HUO\`
M#G3?^%<_L;>,O@KK$GB_3$N_%O@KQA\./VGM;O--;2M:>70I_`>@^#=>GT?3
M[BY6UO+SQ7<V0MK%M-M]&6^2\U^T!^RC\.?^"I#8S^V-^P$Q`X4?\$U?VB2H
M_P#.KK8YST`_+@._X5O_`,%2@&Q^V-^P'SU!_P"":_[19'([`_\`!5M0O7MD
MCCUKSL9@L1BX580S;&X5UHV3PGU-<NJT@WA/K*M;?ZTFNC2T/L.'N*<JR*OE
MV(K\`\(9_7P$U-XC.GQ+BECFN:RQV#AQ%#(:D/>2=/\`LGZK)1BY8:4M7\Q_
M`#]IC_@I?/\`"+PC+XU_84\1?$_Q08M734O'?B;XO_#'X$:[KRGQ#JRV+ZA\
M*]6\):7JGA5],L?LFD*USI]E%K%I80>)+.*2TU2#?];?!KXT?M;^,?'NFZ!\
M6OV)G^#G@VZM-3>_^(/_``T+\,/B'_9=Q;Z?//8V[^&M!TZQUF\CU.YBBTY;
MBV:46C7,-U>VHM!<M%A?\*Z_X*D#&_\`;%_8%8[0,#_@FQ^T2&R.!@_\/73@
MGU'.>V11_P`*Y_X*CNX(_;%_8%4XP-W_``35_:)9CGJ&8_\`!5Y6..HR.0>]
M*A@\31]DIYKCL2J#Y9<T<K:DE&S4G]2^M6Z7^M+$ZW<KBS?B?)LTJ9C5I>'G
M!V45\PGC)K$8#$\80^I/%MM/!827%DLHC]4;?U7#/*WEJ247@WA8QPR^+?`?
M[>7QJ\#^*?AKX"_:.^(?A[2K7XE_MD?M)S?#3XHOX<\*^&-$\<_LP_"7QA^U
M!I?C#X0^(]UHVFZ=\2?V?+?X9^"-4UK7M+M/#>K>,?A5JWA+Q197>M:WX>^-
M=Y8^;_"O]O[]I'XY?"3X^:#;^(/BU\*?C%XO\??"KXH_`&V^(OP$TG]ESXCO
M\#/BW\1X/#M]^S5^S+??MK?"_P"'OP+^-_[1/@WP_H9TOP;X]\8VGCOX0^)?
M'OQB^']CK_BG^Q;H7FC?9'BC]D+]MSQMX9MO!/C/XP_\$K?%_@VSUCQ9K]IX
M2\3?\$D_BSK_`(9MM>\=:9XOTKQQK=OH.L?\%2KO2X-8\9:3\0/'VE>*=36U
M%[XCL/''B^RUI[NT\1ZRM[)\1_V2/VXOC%ITVD?%OXS?\$L?BEI-QX5USP+=
M:3\1_P#@DI\6O&^G3^"/%.I>&M6\2^$9[#Q/_P`%2M6MY_"^OZMX(\&ZIK?A
MYQ_8^KWOA3PW?7]E>7F@:0UIZ1\@>)?"3QA^TE^T5XO^%?P8'[:7[7/P*UGP
M=X._:NO/BU>7/PB_X)\6'[0$_C7X9?%KX#Z#X.\'_&F>V^#O[47[-&L:GX8\
M&?%.>[N_%/[-5IX$\'^+K75=$O[ZRTG6[+6-%M/-Y?\`@J)\2O\`A8G['#33
M>--:^']AX-\#ZY^U;XG^$'[-7Q/^(WP:^()^.WB2]^&?P^\;7OQA\,>"OB%X
M(_9E\#^#-`T^P_:UO!\1/BQX;N]7^#_CCPG9K>^([-F-[Z9XC_X);?%GQGX,
M^'_PY\8:7_P1(\6?#[X2Q:];?"KP'XE_X(B>(]=\&_#2U\5:E#J_B2'P!X6U
M/_@I?<Z%X.@\0:K;PZIK:>'[&P&KWT,-[?BZO%WU[U+^R_\`M[W&B^/?#$_Q
M[_X)@S>'/BI!-;?%#0)O^"4?QEFT3XDVL_@_2/AS/!X_TIO^"IAL/&$%S\/]
M!T/P(]MXAMKY6\':+I?A8E]#TNTLD`/+_B)\<_C#%\0/BK\5=)_;"B\&ZO\`
M"G]IFU^!O@/]@[_A'OV?1X7^,&@^%K?P!JGB/PUXDN/$_A&[_:/UKX\?%#P+
MXWO_`(H?#+5/AC\9?`?@_P`->&_$/P9OM>^$GC'1-*\<GXD['[??CO\`:UB^
M/OPN^&7[-.J?ME?9M0^!/Q5\=ZOHG['=C_P37_M.?Q9HGC;X=>'O"VI_$S5/
M^"B%J=-3P?:C7M5M!9_":Z_X2-[N^FNM1LVCM+-ASOQ7_P""<W[0GQW\::-\
M1OC?J7_!&KXS_$'PYIVE:+X>\??%;_@B]XV^(OC/0='T2^N]5T?2]%\4>,/^
M"F^KZWI&G:1J-[>ZG86EG?6MK97M[<7EDJ7=R[-]"-\&?^"EDFOP>*G_`&JO
M^"=C>*;?2+KP]:^)'_X)A_'UM=M]`O;RRU6]T.'5_P#AZU_:4&D7>H6-A>W>
ME+=BSNKRQM;I[5I+5)*`/GOPQ^W7^TW\.?%?QL\+?''X=?"77M/\-ZI\1M`\
M`>.D^+7B#PQ;ZG\8OAU\'O@3XPO?A9;_``Z\'?L\_$'Q+;?"_7_%'Q`U;2_!
MGCZTU?XJ?'K6?%\]MX'T#]G[Q@;OPU?:OU?[-O\`P4C^*G[0DOA:%?V9_#?A
M#[)X;_:8\3_&:36OBI\9_#%WX$A_9Z\56/@>PTCP?X'^-'['OP3^+7BCQ!XS
M\2Z[H?V_2?BE\-/V?KOP=I4'B74"/$K:5X<LO&6UXM_9"_;;\>Z9XBT3QS\8
M?^"5OC/1_&">)D\7Z1XL_P""27Q;\0:9XIC\;:/8>'/&0\16.K_\%2;RUUH>
M*/#^DZ7H7B<:DEW_`&WHVG:?IVH_:[*TM+9:7P]_8S_;+^$ND6^@_"GXI_\`
M!*+X8:':Z)>>&K71?AY_P2)^*G@K2[;PYJ<>E17^@P:5X=_X*AZ3:0:->0Z%
MH@OM)%N+&[31-+22R8:99[0#QN\_X*L_M">'/#.F>,_B#^R%\&?`/AW4K'X0
MZ@EUJ?[8_C'6[M#^T_X$UOQ#^S-H%OHGA;]CG7]3U_QAX@\=>'+_`.'?Q:\+
M>&+36=6\(WFH>%6^`Z_M/>*/$(\"67K7PV_X**?&CXQ_`_X>^+?AQ^S'X&7X
M[^-_C!\:OA7-\)OB?\:?C;\"_AUHL?P*T[Q#JGC#4[_X@?%_]BCPG\;=(UFZ
MT_2+$:+X+\=?LI>`]7>^N=4;4;O2O"_A^[\27<_BS]BS]L;Q[X6U'P/XW^)W
M_!)WQIX(US1]!\-ZSX/\6_\`!(3XI>(O"^K^'/"NF7VB^%M!U7P[J_\`P5!N
M]+OM'\,Z1J^KZ5H>E75F]EHUAJ>HV-A:VEG>72OR-_\`\$[_`-HS5/A+#\`-
M3UG_`((X:E\"+?5=,UZW^"E__P`$8?'5[\(K?7M%M+:PTG6H?AQ<?\%-V\&V
M^K:3I]G9VEAJ2Z2+JSM+6VL[*5$ME4@&-^S7_P`%>]8_:&^%?QA^-2_LE_$3
MP?\`#GPE\,KKXP?"?Q/J5M\<K;PG\1/"-OXEB\.V^C>(_BYXX_9@^'OP"/C_
M`%2VOM*UW1;3]F#XQ_M@_#;5]'A\27^G?%B[T_2-'O?$O8?&S]O7XO:5X_\`
M$V@^!_`OA2T^%G@OP5^V;+XW\6Z=\3HH?BO!XG_9M\;_`+/?@[P[J/@;2M8^
M"OQ"\`>1JE]\7+FSUK0_%%K>?8B;F^^V&\\)C1/&&;X>_P"">7[1_A+4?BOK
M'A77O^".7AG5?CWI&M>'?CGJOA[_`((R>/-'O_C1H/B0WLOB+1?BS>Z;_P`%
M.+:Y^(FCZ^;^_;6]-\8OK%EJYOKDWZ7+74I:;0_^"?\`^TWX8T#PEX3\.>*/
M^"/?A[PK\/XO%-OX#\,:'_P1K^(.E>'?!,'CBRM])\9P^$=$L?\`@IU::=X<
MB\8Z=8V6F^)ETBUM%\16-M;V>I"\M+=`H!P_QS_X*M_&WX->&=5\;V_[*7PH
M\2>$M9B^+'BSX/P6W[2OQK\2?$_QA\,/@;XJU7PC\3O$OCWX$_`C]A7X\_&7
MX<:QHFI-X.NFO-$\%?$OX$>#M(\175E\=_V@_@EXL'@3PA\2?H3XD?M.?%#_
M`(5G^WCX]\(Z^_AS_A6/[%'@/XX_"&WFT;PWJDO@GQCXH^$GQD\8S:C.U_HM
MS:Z^PU'P[X<?[+KXUK1@=)8"Q%E>7=K=>%^)_P#@F)\9?&OBOQ#X[\96_P#P
M12\7>-_%GC#1?B%XK\9^)_\`@B5XKUSQ3XE\?>'(;^'P[XV\0^(=5_X*8W>M
M:UXOT&#5]631O$VIW5WK.DIJNI"ROK<7=R']R_X9E_;Z71]=\.?\+]_X)C#P
M]XI\(Z9\/O$V@_\`#J3XSC1_$G@31--O]#TGP3KFF#_@J9]DUCPAIFBZKJFE
M6'AG4[>ZT>RTG4=1L+*S6SO+I7`.8\;?\%%/BQX#^)/Q@\-ZI^S;X'N?A]X2
MU[QE\,?A'XYA_:&UJ/Q?\2_B[X5\*_!?Q%8V7C_P`?V>FT+X0?"C5;_XQ?V7
M??$?2OB;\5/$GARS\-ZCKK?"^\L+I?L?DOB'_@I-^T+\&OAG;WOC;]GZU^+W
MQV\6_M4?'SX5I\,?A9?_`+17Q8\$^!/"?P<LX+[6]-\/>./V8/V%_C9\6?&]
MQ:7$]AIGAB\\8_LX^`;76/MNH'Q[XI\!WNC_`&&\]SUS]D_]NCQ39Z]IWB;X
MW_\`!+;Q%8>*8O%MMXHLM>_X),_%_6+;Q);>/M`M_!_C>'7K:_\`^"I=U;:Q
M!XT\*6-CX8\4KJ:W0\2>'+.VT36UO+"U6U'E>J_\$W/CWKWPFT7X!:Y=?\$9
M-:^!'AO7H_%7AOX)ZK_P18\8W_PBT#Q1#:7]C'XDT3X<W?\`P4QN/"&DZ^MA
MJ5]:KJUII%K?"RO[JR2Z5+V[W`'T7\&/VYO$OQA_:8N/V;G^!B^!=0TCP#%\
M8_$.L>+/B3#8Z]HOPQ\1^%_`.M^`M)G^'5UX(M?$MO\`'BUUGQS8Z9\<O@WJ
MO]CV7P)T:?PGXIU3XB>)D^*'PLTGQ?[OXJ^)_P"T/I7B#5].\-?LQ/XGT*SO
MI;;2_$<OQE\$:&-:M8\&+41H]Q;7%W8+<'I;7)%T@QO48`KX_P##O[''[:/@
MU_#4_@[XL_\`!*7PM-X-\2^(/&7A";PW_P`$C?BIH,GA3QAXOTF;P[XL\5^&
MVTS_`(*A6SZ!XB\4^'[BXT+Q+KFE_9=7UK1Y[C3M1O+JP9K4^P_\*X_X*EG&
M?VQ_V`V_[QK_`+18^F/^-KC5XV:Y?B,QH4J>&S;%Y2^N*RK^S6_1?VIE>:^[
MUT6ZW$^9KW:GL?DG\O>37GT_0ROBE^V#\8?A!9:3>>.?V<[/PLNN7PATV2[^
M,/A[7A?QV4UE/JL,-IH&C7<\)%C*+4ZC/ML["[O;:Z=;Q2ME=^C:;\<OVD]9
MTVPU?3/V35O=+U6RMM1TV\M_CSX"$=Y87L$5Q97<)_LUMRW,$\3J<;><@D$9
MXL?#K_@J4!C_`(;'_8!Z\9_X)J_M$?H/^'K^.?IV^M!^'7_!4KC/[8_[`)[#
M/_!-7]H@_EG_`(*O\?A]:^7I<*<2QQ.*G7\1<_>"DE]3P:ROA=8G"MK][]8Q
MG]@NCC%UC?"X7E6[Q.YCR5?:-_6YM:6]S";K_MU_=:WJ8G[2WQS_`&F_#/[*
MW[2WC6T^$GB+X)^,?!OP<\3^(/A]XP\)^.?@Y\1?$Z^+(!!!I]IX<T3QQI]S
MX!7Q#F=KG1KCQ_97O@4WD,">(,6!<'XMN/VU?VS/V0/"-K;_`!0^!O[6?QX\
M1?%7XF7>G?"/PK^U)H7PLUSX[Z?X6\&_#TZ]\4M4O8/^"+'[*W[77@B?PB=9
MN/"FF_";3=>^&.C^([[6;[XDWGQ+^(/A#PII/@+^U_M77?@Q_P`%+?%.C:CX
M>\4_M5?\$ZO$GA_5K9K/5-#U[_@F%\?-8T?5+1L,]I?Z7J'_``59N;2]MR5!
M:WN;9U8@';D5YU\9_P!CK]M+]I#PI;>!/VA_BS_P2G^/7@BPURT\267@SXU_
M\$COBO\`%'PM9^)+&ROK"R\067A_QS_P5#UW1X-9M-/U;5;.SU6VLUOK6SU+
M4;..Y5;R\W?899A*N"PBH8G,<5FU97OC,9]56*U_[%N%PF&V77#?\#9+E7IU
M[_=9%/Q=_P`%.O$6C_M$>&/A!X=_9*^->O\`@RZ^'?PU\6^._%]Y\./VF[/Q
M9\,_$?Q9\(:GXRT30?&&G^%_V5O''[//@[1?!VG_`-AVOQ8U;XM?M7?"OQCX
M.NY_$JZ;\,_%I\-V8\1^E^-OVB?C5XC_`&*_@[\5K\>$?V6OB#^T3XJ^`WA:
M;Q1HGBK3_C9HWP(\)_'WXA>'/#FA>*8-<\=?#CX?>&M9^)%SX7\2Z)H.AVGB
M#X?:S\.?#7QL\5:%9:A9_%;P/H]TWB_QKQ!^P#^U!XM\<^`_B;XK\6?\$@/$
MOQ)^%GAJP\(?#'XA^(/^"-GQ!UCQO\.?"6DC4!I7A3P#XKU'_@IU>:[X/\/:
M6-6U5K#0]`O;'2K-M5U'[':+]LO`_JVI?L]?\%$-9\"ZA\,-7_:2_P"":VJ?
M#/4_"ESX#U+X=ZC_`,$LOCC>>![_`,#WNCG0;OP=>^$;C_@JI)HESX6N]!F;
M1+OP_=63:0VD_P#$N>Q^PL5/HC/GKP7^VW\;O@7XJ\<_`GQEX>^-7[0'BKP'
M\9+^+Q'XM_:BUC]E'X7_`!#T'X#Z;\&?%/QAU?QQH<W[#.B?$+X?_%"_U30/
MAGXKU;X2^`O%'P>_9F\>7H\5>"?"WQ+_`.$=M#>_$>O5O"?_``4A\8B631OB
MQ\"/`_@[Q:OA"^^*(@\`_M#GXI^!X_AA?_L^?$#X^>`=3O/'-S\'/A\UMXQU
M6V^&FN:#XS\++X>NM&\(6E[H?BOP]XV^(VA:Q:9J?##]BK]L7X):!X=\)?!G
MXG_\$F_A'X5\'ZSKGB'PIX7^&/\`P2$^*7@'P]X7U_Q197&F>(M=\.Z)X5_X
M*A:3IVC:QX@TZXGTW7-2TRUM;S5[&XGLM0NKQ&93P,O_``32^.<_P_'PGF?_
M`((N3?"T?$,_%[_A6DW_``12\8R>`#\639S6!^)Q\&_\/,?^$<_X6";">>S'
MC0Z7_P`)*+.9K7^T=C%2`>^O^W9XXD^-'@SP+:?`OPS+\*[[2/V6KKX@_$2Y
M^-<T'C_PUKW[74_BG0_AEH_@GX/6GPGU2U\=:;H?BKPTEK\0M=U[XE_#9=(\
M,7]SXG\*V'C&]T#6?#=I]`_'?XH?M&^`]=T?3O@O^RU)\==&O-+>]U;Q#_PN
MWP'\+X]%U/[7-%#HZZ9XJM[O4-2)MH$NI+NW6WM`;FVM4-PWVPV?P79?\$^?
MVO;?]H"+]IR[^-W_``3&UKXRZ-X2\,>"?AYXTUW_`()-_$_4-=^#OAWPUI/B
MCP\VF_!_Q(W_``4U7Q7\/K;Q-HOBJ_TGQ7::'XA%EK&E6^FZ>;2TLK=XKOZ=
M/PY_X*E'G_ALC]@$CV_X)K?M%+QUZC_@JX>O/;\ZWPU:GAJ_MJV$PV/H]<'B
MI8N.$;:VO@\7A,6K/:V+5WW6ARXNC5Q-!T:.+Q6`D_\`F+PGU5S7RQ6%Q>%_
M\M6_GJ>3?$_]J_\`;\\(>`?%'B.R_P""?;Z'/IEAYT6LM\??!7Q0CTHM<P0B
M]E\!>!=,LO%?B"V@\TO>6^FW5L;6VW7]XXLK2\"U_A/^UG^W_P"-/AYX7\37
MO_!/W_A(;C5+*64ZXGQV\'?">'5A'>W4$5W%X`\?Z?JWBS0;<P0P!/[2N[DZ
MF,ZQIV-/O;-3[`OPZ_X*DA>/VQ_V`L$'E?\`@FM^T0..Y"G_`(*N;0/4Y(']
MWL!OAU_P5)*\_MC_`+`6`!RW_!-;]H@\=B5'_!5S:1Z'(!_N]C[_`/;^3?4?
MJO\`J/PY[?Z[];^M_7.)[\O+R\EO]8?K&_O_`.\_5.;_`)A.;WCPO["S/V_M
M/];LW]C]6MR_5,AOSWO>_P#97U?RM]6O_P!1'+H=I\(/C/\`M8>+_'.FZ%\5
M/V,I/@]X,N8=1>_\?I^T+\-?B"NEW%O8S36%O+X6\/V%IK5TNI7:0Z>MQ:F3
M[%Y\-U=+]E2Y,?YZ>`_V\?C5X'\4_#;P%^T;\0_#^E6OQ+_;(_:3E^&GQ1D\
M.>%?#.A^.?V8?A+XP_:@TOQA\(?$>^T;3=.^)/[/EO\`#3P1JFM:]I5IX;U;
MQC\*M7\)^)[*[UO7/#OQKN['[6_X5W_P5*49_P"&R/V`5'_:-?\`:)`_/_AZ
M\OUZ?G7DWB?]D7]MKQMX7MO!?C+XQ?\`!*SQAX+L]8\5Z_:^%/$__!)7XL:]
MX8MM>\=Z9XOTGQQK=OH6L?\`!4J[TJ#6/&6E?$#Q]I7BG4TM1>>(K'QQXOLM
M9>[M/$>LI>^%BJ]+$U/;8?+\+E5';ZI@WC)85:/KFV,QV,ZWN\7;31'MX+#U
M<-15.MC,5CY;_6L5]53^["87"89?<F?'?PK_`&_OVD?CE\)/CYH-OX@^+7PI
M^,7B_P`??"KXH_`&V^(OP$TG]ESXCO\``SXM_$>#P[??LU?LRWW[:WPO^'OP
M+^-_[1/@WP_H9TOP;X]\8VGCOX0^)?'OQB^']CK_`(I_L6Z%YHWK_P`)/&'[
M27[17B_X5_!@?MI?M<_`K6?!W@[]JZ\^+5Y<_"+_`()\6'[0$_C7X9?%KX#Z
M#X.\'_&F>V^#O[47[-&L:GX8\&?%.>[N_%/[-5IX$\'^+K75=$O[ZRTG6[+6
M-%M/;?B/^R1^W%\8M.FTCXM_&;_@EC\4M)N/"NN>!;K2?B/_`,$E/BUXWTZ?
MP1XIU+PUJWB7PC/8>)_^"I6K6\_A?7]6\$>#=4UOP\X_L?5[WPIX;OK^RO+S
M0-(:T\6\1_\`!+;XL^,_!GP_^'/C#2_^")'BSX??"6+7K;X5>`_$O_!$3Q'K
MO@WX:6OBK4H=7\20^`/"VI_\%+[G0O!T'B#5;>'5-;3P_8V`U>^AAO;\75XN
M^N8[#S.7_@J)\2O^%B?L<---XTUKX?V'@WP/KG[5OB?X0?LU?$_XC?!KX@GX
M[>)+WX9_#[QM>_&'PQX*^(7@C]F7P/X,T#3[#]K6\'Q$^+'AN[U?X/\`CCPG
M9K>^([-F-[[M\1/CG\88OB!\5?BKI/[847@W5_A3^TS:_`WP'^P=_P`(]^SZ
M/"_Q@T'PM;^`-4\1^&O$EQXG\(W?[1^M?'CXH>!?&]_\4/AEJGPQ^,O@/P?X
M:\-^(?@S?:]\)/&.B:5XY/Q)]0E_9?\`V][C1?'OAB?X]_\`!,&;PY\5()K;
MXH:!-_P2C^,LVB?$FUG\'Z1\.9X/'^E-_P`%3#8>,(+GX?Z#H?@1[;Q#;7RM
MX.T72_"Q+Z'I=I9)Y+\5_P#@G-^T)\=_&FC?$;XWZE_P1J^,_P`0?#FG:5HO
MA[Q]\5O^"+WC;XB^,]!T?1+Z[U71]+T7Q1XP_P""F^KZWI&G:1J-[>ZG86EG
M?6MK97M[<7EDJ7=R[,`>F_\`!0SXB?M&>%?$?@>R^!GQ*^+>@:3H7PQ^)_Q$
M\?\`A#]E^/\`8<\0_'NV_L*]\)Q>'/B=XW^'_P"W!J>D:)XH_9@\*VX\5:7\
M0;?X->(/#/Q@N_&6M^"=#T#6C8ZI?76C>>VG_!0O]H2?Q)\3]#\)?!_X!_%:
M)/']C'\#=:U+XZ^,?@)X;\5_"#P[^Q]\'/VF?B+XO\<S^(/@9\2]2\'^-[D_
M%/2;GX?^`K6T\2"]LM4UNQ\7>)_!^B_#'5_'WC#IOC-^Q+^V#^T?:^&[']H;
MXE?\$F?CQ9>#=5FUOPC9_&7_`()!_$_XGV_A36IXHH9M7\-0>-O^"H6OV^@:
MM<006ZOJ6EBSNV2&!'8JNT9?Q!_8,_:H^+8\2-\5/&?_``2&^)A\9:YX-\3>
M,!\0_P#@CC\1_&1\5^(OASIMYHG@#7O$G_"0_P#!3O4SK^L^!-&OK_3/!FIZ
MK]MO?#5A>W-AH-W8V=VRD`Y'XN_\%+?B9<?![XI?%GX??"[1/!7P97P3KMO\
M+/BO<_%#2=8_:'F^*NB?!CP[\=I]!O?V0O$/PP(\0::?!]YXBM=%3X;_`!-^
M,'Q)U>]TFWUQO@Q:^![Z]\8^'>T^.7[9OQQ\3?L->#/VH/@WX?OO@WXHU[X^
M_"0V'P]UFRM/%_Q+N?A=I7QATJQ^(OP8^+/@GQ1X)LU^%/QX\3^']#\8_"7X
MA^`M)_X2;6/@[X\N+JQT3X@ZOKN@F\MI]4_8>_:YUWXBZ]\7]9^(G_!)+6/B
MUXJ\(1_#WQ1\4=4_X(^_$[4?B)XE^'\)LI8O!&N^.+C_`(*@W'B76?!^[2M+
M/_",ZEJMSHP_L_3S]A!M;4#MX/V:/V_H/[5\G]H+_@F1`=;\<V?Q/UL1?\$I
M_C7&NL?$JR&F"Q^(6J!?^"IH.H^.;3^P]%^R>*KHMXAM3I6EE+X&RM-H!Y#X
M?_;Y^+5OH_[:'Q>TV+P;\7?"VC_%SX8:'^R7\+KE_'NCC6_`^K^'!I5_!I5Y
M^SM\`_VI/CK\2/$'C.Y\&^-_C)HNE^#?@C\2?$@\-ZK;6!T7PWX5\/ZSXCTC
MRWQ1_P`%9?B[K'P?\)?'+PQ^SIXFLOA[H^@?LF?$+Q_IOPEOO&OQH^/OC76?
MCA\2-4\.WWP!^$?[/FL_L\>$_$GBC^U-'\'>*K;_`(3KQ3JOP@\8:1>ZIX1^
MW?#_`,-"Z\7ZMX#]O\1?L'?M5^,/AW??![Q=XU_X)$>*?A+J5AX,TO4?A=XD
M_P"".OQ(UOX<W^E_#N&S@^'VFWG@C4?^"H-YX9N;#P'!I]C!X,L[C2S:^&$L
MK4:&MD+>/;U&@?LD_MQ>%;.VTWPO\9_^"67AO3[&[\.WUGI^@?\`!)3XP:-9
M6M]X.U'4-=\)WEM!I_\`P5*M;:"X\+ZQJVJZMX;N5"OHVK:IJ-[I[VE[=W3L
M`<GI?_!3?XD:S\>?AQ\%=`_99NO&FG^+O!7PQU[Q1\2_A5J'[47Q8^'?A77_
M`(U:%JOB/X=SV/Q3\&_L07?[/%Q\)[;P\WA#5?B#\1_B1\>?A!XE\-VNK^)&
M\)_#'Q[9^'-'O/&'KWP9_:/^.'Q6^#?_``3JUGQO:^%/A[\2/VIM*T'X@_%(
M_#G4SXH\+:?X9T3X2ZW\7+W0?!]_XX\$Z9<@^.[J'P?H6M:7=:.?$7AGPQJW
MC6R\*>);[6O#MC\2%\1/_!/3]I%_'?@?XI/K_P#P1S;XF_"Y;M/AG\19/^",
MWCS_`(3WX=QWVO\`B'Q7>CP-XP_X><#Q%X16\\4^*_%?B>[_`+`O[`77B+Q)
MXBUI]U_K%]=W70M^QI^WI8:-\+/#_@7]IW_@G5\*-'^"OCH>/?AQI7PO_P""
M6GQ?\):/X8U&^A\16'BO2]/\/6W_``5!N/#EOHOCS0?&?C+0?&-M::3;7MU:
M>*]4UK1+_1O%BZ3XDL0#D/C;^UC\<M%_9'\&^,_!OQR^&'P_^+?BW]K?]K#X
M%V7CCXIR?#_P]X&L8OAEXC_;$TGPKX<\2SZQIHT/0?\`A#;?X2^%O[9U,VAU
M>R/A2ZU#Q9_;%E_PDMIJWO/[&/Q:^+S^#?VA?#7Q9U']ISQK\5OA!J&GZ]#\
M.?VI_"/['^A?'O3=&\2^`X-<\+://XO_`&$M;U3]F;QQH'C#5]$U[_A#+O2M
M)\-^._#I%WHOCNQO\:)K%[X^G[`G[4'_``L_QK\;#XK_`."0`^-/Q'T+4O"O
MQ%^+H_X(V?$(_$_Q[X8UK3;'0]6\-^,O'P_X*=#Q7XHT#4]&TK2])O\`2=<U
M>^L+W2+#3K&^M&L[.U1>I^#7['G[:W[.?A.;P'^SU\7?^"5/P(\#7>LW7B&Z
M\&?!G_@D=\6?A;X5N->OH;.ROM=N/#G@G_@J1H6BS:Q=VUA86UYJC6;7MU:6
M%FC7+K;6JJ`<=X+^/WC[X,_"#P-^U-\0/VUU_:83X\_L^CXH^$OV<-:\*_`'
MP-X(U'QOKDOPWFLIOV=/B5\/_!/@GQ[X(^"'@S6/B);Z#X_O/CQJW[3GB;1O
M!VJ^$_%%_P",K/6_"?B4^/\`N_$G[>GQ]TSP9I-AX>_9<^&?B?\`:(M_C!\7
M?@YX[^'B_M1ZII?P7\-ZS\'_`(2WWQNU;6?#OQW_`.&<;WQ7XRT?5?`XTG2[
M*WN?@+X:UK3_`(BZM=>%=?T?1]/T#6?$MIQOA;]@7]J'P/JWQ;\0>"O%_P#P
M2`\):Y\>X=6MOCOK?AC_`((W?$/P]JGQHMM<GU2;7+?XM:GI/_!3FUN_B1;:
MM<ZWK=UJUOXPGUE;^ZU;4WO=WVZ[+=3X-_8\_;7^'7A+P=\/_A]\7O\`@E5X
M$\"?#V/78O`'@GP9_P`$C_BSX7\)^!8O%$.J0^)(_!WAS1/^"I5CHGA@>((=
M<UJWUL:'9V8U=-6U--0^U+>7F\`\7TW_`(*R_&BY\:ZGX8U#]D'X=Z?8^%OA
M+H_[4?C'4D_:RU*\U/2_V5O$,?PLO]*UG0_#?_#-%K<^)_VD?[)^)FZ^^"-K
M>6?PLM-8T+^PK/\`:<O3X@T6\NNT^.O_``5)\:_!_P".OQG^$FC?L\^&/B+H
M_@3X4?%CQO\`#CQ?IOQ)^/'AZT^('C?X1Z9X3GUWX;>)O&.L_L7C]F_PQ<V^
MO^([GP_KG_"L/VE_COX\\!7=E:_\)U\,-#O[K6-(\.<KXF_X)G_M,>-?C-\.
M_CEXK^)G_!*SQ+XV^$OA[2M"^&ZZ[_P2%^(6KZ5X*O\`PWJ?AO4_`_C7PK_:
M/_!3*ZU/P[XX\`0>%=/T7P!XFT#5[&Z\):)/=6&FK;`VIL^VE_8%_:DN/B!X
MT^+%SXP_X)`S_%/XBI'#\0?B7-_P1P^(4GC_`,=Q0:.?#MM'XR\9-_P4Y/B3
MQ.MMH$LV@VJ:YJE[MT:=]/7%D3;D`XCXH?\`!4/XJ_":UMF\4_L]-?\`QIBU
M#QM\+[OX+?#'X@_%GXT?"*Y^(WASXS>!_!\&KV?B_P"$_P"POXX_:I\0Z>W@
MC7+G7K35?"_[.%V;35C<^%+_`.&6L6=U9?$O1O3?B9_P4/\`BIHOP_\`V8?$
MX_9E^)/PX\-_M"Z7K5O\5_B!XZ\+?M1^&+S]FB>R\5Z)X'O=2@TJP_8.^,BZ
M/J%L=4U7QUX*U7]MKPG^QK\-M9\,V'AR_P#%FM:*MYX]T;P"OCK]B3]K_P"*
M&B^*/#7Q*^)/_!)CXA>'?'*W<?C;0/'7_!('XG^+-&\81WVOZ)XLOH_%>EZ]
M_P`%0K[3O$`O/%/AKPYXGNUU2VNA=>(?#VB:VX;4-)L;FU\\U_\`X)I_M#Z]
MIGPSLT\2_P#!'G2-1^!.FO8?L[>(]-_X(KZ_<:Y^S?<QWL&N:7K/P('B+_@I
M!K^A_#C4O#_B*VL?%&C#0=(324\2:?I]]>Z?=FV*,`=O_P`$GOB3KGQ>U3_@
MHMX^\3Q6L'BK5OVX/A[8^+3IB%-)N_%GAO\`X)D?\$Y?"GBG4-$4D@:%JFOZ
M)?ZIHQ0W5L='O;-K2\O(]MV_OG_!6+_E%E_P4L_[,`_;(_\`6=?B-5S]@K]D
M#Q;^Q_X.^,.C>-OB5X#^)OB3XO\`Q:\,_$J[O_AE\(/$GP5\%^&[#P3^S5^S
MM^S%X<\-:9X0\8?&S]H/Q-J%]_PC'[.VC>)?$OBC6/B5>W?B'Q+XCUF[2PL4
M6,-3_P""L7_*++_@I9_V8!^V1_ZSK\1J`/\`.M^`O_!W!_P4?_9F^!WP:_9M
M\!_!3]B35O`W[/GPH\`?!#P9JGBWX<_'F_\`%6I^$_A'X.T;P-X<O_$][HW[
M2F@Z->^(+[2?#]G/KEWI>@Z+IUQ?RW3Z?I6F6;PV4'K?_$:G_P`%3/\`H@?[
M`/\`X:S]HK_Z*FBB@`_XC4_^"IG_`$0/]@'_`,-9^T5_]%31_P`1J?\`P5,_
MZ('^P#_X:S]HK_Z*FBB@`_XC4_\`@J9_T0/]@'_PUG[17_T5-'_$:G_P5,_Z
M('^P#_X:S]HK_P"BIHHH`/\`B-3_`."IG_1`_P!@'_PUG[17_P!%31_Q&I_\
M%3/^B!_L`_\`AK/VBO\`Z*FBB@`_XC4_^"IG_1`_V`?_``UG[17_`-%31_Q&
MI_\`!4S_`*('^P#_`.&L_:*_^BIHHH`/^(U/_@J9_P!$#_8!_P##6?M%?_14
MT?\`$:G_`,%3/^B!_L`_^&L_:*_^BIHHH`/^(U/_`(*F?]$#_8!_\-9^T5_]
M%31_Q&I_\%3/^B!_L`_^&L_:*_\`HJ:**`#_`(C4_P#@J9_T0/\`8!_\-9^T
M5_\`14T?\1J?_!4S_H@?[`/_`(:S]HK_`.BIHHH`/^(U/_@J9_T0/]@'_P`-
M9^T5_P#14T?\1J?_``5,_P"B!_L`_P#AK/VBO_HJ:**`#_B-3_X*F?\`1`_V
M`?\`PUG[17_T5-'_`!&I_P#!4S_H@?[`/_AK/VBO_HJ:**`#_B-3_P""IG_1
M`_V`?_#6?M%?_14T?\1J?_!4S_H@?[`/_AK/VBO_`**FBB@`_P"(U/\`X*F?
M]$#_`&`?_#6?M%?_`$5-'_$:G_P5,_Z('^P#_P"&L_:*_P#HJ:**`#_B-3_X
M*F?]$#_8!_\`#6?M%?\`T5-'_$:G_P`%3/\`H@?[`/\`X:S]HK_Z*FBB@`_X
MC4_^"IG_`$0/]@'_`,-9^T5_]%31_P`1J?\`P5,_Z('^P#_X:S]HK_Z*FBB@
M`_XC4_\`@J9_T0/]@'_PUG[17_T5-'_$:G_P5,_Z('^P#_X:S]HK_P"BIHHH
M`/\`B-3_`."IG_1`_P!@'_PUG[17_P!%31_Q&I_\%3/^B!_L`_\`AK/VBO\`
MZ*FBB@`_XC4_^"IG_1`_V`?_``UG[17_`-%31_Q&I_\`!4S_`*('^P#_`.&L
M_:*_^BIHHH`/^(U/_@J9_P!$#_8!_P##6?M%?_14T?\`$:G_`,%3/^B!_L`_
M^&L_:*_^BIHHH`/^(U/_`(*F?]$#_8!_\-9^T5_]%31_Q&I_\%3/^B!_L`_^
M&L_:*_\`HJ:**`#_`(C4_P#@J9_T0/\`8!_\-9^T5_\`14T?\1J?_!4S_H@?
M[`/_`(:S]HK_`.BIHHH`/^(U/_@J9_T0/]@'_P`-9^T5_P#14T?\1J?_``5,
M_P"B!_L`_P#AK/VBO_HJ:**`#_B-3_X*F?\`1`_V`?\`PUG[17_T5-'_`!&I
M_P#!4S_H@?[`/_AK/VBO_HJ:**`#_B-3_P""IG_1`_V`?_#6?M%?_14T?\1J
M?_!4S_H@?[`/_AK/VBO_`**FBB@`_P"(U/\`X*F?]$#_`&`?_#6?M%?_`$5-
M'_$:G_P5,_Z('^P#_P"&L_:*_P#HJ:**`#_B-3_X*F?]$#_8!_\`#6?M%?\`
MT5-'_$:G_P`%3/\`H@?[`/\`X:S]HK_Z*FBB@`_XC4_^"IG_`$0/]@'_`,-9
M^T5_]%31_P`1J?\`P5,_Z('^P#_X:S]HK_Z*FBB@`_XC4_\`@J9_T0/]@'_P
MUG[17_T5-'_$:G_P5,_Z('^P#_X:S]HK_P"BIHHH`/\`B-3_`."IG_1`_P!@
M'_PUG[17_P!%31_Q&I_\%3/^B!_L`_\`AK/VBO\`Z*FBB@`_XC4_^"IG_1`_
MV`?_``UG[17_`-%31_Q&I_\`!4S_`*('^P#_`.&L_:*_^BIHHH`/^(U/_@J9
M_P!$#_8!_P##6?M%?_14T?\`$:G_`,%3/^B!_L`_^&L_:*_^BIHHH`/^(U/_
M`(*F?]$#_8!_\-9^T5_]%31_Q&I_\%3/^B!_L`_^&L_:*_\`HJ:**`#_`(C4
M_P#@J9_T0/\`8!_\-9^T5_\`14T?\1J?_!4S_H@?[`/_`(:S]HK_`.BIHHH`
M/^(U/_@J9_T0/]@'_P`-9^T5_P#14T?\1J?_``5,_P"B!_L`_P#AK/VBO_HJ
M:**`#_B-3_X*F?\`1`_V`?\`PUG[17_T5-'_`!&I_P#!4S_H@?[`/_AK/VBO
M_HJ:**`#_B-3_P""IG_1`_V`?_#6?M%?_14T?\1J?_!4S_H@?[`/_AK/VBO_
M`**FBB@`_P"(U/\`X*F?]$#_`&`?_#6?M%?_`$5-'_$:G_P5,_Z('^P#_P"&
ML_:*_P#HJ:**`#_B-3_X*F?]$#_8!_\`#6?M%?\`T5-'_$:G_P`%3/\`H@?[
M`/\`X:S]HK_Z*FBB@`_XC4_^"IG_`$0/]@'_`,-9^T5_]%31_P`1J?\`P5,_
MZ('^P#_X:S]HK_Z*FBB@`_XC4_\`@J9_T0/]@'_PUG[17_T5->2?'K_@[@_X
M*/\`[3/P.^,O[-OCSX*?L2:3X&_:#^%'C_X(>,]4\)?#GX\V'BK3/"?Q<\':
MSX&\1W_AB]UG]I37M&LO$%CI/B"\GT.[U30=:TZWOXK5]0TK4[-)K*<HH`__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>txmd-10k_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd-10k_3.jpg
M_]C_X0]817AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````D````<@$R``(````4
M````EH=I``0````!````K````-@`"OR````G$``*_(```"<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,30@*$UA8VEN=&]S:"D`,C`Q-3HP,SHQ,B`Q,3HQ.3HS
M,0`````#H`$``P````'__P``H`(`!`````$```+0H`,`!`````$```%6````
M``````8!`P`#`````0`&```!&@`%`````0```28!&P`%`````0```2X!*``#
M`````0`"```"`0`$`````0```38"`@`$`````0``#AH`````````2`````$`
M``!(`````?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,
M"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,
M#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!,
M`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%
M!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%
M!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'
M!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#T^FFDTU_H
MV_1'8>"GZ%/^C;]P52KJO36T^[)K'HAK;/</:3[=KO[05HY&."6FUDM,.&X2
M#S!24OZ%/^C;]P2]"G_1M^X)OM&/_I6?YP2^T8_^E9_G!)2_H4_Z-OW!+T*?
M]&W[@F^T8_\`I6?YP2^T8_\`I6?YP24OZ%/^C;]P0KZG!@./34]\ZA^@CXAK
MD3[1C_Z5G^<$OM&/_I6?YP24YM^99C/%>15A4/<"YHLO+=P&WZ,X_P#*46]2
MQWN`W8(VC=8&V[R&[V,W!OIL]OI.=[_]+_VXM/[1C_Z5G^<$/(=1=4:VY/HG
M2'UN:'"/#=N:DISJ^IU.823@Z$-#FVR"27.V/#JF>C^A9N^G8F_:U!@AW3ML
M\_:.1S[?T'N?M"M.HG_O5N![$&@1I''V?;_G*?I5>IZGV^SEAV[V;?9MD;=G
M^%V?I?\`OB2FH[J36N$C"B/T@]1WM+=KK=KQ1^EVUW46?1I^G_;1L=^;=6VQ
MN/B65/U98U[@"TZ[MAH=^8KWVC&_TC/\X)_M&/\`Z5G^<$E+^A3_`*-OW!+T
M*?\`1M^X)OM&/_I6?YP2^T8_^E9_G!)2_H4_Z-OW!+T*?]&W[@F^T8_^E9_G
M!+[1C_Z5G^<$E+^A3_HV_<%"ZFD4V?HV_1/8>"E]HQ_]*S_."A;?0ZI[6V-)
M+2``X23"2G__T/0Z^I=.;3JUWZ,-:_\`0O.OT?;[/?\`1_,5BF]C7WAP?_.'
MACR/HL[AJ#7U&P4_T/(.P-`AK?=/YS)?_P!6C46/#[P*G._2G4%O[K/%Z2DO
MVFOPL_[;?_Y!+[37X6?]MO\`_()>K9_H7_>S_P!*)>K9_H7_`'L_]*)*5]IK
M\+/^VW_^02^TU^%G_;;_`/R"7JV?Z%_WL_\`2B7JV?Z%_P![/_2B2E?::_"S
M_MM__D$OM-?A9_VV_P#\@EZMG^A?][/_`$HEZMG^A?\`>S_THDI7VFOPL_[;
M?_Y!+[37X6?]MO\`_()>K9_H7_>S_P!*)>K9_H7_`'L_]*)*5]IK\+/^VW_^
M02^TU^%G_;;_`/R"7JV?Z%_WL_\`2B7JV?Z%_P![/_2B2E?::_"S_MM__D$O
MM-?A9_VV_P#\@EZMG^A?][/_`$HEZMG^A?\`>S_THDI7VFOPL_[;?_Y!+[37
MX6?]MO\`_((=F8*R&NJ?O=]"L;2X_!H?_P!/Z"#59U*]DWT.Q/<X>G6YECB`
M88[UG.:QOJ-_,;5_UU"TB)J]AXIWYN/7&_>"XPUOIOD_U6;-SD,Y5UGT&.H8
M?SGUO<_Y5M;M9_;?_P!94ZFMIDUX[PYWTG$M+C_7>ZPO?_:1/5L_T+_O9_Z4
M258&POS_`(-?$;7BBT>KDWFVPVDW->_:7`#TZOT;?3I]OMJ:IY%['5%H#Y)'
M+'@<C\YS=J+ZMG^A?][/_2B'D6/-)!J<T$C4EL#4?NO<BHDDV7__T?1:LGJ8
MI]N&T[0T5_I@-P_>=[?9[?ZZ-0;M]^UK2/5.I<1^:S^0A,'5O2_1NQXAOI%P
M?Q'N]0!R+2+]]^US`/5/+2?S6?RTE)MV1^XS_//_`*32W9'[C/\`//\`Z331
MD_OL_P`T_P#DTHR?WV?YI_\`)I*7W9'[C/\`//\`Z32W9'[C/\\_^DTT9/[[
M/\T_^34;'W5,-EEM3&-$N<X$`#S<;$E,]V1^XS_//_I-+=D?N,_SS_Z331D_
MOU_YI_\`)I1D_OU_YI_\FDI?=D?N,_SS_P"DTMV1^XS_`#S_`.DU![KF-+WV
M5M:T$N<00`!R2=Z"_/JK:'.RJ((D1J2#^ZUMGN1HJML[LC]QG^>?_2:6[(_<
M9_GG_P!)JF.H6O\`YIC[)[^A8P?YUKF*7K=4>T[:VL)'M]N[7^5OMH0H]E?4
M?R\$]EUE3"^P5L:.27D?^BT/U,Z\?HV"BO\`?<?>?ZE;J_T?_7O^V%4Z=C=7
M?C4W9SF,S0WWN>/4<"9W[&5/KQZ?;_HO^N*V<-[C-CFVG_A`7#_MO>VK_P`#
M2KN:\!ZOQ38'R^K^L=!_BR]7^.PIMKJ);2QMKW'WN8YUCB1_I;=FW_MVQ/1D
M]2NJ+W8;<=^XM%=MLF`=N_\`0UVM]WTOI(X;D`0'5@#@;3_Y-/&3^^S_`#3_
M`.31L#HM-DV2CVY[A[G5M_J3/^=8U_\`Y[4?L]Y_G'.?_P!=<W_SS74C1D_O
ML_S3_P"32C)_?9_FG_R:5E5!#BX;</U?L]+&>O8;K?TCS-C@UKG^]COW&J60
M;O1.YK0V1)#B3R.VQJ)&3^^S_-/_`)-#R!?Z1WN86R)`:0>1_+*1).IU2`!H
M-'__TO1F8W435[,W:'!IKFII+!^[S[T6ACR^^+"/TIT@?NL0Q@&UA?\`:;ZQ
M:&':QX`;M:!^B]OMW_GHE-6Y]Y+GC]*>'$?FL24K+QLRZG9CY;L>S<T^H&-?
MH#+F;'?OJM;7DAQ&3F7T-[65BGT_F]V.Y]/_`%W_`+=L5[T!^^__`#BEZ`_?
M?_G%&]*_W_M534_9`=J_,RG_`/72W_ST*U"[ZOX-]3ZK#8X/$$N=O/C_`(7>
MW_.:K!PC7KC6.8.327'8?A^=3_UK]'_P-B5;FEXJM-E5IX:YQAW_`!=GT;/_
M`#Y_P:%?7\U?0?8P/2,;MV;M#2`6Z"&G:5#]E8X^ECTV?!C0?\RWU&_^"*YZ
M`_??_G%+T!^^_P#SBA7T5KW:#NE])VN%N-36""';J*P(/TOTC6[?_!%8I;C4
M5-JHN974P`,8S8`&@>T-1CC,<"USGN:=""XD$>:<8[&@-:YS6@0`'$``>"7J
M[Z*8>H.UY/P:#^1J7J'_`$EG_;9_\@I^@/WW_P"<4O0'[[_\XI:]Q]BD-=_J
MUMLKLL+7B0?3(_ZIBEOL_>L_S!_<B>@/WW_YQ2]`?OO_`,XI4>I_!3#=;XV?
MYK5&NY[V[IM:)(]U<'0[?H[=R+Z`_??_`)Q2%+3J+'GMHX]M$J/=3#U#_I'C
MXUD?]\2]5O?(CXAH_P"J"GZ`_??_`)Q2]`?OO_SBEKW'V*69-@)9?O`,$MVG
M7PT4,ACQ22;"X::0/$*;<6IN[87-W&7;3$D_G.C\Y0R*@VDG<XQ&A<2.0B+Z
MJ?_3]*=@8N34PW-+I8P&'.;HWW-^@YOYSD4XF.7.=L@O.YT$B3QN]I\E"G[9
MZ3(].-H_>\%+]<_X/_I)*:N;CV-=6W&]$`R7"][P9!;L]/8?S?\`R"+331Z3
M/7+?6VCU`Q[MNZ/?Z>YV[9N37>OO]^V=CIVS&SV[]V]4W_9-@XVR=OH[MTS^
MDV_9OTG_`!B2G0]'"\?^F?\`R2K9^'3?5Z#&T65//Z=E[G%I;VVM#OI;E5'V
M;7^D?2//VKF/S/[/[BE3]FV-]#U-GJ>W;ZW\YI_:_K;_`-"D+O138HZ=TXU`
MWTX_JZ[O3^CSIMW?R43]G=)'^"K^_P#VH.1Z7VAGVGT_M$.]+?MWQ'Z3T_[/
MTU4'[-[;^/\`NQQ/G_*1]7BG[6YE=.PW5;<:K'+G:.]4D-V'Z?\`-^[<GHZ=
MT]M0;=73N;H-A,0/H_3=N5;]4W.CU)UW[/7C=/NW>G[?6_\`!4F_9MS8]>9$
M;OM/[WMG?^9ZGTMWZ/\`TB7J\5:MT]/Z0.:Z_F?]J%D=.P/2=]EIQS?IM]6=
MO(W;MGN^BH8FSUG?9?5W[?=N]7;$,_[D_H?H^G]#W_\`@B61Z/I_IOH[M-F[
M=OVGZ'V?]+O]/]U+U(U7Q>E=.KK++:,9K6$-J%<QM`'TM_\`*W(XZ?T<B134
M1\E2?]G_`.'G:R?3^T3$#9N]/^3]/?\`]=5B_;ZS?M&SUH.S=MW1^=L1UZVK
M5G;T_IPJ?Z%-'K0=F_Z,]M^WW;4+$Z;A,!;=CXC6\M%(@;G%QMG=_854?LV-
M-_'_`'8F)\_=])$=]DWV;O5GW>I_/[?HOWSM_1;O3]3_`%V(:^*F]^S^D?Z&
MK[@HOZ?TO8[TZ:2^#MF(GMNA4V?99.SUN!/](XEO[_M_T?T/S/\`@TQ^R[6Q
MZVW:W;Z?VCZ,,V?S?\C9_P`)Z:6OBI/A8=>.2+68U++/>_T'.;-IANZ#&[<U
MOTOIJY;BT-K<X-,M:2)).H'F50H]+<[TO5^B=^_UMNW]'N_I']C^;_2?SG_"
M*_=]L])\^G&T_O>"!OJI_]G_[1<44&AO=&]S:&]P(#,N,``X0DE-!"4`````
M`!``````````````````````.$))300Z``````#E````$`````$```````MP
M<FEN=$]U='!U=`````4`````4'-T4V)O;VP!`````$EN=&5E;G5M`````$EN
M=&4`````0VQR;0````]P<FEN=%-I>'1E96Y":71B;V]L``````MP<FEN=&5R
M3F%M951%6%0````!```````/<')I;G10<F]O9E-E='5P3V)J8P````P`4`!R
M`&\`;P!F`"``4P!E`'0`=0!P```````*<')O;V93971U<`````$`````0FQT
M;F5N=6T````,8G5I;'1I;E!R;V]F````"7!R;V]F0TU92P`X0DE-!#L`````
M`BT````0`````0``````$G!R:6YT3W5T<'5T3W!T:6]N<P```!<`````0W!T
M;F)O;VP``````$-L8G)B;V]L``````!29W--8F]O;```````0W)N0V)O;VP`
M`````$-N=$-B;V]L``````!,8FQS8F]O;```````3F=T=F)O;VP``````$5M
M;$1B;V]L``````!);G1R8F]O;```````0F-K9T]B:F,````!````````4D="
M0P````,`````4F0@(&1O=6)`;^````````````!'<FX@9&]U8D!OX```````
M`````$)L("!D;W5B0&_@````````````0G)D5%5N=$8C4FQT````````````
M````0FQD(%5N=$8C4FQT````````````````4G-L=%5N=$8C4'AL0%(`````
M```````*=F5C=&]R1&%T86)O;VP!`````%!G4'-E;G5M`````%!G4',`````
M4&=00P````!,969T56YT1B-2;'0```````````````!4;W`@56YT1B-2;'0`
M``````````````!38VP@56YT1B-0<F-`60```````````!!C<F]P5VAE;E!R
M:6YT:6YG8F]O;``````.8W)O<%)E8W1";W1T;VUL;VYG``````````QC<F]P
M4F5C=$QE9G1L;VYG``````````UC<F]P4F5C=%)I9VAT;&]N9P`````````+
M8W)O<%)E8W14;W!L;VYG```````X0DE-`^T``````!``2`````$``0!(````
M`0`!.$))300F```````.`````````````#^````X0DE-!`T```````0```!:
M.$))3009```````$````'CA"24T#\P``````"0```````````0`X0DE-)Q``
M``````H``0`````````!.$))30/U``````!(`"]F9@`!`&QF9@`&```````!
M`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4````!`"T`
M```&```````!.$))30/X``````!P``#_____________________________
M`^@`````_____________________________P/H`````/______________
M______________\#Z`````#_____________________________`^@``#A"
M24T$"```````$`````$```)````"0``````X0DE-!!X```````0`````.$))
M300:``````-)````!@`````````````!5@```M`````*`%4`;@!T`&D`=`!L
M`&4`9``M`#$````!``````````````````````````$``````````````M``
M``%6``````````````````````$`````````````````````````$`````$`
M``````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``%6`````%)G:'1L;VYG```"T`````9S;&EC97-6;$QS`````4]B:F,````!
M```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$
M;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T
M;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R``
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG```!5@````!29VAT;&]N
M9P```M`````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-
M<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT
M27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG
M;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L
M:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O
M;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET
M;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T
M=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-
M!"@```````P````"/_`````````X0DE-!!0```````0````#.$))300,````
M``XV`````0```*````!,```!X```CH````X:`!@``?_8_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!,`*`#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#T^FFDTU_HV_1'8>"GZ%/^C;]P52KJO36T^[)K
M'HAK;/</:3[=KO[05HY&."6FUDM,.&X2#S!24OZ%/^C;]P2]"G_1M^X)OM&/
M_I6?YP2^T8_^E9_G!)2_H4_Z-OW!+T*?]&W[@F^T8_\`I6?YP2^T8_\`I6?Y
MP24OZ%/^C;]P0KZG!@./34]\ZA^@CXAKD3[1C_Z5G^<$OM&/_I6?YP24YM^9
M9C/%>15A4/<"YHLO+=P&WZ,X_P#*46]2QWN`W8(VC=8&V[R&[V,W!OIL]OI.
M=[_]+_VXM/[1C_Z5G^<$/(=1=4:VY/HG2'UN:'"/#=N:DISJ^IU.823@Z$-#
MFVR"27.V/#JF>C^A9N^G8F_:U!@AW3ML\_:.1S[?T'N?M"M.HG_O5N![$&@1
MI''V?;_G*?I5>IZGV^SEAV[V;?9MD;=G^%V?I?\`OB2FH[J36N$C"B/T@]1W
MM+=KK=KQ1^EVUW46?1I^G_;1L=^;=6VQN/B65/U98U[@"TZ[MAH=^8KWVC&_
MTC/\X)_M&/\`Z5G^<$E+^A3_`*-OW!+T*?\`1M^X)OM&/_I6?YP2^T8_^E9_
MG!)2_H4_Z-OW!+T*?]&W[@F^T8_^E9_G!+[1C_Z5G^<$E+^A3_HV_<%"ZFD4
MV?HV_1/8>"E]HQ_]*S_."A;?0ZI[6V-)+2``X23"2G__T/0Z^I=.;3JUWZ,-
M:_\`0O.OT?;[/?\`1_,5BF]C7WAP?_.'ACR/HL[AJ#7U&P4_T/(.P-`AK?=/
MYS)?_P!6C46/#[P*G._2G4%O[K/%Z2DOVFOPL_[;?_Y!+[37X6?]MO\`_()>
MK9_H7_>S_P!*)>K9_H7_`'L_]*)*5]IK\+/^VW_^02^TU^%G_;;_`/R"7JV?
MZ%_WL_\`2B7JV?Z%_P![/_2B2E?::_"S_MM__D$OM-?A9_VV_P#\@EZMG^A?
M][/_`$HEZMG^A?\`>S_THDI7VFOPL_[;?_Y!+[37X6?]MO\`_()>K9_H7_>S
M_P!*)>K9_H7_`'L_]*)*5]IK\+/^VW_^02^TU^%G_;;_`/R"7JV?Z%_WL_\`
M2B7JV?Z%_P![/_2B2E?::_"S_MM__D$OM-?A9_VV_P#\@EZMG^A?][/_`$HE
MZMG^A?\`>S_THDI7VFOPL_[;?_Y!+[37X6?]MO\`_((=F8*R&NJ?O=]"L;2X
M_!H?_P!/Z"#59U*]DWT.Q/<X>G6YECB`88[UG.:QOJ-_,;5_UU"TB)J]AXIW
MYN/7&_>"XPUOIOD_U6;-SD,Y5UGT&.H8?SGUO<_Y5M;M9_;?_P!94ZFMIDUX
M[PYWTG$M+C_7>ZPO?_:1/5L_T+_O9_Z4258&POS_`(-?$;7BBT>KDWFVPVDW
M->_:7`#TZOT;?3I]OMJ:IY%['5%H#Y)'+'@<C\YS=J+ZMG^A?][/_2B'D6/-
M)!J<T$C4EL#4?NO<BHDDV7__T?1:LGJ8I]N&T[0T5_I@-P_>=[?9[?ZZ-0;M
M]^UK2/5.I<1^:S^0A,'5O2_1NQXAOI%P?Q'N]0!R+2+]]^US`/5/+2?S6?RT
ME)MV1^XS_//_`*32W9'[C/\`//\`Z331D_OL_P`T_P#DTHR?WV?YI_\`)I*7
MW9'[C/\`//\`Z32W9'[C/\\_^DTT9/[[/\T_^34;'W5,-EEM3&-$N<X$`#S<
M;$E,]V1^XS_//_I-+=D?N,_SS_Z331D_OU_YI_\`)I1D_OU_YI_\FDI?=D?N
M,_SS_P"DTMV1^XS_`#S_`.DU![KF-+WV5M:T$N<00`!R2=Z"_/JK:'.RJ((D
M1J2#^ZUMGN1HJML[LC]QG^>?_2:6[(_<9_GG_P!)JF.H6O\`YIC[)[^A8P?Y
MUKF*7K=4>T[:VL)'M]N[7^5OMH0H]E?4?R\$]EUE3"^P5L:.27D?^BT/U,Z\
M?HV"BO\`?<?>?ZE;J_T?_7O^V%4Z=C=7?C4W9SF,S0WWN>/4<"9W[&5/KQZ?
M;_HO^N*V<-[C-CFVG_A`7#_MO>VK_P`#2KN:\!ZOQ38'R^K^L=!_BR]7^.PI
MMKJ);2QMKW'WN8YUCB1_I;=FW_MVQ/1D]2NJ+W8;<=^XM%=MLF`=N_\`0UVM
M]WTOI(X;D`0'5@#@;3_Y-/&3^^S_`#3_`.31L#HM-DV2CVY[A[G5M_J3/^=8
MU_\`Y[4?L]Y_G'.?_P!=<W_SS74C1D_OL_S3_P"32C)_?9_FG_R:5E5!#BX;
M</U?L]+&>O8;K?TCS-C@UKG^]COW&J60;O1.YK0V1)#B3R.VQJ)&3^^S_-/_
M`)-#R!?Z1WN86R)`:0>1_+*1).IU2`!H-'__TO1F8W435[,W:'!IKFII+!^[
MS[T6ACR^^+"/TIT@?NL0Q@&UA?\`:;ZQ:&':QX`;M:!^B]OMW_GHE-6Y]Y+G
MC]*>'$?FL24K+QLRZG9CY;L>S<T^H&-?H#+F;'?OJM;7DAQ&3F7T-[65BGT_
MF]V.Y]/_`%W_`+=L5[T!^^__`#BEZ`_??_G%&]*_W_M534_9`=J_,RG_`/72
MW_ST*U"[ZOX-]3ZK#8X/$$N=O/C_`(7>W_.:K!PC7KC6.8.327'8?A^=3_UK
M]'_P-B5;FEXJM-E5IX:YQAW_`!=GT;/_`#Y_P:%?7\U?0?8P/2,;MV;M#2`6
MZ"&G:5#]E8X^ECTV?!C0?\RWU&_^"*YZ`_??_G%+T!^^_P#SBA7T5KW:#NE]
M)VN%N-36""';J*P(/TOTC6[?_!%8I;C45-JHN974P`,8S8`&@>T-1CC,<"US
MGN:=""XD$>:<8[&@-:YS6@0`'$``>"7J[Z*8>H.UY/P:#^1J7J'_`$EG_;9_
M\@I^@/WW_P"<4O0'[[_\XI:]Q]BD-=_JUMLKLL+7B0?3(_ZIBEOL_>L_S!_<
MB>@/WW_YQ2]`?OO_`,XI4>I_!3#=;XV?YK5&NY[V[IM:)(]U<'0[?H[=R+Z`
M_??_`)Q2%+3J+'GMHX]M$J/=3#U#_I'CXUD?]\2]5O?(CXAH_P"J"GZ`_??_
M`)Q2]`?OO_SBEKW'V*69-@)9?O`,$MVG7PT4,ACQ22;"X::0/$*;<6IN[87-
MW&7;3$D_G.C\Y0R*@VDG<XQ&A<2.0B+ZJ?_3]*=@8N34PW-+I8P&'.;HWW-^
M@YOYSD4XF.7.=L@O.YT$B3QN]I\E"G[9Z3(].-H_>\%+]<_X/_I)*:N;CV-=
M6W&]$`R7"][P9!;L]/8?S?\`R"+331Z3/7+?6VCU`Q[MNZ/?Z>YV[9N37>OO
M]^V=CIVS&SV[]V]4W_9-@XVR=OH[MTS^DV_9OTG_`!B2G0]'"\?^F?\`R2K9
M^'3?5Z#&T65//Z=E[G%I;VVM#OI;E5'V;7^D?2//VKF/S/[/[BE3]FV-]#U-
MGJ>W;ZW\YI_:_K;_`-"D+O138HZ=TXU`WTX_JZ[O3^CSIMW?R43]G=)'^"K^
M_P#VH.1Z7VAGVGT_M$.]+?MWQ'Z3T_[/TU4'[-[;^/\`NQQ/G_*1]7BG[6YE
M=.PW5;<:K'+G:.]4D-V'Z?\`-^[<GHZ=T]M0;=73N;H-A,0/H_3=N5;]4W.C
MU)UW[/7C=/NW>G[?6_\`!4F_9MS8]>9$;OM/[WMG?^9ZGTMWZ/\`TB7J\5:M
MT]/Z0.:Z_F?]J%D=.P/2=]EIQS?IM]6=O(W;MGN^BH8FSUG?9?5W[?=N]7;$
M,_[D_H?H^G]#W_\`@B61Z/I_IOH[M-F[=OVGZ'V?]+O]/]U+U(U7Q>E=.KK+
M+:,9K6$-J%<QM`'TM_\`*W(XZ?T<B1341\E2?]G_`.'G:R?3^T3$#9N]/^3]
M/?\`]=5B_;ZS?M&SUH.S=MW1^=L1UZVK5G;T_IPJ?Z%-'K0=F_Z,]M^WW;4+
M$Z;A,!;=CXC6\M%(@;G%QMG=_854?LV--_'_`'8F)\_=])$=]DWV;O5GW>I_
M/[?HOWSM_1;O3]3_`%V(:^*F]^S^D?Z&K[@HOZ?TO8[TZ:2^#MF(GMNA4V?9
M9.SUN!/](XEO[_M_T?T/S/\`@TQ^R[6QZVW:W;Z?VCZ,,V?S?\C9_P`)Z:6O
MBI/A8=>.2+68U++/>_T'.;-IANZ#&[<UOTOIJY;BT-K<X-,M:2)).H'F50H]
M+<[TO5^B=^_UMNW]'N_I']C^;_2?SG_"*_=]L])\^G&T_O>"!OJI_]DX0DE-
M!"$``````%T````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'`````7`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!#`"``
M,@`P`#$`-`````$`.$))300&```````'``@``0`!`0#_X0TL:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60]
M(E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`U
M+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M,#DZ-3,Z,#(@("`@("`@
M("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+VUM+R(@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z<&AO=&]S:&]P/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(B!X;7`Z0W)E871O<E1O
M;VP](D%D;V)E(%!H;W1O<VAO<"!#0R`R,#$T("A-86-I;G1O<V@I(B!X;7`Z
M0W)E871E1&%T93TB,C`Q-2TP,RTQ,E0Q,3HQ.3HS,2TP-#HP,"(@>&UP.DUE
M=&%D871A1&%T93TB,C`Q-2TP,RTQ,E0Q,3HQ.3HS,2TP-#HP,"(@>&UP.DUO
M9&EF>41A=&4](C(P,34M,#,M,3)4,3$Z,3DZ,S$M,#0Z,#`B(&1C.F9O<FUA
M=#TB:6UA9V4O:G!E9R(@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HT83EA
M-#8U,BUE,S8P+30X-S,M86(T9BTP-6$V.&(P-6(U8S$B('AM<$U-.D1O8W5M
M96YT240](GAM<"YD:60Z-&$Y830V-3(M93,V,"TT.#<S+6%B-&8M,#5A-CAB
M,#5B-6,Q(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z-&$Y
M830V-3(M93,V,"TT.#<S+6%B-&8M,#5A-CAB,#5B-6,Q(B!P:&]T;W-H;W`Z
M0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#4')O9FEL93TB1V5N97)I8R!2
M1T(@4')O9FEL92(^(#QX;7!-33I(:7-T;W)Y/B`\<F1F.E-E<3X@/')D9CIL
M:2!S=$5V=#IA8W1I;VX](F-R96%T960B('-T179T.FEN<W1A;F-E240](GAM
M<"YI:60Z-&$Y830V-3(M93,V,"TT.#<S+6%B-&8M,#5A-CAB,#5B-6,Q(B!S
M=$5V=#IW:&5N/2(R,#$U+3`S+3$R5#$Q.C$Y.C,Q+3`T.C`P(B!S=$5V=#IS
M;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0T,@,C`Q-"`H36%C:6YT
M;W-H*2(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/"]R9&8Z1&5S
M8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@/#]X<&%C:V5T(&5N9#TB=R(_/O_B![A)0T-?4%)/1DE,
M10`!`0``!ZAA<'!L`B```&UN=')21T(@6%E:(`?9``(`&0`+`!H`"V%C<W!!
M4%!,`````&%P<&P````````````````````!``#VU@`!`````-,M87!P;```
M````````````````````````````````````````````````````````````
M"V1E<V,```$(````;V1S8VT```%X```%;&-P<G0```;D````.'=T<'0```<<
M````%')865H```<P````%&=865H```=$````%&)865H```=8````%')44D,`
M``=L````#F-H860```=\````+&)44D,```=L````#F=44D,```=L````#F1E
M<V,`````````%$=E;F5R:6,@4D="(%!R;V9I;&4``````````````!1'96YE
M<FEC(%)'0B!0<F]F:6QE````````````````````````````````````````
M``````````````````````````!M;'5C`````````!X````,<VM32P```"@`
M``%X:')(4@```"@```&@8V%%4P```"0```'(<'1"4@```"8```'L=6M500``
M`"H```(29G)&50```"@```(\>FA45P```!8```)D:71)5````"@```)Z;F).
M3P```"8```*B:V]+4@```!8```+(8W-#6@```"(```+>:&5)3````!X```,`
M9&5$10```"P```,>:'5(50```"@```-*<W9310```"8```*B>FA#3@```!8`
M``-R:F%*4````!H```.(<F]23P```"0```.B96Q'4@```"(```/&<'103P``
M`"8```/H;FQ.3````"@```0.97-%4P```"8```/H=&A42````"0```0V=')4
M4@```"(```1:9FE&20```"@```1\<&Q03````"P```2D<G5250```"(```30
M87)%1P```"8```3R96Y54P```"8```489&%$2P```"X```4^`%8!80!E`&\`
M8@!E`&,`;@#]`"``4@!'`$(`(`!P`'(`;P!F`&D`;`!'`&4`;@!E`'(`:0$-
M`&L`:0`@`%(`1P!"`"``<`!R`&\`9@!I`&P`4`!E`'(`9@!I`&P`(`!2`$<`
M0@`@`&<`90!N`.@`<@!I`&,`4`!E`'(`9@!I`&P`(`!2`$<`0@`@`$<`90!N
M`.D`<@!I`&,`;P07!#`$,P0P!#L$3`0]!#@$.0`@!#\$0`0^!$0$,`0Y!#L`
M(`!2`$<`0@!0`'(`;P!F`&D`;``@`&<`Z0!N`.D`<@!I`'$`=0!E`"``4@!6
M`$*0&G4H`"``4@!'`$(`(()R7VECSX_P`%``<@!O`&8`:0!L`&\`(`!2`$<`
M0@`@`&<`90!N`&4`<@!I`&,`;P!'`&4`;@!E`'(`:0!S`&L`(`!2`$<`0@`M
M`'``<@!O`&8`:0!LQWR\&``@`%(`1P!"`"#5!+A<TPS'?`!/`&(`90!C`&X`
M_0`@`%(`1P!"`"``<`!R`&\`9@!I`&P%Y`7H!=4%Y`79!=P`(`!2`$<`0@`@
M!=L%W`7<!=D`00!L`&P`9P!E`&T`90!I`&X`90!S`"``4@!'`$(`+0!0`'(`
M;P!F`&D`;`#!`&P`=`!A`&P`X0!N`&\`<P`@`%(`1P!"`"``<`!R`&\`9@!I
M`&QF;I`:`"``4@!'`$(`(&//C_!EAT[V3@""+``@`%(`1P!"`"`PUS#M,-4P
MH3"D,.L`4`!R`&\`9@!I`&P`(`!2`$<`0@`@`&<`90!N`&4`<@!I`&,#DP.U
M`[T#N0.Z`\P`(`/``\$#OP/&`Z\#NP`@`%(`1P!"`%``90!R`&8`:0!L`"``
M4@!'`$(`(`!G`&4`;@#I`'(`:0!C`&\`00!L`&<`90!M`&4`90!N`"``4@!'
M`$(`+0!P`'(`;P!F`&D`90!L#D(.&PXC#D0.'PXE#DP`(`!2`$<`0@`@#A<.
M,0Y(#B<.1`X;`$<`90!N`&4`;``@`%(`1P!"`"``4`!R`&\`9@!I`&P`:0!9
M`&P`90!I`&X`90!N`"``4@!'`$(`+0!P`'(`;P!F`&D`:0!L`&D`50!N`&D`
M=P!E`'(`<P!A`&P`;@!Y`"``<`!R`&\`9@!I`&P`(`!2`$<`0@0>!#$$200X
M!#D`(`0_!$`$/@1$!#@$.P1,`"``4@!'`$(&109$!D$`(`8J!CD&,09*!D$`
M(`!2`$<`0@`@!B<&1`8Y!B<&10!'`&4`;@!E`'(`:0!C`"``4@!'`$(`(`!0
M`'(`;P!F`&D`;`!E`$<`90!N`&4`<@!E`&P`(`!2`$<`0@`M`&(`90!S`&L`
M<@!I`'8`90!L`',`971E>'0`````0V]P>7)I9VAT(#(P,#<@07!P;&4@26YC
M+BP@86QL(')I9VAT<R!R97-E<G9E9"X`6%E:(````````/-2``$````!%L]8
M65H@````````=$T``#WN```#T%A96B````````!:=0``K',``!<T6%E:(```
M`````"@:```5GP``N#9C=7)V``````````$!S0``<V8S,@```````0Q"```%
MWO__\R8```>2``#]D?__^Z+___VC```#W```P&S_[@`.061O8F4`9$`````!
M_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_
MP``1"`%6`M`#`1$``A$!`Q$!_]T`!`!:_\0`[P`!``$$`P$!````````````
M``@%!@<)`@,$"@$!`0`!!0$!`0`````````````%`0(#!`8'"`D0```%!``"
M!08("0D#"`<%"0(#!`4&``$'"!$)$A=8F-@3%!46UQ@A,526UE>7MT%1,G+2
M,Y0X>&%Q(K(C-CEY"I&Q0E*2PB0T-489@6*"<Y.S)41T14?(\*'A0V-5)B<H
M$0`"`0(#!`0'"0H+!P0#`0```0(#!!$%!B$Q$@=!46$3<8&1(C(4%:&QT5)R
MDI06",%"8H(C,U.35%7ALL+20V-S)#2$%Z+B@Z/#1%;P="5&LX5'&/_:``P#
M`0`"$0,1`#\`^K+2?2C31^TSU&>WS4C61Y>G?6'`3D[.[M@7%;BZ.;BMQ1$U
M"Q>XKUD4.5K5JM08(PTTP8C#!BN(5[WO>]`2;]Q+2#L;:J=WG$7T0H![B6D'
M8VU4[O.(OHA0#W$M(.QMJIW><1?1"@'N):0=C;53N\XB^B%`/<2T@[&VJG=Y
MQ%]$*`>XEI!V-M5.[SB+Z(4`]Q+2#L;:J=WG$7T0H![B6D'8VU4[O.(OHA0#
MW$M(.QMJIW><1?1"@'N):0=C;53N\XB^B%`/<2T@[&VJG=YQ%]$*`>XEI!V-
MM5.[SB+Z(4`]Q+2#L;:J=WG$7T0H![B6D'8VU4[O.(OHA0#W$M(.QMJIW><1
M?1"@'N):0=C;53N\XB^B%`/<2T@[&VJG=YQ%]$*`>XEI!V-M5.[SB+Z(4`]Q
M+2#L;:J=WG$7T0H![B6D'8VU4[O.(OHA0#W$M(.QMJIW><1?1"@'N):0=C;5
M3N\XB^B%`/<2T@[&VJG=YQ%]$*`>XEI!V-M5.[SB+Z(4`]Q+2#L;:J=WG$7T
M0H![B6D'8VU4[O.(OHA0#W$M(.QMJIW><1?1"@'N):0=C;53N\XB^B%`/<2T
M@[&VJG=YQ%]$*`>XEI!V-M5.[SB+Z(4`]Q+2#L;:J=WG$7T0H![B6D'8VU4[
MO.(OHA0#W$M(.QMJIW><1?1"@'N):0=C;53N\XB^B%`/<2T@[&VJG=YQ%]$*
M`>XEI!V-M5.[SB+Z(4`]Q+2#L;:J=WG$7T0H![B6D'8VU4[O.(OHA0#W$M(.
MQMJIW><1?1"@'N):0=C;53N\XB^B%`/<2T@[&VJG=YQ%]$*`>XEI!V-M5.[S
MB+Z(4`]Q+2#L;:J=WG$7T0H![B6D'8VU4[O.(OHA0#W$M(.QMJIW><1?1"@'
MN):0=C;53N\XB^B%`/<2T@[&VJG=YQ%]$*`>XEI!V-M5.[SB+Z(4`]Q+2#L;
M:J=WG$7T0H![B6D'8VU4[O.(OHA0#W$M(.QMJIW><1?1"@'N):0=C;53N\XB
M^B%`/<2T@[&VJG=YQ%]$*`>XEI!V-M5.[SB+Z(4`]Q+2#L;:J=WG$7T0H![B
M6D'8VU4[O.(OHA0#W$M(.QMJIW><1?1"@'N):0=C;53N\XB^B%`/<2T@[&VJ
MG=YQ%]$*`>XEI!V-M5.[SB+Z(4`]Q+2#L;:J=WG$7T0H![B6D'8VU4[O.(OH
MA0#W$M(.QMJIW><1?1"@'N):0=C;53N\XB^B%`/<2T@[&VJG=YQ%]$*`>XEI
M!V-M5.[SB+Z(4`]Q+2#L;:J=WG$7T0H![B6D'8VU4[O.(OHA0#W$M(.QMJIW
M><1?1"@'N):0=C;53N\XB^B%`/<2T@[&VJG=YQ%]$*`>XEI!V-M5.[SB+Z(4
M`]Q+2#L;:J=WG$7T0H![B6D'8VU4[O.(OHA0#W$M(.QMJIW><1?1"@'N):0=
MC;53N\XB^B%`/<2T@[&VJG=YQ%]$*`>XEI!V-M5.[SB+Z(4`]Q+2#L;:J=WG
M$7T0H![B6D'8VU4[O.(OHA0#W$M(.QMJIW><1?1"@'N):0=C;53N\XB^B%`/
M<2T@[&VJG=YQ%]$*`>XEI!V-M5.[SB+Z(4`]Q+2#L;:J=WG$7T0H![B6D'8V
MU4[O.(OHA0#W$M(.QMJIW><1?1"@'N):0=C;53N\XB^B%`1DW8THTT8=,]N7
MMCU(UD9GIHUASZY-+NTX%Q6W.C8XHL42Q0C7MR]'%"5:):D4%A,*-+&$PL8;
M"#>U[6O0'__0^TW1+]R#3;^%37G[HHA0$JZ`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"TYQ/8-C*,.DWR3,XGCZ&,@"37
MJ73>1,\4C#06H4%)$YCF_ORQ`U(`'JCP%`N::"PC!A#;C>]K4!^02?P3*439
M9]C*:Q+(L%DB<Q7'II!9&SRV)OR4E2<C-4LTB8%C@T.B<I6F,*$,@X80F%B#
M>_2#>U@+MH!0"@*$.41HN2IX69(F($Q5L2R4)8F-V0!DJF--Z]"U+Y$G8KJ+
M.AS$A='-,F.5A*NG*4*"BQ#L,P-K@5V@%`*`L9@R=C:5O<ZC,7R#"))(\7+T
M35DM@896Q.[UCQT<FVSRWMLX:V]>H6Q->N:!65$DKP)S#$U[&AM<%^E0%`QW
MGO!F7D<B<<39HQ/E!OB`B0RQ=CO(L/FR.+B4$J5!`9$IC3PYDL@CR$1PP64B
M*Z0"1BMQL$5[`5DG*^+5$>@\M(R5`#XIDUP8FG&TF)F,=,CV0G24)CED9;8.
M]`<1-LL<)$D3F&H"4!B@Q66`0BK#"&][`7_0"@,333/F"\;S&)8[R)FC$T"R
M!/SDJ>"06:9%A\7F,U/7+AMB$B)1E\>$+U(S5CD6).4%&0=<P^URP\1_!0&6
M:`4!2'^0,,49'632E[:(U'&%`I=7R0/[DB9F1F:T10CUCDZNKB<F0-R!(0"X
MS3CC`%E@M>XKVM:@*G8XFY-E%C2[D7+\M8^PPW)N3</3L;8SCT/)]#X>EQX<
M/AH"WF>9P^1.;HRQ^5QI]>6-"PNCTTL[ZUN;FSMDJ3*5L8<71`B5'JF]#(T:
M(XU`<:`!:PHD8BKC"$5[`7+0&#LH;.ZUX0>FV-YIV%P=B&1/+7=[:&#*&68%
M`'IU9@JS$`G=M:Y6_M*Y<UV7DC(NH*+$5Y8%P=+I6O:@,CQ>=0B;Q!JR#"YC
M%9?`GUI"_,DWB\A:'^(/+&(L1H7EJDK2L5LS@TB*`(5E!)PR;AM>_2X6H"Y4
MZ@A602J2G$J4RDDM0G4)S`'$*"#@!,).).+$(LTDTL5A!$&]["M>U[7X4!CQ
MWS+B"/X[,R\_95QNR8G)()4G90=YS&&W'9292X@:$Z@R:K70F-`(/=C`I0#N
MIL$2@5B[7N.]@T!U8QS7AK-C>Z.V&<MXRRXU,BXMK>G/&,]BL];VAR-3@5E-
MSHMBKJZIF]<8D,":$DT0#+EBL*UN%[7H#(1J]"0K2(#UJ0E<O`I,0HC5)):M
M:!$$H2P:1,,=CE($@3@7-N`(K%V&'I<.-J`]=`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H"*F]O[D&Y/\*FPWW12^@/_]'[3=$OW(--
MOX5->?NBB%`2KH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@-5_,181(,Q:'YJR'C>49=U@PCES)[UFR*1B"O>5@PF52G%#
MM',+9\D.+(\WOKO+X]BF0FN"8P]*V.*EA4/Q+L6679"(\H""LNR+&7!7$)1C
M;%>X&CG+]R=FW9F49`R#@#&.4\=Y5SCFU5`L6I,1YC48VAL%=,TXBQ-DI_!*
M/,RSV-JM+9*S-JES3B2NA8'(#%Y#=S+\@-2"7Y"S!N5C?)T8:>49$S8_!(Z-
M@BYIN;),9$-TI)(H2DB;I#7R9WQZ]!4R6Y5U;=C]\(\]1W2B(L.X%G9!ROL?
M",AR/`\VSQOVRN$#Q%S"D^L2''L>R5-,C9;G^.]JHO$=07_)SNTPQ\73`A<R
MO(FED<I#YM%Y>D\K9U6'^;W&8!FM]S1NM??+#):L.Q[`XM>P>)8%GN`(S,NR
M/$)N*9/J8Y^O\IBT#BV)B\`QO`=\^&%69Y@OES_.C9&680(U$A!9(6!C(AJW
M>A.ON)75WS1N$GG$^Y;K=E_-.8)EC;(>4)E"LXR?875Y=.86>V8_C+/DS&D>
M3P(U]0*V:(6+D$98?/GE"W*W!"8;<#D\9CV??,-X]5SN6[[XBB9.!=GB=;)+
MB`[*V7I7F3;]AS$\I,2D2Z6#PG&,HRW&3Q`O1)V-F_)<694DB:3G(4@,<3T9
M*P0$A(J#?PC*<9SC/YOL>1/4?,5UXP9+L*1ZSRNUH;=>YMK!B#KX<VB$EQ]2
MAD4);<O21\6)IB<L5!:')`$I*M)(+4D'@7%OU.]J6;8C+C=")CL_$9^VP'7Y
M3RXH3AJ,RIYP1F?)J^8/(\V(L^JF.+O,)<;HE:5`WOR29N#<@8X0=Z5:[`6#
M4+"0,K:R8"<,?ZJ<TQC&PY_LZ9?V@YA$B1HBB5DCRQ(VN2'O['&G;$"&?+6%
M)(U[XSD$WC8E2\"-R46(L)98H7E``4KE(&R-J?LLP2`7R1+=187AS6!CQ=DC
M-6KL5U9R<ARRQQ:51C*N&KLL;QIB15D"-8[9&*/J1KE[,>>S/;LO;+.[K<HS
MS("$.=M2<]X?E&_INLK'DU7'=1(SCW*_+K@!$(-<87A&9[FRB1KMY9GK^A31
MIS]=Y[C/'K*\7@[2W)G!1"[29P;FM$8-W+($!ZR\J;/6P0QMJ[(NSLCQ'D#;
M&2-&,<DL3CN)!5$-QVGP`S&)HQDG+KU@5YW-R;''?,[BJ.B*A$SQU.OD91K*
MO>36U,G(/`EQRR"=MLQSG'&6-I\@;3,J[&VB.G1)V,IBA>,98[EV>9\UYY9-
M@9'DR%JHRT6E64V8R*,%U2,1X4[$K,`?9,`Q468(#%V0[XBPY.>9'"-NM,LH
M;696V:S8BE."6Z-:_P`OR@FV@Q(NQ;CEBPQAV'9?:X^\Q/$)N#Y9&W!$X!?7
M:.)(NHZ<F`.P5PU0@+G5;#[3-^;%.`C4NRIF0T',+R9+'0I!C+(#M`6'3%XT
MRR9)\8IUN6R8J=CYT@-\Q6;&M+YLZ&KS)2D\@8`(PBM<"+#=%^8/!<<L&1",
M];ZS"7QW17EX;.G122I9`[H7W;J?Y8<HOL?$7J/)8:2K6QXG&S006[XVZ'HY
MD"I&YC2%+C`*P`=^Q64]H\OX:GFKI[#LY-I;&<+<Z")[)LJS#63%$1<U(QRU
M1IBR*)>JA14=R"HE,)=F]1"`QU8X"7I"A!^$RURK@7=/)KM3D'=E7C6/$[9L
M<`EV2]D,`Y6@CJX96<8LUX:>=/LH(\221`SL6*(YKCA3'[[F"*,JB#RI))WV
M9N:MTN4[N`+C5(DH%@ZV3?;7`NND)S%BV"[-3J%:FZ^\N@;C@ESQ]/$V1<\,
MBK`N5\/;$XF);)-"B)I+9IB?*"YH>""3./H43)8!711GV+.`J,L<.:!C_8'&
MF*)CF'*Z:=M$-TS/Q&_H&/.N0(#EF52:3BD.ZRF8-.*L>*\)RDAL?W1='!D3
MAZCQ</A2-N=6PLL?34'@;:.9AA]#DV)ZP*2,5(\BO#/OAI*L>CRH$GF;FTX[
M:=@(NY3%8XC"TN:M!#VMG$I4.)IG01D)[F#.N$%Q7H#4;EA!L_D!IV$P<R.F
MW!^9)=?F0XKSGKRRPB8,NL44U`4X5SNW:F.&!%B2*M$`8'YX<&G'A<7<8VK5
M222/#V]I'?IIR50&\#S1[,6RR'*VDS#AX_<EJA\'>>6M";-<L29V4,\TUQDL
M)@4>S_+W7$"?"3="B(0WKI:XHI7*LDR`Z<L<J9#"TB1K;R48E`&>Y5@S*[UR
M-]?L+-,%E;1DXG,>J!%HZ\8O=I@\P_T9OSCQ\4RB38Q6)T:QV88BQIQ/#B0J
M\V3W;4YAIQI1'2-"!@#+^,]U]<\A;P/J8B2N.P<Y+TZ0)]BM<L%27%>)I!R[
MV?,[EUQ.T7B.&V?),F3[<XE6RQ[22U0-1(I>&%KVUUBB,`23R$P%-?V?;"0-
MN"LOI9;L[-,F-V%N;_!]1)5%X_GY.,E]DN+L:R76F'SASRK$6612A:Y/$.?@
M1*73AO8QR4MM;@&F*5-DAJH#-[IF7:+;G+")BQ;,-U\=ZZ3;/'+]@[E/V#'6
M2L,O7J6IP!M1)-EO5-XE\(;9)$6H628_%VB4O-DR:Z%U"6G*4$G#),N!F745
M%N+&LXZ>S2>Y(VJF#3G"4\PR&9]AV5$[VYXXA4)Q/D>2%:N*BF)9'42'&[N:
MQ1]-9`^#&0OEB5P,NH.6@NF\B!OMH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0$5-[?W(-R?X5-AONBE]`?_]+[3=$OW(--OX5->?NBB%`2
MKH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4!9PL>PD60"LK"C#/?(Y,./QZ5,[I`>GRX2J>TTD41@*[]99G-?4A2N
MY7Q>6!87QT!#K&',!QCD;9_9'7)2Q.D+;,!,B]\:,T2=U:$.-<LD8\NRMNR!
M<37*#4QK=;6>72QF9I2<LN`@I8Y!N`=P%&7L!<"?F,:2*\<.F6$FQ$)4P=FE
MK5!G!:G*D!ST"4OT<.F;"UIX:6RBF:_T]"$QSZA/(;S4ZQB(-<23!HBC#P@9
M60[5ZX.;.]2!LS5CQR88\DPXO>7EOD2):UH4&PHF@&#UQBY,,U,8BRE=_1>A
M30"$6MLI+N"]["M>@,%OG-#Y?$:<9.T/FVN'6]TAIRQ/(D!DA&8I1&-$F<(=
M)O(E$)31.1<&DC4H32,:7RX(U<JXW2Z0N]AW`S(X;?ZQ-68VO7]?FZ`)\O/+
M<UN:"&W>0&'C)?F9?(X\C4NQ0#&!O>Y)&VM2Y-K<H5E.#BW$&*DQ)I`;F6`J
M&"]J->=F/6OJ(RQ%<ECA"AI*DY+`>JLI;$\A(5JHT]62N"5$H71>5)6]0:TN
MZ8)S6ZE$&C2*#@ECO8"+T9YJ.HQ6.V6>9LR3&-=U,DGF>X>P1+(TA0FOSDS8
M`V"F&N\FR%8ID`MLD@ITHB@5)[B?8I&TIEI7GQI-[#O8#GDCF5X>Q;DX_#4E
M2H+Y`>'/8]%`24$WCBJ*.B?6O!T-SA*5&19@#_Z;AY0Y,TR*+`0ZA,ND2%>?
MGB"F-+N(#*B#?76%7+F3%!F6H-?.3W$4$B3XI:Y"6]KAO:_'`,JD05)*$*2\
M563)5!A>EDK;92!R6,]PN!2:Z083+@4#WYHU[L.H^S?5])+,^VTKU-BD?B%W
M1H]-0]3M@_Q!@85+TNM>[:O*B!TO+,6V3WM<\)(K%7XWM0%68.8QHS*7&<M<
M?VAQ&Z*<;(K.4U,320OT<R-P,@M^)W!PN[F%`:5Z%@R6[)&)V.2GGEL[FJ)(
M773F&EV$!=^5=V=4L(FOR?*6<H1$ED8F2''S\W*E:Q>Z-LS7PA%DRS`>U,Z)
MQ<1+&['+DG?G"X"A%MC,>!8L$0G%8RX%.DF]FI,6FBO'"[.4*6SU-"%>04\7
M8UIKXK>&!-`%>5"B&)P;"%+$\2-TQJB&_H6@A6-S6LW!<20-**QUP,,0'FR:
M$3/'6$\AO.P\"QB#.^.8!DZ*QC)KN1$Y&S1S);:Z+X@9,R5W!!$_32IC6MZ,
M]:>2C<'-*)*D./.$6`8&4'/F&:4L^,83F-RV,QXDQUD5]DL:A[Z-6X"4NKY"
M!K0SM`9'BVX<F:A8_"WG#D`UB-.6Q$EW,7B3E\!7`N!;O-J`WYCCVORK8G%H
M<PRI;&6UBA!4E2JEZQRF\7!-((W#7);',Z%PGT7,LL8"%"DHU\*^!"%0*UPT
M!1<$;VZZ9[U6-W*9ID3"L#H+Y`&_RS(_D8B1&$N-Y8^1&0+'\Q>=9,C(\]8Q
M&%<#!^4`<6&W$P70L!A+(?-(P$WN^HD<P>L:\]ONX&P[WK_$2VN1F0QMA3C`
MHZJEV57"?J'N/K'>-2.%L!:;S>.+4"5T=%3BD`&Q"<T2H`%+S)S&I!`M]L=Z
M.XZUY<<L.KE%V:<Y2?R\HP>$R^-0B1C<"DTOQ?C"3#)=<PQ^'A:CCI(H(5MH
M48;63(O/W#_J=`79).9?AR'Y>VOQM*X3E:,QC4'7XW/\]RI)(>OC48FC6WR"
M5QQ_8<1H)"6U.V0?03K$SD8G=*`+,K<S+)4JD\19HP`8]3\S:0!=!X>>]3\@
MQW;YYFF/HUC[6QRR#`Q!F##DW'4YRPQSQ3E-*8?&&&.Q>%XNDH9,#S=6K9W5
MG$D**6A4HU"@"<VL^?8YL]A&$9MB[)((NAEH)"@<HG*TZ9/)(?+X3*GR!3V'
MO5D2A6WGN$4G$8<6XQ0E..2*KIO+$&#)&`5P,[T`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`14WM_<@W)_A4V&^Z*7T!__]/[3=$O
MW(--OX5->?NBB%`2KH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4!3GBSL)I=`L`VXI]NW+;,ICP4I/:2W:Z8VS<-T
M(1')UAS<!9T+GA*,`:(KI6"((N%[`:2(IR;2X#$]9I!&<X/[UL1B]VRLOSG+
M,I.V1\IX-S:FVKC<H1;@-Q>NDQG[G`(TSY.FTE3R!(C)*M8`V1&D4FF`,/.$
M!8,>Y46R;3A4R$NV2\+2);&LK8HFV),5*9CMPB@&&D&.\;23';^\X$V#3Y@'
MM?KS)IB<_E+D+6QOBV-1AK1FL"9*I1.*E2$"ZC>5WM<F//CWO3XYG,8RJR:#
MKMCYYD'&#Q;*TFG>C,\CLD`.$$1F0MD21,.6V".I42A0O`<X,YZ6Y_\`]0&J
M,N2!EQ%RPWI+$L7Q\>0H8:OQYBSF=0(3IZEJ?**7;F"9(1SIND"`8G&ZA"*&
M)R!IW:W3$8[#,N((B[7O:@,"P#DV3"&Y>C;N[9'QI.,5'SC7/-\S)E:?.JV2
MMV8<!8,@^'0IHCC1-F!#KX^Q]U7X[;W9G=I$P+G:.D*5S=<IQ)/*-3@2YY=V
ME&:M1%V0B\@9-A*V!O$:A$2@V&L5F9468NBRN'+Y4I=,AQ-NS-,IX^X<339)
M($R:V/8PN!"8Z!NL)``8CQW`!AB(\JR:1YGRDVKLNPUP/R#J?S"-;T:HB$NR
M<;4OW5VSR%L<Q2(X1T@4B/:H.S3%.U."0/1&XJTEU!8R2Q!)"!:,IY366%C8
MI21K-6/2SI"LV/8939]ADE,3A@FQ&A^(-35BQD]'R$L?KA$YMAM$^%`4V,1+
M6I:H1BN2HL6JL!Q_\K/8QPS1A&5R;8B'23'N"L[8JS3%B'$G+5G$EA@>`!X-
M.Q`Q8I;YTVX'C5FXU:L=4T[.:'68N91Q:!:;8LBQXP)=!T;DON?:-:S"R&QB
M>M2)QI%+7V7!CZ\#7-2=3I/!7]\1M+1=S,5LQLS)B)A201QY]D8CPB,L;8-[
M7`PG$.5203C7`^)<@SN./\,QSACF!8;R$EC\66,1\O;-W,@L$U(<F$1CHK]!
MKH39G$,TPRYIBAS\FK*$2,NU`81D7**S>=`M:I*1GB#Y#VDQD;LZ=GN?S*V=
ML81#/[YM<5"$4SGAZK!.6XAD../T1:,71UM2-8G%8S.K"E4-AY:8)Y2I,!D+
M'/*SR5B;/&+'_&N2<88TPM"X3C2(S0&+F?+$+F&3XS`M?7;!ZW&$YQ4KR1*-
M?Y>RK5S@4ZL<S<FTZ>Q=L2%,A*]60`*L(%&@O*?R:1@":8KR;E'$K[+)1B+E
MLX7"^,4`?A1T49Y>>6EDR0+W%KD#TN<#U.28P%-8Q)8^Z=M=QGF`$:5<%`4'
M-G*(RE,,HRO-$#RU`5$JD^5-N7$<2FBO/D,B!.*=LV/#:=T2*7C!&6,>2URE
M\/?\0%"5HCSC&&4LK@>W*BT@[%+0`9LAO*X4P-.\M$=G4%0L)F?>6UE6.HVR
M`N#59IB>A$(P=#%$1L6=)7D\L<M(Q(?Z(O=2<!F3+BR!B4V*$8,"YFSE^Y-%
MH!(-,GK*D##)HQF%9DK"F2$<)=G6/W1P[9I)LSA]'EJ"/;Z,+\=Z<;$[7)B$
M"TE.I2^4.0B3&W+L4!V8KT1S`AS[$=H\KY#Q8')KIM%*MCLN1+&45E":#"2#
MTI7::0*%P=TD+U=Y6.34S@2/+P^.24L;F;TDQ:1,42G%8#%&_O+SV0V[VEP-
M+&;(>%T^"H:YI)$1)9/CI25L;JM+(^:S+UTLULR%&7QC/<WK)7H4A.7=YZ1<
M;5V.5<'%*?=M"!)?8_0@K9+*>P\HDLZ3LT)SYHC;3LYI0L:A5(XR^6R%D";I
M\CD+ANJ5O<$K:*8)_)-PBRA&'H[],[H&=&P$<C-`=N'?)3-N-*,Q8$<MV(+*
M\8WA"1%"9TAU[48U@>*\L8DEL2>BKO9\]0/>5TN;7Q]/<"K*RV)<0W(TY"HE
M.>I5@;#M0=?E6L.O\-P^Z2[U]DC:Z3Z9369@:2V%)(Y]E;(DKRK/'!J8RU*V
M[.P^MTT6%MR49Z@Y.@+)+-.-,"(P0$EJ`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@(J;V_N0;D_PJ;#?=%+Z`_]3[3=$OW(--OX5-
M>?NBB%`2KH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4!`SF@Y-R#AOE\[:9.Q3*W*#9&B&'9$Y0^8L
MQ+<>\1IZ,$E1)WEI*=D+FV"<T-E5QD>73GE6-L&X@"M;A<"`>=]F\A\JC+#Z
MW2O.N:MS,2R;47)^9T&.,N6@KME?'^8,?9CP7B/'UTF1\;X\BZ]+BO.3[GE,
MT'D.;*ZJ&QQ9AJ6X2BYIS?<#+,.YC^Q$X6,&$V;6..-NT<ES9+\8L76(_9IP
M_@"00R`X/9LZ2S)[&]9.P-&\UJ;("W]-$@LPX>6H$_W,5^7]$EB4W`MEOYM>
M07G/@\:->K;PX1#'D\UXPQG]PB:_(>3WF&Y9SU"8=-'@R'33'N*'C`C]CO#"
M:?-875<[RQB<WE-9:I0(+62E%K`,2MW.)V=50\.1ENGF*6^'"U#3[YF`#L@\
MK'Q-K^SS\4`E$2$2##1"-1F9ZX6>&,D`[,'F5AIUBXE2$'E0+G@7,>S;@]_S
MI*]B(N@G&LR?F";=Z\0W(K?,4QF78PAQYCR49A@;2AQ4WP1H856.FMNQZ\QN
MQRB0&OUEGD%R@OS.YHP`(ES=MA)3C$,B2Z<)?7V?'Z8*\)H'B3YGQWBYW3[J
MY7*Q;'X?,LD92UWARPV;8D`L2OSTIC#1(&!W:5%[-JT9Q=P#`EOS!)!D"*X9
MQ?,9+LMD;74"(:ILE>--3(@T9$SOLAG21Q8I)BO">OKU-(B_N(@VGI:I6,KU
M9$8ZH$X37,UK:D[F;8#7'*MIMZH?'<MY(S%EA3$<NZ#1SEG1S(.$X&A@AV,\
MUY!V3M`1[(7R67:.OCB[FOMYZ8RQPV.N#4A:7-GNJ1A,"<8`0$OIAMOEO5?:
M[?R8;092;Y;KIA_43#.><38GQMCE0VF0M%(<LYZ@"1I7/%U4CD\^R;DM;$&H
ME8O-NW,;8,91928A.4I6&@5GE"[93;:6+;A"RAGB!9OR!CC<"7M`2<9E(;07
M%^/)1CK&DJA&,8<X)6U`LD\7AB]<[MA+VN$>M>E:)2K$(!9I1)0&WV@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"*F
M]O[D&Y/\*FPWW12^@/_5^TW1+]R#3;^%37G[HHA0$JZ`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`8
MYR]B/'&>\7SO"^7HJAG&,,FQETAT[B#F<N3H)%&GI.)(YM2I0V*D+B04J('>
MW3(.*-!?X0B#>UKT!&J"<N'2'',5RU#(YKQ#53%G:)E0++OKDLDV2'F=P9.4
ML+20UZE&17Z52B\6;S'`\],WE+"DB96:)046`^_E*`Z5W+>TN<L5E8:<,,`6
M0LG(8LM%JC\@Y3,R';)8XL&"&S<68KSCK>,D1\##9A,4"?+C-8[>CQ\4?]A0
M%<;^7[ILSY`@&3F7`</8I9C!CQU'H79A/?V2+-R##[4L8\2J%^/VIY1P&1OF
M+V9>:ECKFYMBQR92!6`C/)"$-K`5DC1[4]-%@0E/A&)DQ4O`M]8`,A8WD*,.
M`[NMWSJRM:SIY6S!9V%<^PNEYS8=_@-X?!0'BCNAVHT4S(]9^8L)1Q)E20OT
MYECN_'.,F<6I5,,F,)<4R!,PPIS?5D%2S.7Q,OT2O=R6TMR4-0QHQ'73&&%"
M`I.-^7EIIB1LNS0#!C"RM8);BB:(D:E^FC^6S/&"90KFN%T4<O))*[CC$1Q9
M*EYZYAC[?=,PMAQYER$8+#%:X%T;'Z4ZR;;.N-G[8'&09T_8?,F!V,7U/,)]
M"WN%'3]I1,4S-9'>`RJ+.*<V1,K>4D4"N8*XD]A%VX!&980%)#H7J5ZWXHGA
MN'FY;+,)Q^$Q?'SNYR:<.HDK/C)8X.6-`2A(Y2=4WY&<,;NKLJ61Y=(RG9<R
M+%)JA$<0<8,=P)`)<7P!%DY[S.DBS:1E&20:-XU?)H"Q_I=R@D/?91)HS&5%
M[G73>CF=^FCHJ*Z)=A^46F<17MT;6`0?%\`QLKGZ^"Q=MC2S*4]<,H9!4-]C
M[#E,_=6./1MQE#EY8XZUW)6Q11N3"\G8!?DT@.`;7XWN!?M`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0$5-[?W(-R?
MX5-AONBE]`?_UOM-T2_<@TV_A4UY^Z*(4!*N@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4!%3>W]R#<G^%38;[HI?0'__7W49.R'EK#NH.AVP&--CL
M@L47PE@#EY%YNQU`WS%XL?X!PS+$\=.RQL7L7BU<6XY?SLQ3*!MYL>8X^R62
MJD1J4]P;PB/+5*"0+#RSM9MEJU+-B\SY"EV59*MR^U\Q)RTH%']B,4Y=UL;5
M&!$DGD$)C<HP7"L=$NL<'#L3PA4]"<C)*\B+>T#BW/!*(XP@-P-IVF4AR-"-
MA]LM:I!G&<[)Q'%F,M6\OPZ99$7,+S.&^0YO9,L$3>,*I"Q-[2E/CSVX8P2O
MS,B$GO9K*>#B"!^9!2$D@:EQ;C[88^U^Q/G9)LK)9+,MW],\@YJG#-*D<1>(
M7JC/$FQNKV-6Z=8N81M*`<4A^,8GL8Z,2MM<35B1<[L;>K5A&I"NLJ`W':02
MF?L^7]VM995DF=9EBFM65,6(L<9)R:O;GW(/H7+>#X7D]YQ]*Y4UMK01*%D)
MD+N><E4J$X5Y;6ZI"#Q&6*+,$![=N=J-DM;I5BMMAFO>'\LL.=,VP[`6+S'3
M8J68VDXYI*X9+IB-SF;9[N\X8F&,-B>"N!5S$CDY*C>)(K$AN,0``7VV9<W;
M-;D1CSIGCI$[#3%B<4;;MHWN;>F5WX^5)1.*G";2I7)P_P#"8-*G$+\(+4![
MNMG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z
M9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D
M]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LC
MH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?
MO3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG
M<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]
MD=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV
M#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!U
ML[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-
M/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL
M>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`
M.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z
M9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D
M]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LC
MH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?
MO3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG
M<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]
MD=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV
M#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!U
ML[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-
M/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL
M>P?O3-/LCH!UL[D]CV#]Z9I]D=`.MG<GL>P?O3-/LCH!UL[D]CV#]Z9I]D=`
M.MG<GL>P?O3-/LCH#\OEK<BUKWOI]![6M:][_P#_`%,T_%:W&_Q8BO\`#0&.
MLY96!G+E=;`Y=`P&Q:V0=*LZR6\=/<2G<UF$NQ!,;C;QNA*5$4ONG&&X?*A)
M+L.WP]&WQ4!__]#ZKM:=+=5LY:XZ!9JRU@V"SK*,`U0U<(CDO>F\\2[S2*P2
M(R^)-T@3)E2=MF35#Y>(3NSI'DA>F:740EB0!*@0C+@2:C&BVH$-R=D7,<<U
MYQF@R+EA)-4,_?C&(#@0^ILF*BUV3RP,#F:LC;/?**\D"B4"0(THY&H#8URN
MJ,M85`=^.=(M4L21=EAF.L)Q.+QZ/Y(C.7&I(C&\*%1&0X4@*:(9(CG=P=%;
MRO%#V1.4WM290H-1-S<04E3DEIRBR@@=,9T7U`AYV93H]KSC-%;8)M?F3+Z0
MUA`XMDPC\J<71YE$9,:7,Q8ULD6DC\]K')P;&TE&@6N:HU8<2-4,1MP,HX1P
M)B#7&$VQWA."M4!B0G=QD*QO;C7!>L>)"[>0"YR"0OKTM<Y!)'Y<4D)*,6KU
M2E4(D@HKI^3*+"$"&7,3_OCRU/\`,KQ+]Q&R=`;*Z`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"&6
M].WA6E.&&W+QV/E.2PN.0(W!+1Y+)2(J82*0HWI79TNYJ&=[+&!)Z'Z-R?(V
MN/RG'I6Z/PP6H<[606$+YVSJXU8PX>+A])-XXX/=ANP/4>47+27-75-?34<Z
MC8.%E5N.\=)UD^[E3CP<*G3?G<?I<6S#<\2%^H'-\2[8;!Q'`Q>O;E`ARIFE
M[O:5*,EH)&2@]5&0UYNG$SD0YH-477V+\G85E`/)WOTKV%\50&2:W6<YG0RY
M98Z;G&3XN\4L.%8[N%;_``GJ?,S[-%3ESHO,M82UK3O%;U:,.Y5K*DY=]44,
M>-UII<...'"\=VPW.UWA\MB@%`*`4!P,_5F?F"_JWH#4XD_P59[_``#YK^Z.
M;4!__]'[3=$OW(--OX5->?NBB%`2KH!0"@%`:U.8G_?'EJ?YE>)?N(V3H#97
M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H
M!0"@%`*`4`H!0%E9`R1C_%$8<)IDV:Q:`1-K*,-7R*7OC='VA,$LH9UP"6N:
MA,2,X198KA+#>Y@[VX!#>_P5KW-W;65&5Q=W$*5%;Y2:BO*R5R;(LZU'?T<J
MR#*KB\S*H\(TZ-.52;Q>'HQ3>&+VM[%TLUVJ]_LCYX5JH[H)KS),TD6-&D%L
M#E8MSQ/K:VF!,+"-6V/3HD+E^10$ECN.Y+0B!8=K?T3;US$M2768R=+3>63K
MK]-4QIT%VIM<4_!%>,]MI\FLCT?3IWW./6M#*IX8^SK1PO,SEO\`-E"#=&VQ
M>S&M-X=,2/>R/+-VYVAQZD699W$0RS+5I.RNB2%%1Q?$-9(2RD)W0IX*CD)9
M`*Y-)9:+SA.!&\NRFYQ)-CK>3L(RXKQF:Z3SO-[5.]SQ3O>--0X7&A!;<>&*
MQE*6["4GL6.S:=IH;GURUY?YU4I:<Y8SMM.>KS@Z[JQK9I7FW!P=6O4X:5*C
MLDYT:,<)2X7CA'`M31?E*YOU7V@@^<YIEC%4ICD789RTK&.+M,N2O:H^4QXY
MG1&ICW4`4`"DIYEAFV'?C<%N`?AK#I[1>89/F]OF->]HSI0C--14L?.C@M^P
MD>;GVD-)\PM`9MI'*].9C;WUQ6MYQJ59T732I5%.2:AYV+2P6'3O-^U>D'QP
M*`4`H!0'`S]69^8+^K>@-3B3_!5GO\`^:_NCFU`?_]+[3=$OW(--OX5->?NB
MB%`2KH!0"@%`:U.8G_?'EJ?YE>)?N(V3H#970"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!@+.^T>`=:&0M[S
M9E&+P<*O@!H95JWSR62-2.QGD4<9B#8!9)9`K4#*N`(4J4VW2^"][?'4;F.;
MY;E5-5+^\A3QW)O&4NR,5C)OP([+2'+[66O+IVFE-/W%VX^G.,>&C36S&56M
M+AI4TL<6YS6S<0NML=O!M):R?5+`Y&N^-%U^B#83;-M5H9$O;S`EC`ZX]P(U
MG"?%8SBKW$F/?#TR0SC:XRK6^"\#[4U!G&S)LN5K:/\`IKE-2:ZX45M?8YM+
ML/4WH;E-R^?'S%U@\[SZ&_+LGDI4XR6^%SF$UW<<'Z4:$9371+JO6`<MC%`9
M.BR;LS,)ON3EQ&>6L227.RM.YPB-+"SKJ"[0/$",!<!BR,@R_P#9!$F5G`X6
MOY7C:W#8MM*V7?1N\VKU+^]3Q4JSQA%_@4EYD5U;&^TB<YYZZC>7U<AT%EEI
MI?3<EPNEEZ<*]6.&']XO9?WBM)K>^*"?Q38BE2)4*9.B0IDZ-&D)*3)$B4DM
M.F3)R06+)3IR"0@*))*+#8(0!M8(0VX6MPKIXQ44HQ245N2/$ZE2I6J3JU:D
MI59-MMMMMO:VV]K;>]L]%5+!0"@%`*`4`H#@9^K,_,%_5O0&IQ)_@JSW^`?-
M?W1S:@/_T][,NROL-@73_0#.6.,V25FQG"\%\OF+3W'L<A.*'G%F.HI,K0HG
M-.==PGV4*56718H!B4)K;'T\'*1.36^!\_4B4([J#4`%@Y$YANU>(\9M^W"2
M>WFS9GXKF8L,8UTD<7B!L.P\9JBLRL;@.2Q9RC3,RSEW6M;7B<RT[]*NZU([
MW=A"2EMMTI'2`V>:CSC-$9V"VHUCROF%WV*2X@QUK3E^*9$?8U#V";A59Q:<
MJ(9G"G1+`6>-Q<3$FE&)3'..%>9>?)4#N)(>I5A3$G7`U8J-\]RH%@W$>=S\
MRM<O?]YM0YOFQBALB@,1!#M3<A@SSK5CN).D,2,J1H?G;&\,@NROFSNGD[@\
MG.$@CR95YP06L5)+@;;M-,@Y.#EO<K6?)61))F4O6;)6,$L'RS,V>*-$V?8;
MF+#D5R:1%YJ."Q^)P]YD4*?'%<2!<C:VZY[4H16.(N<`9YX$5>9I/M@4&8="
MV>.Z\,TCA[+S#,-+H5-%&;6)@/F;^;@W/(5+&KBQ\07KHRG2@6+/^MC4*;#\
MTM>Q?`VU@@3)Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:
M4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%
M^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#K
MNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT
M.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#
ML+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:
M4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%
M^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#K
MNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT
M.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#
ML+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:
M4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%
M^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#K
MNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT
M.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#
ML+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:
M4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%
M^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#K
MNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#KNW@["T7[VT
M.]FE`.N[>#L+1?O;0[V:4!%/+G-)R1A=^0PJ1ZJQF8Y.<'`E"EPSA[:>#Y.S
M&;89Q99RF\$:(,E/1$$A,O>UUAZ6Q@@]&U^-0>8ZBRK+9JA4KNK?/=1I+O*C
M?R8^CX9-'IVD>3^O-8V\LTM<KA9:9@DZF87U16EG"/3A5J?G&DL>&E&;\IXL
MGS/FT9\0-"K&F$(YK5B=]4&DO#4;F")(-JP,8TP1%K4ZY\@TYQI#UBHWB#R%
M@B7H[_TO*BX6M>,7UISK>XY98/P5+AK^)3?E:.SG_HARY]%5]:ZIAN]*TRBG
M-=+_`.YNHX[-G!"74L=E,P;KIDO`L@/G3/R[6O).6E9YBAPSCFS<V)Y,RZXG
MC.L?=3ZSOV,CBV(=S`\;%M9*(D/Y(0]&UK6DLOTWE6757<0HNK>O?5JOO*C_
M`!GN_%21Q^K><>N]864,HNLPIV.FXI*-A8P5K9Q6&&'=4\.\V=-64Y/>WB3,
MZ[MX.PM%^]M#O9I4Z>7#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM
M%^]M#O9I0#KNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0#
MKNW@["T7[VT.]FE`.N[>#L+1?O;0[V:4`Z[MX.PM%^]M#O9I0'$>;=W[@'QT
M6B]K=$7&_O;0Z_"W"_X.K3X:`CXBO>_)3G-Q6Z(Q:!9F$8"U^E8LT6'YH(TJ
MPN%NG8HR]P]+A;I<./"W&@/_U/J5UTT5U:SYK5I+EK*N,0R.9)M0M261\&GE
MLWCT;R-'\>PV*SO'\;S#"8U)&B&YDC<&FAYCHTM\H0.R1"K-,$46&QI@1@2J
M;M$M4VV>9'R+?$K>[/N54.46Z7-LF?Y9*X2%-G(:(W.%XOCJ2/SI`H,IS.>W
M$&2LYE;4!T@,+Z2T1UQ#N(#NQEH_K7B!G2,\#A<A;?-9W!,BF/B_*>6'^8.L
MAQ<QDQ?&R.1S9^F[E+I3#()%DY38UQQR6JH^D0%V)"BZ'&UP+=8^79II'T^5
MD"/"#(L9<R1*6P"81I]?)?)(JWP">RA=.IG`\=Q=_D#BPXCADEG;B<^JVR*I
MV=&8\W`L\G8\D@98&<,)8"Q=KS&WB,8N9'-O3R:3+YK+WV32R79!G$WF+FD;
MVY9*9QD"?ODEFTQ?AM30C1@5.2]2:4B1ITY=PD$E%A`ASS$_[X\M3_,KQ+]Q
M&R=`;*Z`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`="E2F1)SUBQ00D2)2C%"E4I-+(3IR"@W&:<>>:(!1)10`WN(0KVL&
MUN-[U1M13E)X11?3IU*LX4J4'*I)I))-MM[DDMK;Z$C7=D'F38F*D[CC'6F(
MS7<?,"`VZ17%,%I"G*&QY988`7]><O+.AC^+)"K#Z1@[*59H+6X7*XWM:_,7
M.JK)59VF54*E]?+9PT5C&+_#JOS(^5OL/;,EY%:CE84,_P!=YE::7TS-8JM?
MR<:U1?U%G'^\56^A<,$_C88EE7UTWAVDM=1M3G8C73&2\/\`:Z^:H.2A-)ER
M$P)A9S=/<^.9%WH\9Q?1L<2QITZ85A"Z)EK\+AU_9>H<XVYQF*M;1_T-N_.:
MZIUFL?#P)+M);Z[\I>7V$.7FD'GF?PW9CF\4Z49+!J5OE\7P+#;PRKRE)8+&
M/7,[!&K6O^M#,8S83Q=%X/YV'B[O:-'=;+)"=?HW-5227N8ULE?E!Q@>F*ZI
M49:P[WN&UOBJ>R[)\LRFFZ>7V<*>.]I8REVRD\9/QL\MU?S"UGKRZC=:KU!<
M7?#Z%.4N&C370J5&'#2II+8N&"V;\3/]21Q@H!0"@%`*`4`H!0"@%`*`X&?J
MS/S!?U;T!J<2?X*L]_@'S7]T<VH#_]7[3=$OW(--OX5->?NBB%`2KH!0"@%`
M:U.8G_?'EJ?YE>)?N(V3H#970"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0"@%`*`M2:SN%8WCCA+\@RV.0F+-10CG&0RIY;V)G1@"$0
M_P"V7N1Z9,$8[!OT0=+I#O\``&U[_!6&XN;>TI2KW-:-.C'?*322\;)'*LHS
M7/;ZCEF2Y;7N\PJ/"-.E"52<O!&*;\+W+I-<JSF%RW-ZM1'=`\`2C8D=CS49
M^<)OY]BC6QD-+Z%Q*RI@_(B7Z?!+#T^"=F2"\K<-N@=PO:]<O+4U;,).EIO+
M9W3QP[V>-.@NWB:XI^"*V]#/<*7)7+=)TX7W.365ODBPXE84.&[S.:ZG1IR=
M.WQV>=7GLZ8[,#BFT"R1GI20^[^;#2+-2.Z@M:7K[BD3EB?7)L&6,8BT+HV-
M*LB99'*)`*UO+.RPNQE[7Z171O8-J+3=UF+534F9RKQQQ[FGC3H+L:7G3\,F
MO`5J<Y,BT?3G9\F]%4,JJX.+S&[X;S,Y[L90E-.C;-_%HP>'1+':;$<?XVQ]
MBB,H(9C*%1>`Q1L+"4ACT29&]A:B+!`$'3\T;B$Y1AX[!MTS1V$89?X1"O>]
M[UT]M:6UE1C0M+>%.BMT8I)>1'B6=9[G6H[^MFF?9K<7F8U'C*I6J2J3?CDV
MTNI+8MR2+VK8(H4`H!0"@%`*`4`H!0"@%`*`4!P,_5F?F"_JWH#4XD_P59[_
M``#YK^Z.;4!__];[3=$OW(--OX5->?NBB%`2KH!0"@%`:U.8G_?'EJ?YE>)?
MN(V3H#970"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0&
M)LXYLQ_KMC"39@RBX.#5!HC9JN]KFMF<Y`N(L\O+>P(/(-#,F6.*ORCDZ$A%
MY,L70#>XA<`AO>VEF&86V5VE6^O).-O##%I.3VM);%BWM:.CTEI3.=;9_8:9
MT_1A4S>YX^[C.<*<7P0E4EC.;C%>;"3VM8O8MK(#H^<YH$I5$)SLF2]M*.'<
M`U[GB7):1O2_T!B")4I]61^2"8,-BP<`WN(P80VMQ%:N;6N]--I.[FEUNG42
M_BGL=7[+G.2G3G..0VU227HPO+5R?@7>[<-[ZDF^@Y^]!N;M%;S34'7ZV&<<
M.!?`C9/;%"M81*DAQ?2+<X!@E`.TO?.E:UQ$*'4U$D'Q#88+<;]&OM?/<W\W
M),L[BU?]/<IK9UPHKSGV.32["GU`Y6\OWWG,S6?M3/8/;EF42C4PDGMA<9A+
M\C3ZI1HJ<UMP>[&[83RV,;N4D;LE;8SR:[G97;S;*T+IF(XDO&485^6\XX0?
M"K0(J!L28HR][`LH)7&6#?\`+M>]ZS6^E;6=6-WG5Q4O[U;4ZOYN+_`I+S%X
MTR-S;GKGE"QKY%RYR>UTMIV:PE"R3]:JK##\O?3QN*C:W\,J:QZ#8NA0H6Q&
MF;FU&E;V]$26F1H4*<E(C2)R@V`4G3)DX"R""2@6M8(`!L$-O@M:NIC&,(J,
M(I16Y+8D>(5JU6XJU*]>K*=:;;E*3;DV][;>+;?2V>JJF,4`H!0"@%`*`4`H
M!0"@%`*`4`H!0'`S]69^8+^K>@-3B3_!5GO\`^:_NCFU`?_7W=/[_L<S8*Y=
M3)KMM!D-NSE.=3]-VW7#4W&T#ASC"#3VEHA@\^;#;B2%Z9),_*=<62"NB-M/
M&2IC@6\\KS9I,72%T0EE@6-ES<#;W5>6[(Y9RQ(<SN*G)S1O\XZ.H$>5M<\E
M:L&FX*129_Q]&Y'C/&D$-R@R.+!BB&'R2RYPDRL!RY&Y-SL!O4W3%7`VAZ=2
MG+$-V&VOUFG>;Y9LHQ8FQMK%F"(SJ;I(H&=(W?.+1EA+-H@O70YGCS,;'ECY
MBHMY84HD?EFY,\&I;'&I2DH2P-4-]V=PL>8%Q'GH6PZV5RS>/3J=YK=(U*(O
M"%D(U*R`1L)K!C=@EN-V9.TM:U)!,=PW9)4U."!^5.A3B]L*%6H%Y0U<2H`W
M!Z43')+;EW=+62=Y)F>:&76?)N*TF/,HY&+CQD_6QG+^$X?D]7"9@\Q5BC3-
M)72%/[HK$G6^8IU=VIQ1E'V,$58XT".?,PE.PB;+N@+;',,XV>8<W\Q+#:B%
M2IWSH[QYVDS^;@O/UE+8_P`42X5D0(FU)0J%E_/27%V.'YL7P2V\M?R0$U.L
MS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF;R=DG!G?$
M?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=\1^\*]`.LS>3LDX,[XC]X5Z`=9F\
MG9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF;R=DG!G?$?O"O0#K,WD[).#.^(_>
M%>@'69O)V2<&=\1^\*]`.LS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`ZS-Y.R
M3@SOB/WA7H!UF;R=DG!G?$?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=\1^\*]
M`.LS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF;R=DG!
MG?$?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=\1^\*]`.LS>3LDX,[XC]X5Z`=
M9F\G9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF;R=DG!G?$?O"O0#K,WD[).#.^
M(_>%>@'69O)V2<&=\1^\*]`.LS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`ZS-
MY.R3@SOB/WA7H!UF;R=DG!G?$?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=\1^
M\*]`.LS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF;R=
MDG!G?$?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=\1^\*]`.LS>3LDX,[XC]X5
MZ`=9F\G9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF;R=DG!G?$?O"O0#K,WD[).
M#.^(_>%>@'69O)V2<&=\1^\*]`.LS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`
MZS-Y.R3@SOB/WA7H!UF;R=DG!G?$?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=
M\1^\*]`.LS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF
M;R=DG!G?$?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=\1^\*]`67D'97:'$L5<
MYUE/`6LF.H4RDB/=95,-VW5F940`EF&V+&I4:L=(Y4<$H5BB"@F'G#MT2P"%
M>UJU[F[M;*C.YO+B%*WCOE)X)?P]26U]!+9)D.=ZES*WR?3V4W%]FM9X0I48
M.<Y;4MRV)+';*348K;)I&M3.6?MV.9!J[D**8:TO'%L6N+DV653MYR,!R5Y<
M9V:6,;BQG8,:Y1&,6."Q$J6H/.ECB[)4J4"$@8"?*'##PX'.[_--39;<V^29
M3.66/#\K4PA*IA)-*E"33PQ6+G)I8;EB?5G+32NB.2^L<DS;F9KNVHZTAWB5
ME:XW%*SXZ,XR=_<4XSBI\,G"-"C&4E4:<I<*9`?6;0;?'&NQN#\BK-67@Y+!
M\B-4C/*ETY@<?BP@HTJ\`!2!]9G6;N[.W$G'!'=0E9G0\`PAZ*<5[](/,9%I
MG/;?.\JN+K+)PMH5TY2;@TE@]K2DV\.Q,]MYH<Z.5^;<M==Y7DFMK:XSBXRV
MI"C2C"YC*I4<H804I4(Q3DDUC*26&.+/I7ZS-Y.R3@SOB/WA7KVT_-`=9F\G
M9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF;R=DG!G?$?O"O0#K,WD[).#.^(_>%
M>@'69O)V2<&=\1^\*]`.LS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`ZS-Y.R3
M@SOB/WA7H!UF;R=DG!G?$?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=\1^\*]`
M.LS>3LDX,[XC]X5Z`=9F\G9)P9WQ'[PKT`ZS-Y.R3@SOB/WA7H!UF;R=DG!G
M?$?O"O0#K,WD[).#.^(_>%>@'69O)V2<&=\1^\*]`.LS>3LDX,[XC]X5Z`XC
MR9O'<`^.I6#+6Z`N-_?$?[\+=&_'A:VJ_P`-Z`C"CXWY*<ZN*W1'?0/,]S`V
MOTK`-OB":7-+"+A;I@+,O>UA<+=*UN/"W'A8#__0^GW6OE[:A9PP#IWG_)6)
MSWG,2C3C4B,*9VTY&RM#755'8!CN/R&'L:HF$SF.MJEJ8WUT/5ED&$"+&H,N
M,RPQ6M>P$N(MR_\`36&9'GF6(]K[!$TUR4@R$VRT]:4Z/<</19>4$J\N%,D$
M?'-R@D/%EA60$V4#9VU`.1&\1N%U(A"O<"HXWT:U6Q%&VF*8\Q*ACK0RY&AV
M6$(@R><.;R.<X\:$\>@3BY29ZDSC)7IKA4=1DMS4U+%:AH;V\DM*0E`0`!=@
M/!'=`M-XJ+,=F77Z"E)L^,4EBN4FM<4Z/3&]Q.9O;K*);$6=@>G-P9(/$9+*
MGM6[+FMA3MB!4['B6F$B5<#K`9?P?@'$6N$-40+#,/*B$<7O[E*W@)KQ(9.^
M2*4O!2-.Y2652V7N[_+97(%:1N3)Q+')<J4^;)22;#L426`($-N8G_?'EJ?Y
ME>)?N(V3H#970"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`Z5
M"A.D3GJU9Y*5*E)-4*5*@T!"=.G(`(PX\\XP02R222PW$(0KV"$-KWO?A5&U
M%.4G@D70A.K.%.G!RJ2:226+;>Q));6V]B2-:4YY@+CD>4N^(-",;^]!DEK5
M#:I-DPQ>8Q:SXK6],99ITOR:$`B)8X(O)B%Z)8;J%!W#A8T(N-JY2XU+*ZK3
ML=-VOKEW%X2J8X4*;_"J??-?%ABWUGO&4<F:&1Y?;:FYQ9[]7\BJ1XZ5KP]Y
MFEW'>E1M=]&,L4N^N.&,=[BT>S&_+Y)DLO:<T[O9$4;8YG:U%G".LKRW^A\`
M8J4WN686FQMB,)AC.<H1"#<-G1V"K6GVOT[A+,^&JVNF55KPO]073O;]/&*:
MPHT_[.GNV?&EBWOV,Q9YSHG899<Z6Y3Y)'3FEJBX:E2$N/,;M==U>>FE+?W5
M%PA'=C)&R0LL!0`%%``666`)9998;``6`%K!````VL$(`AMPM:WP6M75[MBW
M'A;;DW*3;DWM9SH4%`*`4`H!0"@%`*`4`H!0"@.(Q@+`(PP00``$0QC&*P0`
M`&UQ"$(0KVL$(;6XWO?X+6JJ3;22VAM)-M["EL[^Q2$@Q4P/32^)B3A)SE#.
MY(W,@H\-K7$08<B./+`<&U_A#>]A6_%66O;7%K)0N;>=.;6*4HN+PZ\&EL,5
M*O0N(N5"M"<4\,8M-8]6PJU83**`4`H!0'`S]69^8+^K>@-3B3_!5GO\`^:_
MNCFU`?_1^TW1+]R#3;^%37G[HHA0$JZ`4`H!0&M3F)_WQY:G^97B7[B-DZ`V
M5T`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0$)-A=\,1X.DB?%4
M;02//6Q+N7>T>U^PVD+DT[-,$$5RE4L/*'=GQZQ`N&PCEKL<18!5^F`LRWP5
MS^9ZBLLOJJSI1E<YI+T:-+SI^&71!=LL-G0SU?17*#4FK;">HKZM0R?1%)_E
M,QO6Z5NETJBGY]S4Z%"BI8O8Y1,`)]3=D=P5">1;ZSLN$XJ--`L;=,<&2%Q0
M1,Y/8T`R$V<,HH34C]D=7<LJWEV]`-*U!&*]P"O;B&HU9+FN>-5=1W'=V>]6
MM&34?^+46#GVI81.SGS'T+RRA.QY.Y.[O4*7#/.[^G&59/#:["TDG3MEB_-J
M5%*M@MJW,V6P:!PK&46:(1CR*1^$Q!A2EHV>-QAJ1,K.WIRPV#8"="@))(",
M?1XC'>UQF"XB%>XKWO75V]M;VE&%O:T8TZ$5@HQ227B1X/F^<9KG^87.;9WF
M-:[S.M)RG5JSE.<F^N4FWX%N2V))%VUG(T4`H!0"@%`*`4`H!0"@%`4%_E47
MBB7SZ4R1AC2*UA"NL?WAO9TM@@MQ&+SAQ4)BN`;?'?C\%;-M9WEY/N[.UJ5:
MG5",I/R139@KW-M:QX[FXA3AURDHKRMHB9-.8GI'`E!R)\V4QBL<B1B)$UQ-
MY%.G,2BW&P4H44+3OQ_G!@K<`AO:U[WO:NSL.6&O\RC&I;Z5NXTGMXJD>YCA
MUXU7!8'+W>O='64G"MJ&V=1=$)=X\>K"FI;3%8.93$I98TO">M&W6;#0&>3+
M6Q[";O%(X.U^%@*+R"?J8T1YF*][?VH"S`\+_!QJ8?*J]LL'G^K,DL%ANG=1
MJ3\'!151X]C:(U<PK6ZQ63Z=S6\?7&WE"'AXJK@L.U)FO?F8[$[D2W79*5)M
M<93K+AY\FC4TRV0+<HQN22V1%'$J#F:-OC7"Q6%%8P[.!8;J!GJ1V4G%EIAV
MM8=[&>F<J-,:&LM43E::IHYMGE.WE*G!6\X4X8-*52$JOYRI&/HI17"FYK=B
MN$YB9]JVZR"*N-/U,NRF=:,9R=:$YSW\,)1I^A"3WXO:THO?M@7RGI)D.,[K
M8RC>-#5X&&6D20C*,=0&G`854'1QYR6&/SRW$F%H0J6=]+1>:*AAL98\[R0;
MW\K<`O1N<MKEEWH'-KK-HQ]8HNF[>;PXU5<XK@A)[<)0XN**V8+%[L5Q'+"X
MO[;5^76^7.7<55-5H+T734&^*2W8QEP\+>W%X=.!]D-?#)]9B@%`*`4!P,_5
MF?F"_JWH#4XD_P`%6>_P#YK^Z.;4!__2^TW1+]R#3;^%37G[HHA0$JZ`4`H!
M0&M3F)_WQY:G^97B7[B-DZ`V5T`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4!@+8'9_!NK\6!*\TSUJBI*T8DT>8`^5=9E,7+AP*9X;#VP"J029T4&W
M"`):4@80"%:Y@@!_I5&YGF^7Y11[Z_N8P3]%;Y2?5&*\Z3\".RT9H#5O,#,)
M9=I7)ZEQ*"QJ5-D*%&/3.O6GA3I02VXSDL<'PIO80<LIWEWE^!$"1:#:P./"
MUUBHM(?M]DUF,'<722)^DK8\&MB\DJUK#'YR\@`;QM;A?A;GL=0ZA]'BRW*'
MT[/6:B]U44_'(]:[OE)RD_.NAK'7]/[U-K)K6:^,]E2_G%O<N&@VNLFWKUJQ
M@S5R-'QS#4&01XQS,LJD\J6F'/D[FSF+@(]WFDT=1JI!(W!0=:YE[GGW*+$*
M_DP`#_1KH,LR?+LHI.E8VZCCZ4GMG-]<I/;)^%X=6!Y1K7F%J[F#?POM49O.
MM&FL*5&*5.WH0Z(4*$,*=**6SS8XM>DV]I(6I,XH4`H!0"@%`*`4!XG%S;FA
M(:O=G!$V(2;<3EKBK(1)"K7_``FJ%)A1)=OY[VK)2I5:\U3HTI3J/<HIMOQ+
M:65*E.E%SJS48+I;27E9&&>;RZ>XS.$EFFR6'VM>$(A7:DLU:'UYX!_*Z+-'
MSW5T&(-_CM8F]ZZW+>7NN,VBIV&E;Z=/XSI2A'YTU&/NG.7NL]*9<^&\U!:1
MGU*I&4OFQ<G[A@DWF?X-?50T&'L;;+9^6B!<2(S%.!YJL95][7X!L5(Y.EC+
M*"P_P7$;:_#X>'#X:Z)<H]0V\%5SS-<JRVGT^L7=)37AA3<Y>X0KYCY-6DX9
M3E^8WT^CN;:HXO\`'FH1]TX"VAWDG1(K8JY?[M%PF6L).\[`YEAD((!87P6L
MLC<:*DS^4(/&UQ6!<?XK?#55I'E[E\E[8YDPK=<;.UJU7XIU.[AY<"GUDUG>
MK_XS0TJ75*ZKTZ:\<(<<CE:(\TZ=W`:\Y?U3P*B4!#<:.!8[F&5G]!>_P##=
MPF[HSLBL=K?%<*<%N/\`LJGKO)_+L50R3.<QJ+IK5Z5O!^*E&4UY1ZKS+O<'
M6S7++*#Z*=*I6DO'4<8OR'&VA>49>8</-.^^UDV3*K6NI8L?O,9PE'^GPXB`
M01"F8QV"G%>][7`)8*_1^"U[57_4;*+)160\N,FMYQW3K1J74_&ZLN''\4?4
MG,KMR><:WS.M%[XTI0MX^+NX\6'XQ7F3E<Z4(#K+)-BA3E5U\H`XQUS#-9KD
MM2<>7>P@GF)9._+&GRG2MQXA3!MQK6N.;NOJBX+3.59T<,.&VI4J"2ZL:<%+
M_:,U'EMH^#X[C+'<U.NO4J57CUX3DX^X2WA>$L-XX*))@&*,<PL"<L)10HQ"
MXZR&V`"UK!L(]O;DYY@K6M\8A7O?\=<7?Y_GN:2E+,LYNJ[;V]Y5G/W)2:.I
ML\GRG+TE8Y9;T4OB4X1]U),R?402119%&X_+V-SC,K9&F21UZ2&(7=B?&]*Z
M-+FC-X>43+F]:4<E5$BN&U^B,-[<;6O\=K5L6MU<V-Q1N[.XG2NJ<L8S@W&4
M7UIK!I^`PU[>A=4:EO<T8U+>:PE&23BUU-/8S&6)-=<%8&`Z!PWBB#XX$]BL
M)W419A1MRQQ"$5C`$JUP`76')2S+=()-S/)!%\-@VO\`#4MG6J-1:C='V[G-
MQ=*GZ*J3<E'M2W)]N&/:1V5Y!DN2*HLIRRC;\?I<$4F_"]^'9N,SU`DN*`4`
MH!0'`S]69^8+^K>@-3B3_!5GO\`^:_NCFU`?_]/=H]==BG#W+DB^O.T&;D&Q
MTSU+TO!@G6G%*)@2XFQ]'6%%#5&=MI]Q!JD;J?*L&^J*HEC"D<C$(#EB<+;'
MR5+ZX><)0,6S_=+:G%.+4&WD:S#.)A/<]MW-18WG!#_=K=\58D3:F*,NWQ#*
M(#!BV+SV)K</)L6HRY&:J/4^G;NBGTETS1(QI@-JFES[/H-L1MIK:Z9PG^R4
M)QAC'5?+\-E^2GIJD\W;I)FU@RNGF\;/E3<C0%J(_(56,4,@:$-R?)-87D\E
M-<*&Z0@D#4B9M]M/`->\4YV;MFIC(YIN_IAD3,^1VR5#C#Y#-59VBV1U@QLE
MG^*H\I;$8(+%L71;8IZCZAL4C/1+'1C;U:T!BLE;=4!N5T<DLZ9,O[NZSR'(
M\^S'#-;,KXM0XWR+E%Z3RK(!39EG!T*R?(,=2>8ID:`<G40B0O)QZ0Y67=Q(
M;'=*G.,-`42.X&`.9>Z[)$9=T!)C<$P<YP9-S$L-G05R?<LSYCEKS(.HK/WG
MK=*F1OPM(F>,M%@C6^26I'!V._LB>DE_M1^2`FKZP\P'ZHM.N\9FOPM4`]8>
M8#]46G7>,S7X6J`>L/,!^J+3KO&9K\+5`/6'F`_5%IUWC,U^%J@'K#S`?JBT
MZ[QF:_"U0#UAY@/U1:==XS-?A:H!ZP\P'ZHM.N\9FOPM4`]8>8#]46G7>,S7
MX6J`>L/,!^J+3KO&9K\+5`/6'F`_5%IUWC,U^%J@'K#S`?JBTZ[QF:_"U0#U
MAY@/U1:==XS-?A:H!ZP\P'ZHM.N\9FOPM4`]8>8#]46G7>,S7X6J`>L/,!^J
M+3KO&9K\+5`/6'F`_5%IUWC,U^%J@'K#S`?JBTZ[QF:_"U0#UAY@/U1:==XS
M-?A:H!ZP\P'ZHM.N\9FOPM4`]8>8#]46G7>,S7X6J`>L/,!^J+3KO&9K\+5`
M/6'F`_5%IUWC,U^%J@'K#S`?JBTZ[QF:_"U0#UAY@/U1:==XS-?A:H!ZP\P'
MZHM.N\9FOPM4`]8>8#]46G7>,S7X6J`>L/,!^J+3KO&9K\+5`/6'F`_5%IUW
MC,U^%J@'K#S`?JBTZ[QF:_"U0#UAY@/U1:==XS-?A:H!ZP\P'ZHM.N\9FOPM
M4`]8>8#]46G7>,S7X6J`>L/,!^J+3KO&9K\+5`/6'F`_5%IUWC,U^%J@'K#S
M`?JBTZ[QF:_"U0#UAY@/U1:==XS-?A:H!ZP\P'ZHM.N\9FOPM4`]8>8#]46G
M7>,S7X6J`>L/,!^J+3KO&9K\+5`/6'F`_5%IUWC,U^%J@'K#S`?JBTZ[QF:_
M"U0#UAY@/U1:==XS-?A:H!ZP\P'ZHM.N\9FOPM4`]8>8#]46G7>,S7X6J`>L
M/,!^J+3KO&9K\+5`/6'F`_5%IUWC,U^%J@'K#S`?JBTZ[QF:_"U0#UAY@/U1
M:==XS-?A:H!ZP\P'ZHM.N\9FOPM4`]8>8#]46G7>,S7X6J`>L/,!^J+3KO&9
MK\+5`/6'F`_5%IUWC,U^%J@'K#S`?JBTZ[QF:_"U0%KS/*^Z..8R[3.?0K1N
M&1)A2C6O,DD^T6761D;$I=N(C5CDXZP)TI-K_$&UQ<1"O:UK7O>UJPU[BA:T
MIU[FM&G1BL7*322\+9(97E.9YW?VV5Y-E]:ZS*M+AA2I0E4G)OHC&*;?DV;V
M0^A.Y>_>X#9*([JMAC"\(82C3$K/N%*Y+DM^PPX`"A/$??'\-F>),:3&9N!+
MJ6$@M:6C6-'DQ7-'\00"Y26=YEG4G1TS;<-KN=U635/_`(4/2J/J;PCUGNU#
MEGHWEM368<Z<Y[W.\.*GD>7U(SNNQ7URFZ=K%[W"'%6P]%XGOP+I?M'AN3`R
MW+\9ZP[!;)+R;"?]@<S;,9HD4J+/,L"XT,!9CM6U#)C*/I;A\F0E:@EC\E:U
MAF"M\%I'+=.6-A6]=KSG=9J]]:KYTO!!;J<>I1\IR.L><.I=4Y?]6\LMK;)-
M#0?Y/+K%.G1:^-<3V5+JH]\IU<5CM45O)M>L/,!^J+3KO&9K\+5=`>3CUAY@
M/U1:==XS-?A:H!ZP\P'ZHM.N\9FOPM4`]8>8#]46G7>,S7X6J`>L/,!^J+3K
MO&9K\+5`1_V5VYVTU0QFHRKE7$&KBI@"[MD=1-,0S_EARE#L]/A@TZ`EH;WC
M7!A;%=T?1$J4`/6HP73$&6L<`=P<>OT-I&YUKJ*TR6C6[J@TYU:F'%P4H+&3
M2V8R>R,4VEQ-8[,3FM6:DH:6R6YS2K2[RLFHTX8X<=26R*;VX16V4FDW@GAM
M-8^.>=QLB%^4H9EB/%<\#(5:=!&&J-&3>&JVAU<%I*=O1".0(LH.TI+4".\@
M40G;`JSU`R[6N&UQ5[UJ7D'DZRJI6TUFM2EF-*/$_6IQ=&<5MFY2C"+I-1QE
MCYT5@T^L\@R+G#F;S"-//<OIU+&H\%ZO&2J1D]D4HRG)5,7@L/-D\=G4;#,;
M;I<Q/(`%I"CEC+8N=>XRVMVD&?4\<:QVXV\DK<6Z<8PACX00(-^(B@%#.#\7
M#C7DZT+I++TI9WS0R]]<;2C6N7X.+",<>W<>BO5FH[S&.5:!O5^%<U*5!>'A
MQE+#LWE\.O\`YN<Y:E9K*'2C!*W@/S!`Y*,GY3<C.E?^SLK=$Z%J9D9@+?E7
M`D4AX_%85OAK(WR;RU[(YYF=3#I[FUIX^!=Y4P\:99AS-OL,99380Q_K:\\/
M]B&/E1&0W57G#S92:?ES:[&1Z2YA@;LN%<KS+##<L2CO<-B5"INUA?7A(+R7
MX25'2X_'>]6/7FE<O7!D7+#+<>B=W5K7,EVX-Q@_`U@7K2.H+SSLVU[?8=,;
M>G2H1?9BE*2\3/4AY;L^,,LJG>OV#<U.?#B)QS9OYME/Q&CO?B8(YO4:Y(6@
M\)GX0&)QAM;X+5AJ\WM;X<&77%EE]+JM+2C1\DN&4EX4T7T^6VE,>*^HW5Y4
MZ[BXJU?*L5%^0D5`-><VXK3D)L=:3\MZ'@2WZ1!K'DS(B187>WQ7LOMJ1==>
M_P#+<R_PURV9:PU7G$I3S34=[7;WJ=:HU\WBP]PZ&QTUI[+8QC89):TDMW#2
M@GY<,?=,\@?=_B@!++P_IP66"U@@`#8K-(`!#;XK!"'5FP0VM_)7.MMMMO%D
MTDDL$MAR]8>8#]46G7>,S7X6JH5'K#S`?JBTZ[QF:_"U0#UAY@/U1:==XS-?
MA:H!ZP\P'ZHM.N\9FOPM4`]8>8#]46G7>,S7X6J`>L/,!^J+3KO&9K\+5`/6
M'F`_5%IUWC,U^%J@'K#S`?JBTZ[QF:_"U0#UAY@/U1:==XS-?A:H!ZP\P'ZH
MM.N\9FOPM4`]8>8#]46G7>,S7X6J`>L/,!^J+3KO&9K\+5`/6'F`_5%IUWC,
MU^%J@.(Y#S`.@/I8AT[X=`7'AL9FKC^3?X;<=6N%^'XOPT!%]'Q_\E.==+A8
M=]`\SW,L&][A";?$$TN:$`KVM<183.-@WO:UQ!X7O:U_@L!__]3ZBM<.7_IM
MGK6W3C,V7=?X1-\J&:AZHLYTZ<;.Z5_4M,*QE&W:)MBI6UNB"RM`P.:XX],2
M8$199IHA<.-[T!-]AU`U?C.2LFY?9,%8W19%S(VO;/DZ2>KB-2.7MLI"A#,4
MCDVJPJ&8LN=":THY!Y%.5=^.3%&.%U)A8!!`I>.]*-4\315EA6.L&0:*1J.Y
M(CV76=N;D*D0TF1XBC+;(C*;KU2M0Y*5L39R"D#66<<8G;F\@I(G++3$E%``
MXQC2/4>'*<R*HYKQBQN'L$@>VC,9%XLA6()TQR98Y.<ECKBUKPJFU)&I&\/2
MQ>X-J0I.A6N*LY6<4-2:8:(#)6%,#X@US@Y6.,)0%BQY#2W-P?#FED+4#,<G
MUUN5=R?GQU<%"UYD#ZN"G*`:M7*%"H91)9=Q]`L`0@0OYB?]\>6I_F5XE^XC
M9.@-E=`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!Q&,)81#&((``#<8QCO8(0
M!#:]Q"$*][6"$-K<;WO\%K4W;7N*I-M)+%LUP9/Y@S<ZS!TPIIACY=MKG%`8
M-"]J(LO+08,Q8KO<15U.5LOWL:PH1HS;AN)M;Q*EYWPE_P!D97*WFIHSKSR_
M(;5WN8+8^%X4:?\`:5=R^3'%O=L/<M/\EZ]OEEOJOFEG4--Z2FN*FJL>*_NU
MOPM+/94EQ+'"K44*:]+SD4>&Z!/V5Y,TY9Y@620;)3IM4END;PTU)53%JWC%
M8`83"0Q[')XKCG3LD\D"WI5_\N:;</&Y%K\+U90TW4O*L+S4MUZW<)XQI)86
M]-_@P^_:^-/%]ALYISEL].6%SISDSD3R+*)Q<*M[-JIFUU'<^\N5_AX2Q?Y&
MWX4OC]!LQ2)$B!*F0H$R=$B1$$I4:-(26F2I$J<L)1"9,G)"`D@@@H%@@`&U
M@A#:UK6M:NLC&,4HQ244MB70>#5*M2M4J5JU24ZLY-RDVVVV\6VWM;;VMO:V
M>BJE@H!0&.LD9>Q7AYD.D>5<BPO';&02:>)RF4D:8^G&63;B9=/=R5)QJQA_
MY)5ABO?X+6J4RK),XSRXC:Y-E=>ZN&\.&E"4WMZ^%/#QX&AF&:Y9E-%W&9W]
M&WHI8XU)QBO%BUCXB#ZOF11B=+3675'!.<=JG.QP4X9)$8FH@^(TYAEQ`":X
M93GY3.T`3!-M;I"3$*[]"_3#:X?AKT"'*R[R^"KZRU%E^3TL,>"I456Y?9&W
MH\4L</C..W8]IQD^8-M>S='3&2WN9U/CP@Z=!>&M5X8X>!2ZSRV@O,MSG<=I
MWE;$6GT,6`-+''<,LQN6\MA3B%Q`%7/I@!)$&=<(H?1N8W(CO)#!TK"':_"]
M_M#E3I[#V=D][GE_'#S[J7JUMCV4:6-62[)R6*>&"*>I<P\ZQ]=S.URFT?WM
MO'OZ^';4J84XOMA%X=I1I7RF=?IM"I:WS*:YGR%EJ2-ODD&>,H9$>9U-HN\!
M$6H`XL+,M.1PU$WGJB^"A"6@++,3#&4`95Q6,#GLN<^I<OO[*I8V%A;9+2GC
M*TMZ$:-*I'=PSDDZK:6Z;FVI)2:>&!ANN5^17EG=4[N\NZ^:5([+FM5E4J0E
MOQC%M4TF]\5'!K%)K>1>U<Y,CEBK-,8R?F/+$=F[%CR1))1$HI$8ZXM@7U[:
M#_.H^MEJIZ5*@D)&I>64JNC2A,L<>6"PC;`#>P^NU?SVI9QD-WE&1Y-5M[BZ
MI.G4J5)QEP0DL)JFH)8N2QCQ2PP3>$<7LYO3?*.IEF<6^99MF=.M0H5%.$(0
M:XI1>,7-R;P47A+A6.+2VX;]]-?.9[:*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`<#/U9GY@OZMZ`U.)/\%6>_P#YK^Z.;4!_]7[3=$OW(--OX5->?NBB%`2
MKH!0"@%`:U.8G_?'EJ?YE>)?N(V3H#970"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@(=[&[OX5US<F^#KCW[)^;Y&"P(7K_`(D:QS7+,G5'!M9&(4?;QW#'6@TT
M8+#<'(Q*F`"]Q6N/HW#4'FFH+#*YQMY.5;,)^C1IKCJ2_%7HK\*6"/3M#\IM
M5:XH5LVHPHY?I.@_R^8WD^XLZ27I?E)?G9I8X4Z2G)O8TL<2,H-=]M=U!A=M
MQ9BJUYP0L&!0AU)P;*#RY3)VL8O+$H\^9C;[$+'$)Y=@!5,K%Y!$*W$(C;#M
M>HCV7G6?^?GE=VN7/=;4I>=)=5:JMK[8PP7:=Z];<M^5:=ORQRR.=:OBL)9Q
M?TDZ5*>YRR^REBHX/%PKU^*?2HX&QW&&*,:85AS7C[$T'C6/86S%V+;H[%6I
M*TMQ5^@``U!P$X`F+%Q]@6N:H.$8><*W2&,0OAKJK2SM+"A"VLK>%*A'=&*P
M7\+ZV]KZ3P[4&H\^U5FEQG6I,WKWN:U7YU6M-SD^Q8^C%=$8I1BMB21D&MDA
M10&'LL[!X.P0UC>,Q97@>.40`!,!:521M;5RFPQ6`"R!J,/NZ.)@QBM8(4Y)
M@KWO:UK5.9+IG4&HJRH9'DUS=5/ZN$I)>&6'#'QM$3FF>Y-DM-U<VS.A;P_#
MFDWX(^D_$F0V'S"7G)YPFW435O-^P(C33$Q&0'YEOA7#)1G1XDJKSC(1*)<Y
MI17L+B%(W&"_H\.(>E:]=TN6=#*(][K75^7Y;@L71A/UJZ?6NZHXJ+^5->,Y
M)Z[K9D^[TKIN\OL7@JLH^KV_8^\JX-KY,3KMAKF(YP"(>8=D(/K)%E@"QB@V
MKL;&_P`V*+L*]AIEV6\ADG"1*Q%\!7,;FZQ817O:W2MPO:OMWECI_!9'I6XS
M:\C_`$V83X*3[5;47M79.>/@'LG7N<XO-M04<NMG_1V<.*IX'7J[GVPAY3(F
M..7%JC`7@F6O<$6YIR"4?=6+(N?W]SS!+1JQ<;W4%&RXU:T-Y@1"%<%TJ,CR
M=A<`\`VM:T7FG-+6694)65OF,;#+&L.XLX1MJ>'4^[2D^WBD\>DW\OY?Z8L:
ML;JM9.\OD\>]N9.O/'K\_&*\45@3B2)$B!*0B0)4Z)$E*`0E2)"2TR5,06&P
M2R2$Y(0%$E%AMP"$-K6M;XJ\^G.=2<JE2;E4;Q;;Q;?6V]K.RA"-.,80BE!+
M!);$EV(]%6EPH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@.!GZLS\P7]
M6]`:G$G^"K/?X!\U_='-J`__UOM-T2_<@TV_A4UY^Z*(4!*N@%`*`4!K4YB?
M]\>6I_F5XE^XC9.@-E=`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%FY$GT7Q7!)?DJ;K
MS&N'P2.NTJDSD2B6N1J%D9$9J]R5%M[:G5."T9*4@0K%$EF&#O;@$-[_``5@
MNKFC9VU>[N)84*<7*3P;P26+V+:_$2F29-F&H<XRS(LIHJIF=Y7A1I1<HQ4J
ME22C%.4FHQQ;6V3272S7H+G$Z`V"(76Z_"X!$*P`XIRF(9@K!O<)98?4_P#I
M&&7_`*(;?A%>UJYCZ\Z;_;9?JZG\T]J7V8^<K:7U:H[_`-LM/*_RVY=);GKW
MNYO%_8XD:GS1W6=QXV%ER=-)!^SN2&8T(K@58Z@"NYK;BIJ=$IH!D.3K<YPL
M'@827;\FV+UG4&H=EE"67Y2_Z2:_+U%UPANIIK=*7G=*1O>Q^5'*7SM27-'5
MNO8?]G;S:RJUFNBYN%A*[G!IJ5*CA3Q\V<NDF'KEI_@C5MN7@QA%!F2Z0WN?
M-LJ2]<?+<KS]P,'8U2X3"=N_EGER,4'V\I<@`B48!_"62"IS*\CR[*(R]4H_
MEY>G4D^*I-]<IO:_!L74CS'7',S5_,&O1>?YBEEM'90M*,51M+>*V*-&WAA"
M."V<33FUODR3M2YP)'_,FU6N>OR?RV8<QP6$*1#"40RN#T0JDZTXRPKE$-\4
M;//I(X'G7#P`$E*.XA<+6^&]=+D6CM4:EEAD>1W%Q#IG&#5-+I<JDL()+IQD
MB"S;4V09%''-LVH49=$7).;[%!8S>/9$BC[]67<NW\UU&T]RSD5$J`99'E+,
MX2\"XIM<(K<%:0V4%FR^1I;EBL,(4R`JX_A#T@BX6OV7^GF29)Y^M=<65K46
M^WM?[Y<>!JGA3@^CSIO#?M1S/UTS7-?-TMI2ZN(-;*UQ_=J/A7'Y\UX(HY6U
MPWES7<1^P>W";#\<5&!,-QEJ+'+1P\"4X%O+MRW+TV)<Y<H&&UN@(:9(G`((
MA<+6OP%5/K3R]R#".F=%.]NDOS^93XUBMTE;4G&FNO"4F_>'U?UGG&,L]U2K
M2W?]#8PX-G4Z]3&;\449>Q/R^]2\0.!4B9\3M4PG(.(C\CY75+LJ3Y6>+CTE
M9LCFY[RH3*A6X6N),$CC:UK</@J%SKF7K3/*4K6OG,Z&7O=0MTK>BEU<%)13
M7RL25RO0NE\JJ*XHY7&K>]-6LW6JM]?'4<FGX,"9@``+`$LL(0``$(```&P0
M``&UK!"$-K6L$(;6X6M;X+6KA&VVVWBV=<DDDDMARJ@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@.!GZLS\P7]6]`:G$G^"K/?X!\U_='-J`_
M_]?Z"5CYG>&84Y%<EA6<G:$XBD;WIGBK(&(8RP)$*K*2B8ZXRAP&HFT_-7GN
MAL,9$L>(N1'T25*4K7"NH6*%`"B""P(F94V;V,UG69]S6\SZ29(E6>6[F;/.
MJ$MQKNC(<[8<QPKUY32)_9(G,M6BH2T8EB;3BG&<,5&'/"5P?5C1+V]2W/*4
MNZP(P@;5=+Y"_0?9+;?7E'FW(&?<98[QEJ+DZ$2#*<],R)*6V=9IB>4"IHQ%
M3]U.4N*QKG*;'+/)T;98RZ%I&]'^8$IT!Z9,4!J#5;6[%PG73$.;6#:7([Q/
M]R-'\G9@SY9_E:"31C7*9(=H-9L=*<H8LB[NF,8L0(<3L6>9/%@MB).E;CE#
M$C4K2#W!"K4'`;K-'GV6,>9]ZM=5,[R!E#&6O.8<7MV,)CD^9.62)HSAR=@J
M"Y*FF+W7(+V>KD,F)A$D>[K$GI50K<T2-Z*2F'C)*3A`!'3F9SC81#F'0AIC
MF`HK(8<T<PW#2R$S%=G%)'ULOD!N#,]!5,KE%+X[=E$71I0JUG_7/.UMQ^:!
MO8G@;P`!,SKDWD[$F/>]ZT>Q.@'7)O)V),>][UH]B=`.N3>3L28][WK1[$Z`
M=<F\G8DQ[WO6CV)T`ZY-Y.Q)CWO>M'L3H!UR;R=B3'O>]:/8G0#KDWD[$F/>
M]ZT>Q.@'7)O)V),>][UH]B=`.N3>3L28][WK1[$Z`=<F\G8DQ[WO6CV)T`ZY
M-Y.Q)CWO>M'L3H!UR;R=B3'O>]:/8G0#KDWD[$F/>]ZT>Q.@'7)O)V),>][U
MH]B=`.N3>3L28][WK1[$Z`=<F\G8DQ[WO6CV)T`ZY-Y.Q)CWO>M'L3H!UR;R
M=B3'O>]:/8G0#KDWD[$F/>]ZT>Q.@'7)O)V),>][UH]B=`.N3>3L28][WK1[
M$Z`=<F\G8DQ[WO6CV)T`ZY-Y.Q)CWO>M'L3H!UR;R=B3'O>]:/8G0#KDWD[$
MF/>]ZT>Q.@'7)O)V),>][UH]B=`.N3>3L28][WK1[$Z`=<F\G8DQ[WO6CV)T
M`ZY-Y.Q)CWO>M'L3H!UR;R=B3'O>]:/8G0#KDWD[$F/>]ZT>Q.@'7)O)V),>
M][UH]B=`.N3>3L28][WK1[$Z`=<F\G8DQ[WO6CV)T`ZY-Y.Q)CWO>M'L3H!U
MR;R=B3'O>]:/8G0#KDWD[$F/>]ZT>Q.@'7)O)V),>][UH]B=`.N3>3L28][W
MK1[$Z`=<F\G8DQ[WO6CV)T`ZY-Y.Q)CWO>M'L3H!UR;R=B3'O>]:/8G0#KDW
MD[$F/>]ZT>Q.@'7)O)V),>][UH]B=`8AG^\^9\3@/-RKA363&I:8L9Q_KOOU
M!V`X!9?PC$%$KQ`%P.N&W_"64,7\E:-UFF66*;O,PHTDOC32?DW^1'3Y)HG6
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M_`[2#6>\<\Y7)>-,O->9!XW!"#X?*2[0_7S)<&;6V1M`FXVY[;(0Y&PXEE"U
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MO`V?F#F>K].9)"*S;-J5*Z:_-1?>5<<-L53AC)M;MRQZ#ECC=O>+/\;)/Q9R
M]'O&;FK4&6+EVP.5&IEQV4UW'Y-*\-R=H94DVDY:BPK&>1)0I+V+^(=[\;6Z
ME:&TGD2XM8Z[MU<K?;6$7=5<>IU?-HP?1M<MI`/5FH\V;CIG2-;N'NKWC5O3
MPZU3\ZK)>!+883DN(.:IE=<])<^^54Q8:I4G;X;JWM-','Q1U:1F7\F6^/CM
M@!UR89902*X#"@N5KAMPN$VPK58];:1R)J.CM!T95XM?WC,9>LU'A]]&C'AH
MP?2L>+#<TRY:5U)FR;U+J^K&C);:%E'N(8/[V566-674]V/1@9*PW@2>8'4!
M=,><K[")$HO8`E,ZDFVC;-)ZN4!N$0UBJ8RW#+P_75'F`L,P19Q=A#^'AQKG
ML\Y@:PU%%T<SSVL[/HHP?=44NI4J?##!;EBGL)K*=&Z9R22J6&44E<]-2:[R
MHWUNI/BECUX-$K>N3>3L28][WK1[$ZXTZ<=<F\G8DQ[WO6CV)T`ZY-Y.Q)CW
MO>M'L3H!UR;R=B3'O>]:/8G0#KDWD[$F/>]ZT>Q.@'7)O)V),>][UH]B=`.N
M3>3L28][WK1[$Z`=<F\G8DQ[WO6CV)T`ZY-Y.Q)CWO>M'L3H!UR;R=B3'O>]
M:/8G0#KDWD[$F/>]ZT>Q.@'7)O)V),>][UH]B=`.N3>3L28][WK1[$Z`=<F\
MG8DQ[WO6CV)T`ZY-Y.Q)CWO>M'L3H!UR;R=B3'O>]:/8G0#KDWD[$F/>]ZT>
MQ.@'7)O)V),>][UH]B=`.N3>3L28][WK1[$Z`=<F\G8DQ[WO6CV)T`ZY-Y.Q
M)CWO>M'L3H!UR;R=B3'O>]:/8G0#KDWD[$F/>]ZT>Q.@'7)O)V),>][UH]B=
M`.N3>3L28][WK1[$Z`=<F\G8DQ[WO6CV)T`ZY-Y.Q)CWO>M'L3H!UR;R=B3'
MO>]:/8G0#KDWD[$F/>]ZT>Q.@.(\Q[R7`/CI+CVUN@+C?WO6B_#^C?\`!;"?
MPT!'9%>]^2G.;BMT1BT"S,(P%K]*Q9HL/S01I5A<+=.Q1E[AL+A;I6MQX6X\
M*`__T/LBTZ@L+F^DFAQTQBD>E)L(U_UHG4.,?VA"ZCB\T:,,,"!JE;`):2==
MJD+<B=E11*LCH'E%J#`A%:PQ6N!E*,ZF:QPW)>1<R17`6)6#*>743JVY-G;7
M!(\ED4W0/YR=5)$LA7%H;#7DRI8C)/=K"M_]54$EFJ_+&`"*P'1!-1-7L815
MD@^/L!8IB$1C>1&W+;!'V.%LJ)M:,FLI82&.=(""TO\`U>3,*0L"=`J#?RB)
M(4601<LDLL`0/3&=3]98:XY==8O@/$K(OSZ!R)S4>A@L>!;)Z1Z](">F^9D"
M0"3O;6]GNZPY:E.`),K4K%!QP!FGFC&!>F(<+8FP#"$.-\*X\B>,8*W*EJY+
M&(:SI&9K](.)OEW!R4%)0!&M<UYMK7.4G",/-X6Z0[\+<`(1<Q/^^/+4_P`R
MO$OW$;)T!LKH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@*0]R%@C*`UTDCXT1]L(M<1SB]N2)J0$A#:XA"-
M6+SDZ<NP0VXWO<5N%JLJ5:=&+G5J1C#K;27E9LVEE>7]:-O8VE6M</=&G&4Y
M/P1BFWY"$N0.9KH]CQP4,2K/<9F<H(M_1B6)T;WEJ2*A7'Y*P$K=CQMD7E+^
M4_HWO<80VO\`'>U<_<ZMT]:R=.690G6^+3QJ2\D%(]8R7D'S:SRC"[I:-N+7
M+W_37;A9TET[97,J?1V-F/#-],US\9).NN@&R<[3+BQ>82W+P8WKS#!"N'B2
MK$IFJU:_*6XR_P`0R4(A7M\80WK5^LE]=8>R=-W56+W2J<-&'EDV\/$32Y.Z
M6R53EKCG)D5G4@_.HV?>YC7[5A0C&FI=DJB7:RR)%,N8[)B`'SC,^C^EC/<S
M_K1-UJ[,,V2)[_KBS%TM=(A"@*R;?D&A+&#C\(B[UOVN3\Q\Y<5:V=*A%]%*
ME5N)^\H^/`U*^<_9DTIQ]Y3SS/JZ6R5>O;Y;;MKIPCWE?!]*;3[2,\R0:=&7
M,2;:\W7)^9AG'6L?%XCF%GQO#U9W2Z5R2XM@E"):;Q_)L`I;QN'X+]+X:ZNR
MY$<Q,ZAQ7>7YW<PWM.+MH>-80P7XQSUU]JW06F9I:-T?I'*:D=BJ2IO,;A>"
MI<2J)OI_-O;N*QCG(7*$QFY^6PGK)*,LR0L5C`R"/:SY1RJ^+E5[=&ZTB5Y&
M8S['+%%[<;F%J@WO?X^%=19_9XS#+E&M=9=E-D_C7-W;\2[7C.I)/Q'`Y_\`
M:VUAJ>,K:MK;/+FV>Q4K2C6HTL.B*C1A1@X]2VDOB-WLK*DZ5#B'ES;4/#4'
M@4@]:&J`X9;$Y-[WZ(KII-(>FE(M>_&]@$C%;C^3>IVGRYR"TCPYGS+R6APK
MT:+JW'B7=4TO=1YC7UWG=]5E6M=$9M<3D_3K<%)OM;J3;]]GKZXN9G*#?_\`
M'-.\'8Y1G6L).KR=L,*1JB@B^*ZUI@<9L(L0/PA">*]_Y*K[#Y3V:_O6N,PN
MIK>J%EP+Q2K5/N&/VMS$N7_=])V=O%]-:ZXWXXTH?=,.[$X3YH.;L*Y+B4CR
M+K$SM4@B3F2OQKBZ*SI0_3$DD`5@H>VSR8/#>0Q'/UD_FMSS4YI(PF7+,Z!8
MQ##.:8S_`)1Z?S[*KVURO-YUJ5:+C7N*E)0I-[.]E1I1;FH8\6"DFL,5BTDX
MG/LGYD9QD^8VMQ?Y="E4I/&C1A4<JF&WNU4J22CQ8<.+36W!X)XKYRL8:Q9Y
MRIE5GQ!'<5Y!:I<)_;FY^$]11]8$L"2A7DEN3_(G1:C3)&I*P$V&=TP&W,&8
M`(2.F8(%K_46;:MT[D^3U\[N<XMIV2IRE#AJ0FZSP?#"$4VY.;V8-8)-N6"3
M/`LMTYG>9YG1RJWRVO&[[Q*7%"4526.V4VTE%1W[\6UYN+:/LLPMJ1KAKXG+
MMB?#T'BKMP"-9*"&4E?+G%5PM<]6NE;P)QD:@U2=<1@^FJ%;IBO?XZ^%L^UK
MJG4LG[9SRXK4>BFYM4XKH2IQX8)+=LB?6F3Z6T_D45[,RFC2J],^'&;?6YRQ
MF\=_I$C:Y<Z`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4!P,_5F?F"_JWH#4XD_P59[_`/FO[HYM0'__1^TW1+]R#3;^%37G[
MHHA0$JZ`4`H!0&M3F)_WQY:G^97B7[B-DZ`V5T`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H#3#D+G9Z^0O*3A"6;'V1)W#&%Y5L;]DR/C926_SEM5F(W)7
M&8\O5$NLF;$QY(K%G!$G\YZ-[DA&&X!#]WRSD%J6_P`HI7]?,[6VOZE-3A0G
MQ.6$EC%5)I.-.336*>/#]]@\4O([_G#D5GF52SHV%>O:0FXRK1X<,4\&X0;Q
MFD]SV8]&*PQV[0F9QC(L0C4\A;NE?XG+V5ND,>>4=Q^;N#2Z)BU:-0$!H2SB
M#+E&6L,HP(#2C+7`,(1A$&WB=_87>5WMWEU_0=.]H5)0G%[XRB\&NI]C6*:V
MIM,]3L[RVS"UM[VSJJ=K5@I1DMSC)8I_"GM3V/:716H;(H#\O>UOCO:W\_P4
M!UW/)#^4<5;^<P%O]]ZKPR^*RF*72CKNL1A_*5)@_P`YY5O]XJN[N;W0?D*<
M</CKRG7=S;0_&X(K?SJR+?[S*KW57]'+R,IWE-;YKRHZKO+.'\IU;;?SKDMO
M]YM5[BN_Z&?D93O:7Z6/E1UW?V(/Y3TTA_G<D=O]YU7>K7+W6\_FOX"G?T?T
MT?*CJO)HX'\J0,EOYW5!;_>?5?5+I[K:I\U_`4]8M_T\/G+X3KO*XL'\J2L%
MOYWENM_O4U7U.\>ZTJ?-E\!3UJV6^XI_.7PG5>91`/Y4JC8?YWQLM_O557U&
M]_8ZOS)?`4];M?VFG\Y?"4A\RACF.,SO('J<19"T,38N>'58)[0&V2-K:F,6
M+5-R4YYJ@VQ*<H0NB``ABX<`VO>]K5GM\HS2ZKT;:AE]:5>I-1BN!K&4G@EB
MTEM?7L,5;,;"A2JUZMY25*$7*3XEL26+>\T:)^>]&C<C`(-P`^E8:,<0I?6@
M,J(,R(6TB4>2M)!PCT0%L$7YM_UB[?9S\[L#^AQN;_0KZ#G]G:Z65N4=2TWG
MJACW?=ON>+#'@[WBXM^SC[OAQVX8;3QF/.JW>8*+R.:RERPX^-=[ACZ7=\/#
MV\/'CAV[#9S*.8AI!#4J99(-G,3IB529,K)\SD0'H^Q*L@"@FQR5D)<528^Q
M9EK#*,``TH?$`PA':X;>46G*[F'>N2M](7SP;3<J;@MFQOBGPIKM3P:VIX'H
M=QS`T5:X*KJ:TXGALC-3>WHX8<3Q_!PQQV88D?7?FYZXK>DFP_"-@<^N)ESR
MT(<:8;E@V5885?@"Y<AD*1E0&IS;_$,BRB]K7XW#6]+E)K2E352[AE]K'I[^
M^MJ>'A2J3EY(LOH:]TA4K.G*_NY123_(V5W6>WJ2I1CCV2G$Q"_[U\QZ>V\G
M@[ERRB*I5(+@3/.9'-06H!T^(0JA,YAT#2%@L&]AVXKC>'Q<!6^./J<NIP;5
M]S/TU9I;U%W-]+P)484XX^%X8G56>MM"VZ4I:#UEFT\=BA&QRNF_#.YJ74\.
MO"FFUNP9A9VQMSS<R*`AD\]C6(V)2$R_HZ%2R"P8Y,`Z]^@`QTC+1-98$2<-
M_C"K".][5H3T-R^AMS;G)G%RUOA8Y=2MX_BU:TY3\J.IM^;]:PCAIC[,F04Z
MFS"MF^;75_/\:WHQHT/"EB4IIY/^Q,C7D/V5LE8%F$B,&6>L=\K(,Q;(*`*0
MWX^>(FJ>2V+QM`X!XWOTRTURNE\-P7M\%8Z6F_L_V<N\N-+:@S>NOOKR^4$W
MUN%)-+P)&S=\_?M/W5!VF2:LT[IG+FL%3RG*Z5-QB_O>]J)U)+M<L>TFK!^7
M9F"*-Y;2GW8F<&9+@"$V/8!P=A/"2`KX.B,*-S8XZYR`%KA^#B-2*]_CO;C\
M-^@M=5<O\GAP9!R>RFBUNE5G6K2\>V"?D/*<YM^96JJ_K.K^<6=W]5O%IS26
M/8FYX=G5T%[JN6-AZ2W*,RAF;;;+IP+A$9><['3L"8^]OC"8CBBB,D7)O\7D
M[VN'A\'#A6W'FWGMJG'*<CR6RAT=U94FUX'451X]I"/EOD]9\689KF=U)[^\
MNJBQ\*AP%XQ_ED:'QQ2!<GUK@3NXAL&PW*6W>YFO47#\-AJ3Y6[/%SA7O\?&
MW"_XJT+GFSS%NHNG+55S"E\6GP4DO`J<8X&[0Y=:)MY*<=/4)U.N?%4;\+G*
M6)):+X&P=""RRH;AS%L5`5:UB_5Z`15H$&UOB_M$#40.]_Y;WXUREYJ/4&8-
MN^SR\K-_'K5)>_)G16V29-9I*TRFVI8?%I0C[T495+++)+`426`HHL-@@++`
M$!8`V^((`!M8(0V_%:H=MR;<GBR222226".=4*B@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0'`S]69^8+^K>@-3B
M3_!5GO\``/FO[HYM0'__TOM-T2_<@TV_A4UY^Z*(4!*N@%`*`4!K4YB?]\>6
MI_F5XE^XC9.@-E=`*`4`H!0"@*2X/S&T'HDKJ\M+8I<C?(-R=P<4:(]>=Q"'
MR*(I2<48J-Z0[6Z)=A7XWM^.LU*VN*T:DZ-"<X06,G&+:2ZVTMGC,52O1I2A
M&K6C&4MR;2;\&.\JU83**`4`O>UK<;_!:WPWO?XK6H"RWK)&.XY88I#/86PA
M+X^4N]2EC:[`X?'T[KEQ%@\/Y:D+?*<TNVE:Y;<56_B4YR]Y,TZV86%OCZQ?
M48?*G&/OM&#)+O#I]$;F!?ME<,IC">/E2$D]87=0"]OCL),SK%Y]K_R='X:Z
M6TY;Z^OE%VNCLQE%[FZ%2*\LHI$+<:STG:8]_J*S3755C)^2+;,)O/-;T1:P
M#NAS7:6&EW%82:&0B?R4ZX@_!T0>81@1)@KW^+HCO4N^4&OJ.#S'*:5E#KNK
MFVMUX?RM6)#5N9^B*2?!G/>OJITZLW[D#'"_F_ZX="_JMCK8Z9F7_5V:\2J6
MDHS_`)-_*2AW8AEAO?A^4"W"U0M]IC(LF;6HN:ND,OPW][FUM)KQ4G4Q\3--
M\TLCJ+^YY9F-=_@T'%>6<HE@K>;;(%AEPPO2S-#X3?I6`L?I-$XRG!\%^B)1
M8D#\:"W'AQM:PKUS5?4?(/+VXYC]HC(747WMK1O;QOLBZ-!Q?E1B_P!0LSKR
MX;'1-Y4[95*4/<QD_<+%4<S7;IZ4F%1O5C&,73_$6HFF5'ES/`*]_@L:A:(X
MT=+A:_PWL=:W'X*C)<TOLT4&Z=/6NJ<RK+]DR&Y4)?)J5G%>6/:;-/.>9EZ_
M[CH2,8/<Y2K5'Y*5+WF6FZ;I\P=YN;TW+6K&B<5N)"A$QGOH@`%\0A'2S(S<
MG$(''X^A:WP?%6N^=7)>@Y*PY4Z^S'#=*IZE:0E\Z;E%>%8DE0R'GGFCPM=.
M.FG\3+[VH_\`:BD8V=-B=P78L1<SWN@,-*^&UU,0/U4A`"[7O\5KRB1R!>$0
M>/QCN*]:DOM!9!1<GDWV6KF75+,,^H1B_E1I8-=J1-6_)W[1&:))Y9GN#_09
M5P_QXM^4L)=D-4Z@&FR'S*DZY`I"-.L$?NY$H<4,E0"Y*@*MIQ=#5Y-T@RQW
ML8``NC</&WQ7K5E]HW7N*]B<C.7V7RQ7#*YS"I=2B\=C:2;V/I6+ZMI-V_V8
M>?F8X0K:<U=64MF&"H8X[,.%);^KQ&K,W!.0CUWDXZR@<F%:I4W8GP2Q(D0G
M-%U1Q38O6`4G%JTI:M(`!P.)=Q#*&$7"UQ=&WTUDOVX?L_5].>TM4:KGENI;
M>'#=9>K>O7K.X@L*L;.=.FZ5S1E-/N:CJ4\8M<:BU(^6-4<J]3Z9U)F^G,+>
MZ5I7E2E7HU%*@I1]).3PEC3EC3J81:XX2X7)8-[/==8URWW>&LD7R0V[#*)[
M&VH#?+GF,Y*S4E87%^2>4N\JV^(163M((T@$NN,)*<AN`2$NUKB$(=Q#%\\5
M_MPYQ<7][>YAI*ZRG*:M1RH.5C;7T.Y?YMSKTJ4YN3APRDVI*+;7%@D>[7GV
M?[S266Y56U=I?-*-M6HTYQNXUZL[6JJD5)5(3MZLJ<824DXK"+4?2BI8E_N@
M>4DUN`6DN!;H2%Q,,\DG2L2[:5Z$L,_`6D,*EUB%0[_\D`KW_DJ<RW[7WMIJ
M.3ZBLKBJ_O:=A;<?S948RQ\1Z#IC[+>1:OM_6<BU5D=6FEBU//53G'Y5.I6C
M4CXXGN]3M`U71]`Z-\S*3C%^K"G8=@TOE/\`D]&[SE%O%\/\MK5/2^T=KC="
MRN'_`/K+=>_31TS^QOD=!X9AKK3-NOP\\J2_B.0%B77!5_W'RK^8PY<?R/3L
MKF\<Z7XKC])YH'T+7_EK&_M$\R98]UE5SX[*SC[\"J^R5RRI_P",YOZ8C\C,
M+VK_`!8[3HO@*(JA6LR\G3;!?85[=$3_`+4)(X'A^,RSAELT8+?CMPO?^2K'
M]H/FS+\UD]3QT;&/OP,R^RUR(I_XSG;E$7^!#-:ODX45M/J>YN0+6:^3@_)1
MB_)%,]_E*`-N/Q>4`V29QZ-[7^/A<54GSYYTU<.YL(0^4K+[E(P__P"<?LSV
MTL;SG)*I'JHY?F,O=G57O(ZQ:-Y;6F<$/*IU_9RA?$;(]^LO.9@/Q>43LR(X
M`_Y>!E87SOY\R?FSM(KM]7^Y;FTN17V0:4?RVO\`/:TNJGE]6/NSNU[Q[BN7
M%F]SM:P-(-'HOTOPN^PVSDGN7Q_"/S)>EL9P_DM\-7KG1S]EL6;9?#PTX/WJ
M2,+Y/_8WM]LKO5ES\F%*GC\ZLSU_^5'G1PMQ-Q3R\XY87X$H]II&<7;\0KND
MP3D&"M_)PM5?]7N?\O\`[?E\/!;Q?OTRU<NOL94-BT;K"X^5=V]-/YLFT=0N
M3=EY?^N?-+H_Q_\`[;@S)<BZ''\7IS*27RG#_P!;XZM?-;G]+_\`HEO#Y-G1
M?OQ,BTA]CBCZ/)?/Z_R\XG3_`(D6>@CD>25=_P!]YNPJ@Z7Y?JKK&%%P_'Y/
MTAE)9T?_`$\:?ZG<^)>GS5G'Y%G;+WXLMEDOV3*/^%^S?5J?V^=WDO+PQB>H
M7(+B2L01..S4B)MQM<9<>Q##68`OQAMYR].][!XT?,;G=+;+G%F*^30M8_\`
M29:J7V::6*H_95R27;5S#,JC]RK`J:KD-879&1X=!YFR])75M:')>VMZ-HA#
M>)>Z(T)Y[>EL62P+#AV4+"P!N`%[#':]PA$&][7MFH\S.<MI4I753FMFES&E
M)3=*<;94ZJB\72FHT.+@J8<,N%J6#>#3-*MEW('-%++:/V<-,Y?&Y7=>LPJY
MA*K;=YYO?TG.\X.\HX]Y!S3AQ17$FL4:-K:I;C&,MEE]2=CBG0QM\O=&'$LL
ML,I<)+Y2Y-KC0B_(/OPM:_&_P?CKW67VJ-(K3WM.GH[/?K-W6*L';/@57#T7
M=_FG2XOON'CX/O.+8>70^Q=GOUU]@U>=.B/J(KGA>;+,Z7>.WX\'467I]^J[
MI[H<7=*I_2<'G'U_8/T9U1Q`PQY3%M?\>(9&!I:CG!\?HVDD4G&[^8D76K%+
MM(RW)<G<3E5QB-N4(JUAWO:P0VX6M\[7V=9OG%U7S',LQN9W%:;J2C*O6G",
MIOB<81G-J,(MX1BDDHI)))8':2JJPMZ>39=W,,MMHJC3=*A0HRG3IK@C*I*A
M3@ZDI12E.4G)RDW)MMXDOTB-(@3EI4*5,B2E6O8I,D(*3)R[7OQO8LDD("P6
MO>_X+5']+?2:4I2D\92;?:>FA:*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!P,_5F?F"_JWH#
M4XD_P59[_`/FO[HYM0'_T_H4M.-DL>X5Y&[ECS+3-",&31=IMB?*V/VR&%N,
MXRH;,]<I2OLW.D[=7,Y!%H`Q`C214)&WM8G-S7\+#7)TY5RE`$5IOO/MKBK$
MS5N$VY7DDPE.P37S0F$S7I];XROQ=ALS5`W+@L*R6",;?&T\A0+<9)L4DERT
M;@N5@?[N:FZD)1@$@B`-JNFTFR?"]AML-9Y=G"9[*1K%&--7\OQ";SV\95SE
M$^9P9\M)YM%%KO%VMC;CX\YNV+2'MC2"2])M(>#4Q9HD9:0LH#4Y?=#;G'N`
M<2YX+V/>I1+MX=-Y]FN3,$H984Y0G4V>IMB-7L:LTSQDR`:&U0RPG&T0V.7L
MRYO=U#BG<'EC0*U/$\2X"D#</I'+<BM67=UM9)GDF;9GCFM&4<6(\=9.R4:R
MN&0#H_EW"4.R>Y0.72*/L["WR9QA,A=E)B968D*6A:G-&2?<SR(#3`,`<RZ0
M[`$99Y?J&.8HQ4ZQ!%S%<.'0R1O><I.P/DB?3,$[`V4-TCBR'`\E2Q)G3V.5
M\%J9T>3Q^;E_]4MY87D0)N^OV[G9BUW[X,X\'M`/7[=SLQ:[]\&<>#V@'K]N
MYV8M=^^#./![0#U^W<[,6N_?!G'@]H!Z_;N=F+7?O@SCP>T!^AGN[@A!#?63
M74%A7M:XQ[@SOH`M>_#I"Z&G9@^B'X[\`WOP^*UZI)M1DXK&6&Q=96*3:3>"
MQWGQV;/JYD][*9V<LG-]FB?`R]-5;Y'R7IP?&R'NXG8R]D$5<EUB#+-9"0LD
M29620CNJ!T3_`")(AW+!^@_+S+LFRK1F04]-4J<<OKV\:DI02_+5YI.O*HUZ
M53O>*,T_1<>#!)8'QWKW.,\S[5&95=2W52M>6TO5Z:F]E&WH^;0ITTMD81I\
M+6&UMN3;DVS;)H!G+=>?XD8L$:_9=U6856/`NQ2..Y8/E;OG0UD='1=(`R-2
MSJUYY#_&3E#D=9*N3EFV"6&P#>C<(>/SUS&R?E_IC/<PKK1>9UZ-6HY2E:W%
MO1LHUY-NM22X*E2G553%U82BDIR:@MC2]YTQ+FAJ?3>5YW>ZFLZ=&=-4Z=6Z
MHUZUQ.E02HTI2G#"G)*$(P@V^-Q@G)M[7-20X*YR+\E$#WOL"-?E.EP(C4,]
M6CR+"^(-G`[&<F-%</X_AKS2>L--6^W*N4EI*:Z;S-+JHGVN-"A22\"9T-+2
MV?7*X<RYH5Z7_M\KH>Y*I=I^-Q\1'23Z2\X]Z`86HVTA<@*'QXEG[$Y<@0!_
M!^$$%UZ(`7;\VU:=7F'J;''*M#:+L'T8VEW>X?2*\,?&;L-`Z8FL,UYCZQN%
MTJBK"V3]V>'NF#5W*IYD,E,\I-Y?@^1BN*XAB6;;[+/'3O\`C&6Z8.)+,O>W
MQV%:]JTJO,7G*TXV6L\FL(/]ER.RBU\F5;OFO#CB;=/E[R7V._RO5]_+^NS>
ME3Q\*I6TD<$G)HV7$:%0ZQ[7DQ5;XU:7)BYW56_D"HENM;H9>U[_`/*XU!W>
MI.<^8QE3O.?>HX4'OA;^KVT/)1HQ:\3)FUTKR`LVI1Y(3NIKIN<YNV_&Z5*!
MD)KY2^PS?8-A-4(#T>'PL.=(G&1?^R-/I$XC!_)\-^%<9?Z4S3..+VWS(U/>
MI[U5S&Z:?XJK**\2.GM+[E'EV'J'V=M.;/TUQ?W'E<JL6R^".5]FFP0!<8N]
M.-P?!;S7?I5'2[V_%T&304@RUOYC+<*YJ?)C0U9MWEM<7#>_O:LJN/A[QSQ.
MDM>9&1Y<U[)Y*:*MDMW]QJU7Y:MQ+WBNIN67.R@>36X1/>2_^(#ES-\S@"/C
M\?2"VZA-]OZ7\G"M^TY2Z$LDE:Y+3@OP8PC_`!8(EH<\<_H-2LM&:4MY+<Z>
M46F*^="1447+(`D-N>?I9CIT.%?B88Z<S+9D_P`K?\9A96N1!-[W_#P#:IFE
MH73-'\W8->"<E[S1O2^TAS24%"WO<MH06[N\ML(X>!^KX^Z767RZF*P+`6\M
MW5UZX?!<4AWNSX_7%;\0PNVMBLL7_I#6[]4\@P496'$OPIU'[\L#5E]HWG3C
M^2UU7I+JITK>FO%P445UKT&C;+>PF[E7:(%"#?C:YVS$R6WO?X[W%Y[J&HZ5
M[W^/CQXU6.D]-PVQR:AC\G'WS0N>?O.>[Q[_`)DYJ_!6:_BI&2VG65[9.CZ-
MY87+](Z'Y/E,VF*^'P</_MFDJCC6U#(,CI^CE%M^KB_?1`7/-;F;=X]_K_.'
MX+NO'^+-%^HL:Y=;`7`V\N_19O#T!`L%#G8Q&'HB#<-P_P#5](@<`B#?A?\`
MDK9CE>6Q34,OH+'JIQ7O(AJVM=97./K&KLTGC\:ZKOWZAK$<>5?NTM7NBM+E
M$+2E7N;HN1-2//#$:D9$:]<H5(V5`8=J'Y8U"RIC@)B!&?TQ%$AN+^E>]>0R
MY":$<IR5NDFV\.[6S%XX>GMPW=IW-#F#ROI4;>E4^S+I6K5A",93E<YAQ5)1
MBE*I/"IAQU))SGALXI/`VI8F;]R<38S@V-$NNV`925"8PTQP<G>=LY6D>),>
MW)0$K)`[)$6GPT29Q>U?E%)Y9-[E`--%8']'A:O6,DRBST_E%ADF70X;"WI*
MG&.W#A6_9B]C;;PQ:VGF&87M"YOKVXR[+J=AEU2K.5.UI2G*E;PE)N-&FYMS
M=.FGP1<GCPI8E%FV.,Z9"%<^4:/:K*7"]Q#"]-NW,[C[\6:*W"QY;ZP:A-CL
M$X'_``B\MQM^"N>SWEUHC4C[S-]-6T[C>JD8]U53ZU5I.$\>I\6P@KC+;"ZP
M=Q:0E+KP6/EWF*^J'F(Q89)V'2H7"P$""$J.3[<.8Y<AP"KBM80`II'J&%\3
M%%%\>B`I5:XA?&+\7+_Z89SE"4M%\R<TLE'T:%UA?6W@PJ_E8KY,L>ELPQRZ
M5!86=W.G%?>M*4?(]ONDFBYSNS`&L!LPPYC/,PR6SRJ@[%$X5Q=SNY^2Z7FM
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MM[8M^Z;L*E.HN*G44H]CQ*_Z_;N=F+7?O@SCP>UOEX]?MW.S%KOWP9QX/:`>
MOV[G9BUW[X,X\'M`/7[=SLQ:[]\&<>#V@'K]NYV8M=^^#./![0#U^W<[,6N_
M?!G'@]H!Z_;N=F+7?O@SCP>T`]?MW.S%KOWP9QX/:`>OV[G9BUW[X,X\'M`/
M7[=SLQ:[]\&<>#V@'K]NYV8M=^^#./![0#U^W<[,6N_?!G'@]H!Z_;N=F+7?
MO@SCP>T`]?MW.S%KOWP9QX/:`>OV[G9BUW[X,X\'M`/7[=SLQ:[]\&<>#V@'
MK]NYV8M=^^#./![0#U^W<[,6N_?!G'@]H!Z_;N=F+7?O@SCP>T`]?MW.S%KO
MWP9QX/:`>OV[G9BUW[X,X\'M`/7[=SLQ:[]\&<>#V@'K]NYV8M=^^#./![0#
MU^W<[,6N_?!G'@]H!Z_;N=F+7?O@SCP>T`]?MW.S%KOWP9QX/:`>OV[G9BUW
M[X,X\'M`/7[=SLQ:[]\&<>#V@'K]NYV8M=^^#./![0#U^W<[,6N_?!G'@]H!
MZ_;N=F+7?O@SCP>T`]?MW.S%KOWP9QX/:`>OV[G9BUW[X,X\'M`/7[=SLQ:[
M]\&<>#V@'K]NYV8M=^^#./![0#U^W<[,6N_?!G'@]H!Z_;N=F+7?O@SCP>T`
M]?MW.S%KOWP9QX/:`>OV[G9BUW[X,X\'M`/7[=SLQ:[]\&<>#V@'K]NYV8M=
M^^#./![0#U^W<[,6N_?!G'@]H!Z_;N=F+7?O@SCP>T`]?MW.S%KOWP9QX/:`
M>OV[G9BUW[X,X\'M`/7[=SLQ:[]\&<>#V@'K]NYV8M=^^#./![0#U^W<[,6N
M_?!G'@]H!Z_;N=F+7?O@SCP>T`]?MW.S%KOWP9QX/:`>OV[G9BUW[X,X\'M`
M/7[=SLQ:[]\&<>#V@'K]NYV8M=^^#./![0#U^W<[,6N_?!G'@]H!Z_;N=F+7
M?O@SCP>T!Q'/=V[@'QUCUWM;H"XW]\&<7X6Z-^/"UM/?AO0$4$?&_)3G5Q6M
M8=]`\SW,#:_2"`V^()I<T`!WL&XP`,O>P17L&XK6X\+<>%@/_]3[$-2\7X_R
M9I-R_5$]BC3*3L:81U@RA`S'4D9PHOD"/X49VQEE;7T#`>2=FU`_+"BAWZ5K
M!4#^#X?@`R2PZ6ZK1K)&3LMM&#H,5/<QM\L:\D.JQ"H=6^2(,@70BR*GO&'9
M4NBK3;)1K6F,DHD*)*.1')RS'&ZHP`16`\&.-'=4\1QEGB&.L.,498V+(\4R
MTW%D.LH6N09]`VPEC@[RM?W1]7/[JFAC`E);VIO5*CFUN;B2DJ=.6G+`6$#R
M1O0O3N)&9E&Q:]X\3%;`,\ACF64"IM4.S/)HQ+G9TD$KBJ5D=U:YHBL3DLD>
MU;HO:V<AO;U;JI,6FDC5"N=0&6<(8"Q#KA"S,?X6A2*$Q=2]N,F<DQ*]Y>W1
M]DKN!,4Y2.32:2N3S)Y0_K$Z%.2-:XK%2FZ=.25T_)E%@"!#3F)_WQY:G^97
MB7[B-DZ`V5T`H!0"@%`*`B?+=%]0IX_*91,M?,<261+5JEQ6O3NS75N*U<K4
MF*U"A:J,/N:K&8H-$+^TN*UN/"UK6^"MC2UY?:(L<WRS2>87-AE]]6J5:].E
M5J1A.K5;=2HEQ-0G-MN4J?`V]K>)S]_I73F:7$;K,,FMZUROOI13?C?3X\2@
M93T`U9RK$V*,JL;I8.X0PX];CR>XQ6*H-D7'+B>;8^ZR'R]F&6Y("['AZ7FA
MESD(O^(F]7Z.O*FA+:M8:=BJ>5U:U2K5H3<JM*K4JR<ZLZD:CEQ3J2;E.>/&
MY/'BQ.EL*TLLIJA9Q4;9;.##S,.KAW)>##`CM:=[OZ3?V.6F5XWBUQ;@\`Y8
MQZS)D>S<`:2;`XJ)_CI.84UY21(4P!B-7M`B5PK!N8<7>][!KMO5-*ZIVY=5
MCE6=R_H:C;M:CZJ=3?2;>Z,\8]"9(]W8WVVC)4+GXK?F/P/[WP/83NP9L3A;
M9.(`F^%,@L,Z9`B"0X@;5%RGF/+[V%TVF3Q]8!.]QQV)&6((DZP@DSB&][6O
M;X:Y+-LES3([EVN:6<Z57HQ7FR77"2\V2[8MFA7MJ]M/NZ]-QE[_`('N9FJH
MLP"@%`*`4`H!0"@%`*`4`H!0"@%`>%Q:VQX2&H'=N0NB$\-PGHG%(G7)#@WM
MPN$U,I+-),#>U_BN&]8+FUMKRE*WN[>G5H2WQG%2B_"I)I^0I*,9+"237:1I
MD6F^!'I>:],D778WD9IMS[R+%;ZZP%SL=?\`_FW*8U!+4:,/X/*)A\/P5YMF
M/)W0=[7G>V65SRW,6\>^L:L[6>/7A2:@_'!FC/+;23<HT^"?7!N+]S9[A;X<
M1;00+B+&^PZ2=MI9EQEQO.<5)=CO)A_(3!FD7$VO8K>3MT;"-)&+C?I"%>H[
MZH\S\BVZ;YAPOK9/%4<SH*H\.A>L4."IV8N+?2VRSU>_H_F+Q3CU5%C_`+2V
MGX'/F=8/8(,O:SR92D*Z8E4IPJ](,B-(2`<>DI%'E`FF3)BP`#<0K7`8*UK\
M+6%?XRU[KK(TEJ_EI<RI+?7RZI&[IX=?=/NZT5AM>*;ZL1ZW=TO\38RPZX/B
M7DV,O:&[:Z_3544V),AM<>?S+]`49G)2N#2$D[Y.8VR@AL&-1_ZA=QWJ;R;F
MSH#.JD+:EJ&E;W[_`*&Y4K:JGU.%90V]B;,M+,;.J^%5DI]4O-?D>!(HA00J
M)+4)CBE"<X%C"3R#`'$FEBMQ",LTNX@&`%;XKVO>UZ]#IU(581J4IJ5.2Q33
MQ376FMC-Q--8I[#MJ\J*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`4!DE,=DBA_2,3PA=5,6>SHY(2$AUC#&A\3I$BXYL6AX6N4
MI+2+R1WM\-N`_CXVO:VA99IEV95+^E87D*M2UKNC547BZ=51C)PEU2491?C+
M(5(3<U"2;B\'V/J*_6^7B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0'`S]69^
M8+^K>@-3B3_!5GO\`^:_NCFU`?_5^TW1+]R#3;^%37G[HHA0$JZ`4`H!0&M3
MF)_WQY:G^97B7[B-DZ`V5T`H!0"@%`*`4`H!0$$<YZ"XRR7+S,R8HD4FUEV.
M*#<:;-6&S"&9:^&]+I>:9*B-[`C&2F<^UQ!.*<"?.#`"O:QX;6M:NMRG5]]8
MVRRS,*,+[)/T%;:H]M*?I4GU.+P[#?H9A5I0[BM%5;;XLNCY+WQ?@,.H]Q<^
MZJ*TT8Y@.-R3H-YP4A;-Q<&LSJ]XE4@&(LM.IRU"2"U<GQ.X'7%P-/"6J:Q&
M\?)W`#X;24M-91J",J^C[U^MX8NSKR4:RZU1GLC674MDL-^+,[LK>[3EEU3\
MI^CELE^*]TO?-E,-FL/R)&FJ90*4,$SB;ZF`L9Y'&'9"]LKDF';C8U&XMQRA
M*=:U_@%:PN(16O:]K7M>U</<VMS95ZEM>6\Z5Q!X2C).,D^U/:1DZ<Z4G"I!
MQFMZ>QESU@+!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`LB98TQ[D-&8@G4)BTM2
MFE7)$7(&-N<Q!+%\823E2<P\C^<`@WJ$SC36GM0T94,\R2UNZ36&%6E">SL<
MDVO$T8JM"C63C5I1DNU8D=E6FT+9#35N'I]E3""\5["+(A$Q7K(P$72M>X3H
ME)1/#0<3>UN'0#8L(0_`'A7GE3DYDME*=;1^?9KDE=[E;7$I4?'0K=Y3:[%@
MET8&F\MI1Q=M5J4G^#)X>1XHZQ-VZL`O>[>_8ESTSE"``*9^;UV,)H,@/QB`
MO:QN<7/4="W#^U++L,7PW%:K';\Z<@?]WO\`*<^LU@N&K&5E<-?+AQT&\/C)
M8O:VBF&9T=TZ=:/;YLO<V"VW(8H8%/FO">7<2W\IY(Q^''_7J$!N&W$TV\IA
MPE]BB"[<.(C4Q=OA^#C5?]6UE4E3UIHK-\IVX.JZ7K-MVOO[?BP2ZW!%?:'=
M[+JUJ4^W#BCY8XF<X)FW$630!%`LC1"3FB%T+HFUZ1B="S.'2\F>T'&%.B<S
MA_PF$A%_)7<9%K72.IHIY#J.TNI?%A4CQKL=-M33['%&U2NK:O\`F:\9/L>W
MR;R\;2J.BE(X39W1WE9;""3C8K#OY^%@,<!-8'41?1Z-DHG`%RN/'CTOP<*F
M%FN7/-)9(KN'M54%7=+'SNZ<^!3P^+QKA\)D[R'>=UQ+O,,<.S=B7!4@7B@.
M!AI9(;C-,`4"WQC,&$`;?SB%>UK5;*48+BG))=NP8X;RA*I9%47'SV31])P^
M/SIY;D_#^?RJD'"M&KF^54?SV9V\/E5(+WV6.I36^:7C1;:O+V)V^PKKLG8]
M1]&W$7G,SCA-[6M_ZICD&]1U;5VE+=-U]39?##KN**]^98[BW6^O!?C+X2RU
M^T>N+8*X%V<<6DCM_P`'KJQ&CO?\00$K3!"O_-:]0M?FARYMGA7UQE<7_P"Y
MI/WI,Q._LH[[JGY46ZHW+U>3<>EFB'G</D)R]QX_S>CT*GI?^BHZISDY84]^
ML[.7R7*?\2++'F5BO^YB48W>#6JU[V0SM<\BM_PLT+FR^][_`(@]"/!L*_\`
M->M.?.[EMM5#/9UG_5V]S+_I%OM2QZ*K?@C+X"G&;OXA%>UFZ-YI>^-^`;LV
M&IVL"+C\5["NU%!M:_X[WM:M:7.[2+>%OEN=5_[/+KJ7\A%'FEOT4ZK\$)?`
M=X-OFQ;:WH/`VR[T(7Y-BL3+$-A?BX7<G))>W'^6UJR+F];5E_<M!ZEK/LL)
M1_CSB/:,7Z-I7?XGPLZ_>@GRD5PMNH^PYOP\`B<VR)LP!?BO>ZB2FC!;^<-K
MU;_J?G]1X6W*34+^7"A37NUF_*BGK]5^CEU;QI+[IW!SWGY7_P!VZ>SB_'\F
M[QD:`LW_`#[&'*;AJY:]U]6_PW)^^_XEY:T_?<BOK=V_1RV?CE%'C<LO;6IT
M"UUOK9$6!N;DBA>N627-#'8E$B2$C4*E*F[8UGW"4G(+$,5[6OPM:L5SJ[FK
M3H5KI\M[2WMJ<'.4JV8TL(QBFY2?!![$DVRDKB_2<O4HJ*73-?`:_L5[C9K?
MLXR!>QIH4M79B5,;$SQ>7OKNV0N/JF4@].Q`;'9&B4JPGN!(S"A"NG#YX><"
MXK6O8/#P#2W.'6M]K?,+BQI64Z^<3I4J="XJU(6]*5--4E"<8N2<TW%O@7>2
MDFTG@0]OF5U.ZG*"CC5:24FTEANP?_K$V#A?]Z#/CQ[KBF_/FLY4</\`X;.5
MQKZ"5_SRE_\`7].1\-S<OWJ:)CCS7]#0^=+X#N\_WG-_\/ZSI/YW?(BGA_+\
M!`./"K^_YY3_`.PTU#_B7;^X5QS5_>T%XY'[Y/>@[_[3K&CX_C3Y)4]'_88#
MCPIP\\I_TNF8>*\?W1_\KUT%\XZQM6]8_P`F6ZQ)_P`V,Y(4</\`G.9/&K7:
M\]);LVTQ'_@WC_EH<.:_I*'DE\)PM'MZ3.'E,CZY$?C\W@<Y,X?S>7?_`(:M
M]G\\Y>EJ/3D?!:W+]^J.#-?TU'YLOA/WU2W=,_+S!@PC_P"[XUD)G#^;R[]\
M-7>R>=LO2U?D<?!9U7[]4=WFG[32^:_A.7J+NB9^7GG$Y'_W?$RDS_Y[[5?8
M?.>7I:[RF/@L)/WZH[K,_P!KI_,_A.5L<[BC_+V1@)'_`+C"Z`SA_-Y=\I]7
M.<,O2YD6$?!ET'[]0=SF7[;#YG\)SMBW;@?ZS:F.$_CLGP5&!?[+G/0N%7?5
M?FW+TN:=LO!EE'[M0=QF/[?']6OA%\/[1F_K]M`AX_'YIA:&D_[.DO'PI]3^
M:$OSG-G#Y.76Z_E,>K7_`$YA_L(_.HW8HW]?M[)`\;\;^:XK@Y/^SI&#X4^H
M_,2?YSF[<KY-C;+[K'JM[TYB_F1.L6ON=3/UNX>1;<?DT%@:?_9Q2&\*L?+_
M`%U+T^<&8^*UM5_)8]3NGOS*?S8F(LW0?)F%L:R3(CYN#F-7=H3@*:&E.R0!
M(-ZD"X?FS,TEWNQ&BZ"I:,-S;V_I`(",5OR:Y'6V1ZET7IO,M17W-_.)]S'"
MG35.UCWE67FTZ?YI^E+#BZHJ3Z#7NJ5>UH3K3S&ILW+".U]"W&N_6G($Z!E5
M/&R,P2C&U\K/5POLH1MC:_EN<T5W-&T*WM&_DC3&>DUYXTXC@C*'81P`WOT;
M6M;YZY;9_GD=50RZ&K[K+7FM;"K6C"%53N)8]W*I&JL//FW%R3B\916.!#65
M:MWZ@KF4.\>UX)XRZ,<>LVX"Q=MN@^!LVAC;J`-OZ!4BPLPA%?A\7E%+6[DF
MBX_A^"OK7ZK\VK?9;<S[:K'JK9=2]V4*B9T/<9@MU_%^&"^XSK"P;RH!?V.0
MM=7\H-K_``.D*FS0>;P^*US&MX/)+O?\R]6JPYXT'YFH=.UX?AVUS3;\<*C2
M\@X,U7]-1?AC)>\S@:_[SM]PVOCS7:1A#^6-!-IJPF&6_#<`'!G<`6%_)>]K
M5;*_YY6^">GM.W*73&YN:3?BG3FO=#GFL?Z&C+\:2]]'<#*FVK=;B[:N,#Q:
MWY7JQF:/`N+A\?0"\MJ87^WA5ZU3S9MUC=\KZ%;^QS&E_P!2"'?YA%>=8)^"
M:^ZC@/8S,2#_`+XU`RX#H_E>@'^$2/\`GZ'D75%T_P"3XN-4ES%UC0_QG*'-
MU_95;:MY,)QQ*>NW*]++JGB<7]T_;;;B1!Z4CURV9CX?PB'C0MV!;A^'ILST
MML.WYO&G^K3HK',>76IK==MFJG_XZDO<*^T</3LJZ_%Q]YG65N_AP(NB[,F8
M(W>U^`KR'#\Z;P@X?'<0[-)P+AM^.U[VJV'.[1R>%W99O;?VN7W,,/'W;0]J
M6WWT:D?#"2^X5E-NSK`HO8!N5&]M-_XB7ACE+287_(9=>QD%AO\`^U6[2YU\
ML:FR6J:=.?54I5X->'BI)>Z7+-+%_P#<)>%-?<+H;]KM:W,82TF<<9W-'^22
MHE;4B.OQ_P#Z2T].9;_94G;\U>6US)1I:XRSC?0Z\(OR2:9>LPLI;KJ'E1D!
M!EG%;K8(FS)4`<+#M:X?,YA'E-[\?BX!)<1WXUT%#5NE;I)VVI;"IC\6XI/W
MIF97%O+T:\'^,OA+O1/+0Y6M=N=6U?:_Q71+DJJU_P";R!IG&I>C>6=Q_A[J
MG4^3*,O>;,BG%[I)E2K9+A0%O1F5QN9-QKO%GE"^MA+F[,QJUO.L<06Z,;@H
M:G9$(5K6X'H7!*86.WQ<0\;<;7M>\?EF;9;G-M*[RN\IU[:-6I3<H/%*=*;A
M4CX8SBT_!U%D*D*D>*G)..+6SK6QEPU(%XH!0"@%`<#/U9GY@OZMZ`U.)/\`
M!5GO\`^:_NCFU`?_UOM-T2_<@TV_A4UY^Z*(4!*N@%`*`4!K4YB?]\>6I_F5
MXE^XC9.@-E=`*`4`H!0"@%`*`4`H#SK$:1P2*4"]*G7(5I!J58C6$%*4BM*H
M+$4>F4IS@C)/(.*%<(P"M<(@WO:]N%71E*$HSA)J:>*:V-/K3*IM--/::U9C
MH`ZXQDKKE;0?)@M9)ZY*3'*08I6(U$AU@R2M,$(1H9/C$!E@Q!P4>5'P<V'S
M<XJXN-B17^&NXMM84[^A3R_5]CZ_:16$:J:C=4E^#5^_2^+4Q3ZR3AF"JQ5'
M,*7>TUNENG'P2Z?`SUX_Y@A<0E;5A_>''*K5#+#D<6WL,J=U]G?77)JR]RP!
M,Q]E[@6U(E*D8^/HUXND5D<;`N,P=^%6WFCG<V]3,M*7JS#+H[902PN:2_K*
M.]I?&ABGOP2*5,N<X.M8U.^HK>EZ<?#'[JQ-D1)Q*DDI0G-*4)U!19Q!Y)@#
M23B306&4:4:"X@&%&`%:X16O>U[7XVKB&G%N,E@T1FX[:H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4!^7M85KVO:U[7M>U[7MQM>U_@O:]K_!>U[4:36#W`CW
ME#7W7>4-[G)Y_CF)E79FY>Z+92@1>KSZWI$A`UBQ8%\CXFYUZ111-QWO<P7'
MAPX7^*O/M3\O^7F:6]SF>?Z=M%W-.<Y5X1[JK",4Y2EWM+@GL2QWO<:=>SLZ
MD93K48[%CBMC\JP9H009)<6O)WKJQ2+*4:8?2(VI,YI)$ZN4^:L:&+;%A:4[
M^\E+!GJ$S3:Q@"S0"+`;;@$-KVM>O@NAJ2XM=3>V[',<TMK'O'",XU:D[J%F
MY8=VJM12Q<:>U1DFE)8)')1KN-?O83J1ACACBW)1ZL7V&ZIOU499(V(791L3
MLQ(F]V1)7%"L*RTK;B5:%<0!2E4EV;6M(+R9Z<T(K<.C\%Z^TK?E799E;4+N
MIS#U+<6]6$9QDK^4%*,DI1:X(1V--/H.G67QJ14O7*[BUCZ?\!Z0:38J'_WC
M+LWO?_*],9DFJKI_CZ70<">/&LBY*:5E_B<WSNO_`&F87,O>FBOLNW^^J57X
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MO$BO%)DY-K6)()*M;X+6**`7:UK?%:U@!MPX5OQI4X>A3BO`DB[!+<CNJ\J*
M`4`H"V9E$&&?1=ZALH2GK8](48F]W1IUZYL,5HAC`,U-=:VJ$BTHH^P.B98!
M@>F7>X;\0BO:\9G.46&?Y7>Y-FE*4\ON(<%2*E*#E%M-QXH.,DGA@\&L5BGL
M;+*M.%:G*E46,)+!]'O$;B=&=8TQZ=2GQZH3J4B@A6E4$S":EG)U24X"A,H)
M,#(;"+.3GEA&`5OA"(-KUYQ#D=RRISIU:>GI1J0DI1:N+E-2BTXM/OMC32:?
M6C1]E6*P:H[?#+X26P;=$-@\;WZ-K6XBO<0K\+<.-Q7XWO>_X[UZRE@DB1/V
MJ@4`H!0"@%`*`4`H!0"@.LPHHX-@G%%FAM>PK!,`$8;"MQX"M85KVM>W'XZM
ME"$UA.*:[5B,$]YU>9([7M>R1-QM>U[7\@5QM<-[7#>W]#X+VO;C;^6K.YH_
MH8^1%,%U(]-92HH!0"@%`*`4!3E;.T+P]!<UMRT%^/$*M"F4AOQ^/^B<4.WP
MUK5;.TN%A7M:<U^%&+]],HXQ>^*9:*[%&+7/I6<<;0%?T[7L*ZR'QY3<7'X^
M-SFX=^/PU$U]*:7N<?6=-V%3'XUO2?OP,3MZ$O2H0?B7P&/735+6MY'Y1QP=
MC,\SC>]C`1-J3&!O?\(!I4Y`@7_EM>U[5S]URJY;7CXKC0^62EUJA"+\L4C#
M++[*6^UI^1%KJM)]85%K^2Q8@;+_`!V$ROLJ9KAO^"X+-KXF"&]OP<+5%U>2
MG+&IZ&EJ=)_U=6O3_B546/*[%[K=+P-KWF4DS2/#9?\`W.\9;C7_`"/5[+DX
M0^3_`!=#RCJHZ/#\%:DN2>CH_P"#N\VMO[*_N8X>#&;+?9=M][*I'P3E\)'G
M9K'B+7'&*F41C/.R()*YK4S!$F-;E!8^(E[HJO<U0:O(6-YJX;8W-9)QIURS
M`CM>P+=*UQ6KSWF7IZARYTQ5S3+-=ZD6959JE;TI7LJL93EM;FI0<G"$%*4F
MFGN6.+-*^HJRH.I3NZ_&W@EQ8[?)N2,0\NG,AL9FSQAU\.4`9YY<Y]BXU0%`
M"DDN;THANJ,)A]PEA%(6HCROX1C4)/PB,O7(_9VUC++,[O-'WLY*SO\`&K0<
MD\(W$(XSCB]GY6FN+K<X=<C7R6YX*LK:6/#/:O"M_E7O&Z.OLXZ84`H!0"@.
M!GZLS\P7]6]`:G$G^"K/?X!\U_='-J`__]?[3=$OW(--OX5->?NBB%`:#LI[
M0;0:PON?\X3";Y!FK[F]JYDKOIZY0?;5BSGK_$U6OJ:2R",Q:5ZXQS'#;&HN
MCQQBN$*UQCN4_OZA')FY<W/25(-05P`VK:6/DV@^Q>VVN"C-^0MCH#C/&&J6
M7(7*LG29%,YHVRG-<<RJ1-X^;,22$XU##*#<9M\B;&^Y?FS39Y/+26+0#2)R
M0-1ANV^S\#UYQ/G-IV@G3_.-VM*\CYDRNAE"^/R&'ZNSE%LKK%C<&1<4QM<W
M)DN.(_BN,["OT<,:Q6N@5.+&WJUI1RU.M&I`W.Z.2&:L68=X-:GG(F0,O037
M#+6+D.-<@93D7KK/DJ+*V#81DV3XVD4W$0G62@<(D;P:I2&+[&.29N>$Z<XT
MPLHB]`1YYF+CLX5E_04J+P_`J^!I^8AALV`KI!DG(;/+W61=1F?//4$M:6W%
M+XRL#/8`U_DU:1:Y'?V9'%/Q,'8L":'IOF)?5EI;]N><O#O0#TWS$OJRTM^W
M/.7AWH!Z;YB7U9:6_;GG+P[T`]-\Q+ZLM+?MSSEX=Z`>F^8E]66EOVYYR\.]
M`/3?,2^K+2W[<\Y>'>@'IOF)?5EI;]N><O#O0#TWS$OJRTM^W/.7AWH!Z;YB
M7U9:6_;GG+P[T`]-\Q+ZLM+?MSSEX=Z`>F^8E]66EOVYYR\.]`/3?,2^K+2W
M[<\Y>'>@+-G\6W6RK%':"Y+P%H5.X<^D"3.T:E67,R/;.N*$$0.)J)?KB<38
MXJP[W+-#:QA0OZ0!!%:UZV;.]N\ON*=W8W,Z-S!XJ4&XR7C7NK<^DOIU:E&:
MJ4IN,UTK8R(^,M9N9+JJ^/+W@19@5PP@G2%KDNH3]F3+&2T05HE8O2+;BC)F
M0L?PYPQNF\T,$:C2*CEC?YQ:P#+6!P%;MHZAR34<51U=9]U?[E>V\4I-]=>C
MZ-3ME'"74B35W;7F$<PI\-7])!;?QH[GX5M+JQ)S`]E\N3M;B93C+5W!^<$:
ME6$[`N><NYOAN11(BU/DT*R/K!Z\!B^04RU.,!ECF)2L+MQOPO<%K#%$YOI+
M,\LH>T*$Z=YDK]&XH/BAX*B]*E)=*GT])KW&7UJ$.^@U4MGNG':O'TI^$F!Z
M;YB7U9:6_;GG+P[URQHCTWS$OJRTM^W/.7AWH!Z;YB7U9:6_;GG+P[T`]-\Q
M+ZLM+?MSSEX=Z`>F^8E]66EOVYYR\.]`/3?,2^K+2W[<\Y>'>@'IOF)?5EI;
M]N><O#O0#TWS$OJRTM^W/.7AWH!Z;YB7U9:6_;GG+P[T`]-\Q+ZLM+?MSSEX
M=Z`>F^8E]66EOVYYR\.]`/3?,2^K+2W[<\Y>'>@'IOF)?5EI;]N><O#O0#TW
MS$OJRTM^W/.7AWH!Z;YB7U9:6_;GG+P[T`]-\Q+ZLM+?MSSEX=Z`>F^8E]66
MEOVYYR\.]`/3?,2^K+2W[<\Y>'>@/P3SS$16N$6,=+!!%:]A!%G+.-[7M?X+
MVO:^N_"]KU1I---;`=7I/F%_59I/]M^;_#M5O=T_T<?(A@NH[;/7,1#:P0XQ
MTL"$-K6L&V<LXVM:UK<+6M:VN_"UK6J]))8);`?OIOF)?5EI;]N><O#O0#TW
MS$OJRTM^W/.7AWH!Z;YB7U9:6_;GG+P[T`]-\Q+ZLM+?MSSEX=Z`>F^8E]66
MEOVYYR\.]`/3?,2^K+2W[<\Y>'>@'IOF)?5EI;]N><O#O0#TWS$OJRTM^W/.
M7AWH!Z;YB7U9:6_;GG+P[T`]-\Q+ZLM+?MSSEX=Z`>F^8E]66EOVYYR\.]`/
M3?,2^K+2W[<\Y>'>@'IOF)?5EI;]N><O#O0#TWS$OJRTM^W/.7AWH!Z;YB7U
M9:6_;GG+P[T`]-\Q+ZLM+?MSSEX=Z`>F^8E]66EOVYYR\.]`/3?,2^K+2W[<
M\Y>'>@'IOF)?5EI;]N><O#O0#TWS$OJRTM^W/.7AWH!Z;YB7U9:6_;GG+P[T
M`]-\Q+ZLM+?MSSEX=Z`>F^8E]66EOVYYR\.]`/3?,2^K+2W[<\Y>'>@'IOF)
M?5EI;]N><O#O0#TWS$OJRTM^W/.7AWH!Z;YB7U9:6_;GG+P[T`]-\Q+ZLM+?
MMSSEX=Z`>F^8E]66EOVYYR\.]`/3?,2^K+2W[<\Y>'>@'IOF)?5EI;]N><O#
MO0#TWS$OJRTM^W/.7AWH!Z;YB7U9:6_;GG+P[T`]-\Q+ZLM+?MSSEX=Z`>F^
M8E]66EOVYYR\.]`/3?,2^K+2W[<\Y>'>@'IOF)?5EI;]N><O#O0#TWS$OJRT
MM^W/.7AWH!Z;YB7U9:6_;GG+P[T!P&[\PXSAY3%VE0^CQN'IYQS@+HWO;A?A
MQUVOPXVJUQC+#BBF#C9TYAEKV%;%FE%KAOQ#>V;\WVN&_P".U_=VXVO5%3II
MIJ"Q\`.WTWS$OJRTM^W/.7AWJ\#TWS$OJRTM^W/.7AWH!Z;YB7U9:6_;GG+P
M[T`]-\Q+ZLM+?MSSEX=Z`>F^8E]66EOVYYR\.]`<1O?,1Z`^EC+2[AT1<>&<
M\X\>'"_'AQUWX<;4!&Q'Q_\`)3G/2X6,]P/,]S;!XW!8Z^'YI<X)=[VM<183
M>-@WO:U[AX7O:U_@H#__T/M-T2_<@TV_A4UY^Z*(4![8KI5J5",F9%S'%-=L
M2LF2\M(9(VY%E:.&M'GDJ0S500KG:=>E-(,;2@9`6IBE$A\B05=^4%`-<+J3
M`A%8#ECW2_53%$49(1CK`V.HE%HWD=CR\R-#2QEEE(,E1A,!!%Y@6H-&:L,=
MHNUDE(FRXS!`;T!!25.$M.244`#E&-,-3X:LS&OC.O6)VL_8)*\-V9PEPYI/
M29":9$H<5LA8WY`K(4(!QZ0.3PL6+V\HLI$L7K#U1Q0U!QIH@,A87P7B'7:#
MIL;X2Q]',;PI,X+W>[''$=R"UCRZC`8Y/3LM/,4.3V]+[E`":L6''J3`%@!<
M=P@!8($+.8G_`'QY:G^97B7[B-DZ`V5T`H!0"@%`*`4`H!0"@%`*`4`H#`N?
M=9,';.1@$6S1`&B6D(A#4,#Y<)C;+XBY7"*Q+Q#Y:VC2O\;=$QE[&!,2G@L(
M8;=,(P_T:E\GSW-<AKNXRN\E3;]*.^$UU3@\8R3[5X,#8M[JO:RXZ%1Q?2NA
M^%;F0ALR;SZ2<1Q=8^;Z:UMUN-XN_K4:';7'C.6(5K%L#^8!,Q9J0-R;HV`G
M563/!W0Z(!7MQO75=[I356RXC#*,\E]_%-VE1_A1VRH-OI6,%TF]Q6%]Z:5O
M<OI7YMOM6^/O$Q==]ML$;1-*Y;B>9%JWYC'=/+\>2)(HB^3(*X`N`)[=,8,\
M!3OC.H3FF6!<RY8THQ_`6:/XZYK.M.YMD-2$<PML*,]L*D7Q4JBZX5%YLO!O
MZTC2N;.XM6E6AYKW-;8OP-;"2=09K"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H
M!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4!P,_5F?F"_JWH#4XD_P59[_`/FO[HYM0'_
MT?M-T2_<@TV_A4UY^Z*(4!*N@%`*`4!K4YB?]\>6I_F5XE^XC9.@-E=`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H"'6P^CV%-A'=%/CB'W%><V`-AQ'/^(G(4+RI'
MU1(;W2!4O2`%B)0S@-L'RB!T*5)S"[7`'H<>E;I<FU7FF34Y6:<+C*9^G;UE
MQTI+IPB_0?5*+3QV[3=MK^O;IT\5.@]\);8OQ='A1&X.P&W>F(K-NV\*4['8
M*0"N2EVKP9&C132,M98A`(69PPN@\LJ("23T+JG=AN<E#\(A$W$*_"<]CZ<U
M/Y^G+I66;/?:5Y>9)]5"N\%X(5,'VFSZO9WNVSGW5?\`1R>QO\&7W&;#L4Y@
MQ=G*&MN0<0SN-9#AKJ"PD;[&'(AP2V'<(1B2K"P7LJ;7`FPK>53*2RE!5_@&
M`-_@KC,PRV_RJYG9YE:3HW,=\9+!^%=#74UBGT,CJM&K0FZ=:FXS70S)%:)B
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`X&?JS/
MS!?U;T!J<2?X*L]_@'S7]T<VH#__TOM-T2_<@TV_A4UY^Z*(4!*N@%`*`4!K
M4YB?]\>6I_F5XE^XC9.@-E=`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0'Y>UKVO
M:]K7M>U[7M>W&U[7^"]KVO\`':]`:\,J\ON,F3)QS7JC.G?4C/JP0E3G(<?H
M4JK&615`!6/"CRQB-1<N*RA,K/+#8Q426F7!Z0A^4&/A79Y?K&NK:&5ZAM(Y
MCDZV*-1M5:?1C1K>G!KH3QCV(DJ.8RX%0NZ:K6_4_27R9;U[Q9K%O=/L`O+=
MCWF&XR)PVI5JR6F.[*P'TE*-9YVI&(1"<UR>+$&O>)W=>,(;^9/1=B0B'Q\N
M`'"MJMI*SSBE.\T9?.Z26,K:IA&ZIKIPCZ-6*^-!X]F)?*PIW$74RZKQKI@]
MDUXMTEVHGU;,6*!22#1`K(T+42;)K.[2#'C*ED36K731C8R2%+J[QLM,I-L[
M-R-.I`,1Q-Q`N'C<-[V"+AR'LS,>XN[EV554*$E&I)Q:4)2V)2Q6QMK<R/[F
MMPU)]U+@B\&\-S?0S)%:)B%`*`4`H!0"@%`*`4`H!0"@*7Z<9;O5XW9X:[R(
M+6%\$P>D$GIJS*-6)`%XNU>6\^LUB7`N391Y/R5S;7!TNE;A63NJO==_W<NY
MXN'BP?#Q88X8[L<-N&_#:5X9</%POAQPQZ,>HJE8R@H!0"@%`*`4`H!0"@%`
M*`4!8[+DS'TCF<OQTPS*..\[@)#,IFD20.J52_1E/(2#53*<\-Q9@E",MQ3D
MB$7<5OAMPX\.-N.W5L;RA:VU[6M9QM*SDH3::C+AV2X7N>!DE2J1A"I*#5.6
M.#Z'AOP+XK4,8H!0"@%`*`4`H!0"@%`*`ZCSR4I)RE2<4G3IRC#U"@\P!1)!
M)0+F&G'&F7"`HHH`;B$(5[6#:W&]52<FHQ6,F-^Q;R+^O^YNO.SDER/$</3M
M-(W[&#R:V/:(PD2*[NW%#*3!F$1$<+A)H4>Y"&D`Y)^D3YP5>U^`3"1&SV<:
M8SK(:%E<YE:.%&O'&+W\+W\$_BSPV\+VX/L>&W<65S:PI3K0PC-8KL['U/L)
M2U`&H*`4`H!0"@%`*`4`H!0"@.A4J3(DRA8L4$)$:0@U4K5JC2R$R9,06(T]
M0H/-$`HD@DH%Q#&*]@A#:][WX56,93E&,8MR;P26]OJ02;:26TQ'A78##NQ4
M;<Y;A>>LL]8&:0.L7=%K0,\(D+RT*1IU"=0E5DIE99"D(+'I3[@\@L2F`.(&
M84,(KR6:9/F>2UZ=MFEI*C6E!32>&V+76L5LW-;XO%-)HS5[>M;24*U-QDUC
MXF9CJ,,(H!0"@%`<#/U9GY@OZMZ`U.)?\%:>_P``^:_NCFU`?__3^TW1+]R#
M3;^%37G[HHA0%.W]RED/"&DFU>7L47"3D7'&",DR^)N`DI"T+$Z,L97K`R<2
M160J1*0Q4@L;E<"@HU,*R7@<`1?2#<"-.F$C<()LGMOKZSYIG6<,40#&FG^1
MH(\Y1R,KR3(6_(F:HAE"TT94V1)$M<79<DR&BQ\R2I.U`/NW-1KV<)N3I4*I
M.G+`T_J]I\_PO7+$.:8WM)DERR)N#HUE+,&R2EYFB>3L&O\`,4&T>L^.5N6,
M9Q=X+51K#!6(V/-\KB1+8UI$#<8-A2'K4Y[BVJ5)@&[/1QYDK#FG>[7H$UGF
M1\3Z_9FQDVXLD^29N\Y-E<?'DG!,$R//,5K<B25:Z2F2IX1)WNZU,%W6+7-`
MF?"THSQ$%)@%@6/OCA/?G,$RPC(M?V;4E_C.N^R..]@8=&<KS[+V/9-,#HW`
M)Y"GR/R"4Q;&^26:/EB/R`H4)C2&M;<928`!A`,=Q!`O%NRIS82T",#UIGI2
M>[@)"%Q/9MZ<J@:#E5KBZ9C<!QTI"O`E&'A<(3K=.U^-K\?CH#V]:W-.[%VG
MG?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X
M*J`=:W-.[%VGG?KR3X*J`L"02?FVO&0,;2]OUJU688["T\])E4"1[RY#,:LB
MFREG:T$74.:H6EH1MXH,XHCE9=O)G^=><W!;R-P],0%_]:W-.[%VGG?KR3X*
MJ`=:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-
M.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-.[%VGG
M?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*
MJ`=:W-.[%VGG?KR3X*J`I#_..9G*&5TCTCT5TFD+&\(CT+DR/N[<^=F9R3G@
MN&Z9S;%VDIR1>C$/A<91@>B.UN'&WQVR4JU:WJ0KT*DH5HO%2BW%I]C6U/M*
MQE*+4HR:DNE;#YJIUIMMWB_:""8FMCLN/9FF+T"88D%AER<^K9C"6X^FW!3C
M*5*TS+>*Q/&JM4.ZP*DI`-$4&QAA0@*"[G?466ZHR',].5<TN+E*RA34;B-7
M"=12<>'AJ)+\K*IAA&27G]&#32[>C>VM:SE7G/\`)*.$U+:\>I_&;Z'T^(VP
MF87_`-0`2<:65FS"ZLHHTPLE5?+<>(LJ*`,02E%TPM.A"3W.+M85P7$*X+WX
M=(7#C?Q.KJ;2O>U%1T#0=#B?"Y7%=2:Z&TFTF^E)M+K.;=[88OARJ/#VSEB<
MPXB_U`P?BR_@T7Y^7(^+_=IX&K/K)I?IT%0^DURGKEC^ZX_/D=X<5?Z@@/Q9
M8P"+\_*S$+_;PU`M3ZQZ5?\`]#I?2JP]<L?W7'Y\CO#C+_4%!^+*.NPOS\H,
MHO\`=J*&J?6'2;WZ$A]*JE/6[#]UKY\CO#CK_4&A^+)6M8OS\E-`O]O#4JU5
M^L&D>G0R^E52OK67_NS_`&Y'>&!_Z@\/_P"8>KXN'_+R(U"_V\-3K53V]H[_
M`,'?TJI\`]:R[]V?\QG>&%_ZA$/Q3W507Y\^;1?[M4@U3V[HQ[]$3^EU/@*>
MM9=^[7^L9WAB?^H3#\4VU)%^?.4`O_TKVI[;T4]^BJOTN?P%?6<M_=LOUC.Z
MT:_U"H?_`!?I\+\^:)+_`.WHZNAXT]LZ(Z=%U_I<O@*>LY9^[I?K'\!SM'O]
M0K;_`,4Z;"_.FA?_`$-9`U7VSH?_`,,N?I;_`)I7UC+/W=/]8_@.=F'_`%"M
MO_$>EXOSIH;_`-'6L-/;&A?_``Z[^E_[I3UC*_W?4_6?P'.S+_J%;?\`X[I0
M+\Z9K/\`HZYAJOM?0?3H^\^EK^:5]8RK]WU/UG\!Z$S-_J$1J"`'OND!!`SB
M@'J!2YW4>0)$98)IWFY.OY`U%RB[W%8NPP7'>W#I!X\;5CFV@&XJ6D;]1QVM
M7<7@NO#@VX=72._RGIL*OZQ?`:@TBC?^_,%-*)42\.\`I&)`K,.)27:+1OS>
MP?+J4MKWBG4,%@X*"PAOZ-\VZ-P7\\X5[7*.COJ>L53^JG!BM^/%C\_UCBV?
M&QW^:=(UEWL]>CZCA[OO\>/C\1M[4,W^H2"><`E]T@.)`<:`D\$O=R;'E!&(
M)1WD#M?3AD^5+M870N(5P7OPZ5^'&_BCS?0&+X=(7S6.S&[CN^9T^X<WW^5=
M%A5_6+X#HNR_ZA6__P".Z4!_-F:S_I:YBJGMC0?1HZ\^EK^:/6,J_=]3]9_`
M<+L/^H5O_P"(]+P_FS0S_I:UBJGMC0O_`(;=_2_]T>L97^[JGZS^`X7CW^H5
MO_XITV#^;-"_^GK(*GMG0W_AES]+?\T>L99^[I_K/X#A>-?ZA47_`(OT^#^9
M-$EO]G2U=%PJGMG1'_A=?Z7+X"GK.6?NZ7ZQ_`=`HG_J$Q?'-M20_F3E`'_]
M*]ZK[;T4MVBJOTN?P#UG+?W;+]8SI%"O]0B+CQGNJ@?S)\VA_P!G'5(54]N:
M-6[1$_I=3X!ZUEW[M?ZQGG%`O]0>+_\`,36`/YF1&H/XOBXZG7JOM[1RW:'?
MTJH/6LN_=G_,9T"QU_J#1?'DK6L/YF2F@/\`LXZE7I[?TCT:&7TJJ5]:R_\`
M=G_,D=(L9?Z@H7QY1UV#^9E!E#_OU%O3ZPZ3Z-"0^E52GK=A^ZU\^1T"Q3_J
M"!?'EG`0?S,K,0?]^H%ZK]8]*K_Z'2^E5AZY8_NN/SY'0+$/^H&'\>7\'!_,
MRY'P_P"_3P5/K)I=;M!4/I-<KZY8_NN/SY'6#"O^H`/-+*/S;AE&2<,)1ZHO
M+<>/$E),OT#5!:<.GA(SS"2[W$$%C"[B%:UNF'\JV2CJ72G?4E7T%05OQ+B<
M;BLY)8[6DVDVM^#:3W8E8WEAQ+CRN/!CMPG+$UEZ_:[;_CVPR'',-ER>"[+X
M_O(5V2IY+G\UG9B+R$TU38Z8352Q39!)6_(R@(5#=<#>\V5AM94638!`C"O8
M=09YI6EI>C=75*E=954BNXHK9QRBMD8I8.EP;IO9P^CM;2?0W=S8QL8SFHSH
M->9%=+70OBX=+Z-QLLM@?GS#M_;Y@QX/CPX^1V.:DW\_#R6EOP5XU]:<A6[0
M-CC_`&U?X3G/7K7]U4OG3.5M?N>>/]?E6(C_`/<[8$I?_EZ4WX4^M>2K=H/+
M_P!96?W2OK]MT952\LCE;77G;B_7Y)91_C\CNDJ2_P"SR>DM^%4^MN5+=H7+
M?G57]T>OT.C*Z/ED<O=LYSX_U\^*'^/R.^KRE_V>3TAOPI];LN7HZ(RS_F/^
M44]H4>C+*'N_"<K:R<X<7Z^9.!G_`+GF,2E+_P#+T=OPI]<+/HT5E7S)O^4/
M:%/HRVAY'\)RMJWS;Q_KY-)1_C\CS.IPE_\`EZ,WX53ZY6_1HS*/U4G_`"A[
M1AT9=;_-?PG[[J/-6'_VAVFA_'XP_P#FL9'*!?\`]DK1>W"GUT@O1T?DR_X#
M_G#VDOW?;_-_A.%]1.9P9_VE+*5/'X_*<V;+0./_`,+1\/QT^NT_O=*Y.O\`
M@?[P]IO]AM_F?PG&^G',9,_[3$GQ5^/RG-SS8#C_`#^2TH#\=5^O%PMVG,I7
M^77PCVG/HL[?YAQOI7OR9_VG%ZY5QX]+RG-_V`!Q_P#@Z9`X4^O=^MV1Y4O\
MM'X1[4J]%M0^8CA?1W=HS_M.#+JN/Q^4YQFR0./\O]EIV#AQ_DJOU^S1>CE.
M5K_*P'M6O^@H?,1QOHAMV9_VG6I$JX_'Y3G,;2@X_P#PM10<*?Z@9TO1L,L7
M^4I_`5]K7/12H_JXEH3OEQ[=R^(O<;C^N\7A;\\I@(DDN=^;9LWDAK:BS3B[
M+/2L`D&J25DE3<I2=,LY*<:5TPBOP':];=CS(S>WO+>M=9=85+6,DY1A;TZ<
MVNN$TL8R6^+W8K:9*6<W$*D)5*-*4$]J4$GXGT/J(H88Y6>[9<Z='<_#S+=J
MQM,%42>V1[V'EFN)N1VVS?8XY7CG)V.\<Y+DGJ8I\JFN8I"A1>7XW*!>QI)P
M"N^U3S&RRWRVA'(W3NKZXBI+O(J4**ZZD))J55/%*&U+TF\&L96^SBC"C#U;
M"=2:QVK%1\*?WW9XR;GN`;)!X^2T\82?A^#H\ZG;X7"WXOZ>J-^->;?ZAZBZ
M:&7/_)T?@(;VO>?$H_JXBV@VT0?U>IS05^;SHMM!</\`GZF7JO\`J%G_`$VN
M6_1*7P#VM=?HZ/ZN)^^X;MD']7K`W%?F\YS:H7];4>]4_P!0,\Z;'+7_`)2E
M\`]K7/32H_JXG+W$]P@_JM<4I7YO.6VA%_6U#O3Z_P"<].799]%ICVM<_H:'
MS$?MM&MT0_J\!@*_-YQ^RXOZ^GUZ?7[-NG*\K^BTQ[5K_H*'S$?MM(-X0_J\
M*&%?F\XG8X7]?3F]4^ON9O?D^5_18#VK7_9Z'S$?ON3[XA_58E5%?F\X/847
M]?345/KWF#WY)E3_`,M'X2GM2MTVU#YB.7N6\P`/ZO&[B5^+H\WW/8N'_/TP
MO3Z]7O3D.4_1H_"/:E3]EH?,1^VTTYB`?U<(>"OQ='F[9R%P_FZ>E=Z?7FZZ
M=/93]'7PCVI4_9+?YA^^YUS(`_JXT_E?BZ/-PS2+A_S])A53Z[U^G364?1U\
M)7VG+]CM_F?PG[[H',O#^J:Y*5P^+H\VK+XN'_/TBO5?KO5Z=+Y1]'_WBGM.
M738V_P`S^$_?='YGX?U8)85^;S9,K"X?B_+T=O5/KJ^G2F3_`*A_SA[2?[!;
M_,_A+`R?HSS4,@PUUB`WER3,3LG4ER=JDG,3R#EMMD[&4E..,C%H8Z:L8R;%
MREV5%E%@$K>4R2U[\#KV!>][3&0ZZR^AFEK4S+3&7TK=/\[0I85*3Z)K%O%+
MI2PEAMCM6#V+7-*4:].5:RHQA\:,<''M_P#6TPMRY-;>8EC.8';`X4Q>P(6!
M$ZO6/9OBW->3WO!1&2BV<E8A.",E%B7+BLY'#)';HD+A-Z40CRS`(U!I`CN/
M2\R]1Y)7R^EE%&%.[OY\-2-2+Q5"+P?$I+?*I'9P;DGC/!\)NYU>6TJ4;>*5
M2J]J:?HI]./6UT>-[3=GUK<T[L7:>=^O)/@JKPTY@=:W-.[%VGG?KR3X*J`=
M:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*J`=:W-.[%VGG?KR3X*J`_;97YIE
MK\1Z5Z?&@M^46#>[(Y8AA_"`)@M)S0@N+XN-PBM;\5`6(X8@R+@/DW92P]EM
M];))DJ!Z,YX9YD[,J]8ZLYCT/%DZ7*$;6ZKVUF6N;>TA6!2$J3$B41Y9%AW)
M+Z70L!__U/M-T2_<@TV_A4UY^Z*(4!*)8C1N*-6WN"1,O0+TQZ-<A6$%*D:Q
M&J*$0I2*TQX1DJ$R@D8@&%C#<(PWO:]KVO0&!H1J?K)C6+,L(@&`L1P^(QS(
M2'++!'&"!QQM:&?)K4&Q;1/6U$G0`)1RMF3@`2B6@M8]&G++))$`HL``@>R-
MZO:X0]SRT\Q?!.)F)SSS9P!FE6VP*-)S,I$NX%P'A+.@@;O)R1"\"=59BPA3
M8PE4<K/--",P\T0P+LQ-AS%.!X2WXXPOCR(8O@C6>L5H8I"6)!'V4E8XG74N
M"X2-O))`>O7'BZ9QYG3.-%\(A7X6H#)5`*`4`H!0"@(IM&\.IS]GIVUC9\WQ
M%PS8R+Y`RN41(L[W1%2>)1M-,9;"2)F)L#!%V08E$5@'1UCQ#F:]MK=Q4J4I
M1(!C"!1HSS`=.)CC_*&4HYGJ).,#PV.-=83]YK(486I/.%%D6/W-K;E[*E=I
M<QY)7W\VC#@S$."*2JK7);#59MK@L!1Y%S(-((E$L5SB1[#PYJC.:+RV^/UJ
MA%)[J5B;'SL6P9$<I(SE,)CUC]EQO(#@-\C72%.UHX^O&%,X&IC[V+N!-DHT
MH\HH\@TLX@XL!I)Q0PF%&E&!L,LTHP%[@,+,!>UPBM>]KVOQM0'90"@%`*`4
M`H!0"@%`*`AQ"^8-I?D*69+A41V'@+H]XAC\]ED[.-/<VJ.((MBET,8\IR1D
MF;PVM\.FC#C)\*$BD2QD7N*=C66\BM&0;>P:`JS!NYJ1*<*Y"V619JAB3#F&
M?3163I[*BG6%AQP8V-C8\KTDK:9FU,4GCJI>SNJ!6C(/1EFNB9:D-2!/`I3B
M,KBTFL=C![LA;JZL8H=<8,N1,T12*N.8FIBD$"*<0.]R5D;D[LS1^.2F0K4S
M8H0P2*/TCD2%L2.C\8V-ZAS5%I`'"4BL55`2CH!0"@%`*`4`H!0"@%`*`A1"
M.8WH]D8O*:F'[)8[<V_#,6>IW/GE0I=&:/I8'&WU?%7^>1F1/K8VL>0H,SRE
ML.:U+S'E#JVE.5@I1'V4&%EC`J)6X>EG5%,=S%N6<:Q_&6/RG.`9`R_+D2B%
M/$).8GT@"W'$P2RUH99U''HJ1.:>Y,?6I"5JA2M3B)3#$I)N9E[ZMW/J_>R]
M7XN+AQ?#Q88<6&['#9COPV%W%+AX.)\&..'1CUF:UV>,.-N6H5@=;D:+D9ER
M)"Y#D>&XS](!,F#S`HJH;4;[,`LI03%2&.HEKN0196IL22<H$(HH0S"S`@Q%
MIEN@%`*`4`H!0"@%`*`4!1I'(X_#X\_2Z6/;5&HM%F5TD<ED;ZO2M3''X^R(
M3W-Y>WET7&D(FUJ:FY*8>H4'#`4226(8Q6#:]Z`AG&^91I!+L:RG+4?SZP+X
M9#9#$(H^V%')VBF%I!D1&6Y8Z;&?&KA%4N2).;D5K,NKCPFQI6%OB0LT]"(\
MHHT8`,H*-N-6F^)X-R.;FS&Q,5VEED*@.`Y"6])1AS%,IP`V\0C$/+("->].
MZHLLWID>3Z2$)1OG%B;%F=&N+:2;V(%*:=W]47W8!=JXSYMB;CG-N=G6-JH8
ME+>3$WK@PQU++W^`)IAZ+M!EV26")K"W-?&R',Q]1-XO.#TA9-A#M0$JJ`4`
MH!0"@%`*`4`H!0%@Y2RGCK"6/);EC+4R8<?XX@C.H?I;,),N+;V9E;$]P%^6
M4'F<1&GJ5!I9"9.4$Q0J4FEDD@,-,``0$9!\QG2TK$`<Z&YT9BL<WGSOBLU2
M;&)X5+D628^SJ)+((,YXP'%0Y/:9/'XJE,>%Z-2SE'(F8-W`X($?]O0&9U&S
M.OR:48(A0\OP(Z6;/-KL]Z^1]%($;BYY=8&&%*,BO$BA"9`-2-XC;="4UW$U
MQ!P1!(&5_:],XH(P+9Q3N/K)G')LXPYBC,$:FF1\=CD`)-'&TIX)_HQ&1`A\
MP4QMW<&Q&Q3A##)@8%H>5#(J<2&EU&%(K&2H%8NX$F*`4`H!0"@%`*`4`H!0
M&',Y;`8<UKA`,B9NG39`XJID+%$&I2L3.CJ[2282=7YC'(?#XM'D#O*IG+GQ
M385DC6U(EB\\)9@P%7`6,00,)//,1TH8(7B?(CKL1!$\)S:D6.6.I&4)Y6-[
MBT-<A;X@^OS^)"TJ38''(Q,'5,T/#B_A;$+.['!1+32%-_)4!GI7G+$*+,[+
MKLHR'%PYRD$`?<J->+2W$L^8FXXC3TR1QXFBAI(L:<W1XA]D21(6H4^1`I/,
M$`GRERC>@`AV<L1Y!R3ES$$)GT>DV2\"J(4CS'#VE2-2ZX\6Y%8#95"D,DL$
MJR9(OD$<)NM)(L8(T*<0!C""Q@.D!E:@%`*`4`H"*F]O[D&Y/\*FPWW12^@/
M_]7[3=$OW(--OX5->?NBB%`2KH!0"@%`*`4`H!0"@%`?/3F+&V>-LMD<TXGE
MNK6;,%8?BX-G(AJL]QV'8J3X*F&=,K80G>-''>K8F>QW(AT]/$ZHY\[M4484
ML94+4%U9SRZW4+U"$MH`Q2/7+::>N&$=B`ZQ92@)&E^+>7AC>0X'=E&/R9]F
MN0:M9GE,SS1?#Z9JGZF+26+P6./X%,35.2YL*DR\`RTH2_Z!@@+#RWI?M:YL
M&8LI8]Q5L#CS(>[BC?J'*8S`&S`,H4LF'=F7F-GXLQAL2TY)D9J+##X^N[8H
MEJZ8QI2\AC05JUM<T:U8-%8@#Z3L!8\7XAP5A7$[JX)W=TQAB7'&/')U2#4&
M)7-?"H<S1I8X)C%A9*LQ.M4-@C`"-`$RX16N*UA<;4!EJ@%`*`4`H!0"@%`*
M`7__`&X?_P`/AH#Y@,EX1V9W2;=GF22Z=9GP')6K#&9,7Z4XA71C"D2UI@L'
M.R;#9M,SY3/HMDIV7ON>]O@X];RO+>AT<=BK2H$W^4N<<[.2X"4$FUCG.U&.
MN:WF2::QN[5[SV)HJTZT8(SI'H`9E$.3\*ZTSR#,>0G:/7D<JA40DKMD&;>C
MX^H.=+*2"V@I<(:<LU.90&-]BM:=E`,.9,<QK7F590==V^7=JYJJPS9(Z0WU
M?UZRKB4W)K9,B\MKW-Z`X1V%L[;E8N3H7%M*=0+G1E5)"R[*S$7G('T.H4YJ
M5$C2G*3%AR9*G3FK#K<#E9I)0"S%)MN(N!AX@W$+X;_#>@/50"@%`*`4`H!0
M"@%`>=698I(J-$G-5A+3G&"2$E@-.56`6(5TY11@@%F&G6MT0A$*P;WOPO>U
MJ`^819A[9G:Z+Y_G4]TCS3B+-,?QUCUCUDUZD#%AB%:YXSUWPSMGAK-S]KO$
M9E$\FR)+.<[[)-^)&MP=7%R:6F,H/,$30B,1$(U2QR`D?E75C)FSNK?-4R$]
MZW.B.4[1N*J=ZI8%RJT0$S)<:FD!U3BV!([DP]`K=W"-XWR=.WMH7W17$XEN
M#>VW3C4*"33C"B@)H3+6M8GY@.GFP\,Q*SI"T&(=EXWL)E5I;XP@?5+HZ1+`
MK#B-FFKK90GD\F)+(BSH0V%@"L3(+$'7OY'RMKF`;)*`4`H!0"@%`*`4`H!0
M&*LZ.)K3A?*SF1B-9GU0@Q]+52?!Z`J-'+,N*"6-:-/CD@N9*$L2N*8G6"@O
M=R,"B"$^]SN)=A6N!\_>-\>[(.DNQYO/E?5+8]\V/Q[LM`\D;`X[/A.,8TAZ
MEE>O&P6$<?XDT_CC?EQ_+FL4U2>LN&.BX][.:GZ4+71S=2`VN<D:4@&;6K2+
M*(=;]'G5]P4QG9YA',8:]C'E'8B"N4RU[P?EO<2=9_FL.23,]>(*=+$XE*4)
M,B2L:T\I<M2#`0%6664*X%YM27+&6>8@UI\JZ@9XQAKG@7-TUD^OOJ/#,0%X
M@R?FAQAKRQ/.[&P$Z;,G)9@?YZUR1W9XC'26`Y4G/5#>'@9ZH]`2T@;N:`4`
MH!0"@%`*`4`H!0$9=QI1-(7K;D^4XWUT'MCD1D;6AP@6!+7BX$\UFB:1LQL7
M4N"B8*DC(A:X>]A(?%*CI"6$$-HC$0#%@2"Q`:7L1XQSIC"6X-W/=M<=K<P9
M.;,O;1K-NF"2P?%4%RQDG)&P.'\/Q*!Y:P[C!'F.10YJP-C%JP^V8^:F]7(1
M/K.QJ;JE?G=P.2X\#/&#=%LCXB0\FM8_8MBSAE;6Y#+(AL%D2.D1)4ZX\@2_
M6C/2-@QS>9&F(Y!((!&,G9`3-2-(WB4I!*C+*[$A+N,X('NP7!,]3+F11+.+
MIJYD[`D?QUA7/V$LK-N2I1C:6Z\QUL>,B1-^QD^Z0*X8:AD5Y1G51'"Y!/5B
MMI;T]T)"9"O"%S2$`N!NUH!0"@%`*`4`H!0"@%`03YA$YSC`<*,3OKAKJLV#
MS(JR3&FF(K$T7B$U!@'TJA>V][V+%$);+X)>7+,<L"I4!&SMKLWN#NK7EI/.
M4R0Y4H*`TZN.KN8H-CR5DXAU?V6GY.VG+LS/IT:?F&^+6[,T/V;R%FW,\_F>
M8-FB$$[.AT5@F:7S-ZV3'N$>6."-N)9PH`HDG2;4EP-BSOJ9DB&[78%R9B2*
MPQNG+7H;L1B'(>R"R+,:A([9P`CU<CN#W'*:1*Y,T\GS641`7,],E\L,!"%$
M<18]*(TNXP,4\KW4C;+5O9'<0W.K3B55!\AP?69:GRU`[2PQ^SUFID9I^9EO
M)\G52R2/#TJDKR]/XSWHU<03?RZE(G07LA2`*+`W;4`H!0"@%`14WM_<@W)_
MA4V&^Z*7T!__UOM-T2_<@TV_A4UY^Z*(4!*N@%`*`4`H!0"@%`*`4!T&J4Q%
M[!.4$$BO;I6"::67>]N/#C:PQ6O>W&@.OS]#\M2?M)/Z=`//T/RU)^TD_IT`
M\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M
M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_
MIT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]
M#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^
MTD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0
M#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/R
MU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23
M^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//
MT/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G
M[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=
M`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_
M+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)
M/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\
M_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2
M?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_I
MT`\_0_+4G[23^G0#S]#\M2?M)/Z=`//T/RU)^TD_IT`\_0_+4G[23^G0#S]#
M>]K66I.-[VM:WG!/&][WX6M;^G\-[WH#UT`H!0"@(J;V_N0;D_PJ;#?=%+Z`
M_]?[3=$OW(--OX5->?NBB%`2KH!0"@%`*`4`H!0"@%`:O8C@3!V:]W]Y5V8L
M.XPRHMCR+5MJ8%F1()&)FK8VLW&,@<36UH4R%L<#VUO.<%QQXR21`+&<8(8@
MW%?C0&>)3I]H'!XV]S"9:SZJ16*1IL5O,ADD@Q'BYI9&1I0$B/6N3HY+F$E(
MB1)207$,PP80AM;X;UFM[>O=UZ5M:T95+BI)1C&*;E)O<DEM;?4BZ$)3E&$(
MMS;P26ULBH*3<CP!0S[F<N<199(S[^39\%&C$667<R_DBBT`S3C!!#_1``(A
MCOPL&U[WM:N@^IFK<4OJY>XX_HI_`;?LV_\`V.I\UF"\(;$<ES+XIYZ=PMJ+
MA@$4E!S7'!99QWAJ*"R%%!EANU3>.%N+0E%9&X'EG!&C'Q5I`@+$=8/E;6M+
M9KRYU-EOJG<V%2Z=2GC+N82GW<^F$L$]JV82W/;AN,]?)[VCW?#2<\5MX4W@
M^I_"209T'**FUGMMQ#BC2[.DY:8R]RE#BS#\)P)+,DRI$P)K*5R2*QXST:4Y
M.'1$$(0C4$E!N*UQF`#Q%;G;[3F?Y;;N[S#)KFC:II.<Z<HQ3>Y-M8;>@U*M
MG=T8=Y5MYQAUM-(P3CW+G*FES>R2">Z/0;6^%R/(\[Q,R9!V3UZU_P`805=/
ML8M^1%F0&$4C'(7A(@'%U>+7=":<J\@0H7%!+3#/L*XPPIK$SA8,Y709,*%B
MQ5HT&8`A]\A#BPHE@ZT@!`@HK.8IL)GNBLO#$PMM_.;N-R_-+)_[3RG0_I4!
M1(YC#E,3!TCC)$H1H#*'B8,:Z31-LCK+@%[72>.-I#FJ<'Z/I6TE2<\,Z)*R
M+335*>QA("D9X[BL$DRX0/*5C_E%GPI;DDB)\O@_';;(4\1<)V2UZ^FPY%*E
MA`%22.*I,66)F(?%24P)I:41UCQE7Z=@W#\-`5?)N&.5_A_'L]RED'".GK%"
ML9M#Z\3)T'C#$ZDQK+CD%-R:Y-H429F-6*G_`-02?2Q+>4`2Q0@&`XLL18PB
MN!;;#`>56]I&5>IPMIM%T<OER2%8\/E\$P2P]9KRX1N+2IN!C\E0`2F0B7M4
MQ0^33A`!=8PSHC3AZ1=Q@8YRXZ<H/#@<>&/6$]598GR'LM`=3K*\;XAQ%.DD
M#R]DA-)%$<292/9D!@(`P!O%E):I<OZ`$QEP6$'A>]P@6%,<@<K2.3S)V+8O
MHQ%,O9(Q3GR!:VOT,Q7JYB9Y='3)^0,,O^>4:2-J9`;&&9S9H]C^+N`W=8-4
M26B6I#$O`9H;VH"3NOV%>71LICVV1,>:DX+1I4<CDT(ED4F.NT#BL]Q[D"%.
MQ[',8!/HJOCMUL=ED;=4XBU"<=QEF%B+/(,-3G$G&`6I$8MRG9:X@8A8;T[B
M,G699R+A6/Q"?8XPM#Y;,)WC#(#YC*1(H9''=&2ZRA(IET=4IT)J0LRZNX0V
M"&P[]"P&7(KK3RVIU()C$X3@W3*82C'CD%FGT;B\`PT_OL(=Q#/*"U2UI:FQ
M6OCCC<U*:'R"PLDWI%#MT>(16L!?ON*:4]D?6S[$\<_1V@,#96QQRF<%/3;&
M\S8[T7Q=('EK$]M3).H5AF,NC@SA5&H;NB1"ZM:92<@\](&58T(;@N8`0;7X
MAO:T;>YQE675(4K_`#&C1JR6*4YJ+:QPQ2;W8G8:=Y?:YU=:U[[2VD<QS"RI
M5.[G4MZ%2K",\%+@<H1:4N%IX8XX-/I1KBVDVRY6^#7J)-N'=,-1=JVZ0,+X
MZO3YBU'@^R.(.+8M1)6]@>0HX1).@X/I*DT\BPQ$B\F1>]@"#>PJY;.->9?E
M]2C&QA"\C*+;=.K'"+36">"EM>];MQ[CR^^RWJW5MKF5?4]S<:=K4:U.$*=W
M95>*M&<9.52'%.EC&FTHRP4EC)+%/82GA<_Y*,DAL2D4@C_+TA+\_P`987I[
MA;RVX($\1!W=6I*N<HN[7$UI!^DV!8>-(?TBBK^5*%Q`'XK3%#5>05:%&K5S
M:VIU)03<74CC%M8N+VK:GL>Q;CSW->1/-:QS3,K*ST'G%W9T:]2%.O"SK<%:
M$)N,:L/-?F5(I3CM>QK:]Y5_3_)_/S%CG";/@W62327,&$,C9\Q4_1;!V,Y!
M`\AQ#%#PH9YRRQ*8MK,>U/$Z9O1ZQ4)H+O=0)$@5&V^!.;8,Y;7-O>4*=S:5
MHU+>?HRBTXO!X/!K8\'L\)YEG&39MI[,[O)<]RVM9YO0:52C6A*G4AQ14H\4
M))27%%J2Q6U--;&>UE.Y4[]D+5K&*'5K"89/M[A\6;L4^<:VP,IH11!1&D$L
MCR*=/-F(:"(2F:LYJ\3(WG#&:YF,3H`F][HQ\<Y&F(P9=Y6)D)RUE(K0`D_$
MV+H3E6>M654NG./5D#RZTX7GA6,I\V8O>$A1YMY8CG!UD2%HD1,=<7>P3%"`
ME2E)..+`OI`_\L(J";"2^>:,1/$$AUDAZ">Y,Q%D[5+'#5EE3$Y"B=38,\0)
M@8TLB9LCD9%>&)8RLEF5R6"5OZ8;<.Q2JUB[@>MY<.66",88>\>Z,0O.,ASM
MB\W-,.QCAS5_%<DR0V8N1)&DUYETV97>T=;(:F9'5\3M!J5:N+<%+Y<;<D(4
MJR3BBP*C,3.6!'L%X7V`BFFF,<PQ38*<1''&*(_BO6?&CG.)#-)@%]\@PKF&
M4(HD1%E\?.B[B0\ENRE"-I5(CB%%@'`N70%`QG,^4/D9^BT2<=<=>L1S"5#R
M$TD1/-^$,.XT?6V=XNR:PXCF>+5R=X`).MR(WS&3MX"4+<:O*6)EA)R<XP!@
M.D!(57BGE/M]\C>?P+09!;#]P6RR):PX$2`QE<QR,90>OYBA.6"'\7DH:/\`
M^H73_P#6P")_66N&P%)#!^4$-ULQ`C?+Q&]"6,3>%H`BUX$Y"7R=2)%&T04(
M0W4W5ORP%R49?1Z:DW^B780O@H"M'8BY4J=3D-$HQWH:0KQ&G-5943'1O!!1
M^-TR=8)N4*)T4-*$<4)3N(+IC!+K$6`HM<H7`=NC0'K083Y63J[P]@;,8:*N
M+[D.-*9G`69#%L%JW6;1!&2O4JY1$V\A(8KD,>3)VI48-8D`<G"!*<*X^!1E
MP@6?D:#\J3%RS&[7*,,Z?7>LP.)+3C%E:L8X@<7":+UT!F>2F0+1Y)L"C"BD
ML5@3D:VK3S24*PPL(`'7N.U`5I#BKE7*+&)G'$ND4;?T&.&W+4BB,DB6!6N5
MP_'KDUHW@$KEK,(LTUC8$R%>4(Y>8+S$-AV%8X0!!$(#QPK&'+$R1DM!C#'N
MNFL$X<G7$X\SM,HB6&<6R+'SK#"9XY8V5^C9HT-"MG6O2"6M*A,H1EC$81<H
M73X"M<-@+=Q1'^4SE]@Q([L.&M/V!XSDPE23&6/9SC7#$3R?*&@]6](TREN@
M+DCM(%EE9L=6W*\@4;8P*8RX;W\F/H@>$A+R>U$KR3%R\>Z.638ACT4?LD38
M40P/U=PY1,I?-8,S120S,)8FAEF_K#`5Y9K4K&0J`'R=[!%<?`(&;4FM_+5<
M'%(SH,(Z8+G=>XLK0@:T<!PTJ<5KI)(PIFT=;T:$AL,4J5C]#$1SNC+`$0E3
M628J+L(@`C+`9!]Q32GLCZV?8GCGZ.T!C6;:\\M#&J]$U9`P?IQ#')Q1C<$"
M"2XUQ*SK%:$!UTPEB=.M92334UE`;@Z=K='I6O;CQM>N:SO66D]-UZ-KJ#4=
ME97-2''&%:M"G*44\.)*33:QV8[L=A@JW-O0:C6KPC)K':TC#DY9.51$6$MX
M:,$ZASU48],C3Z$AF-,1O#F20Z.!"=:[*2DK*==.VLK>(U4<,5K6N$KH6OTA
MAKC\\YSZ`RBQC>6FH+6_JNM3I]W;U:=2:4YI2J-1;PA3CQ3DWT1X5M:-:KF=
MG3AQ1K1F\4L(M-[>GP);2\18\Y2H!7"+'VBP1!OP%:\+PSQM>WQVO_\`2_@O
M:_Q_BJ8?-/ENFT]=95C_`.YI?SC+[0L?VNG\Y&`\T2CEB8@D#0PM6B,1SH4O
MPY,<_.<BP#K)AR?1>+8G@4E3Q.32A]>%2Q@`>-$\FF`"A;0N#B;9*=T"+W!P
MOUV69IEV=6%OFN47U*YRVKCP5:4E.$N&3C+AE%M/ADG%X/8TT]IL4ZD*L(U*
M<U*#W-;42&A.+N5)D4+7:&8QT@>UKOC./YE2LA,$PXGDI.*Y2PMTH89ZYQ=8
MTII"S1EPC[NE5A5+$Q!82#P"%<-A6K?+SO9\4<I^0IX*K88#H.\ILH/;G&<:
MGM;#@1>7D*1LHB`/#!"!)DYMI4]-0U15E*5#Y<\BYH.F$/2#Q`PS/B.7#!LB
MR:`HM`&?):''4BA\2R_D?$NG\(GF/<0R:<`9U30QR]8V-@)0\NC>T2-M<7<B
M-M3\:PMK@0I<@I21W%8#+;OCCE(1]0XI7V'\OMF5-$Z(Q>[IG1JU]0GM62E2
M>ZM/CYR)4EE&()L<DM<T+4;8"ZY7]+R71^&@+R>=<N6A'6YP>)!A?2AB:6DN
M5G.KH\PC"C8W-A4#<DK-.37!:M;R$R(N&/"XA([",$&S<I.`4H\F,80W`K<+
MU-Y>F2(TW3/'FNVHT[B#Q93=IE,.QAB62QUSLC5GH%GF#RS,RQN5^:KDIA)G
MDS!>3-+$`7`0;VL!6G72G19C;')[>M5]8&EG9T"QT=G1QPWC-&WMK:WIS%:Y
MP7*U$?+(2HT:4D9AI@Q!```;BO>UK7K)1HU;BM2MZ%.4Z\Y*,8Q3<I2D\$DE
MM;;>"2VMEE6I3HTZE:M-1I0BW)MX))+%MM[DEM;(G!>N2*,%C`6Y=`B[EW-"
M.S3@BX1`Z'3Z0;V1?TND'XN'PW_!\-=F^6O,%/!Z+S/'']GJ_P`TYCZ\Z-:Q
M6J+##^VI_P`XCOA[8_DUY3EDPC;[KCK;AMN8?+*8Q+\N8GPK%(QD!K(7"0C5
ML"X]*.Z9:/\`LU!:)58I28D-"8&U[A,"7T^><D];9/96-U;V?KU6I@JE.VC4
MJ5*,FL<)I1VK?%SCC%26#WIN`RGFII7,[J[MZUSZI3AMA4KN$(54GAC%N6Q[
MFHO!N+QZTI-MI/)PD1CBBAD,T4GT@01V42<F(P:%X5DLM>&V'1YQE+^%B8&]
MO,6NBM&QM*@^Y9=N/0*$*_`-KWMQ.9Z)UADUE6S+-M,WUME]/#CJ5*,X0CQ-
M1CQ2E%)8R:2Q>UM+>SJK'56FLSNJ5CEV>VE>\GCPPA5A*4L$V\(IMO!)MX="
MQ+9PV[<H_.\+PYD7'^O&O)\'S;@?(^Q,:DSQK[CUF:V&!8@=82Q9/1S@Y8Q!
MO%Y9!GN=I4KBWFV$-,<G4V$*UBK7'RY/E@->2>5=*,*8(S)`]&8Q/5NR,HED
M+Q1A=BU4Q<U9Q=)1`6V4/LY8WV'3;U2:X<Z12/0]<X*4[JY(SS$P2O-P'&GD
MEC`ITKRKROHBJ/-7<NUQ612.8>Q=G;*TZ1:0Q$EDP5CG+*B8DLCGF*/N[>U9
M(BZZ.IX"[*W](0PK5#*A2#4J0@)_IT!GL;!RKR]D;ZN#UOUR!/PX1'GT<B'@
MK&8,8%PTMP"1=I'D,3/9AM-[L5[O]FGI^<^K@!.7_9;7,H"S,.JN65F:=P6$
M-NC4/@Z?,<?D$KU^G.3=4L?1"![!QN,I0NSHYXL=C$"QR--,BX[/B-$](V9R
M<F#I.21.>C+-.`!S//Y9I6;)7AHC1F'N:#'\UMC+(F:F?5+'SKA/'>2[X](R
ME>&SF2H4!TDC'D82N2JCGQ4SEQ5.:L)3&N@%([%6`R?BZ$\I7,B#$*O'V,])
M'M=GG'+?EK$<7O`L-HYM.L>.:$]Q(E+#"U;63)EK84E1GW/&!-?S<28\)G1$
M2;8(%&]!\I`^21A@:<3:9R-OD[%DU_#.HSCS"S_C:/)\2.&/FN7H)?.FU&H8
M(R\%KLFM):5*I-`:IN<+HV_HVZ0'MDT&Y9$/VAQ_J)(=6<!-^6\F8?G6;8M<
M[`&.`1,Z'X[>FAED*99(C&8!:*0<742HA*(K@:B1*C>F&Q-[7`LK7]PY0>QV
M/<6Y&AN%M4HPAS6_3B.XJC&4,0XDQW/YTM@.19#BUV-C4)D+<0^NZ-?*XT>!
M`,@HRZPDTD0+<30AH"[6:-\IJ1Y0<,41W#FG<A>FB-I7]VD#%CC"SQ"&I>OR
M&@Q8WP9RE3<D4MZ+([E-G1.B3L9G17GFG```%S!!!<#MD<;Y1D971=L58STJ
M=%\NSG'=:VU+&<=8AE!R/-TK;Y$YL6/G\#$T+[QQ^7)(HOO8I;Y`5A)Q`X=+
MA:@.S)D"Y9^*9\TXWDFJ&"EDD<I!A:+J0Q_7K'3PCC[UL'D)5C3%*21J"64`
MFN\DD#8M-MT@"N2@0G*!VL6$-Q`8KRH\<L?&,]><2(]&(7E+,#7D1;C9%BS%
MNL.)GB7R=W9<(1?863N47]8A1:/NC/%\9S%`H5<5Y:PY6=YJD3J3_P"A<#)$
M[A?+8@6%\<9K6Z9XT>4&8G"&1_%..V;5*,E9@G4SGS>H=8_!$&.Y#%6%W8Y:
M6V(%BEQ(>+MI+.F0*SEYJ8I,<,`'7#8URM)#%&"2S/6W6[`CC(LA/6)$4$V)
MPIB?#\Z,R>P+2D+A"6UIDS>4@EKD8-208D4,*MU;G%.I*-2*3RS`BN!>"C&G
M*322E7!U4,Y?J::(),WPI;$3VG7XF3))B[.9C*UQ-2PF%!="9(X/)(TA*$15
ME)BH`B@@N9:X:`]0\3<J$L_(28S'^A`%.)./6FGO'\"V/QOP<S&6]IV3YMY2
M)BL]%"1\%]B+^=AN3^LMT:`XE8JY3IRC'R,F!Z"F+,LW26Q:D`Q8#$JR/=>X
M*6E%:"IK$>6E=UCLC-2%60A/\HJ+$2'B8&X:`\T,Q/RP9F=#F@O`VH$=FT[B
M[A-(YC.3P#!2#(RZ+-9[F0X/Q$52`<%BQI2>AE0S%*:YZ<!9!@A#MY,SH@>9
MMQIRMY`Z8[0Q'!6HTY;,GS"28[C4N@V,,.RV&%Y"C$64393!7F1,C>L1M4J<
MHLA5+$2,S^T4%)1\.%Q%6,`J.S&DVG#/K?L(ZM6JFNK<YM^#<MK$"]'AC'B=
M8B5D0"0F)U:105'@FIE2<T-AEF`O898[6$&]KVM>@)8ZX*#U>O&!52HXU2I4
MX8Q<H4*#S!FGGGG0=C,...-,N(9III@KB$(5[W%>_&]`9GH!0"@(J;V_N0;D
M_P`*FPWW12^@/__0^TW1+]R#3;^%37G[HHA0$JZ`4`H!0"@%`*`4`H!0&M)L
MR*/`^X6X3Y-,7Y_=V')B+6]RA$@QMKYF3*T=?$T=Q[(8_(2RY#CJ%R1D2+V-
MV2A*4I%"@I4"QY([%W+'85`9:=]OL3R!K7LC]@W;%[975*<A=&AWT@V6<FMR
M1*`7+4(UZ!9B@Y(L2GEWN$99@!`%:_"]KVJ^G5J4:D*M&I*%6+Q33:::Z4UM
M3[45C)Q:E%M272C$ML@Z8VM:UM(\KVM;X+6MRV<RVM:UOP6__P!'U(^W,[_?
M%U^MJ?SC-ZU<_M%3YS^$\*&8:2MOGOF6CV6"?2+@I=5G'EOYL-\LX++%V4J/
M[;"AGD[FV*#Q"'HAMP^"UJOGJ#/9\'%G-T^&*2_*SW+<O2*N[NGAC<U-WQG\
M)=T8S=JW"7<N00S4G.\2?B2#TI3W&.7GG=@=RDRH(0JDQ;DU892+`$*0AM8P
M%AV".UK<;7K6KYIF=U3=&ZS&O4HMX\,JDY+%;G@VUL+)UZ]2/#.M.4>IMM$/
MF"+XG;DN$F^01O::7MN&]FMK]D1-SQR[-FU2"2*=GB-ATZ:,%HW"$KDS8LQZ
M7GT=KN(P'^D`MQ@0$I[*O[+1,1"**:*XSC%GUH.?MI)"P/4%6($[N\\O7=\R
M81O)*_3L6FYSC&VQ-=+CI+B<B+\'4AI4-:EX)*$8TA7>9B`86!E/*>$$<AG+
M+/8XKV:]4\5MT"D..L2)^7=MFP*_3&)=8,BX`3X^95;)&V>!(VS(@YL-P`_O
M;<ZO#1<5FLLT#5\``(_0+3@YUQS@R4Y`MFJ-YQ@&),-XV'!HQRYMVHA@1#"8
M9K1+,".+#,8MC@35))!EQN19$7BM(&Q\)9[D(P-9*6[8>;T@,_N6NC`J9.JE
MK?=B6C7TJYDA31,[EF;<.V103LW0ITT+"&TI7-Q[`1CQMCIJ&3HT=D0W,*I.
M:W#5"3F%G%@5%CPI:-3\>46YRRNNE\P1O,;RJAD7*EVEE$'*ATA,P*[.1F&X
ME)X\\HH[/"I'@HD92U_],-YR18C\LE$>T$C/`MM!JKC]0V/L-D:O95-B<V;G
MRZ)XIAG+LW,+B<9,ZL=AH.A>&BTU;).]0^1%RK.3?(KM#.N+A;>LB]A-;6B-
M<E`RP*]&,*.^.%D.GT`GVP+WG!@R#@K+4OG&7>6/N4]1[*64,<81S[B'+$WE
M+-"RHR\I'7,3OL`N?TH4ROR3()O)2#"K`.Y@0)?:N9-6ZYN,G;7J-;)Y*:\L
M2O+V=LVSHC0[;*(/#OL)D>714QI;L=PX<-?D\5Q#'<?-9[>2E6J')RN-&D,.
M7FGF*/*`1=4:_8O4/^:).,>TAK[EF1#?6MS5<MO:)0N@Y(M[)%O`!N)77C0%
MJ\HIR>4[)81`TG!8B`Y!L&_1(`!FK6%P5ZRK3D+,BRT_0UM<5[1%PVY6NT+1
MD];C%^R7.,IR-#DC)2&*)U\IR@H?)K<E.O3`21VXRE3@H:SER\0B`-@_OK8]
M^J'<+N7;/^RV@,?2_/>L^05R5TGNJNP,W<T*2Z!$XR_E]9\DJY&AN<-1=$E5
MO.&UJA.DNH,$/R8!6!TQ7%PXWO>M6O965U)3N;2E4FE@G*$9-+JQ:>PFLLU)
MJ+):-2WR?/[VTMYRXI1HUZM*,I88<3C"44WALQ:QPV&$IJU\O3(BA`JF.A&6
MG8]K2J42$8>7CL$VV(2K#2SE!7DVG$2`LRQAI5K\1V$*U_BO;C?CH5].Y%<N
M+KY3;MI8+S$M_@2.KRKF[S0R2%:GEFO<UI0J24I?WBI+%Q32?GN36"?07JW3
M#21J;T#6@T=RL0A;$:5O1$WY;N:CKDI$9`$Z8JYRC"9IYMRR2[6Z0Q"&+AQO
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M8I$86EF9J-.(OS,HX60U2E3C6HC(#AL`Y.+UEB-/68\8Y<@!<[@/*EVO@TSR
M6[9'D;1(XC,MR6B)-+'CG.#SB.S,!.@7,[2PO*]0<8KNL2^4/3J`,OS2!*\Z
M31=D38R:[6+Y-(I-K^3*D&O7+VW/PVQEX<UMD\XRQ`\8PM]7-DDR*R2)\V%D
M[?+'R1GNIHS$C$F:T*5&`9R@P"A07%KMK\X.,AU:R)M%#Y641F:#PISSERX-
MRLUH8KA3,F14&:RHJ^>33QF23K(&*\U.,E=V)Z5N0$Z]FD0VER(-$F3+R0+C
M(Q+BZ2ZH:OZPY=8]IYH5@?8!'G[)$A;=#=PVQLSC(2I7DZ9R$29M*BC>\XZ4
M3:6Y'&[C**6KDS0:6)$3=0GL`RX'9E3`FKLQ3KX]C3$VQ>'H`'6*>ZYQ6$-_
M+GV=>T,3<<B9IA&;9#DQ(MO#$"HYT=9%""A+PVN%>O<!EKC%ES20\0,1%ZR,
M3_D]UR'E"6;,SU(M6H"#&9;RU]M33)#&VS=2"[EHF^0M9T?(Q['1IU<-%&K(
M(XR-[0==1=Y4%'KC%`1@7[,M=,`RYOFI08?L0VO,OCV^305(!<LW9!2X-#EN
M]GS'^<0OUE)4*3+CU>+BX$6U7N`THUS&<!44-'<KR8@,82366\KRHMS"^SG8
MQ]E;(X/#[`4\CY:^Y+FP/3W?:N%;5P]+E^+HVQKB08.QNT1NQN+)#V]C*=C3
M"WXPWTL`RY@%82:R057FPO+DP]XEY12=XQ)-\EQ:,\NG<J!MK7D'#;=D5ICI
MF`XO&FA#C^%Q!>CR(8,VTB;9"[$+"%BJQYIKPKL6!YHWKPX(6^+"E,VS2_OT
M'A.',-Q8YMY6&W[6QIL/8@P1L1KT`3FF5I7!T4Y/E,5V!&ZB5$'IV=O=6@)1
M:8Q*HOT`*D1@8^/Q+(&/H-+,Y,,8F):.1M\I<N51LD^YA;<C#QEB;%TB1>OK
MM"W(,<Q`\LN)2+)4[$G0R=L2+2TI3EP;DQHP,U::0N(ZI93F^5W<S:[(#C/"
M,N#7Q]IT!W&;$C4X9>S2?FAQ$1)YDRS&4R,MD7JC4'G;F::XN8A>=J#`F"$7
M0&-(#KGB6%1:),:J^UCR_15OTK:B9LCY<6T#1)BT&GN4\F9)'9C=O512Z,"O
M("?)JE`D,+/%9C-"8?>RH)PBK`86#IVVV,QX\&R#,7K!@]FUVAN(&Z.\L/=K
M&\3?X?KFR9YB+*X;!*,?B9Y;,\B26*9W/N)Q853*E:79MN:E)NE6GI@@9]PQ
M@[&6$-@=><^QA+L\8JUWP7&=98]#/_+CVJLPN>&F^+.I<H.\Z=8V]/33E9;D
M5Q"J8'LI4(AAAP5$=$G5!7*%EP-LGOK8]^J'<+N7;/\`LMH"UWW9[!$I4$+)
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MV7JE"*BEZO2>"2P2Q<&WLZWB7JUMDDE;PP7X*^`B'F'&6G>?-AHEF7+>NVRD
MQ@4+P)(<),F$EFANUR&-%J)/DAFR$[R95=FA;:Q.C0X%LP4*IF6MJE.IZ=S!
MBZ-QECG;6TM;&WIVEC;4Z-I#'AA"*A".+Q>$8I)8MMO!;6\3-&,814812BNA
M;$10R!IWA_(,UV57*E.W3/`\_'9]?6`+=H7N;?)^*Y1L)AV,87D+6SJRV9'B
ME7C6-Q^*E72(@QXMS6MQUFM4ING3$FUL%3/.K^,\88%S,T9[E4.S]*9TG:<M
M)W1KB/+XW9*8"I!DQ%K^PI91%'K*B+(DQ9W)LB^!PI%XAJ1#7`<P$@N4G0@"
M<!;V=,8I<D/.7VG&S]L_C7$V=<PL^P$K;%_+]WC.S)BC,Z6)L4+DF0M=LH8]
MOC]*SNDK98VD.*2R=$]H&AX\LK++4)C;-Q8%I9#UWA+W'%+/CXG.#&Z2EGWG
M@>17;(/*\VAF25WQ[OAE`C(LW?HTC;HPS*VS.\#1MZ5K1/:L]2U.Z<)H5J+R
M5R2R0,,Y_P!?96=A7*T0QP3L%D9E;89GJ+X%QI)>7)M,;-%*K:/->OV09@Y9
MGG<H9K1"=I<=WQ<N,NC3HFD,D;%IA:DP*L!5C0-JFK638AKK'LI))'%-GIQ,
M<P9PG^=)JZ0?E^[2X_Q\DDDY`RH3FN"Q!;CYY=VIC3MT>3&'&+UJM>X.9JM:
M>9Y13<(0)+*]R\9."14@7X8VZ6H5J<Y(M1*])]FU*16D4EB)4)52<[%8R5"=
M02.X!@':X1AO>U[7M>KH3G2G"I3FXU(M--/!IK:FFMJ:>U-%LX1J1E"<5*$E
M@T]J:>]-=*9A\.1M-0V#8.E&6@V#:U@V#RW,SVL&UOBL&UL(_!:WX*G'JG4[
MWZCO_I%7^>17U?R']R6GZFG_`#2U(\X:(Q5SD;NQ:-9B2.$L7V<GTTWEY9_7
MEJ5=AG&<4R5QQ`K2-1'E#QB\BD+()Z5^/1XUN76N=8WE*UH7&I[Z5.C'AA^6
MFL%LWN+3D]F^3;[35H:3TS;5+BK1R&T52K+&7Y.+Q?8FFHK;NBDNP]LMG.K;
MQ#9O'X?JWG3'DDED&FD+;9O'N7/G=&\1J\SC#I%U+HE.:L/M;@,)"5U'<TDM
M03<\KI%W%:PKU%W6?9Y?4*EK>YU=UK66'%"=:I.+P>*QC*33P:36*V-8DA;Y
M1E-I6A<6N5V]*O''"4*<(R6*P>#44UBMCV[C6B[Z@X[-=7D,5R!N]#H1DG4^
M.ZP9V@K;R]MI0D31V4/.`4.;,X8X>"(J2KQ9.\_8?P,GBKX6$*TL2A0F>+B&
MN2GB61)(E\RK!D4*;\LQ;'ML_P`UQ-E7+;/FMTP3NCRV-N-I8(OG1F.@X]G#
MB_S%_CI&4DJQS-96)]CRYH<T2IB=4"THSSI&X6*2@4Y#B*<QB*SG&\+R[L@3
M!,TZP8GUCS9(9ORS=TISFHUCQT?F1(]/.)9<[F'QQF"]Q',JEF9"Y2ADRA@2
MMR0:@]T&`73`K"[6O!RR3CGP56^R>:!SZER*D;BM/]T@XC38*3XNMK0/70S%
MEXZ-E//5:C#-AQDMO;TQ=X-],V_)\UH"[,:MN28EE?4QVG\^SQDS7_39C=H[
MB?%:7ED[@0O)S@J%BV1XEB63<AY1(9GF/R><QR#2`UI5MB-B:F1Q$<:Z`\V4
M!*2!`[L@PEIR+M0V[`.R?.*=F;)\AF2.2-'+%VBBVV:6&)H]9C<-;%V<8=$&
M"*9`UW?5)RDXY!*6!X7E(5AZ'IFWLE5I`(YH=1(\J:62#RV2[$GX\4-.OU\@
MK(/RSMLHSE]1*=8\,NN!L9J</S]TC;VDQA#7F%*4JQ[;S$B]46Y#=RD"@I&]
M'ED@7$_:U()Q;!LDF,@S:QY,UD1H#,'NN(^5=M3"8`CE4-8L11?&,IR=##61
M0IRT@:X_BLU,Z,KRJ4(DZ=U+`QB;3FU*KN!(3;:&Q+9W)H\ML3MN-AZ;)<4P
MK%<=?6CE\[3/KK&TK5E%QE62E:56*)-I2MGROBJ3/D,5(1E6$F+<K++F&>2\
M@(#`KSK/'3'**-45E&SL?Q;$,FQW(\;A)_+DW$*.A9<+W,<]MHO&XV.,-4?1
M2D'HE2CA]U,HN[$L8&[TFSI$RA6I+$!ZH_JWBV'3+5_)$/7;6LTZU-BSU'<=
M'%<N;:U/#G59.\XOV4\IN<KAB./%-3N"9PJ6.C$C/&"[O'GU0!_;EA*@!A1P
M%`P5JA!<%DXT.9A[".K[AB;Z^*L?O[GR\=Y75<^XNP/*LM/=H[D@+W9R0EY#
MD;5F->%.X1Q,U,S:\)++KH3RUBA,$#/69O-LD9US?)8Y"]MHD#)]M1LZXRR<
MZ:,[.RMEQIL!J!.W8]KATT@A4)8'Z4PB;,*EN4C"A5I`^0&Y@"I(5W(N("RI
M]C=WR3'INKG1$FR;.LOYC<<OYEAF7N4KMI-M:9$H*Q1!<.8[;X7&[LZ7,./Y
M1B"+P0HYJD:&1%+7!2Y.059=BE"6R`#.+D4U%8`U2QQ')+O`XYLT^E,1G6.L
MZ94T3VJG2>92:/P^68^D37DZ/`A"*1N\)FL&G3JUB+3O`'EO+&E467*%*40S
MP,$Y9QO,\VB]:,EY`SG,LG33$N>=?\M.$DY66U+GC9APOGF5PR4*&?6F%ACJ
M9Q@TSQL3!TR-J=Y2MD8G4PVZIR".Z=*G)`\I^K>!S6!3'D;9L\D4J\;[-8Z+
ME[ERV-F'>4%*-C=JH/LP1,W=Y%#2G-Y>H25!D[.I'<P)SJK%9P"--T/(7`Q)
M!<,S>2MTBE$I1YVP[*&O*NU;OBIDC'+DVFM(G*'YVW,1[`/Y.P.1(_'%B^5>
MMT;A#:G97*+^@)%&1N8UX3PNB4JX`+^Q_JOC6&15Z9G!?LV\/[LR-3(WR-'R
MUMM"AQ=.@WKE.\II+2I?VU^DAZ.S[)0LA(CG`2H2E$4['&#/$(JP%#QWJ#C&
M!918IJM/V;G$<1N<'F;TUR7EZ;J'/ELAXZQWD+&D;%$VP*0..4^.U;%/KF+F
MUY:W59:Y2U,G/`F=#`IP+SQE!UN*!8#QRH8]J9;`(ML_#]@UID5T?V_;8AAZ
M*X$P>=!8?CR)#R='IUE]V%E69G(3BT:EZ=&J,M@%C:A\U;DZ0LX#9;GW:^*3
M;`^<(='L-;@*Y!*<.Y0C["B%ICL^7=P>W>#/J!I;2S+XLN`L]R<#RR"Q#N$L
M)AEKC$`'2%8"8F!61UC6#,+QQ]1'MCW'\3XZ9'EN4AZ"AO=6J'LZ!P1*`\;]
M$]*K(&6.WX!!O0&6*`4`H"*F]O[D&Y/\*FPWW12^@/_1^K+2?/65&[3/49`C
MTHV;?DB+6'`25,]M,KTT):W<@C%$3**<FXI\VW9GHI$M`&QA05:1*HL`5K&%
M%CXAL!)OWALN]A+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!XR:
M`>\-EWL);5_._2#QDT`]X;+O82VK^=^D'C)H![PV7>PEM7\[](/&30#WALN]
MA+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!XR:`>\-EWL);5_._
M2#QDT`]X;+O82VK^=^D'C)H![PV7>PEM7\[](/&30#WALN]A+:OYWZ0>,F@'
MO#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!XR:`>\-EWL);5_._2#QDT`]X;+O82
MVK^=^D'C)H![PV7>PEM7\[](/&30#WALN]A+:OYWZ0>,F@'O#9=["6U?SOT@
M\9-`/>&R[V$MJ_G?I!XR:`>\-EWL);5_._2#QDT`]X;+O82VK^=^D'C)H![P
MV7>PEM7\[](/&30#WALN]A+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V$MJ
M_G?I!XR:`>\-EWL);5_._2#QDT`]X;+O82VK^=^D'C)H![PV7>PEM7\[](/&
M30#WALN]A+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!XR:`>\-E
MWL);5_._2#QDT`]X;+O82VK^=^D'C)H![PV7>PEM7\[](/&30#WALN]A+:OY
MWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!XR:`>\-EWL);5_._2#QDT
M`]X;+O82VK^=^D'C)H![PV7>PEM7\[](/&30#WALN]A+:OYWZ0>,F@'O#9=[
M"6U?SOT@\9-`/>&R[V$MJ_G?I!XR:`>\-EWL);5_._2#QDT`]X;+O82VK^=^
MD'C)H![PV7>PEM7\[](/&30#WALN]A+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/
M>&R[V$MJ_G?I!XR:`>\-EWL);5_._2#QDT`]X;+O82VK^=^D'C)H![PV7>PE
MM7\[](/&30#WALN]A+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!
MXR:`>\-EWL);5_._2#QDT`]X;+O82VK^=^D'C)H![PV7>PEM7\[](/&30#WA
MLN]A+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!XR:`>\-EWL);5
M_._2#QDT`]X;+O82VK^=^D'C)H![PV7>PEM7\[](/&30#WALN]A+:OYWZ0>,
MF@'O#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!XR:`>\-EWL);5_._2#QDT`]X;+
MO82VK^=^D'C)H![PV7>PEM7\[](/&30#WALN]A+:OYWZ0>,F@'O#9=["6U?S
MOT@\9-`/>&R[V$MJ_G?I!XR:`>\-EWL);5_._2#QDT`]X;+O82VK^=^D'C)H
M![PV7>PEM7\[](/&30#WALN]A+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V
M$MJ_G?I!XR:`>\-EWL);5_._2#QDT`]X;+O82VK^=^D'C)H![PV7>PEM7\[]
M(/&30#WALN]A+:OYWZ0>,F@'O#9=["6U?SOT@\9-`/>&R[V$MJ_G?I!XR:`>
M\-EWL);5_._2#QDT!&3=C/65''3/;E`LTHV;84BW6'/J52]NTKTT.:V@@_%$
?L*-<G$ICVW>7HU$B`*YAH4B14HN`-[%E&#X!N!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FIXED ASSETS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 28,987</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 47,883</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 27,484</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EEOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 2) (Stock Options [Member])<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">0.07%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">0.65%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">0.61%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">68.05%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">33.35%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">40.77%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">6 months<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1.77%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1.71%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">2.23%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">82.29%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">45.76%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">46.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">6 years 3 months<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXVAM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2011

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2011

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">$ 4,691,847</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">$ 1,850,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">$ 200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Value of debt converted to shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" onclick="toggleNextSibling(this);">(6,716,504)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">1,165,981</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">1,905,409</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">64,380</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">212,853</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">17,253</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">696</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInAugustAndSeptember2012Member', window );">6% Notes issued in August and September 2012 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInAugustAndSeptember2012Member]" onclick="toggleNextSibling(this);">1,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedInAugustAndSeptember2012Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInAugustAndSeptember2012Member]" onclick="toggleNextSibling(this);">1,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedInAugustAndSeptember2012Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInSeptember2012Member', window );">6% Notes issued in September 2012 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInSeptember2012Member]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedInSeptember2012Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInSeptember2012Member]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedInSeptember2012Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember', window );">VitaMed July 2011 Secured Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_July2011SecuredNotesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate principal and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember]" onclick="toggleNextSibling(this);">1,054,647</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_July2011SecuredNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Numbers of shares converted for debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments[us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember]" onclick="toggleNextSibling(this);">2,775,415</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_July2011SecuredNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1[us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember]" onclick="toggleNextSibling(this);">$ 0.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_July2011SecuredNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Value of debt converted to shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature[us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember]" onclick="toggleNextSibling(this);">6,716,504</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_July2011SecuredNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense[us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember]" onclick="toggleNextSibling(this);">33,204</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_July2011SecuredNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotes1Member', window );">VitaMed July 2011 First Secured Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotes1Member]" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_July2011SecuredNotes1Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotes2Member', window );">VitaMed July 2011 Second Secured Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotes2Member]" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_July2011SecuredNotes2Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember', window );">VitaMed Promissory Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">4.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Numbers of shares converted for debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">266,822</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">$ 0.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Value of debt converted to shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">735</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">7,366</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of interest rate terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier
of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory
note(s) issued in an amount of not less than $1,000,000, or the Funding.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">2,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember', window );">VitaMed Promissory Notes [Member] | Brian Bernick [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">5,341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtInstrumentRemainingFaceAmount', window );">Aggregate remaining principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_DebtInstrumentRemainingFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">txmd_DebtInstrumentRemainingFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">VitaMed Convertible Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember]" onclick="toggleNextSibling(this);">534,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleNotesPayableMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember]" onclick="toggleNextSibling(this);">4.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleNotesPayableMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Numbers of shares converted for debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember]" onclick="toggleNextSibling(this);">1,415,136</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleNotesPayableMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember]" onclick="toggleNextSibling(this);">$ 0.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleNotesPayableMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToVariousPartiesMember', window );">Notes Issued to Mr. Finizio And Mr. Milligan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToVariousPartiesMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedToVariousPartiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToVariousPartiesMember]" onclick="toggleNextSibling(this);">6,344</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedToVariousPartiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty1Member', window );">Notes Issued to Mr. Finizio [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty1Member]" onclick="toggleNextSibling(this);">888</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedToParty1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty2Member', window );">Notes Issued to Mr. Milligan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty2Member]" onclick="toggleNextSibling(this);">$ 1,519</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedToParty2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtInstrumentRemainingFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to balance amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_DebtInstrumentRemainingFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotes1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotes1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotes2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotes2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_July2011SecuredNotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInAugustAndSeptember2012Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInAugustAndSeptember2012Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInSeptember2012Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedInSeptember2012Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToVariousPartiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToVariousPartiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`T$38L2P(``+\F```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VLUNVD`4!>!]I;Z#-=L*
M#_-C-ZTP6:3MLHW4]`&F]@5;V!YK9I+"VW=L$E1%%(2*U+/!`MOW'BST;3B+
MVVW7)D_D?&/[@HETSA+J2ULU_;I@/QZ^S&Y8XH/I*]/:G@JV(\]NEV_?+!YV
M`_DDWMW[@M4A#!\Y]V5-G?&I':B/9U;6=2;$MV[-!U-NS)JXG,]S7MH^4!]F
M89S!EHM/M#*/;4@^;^/'^R2.6L^2N_V%XZZ"F6%HF]*$F)0_]=6K+;/G#6F\
M<[K&U\W@W\48C!_=,)[Y^X+G^[[%1^.:BI)[X\)7T\48?-OR7]9M?EJ[24\/
M.9+2KE9-294M'[OX!%(_.#*5KXE"UZ;3,>U,T[_D/K%_NMCSZ2"N'&3\?M/@
M"W-(D!P*)(<&R9&!Y,A!<KP'R7$#DN,#2`XQ1PF"(JI`(56@F"I04!4HJ@H4
M5@6*JP(%5H$BJT215:+(*E%DE2BR2A19)8JL$D56B2*K1)%5HLBJ4&15*+(J
M%%D5BJP*15:%(JM"D56AR*I09%4HLFH4636*K!I%5HTBJT:15:/(JE%DU2BR
M:A19-8JL&8JL&8JL&8JL&8JL&8JL&8JL&8JL&8JL&8JL&8JL.8JL.8JL.8JL
M.8JL^?^2-<1Z#O'I]=]_'=.8,_T0'W8M^2O_I[L?>FYS;1Q5WX.+1::K!_AS
M]ID<I6G+NSHV>J[\$`YS3^V/-:-[9P<?"U>.+@_PTJ@:[YX-<1"YT-"A4W6L
MFW38&,M:ER]\58ZBL0Y6475D-Y_J9\O?````__\#`%!+`P04``8`"````"$`
MM54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?V
MA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:
MCAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AE
MW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+
MJ<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$N
MGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````(0#0&O.4
MFP(``&0F```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**``
M`0``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````"\VLUJVT`4!>!]H>\@
M9E_+=_Z2E,A9M!2R;=,'&.2Q96)+1C/]\=MW<%O%@>8T"W$V`<ED?&'N/=_(
M]NW=S\.^^A['M!OZ1LEBJ:K8M\-ZUV\;]?7AT[MK5:4<^G78#WULU"DF=;=Z
M^^;V<]R'7/XI=;MCJLHJ?6I4E_/Q?5VGMHN'D!;#,?;EE<TP'D(NE^.V/H;V
M,6QCK9=+7X^7:ZC5LS6K^W6CQONU]JIZ.!W+6_]_\6&SV;7QX]!^.\0^_^,]
MZA_#^)BZ&'-9-(S;F!LUW4KU^17M%Z5F5;]0CK#+$52.L>1RC$7E6$TNQVI8
MSA6[G"M4CBO#16UEMX3E.'8Y#I7C#;D<;V`Y)?CFVZPV[-L/7=CU9=$_N3/=
M0E6P&QCV+WNXX6P+VP7!+MS,V2Z324_M,MWZR]0-ZAMA,R60*<UF2D.F#+N3
M#6QEPYYR`\?<LIFRD"G+9LI"IAR;*0>9<K,R-87,R[GCKE'N^%E3.>73OCQO
M3&3^OD;OS^X5V"J>'<(>AK"PB1),%-L$@29HM@D:FJ#9)FAH@F&;8*`)ACWG
M!@ZZ99M@H0F6;8*%)KA937@-4?"D[MFYXV'NL/<*;Q5;+`?%8H\5G"IA`R$0
M"&$#(1`(S4YD#1/9T%L']HYA3[F!8V[9B6QA(COVP=3!@ZF?=;)2%\:X_I+'
M\HW*Y:/,Y6WT1*/9)R\-3UZ6+82%0C@VY@YB[ME&>&P$^3-)N%7LS(&1(VRN
M!'*EV5QIR)5F<Z4A5X;=.@;VCF5S92%7;E:N7O-X!0^"PO9*H%>&[96!(6C9
M7EGHE6-[Y:!7GMT['O:.GQ6)7'X3$Y\^RSY?UN>_N&/(AL-^82<?##YAHRD0
M36&C*1A-]EZ9:;/J9[\-6_T"``#__P,`4$L#!!0`!@`(````(0#7=;"WTP0`
M`+(2```/````>&PO=V]R:V)O;VLN>&ULE)A14^)*$(7?;]7]#U3>[P(A`;'4
MK0#C.K486!)<?9K*0I34AH1*XJK__G9`XYDTIM8G;'#.=)_YNC.5LZ_/V[CU
M)\SR*$W.C>Z7CM$*DU6ZCI*'<V/I7_YW8K3R(DC609PFX;GQ$N;&UXM__SE[
M2K/?O]+T=XL$DOS<V!3%[K3=SE>;<!OD7])=F-`O]VFV#0H*LX=VOLO"8)UO
MPK#8QFVST^FWMT&4&`>%T^QO--+[^V@53M+5XS9,BH-(%L9!0>GGFVB7&Q=G
M]U$<WAPJ:@6[G1ML*>_GV&C%05Z(=52$ZW/#IC!]"K4OLL?=Z#&*Z==AK],S
MVA=5D?.LM0[O@\>X\*F\-W7RR[1,LU_^9VG%310^Y>^+RK#U_#-*UNE3^:]D
M[4L5]2B!I_U//Z-UL:'?.YU.]=U5&#ULBK<O2;X-^GL':9_]9RO9E_?FB**3
M4B(IHN)%R>3@?I32$9:N2ZJL:[2RTXC^R.2Z6R:.*N.9Z\VF<N+X8J)&SM1Q
MQT)Y5T+X'DB8(&%^0D+-`U#I@<K>ZP\3\7S*YUJXOJ=FEVHV%Z!B@8K5F(NN
MXODS4"'?*U/L3ZB,'?2E#RI[)K`B_TJH\>QZ[KAWL'$?=Q[4=_:6U]?.XJZL
MVI/?7'DIQX[K*V<\GBU='V5PZY.ZC'1OR+S90MMX`,D.ZRMFE.U"C9>+!2U4
MCN?I`/1I)E1^=3OUU9?REO#AJX:XBK$W7XBY(R=*W,Z%Z^$9#ZAQWK=CQ$G7
M=]QO<C05?,^!ACO#3*]S*IV1G$I?"CS5`>+>98RY,U]X:N[<.90`',D`^>XR
MJ(B_\?>KV70B%IX2/Y;2Q],9(-9=QI)TB22A?.=6SQ1AZC*:%F*Z[^NYLZB7
MB/AT&3^CI2==X7G$+\T#UU\XOJ1!@<4B35V&$V5[+?U#!SONI-3QI?M-N..:
MU<@5C<O:=/+$5(S+R?1C226(Q?1.74J79I1TIFJ"Z2!I)B/-6XX\LKQ$6Y2=
M@96<(&LF8ZVY(PFV:LZ>('DF(Z]9B)![%T+^3,9?U=S*#W[%88XK$4&3(:C#
M?VC7(R*(XN%1AV,->_W(8B329$366O[(>@339&"RSC^B@&2:C$S=`Q@`>R7T
M$M'L<31Y.Q_)!;'L,2RQJ_GB(8+98V`VMIB"0H;(98]SV=AC"/@0N>PQ+IL!
M)S(KP,N;4#7>*:AW?>-#D.A\%T):>D>FYNMC4$W"(HAB;)4>8D)!+0<=D]=6
M.:*B0<)PU7KE=;5R@RRCV^N?$`O10&'0'M.!U1:20D&MEGK3\3(L1(2"F@#O
M.JP%$T%"+(;LASHH@2/,8K1^**&05`M'&`6U>O3#Q1E0UH7)(*@6`[591TL(
M0;48J-J5X@W6"A1,"*FU&+7-.IC04+.9@7ODL@)I04)#S6D&;K..EA!:;3.&
MFX7PZ6F3:C5<**B=?8,0E&4CR!3\O8C&H8TN4_`)&:TD--EF.#>4I"B!:EK:
MFL6,9NUIA`U>'U8VPDQ!K:IC.I@%(FPSA(^MUCW%D6LS<FMW7J"VG+J8!XY<
MFY'[P17X50]T^CA\*:BYT?R8Q@[H([@4?$H(<>DCO!34A)HOU9H0XMOG^-9O
MU9K9:!'RV]_SV]Y32:\T5D&\HG<MY<?^985E]P_W]_;;ZZ:+_P$``/__`P!0
M2P,$%``&``@````A`'VX`JC8!0``(18``!@```!X;"]W;W)K<VAE971S+W-H
M965T-"YX;6R4F-MNJT84AN\K]1T0]S%S8H`HSE8P2KNE5JJJ'JX)QC:*,1:0
MPW[[KF&-86:(4Z(M9<>3+XM_'69^,G??WNNC]UJV7=6<UCY=$=\K3T6SK4[[
MM?_W7X\WL>]U?7[:YL?F5*[]'V7G?[O_^:>[MZ9][@YEV7L0X=2M_4/?GV^#
MH"L.99UWJ^9<GN`GNZ:M\QX^MON@.[=EOAU^J3X&C!`9U'EU\C'";;LD1K/;
M5469-<5+79YZ#-*6Q[P'_=VA.G>7:'6Q)%R=M\\OYYNBJ<\0XJDZ5OV/(:CO
MU<7M]_VI:?.G(^3]3D5>7&(/'V;AZZIHFZ[9]2L(%Z#0><Y)D`00Z?YN6T$&
MJNQ>6^[6_@.]S9CT@_N[H4#_5.5;9WSO=8?F[9>VVOY6G4JH-O1)=>"I:9X5
M^GVKEN"7@]EO/PX=^*/UMN4N?SGV?S9OOY;5_M!#NT/(2"5VN_V1E5T!%84P
M*Q:J2$5S!`'PU:LK-1I0D?Q]^/^MVO:'M<_E*HP(IX![3V77/U8JI.\5+UW?
MU/\B1'4H#,)T$`'J]<_9TB`!"AKRR_(^O[]KFS</A@8>V9US-8+T%@)?$D,9
M8ZK7,H4459`'%67M1[X'2730GM=[*>^"5ZAHH9%TCE";V%P(53X5-3,6`I`[
M:H9"F)H_;L)%FH*5M$O4%!<@]JB5.4(^("(;R>:(G!!++/^*6`6O?3@U1FTR
MMI^<(L+'?#;N0F8L6$J@O<O+IN"U#VE.2A)'"2+AT&X:$B89=9"-B<11%(:)
MDTYF$CRF,:%\?(RE'O;)<O4*MM5'9`P[#%>*B!S4<QG!DZ<'#\3&)&@2PK^I
MQ3B@%L%%3*^)EU\1KV!'O+-54D10/#PT%((Z^VUC(C*FDA`G2&823,@D(5.-
MK-+#OEY>>@7;(QPY^RM%Q!AA=R$S%BPERD^-T^KSG:]@IXY.BU-$L(Z,42:(
M*W9C(C0A5,3<'0,+$40FD5%K2W_R%?T*=O0+9X@10?V",QHGW-E@&Q.!20DI
MDTX5,A,1(F%<3AVSY%,PSN7U'V@G@=!)0#.800A3Z-1V8P,Q%4Z$S`8DDU>&
MF"HW63P[`^UH=W98JAG4+D.>A"*:R4</0X;#$2G8/`.3H;&D,6=3B^P&*-]9
MG@2ZE'F(NP)3B@P*O`D%$91(YZ38V!`+8Q(SX<QB9D-4PDX15_-0'K4\#W0T
MV&:C&47.F*?4<#T\OF<KF;EBEU6YT'(YZ%E661WC2RDR6%8A0^D`&PO@`DYP
M>V=D-F">WK9TY4'+I:-CF=+C:;^@,:KW6CAW],A&G,RDFP"+&)])1P`Z,O9+
M3!O#EJ],:+E\M"Q+OC.K*35M[0:.`\*F9^O)L!!X=>$)FTX\M'8=9E$.RJV6
MYX#>9N7@/#RE%__[L(`Z"63TQJ54PKN54XM,Q[DP"8']/773;H0RL>5)H.59
M24Q'EIXC9`R;I[BBY;!D/O,6(*`QTYEKJU66M5PM&IREUIG9E")CJG57,LU<
MRDDXB6(Y!;(4LB]9Y4#;=A,[1I=JQE`X6\GTBE8(;[4R)-<$?LD/&7J45<*I
M-]APS5S*$X$#3,.&0VLC3%(P&X?);`9>:>#=G$X[Q*XR"%H^!TS13I6=LR'5
MC$XB%(Q&C#I'Y,:&6"QHPHU7_R'7S(8XO'@1QJ>FVGDH]UH\SPR]SFJ&ZX>:
MN7)^Z6Y@G,^8[/,X=A)?<E$V=]'8&854,_@G)KR<?-P,#*2A:\VPH/]IAK(O
MHQGJ3H3#=O[\KPUUD>,,5^+,3:J99/BC\X:LC.--=P2#C,#,EF81IK[;O7!\
M=6$.<W]-'$])X9IM>CV`'1[!&P";5.@\+(A%\/X3<2>2NK";(B54<C@+)A/!
M=/!&#F^LZK+=EYOR>.R\HGE1MVT,"CFNCC>!#TQ=CCCK*=P0#M=IP?@#N*`[
MY_OR][S=5Z?..Y8["$E6$?2@Q2L^_-`WY^&>[*GIX6IN^/8`5[$E7%&1%<"[
MINDO'^#!P7BY>_\?````__\#`%!+`P04``8`"````"$`!\-NXU48``#HK0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6RDW5M3VUC6QO'[M^K]#A3W
M'7S$D$HRU;;.Y[.N:>(D5(>0`GIZYMN/9&W;>Z^_!G"F+]+)+VL+H[6U)3T6
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M;O`%1CN[#F2/9Y^W7V[^^OY<//SM;>^^?GONVKWLOJ/^&WO_^=_6]NFVVZ/=
M9M[-EOV6;A^^=R^@^_7L_JZ?&MT>N?G7[O]_WWU^_O;Q?'[Y;KF:S*==^=D?
MVZ=GYZ[?Y/G9[5]/SP_W[5`T59L:-C)3&^E&J(U,9^]F5\OI\O*$K5RJK713
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MK$9\3\U8C=A.NZ_ION^+;N(=9E]W3!BS;_SDM)]D?74_R?9[;SU`M_'#KIB9
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M?*3`WF_R^&7E&<?9E^S7;U>")\&7$$@()4028@F)A%1")B&74$@H)502:@F-
MA%8#8P)TU],G3("^6DX`L=*NAQIM`@QP^=\G@!QAZR/&9H0C1[@2/`F^A$!"
M*"&2$$M()*02,@FYA$)"*:&24$MH)+0:&.WN;H1.:'=?;;9;GCK60\G0W.GT
M<GE])<Z8&Z/B>K)<3,2,L8:*XXRQ]2&7BSDNB.0`5X(GP9<02`@E1!)B"8F$
M5$(F(9=02"@E5!)J"8V$5@.C_=U=U`GM[ZO-]J_DXKT>:HZ]VTBP!AAFR%6W
M`9P`;#G$D>!*\"3X$@()H81(0BPAD9!*R"3D$@H)I81*0BVAD=!J8/2W3UCU
M6^Z7;WKZ:ME?<?2NAQJMOP,,[5Q<7D^OY+G8TBNF5[M3OGG&M_6*+KO%C'#D
M5W4E>!)\"8&$4$(D(9:02$@E9!)R"86$4D(EH9;02&@U,"9`%TR=,`'Z:CD!
MQ+W!>JCIKA\/UWRRX9M]R?[BRY)@2W`DN!(\";Z$0$(H(9(02T@DI!(R";F$
M0D(IH9)02V@DM!H8#>Y38J/#?:HV[_#E0WTW3+9:W).N59%VL$,L)</Q_]MT
M,I^LKB[%?:EM%JWFUR.'.#;M0CR(#PD@(22"Q)`$DD(R2`XI("6D@M20!M+J
M8LZ)/@-[^[+?OT.`PUZT<*V*]+DP#!LZ/YMV&;Z8/Y8:,U1,5S-98!\VNDMQ
MM8AA%\DZA[_>+R0NQ(/XD``20B)(#$D@*22#Y)`"4D(J2`UI(*TNYI3H(YT3
MIL20`.EW]JN)2)+6_5M!W;S1IX04"S4VQ(&X$`_B0P)("(D@,22!I)`,DD,*
M2`FI(#6D@;2ZF&WN<YT3VCS$0-W%P^%DSCQNJF5%N^-R`[$@-L2!N!`/XD,"
M2`B)(#$D@:20#))#"D@)J2`UI(&TNIAM[M,;O<UO/.D/H8]Y5!]SW5USUU,M
M&5+MEF*AQH8X2M3B/W)1[V*,!_$A`22$1)`8DD!22`;)(06DA%20&M)`6EW,
M]O=ISB^T?PB!S/;+]+U_;D,LZE(LU-@0!^)"/(@/"2`A)(+$D`220C)(#BD@
M):2"U)`&TNIBMKM/;_1VOW)I/X0]KRSJ6B*DCG(I5O^4A#$5;(@#<2$>Q(<$
MD!`206)(`DDA&22'%)`24D%J2`-I=3';W(<X)[1YR'S,HUF^^=(_WV*T<`.Q
M(#;$@;@0#^)#`B7Z24$FB"%&19`8DD!22`;)(06DA%20&M)`6EW,QO?AS0F-
M'[(>L_$B0E_WCR:)QDNQ4&-#'(@+\2`^)%!R/=V]ZS-Y-Q&7'2&&1)`8DD!2
M2`;)(06DA%20&M)`6EW,KO>)CM[U_AINT9UK7UG=AR#(Z/Y4O(.ZGFIID5K=
MI5BHL2$.Q(5X$!\2'.1XG[&:BF0Y/!3M[_8C2`Q)("DD@^20`E)"*D@-:2"M
M+L8,Z)_V,V;`RYW?E8O(;BK3656DW9-#+(@-<2`NQ%.B`J"1*WS_U8H`6PTA
M$22&))`4DD%R2`$I(16DAC205A=S&IR6UO5/>78KN[D`B.1MK8KT:3`,.XJ%
M&AOB0%PE0],7D^GD2L1"'L;XD``20B)(#$D@*22#Y)`"4D(J2`UI(*TN9MN[
M#IYR]/?ELNTRI)T-1?/A)&N^R;8Y_.5^?;4@-L2!N!`/XD,"2`B)(#$D@:20
M#))#"D@)J2`UI(&TNI@=/RV<ZQ^11L?%P;961<?#>@.Q(#;$@;@0#^)#`B7J
M`G\V\F9OB$$1)(8DD!2207)(`2DA%:2&-)!6%[/OOY;6S4;2NJFX;%ZK(KW_
M2.M08T,<B`OQ(#XD4'*]6X'F[\3E28@!$22&))`4DD%R2`$I(16DAC205A>S
M]WUXIE_EOW*--V1MYLE=1G3]CS/M[NWZ=\W$I?_F\)?'57Y?OA<;-0[$A7@0
M'Q)`0D@$B2$))(5DD!Q20$I(!:DA#:35Q>QXGYJ=T/$A9#,[+F.<F4SB-A`+
M8D,<B`OQ(#XD@(20"!)#$D@*R2`YI("4D`I20QI(JXO9YM/2NMD0Q'49S`OO
MM*DB?3&7^9V%&AOB0%R(!_$A`22$1)`8DD!22`;)(06DA%20&M)`6EW,-O>I
MV0E'\Q"R&4>S?+QU/9-)W`9B06R(`W$A'L2'!)`0$BE1^=WLW7QI_R9.[C%&
M)9`4DD%R)>IKS=]-AD<"=P%#]\L47[G`-DI(!:DA#:35Q9P88_'=Y:O/7<W>
M$M^I(GT=0'R'&AOB0%R(!_$A`22$1`<Y+G"KJ4BEXT/1_E(D@:20#)(?1/MB
M,W$E5!R*]E^LA%20&M)`6EV,2=$_=W?":K$K?^V>7A5IDP%B06R(HT2E==?7
M,[G#7(SQ(#XD@(20"!)#$D@*R2"YDN&[&OO1D`)C2D@%J2$-I-7%G`:G)7KS
ML41/7O2K(GT:(-%#C0UQE+PT#>1V/6S%AP20$!)!8D@"22$9)%?RTC20WU6)
MK520&M)`6EW,:="G<6^_=ICWY>9J<'DM[P14D3X-AF%'L5!C0QR("_$@/B2`
MA$J&5DPGD]5<9%81QL20!))",D@.*2`EI(+4D`;2ZF*V_;28;\Z8[_):G#C7
MJNC8Y`W$@M@0!^)"/(@/"2`A)(+$2@Y3H[N8,S/J!&-22`;)(06DA%20&M)`
M6EW,MLN4[^6D9\YT#S]+IVKTKN_#O3[ZP9%EJ0'##E[-+T5::&.##L2%>!`?
M$D!"2`2)(0DDA620'%)`2D@%J2$-I-7%G`"G17WSD:AO(MX37ZLB?0;(-,]"
MC0UQ("[$@_B0`!)"(D@,22"IDF'JCKQMD!D%8S\DEF.C!:2$5)`:TD!:7<Q9
M<%K\-Q^)_V:8!8C_U+#CO+`@-L2!N!`/XD,"2`B)(#$D@:203,GQP2'QGF>.
M(06DA%20&M)`6EW,KLLT</?91OTD>>4L,.1[1EXT$[G*>BY#P`W$@M@0!^)"
M/(@/"2`A)(+$D`220K*#Z'?ZXFF'_%"TO],O("6D@M20!M+J8DZ!TY+"^5A2
M*.;V6A4=#_,-Q(+8$`?B0CR(#PD@(22"Q)!$R;#8SZ;RLVY2C,@@.:2`E)`*
M4D,:2*N+V?2Q%+#/!5XY[$=2P!F:+S._S5R*!;$A#L2%>!`?$D!"2`2)(0DD
MA620'%)`2D@%J2$-I-7%:/?BM'QO5_[:QQVI(NT8AU@0&^)`7(@'\2$!)(1$
MD!B20%)(!LDA!:2$5)`:TD!:7<PV]UG1VX.;Q1`MZ2=Q!C>J2&^S3*0LU-@0
M1XE:.L=B7(SQ(#XD@(20"!)#$D@*R2`YI("4D`I20QI(JXO9]CY).Z'M0_!F
MMET&-XNA2&^[%`LU-L11,K2]2]40G;@8XT%\2``)(1$DAB20%))!<D@!*2$5
MI(8TD%87L^TRKWO;#U,NF-MU/^%NYEEK5:2W?QAV%`LU-L2!N!`/XD,"2`B)
M(#$D@:20#))#"D@)J2`UI(&TNICM/BVG6PR)6W>U_L*#&ZKHV-0-Q(+8$`?B
M0CR(#PD@(22"Q)`$DD(R2`XI("6D@M20!M+J8K;YM#2N_\$;\>;+:B;BT[4J
MTMN,-`XU-L2!N!`/XD,"2`B)(#$D@:20#))#"D@)J2`UI(&T2H;3W^[38X[O
M')AME_';&Q?SL1A.O@6[0`P'L2`VQ(&X$`_B0P)("(D@,22!I)`,DD,*2`FI
M(#6D@;2ZF.V6N=O+]]V+(4E[93%'W*:&'8]["V)#'(@+\2`^)("$D`@20Q)(
M"LD@.:2`E)`*4D,:2*N+V>;3LK7%2+;&Q7PH.C9UHX8=Q8+8$`?B0CR(#PD@
M(22"Q)`$DD(R2`XIE*@[COGR:C(5"56)016DAC205A>S[S)>>^7P'HG5Y%O,
MZX4,T380"V)#'(@+\2`^)("$D`@20Q)("LD@.:10HM]I'L^UNQ\F+HV2X:$K
M45)ANS6D@;2Z&!-A>5KPMBLW'Z59S>2C-*KH>+AO(!;$AC@0%^)!?$@`"2$1
M)(8DD!2207)(`2DAE9+](K%8=1\#9]X"UQC40%I=S+[+).YMEW-+)G*KF8QF
M5)'>?R1RJ+$A#L2%>!`?$D!"2`2)(0DDA620'%)`2D@%J2$-I-7%;'>?C;T]
M@5L.4=K+EW.J2&\S$CC4V!`'XD(\B`\)("$D@L20!))",D@.*2`EI(+4D`;2
MZF*V629N+Y_6ER-)VU0F;:I(;S.2-M38$`?B0CR(#PD@(22"Q)`$DD(R2`XI
ME`PK]?*R^[!.>6548E`%J2$-I-7%[/MIT=MRB-ZZH_40O3&3445ZWX=A1[%0
M8T,<B`OQ(#XD@(20"!)#$D@*R2`YI%"R/T,ON\]=$==J)095D!K20%I=S+Z?
MEL4M1[(X.5G7JNC8Y0W$@M@0!^)"/(@/"2`A)(+$D`220C)(#BF4J+Z/?<Q^
MB4$5I(8TD%87L^\RC'MEG1\)X?!$Y!(A',2"V!`'XD(\B`\)("$D@L20!))"
M,D@.*92\V'>Y"RMLIH8TD%87L^^GI7++(7`SUOF)?`A.%>G'N\SI+-38$`?B
M0CR(#PD@(22"Q)`$DD(R2`XIE*B^+Z?R<:(20RI(#6D@K2YFUT\+Z98C(=U<
MG)K6JDCONHSM+-38$`?B0CR(#PD@(22"Q)`$DD(R2`XIE!RZOEHMQ,/#)095
MD!K20%I=S+Z?%M(M1T*ZN7C1:U6D]UW&=A9J;(@#<2$>Q(<$D!`206)(`DDA
M&22'%$I4WZ]7\ROQ3&R),16DAC205A>C[?W/.AOWZF^+9G;#1#0W$2]^K8JT
M]D,LB`UQ("[$@_B0`!)"(D@,22`I)(/DD$*):O_HO[E18E0%J2$-I-7%G``R
MFWOYZNYR+),38>%:%>F-1R:'&AOB0%R(!_$A`22$1)`8DD!22`;)(06DA%1*
MU.28+[I05D2?-08UD%87L^]]?*:'=&\\\(?4S;C*F\NKO,NA2.^_%`LU-L2!
MN!`/XD,"2`B)(#$D@:20#))#"D@)J2`UI(&TNICM/BVLNQQ2MY<S656DMQEA
M'6ILB`-Q(1[$AP20$!)!8D@"22$9)(<4D!)206I(`VEU,=M\6C9W.9+-(9-5
M17J;D<VAQH8X$!?B07Q(``DA$22&))`4DD%R2*%D6*GG\^D"_YQBB4$5I(8T
MD%;)\*5D_&M.!!G6O7%Y'PGM\&F%ET.1/B&D6*BQ(0[$A7@0'Q)`0D@$B2$)
M)(5DD!Q20$I(!:DA#:15,GPNX^3=_'CA93;_M,3N<B2QP[V<*M*;+@,H"S4V
MQ(&X$`_B0P)("(D@,22!I)`,DD,*2`FI(#6D@;1*AH/^:GE]J?U+C6;;96#W
MQF-^)+B;XUY.QG2;2RD6Q(8X$!?B07Q(``DA$22&))`4DD%R2`$I(942=:*8
M[CX033QF@4$-I-7%[+^,[M[8_[$(3SPDMKZ4@=T&8D%LB`-Q(1[$AP20$!)!
M8D@"22$9)(<4D!)2*5$'\G2Q7%R)9]/KUTL:;+?5Q9P0IV5ZER.9GGP0:*V*
M]/,`,CW4V!`'XD(\B`\)("$D@L20!))",D@.*2`EI%(R3(39V+^V7&-0`VEU
M,?J^^K50;S=,A'KR8Y_6JDCK/\2"V!`'XD(\B`\)("$D@L20!))",D@.*2`E
MI(+4D`;2ZF*V^[0(;S5D<2_?VZLBO<V(\%!C0QR("_$@/B2`A)`($D,22`K)
M(#FD@)20"E)#&DBKB]GF/D/3$[N7D]K5$+EUO[[PW(TJTMN,I`XU-L2!N!`/
MXD,"2`B)(#$D@:20#))#"D@)J92HU7P^]O0L!C605A>S[S*Z>]MEW6K(XHS^
MS\7UQEH5Z?U'A(<:&^)`7(@'\2$!)(1$D!B20%)(!LDA!:2$5)`:TD!:7<QV
MGQ;AK88L[I757`9V&S7LV'@+8D,<B`OQ(#XD@(20"!)#$D@*R2`YI("4D`I2
M0QI(JXO99AG0O;*:CP1S^&&HE8SA-A`+8D,<B`OQ(#XD@(20"!)#$D@*R2`Y
MI("4D$K)834?>=\-@QI(JXO9]].RN=5(-H>G*%71\6#>0"R(#7$@+L2#^)``
M$D(B2`Q)("DD@^20`E)"*B6J[[N/YA"/,=48U$!:7<R^_UHXMQH+Y^2/-*LB
MO?\(YU!C0QR("_$@/B2`A)`($D,22`K)(#FD@)20"E)#&DBKB]GN/B\[X6)]
MB-=>.8L/17J;I5@K*3;$@;@0#^)#`D@(B2`Q)(&DD`R20PI(":D@-:2!M+J8
M;3XM85N-)&QXOU45Z6U&PH8:&^)`7(@'\2$!)(1$D!B20%)(!LDA!:2$5$J&
MU7QX;!ZKN=RI#3;3ZF+T_4HF;"]?O>W*1;*&9^)5D=9WB`6Q(0[$A7@0'Q)`
M0D@$B2$))(5DD!Q20$I(!:DAC9)A;BRNKF83^615JP\R^WY:U'8U9&;&/3B>
MB5=%>M\1M:'&AC@05XFZIIDNK\6/VWD8XD,"2`B)(#$D@:20#))#"D@)J2`U
MI%'R7W=.JP\Q)T$?D;W]W'XU)&K&),"'0ZLB?1(,PXYBH<:&.!`7XD%\2``)
M(1$DAB20%))!<D@!*2&5DN.'3(NTJ\:0!M+J8G9]+(;K/]'HE:5_)(;#9T-?
MR=!M`[$@-L2!N!`/XD,"2`B)(#$D@:20#))#"D@)J0ZBY=W:`S*[S[RH#T7[
MSYAN(*TNY@PX+9F[&D(WX[B?R/?55='Q*-]`+(@-<2`NQ(/XD``2*EGN_BW8
M&4\B$8;$D`220C)(#BD@):2"U)`&TNHR=/WBZ=MV^VS=/-]\^G"_??RZW6R_
M?W\ZNWWXZT?WCLJBVQ\'/7O<?OEX_OOT_>^S\VYF"5]/W]O3$7>F[Z,QCZ?O
M\YU?'#;T].G#SYNOV_CF\>O=CZ>S[]LOW4N8O.M3IL>[K_T;`L,?GA]^?CSO
MKA[^>'A^?KC?_?;;]N;S]K$OZ(J_/#P\[__0O="+OQ\>_]Q]FY_^(P````#_
M_P,`4$L#!!0`!@`(````(0!.;+7\#PX``(17```9````>&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;)S<6U/C.!K&\?NMVN]`<3^`G1.DFMZ:Q);E8VUM[>$Z
M#:%)#1`J24_/?/N5(R61WK\Y>/9BMOO7KQ3R1+;U&O"7?_SQ_'3V^W*S7:U?
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M[Z"-_6RS?+@]_S6:-N/H_/+KEWU`_UTM?VZ]/Y]M']<_L\WJOEJ]+$W:YG-J
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M\.45$LI/O%+552.^XOI0<WBEQH-+\\D=/SZS.(./K_N<<?B4VNKV4SI,.SO`
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MVSWM^$8<'>KPKX<=529!2\@E%!)*"96$6D+C09"P::&"A-OM_<`T1N\GW8X2
M2<N3Z<S6>$E+2"2D$I2$3(*6D$LH))02*@FUA,:#(+VVEPSB>S^V??E'5WM7
MY`4'22`I1$$RB(;DD`)20BI(#6E\"4-L>Y?/'^5MXRT77RP.NYDK\D.TPTZ2
MH":%*$@&T9`<4D!*2`6IG;B+PKACO]'X@\)4VW:@1ZJV>WA_2Q79HE.&<T@"
M22'*R3OO*\,@#<DA!:2$5)`:TO@2IMKN^OU4/W>^;&_RR#4[%'<89J[(3]<.
M.TF"FA2B(!E$0W)(`2DA%:2&-+Z$8;;-@!_F!V=/VSN8*]EQUS^^$5OX67N+
MRB1]BFP.22`I1$$RB(;DD`)20BI(#6E\"4-L=_H]0K2-07"<\^SI=0_[OF?>
MWFX.8DT@*41!,HB&Y)`"4D(J2.W$;>TZ3Y[>NPI#;;?]/4*U74(0*OK1R&LE
M7*A2$M2D$.7D[;>588R&Y)`"4D(J2`UI?`E#;7?Y?JB?/'?:YB`(=R@ZGUGD
M=1`N7"D):E*(@F00#<DA!:2$5)`:TO@2AMENZ/TP/SAWVOW_!^=.6^2?.Z4D
MD904HB`91$-R2`$I(16DAC2^A"&V^_H>(=HV(%B)L>C29Y'7*[B5*"5!30I1
MD`RB(3FD@)20"E)#&B<WT?XVSM7%U6G+'60:RY;H<T?Y?IAH*0>B%9^Y(F^!
M0A)("E&0S(G;D9I[*V/9SVH,RB$%I(14D!K2^!*FVZ]7BCMZI9&XISES17ZJ
MZ)50DT(4)'/B+E63R6@8G;XAL3\X-`;ED`)20BI(#6E\"5,UAW2/\T#<EHNU
M.I+G`5?DIVJ'G21!30I1D,S)C3L0!Z*/T!B10PI(":D@-:3Q)8Q4-DKO7Y_B
MK@;I=(;9KY69*SH%.(<DD!2B()D3NU`[[U!K#,HA!:2$5)`:TO@2IMJO8XIM
M,^1?L'#?V=7XH<H6*G$U-I[!()9W55-,HB`91$-R2`$I(16DAC2^A)&V/8"_
M!_CD]<JV#GZTDY&\I]_^8$S0-<TA"22%*$@&T9`<4D!*2`6I(8TO89C]^J;8
M-D#O[TI=D;]`T3>A)H4H2`;1D!Q20$I(!:DAC2]AB+)/^N#4V=$?H:./93<T
MAR20%*(@&41#<D@!*2$5I(8T3NR9:?\-V]/N)@RU[5O^PF%NVYWP,,>V5/9$
M\UA*`DDA"I)!-"2'%)`24D%J2.-+&&:_OBFV#9#)Y)T;=Z[(/\S1-Z$FA2A(
M!M&0'%)`2D@%J2&-+T&([7?9@A7Y_F&^+Q>;3ASFKL@+$9)`4HB"9!`-R2$%
MI(14D!K2./GX,!_TZX_VY2+42.RG9Z[(#Q7]$6I2B()D$`W)(06DA%20&M+X
M$J[,ME'QSY4?K,RV_*/O:@YLD1^BE`0U*41!,HB&Y)`"4D(J2`UI?`E#[-<`
M#3H:(-Q"=D5^B';821+4I!`%R2`:DCOQ#L+P)X&*H*#KIZ-*3%I!:DCC2YAQ
MOW9HP'9H@OMWKNB4Z!R20%*(@F00#<DAA9/3?3?QHU,EAE20&M+X$F8J^Z$/
M#OZN/NBT![.-^P!]$"2!I!`%R2`:DCNQZS8>CZ]CT:<5&%-"*D@-:7P)0^W7
M%PUL@V-.D,<-TP0WF%R1OU#1%Z$FA2A(!M&0W,E;-Z$*C"@A%:2&-+Z$D?;K
MD@8=71)^E-$5^9'*OBE!30I1D`RB(;D3NTZCCN]7%AA30BI(#6E\"4-M^Y8>
M5W[;YOCK%/>7!K(5FA_%_A:(N".<N'^V,4P&8W$7,#T./_Q(G8)D$`W)(06D
MA%20&M+X$L8K^Z;V7E/4GC4^.,G:3LC/>2)/8K.!;)?FD`220A0D@VA(#BF.
MXIW$8M$ZE\>BPX=906I(XTL0\+!?3[4O%]M_>6]SYHJ\DP(D@:00!<D@VHF[
M5$5C<2'-,:*`E)`*4D,:7\)(94?UN?NC0]LB!4MV)+8N,U?D1XO."C4I1$$R
MB(;DD`)20BI(#6E\"<,T>?0XOP[;\H\Z*U?DAVB'G21!30I1D`RB(3FD@)20
M"E)#&E_"$/MU5L//=%:NZ!39'))`4HB"9!`-R2$%I'3R]NZ@PI@:TO@2AMJO
ME1IVM%(\<]HB/U0IB9OH5)-"%"2#:$@.*2"E$QOJ:"!_WZS"B!K2^!)&VJ^3
M&G9U4F)S-'-%I[CFD`220A0D@V@G;Z^X'&,*2`FI(#6D\24,M5\G->SJI,2.
M<N:*_%#12:$FA2A(!M&0'%)`2D@%J2&-+V&(_7JGH6V"WK]_[XK\$-$[H2:%
M*$@&T9`<4D!*2`6I(8TO88C]>J4A>Z4)[M^[(C]$V3XEJ$DA"I)!-"2'%)`2
M4CDYG4/EKK7&F,:7,%39(;W?&`V[&B/YDSBNR`]5MDH):E*(@F00#<DA!:2$
M5$[>O.M78TCC2Y#IJ%]3M"\731%^9LP5>9E"$D@*49`,HB$YI("4D,J)NYZ9
M'T6+!N)*4&-0XTN8JNR+WE^IHZY^2*Y45^2GBGX(-2E$03*(AN20`E)"*B=O
MW0BL,:+Q)8Q4=D>?:S5'MMTQ__7NELK?"W%%?K3HDE"30A0D@VA(#BD@):2"
MU)#&ES#,?EW2R'9)[U_C79$?HAUVD@0U*41!,HB&Y)`"4D(J2`UI?`E#[-<5
MC3JZ(ESC7=$ILCDD<?+VUCO%&`7)(!J20PI(":D@-:3Q)0RU7U\T8E^$F\RN
MQL_4CCI)XFILIN/!4-R,2C&'@F00#<DA!:2$5)`:TO@2)MJO*1IU-47RIQY<
MT2G`.22!I!`%R2`:DD,*2`FI(#6D\24,L5]3-/I,4^2*_!#1%*$FA2A(!M&0
M'%)`2D@%J2&-+V&(_9JB44=3A-M(KL@/$4T1:E*(@F00?93V>U/7U^*@R(__
M?/AV10$I(16DAC2^A(GVZXA&'1W12/ZVG"OR$T5'A)H4HB`91$-R2`$I(16D
MAC2^!"&.^[5`^_*/[KN[(B]$2`))(0J2030DAQ20$E)!:DCC2QABOX['/!$3
MOR6#8]L5^2&BXT%-"E&0#*(A.:2`E$[L8Z-,SRB.I0HC:DC[<-#C[P'82.VS
M/NV#%I^7F^_+^?+I:7MVM_[1/L?3_,;\UR]'M@\9+>.I>7"9.>\(K^.I>389
MO8FGYA%E=/.PTE^[?!9-T_T3/\7\.IJ:QQARGED\G77-,X^G\RY/XFG2Y6D\
M3;M<Q5/SC#B^KHZGYC%P]"*>FB>]&;\\O@'S#-37Q?=EO=A\7[ULSYZ6#R;;
MJXN)V1IN[%-4[5]VZ]?]<RZ_K7?FZ:?[/SZ:I]TNS0,FKRY,\<-ZO3O\I7V!
MX_-SO_X?``#__P,`4$L#!!0`!@`(````(0"TC4YN#@L``(`\```9````>&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;)R;66\B.Q[%WT>:[X!X;Z!V0$FNNA:7
MEQEI-)KEF2:5!'4($="=[F]_764#]O_4)4`_=)(?QZ;J>#ME\-T?O]:O@Y_-
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M_+';;];_-Z+`5F4J"6TEL;YZ^WHX"J=)D*17U*+?K[N4[%1+,HK#))M><RVZ
M8W>UZ)^':PFNKV5F:]$_#[6$HR">7',_@6Y,XVW;JD=?KC4W.#:1_N54S:7V
MCDV#=_VG7.P7#W?;S<=`#TI=V^Y]T0[Q8-Z^QZ'GF'8^]J6_ZDJZ#[6U?&VK
MN1_J-M.]9*?[_\^'+)W<C7_J/KNTFAPU@:\H#HJV@[;5EA14!NC_C^^39C._
M%M:GF?J:ND]#ZN%&X]Y3FI%ZQ$%SN&))@7+`6'M^-%Z/%L_X_J%Z\+=5M_X>
MWB<_@),1H7^+18\B\R4E2E(BJ5"2I:39&&K26>R_56TTVHQ3P\T27\.QGBPE
M=R7Z-)%?C^S3D.M1?9K3]7@M%5W54JW::RD*"@I*"BH*&`6U`:Z=64R:A=-"
M@@))@7*`9X&>TJ_HK*WZ?J@=/K9U0L96;B1I-U,$$_//;\7B<TEI)-%Q5%04
M,`IJ"C@%@@))@7*`YY)>NCR7VKDTTK/^^:'=EB)ND5DF-Y*9<:OZ0OI[<?[E
MTKSLN$0!HZ"F@%,@*)`4*`=X+J7$I?/NM&K?'5A7C"3JW"%K3G'FM?+PVF%.
MK2A@%-04<`H$!9("Y0#/%[W0>+WGO"^MFOA"QG]N)/V^G'FM/+QV](4"1D%-
M`:=`4"`I4`[P?&F?4=R$<MZ75DU\(<,E-Q(S]X1)_^1S@:8T&F=<4<`HJ"G@
M%`@*)`7*`9Y/.J1>X5.K)CZ1)3(W$CM')^EDEDT",H\7GB:.9UF:)21"E$;C
M^$0!HZ"F@%,@*)`4*`=X/K6!_`JC.CEQZA04NIB:6\UYJWS17WAE18Y90!B0
M&@@'(H!((,HEOF=MBG4'X65+6_M`07I9EJ;^.I];4=+-WW&894&4D"%;>)IL
MFB83T)1$,TOB*6FGRDI.[C(@-1`.1`"10)1+?"_;Z'F#ER:QNJE*#S;JI1&=
M;K`(##%=,TOBD%A;6L&I2`6$`:F!<"`"B`2B7.*[U$;1&UPR"=9WB<:IP(BL
M)V$<S(@IA56<3"F],D$Z"R):J()"#$@-A`,10"00Y1+?MS:<WN";R;2^;V2R
MSP,C,KY%<9+%9"P7OF(R"T@>*SU!H%^?$$5E%2?K&9`:"`<B@$@@RB6^BVUX
MI2[&&IX/'^V6&YWO,G*#N179Q2)*TPD9Q855G"PHO3)AFD[I,*Z@#`-2`^%`
M!!`)1+G$MZW-MM2VSY^``A.)O<Z7T31K10?;)M&4&%M8A6N;J=B4">-)1+<<
M*BC#@-1`.!`!1`)1+O%M:Z/O#;:9Q.S;1O9+\L"(K&U3''"%5;BVN66B8*(W
M\XG7%11B0&H@'(@`(H$HE_B^M5'8]>V3T6F2L^<7G<'RP(G77;@K@)26&$^_
MI%F@\P@)SQ648D!J(!R(`"*!*)?X!K49^`J#3&3V#,K(TI@'3JZV!E%2@J8"
MPH#40#@0`40"42[Q[`AI\K\LQ7;%_">`+"/MG5O1:1050$H@E26F)^G9*8JG
M9-%E4*@&PH$((!*(<HGO$TW[Y\=5V)/R,Q*]<RMR_3'%3J0$366)V?G2'[V0
M6AF4J(%P(`*(!*)<XINCAX<WIB[L1&TQTHG@42@THI,E!9`22&6)Z439M.?!
MAT&A&@@'(H!((,HEOD\TP'_2B7J">T;B91X:D>L/)25H*DN,/TG2;OGXCTT,
MRM1`.!`!1`)1+O'MH3G]$WMZ\GE&<F,>&I%K#R4E:"I+K#WA)""N,RA2`^%`
M!!`)1+G$=Z<O?W\>)-N/F>D@HQ_9Y5;DNF2*G4@)FLH2X]*TVS4D"95!H1H(
M!R*`2"#*);Y/MP7NL"=P1S0Y6M')E0)(":0"PH#40#@0`40"42[Q;;DM4(>7
M!&HK<FTQQ4ZD!$T%A`&I+3%=K#=V<R@D@$@@RB6^3S1`7[B6]03I"`(1!.F0
MDA)(!8198@=>$.MM/3)!U9]+.-0K@$@@RB6^<=<%Z[`G6,.3AQ6=NE$!I`12
M`6%`:DN,A<$DB=.8+!T<"@D@$HARB>=/.U5[(>G\ZM;)23A*R"*=6Y'C#Y`2
M2`6$`:DM,?[H#>@DID&30R$!1`)1+O']N2YA1ST).R'+3VY%KC^0L$%3`6%`
M:DM,"I^,(K*?RJ&$`"*!*)?XYM"$_4GGZ4G6]#M!>03)&D@)I`+"@-1`.!`!
M1`)1+O'MH$'ZLDDZZ@O4=)*V(K?/0*`&306$`:F!<$OL1)ZDB5[B_!PNH)`$
MHESB^T03]84^]21KNK681S1'%T!*(!40!J0&PBTQHRT>T<]X!)200)1+?)-N
M"]913["&IU<K<CL3!&O05$`8D!H(M\1TIOX/#064DD"42WRC;DO644^RGL),
M;42N4924MJ*3I@+"@-1`N"5V[0^G<38C\4E`(0E$N<3WB4;M3R;KGH@]I4\>
M$0W4!9`22`6$`:F!<"`"B`2B7.+;<5NBCGH2-6PQ6M&I2Q26V.`RBX,@2\D6
M60FE*B`,2`V$`Q%`)!#E$M^HZQ)TU).@88_1BER#3#'[S;D12;TE%*B`,"`U
M$`Y$`)%`E$L\;^+KTG,G)^EY2K?MK<CQYDA.7]/,IB0@E$?1\<M@0!B0&@@'
M(H!((,HEOD,T/U^VUL<].9I^222W(M<IR-&@J8`P(#40#D0`D9;8I:YOC"NW
MD.\3C=(7^M03J6$5BR%2`RF!5$`8D!H(!R(LL>N:WO-.IF1T2RBD7.+[=%O&
MCGLR-MV=R*W([4^0L4%3`6%`:B`<B+#$]AZS<4EBMX12RB6^4;>%[+@O9)/V
MRJW(-8K&[A(T%1`&I`;"@0@@$HARB6_+;;&Z_48)[%>3*3BW(M<6B-6@J8`P
M(#40#D0`D4"4)78L1EFW.WY\M/.-HK'Z?%R,>^(T+/M6Y!H$<1HT%1`&I`;"
M@0@@$HBRY/`QYJF%?6]HE+YPLNZ)U/!LI@\?MCW-]8B2$C05$`:D!L*!""`2
M2'L\LKU"\S70J/O.B?,YG3'*G'\TY]?6S?:Y*9K7U]U@N?G1GFW4WR5\N#MB
M<_!2AG-]RD6'%\)5.->'79#K@YI?^W@>S,ONM".IA^N#G7T\#^=Y7SU%."_Z
M>!G.RSY>A7-]&@BODX5S?2@(.0_G^MP/<A'.]?$?S<?'&]#G/]\7S\T_%]OG
MU=MN\-H\:0\GHTQ/+EMS@M3\L=^\=\<$OVWV^N1G]^N+/NG;Z/-YDY$6/VTV
M^\,?[1L<SPX__`D``/__`P!02P,$%``&``@````A`*TI=,HN'0``X[D``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-3`N>&ULG-U;<]M&VNWQ^UVUOX-+]R,+
M/%,5YZTA<3[5KEW[<*W8<JP:VW))RF3FV[\/V`VA>_TY,A%?),XO#R!IL0EB
M@13YRW_]Z]O7=_^\?WI^>/S^X2JYOKEZ=__]X^.GA^^_?[CZO_\G_]ONZMWS
MR]WW3W=?'[_??[CZ]_WSU7_]^C__QR]_/C[]X_G+_?W+.]O#]^</5U]>7G[<
MOG___/'+_;>[Y^O''_??[?]\?GSZ=O=B__GT^_OG'T_W=Y].&WW[^GYQ<[-Y
M_^WNX?N5V\/MTR7[>/S\^>'C??KX\8]O]]]?W$Z>[K_>O=CW__SEX<?SN+=O
M'R_9W;>[IW_\\>-O'Q^__;!=_/;P]>'EWZ>=7KW[]O&V^OW[X]/=;U_MY_Y7
MLKK[..[[]!_8_;>'CT^/SX^?7ZYM=^_=-\J?>?]^_][V].LOGQ[L)QAB?_=T
M__G#U=^3VSY9+J[>__K+*:'_]W#_YW/P]W?/7Q[_+)X>/K4/W^\M;KNAAIO@
MM\?'?PRCU:>!;./WV#H_W03_Z^G=I_O/=W]\??G?CW^6]P^_?WFQVWMM/]+P
MD]U^^G=Z__S1(K7=7"_6PYX^/GZU;\#^^>[;P[`V+)*[?YW^_>?#IY<O'ZZ6
MF^OU]F:9V/B[W^Z?7_*'89=7[S[^\?SR^.W_NZ'$[\KM9.%WLK+OWO__Q?5B
MMT[6FQE[L:]W^E;LW^->UM>KQ7J[F_.];/Q>[-_C7O;S][+U>[%_CWNQ`.?^
M1'8O._U$]N]Q+W\AE[W?B_U[VLO<FRBQE>5NZ&&)^1OI+_Q(R>N"L;^,^_D+
M-U,RKIGA+^-^[*\7KKAD.?XX]I=Q\^1ZMUZO-KOMY2LWL27K8OE+:_>]NS>=
M[ISIW<O=K[\\/?[YS@YY%L[SC[OA`)K<#E]CO%NZ.]'K'?4_W4_M#CKLY>_#
M;CY<V2*TN^"S'5W^^>MVM_OE_3_M@/#1SQPXD\03QW%BN/</NTT5,@?VS]>O
ML]GNX[WDXT;AC'POQ3@S?J5RA'`CV7$USHP;U0J-`_MG\.W)EV['C<(9^4K=
M.#-^I7[<L<%[N^5>;SY;B-'-=_YH.MY*P_1P*XV[/8PP?2^+.,SCF8EM/))R
M9",CF1O9+TXK8Y78L3+>1WYF'WN9*70G-S)0GMO))OY"E9L);Z'M3M*OY0O=
M;&[BG33GOM`JGFGYA3;ZA;HS^]G)#]6?F=DO7[]6M!CL"#-C,0S3T6)0."JD
M"ID#NUW'%97K2(&14D<J!]%MLI)#0XW=-+J;]H+==+I1'T"4I1T*9V0Y3'^X
MLD?/U_O]=B^+YN!FEJ]1'152A4PA5R@42H5*H59H%%J%3J$/($K-'L]FI#9,
M?[BR!1ZD)K?[P<VL3P>.9+E?;/>)W*6/;F0*-E7(%'*%0J%4J!1JA4:A5>@4
M^@"B'.V<,,IQ>%1>VOG0VX?W82O-4X[G!S=CJ_XU\\U"`QUGQCMUJI`IY`J%
M0JE0*=0*C4*KT"GT`42!VIE)%.C;00[3&N1TS#V=FAS<S.:T,.U$;G,C]_>C
M&PB6I4*FD"L4"J5"I5`K-`JM0J?0!Q"E.)3Q\&3Q[12'Z3C%Q59.#`YN)ER.
M*QDYNA$7],)B7LB23L=]C,LU4\@5"H52H5*H%1J%5J%3Z`.(<K7"-"/783K.
M=;N7LX^#FW&AV>G6=K&1]7N,)K;KF]5:SCQ2-S$MX$PA5R@42H5*H59H%%J%
M3J$/(,IUZ)(S@CV-:[*2RL$/N6A7RT6RVR_E%/\8S23+]3I!_FDTLUKM%\N-
M+.S,CTRW0`XI("6D@M20!M)".D@?2IS\4%@N/U0,95W6]$X6[,'/^`/!?B5+
M_NC__Y16"LD@.:2`E)`*4D,:2`OI('TH<:)#$0@3O>R<8+AJ(<EN]_*`?_!#
M4W1'2`K)(#FD@)20"E)#&D@+Z2!]*'&8PVE_&.;;CV3#11P+T0[?KV=-/+_W
M0V&(;K-)4LQDD!Q20$I(!:DA#:2%=!"[*GSZX4\_11SBT`+"$"]<D:X\Q*?]
M\J!_&"Y%6>)3=$=("LF\[$\G98OKFYM]^$>.TCFV+R`EI(+4D`;20CI('TH<
M]%`3PJ!_LEI=JX@"3O`P%E2/TPGM<;@8'T6>0C(O[AB\6]_8G]=+$:>]Y-BF
M@)20"E)#&D@+Z2!]*'&H0U68$:IK%E&H>UE1AR2H'SY4E10SF1<?ZG)Y)E3=
M2X&]E)`*4D,:2`OI('TH<:A#<PA#O?"0X`I''*Y<E3LD02OQX:JDF,D@.:2`
ME)`*4D,:2`OI('TH<9A#70C#_,G=WK6+GSQ(N:'PN*J2)BH9)(<4D!)206I(
M`VDA':0/)0YQZ`8S0G15(EJ)/'8&?<.O1)4T4<D@.:3PXL]Q=TO[$Q]?2VQ3
M06I(`VDA':0/)0IU,:]7G<;C7K73!XZ#'PI6)B2%9)`<4GA9C4\^:-$ML4D%
MJ2$-I(5TD#Z4.--YC6EQIC'=Z,53/Q1FZC:;),5,!LF]N&6YNEG?;*1!%-BF
MA%20&M)`6D@'Z4.)0[4[\HQ[_V(8UX4JK?S@AZ8(CY`4DD'R5YE*Q>Y&[N[%
MZ]!X<:N$5)`:TD!:2`?I0XESG=>?%JY"A$?5W8WT]X,?"G,-FL?I.)MB)H/D
M7O;)Z?Y^<[U:[W9A#9"J46`/):2"U)`&TD(Z2!]*'+&VJ[<?_1=L53M]@O3@
MA\*(M6>EF,D@N1<?<7*=++*_R=VDP%8EI(+4D`;20CI('TH<Z[PN-;PJ2(X(
MJY4<_`Y^*(P570HS&23W,J[<^)&_P'P)J2`UI(&TD`[2AQ('.G23RT^P%J[*
MQ(<"!*I]Y^@WFR).(1DD?Y7P$(O[OWZQ\G6S\:!;06I(`VDA':0/)<Y5J]1/
M[O^L4+L;[:<++4Q'2`K)(+F7M\X']"N5V$L%J2$-I(5TD#Z4.-2AVH2+];)^
MNG"-*%ZTVD_]T+1$CY`4DD%R2`$I(16DAC20%M)!^E#B,(>*$X;YDQ7J&I%%
M^<9%U(76IB,DA620'%)`2D@%J2$-I(5TD#Z4*,3A6?T9(9[&XS/4+?JI'PI6
M(B2%9)#<RW]NHP6V*2$5I(8TD!;20?I0XE#G=:GE)5W*#X6AHDMA)H/D7ORQ
M<[-(]-F8`MN4D`I20QI("^D@?2AQJ$,YNOSN;J\EUS.GW8V<)![\4!BJVVR2
M%#,9)'^5Z=C"+O4Z-#ZLEY`*4D,:2`OI('TH<:[SNM3RDB[EAZ84CY`4DD%R
M+^,9Z="EEF]U*>RAA%20&M)`6D@'Z4.)(Y[7I9:7="D_%$:,+H69#))[>>U2
MJX1="EN5D`I20QI("^D@?2AQK/.ZU/*2+N6'PEC1I3"307(OX\J5+H7Y$E)!
M:D@#:2$=I`\E#G1>EUJ>ZU)ZSN^'W.--LE[=;&3B&$UL[3=JY,I,Z@>FVR2#
MY)`"4D(J2`UI("VD@_2AQ!G/ZU7+,[TJD2<]#W[HK8RU#Z5^FS!4G<DQ4T!*
M2`6I(0VDA720/I0X5.U5;U>!)?L47\+FAURHMBSQ,E4_,"680C)(#BD@):2"
MU)`&TD(Z2!]*G*G6J\NZZM(UJ*BK)OK$@!^:HCM"4D@&R2$%I(14D!K20%I(
M!^E#B<)<S:M9I_&?O>#'#P4A0E)(!LDA!:2$5)`:TD!:2`?I0XE#G%>K5JQ5
M[*I^R-W+%\,SGO+H<_034\PI)(/DD`)20BI(#6D@+:2#]*'$H<ZK5:LSM2K1
M6N6'ILB.D!2207)(`2DA%:2&-)`6TD'Z4.(0YW6HE>M0;U^*\D-AB&ZS25+,
M9)`<4D!*2`6I(0VDA720/I0X1&U)ESW@K-B6MGNYR'[P0U-T1T@*R2`YI("4
M7MRK`&^N]=79%;:H(0VDA720/I0XVGE-:<6F=.;(J;WHZ#>;0DXA&22'%)#2
MBSM*+Y?):JNOWZBP40UI("VD@_2AQ*G.JTNK<W5)SXS\T)3A$9)",D@.*2"E
M%Y?J)EFL=EMY_K_"1C6D@;20#M*'$J<ZKR"MSA0D7.?S0V&J6G92S&20'%)`
MRE=YXUI@]3HT7@NL(0VDA720/I0XUWD=:<6.Q-=,^*$P5[?9)"EF,D@.*2"E
ME_&*RO5J=7K][_`:X-,?N2=5V$,-:2`MI(/TH<01:V5ZNX:NSE0EO&;"#TV!
M'B$I)(/DD`)2>GF-6']AO,(F-:2!M)`.TH<29;J>UYQ.X_$35'S!A!\*,H6D
MD`R20PI(Z67,-+X06&&^AC20%M)!^E#B0+5%77::M6:;VB7R<''P0V&P;K-)
M4LQDD!Q20$I(!:DA#:2%=)`^E#C,>>UI[=K3VR?^?FB*[`A)(1DDAQ20$E)!
M:D@#:2$=I`\E#G%>>UJ[&F113D_DXSEH/Q2&B/:$F0R20PI(":F\^//5Q!Z?
MXOM]C4T:2`OI('TH<:9:IMY^*%JS1/'94C\49NHVFR3%3`;)(06DA%2O,MWL
M>(ZU?AT:SZL:2`OI('TH<:[SFM2:38IG47YH2O$(22$9)(<4D!)2>1D?H.R\
M:B>G4C4V:B`MI(/TH<2ISFM2ZW--2G_#S`^%J;K-)DDQDT%R2`$I(947GZJ]
ML>`*3ZO6V*J!M)`.TH<2QSJO2JU9I<Z<.VEQ.OK-PEAU)L-,#BD@):3R,BY6
M/:KJUVVPAQ;20?I0XD#G=:CUF0Z5R/7E@Q^:XCM"4D@&R2$%I(14KS*\9YK<
MA>K7_SD=3;7>M9CI('TH<9[S"M/Z3&'B([\;"O-42?V.IID,DD,*2`FIO/CG
M$_;;I;RVN,8F#:2%=)`^E"C3C1:FR\[O3YO%Q6FG;W5T\$-3;D=("LD@.:2`
ME)`*4D,:2`OI('TH<9A:EMX^C=JXMO/V^;T?"D-$2<),!LDA!:2$5)`:TD!:
M2`?I0XE#U))TX8IT92DZS\>%_8T;"L-423&307)(`2DA%:3V,KX%P%J>B&BP
M10OI('TH<;3SJM/FDNKDA\)(49TPDT%R2`$I(16D]N(.J<GPZ^E:IQILU$(Z
M2!]*G.J\\K0Y5Y[D'/K@A\)449XPDT%R2`$I(16D]N)372\7BX6\,*O!1BVD
M@_2AQ*G.JTZ;<]5)GVGV0V&J;K-)4LQDD!Q20$I(!:E?Y8V2VKP.C:=5+:2#
M]*'$N<XK3YMSY4E/2OW0E.(1DD(R2`XI("6D@M1>QO-^*ZE;N8,UV*B%=)`^
ME#C5H4M<_G+SC:L>X8,5?__1#X6I:F-),9-!<D@!*2$5I/;B4]U>KT['UM=_
M++._R07>!OMH(1VD#R4.>5Z?VK!/L:#ZH3!D+2TI9C)(#BD@):2"U%[&I1M7
MU@;S+:2#]*'$@<XK5)MSA4I.60Y^Z(U'BJ,?F3)/(1DDAQ20$E)!:D@#:2$=
MI`\E2G6KE>KM%G`:ERJ%WX7T0R[5Y8V]K:RT[V,\L;E9ZP-T&DW8.P':FRC&
MRROS$],-DT,*2`FI(#6D@;20#M*'$H<^KWIM78>*#L!XH;0?<J';!R;@K>B.
M?F(*+(5DD!Q20$I(!:DA#:2%=)`^E#C4H1Q=_JBV=5TJ#)4OE/9#?B7O-AM]
M-]"CGPA#=3N>),-,#BD@):2"U)`&TD(Z2!]*'.J\$K9E"=LE<NY]\$-30$=(
M"LD@.:2`E)`*4D,:2`OI('TH<8CS.M?6E:>WK[3XH3!$="[,9)`<4D!*2`6I
M(0VDA720/I0XQ'D5:_C\#WEW";[.SP^%(:)B82:#Y)`"4D(J2`UIO+@#D+TR
M</@3/PZVV*B#]*'$J<XK6-MS!4O:RL$/A:FZS29),9-!<D@!*2$5I(8T7ERJ
M^]5BM=])^VZQ40?I0XE3G5>PMN<*EGQ#!S\T97B$I)`,DD,*2`FI(#6D>94W
M+A"TKT/C!8(.TH<2YSJO4VW9J?@,M1\*<T6GPDP&R2$%I(14D!K2>!E;EET@
MV$1M5E9*BSUTD#Z4..)Y+6M[IF7A=7Y^*(S8;39)BID,DD,*2`FI(#6D\3)=
M+0A_$WN_W^)J08M]=)`^E"CDW;S2=1J/2Q>O#?BA*=(C)(5DD!Q20$I(!:DA
MC9=Q'<O#&.8[2!]*'.B\0K4[5ZCTVH`?"@-UFTV2^AGW0+)>;1=:RS+L)8<4
MD!)206I(`VDA':0/)0Y5"]5ESVWM6*QVB;ZCCQ^:HCQ"4D@&R2$%I(14D!K2
M>'$W;;*Q4P3]V*$6&W60/I0X76U6%Z9[IF$MY)3PL'-#8;HJJ9_Q/U]BOP.\
MD]UDV$T.*2`EI(+4D`;20CI('TJ<KE:N"]-U'2J\*+!;Z/GM3HO6$9)",D@.
M*2`EI(+4D`;20CI('TH<YKSJM7,=ZNW^ZH?")8KJA9D,DD,*2`FI(#6D@;20
M#M*'$H>H3>O"%<G&Q5\!W&F_.D)22`;)(06DA%20&M)X<1\VIB>L&.\@?2AQ
MKO.ZUHY=B]<%_%"X.-UFDZ28R2`YI("4D`I20QHO[NAMG]QTYKH`-NH@?2AQ
MJMJT+ERM9QJ7?JC48:?]Z@A)(1DDAQ20$E)!:D@#:2$=I`\E#G->I]JY<O23
MXZ<VJ*/?+%RB.I-A)H<4D!)206I(`VDA':0/)0IQKYWILA5YVBSN3CQ^^J$I
MNB,DA620'%)`2D@%J2&-%W?\E&>N6XQWD#Z4.-=YU<G:V\^OJ_JA,$]4)\QD
MD!Q20$I(!:DAC1=_]GOV^(F-.D@?2ISJ7^M.]G&OFBY_$\T/A>FZS29),9-!
M<D@!*2$5I(8TD!;20?I0XC"U*KW]'/7>=9VWCY]^:(KL"$DA&22'%)`24D%J
M2`-I(1VD#R4.41O13T)D$^)YTAY-"))",D@.*2`EI(+4D`;2>O'W?/L]Z_@Z
M5(<M^E#B2.?UHKTK.%&YQ*_S^Z%P7:(782:#Y)`"4D(J2`UI(.VKO''AOWL=
M&B_\]Z'$N6I5^LE2947B9?X]*A(DA620'%)`2D@%J2$-I/5B#S+#;[#8QRVL
M[%4=P1]Y8KW#'OI0XHCGM:8]6Q-?`NB'PJ6+UH29#))#"D@)J2`UI(&T7GS$
MV^LDB-?^NL.%_P[[Z$.)0QZ*SN6O2-F[7A0>'WB9WP^%(;O-)DDQDT%R2`$I
M(16DAC20ULNXCO6`J]]_'^XA#G1>D=J[_A,&NL/OJ/FA*;XC)(5DD!Q20$I(
M!:DA#:1]E>&X(&V@>_V?TX$VZ(%1GO;;V[-6J)N/V]0.OZ4V3@61DNQ#>H>O
M'7X.I7THKY)]*J^2?2RODGTNKY)],*^2?3*ODGTTKY)]-J\C?X*P6<MON=E'
M]>HV]EF]`4G"6J\NJZW)S9F>=:-/48U34=)H6IRRI'7*DE:RI)4L:25+6LF2
M5K*DE2QI)<M6R;(-2+(=:L_EQU=[CN.TXNQX,[V[@CZI<QBGHDS=AA/9ZE6R
M3)4L4R7+5,DR5;),E2Q3)<M4R3)5LDR5+-.`)%/M6I>N5U>Z;+]!MERO;FH*
MTC[/6\FR5;)LE2Q;)<M6R;)5LFR5+%LERU;)LE6R;!VYWXE;7LN5;0LZV$2"
MGM?'DIM+"MDX%06L)<T"5K*`E2Q@)0M8R0)6LH"5+&`E"UC)`E:R@!WYH_'B
MS.?B6LC!9A+RO(:6W)RI:`MY@+4CA#8R6\5*%K*2A:QD(2M9R$H6LI*%K&0A
M*UG(2A:RDH7LR'^,XW*EGYMA$0<;2<3SREIR<ZZM20FWB%'72!:Q3EG$2A:Q
MDD6L9!$K6<1*%K&21:QD$2M9Q([&3\I<;Z6\6<3!1A+QO+*6W)QK:_HL]C@5
M'2K0USAE$>N41:QD$2M9Q$H6L9)%K&01*UG$2A:Q(W^HV";)7L_=+.1@,PEY
MJ"%S3B9<;0D?\/BV0LF-EAL[5"C9.E:RD)4L9"4+6<E"5K*0E2QD)0M9R4)6
MLI!'FA[G=POY%4N+>9RR#B(QSZMPR<V9#H?/MQRGHK4<E![W"9><LIAURF)6
MLIB5+&8EBUG)8E:RF)4L9B6+V=%8F>W2SV+OGJ5P_^2)1K"/./%DZ"8S%O9I
M7CH>7M*9^*DP<5#*J8R4DPI22:I(-:DAM:1N))_X[MH^1CG\L\:5H'[<Y)2!
M9#YTECF9NXX3'DQXZ2=)@B;D/QP;9)GKE&6N9)DK6>9*EKF29:YDF2M9YDJ6
MN9)E[FA<Y?&%(<LWV$+R'?K+G'R'>5G3"=I)XJ;\`\AJG>SQCOE)-+.P5UXL
M9#=V`[C=3'<-NP&4[`90LAM`R6X`);L!E.P&4+(;0,EN`"6[`90L](`D]*'+
MS`G==1_;WU0)SX0^-J33->YX"1R39/R_X\4LBU?)XE6R>)4L7B6+5\GB5;)X
ME2Q>)8M7R>)5LG@#DGB'%A/&>V'S3ES[B6)>RN/#(?%3TZ*T;(/:Y!\A09:M
M3EFV2I:MDF6K9-DJ6;9*EJV29:MDV2I9M@%)MD-]";-]^QFE)'%UQ\YBIJ7+
M*T5^*LHTZ$ECIDJ6J9)EJF29*EFF2I:IDF6J9)DJ6:9*EJF291J09#KTE3#3
M2]>KZSG1>L5['R5)T(;&QSHE.Q8H6;9*EJV29:MDV3KZCY]M,`Y,-[<EK;NQ
MI)4L:25+6LF2#DB2'DI+F/3/5J\K.5'"O$J?!%5H3%C)$E:RA)4L825+6,D2
M=N0>7]>;W=K>\"@^X-MRULTL9"4+6<E"5K*0E2QD1^Y;T$];D-2'#C,G===Y
MPM1W-VC=2=",QM25+'4E2UW)4E>RU)4L=4?^K.9F;6^VL))S%HM=M[/8E2QV
M)8M=R6)7LM@#DI2'WC(G9==SXI3Y:!>TH3%E)4M9R5)6LI25+&4E2WFDZ1$#
M;^%K,8]3X^F,Q:QD,2M9S$H6LY+%'%`<\V)F"3S-RPDS:[>?FHZ(QP24DC)2
M3BI(Y4AC8[!>_/8G)8P;3-]B36I(+:DC]1%)XD-YF;&P%Z[LQ`M;WO/DD/BI
MZ<>QQ(.6=%KKEKB2):YDB2M9XDJ6N*/7Q/'!">/$]#U9Q+H?BUC)(E:RB)4L
MXH`D8@MK5L3#?+RHS[3LA9N:?AR+6,DB5K*(E2QB)8M8R2)V-$:L#XG8PO+5
MG5B^2I:ODN6K9/D&)/D.767.$G;=QO8WG34O\0BX"!J0/S:#+%^=LGR5+%\E
MRU?)\G7D7CR]6^\W?/S#5I:Q[L@R5K*,E2QC)<LX(,EXZ"QS,G8=)\QXM^!A
M(FA"8\9*EK&29:QD&2M9QDJ6L5)%LDQURC)5LDR5+%,ERS0@R73H+',R=1W'
MSE&F=<NVMPB:T)BIDF6J9)DJ6:9*EJF29:IDF2I9IDJ6J9)EJF29*EFF`4FF
M0SL),[VP[2U<JPG7*W__(O%38_?2)Q3L"!R4H_%!3LF25K*DE2QI)4M:R9)6
MLJ25+&DE2UK)DE:RI`.2I(>*$B;]D[:W<)4F3'BG'^AK)P[:A2Q3)5N]2I:I
MDF6J9)DJ6:9*EJF29:IDF2I9IDJ6J9)E&I!D.O2/.9FZOO*S(X*;BLX4E"Q3
M)<M4R3)5LDR5+%,ERU3),E6R3)4L4R7+5,DR#4@R'<I&F.FE1P174L+U>NZ(
MX*;^PPMK;/$&56<\("A9T$H6M)(%K61!*UG02A:TD@6M9$$K6=!*%G1`<=#+
MF=WM-!^?YN[T68J#O=FTW7SARR^/I)24D7)202I)%:DF-:26U)'ZB"33H52$
MB_<G!]FE*R%V9WCK%,%/A0<$D&4:%)K3TK5,E2Q3)<M4R3)5LDR5+%,ERU3)
M,E6R3)4LTX`D4[M+1YE>>$!8#MO%Z_7,`<%/N0-"<JUOV&6KU^UF"M^25K*D
ME2QI)4M:R9)6LJ25+&DE2UK)DE:RI)4LZ8!<TN^?O]S?OZ1W+W>__O+M_NGW
M^^/]UZ_/[SX^_O'=EJ5=0`[XW=/]YP]7Q>*V."7R.NZ\7-R6Y[Q>W-;GO%G<
M-N>\6]QVY[Q?W/;G_._)[=_/^2&Y39,KNRHFWV>>W!;GO$QNZW/>)K?=.3\L
M;@_GONYQ<7L\Y^GB-CWGV>(V.^?YXC8_^?O7'^#YUU]^W/U^W]T]_?[P_?G=
MU_O/=AO=7`]OQ??T\/MPWW#_\?+XPVZ[JW>_/;Z\/'X[_?7+_=VG^Z=AP(8_
M/SZ^C/\QO)SFS\>G?YS6P:__+0````#__P,`4$L#!!0`!@`(````(0#:8(;G
MS00``),1```9````>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;)2878^K-A"&
M[ROU/R#N3\`0\J4D1PMHVR.U4E7UG%X3XB1H`4=`-KO_OC,>/FR3)CE[L0J3
MU\/CF?'8SOKK1Y%;[[RJ,U%N;#9Q;8N7J=AGY7%C?__G]<O"MNHF*?=)+DJ^
ML3]Y;7_=_OK+^BJJM_K$>6.!A[+>V*>F.:\<ITY/O$CJB3CS$KXYB*I(&GBL
MCDY]KGBREX.*W/%<=^8425;:Y&%5/>-#'`Y9RF.17@I>-N2DXGG2`']]RLYU
MYZU(GW%7)-7;Y?PE%<497.RR/&L^I5/;*M+5MV,IJF27P[P_V#1).]_R8>2^
MR-)*U.+03,"=0Z#C.2^=I0.>MNM]!C/`L%L5/VSL%[:*/<]VMFL9H!\9O];*
M9ZL^B>MO5;;_(RLY1!ORA!G8"?&&TF][-,%@9S3Z56;@K\K:\T-RR9N_Q?5W
MGAU/#:0[@!GAQ%;[SYC7*404W$R\`#VE(@<`^&\5&98&1"3YV-@>O#C;-Z>-
M[<\FP=SU&<BM':^;UPQ=VE9ZJ1M1_$LBUKHB)W[K9-H[8=[$6P0LF#WVXA"1
MG&"<-,EV78FK!54#[ZS/"=8@6X'G;F;$T<_U_Z8*<T0G+^AE8\]M"V910W[>
MMPMOL7;>(:9IJPG'&J8KHDZ!`42WL6)P@+>'ACBJT+?3T+&A&-DZKR$9P'</
MZQD@-Q1S71*/);-!HL%"WIZ'1;&LDYYMX2WU5X>D"628I_[2GP:!KHA4A8^]
MPE3$JH(M0#,;DJ'10TVH]%@?/JR?^R''0<8L?%=G#$DSD[,(V,R%/UT1J0I_
MZ;&1(E85$`E-H<T"5IDZB_OT*#;IA^C(R@Q)`U$<\N2;5=1INL*+%8-&-_L9
M.A0;=)Z1_Y`T?E_RD6F(%8.&`DM8#=1SZ<9!!I+OZ\D,2;.4Z78G1C@C^G8`
MCA6#QH<[JM*N[B<2Q0:7-S.X2#.\.3(-L6+04)8ZRG.APD$&TBA4I*%0!1//
MC!5]/1#'BD$#9+!.U6`]1RA'F8A3(VJM:("(1I98M>A<V-:5)"(7\QXV%4:[
M`31>9<V9E=^*](5IY#SJ1?W*5"TZ*_9Y@_5Q_V.T.^BHP_9`+:0540?T`FR`
MHQ;8:H8XQZI%)\66KI#>7QJ,-@"=<+1CDX@(V<*;SN"DH5="U#I2"6F4M.B$
MV*Z?)Z3FKA.:6R$CT?#V:&2)58O.@_U8X<$ZG(/M0>2HB^M<1E1"/!S".H=(
M#+4Z-?>W7C2483<,+#HJ]FL#]8DRI"ZOHX[*D$1MDJD*1Z3*=M&>S!2+3HJ=
M6R%]$$SJ\SKAJ`Q)U"X4>5(8`2K[10NH6'1`[.<*X)-=D78!#71J=.:0*5N%
MI(A&EEBUZ%S8QA6N!X&CIJ_QC`Z*C$04N,"?FD?R2!.PA>O.C3-,W"K&BQG[
M]?.X4JUO*G-F+II6U.+>Z(:M8%CML6K1HND9>\S]:$JUCK>8&J$(6]'2IX,W
MFYM'VJA5J'RT9]T('V3N)\*':I///&'!!1A%="^XE<RH5:A\-$;AHSLP71$+
M7AUYQ/.\ME)QP?NM!W/OK?W=^T5>O0U["'=R>8%U^B_@2GQ.COS/I#IF96WE
M_``NW0GVW(HNU?30B+.\F.Y$`Y=A^?$$/WYPN!*Z$Q`?A&BZ!^R4_<\IV_\`
M``#__P,`4$L#!!0`!@`(````(0!&D!-L8P4``#05```9````>&PO=V]R:W-H
M965T<R]S:&5E=#4R+GAM;)18VXZC.!!]7VG_`?'>(>9.E&348/7N2#O2:K67
M9YHX">H0(J`O\_=;IKC813I-YJ$G*1^*4U7'58[7WSZ*D_$FJCHOSQN3+9:F
M(<Y9N<O/AXWYS]]/#Z%IU$UZWJ6G\BPVYD]1F]^VO_ZR?B^KE_HH1&.`AW.]
M,8]-<UE95IT=19'6B_(BSK"R+ZLB;>!K=;#J2R727?M0<;+LY=*WBC0_F^AA
M5<WQ4>[W>29XF;T6XMR@DTJ<T@;XU\?\4O?>BFR.NR*M7EXO#UE97,#%<W[*
MFY^M4],HLM7WP[FLTN<3Q/W!W#3K?;=?)NZ+/*O*NMPW"W!G(=%IS)$56>!I
MN][E$(%,NU&)_<9\9"MN^Z:U7;<)^C<7[[7RV:B/Y?MO5;[[(S\+R#;425;@
MN2Q?)/3[3IK@86OR]%-;@3\K8R?VZ>NI^:M\_UWDAV,#Y?8@(AG8:O>3BSJ#
MC(*;A>U)3UEY`@+PURAR*0W(2/K1_O^>[YKCQG3\A1<L'09PXUG4S5,N79I&
M]EHW9?$?@ECG"IW8G1,7V..Z#1]O/VPAD38NGC;I=EV5[P:(!5Y57U(I/;8"
M+WU`^/HAQ,\BA-"DDT?I96,&I@'D:RC+VS9TW;7U!JG,.DP\Q3`=D?0(F3?I
MEBL&"_@.I"$#*NGKV>^Y2;#DUGN-T0"^![(V(7(%$>@0/H7X(T0CZ]Q#5H(W
M)C@?N/F.H[\Z1HPS!)10`U<,&A4H\/R\2?#&A,XU4`E=CU!!C$*%&KABT*B`
MW.=3D6`]*Z'K$RJ(\5OQ,=>.'#>*=$BB06QV!<)5B+/T`M_^I*K^/?PEF/(?
M_;9:CQ$#E1O2[1)(@A`,T69+^4^/D*L(%CB.[2D0+?^P5^?G7X(I_U!_=8P8
M)/?@^)X7$MTFB+@5(=><A,SUW'"LL\9?3E2E;]UN`1),^1-QQ(BYQ2[Y&L)O
M0K0`HGL"D&`2@$=J'R/F9@!?0SA"NC)Z#';24&>-/H/9.;\`+9H&0-I_W(&Z
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M;Y0;[ONK(++'^%70)QW`OFLRM6@2B$>%VX'40'RE`76!X(Q309-H^15/H3=&
MJU<$-*DJY;9";(FF@5`==R"-HT-`R0`:1*-:=(K@Z0Z*$DU^&'GDJ![;"%)$
M/+%PU:+SN6M2R1__-&63&=N!O+;[NV'DV$%`."<:A@51P**(Z)QK&,<-'3\:
M9:8'<=<(D]<?-(BI@!&$1RO']VTG#$;5=?I5,=<#Y=W+NB,:#52/XJ[I!E=/
MTRB(,.,.A*5P/"^*/)><Y9,.,\I'WFI)UZT%&>(E%5[F%*(ZB$2<3K61E:_R
M`LJ&2@_6X7+LT9:W!L0>PZ59>\-D#0MP9W5)#^)'6AWR<VV<Q!Y<+A<!)+?"
M6R_\TI27]@KIN6S@MJK]>(3;20&7-W#$,(U]63;]%SE"AOO.[?\```#__P,`
M4$L#!!0`!@`(````(0#U9^?9BP0``)H/```9````>&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;)1776^K.!!]7VG_`^+]!@SF*TIRU1"Z>Z5=:;7:CV="G`05
M<(1IT_[['3-`;=--TSZ4Q#EG.&=F8.S5]]>ZLEY8*TK>K&VR<&V+-04_E,UI
M;?_]U^.WV+9$ES>'O.(-6]MO3-C?-S__M+KR]DF<&>LLB-"(M7WNNLO2<41Q
M9G4N%OS"&OCER-LZ[^!K>W+$I67YH2?5E>.Y;NC4>=G8&&'9WA.#'X]EP7:\
M>*Y9TV&0EE5Y!_K%N;R(,5I=W!.NSMNGY\NW@M<7"+$OJ[)[ZX/:5ETL?YP:
MWN;["GR_$IH78^S^RRQ\718M%_S8+2"<@T+GGA,G<2#29G4HP8%,N]6RX]I^
M(,N,!+:S6?4)^J=D5Z%\ML297W]IR\-O9<,@VU`G68$]YT\2^N,@EX#LS-B/
M?07^:*T#.^;/5?<GO_[*RM.Y@W('X$@:6Q[>=DP4D%$(L_!Z&06O0`#\M^I2
MM@9D)'_MK]?RT)W7MA\N@LCU"<"M/1/=8RE#VE;Q+#I>_XL@(D5-0;PA"%P_
M"'*#Z`]$N`Y$0A81<1,_@KO?(-*!"->OW1'"]G[A>M<='<Q7G_Y=WN6;5<NO
M%O0T9$1<<OF$D"4$&_..FJ=*_%\A('DRR(.,TL>"'`OHGI=-&/DKYP4J7@R8
M+6(BVYHPGHY(1X2LB0R[&Q<42J1SLA$BFPLL3;Z@AJJOC_MHE"_!:QO>)9,T
MWP_T&VT1X_<-(\6EYL+.7,B4!4T;M,G]VB1X;4,H15ML:$-,T">>1&X84#.U
MB'A7OU,I81A$L<'(%(8F'EI5%2\;QH?'_7:")<DTD1@F$!/V)F)"/=>H0(H`
MQ8/*2"CQB=%RF<+0/$"CJQYN:Y=@0SMU#>V(0>V4>M0W`"D"%.TJPPO"Q#,8
MF<+0M(=?T2[!IG9B:$<,:O>BD$:&DA0!BG:-X=$@,!B9PM"TP\.OYKU_V43R
MA?Y)^TB>;B.,J&$#,6B#Q$$2FNV#@#A1GJ0P,D`[+4H4):YI[9,HFEVY.3'>
MK9\_*I*D>_6IT==;Q`Q>0S=P#4"*`*5D*L-W0]]D9`I#\P#I4CW<?E0DV-1N
MU@DQJ#WR8$CJ=4SQ=T6Z2@@\$ALOOTPA:,H)O)7NE]ZC3>U&=VP'$(I/7$I#
M0_P`4-1K%.*%GF_4*E,YN@$YVY3^N9U[@I-0&Q2FONT`&@P0/S22F0X`U0#&
MA7$P#2`Z&\(CQIS"1([`^RW@P-0M&/?:]B%AYMS0DTZ8]YT$AD;C<>#"GUZZ
M3.7H99"3\'X/.#=U#T:6MP1!.+#]F,(#:4S#=("HA=!(H4M(;)`RE:1[D)/P
M?@_#W,3=L=SL;,EL*9TO[>9+F;:D:Y(33M$DIP&%M:]N/7%0J@F?O=:W\B@!
M;R:9GZF+PVCV]$ZH][Z9+<ECT!!KZG8\UN"^NF;MB:6LJH15\&=Y9*&PI9E6
M\3BU)4O8[0+?6-_)8]8'ZP^$P@_T@U_`VG@R<Z9@<#*ZY"?V>]Z>RD98%3N"
M#'<A#R,MGJWP2\<O_:Y]SSLX$_4?SW`&9E!Q=P'@(^?=^$6:G4[5F_\```#_
M_P,`4$L#!!0`!@`(````(0#U,3F-<@(``/,%```9````>&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;)14VX[;(!!]K]1_0+ROL>/8V41Q5IM$:5?J2E75RS/!
M.$9KC`7DLG_?`39N+JLV?;&-.7/FS)F!Z<-!-FC'M1&J+7`2Q1CQEJE2M)L"
M__B^NKO'R%C:EK11+2_P*S?X8?;QPW2O](NI.;<(&%I3X-K:;D*(8367U$2J
MXRWL5$I+:F&I-\1TFM/2!\F&#.(X)Y**%@>&B;Z%0U658'RIV%;RU@82S1MJ
M0;^I16>.;)+=0B>I?MEV=TS)#BC6HA'VU9-B)-GD:=,J3=<-U'U(AI0=N?WB
MBEX*II51E8V`C@2AUS6/R9@`TVQ:"JC`V8XTKPK\F$P6&2:SJ??GI^![<_*-
M3*WVG[0HOXB6@]G0)M>`M5(O#OI4NE\03*ZB5[X!7S4J>46WC?VF]I^YV-06
MNIU!0:ZN2?FZY(:!H4`3#;P,IAH0`$\DA9L,,(0>_'LO2EL7.,VC;!2G"<#1
MFAN[$HX2([8U5LE?`90X43W)X(TD!?5O^X-H<)\E6?YO%A(4^0*7U-+95*L]
M@J&!G*:C;@23"3"[RE+PY_W*0(V+>71!/A30!KJQF^7Y_93LP$+VAIE?8P;G
MB,4[B%$/(:"O%PFEGXK\NS@'+C"<O%Y<FF8]KR]@'C"I]]=5M#CY<989++D]
MLP,7&*CZS'D^OL@<,/#\@QG%YYC%$>-&\M2&X?^(<>`+,:/D/-$\8,:^@W$T
M/-]=A%UOTID,&-G;/7'@2QD7@S`/F,S+&"9I=N$9G&S'\=Y^T!7.;1CKCF[X
M,]4;T1K4\`I<CJ,1$.AP:L/"JLZ/[UI9.&W^LX;+E<,DQ!&`*Z7L<>&:T%_7
ML]\```#__P,`4$L#!!0`!@`(````(0#/Y,ZJ:0(``%(&```9````>&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;)1576^;,!1]G[3_8/F]&$@A"0JI6E7=*FW2
M-.WCV3$F6,$8V4YI__VN[9319FN:EX!SC\^Y]UQ?L[IZE"UZX-H(U94XB6*,
M>,=4);IMB7_^N+M88&0L[2K:JHZ7^(D;?+7^^&$U*+TS#><6`4-G2MQ8VQ>$
M&-9P24VD>MY!I%9:4@M+O26FUYQ6?I-L21K'.9%4=#@P%/H]'*JN!>.WBNTE
M[VP@T;RE%O(WC>C-,YMD[Z&35._V_053L@>*C6B%??*D&$E6W&\[I>FFA;H?
MDTO*GKG]XHA>"J:54;6-@(Z$1(]K7I(E`:;UJA)0@;,=:5Z7^#HI;N:8K%?>
MGU^"#V;RCDRCAD]:5%]$Q\%L:)-KP$:IG8/>5^XOV$R.=M_Y!GS3J.(UW;?V
MNQH^<[%M+'0[@X)<747U=,L-`T.!)DHSQ\14"PG`+Y+"G0PPA#[ZYR`JVY1X
MED?9/)XE`$<;;NR=<)08L;VQ2OX.H.1`%4C2`PD\#R1)&J6++,GRTRPD9.0+
MO*66KE=:#0@.#6B:GKHCF!3`_.^*H!2'O79@OP62-="%AW6>YROR`-:Q`^;F
M&).."`*BHS*H396=IS/HS-L9N$TEAK&:9#`?^7V6-P$S\QV="LY>"KXMY,`E
M3GV1:9QDKS1".`OA+)DMQOB+&B_/D73@B>1K8T,X/R4)!VIJZ]M5.O!$\K63
M(7Q2,C]'TH$GDG^-"\T+X9.2\W,D'7@BN1Q[%21#^/^]#-="F)J>;OE7JK>B
M,ZCE-9S".)J#33I<"F%A5>^G9*,L#+-_;>#NYC!"<03@6BG[O'#7SO@U6/\!
M``#__P,`4$L#!!0`!@`(````(0!N\=.\FP(``"@&```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;(Q4VX[;(!1\K]1_0+ROB>U<O%&<51)KVY5:J:IZ
M>288VRC&6$`VNW_?@XF=V[;=E\3`,,S,X;!X>)$U>N;:"-6D.`Q&&/&&J5PT
M98I__GB\2S`REC8YK57#4_S*#7Y8?ORP."B],Q7G%@%#8U)<6=O."3&LXI*:
M0+6\@95":4DM#'5)3*LYS;M-LB;1:#0EDHH&>X:Y?@^'*@K!>*;87O+&>A+-
M:VI!OZE$:WHVR=Y#)ZG>[=L[IF0+%%M1"_O:D6(DV?RI;)2FVQI\OX1CRGKN
M;G!#+P73RJC"!D!'O-!;S_?DG@#3<I$+<.!B1YH7*5Z%\VR,R7+1Y?-+\(,Y
M^T:F4H=/6N1?1,,A;"B3*\!6J9V#/N5N"C:3F]V/70&^:93S@NYK^UT=/G-1
M5A:J/0%#SM<\?\VX81`HT`31Q#$Q58,`^$52N)L!@="7[O\@<ENE.)X&D]DH
M#@&.MMS81^$H,6)[8Y7\[4'AD<J31$>2,:@_KD=!E$S"R?3_+,0KZ@QFU-+E
M0JL#@DL#9YJ6NBL8SH&Y=^9U#%[_9A4\.I*58TGQ#"-P8:`\S\MI/%N09\B4
M'3'K6TQXB=CT"!>@H\W.)@CH'41#%.>BWRY#K\V!G;:>=>TG@'L0&UT)>0-Q
MY2:[A4Q/D`NQ\:58EW`,-_#?HMVF%,/S<=*87,6U]IAX,+:YGLC.)BXD0:'?
MGY\#IQC\#E*F<7(9V-IC)EWEH^0^.471%7)SOCZ>)4E\N1]ZUYUQW#\;)^-A
MW>OVG>DOKN2ZY!M>UP8QM7==%\&YP^SP(*PBE\S5_!H>BJZMR+``C=K2DG^E
MNA2-034O@'(4S*`SM6]U/["J[=IEJRRT:/=9P8O,X:*.`@`72ME^``>3X8U?
M_@$``/__`P!02P,$%``&``@````A`-0^7JS'`@``N`<``!D```!X;"]W;W)K
M<VAE971S+W-H965T-#`N>&ULE)5=;YLP%(;O)^T_(-\7,%\A44C5I.HV:9.F
M:1_7#IA@%6-D.TW[[W=LIR203DMO`./'K]]S?#@L;Y]YZSU1J9CH"H3]$'FT
M*T7%NEV!?OU\N,F1IS3I*M**CA;HA2ITN_KX87D0\E$UE&H/%#I5H$;K?A$$
MJFPH)\H7/>U@IA:2$PU#N0M4+RFI["+>!E$89@$GK$-.82&OT1!US4IZ+\H]
MIYUV(I*V1(-_U;!>O:KQ\AHY3N3COK\I!>]!8LM:IE^L*/)XN?BRZX0DVQ;B
M?L8)*5^U[>!"GK-2"B5J[8-<X(Q>QCP/Y@$HK985@PA,VCU)ZP+=X<4F1\%J
M:?/SF]&#.GOV5",.GR2KOK*.0K+AF,P!;(5X-.B7RKR"Q<'%Z@=[`-^E5]&:
M[%O]0QP^4[9K-)QV"@&9N!;5RSU5)2049/PH-4JE:,$`7#W.3&5`0LBSO1]8
MI9L"Q:$_P^$\GH'*EBK]P(PD\LJ]TH+_<1`^2CF1Z"@2@_OC?.1'>8K3##;]
MCTK@'-D`[XDFJZ44!P^*!O94/3$EB!>@_'9$$(IA[PQLEX!9!:?PM,KB^3)X
M@M251V9]R41C8O,&,1N0`'P-YB#DZ\T9N$!P/9E+PD'7!K!V3&JMXSP+DW0,
M;$9`FH9Y/``C9Y"JZYT9>.P,CFW0=<X<DUEG-SB*9NDT;2,"*B<[28RL)>^Q
M9N"QM2S!$VN.<=:R.)J?4F*M;T;S.,;YL'[D"VKT^I09>.IKDI"U8V+[D9CR
MW)R]&.V<O6=G`T]WGI:18UQ&<!SA=`)L1D"8)^D_<C)[CS,#3YU-SF+MF+.<
MG+T8Y<3\F:[^[@T\W7D2\MHQ[M-*XWQ^JDY7)>?S208M:U(EKOFZWM23'?U&
MY(YURFMI;1NKZ932M5[HG3#0HK>]:"LTM$S[V,`?DD(EA#[,UT+HUX%I[L,_
M=_47``#__P,`4$L#!!0`!@`(````(0!(Q5M1F@(``*\&```9````>&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;)15RV[;,!"\%^@_$+Q'U%NV83E('*0-T`!%
MT<>9EBB+B"0*)!TG?]\E:2N6'*3NQ1;%V=F9W26UO'YI&_3,I.*BRW'@^1BQ
MKA`E[[8Y_O7S_FJ&D=*T*VDC.I;C5Z;P]>KSI^5>R"=5,Z81,'0JQ[76_8(0
M5=2LI<H3/>M@IQ*RI1J6<DM4+QDM;5#;D-#W4])2WF''L)"7<(BJX@6[$\6N
M99UV))(U5(-^5?->'=G:XA*ZELJG77]5B+8'B@UON'ZUI!BUQ>)AVPE)-PWX
M?@EB6ARY[>*,ON6%%$I4V@,ZXH2>>YZ3.0&FU;+DX,"4'4E6Y?@F6*Q33%9+
M6Y_?G.W5R3-2M=A_D;S\QCL&Q88VF09LA'@RT(?2O()@<A9];QOP7:*25737
MZ!]B_Y7Q;:VAVPD8,KX6Y>L=4P44%&B\,#%,A6A``/RBEIO)@(+0%_N_YZ6N
M<QRE7I+Y40!PM&%*WW-#B5&Q4UJT?QPH.%`YDO!`$H'ZPW[HA;,D2-)_LQ"G
MR!J\HYJNEE+L$0P-Y%0]-2,8+(#Y?4=@Q6!O#-B&@%@%77A>I7&\),]0NN*`
MN3W'A&/$^AU$-D`(Z!K$@>7+Q1EPCN'$G8A+!EYKX-9A(EM7XVA]\F*4&4IQ
M>68#SC%0#9G#^32SPR2V:+/YW/?]L;3U!X"1LGBLS(QB!`/]<>-,T$1A-FV<
MPZ1689Q&63A5>`J8A7$8!H.%D4(8Z<MK9\`39?-TX'5=<QBG+(V3.!KOKT_W
MPRR,WIR-=*7_H\N`I[K>IM3I<AC7TR"&S.E4V0B1)7Z<O,V%T^;N''<D>[IE
MCU1N>:=0PRKHK.]E8$ZZ&\<MM.CM$=P(#3>%?:SAP\!@FGT/P)40^K@P=]KP
MJ5G]!0``__\#`%!+`P04``8`"````"$`+'-*2#\#```S"@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6R45EUOFS`4?9^T_X!X+P02R(="JB;0;=(F
M3=,^GATPP2I@9#M-^^]WC0.SG:Y-7T(X'!_./=?&7M\^-;7SB!DGM$W<P)NX
M#FYS6I#VD+B_?M[?+%R'"]06J*8M3MQGS-W;S<</ZQ-E#[S"6#B@T/+$K83H
M5K[/\PHWB'NTPRT\*2EKD(!;=O!YQS`J^D%-[8>32>PWB+2N4EBQ:S1H69(<
MIS0_-K@52H3A&@GPSRO2\4&MR:^1:Q![.'8W.6TZD-B3FHCG7M1UFGSUY=!2
MAO8UU/T4S%`^:/<W%_(-R1GEM!0>R/G*Z&7-2W_I@])F71"H0,;N,%PF[EVP
MRI:NOUGW^?PF^,2U_PZOZ.D3(\57TF((&]HD&["G]$%2OQ02@L'^Q>C[O@'?
MF5/@$AUK\8.>/F-RJ`1T.X*"9%VKXCG%/(=`0<8+(ZF4TQH,P*_3$#DS(!#T
MU%]/I!!5XDYC+YI/I@'0G3WFXIY(2=?)CUS0YH\B!6<I)1*>1>!Z%@DB;Q9&
M\\5[5*9G%7COH!)ZX2(*HOAM+[ZJJX\I10)MUHR>')AZX)QW2$[D8`7*0SZJ
MFC&Q_P4&24F1.ZF2N'/7@2PX-/EQ$\_BM?\(G<G/G*WBP*_&F9N<W:5.8#+2
M@2%;)5^=:8`/-8V%0=AZ82\W?/`OR=+_H+I5@&'6]GI)"2VO+S`LD>R2$O^C
M&/5`^Z^O1Y(3%\2UK!>FNZWB1'VWPL5\;O5K9SR?SA83<WRJ/P\F86Q5G^G/
M37VCKIE9EYR`4UCFK_=+#K+K6YK^MHHS'7NZLX'4!C(-,#S"PK@^>TFVO$56
M=EO%T;P-@-:PR)[Z`V>8I)D&&';C]]B59-NNU<JMXFAV;2"U@4P##&_PC;@^
M2DFVO=E1*H[F;0#T**?FW$@'SABE!AAVY3'`^CR^/3OE(-OVS'2P51S-M@VD
M-I!I@.%Q:7I\?>5(LNW-CE1Q-&\#\%JD`V>,5`.47;5)J]VGP>R`=[BNN9/3
MH]R`0_@0C>AX-K@+Y?JU\!V<&?H=UA\?P)[=H0/^AMB!M-RI<0F2$V\.2X2I
M75_="-KU>]Z>"MBM^[\5',XP["03#\@EI6*X@1?[XW%O\Q<``/__`P!02P,$
M%``&``@````A`$8:4^];!0``018``!D```!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&ULE%A;;ZLX$'Y?:?\#XKT!<TN(DAPU5-T]TAYIM=K+,R5.@AIP!/1R
M_OV.&0?&AB;AI6F<SS.?Y_)A9O7MLSA9[[RJ<U&N;39S;8N7F=CEY6%M__/W
M\\/"MNHF+7?I291\;?_DM?UM\^LOJP]1O=9'SAL++)3UVCXVS7GI.'5VY$5:
MS\29E_#+7E1%VL#7ZN#4YXJGNW93<7(\UXV<(LU+&RTLJWMLB/T^S_B3R-X*
M7C9HI.*GM`'^]3$_UQ=K17:/N2*M7M_.#YDHSF#B)3_ES<_6J&T5V?+[H115
M^G*"<W^R(,TNMMLO`_-%GE6B%OMF!N8<)#H\<^S$#EC:K'8YG$"&W:KX?FT_
MLF7B^[:S6;4!^C?G'S7YWZJ/XN.W*M_]D9<<H@UYDAEX$>)50K_OY!)L=@:[
MG]L,_%E9.[Y/WT[-7^+C=YX?C@VD.X03R8,M=S^?>)U!1,',S`NEI4R<@`#\
MM8I<E@9$)/UL/S_R77-<VWXT"^>NSP!NO?"Z><ZE2=O*WNI&%/\AB"E3:,13
M1N!3&6'1;!&&0;28WV_%5U;@4UGQ@EL4'#Q.&YVGM$DWJTI\6%!R0+@^I[*`
MV1(,7L*"A^@"]56<($#2R*.TLK;GM@4AJ"&Y[YLH#%?..R0D4YCM$,-T1')!
MR#P"O8XCA(MR'$_9A8H$2RHRA9+;%A?`=L?-,_R.(.8=1&,"$;J?B02O;1"0
MSG$41IU=)(>8MN[;A80L:)XAP_=[EN"U#<?J//NN;WA&3-@FZX$Q/PI<'9%H
MB-AE40_0J$'EWD]-@LV@],'&H""&!(4L:)ZC*9XEV`R*40E;Q$1M4)@?>)ZW
M,()"$?,PG`<]0*,&O7!_4"18IQ:%O5T,"F(4->`5+@Q$0A$1]!\!:-3D(\UH
M>1_T]'I;R4TFQ5B/S18Q)&]D06,0ZPRN>Y;@6Q6#&.*9+&B>&1R4'OZZZQ:M
MG]IWS9I1(,Q,-`_CA8%(-$0X]^9>+P,Z.ZF`)#4WV*%>TC8?E@U#T#5V%'&5
MG=1)PDX^*VX7#D-UU5@2)<'B5B"20+JBQVB2!K,Q$3;U1H&H]Z]DF$W2X19]
MLWY09U5GN[X?F8VMS"`BC'TB2GIH)BFQO/T,6MIPO56@:^30S&URD\2:#=4Z
M"HV^VBH0S1MN:U?TT$S28X92"O+5/4"'CVX%HMYQVXAW*82D<V[T-<HF[9@1
MU4$0AMUG<3BX3'T-T",S28P9"JO.S;Q:*!!R>_""N)<[O.0H@(^7CR#N'R0:
M-6^26+=HO=F&<JA`2,V+`_.6FF@`GP6DZ'1NDZ3:&Y'JR,C85H%`>OJJBXR:
M3T9!?0)TCE)Z2=G=)]B>W&7$,>@SA(*M0*3XZ8K.8I)@>V.";=3/5H&H]Z\$
M6[X:T1A<;[T6K9]]V'H*A#44LWG0AQ_+^PI`C\PDO9;OF49>AK=Z!5*M-TJ.
MZO7#(HY('>KL)@FV-R;8YM-$@6B%!\;#.%$8U:$NN4SI["8)NH?*3&6+GEO5
M-)%OE<C+"NW(H+OUZH0,C;^SV89:'X6]!T4,0;3<R8K.8I*:>ZCF8*Q7G,$K
MJ@)1[[BM7=&\R]O@_<W6HF\UFP)A.01^S!9&=!*%&&$S2:+]H40/VTN!5'NQ
M.'`-$4\48H2-(<;7A<@?$>'!*Z$"X3M\P.+YPE0BA1AA,TF483!G2L^P?12(
M-C>\A7;-@AW5@;H9#T[L<"95\.K`$WXZU58FWN0TSH,K0K?:30H?/3G>,=:W
M,$%LQVU.]P,,\,[I@?](JT->UM:)[\&D.Y.SM@I'@/BE$>=V$O8B&AC=M?\>
M853+87SDS@"\%Z*Y?)'$N^'OYG\```#__P,`4$L#!!0`!@`(````(0!7C6QY
MK0,``"<,```9````>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;)1648^;.!!^
M/^G^`^)]`1-((`I9;;*[=Y5:J:K:WK,#3H(6,,+.9O??WPQ.P(9M2WA(8/C\
MS3?C\3"K^[>RL%Y9(W)>)39Q/-MB5<JSO#HD]H_OSW>1;0E)JXP6O&*)_<Z$
M?;_^^Z_5F3<OXLB8M("A$HE]E+)>NJY(CZRDPN$UJ^#-GC<EE?#8'%Q1-XQF
M[:*R<'W/F[LES2M;,2R;*1Q\O\]3]LC34\DJJ4@:5E`)^L4QK\65K4RGT)6T
M>3G5=RDO:Z#8Y44NWUM2VRK3Y:=#Q1NZ*R#N-Q+0],K=/HSHRSQMN.![Z0"=
MJX2.8X[=V`6F]2K+(0),N]6P?6(_D.66A+:[7K4)^IFSL]#N+7'DYW^://N<
M5PRR#?N$.[#C_`6AGS(TP6)WM/JYW8&OC96Q/3T5\AL__\ORPU'"=H<0$0:V
MS-X?F4@AHT#C^*V,E!<@`'ZM,L?2@(S0M_;_G&?RF-BSN1,NO!D!N+5C0C[G
M2&E;Z4E(7OZG0`1%=23^A60&ZB_O?<>/0A+._\SB*D5M@(]4TO6JX6<+J@9\
MBIIB#9(E,%\C4SJZ6'\5*LA#D@=D2>R%;4$4`O;G=1V%T<I]A9RF%\QFC"$F
M8GM%X%:`O$XC1*YK_#CK5RD(1BF8.M2V40;@[K3YBX'C,63>0PPID*+I4A"<
MV-`$.L]1&)NN-PHSZ^1N-8/A.;C%,X(3&\+J/`>S/B*5%X69M;OE.]',%+8U
M7WM!K%_]WAH:H9BG9P?!`XU!:(K8*(R6G:NA#RSR>N6&F/DM8A!LBHG\H1B%
MT<1H!L,SG(/I:4#PGXI$833/FL'PC!\<[33__J0@V(PYF/4;JXI$86*BSK03
M><85/MWUR6\7;(T%"X?H51/'D;[`4![?HAS!`^6!/R@=A;DH]YP@\&-=^P"^
M'<'GP<=P0S6!3\GTA+?HH>YAE5U`T`:ZLZN7N,IR!QJV2H(]='(%M&A34.3/
M!XF\@+3JTRUF.K"13O>NVBY43!_IJ#\2!=*]:Q;3.[;.Z=Y5HP6RSONX_(D"
M7:J(.,1_NAM6SA#C!3K&5'A3$R<?=/%1F5]`?9V'4:2?N4'7WX[P0=1_ADVQ
M-W5S'(=&9W)4VQ^T;S\PZPT'.61J=UP)4G.9&EM*UAS8EA6%L%)^PIG+A][4
M6;MY\,''3^K`OL$Y$>UN]P+&M)H>V!?:'/)*6`7;`Z7G+$!$HP8]]2!YW0Y+
M.RYA0&MOCS"0,Y@P/`?`>\[E]0$=="/^^G\```#__P,`4$L#!!0`!@`(````
M(0#+);*:K`,``"8,```9````>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;)16
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M]5?<(<@VU$E48$?(O8!^J44(%KNSU7=#!;Y3JT;[\M3P'^3\&>'#D4.Y8W`D
MC"WKIP*Q"C(*-$X0"Z:*-"``_EHM%JT!&2D?A_]G7/-C;H>)$Z=>Z`/<VB'&
M[["@M*WJQ#AI_TB0/U))DF`DB4#]^'OL9'$<)5GZ3Q97*AH,%B4OURM*SA9T
M#;R3]:7H07\)S!=G4L?D]36KX%&0W`J6W$YM"UPPJ,_#.DN\E?L`.:U&S&:.
M\77$]H(0"12TA1)P0>\D&E*ABGZY#!=M`BRT75@W,@#<D]C`$/("(M4AQ1R2
M/$,TL>'_B!7@W`;R25L6Q/JK-Q(33H:V9J!0`IH4*+":-U'LZ-4VON1/+,IM
M.,J>)25&Y382HT@R`X42T"3!ZU5);Y=2@/7L1&%F9$=B%O[0A8FS,#X?;R)]
MP=98$.D+TH\WH;Z@,!;XGO:)U`6:U>1_K`JP;C5+C#;=2,QHU7.2S-/%Z[JW
M!CP,PUA5;K`7!CSRTE2%/[>`9A+.@.OK*<"&2<^0L9$8Z&BE_8R*;%_`>`:F
M>!NC>1#7MG(FOMV3`FQX"!(]\QN)4;:'&2B4@"9EH4NY;L>*1?_:L1*C2#(#
MA1+0)/EP?5Z?G@&MYV>^9T?0V,F^D\*N,_I@.\/H^\Z?K2CT%8$3A"I&]R1N
MFJM+[LM[23NE9YMS!$V[,PN"3#U:C![9FO@H3I.7]]MX-TH1$W_T3*A;$S?5
M]=;DO:99FVU)&+5$@^E[TCQ6KP&)H>TM)FE$CF5R:FD1/:`M:AIF5>0D1JX`
M#OHI.HV#M\,T:,0W8DP4UZ8[_0!36E\>T+>2'G#'K`;M@=)SQ$!%Y9PG'SCI
MAUEI1SC,9\/7(\SC"*84SP'PGA!^>1`O$//E,&RM_P(``/__`P!02P,$%``&
M``@````A`!B*#V=Z!0``=!4``!D```!X;"]W;W)K<VAE971S+W-H965T-34N
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M3^)>>I'M/#[T`?JW5&^M\=YJ#_7;;TVY_:,\*8@VY$EGX+FN7S3TRU:;8+,S
MV_VYS\"?C;55N_SUV/U5O_VNROVA@W2'H$@+N]_^D*HM(*+@9N6%VE-1'X$`
M_+>J4I<&1"3_WK^^E=ONL+']:!7&KB\`;CVKMOM<:I>V5;RV75W]AR`QN$(G
MWN`$7@<G7K!XLS]LAAV7S6#Z^),=5-$'1>9=_OC0U&\65!KP;,^YKEMQ#PXO
MT4#N8WS>"P_$13MYTEXV=FQ;H+R%G'Y[3*+PP?D&>2@&3#K'"(K(+@@==.U6
M&@8'^(ZD(6PFZ>NINW#38,WMXC5%`_@>R7J,R!5$3"%R#HDF""$+N5E.5H,W
M-O2:D5L21?2C4\3XHZ",&Z1A(%0@P<NI:/#&!IT&E4EBGZ`4,085-$1]"<1A
MX/F4NS0V$&9P=)8STV#.+*$?E"+&8,8-TC`0*M$M5#3X9_E"C$&%&Z1A(%3@
M0"V/B@;SJ*Q95!"#Z1%AY'MQP&N?0/S8]X.$Q582B!NN71%-1YD(T$/3Z"X?
M'U0-9@)BEPE`#`KP@@!F)T-D!!$F?A2SHI4F(A0>].W)!V&_OH6]!C/V1D?`
MXX(89'^7A$$8L_.1$<2U`T0`8NV+V$@/82]@-"X/?H]F_.,IJ\A_`/G]\;XS
MX]:O9S]9E^/ZU%."*3N4O>[]BTM'X*0@S2IFE9T.H"'\`=1^S%IK1B&1F\1&
M;?0:)84$D?"G04<5Z!&Q7`$.%*J`54<J$#2<WRA>PQ%@F(QBKIYQ23'\D%,5
M>I8L5X&3AZH(V!D6"!I40`^*@HCE*ALP4].4IH4RU#-E.4.<0-`#QK$6"%8&
MJ3#&U%#9W")-#.6C!\MR/CB&2,0BWK;U]U-H+NO^W(E5P"*:L741KLD?C;\D
M:'=EJ*<Z]%1:K@-GF*DCF'\%1!#J"%:\OV3"7/=7/NL_DJQ[JVDN4>)Z/BTG
MCM/,))[PMIP*!%T28+3<H3SH.D^09/O?31#5H0?5<ATXUJ@.5BBI0-!%A\\*
M+1O6S6.'.WH+9:<GD<%._W+P8>1\/.,%SB]P.AZ_)&0M+!U`$XML9I&FA?#R
M;AI[/9J-O=GQ&T#0MB;2\=3UL02N@EACD5=![TQ`[Z8)V*.9D%D9#R`J9#I%
M@Q"<I13$U,JKGB:U-"-0DV:E?%PAGD9S(;R.!Q#ER(MY!%U^^4G30BF"IQLH
M:C3[UA].6>S#F'H(,HIX9I&FA?*Y::;INP,>LGD1(RCL9TB8)'$B?#YU!T>(
M\:+$#81@NB3!B,"-8'Q/D:<J;IJ$^OJ$JYA7,(+PNT/@K]>1+]B4R`9'B+FN
M5!+,3"E5<=,<A*NKN8I9^2((XQRXL>>N^:^4;'`TU8^^%=.NC5:,EUQXGU.I
M9J\R=3RV5E&_Z@LL#U(]6L?+M2=/7QPP>PJ7;OT-E3,NP)W7.=^KKWFS+T^M
M=50[<.FN8DA`@[=F^-#5Y_X6Z;GNX+:K?WN`VTT%]S?N"L"[NNXN#_#!SGA?
M^O@_````__\#`%!+`P04``8`"````"$`VU[E>:$#``"="P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970V-"YX;6R<5MN.FS`0?:_4?T!^+]<`(0JI-@':2JU4
M5;T\$W`2M(`1=C:[?]\Q#L0VV^ZV^Y`-)\?'<V;&9M;O'YO:>,`]K4@;(\>T
MD8';@I15>XS1C^_9NR4R*,O;,J])BV/TA"EZOWG[9GTA_3T]8<P,4&AIC$Z,
M=2O+HL4)-SDU28=;^.5`^B9G\-@?+=KU."^'14UMN;8=6$U>M4@HK/K7:)##
MH2IP0HIS@ULF1'I<YPSBIZ>JHZ-:4[Q&KLG[^W/WKB!-!Q+[JJ[8TR"*C*98
M?3JVI,_W-?A^=!9Y,6H/#S/YIBIZ0LF!F2!GB4#GGB,KLD!ILRXK<,#3;O3X
M$*,[9Y4Y-K(VZR%!/RM\H=)W@Y[(Y4-?E9^K%D.VH4Z\`GM"[CGU4\DA6&S-
M5F=#!;[V1HD/^;EFW\CE(ZZ.)P;E]L$1-[8JGQ),"\@HR)BNSY4*4D,`\&DT
M%6\-R$C^./R_5"4[Q<@+3#^T/0?HQAY3EE5<$AG%F3+2_!(DYRHE1-RK2`#1
M7W]W37?I.W[PLHHE(AH,)CG+-^N>7`SH&MB3=CGO06<%RJ,S$<?D]4]6P2,7
MN>,J,0J1`2XHU.=A$SGAVGJ`G!97SG;.<53&;F3P!'+91`?2$;CM$X1+524;
M.;R@8')R"OF3G3Y?N]$0)W-#8RA;`8#VY-!5]]T]P]!2D,PI@49)YY3(T1T^
MQXFF:!33WK^8YN08P:4U>8Q<>](=2K(5'&]*S$X'$AU(=2"3`"78A1HL[T4/
MSNK?*\47Q0A2,@4=!H$6M.#X0V,NW#!T/-]3*3N9$BX#WYY1$I42^8NEKXJD
M@G%+3B8!BE,X]7(OOLXI7Z0ZC5SM"&T%YQ;!3@<2'4AU(),`)6BX'N2@_UX6
M3GZIEP1'"E8'$AU(=2"3`"58N(OD8%^78;Y(S7`8+M0:;P5'"EH'$AU(!1`,
M[>?:'MS[6H-F,@.:<VF[BQM%\<5'"NV^?OF,\$6:KZ5^L`5'\J4#B0ZD.I`)
M(!+GS+1OQT.Q$/V/!;Y(LS`[YH(C6="!1`=2'<@$(*X*/W)L_C=U@&(#!H[_
M*,6P2C42N=JK9'LE24YF2#)#T@F1KL*EUKY\3.*)'*2%'3'UB*&@P?T1[W!=
M4Z,@9S[1>%#,"9VFK3N7OP`T?.NLX(T]QU,^G7'<FA;`<-3E1_PE[X]52XT:
M'V`KVPSAZNG%>"4>&.F&$65/&(Q%P]<3C,$8A@/;!/*!$#8^\`VFP7KS&P``
M__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H
M96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B
M0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$
M(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:
MWIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&
M`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&
M.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!<QM6)M85W?
M_-)UZ8+Q=,WP%,$H9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&
MK9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%
M-Y;P]<YVM]MT\`9D\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'3#C;+85O`'RC
MFL(7*(B&/+HTBPF/U:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.1H)BS0!O$ER8
ML4.^7!K2O)#T!4U4V_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?_G3\Z-'QPQ\M
M+6?A+HZ#XL*7WW[VY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\
M]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V
M">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#
M\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G
M^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U
M."O3>H<<NDA(",Q*A!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`
M&$>],9&R;,UM`?H6G'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P:3?$45*&'=`X
M+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXG
MW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=
M/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5G
MY*8TO;>$#6C<AT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S21
M0*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09
MHW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]
M$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<E,7*DB):#QL,
M^NQXBM4*W%J:[!MP.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN)B>+T5';:S76
M&A[R<=+V)G!4AL<H`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ-PEJ</MA[;ZD
ML%,'$B'5#I:A#0TSE88`BS4G*_]:`\QZ40J45*.S2;&^`<'PKTD!=G1=2R83
MXJNBLPLCVG;V-2VE?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J@GZ!ZSEM;3/E
M%N<TZ8J78@9GQS%+0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N_*J8E+\@58IA
M_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005W
MU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>94FRE)")J(*X
M,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?
M[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4
MX9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F
M!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q
M\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q
M)4TPP:<J@:&''I@\@.2W',W2K;\```#__P,`4$L#!!0`!@`(````(0!3"-#]
M_@P``-A_```-````>&PO<W1Y;&5S+GAM;-1=^X_;QA'^O4#_!X)NBP3H62_J
M)%U.%UCRL3'@ND%\10LT14%)U!UC/A2*LN]2]'_OS/(U*U+B4EQJY0CQ290X
M\\TWCYU=OFZ_?_9<[;,=;IW`G^J]UUU=L_UEL'+\QZG^]P?S:JQKV\CR5Y8;
M^/94?[&W^O=WO__=[39Z<>V/3[8=:2#"WT[UIRC:W'0ZV^63[5G;U\'&]N&;
M=1!Z5@0?P\?.=A/:UFJ+.WENI]_M7G<\R_'U6,*-MQ01XEGAI]WF:AEX&RMR
M%H[K1"],EJYYRYMWCWX06@L7H#[W#&N9RF8?"N(]9QD&VV`=O09QG6"]=I9V
M$>6D,^F`I+M;?^>97K35EL'.CZ9Z/]NDQ=^\6TWU:UV+39X'*P#QIU]W0?3=
M'^(_K_[\ZE7W/]]^]Z^?[-6_?_ZF^-W/W^J=5`V1"3XX+O-U]ZA8^#J6W$DL
MN+M=!SXQ9`(T(5LWG_S@BV_B=Q`,8![^[.YV^YOVV7)A2P_A+0,W"+4(O`SV
ML2V^Y=GQ+^:6ZRQ"!W^VMCS'?8DW]W$#"XSD=YX#;L*-G5C#>?4L$$UJTQAA
M<#8-<`NUR0.3+-QXW";KEQ*;.%W#:EU-^.-T,2N.VR5-5S$N"APVT97YBN@)
M'Q=3W32AAO2Z7:25.JPE99-Y%_2=3=GU\&R6#<R!.9)J&1>+1;^APH$ID\H*
MA>:;T=NST2E?V2'KDC)\K@S`A)/+H@.I>R2_1R:^SA$G9Q[0VO$8D\H5?99Z
M>6U\<#Q[JWVPOV@_!9[E([%T4&._YL9D+O#:$;^C(2!?1<OBL^`ER)/!J3_$
M%Q^\M1W`)0C141ZO)XEOF2&87D1O7.?1CYO![6X#\XUEZ&PBI*:,/TFVB8N6
MU+=6NN<--)+N?M*Q[IA+.D'&R+!:SMBI9C$P6R@-CNMFTYW!$"<$L.7N%F9>
MD1WZ)GS0DO</+QN8#O@P243S.O'O*G[]&%HOO3A!Q';8!JZS0A2/<S8)2?)L
M?GUOSN^97H),%,4!H:8Y'[4@]'XVF<M'.I],9`OMF_"2+/3-$%^2A9KPWUP:
MITDB&;)`9O*TR,%%@^[KT60R&?>NQ^/QQ!CT#(.1O$@BVO%7]K.-ZPC2:"HB
M&`*"R6`\N>X#D*XQ9JK.BF```$;#X7C8F_0-^)]5LO81R.9TJ*OV*D&@R*L$
M@2*OLGEK1T+E3S(%EO`4YRI!H,BK!($BKXXD5^"1<J\2!(J\2A`H\BI;;968
MJ[`TKCA7"0)%7B4(%'E56O.95&`X'J'8JP2!(J\2!.?V:CJMFM_?FVSMK=B9
M2>N/$UW8Q-?7Q6:-,$]=!.$*UA32`W,]`^:(\;:[6]=>1S`C#9W')_P;!1OX
M=Q%$$1SQN[M=.=9CX%LNO.VD>Z1_C^P)QT3A\.=4CYZ<Y2=0QBVYQ=S$*MK2
MD.6'@;,)8V1T1\:P?QU/V"2I]NR5L_.*UF6Z2^,2:$1NJPTG'/J9DB0<\F7?
M#GHA<9_@'LS5S-.".T!,I"$AN(<,&_-#(*(VDCW$;"0["-I(]A"U$5*G++E2
M)E?!#@['[SO8-,?=;KS:+*KGN$`"O"1BRD&0?8I\5NY2PFCE/G5MA?I2R(U9
M'U^L.RZQM&*/HIT5.Y186;&'J(U\W*3>Y81G2Q=8GDN0[/'-_?PT&*`HWC'%
MLU<$D_J$1\'BXV#"Y8XWMZ!GSQ19>H3-*&&W)=-/@01TE8W4R9`-'<#2=MV/
M.";_<YVU`;"R=G?[O"8GTL#937BF"9ZG@V]A^3IY&P_Y\0?0=6BG_L&=-&NS
M<5\^[+R%'9KLE">F@FW%9?+\TXSU*OEG=F3$L]G:H!Z+^3$,(GL9L5.RV"&%
M0W@&!_#T$D$B>)KH-P[H!YZ$^6BB']:>2IT(O"C5#\$EK%]F/.#)9TE0@PMH
M4!_#(Q,!K#"D",`)*A#@R7()!Q">*A#`S"U%``&:(P`X1Z*B21[T2#6#&,A5
M@OZV5$*-2:WD5+9HY:'R"_J/6&ERY;<1S:3>0J#G-,.'(P`:J3Q48E65&.)V
MR+2<`OAPA`(31ETY0U[O4,U71@@INH`A9P3*P#%&Y$4EJ;F@,P=PG)&9Q#Z$
M!`66(M40`(X2",01/47C;X]B4#0"TVA0-`13"-P8?,:<H)[@1DA%&`"/DJS(
M^X0>-V*<D08"056%)-'05U4B*095-3)W15]5B2005%5(Z@E5)9)B4%4CB2M4
ME4@"`1A14B&I)U252(I!58W,73%052()!%45DGABT'*)[-!ETW@1E:R?3O`P
MZJ&E1W!0.OW?]]7SNG(AM7=HT@2RTMWCV5,\<P1?L+D4F4KCY8D6GE6.:Z?:
M4Q`ZO\$D$R]37,(&.]3QLM;(6=(M7T)K\V`_PU0T/O3TO&YD8`6F7#\LKNO:
M>957:F,3Z<K%\#UO\`O*E5ZI!(%AH!H#+NJHQH#9E&#X"E)#.L2ZF0*#9$H7
M,I<L]\);;OCF"XGLT"4NPX9>#(0)3L;B4U$Y:#7[9;>-G/5+O?J!,ZW+0M0'
MHR\+D;#3#@XZ=<.6A$P/>JS+HD-ZR%06?TJ'['AMXAK96$JSN0E`V;'3!$N;
M9*6-W*F1--B?WO,C`E^,3;8@7ZLTX^DWI]?E-M!5,D6:'9KP%5C*Q\[&_+&3
MD1H0N+]R<EGN;0%=I7L/E-0!AP4/T8A3-4N.$[61&8>BL0)N_7`\R8BFX<E5
M'[AWSH637@'WZR`=0CN?`U0%^DE1T710XA'"`L^Q5#P;0BP<0M.H@\UPG=IT
M@1,FV3U5:=-7BR/9$Z8ZRFEOP`4L?#@6KU*B0[KRR_-%<T10.,02EN_2#CJH
M.2(8M"\,$;870D6M58Z$FIQ"7M4?;H5<*[>G*:#FB32Y*=5)8YG@%.L0QWQ/
M4X!;G^23C&A*.M<.%XPXQKE03!0YUO`V%/%*)9P-WSEVF(06Z[UIQL5WO!RO
MQ0;]<J-#>O]T:F^PY_%:L:DDE;B"4`ON&5))=@]ZJE>!EP6;]2=7QYS4\=&&
MHEAA:I65EIWV]99G=I?5$\NS_.!ORF/+;BX&83;,U>21`UJUR""A"6I*;,4X
M=ZR!:+5(TU,0:!_!U9\BOR+C\DFXI2[M5.27T'`B%5`/PO98)5=/F32$IPY\
M_&&08D>H+%,@F-;I^2&RC[A=ZM&_[,0'20!YYU:D)U^USY*L/+ZJ7.`!*LE=
MOOF_#$+A;J*7L.;#SI`J2=@*RD1&-M[Q0I%Y0O_0E[V:5Z<D]V&D6LM<N*NC
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M\KFN+%`?RQJ`M406W-VNMBR(SD067O"=\V5`J-;%!;LDLGCNAX+<&V5^9+=&
MR'&AR2*XJ*S<C]A3$5E@<EU9N1_!<506F%Q75NY'0$AD&:"DKJS<C^`%*@O"
MK:ZLS(\&.([(&@IR?UWJ1SY6\3IF$5Q45NY'/E8'@K%*9>5^Y&,53:Z+*_<C
M2"5\&?!%75FY'_DZ80C6"6IC[D>>^Z$@]_L5E8_XOF#$QU)RW\$[PA&NIXEP
M%$O)O<9'^4`PRF,IN;_X^#8$XSN6DGL*Y!&+#/A"W*+,1P.>74.0W9FU2JLN
M'S`XSHC`@`>"+7<N/#<YP*<NL^OT\2@7,0CORB(DZ<E>?M+F<-O53!"?#SB,
MB@BZ?]ZXEF]%0?BBX;7YF3C>Z4-!<7\)@HPC7@(N"(@`^@&>40V/O]:`EY@A
M/H9Q:;^.F"P7>'KP1EUUQ,#>,1H^_G"UNHX8V#L6PQ=5[)]$Q+SS-[O,0WPM
MQ:%;1,1[Q_]DK_C(X1G&8P\BDC[8NRB$Q^DE%O$IA5,G(2%XL]Y,!E\BXL?Y
MI7<63OK/#W!OWE0ESI9([N"I"B(Z_[:+"(VX%Q&"%TJ+"'EP(KBM>F([G\,(
M2TA$`/?+R$3L511!&?^P0A^SA4O=O1@]8%%^]Q'H_E?/^8V;&>\1/L6=W=(Y
MFP\`42M[;>W<Z"'[<JKG[__*'E@`P93\ZD?G<Q`Q$5,]?_\>GP0!60P+U5!N
MWF_AZ0+P5]N%SE3_[_UL-'E[;_:OQMW9^,H8V,.KR7#V]FIHS&=OWYJ3;K\[
M_Q]0AH^\OX%GIC=XI+QGL7N[@Y";K0L/G@\38Q/P'_-M4YU\B.&SV[\#;#@[
M-S6BL\7[7W]\LNWH[O\```#__P,`4$L#!!0`!@`(````(0#_(IBS"X0``&NT
M`0`4````>&PO<VAA<F5D4W1R:6YG<RYX;6SDG=MN'%F6GN\-^!T"0ME#`:2*
MI,[551I0/%1Q1B)IDNJ:QF`N@IE!,KN2F3D9F6*QK_H=[!L#-M#P`\Q#U*/T
MD_C[U]I[QS%)J;I5,&!X7"UF1NS#.O[KL'=^^X\_WXRSC\6\'$TGWSW:>K+Y
M*"LF@^EP-+GZ[M&'\X.-5X^R<I%/AOEX.BF^>W17E(_^\<U__D_?EN4BX]U)
M^=VCZ\5B]LW77Y>#Z^(F+Y],9\6$;RZG\YM\P9_SJZ_+V;S(A^5U42QNQE]O
M;VZ^^/HF'TT>98/I<K+X[M'VRZVM1]ER,OKW9;'K'[W>?OKHS;?EZ,VWBS=[
MT\'RII@L,M:1[4\6H\5==CCQ"5AWMO;A;"_[ZO&W7R_>?/NU7O'7MK:S]]/)
MXKKDG6$Q;'^]5PR>9$^WUK/MS:UG[2_?Y_,GV>8+^_)Y^\M_6DYX<[/_S;"^
MT^)J5"[F.:L^RF^*]A#GU\4\GQ7+Q6A0OM];9SN#)^UGPDB[['R>CWED6/R<
M_7-QUWXND>?\;M:9:&MSXY]7OG!2S$=3D728[>6+SKL[$'UHA#\8YU?M47:7
M\SE+RPY&Y8#E_:'(YRM'"EO)LQ^+\7CCI\GT=I*=%7F)3`VSP[)<%O/V\$?3
M]B=ID-]/Q\O)(I_?,?>X^Z8_]P]E=EK,IO,%HIR=+?+%LLS"DML#_Z$HVQ^%
MN6S\;!?:7$WG'<+O#`8%\_/M\+Z59"?+B_%HD!V,I_EBQ42[TYL;)/EL,1W\
MM)Z=7>?SHLR.EPO3/7;0?BWQ/%`_</(`3>GLY>`/#[UMO.M]]V@ZV=BYO!R-
M1^RR,_+N\='9\;O#O9WS_;WL[<Z[G:/=_>SLA_W]\[-52EG7NJ?M=461VBG+
M8E%^T_DZ+Z_;G\$#&8PRFQ>#8O0QOQ@7Z]FD6&33RRP?CZ>W^6109-B*;#A=
M7BPNE^,LCZ_PR%?;6^M;6Z_-LGRU_6+]^?/GZPQ5SHK!8O2Q&'=X?CCY6$P6
M/<)PO$"ELT%0BMQVT%[L^72!IMS_S,'H9\3)W[>=M`?QB5:0Z&1>S/+1,"M^
MQ@J7'8T^1&TF5R.(%&9H#WY6L#K9UR&Z4XXZXNH[F-I>[]MC_W>1O^]&^04B
MM1@5728GAL[R.W&SO<*]XK+`\`SA$IQ8=KYO\@&YC3.U!VHRXYX'I9NCA>Q@
M:7*RBU-!)?&3K+\]ZB]_^>4O[<],JZ^GXR%^]A^R_7]?0N".<,.YL+%21B#;
MR&88U(_Y>%ED7VT^V=S<^EVVM;F^N6G_/RO=1.3+Q?5T/OI3,?Q=-IG&3T>R
MJ`@1=GVZVH8$F[-ZNNWG]\ZW]?S%^N;KE^N;07^VGCU;?_WRQ?K+YR^S_A7<
MKUH[PR$B,9V@(B;#HTDVR&<C5*9-4&1D>;,<F^$=%I>CP2I!M;TERA=&^?9@
M+@<U_AO=/N7->\W?"28<\%'@X?/QXU7F4(ZI,!>+,3H83;!6(_9_(MT3M/G7
MG0NAB,'BW]K+WKG?N+4?;XG7>DVZUB#T<#H>Y_,RFV'#3+0>/SA`1P(_]0V7
MC4]]^A,%^/,W5!?_]:@YE3ZUU]?[>/]6>A^];Q]U-WIVCC=]OW^$"ST^R(Y/
M]D]WS@]Y8)4$U1WJ=GO1P,KI36'PQZ5LM3R=NCDM>WW.[A2XCX1>3:?#,BLQ
M9>V9OI]/2\1G/KWLZN(Q4I4;#@MNJ6OUS_)QP=0851X=KYL*YL.;T<1`M%QQ
M>\+3H@1Q#J[MT2&+'T]G4J3V<WO%#&@`?)$ZR2+F-P*%?[(/V@\']]9>;_NQ
M:D-C=MWYUKSCR$FO&=?"MCLZ]1[H#"#.)\44=.IOM$?#91<`DL6*KX/-`.,.
MX%%G+>GM%8#@W32?9%?+7('*7?\0[\18:%?\+!8N1^5UM%?#XJ)#[K=P4`89
M(S:8@I4LLLPN"_#WO,/#0&ZCU\H%,OM%`8`KLD7^<]?AGLRG'T<*7PWD!:KW
M/GD$*NSC5_R\,G[KV45>@MC%O.%HO!3`_S0K^6,QNKK6XSE;SZ^*;+*\N<"F
MHCO!7M;L@(WI'W=$H^%;FC;A[/QX]Y]_.'ZWMW]Z]@_9VM[^P>'NX?GC;/^_
M?3@\_\,J.Q&,TIF!BW]]7VA97:=2N>`3P4@\PZZ[X&SE*S5?##:3+U[YK/&[
M+>!OB90G$T5I%SFJ`%K/%UG=JFT]^$9EOA]X\\Q14T`G[&XV)V98%-ELG`_,
M0J;@0>K4GO@S7X_+>G"8XN?!-;@\Q"D]6M69N//&I\VE.*CXN9@/1F4AF9S.
M9!8[5J,YW8J7/FU&:%R?\#:?R]0\,..*EU;-N'\S&T_O"OR<V)N]S4L4$'E7
M"-1KYG\,JX@P53N\=/"URI#VO5(6\X^C0=<DM9_-2VQAM9J->>'0%8"_Z`28
M[9>UMD%/X+LK5<%WF%^#E;<]>R+AT+;NC<E[XA=R0?>H8@=@-!^/#&IK<.<U
MI16*R+72N(;%A6MU.K75ICE7>XZG]S^^:FF=U^Z7?7GB^6@@"^]Q$TG+AZ2Y
MK3_]8\0%WK^-]JZ?W?]X'/3!U^YQ-[L[9S]D!^^.?UP)06M/')P>OX^@]>C[
M;&?W_/#WA^>'^V?M=>X,_[@L0U"]F!+,@Q8&9/,L=R,OG?&I\CB2_>R21$Z9
M+24AV`8RS`%/$AB-/O;G$>JXKS-Y#0+*#(X>2HLT048GD_30^`)*`(G24E7M
MA]TC/RS^.ZU%$_AZ(N0!RU4?/X`L@TJKK->NN2+!T3JA+9]E@*@6*7>2&"EY
M4V7CVMOU_$Q_?HC7YTI<A&5ZNL6333%I5IN]?^1['A#0^T1Q:H_=%O'#H]_O
MGYT?WBOB)P`+\N.&RQ.LR"\`E9;V[L7K)TM"&BRAI))@"D$'E@N&*G?1&]^<
M%I=+Q1BDRX3+'QO4?""+MX(0(_!Z:7%:I5</$>+@\(BL[P.$F$\'14'@>#F?
MWF0EH9X6B:E7RMO,:")//U$:[]?AQ`K\@KK6)JR_$+UD>UO--R93DMTN['A0
MPMK^5&3S)1C[4S8>37QS9"B[@7#SA4B(56NB?.$\%;4^8?3&\[Z%L/"&T^\@
MCM7OM:G4DIN90J\A^GIQ5X-/JV6';`1U0(0;T](/:<IK0J\4#T@'K$+57L<N
M/F&=0B7IS56/G'TX.7EG>92==]G>X=GNN^.S#Z?[EE1)RIP='AT<G[ZW!$O'
MEFD23T3*@>,B+`QO+Z4QS]GN#_M['][M*W-S='RTX1/U:$AGLC[4E^QZ>\[T
M<)1L\XJ=D,`$.`\F=>7ZVQ'1KQOFR#0FB%L=5C\T__D/^]GN\?N3G:,_M+=Y
M/+_*)R%1LPZ>GY!W&@VK1`XIS1*+EQ!P2(60>4A9U?*>!.K1\?E^MI7]]<__
M/:LMHIN]/^\IU9*@RHZ*C_DPQXS-J3+:(M8S!*7YN#XAO6'12#ZY6\\P[MGB
M=IK=DI4>WV440@4EEQ?E:#C*YP#R]0Q`D[\OABH+OWNWJZGV"!BP$@7FA4H$
M+T0GIY3-S<P&9J+?^XN>/7L['>3?SXMB$LO+]ZPY/?LD^S`A$<<263.(;$'2
M)S,'?*N(<2XO!-776[M<7S$U0XS'L9*6:0,EZ<C%Z`;KFLH=X#QH\M<__Z_I
MDD@G;.>O?_[?^NBV6`__XDO[)]OD\V7YA,_;`G-D22;9A+?+$D/<3<W]2'*!
M5>39+>N8_/7/_[/,KHM\O+C&'O$Y!FVX',AE&U&!2913(3=N2I;+72-6A^]O
M%$3GX]&?%"V%]R!;/K\JQ""T:,P:5$$TL&7S/<EVR*1=&G&18W,4$!K"0NH@
MW+P;]!XYIOKKU0$H?NM+KR]I.M%JM0!C%[Y'M8:,`"4?EX!G0M-257+9KWEQ
MI8()A<LLG\EP\Z!P17TK29/$B7SX41'F,*.^A)\F^V9Z<)?-L!@W9$O4N\`@
M<>]/)!/9<+XD$\G`4E2XG""[>-M:H"@^+,K1E51`4H"L?%2=V;93WMW,%M,;
M(Y@6BD-=#ORKP++YJ/Q)<E0NQT8$0Q>P=3K+F3;YO+A^+Q1YU6X=>PZ#AJ+=
M]71!?(&QEUR3]"FFZ#/U%_[2O!]STE/L<SB_DT0]H87!9"BDG`/UX6&<)]*I
M10HX>#TB72VMHO<E4R"9#T=39P-4O.*38BY*6Z^-+(?\Y/3F@OD5Y3/""$D5
MK_/1C01I6,`9C6/[EW+"5L.<D=0%M?M!/H#IRGW>DHD<3DMM5*LL\-O%A"*K
M-D&FH)@`_<5RC%&1\2JJ*_Y2_I>(HA.JN]HB]!>*7)/])[0K,'J+_^*QJ0XO
M&G]RI=H62*1M(-&L&%Q/IN/IU1T+8ZFV*L3']EHK`Z"(;#N\5?I2KLFX9A>C
M:?XQ'XV]VLMVU:[4)>$3NFB0;*\SFD[=Y)/E)9"%[+2QFR@-_;D@Y9M=D*D2
MNI$46&&"C/`,<1O,1Y8VTQ]P!MF0Q:96(8EA461E]+]3,L`;;&##HKYB;M[A
M^'S7#;P>[W3\G'UX_W[G]`^"#V>'WQ\=DMC=.3HGBMX]_G!DT<8)[1:[?>&T
M]S2((2=X256F'W)]V^;Z?OV4)W-T:#3#78@G#??<-LSG$EE6:%95:WS0W@7]
M='W7JTM5WYFGYB2,,?K['E\:7*(]6O-R%$\SNM,`EW#/H%%87,Q!._I'L\@@
M8F+1,CSW1V0"AYH5<L-P'MDP#8VVF\<Z+,5:J-7-5-YB3Z2[,O`(`=UL6%)-
M8)+/U^X?;W*4\V>%,:8%E\50E3'<">\@K,(`8`&1Y*M0I[?Z1>_89K1L_1,*
M94H!"U=C"DVZ[ZPJ`AMC7A);C-QBTA19=J7T'+M59#N1*:>I\<:HW*Q+[\6F
MF_AX4S3FM/>IC?";<H9'^>Z1U(ND:O'HC4^2.%_E$\SXXI;Q#>QDBO&Z,NM8
M9D,Z)5@PGT[4>RA'J(7"Y1LWVW2,C(K;JO^G-JA<Y)**G<,5ZX^)^Y/Z8\*P
M&0()_!O_=U5L7.0#O(^^E#>5P<2"PJ#[.HZB#QA1TK)TYW*&1<LAO"W,Q#NU
M?/%I[&C"L%QCEVCTD,>-J^354=4%Z=ZJ^)GGI&'*ITUOL%C\KYL[IX$TC\6"
M2HTX?02>Y50;14P1A:23E)"]O=[,AOD=8CI%"W`]>`W:-2<+$ZY;FH:$9^23
MXA?U#63Y%5K`N`8M[J=2H(UM;TAZ;[C4IIT#8.[QTOEM/HPYY/[---3H@N^B
MR`O9Q!\U<XUP@]E@-*=O1"UU("-I3A2C*!Y@>0&-@4RW+"B/)`+-Q"3*M&B@
M-DMJQ[:+H<<,IK#V`0'`5/&>,[88/LE<&]`"_=\)_RG_I)8?.G$W'WW]YEMV
M).AV=?'=HX.#[>?Z?_IX?@"&\.?.#4L?(=6G4UR9OKW$%;%('T8??&TC+]Z<
MFUJC_):6`I\!@]$8]!R6(E@#ZZ@)JJ]$D"PD:C7E/Q-`$J18`C4$:0'OPO5P
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M%M>$E=-DS$Y[6I3UJCW[9%YLO,LQNM>`LOZFRONY'OH5.@0*#*Z'(>9:W0$B
MR'=P*NH@_^@)C"!":#W3VK,1Y37Y_O$(JFK3(I)UNURH11$_:?@1#!'"0M,J
MD3-\`QG<&E]8>P0V\]##0-;*$.J%)!=P&1__](&T2>GFA?B@?FK6H^9-.3TB
MX*$9296YBXVQTSHQ-$AB6[R,OSTDE&"$O#Q28G%7;_]-?$C^&(3HVN!I/!.7
M(&JBX,22^CVBX3VP.[T]M/NK$N$@+8N7JU2YM%73I>RR+%C5-PA10E^0N3#W
MZZBE\*`:\8*N1BLPI!X%I16ORIM0Q8;29DP=H6%(U5T\)N@WS^&Z$3N)):7T
M-+M'PE;E(R4[Z-B1\:T*6K%`XVY%S<20AYT)GBHFH2TWK;IF;10#JO%D`]\+
MX#1S8P&(D3S:\J'$LF>-!&0(>5R@VSR0[Q6"K83]XIHTDI99RJ:@/30*=G#N
M.R5VU6F9'=X@/1_=IKI_JW0^\6A4>^@SV?2W4&+."16R)))*%$0:)RZ-M?;.
MC@ZKHF"_))Y`-MR-U-S0JGQ`J[$!![<"WT()LT?YD!H&U-<Z1#=K93+YJ=*9
M.PY%M6PRFYS%F0_+[.V4_[&8\F#G[.UZQ./-AW8YR2-9E?FW9W?.=M>SI_3U
M=J''"*C0!S]8V0W0?.MO0!X5*3>^IX/P=J0(&;)9+=!E1`#H'@ST=UC$>F>B
M+[?C?L?5I?F7H7?_["!)N"_F/XE-7>;<9B[&9HQZ+66]83(FSJ0T5X`I-V'1
MDEO$$,8CRT@>PJ&ZIUV0XOG0[*KAF+`8Q%*FEKR0KP._>H7Q02<L/Q,F-Z_;
M\,GU95>FKE+P\>@R)ECCT!4ZZ[.7E4]."Y&]KR_&HIP-13FDW%>OQD!B".3-
M>BMT`*(K#=`X?6'TPA3B#`1!&75"K(-;@5<6*<C@*KC!5S1BEQ$Q';0551R1
MRIO0`'0G]8=D0#4<V9TY+(,&%M((J\0<-`UVU@*83L`9M:_!\\]B^<8I7&9K
M9YC_(PH\V<O'$<:UD'NU!4SJN^GD:N,=;G!(OEM.KX/FWV#]`DUD]]+*#62;
M\<,4]M2^S6B0V;O"SVGX!PDJ(D)#,AX5(:OVAL^@:5C9*IJ>"137YF@Q2ZEF
ME^!+,@S36[CT39<H?_WS_W$35?G+&MC`]2N!#K8@YZ14@TAK%8P0>]#*."A^
MUQZ!0;LS-8?%%8Y"!:LS]NSZCD984_201NC,4!\,#`5LL"6*L>3(E%=%?$/0
MB70TEJ[@DV\#_IE.[AV<B@3MQ(A+<Y(+J369>=47%+&Z3I`Q!(M(MPA3&W,:
M*Z,=,WT)X\9$'PL2<<O2PT*2Y"E&*#L+3)`2#RL\X0:Q1A.T&88ID\<2>8`D
MCA<4!/4&%'AXL9UZ(]0&Y88C(%)^'EG,5>OQ2>)^.JL)73(;`6]7N%*#Q$:J
MF.X#4U):0(W,'.<AQ61QB`4!ZL(2E(4<,E0%`RCZQ>!4=0>^9W%DG):B9'@#
MZC4BUKA<DU983K)@,FP+:H,<-@L)-YR!):#&HY^4=N#CB=DT^SX.R_K!$YBY
M4O"3Y58%2T)BCK&Q10C?Y$EL*4=*0Q\!?7R*DV*2IP<T7_:`1)K'*N,7S/*4
M@S0*EQA-"0FSK"DDDV%'-R`JZ;OJ56MY*Z]-:H/%]L!9S16D82RI)YT*?M52
ME#(!QA_[Q]5\NIP9C9L&U;P,[%-6*\2:2D5`6XV+<'M1%^XEPVK&):;Z;%QH
MZ)[&<A^\1JVN&-O0'C"05$0.+CEOIV)1E#4G!$>+KL0_Z%/,(#=/1NQ=>U+*
MX931=CP?$PO=5AC7]B,=36\T2`A7XB;^N!Q>26_-[T8>(CB6&@X=>.PE1NS5
M.EW^^(I`!P;X210A\Q`#>:9,J-7LO'*2+EW\@V48:ZIU*UZ3")B@5LOP#!QB
M$<Z7=EP?ID+9&=*ST[15(F6D5QZFR5>G;6*L?+MQM3)>%6^UO-@MHN5&,IG!
M9]EE2EP%RIAEEK6V_/8?L520PDQG(!"+-!^<R/,069RNUP4ZJE&9@-#VD/TN
M&_;64=^X)"494]4U@V^"F5$PH?(>HAK/5LG\:)/4RV<X,\K<HR'N\DJ;)963
M<RR!JB#S.B5$?_%:A9PKDV*=`/!!4(STAK+\T(BUAY0(%C@!Q28[6E+`*!/@
M8XT](1=S*^QCF>;<#*;-KE41JEV261(:OB@6MZHTZ6/71?0ZNU32P'F@G:P6
M(Q/^J"D!>%3O-J7503'&B+8*2*GC8M8@D`^NU7K1J%,D+\`0X-0F+95^%/"4
MRG@^K-6^RT8:;D&;H_-%LA4V^20[T_QA@6;Y:U9;)?.0D];V&6Y)BX"Y3Y<!
ME=HL#5L2V!BS,5VW"UK%XN=J=N*DX'P:!+JD5BNF&W8J]5RL!NM3^7)/V,2]
M9<I_&W5%E]J"K)!3J]'(FGB%C?@&`8>N,35H^5*M^GHTLREMR0A[*-/XC*&:
MC2T5=)HK<5TK]F3Y!>>((IT7"`UU.N6)8H[2YJS.HB="B7`U,F*A4MK0*6:\
MAQRVSP^DP>CR&"D2"';/S7)-(P-IZ^N_IM$`7[/.K@7"<F\D,`N6YK:CP*%Q
M`Z,G69BHUJF:4],S,A?>0X8JB)6#&_9[;HG86W)E''VN^5+DIXH,#,!T75LM
M.6D)+:$`IN\)B[@>Y*D)$__8[F2)#J17O[=3VDQ;Y6P.#;$9@FPCG6/DH5FF
MG2\=:IK%P[="?\BJ*HX4+18BL1KIAH/T86RY,XUHM4\;A2JG$>+"OVE(MPT_
M!S6$:^R^9I8N`(G!<YAVTZFQV$!\;]`L0H&0Y39)4#4P[!N3;ZTQ<IC1Z,.+
M=X8PMH)M"*5=#5N;\'H$IJ%E^J[%F'L3;XJ<N<]#1B(ZGR[<0"0!/%J265S$
M&'VK&5&OVPIPRU1@#C#XYBARWB1ANA$`4O5*6BL[PKDC`FP2=*=$R*OMWS8E
MUY\BJ@GS>W*BQ&XFE[6@_POGZ-#H.I$KBEU95EW,5[L/5D0Z`@MQZOCF?U^2
MG1!0T6DL60J%<E1JW#;1=XY1<7RJ4-8=JJET#5YF:T'>*)-A)%7A:\VRG$PO
MU)U@"'<T(1]/;L1?>DIB9*="?_5AW=>SNF#E).#>QRKNAQ./=C522\),&Y*D
MZED+9"1W%5W,U&DE>`WM4]F%>+JZF:,)NVL;H^7$"[<LYE=1$<K6=ML)2'W6
MSOFOYE1B3PD2(TR(S&D.V\-2<=19D/2TQAV-*&$Q5BM"BFND`[>@B0Z`/:21
M=:`2CHV4_D)WITL:RI);FU.A2_V]ME*:=<GC+6@=LI!4Y3]AH5I!H<^Z]P:]
M07JZ3*GM)6QS]99:IF_Q9L=.P;;3>Y)J^;*4Z,-I!E6H$4AM#T91>@4_P_1U
MUM#29)-3LWGTB83L79@<NWGCQH8P7=(]X7`@O&E85D>I=3!XKS9*8%`T6F`M
M96()#IGZ&DA0[/N)$"*2Z?,P@^.X7M!PZ#C[O.\\^UM3\]`8Y#A+N]'J4Z;K
M9DJ7S;I\2&%7X03<;J?>S64E[&\.)O9V>'BC[@5241:WI<2;IZ:8PP)7DMN(
MN%^==3Q83'6"_9E==[;5832@,X`1-[.^-5_*TKJQ*D4TPQINY+E+71&,("-I
MZ8YJ3XP0Z5Y_3?(952&"R11PZ!W95Y(!"J/`J@MOYC23K9`ZA5BZ5*"*L2J%
M9=_><MW&34:AU%X59+>],OW-=@%%M>!,JS)\8`@]R/HG;=2EGF*T!ZN,H_BC
M)"2(\2LJ3)W%G"#3!,]D05QP-PYN^<,AEG@1&S:J4+E.%KF=^O@7SAWP/"X"
M0T%J9C$.5>F*;1HW-`RCPTDP[V&B8&A(Y4J^]:1OS@H?MD[VFIY@TTZ&)X:V
M/?V3NJVJ5(BUML!I5KLDD.Y;"=]J^`"'W=@I@]B;:;3MJ\^?+3?-]&J(>2@`
MTBUVO7SVVV*\-UTS(_CVA:NLZI3IEXM+=5ARH)$*/!PW(177[9XQB^*G$R29
M7)>X4WTJ@>QE#1)T4<BFE4NTUM`T(Q,\YC3V$[@GP*3Q%NHPMTH&<;A2O;Q=
MGZ>AFVG]I*GN7[)KJ`:R'">(L2Y6.NQ#DD?)Z]$UA6]-ZDLFZC:98@W$%;C`
M*SX!0NCO2?9\\[]0HZW*'&$]GOZGV:S"YF;M0S=>A3%#^A]J1*TG"5ZOFZ3T
MWU0]?6#77L3@:$$V35Y,C%5]$-AP/U&"GC3A9\/(7Y#G1038KS"V)B`KS#$<
M&?=DG>K3-.4$JI)<32GDNBS%#HK^+=E4;0S4'-NS,P@55@+O&`Q30?`:.[0-
M&-7"5![$2"22M*S$XHW"?;-N81#)<TQ[F:&RVK"R_$C1H8BB9,^ITJDT]IWY
M'1-\J28<M^;YI4M*04:3P70\@U3JKJ=[QD!<?\P^)_NBA]DT@73?S)WUGBE)
MMN$P9)<T]LI+--1H9$&BK5S`(3Z*$U9G$])>VF"NB8TG[+:**X\OFYIJ!?<-
M'1^JAX(2DJ2684+-@8R+;CT.G/EQ6O9MT(>`WUPGXO43T758$<2R_]:&0[U6
ML9X"2K*2G[0+Y-#JO.%0LF6X@!_FN\,I9\E[_1/$!EM$1K*8`VK(/@[46*XX
M3^?]AGQC!+2L2VQ6RR@@7L=.LKB+\-PL'A\GF\WY$ITW4[)%F;@6=ZRT5H/=
M(J+1'*89!YK1J)E'3)MNSI+XJAA1']*M'NO%?/MQQ$C[&A"*I\M#`B^:8-NJ
M3:#4D1;REES\3QMG`_K)BG+C/3Y#=4_+]5J0+Z,?,#"(I/-&]M[QL5P!5[3.
M%H:+[`7)2Z]OWGJE]#RV.)7#-*S%7EJGL@XX)^UYS"V\DL:@P\HS?"19ISFT
M_W2N3.\G(%7O1K']VA`"]>D1$Q'/860?IV,0CG>%BI!TQ^"U<"`@VYQ8$]LT
M;[J,^V=K*?EJZ+*/&I!3J27GLC4K#*1D'46!Q[%#A'4H6(M"&%4I-!C#,ZT*
M><:_04/]4<^@^2>UJ2R'$5O$8V;L^28WLCKRJJ&7+]>Z]2:0P`W@B9_`MU*H
M+JW9#Y?6A#Z_VHJ^3"O7F_]_NM;>(-)*A<+PWY#=_8G0WR[C^?_*CKLJ]H4$
MVI)`X#Q9@SJ0->=3\_(&=H/5\[0;/J=F+*QVG.Z+[!T-LV/!9,CXK>6D=NNN
M5N8\W.QKIL>7-L2("X92`/6(=^WBL:V6OF<.`-A=?FLC_ZAN_1HC,X+["E`,
M<KTV"B_4-F!P3"Y1X.V\HD8LL]>`L'97?]/6%T]6.,Q)'L+A0["].MF*5<9;
M-7O=L,;:G\'HD<[]R)N0TR3CHI`YQE)!.!\&]%I@`P_(JY&'L52-*L4K<6!H
MK^R!@`Y':@X#4EG=R5+I*YRXP8@@%?CK-F*L@:"X0BB5D^VJ]\\'CQ413'1O
MUEIC[HG.K`0/@V=N>5A^M$!W/NV%FGBK+7SQ9M<`,F!!H)W\E?KL%=.D]*NP
MN@-1@1VK7X+C;R+0G5S%HEE$G>!%<1!$[)<_`W3:&5!QR5)R8^L3U<$MY)Z)
MJ@#2`M;&=55-SGAX!.2I\26X=GM+HI96`CS0E`N[]9S-V)T\+0XE3!E+[#78
M7@=-41MLEBKJ]IR3,%@*)Y5%BKG%9L9F\29&5:>>;Y2-:3ZR&ADU`EC:Q"PZ
MD_"([#&068$N7_S6&&;E/K\\8#'^5GI740IU3*D]J]3)S%[:;?=8R)BQ%HRV
M>*A<@AOA*PUY](N1RD/,!.@K<@.=.>P*YI:0A6!-8X9@2@WD9OG\4&\\966V
M,YV4(H]+E3.F]J!.[3RB`G?.Z]L@,\*8VM$\LA6U<_]25-W$X?BWLCX6%DC&
M$OPM^2F0^+2W79:<7[ZF6;MV4,."6H6#.H_)V[8`KT=A"]Q70$`^X:172FBG
M?+:"BL]<-C0Q&O*J$YJN`F^BB_>1T=$(_>/04&,%`7@QI><#5:I*&X$W_2PQ
M1JV&_$3B]HW-?2$L?30?;LAZ<CE)?D>/\)-?_O)6*:;/)(/'VD8)\2F1G%!O
M-B/T)8F8WX3F,\L[AIIE]:!G&:D^$'N?(Y51^E.6S^ZW5JV:?,\R%&%N\C^B
M`*G-)QU*EBS+=[9:$4M=E1VY\8FD\Y0'X\G*4OYA`9BJ(_7T;SV%6JP5-R!7
M0'9OY7H$PU:*@+Z#=/,HWF)"T[:2"L.EVI48N]8H-L].@N(T'[S7"$=J&',C
M?=U_AMM[G$"N(>JAL20;"6*=5N'N!/*_<*?7G/<,8X4XM6I)'^1S0U>>)V&,
M#5SA--<3IJ>ZE$:?6HW-3GC-5"NRQ)(D*R[!5A!]-[U<]',II\`P,XF6#!?Y
M7V]AO"Q@./SRC>DK3HR2!>!@5M987V/0-%9`.C:$$G-:G@U%?LB9'?IRQ-M*
M^J*ZZ=-DX*R26KL-`>NK]9`:7F*P51#']-.EY'D<:^[U@I'(ISWH[BO#!4IG
M7G!EGG:K>P5(8&*(XR4+OE6:,U$Q]?)U>Z!XV6Z+#AECFY(CBE*.3XS>_D[G
MZOLC2.0+HL5[(<@.Q_X^TC=/-TEO4O_DBIH[NT<"HBG!3-&#(U,8!BN;NLY"
M6<]A11Z$9V,!%^;PLH1;?.#7LZS/$#E;DD]R47?E^O*>OZ%2DIJ&=LH6&W?2
M&3/?-!+DS$X`T$6JVHK$OS<$.:D[Y5]A2M3]:09M(G-OU_T8%<W$="_["3[^
MMR)GS8"%GA2[7$F7W12BF`X9P/+`_1DI:F[E(GZXW[8U8(S?=M;D2H<9`T:^
M*NRZ$^<,]T8!L?M9@@P$<0W<E;%9<HD.-S/)]P<3;88VB:@A(4%G;<;TP).=
MLE.CGZ4G^A$WZ(&/P79HU\N961'N6L+4A`?2V:HT#99O1#@`AO+;J69U@4DV
MS6(P.\WM)W*QPL48"QX.$&X_2Q/X:>@J45ZU"],4_#TFR#.>\98^[P>V)DXW
MHEWB(_UH>+6"<)R?:$<)9<Z7AYBW2A/7Z"I_TK\E\MCZTJYI$!6#_\+@6UT:
MFZLR$3-;?1RRITLBQ*^HMT#/_N'I\L;@:`9S@_Z.<0[XH%BU$)YQ<.YFS.J,
M"*ROJY9)2<N\9S/`$HR#)13PHT$99O!5/J6^0F"1)=0#T[6NGD6V0G6A#1U(
M3-<T";;K]SA<SB5,)"FXB$X2RDDNNUI&TA=?Z!B$+Y><[O<UOUGN3K==DD)9
M<)T(:A=+].;6D06'P3I'@1%`1R$1M+L1R'2CH@^CTB,F=U1\[QPG1U34HKD0
M\+!0UY<#**(.61'QM)`1(.C3+,%J:'4&A_AHB1D,5VR$#U4XX7B2:C3(/>>R
MJ+'%Z<CT<<R#U^HCFQU-^J=O4KN)A3BM-<<KG5`:*;M`EQ\`,%IP\@F'3,`6
M[H71*JSGF1VB;IP.CN%J:L>DDI:N<-0A:9;+'N9D@;`+EJ+J=8IGA9U_RKC5
M5]6ZR547AB/L@OI8+[LF1VSQ1C"H3`)(-^?%5K/:,NLW3ZI9(<)41`*<\2LN
MPSR&3'&>Z@BH!]%Q;81)9.=DK^)Z#4A:(!;*==JFU6?$HA,LO'7Z2O?%!P#1
MC(*D,7/H-WB$O2(#Q(Q*%OFQ6EY(JS&8RU!JLY)<Z+AW&#"Y#9%-%M0'G>E.
M#S=4P&,&K2K2]7,;[8'3&N*PF&A`2?@KZHW&19ITY-D\IZN3T#1;_D`)F2_.
M%N:4.Q;>N@M$B;2YP&(6#.5,H4(;($B\=.EIF<C%F[-Z8/(#6[=C,Y;%;,9N
M9DIC;E71:PI#1*\4TGB#`"N)*=!&Z,*VR!W[,^RR$;1($TP9\63&6LFA=#$U
M55>43\U\$:Q4)ZMW=.AWP1E;WGYP&[5G?5$6!E9+KP\6'E`\_=6+UZ_67[WD
M)V:_VMI:?_GTM9F"KUX\7W_][%G]>IS/.8'2_`V]#J-.H5SZ6:P]G:#PG\7*
M]CTCW\E$-UZH_8X6)F>>G?[7_&;VNSV:IL/;XI<U.5BZU1I5_!%@7_PI!@!]
MZ)R0SE1Y#6"<?LD.>Q>6R$\#IPN>,8C,MWMZS#^<A+P+GVFE3/?&IA>5?^<Y
M,UP\0WT\3:ZR$":R9V6ZK,<PA`F=;0)0JM9N78JK%`_5'4855M7M;[J)7+]E
M%5LM5.OQ@'95-T@<'QWVRW.5CI*],O-TX>T`5$4L^1(.,P4*UW:`49'L\+ND
M+Y^O;[[:=J'97G_!SQ$_VWR>TFOW"HV]Y)U.4"V<-AUC!J%PG*N'(%BQ1.T:
M<;0Q$HZV$Q$]/4,S2XZ*+VBX4^!Q7&=&S_#I'+TZ*4C%^+V]&C'>)D*H4(P=
M$U0\]8!XD?\$OL8AR)AU1\J-S.K@\`8M;O0MY>_-I27)T5PU(>^*A-X"<ZN^
M4ENBS+;+&Y<0N-'0*D:3#4YL8ZHP-%P*TC;N$4@>[.VH6^2&RHS2N1AWNHI*
M25B+D+5OM-"2<,[.5`_LRD&9*HY1(=V\Z7JHC]SS^+^F_+K7E+N?]79S5KCS
MSFYLJ9'5'.BOHE:LQN`:'9]I^KJ4\$5*U%'9M0L$T`9=F.2KXX'+Y=SDA?](
MJ%.ZN\Z?0!$3>E%\-IKI?DDPH/HY=6.P"QXG8'#[33$"KW&*F!&4A='IH.FE
MSCG;)8!)(!`D&JVT?"W#Q9"\TI#?M)Y9S6$&?K7#'G'Y)IWFGGHD.)H`%T(_
M51+L&9+5./Z:^":++B_-(ES&+/^#N&M5M]/Y3VGW37%Q0NH^-P16EZ""R94B
M@-4@/`_;D9-^:PC9NO:SIK+P)Z`"E2_:COH&76P8-QGNJE*8T\U:##<<C%.U
M1%X=[>K^E.A!DFU47!7L)39?Q=CEL'8`08T!CL7=?*OEB((E1#+L$E]-PRE+
M[;]3:3H479$+>[@I`IU]R`C'1&_0ESNPB\X,8()2?4D>*R6$?4K+(-A3(0]*
M@B8/4IZK'3>D",)J%>#<<$FM[<^EP+A"#H4?PC%CG21*NVD*0*!4>B*5_I/_
MK9:JM]%:K"<A+/+B=WN:C[7>8*M'U^Z6@/]2"&&L,0$?;V'CKKP*%^:%'DFY
M,,L2`4LPV$_XR,^X'Q<J;O6[2@E-J*R1,+@/#8;<<#2%N:MYZ\(L"OF[8<\(
MDRU3[HGN./YR.3.3`N=4U\(CZ/0@J0J4-FPK#@1#F:G([!?I.UAJ/Y_KKK@R
M.P%BG,GKMV.I>RL5@W2E*HC,!V*=`&(&,K2S?W(F0XX_[AX6V'[Q&Q\6Z&ZV
MD]?X0AU!T3@T.B\E`$M"&DF>9#<4KBC66E:'*@+4"\WVY3<6#P_"@_9[G2XV
M-HBW(`[LA:0BDI#;\&.=&ZM_K%,7^M1_IH@8+]S`X+_)+6-0X^BN/WRF']F$
MQ7@EW=<G.QYZCS6M"VMC@</P(Z/:T^<O48ZQ/G-CXAF_0V%EQ.3(,`(VGY3"
MA#%5$U<.TK/Z,_4`?^Z8@E3`*XNEP]4-8F[J&+$_!'_M]S/DM2W>-4L4M$D"
M@=F*%.NJEG3:#J'S%M%#.)5T:U<15.89N#C:2&30;=?!-.C2"BO>>7S,$K!M
MI).2-M0Z!,[AID?0%\19MU@P0AO'H4J/!>#0H+?_,I>\KSNDUK*"<S13)K9&
M&]+:=5ID$C]+3@T\/6;FDZ0X=AHYU*6<*A;XP1J:,$3?"5>3B`2)`O*:E7#*
MLMM64FM$+7(V<:E?E-#.`)CXAW[M3KSY8^A3:K_T`>L,7_>C;VI_?RQJ(#[W
MAODX:83:O;0G9(R2;0.KOY?L'KVDJA!_Q<`!JVJ8?$_7N$,$$:618M$J=\AX
M<9C(K/CW.SLG'K%`,\LH!6;Q)GOJRT;@B<.=2^@F<F=PJGZXM?+0THAX6B?(
M3+A/0PM+,AKZ[[4VE9L5L\8CS\B:(4PU+%6!?"SEC$%7;>L*F44;)#D,9H:U
M-I[9KG`5.UR#,VG!]<B$2Z\A0"U62`.K3@7Q9-KY[]54G/"4IEUBP@F(YJAZ
MM/=V%5L97\90RUL0(,$R7@T3@AR$(MS>;,=U2&"6=EERZ(@SV6_T2'I;$5H0
MKY=W9*%`Q1ZVY1HRAWM:?\4EOYQ%_&G>$&2*X^QI4]2M@:"2-)/5H9C(X4PY
M1=A@5M#W5D)N.Y2RPX^6Y&.>]14*6GLW$*PE:4FX;B4+`3V+TM,1C6A2(7)B
M6Z@YQW8B8WPB(:8!SH7K:3HHZ92"OU7/#KWQ<*=2KA-^S@9%\U]6;EF"U=#I
M<)+M+*^6N`D2&,^<#P?<<0M8+G4'>VV",[E7NP[WPTQQ@BGDSMF'=7I;GMCK
M&VJ].W%CYF@"%3GPW_J%>@S@QWU+;J85%W=U&RFE^+6SY<5B.J,*O+WY?./9
MYN-OK)D3SQ`@R`<]IV.'UK/I+$>:]_E[<6>MHCMT:80+*A@5C<+)@)GSK#$3
MD/GL@R]UZSG<#(;!$^">[)[2!&<_>P!D"9?'(5S(BN2EXHS)E!H3(^REIQ4>
M@[V%0G1?`<EJ=A4N#W(#^^7;`J0'K"E2)?;A&<BO4\6M`-LQ^BN7`C16+4*)
MKG",36/U&E11(HC'&N):W9[$-!?I*PN_JB#GL2B&P:)`.N4T?6B-<E54YW23
M-81J5;>IW*7?UAK@G,XG&]#S\W;)/6XA?HCQ"V..!>/\=),C0/_](N%_N_8U
M?7J1?@!QQ5A/,L"ZS(/NCI:S86D,22N[;'EM:2PR3NF>0A(>)]=SM6@IJ03"
M$E3"O:D,TDP!D__XA3E7)[6Y@:'7/Q20J58"@]*RT#3]79=OV!&*[,DN!8#&
M-@SP/.CBY1&K:*`?F&%"WF,/6_9#;VI!AYX3$>G0B5YS8K=K9VN'F)UTVJEE
M5UZO9Z>A#=@LJG1<^6UG*\<Q0P-.MG9N=H3\+;?$G#._U%%6R^]JU`^L)!0B
M5IK'\E*KZDYVNR79A'!!`IRPUF.39=JEF'-27@K@$3^38D0"/!4!>U,>0,J6
MUF,2USBG'/J_-;49%/N%&+>6O%D)";'03$MR9AMT0;E,N3F"JE`6W&['EDT*
MW?]W5F,G-X9F;:5W/J@0L>W4;@%CUB6FRXY]1[]J&F1(R3ZN7!?TF@3_%>4T
MNUKR`W18DIBLJR>>K#XXNK0>>)1!'MUNI:[_EA!;";0PGH*;')=*@?2%.U/!
M+6OR554:R]6D6TQTA;&,4<B'%!9^#Q@$>51-6;=DAW&[#T$*.ZI150K[EUPS
M5INO)49-8S5;\DM)@ZH(:$PS%!;<F(#'!K380(PH>CA7Q16M,CX3CT)@4ZTT
MDMDYT_6ZS8GFY4$K5D>*T4K%EX/U-TWPS_ILGEFF9/<L:YI];V@\5+BKOIKX
MNT&!S+H'!FL%^Y)Q@FA_HPFJ0J3#2?9/2PRT%V`D+PW\XO[^Z09%06P1\E]D
MY[H*)EH*+HH`;K1!"T+^@<1G.O;#*]G;P`9W;/PDZ2([AEXN3^]TS<LNX=8=
M;"7$QM7EV5GH6=;;>L`04Z[Y8_]E_0VJANKBX>=E3+PYTK,T$)NVM$\@Q'7&
M5YF!OY)Q:'\]F()0'T<L9E1@KV[[Z+2;#+V2A%X$ZHL4,E_6+AE55^S0/#W^
MGF<M.DV`S@Q`C38+MA-%--!&(7-5Y[8(W]!YC3;Q#BJ]K0<";?1GU?*:J(FM
M$VW0.UF?%9-7-_J&);N97+$OE$WXT.XN,3N!\N=46##O.B6DA5CXX/I&>\C?
M>TM6P4K*SIW5GJ2Q+*6[`2J@@I3D?NZC^:_:=@PP0T]05U("IC=I&3KL"'@9
M4MQ"-NF[A+$.#\SC=L>2:DKJ!!R;EO(2'`@LL/*J1\DKK9/"V_#<0^;NZ2KQ
M;VQJI.LU%AV(%,W5)T*D3HB&/4J`E(UC=I("QY@*FQ16LF5VZ6VXF>[LND#*
M`H39WFK&00BKW4-Z?'FI+F^1?J>Z!>]=N.G)8WT=[K4X1^,G9Z4_<#5X<&+:
MV`=9YU^\Z33!T_HY2+DF<EO\ZJD5O^I?.8@2<_VZ-WZT@25&FY(PKEQ`96!2
M1YNP4[B95BH(KM$/[0T*RZ_=<`]ZP8\,AAW73R3IO7B1G6I@,G0H#]H;:_":
M$(L$_2W?!HAGC9^U.#RAHBESS;P;-`#KD&J=F=VO(NL@`G$'+GZ@WH3$5B0`
M".^*9`26.=U"32"D,):8P)%:O$(<^^KW9U7D2U2U]*%2%X8)`4;,2'0B+,NI
M'+EH6]G];P;S[WD6J-9$[0=)($YCHYN"><\&-,6K@X5"O-4-B2HE%A2(0><_
M<2FPSEJA-N[01=6';4)S$?P@\B>H=D61NBC&%`]$J&JR'24'\P2CF%)=EB3H
M9+[51.`IH2KTDCT@Z^GX7GHL-/M0JA7TJKXXDV6,+[(.YG&#0O/,<F$;UH^M
M)0.+/:VR0S$,"F75^$M(")]6$[!;"%<[NSVE407I3;]NU,HN<<+6LS/&,I,V
M>+<="T:U/#$+KUI%T*$@K5*GN`1+0`3_;9"CYVC3X='O]X_.CT\[OV*??MNN
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M#B=T\K@3U*4N=H3O(=8_-];?-[S_..'GLOJ`<RW\TC.R)[GDV+/^W:$=N:C>
M'RAL$VIM:WM[_>7SSKVZ'7ZMO7ZZ_O)%N%"ETG<G]'V[W*O_T&#LM@C`(=PO
M1B"'Q:B;%1G;9W4O:397%[1_M?UJ_?6KEW3"/GNY_NK54U?/K[9?KC][Q1L5
M/E*/8@NNZN$5=*%RK/YY7?5H=5KUV;Y^M2E<T^BULE_XLU\G!$H39X9[Q^10
M*5XASC&[:0\.!<B4H.%1DZ2.]SDYW3_9.=S+]O_E9/_H;+_-GI.@'_NA8ZEC
MBAZP/R\DA*TYNDX@SA*YL]H5K'Z7S-=2J>ZEQ4V]M@*95$.[?,,]6N\2U5IS
MFRZ'1^<[1]\?OGVWOT)UOZ__.B"`+_Y<VF=;\)?!@SXPWWG=8X92OJJG"K!!
MJG*H#I]3(2\D_L31NE#R,=WD_I,DLOL2*R!B7'^P%@@KWW4TQDQ"^].G'0?^
MO0%Y2\]8I&4_\]8F<=V"[-06U7[N"%C6%0O>6$XZWO_'V">3[=`TKRZP[ING
MZ9<UZ[.J<TJ-66MWG+GN&*?PI#;3H55K]W9(Z_AD_W3'-U(K6ZF/?X=;%%0$
MYI>S:>0F&6YW->@7*[]0S](O_]%9QY>9:<6)KW)ZN2"EAXD"RT>.091:<\K:
M]OJSUR_:?-^K'0DP=9=$TGXV4R.\6J(NU%S??FOM-><7GCUM?XP+_^4O75F8
M?)VWG]R9F=GE!`B1H(IZJ-8\GU&RIF'UE[]P[)$`20L(/<+M]]>V7M/\OM7^
M6%>RY2[EGR)%BS<_]$Q/E;XU>[8V\VI>1V3?"Z;1$:FRRQ"1YQ=?+1D7?VK\
M:SM'X.ZEO=BU+2Y??_%LL_UY5[U^C3*M/7O]NCUR'[,A]H/<?O5Z_<6+#K'7
M7F^N;[WH6;ZB*ED_?(0L9EN7LUH'2`>9&O4Z*_([K9Z^""=O8X>@%<?DENT@
M[07SV2%=P9*D$++,08H;G?XF[%:QC*M]<+%F;W[Y#TI1$BYMK7E/U"?\SO*E
M-351<IY/_4=3K"H0DX:>4@V[BN>-`PDYFTY!51T>$85$W>ANPL;7Z;`^[>H1
M;]_0WW4S3[(]QQ#_E[US6XHLN=+TJX2U4=:4&82".$#0TI19)$F6D$A()61)
M9;*V,4Z911<)-!!5E;*YF(>8R[FH9]&CS)/,]Z_E[MNW^XX`LKJDN9BVED3N
MV`?WY>M\U/+-)XK/K%,_C,8X:AWWPL+J`3X8)G%L?('2W>P0A?'DW/-39+=?
MSXE*J((W4'$`G+5*U]A4(G#WZ)3=PAA<\S['X^#*B&#/XE7_%BIN&X5:+"V@
M@W,P]D86CF.^!4JE$42$RIUQ#[&0@>8U5R</\I1EZ'Y#<Y'8+$:8#:Z<]-[U
MC_JD&Y'0S!18CR>:%'#WFKR5J>[=FZCA4AD.AMN=(RA&WM#&>N=X>4:V<D'3
MH_(:%>GA%M"1$9]XD+1GK8E_P`PO;VP:8*SB`,".W>;?+':A:XLV$<+GQ18L
ME6DX&`T-^2V%8,GA.B""46&>G.`,0M:!<S@^@YB!5_5F=#=0'@K9?+.YMD(<
M0CX%!J/POT+GW;GL`.!*'J#F:+\F\G-&Y/K%W<G?+IG#\`?FRW'Y[1Q_%(\<
MD??[76_V7AF"!B"_\$<"_2>5)4&:D8\K())_4ZN&:SU"%`&UQ0K".8.[P7&?
M\=;//*AJ24$M\]..QH4;<2/,-?+25S8&:\--O&F<OBR[K:U-X^./TGYI&Y:6
MWVP13>K-(00//00.WEYA-$ZOJ3C$P"8/U-F02$9".A^-TQ#NMTHNVO74G5P%
M+_C.5[LA+Y7TLR5:==MUL;\W>[&WOW>\MUNYL-R/DD5(GN$=G'9XIQ[]5'11
MQ2";P@=/]E/)!%3F75%^LM!<U+U4N-P!<QS!-]=SBMT,67`PQRJXI0__<.)L
MFB5V>([B<KQ:2TB(*183>@/"ML_/S0>0")]^V$NX+[A@_MGVQ.I&4#7;.CRU
MX#<_6G**L#NU?E&`S`>;<%7M<=J[90)0V.2=-5G@K*L;6B\&>+?(1#LB;Z90
M/Q#?F*R-AH;BUQYQ^!V;Y_?))/+?R_]K[\&.-`>;CO`-__4/M</0//XP1PX.
M!P,:B*,YG"N<H,"7T-*<I!2TD1IGV9>7ULM0[J4>Y2/C@8(;7H(1?08[60&)
M!()5T.=9_#PJ[>B.#QBOM*_#CL,*^-G%[LIX8VTTV>9FM2EA/:3A7IV0%&S:
M1`SQMPH$T%<L<)BS0?/HV5X4^@JB(L=1.X9H`NH(PBF<_HJV]\^."?DR'KY2
MX.2H]V;V[0SW4AM5LF:LI'4\P?^_;1QVZ1N5[V*$J7-^XV7>.L1D(,82<'($
M;ZY^D`$1^IL=X%HOUW<(&H4H(]$9`1WM&&R"V-"0+=JH3)#4PN'J!FW$JBPM
M0]C"JCB[A3`L!V^9>S]1PO;W=RR-Q7X-B5I/7*0])\';N07/9^C\R9+::&B"
MX20</K\C6'2.)DO%KPM:[]YT8GK$8#!8XS\$)3&0YN3&XHG4Q-&K$*M#47]@
MZQ9;#F%7%`&;%21X;WYA1*20[L>^'/Y\4+I*K(2QA,%0(VJK84V>``\M:'76
M(XEU08D+]ZHE2+M2K)V/)]76JU;16&7&L!BE[L331EL6IND\[.>XH%,U,CDG
M4]V]J6R/.W2E7E;H9:#MINI6>Y?*E?085^VU(50N]?T[-=,+VDZT6C'$M#I+
M(R2UA7^B\X1>,M*`@Z).+!?3G:WP/0-A8/GZTOS:@VH2X!><#^C,1V<<UE7/
MN8\P5G<*B,T9Q@&'>2G<(\!&Y\;`,%EM>"T6&(5V6I^^=&/WH`O.E?$>8?'H
MVTGW)FS-&8(E'8!\=7%Z9^'^H4<RQLL07>^X5]J1L]4LU5[IV2P<L`MQW/]+
M@P1L,_7=YG+SG8G![;5%[P1%I_X51(H1AJT3$A+!P\HYG(5X:A_P%PUS-A(<
M]RMXT.@H049Z<#QX+P]3GTR_B^!-)PD"Z_-T]?J,@UQ@88]LN\WV`YA9$[71
M2CR5\:J>Z#.HN#%]3%F%2EWIC\I^)_\QUAD;BT/B@3.R%34/-D,K-J$EJ6,X
M<3@O*844!Y)5K39',AXM>Y<S7!GUA[D07SVZN`A=50=?5G;5BQMF2:K*/R0K
MOY`;1O7.^^+FLY@O9.!Y8[G<]XKP=\D+U(YPS);-]0WY.:]!P>>(BU>7=Z!2
MJ&Q[02-.L^#@R:.`=Z>Z9KT6V&G(?W0M]%*5GSC9+7W^`\0"4-6B5$1I'5+H
M00$CYJRNG/?%'"48]!,?BRWT.#V,33\@HQSC?[@@O*?#Z:?>6TTG?%!)S^7?
M+EW^_>'F.^!#J3]=$;#+/9A'@GP@1G2L6^,`6J_><*$-O3IA`.FGWC[I6PIV
MO2$.'OJZBAH$6B4P@84/,FN<WE]?/M`Z##+_XQT4KF]9RPEN#]\L/NFLI`NP
M-8-S,C>G/.L>]0?#3-(U1<(G9N7J.Z/-@352M6.(S`TF'1B+\15WGUPS_9AR
M(&WS!#9^L6X)+FK40P8[3QC;;>&'Y"1\O6/ED9?H@Q#(V5QO;;Y*D81BP'T0
M+4K8]!V9AH$B2`%2&43D/R[RX]Z'_='D"]^5Y*QX=O,!9Y?&^`X4U]6HRL!$
MA^Z]R45/XF+0[G![>VT(^6KE@4$B"S7+U=D?ZI>EC;(?[;V@!"`2JB:`84+1
M#@!9.)OC164W?=&`JQ?&E[=?[&NNJ<OV7Q)7%Y7DM.&"8CEVLXU@(;#[6S7O
MLR,-;?;JA2PE\X\<@5<@O6:J7$Z3^G<D20-)(P"BLNO8P/,)G*:HM1#QA9A2
M(^(C##OA?A@5E*'78"%:.5-FFYE99A_9&B5A"`J@^8B#^GDW.HS81,),<XY&
MZGKZ0E2-E"1R?OH=*X\2,!'RM96$DN)L4M%0"2FB#IYZ4WU$AM($M<XNX%-)
MEM>LV1!?.KFV[!3^&"]\LIO?I;QHWZ#N(`?<MJF5K;71YF;;^2<^W8`Y>&<B
M=Y'#.)33Z"RJ^\00#*H`QYB[I*PTAJ4IC)6$3D8=2XGVF$X_Q]4AA1FJLTJR
MN7*5()P7/FS`"*Y;F2[-JSAD1"A[LWU\0!N@I8_I&BUS2%!:V7:)2,TBO+#%
MWR/`3$Q*'97%XGF9U\APDO?MJ)%0)\L_0;S7/V)ZF!+J\6[S,+FE-#I@F0E6
M`M"1#84U6Y3UM<$E_>7>4-54IP0[W[`MU*<?\':.L7G8%<,A`/&1W`*,0&=L
ME,]$Q;L$XN)C?6RICYTL'*5:7GZBY4J<0)M'E($:P2%5!3B>RR>D*)_6EO0,
MB49,.3;IFKH?9^$'"O[^6]-E`N)D7,OL(D,7>8*F:Z1FV4?H+#>:;*UMR&P+
M(1*<Y>(F6D)4FX.N;"9S4I9;:,/BMF6@F)&R1'GF:9W90V0QZ(4TT^7I$U>5
MWU#/3F\EZD2C!@Q>FW+2`"Z@@@5_/&L19"E7P\;B<GB[*D(:?P.(E:..4*EY
M>SH6@T",J"0(""QXC2C$EPJ#PJBG8U<-OA2=:?7IQ\.#SE.&62#^BM#=C@WG
M%6@/>2P7"I]KJ+72%%G!"E7&&_2I7I7B3=0XG*<>9'C?&VN<;7BGX7VY+M8!
M`]``$0\I(Q4,MY-8%KP;>VQEE*!][I%?8T0$T<#!H$*%&MQA09'F,_RS4JMD
M.&3M7Q!""W%MLK:)Y8IQDO6L:7E+@6C;1@0P@D`^6D7@U;4,)';FZ:R7K6"T
M-B*[D:-9OH+6T'E][`F(9X@=1^``$=,R]"P$&KHD/K8-Z229_T$LNM0Z-<YK
MO#58Q^#M\-C^>EVKOWK=FFXC>MK]2=5"<Y+.)32"",W<Q[^.$_\K$V96O59A
MAN`G@,T-)67HZH*L_GRE@4,0?2%+WM$^H)0&4S6Z5H.M";4:PG\<38W?!QV(
M[+E[W`I_#LZ+F<A;IFB@.JE8.FPK'-@8F!5/A%*1"(V%N`\UY_6\KIP&M'G<
M?F&\&BPN]1U"CQ*H@FX<>E^%+8<6IF:5O$<M\/$R`8+FM?U(@A2)AM&2\]B2
M+='T-&J)L#-LI%>K=LMZ-L#.)QM;I)VA-S=D(+3V)Z23Z%O.,K=1*:>N=#;9
M(]QJA9YP_^(8V8%]EO_%$("MD)6\B91QCEW:`C7P.L[7JC&=O<0V*F?J1>15
M4@)BF40:P)@?A&B#6^E;E7V3PPFW6HI<^+O-$'Z!_MN.HZ#C>$PIF.XF`U3=
M)Y]'2^1F$FNTMC$8FB+`XN#_465E-UWR2L#H$#U"XZ*!`"&0Z'7CS8F6<C8]
M7=L83\A+V,S8LE2C7#@\28G-HC@AII>I:\:+92C+LFBY$=8V28Z<CK?B&75M
M3/3EYP40P<86A#GP;@578"I60B6V6N(3:>5%IHM_Z>QA,?G_KJ@PVHLJM'"M
M<\]/4(-;&\A5X$5*>0HF%1M"17;+,U.HEJ"'?LKP*_C^08V5X=J(TH*-X=18
MM/T384W:J%2*9RJ@YJ"`2U>BO%X\ZWG"RI/Z:+)=8KT#E4PNN54$(6BGF=;7
MTN;SC:+-C\-&G7G1^DIVI+7I)D2TG!@CZA7G*=0P7XG-<BKHWJ'=K6JWC_D5
MO@7HA;`C=J[MZ'%8N8\T6W;:>8R<=)`%AVQM#@EA92IJ;`UKT370S'5IK.#W
MV"!"O%:8*42[DJ<'`69GX,UYH@C;_`)L%PUB>7-*RH&[HE$6JI<&>'YR$[@V
M$XDBS4*H2+);ZH5X5-YR1'X8CT%66,91H"7A_$R18",SO:D)`NO,R$P^_\!=
M5>B)W:9:!.YCD^&?IN['3LST<B9Q_M21].[BDK$YJ.GFTWZ6KKZ53(,E=B'0
M6TAB`7$>C6=12H38V:!UAPO>"G).!^+9I1RB0=[%B<7EB:N'8G?#;-2.[8G.
MMGPBQ+/<WQ+#]+9$CX,V;D;A3?;.ZD5"(/.(\14YG`O[B/K.!3QZUMA?)9/6
MBJ4+5NS^.G93$X(<J:^A.<F3:R[HI<N\48D$T<DV@\4?W/"'9P\*P`3GIIQ]
M-M9$OYJRHJVV_%#F_L>V-#K'ZG>&9PIO#A)M)[Y;2ZU!=+UD,R>6%]!VKAG1
MI:AJN7QW$1.H.*;/H"W*R/QY2_KL4ZMR[?>JC@WP@'!2XPZ_(=QMF<?=]MY2
MWH3J,;`F6+2\B/%L2H^&1_,ZCU-^D8]SRU=O6!*K<L$2HT!L*Y&H:0T&7Y%+
M\:D>834+SK&KO_\<`PG@A,@ER\3NK4RGTRYB)=J011RLTU;Y":%FQ$9I(1'=
M0LLV<`%=.%X,'JAFT8^^OFNQ,FEHSE3SE@J]=VXH\;ZS<!Q'%;L);8#SGFUP
M(*]J!ZVG.]=Z,2H<T$:3%XEO:(C:HTI:ZRLTOU+.`JLV>=@P@TE@!6(L)B0>
M%U(NY)Q'Q/450HN!&W!:J\+C4'RI]N5&6+J.T%JDHR;/D?MOB(.P]_[S()>:
M%,&C+/06O\IVXMG"7\BR9A-5$%(;;B1_DVDD-&A"D;I+BH"%4<E$POUV=Z^.
M$?QP=W'SWMT"]@023_5JE[)[$<+L3]W`\]"T^O9Z`]V0=.0]_DP2.Y=,':_T
M..D0]^_=)=G`AZU+F?`QWUI=&U20ZCG=4%F(!*.KG7,3"J#:D@5%IX`#V#S7
M>H$^P'^NU_-(:Z/`14'(5VTIVK`<<&K.]@ID1#VGV87#H%JK>]!Q8AXUC^'$
MY$3-H\R7\3MPM"Q<SW[4>%,YB'$+L`+L;X#HV`;_)"AO.I2.FLB0QJTN!/XJ
M<HD3DA9MV@.:Y9*[`XDEA,N-5C\_^9+.?\-VDPW+W^E^1XM([>JJD2.*T8!U
M?/E274FT4>6WVQ#1V+I<4WVUT%/:"?C.+\G4.E>4GZP&W#=42,?#BEZ$YJO&
MZIQ5YV8_JC+Y#4']#^ULQ"G#XFPE^:$W'H&.@TQ.%2VC00]C'J7NO<`L,:&U
M-IB,*:/;<OHIA1IE\8S-&=-*=<EQ@13DWXZF1M!V7Y#[[F=BQV+1V-=J<F>I
MNPVHR+?VS#XM9A,+<W-M,AA+-Y3?Z4ZQ5![VW#3P1\W=M,7@S)/Q+]B@$CXG
M4&F$HN<\4T.^^:I69!@L-E]#"9>5T6AMZ.M,%LXO6U,E?(+V0]N%8`=IWSLM
M.1:9;ZF\5N]J]`2\?_&I0&6%'">V&(@BWG?@$<<HL)8'.H,06VCR%R^-_UQJ
M#Q%TE6T6`6UAW?B@)Q!(>N@N2I;%JZ"I\L`VR6+9VI@N0V/+F!-6Q'?;QI\K
M"5V8ME]1"4(R6Q6-!N>E?<)P+>'6,#M)PF`P4U!#IVUCR:N77QJVIRFN>BQ)
MQ\"S(S?2Z::,ZM5+'G5'O?)TH:ZX0'$R7F%N4M@(HY0NSD,XL4",U?LOH\HL
M<N;_D^IR#7.GZXEB:UQO`H<)E9(!^NXV4&QDL&'5X0;1>J9RL4[SO4M+E9"-
MYC1MTJA'XMXV.:0GVP(:H8>N%CX4]^UG^S2<3JFC0K/<A.GW7M1JNLO8QB7U
M.5^,28.&#%&I-IK*E2S`BYKT"S864C5+^]D4+&+F77N+T=E?\-5H)]GF@NPS
M-@_9#LECF0Z'R\BTEC;12DXB,:!SYO-GN:43.\J.2#"-3#)`9X;52:(684VR
MI4#U^373`^CG9O'U+/N@AFBC^^!+I>Q;V%LZ,IQU+,"<M?3=W%0REL%!O7A%
MFQ=-KC*/V:Z\6^@$J(&4+#R<]R.$L,53">P+VMA?T_*41CJ:KD(8B#QAW`_&
M:KJ2(1KW::9N)!X0S=^@RT>D?98E&)/)Q(1S1:@BH<IL)90]WNB$Z>]*?WWN
MZ)!(;5-4_%00C@$]S<"`R]F8!5<9XXW.@MP$,:9BW3U-*4F2LN&4*Y/16,??
MEA+5.Y:;3HME1JHU\N0X&D-B<S>)G-14R3C3$;4]H"^)MN;,-.6.A/)A;:?P
M-2_9?QXA2-9"@&22-!"$EZ5P!"4AE#RMAH\9>QM23-<VZ&OP+.4T$L-R=J$M
M+WEM$&,=S*-$.!EE>MDR7=-.)"F\DJT)=^!<Z,4$)22UHPKT"_7?<HE'QX<[
M?_S]X?[+W;='_]K;_=.[O>-OJWNR="GN<95,"/]8"S""Z+1?ZN7?P'^TX"MO
MR`+V[KQFM)>+F#U4>KJBS"#GR;D*9V(4I3FXXH5$-HJ14W`^ZLMO[JS?A@()
M47%"NL9\,0HV%K[1]</`+L0\FRE5'5XH&W[U_*V%H@H+"3<KR4.RG[>QC<GF
MVH!8OWS^S7LK26F2.FQ1+'/9'O>"WGD?.UC`<<;E.<*57%ES\]C/L.WN"CWH
M?[S#4L?";;R@YG;Z&G\#S;9Z1UC4]SV;F0O_XBP]ORN1-OX<-,6@K)@71R_$
MG]2[)BG+M%X%9I*BVG[O.[E]P@/*FKCB=?+0F'F1WD:>/UX7ZP=O+A'=PA>G
M:Q-&$X]`_\60=3'@#@;>*C81WA0TT_1":10KX_[F5FYDV_KL*;;D68!Z15I9
M"W!&)]'.TFV+]XHR,!J8/R1,Q&!M*9,L5!O"HYKH"64_])W;VE[&B8-3!$5^
M9/6U<1;-DF5$OX^=$TD<':O11IZ]$'7K2K9."*9*-9)#2S`S?&]WF5D9#_O3
M'C4M5]:SPD>)X#<@;TE/M$`>4VG,285W)Q;I^[_=EY&^%;P&3<4=VASST:S/
M=KI)UA+8BM`)HWS<?SZN.,Q+3Z(25);(&YZ.>GRCM%K!B55DX<D3LX\CQX3O
MZ?2G#%*<MG+V2F[1#_[6Z*C+GUY,"0[SYL!!]]ACHB>[=XOZP8WM45J3./7*
MB$R5K?&F]#[+FA)O,E,7G8#(&CDDL>%ZKI((.*T-2ASI>3-AP0N?BBDU`8./
M=V^`L"/:(#:KSSEO+@#,<HCHJ'QR0R=Q0*.^P$*K"KG6ZX`7C"V-ADA.39M+
MZZP%OQK]"LX>0`G?R)QFF&9]XYZ5D1K)G,4GE9!5C#HZ[?X784SRP^;'/8(!
M3D@C:P!7(HM'$3>FEFL<S[%CE5U2912S+IO6"<B5$'ES`AD9V)\C6/Z@YLJ:
M5ZY2[U\L3IJW&:ON%"5"1R%&<M;<X\22`!G2HPUEG7ZC2P#X3`FRT=_**BP+
M=#4F]MGBI'NOSQ8EXR=ONH,[^N$/7;Z,3.)X,H'J9D0`[IQ9L-2&^W`FW>(&
MRHSD?4*I]MHVSO/)=&O)`8F-J&0LUZ'$QQ'ZO,`M,E9Z#!8HY3&))>B(F-M3
MA=.T/_D'"J<.=2[+A,C+PYY#>D</E^\OB$8?T`WJBI&C2:T+]:5[N/]#8\7S
M7Z[I^=>\D/)Y="E/<L7"2\;V3+H<MMJ7_%)T&`WZPW\@.BS251J<"!I?['C2
M,.P@?42:GZV2B"9S<UD!J^&C0J=0[TA`PGBL]*DNN5/E!(5-9!Y#+-*8XTMA
M1TSF11IGGK,E?H^NG%<>KI)Y@TM&^DOD71(<)PS+)2@.EPF&3U6#(^VI!%M7
MXF^NF*1:Q?8^I7-)A$7WD)=LJ_:(ZTULLUI3QQXA:E[V"(@Z8YE\Z8%&<VA'
M"CYX0%-^.!;0%<',MZ60=AF]+/G;7NXS!%>]"+/-VSSFX(-$WE0U6)XL03<_
M;W=Z:;[:FSO<L[E5N5`5:"T83`":-J8%<U$EQG+Z)H;#]);L,DW&HNF0')V>
M/B11Z(G244!Y%+_$BQ%";D1">.XA:*U'`!SV"1$KD&6J7IQ@EM%E,B!8.'D$
M(.8*!K)EO."E!,#X!ZO\X&J3-`=LZ6?W%W>*76$LB/_:E.M[&?P)*JS`8),>
M,UV?6#&U^>W6%W0JY!+6'&0C8YL179@$:@=FBYU,AEIND\%I<2!OF::688:Z
MR98+=)>.69JM#K?%IU9X):,LBW*,Q4H`VRH/W99&K<6V,O8G](-8E)NMCUO6
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M,E64_(WL,64=64+I*'`HNMD49-ZL@>FZW@6^_5HC[8W^=-BPU4H[.8;\?)2Q
MN)8WS+VYNOD@#Y*+WU0$:>RG#H@F,./^$C&_0)Q\OWYTAC2'IU%H>''E@J7C
M!P!%%$#I=GJ2+VK))VH7K`QF_8U5&^:&YSFFM/2"H=@LY\`G'7D-FB%Z?GG_
M_?I[=`C)<!P:2D.36(O*AMR=^H(^'+90`2?@)`-I0X5?HVM6_NBG<1C'SCAZ
MRIPYK(@Q7%Y+>&]%":PJN5P:K"90G)IZ6Q-.`:<U4T-;.<('`&!N.BP?0KCH
M;$<[>^EK63*&J<^"C703UX4D%6\Q)E.;[)4I>C'9YL^!TZBD6N1T[,6@;YK0
M,#AD!`OJ)V'_I'90R,8NX9]\(N&<%_2F`BH"G3>E"F>^UB[B\G01Z;P=E9RM
M!XDC29(7%&ZDV.Y-Y431?E8..I=S4=.*50V&MYJ9>]H4X)FBJ\7?T*5+OE?:
M=+F<A90CD,,+MCL^!^PU_>TDKVP$4L6AXS[2#!?"/.#-O=>;FB@6S&+P4G^;
MQQ`B%A\[Z47Z4J:1_,CW]+KNM>EV/.X/M[_X;8\L`WI=B51C2M.@/YWR@_!1
M206A2>>G2Z6@L\+!%\F2T(?M]42C\:77A&,O<4Q;&>)Y'@RW[!):_GC"O@BF
M2__0K&S4/C5=T"Z;0*ITCVL1%;MRLGLBLK5/EA/14I^995B[)R&?4,/OI%-8
M$%!!+$\OPEW0/8R1WH\^;L+&/$C)M?[F)G7!+./Y[$]"+W:N)Q`6#01_B#XV
M/AH";G7L^AHZ-"IY*G(C3^Q6]J/.RK3J]U".O,L$0>=GW'COZ5@WIQ1$T\1;
MW=-?,6C&#N8E\R=ZL_./&H`6],846WOU<H;\%%-"9IGC5Z_7Q`I4[;BJ7%"`
M<B<(5FX^.[D%,AK'YM3^0"JMI[JPR!_F5TR-ML_'^T_H*G;['>C`_=]\,UMH
M8"0PTV8<UIKIOS=W[QEU::1Y)UW!]A^2Y1H6G/.Z*2FATMT:I:K2/IID11[D
MQ**;'GZYJ*02H<@>.C%#Y'MN"$5=MZO3JHK3O<SD#LRD\>EF>\4]T6S5Y1@+
M,@C$O>FX$QN?/NKN,BMZV!\P=QC9;R"`9+`,Q5`C8U3)P-65_=/\=^`"0[15
MM&[_C/&>4N@,F6\U&B6'CCE2X4DJV84PK164I[O0>_^6*Y`I95GF3A=#O`Z9
M472ODW$'-AW0R\00-2S`;#[";J)QD-2P3$)`&'Q.(_YUAF;RL3:F2D>GCRJ#
M8SY<L*>G("J8^%LH\T>(^*[6X,5S32G6,KH.W%6C@%Y1"Q%LB3ZB3WDI4/*T
MF5.NK?#1L'*R-MALFLN'=\7S45">A,+X"N.E28$,52#BI%I@ESX8V&04*WJM
M;B^%RF2A2)GTI]TB9:._,7Q$I/Q9EFC(&-<"X:WHIL3,PY[!PVO&VYA1?Y8[
M`/@!-&GM_+>/H.`"@+F4+F&^2;X?@?'`NI*!_$NAJSU^%H3'G4)[HS_>>`3"
MLR4F6P(]O7/&X!AEXT2TD3Z:QQC<(NN,L4:LF&XAY6!EB\23X6;7G5<W0C,I
M^5"9=OI,T1MS3_3H`@5##'-L0B-ILAV;B,NL%8V%^/19*^Z<)>*,;QPE2F*>
M3:&+":3;!Z7JSNUT9(Y(Y;DR1I:$K?A@R;^,/8OG4QMX"WOC!618,_@+:8G@
MDQ[\0+7&K4D9N_E!M9PP+S+L;2W7I'W?,$J0+DX7H/=%H[\!TLES#(W*I;Z7
MUWQ'AVMI:41M(,DI9_<M)UO36:21RRW'!,<%LZU<C^UV($U7*IM2+ZZ&&A/;
MU@&'+#$4HSF-T8UM9N[=<1`-Q<@,&@G;L?*N_DB51K%@]:7MU.EL#[I4^[=@
M0=UG%M0V/6]>J'^:J*ES=T9&^G7!NU2B%KP;UJ*FP^5NXJK[Y3:>IK1SU&9F
M`FL?CM%]Q$V6?+[[!9OJ\;4VW1JAOIX0[94CQ?LS9S*O$&GZ2()M*=>:(2F=
MUM*DD^]B+$GD:0>+C*52LK4%S))#44Z1Z_&ZZ9'6/9_%MESB>0@#MWN]L@4(
M`;JO3">,1:/NK+38K)%03*$REXK\T#*,)*>UD]3^(UYH?^5`Y"C5T&2Z6I;`
MCD+(QB>(.K8T?K[<.]/^?*D(P)=BCD%X9<F4<KT9);+%C##GVQ9"BQ/QI*'0
M@J(")42IUCA8:]X_KRG\3[S%]&-#9M./!;"HD>GOST7?J=2#VMC?Z`^D4"S&
MW]_B;&TT,]H$KVV1L(WTS%3<H"!\IK#O/*-/S:$_YX3PR5<M&,M#XE1;1R1-
M,S0A2:?#66+?Q3/R^7LFC9,_KN$6W(F5:YV0(,+4Y(]X33AJ6<Q8='`(^"AO
M]EJ2"YH74=05;^+1PG`W>R6?$$CH3)9\;F)W/HY`1_^ZD933N8:^9-7K]!N:
M--7@JNF,TUK31X@=S?%0J.=ZTD/2CZ@2=^=T#M9T;(^26>&*?2YY;-+='ZWO
MF=:3+E%(B_A]N,/&;P_=]5596W&4E;AC6SQ))==DXN@.2J0?UM.R%/;[P2)C
M+DMBN2G%OM740#W]_?7-C^L8<AI;>7U/OACXG+RY$-G=A7QSO^VMGBX]H+"Z
M19Z59*;.@L_$R6SUC+)E?22GH'2.$);WC2#/-MCX9A1[(E$^I`.$<<8M&<>4
M/XSBZHAOS!.D[$(RXIS9=_(9"72:,8R&M`"?BO4^QG4Z7:S#_F1+HM,4?WA]
M0R*Z6KD?M[HYTJ"_M9PC(5.6E1&L#&GGJE1FK!?(163WN"DSFI)PNCUN&%W'
M,\FH>;K_TT37R#`VR;#&2AD-MJDE(MUJA6;U:Y/4JXNLL@&9L2RF\8QJ$]WV
MK[F1PZU"!(X.(S4=,VBBPWRN`7;,,W!X"ZJYM6`>;KR4<M'HC0WKR"@XQ)`,
M$6%[2J^VD+NI<)E>%NP1A<0I6:7RU`R2AY/O6:FHI8/-ME0)BUR(G8:PC'B+
M%I5C,5Z:#`6[DE*#BI&.IBUI!,QDFK3T@*Z&3BTI`]"[C)(DNX,BE#)Q8AOD
MH-(WUZ,ZGT=$I,\?E@V>XHTAJK36HS`D]B/IT-YQ]65YI(:@IMN8?M.E[A-"
MS1[H\I0(_/7"I>*MD`B+JKY-+%3*8H8&3^`T3^4FF]U^$;B)%'=Q_47ZN5!]
MB0J\8$]D`(RWR=SPB0G9GLR6C_C8]=[8-Z2)^2[CN/W>R@0;:4@=BH#7A"%-
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M`!3]7"68JT<E/6(Z4DH%RAPI33P-:FFT,CL<^Z#D9I9ID\+`NMX5I3EOEXAA
M)'7'W@O=TXQ/DIKEA<`7&-3"!]OGJ:985!PY$4Q,<&IV5<+Z;7>^3WG;%^4%
MI1JL*SA4_[`UY(=!!>YO4O)1^8@E-*R/%8/J^&ESO,X-TXI*CA6D6`4:%F8(
M4V>S_/96^D/Y7M,<NK>>':E\\1Z!--WYABDDEO7:2HTRA]??F"(.U[;;+"Y_
MK!DE<S@M4X//49*_(Q<8;?L!%,#P!K4NB=O+U2^=F5"S<JS$9(4[LL*J,]TE
MI,?SX'IFCND%:B'&ETQ_-XSTQA`H,YY=+#Z?I7GIHU(ZK(8-`?O^"DU_KL];
M<SP!,U;/Q;5(6MB;(0+:71[R0@48.U>#>`\\/3Q$Y`)/!,%F0K4)`^(;LW59
M$$5KO;VXX/WR[*@6S`'7NL_DN1?KRM3^@>;PH@5?6*ZBL8)%Z_1318G-EM?Z
MB/)L@6TX*-+M6+^I(WX\<0,G`@GV.9YB2P(1F+)7MG?<WIF:588W*O5/;[R?
MT]/D[%)AGNPE^!"9;N8".UMC/"4D\H:)Y0X[Z="K,/6=-YW)H>&0T+IN"6"5
M5()F1P<>W+@X$D_.*>D$^[1#7638'Y:;$2'E03HOW-!Z3\KO)I.G*>^V1_P*
MBP'GY5>S@!DY0L`6SYJ_P]3%6(-Y3R5GZ(W"G[1!1D=0ZK[8?="1B)4EU#GS
M;0AIC&D:B^1SW.I3I@5Q.S';AN8(60:"@$N*!$^9M6O7V:H!VZLK0HP"HO*E
M!ROA8[N<U=;E'B(_*%NGDMF;[:6DG%E`G6,`ZG\WN.Q5S0VL!3C;,,1DB))7
M":^%18B5:#ZS;<E39\P3T2I8K:_P+=+@R(JXN(,!X=([P\^O][<OA;NTHWR'
MP,T+@!VL9B3&9E%!4J6C-]M3EC__H<=PM')#>'!!,P@!X>["DFG(LK><G$`U
M'<TPU_"T1&`JE_GT0J,X76(W^3C9@F:&.Y6J8,83JS16$PY'W!G_SG",OVF8
M9W"+:;7,EB4?+"GL,(^VCK)X29O<,`R/[,@;4BNHBSO\"FG`)%N(7Q$+!8EO
MA3KFM''+SG4.CB;4L\,^1NX4D'YO+S%SQ"/2(GBRSR3VY,?B50F335PQ"(-4
M-%%#\T4G3AB!QOCVOK_XE$JJP3)*1]'P1<,Y88N<Z2:JK+:<K/4F(WKJ=2('
M##2>XU)G^Y'J5)Z"7T]!!V?YMOMA:B(=<+CCY`-,*WDNLE>LR,GUN1GDSEYB
MH3\B76RY0^?TD^WX`2OOR2GD.O/0/K0MT/117PD:C.8MZH),XHX,\B96G+2/
MF.3?O"9LR%?]_Z1J/>@/ME!OM[9*2A[T-R?ZH=)3^0'YW!]6YL_FM#^8K$_Y
MJ5)[1R-&A4HCWMHLOS/&P;"U/MXDXZ_\:="?K&_VAY/R>O?5X\5G]<]7@5LX
MTN]]MO(KU#+<%/LHF/3_5X.#<?,/5H-K)?^9JK`G6F>,)_"+8'BT<*<QX8+'
MVG3!4&\D0TN((2QQUH,6'QW`]Y<?29(U&>K<N6+A,Q3VY$Y++K1"SY`,2Y)5
M$O0)#C:$RY7&4/U;2<D+_&R'KN:7=T?O6NVL^MH'UI4/K"JQG\*%Z;3Z!:UG
M8U1QEE6O^*[NIFM6=6US,%7U?G5]JD8.6Q5W7!U34S:N^5]W!%$XE=>K1<DH
M)3#D/P5&4!>-X9]'QUF9](=9#G5UV.;8#/G(TD&2F2-TN\:XEWX8/RM?[@?F
M>*,^H=)H<>[.]TP2H=N"W$C3`"FMD%;F$E.X\_>?>ZLK8Q4M4GQA44=:(`_6
M-B<3PR="9U,"P(--7/\AG&@U&>H:VY!XT%M"!JWP$*NNL8]1G-F!4N_Q)=P3
MLF/&'FU[UX%.4A6R&P2RT_QY')O:%VX!\T1X58MCNZPV`T0S<"$8UI0^D!_I
MQ7_YRWWN6.S!T7SFOCJ6;G1P__K\.CN'9J>=IQ>=WFQK;B7BK#B>9BH6:*P/
M=FNI/:938W<U8<\5^B*J7H;S"0Z8PN$"U+)E!3]#]$.FLLC@>(`Y#?O;CBU]
M8HU,O_D)N*N=-ZF@:.28L"2`L-C`0RF>QMB]O,:!3`[:`QS.>A'<\#XT3?1T
M):/9^=:.Z)%ADQ`.3<XB%/\<"*J>U/.UA#^&^![B;&%WA0I[1<LE<UO$L[.`
M6LL2-KLW6>-OC]ZM!:M;Y)HXMO`<JR<Z)"0M'B_)P(L@4%>9DT,*5:R4O:AZ
M7.@)C@<"+VCE<JDM0$PZV)B";5L<64[Z,K069!UDF"Z"9>,QB/DYF09Z/&,I
M>F.PA5A`2^$RN=A,<M"#9EX'FPD^&>.U=7.UO8.=P]>[O>/97W:/2@&"2:S>
M],<0QDLF*8+?<H;^=7:J(I*SAW]OWV\C6P\.CW?]<C:I<_Z;KW[W*TWKC`(X
M^]HI7_OUOMA=*]YC.H@:@N;0S);VF\9Y_@I9]D0I%5%4/$.>&N-*"!/SD]D@
M"!B[+$@=$MQ+^=IG-H083Q:NYM!UM,-YV<W:H8.857QQ#E.[LN9-;?Z&2^H.
MUSL?EE=*I-!.32&%F?9HUN6+A,CH0!:IXYZP2`L#@-@*RS478EQ]Z-HQ'(S&
M7>LUOFYUQ&[4IY&9VC5\^>/MW&)5+BG?A^6KN</<DO6LC%,L3Z"7'R0-?2=?
MS0LMC?_;?4@5V/\B1?%5]7()#CW8)H>'KX[XO.W4?L6!1J`)@,75Z;$@;\HG
M9^?_,0]MKR'>QI?!S#:<K+@1[\LG5B>#?F7K?OE%==N(IDS5Q8UIOPHVO4&!
M/[F6FTE@<[]D,[.T_OZTX[W#8;]2/M_$5H2]U1<N;+\T_:[A-?7F#A$;$9OM
MF/!?`$LMC#;EIUYVSY'=PJ=9L6M$.NGGL5U#C.`&UM..`8B;REAX&1OZ-JNF
M2I$U==@5.O1"12@/X*WU>GW9VV%ZW^5#^>NQZ0MI_Y%BP!X#0WF[8N1.)`E;
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M/[(AFJ?R6B@7\TIO2^7&("3Y`J\N[SC4=P1Y.&.=X0E9JR'!D,9=9JT1\8*F
M[5</&G/&]U:Q^\&7%OLLA2+.*V&F9*]I<,$^)#0,/W[28U>7'VTYH':<7N#A
M9X_MQJQ[PFT:N1"FYJVU)N&Y=?SV0AT>7YW0'OA3;S^\56<%`=Y_=WE+_R#2
MQW0>1[UMX\78LW__66#(.U)TX(4.!OFJ>:^S.&GBOO.`HMJ:G4_0:86U\<@.
MK#8&0:F+34XJSDDTAEM`27[@'$&&[%WQ[EP8D/S#SR-!23:?C?R279+6967V
M<1VNB36_BD<IDB[E;-EPB-ZJAIID\PI[K]5T^0,H)7BQ*L\QE:3EQOQ:?*@U
M#`-%CTZNT*5UX81Y+AZ`\=%'>;)=0>?T)FAM*40D0,@LDPY%G-K:B\96'^XM
M&>I)O#!M<#LZJ1(6P*MY0A;*P%!?-+FB\Y@3I\,VY*CA]^&4QU](V6V5)(IG
M9YAKB%<-#S%:+-(ATSFO1G`K*^-+IV32*+PI@VQ]N1\L*.;\@17)9C5/*&"H
M%M0^?0CKN3,N=3#%6UNX$HC4U/]\4D]>\_(/GG$)2H!UY:)%0?D"<Y1X^EC+
MF$Z!@^U3+Q<2)*W4Z!/L?7>M@#E&P4)H%J=,>TMZ>`FK>_YHF(9K$(W$"VBX
MAD=PN#44U>!J8LJ4K)A,H9"=!H9Z&1Y2(?><HLHD3`]-<,`J/$]IJ89*D0?9
MHGV239:0,K95L-VZ[^A,#2I5<J3*`<03(N.:7C?'K.GD]F).X;/SC5(?:T7*
M4V7ASHW4UMY.'U\#O.J:9V_1K\DM"3;!U0D3,Y%_YI0(N1R`9=%7S1_D/T+B
M8,J%RI!<"?,H>%2Y*AZ%G)*P,`<HP-7_&I<P:[4ML+M!$&3#M9(P:+P">D#(
MK#5*=WRR,#";)99$/$8@7/WNXH?+BQ]9);A(=O0%#FD#P"+^*<-;CD+:X^,A
M=%L3DT(^*[[WE#<\MY#&T3+AOPTRCSGAQL56D'8K`T?>\8!&!O*?MCU:)HO]
M;`!%C::5VSQY)"3Y7+SZO/-P^NRU\`L0Y;`/K\0_S`$Y(G+!Y9Q,VFLK==ZO
M9FE`@SHCP3I9@)%-O@J09!XTC+`@2834V)+=7WX\%1)8@9Y9`SHA'CO!HGP(
M75645(@NIGJ7U,E&OY-.!?IH_2I.5*)<Q#H.V,1LIG`,*8C8GFZ83+<T0$`C
MAK\T2M'0^-]_KEG>GT-K-IDJM#9P$LH99:7MFFMNKW$#BI=!@W=2C;7KB"^,
MFW%-I'$TBI7N@,X0I^?)B'33AZ$*SXI)"A-&E<H@K4H;0\X-+#17H;_VO?,=
M=>F:<L*_]>Y:(PE'7GCT?GW_8>:D>_'N:.]@]^BHMW-XL+-[</QV=KQW>%#Y
M1Y7A"S!`A'?X9"S)QC(K%WE(H_DRZJWW%GRBX[11#F*"H0"6A(41[;WZ[L#3
M#!,9J1A8?YOXIL,OUGK;4_Y+:]W:_"("/[Y8)JWZ%H%*]E8IH;3$.(=H1#B/
MXFL957N$AG$`W),E;^?_P^4#)D:0+M?D8UZ1OD3JT]TG7Y.3:-HT"$4R(2)7
M[5DIJ/?D0VLZK+I`\AV5`TREQ,<3LCV16<W5]MV"Q!FX>.T%HH2\88GL%"'M
M/@9-9[15YM^VI*RKU@=(/[YE#U=\R[UDLO0)]2E7T)'#987<&E(,2,5"!.'>
MPVM[=]]'PP'2:)W1LQ&.X+W..MUFGBQL&!V0),PMBTKE@!1SK?6VML/Q#J?I
M>+-@&'+,OJ)M;V\)'?1?]J_F_N2:B'?_&H?_ZND(%=D@[`K-3AZ(`BK9<0DT
M9G>:[VACD(`@3+DW?P%H#-_.8(KH\%P\<P;!UYK?&"<]8XCT&@_^[Q?QCQV-
ME1;,N/B2OU&-XCGV9FN]%VN]'?OY97:8Z(N;Y/EN8^)9(28UM=N#D?T]E3!F
M?*O>2"AN0.AI.F)X0ELV@Z&^!?Y`RH]_J]<,<=$-%4SD;S5#'*M;&D,8)],I
M*90T1K1W4OC//1O;W+?TG2.O!5S9W%J;;*,`KHRW$0-Z;&5*XZSM`7_9"RO%
MH5C<L!+7!)=>[QV_AH<>]68'N#@/#X[W#K[>/=CI\`A)SEQ:"SPGG!V+MT(8
M(N6GA*`B@QW;>3_KVX>W\BM*"]@GZ;_RY<.RKG2=I,FF#R`.3$^ZA,O0L5S2
M_\7-V4GO+1T"R,]^=859>4ZF>TM_V!R!I]>HYUZYC."P'/O<26P?,MR6(LGV
MP6TDJ$T7<VMT9.=!?H2UJI5LICN<6_JAT]G4,W=\T3"D6_4M$$-$-Y$R"C&(
ML;-A70OY/<K=]]7!K>[,DD!,X].B=FE;%2$D*UHO<JZB^H<ZA<:]'1(V&*HK
M='&TQ4D86J?#_\3>@[M68/PX_XBB8-67J*JJ"Y"HR9,7??U:!)D8X.9XHPYA
M'O.,(I)J:<C#R"XMG2_%_!%3\(`A_->YZIUN"`=JB[HX)Q&$BG.HB?;5.=OK
M+7#&8@WA"T/>`*D0VD(9TO+MW<%+KX6/X0!,@M!+R=*XPHULV.+G\U^R;L6I
MIQ3JQW6G6<J+HM^C[M67*\?FW09=NU>^',8XW]BOGYY[J1Q9SST4G=KQ!>@S
M#A(<H\/:PBV8"RX^%OG;@"&2].B/#UF%3?=YU9QI9L91:9!CZ13X&?:9T'2.
M`:B,*/YC"=>1+\@0PN8(Z66U'O>MJAY[N_0$A?SRSY;F^/_YG_^K?OK82"?2
MC,,U+JE\P8&U!!1C<<X"UJW[$XZ5U?V@Y-/>O'_Q`;)ZXQ.UQ3K*5W7;Z3*D
M:8AR<Z6Y!C#)S,02GT"7T81NO2\:4`RHIV,*.F"7K0XOUANOB0^%<#<TF+]?
M#>/<V&M>[:H=:L1I"#W]>#.G=V\(>*O@BDHQ6(:%@V/TYRR/%*L%G5?4<!F?
M/OJ=R55JR0V5`AOD$7-U^*0%Y1I60O'P_?OU%R&P=&2!I9E,L0_NO"EANA!1
MY00R1IN,_Q"D`3%)IZ,Z`9D4`E?9^QT2MG'=+W42:*JHCK#$*:",0;A8L].D
M%`32:`.I$RZHUNS'SK/S]Z!A`CB-N+`T/\"&EM(%S:M+$NJ!.`8_37.E;/LS
M7)I+:^<=\3K_A#0)D/LNM;-TMK#_-+RB.I.CW?W='46K_O2.<-7NV_UO>Z_V
M#F;H*;/]WLO9\:RW^NY@]N[E'O=4%9%_(I0#`@$[?+4!2?:N84M\6QT-GI,]
MTX.AV6S9YR\H,YE_-7,YLB:^E1G,7OQNV7)4JP18-`>/1YV,+8[I/6E$G)X[
M/Z3-EI:C(L$9&RUI08_T`K0KYK.Z)^_+S?P>I@(R,3D%I4@Q57=1%J=F/I&0
MZ)\!#B7D849HQM(N_MN_8!=CI9W=7=X^_,NOE\5T'X+^.5!M?2$MXY^]ONMS
M/XAJ?2&]XY^]OKN.]3U\-7[XKL2?8&S7J$/3H6G83!,B7J7\":6S?,DJQA99
MP?5EM)%!]9)]LD(-":7+PPO,M;:FY&$:&DC\G5]>*7FI>AWU,%6)RJJ*9#KN
MK(O%N7.CR@@WB;&0?%A^G12^*K]M#8*MM<V.Q/+I&BITQ_(&D_*B1-9B0B9#
M>[A=K7X50Y>NW>6K5L=KPTD%]E6FJ`X[0=4%U'J:LR`]+C]U].[%$9/$=P^.
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M3\%R'P!0]US.:"$.&^TFA83]LOS=`GJ^^P93.???D%5P3@3P',]%<">D[LE/
M]>Q($,BG)3?,(J].^+';K2,=*2[",N-.23\QPT74V73>#/-8G5F8K+&[W1)W
MPC=RBLD/#B*1A!;6\>V*W;U[_7KV]MO>X:O>T=[7!WNO]G9F\,;9SL[A._/S
M]=X<[N_)U==;?4/*K?QXA1KV\-4>12'P+LTG+M^/I6<#VGH4C)&Y%(+;$+OF
MGJ2$6K(\YTPA-"<N$5J\WEZI;[TC`+9R@W'T-C_DI6C!;[1N?B.O1FL\44TW
M70>*A[`,3!UY37MP3F);;$9TKB8.Z_L<R'E(#2TW=P@74P8=(8'YG4(%V"J8
MZO]!5%RHA85$Y%EQ9YT1/9"(YJ,Z!PV&T[%&JORH+EZN4/L`=VXG*L?+;$2=
M?-3F[E*XU&_ST75^,V)DH_O+'1M\BPPXN0O=1E\24;BZN=5VRYWM,L@"!+Y7
M+D#O2&VKRCO>DCMQ_8"]M-?T_*$U*!=FH1G&[`S37^4V'^1ON.9O'PE9X<C1
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MS#<:9<?RQG)/QZSD.>\[A^G`_[0!Y]SH'>PI=QY;2-"=*`8`LZM,DN#4Q>."
M;@_'TAN4C6[>SXZN9OF&@[*YZ%SR"J<GH9*).&0S`@V_J48!&J64L,F7D.+0
M>M:9AFUN"1XNC?4M7*>4[1APG)GQ8Q)'RAD>1&>6RQ:Z/%10/?FX1^\)_+GQ
MK]&Z<XX+%(R(Q?)97\GJX\\0DR\M2>&^=Z`,(5E\7^+\/'K96ZDD)Z(922?'
MK%KD8(0!Q%V<M:86]/ZZKV#<'H')^Z)6\($\KA_,/QV#&.X>].(PV9I)S\B;
MO0>D[.!#V4=?6QSTWWO_@R1K#S'^-5PJ8;*;0ICP"G*8\7Q3<%G>-7+B*R]W
M?_&$K`Q,@T5?W.I^UW-TF'`XU5',0-VDL&1CD7=_4H<9D,0R>\!XU.&DM]2:
MVO)#XQOKZ2/FR5++N_P#')SK?O^7NFOKJ2,YPG]E7BRQ$FN6RY*U$JUT%DPN
M6N,C8V\4Y0D;[$7!8!T@UO[[?%]55W=/==?,$!)%>;!DSO2UNKKN55TDH$I6
M\D`4]7UX_47DJ`AH.=XM:E")3`:="&'';-$DF-E>(*`P.21'R$HRO?Q6QC+1
M\BMT7"LF+]45LFCL\%*>5,+6-M[C@P&R&5":Z$:Z.5HM=C=#0&D1_XM<>LRI
MOICHC!HI;QG,^[#NR'?+`;X_O&+\A?AB6[/K:H$T5ZD^HHG2[<L,BLV76\E-
M^WKY_@YT.:0"HSEP3U"PTD,7YB$H"EBE__!Z_?(-JJ/@B3X(+P@-!&<%W8V@
MOI?>>/:CK&@%HFKZ)_BH&.T'T01!XK_I$X*H8JOO:0YK&1X/)RD%;8C.Q$%,
MH"<3II)J#+W69.[@J"'RP)'TB!ZGD'P`82B/?M>V6=YF;E8J\N=G.A,L[Q"<
MN8:@1<DK`NLK>"FOOD"<@O7@`N60-P@#)0I8,...A%,F<T4T2"XE:\5D1FBQ
M[J(%O%\J";X(T`/.PW$#6,B0T/);@T<I"NDN^HYN,I"'X<2)[X9'7ACM>>=Z
M">@HHG+")M=V3+%'BLSR.W],`?3"ZM9>7'Y`\D)[]U'YY8=O6Z?+<>H'>X::
M,"6("OA5E`\/I7>(E#I'F@*]._I6<',`\_L*P?E:V!',7AO6(C$#JU_#WW<;
MH0L.TI3*AKA[QE0:)(2&BT:-YS\UCC:OG/8-/`!_4#UUP)^\$9[F#=@Z1K8-
MMJ/8CWAP>!+PA\RN[@NN`+^D)#P$2>U__P*-/R,D%YN"N2<!$`8P*V!8FTT&
M6`'?0TUMM2'9"_2@-D'F5)(5UZN_K6@9V%J./M\-4RQC=_(KM+7G0TKW:7QC
MI[?_?#ZP'A'U-G^`2#][/B#0DQ_WNQ]3S^8CC.CH":-XKR?>X<X+:GK"9!SW
ME`79VV-^03HG#K4[YP/G5+=5LT^D&^:/#82`,?%'65`$6UV01A@T<\JPT5;J
M.1L(Z;`O^D=V?/G^'K9:1/4]B!UX2@-Z8P]/R,V@_5G^HPG#'KI0M!@C!3;#
M3*A'-;Z1'-7D??'CCA<QV72EY`96,O@;+6*A.,MATK7"7&(!A9D3!BMPT0?D
MP)M1G`]J^"6X<<&&KQIQ:)3A&3%4T39!4BSE&AD`B#0#F[_$+^>(;`6+_@0-
MC_G<?A&9HYM>"CL[XM4H!!QI!O<IP`@O!FR^MT/22+Z)!82D!_H<9#^ME`@1
MWZW`M%M&Y/A2XT^2J=G@3W]:S_@.B4K'RIJU^/V8V$KM/.$!'3QDN90>?Z6`
M`."PN(C9FR``D3I+QA+T-_R)XN7)].`W,<9-^"T2X-(YW`!PODM&.^40BWJX
M1E5FI1^]U/)+*JKEN31X92\_(`81:5W"CRRYBO7O+P`31FU2EV65YD;^':.<
M7X=E3`-`EL-\*I<QPN!W$EO*<Y%L<M;X0:3([68C!X.$6`A(=/3K`8O36Q0.
MG!1*K7S_3$Z8:@%/&R<,^@AO3>(@3<C;6\SS_OSF'T).N/=T8"98U!-Q3385
MGCW:>R8P.;^Y@;$C5WP_%PF.(^'M+I$Z94',&.LLJ*')&7,YD8=E=`MD40#(
MY^9*<WMV`@IV=8#31`P)0]S0Y>6N5/*:5P0`9[QJ#\H'];[9MMPM..UX;N<;
MI%$Q-ACA\M_(3SD:&\"X`?G9W*5G8M@>D7&"=DQX%WL8!]VZ0E?)1I645X#/
M]@%A"CG'6#W[0H53GH#)$/U0D.P&2+:%(/R410]$1K0%)&^*K&B+S_"&(RI)
M4F406,_$3$G.A`K#@4\>1/UI$,96$>(S;&[=LA$_KT-*20>@;!P+.WQ&7]_X
MJFQ!7'D@P`@8\-Z-_$%Q*::^^2T97FO8<DL-"(]5HP'UP3%S2;Z]!2,7Z?T!
M;M<59G\)ZQ?8271YR[LX%GNKL&XMBM.SKIE7`%D@FN>D/.P;32!B"/+=Q(6Z
M8,\[QM'B6;LP!5`\L?"SK3+:)5I<D#)7#\4V8,SHNF)$8>!I/_%PXG'FP.U[
M;HDS&%?073C<M^C$X,L63:VF*;QG))_`+:.KA\C(,UJ).TNSS#6\6;3N&[,G
M42_8H[)MFQ`SI^<,L::NLKARC(9`*U_U)RQ=D,K6U6'J\1K9'A$F6;9O)D.V
M$S[J2IJ>\A`4:1D%2EC>$$(BKUI"-E,T\XL$:3D5UEO0+U7I)UTIH2Z":M$Y
M=@99V-,HIZ1P88Y=3`D7.[!(5Q7-J!`7O2!=G[)7&IQZ\O210$/J`ZI4XR49
M&:D19=HE:GFC90MM>Z,?TB06[M.Z-^3?``/.,BK@$=^U'&M7@G?FN(#-KI"[
MEPB`F7,17"+O(B\>5Z0AJUBDK^@4_4%LWW_8N1\%VO?ZY%I"4:>^DWZY^:.^
MIXT^+/<4!1]Y_0_\<M6<H'I_TU/M&\%'F3,R830"?KK5E<-<S>K;K)W8R)+5
MK;)"Q#A#4Q*J8,PZ7,=OK1H$9G\ZL)!%KT_TI=7P@M8\+LV%G'1IY@=4+QBD
MLMFE;.N;.7Z`:D7+MY5BX9BM)#)A7O!'O.`#"C4QB8DY3]IU=)1@@'DI$_+!
M>H,2/!"A\1:+QH>%A"&:J,$9O^,SGA8E22B(RTAI5<L.@6)XH^@CBKSY8367
MCE]$M#4K;M?\40E?5@I"UP/(U#@JU8_\1'^\O;Y@P8TSE+N*Y;MZE\!`:``:
MN`TM".X?IPO+B3<<I)1F&2\J70<9$KA_>4VC\"?6;E`_M(1X]DP9?V%0*^-"
M6>T,'EU;$Y8T(6R5J&JE`>)>&%]N#Z)]U5;]SV\EZ?(_OJTG#]BG:F?W>%_S
M>GLXO?J`U^`>[@:I*FH!_4O!MY!73(B0M5&VD>K,E]^X>>P#_`KW0`A10/UY
MF,<LEW*'A`$DTB+WA=TS?]QW?7<#_9=A>N#7#!X6D2I2.M;CZ,)O\R/G?M11
M0&P=J!*$`9XQ-_#ZBGD:.=-B7O5ZF6+^$PVJJ.'"B]F0/KL-"`K1APG\QO)"
M!8?./W_Y/?]E7,J'M8OZ7S1WP_'#"QR3%SXF2MNBV3LBT(^5VZ@5PR2T=A@,
M/W[MR0/J?_ZE/)'8LR^QE@^,ZXBE[GTM174M1#Q663NQAGXMFJ$-Q@#BS=Q7
MI8,2(`>ZV#HF\W%T\68/R+3H$#Q>W_V**P$3<`O#Z0GWX<];-.&K6Y2,Q@.5
M$MZ3D2824W.#(A+CVEHE3DYIYI@8SPJJ1P];^[.`RO$1QC#(;U#%>XQZ;EDS
M9B$80$IX<(YL3+FQN!%"C?RBG-%A)Z\A@EW_WM#(J=7-$,3^L=B-JH@LO'&*
MG-G&,%Z,68ENZAD^>?U",*@VA7):N'5!\\FN(`M72::8HS.'_>B&N8C!5S/Q
M?<:A\O/;T7DM9;.P<@:AER*P3;R:XU%*A9E1_6;29&;'DR56="A@7I6#SP*R
M,R-62<M/N:=`1E6Y%*TR[!V(6\`W5-6G"/PBW`9B9YM`)(].+GHS-40ZYUW@
MRXYNC?UBVV^E>.?_PX.K5&+^ZP^N.IC]6*BQ:`S0=!Y`;#8BA5$[IF9`X_]L
M/U4A?#,QUFD(Z9\Q"LSS(',,1`[/63Z*C1653*UTHE8?A9<%'>$N2.-P?5*M
M[7_R!N?CMRJ^%^A45R(8:1X"?98A+&J1S$]7V(G_,DFX0*P:3K4]]$/'&]Q0
M_?"K.@+\M'G82CV`:Q1J)'QJ-Y_"YGW$R:.9B:'A?U4+UMB*OW\@_EY?3[08
MK?BRJ]CP*$"%*=TE89_)&LVF+EGA"NTL8+`P:5@NLR+T<T?]23'L\Y38QQ=&
MX8$ID'U^P&*Z@'L7WCA6/1#KO=_=)&*)NIG/Q)AJA%I'U^?P;D)/2CU8(.:-
M5`>;BL>97@`9<1VM7D30Q@Y2<^:CFK&N2A4>2F9UN[4&<^@+RY,Q^%GW*0J-
M!V44.YR$GL%B/WV_:0CLAZ)(NLK)@.E'-;NFJ;'-7>J#-1IF=)U"`F"3!L\Q
MVF>1&-N[:Y^/HLMM#4:+F;W;B=KT[K;=ISV3E.#Q[(7M6KL?%K;[G;4[[`YG
M&#$KH5E8<81:X[2PGFOA)+V;-'=Y?3N/!PSO+A4')=1,WJ0"O_Z*QPT:.VMW
M9<V=[;::,'*YMT<>$TPZJM0\U+;B*>JTS/M5CP;%[:&3W`@Q/I>MK]#7@UDO
MY=K,S;E@R/#7H+2\V&CM</UHV=@-D:HJO>V;T2Y2*?QU)>EHY*".\F,.I'9O
M'?@EU=;,R8^->PL\F;)D4DC%OC1UP%9*=EB%$EL[HE]M9Q#(A6=2`M<J!T20
M/+9'K1#!)[6"HX9YDI_R2A=/DOL>/:'O\;_1=ZH.[6.0Y7"8"@4OI1<EV[:B
M4UK3M6-J.XRXL<R#B@@_,7152G-"HI':$PV-.]&\R7X11RUG845590"/-F^`
MI[!^4;1`:?O@:[]XY$SB;>($H>C@5NZ*;6K%BD$9ZRC2WZ]Q0?F^N:4L+=35
M-[JW9HFF6-1CT`Q!/D@,2!5P_&;U8RH"Y3^>N1)4D\)DV[ADS_9K0N6KY^<M
M^ASE%J0=(A\8N@K5Z%O-[VP=VV6,G;N[^Q__!0``__\#`%!+`P04``8`"```
M`"$`ZR[J204#``"_"0``&````'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)26
M76_:,!2&[R?M/T2^;SY):!"A:NBZ5=JD:=K'M4D<8C6)(]N4]M_OV*:`PT>!
M"TCPZ]?/.3XYSO3NM6V<%\(%95V&`M='#ND*5M)NF:$_OQ]O;I$C).Y*W+".
M9.B-"'0W^_QINF;\6=2$2`<<.I&A6LI^XGFBJ$F+A<MZTL%(Q7B+)=SRI2=Z
M3G"I)[6-%_I^XK68=L@X3/@E'JRJ:$$>6+%J22>-"2<-EL`O:MJ+=[>VN,2N
MQ?QYU=\4K.W!8D$;*M^T*7+:8O*T[!C'BP;B?@U&N'CWUC<']BTM.!.LDB[8
M>0;T,.;42SUPFDU+"A&HM#N<5!FZ#R;S($#>;*H3])>2M=B[=D3-UE\Y+;_3
MCD"V89_4#BP8>U;2IU+]!9.]@]F/>@=^<J<D%5XU\A=;?R-T64O8[A@B4H%-
MRK<'(@K(*-BX8:R<"M8``'P[+56E`1G!K_IW34M99RA*W'CL1P'(G041\I$J
M2^04*R%9^\^(=$1;DW!C$@']9CQTP]LXB)./73Q#I`-\P!+/IIRM':@:6%/T
M6-5@,`%G%5D$^3D>&82DYMRK27HJJ`5LQ\LLCJ?>"V2PV$CR0TEH*^9'%..M
MQ`.\+2-$?CVCFI0A>`)WC,G67H>1&TFD-TS%-=_[PP*`Q.P#G$^.$F<(K'8+
M[^(R"QM)K#,7!D&0VF!S:SR)]Y)K88ULK,OV3DT:X-W:R^=&DFJ\X,M-9`_/
M3PY;<%#8E^=,B0=0@YSD1I(8*-]\!F!G)19<<@V<$MMPB6^OG!M)I.$&8_/C
M8Q;.^!H<)1[@!`,<(SF.<WS,PE''UM4]04T:8`V>^-Q(3M;5R6$++K7ASC^+
M2CR`&E1S;B2FKL+X>&&=UUAX`33/_>2=Y]/J`>!HL)D;S:;RX\1/Q_Y!Q[!%
MHU$Z3L;QKNW8B(.>_P&BZ=/[_2PY:/9&\P&B)3J!:(Y@<T+U>$E^8+ZDG7`:
M4D$[]=TQ/./<',#F1K)>GT0+)N'@U)<UO"@1:.>^"^**,?E^HX[X[:O7[#\`
M``#__P,`4$L#!!0`!@`(````(0`<JZ'$#`4``'D3```8````>&PO=V]R:W-H
M965T<R]S:&5E=#(N>&ULE)C;;JLX%(;O1YIW0-PW^`Q$2;9V4G5F2[.ET6@.
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M2YB!2GO0%+ME^!W/-R0.H]6B3]"_9?':6I^#]B!??VO*[1]E74"VH4ZJ`H]2
M/BGTQU9=@INCT=T/?07^;()ML<N>C]U?\O7WHMP?.B@WAQFIB<VW[_=%FT-&
M(<R,<!4IET<0`'^#JE1+`S*2O?7_7\MM=UB&5,QXC"@&/'@LVNZA5"'#(']N
M.UG]IR%L0ND@Q`2AH-[\3F8DX9B+KZ-$6E$_P?NLRU:+1KX&L&I@S/:4J36(
MYQ!9S8Q"?CZ?&4Q)W?-=W=3?"G0+Y7A9$;&(7B"#N4'6GR`NL?F$B,](!/+.
M&F'FML;KVA2\#&'G#=J2<]A>_EHCM,^NFL_&NN`,#`FY?6`%+T,(-0R<>@-K
MA/<9XY@*+-`PY5[;QD$83C$1Z!S%$<=<<:IR[.*:_*B<NLD528?P.CL:$;JL
MF#."?8TV@46*8DX_EPAR;L^?@CUI^!Q62].(EH9Q0C`>!M;I<PC$(,5#\9WL
MB2G2%.Q)(YXTC1AIG,9L5%F;("R.8\S/,1QI\11I"O:D>3E9:T1+`Z^@G#)V
M'EFGS4%2ABAEPX9VQ*F69OG%];VH8$^<-_):(UJ<H"3UQ&^<WS&]5,YTBBP%
MNQ9!AU+HE:81RR*L"TX^,)CE[0GI:2\C0Z+UT(8Q2XF1F`@_*2X2<\3X,`%7
MGN?OU^N%M2?;'D:]S;\VC)%'H`$EPQ;3J\E!A.`VX:I3QGOS:L+:IAUUWM!K
MPWRHXPAY]K9Q"<I%,A3`%3?)_?'8_JEO_X;1XDB<(&C>WD9T$<YQ3(8HKCS/
M_[^H[-CXF9>9-;9]G8.MIVQ<6IL1!&%!K2WK"ISD_NIQRMN4S$O.VC#6KK2O
MN(-/\G<\-GCF&[QA=/'`J6)L5<:L>\?B,79:IRMODL?CL<DSSQ+6AM'R."%B
MU!H=`IX\"$^&%>"JFV3R>.SR?G]9&T:KHPE#L&S\E6\[/14(^ON`N/(FF3W6
MSFV[!AO,TEBN9K0\C."1AB;>XMN8.)J)*8[32\9!)K6$GG9;@M5[M3[#@,6<
MGRV9Y\N;ZXR30#*I*?2TVRZ9;[N&L7:F?<4=W//\VYY;R=C[V;`\3)8T<SU+
M5QE7J.?_2JCX\M6(C/L`'[:9$:H9L]RX0.FHF`[!6!H/A"MR4A<@XR[@=Z"U
M88RXA*0)2?P%N7$ARE$B$+_01]7+Z>U-OJ?=[<!]*S:,EGB'*8M9FM!A^#[+
M&Y=*$*=$6*^I;AHGM0LR;A?6&Y"IL=T+6$*3%(_>"$P</0_.1`K&>*G.7L.X
M[3T=SD3\!W#N/X`;QKR4?M[U'>9"U]>')_ILX93MBY]9LR_K-C@6.]@X:!;#
M,FCTT8G^TLE3?X;P*#LX\N@_'N"(JX`7<C0#>"=E]_%%'<Z<#\U6_P,``/__
M`P!02P,$%``&``@````A`#"^*]%'!0```A0``!D```!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&ULE%C;<J,X$'W?JOT'BO<8A+BZ[$S%][M=6WMY)EBVJ1AP
M`8F3OY\6LK'4S$[L/`33YZA1=Y\60IT?G\E1^V!Y$6=I5R<M4]=8&F7;.-UW
M]7_^'CWYNE:48;H-CUG*NOH7*_0?SW_^T3EG^5MQ8*S4P$-:=/5#69[:AE%$
M!Y:$12L[L120798G80FW^=XH3CD+M]6@Y&A8IND:21BGNO#0SN_QD>UV<<0&
M6?2>L+043G)V#$N8?W&(3\756Q+=XRX)\[?WTU.4)2=P\1H?X_*K<JIK2=2>
M[M,L#U^/$/<GL</HZKNZ:;A/XBC/BFQ7ML"=(2;:C#DP`@,\/7>V,43`TZ[E
M;-?57TA[X^G&<Z?*S[\Q.Q?2;ZTX9.=Q'F\7<<H@V5`F7H#7+'OCU.F6FV"P
MT1@]J@JPR;4MVX7OQ_*O[#QA\?Y00K4="(C'U=Y^#5@104+!3<MRN*<H.\($
MX+^6Q%P9D)#PL[J>XVUYZ.K4;3F>20G0M5=6E*.8N]2UZ+THL^0_02(75\*)
M=7%"8?87W&I9OD,<]P$O]L4+7&LO=T\!)EO%`==Z\,-QN!<GGNSDX3B@LZJI
MP+6>RMUQ!)?!<*T'/QP'`1F)JD+=;FX>CH1<"\M_U'[NCH6`'L0T(+'U\'NC
M,812*^$/PC)\[N3968/%!&(J3B%?FDB;@.>KY(5`ZR;XOQX`\7,O+]Q-5X=2
M@[P+Z-N/YX`X'>,#FBVZ<'I-CFM[*J=_Y?#>XHX'V##$AA$VC+%A@@U3;)AA
MPQP;%MBPQ(;5U7!+`5&#6U\9U^`VDL&`>M1%`8$H1?GU^G/-/6?SW%_=]H0!
MG-?%L-29])L,/[!5SJ#)08QAD^$'J.BC)L="-1\W*9Z+4C=I<ES\J&F3XP>N
M&M2LR7'1=.9-BF>CR!=-CNL'ZJ.638Z'.:LF!U5J_0L&FO"F29%B4G0%2XBB
M*][L%):WW^N+C^KJL`#7<G)L5.:>X-!:@WUL&&##$!M&V##&A@DV3+%AA@US
M;%A@PQ(;5MBPQH:-9%#R"R];);^_SRMG=W6HWBVO#A):3W"<:D6U+0>5OJ_`
MQ$=J'\@P]1RDK:$,6SY%/3=289>J^AXKL(6[<:+`IH^<3V68.!0%-E-@RT:C
MYPIL4A3W0H9]@AM31CT+)64EH\0Q+=?"#M8RQ?<\QPE\-3<;F4%]XIODECU%
M,;##>D`QG*TJQD.9Z0F*6PF&4@_EM:_`A*!Y#V08-C@H<T,%-DU3C7JDP!2O
MO6,9)JZ-BC9188)F/E5@@CMA)F`JMAXFBFLNHYZ%PEK(J(VW)$L9I;C%5@(5
M^2:$.K9-4&!KF>+ZQ#5-5+2-S+!L-PBDU"IR@0W:`W+A;%4N^`74$Q2QOCP1
MEYHWG5;[K[Y*\'R*^F6@$DP_0-D=*H2`^.@)(P7W*7[UCQ7<<STT?J+@D%ST
M_*F*4P^59Z;@CH>W)W,%AS48/7^AX-!2#FJ+I4J@5H`(*X7@V!;Q+((X:X5C
M^38)J+2F5+7:*!SJ$,NTZ.U%K0@)=NJ*D.[;"?!1JJ`"K/:>X`15(SZ9+23U
M/H:QG!3<:\$B(_]YPR<T8*@,,%LF*N_H&WS\#3[!^"VA5=*G&$?/GWV#SS&.
M=@`+A!-;SD=C*5EB.IK."N'XU;E&.'X]PND+ET!=7GI;:86^Q-F*^,1,6+YG
M?78\%EJ4O?-S$[X^U];Z2.?%XOM&9.^1-GQC->TK.`*J[$8]`(Y@3N&>+<-\
M'Z>%=F0[>)39\F!9S<4ACK@ILU/UP?N:E7#X4OT\P%D;@^],LP7D79:5UQMX
ML%&?WCW_!```__\#`%!+`P04``8`"````"$`;)XUVIP"``#?!@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970V,BYX;6R455UOVR`4?9^T_X!XK_%''"=1G*I5
MU:W2)E73/IX)QC&J,1:0IOWWNT#B.DW7-2^Q">>><\^]%[R\?)(M>N3:"-65
M.(EBC'C'5"6Z38E__;R]F&%D+.TJVJJ.E_B9&WRY^OQIN5/ZP32<6P0,G2EQ
M8VV_(,2PADMJ(M7S#G9JI26UL-0;8GK-:>6#9$O2.)X2246'`\-"?X1#U;5@
M_$:QK>2=#22:M]1"_J81O3FP2?81.DGUP[:_8$KV0+$6K;#/GA0CR19WFTYI
MNF[!]U,RH>S`[1<G]%(PK8RJ;01T)"1ZZGE.Y@285LM*@`-7=J1Y7>*K9'$]
MPV2U]/7Y+?C.C-Z1:=3NBQ;5-]%Q*#:TR35@K=2#@]Y5[B\()B?1M[X!]QI5
MO*;;UOY0NZ]<;!H+W<[!D/.UJ)YON&%04*")TMPQ,=5"`O"+I'"3`06A3_ZY
M$Y5M2IQ-H[R(LP3@:,V-O16.$B.V-5;)/P&4[*D"2;HG@>>>)$FC=)8G^?3_
M+"1DY`W>4$M72ZUV"(8&-$U/W0@F"V!VSC*HS]O.P)*+N7)!/A30!KKQN)HG
MV9(\0@G9'G-]BDD'!`'Q(0-0/3\#%U1B.%ZC#"8#O\_R.F`RW]FQ8'8L^+Y5
M!RYQZDVF<9*_T@C;N=_.BB2=Q`/@R.3D'$T''FE.!\K@*VQ/@^8LS8IB`!QI
MPFB-"_N^3P<>:;Y0!LVPO=><9[/)[&W-Z3F:#CS2?*$,FF%[KQFGQ;\TBW,T
M'=AIO@Q.GKTV&S!!.)GD<3H:[J,*N^M]='C>K[`#OU:>#U4,E@,FC-/;RN&.
M"D>XIQO^G>J-Z`QJ>0U'(8X*Z)0.-U186-7[H[I6%FX6_]K`AX3#.8XC`-=*
MV</"W8'#IVGU%P``__\#`%!+`P04``8`"````"$`D3;_$&$#```("@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6R45EV/FS`0?*_4_X#\?@%#0D(4
M<KJ$7%NIE:JJ'\\.F&`=8&0[E[M_WS4.!)SK*7T)89D=9G;7-JO[EZITGJF0
MC-<QPA,/.;1.><;J0XQ^_7R\6R!'*E)GI.0UC=$KE>A^_?'#ZL3%DRPH50XP
MU#)&A5+-TG5E6M"*R`EO:`U/<BXJHN!6'%S9"$JR-JDJ7=_S0K<BK$:&82EN
MX>!YSE*:\/18T5H9$D%+HD"_+%@C.[8JO86N(N+IV-REO&J`8L]*IEY;4N14
MZ?++H>:"[$OP_8*G).VXVYLK^HJE@DN>JPG0N4;HM>?(C5Q@6J\R!@YTV1U!
M\Q@]X.5N@=SUJJW/;T9/<O#?D04_?1(L^\IJ"L6&-ND&[#E_TM`OF0Y!LGN5
M_=@VX+MP,IJ38ZE^\--GR@Z%@F[/P)#VM<Q>$RI3*"C03/R99DIY"0+@UZF8
MG@PH"'EIKR>6J2)&03B9S;T``]S94ZD>F:9$3GJ4BE=_#`B?J0R)?R:!ZYD$
M^Q-_,<.S\#]8@C,+7'N6FR5,S\D@ND^^68)KBM+6."&*K%>"GQR86[`M&Z)7
M`5X"<U=<4XJ^W/^J-I19DSQHEAC-D0.%E#`AS^O(FZW<9VAK>L9LWL*$8\RV
MP^@N:N*D"UR(\3AEUR'T"(&GWAAT:FCL[6GI]&NPUM^]=V,"P-T;\N?C%V^O
M(6%D>4ZN,?Z897>-""\O&AF"H1D:TIT*8#&];TPGQ0AVPM['S(_&$C8&$_3F
MMW8@L0.[06"D$69TJ/%];1H<(RA`KRWR+M[;_F\,9J#-#B1=8,BR&#O<=1A[
M1F#@;Y>KP;9<NY0&,Y!K!Q(3F+5K)/#PU&+8#1)&E0W'4F_KODZR)&-O7)N-
MP0PDVX'$!,)6,EY$T11/QQR[0<I(-&P(M]=7@VVQUF+?&$PGQ5M$EI+M$!!Z
M.+0F(1D^#T(\CP++RA"`O3#`ER4]LJ8_+@;[YON3KL&V-6LCV!C,>3#\*+2$
M;<WS2Y^28<(4A]A*@"-9O[1-,,K-"6MV_XJ*`]W2LI1.RH_Z]`R@OWVT/]@?
M?+TM6/$-7L).?1U/X$.@C;M]`AS$#3G0;T0<6"V=DN;P*F\RAS$7YB@W-XHW
M[5FTYPJ.X/9O`5]<%,X`;P+@G'/5W>A5W'_#K?\"``#__P,`4$L#!!0`!@`(
M````(0!PA?='(`(``(X$```9````>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM
M;)24W8[:,!"%[ROU'2S?;YR$#0LHR6H1HEVIE595?ZZ-XR06<1S9AL#;=VP#
MI:6JZ$T2)V>^F3DSD#\?9(?V7!NA^@(G48P1[YFJ1-\4^-O7]<,,(V-I7]%.
M];S`1V[P<_G^73XJO34MYQ8!H3<%;JT=%H08UG))3:0&WL.76FE)+1QU0\R@
M.:U\D.Q(&L=3(JGH<2`L]#T,5=>"\95B.\E[&R":=]1"_:85@SG3)+L')ZG>
M[H8'IN0`B(WHA#UZ*$:2+5Z;7FFZZ:#O0_)(V9GM#S=X*9A61M4V`AP)A=[V
M/"=S`J0RKP1TX&Q'FM<%?DD6RPDF9>[]^2[X:*Z>D6G5^$&+ZI/H.9@-8W(#
MV"BU==+7RKV"8'(3O?8#>-.HXC7==?:+&C]RT;06IIU!0ZZO175<<</`4,!$
M:>9(3'50`%R1%&XSP!!Z\/=15+8M\&0:94_Q)`$YVG!CU\(A,6([8Y7\$43)
M"14@Z0D"]Q,D2>^%D%"0[V]%+2USK48$.P,IS4#=!B8+`+O&)F#/WQN#CES,
MBPORH:`V,(Q].9O%.=F#@^RD6=YJTHN"0/)+!9#UNH)_9W;B`L/U*G-RX?KJ
MED'CM^&W1)/_2>3$?R;ZU4!(%#29-R")LRR=/R;32S$A=UBI8/E`&_Z9ZD;T
M!G6\AA;BZ`GFK\-"A8-5@[=VHRPL@G]LX7?/P?<X`G&ME#T?W,I>_DG*GP``
M`/__`P!02P,$%``&``@````A`$T.Q[DO`P``;`D``!D```!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&ULE%9=;]HP%'V?M/\0^9U\$@B(4#5DW2IMTC3MX]DD
M#K&:Q)%M2OOO=QU#B$-+6QX@L8^/S[G7OI?5S5-=68^$"\J:&'FVBRS29"RG
MS2Y&?W[?32)D"8F;'%>L(3%Z)@+=K#]_6AT8?Q`E(=("AD;$J)2R73J.R$I2
M8V&SEC0P4S!>8PFO?.>(EA.<=XOJRO%==^;4F#9(,RSY>SA84=",I"S;UZ21
MFH23"DO0+TK:BA-;G;V'KL;\8=].,E:W0+&E%97/'2FRZFQYOVL8Q]L*?#]Y
M4YR=N+N7"_J:9IP)5D@;Z!PM]-+SPEDXP+1>Y10<J+!;G!0QNO66:82<]:J+
MSU]*#F+P;(F2';YRFG^G#8%@0YI4`K:,/2CH?:Z&8+%SL?JN2\!/;N6DP/M*
M_F*';X3N2@G9#L&0\K7,GU,B,@@HT-A^J)@R5H$`^+9JJDX&!`0_=;\'FLLR
M1L',#N=NX`'<VA(A[ZBB1%:V%Y+5_S3(.U)I$O](,@7UQWG?]J/0"V=OLSA:
M46<PQ1*O5YP=+#@TL*=HL3J"WA*83\ZTCM[K:U;!HR*Y52PQFB,+7`A(S^,Z
MBH*5\P@QS8Z8Y!+CF8C-":$"J&C3P8`#>GO1$(JAZ)?3<-*FP$K;B371`\#=
MB_5'0EY`S$U(>@F9G2&&V.`C8A4X1E`V>FW3>61NG6A,T!O:C`?2P8`A!1+\
M_K@I<(S`YUG*14XU9N%U*7?M8&I*W8SG0W,^?7W>T`V79*A;'=(`+O'UO*M%
M8_TC?8G&'/6'=N0:G^#+9'PR/KH@'2T(AY2&QYGI\;HW!1Y[&\4VT9BCMXEK
MA^["<#>^?6-\X$^OX=,QWHO.P3*<05D89N^Z,P4>.5NXYJE)-*8_=9XWMF(`
M)I%M&G&-).A*8ZZ`,NZ?RY=A1G7T0;V\;D:!QV;.O-W.B<;`C3U?LW,AZ2";
MMR'0_-1.K[!H`[J[Z>)?$[XC&U)5PLK87G4N'ZYP/]HWU5M?59G1>`+-MFM-
M3C\!S:[%._(#\QUMA%61`BA=>PZGG^MVJ5\D:[N6LV42VESW6,*_&@+%'@XH
ML@K&Y.D%-G;Z_TGK_P```/__`P!02P,$%``&``@````A`(S+>M;8`@``+@@`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-3@N>&ULE)5=;YLP%(;O)^T_(.X+
MF.]$(553U*W2)DW3/JX=,,$J8&0[3?OO=VSG`TBSIC<)X,>OW_<<8Q:W+VUC
M/1,N*.LR&SF>;9&N8"7M-IG]^]?#36I;0N*NQ`WK2&:_$F'?+C]_6NP8?Q(U
M(=("A4YD=BUE/W==4=2DQ<)A/>E@I&*\Q1)N^<85/2>XU)/:QO4]+W9;3#O;
M*,SY-1JLJFA!<E9L6]))(\))@R7X%S7MQ4&M+:Z1:S%_VO8W!6M[D%C3ALI7
M+6I;;3%_W'2,XW4#N5]0B(N#MKXYDV]IP9E@E71`SC5&SS//W)D+2LM%22&!
M*KO%2979=VB>)[:[7.CZ_*%D)P;7EJC9[@NGY3?:$2@VM$DU8,W8DT(?2_4(
M)KMGLQ]T`WYPJR05WC;R)]M])7132^AV!(%4KGGYFA-10$%!QO$CI52P!@S`
MK]52M3.@(/A%_^]H*>O,#I`3^E&2(N"M-1'R@2I-VRJV0K+VKZ'07LNH^'N5
M$.SOQWW'3R,4Q>^KN,:23IACB9<+SG86[!I84_18[4$T!^6W(T$6Q=XI6$\!
MLP+:\+Q,TW#A/D/MBCVS.F?\,7'_!I&,D?P<B4^("]:/_J$JU_M7<&;#6WGT
M'\ZB\=(KPP2Z]"KT_?1!/G@PLA)\Q(J",QND!E;BB17#1+K08>#-4!B<JJ`[
M<C]$4)@D031%\B$2S7POC=%QG9%_:/_UI53PU/_$W,HP@?;O'=<TQLU8K,>B
M,(G0R90&\B&`TC@(3]49N887Z'K7"IZZ3L?.5H8QSBY4?8B@*/"1%TY4\B$2
M(R_QO5-U1O[CC_A7\-3_;.+?,,;_S84`(^9"@A'SWPC)1R(H>!PA\H))!,/`
MQCV]'*?JF?WS/@)?!+72!173`W/DFP.QQQOR'?,-[835D`J6]IP$VLC-@6]N
M).OU`;AF$LYI?5G#=YG`0>$Y`%>,R<.-^J0<O_3+?P```/__`P!02P,$%``&
M``@````A`&7T7Z]T"```P2P``!D```!X;"]W;W)K<VAE971S+W-H965T-3DN
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M]GDQ7`Q5I:?'[4[U0-O>.Q4OR_ZWX$&.9_WAT^/9H/_MBL_*^;]7O96?V6FW
M_<?N6"BWU7G29^"Y++]KJ=AJI!H/H34[GX%_G7K;XF7]L:__77[R8O?Z5JO3
M/54]TAU[V/Y*BFJC'%5E!N%45]J4>W4`ZG?OL--#0SFR_GG^^[G;UF_+_G@V
MF,Y'XT#)>\]%5;.=+MGO;3ZJNCS\WX@"6\H4"6T1U<(6"<)!&$V#Z:Q#E9FM
MHH;FI<K=A["PC=7?IO%T,`FG\ZA+1P+EO[%#=;BI$][KQ]!X>SY5R;I>/SV>
MRL^>&O^J6/6^UE=3\!"H%\U),I9>3MOOSIHZ7;K*-UUFV9_W>^J$5&JH_7B*
MHNGC\(<:'ANK6:$F\!5QH]!C09=-*$@I8`UH/W@V7_AELT;3E.44"`/4[\OA
MS^:17R5O-$T5Z8"A<O-BJ1IRGJ77QWOCG%9KYYJR*P/<8PGG_J'$*)D127)%
M$HW\,BEJ0E_!4#&+J+M7-`OR2?R:AIQ\@9KYA!Q/CII91.K(*YI%6\<[4^-.
M9TJKEWTU!5P&213-?,-61C.^G,V8@H2"E`)&048!IT!0D%,@'>!9,.ED@58O
M^\KABP7S$?%_9333\R0PF2V":$+&9NPJ@F@Z4C^^C8FK4*LV"%(C:'UF%&04
M<`H$!3D%T@&>:6HQZ7"%:S4U;>)W>&4TL[-I8:#6I[$OB%U!,`_I^XEY?WPN
M,%N089DV[S:3#*,@HX!3("C(*9`.\.Q2JV<'N[3:MRN*R`A:&4U[^F,*$@I2
M"A@%&06<`D%!3H%T@&>!6AD[6*#57\TT1N-80$%"04H!HR"C@%,@*,@ID`[P
M+-"QWDT:MY=%K::C@*S(*Z-Q+##`7D6S<3OKFS1!]2D%C(*,`DZ!H""G0#K`
M,T3EP0Z&:#4UA"S%*Z-Q##'`&!*$<VH(U:<4,`HR"C@%@H*<`ND`SQ`=<3U'
M=!@=*WA[J)R;$6MH`EE9D>,-D`1("H0!R8!P(`)(#D2ZQ+=%!\W[KQR=XK^<
M/:S(M<,T:TD"FA0(`Y(!X4`$D!R(=(EOAPYX'>PP>=#-+%%$9Y+`B,SR2<)(
M;-\T5]%D-($TDER:-^MK>B'Z5H@49)<W&WD&A`,10'(@TB6^:3K_=3#-Q$7?
M-#K;!$9D?9F!+;$G&(\B4"16T0ZZU&LSP:(,FF1`.!`!)`<B7>*;IW-@!_-,
M;/3,6]"4'!B17:LFBP6]CXFMHO4F`9)^685!FPP(!R*`Y$"D2WR[=`[L8)>)
MC;Y=9*5:Z>=&:E)KS8B!)$!2(`Q(!H0#$4!R(-(EOATZ$W:PPT1(%1HN]UAX
MFQDX.?.<;6(@"9`4"`.2`>%`!)`<B'2);X?.AQWL,''2'1WS`)XL.9G3VD%)
M$E"2`F&6V+RDIBMZ8YI!&PY$`,F!2)?X]NBTV,$>$RY]>V!U<Q*HM8>2)*`D
M!<*`9$`X$`$D!R)=XMNALV('.TRT5'VY=?$X^=/:04D24)("84`R(!R(`)(#
MD2[Q[`AI0KZ=C,]R/QG/`WHO;47.U`HD`9("84`R(!R(`));8E?&Q2(,27Z2
MGF+L7Z:^7=V2<V@BL'<QP>,M*W+M@N0,FA0(`Y)98CI^Y:D8]P37'HL)*)H#
MD2[QW5(=[W"MA5I.!M>(/M>R(M<MTZPE"6A2(,P2.RB"&1D2&;3@0`20'(AT
MB6\.#=#WW9N&&*3G4S#)B%I+8MNL)0F0%`@#D@'A0`20'(ATB6]+MV@<FM1[
M>WZVHK;S,9`$2`J$`<F`<"`"2`Y$NL2WHUOTU=]`TDMH2L.-%;EVT#"<@"8%
MPBRY$6Z@#0<B@.1`I$M\>[I%X="DW"_F8XC"MEEK6`(D!<*`9$`X$&')[TW-
MH8UTB6^/CJCWAYW0)%K?'IA;:.R-;3/7'JI)0<.`9$`X$&&)7=+&$W(7G$,+
MZ1+?'!U077/NG(!-KO5,FD($,J+6DCBD)`&2`F%`,B`<B`"2`Y$N\6W10=6U
MY8M$:'*MZMV-@!S2\!L#28"D0!B0#`@'(H#D0*1+/#OTT^(.=ISE),.$Y,NS
ME14YHP-(8LGOYX$4VC`@&1`.1`#)@4B7^/9T"\3C*X%X2N\NK<BU!P(Q:%(@
M#$@&A`,10'(@TB6^'3J+WG_QC+7\J^_EK,BUPS1K20*:%`@#D@'A0`20'(AT
MB6\'S;BWYY+QE6P+-P!6U'8^!I(`28&P"S%[B\@@S"YO-X_4.1`!)`<B7>)[
MTRWHCDW0]9<=^@#=BEQO3+.6)*!)@3`@&1`.1`#)@4B7^'9T"[ICDUAO+SM6
MU'8^!I(`28$P(!D0#D0`R8%(E_AV=`NV:M<EY'Z\<B#8VF:M00F0%`@#D@'A
M0(0E9AM/,`W(V,VAA=Y*JCMU/CICCMD9:K8;'HK3:Q$7^WW5VY0?>M>G_K+M
M0B\[4K^%>N\4X:O@0>W\0\Z"![673_'AI8':0/J^?BW^N3Z][HY5;U^\J(\:
M#>9J`)[,%E3SHB[?SYL?G\M:;1T]__NFM@H7:M?A:*#$+V59-R_T!UPV'S_]
M!0``__\#`%!+`P04``8`"````"$`8G_5OF4(```4+```&0```'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6R4VEMOXDH2!_#WE?8[(-Y/L`T&.PHY&O#]KM5>
MG@DX"1K`")/)S+??;K<QW?6?"?B,=$A^+C=V=;OD<OST]\_];O"C/-7;ZC`?
MZ@_:<%`>UM5F>WB;#__S;^\O:SBHSZO#9K6K#N5\^*NLAW\___,?3Y_5Z7O]
M7I;G`1OA4,^'[^?S\7$TJM?OY7Y5/U3'\L"VO%:G_>K,?CV]C>KCJ5QMFIWV
MNY&A:=/1?K4]#,4(CZ=[QJA>7[?KTJG6'_OR<!:#G,K=ZLR.OW[?'NO+:/OU
M/</M5Z?O'\>_UM7^R(9XV>ZVYU_-H,/!?OT8OAVJT^IEQ\[[ISY9K2]C-[_`
M\/OM^E35U>OY@0TW$@>*YVR/[!$;Z?EILV5GP-,^.)6O\^$W_;$PS.'H^:E)
MT'^WY6<M_3RHWZM/_[3=)-M#R;+-YHG/P$M5?>>AX883VWD$>WO-#!2GP:9\
M77WLSO^J/H-R^_9^9M-MLC/B)_:X^>64]9IEE`WS(`YC7>W8`;#_#_9;OC18
M1E8_F\_/[>;\/A^.IP_F3!OK+'SP4M9G;\N''`[6'_6YVO]/!.G\H+I!C':0
M,3OZ=KOQ8%BF;DY[C#)I1V&?W2AW'P([V.8\V&>W<^_SF+:#S.1!>I\'N[2:
M0V&?W:'<?1YVNS/[[';N?1XZ6T9B5MF\78?I?2;Z96+Y#]TX=Y^+SM:#.`QE
M8?1=7?IE8>AL?KJCN'M]C<2*;RX@9W5>/3^=JL\!JTHL-_5QQ6N<_LB'OEPZ
M8J%W%].?KB6V_ODHW_@P\R%;,NPRJ5D!^/%LV>.GT0]VT:[;F`7&3"<S-69Y
MB>$7%A_8H>!2\"CX%`(*(86(0DPAH9!2R"YP38&NGEQ^B;B<7"'!B,U'-REL
MH2F3\OLZ=LD]C^:YOPR[$,`&[R;#4(]DB1&6/5%C'(PA$2Y&6+:ICN)AC$'F
MW,>0V92D+L"8*?VJ$&,L>ZH>3H0Q4W(X,8;,)N3,$XR96K;Z52G&S&A,AC%D
MIO+?1)`#+C!$.B=E7;$*U&-=\>CYD!7P;AE9-OGNA8@9=VMO2<&AX%+P*/@4
M`@HAA8A"3"&AD%+(*.04"@F4O++:W".O/'H^9+/6Y=4TR0);B!BSJ:03PR1I
M7RJ;=8NL<D?>/)Z99$VY\F;#&I-KS5,W3TD9]Y7-!KT*`V6S9I'!0WFS;H[)
MB47*9F-"]HZ5S=J8G'<B;[9T>D'*6V<&24HF;]5-S9@:=(!<#K%F,].T+?6:
M+^2(L:5;FG[-GK)BV!U:CQ7#H]458]&O7H@8Z4JDX%!P*7@4?`H!A9!"1"&F
MD%!(*604<@J%!$I>V1U,C[SRZ%L53L1(>:7@4'`I>!1\"@&%D$)$(::04$@I
M9!1R"H4$2E[9G5V/O/)HNE[)U;@0,5)>*3@47`H>!9]"0"&D$%&(*2044@J9
M`%MORK7V,",W03G=3G)1D.V&I2G__:&&\*<7]-9]S)J>K^\6^5[JW-B:II:Q
MA8B1YH:"0\&EX%'P*0040@H1A9A"0B&ED%'(*102*&N>=9]*?K_.*X^^54M$
MC)17"@X%EX)'P:<04`@I1!1B"@F%E$)&(:=02*#DE3?F/1+;A*LKUK+)%;1H
M@Z34@C@@+H@'XH,$("%(!!*#)"`I2-9*5UK(#5$.>Q2RJ&GGW:9<+[Y>S[IH
M3N7;5%LC7[]H@^2TB]VNXD","^*!^"`!2`@2@<0@"4@*DH'D((4L:J)Y0]8C
MT:)_8U6HZP>PS^+/GEAYN:9U">*`N"`>B`\2@(0@$4@,DH"D(!E(#E+(HB::
M]V,]$BW:-WE%_Z:02#U>\P1JR1_@*:EW0%P0#\0'"4!"D`@D!DE`4I"LE:Z0
MT$X^OQ500,"U^5%GA3=!\JSP1XJW[TOX`\Z;-R9MD'P9B-VNXD","^*!^"`!
M2`@2@<0@"4@*DH'D((4L:L)Y,R0G_$9A%[W3C7HC-5CM94#%X7]A42X,%\0#
M\4$"D!`D`HE!$I`4)`/)00I9U$3S[JA'HD4S)=<;?-##G[DK25R"."`NB`?B
M@P0@(4@$$H,D("E(ULJT:8GTJ6;;)NDR<C7$M*:V=NUTFD57J"&6-M'T/U4=
MWD/)<W-GU1&MESQ'MD8>#2UT$72M,4L0!\0%\4!\D``D!(E`8I`$)`7)0'*0
M0A;U8N!MDYSP&U5'=%DWJHX(DA--Q=&IN"`>B`\2@(0@$4@,DH"D(!E(#E+(
MHB::]U$]$BW:+GE%_Z;J2+U96]ZI.#H5%\0#\4$"D!`D`HE!$I`4)&M%5)V)
M9HZM\;5>-">:*R&Z8>CLG_KXHU!#9KH^T:_/J96Y,6@K>U_5:7936UJH?8LV
M2+H80!P0%\0#\4$"D!`D`HE!$I`4)`/)00I9U(3W:V(-T8U^777:(#G1T,1"
MC`OB@?@@`4@($H'$(`E("I*!Y""%+&JB60'I474,'JZN:*PZ;9"<:+';51R(
M<4$\$!\D``E!(I`8)`%)0;)61-4Q3,N:&N0O4[D2HK/WBG2;5ATE9#HSI6=<
MZLS0KO?.FH/=KZW1/SL:M-==@C@@+H@'XH,$("%(!!*#)"`I2`:2@Q2RJ`FG
M#>W7=SJ&Z$AOU!S:MB[;W>1+@<:X$..!^"`!2`@2@<0@"4@*DH'D((4L:J)Y
M0WG_G0Y_J^YVS:%-ZK+=34XTC7$AQ@/Q00*0$"0"B4$2D!0D:Z5]0X#]"8?6
MDUR)L,8:]#7\E4R>0#'&M3L3<R)>MA3OBNW+TUNY+'>[>K"N/OB+E&/6UW7:
MO>3YS>`O@A!?Z(_L92GTC+T4VOBHVX&]DWE<O97IZO2V/=2#7?G*OHK_/6TX
M.(FW.L4OY^K8O+GV4IW9VYC-C^_L[=N2O3"F/;#@UZHZ7WYA7SSJWN=]_C\`
M``#__P,`4$L#!!0`!@`(````(0``!H\W5`0``"(/```8````>&PO=V]R:W-H
M965T<R]S:&5E=#$N>&ULE)==CZLV$(;O*_4_(.X3,`GY4I*C#6C;([52U<]K
M0DR"%G"*G<WNOS\S&#NV.=VR6BF;#*]?/\S8`]Y^>:LK[Y6VO&3-SB?3T/=H
MD[-3V9QW_E]_/D]6OL=%UIRRBC5TY[]3[G_9__C#]L[:%WZA5'C@T/"=?Q'B
MN@D"GE]HG?$IN](&KA2LK3,!/]MSP*\MS4[=H+H*HC!<!'56-KYTV+1C/%A1
ME#E-67ZK:2.D24NK3``_OY17KMSJ?(Q=G;4OM^LD9_45+(YE58KWSM3WZGSS
M]=RP-CM6<-]O9)[ERKO[,;"OR[QEG!5B"G:!!!W>\SI8!^"TWYY*N`-,N]?2
M8N<_D4U*5GZPWW8)^KND=VY\]_B%W7]JR],O94,AVU`GD1W_H!7-!3U!Y7P/
M*W)D[`6'?H50")/P3H"3\'_5-$\1SA+H:<SO:LKGKFR_M=Z)%MFM$K^S^\^T
M/%\$S!1#&C`;F]-[2GD.98"YIE&,KCFKP`(^O;K$]01IS-XD77D2EYT_6TSC
M93@C(/>.E(OG$BU]+[]QP>I_I(CT5M(DZDW@_[V_OIZNXGB^6"W'N\QZE_G#
M)1J+$LC;ZC*69B+;;UMV]V"]`CB_9KCZR0:,57KDS>B$_5>^(%%H\H0N.W\)
M%=WY'(KVN@^WP2N4)>\5!ZF`3ZT@MB)1"JP!FJ9&(`!:C0Q9-)&_7TE%AF(D
M4ZX'&3!!(@=DJ)C9BG2HF&N%A0HE&X^*XIT/WCI%L7;M,G*0"OC4BH6M2)1"
MW6YJ!"PRJ/5X,A3;9$M[WH-4S+K21_%R[F0L4=<UEQ&PN&`[C.="L<VU<KBD
MPLS8VE8D2J')C(!%MO@,&8IM,N+N""F9=RF;PZ/DL82Z8B?R^DROW-0(6&"P
M[<:G#,4.F+,1#U(B<W;\WF9.E$+GS`A8:/CH-;K+QUL5Q0Z:LS4/4H++K-A/
M)B2:S`"^P'XS(6YAE59#&@$+<OT92!0[D,Y:/TB)N>:(6ULET6Q&P&(C\)0<
MG\%.[="Y/:37?(BG-9K/C-B`V*5'EYC(GF[V..*TL$.OL0"==I-HS0-0.G?;
MQ0;$9CT>4+9V"]#M*41J+$!W\6G-`U"-@H@-"$:?`$2U7>+([2Q$:AZM(QE$
MTCX2=_M[MEXOR"*.'FFV";%9&RG$EX09+,R/MS.1+=Y,9>2VFEYCDLI1BXZ+
M+.$OCF-G6&H.LTFQ>1ND_T,H6[U%Z'8<?%>$?)O%CIP-GVC-H]AJU*#8V,3'
M`\J6;P$ZK>1`U&,!NV`4#EJ-OOZ`4R,&<-C&Q\/)IF_!#9J-\6"03S7B1E(S
M8A<3&[:!,W+9R39O83GKYP"G%%E4E9-D$,&3#&KD0ER'<Q*NEX]=+D'E"42^
M3]>T/=.$5A7W<G;#$P6!-:RC^HC4GUWT!3AL7+,S_35KSV7#O8H6,#2<XKF@
ME<<5^4.P:_>V?F0"CAG=UPN<12F\*8=3$!>,"?4#"ZM/M_MO````__\#`%!+
M`P04``8`"````"$`/K@IU_P"``"1"```&0```'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6R<EEUOFS`4AN\G[3\@WQ<PWT0A59.J6Z5-FJ9]7#M@@E7`R'::
M]M_O&.<#2)>ENTEB>,_KYQP?VYG?OC2U]4R%9+S-$+9=9-$VYP5K-QGZ^>/A
M)D&65*0M2,U;FJ%7*M'MXN.'^8Z+)UE1JBQP:&6&*J6ZF>/(O*(-D3;O:`MO
M2BX:HF`H-H[L!"5%']34CN>ZD=,0UB+C,!/7>/"R9#F]Y_FVH:TR)H+61`&_
MK%@G#VY-?HU=0\33MKO)>=.!Q9K53+WVILAJ\MGCIN6"K&O(^P4')#]X]X,S
M^X;E@DM>*AOL'`-ZGG/JI`XX+>8%@PQTV2U!RPS=X=DJ1<YBWM?G%Z,[.?AM
MR8KO/@E6?&$MA6+#,ND%6'/^I*6/A7X$P<Y9]$._`-^$5="2;&OUG>\^4[:I
M%*QV"`GIO&;%ZSV5.104;&POU$XYKP$`/JV&Z<Z`@I"7_GO'"E5ER(_L,'9]
M#')K3:5Z8-H26?E6*M[\-B*\MS(FWM[$!_K]>\_VDA"'T;]='$/4)WA/%%G,
M!=]9T#0PI^R(;D$\`V>=F0_U>3LS2$G'W.F@/A34$E;C>1'YX=QYAA+F>\WR
M7..-%:LW%/%1X@#?$1)2'T)>AM/B#,'.&\!%1]\^@:71^'U]=4:KP8/1S%"2
MZV?6X@R!U7%F+YXDO32:L"]:@'$2!6.TU5`0^FZ8GMA'9,%[R+1X2N:/)UX:
M3=23^6F0Q,E8L!H*<!#&WBFW$1FT]+!FU[64#IH23DJS-!I#Z*5ID$X)AP+L
M17&8G!0CQ.A_$'70%'':]4:S1PS2-,&3(EX0C`CC,>'EEM?B*=FI;4S+&XTA
MPXGNO`G94.#YB7MZ/P+35]K@P+@,IL53L-,>-V!&`VU_W#7!1+(RDGU5(]?]
M6^>E[V'3XBE;.J[)TFC,;L6A'P?N%&VH\((XCO&I)4S=S*UB#MV.;.A7(C:L
ME59-2\C8M6/H6F'N%#-0O.L/US57<!?T/RNX^BF<4ZX-XI)S=1CH6^OX9V+Q
M!P``__\#`%!+`P04``8`"````"$`\AA_JEL#```-"@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6R,5M&.FS@4?:^T_X#\W@"&0(A"JDG0[%;J2JNJ
MW7UVP$FL`8QL9S+S]WN-$VH[G9F\).%R?'+N.<:7U9>7K@V>J9",]R6*9Q$*
M:%_SAO6'$OW\\?AY@0*I2-^0EO>T1*]4HB_K/SZMSEP\R2.E*@"&7I;HJ-2P
M#$-9'VE'Y(P/M(<[>RXZHN!2'$(Y"$J:<5'7ACB*LK`CK$>&82GNX>#[/:MI
MQ>M31WME2`1MB0+]\L@&>67KZGOH.B*>3L/GFG<#4.Q8R]3K2(J"KEY^/?1<
MD%T+?;_$*:FOW./%#7W':L$EWZL9T(5&Z&W/15B$P+1>-0PZT+8'@NY+]!`O
MJSA"X7HU&O0OHV=I_0[DD9__%*SYQGH*;D-..H$=YT\:^K71)5@<WJQ^'!/X
M1P0-W9-3J[[S\U^4'8X*XIY#1[JQ9?-:45F#HT`SPW/-5/,6!,!GT#&]-<`1
M\C)^GUFCCB5*LMD\CY(8X,&.2O7(-"4*ZI-4O/O/@.(+E2'!%Y(4U%_NXQE>
MS.-Y]C%+:!2-#59$D?5*\',`NP;^4PY$[\%X"<S7SHR.J=>W6H4>-<F#9BE1
MC@+H0D(^S^L,%ZOP&3RM+YC-+29V$=LK0ANH:2NK$(+>231888O^?0Q7;1JL
MM5U9-Z8`W)-8[`GY#2)W(=4M)/L%<<0FKECM</KFWKF*UHM*!.?'I#%+(E?"
MQF"2J;&M7ZBL@B,)@K;]TY(2>"C>]U$O*A'T;4GR$MP83#;N@"3*<93,O6VP
MM2&X*'"&4X^E<B!S@!2+-[P%'^U&WF]`@_T&O.0W!F-YZA<JJ^!XFKE2[HM9
M+_HH9H.Q)/F%RBHXDN!YM-VY+V:]R'?)"VAC,";F.,L+G*:)NSFW#F2>)3A/
M/:\K!Y+D29(N%A.+TXB>H]8A]7[,&NPWX*G;&(SEJ5^HK((CI7"EW!>S7O11
MS`9C2?(+E55P),'D<^RY+^=QE>^3'_0%=$DZ*7!>Q-F4T7A(;UU,BHLD+;R'
M7@]G[<"%!\<NQG1CIJ\93AT5![JE;2N#FI_T9,5PIDS5:>H_8'WZ>?6-?AO0
M]7"Z`<-X(`?Z-Q$'ULN@I7N@C&8Y/,S"C'-SH?@PCL0=5S"&QY]'>.VB,(RB
M&8#WG*OKA?Z#Z45N_3\```#__P,`4$L#!!0`!@`(````(0#.QL"?41(``.!=
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*R<77/;N)*&[[=J_X/+
M]\>62$FV5'%.C<5O\;O.[EX[CI*XQK92EC.9^?>G0:#5`%Y&LF?/S3CSL-$$
M\*+QT:3XX9]_/CV>_;%]V3_LGF_.IQ>3\[/M\_WN\\/SUYOS__E7\H_K\[/]
MZ]WSY[O'W?/VYORO[?[\GQ__^[\^_-R]_+[_MMV^GI&'Y_W-^;?7U^^KR\O]
M_;?MT]W^8O=]^TQ7ONQ>GNY>Z7]?OE[NO[]L[SX/A9X>+X/)9''Y=/?P?*X]
MK%[>XF/WY<O#_3;:W?]XVCZ_:B<OV\>[5ZK__MO#]SU[>[I_B[NGNY???WS_
MQ_WNZ3NY^/3P^/#ZU^#T_.SI?I5_?=Z]W'UZI';_.9W=W;/OX7_`_=/#_<MN
MO_OR>D'N+G5%L<W+R^4E>?KXX?,#M4!U^]G+]LO-^6_353\/SB\_?A@ZZ'\?
MMC_WUK_/]M]V/].7A\_EP_.6>IMT4@I\VNU^5Z;Y9X6H\"643@8%VI>SS]LO
M=S\>7_O=SVS[\/7;*\D]IQ:IAJT^_Q5M]_?4H^3F(I@K3_>[1ZH`_??LZ4$-
M#>J1NS]OS@.Z\</GUV\WY^'B8GXU":=D?O9INW]-'I3+\[/['_O7W=/_::.I
M<:6=A,8)_35.9A>S8'YU/3@Y4G!F"M+?OW]WJN?0!/IKG`3!17`]G\X7J@U'
M;K\P)>FO*3E_6\$K4Y#^FH+3Q=M*4MP-E:6_[[OETA2DO]Q*DO0MK9S2H!KN
MJ?YARKY1GRD/#_4/OBWUUI$^G=)(TG>3(?7&7IWR.%+_X+N]4<HI#Z6IB!F<
MJ"FK.+5D/#Y@IBR?^@?7</0NESK.AK"-[E[O/GYXV?T\H[F0.G+__4[-K-.5
M\L(!J[OT$,*_BF`*7>7E-^7FYIPJ3L&YIVGGCX_!\OK#Y1\T5=P;FUNTF;H6
M:[90\X)R&_D@]D'B@]0'F0]R'Q0^V/B@]$'E@]H'C0]:'W0^Z"UP2?(<-**1
M^Y_02+E1&G'OWC*P1/,$80LN$OD@]D'B@]0'F0]R'Q0^V/B@]$'E@]H'C0]:
M'W0^Z"W@"$+S`0@2TFPVOLIQC*A2-^<48U:,+-T.O]4VH5[/5`BL@41`8B`)
MD!1(!B0'4@#9`"F!5$!J(`V0%D@'I+>)(PG-MXXDQZ50UC3CD3=+"W^^TD8S
M>U(+)Q-7L/7!Z!`B0&(@"9`42`8D!U(`V0`I@51`:B`-D!9(!Z2WB2,/K6/O
MD$=9#_)PI]YJ$M*?@V"S*T^*@PV7BH#$0!(@*9`,2`ZD`+(!4@*I@-1`&B`M
MD`Y(;Q-'"MH?O$,*9>U*H8DC13CQ5_*#T4$+(#&0!$@*)`.2`RF`;("40"H@
M-9`&2`ND`]+;Q-&"YI9W:*&L72TT<;2`L#C8'*0`$@-)@*1`,B`YD`+(!D@)
MI`)2`VF`M$`Z(+U-'"EH77:DT!OABRN*H]=O#_>_W^YHYJ$=VLC"$M*&5V^#
ME1-7(4.6AUW7VA!]^AUVN9K,KX=]\XPR%C-W9HL/!BQA`B0%D@')@11`-D!*
M(!60&D@#I`72`>EMXLA#YTQ'GA$9Z'3-.BAK5P=-YI8.FE#L<*=&FBQH(W=8
M9,))X&EQ,.)B"9#4$-G%90<;VW7HNLX/1NRZ`+(!U^7!QG;MC:#J8,2N:R`-
MN&X/-K;KA5OK[F#$KGN;."*J$[^CXM\*LL&+JZY!MKP&V?H:%,@@B!$EB%+T
ME:%5CJA`M$%?I5C9_3QW^[D2*^[H&E&#[ENQLMU[NZ=.K-A][R!72'54M=,&
MQ\-1I6N\>#1H3E>L8/.VX&LN:`6I012E7,\848(H15\96N6("D0;]%6B586H
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MF&K\CEZ#:BS8,)(&M8RD0=VX>R_2>J>@J[PZMMO*J^DBH"<(I^<+?>`GU]S6
M6Y7Y5H-`[9LY%QQ.O6&X-E;.?*$+!C*<8[;2PWD6+J?77JL2-I%2*2,)E8R1
M6.4&>5.!M[DII*"T9F04F*K+'4LIR#U3,3*MF2ZOKF$(0!\T7$I\MXRD-9U!
M'/C>.MH[)5SM22='^Q-1K\R]O9=&5@BLU1,_LK)0Q$A&2FP0Q2%W48)6*2.Q
MRAB)KQQ]%6BU822^2D;BJT)?-5HUC,17RTA\=>BK=ZQ<+52>P([#$UKHM((3
M?!JYB_746[G6ZIF4DD>&5,1(AE1L$`TID<<4%*N4"XJOC)%8Y>BK0*L-(_%5
M,A)?%?JJT:IA)+Y:1N*K0U^]8^7*HW('MCQOGR9UUL%12B-OK?3B=JT>!?J!
M9)`,LMA8F;5R<35?7GNK6<*.I%3*2`9PQDBL<H.\Q=*;MPHLN&$D[DM&XKXR
MZ$C5:RS5,!+?+2/QW1GD5=U;0'JGH*NW2D:`WM3];\\'J2>J_G2ID1>BL)_6
M5DZ(FH(2C[%Q/U,)*-KN3<)PX8V@Q)A8JVK*2$(C8T?B.S=H3B%OK>,@O*FG
MQ-0&W9?HOF+TZZK7[$A\-XRDZBT[DJIW!GE5!^'MJKO"JP2&+_QT_LY<X%2G
M09R@U\@)^J6WY5B;<L[BJ<O-:%D]:#%RE#)6"ST:PED0!#`<M$T@89+B_3*#
MCM\O-U9S%1&'G5X`AZG#'<5J9`=EK"2BRS=5HF(KTVAJ\?S::W1M;*Q&-XSD
M?BU[DEQ#9Q"UD)?`G@L.'>B,&@JQXZ/F7[OOM',Z=00?W+@[+(/"Q:$::T01
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M#*UR1`6B#?HJT:I"5"-JT%>+5AVBWD&N/"KO8LOSUKR_RO1YYQ2#W'/*Q%NO
MUL:*YF\1RB1_[,D"-ZM<4"?#QO+^;"';_Y21W"UC=/1NN;%RDWV!=T@N1GU!
MRI>MI!(EHZ.5J-B*FSR;>Q6HV4*:W#"2N[6,Q*HSB--_\PMO"]P[9=PQHW(Z
M]I@Y$=(Z!>2$M$;.J28,O+5MK=Y^]E(9C.0P$AMT).V/A5)&LIG/&(GKW"`W
M'1!X:V0A!64"QN,*6\D=2T9RQ\H@TYA@XF=E:BS3,!+/+2/QW!E$;5$'_\F%
MU]F]4\256Z6/WB&WSC8Y<FMDA?PZ`!0QDD$:&V0G%-$J920#/F,DOG+T5:#5
MAI'X*AF)KPI]U6C5,!)?+2/QU:&OWK%RM5`9B'=HH1,6CA8:S6A1E2,XY'L#
MD^F0,14QDC$5&T1CBJ?R!*U21F*5,1)?.?HJT&K#2'R5C,17A;YJM&H8B:^6
MD?CJT%?O6+GRJ)R$+<^;\[VTAX3E5"/OL9@W3:]-02NV(D8RR&)&>B&97P57
M@9=$2MA$2J6,9`!GC,0J-\A=*:?>_%)@P0TC<5\R$O<5HU]7O683*=4P$M\M
M(['J#/*J[DWPO5/0T5N]P8]ZT]3V]GSOX,)-WACDKHY3?Q]EK&AKQ\$7,9(]
M<,Q()[OFRQ#R>VPA8SYE)*XS1N(Z-VA&4X4UD_BZ<T%QOV$D[DM&XKYB],N:
MUVPAKAM&XKIE)*X[@[R:^[)SP<&]*_M_)"=$/]GP0]X@)^0AVVN,[(AGI$8>
MYU5Q`\U6^JW1J_G\:N;-)@F;2(RDC"22,D9';Y<;JX7SYDS@'4P+]N5LA&$'
MS592B9+1T4I4;*7;O%C,,=?+)M+FAI'<KF4DB=W.(&H@1V#/5H,O=\SX62D_
MC_BV7&^(V2J#[%POH@A1C"A!E"+*$.6("D0;1"6B"E&-J$'4(NH0]0YR-5(I
M'EB^Y^HEN'?^N#'4R2)[XV40R20Q&OJK\%JL>$Q%B&)$":(4488H1U0@VB`J
M$56(:D0-HA91AZAWD*O<^[),(6:9#'+D@1]&B)&HHUU9T1>C58(H190ARA$5
MB#:(2D05HAI1@ZA%U"'J'>2JXR>9CB<,*%,*"Z-&CCIAX+^E8@I:6D2(8D0)
MHA11ABA'5"#:("H158AJ1`VB%E&'J'>0*X_*L]C3W@EY=%K&F=LTLCI^K:2B
MY(V%(D0QH@11BBA#E",J$&T0E8@J1#6B!E&+J$/4.\C5@K8SCA9JF[`(AQ<)
M3LBB2GH'"8.LI\#A`<DJ-%UZ6<6(K<CXL)^T3PYNE56NX!W#1Z<6G.&C$?4*
M3ZOK$%"$*$:4($H198AR1`6B#:(2486H1M0@:A%UB'H'N5J,)2"6RV'XO'<+
M@QF)4*.%'+C6@F2DC(PG4]!).@5RHG7:,/,/U<?'_6#NCGN#['HBBA@-9T6W
M!O[Y[D0-\"!'"5QO]ELCBA#%B!)$*:(,48ZH0+1!5"*J$-6(&D0MH@Y1[R!7
M"__<=$(+/!_--%)SKDQFH??2T5JL>`Z*$,6($D0IH@Q1CJA`M$%4(JH0U8@:
M1"VB#E'O(%<>_\AT0AX\%]&KB!`J@"*TBA$EB%)$&:(<48%H@ZA$5"&J$36(
M6D0=HMY!KA;O.P2I1P#>AL$@+U2\MS;68B6A@J<@M$H0I8@R1#FB`M$&48FH
M0E0C:A"UB#I$O8-<>=YW"E*O4OKR'$Y!W/%K8V5MG2)$,:($48HH0Y0C*A!M
M$)6(*D0UH@91BZA#U#O(U4*=3NP]JY^->]-O]V?ZC&-O90U2CPRLQ<;;7Z_%
MBH6,$,7L7C+7B5C9[KV<>RI6[#YSD-L5ZD1@=\6)&=P<(&0/>*N^=T,C=:$S
M]<$$?KHE!ER?R"!Z[Y)1S$B2K@DC)SGL_R`T92O]A"B83T,OK9VQ!:9EU3.`
M][0>#R^#!VK]U?!@G5KO/5A;BP$W-3*(WIIB%#.2)Q<)(UH-#V,)LOJIL:(=
MU/`-M;'6ZTKKN[G:JWTY:T]6)Z37NWAGN)N-O?J.`GW`;0(/DM7+0&ILR!B.
M#'*DUU;6(XU$K(XVWA0\(KVQ0.GG]CGC9.,':_>889`H[PV[M1BPS)%!MO*,
M+.49'5?>6!U17OQ0!1SEU=MT;U=^L/8:KT\X)*Q17DYSPX=-UJ:,K;Q!MO*,
MK*!G=#SHV>K7RK/%B/+VF>*T\GBD4`^,:51;*JX118AB1K;6X"LU5M9[%1D7
MM!Y&ZB^JZD\S/FU?OF[7V\?'_=G][H?Z6BH]E?KXX8#UIUQO9_0M5QHN-!C@
M2D!7A@=9<"6D*\-MX<J,K@PM@2MSNC*$O'\EF*S4R_8C-0BI!O1H9NP*U8!2
M_V-7J`:4=AZ[0C6@C.?8E05=&3)-?MWFTY4:M5B&/H'[VVC-J#O'[&^I*:/V
MJB%C_F>KWTA@O/&MZN$Q3JT;;1RU;;1I5ZM^>'#I-WFV6*F=!]Z9=AHKM6G`
M*[3<K]:TH(Y=N:8KUZ-7EG1E^*6#7X/YA#I];$#0*^34BV/=12_VKM1KNU@#
M>DUWI5["Q2OTTNU*O5*+5^@56KK/V)7;<+FZI2P1EJ&T%[5G[$I$5U1F"<O<
MAM>D_ECOT(\\J`;C`RE8W8[VP9IZ9SUZ):(KZC5TK`']RF"EWD;'*_1C`^JW
ML2OTTX&5>NL<R]`O"*A'QT8MO9).5\;*T"\%5NHE<_36+E?]V/B@3]%0C(WU
M9S2=KM1'6]`7?:1EI3[!@E?HDRLK]4$5O$(?4*'[C%V)2+8QU6YI<(Q6;$UC
M8_1"M*0*CS4E7:[4!X.P5MF2&C)V8;-<J<\"88ERN:+O-(UPZD?U\1^\TBQ7
MZA-`=.'R$)OT?>WO=U^WU=W+UX?G_=GC]@NM*),AB_RBO]"M_^?5_#[MT^Z5
MOJQ-&P3Z&C!]27U+7R&=J*?F7W:[5_X?=8/#M]D__EL`````__\#`%!+`P04
M``8`"````"$`G@AFJ-D'```2(```&0```'AL+W=O<FMS:&5E=',O<VAE970Q
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M@:>Z_B1,LX-`X#QGWG&_`K\WDT/Y7+R>NC_JM[2L7HX=++</$8G`UH>O8=GN
M(:,@,W-\H;2O3S`!^/_D7(G2@(P47_KK6W7HCINIZ\T6MK5R%Z#R5+9=7`G)
MZ63_VG;U^1]I9"LI*>(H$;BB2##S%Y9KPYC?*^(J$;@J$7LY6_J^%RS%5-X9
MWE.><,7A=0CO^(%J'SM<<<1@9GM6(&;]CE^@_!;:[SMG"KNN'Q&N=\UTI?S@
M>M=,;:@GN;RBL-32O3_7N2R0OM["HBL>'YKZ;0*;&$J@O1;B2+#70A<K329J
MJ+W_*CVH.:'R4<ALII`ZJ*H6]LOG1]?U'N:?H<;WRF;+;6S38H<6HJ"%;$A!
M1$%,04)!2D%&03X"<TC+D!LH_/\C-T)&Y`:CVB+0R7)((M`"74(*(@IB"A(*
M4@HR"O(1,!(!F]=(Q.UC"&M!6&^FL!E&M>";`6ZEC2L/'+'4.T9"1B)&8D82
M1E)&,D;R,3%"A]/GCM"%->PD4!O%3O>!-/+,S1*8"=H-1D,),!(Q$C.2,)(R
MDC&2CXF1#CA"[TB'L.[3@4%L)7'A,B3(6Y#0!QOT"AF)&(D921A)&<D8R<?$
M"!WN#W>$+JS-T"4Q0G==&OM@-,3.2,1(S$C"2,I(QD@^)D;L4*MWQ"ZLS=@E
M@=@QK!TC(2,1(S$C"2,I(QDC^9@8@8H&FM\.9Z)5Z8[5_M.VAKJ%^\6-$]"%
MVYZ\&0H1,WY%5CI^171&0DD<:`:&K>$$Y,80#4:8R)B1A)&4D8R1?$R,E,"$
M?CPE0L1,B2*CE"@R2HDDKM4W%(YEDY,T&GX?LL%(PE33P4:T*:#JFN=/-OR.
MJOF8&+D1'9.1G!MU`6TG%D9O;J9!(0>$AF5WW:4YI1U:Z?MEB&CLZ`0T0VCE
M]"FT%U;@>Z2F8K3I'TGZ"DX0Z?%21.^.EZ&5'"\(_,62#)>CB7P"&O=;MFC$
MZ.YS`O&(<VO#C1,K6SBX\>*:;7NQS12>TL:)7='$2D?'&QQ#[8A:D4*>W6=Q
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M:KM6X%+MW/`RTR3ZRCO2)-M0HYHD(M5$;G8[6UGI%0\1Z16/$,D57SCP6LP\
M[6*TT$X)(BV=(M)6&2(I[3OVDMS(<[3HG<PDB9[TCB3)%M9(DD2DELA.V=G*
M2J]WB$BO=Z20JJ65Y7GD`37F3@DB+9TBTM*9*6U#C^N2,LT-+S-+HDV](TNR
MJS6RI!K=<1_CTNAVMK+2ZQTBTNL=(9+KO;+=@*QWC!;:*4&DI5-$VBI3R(=;
MZM`7.@LBGQN.9J)$SSI.E'RQ=^>3C"T[7R-_$I$JH\^QRM$XL92C[N\C9>5!
MLO\[R!BU=`TEB,:5QN0SM`IDV^9;\)^YU7,TZ;6-!(JSYL<3V*N81[Y"'LQW
M"-KUR,KNE)6CJR1$!!MX<.0=/UHM^Z#=);SX=DG7&Z.-KK<$D1XO1?3N>!E:
MJ?$"R[:79+P<;?KQS"S?:OEM7Y?IG_45TO>M!@321.^L"KEP3QBRY7ID9CMM
MA7U#R%'$4<Q1PE'*4<91;B`S/:*CIKO868J.[,X7]([LS<<[6:%@O/M<VB[N
MM)7.D-0"1T01MXHY2CA*.<HXR@UD9D@TO.,,O=^"B6.+M&`*F87BT]9>6V',
M(4<11S%'"4<I1QE'XI.CF#U,%28ATR`_(<I/.N>R>2EWY>G43O;UJ_@\"#W9
MX\.`Y;?+;;"&%WT@0/EB#>_%;G!'?.SLSP7JX3CPBW/3Q\4/I,0G7*[A51,?
M)5RMX_Y=$+%/5VMX_<+MX0OLQYLCPV1OSQ4F=$-G"Q/M#W\R[D</]&_]L/76
M\'J<3VCKK^'=,?#YH`1?9*_%2_E;T;Q4EW9R*I]A2:S^;&OD-UWY1Z?.N*>Z
M@V^Q_7%WA&_O)7P6L<16?Z[K#O\0`PQ?\Q__!0``__\#`%!+`P04``8`"```
M`"$`IN]3.#H%```B&0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R<
M6=MNXS80?2_0?Q#TOI8E2G)LV%XD#=(NT`6*HI=G1:9M(9)HB$J<_?L.1Y>(
M%!F3?4GBR>$<#F?F<,)LO[Y7I?=&&UZP>N>'BZ7OT3IGAZ(^[?R__WKZ<N=[
MO,WJ0U:RFN[\'Y3[7_<__[2]LN:%GREM/?!0\YU_;MO+)@AX?J95QA?L0FOX
MS9$U5=;"Q^84\$M#LP,NJLH@6B[3H,J*VN\\;!H;'^QX+'+ZR/+7BM9MYZ2A
M9=;"_OFYN/#!6Y7;N*NRYN7U\B5GU05</!=ET?Y`I[Y7Y9MOIYHUV7,)<;^'
M<98/OO'#S'U5Y`WC[-@NP%W0;70>\SI8!^!IOST4$($X=J^AQYU_'VX>DM`/
M]EL\H'\*>N63GSU^9M=?F^+P>U%3.&W(D\C`,V,O`OKM($RP.)BM?L(,_-%X
M!WK,7LOV3W;]C1:G<POI3B`B$=CF\..1\AQ.%-PLHD1XRED)&X"O7E6(TH`3
MR=[Q^[4XM.>='\6+.$I6=R'@O6?*VZ="^/2]_)6WK/JW0V%(HY>H]P+?>R\D
M722K);%P$G0[P@`?LS;;;QMV]:!J@))?,E&#X08<ZR."4`3V7H!W_LKW8*\<
MTO"V)TFT#=[@Z/(>\]!AX.N("4=$`*0C,[#9,PNP8!9G*[;RT!FF-!\;D6B(
M"XT`[WQHVW'S)"'C]COF#D.P8*;QQ"Y$`@Q'#KXF3!\1=$P]",IU`HK'[4AA
M0AG9GZ8`(_MXG+T%&$>J>*5G2F4FT0M1*NK^1O&(=3)I;X%4CJ0D2?2L4'3V
M\0FP3-5;L*&D<Q,2/:E_$4V\7"]@:Y^W@E@G4_26:4F2)-5'LY99/Z<28)FJ
MM\RC":%6U'"LDH,+99+!)*?'4!2A:/O).7X>$:(5-N$`3-/C,U5@*)I_0F:=
M-%RH\/9",N4ER9T^;:)?I\0WHNR4`A:-;88.,$HP2748*O)AW5:X4(FI%PXY
M<VM#3$[*(6X]I1@'DZ8:-5(1ALGBIE2$<ZT83%*>TJ4A)B>U".=R,9BF;,9J
MU$B(7<_--23L35+F4L,%&CJI"**5.C'J2*33D219K&ZF#E?*-(-I>I@D_;CL
MI#Z(`&7?8HA6V(0#,$W93*F+-$)"5LO;!8H+%5Z=D*0?PX,<I9.01',A&4SS
MIHLT0A(FQ"9UO6Q,]`J=*8=)4L,((D8`A]3-E00=*&S&U&FTQ:KKHKFV#":Y
MZPR#2.2D+8A6"F6<13[&'F.4&FVQ&D^BN;8,IFECD-0PH$1.VH)H)4JCMA"=
MMM@,D+A09AE,<N8,,PIQDA9$*VRCM*BW-]$(21K?UA%<IY!H=<0PD!`G'4&T
MPM9+RUQ'B$9'DM!"1G"APM(KBUQZAH&$.,D(HA6V7EDT,?U?T2!ST1A,4NFM
M#`,)<1(-1"LQ.8@&T8B&W0V`*Q7B7DBDU*T,$PEQ4@U$*VQ&U8@5U?A\]$:T
M['HPR?DR3"&QDU0@6F$S2D6LD0HK2<>%"HM.*U:&F2-VT@I$*VQ&K8@U6F%U
M&>-"A:77"CE/AI$C=M(*1"ML1JV(-5IAEZ>Y5J`O():;R#!@Q$Y:@6@EIE$K
MU&LJUBG#&D[Z1C?-APGT-(O(,$S$3K*`:"6B419NCTR)(A3B#VFK>PL7RKR#
M2<Z;8;R`!VB'\1?1"MM<,[H7Z>[!MJ+-B?Y"RY)[.7L5K\T1/,&.UO$E_#X2
M[PVJ/=[<=R_DP?@;>*&^9"?Z/6M.1<V]DA[!YQ)O^*9[X^X^M.P"&X5G:M;"
MTS3^>(;_15!XAL4_E8Z,M<,'47'C?S?V_P$``/__`P!02P,$%``&``@````A
M`">JU6";,```"R(!`!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&ULK)U;
MD]M&MF;?)V+^@T+OIU2\%%FEL/N$720!XD)<XLS,LUHNMQ5M60Y)W>[^]_,E
M,Q-Y67!)T#G]8+L7=^XDL#(!Y`:(^NX___7^UQ?_?/KXZ=V'W[Y_N;JY??GB
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M`!U6/NF0^<^_;/;WW[WZIXYR;UW,CXQ9I1&//L(<TDS:0PZ..3CEH,A!F8-S
M#JH<U#EH<M#FX)*#+@=]#H8<C!%X)3V3(\V;_PE')HUQY/?NCQX$:>M,B(_P
M30XY..;@E(,B!V4.SCFH<E#GH,E!FX-+#KH<]#D8<C!&(!&BHU$B9/[$[.>&
MB?[^I>96-#<>TAW]HXW9V#.P&?J/(`>0(\@)I``I0<X@%4@-TH"T(!>0#J0'
M&4#&F"0J='!?H,)$ZTBG;)&+_#AE@S:2'X+N;U-ACU/0-#5`CB`GD`*D!#F#
M5"`U2`/2@EQ`.I`>9``98Y+HT?EK@1X3?=7C=^J/EFQB8=M]IF**\:T.($>0
M$T@!4H*<02J0&J0!:4$N(!U(#S*`C#%)5.BZ8($*$YVJL&23G./O\S/X%#2Y
M`#F"G$`*D!+D#%*!U"`-2`MR`>E`>I`!9(Q)XD([<8$+$YVZL&2C_-,A"M-B
MBIE4@!Q!3B`%2`ER!JE`:I`&I`6Y@'0@/<@`,L8D4:'S\@(5)CI584FB8G.?
M7T=-09,+D"/(":0`*4'.(!5(#=*`M"`7D`ZD!QE`QI@D+K247>#"1*<N+$E<
M8%I,,9,*D"/(":0`*4'.(!5(#=*`M"`7D`ZD!QE`QI@D*DR-8(&+:W@JPZ'L
MA+')3MXA:O)!="0Z$15$)=&9J"*JB1JBENA"U!'U1`/1F*!4CUDKQNOVYY<@
MIFR3S16'GI\L(2C8L:G4SJ,CHTY$!5%)=":JB&JBAJ@ENA!U1#W10#0F*+5C
M%HX+[-AUII8E?I?^:&IE$I;8V=QO\\DS1?F&A]#0HR/1B:@@*HG.1!513=00
MM407HHZH)QJ(Q@2E>LQJ<H$>N_A,]%B4Z,&9QBPSK4.OXD!T)#H1%40ET9FH
M(JJ)&J*6Z$+4$?5$`]&8H-2.64PNL&/7GLKG]_*/IN*K';_7*6RZ/-[<W^63
M9XKR#0^AH4='HA-10502G8DJHIJH(6J)+D0=44\T$(T)2O68!>8"/78]FNBQ
M:*\3R:2'DV<*\BH.IAIOM(8BV9'H1%00E41GHHJH)FJ(6J(+44?4$PU$NOL8
M[8G4CEERQG9,/7]]=Z,&2ROZ=O&:B'/KV7C9N;G?Y?-JB@KF@([F/DEZ<#P1
M%40ET9FH(JJ)&J*6Z$+4$?5$`]&8H-2<6:'&YKYP16<7M(F>>(U[O7_R:&XI
MI7OY0'0D.A$51"71F:@BJHD:HI;H0M01]40#T9B@U(59H<8NOGT6V;5NHFE:
M_H;#W^8^+VJ:>W&Y.:`CHTY$!5%)=":JB&JBAJ@ENA!U1#W10#0F*#5G%K2Q
MN2_,(KO^3?2X);%]L.)Z*V8%="`Z$IV("J*2Z$Q4$=5$#5%+="'JB'JB@6A,
M4.)BO:R$<`U/2P@.)9?9F_OL?LUCB)I..$1'HA-10502G8DJHIJH(6J)+D0=
M44\T$(T)2O4L*R&L64)P*"H%/!(=B(Y$)Z*"J"0Z$U5$-5%#U!)=B#JBGF@@
M&A.4NEA6,%BS8.#01H>JZ:)Z<Y_=9GX,46&JN!K"]7FVZU7#D5$GHH*H)#H3
M540U44/4$EV(.J*>:"`:$Y3J658P6+-@X-#V^N"?O38C.A`=B4Y$!5%)=":J
MB&JBAJ@ENA!U1#W10#0F*'61EP?,M=GFWCP)N72)LV;IP*'TC/.0W_P/46$:
MV5S1L?#(J!-10502G8DJHIJH(6J)+D0=44\T$(T)2M699>O77YP9H[H$CB_.
M'$KTH'00@H(=FRJQ`W1BPX*H)#H3540U44/4$EV(.J*>:"`:$Y3:,2ORV,XW
M+WK6=FV?B)N6^]'IZ2%_>L`UC#0=B(Y$)Z*"J"0Z$U5$-5%#U!)=B#JBGF@@
M&A.4FEM6.EBS=.#0%^85BPFAG9]J1Z(344%4$IV)*J*:J"%JB2Y$'5%/-!"-
M"4KMF&5[/*^>7Y*N[2H_F3S3PC^>//DS!JYA,GFFAD$/T(D-"Z*2Z$Q4$=5$
M#5%+="'JB'JB@6A,4*K'+.X7Z+&U@$2/*P_H$#==>O.D-`5Y%8<UT)'H1%00
ME41GHHJH)FJ(6J(+44?4$PU$8X(2.YME-81K>'K)X%"Z,'K('T,(49,>HB/1
MB:@@*HG.1!513=00M407HHZH)QJ(Q@2E>I;5$/1\<WY%YU!TU'HD.A`=B4Y$
M!5%)=":JB&JBAJ@ENA!U1#W10#0F*'61UQ"^^?K-//J<77@[E%P@;![RYQ%"
M5)A%KKP0/2["J!-10502G8DJHIJH(6J)+D0=44\T$(T)2LTM*R^8IZ%S/18E
M>G`*<NVBJ78@.A*=B`JBDNA,5!'51`U12W0AZHAZHH%H3%!JYW^NX+!AP<&A
MQ-SF(7]6(42%B<6"`Z-.1`51270FJHAJHH:H);H0=40]T4`T)BA5MZS@L&'!
MP:%$#R<62@F'T,X+.Q*=B`JBDNA,5!'51`U12W0AZHAZHH%H3%!J)R\X/+\P
M,@[RP]YL52%_(,$UU+^\BP/1D>A$5!"51&>BBJ@F:HA:H@M11]03#41C@E(]
MRZH*YCG?7`\*!H\N2KT&%X@Z,NI$5!"51&>BBJ@F:HA:H@M11]03#41C@E(7
M9M7^]8O4C5WDQXM4A\RQ<EJD;A[RIPY"5-#C"@;;R=B142>B@J@D.A-51#51
M0]0278@ZHIYH(!H3E.HQ*_D%>NS"/]'C:@$ZDTQZ>)Z9@H(=H*-9Z6HBZKCK
MHTY$!5%)=":JB&JBAJ@ENA!U1#W10#0F*+&CFVY+[%S#TQJ"0^98.=G9/.3/
M(80HO^,/1$>B$U%!5!*=B2JBFJ@A:HDN1!U13S00C0E*]2RK(6Q90W`HT8/)
M$X*"'9LJ.AD=&74B*HA*HC-11503-40MT86H(^J)!J(Q0:F=O*KP_$7:EJ4#
MAQ([FX?\R800%?2P=,"H$U%!5!*=B2JBFJ@A:HDN1!U13S00C0E*]2PK'6Q9
M.G!(\]/O^$>B`]&1Z$14$)5$9Z**J"9JB%JB"U%'U!,-1&."4A=YH>`+4X7%
M@*U;T^L,/IUGMK?YTP<ARAL[$!V)3D0%44ET)JJ(:J*&J"6Z$'5$/=%`-"8H
MU;.L&+!E,<"A9*K8J`@=&'4D.A$51"71F:@BJHD:HI;H0M01]40#T9B@U,6R
MI?^62W^'DK/*]C9_H"!$A:DRU0P\.C+J1%00E41GHHJH)FJ(6J(+44?4$PU$
M8X)2/<N6_ELN_1U*]>2KS1#D51R(CD0GHH*H)#H3540U44/4$EV(.J*>:"`:
M$Y3:658,V+(8X)!9,D7GF?R!@A`5]+AB0/2P**-.1`51270FJHAJHH:H);H0
M=40]T4`T)BC58];?7U\,V-KE>EP,<,@LF8(>3![;+CGS`!U#*N_P1%00E41G
MHHJH)FJ(6J(+44?4$PU$8X(2.W=Y,>";[Y)>,Z5U`H?2H]YM_JQ!B/).#D1'
MHA-10502G8DJHIJH(6J)+D0=44\T$(T)2LTMJQ/<L4[@4*HGGU<A*-AAG8!1
M)Z*"J"0Z$U5$-5%#U!)=B#JBGF@@&A.4VLGK!-\^KUA"N)LJ`=$!\39_^B!$
M!7-30X^.C#H1%40ET9FH(JJ)&J*6Z$+4$?5$`]&8H-3<LA+"'4L(#GUA7MEV
M"O(J#J&=1T>B$U%!5!*=B2JBFJ@A:HDN1!U13S00C0E*[>1%!3.O5@^KZ^\=
MGB\PW+'`X%&0\!B0>6MKMH`Z^$]UA1\N16[#XPGI=UVVPK[C"MNA:)`\$AV(
MCD0GHH*H)#H3540U44/4$EV(.J*>:"`:$Y2ZR%?8"\8-5]MW#L7C9D)FW&1K
MAX-OD(Z;<&<^_:[+EIMW7&XZE(P;&Q6A`Z..1">B@J@D.A-51#510]0278@Z
MHIYH(!H3E+K(%Y=FW.PV-^9-U%\XW'"=>>=0/&PF='U)=/KNB(-OD`Z;<(F6
M?M5E"RV]L3]_0,&A:`WU2'0@.A*=B`JBDNA,5!'51`U12W0AZHAZHH%H3%#B
M8I<OJYX?*]?P=.WD4%:3R.^QABA_R7`@.A*=B`JBDNA,5!'51`U12W0AZHAZ
MHH%H3%"J9]G::<>UDT//UR1"4+!C4T53[,BH$U%!5!*=B2JBFJ@A:HDN1!U1
M3S00C0E*[<RMG;[M)ZT[+IX<THDPOH3+[[^&J*".BR=&G8@*HI+H3%01U40-
M44MT(>J(>J*!:$Q0JF[9XFG'Q9-#T77*(]&!Z$AT(BJ(2J(S4454$S5$+=&%
MJ"/JB0:B,4&IBWRI](5S$)='.XN^=`Z:HL)4`3J&7#[J1%00E41GHHJH)FJ(
M6J(+44?4$PU$8X)2/<M6ASNN#AU*IHJ-BM"!44>B$U%!5!*=B2JBFJ@A:HDN
M1!U13S00C0E*79C%V]??H]BYM5[TCD6'TK/**G]4(43Y27`@.A*=B`JBDNA,
M5!'51`U12W0AZHAZHH%H3%"J9]F">,<%L4/1O'@D.A`=B4Y$!5%)=":JB&JB
MAJ@ENA!U1#W10#0F*'4QMR`V=?"%[U/<<7GL4#:'LA+<8X@*<\CFBNP>&74B
M*HA*HC-11503-40MT86H(^J)!J(Q0:FW9=6!':L##D5[^9'H0'0D.A$51"71
MF:@BJHD:HI;H0M01]40#T9B@Q(5Y$V]RNC%%I6];X%Q3I94#A[)IE%4D'T/4
M-(V(CD0GHH*H)#H3540U44/4$EV(.J*>:"`:$Y2J6U8Y,"_US7X%Y%"J)Y3T
M[,NP0E"P8U-%T^_(J!-10502G8DJHIJH(6J)+D0=44\T$(T)2NWDE8/GESQ[
M5@<<2NVL\D<60E30P^H`HTY$!5%)=":JB&JBAJ@ENA!U1#W10#0F*-6SK#JP
M9W7`H50/)H]M%\V40VCGA1V)3D0%44ET)JJ(:J*&J"6Z$'5$/=%`-"8HM6,6
M[5^_"-K;-7[\H)9#9GZ&NZ.K_+F$$.5='(B.1">B@J@D.A-51#510]0278@Z
MHIYH(!H3E.I95B\P-ZCR,X\K#H1?PCVZJ.C'<0>B(]&)J"`JB<Y$%5%-U!"U
M1!>BCJ@G&HC&!*4NEM4+]JP7.*0[2'X2/#J4N+`-S7VF:$*%QPWL^TF9ZT14
M,'T9HN+TX:[T-?TY1/FO6A'53-^$J#A]=K1N0Y1/?R'JF+X/45'Z=7:=.X0H
MGWY,4.IU6:%AST*#0XE7&Y5XM2B*.K+AB:AP*,I5,NI,5!'5S-6$J&B7KK*;
MCFV(\KOT0M0Q?1^BHO3K[.)J"%$^_9B@U%A>COC"%1^K#GN+(A>/#D5[^<"H
M(]&)J&"NDE%GHHJH9JXF1$6[=)7=S6I#E-^E%Z*.Z7M&#41C@E(]RZH.>U8=
M'$KTV*A$CT51U)$-3T2%0U&NDE%GHHJH9JXF1$5ZUEE9N`U100\VJ&/ZG@T'
MHC%!B9[[N4+$ZN[Z=,OG7]Z]_?N/'W3>T>7<S*S:Z,^:7T\0/URSI#4(AR(?
MCPY%>_K@D%YWY[?[2'0B*IBK9-29J"*JF:L)4;&UK!#9ABC_[2]$'=/WC!J(
MQ@2EUDPEX.LOU.]MX2"^4'?(O(`]7%>L\POU$.4W\.!1^'7LT:.U_3/WMW?[
MW3H[QY]\3&A6>!3^>E'ID0;E]*W6N^Q;G5V4'N`U3TS=WFRRZY4JI/%?N_8H
M=-9X%+Y2FV;>WV1'T0N;=!Z%Q+U'SV[%X*/<7MO>;W;YZW]''W/]BND(6%;G
MN&>=PR'S\]!I7V_7V97EHXO2*ZS]KCQX%.Y]'7VNU=7(:K_9K._R7^F>V*[P
M*&0O/=(*?OI:,T/`;H\>QKT^HWNSQA"P`7IKNO_>M<\<.FL\"E&M0\KL&UX8
MU7D4HGJ/0JZ!N<8D*C6ZK#1RS]*(0^:G/M.NV^9[YM%%:>;[#3QX%&;"T2'S
MD'R4"[/:?@GS)S6FJ'7^EWL*GS[T6'J4-.1$M^G#1,^N0ZN0QF]+[5'HK/$H
M;%[KD#+[AA=&=1Z%7+U'(=?`7&,2E5I>5F*Y9XG%H6S>9GOFT44E\];FBJ;$
MT4699]J#OWV6Z^1SA9%=>!3&?^E1B#J']'XO5XRJ/0JY&H]"KI:Y+HSJ/`JY
M>H]"KH&YQB0J-9977:[/C2^^0F(QYMZB;+IFIYQ'%Y5,5]<P#-ZCBS(/F4\B
MMYOL*O/D<R6SCM/5IH]Z+&<;<KK:AM-TS2\GJI#&CX?:HS#%&H_"%&L=2J:K
M^Y8AJO,-0Z[>HQ`U,->81*7REY5Y[EGF<<C\#8C(3'8E^1BB_)XY>!3&[=$A
MO9OF>M9;KQXVV_R],2>V*SP*LZ+T2$?8Z6O-G&9=]<F?9G?92KT*:?SWKCT*
MG34>A4UI'7(G\.U-=LRYL$GG44C<>_3L5@PNRN^V_<-^]9"_J7<,J;0EZ1A8
M5A*Z9TG(H6RFXU++-HSFW<$UU/G5[]ZC1_:R<;VZ-?]+?S1P\C&A6>%1F!NE
M1\G1@)/:%:I<?S?[K+Q6A33^.]8>A<X:C\)7:AU*)K7;!2&J\PU#KMZC$#4P
MUYA$I4*758SN63%R*#L'9]>@CRXJ.0?;7,DYV%6?X@/$FN=@-"R8OO0H3+2S
M0]'U;,6HVJ,PMQJ/0JZ6N2Z,ZCP*N7J/0JZ!N<8D*C5F:B$+UKNV=)*L=RW*
MIF!VU'F\MU')%'0H#+:CB]+`C8Z=-(:&!=.7'H7TYY#>3ZB*4;5'85XT'H5<
M+7-=&-5Y%'+U'H5<`W.-251B[$%'E<38-UTU7;.D=26'LJF77S6YJ'CJ>13N
M?1U]+LVM<!*$2-\P#-["HS#$2X]"U-FA>.HQJO8HY&H\"KE:YKHPJO,HY.H]
M"KD&YAJ3J%3DLE+3`TM-#FE2A;V\W62GD<<0Y4?]P:,P!H\>V;/1:KN>NP+R
M0:%=X5$8X:5'SY_^7)2[IEW=[+.15H4T_GO7'H7.&H_"5VK3S!O4FMBD\R@D
M[CUZ=BL&'V5WV_;^8;/>[[/%_.B#KM\Q'0.FF/+UA]\'6WN)#[\.9;,VOP)R
M4<FLM;GB$Z:+^L*BU><*X[[P*,R.TJ,0=0[IO="*4;5'(5?C4<C5,M>%49U'
M(5?O4<@U,->81*7&3.5D@3%;:$F,692=,/-+G`<;%9\P/0I#_>A0<L+<;K*U
MQ"DT#,<)%I-\5)@#I4?/SH%S^!*V:IP-OBID\=YKCT)?C4=AZ]J0V#>\,*KS
M*.3J/0JY!N8:DZA4LBGH+)!LPK.3J479M,ROBAYL5#(M'0KC\^BBOC0MT;!@
M^M*CD/X<TON]7#&J]BA,I<:CD*MEK@NC.H]"KMZCD&M@KC&)2HV9HD5L[-NN
MBFSI(YFM%F6S-3M7/3ZXFDD8@P>']#Y5OUN/#B6U)"Y(?*XP>`N/0OK2HQ!U
M]NE#CQ6C:H]"KL:CD*MEK@NC.H]"KMZCD&M@KC&)2D7F=:%O$\ERT8-%FFOA
M(+C=9'?`'D.4MW9P2&^8].CHT<Z6BS8/Z_W#*CN"GWRJ,*0+C\+`+SW2X3Y<
M*:-6X*)T"+!W9>ZSB[PJI/%?LO8H=-9X%+Y2FV;.SAP7-N@\"FE[CY[=AL%%
MN6+19K=;;^[WV;EB#*FT'>G`,!6,?(:;/X5XO9G^7Q]^_[.;Z?HSI/YN^H.M
M@B3SVZ)T?F^RK_7H&B9G8]LPKB#Y*'<-O;G3W=I<Y<D'A0E2>!2F4>G1%\Z\
M]CM,U]#WF;\JI`G#PGWOT%G#J-8AEWG-:VAL?>>SA,2]1\]NQ>"C[&[;W-T]
M/-QML\K;Z(.NNRT=&*:`$P^,F0<JXC%@ZSW)&+!(CT^$.8B7NC],07Y7'HB.
M1">B@J@D.A-51#510]0278@ZHIYH(!H3E-HQQ9H%=FQM)[%C4?I<>OYDPN/#
M%!7T`!T9=2(JB$JB,U%%5!,U1"W1A:@CZHD&HC%!B1Y5N1?YL?'IM:YGT8\"
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M;EU86.C*Z=34;Z><6O;%>8JF$H@N)!!Q$FB9?O5NCJS;]2I_`$GRT$RFD%ZF
M$"=3EKGJ0K8C9"ANDNG(JS7/K[U6MZS+>*:30JPCJZ9HBKGZ37(Z="R98I:Y
ME6NVC-1UR=0DZFUF:J$WF9F:>ODR\UQOLC(U>:8WB4)O$C4U];U)U'.]2=34
M9+ZWS)U9PB^92G;)GTXER]*U&:]DIBB_*9I)8)I)8/(%IFD#)CE@D@,F(V#:
M_6#:_6#:_6#:YV!:"X!I+0"FM0#8F+),V+)"Q^J6E0[/4F&H=41AD3%7``EO
M6)4Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!F+66;,5""63#%;
ML4BGV%3%B"8UI]@4%0D#DS`P"0.3,#`)`Y,P,`D#DS`P"0.3,#`)`Y,P,`D#
MDS`P"8M9*FR55T/,<GM]=Z,SX,)W,*VNJ;)"B6/9[,,*(80%F61'WT54=SG-
ML&*&E3/L/,.J&5;/L&:&M3/L,L.Z&=;/L&&&C2G+9)IE_(+9M[++_F3V.1;M
MXL<5V6&&28_-%[65'C#I`9,>,.D!DQXPZ0&3'C#I`9,>,.D!DQZP889)3QR7
MZ3&K\25Z[.H]U6.9^6O6T:5\ME"2L2DLFE!@,@8F8V`R!B9C8#(&)F-@,@8F
M8V`R!B9C8#(&)F-@,@8F8S'+C)GE]Q)C=KF>&K,LFA32`Z8)!28]8-(#)CU@
MT@,F/6#2`R8]8-(#)CU@T@,F/6#2`R8]8-(3LTR/64G'>LS)Z]M>?;9:V56Y
M>O,SYD?/I"Z:;'?9"DLV;=/(L&R"R2:8;(+))IAL@LDFF&R"R2:8;(+))IAL
M@LDFF&R"R2:8;,8LLVE6W;'-+RRM5W:5GAJS+%(A/6#2`R8]8-(#)CU@T@,F
M/6#2`R8]8-(#)CU@T@,F/6#2`R8]8-(3LTR/66O'>OX;5XIVV9Z:LRR;:UE!
M5#*G,#]-)1-,,L$D$TPRP2033#+!)!-,,L$D$TPRP2033#+!)!-,,L$D,V:9
M3+,0CV5^::[9A7MJ#(MYZ0&3'C#I`9,>,.D!DQXPZ0&3'C#I`9,>,.D!DQXP
MZ0&3'C#I`9.>F&5ZS`I[B1Z[(D_U3*OT^.2%0OYJ"HLF%)B,@<D8F(R!R1B8
MC(')&)B,@<D8F(R!R1B8C(')&)B,@<E8S#)C9HF]Q)A=DJ?&IF5Z9`R%C]44
M%0D#DS`P"0.3,#`)`Y,P,`D#DS`P"0.3,#`)`Y,P,`D#DS`P"8M9*LQ4WQ-A
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M"0]-<8TYOTUR.C7U3$XMRV9,)DM.T50"T84$(DX"Y[K8994`"413V4(7LH4X
MV?J:+F0K;IJI,6OK)6KL6CQ58YGI)0S\;38_I,:%Q8\*>)9,-QOG;K1G^TM*
MYGKCO6D?%GJ3I:FI'PBR]%QOLC,UB;8M[TW"7%CH3<*FIKXW"7NN-XF:FLSW
MEKDS"^\E[NQ"/74W+=ZC'K.#C-1-47Y3-*O`-*O`Y`M,4PA,<L`D!TQ&P+3[
MP;3[P;3[P;3/P;H9UL^P88:-*<N$F<5U+.S;RR%KNTY/74YK]\CE#N40US2J
M=TGFU-0+EDPPR0233##)!)-,,,D$DTPPR0233##)!)-,,,D$DTPPR8Q9)M,L
MQ6.97RB'F%_AX.)S6LY'QCC[IB@O1\+`)`Q,PL`D#$S"P"0,3,+`)`Q,PL`D
M#$S"P"0,3,+`)`Q,PF*6"3,K\27"[,H]G6+3:CX2MLO6,3I>3F&1,3`9`Y,Q
M,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y.QF&7&S%)\B3&[=$^-Q<MY
M^[=-5EJ!FJF8'@'!I`=,>L"D!TQZP*0'3'K`I`=,>L"D!TQZP*0'3'K`I`=,
M>F*6ZMGDY9`O'`&O\5G=P['X/;UZ;M/J"96)@V>*BR=>MJX^1F%^XIUF6.%9
M]"[@TK.TB_P'J^<HS'=1S;#:LZB+QK.LB^R`WT9AOHO+#.L\B[KH/4N[P$OI
MHS#?Q9BR3+59ZB^8B1M;&DAFHF/Z9K[+QY5CT19(M2LKA#AY!9-7,'FU+,HG
MKXB31#!)!)-$Y)/$*2X>BEFQ11*G,+^YD@@FB>A"$J>XJ`N\ISX*\UU(XM14
M+)-H%NU+)-I%?BK1U0>"'$FT+-KIDH@X20231#!)1#Y)1)PD@DDBF"0BGR1.
M<=$>QFOKHS"_AR5Q:NJ9)*(+243<,,-D+([+C)F%^Q)C=J&?&K,LG7:6I<80
M)V-@,@8F8\@G8XB3,3`9`Y,QY).Q*2XRAC?91V'>CHQ-33V3,70A8XB3,3`9
MBUEFS*S@8V/?=HM@8PL!J4A7.TBFGF6I2,MTXO9;*Y%@$@DFD<@GD8B32#")
M!)-(Y)/(*2X6F2U3=?R<POQF2"281*(+B42<1())9,PRD:8L$(O\TL6-+2.D
MQBPS!?!0&,M?2ZOCYQ3FMU3'3\?B>PN>N3<GW-X]W*[RY;VTHJ6TH@=IG>+"
ME^,K6'V8_Z7(37Y!).]3(O_UY1T=RCOB)-DREWU_DQ4-91R-9!S)97R*>V9K
M-`A<F-N%V]N=WCV157TU+*9DVJ)L6)B"P))A80L(Z;"P+'WMT0ZE;/-8BREE
MAYJBAH5C<;W4,??*D#O=EM';[[-7LLXTU*A`!QH54P?/[$?-?QOF:K3K_/VY
M&A13GFA0H#\-"L1I4$S)?5N-`\1I'""?Q@'B)!WYI#B.RQ2;$L(2Q;;DD"JV
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M_BG^7WJZKZ*TOOMZ8J'[9F+A:[:>N;[V-]F0O?B`:-NZB87D_<2>W;;!A[D=
MNM[=WV[UG&.Z1:./LIUF@\24/.)CPA<NU=43[L0XEDY^7I.YL&3R>Q:?L#VS
MUYGK._UUI?R%MQHC]GOHD08O26/$L7`NU1B9XIX?(S;,74MO;O(AKE$Q)?(=
M:E2@0XT*Q&E43-E]6PT$Q&D@()\&`N)D'?GD.([+')LBR1+'MJB2'.!U>#;>
MLY-W=A6E`X$-2T[>GH5YH@.!C4M.WML=CP0N73(+\%=/?+:H5XF?FOI]?O9,
MO7HFKXB35\="G+PB3EXMB_+)*^+D%?GD%7'RBGSR&L=E7DTI98E7$Y\?X"U+
MYRXORK8V+)V[CH4I**^691?;V76`9N_4-)J5,U[1J[Q.3;U#>9UZ]4Q>$2>O
MR">OB)-7Y)-7Q,DK\LDKXN05^>0UCLN\FLI*[/7;KM/,7(5NR[)IG/G1-+9A
MT832^=RQ<&=)NETZ77-.9^#M'@MHWU2;/(7-K*U\6)AVTNUZ#0</Z;8LFG;2
MC3CI=BSDDV[$23?R23?BI!OYI!MQTHU\TAW'9;I-Q236_:_5]LW;US_]^_#T
MZ>W3;]ICMS=ZT,:_8G2E]\32JZNZZ"0P[6&^J-\W3:=Q7+"Q?Y-ZBG.EGKN=
M7CJ?/P.J68R6.@=/7\1/13F<XL*7F[M.LV'N'+RZV6:WA21Y2N232S(ZE&3$
M27*2?7^3/7<@XV@DXT@NXU/<,UNC0>#"["Z\N[_?W^MN!:[,IF3:HFQ8F"K+
MDF%AJS+I6=LR,_C"L)BY,G,%G3!1--T="Q-/T]VELW_$:JW75/$/&/F@Z`I7
MHP(=:%1,'83O-C<J;)@F^_7-1#?[;/&A43$EBD8%.M2H0)Q&Q93=M]5`0)P&
M`O)I("!.UI%/4S^.RQR;BLL2Q[9"DSJV+#N#\\K,%7?"Q;$<.Y:<P2U+S^#Y
M3M?<GYI&]F;.X.A5XJ>F?I_KD#[UZIF\(DZS'?GD%7'RBGSRBCAY13YY19R\
M(I^\QG&95U.$6>+5%FU2KY:E<W?FRLR&I:=JQY*Y:YGF41"VW65G?GF=FH:P
MN5,U>I77J:EW**]3KY[)*^+D%?GD%7'RBGSRBCAY13YY19R\(I^\QG&95U-M
MB;U^XY69+=JDNBW+IG'F1U=FKMZ33&/7--2M=*BV+*V@Y7\`3KI=NB]4T'Q8
MZ%6ZIZ9>K72[7L,WD6[$2;=C(9]T(TZZD4^Z$2?=R"?=B)-NY)/N."[5?9=7
MT+Y-]S5-MNYR3-,VS#/^L8!5"/,[^>"9+C`\.T[,_;V`W?Y!9^?L":^3CTI.
MS>RAC.+"EYLY-;NF[M2\NLDK>564R'_5>F+A8J.96#A@M9ZY[#N\(-X'1%O3
M32PD[R>6K#[RM^8//DQUE.N%QN;A8;=991<;HX^:*Z7=F0H,#@X[\VJGY"\(
M7/_/CQ]T0:8&_^*U_B9<ZE]3YB-G*O0$.5O\/8&5:YI<ZCNFDH+7H9%CTVDY
M:C9;EZBZJ9L_E*N1,W7J6Q83"Y-8(V>*"U]N;N38L.E2/_]1B$;.E,AWJ)'C
M6.A0(P=Q&CE)=KU;*[WJOOB`J'BHD8/D&CE3\F>V1B/'A=E+_>WM?GW[D%<L
M-7*F9-JB[#AC:CSQR)D9%?$*T%R<Y2M[QW1OUN^PQQ69CAZV;12G,0`FXV`R
M#B;C8.<9)J&(DU`P"0634#`Y!)-#,#D$DS`PZ8E9IL>4:I;HL:6=Y/1^9YFY
M=1Y68OOL""UC4YBW*&-@,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#(&)F-@
M,@8F8S'+C)EJRQ)C)CX_SEJ6&4L/)1(V147"P"0,3,+`)`Q,PL`D#$S"P"0,
M3,+`)`Q,PL`D#$S"P"0,3,)BE@DS=9`EPFS=))UBEF7"LB*2C$UAD3$P&0.3
M,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3L9AEQDQ58XDQ6P5)C5D6
MG8ND!TQ'0##I`9,>,.D!DQXPZ0&3'C#I`9,>,.D!DQXPZ0&3'C#I`9.>F&5Z
M3'$BUF.6+M_VGM$[6^=(S5F6S;7L0DLRI[!HKH%))IAD@DDFF&2"22:89())
M)IAD@DDFF&2"22:89()))IADQBR3:2H2L<PO71_:"D9JS++,&$YG4U0D#$S"
MP"0,3,+`)`Q,PL`D#$S"P"0,3,+`)`Q,PL`D#$S"P"0L9IDP4U.(A?TW9I\M
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MGQTG#]ID_:F_F6_PH`W67YF;^60G+;M9*SOMW-WLOMVIG]UL/SOUHS^#,M//
M7KMU/[M7]]JI^]E]NE.;W6R;G=KLYMMH7^]F]_5.^WHWNZ]WVM>[V7V]T[[>
MS>[K.WT#%:5FMO1.WV#^6'2G;S!_)+I3/_/'FCM9F#^:W&E?SQ\/M\IF"]SY
M*-W*MNZHSGSKK?K1/;FY3V1;=W7F/M$WT`V`F4_N9$X%[IE/-FJCQVYG/MFJ
MC9XVG?M$^UJ5Y;E/M*]M019;JGVMD\Q<&]G6?<&93S9JHU_8S7VB-OK)UMPG
MVM?ZU<[<)]K7]NHA_VX;[6O]7&"NC?:UGD&?^62M-O-'^;7:S!_CU]K7\T?X
MC?:U?NP^T\]&^UJ_Y)W[1/M:OQB=^62M-K94GF_I6FWTQJZY-MK7]CX`VFA?
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M#H(P%$6WP@I$9@P,@V+$2"UN`6.IQ,\CI8G;][9$)]P9S6D:3OO2M#"X;"^X
ME"B%DLTP,KH*S`;"4-=5@C"@`L:4(=@G5CIE"EFWJ`2$#J_'U#`VU%C#V%!C
M#6-#C36,#376,#;4N,,;=)0H$$5)#5)3L@<Y4-*`-)0<04Z4M"#M0O+_-C]7
MNZEW]MQ[-[[G[&D'7'VW&QS>,S^Z^%5C:029TN_LJX0@K_1XM_W-^M@!G0>1
M\&M@8?*/^$>Z7E=?`0```/__`P!02P,$%``&``@````A`&0O6L=G"P``S3@`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULK)O;<N)($H;O-V+?@>!^
M#!(G0]B>:-#Y%!L;L[O7-)9MH@UR`#WN?OO)4E6J5/7+&'KVIH4_966J\E"J
M5$MWO__8O?;^+`_';;6_[SLWPWZOW&^JQ^W^^;[_GS^"WV[[O>-IO7]<OU;[
M\K[_LSSV?W_XYS_NWJO#M^-+69YZI&%_O.^_G$YOB\'@N'DI=^OC3?56[NG,
M4W78K4_TY^%Y<'P[E.O'>M#N=>`.A]/!;KW=]Z6&Q>$2'=73TW93>M7F^Z[<
MGZ220_FZ/M'U'U^V;T?6MMM<HFZW/GS[_O;;IMJ]D8JOV]?MZ6>MM-_;;1;Q
M\[XZK+^^TKQ_../UAG77?X#ZW79SJ([5T^F&U`WDA>*<YX/Y@#0]W#UN:0;"
M[;U#^73?_^(LBM&H/WBXJQWTWVWY?FS][AU?JO?PL'W,MON2O$UQ$A'X6E7?
MA&C\*!`-'L#HH([`OPZ]Q_)I_?WU]._J/2JWSR\G"O>$9B0FMGC\Z97'#7F4
MU-RX$Z%I4[W2!="_O=U6I`9Y9/VC/KYO'T\O]_W1\&;L3F:W#LGWOI;'4[`5
M.ON]S??CJ=K]3THY2I?4XBHM=&0MTYO);#BJE9P9.%(#Z:@&NNZ-,QY.A?$S
MX\9J'!W5N''KJL\,)+7U?.FH#>KYGADY52/IJ$;.+IKB3(VCH[9XP12I0NLK
MI>-U4YRK@734!B^:HD/I)[-!Y*$,]&63=)H\HA_:Z@73=#AWQ(_K)NIP]H@?
M;+2=O6>BZ7`&B1^73'4@"Z>N0V]]6C_<':KW'BUN-.'CVUHLE<Y"*.,*E,:;
MFORH)*D6A98O0LU]GY*$BNU(Z\B?#^/9[&[P)]7^1LDL4<8Q)58L(0I=J/5L
MX-L@L$%H@\@&L0T2&Z0VR&R0VZ!H@0&YMO$OI<7_P[]"C?`O>V;)0#O<M9S)
M$CS$LX%O@\`&H0TB&\0V2&R0VB"S06Z#H@4,9U*A&,[LODUP3@KI^SXM0*V<
MO#6=M)0R(WD_$"FW`N(!\8$$0$(@$9`82`(D!9(!R8$4;6*XD$K\"A<*:5H9
M2%O+AW9=2Z$1!:TE-#<=O6J$FG0$X@,)@(1`(B`QD`1("B0#D@,IVL1P*]V0
MKW"KD*[=RLY82C*:-@6^`N(!\8$$0$(@$9`82`(D!9(!R8$4;6(XC/8A5SA,
M2)L.DX0<UDJZVZ&5=(T0^]D#X@,)@(1`(B`QD`1("B0#D@,IVL3P(=UNK_"A
MD#9]*$D[Z8!X0'P@`9`02`0D!I(`28%D0'(@19L8#A-M8WNS<_[^(:1-ATEB
M)9V]B6F$FJ0#X@,)@(1`(B`QD`1("B0#D@,IVL3P(>W+K_"AD#9]*,E(=G/U
M'1>(!\0'$@`)@41`8B`)D!1(!B0'4K2)X3#1EESAL5K<=)E"5M[9^STMU20>
M(A]1@"A$%"&*$26(4D09HAQ182#3I6*W?7DAB_;.RD*%3)=:&YN5%M(>E:I:
M:Z:/4@&B$%&$*$:4($H198AR1(6!3(^*+7?;H[(/O)G1#?STLMU\6U:TN:/)
M=RR9(^KW5!<H-^ZT7V2'+45?+'P_;]"*D5X"/(7<>=TZND-G;-[)?2W`F@-$
M(6J.M)1H2DGSR-0<:P'6G"!*47.FI91FJR!S+<":"P.9`1`[]G8`.AQ-3Y4:
M3\L-ON%IB5Q:;O0^_-::[DKLY2D>KNYX/$;UH[HZD+Y"$[>.Q\B*1J!.SXPM
M_\C:\H>L5YN*&&E3L65J8H8GN<A4RGJUJ8R1-I6?-U5\9LJ,EV@%KHB7[!S(
M!.?"4CQM$9&@@+3B9;EZQ5+C9J#'2.OR%9J,ZWA-;JPV-]!#6K8P8.J*M*U(
M#^3KCC^QE:CS,V->MJV4%6M;&2,]K]RV965'\9DM,V2B&;DB9+)W,4(FD55B
MUD6MQ`-LN\2:@>Q&7TE1B;5"<CLUTS]04F:EW5HWJA`M1HQT^L?=%JU42=@B
MY4(K+2V+*:MO%QS,,>^V:*T3Q6<6S2"*;J@=Q%^[4<F>RHBM1&8YSNV.TE%2
M.FT]1OIVYBLTOJW+T7%NK!XAX#%G:R1D*6TL8J2-Q=I8*V!SRV*BI.K[>?.(
MUDZDE-5KBQDC;3'OMFC=_HK/+)IA%3W;WP^K[/R,L$IDENP<[HI*2J>SYRBD
MG[GZ"DW;)>O.K`(*E)19LO;Z%[)Z;3%BI"W&%UE,+K*8LGIM,6.D+>8762P^
MLVC&5O22YV+[1_7VT=ZRO>61+:D17-6EZMQ<.8`\1#ZB`%&(*$(4(TH0I8@R
M1#FBPD"F7T7+V?;K)UM&V:$:_E--*RUJ>JV?PQ:DD>*;ET?;>7&+,]H@0`%*
MA8@B1#&B!%&**$.4(RH,9+A4+!-7N+06-WMUA<XWEEJH\2@B'U&`*$04(8H1
M)8A21!FB'%%A(-.C=JO^2_=K:E=$OK5SEU&KL62DEP-/H8\;2RW`H0@0A:@Y
MTE(?-)9:@#4GB%+4G&FI#QI++<":"P.9`1`-^.6KA"O$+4]+-*$8M%8)>]?+
M`]O.EP.G>@_J*ZD6"A"%J"M"J1A1@BA%71E*Y8@*`YDN%3WT%2X5XI9+)1K3
MFMERJ;7Y7XF]*`VDV'*</4;M)M^=6BNVSU*R?1^/AG-G/+*V\`$+Z>B$C+3!
MB-%9@S%+28,._=__:&(;3%A(&TP9:8,9H[,&<Y:2!B=S=W@[M;:\!<O4]LP`
MBD:W'<!?6Y1DNVPL2A*-C>9I;GE^Y4HI.NBX*J2KQU=2JHFP&I&`=>AF.62D
MU4:,M-J8T50^*AC/)H[EN(1%M.Z4D=:=,=*Z<T92MW,['8VMG"Y8I-9M!D7T
MC^V@G-_.B%>L[*J2R*HJ:W^^4@.-JH+6U6>I\R4$XT(>IS,Z8J3S/F:DZF4R
M<IWAV+K0A(7TN)21UIXQTE(Y(ZE]Z@QG[M#*P8)E.HI#M+CM./Q:<<A&V2@.
MB:SBL)X&K%PI17FBBT,AG6F^DJ+BT`OH9`A%H@;2.MHLLZ[=](9H,6*D+<;=
M%J%T+K&8LGH]QXR1MIAW6[3;;![XT1S-&A--[=^/K6R-C=BJ;KF]:D^&=IOM
M*BF=OAXC.J-#A#<T.?"3SIMUZ5((&6F+$:.S%F,E==YBPKJTQ921MI@Q.FLQ
MO\ABP;HZZE9TON=B>UF;[<H&V@BNZJE;;Z<HJ58#Z"'R$06(0D01HAA1@BA%
ME"'*$14&,FM&-+:V7]W)#:W]5[XD25T(W+*:KEFG_V1H[>=6:J#A[68@+Y,^
M2@6(0D01HAA1@BA%E"'*$14&,KP]HA7$\/;Y74`M;NZM%6HY:X7(0^0C"A"%
MB")$,:($48HH0Y0C*@QD^L_NMS_Q'S;6]#*DR-*QN93;[9Z6XOSS$/F(`D0A
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MR.`9SW47XBD5GJ&G4@OQS`G/T#,F\F37&?JDZDL77PKS'9J60E$7%R[LX%_&
MBR^4)GA)R_&"WE_NX),%O::+G%[*68B7;/`,O52S$"_)X!EZ*89FT76&GL22
M$[LF2$]2R8E=9^A)*,V]Z\S2H;C3_XS@%2P=BCP]X.\XXU+HZ4$UG1DT64<?
MD[VMG\M\?7C>[H^]U_*)BF98O_9TD)^CR3].ZK^HOE8G^HJ,-ASTI0Q]-EC2
M%P-#L1-\JJH3_R$,-!\B/OP%``#__P,`4$L#!!0`!@`(````(0#J6T>"YP,`
M`!,/```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)1776_B.!1]'VG_
M0Y3W(;$A4!`P:K?JSDBSTFJU'\]I8L!J$D>V*>V_GWOM)(WS4<@+D,OU.3[7
MUR?V]MM;GGFO3"HNBIU/9J'OL2(1*2^..__??YZ^WOF>TG&1QIDHV,Y_9\K_
MMO_MR_8BY(LZ,:8]0"C4SC]I76Z"0"4GEL=J)DI6P#\'(?-8PZ,\!JJ4+$[-
MH#P+:!@N@SSFA6\1-O(6#'$X\(0]BN2<LT);$,FR6,/\U8F7JD;+DUO@\EB^
MG,NOB<A+@'CF&=?O!M3W\F3SXU@(&3]GH/N-+.*DQC8//?B<)U(H<=`S@`OL
M1/N:U\$Z`*3]-N6@`,ON27;8^?=D\T#O_&"_-07ZC[.+:OWVU$E<_I`\_<D+
M!M6&=<(5>!;B!5-_I!B"P4%O])-9@;^DE[)#?,[TW^+RG?'C2<-R1Z`(A6W2
M]T>F$J@HP,QHA$B)R&`"\.GE'%L#*A*_F>\+3_5IY\\7,WH7D6@)^=XS4_J)
M(Z;O)6>E1?Z_S2(5ED6A%0I\URC+6;0*Y^0Z2&!G9`0^QCK>;Z6X>-`U0*G*
M&'N0;`!X6!%(P=Q[3-[Y*]^#N2I8AM=]%*ZVP2N4+JER'FP.?#8YI,D(@+1A
M!K;;F3$9F;&V.)4'&VC3T&&:^10:3-[YL&V;R4?A78-KF6W.W#1,6\]B"A$F
M0\D!J\74+665!.W:2EHWTW&J"6UT>S4QV;`WY:PBP-A0+3ZFXS`MIS!ALLM4
M16#]&J:(A,.BH--N%X7)+E45,;O(D8"^W&IZLYU)-(,B?-[_.,ZEJ"+M/HS(
M2,.O7=;/J3#9I:HBBU[C$6B0MIS/@4VVBUR'W#49V4\$-WBK>%?8,+O#5H7Z
MRT)P4[>@K<W.9ZNK"V-&=F@JAW"79C[<:+@1V\Q71%D+@$'-_C$`,($!41U?
MF""J,8D/FBKDBEJ,B,)-W2KG%5&5!;1%5:$!49-,@/1=H`ZY+1>-")GD`Z1O
M!'5H0,B`%:QA/UVI5=\(R*`3+$<$3;("TO>".M071">9@<EV]TT=<E=FY%U`
M<2_?W&(FN\,V:@9TP`QHN+C!#,S(#LV@&7R\V9VW`YUD!B:[PU;Y0WN7CKU-
MZ8`]K%9XC+S2@V9@AW?0'48.#,@P8>GZ[F``8`(#/3C)'6C?'>J0TX-TY)!`
M)[F#R>Z4;?2<`'<*IT;HW1&YI07[!F&P3+E:!Q_:/2K8*X@]H>=,'MGO+,N4
MEX@S7B\HG+F;:'/UN:?X'NK&%YM[>R4*FG_@2E+&1_9G+(^\4%[&#H`9&CG2
M7FKL@Q8E3!3N)4+#7<3\/,'ED\&Y.\1#TD$(73\`<]!<9_>_````__\#`%!+
M`P04``8`"````"$`I2ZGCED%``#,$P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6RLF-N.ZC84AN\K]1VBW&]"#@2(@*V!D)-:J:IZN,X$`]$0C)+,
M,//V7;;C$'NQ=X?NWDPF'RM_[-_+]HH77]^KD_%&ZJ:DYZ5IC\:F0<X%W97G
MP]+\\X_HR\PTFC8_[_(3/9.E^4$:\^OJYY\65UJ_-$="6@,4SLW2/+;M);"L
MICB2*F]&]$+.\,N>UE7>PFU]L)I+3?(=?Z@Z6<YX[%M57IY-H1#4G]&@^WU9
MD)`6KQ4YMT*D)J>\A?8WQ_+22+6J^(Q<E=<OKY<O!:TN(/%<GLKV@XN:1E4$
MZ>%,Z_SY!/U^M[V\D-K\!LE795'3AN[;$<A9HJ&XSW-K;H'2:K$KH0?,=J,F
M^Z7Y9`>9[9K6:L$-^JLDUV;PO]$<Z36NR]TOY9F`VS!.;`2>*7UAH>F.(7C8
M0D]'?`1^JXT=V>>OI_9W>DU(>3BV,-P3Z!'K6+#["$E3@*,@,W(F3*F@)V@`
M_#6JDJ4&.)*_\^NUW+7'I>GZH\ET[-H0;CR3IHU*)FD:Q6O3TNIO$61W4D+$
MZ43@*D6<D>=,IK-'5+Q.!:Z=BCV:32:>/YM^OBD0R?L#UTYD^K@(3`XN`M?_
MWI)Y)P+7AUMBB5'B@Q[F;;Y:U/1JP$R"<6@N.9N7=F!#LLCA%H/3)\"WQA\&
MGJD\,9FE.34-&-H&DO9MY<SMA?4&B59T,6L<HT5L9`3+*B8;ZF"K@T@'L0X2
M':0ZR`;``EMZ;R#[_@]OF`SS1O9J+<'`+-6JC8R0CX0ZV.H@TD&L@T0'J0ZR
M`5",<.\8X4*RW%\39$ZPIY8FI/P@)QRUHVL1XXK9SX9\@TB(R!:1")$8D021
M%)%L2!0+8`U1<N'[76?1,*-`;=!W+=O7(L@%TP=!KFK0I@_J4P&1+2(1(C$B
M"2(I(MF0*';`:OB`'2R:VR$[L1;$]?M)L4$D1&2+2(1(C$B"2(I(-B1*1_V'
M.LJBU8X*`AT=#K*G#7(?)/T)$=DB$B$2(Y(@DB*2#8G2=UC.'QAD%JWV79#A
M(",2(K)%)$(D1B1!)$4D&Q*EHZQVQ9O@B%4)[;$L7M849BCL$G<FO0N;G=@"
MF8C:_X[,;TG>$5$W\1U.$`?V]-LBX&NKY+8/DOD1(1(CDB"2(I(-B6()-.C'
M+6$BJB4=&5C2D8$E@L#^PLN(L:W-EFW_>^\&(C%23?J83E5;:-/^=ZF:#8GB
M#:N3%'/NY`44NS(Q>+AJ0X<<$+H-^WRB+0LRZK8[AA(I#_JZ0S+*X1;.YO/Q
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MVD>&=N*W/(L[\<'[DD^]+Y51W?NFD[$WT=8D=O3`6BZR7[@LCA+$5V5%Z@/9
MD-.I,0KZRHX)8%A6BQZ+,XRU'T#5`=-'Y],`-FG,PUD`.]4=/@\BOI5H.LD\
M@-4;Q\/9R1//*2U^S<Y4[L2OG0"^B;#.V@W@2P'S)R]X`H/P#VLO@%KZ#I\$
M4'H"M_H6P5G*)3^07_/Z4)X;XT3V8.*8S_-:G,:(FY9>P%PX4:$MG*+P?X]P
M:D;@&VH\@KS:4]K*&_:"_AQN]0\```#__P,`4$L#!!0`!@`(````(0"O^94]
M(P8``%P8```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*R9WV^C1A#'
MWROU?T"\GS%@$QO9/L7FMUJIJJ[M,\'81C'&`G))_OO.LCO`[KB^1->7X_SQ
MS"SSW=G=\6;U]:T\:]_SNBFJRUHW)U-=RR]9M2\NQ[7^U[?@RT+7FC:][--S
M=<G7^GO>Z%\WO_ZR>JWJY^:4YZT&$2[-6C^U[=4UC"8[Y67:3*IK?H%O#E5=
MIBU\K(]&<ZWS=-\YE6?#FDX=HTR+B\XCN/5'8E2'0Y'E7I6]E/FEY4'J_)RV
M\/[-J;@V&*W,/A*N3.OGE^N7K"JO$.*I.!?M>Q=4U\K,C8^7JDZ?SI#WFSE+
M,XS=?2#ARR*KJZ8ZM!,(9_`7I3DOC:4!D3:K?0$9,-FU.C^L]4?334Q'-S:K
M3J"_B_RU&?U?:T[5:U@7^]^*2PYJPSRQ&7BJJF=F&N\9`F>#>`?=#/Q1:_O\
MD+Z<VS^KUR@OCJ<6IGL.&;'$W/V[ES<9*`IA)M:<1<JJ,[P`_*N5!2L-4"1]
MZYZOQ;X]K77;F<P?IK8)YMI3WK1!P4+J6O;2M%7Y#S<R12@>Q!)!X'DCR!U'
M6SC"$QVMR8,Y7=H/,/H=QYEPA*=P'+WU'3^(VJ4+3^%GS8=T[S@ZPA&>PO%C
M?@_"#YZ?RQ`6:/>F\/Q4ADOA!T_,T/Y0AB;4'B\%5H1\FN_F:/!2ZBK32]MT
MLZJK5PV6.Q1+<TW9YF&Z+"K6))>WK]+_*E*H3A;ED859ZR`<U%\#*^O[QEI,
M5\9W6`V9L-E2&U.VV*$%*WT6UE.!KX)`!:$*(A7$*DA&P`!9>FU@B?P?VK`P
M3!O,:HM@))8B!%J@BZ<"7P6!"D(51"J(59",@"0$+'DBA`W%<GOCPII@7FL=
MUL2H)I09WW(;FV]1;,IWA'B$^(0$A(2$1(3$A"1C(DD`FY<DP?W4F36L*(@V
MREU=#]QH)B\:2ZF$WJ@O!4)\0@)"0D(B0F)"DC&1Y(`]^1-R,.M.#DQBR\D<
M:J@7:/:@I-[;H)='B$](0$A(2$1(3$@R)E+J<*I\(G5F+:?.B0V//G5K82NY
M]T9][H3XA`2$A(1$A,2$)&,BY0ZU^HG<F;6<.R=2[F3:>YL^=4)\0@)"0D(B
M0F)"DC&14F=-.#TH)ZSW:4]%]KRM8#KA)+FQ,=AP(/)CD@61%1%DV9\..T%X
M`]B=@IQ8T"4,%>,H&X7?&Z%L`2$A(1$A,2')F$B2P`O]O"0LB"R)("-)!!E)
MP@F<05VK,35G\OKQ^^][-0@)2=2HMQ%1E549]]]CU&1,)&U8+R6)<Z,NH&O'
MPNC,91D$LL9[I$DV"K0:3E`/T=C1<E2%T,KJ)#1MRYPK!U2`)MVOFJZ`0T3#
M<!&BN\/%:"6&FRYF\X4\9PF:\!]1XT;,9!W:3R^^+HJB,6_]+/F@5J3:"4=K
MUB]2#]%0DCXBIQ-T;B^6<SG!`"WL/DZ(:`@=(1I"QXAXZ)GC6$KH!"VZT'(A
MLJ9NK-T/"I'W@-"Z8(UO38Z@$!'M$`UEX"$:K'Q$8LX7SG2FO'>`)H-7B&B(
M'2$:K&)$(O9\/E671H(FG9>L"6OSQIKP7SV?W,Q9>Z=L70(I]:0DO4.K8=(]
M1,.D^P+-8/L=MOV%H]84?PEE1*65"C'\,&*$:!@QOCTB6:8_&%%6FG60/Z\T
M[T/A_;`"MZ9H36$#'JFSE-79"2MKJ"4/$1ST@R/='7EX:]$M9L>VELI9$&"<
MH29#1,-H$:*[H\5H)48S;9.(+M[G1BVS1O6>PM^J*VQZ-QN3\0'$^UU)8H[N
M=VOL_@H6`1CAU'@4^10%%(44113%%"42DNN/M;*J.NP:"6^L/G[#P9MB2:"^
M3QZ5TE(Y17=PHT@4(LBG5@%%(44113%%[%IS>`FN$+^FY)=!95X?\UU^/C=:
M5KVP*T@HR<VJQ_Q^=.NX\-,`YEGE#R[TS3>X.8<+U6Z#43U,"`7O1'V\A0L-
MYPV^=(.N(U0B14L7FC!J#W>YC]8-OF5WO+>XY<+U!XVSM5VX%*#\<>8^WDQ@
M.W/A9S-UV((6G11&GP'<[5[38_Y[6A^+2Z.=\P,(/^U.H9K?#O,/K5C!3U4+
MM[K=8C[!+7X.UR535LF'JFKQ`PQL]'\7V/P+``#__P,`4$L#!!0`!@`(````
M(0#!**$9.P8``(\8```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;*R9
M;X^;1A#&WU?J=T"\CS$8&QO9CL[FOUJIJM+V-8>QC<X8"[A<\NT[RS(LN^-<
MXJ9O0OQC]H%]9F"'O?7'+^5%^YS735%=-[HYF>I:?LVJ0W$];?2_/@4?EKK6
MM.GUD%ZJ:[[1O^:-_G'[ZR_KMZI^:<YYWFJ@<&TV^KEM;ZYA--DY+]-F4MWR
M*YPY5G69MO"S/AG-K<[30S>HO!C6=+HPRK2XZES!K7]$HSH>BRSWJNRUS*\M
M%ZGS2]K"_3?GXM:@6IG]B%R9UB^OMP]95=Y`XKFX%.W73E37RLR-3]>J3I\O
M,.\OIIUFJ-W](/)ED=554QW;"<@9_$;IG%?&R@"E[?I0P`R8[5J='S?ZD^DF
MIJ,;VW5GT-]%_M:,_J\UY^HMK(O#;\4U![<A3RP#SU7UPD+C`T,PV""C@RX#
M?]3:(3^FKY?VS^HMRHO3N85TSV%&;&+NX:N7-QDX"C(3:\Z4LNH"-P#_:F7!
M2@,<2;]TQ[?BT)XW^FPQF3O3F0GAVG/>M$'!)'4M>VW:JOR'!YF]%!>Q>A$X
MHHCUL(C=B\"Q%S$GR_G<7BR='[\3B.RF`\=>Q'E<!)Z-3@2.__U.5KT('!^^
M$X,GJ<NYE[;I=EU7;QH\2)"&YI:RQ])T3:@5S#;/S9#_;Z4?\LY4GIC,1G=T
M#3+;0,U^WEJ+Y=KX#'66]3$[&F/*$7N,8$7%9#T5^"H(5!"J(%)!K()D!`RP
M9?`&BN__\(;),&]P5CL$([,4(S`"AW@J\%40J"!40:2"6`7)"$A&S.X8,8-B
MN?]*P)I@HS8ZE/RH)E;R1'<\9L8??I;R/2$>(3XA`2$A(1$A,2')F$@6P#M$
MJH7WI\ZBX8D"M='<U>>!!]G20^-,98/V0]!0"H3XA`2$A(1$A,2$)&,BV0%O
MPP?L8-&='3B)'2<SOGYT>2?$(\0G)"`D)"0B)"8D&1-IHHN')LJBY8ER,H.#
MJ`1'?>\-0>B/1XA/2$!(2$A$2$Q(,B;2W*$R'T@RBY;GSHDT=]M1ZGN(&:9.
MB$](0$A(2$1(3$@R)M+463-+E\4)ZQO:<Y&]["I()ZP;=UX#,UC^^*+(1&1'
M>K(:UH)]3\2#X'%BP2HO*F9AR;;Y0Q#:%A`2$A(1$A.2C(ED"=S0SUO"1&1+
M>C*RI"<C2SB!%:=K+*:FK;@QG!_<("0DJM$0TZO.9-5X.(^JR9A(WK#.23+G
M3EU`]XN%T87+-O3(`B&1=D=)^QZCQ'KI(9(&+E2',,KJ++1-<ZF&!!C2?1UT
M!1PB$I>+$+U[N1BC^.7FL^E\M9#=33"$?XR,VRZ3]6/CA^\[9O+V#19;S-.N
M4]CHEK3^.DI^]QAE#P,]1$++[Y%M=L[-5O;241;R@(X*$0GM")'0CF5MTYX[
MEI+Q1!HEUQSKUAZPB3=WDDT<*36GE,[>[*-$$7B(1*GXB'C&K=7*7A&;ALMA
MHD(<);0C1$([1L2U36OAS)>*>((Q=\J)]70/^,1;0,DGCI1RFLL%O6?='KS;
M+)%R#Y%(N=^COIPL>[5:*MU`0$>%B(1VA$AHQ]_73J11<CFQ7N\!FWAK"'J8
MS)W)D5).RG._QRB1<@^12+F/J$_YDKVP9+\##!&C0D1".T(DHF)$?:G.EE-%
M.L&(.\7$&L6Q2_Q[^<'&@&VG*,M@CY0:4[LEC!)UX"$2RZ7?(QN6\M%:HCPQ
M`0X4&0P1"?D(D9"/$2WX<KR83NE;BT\09@/5(9<9ZS9_WD#>LTK5QY$-:_1H
MTLKWYM[D49:H$`\1]()BH+HZ^ABU["9MSF>./56R$V",J+40D;A>A.C=Z\48
MQ:]GV8[CF,H;)\&8.V7*&MOW7/Y4W;[5OX[[%-X?2S9S!%]NPBW2U,/V)*OO
MT>>=1Y%/44!12%%$44P1VR,5-\%KD.]Y\OVO,J]/^3Z_7!HMJU[9?B9,<[L>
M,-]LW2U<^#Z"(E:YX\+'PQUNP@FX,CWC+5WHK>_PE1MTS:]RA6CE0K])XV'[
M]\FZPW=L6_@>MUS8UZ$ZNYD+NQV4/]GNT]T)[&P7]@/H@-W<A<]GX,8P`]@.
MOJ6G_/>T/A771KOD1[!WVKTD:[ZAS'^T?14^5RUL!'<%>8:-_QSV@:83J+!C
M5;7X@UU@^%/"]E\```#__P,`4$L#!!0`!@`(````(0"M\3I9P`@``.\G```8
M````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULG%I=;^,Z#GU?8/]#D/<TEF7Y
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M[Q\B6:T_YAZ^!-/OM^M3V[4O_1U,M\1`0\[%LEC"3$\/FRTP,,L^.S4OC_/?
MQ;U.TOGRZ6%8H/]NF_?.^WW6O;7O?SMM-W]N#PVL-N3)9."Y;;\:Z!\;8P+G
M9>#]9<C`/T^S3?.R^K;K_]6^_[W9OK[UD&X%C`RQ^\W/NNG6L*(PS5VLS$SK
M=@<!P,_9?FM*`U9D]6/X?-]N^K?'N4SO5!9)`?#9<]/U7[9FROEL_:WKV_W_
M$"3L5#A);">!3SM)G-R))$IOF$/:.>#S(Q!Y<R")G00^/P(I)K,`OL-2P*=U
M%F)J!$M<UB%+]:I?/3V<VO<9E#XL7'=<F482]S"Q24\"GY?3`WDQ/K\;I\$5
MT!W4U/>G(GY8?H<R6%M(>0$B*:2Z`$DHI+X`412B+T#2,V0)+,]4(?L^U7&*
M!OPXAY^.8G:>=EB%$B%JX)_'15;0\<H?%TH4>9P("JE]R$*D12&C+*<833&9
M$+ER$$(02M,G:'(IH6''B1HG1M1-CT01DIZ)YGG$$E4A1`Y=9TJDY@;M&4C0
MT`JW!VV<6-!L]4N$8-"R4#Q@?SC+"Z$DSPTB'"7-7%22NUHDE*!_;J=DG"@E
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M()6%N,CKP*)]"TV&$3TO]"O)0(F$GV>Q%I';&FS("'+Q5`(MMIQR&4<IV\-J
M"W%.>M2)<C"*-YT#ZB/EP*J[%)Z(XBYJ+9:#C$22Y:QKZL!+CWM1%D;UIK-`
MC:0LF$:5@BMK92V6A4IE&KN:'HC6@9,>=:(<C.9Y'"8V`BHEX2)86*5YE(%M
MRQ5(92W(!8B$Z>`N>L2%\C`"Z/&XTA4HES1^5N"EX");G2WF6)]X>XO-`W?0
MGSK0V(WL>;%/S`&*)>7`A*P4GJ+:KD`+YF"1Y9*EK0Y<M+5<<J$\C`AZ/*[D
M`"73C]\[-`[!EH+K;&4M&$N:B53Q\W8=..E1)TK!2.!T"BB8A$+0T9ZHV@QP
M2RW08A=8*A%'L61RIZ^`"(WX)L$>T$S6!#\Q61#&6!09SU5%`"I2\"`4=`C!
M+%0LA)3\+VD*$@E`8K?;4YY,QL<K+L;G83]=0C!%*"W(\4S@X90^:U06XW:V
M.K!HWT)CAK_OE]BT;H^-%\U1P4O-8C#T1`G!=+XB@"Q/(Q5+=C:I+<9QT]Q+
M15*YZJ#<F*Y/Y'9)W]FV5,8(<N12J8*\\#-`;;U\-AZ&QGZ3FL>7U-RM"FY?
M%B2'VX'@*<^.(B,9Y;SCZ[.[N?HS-P>:N<!SQKDR*9=?4G5SX\=J3/#=M;0@
MC#I32<Q(5Q;@EKP.+'ID$LKC)E6/+ZAZ<-:U(!=>92TV#R*+@AN1.G#2HTZ4
M`U/W*WO4!56/W.YGZRI0]=A7=0$7884*&IL[Z5$GRN$F98]#91=1L%D%TF[=
M,`]YFL4IZ^_:(ESN])@/96`DUA/VB3L3"C-5#-=S-AM<SZO8U_-+YUP+\(E\
M[D)XF$O+VWD,7E0]!+^>*2W(!559B\T(R#!+8AVXZ!$7RN,FY9:A<O/KO=)B
M_/#1RUEJBT%""WC^@+N?X/QQ!41I,#$?;VX9BK@0K$]+"\(819(4&9=QBI`J
M,DK.IJD):)%'2D(_,9`F()6D19YX&R9E:G33:Z`K3%%E:>,P'J5$D,<TS;QK
MRZ&[*@ORD^@I.,KBE8DH#R;STS8"&<I]</RR&*13Y(KM$Q493^(L%7"2.NOW
MP*2V&,=6<Z],?'KZDK^D^H,7VQOXP;VT(,=-1*R6*@MQH=>!1?L6FI6;A%Y>
M$GJVE*4%X>$KN#VL[#`RD@G\NX`]_]?G"<['+^:CLL0M`J5CM-9KEHE%A@I-
MFB8X?TE?Z7.5J(P1KRS"3T0@_3Z&1GZ3TLM+2L\>7$L+PD3(E`U7=MCN`GD$
MYWK>%/RHH)G/Y]?MTLCJ[8E`,::)<*E&V1^F?IS;`DJ5RH-$X#1^(KA%VUD&
M#$E$\DM"/WBQ9A;\^&A!F)!@FR*C"SY<GX?/7>%;*`6F\=.Z(`FU'HZSM"1*
M"\+%5W#-SS=;"_#6/K!HWT(#-SKM5<VXUB4&S=;<4U&L%@MR\536@A3@,:J0
MWO^N40T")SWJ1#DPO9ZX^)=TF_5CF7`!KJS%]D(6)=X%@:7"??28#V7"%/M*
M-D*E#HZ*"6+\9'!+;3%(:0'/N2*+O<?M@96^`J(TF#I?H7'A69Q?_)?F;12H
M/'S-0J@T*M@1JZ((>!,CAT,OV\EJ`EH(F61PY\4OAC1!);D$P?2JG%*]2<WA
M%:N@?V(FQJ4%83J0:L1WA<J"7%[KP&)>Z#)_[;.)D`>^LH4O`QU7K\T_5J?7
M[:&;[9H7^#=:=)?!PI_PA2W\TK?'X:6?Y[:'%ZV&7]_@Q;H&+FVB.P"_M&W_
M\04VSN7Y5;VG_P,``/__`P!02P,$%``&``@````A`(VYRK(\"0``KR<``!@`
M``!X;"]W;W)K<VAE971S+W-H965T-BYX;6R<6MMNVT@2?5]@_T'0NRWVC1?#
M\B!D([L#[`"+Q>[,LRS3MA!)-$0E3OY^JUDELJLH.51>9N+FZ>*I2]?IIOK^
MM^^[[>Q;?6@WS7XY5[?)?%;OU\W39O^RG/_OOY]O\OFL/:[V3ZMMLZ^7\Q]U
M.__MX>]_NW]O#E_:U[H^SL#"OEW.7X_'M[O%HEV_UKM5>]N\U7MX\MP<=JLC
M_'EX6;1OAWKUU$W:;1<Z2=+%;K79S]'"W6&*C>;Y>;.N?;/^NJOW1S1RJ+>K
M(_!O7S=O[<G:;CW%W&YU^/+U[6;=[-[`Q.-FNSG^Z(S.9[OUW>\O^^:P>MR"
MW]^57:U/MKL_1N9WF_6A:9OGXRV86R#1L<_%HEB`I8?[IPUX$,(^.]3/R_DG
M=>>=GB\>[KL`_;FIW]OHW[/VM7G_QV'S]*_-OH9H0YY"!AZ;YDN`_OX4AF#R
M8C3[<Y>!?Q]F3_7SZNOV^)_F_9_UYN7U".EVX%%P[.[IAZ_;-404S-QJ%RRM
MFRT0@/_.=IM0&A"1U??N_^^;I^/K<F[26Y<E1@%\]EBWQ\^;8'(^6W]MC\WN
M+P0I,H5&-!FQP)Z>ZZE&%DBH\\^OCJN'^T/S/H.B@5>V;ZM0@NH.#)\<0QJ]
MJY<\!1>#D4_!RG*>S6?@1`OI^?:@M+Y??(.0K@E3GL%P1'5"A/@%LSX:6`#?
MGC1$(B9]/@LG;@$<N)VLEC@`MGNR@FIU!I%QKGX,20<((VLXV1!A`P7X,>DP
M:3F']M%S5-IP"B5B3.]8)0=\-,`H0:*GQR^`EW/PMZ>2%X()0ER7^!MGM<JT
M2CBF8AB=6U48)3SR#&.<THDVKK?#7(!E$[L0HFHO+LA3*81),JJVM]_57(F8
M**IRP$<#C%+**7V<X`#F4856(*@@)NW"JO,B'PJLHUK%SVV6YS*<\7.=V7QP
ME?&&91N'\F/>`2QYIX(W8HBWL;DLA?BY2G0JEI^/G^L\RP;[C'<0UZAU?<P[
M@"5O$<\2,<@;RM@,[\5XL^?*V4(&/`;8Q-F\#PPC7EQ#/(`Y\2B/6+((B4I6
M#G@<0,]48I(L3R\4@X+6-#VJ'5JPDU5,F(C>:,33"!),,Y6ZY!*_H`F3LZY0
M0>+FI?20%0P?@6*".(WB%4I4UK"G201)$ZOM4.8LVRI(Q73&*"R<L>RWG<GE
M'%]NM2F,$TY5#&)TDFDC()Y!5)[FQ@ZYXRX$(8E<F*9A"N6'N6*&(%'P$82N
MZ#1)M%B5%9FA2%L'PC'41F?$$Z3+("<>%"4B_G&/4*@_G+#JUS`11A#2R4Q2
M.,&F(C.(2$U:*.&29PAC<NL&!.<?M&8Z?U2FF+_4A#+L6J&?Q,6.(Y2!P@IW
M/,W`Y]8E45OD7(/<1%PG%@F*%'3.?GNAC!"$4B$H)BU'?(SAO(*<1+Q^4@,H
M/G$,E1%]OE2Q0MU8ER>RJ50<HI(T3Y58QIYC,IUK-[R)^Q"49;H/J$.Q#V94
MQK%6W2BHP6)8_%VE5RJ&N$RY0N3%,\0-],E,F4N5'"1HN@<H6,P#\?)2Q:(&
M#5KGPL>*(8*/J1GG(+9B=6R$94!?I8L=FNNBDEVK)!`NK!L3>@GO-15'N!1.
MC&)/X@DR;GWZ*J'LT)RPE0$G##4"K72A!*3B$*AH)W+B&0)6ELW=4'<\XI#]
MZ16C`UHX,"PF;-V$H8"K)"N*Z-"&1<\PT)=SN;(]0RAE;>:&,'`/?DDV]3G9
M'&)$KC#9-`7T95D[#)%G#C8!'.+I31B/U!3JD@SIJV2T0_-4J$@TR`&4T:BE
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M=GC1)I5B'&/@TP*<$23&,SM9#J>F_$)]&Z&:'^_7.[2LD\%R1[`D$#H!I]S,
MCLHD5DM8P/+SI6<F%#Q/A@7,<W&55AJ400A@5!N"7$D@I*]R]F[*@%133W/.
M+$<AE3\)[QF)M&+IEP9!D:*,1CR-H`]Y!N&[&$`A?3\AB-K%`R@ESTB!JV@$
MZ<!6(V;3A=3'<WB"KY)`<T8"K91``L4!Q&G#B.\QX=<5>S%X044F'[,,:@X+
MGMQ(E@0:J%0T@L&[.1\]IF:&!YB'4\C9Q-YU1M;D6:,T"(J9RQ%/&/(%?E:-
M*X$1M4+'/J[+#BWZ4G1.P+Y$H(@@C1`="]^.<KG</,>HO$M`W[8YYU\2+(N"
MQ<M""A:!D*DUNLAA7]RSP+;$,)DI\L(JT=P\PX#^F#2_I`P6&$TO[@XM,R#E
MC4"G].>Z2*5T50SC=&HRT#CNJ6<8!3J91&9X2JZ2-XNZQ%,AY8U`Z(2#7]84
M?$CE!"N&4<X9FXE8>`[1*?R.UQOA+EPE<?:,Q,EM6DD@<@&.BRI-A,Q4''/6
M3<\PTDWNA-#!:7TG_,8(1T:VEXM.S;2L1WI(TX:%[N,1SNLJ^;-GY$_^%E`2
M:'A[12,8;OB2DT?5BO+'$/![;@3@=(4:3@PCRAL/H^@>I94:6(U&?#S">04!
MFBR$%N6*+3.YA$H"Q6'$:1A&E2E5R,+V-(DB[>#G@NCDQ!D+(?R)OIP10/G]
ML+12[BH:03HVU4I^RO`,H>"K$7P3/=\&G!#$::GO9HFV+(]D)8&B4(]&/(V@
M*P8^/E]4;O=+*MC-DD2'+WVXU`D4$T7Q'$8\8:A*X&?A-%JAK`3@"A,KVHD1
M#;,D42G7G6EVOAR-A!M4P1#>XU!P_6(P@C3Q?A3>']K5AY>ZJK?;=K9NOH:[
M3QHN*O2C_;VL3]VU+#%>PGVM[G+3HG\`UZ7>5B_U'ZO#RV;?SK;U,YA,;C/H
MI0>\<(5_')NW[M;28W.$BU+=/U_A8EP-]X626P`_-\WQ]$>XTM5?M7OX/P``
M`/__`P!02P,$%``&``@````A`%<:F'2^`@``C@<``!@```!X;"]W;W)K<VAE
M971S+W-H965T-RYX;6R455UOFS`4?9^T_V#YO3&0A#0HI$I7=:NT2=.TCV?'
M&+"*,;*=IOWWN\:$0INN[`7!Y?B<>^Z]7#97C[)"#UP;H>H4A[,`(UXSE8FZ
M2/&OG[<7EQ@92^N,5JKF*7[B!E]M/W[8')6^-R7G%@%#;5)<6MLDA!A6<DG-
M3#6\AC>YTI):>-0%,8WF-&L/R8I$01`3246-/4.BIW"H/!>,WRAVD+RVGD3S
MBEK(WY2B,2<VR:;02:KO#\T%4[(!BKVHA'UJ23&2++DK:J7IO@+?C^&"LA-W
M^_"*7@JFE5&YG0$=\8F^]KPF:P),VTTFP($K.](\3_$N3*[#`)/MIBW0;\&/
M9G"/3*F.G[7(OHJ:0[6A3ZX#>Z7N'?0N<R$X3%Z=OFT[\%VCC.?T4-D?ZOB%
MBZ*TT.XE.'+&DNSIAAL&%06:6;1T3$Q5D`!<D11N-*`B]#'%$0B+S)8IGL>S
MY2J8AP!'>V[LK7"4&+&#L4K^\:"P3<ISM:G=4$NW&ZV."/H-:--0-SUA`L3G
M<X$D'';GP"E>800R!@KXL`WCQ88\@&G68:X]!J[/F!Y!0+17!K7IR@[LE%U5
M7"K7/C"4B<[+S,<RKNB+-XM^,NH.I1@^O&<3\;+G]QEXS+RM[M#78BSX[XHZ
M,)0>N`9*+TO:@6#@!J"X3V=45;`VO:H.W*KW9>TB?F:&KN(Q;SN[T:4;U'=F
MQAT<:W218>_">'7>#LS:=#L./);J(D.IQ1M*;LM._A`<>*S416`L!SVZ/&]J
M_3]2#CR6ZB)33,$Z&[ER;9NO@MF[76L/CF5/H:%N&*]?6/3;SZ\8R77!/_&J
M,HBI@]ML$2R-/MIOW5WD/J*7\46R\]N8]&]@&S:TX-^H+D1M4,5SX`QF*["C
M_3[U#U8UD#OL1&5A#[:W)?SW."R.UGNNE#T]@#+I_Z3;OP```/__`P!02P,$
M%``&``@````A`$2-EUK6)```!>P``!@```!X;"]W;W)K<VAE971S+W-H965T
M."YX;6RLW5ES%$F:MN'S,9O_@'$^H,A%"P:,%<K8%_ML;)9C%8A"5H`P2=75
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MSS</_SKN]/FS+^]?U;]]O;V[^O6S7O<_L]W5^VG?Q__`[K_<O+^[O;_]^/!"
MNWOIGRA?\\7+BY?:T]O7'V[T"ESLS^ZN/[YY_DOV:LA.=\]?OGU]3.A_;Z[_
MO`_^_[/[3[=_EG<W'[J;K]>*6P/EAN#7V]O?7=/Z@R-U?HG>Q7$(_M_=LP_7
M'Z_^^/SP7[=_5M<WOWUZT'CO]9+<*WOUX5^'Z_OWBE2[>;'9NSV]O_VL)Z#_
M??;EQLT-17+US^._?]Y\>/CTYOGV],7^[&2;J?FS7Z_O'XH;M\OGS][_<?]P
M^^7_?*-LW)7?R6;<B?X==^(Z/])A.W;0OV.';/<BVYV</M%O-_;3OS__;/74
MCB]9_TX/?O[B?+_?G9Z?/?ZT3\>>>O=,/2]^K.?%V%/_3CU_\#$S30D_0DNZ
MV0\^:C;E[/[/VL>=LLZ6L)]XW)=^;AVGZN'JX>KMZ[O;/Y_I`*#9<__MRAU.
MLE=N=],D]3-DGK;?F[6:KFXOO[C=O'E^]OR9)N2]WFO_>)N=G;Q^^0^]/=Z/
M;=XEVM@6EU,+]UYPNSW$D,=0Q%#&4,50Q]#$T,;0Q=#',`3P4M'.^6IF_!WY
MNMVX?*=DWDVP!+Z)PIQ:3%T.,>0Q%#&4,50QU#$T,;0Q=#'T,0P!F##U5C%A
MIH^DTYQTK=\\UP$AF).9#>F=;[/UQTPWY2XA!T@.*2`EI(+4D`;20CI(#QE"
M,1'J+;XB0M=:1P;M+<@P?E_[1EL-6M`HGHUSHWDZ0G)(`2DA%:2&-)`6TD%Z
MR!"*B54?3BMB=:V/L4YAO/.RW<YO\$O(`9)#"D@)J2`UI(&TD`[20X903&#Z
MO%X1F&MM`_.RU8`$DVYKW]V7<Z,IYP,DAQ20$E)!:D@#:2$=I(<,H9@,]7&[
M(D/7VF;H9>O7GL>#'^0`R2$%I(14D!K20%I(!^DA0R@F,%=:A8N=QS\_7&L;
MF)>M!B28=+MHTLV-YDD'R2$%I(14D!K20%I(!^DA0R@F0RV35V3H6ML,O2C#
M*9Y+R`&20PI(":D@-:2!M)`.TD.&4$Q@KDI8D=BQN8ULI*WF]3SO-A?1M%L:
M3<$>2#FI()6DBE23&E)+ZD@]:3!D$W6+[1]_'V=^;:Y5S)3,NY'"64@ZD')2
M02I)%:DF-:26U)%ZTF#(YN?6UROR\\MQDY^GZ$BXCZ?DW&H*_I"!<E)!*DD5
MJ28UI);4D7K28,A&ZA;<*R+UZW,3Z;AD#S]<=F=QHG.C)5%0[M;K.NH&L[L@
ME:2*5),:4DOJ2#UI,&03=6OM%8GZI;GV-R7SSIW.<#&$A\WL[#2.=&XU=3PL
M'2?*206I)%6DFM206E)'ZDF#(1NI6XVOB-0OWDVDXWK^\4DZ-YKB.[C3GG9&
MYJ2"5)(J4DUJ2"VI(_6DP9!-U*W-PT3=Z;/MN3N?.YYC_?$S:&Y7T>>^I^@H
MBV/"W&J)&Y1GH()4DBI236I(+:DC]22=E`\FBXW;K>S#N!]?P&>^$#`3V-/V
M?#Y,7(ZM`CJ0<E)!*DD5J28UI);4D7K28,CFYU;U*_+S18#);ZP+[#'U/#ZF
MSJV6*0G*,U!!*DD5J28UI);4D7K28,A&ZM;]*R+U98*)-*P<CJ>]+S/0@923
M"E))JD@UJ2&UI([4DP9#)K]-7!VY(^AF_V+]`?2X)WL`'2DZ@,:5T])JGJVD
MG%202E)%JDD-J25UI)XT&+)IKZN<-JR<1C*18IFZ-%H2];L*UJ0Y6Q6DDE21
M:E)#:DD=J2<-AFRBKJ#Y\??_QM<_X?M_I*W>\W-UGYU')]DOEU9+I&,M=3%_
MEN5L59!*4D6J20VI)76DGC08LI&Z\F5%I+[:,9%ZVNG8,D?*23HW6A(%Y1M0
M02I)%:DF-:26U)%ZTF#()AK74C]_D&69M1D+**W:YK"S\^A"V^72:DE[[CA1
MSE8%J215I)K4D%I21^I)@R&;MBMV5LQ?7QN9^>LI.%A>NHK"5E`'4DXJ2"6I
M(M6DAM22.E)/&@S9_-SZ?T5^OEPP^8T5A%FEGL>7)#=SJVG^'4@YJ2"5I(I4
MDQI22^I(/6DP9"-U9<^*2'V59"+U],3G_MQH2124;T`%J215I)K4D%I21^I)
M@R&;J"M>5B3J:QV3Z%C^V,_]^!+F9FZU1`K*V:H@E:2*5),:4DOJ2#UI,&0C
M=57/BDA]D60B]62.FZ##!I23"E))JD@UJ2&UI([4DP9#)K_MWU9*'?=D2ZF1
MS/L_.X^O?2ZMYME*RDD%J215I)K4D%I21^I)@R&;]KI22E\QBD_OC60BQ2IU
M:;0DRE**K0I22:I(-:DAM:2.U),&0S;1=:64^\)1=,)TI*B4BB]++:V62%E*
ML55!*DD5J28UI);4D7K28,A&ZJJ7'S^DZOM'B-13>$@=6P5T(.6D@E22*E)-
M:D@MJ2/UI,&0S2\NG!X_X>R^CA1/R;G(":NC^"+4V-%$.G><9FG.5@6I)%6D
MFM206E)'ZDF#(1OINNI(WTY"I',IM$3*X^;<:(KO,.XJ"#DG%:225)%J4D-J
M21VI)PV&;*+KZB6]?B0Z5T)+HMEY?*%I[*CKJ4ND<\>)<K8J2"6I(M6DAM22
M.E)/&@S92%V)LN*XZ2N:<"GJKCK[>GV)E)-T;C3%=UCZ3923"E))JD@UJ2&U
MI([4DP9#-E%7M*Q(U-<X)M&Y[%D2S<[C2T^ZC'?,?3DI>B#EI()4DBI236I(
M+:DC]:3!D(W4U3$K(O5ECXG4T^/G2=UJ2C-9C:89>2#EI()4DBI236I(+:DC
M]:3!D$G4!6$2_?G+^<==V1)J)'?4"4Z4QE>CEE9SW*2<5)!*4D6J20VI)76D
MGC08LG&O*Z%V+*%&4J136)>D`RDG%:225)%J4D-J21VI)PV&;'[K"J8="Z:1
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M^*$9G0H_3!V5<?#1NIR+M,]XW5)^QZ7\2&;$?:N`#FR5DPI22:I(-:DAM:2.
MU),&0R:_?6KA[K]%]OA[Y]C1+M,G"D9\H7`LX_?XU,J.^'*JSS[C=6O?/=>^
M(P7#>TDZD')202I)%:DF-:26U)%ZTF#(YA>O?=U[W#5_8KRY!MZ/%([W3(^.
M]]C*CO=RULP^WW4+RST7EB.9\>;"DJUR4D$J216I)C6DEM21>M)@R.87+RR#
MTOR)(><:<S]2..0S/3KD8RL[Y,LY*/N4URW<]ERXC62&G`LWMLI)!:DD5:2:
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M^)'T!8XIK$O2@923"E))JD@UJ2&UI([4DP9#-C^WA`ZGY'(R;N5O#)Z.B_%P
MMGJ*9FMT*NYR[!A\<!U(.:D@E:2*5),:4DOJ2#UI,&33=N5"F/;CM?&IKR["
M4\<C!6%=D@ZDG%202E)%JDD-J25UI)XT&++YN0(@S&^9K4\D.58.X>2<2X[E
M?3^2_@GJB^6DL/_5R].QE:U"OG,B\32N0MPS]JOH)YXQZY'COK2.#LZ+3&2?
M\7*2:WS&X[[L,_[.>9&S>-W_^/,\-K>+^XF"YSF1?9Y+I>Z?Y]3*/,_L._7=
MV;H5\[%Y]#S](CI\+XVM`CJ0<E)!*DD5J28UI);4D7K28,B\E\[6K9B/S:/\
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MD7K28,CD=QY7&L%%XY4G'XZ[L@>`D:+I&A5SETNK:6X>2#FI()6DBE23&E)+
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M"E))JD@UJ2&UI([4DP9#-E)7K/SX.O_<US;F@V<N=Y8/'G[*SXVF^`[CKH*I
MG),*4DFJ2#6I(;6DCM23!D,VT765TSDKIY'<7]TOUQ6RZ.SWY=)JB72LG(ZW
MP3M.Y9RM"E))JD@UJ2&UI([4DP9#-M)UE=,Y*Z>1W)_=SY%RDH[EU7)I][#T
MFT+.206I)%6DFM206E)'ZDF#(9/HQ=]72QUW96NID>Q1=K-<F/%'V:75E.V!
ME),*4DFJ2#6I(;6DCM23!D,V[G6UU`5KJ9%,I)C`2Z,E4=92;%602E)%JDD-
MJ25UI)XT&+*)_FVUU`5KJ9%,V)M-?*5J:;6DS5J*K0I22:I(-:DAM:2.U),&
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M3`'#%#!,`<,4,$P!AQ8%'!=83TUAEE'9R5P.+6==-IOXFE30+$AX[CJ9IC!,
M"<.4,$P)PY0P3`G#E#!,"<.4,$P)AQ8EO*ZHRDY854T6'F<3I@G+,BIABA/M
M%"=,<<(4)TQQPA0G3''"%"=,<886Q1E75#__]8#LA.769.9HL=G$5[."9M/$
M5?I^=\$H:3+#E#Y,Z<.4/DSIPY0^3.G#E#Y,Z<.4?FA1^NN*K^R$U==D)N'$
M\9CU5]!S"ET!HYT"ABE@F`*&*6"8`H8I8)@"ABE@F`(.+0IX72V6G;`8F\S]
M9.)\%GRSB:]^!<VF-#6%_>[4=3(E#%/","4,4\(P)0Q3PC`E#%/","4,4\*A
M10FO*\VR$]9FD^E7$J>8+A.F.'W?H)WBA"E.F.*$*4Z8XH0I3ICBA"E.F.*$
M*<[0HCCCNNRO'(]9M&4GWLS18I.XD?;<;!H1I0]3^C"E#U/Z,*4/4_HPI0]3
M^C"E#U/Z,*4?6I3^NA(N.V$--UGPL:7)[-L%ICAABA.F.&&*$Z8X88H3ICAA
MBA.F.&&*$Z8X0[-Q'F]?_N.7R;/Q=N?A=?+)[-%W&U\5"YHM$W:Z>WIX]*7I
MYN5CP;2TT]W+8;I].4SW+X?I!N8PW<$<IEN8PW0/<YAN8AY:E+`K1=8D[$L7
MF[`W]QNU\^<;%Q#CK=2#8Z_N#3_WG$+7S>%A"ABF@&$*&*:`80H8IH!A"ABF
M@&$*.+0H8%>)K`G85RXVX+&:T7%G#GBSC2^,9=.=U9?[\BKAN6N0,$P)PY0P
M3`G#E#!,"<.4,$P)PY0P3`F'%B7LBI,U"?MBQB8\%SA+PHDI/+>:PE3`,$UA
MF`*&*6"8`H8I8)@"ABE@F`*&*6"8`@XM"MC5'V'`/_T%VFR\K[H>;$KPW61V
M1;&-KZ@%S::N"C^LC/PW;Q*F\-%.X<,4/DSAPQ0^3.'#%#Y,X<,4?FA1^*XV
M"<-_XH30>)]UF_!<WSPZN^=60<`PS6Z8`H8I8)@"ABE@F`*&*6"8`H8I8)@"
M#BT*V)4F8<!_87;[*L=F/U8^^B<X=L>7XC)SO_;C3-;LGKM.`Z+P80H?IO!A
M"A^F\&$*'Z;P80H?IO!A"C^T*'Q7R(3A/S6[?>%C$_9FCA^)8_?<:@I3`<,4
M,$P!PQ0P3`'#%#!,`<,4,$P!PQ0P3`&'%@7L:I4U`?O:Q@8\UCM:IP=3.+Y0
METWW=U]6P4IX[CJEKH1A2ABFA&%*&*:$84H8IH1A2ABFA&%*.+0H85>^K$G8
MESLV86_!VO@R&V_W'ICB1#O%"5.<,,4)4YPPQ0E3G##%"5.<,,4)4YRAV3B/
M]UT/X_SYP_%X"W>3]');]W`NX_+>TFR:MX>,EB>L2%B9L"IA=<*:A+4)ZQ+6
M)VRP%H7OZI@P_"<.Q^,MW6W"OA9ZXG!L;@8_?M[1%/"\MVD@%#!,`<,4,$P!
MPQ0P3`'#%#!,`<,4<&A1P*Z,61.P+WMLP&,II(-^<#C&Y;WIWO#+#]YI"L]=
MIS25,$P)PY0P3`G#E#!,"<.4,$P)PY0P3`F'%B7LZI@U"?NZQR8\UT)+PEQ1
MC+>*-^?D:`IXWML4N@*&*6"8`H8I8)@"ABE@F`*&*6"8`@XM"MC5*FL"]K6-
M#7BN=Y:`-UM<U#.WAY\.$G/7*4TE#%/","4,4\(P)0Q3PC`E#%/","4,4\*A
M10F[8F5-PKZXL0G/!<^2<&(*SZVF,'6,@"E@F`*&*6"8`H8I8)@"ABE@F`*&
M*6"8`@XM"M@5)&L"]@6,#7@L:NQ1&!?US.WDIRD\=YU25\(P)0Q3PC`E#%/"
M,"4,4\(P)0Q3PC`E'%J4L*M(UB3L*QB;L+>G%A)SJRE,36&8`H8I8)@"ABE@
MF`*&*6"8`H8I8)@"ABG@T**`74&R)F!?P-B`QZ)&PQ@L).(_>,NFF\TO7RI4
MPG/7*74E#%/","4,4\(P)0Q3PC`E#%/","4,4\*A10F[&F5-PKZFL0E[>VH*
MSZVF,!4P3`'#%#!,`<,4,$P!PQ0P3`'#%#!,`<,4<&@VX.-MX5<$/-Y&W@0\
MW5I>;Y1E"N]P<6]IMB1,RS-:D;`R857"ZH0U"6L3UB6L3]A@+4K8%2)K$O:%
MBTUX+F:6A+F0,#>D'S_F:`IXWMLT$`H8IH!A"ABF@&$*&*:`80H8IH!A"CBT
M*&!7AX0!NY,5YQ<OW-ICY6^+9.,-Z&WX8YUCCM`[7/B;[ET?'J%I2G_>79`^
M3.G#E#Y,Z<.4/DSIPY0^3.G#E'YH4?JN2`G3?^)LQ7B+>IMP6.@<)^YE9FYE
M/TUFM%.<,$UFF.*$*4Z8XH0I3ICBA"E.F.*$*<[0HCA=1;(F3E_!V#C'JL8>
MCW$M;[JS?7AN@J:$Y]T%$Q:FA&%*&*:$84H8IH1A2ABFA&%*.+0H85>2K$G8
MES`VX;"LF28L[)"96]T?VRE.M-.$A2E.F.*$*4Z8XH0I3ICBA"E.F.(,+8K3
MU1]AG.[HNSW_N:.OKV5LU-[,ZFVSPZ4[M]W]V8<Y^L*4/DSIPY0^3.G#E#Y,
MZ<.4/DSIPY0^3.F'%J7OBI,P_:>.OKZ8L0E[<X\R+]\2BXNYU704T/2&*6"8
M`H8I8)@"ABE@F`*&*6"8`H8I8)@"#BT*V-4F:P+VM8P->*YOEH`W.URZV\[-
M@H1A2ABFA&%*&*:$84H8IH1A2ABFA&%*&*:$0XL2=L7)FH1],6,3#@N<Z7@,
MTX2%*4Z8XH0I3ICBA"E.F.*$*4Z8XH0I3ICB#,W&Z;X`:.)TQ^-L_\+])N_#
MIYOWO[^[=9"\O>3V^=O7Q_1^R8Z[B?XJ;[+EVO+EW"[XW9C)7-4Y'U`VN^CR
M7AXTF^9[D;`R857"ZH0U"6L3UB6L3]A@+0K>52CA//[)X'VA8Z;W;C03_&@F
M>&\JH-^^_L?;S4G\B[/*?&X19`Y3YMB[,I_;C7N//H0U`G.+:>\:`9A&`'O7
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MP8%I<&`:')B&`J:A@&DH8!H*F((/+0K>561A\/_,=E?O7WWXU^'Z_OWU5QU\
M3EP!O`3L*S@;\%C5J?8(#E;1D51OB+E9D#!,"<.4,$P)PY0P3`G#E#!,"<.4
M,$P)PY1P:%'"KB1;D[`OX6S"85DW5@4[F"8L3''"%"=,<<(4)TQQPA0G3''"
M%"=,<<(49VA1G*[^"N/\"V=I=KZ6LU'/]5TXF:/CL2;SW"R8S#"E#U/Z,*4/
M4_HPI0]3^C"E#U/Z,*4/4_JA1>F[<BU,_ZG#A2_O;,)AR3=-9I@F,TQQPA0G
M3''"%"=,<<(4)TQQPA0G3''"%&=H-LY]7.(^$>>Q?53+CN;._"Q'WSVN62[-
ME@E+RS-:D;`R857"ZH0U"6L3UB6L3]A@+4K8E54K)JR[MWET4YEL-)U6G**[
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M$#!,`<,4,$P!PQ0P3`'#%#!,`<,4,$P!PQ1P:%'`KB`)`_[IN>TK&YO\6.WH
MG^`H'9W^T]R>FP71PQ0]3-'#%#U,T<,4/4S1PQ0]3-'#%#U,T8<61>^*ES#Z
MI^:V+W9LPF$!-*Z1]S`=*F"*$Z8X88H3ICAABA.F.&&*$Z8X88H3ICA#B^)T
MU4@8YU]9<OC*QD8]5SOA9,8US?W<+)C,,*4/4_HPI0]3^C"E#U/Z,*4/4_HP
MI0]3^J%%Z;OB)4S_J<GLBQV;<%@`39,9ILD,4YPPQ0E3G##%"5.<,,4)4YPP
MQ0E3G##%&9J-\W1EP7=L'Q5\HT4KB^BBY&6V-%LF+"U/M"L25B:L2EB=L"9A
M;<*ZA/4)&ZQ%";OB9<6$/?7%CIFPHYF$N;)86@4!AZ73<:HK8)@"ABE@F`*&
M*6"8`H8I8)@"ABE@F`(.+0K8U2=K`O;UC`UXK'%TU`\6$-$%*4WAN5F0,$P)
MPY0P3`G#E#!,"<.4,$P)PY0P3`G#E'!H4<*N9%F3L"]Q;,)SV;,DG)C"<ZL@
M8)@"ABE@F`*&*6"8`H8I8)@"ABE@F`*&*>#0HH!=8;(F8%_(V(#GXF8)>+./
MKGEI"L_-@H1A2ABFA&%*&*:$84H8IH1A2ABFA&%*&*:$0_,)O[S_='W]<+AZ
MN'K[^LOUW6_7E]>?/]\_>W_[A[N4Y`J6P)_=77]\\_R=]O/JN#,E-/>9MNW/
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M0)S<YEZ[+@`GM[EQT%]M)K>Y<=`?'":WN7'0G\JEMF6NGWZ`)KG-]=-/IR2W
MN7'0[X"DMFW<..B;3\EM;AS\]S8P)S9N'/3;`*E^F>NGW^E+;G/]]`MSR6UN
M'/P'"1XO<^.@W^Y*]G/CH)^=2FYSXZ!?14IM.W']](/$R6VNGWY*-[G-C8-^
M%S:YS8V#?K4TN<V-@WZ",[4M<^.@'X],;+M0-]V)(;%%MP]P>TSVTB_?NVWI
M43AQHZ`?;D_NTXV"?H4\N<V-@GXC.['M0MUT,ZC4%G72/8U26S0`NC=/:HOB
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M1B&]SMKK&:17ICL]`WW7-_%Z=DI'WS9-;=%STQ<;4UN4CKY6E]JB9YU>L[AE
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MZI?DT<CU2#R'=VZ84^[>4`G_9??J%W<*@:_FG3NH.7\Y'P3NW[[^=O7;=7]U
M]]O-U_MGGZ\_ZG3"R?%/@>YN?G-7A/Q_/(Q?$_[U]N'A]LOQ&\.?KJ\^7-^Y
M!KI:^O'V]F'Z#_<`?][>_7X\9?'V_PL```#__P,`4$L#!!0`!@`(````(0!*
M'])U?@4``.04```8````>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULK)A=C^(V
M%(;O*_4_1+E?0D(($`'50,B76JFJMNUU)AB(AF"49&9V_WV/[3C8/G1VZ?9F
M&!Z.W]BOC^T3+W_Y4I^M-]*T%;VL;'<TMBUR*>F^NAQ7]I^?XT]SVVJ[XK(O
MSO1"5O97TMJ_K'_^:?E.FY?V1$AG@<*E7=FGKKN&CM.6)U(7[8A>R05^.="F
M+CKXVAR=]MJ08L\;U6?'&X\#IRZJBRT4PN9[-.CA4)4DHN5K32Z=$&G(N>B@
M_^VINK92K2Z_1ZXNFI?7ZZ>2UE>0>*[.5?>5B]I678;9\4*;XOD,X_[B^D4I
MM?D7)%]794-;>NA&(.>(CN(Q+YR%`TKKY;Z"$3#;K88<5O:3&^:N;SOK)3?H
MKXJ\M\K_5GNB[TE3[7^M+@3<AGEB,_!,Z0L+S?8,06,'M8[Y#/S>6'MR*%[/
MW1_T/275\=3!=$]A1&Q@X?YK1-H2'`69D3=E2B4]0P?@KU57+#7`D>(+_WRO
M]MUI97OST7PZ]8/Y#&2>2=O%%=.TK?*U[6C]MXAR>RVAXO4J\-FKN(OO;NSW
MC>%3-GZ\!]!7/@[X[$5FCXO`HN`B\/G?>P(#YR+P^7!/'#$[?+*CHBO6RX:^
M6[""P/[V6K#UZ(8N)(F<9C$GP\3_V[S#A#.5)R:SLF>V!3/:0K*^K;WI?.F\
M08*5?<P&Q[AZQ%9&L&QBLI$)=B:(39"8(#5!9H)<`0[8,G@#2?=_>,-DF#=R
M5!L)%+,,(V2$;!*98&>"V`2)"5(39";(%:`9,3&,N+\'R%Q@T2L;4EW)A84^
MP(V(F8C%SJ9ZBTB$R`Z1&)$$D121#)%<)=K08>_0<N#CH;-H6$F@IHS=7`<B
MR-<62S#6#=H.04,*(+)#)$8D021%)$,D5XEF!^R"#]C!HKD=<A`;02;BP.#S
MCDB$R`Z1&)$$D121#)%<)=I`@X<&RJ+U@0H"`U4R(3#WNR%(^A,ALD,D1B1!
M)$4D0R17B39VR,P')IE%ZV,71)UD1")$=HC$B"2(I(ADB.0JT0;*:E5\^(U8
M?=*=JO)E0T6!<F?13^"0$T<?$]''WY/%L.-O>W)+^T@0#\[RVTX1>/HFL!N"
M9'[$B"2(I(ADB.0JT2R!#OVX)4Q$MZ0GBB4]42P19#(6Y</8]0TWAM\'-Q!)
MD&HZQ/"B9.Q.=-5L^%VJYBK1O&'UD6;.G;R`6E@F!@_7;>B1!T+*M!M=VLJH
MV^D82:0W-!V241ZW<#[SO841$LL07OSS!$XDNCTNE>C#QV4R2CPN\-Q@9ISS
MN0P1[QIJ<>6RJDM=?-\P4Q1I<+3*>=IP!7BMT$[;8*K/[U9&\5>EOJH46M!0
M:NWZ*-_ESKG3Z<0W-NM8"MU:)1+=M%.);E&9KNU-QPO?F/%<:Z7G'*O)5)M$
M@?[@'N6*RDYS3R`C%0/3O3[JEAM1K^5[BGLBRF>;XMO:G7K^S"AZXKX5/$YZ
MGDATTTZQ=B91KST;+Q9&)W,I="?)6%WWX^Z)ZE!S3R`?"B5E(<],]T24=\N/
MB-6&L#?Z>F%@K-*=C`J$H>[<<\V-*^YCE"Q.)+H]+Y5*'SXODU']\\;^)'"-
M&<RE.,]L/4=9N?B1RY_I%?;!;[Y#BJH3GB-39`,7',PMM93`*,)HAU&,48)1
MBE&&$;MXN?5+>"$N4L2[=4V:(]F2\[FU2OK*+DE@4.OE@,4-SB8(H0:#L9I\
M%D+)<H>[OKSR,5I$\Q!.=-PB6H0Q/W*-^'01PBF'X^%.Z8DO:R-^P^Z:[L1O
MO!#>&;'.9A+"&Q7F3W[X!-;A'S8PLKM\&D*)#O'.T".X8[H61_);T1RK2VN=
MR0'L'?/]L!&W5.)+U^?<,^W@<HFGWPEN$PF\:XY'L!H.E';R"WO`<#^Y_@<`
M`/__`P!02P,$%``&``@````A`#2B_A6:`@``H`8``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&ULE%5=;YLP%'V?M/^`_%[`?(8HI&I3=:NT2=.TCV<'
M3+`*&-E.D_S[7=L)":32TI<$XW///?=<^[*XW[>-\T:%9+S+$79]Y-"NX"7K
M-CGZ_>OY;H8<J4A7DH9W-$<'*M']\O.GQ8Z+5UE3JAQ@Z&2.:J7ZN>?)HJ8M
MD2[O:0<[%1<M4;`4&T_V@I+2!+6-%_A^XK6$=<@RS,4M'+RJ6$&?>+%M::<L
MB:`-4:!?UJR7)[:VN(6N)>)UV]\5O.V!8LT:I@Z&%#EM,7_9=%R0=0-U[W%$
MBA.W65S1MZP07/)*N4#G6:'7-6=>Y@'3<E$RJ$#;[@A:Y>@!SU<)\I8+X\\?
M1G?RXMF1-=]]$:S\QCH*9D.;=`/6G+]JZ$NI7T&P=Q7];!KP0S@EK<BV43_Y
M[BMEFUI!MV,H2-<U+P]/5!9@*-"X0:R9"MZ``/AU6J9/!AA"]N9_QTI5YRA(
MD;.F4CTS386<8BL5;__:37RDL,'!,3@$U<?]P`UF,8X32/8?%L\J,84]$466
M"\%W#AP6R"E[HH\>G@/S^Y5`"1K[H,$F!,1*</]MF831PGL#RXHCYO$:$XP1
MJW<0Z0#Q0-<@#DJ^79P&YPANVB`NQ`.MT?]H(:&Q51>TNG@Q2@Q.W)Y8@Z&3
M%XF#))QDMIC8>#9+HR";V+:Z!"0!3M)L8!@IBSZB3(.GRN*!UWIB,8E1AN,X
MC":FK2X!0>QGT;FVD3(X@[=[IL%39<E$F<6<E`51.AL#5B-`ZF?9F6&D+/F(
M,@V>*CL?3^N9Q=AN8CP+,#Y[8A`PA#3+$>%'88+/XJTV.V3L7>S)AGXG8L,Z
MZ32T,@,DA>J$'3&^JQ>*]^;NK;F"$6$>:_@24#C'O@O[%>?JM-!#;/BV+/\!
M``#__P,`4$L#!!0`!@`(````(0`,Z4I/TP(``,P'```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;)1576^C,!!\/^G^@^7W8B!`VBBD2J_J7:6K=#K=
MQ[,#)E@%C&RG:?_][6)"H8G:W$L2-N.9G=WULKQ^KBOR)+21JDEIX/F4B"93
MN6RV*?W]Z^[BDA)C>9/S2C4BI2_"T.O5YT_+O=*/IA3"$F!H3$I+:]L%8R8K
M1<V-IUK1P#^%TC6W\*BWS+1:\+P[5%<L]/V$U5PVU#$L]#D<JBAD)FY5MJM%
M8QV)%A6WD+\I96L.;'5V#EW-]>.NO<A4W0+%1E;2OG2DE-39XG[;*,TW%?A^
M#B*>';B[AR/Z6F9:&558#^B82_38\Q6[8L"T6N82'&#9B19%2M?!XB;P*5LM
MNP+]D6)O1K^)*=7^JY;Y=]D(J#;T"3NP4>H1H?<YAN`P.SI]UW7@AR:Y*/BN
MLC_5_IN0V])"NV-PA,86^<NM,!E4%&B\,$:F3%60`'R26N)H0$7X<_>]E[DM
M4SH+O"B,YY<!X,E&&'LGD9.2;&>LJO\Z5-!S.9:P9X'O`TOBQ7-_=@8)<QEU
M!F^YY:NE5GL"4P.2IN4X@\$"B$\[`BN(72,XI7-*(%<#;7A:Q6&X9$]0NJS'
MW#@,?`Z88$`P$!V40>U\902C,M864[EQ@;',:R(3F=G_R"`XI7!MA^3C<#:D
M[Y0=9M8-S-A/-!7"&0D3G(</BHKGH/I`.Q)]->-$>Q!,[@@4#9E-'(/B^85%
M<*<^5+:/=+,WX4VFO&@PB;P/_>&QJ4(?&3<O#N/39F#8SC>#X*E4'SDV@ZMY
M-/?=C4[@.GW4+3PWE>@C4S?):3=74]7W;QN"IU)]9"P5S4\KP3H\-AC!R?<U
MNV-3T4-HK!J';V7=[G2KI19Z*[Z(JC(D4SO<BR$LBR$Z[.QUB)?H;3Q:K-TN
M9\,_L$M;OA4/7&]E8T@E"N#TO3ET2[MM[!ZL:B%W6*C*PA+M?I;PUA2P,'QL
M;:&4/3R`,AO>PZM_````__\#`%!+`P04``8`"````"$`J)N4[&0-``"!1```
M&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RLG%MSXK@2Q]]/U?D.*=XW
MQ`820B79FF",[[<ZEV>&D(2:)*2`F=G]]D>RU&ZI6^N$G?,RR?QH_;NM;LM2
M`[GY_8_7E[,?F_UANWN['7CG%X.SS=MZ][!]>[H=_/M?X6_3P=GAN'I[6+WL
MWC:W@S\WA\'O=__\Q\W/W?[;X7FS.9X)A;?#[>#Y>'R?#8>']?/F=74XW[UO
MWL0KC[O]Z^HH_KM_&A[>]YO50SOH]67H7UQ<#E]7V[>!4ICM/Z.Q>WS<KC?!
M;OW]=?-V5"+[S<OJ*.(_/&_?#Z#VNOZ,W.MJ_^W[^V_KW>N[D/BZ?=D>_VQ%
M!V>OZUG\]+;;K[Z^B.O^PQNOUJ#=_H?)OV[7^]UA]W@\%W)#%2B_YNOA]5`H
MW=T\;,45R&D_VV\>;P=?O%DS\@;#NYMV@OZSW?P\&+^?'9YW/Y?[[4.V?=N(
MV19YDAGXNMM]DZ;Q@T1B\)"-#ML,5/NSA\WCZOO+L=G]C#;;I^>C2/=$7)&\
ML-G#G\'FL!8S*F3._8E46N]>1`#BW[/7K2P-,2.K/]J?/[</Q^?;P>CR?')U
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M&\^VF(.%7(:D;$#!@H*0@B4%$04Q!0D%*049!3D%!04E!14%-06-`88B/5V.
MQ!WU_\B1E)$Y@MF]!X!)\TE"P`*&!!0L*`@I6%(041!3D%"04I!1D%-04%!2
M4%%04]`8P$J(6)M80D9B]70_5.$>D:-N!^(>,^Z1B3WA]\I&;0C:6V#.2,#(
M@I&0D24C$2,Q(PDC*2,9(SDC!2,E(Q4C-2.-2:R4B'7>2DE_*J2U6/&$FI$+
MNEXIHY$H`L/HTD[8O#/J;A%&%HR$C"P9B1B)&4D821G)&,D9*1@I&:D8J1EI
M3&*E1^RW3DB/M&[3`Y-ZK\CHLEN\YHP$C"P8"1E9,A(Q$C.2,)(RDC&2,U(P
M4C)2,5(STIC$FGBQ<SEAXJ6U/?&*C(2^<1-<D9N@,X)\!8PL&`D963(2,1(S
MDC"2,I(QDC-2,%(R4C%2,]*8Q,J%V!Z=D`MI;>="$2L78YJ*SJ9+!2,+1D)&
MEHQ$C,2,)(RDC&2,Y(P4C)2,5(S4C#0FL5(AGL)6*M2V]UR>)(_/V_6W^YTH
M=[$?<SQ&1F)[JS:]4L3.D";7N$QIHH[6[9Y6$5^<V8P[:FK?48O."-(8,K)D
M)&(D9B1A)&4D8R1GI&"D9*1BI&:D,8F5(C%!?Y4B=CCY?,ZDJITS1:[L?%S;
M^9CK848:%9&[/DSCY,(>MNB,NC0RLF3246=C2I.S4MP9@73"2,JDL\[&E":[
M_KPS`NF"D9))5YV-*3VR)Z3NC$"Z,8F5?]F7L`K`<2^*I@W<C*VYG5F-?'$?
M&SDBV[PY6D%,`2`SN?XE&;@`*[\][_K3$4E1"`9MAZY=,I:`5'],K@<1H%YG
M,5@I9Z.K"4E:`@;H+`6$SC)`O<YRL%+.QMZ4['H+,$!G)2!T5@'J=5:#E7;F
M3\@CK0$#U>@T#\:>/#&;W8L/2D0=L,6V'S)]WRK<#GSS)'!%\C@'HW$W+@!D
MCG-4B'(X]E2%7%R0]2%$&8AH"0B=18!ZG<7:"IQ-)V0-2U`&G*6`T%D&J-=9
M;CL;>1YY@!4H`\Y*0.BL`M3KK";.1E>L0M0\BRP*9_8B(H_P)U2(.O%;%:*0
M;Q;QE$SM7#8]Q6-%K#1PM0$@<YRC0M3`B?AA+%&D*Q`ZM:9D%I9@A4%$@'J#
MB+45"8+<\XE3BP:1@A4&D0'J#2)W!T&NL7!JT2!*L,(@*D"]0=3N($AM-TXM
M(PB[`D5MGU*!TIP\QA3R\;Z9R\Z%K#=$`2!<W!8:3=`JY%9+0&@5`4*MF&LE
MW"H%A%H9(-3*N5;!K4I`J%4!0JV::S66E9T+V9\X8350[0RA!W?UO7P_04Z\
M6483NM+.P0KK+P!D#G0L!TK>OA,OV5/#$81OU)_>:F@K#"+Z5!"QMB)!D(=B
MXM2B0:1@A4%D@'IG(G<'038]A5.+!E&"%091`>H-HG8'0?:TC5/+",(N0=FI
M.:$$56/'*D&%1!L`JG(NW]`556F@@*,%1R%'2XXBCF*.$HY2CC*.<HX*CDJ.
M*HYJCAH+V;F0G1HS%W^K"R#?'*0KMD9&'P"L,&N!1G8G@)\RE):P@G2'.!#0
MDJ.(HYBCA*.4HXRCG*."HY*CBJ.:H\9"=M9D4^<OLO8+C0%/]8JL.TVA#UH#
M,-#,K.X[F:O+A#4']$#10H`TAAPMN7R$5N:FD2S0,5J!?,)1RN4SM#+ER=*;
MHQ7(%QR57+Y"*U.>+*HU6H%\8R&[)&03R2R)#\Z!JN=DI5JWH<1!PMB'DQ/_
M7+Y!+I_^^"`)`)FI=CS7]4!UQO4F([*O#5$&+G<)")U%@'J=Q6"EG/D74U(9
M"1A@X:6`T%D&J-=9#E;:F7]-SBX%&*"S$A`ZJP#U.JO!2CN;7I*J:<#`T2J0
M?:832D2UI:P24>B#5H$VPDUKX#G&.2I$6>G3N^?1+DB(,E@AS%F$5EC'S%FL
MK<#9I4?*,4$9<)8"PBO+`(G#2'?3,&<Y=38F!\L"9<!9"0B=58!ZG=6V,W]T
M39PU*".<68N(W-.?4"&MN7U0T\@Z'+!6`1AA\0>`>HM_H:W(MIS<;J%3R]B,
MJK,!6&$0$:#>(&)W$&22$Z<6#2(%*PPB`]0;1.X.@M1PX=2B091@A4%4@'J#
MJ-U!T%:!4\L(PJY`V<;Z_!HE^]IDXZF1T1>8<Q0`PG/M0B.S5<"MEH#PMHP`
MH5;,M1)NE0)"K0P0:N5<J^!6)2#4J@"A5LVU&LO*SH5LS)V0"]7',Y\7OD*R
M`KK5D;<*P`KK+P!D#F3+ZD);D>6`M@J<6D;]Z>5`AXI!1,Z!]'`2NX,@W='$
MJ46#2,$*@\@`]<Y$[@Z"S$3AU*)!E&"%052`>H.H/Q5$X]0R@K!+4#;Y3BA!
MU1.T2E`A\V,S<OLB6P7X29J`HP5'(4=+CB*.8HX2CE*.,HYRC@J.2HXJCFJ.
M&@O9N9#--#,7?ZM5(-9EMF)KA,?[.5@9!TJ-[%;!%2GQ!5K!1BKD:,E1Q%',
M4<)1RE'&4<Y1P5')4<51S5%C(3MKM-EF9.T76@7RJP+TP:O0!ZT"&&AF5K?N
MS-6%MPKT0+-5P-&2RT=H93Z$R($P1BLHG(2CE,MG:&7*TU8!6H%\P5')Y2NT
M,N7)H:]&*Y!O+&27!.WY];<*?-[<TTAN'8SG.FT5H!4$%0`R4^UXKBN/XKDN
M/T5_Y9/)#%$%A)>`\*$5`>KU%6LK[6OJL0>W[CWBV3T%8?25`>KUE8.5NB[O
M8D0.#048H+,2$#JK`/4ZJ\%*._/'I.(;,."-`I^V%S\H$-XV;!5$ET@\:;L"
M89\I`"/<L@:`S'&.^E`.Q4Y=UL>(?C0C1!6L#S5$K).`(K3"&)FO6%MI7V/Z
M8<,$54`X!82^,D"]UY7;OJY\4HL%JH"O$A#ZJ@#U^JIM7]<7[-2F)ZP]/-C+
MAVSDF?N`#ZI#]?VL/9EN!9H%S)L$V@@+/_`=XUC&%MK*/A70X@N=6L8V5)\*
M6!"1<R`_%:B!)`BRD"5.+1I$"E8X$QD@<P;93.3:B@1!GAV%4XL&48(5!E$!
MZ@VB=@=!GA6-4\L(PJY`V?0[H0)5C]"J0-8VG,N-I6QLXYT4`,(#]$(CJTF@
M!Z+5$@:B5@0(K6*NE7"K%!!J98!0*^=:!;<J`:%6!0BU:J[56%96+N2G/T_(
M16MNMPPU^J!)`%98?P&@WOI;:"MR$]">H5/+J#^U'(`5!A$!Z@TB=@=!'O^)
M4XL&D8(5!I$!Z@TB=P=!>X9.+1I$"5881`6H-XC:&03]>$?CU#*"L$OPM)ZA
M^&89/;IH-,*;8,Y1P-&"HY"C)4<11S%'"4<I1QE'.4<%1R5'%4<U1_+;^G(*
MU7RI7*AOWZOOU;YN]D^;^>;EY7"VWGV7WZP7NXV[FPZKK_W?C[KO_9-7Q!\$
M^.++C1KA]V)`6W"4^[/&:3\2?UC`H?-E//LB+L'A8#QKVK61.IC,FO;`2OGE
MK&F[2)1?S9KV2Z:4>T)(?!B#>PZ\JYE\ZYN_(M[JGLEWK?DKXEWJF7S#F;\B
MWF`6?ERO!+ZX1/6,([$%_F06BD,C5Q,GZ)D\#/-7Q.%W)L^Q_!5Q;A5^7*_<
M^R(KXF#`QP3363-U\>M9V/:&2,31]4Q\X)_K9-<S\6E]SJOK6>/BXE,H8K;:
M/`X[%^(/0+ROGC;Y:O^T?3N<O6P>11E?M-^.V:L_(:'^<]R]B\>9^#,0NZ/X
MTP_MK\_B3WULQ,?:+\Y%8^-QMSO"?T1(P^Z/A]S]#P``__\#`%!+`P04``8`
M"````"$`3D>LG>L'```%(P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6RLFMN.XD80AN\CY1T0]PNX;6-`PZP&?(J42%&T2:X]8`9K`2/;L[/[]JD^
MNJO+R[*CW`S#U]7E_JOZ4+9Y^/CU?!I]*9NVJB_KL3>9C4?E95?OJ\O+>OSW
MI_3#8CQJN^*R+T[UI5R/OY7M^./CK[\\O-7-Y_98EMT(/%S:]?C8==?5=-KN
MCN6Y:"?UM;Q`RZ%NSD4'7YN7:7MMRF(O.IU/4S:;S:?GHKJ,I8=5<X^/^G"H
M=F5<[U[/Y:633IKR5'0P_O9875OM[;R[Q]VY:#Z_7C_LZO,57#Q7IZK[)IR.
M1^?=ZK>72]T4SR?0_=4+BIWV+;X0]^=JU]1M?>@FX&XJ!THU+Z?+*7AZ?-A7
MH("'?=24A_7XR5OEOC>>/CZ(`/U3E6^M]?^H/=9O65/M?Z\N)40;\L0S\%S7
MG[GI;WN.H/.4]$Y%!OYL1OOR4+R>NK_JM[RL7HX=I#L$15S8:O\M+ML=1!3<
M3%C(/>WJ$PP`_H[.%9\:$)'BJ_A\J_;=<3WVYY,PFOD>F(^>R[9+*^YR/-J]
MMEU]_E<:"47&"5-.H(=VXM_L,%<=X%-UF$\B;[;T(W!QXT*1Z@>?JA];3`(6
M1@LQW!L]8;X+G?!Y<XA3&1\1[KCHBL>'IGX;P1R&"+37@J\(;P5.=)SE)4WD
MOQ=XB#AW\L2]K,<P?(AI"[/ERV/(%@_3+Y#AG;+94!L/6VRU!4\G=QN[('%!
MZH+,!;D%IJ#9"(?D_@_"N1<N7`]YHT$?">:HU!:Z2^R"Q`6I"S(7Y!9`*F&^
MNBI]6(S#RTAGDW=:CV$V6-E<8A4;:2.W`)&L+2$Q(0DA*2$9(;E-D+H`J[NM
MBAO#+`=GEBQWDDHC'\+9&_DSK'UKC$P*"4D(20G)",EM@I3"_F'G\;92;BR4
MZO%M)/'G9IYN"8D)20A)"<D(R6V"-,"N>+\&;HPU2.*C3<9WMQ!CI*7'A"2$
MI(1DA.0V0;)@0/?+XL98EB20FG[&!9$SX8R-445(0DA*2$9(;A.D"E:_K8J?
M"RR<0&Y_\F3@?K!@29#@T'<W26-D%!.2$)(2DA&2VP0I7F+%MY<8-\:R)$&R
M2!Z-C5%%2$)(2DA&2&X3I,J#W=Y-I+_@1=//9E)XPIH50J)#WW=F;V]E9%.4
M4)12E%&4(X2U\[/?*FYNI]23E0(<$'J8&X5`GT9;BF**$HI2BC**<H2P&'[$
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M$K%^DB1B'!"0P&0QU:BWRA0*/"EUP?S(*3MRU`LGFM<-]TN550:2*E$TUU*=
M:V\]8]!+E0@E6B$[T<0J4[Z8RNK27P1.W9]KDX&L\H+A?JFRO$!2)>JSZEQ[
MZQF#7JI$**L*V5DE5IGRI;,Z8Q&5:O?"6>55A"7U?;N6+$50!"3JD^W<3&X]
M8]!'0"*4;(7L9$L4,#/5,^4KA'5A%GKH.RLI5U;2/0H"(!2$VWN8L,9[F$*0
M;WL`[OSNK8QDA>RD:V0E72-K*2L4]E8YLL+ZG*+H74EFM%92"))LRW;G>F_5
MRY:^8,0:)<H*/C1*%;(SK1#*-(N<*^;:%UW9L!^@3+\O$K(XLJ>[\`L/A?`$
M<.=\;Z4UQ@JA"2#=VWNYL@K@V#,3G)YDVDINL%X0SICG%.8YNAZ>)+Q*NK$3
M?*JOWZM?K`,>A+@'O$*6Q"U%,46)1OT<3S6R5X*\(EH)$H$QQ!F+=(JT'ZQT
M6HU!5D0MV5=06XIBBA**4HHRBG*$L!A>!5D9^X$863.A62N1#YK,M`K=ZF?+
M[QMY^=RG(:8HH2BE**,H1PCKXW7._?ID583T2>3;R2(H9@0E%*44913E"&$Q
MO$:QQ/"=YUU/5Y@L=I!.B?!M7N`^)U,=K=N@F**$HI2BC*(<(2R=5Q^6]!_,
M4UFK('T2H3P2%#."$HI2BC**<H2P&%Y^W"]&%BM(C$3.HG,?AO';/7?1$910
MJY2BC*(<(:2/ORJX7Y^PQK600G:R*(HI2BA**<HHRA'"8@8*GW<M.GCIX1YK
M"CF+SCEOM[V5.?(I2BA**<HHXN]CQ301#T"D=/E^5;[P.Y?-2[DM3Z=VM*M?
M^;M3GS]K,%B^V-VP:,67+XR0M"R@93'8LH06\=#`[>//X#VQ*+U(BWF#[+9X
MT`+/P09&X#%H$;4^Z>-#BSCBW186P-C$<45:0F@1QP%IF4.+"*/;`ET&>T"'
M07L(YF`L(92#D81`#L;1@SC"@\ZAF"Q7_/YIH(7-5EM95;LJF`<M@Q%F#%J&
M(@PO_)^&^(8G:_#J$,(A#HD:RM-3L'J""3P@`_(WF#XO6/''6K0'/,:",0VU
M;+P0@C680&\.+8,I]")H&4RBMX`6D<:IB3#\".%:O)1_%,U+=6E'I_(`"VTF
MGOPU\F<,\DNG*NCGNH.?'XAB^@@_-RGA6=6,OV8YU'6GOX#$J?D!R^-_````
M__\#`%!+`P04``8`"````"$`Z$)%0(<:``!'A0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6RLG5MS&SF2A=\W8O^#0N\C\5(L4@S;$Q99]WO%[.ZS
M6J9M15NF0U*WN__])`HXE0"R3(O>F8>1^^/!054EL@`DB^2;?_[U^.7BS\/3
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M]/"A?/AZH*M-<5(1^.UX_%U)LP\*4>-KT3H>(M`^77PX?+S[X\M+?_R>'AX^
M?7ZA<*_HC-2);3_\O3\\W],5)9NKQ4HYW1^_T`'0_U\\/JBA05?D[J^WEPOJ
M^.'#R^>WE\OP:K6>+><DO_CM\/P2/RC+RXO[/YY?CH__IT5S8Z5-EL:$_AJ3
M^>D&@6E`?]$K=WJB(SJDX6CI+SK:7&U6JR#<K(F=:!F:EO37M#RM7QL]_45/
MIT^)$FHX-/H[GE*P6*TWPX4\<60WIB']14^;J\5F-5^%*@0G6LYIM`Q]JG^8
MML'K+H>*CVY*_T"WIT]P3D-$-^&QLKB:![.?'B:&Q]P>'Z]JB7$RMP;*Z4M"
M5TP?)/WCE>>%H3'GL?&Z\\(8F5N#9';UJJ#/,5S4/TX>Y[5.V"'_]W<O=^_>
M/!V_7]!-E:+U_.U.W:+G6^6"S-<#9KP7_.A60/<`Y?)>V;R]I#.@+'^F^]>?
M[\+9^LWUGW3/N3>:6ZF9NXH=%.H&HVSW/HA\$/L@\4'J@\P'N0\*'Y0^J'Q0
M^Z#Q0>N#S@>]!:XI/&.,*%/^$S%2-BI&N+JW`!RTA1<0*-!D[X/(![$/$A^D
M/LA\D/N@\$'I@\H'M0\:'[0^Z'S06\`)"-V!G(!,3Y/(#:5^>TFY->;&<GWC
M7NA;K5GJ"5$-_9T@>T$B06)!$D%203)!<D$*04I!*D%J01I!6D$Z07J;.*&@
M6_H9H5!JNM.1VQB+<+;Q8J%%:\K&413,`U>T&T5C:@@2"1(+D@B2"I()D@M2
M"%(*4@E2"]((T@K2"=+;Q`D/S9]GA$>IA_#@HMYJLM1KSB$O!-D+$@D2"Y((
MD@J2"9(+4@A2"E()4@O2"-(*T@G2V\2Y\+0*.>/"*[5[X379;,;98J>)%8J]
M)BM:<EJ)LG(3)1I%B&DL2"*LTU%C6X>N=3:*8)T+4@CK<M38UMY:I1I%L*X%
M:81U.VHLZX4WIW:C"-:]39P@TGKJC"`JM1M$3>P@:F('41,*(@XG$B06)!$^
MJ=!D@N2"%,*G'#76-9Q[M^AJ%.&@:T$:8=V.&LMZL70'53>*8-W;Q`D/3>EG
MA$>IW?!H8H='$SL\FMCA$206)!$^J=!D@N2"%,*G'#76-9Q[JYEJ%.$:UH(T
MPKH5FDZ0WB9.+.@F=$8LE-J-A29V+#2Q8Z&)'0M!8D$2X9,*329(+D@A?,I1
M8\5B,7/'<S6*QE@(T@CK5F@Z07J;.+%0A00G&'I3>:6**R^?'^Y_OSW2A$'K
MJXEU\Y(VCV9+J5S<(`W&M)2V9B6#[#`9M+!N:1+%$B72*Y6J3*)<HD)ZE:RR
MX^7M@2M6C0&3J)'VK51U$O4.<J.FMI]V*6`B.E1*&L.C=ZNTEL9QWJIR$$5L
M07]X0;#P5\ZL0L,]T%"D'*(?`2V&8L)RMEJ'"V^2CJ'A9@D0;Z12(!I.XU$M
M0N^H,J-:Z?YF5TMOL9&S#0Z[`.+.2B`^I,IU7E]Y-\M:-FF`V+@%.GD6'53F
MJ@6;97CC#;`>&ET1MNL,JC9WS@C0VV-G!&@4T'Y@O-94R7)O2;NA'QHGP3AT
M]D`\FB*#@ODP`N;KY7*QFGEWMUBV2X#8/06R]WT30T`?_"K0'5XMQ!#0@@4?
M9&&<-XOQ5$H@5E5`?$@U$*L:(/9J@5C5`;%7#S2HW)Q6^^8S<EIOLYV(:A30
MS=Z*J'=E=FI'K3,?R;$'XDR(#*(<L[U$5ALO9Z1O/%4">TZ1%,AI*!-=VW.B
M>VO+G&UP+H5!&]Z&ED#A&/@*B"ML-1"K&B#V:H%8U0&Q5P\TJ-PHJ^WW&5'6
MNW7RPPG>JLHXQ<_+6^_*[(S*R5O=T$J)R*@HC3C*B[7G%<.+#R(QR,JE%(A5
M&1"/_QR(5040YU()Q*H*B+UJ(%8U0.S5`K&J`V*O'FA0N1%3^W8[8K^V0M*[
M?R>0&GGIZDTY._76GI^NIB&?9&14*]J><NHOQ1W8>#E9)]-5])CB()R&,EUU
MPS%=_>5$SC88S85!3KIJFPVG6`45IU@-Q*H&R$Y7X=5!Q5X]T$2ZJOV^'?R?
M++1T><")LD:4B'9DO(E^I]Z)4E'F$;D'XG$;&81I=C&_608WWH")9;L$B-U3
M(+K#C@-F8IK5AS5.LZ&W`\_9AB,J3J64JLH@XTSO8;KKCEHV:8#X+%J@DV?1
M&14NV_IF/;^Y\1:5/5O1F;@W`%54.&,,Z!J$,P8T\C)=++6TBI;DN)9[]3ZC
M&A;VQ&R07C8NYC/U/_?BQ;)9`L3F*=!/DEKW9Y)Z<;7V:F0YV^"P"X.<I-8V
M3E(;Q(E8HZ&=U$9E)[7PZM"0O7J@B:16E8DS`JH+&4Y`-?+F8+'2TBHGJ0VR
MDUJCG\W!HF&BW@*FP>',P0:Q?0859TT.Q*H"B*>4$HA5%1![U4"L:H#8JP5B
M50?$7CW0H')34-4OSHB8+G<X$=/(2T'OKK.;:Y63@@;9*:B1LS:>6#6)AHFQ
MM_(B!>(1GP'Q6,Z!6%4`<5Z40*RJ@-BK!F)5`\1>+1"K.B#VZH$&E1,QNF6Y
M$?NE5=/@XM:5#/)2SYL$=T9EIQX0GV0$+\H:G@3%\A<->?`F!MFI!\2J#(B'
M>`[$J@*(TZ4$8E4%Q%XU$*L:(/9J@5C5`;%7#S2HW$">5VI2!26Z*=FI9Y#Z
M,U[E8.E-(SM681K9`UFI!Z1GOWFPF%H!0<3M$B!K^@,Z/?T9E9G^YE?^TP`Y
MV^"X"R#NK`3B0ZI<YZ6H-<DF#1`;MT`GSZ*#2E^V8'.S7*S7WC:]AV@X1G<,
MJ&+*ZV^_"UU[<<:`1E[6^BL@T]#)6MW0WK0:U4\F3'CQN$\,<K)6VV]8E4'%
MV9$#L:H`XDPK@5A5`;%7#<2J!HB]6B!6=4#LU0,-*C=BJG)R1L1TH<6)F$;>
MA.DO<2@NPP*51^0>B(=Z9)`S809+;R\1<T.^3RS$[A0J[C$%.ID#&1^$>N1M
M=N4-OIQ=.)'UV5GS=6E4]CH6B.?%&HAGSP:(IY\6B%4=$'OU0!-SK"KHG!%D
M7?]Q@JR1EY;^JHCR<0@RC[P]$(_/R*"?I:7QXH:):>BDI58Y:6D0'T2.ANQ5
M`'$JE4"LJH#8JP9B50/$7BT0JSH@]NJ!!I6;EJH<84?LUU9%NJCA!%(C+UO%
MJDBKZ$:/(;Y7#QS3?!WP248&.;4DN;PU*EHXP"LQR$J7%(B'>`;$0SP'8E4!
MQ.E2`K&J`F*O&HA5#1![M4"LZH#8JP<:5&X@59'C_Q](72IQ`CE63_@F&"R]
M8L5N,:IP\?<&!7R2$5"HWR19WBS6-W/O#A[#BH=T`L1#.@6B&^*XAI/E(J,R
M19WYU<9;Y.5L@^,N@+BS$H@/J7*=O9FCE@T:(+9M@4Z>0V=4IEBT#,/%DCYI
MX!98>K:B\W`'AJI-^`-C07!X,_U?QV\_>C.=QAK>KE5R?PVMD9O?2^^P=J:A
MD]^ZH96F$51F#;VD3QVL_5IN#)&=WL:*[QXIJTX."]UP7$-OO/CE;,/#0G16
M2E5ED'%>R#6T./L&+GP6+=#)]4,'E;YLR]7JYF85>)6W'J*)-;0JS=@#XW0E
M>:$K.<ZM02-Z?((O=N`MXG>FG?V,A4211+%$B42I1)E$N42%1*5$E42U1(U$
MK42=1+V#W+15Q9HSHJ-K.Q0=#D4X\Z;;6WJJ1>7QDF[6XTTS\!]6V+$*@W\O
M4211+%$B42I1)E$N42%1*5$E42U1(U$K42=1[R`G8DO*UC,B-LC=NH1!%!Y<
M^)U$>XDBB6*)$HE2B3*)<HD*B4J)*HEJB1J)6HDZB7H'N;'P:T2_M*RE3U3X
MTQX0/QZV`^)USMX@&BMJ9[>8^1\`B%B`2,<2)=(Y995Q]F:NC`5PSB4JI'/)
M*N/L+94J%L"Y=I`;`%7&>/WM:ZFK'O;D8I"J`5GW*G]V814.:@]T<O*,C,JI
M`,@]!7O!/@'BZ3H%.MECQCT.%_A*+#K8!IT50-Q9"72RL\KO;$9ORUK_\S;4
M-9M2UVX@5<7AC$`JN7=7TTA5#:Q`>D>P6QH5+X_W0+SJC@SZR9:>&]H]>I-A
M`A7WF`)QC]E4CX&_RLJYX8D>"ZBXQQ*(>ZRF>_3>GZ^YX72/;A!5J>*,(.K*
MAI.-&KG9&'BWB-UR5&$$[X%XV1X9]+/4,U[V.`^6(HBBQU3VF$WU&`3>K3/G
MAM.7='BVM(#*3LGQ4'':U72/WJZYAM>/SM$-HBJ,G!%$74=Q@JB1FXF!OV=3
MRWE*8:H9X6SV0#Q*(X-^EHECC_!*X,7V*1#;9P;1UQ:HFV6PF/N/#N6R40'$
MUB406U<&F9J`=_:UT\"]_JK$<<;UUQ41Y_J;(HD3[L"K?^S4ZEQ=?QY@>R`[
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M'<C:[@)9VUV#?KS=90'"&DN42.>453_8[K(`SKE$A70N6?6#[2X+X%P[R`V`
M7V\X74NE6KZ_2S)(/?;"T\W2WR5!Q?/H'HCGT<@@9X$=K+SE;LP-[1[]!394
MW&,*Q#UFTSUZR]V<&Y[HL8"*>RR!N,=JND=_-<<-IWMT@WA>S8+>H11!U$B]
MW<I!%+LDT]!>8`/Q,C4RR%E@!RMOL1AS0ZM'L4N"BA?&*1#WF$WWZ"UY<FYX
MHL<"*NZQ!.(>J^D>O4%?<\/I'MT@JCK"ZQ=^@2X[V`L_@]Q,%+LDJ'B4[H%X
ME$8&>9GHY5@L&R9`;)\"L7TV:1]Z"Z-<-BR`V+X$8OOJ5?:UT]"-A=H7GQ$+
MO8UV8F%VUD[M2.R8U-,BWHX5B`=;9)#9]WD7*>8&TX-LV/PG4/&P3H&XI^QD
M3SDW.-%3`17W5`)Q3]7)GFIN,-V3&RRU53\C6'IG3\%B[W#N%81NZ<U_%1EW
MT1=ZJAVK,-7N)8HDBB5*)$HERB3*)2HD*B6J)*HE:B1J)>HDZAWD1DR5`,Z(
MF*X8..FE$84'%WX7"+27*)(HEBB1*)4HDRB7J)"HE*B2J):HD:B5J).H=Y`;
M"[7K/R,6NDC@Q$(C^^L)`E-*L)?:&KE?F^-_""HR#:TOFX@E2J1]RBK.ZL!_
M0B=C%89-+E$A[4M6V?;>"J-B%>QKB1IIW[+*LA=?H<,JV/<.<N-Z7J4B&"L5
M\+XUR(FK*3C8<=7(BEAD&EHHEB@QB,J6Z#&5JDRB7*)">I6LLBZI_VQ.Q2H<
M1"U1(^U;5EGVXEMU6`7[WD%NQ,ZK5*@'F&B&<C)1(R=B&EE7>6\:6N&))(HE
M2@RRO%*IRB3*)2JD5\DJZY**+]EA%2YI+5$C[5NIZB3J'>2$9^67*D[OE`>Y
M&QZ#[/`89%W2O4%V>"2*)4JD5RI5F42Y1(7T*EEEA4=\[PZKQO!(U$C[5JHZ
MB7H'N>'Q"QF_5$E:R?J&04[4M,J)FD942<)Y1Z:AA6*)$H,LKU2J,HERB0KI
M5;+*CII76ZY8A:.O)6JD?2M5G42]@]RHG5>Y4-M1[YYGD/O^KO]Q^1VK<()[
M(-XV1D#F<<[9ZF8V#[UK%4/$[1(@WI2F0'953#[E:U3T1]7R9E?^@B5G&QQW
M`<2=E4!\2)5!]$<YKZ^\\DLMFS1`;-P"G3R+#BISV>A+K>DA6*]4T$,T'*,[
M!LXK?*QDX<,@M6ODZE7HE=1V1F57KX!X8QK!2W__SFJ^H*\@][?<LED"Q+O>
M%,C>:$X,`7TZ9G._\#^]G[,+CP#=Q/J41VE4UJ<\*B`^HAJ(3[<!X@\MM$"L
MZH#8JP<:5&X\55'C]3L*52?T<UHC-1=S//WO)=J9AO;;S4"<")%!:OBQ5^BE
M0\P-624_,&54]J<R@'@CF@'QIQ]R(%850+S\+8%850&Q5PW$J@:(O5H@5G5`
M[-4##2HWB.<5559C406C]-8@-RD77HET9U1.4FHO>M@#7I%1J<,=@RB?>8,7
M-TP,LE(E!6)5!L3#.P=B50'$J5("L:H"8J\:B%4-$'NU0*SJ@-BK!QI4;L3\
MHLJO+8!DK45]>HD2U,M&[_Z^,RHG&TU#/LG(J)P/1`6AMX^.X>5,.^+CBT;E
M9*/NT?I(8085C_H<B'.C`.(,*H%850&Q5PW$J@:(O5H@5G5`[-4##2HWMJIX
M<L8M5==:[*WA2B/W#9ZEM[;9L0JIMP?B81D91&]1J;7%?$G?41=LO,2.9;L$
MB(=S"O23.=+4CO`5=7/ZP(C]/_<C13F;XBP*(.ZZ!.(3JPRBVXQ>-'GCLI9-
M&B`V;H%.GE-G5.8B+L+-+)C/O0Y[MJ(S<4?$>>6=E2SO&.2FM5PTZ89.6AMD
M3[(&Z17@8D5?P.A_)CXV_5D?GTJ`>,69`CFI[Y=M,J.B25T%:GGE#^2<;7@(
MZ&.T;A>E45FWBPJ(T[(&XN1M@.P4-_:LZJ!BKQYH(L55H>:,%-=U'2?%-?(F
M7&^ELZ.Z@KJ;.Q.N09P)D5$Y$R[]3I";:#&\G)$N[]/:WIF##>(>,^.UX43*
M@5A5`/&44@*QJ@)BKQJ(50T0>[5`K.J`V*L'&E1.5H8T;,\(XB!W:T0&N5DI
M5DU&96<ED)65!GE+7V_BCKFAM;82030J*WM2(![Q&1"/^!R(50409T\)Q*H*
MB+UJ(%8U0.S5`K&J`V*O'FA0N4'\CU220EE),LA+4"\>.Z.R$Q2(3S*"%]UU
MQA5QL/8WJFAX.D&-RDY0($Z$#(@3(0=B50'$254"L:H"8J\:B%4-$'NU0*SJ
M@-BK!QI4;FS/JS>%LMYD$*6>=>'%5_"P"O//'LA.4&U/WSTR+*16(7V7C/_0
M32S;)4#6O`ET>MXT*C-OSJ\"_T$GML%Q%T#<60G$IU*YSNLK[YWR6C9I@-BX
M!3IY%AU4^K*M-AOZG3@_`CU$PS&Z8X"RX9R;M))[-VF-W$062Z=0JYQ$-HB'
M;V146`<&`?T&I$ACT2R1YBD0B<=;@JPW&959XP97:V\/D+,-#P'=OW6#*(W*
M+C@!<2+60'R^#9"=U,:>51U4[-4#323U>06G4!:<#/)F77_I9%3.K*N]K$5M
M9%3NK.M?Y1A>SDB7LZZV=V9=@WAVRXS7AF>W'(A5!1!/(B40JRH@]JJ!6-4`
ML5<+Q*H.B+UZH$'E9N5Y!:=0%IP,<K-2+IU,=8E'UMXTM`M.!GGK7V^JCKFA
ME7$RB+I'*WM2T]#*G@R(CRL'XKPH@#A[2B!654#L50.QJ@%BKQ:(51T0>_5`
M@\H-HJJ_V)N87ZI!A;J*8^]M#/(2U(O'SJB<!)4U**-2U9;Q/AGXW\4:P^LG
M":KMG00UB!,A,UY.@@I5`14G50G$7A40)U4-Q*H&B+U:(%9U0.S5`PTJ-[9^
M#>K78BM+4^%D:<I;F>Q8A6EI;Q`]9P84`9GOZ0G7-POQ<<D85CS*$R`>Y2G0
M3Z93KS3EU\%RML%!%D#<60G$AU099";J4'PABVS2`+%Q"W3R+#JC,HL0^K#J
M3;CT/X#4LQ6=B3LT5.U#I#W]%#)EF/KA&WQ7S^M_!2?4U13G%J"1^W2S^-X>
MT]"Y!>B&]#`V(A`9%3T`K"N8ZEM[_(<[8UCQ*C<!XB5K"N3<)T3!RJC&A;?_
MH'O.-CC(`H@[*X'XD"K7>>5_%U\MFS1`;-P"G3R+#BJ]\`YFZ\7LQJ_S]1!-
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ME=RJQQ[E!:%G\NB5J=.FQ\&V-3V--=%F-:=7IDZ=GGS=JH>(9!MZ`)9.9BI8
M]*`EO3)U;/1`'[TR=6ST+!E=@JECH^>5Z)6I(]@'LZWZ:)\\-OHHWU9]-$^^
M0A_%HZLS]<HMG<_M9#\[>F4W^<J>7E$/B,E^Z'GGK7I.3+Y"CSUOU8-@\A5Z
MB'FKG@>3K]"SS'34D]>:<G8J95L*SJ2>0C,9&0K,9%SF%!?Z)39Y3/2]0UOU
M/4+R%?K>H*WZ'B#Y"GWOSU9]C\_$*^&6?K=T@M.)3YU'2<-_ZCQ*&OQ3YT$_
M:;>M)\^C";?J-^IDU[?A]G;RA5VXW4V^L`^WZL?ZI%42;M5/]LD7TG"K?I)/
MOE"$6_7#?/3"]7@S>G[WYMO=IT-U]_3IX>OSQ9?#1[K[SX;?*GQZ^*26]OH_
M7LS7+/YV?'DY/E(9[/+B\^'NPX%^JYN^]_?RXN/Q^(+_4!U\/S[]_OSY<'AY
M]V\!````__\#`%!+`P04``8`"````"$`B0O?CPT)``#/*```&0```'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6RLFEMSXCH2@-^W:O\#Q?L!;&QN%7(JX/NM
MMK;.[CX3<`(U@%/8F<S\^VU9:LM2.T!2YR5./K>ZY;Y(:L</?_XZ'7L_\TMY
M*,[+OC$8]7OY>5OL#N?79?\_?WE_S/J]LMJ<=YMC<<Z7_=]YV?_S\9__>/@H
M+C_*?9Y7/=!P+I?]?56]+8;#<KO/3YMR4+SE9[CS4EQ.FPK^O+P.R[=+OMG5
M@T['H3D:38:GS>'<YQH6EWMT%"\OAVWN%-OW4WZNN))+?MQ4,/]R?W@K4=MI
M>X^ZT^;RX_WMCVUQ>@,5SX?CH?I=*^WW3MM%^'HN+IOG(SSW+\/:;%%W_0=1
M?SIL+T59O%0#4#?D$Z7//!_.AZ#I\6%W@"=@;N]=\I=E_\E89*;9'SX^U`[Z
M[R'_*%N_]\I]\>%?#KOD<,[!VQ`G%H'GHOC!1,,=0S!X2$9[=03^=>GM\I?-
M^['Z=_$1Y(?7?07AMN&)V(,M=K^=O-R"1T'-P+29IFUQA`G`S][IP%(#/++Y
M55\_#KMJO^R/)P-[.AH;(-Y[SLO*.S"5_=[VO:R*T_^XD"%4<26F4`)75#(:
MS&S;FLRFH.7*2$N,A*L8:=PW$-36\X:K&#@?F#/;L"=LWE<L3L1`N.)<!X8U
MNC4,ZJ6V!]>O370N!L+U:Q,U(!=X:%A2B-C<,U4#P\%^^=IDC3':A%_$T-G`
M,NWIK,Z'*WXU,)3LESNF.^2)6.>ULZDVCP^7XJ,'BP6D6OFV84N/L6"Z,*.Y
M[2;'/TMQR&VFY8FI6?:G_1YD;PEU^?-Q8HP?AC^AEK9"9D5E#%5BC1*L<)A:
M1P>N#CP=^#H(=!#J(-)!K(-$!ZD.LA88@FL;_T)2_!W^96J8?]$S*P32X:;F
M3)3`(8X.7!UX.O!U$.@@U$&D@U@'B0Y2'60MH#@3RD1Q9O>RBSG)I)=]6$*:
MG+2F,]5)*RXSY@LL2[DU(0XA+B$>(3XA`2$A(1$A,2$)(2DA69LH+H02_X(+
MF32L#*"M\>'$L#0?<J$Q+/&-D#73L[$1:M*1$)<0CQ"?D("0D)"(D)B0A)"4
MD*Q-%+?"+O@%MS+IVJWHC!4GJ@^GJI_7C0R.<@AQ"?$(\0D)"`D)B0B)"4D(
M20G)VD1Q(>2/XD*^$PW8D:;:'[8_5@6D%RRS'44_AAV'[T-,B>I90>;-TKD6
MA)_/ZFV&$W->;USF2,]PM[F/GO<(\8G6H)%AVR%HU?;#L+F/6B-"8J(U:62$
M5JW0TN8^:LW:1/$X;->*QSL\"\<[="V35EW+B0D'IE;A:T^Y%D)RA76:83A#
MEQ/;K/T_UM87C]^=PJ8@S8SG:G'XQ$Q`S(2J&5O5$-UC)B9F$F(FO6HFNV%&
M"1!K&]N'L^L!8M)J@#@QV\NW-=/<NQ9"5E,@3C.L"1`GME4'R!YHNZC7#+@6
M(6(G:(:AG?"ZG8C?GBK/HV="3.PDQ$ZJV=%2(;MA1XD1=!I?B!&35F/$B59$
MVH360JA51,TP])W+"111*PBSB9KD'A=2:VFF;30^L180:V&G-2TO(F$-=DU9
MN;JUF%A+B+6TTYJV!&0WK"E18^V>$K9O[3:U%C6<`JDU-Q^I85BC5*OH$,EM
MR17(FM5E9Q@#K5_R<,S5@O!12AH+$$ECH336"M9<LQ@)J7I3QD[/(B%%]=)B
M@DA:3+LM:OM9=LNB&E;6AK57S.^%E3=S<.S%XEH9'*EE.M?W.I1JU2DBV;JY
M`DW:E6KJG8DGI-12U1<[']5+BP$B:3&\RV)TE\48U4N+"2)I,;W+8G;+HAI;
MUA5>B^U?Q1O48N<!L76,8:]IM"58H+',S35%#D4N11Y%/D4!12%%$44Q10E%
M*469@E2_PNJA^/7Z*8,U@]Q_<IV8&-J&M1)2:D,SUX\>4@H+S:'(I<BCR*<H
MH"BD**(HIBBA**4H4Y#J9=8ZMK/WAI=YIPGZT#,K]G8.'*^Z5-NZUU((QSD4
MN11Y%/D4!12%%$44Q10E%*4490I2/<HZR;9'O[?6\WY4<;1`K9:1O>-G22]7
M"$>@SYM&*8"A\"CR!8(+2@52ZI/&40K@F(BB6""XH%0BI3YI'J4`CLD4I`:`
M-9;M`-Q(:=Z'*I[FR(9%6QX0Y]I:LC;$0/D@CD"3^K\U=>?O4N11Y%-=`94*
M*8HHBJFNA$JE%&4*4EW*NL,ON)0WDXI+.;+@,-QRJ=8&K`TN9<I-W$'4[N;-
MB;9BNRC%6W5K/)H;UEA;A#P4DM'Q$4F#`:*K!D.4X@8-:SH=V[K!"(6DP1B1
M-)@@NFHP12ENT)Z;H]E$.P5G*,/_6=A^W6^PUK$=P.\M2KP!5>+*D:7T4G/-
M\^O:_+)ORH.W@TA6CRN0Z"NTWL3#`7+K\1%)M0$BJ39$-.%O":RI;6B.BU!$
MZHX12=T)(JD[1<1U&[/)V-)R.D.16K=:5:PS;`?EQD+%&TG%^QQI5:6UNVN#
M2RE5)9#,3!>EKI<0&>?C.)G1`2*I/40DZL4>F\;(TB8:H9`<%R.2VA-$4BI%
MQ+5/C-'4'&DYF*%,/4R)`^N>E#A\JSAJ+6K3+9!6'-K[@;60:A<'(IEI+NJ"
M>FL64'ND%PD.;'?>IMX'^R@E<SM`)"V&W1;UTL&!5RW&*"4M)HBDQ;3;HMYY
MX\#/+*JQ90URN\:^%UO>9K=+#ZJ)';W89%KQT#MOE)+IZR""K:X92#<T(76C
M&4==LA1\1-)B@.BJQ?`NBQ'JDA9C1-)B@NBJQ?0NBQGJZJC;OZ?SA@]S1.>(
MA\N50-#3(%I3Y%#D4N11Y%,44!12%%$44Y10E%+$OD<2?1L\(Z\9_GT1_P[C
ME%]>\W5^/):];?'.OAV"0#P^-!@_;!HOGD`3J-#N0*N]8'UGUQT+[M0K@3[&
M-/$[*>T.G*P7[-Q,M<$Y><%.P?0.G'K!3M<=^!SKJ7O.,*!#TXI-JXO#(W8]
MX9.U>((7&W1**WCRS@>W%_`/2"KOP%-W/4``S]S%$WCB+@Y=(;BORP)T=>"^
MKCO0E8$WNNZL#/`'?[YA$R?XG.QM\YJGF\OKX5SVCOD+I,RH_C?IA7^0QO^H
MQ-NPYZ*"#\GJ%V-[^'`PAV\<1@-H9U^*HL(_P"'#YE/$Q_\#``#__P,`4$L#
M!!0`!@`(````(0#'X"U+804``&D3```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;*Q8V8ZK1A!]CY1_0+Q?8Q8;&]F^&B_`E6ZD*+I)GAG<MM$8V@)F
M^_M4K_1"+&=Y&0^GJZK[U*GN+EA]_:BOSAMJNPHW:]>?3%T'-24^5LUY[?[^
M(_VR<)VN+YIC<<4-6KN?J'._;G[^:?6.VY?N@E#O0(2F6[N7OK\EGM>5%U07
MW03?4`,C)]S610^/[=GK;BTJCM2IOGK!=#KWZJ)J7!8A:1^)@4^GJD1[7+[6
MJ.E9D!9=BQ[6WUVJ6R>BU>4CX>JB?7F]?2EQ?8,0S]6UZC]I4->IR^3;N<%M
M\7P%WA]^5)0B-GVPPM=5V>(.G_H)A//80FW.2V_I0:3-ZE@!`Y)VIT6GM?OD
M)[D_<[W-BB;HCPJ]=\K_3G?![UE;';]7#8)L@TY$@6>,7XCIMR.!P-FSO%.J
MP*^M<T2GXO7:_X;?<U2=+SW(/0-&A%AR_-RCKH2,0IA)0)=1XBLL`/XZ=45*
M`S)2?-#?]^K87]9N.)_,XFGH@[GSC+H^K4A(URE?NQ[7?S(CGRQ*!@EXD!!6
MS\?#(<@=QX@[PE3",9A$P2Q>T.GO>,ZY)_QRSP<=8^X(OV+*Z4-KA1U#,P6_
MPO'^E!Y+-55N7_3%9M7B=P>V`R2SNQ5D<_D)1!.2,;92Q+_3$/).@CR1*&L7
M:(`\'13>VV;NSU?>&Q1+R6VVMHVO6^R$!9&3A-V;P,$$4A/(3"!7``\X2^)0
M)_\#<1*%$!=+W@I@R$1@L!06PF5O`@<32$T@,X%<`326L`M,EB'LZ_$=*=0D
M3FL7JD%1,]99;)E-R/8>$6MG(7L+.5A(:B&9A>0JHK&#+:NRN\^*&$.50S"%
MUL*@Q8Q"V,G2:!9&NM%.&DD)+>1@(:F%9!:2JXC&%`ZEQYD28\I4K&_+$*`E
MD)V%["WD8"&IA606DJN(Q@&2JG)@1\TD!OO^4I4O6PPIA]TZHF((1PH[:$@,
MG1I#@J6FV,Q03!H)_GL+.?#0[&(B%9TR9+:46<LL)%<1C2T<ABK;$59PJ0E:
MQ%BGQ9`XIH=I,/5-1G)<,F)(0*]HFJP#1X8]FDJ;H;R#N5'>&3<*Z-1A[`?1
M5$]G+L/`Y!II.#,>)TV,==(,B1>"M'&%[.2X),V0()02'3@2222U;#*&1#YC
MN`C"V#C><M5'8PAU]CA#8JPS9$@\%PR->7=R7#)DB"HK1Q19+9N,(US#9;B(
MC),N5WTTAC[<#X]3I-8Z1PX-,AI3[P8#R9)#JI`"4I04T"!WQB&AY32(+:::
METZ5-`=6]_,/CR2?=1APL0@V6PX-,B_U#;0;#(3/GD.JT`)2E.90%,C),@[-
MX"12[BQCZ^0B%NO@U4;()[V#DH3[)Q6U-O3FS0?L&64!9F5S1ZB*@3)SU$3G
MD"JZ997Q6+/!*N<0BZ6+3-H'A=^_NG=(VV!L90Z!R"IMJ]:9(U@-M!FD*<TA
M56D&:4HS2%,ZB(T9<[XN%E[/!&DO_G,F6(^BE3N#0%HU$U;-2ZLA$PS2"H!#
M@[2ISZ"(-`KB]<*^M805.UK]:#8-_%#?=CFW&2L2TK7<2<T/?(.B'VU.E&N<
MO.R:5<(@A>*.6RG07H.89NPMF[VKU:@]HQVZ7CNGQ*_D#=HGC8&$V>O]=I9`
M\P7)-7'?3\B),S82P`@]2RR?$$;HD6:-1#!"Y3%&X//"TW@L^.PP-GN0P'O+
MR*K"!%I^&W^*DB=(E#VPC1+HG$?P>0)]GHVG\P3Z-AO?QLF.OLH9Q+:+!%J/
M$?ME`A?V".Y/(47LI)6AX$/'K3BC7XKV7#6=<T4GD'%*[YJ6?2IA#SVOM&?<
MPR<.6G07^*2%H"&%;P.N<\*X%P\PM2<_DFW^`@``__\#`%!+`P04``8`"```
M`"$`<(..`[\,```X00``&0```'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6RL
MG%MSV[@.Q]_/S/D.'K]O',FWQ)-DI[&L^WW.Y=EUG,;3.,[8;KO[[0\H"B()
M<-5X>UXVZ2_@'Q`!421L[=WO?^Q?!]^WQ]/N\'8_=*ZNAX/MV^;PM'O[<C_\
M][_\WVZ&@]-Y_?:T?CV\;>^'?VY/P]\?_OF/NQ^'X]?3RW9['H#"V^E^^'(^
MOR]&H]/F9;M?GZX.[]LW^,OSX;A?G^&?QR^CT_MQNWYJ!NU?1^[U]6RT7^_>
MAE)A<?R(QN'Y>;?9>H?-M_WV[2Q%CMO7]1GB/[WLWD^HMM]\1&Z_/G[]]O[;
MYK!_!XG/N]?=^<]&=#C8;Q;1E[?#<?WY%:[[#V>RWJ!V\P\FO]]MCH?3X?E\
M!7(C&2B_YMO1[0B4'NZ>=G`%8MH'Q^WS_?"3LZC=V^'HX:Z9H/_LMC].VN^#
MT\OA1W#</:6[MRW,-N1)9.#SX?!5F$9/`L'@$1OM-QDHCX.G[?/ZV^NY/OP(
MM[LO+V=(]Q2N2%S8XNE/;WO:P(R"S)4[%4J;PRL$`/\=['>B-&!&UG\T/W_L
MGLXO]\/Q[&HZOQX[8#[XO#V=_9V0'`XVWT[GP_Z_TLAII:2(VXK`3Q097RPR
M:47@9ROB7-U,IY/9S?SCD8!E<SGPLQ697;DW4V<ZN^!R9JT(_.PBN71*X/YJ
M`H&?G<;%5W/;BL#/OW\U#M243+$HKC9]%V?'P1R+7SJ5BZ_(&6,P\,LO7!,6
MBZ-7RZ4Y<C#1XI=?N*8Y7A/\\@O7A"7CZ#7SP6L:R=NZ626\]7G]<'<\_!C`
MT@LW[NE]+19R9R&$<7V0=W.W8OS5@@$KA5#Y)&3NAW!]L!:<8)7[_C!S;N]&
MWV%EVK0VC]S&,2V6:"&6(2'K4;"BP*<@H""D(*(@IB"A(*4@HR"GH*"@I*"B
MH-;`"-+3Y0CNJ/]'CH2,R!'.[B,"E327)`0M<(A'P8H"GX*`@I""B(*8@H2"
ME(*,@IR"@H*2@HJ"6@-&0F!M8@D9P^II?ZCB/2)&W0_A'NOND>ED:D[XH[09
MR\>GN`66C'B,K!CQ&0D8"1F)&(D921A)&<D8R1DI&"D9J1BI=6*D!-9Y(R7]
MJ1#6L.*!6I>+F7M-<B&-QK!5Z(RFD[EIM.R,NEN$D14C/B,!(R$C$2,Q(PDC
M*2,9(SDC!2,E(Q4CM4Z,],`D7I`>8=VD!R?U41(C%RP5G0V.\AA9,>(S$C`2
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MS'B6G1'&X[5$SZL[(\-6K9';;/+=FS%)CM^)H&S`'(6=C8J/.8H,1^/YE*0J
M[D304<(<I9U-CZ/,<#1Q;F;F1.6="#HJF*.RL^EQ5)F.W"G92]2="#@RZ@%N
MT`OJ05B;]2")JV]WYB1OR]9FTAT//,LHEJ65-)HXLARNK\DRX'<B.'D!<Q1V
M-CV3%YF.;J9DF8H[$724,$=I9]/C*#,<C1V'/)_R3@0=%<Q1V=GT.*I,1^,Y
M+8=.A):#Z-A<4`^-N5D0+7+U6_V&S.@2C=1AQ$.DC^,UT5I-X?BDK3_DJ.-;
MM6[()`1HI8(($?4&$=F#(/=V;-6B021HI8)($?4&D=F#(->86[5H$`5:J2!*
M1+U!5/8@2%G75BTM"&-!<D2K0F\;]3^A&G-2@;+9X:KU9ME::<A#-.Y6I56+
MIFJ@SZT"1,HJ1*2T(JX5<ZL$D=)*$2FMC&OEW*I`I+1*1$JKXEJU867F0G0I
M+LB%;&K`V1?7KT?1LH4GAK$:3.D"NT0K57\>HM[Z6[56YG(PHP\*JY96?\V9
M(D`K%42(J#>(R!X$>0C&5BT:1()6*H@446\0F3T(LK')K5HTB`*M5!`EHMX@
M*GL09+=:6[6T(,P2%&V9"TI0=G&,$I0(#OA8E4O1G8&JU)#'T8HCGZ.`HY"C
MB*.8HX2CE*.,HYRC@J.2HXJCVD!F+D0/1L_%WSK?B\]-R"82D7;"1Z2RYK7(
M/..S0X2RPG3['`4<A1Q%',4<)1RE'&4<Y1P5')4<51S5!C*S)MHU?Y&U7SCR
MBT]Z:1HE^LFA'P?JF94#?W+L;P>"E<IL-Q!1P.5#-5#?-)(%.E)6J!5SE'#Y
M5%GI\F3IS905RN<<%5R^5%:Z/%E4*V6%\K6!S)(0[2&])'ZRQY+=)%@84/M1
M?&PIGNO]?0!EA0,]1+T/DA5:R5:`,QV3?:V/!JH6`D3JJ14BZG46H57;=[B^
M(941HX%REB!2SE)$O<XRM&J=N;?D[)*C@7)6(%+.2D2]SBJTPH[*C%1-C0:-
M,[-$1`?I@A*1#2>C1"3J;PTXK9':M'J(X!G='?$L!T$YL.T..`[M>/A*!FLO
M0*2<A8AZG46M%3J;.:0<8R6#SA)$REF*J-=91IU-R,$R5S+HK$"DG)6(>IU5
MIC-W?$N<U4H&G)D5(GI*%U2(;$$9%=)UI52F>:N@-5+%[XDO$XC%I[?X5ZT5
M.1N0V\VW:FF;T?9LP(((K0/I;B2R!T$F.;9JT2`2M%(SD2+JG8G,'@2IX=RJ
M18,HT$H%42+J#:*R!\%:!;;4:D&8%2C:6!=4H.QZ&178-L+4?;-T&/(0J>??
MJD5&JZ`=J*P"'*CD0T3**N):,;=*$"FM%)'2RKA6SJT*1$JK1*2T*JY5&U9&
M+L3->$$N&G.S;=,BXZ[FK0*T4O7G(>JMOU5K198#VBJP:FGU)Y<#M%)!A(AZ
M@XCL09#N:&S5HD$D:*6"2!'U!I'9@R`SD5NU:!`%6JD@2D2]050?"J*V:FE!
MF"5X6>=0[%W)`:9%XUFWT5URY'&TXLCG*.`HY"CB*.8HX2CE*.,HYZC@J.2H
MXJ@VD)D+VCG\6ZT"ES<4$6FM`D3:@;)%9JM@3DI\I:QP(^5S%'`4<A1Q%'.4
M<)1RE'&4<U1P5')4<50;R,P:;!:-15S+VB^T"L01@-YI$OVD58`#]<S*@3]I
M%;0#]58!1P&7#Y65VI).I^1`&"DK+)R8HX3+I\I*EZ>M`F6%\CE'!9<OE94N
M3PY]E;)"^=I`9DG0GE]_JP`^86&IEDBL%=UY#KY;;WX2OFP'@A4&Y2'J?9"L
M6BMXKHNO!L]=,IF^4D'A`)'R%2+J]169OF[HUY!CI8*^$D3*5XJHUU>&5O*Z
MG.LQ.33D:*`U"A`I9R6B7F<56K7.W`FI^!H->*-`O-Q@K!D_*1#9L=,WX8T"
M'.?@SNX*A'V'`(W4EM5#I(_CC8+6"G;JHC[&]"L8OE+!G`6(E*\04:^OR/0U
MH5\CC)4*^DH0*5\IHEY?F>EK[I)-9*Y4T%>!2/DJ$?7ZJDQ?M]?TU*94P)>Y
M?%S6:71YI[%%8B?850=K$J"1*GP/D3[.4AW2H7DJH,7G6[6T;6A[*NAZHCCC
MH74@:Q*T5B0(LI#%5BT:1()6:B921+TSD=F#(,^.W*I%@RC02@51(NH-HK('
M09X5M55+"\*L0-$H_'B3P)5]16-]8CW*96L%JR*FVD.D#M"K%NE-`FX5(%):
M(2*E%7&MF%LEB)16BDAI95PKYU8%(J55(E):%=>J#2LS%Z*[<T$N9#/(R(6E
M/V1I$K16JOX\US+0LAQ(*W(GTIZA54NKOW8Y8$&$UH%\.;`&01[_L56+!I&@
ME9J)%%'OG9BU5F0F:,_0JD6#*-!*!5$BZ@VBL@9!O]Y16[6T(,P2%%VZ"TI0
M-O6,$I1HK#\RZ9-^*4Z><.0!([5`,+3B5CY'`4<A1Q%',4<)1RE'&4<Y1P5'
M)4<51^*E9#4Y,COR)6/Y^N!^>_RR76Y?7T^#S>&;>($8]A</=QWNWF[^Y(K9
M)?P1WGIN"HUR%]Z&MMF/%W63)6+_:;+X!(%:'$P6=;,FD@&/TT7='%0I=\"#
M+"#Z%U>\H6T/]A;?W29C/&>Z\.&371X7?,R]$)]8\[_`)]0+\6$S_PM\N`RQ
MV?[BN6*^;!/FN>.%#YMUK@:GYX4X"/._P,%W(<ZP_"]P9@4_MK]XLT7=-.+H
M#,P7?O.F(>'A?`%?UN<>TOD"OFG/>3E?U#8.WS.!.6DR/.I<P'OK[^LOVVQ]
M_+)[.PU>M\]0EM?-FRU'^>:[_,?Y\`Y=;7A[_7"&-]:;7U_@_U"PA=?MKJ_@
MZ/-\.)SQ'Q#2J/M_'CS\#P``__\#`%!+`P04``8`"````"$`/636"EH#``!Q
M"@``&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R<5MN.FS`0?:_4?T!^
M+]=`+@I9;8*V7:F5JJJ79P=,L!8PLIW-[M]WC`-KDVTW[4L2QF=.SIPQ8Z]O
MGIK:>21<4-:F*'!]Y)`V9P5M#RGZ\?WNPP(Y0N*VP#5K28J>B4`WF_?OUB?&
M'T1%B'2`H14IJJ3L5IXG\HHT6+BL(RVLE(PW6,(C/WBBXP07?5)3>Z'O)UZ#
M:8LTPXI?P\'*DN8D8_FQ(:W4))S46()^4=%.#&Q-?@U=@_G#L?N0LZ8#BCVM
MJ7SN29'3Y*O[0\LXWM=0]U,PP_G`W3]<T#<TYTRP4KI`YVFAES4OO:4'3)MU
M0:$"9;O#29FBVV"5!0'R-NO>H)^4G(3QVQ$5.WWDM/A,6P)N0Y]4!_:,/2CH
M?:%"D.Q=9-_U'?C*G8*4^%C+;^STB=!#):'=,52D"EL5SQD1.3@*-&X8*Z:<
MU2``/IV&JJT!CN"G_OM$"UFE*$K<>.Y'`<"=/1'RCBI*Y.1'(5GS2X/ZBD:2
M\$PR`_7G]=`-%W$0)V^S>%I17V"&)=ZL.3LYL&O@/T6'U1X,5L"L*HO`'ZUC
MK/5/I4*-BN16L:1HCAQ(%]"?QTT2!FOO$3S-SYCM)6:"V`T(9:"BS8R`!WI'
MT6"%*?KU-@S:%%AI&UBW.@#<H]C0EKI[!3&W(=DE)'F!6&(C6^S@\-]%JZ04
MP?P8-2;A1.568Z*QL-TTD!D!2Q(T^GK_%#A%4.\H)8P6MAM;C8EUYY>+Q7S:
M6A,0!/-H:1-DYGH2+V>S<=T2#F^+*?PZ+U6274`21B-_O].V&J,+`'VQOYBX
MO3,18>(G,S^V.3*-Z/MAB4[^1[1*FHI^,46+UAAC`TP#F1&P),&;^N\^JJ2W
M]J3&&)*F@<P(6)+466D,HK^_'@H\=6?2CJW&P"LP[MLD3.R6[0;,,!LR(V"I
M6]KJKMMX*FFJ\F5(Z!YJC&'8-)`9`4M2`&/:=.PZ37W66UT\@PQ5%Y',C-BZ
MU-2^NI-P;%^:-&WE&63W<C*#=B-H;*89T1+U":\/P(;P`]F1NA9.SH[J]`YA
M?HW1\69Q&ZH).XEOU8U#Q;UQ`0[\#A_(%\P/M!5.34J@]-TYC`6NKPSZ0;*N
M/W;W3,)1W_^LX&I'X,#S70"7C,GA0?W!>%G<_`8``/__`P!02P,$%``&``@`
M```A`*<=GXF,#P``\TD``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
MK)Q=<]I(%H;OMVK_@\OW:R,)@:'B;,6`/D`@H=J/:V*3A!K;N(!,9O[]GE;W
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MINA%CR:@`.J"$LG@YBZ.^X,[=<\+(QE$;$/_,/<?_@4;CE0@H0J&%SVZ@&.E
M_L$/KW=)[P@X6NH?7/+L36_U8&C&UG1SVGS\<-C_N*()B[K[\6VCIK]@K-QX
M5.FNTHZSGPTS&E_*Y9.RN;^F=M`(.M+<\/O'02_X</L[C>='HWE`C:>8L$(-
M7F4[]<',!XD/4A]D/LA],/?!P@>%#Y8^6/F@]$'E@[4/:@O<4GC:&%$__W_$
M2-FH&/'3?6`@00O=D$U8P46F/ICY(/%!ZH/,![D/YCY8^*#PP=('*Q^4/JA\
ML/9!;0$G(#1C0$`BFL:ZER(>(ZK4_36-L7:,A*.1^\`?M";2BXX:`A,@4R`S
M(`F0%$@&)`<R![(`4@!9`ED!*8%40-9`:ILX(:$%V0G)^5`H-<UXY-;&8M#S
M.O^#%D6TI+2BR)_4)JVH'2)`9D`2("F0#$@.9`YD`:0`L@2R`E("J8"L@=0V
M<<)##_$=X5'J)CS\4!\T<6+1'[IC9])JN-04R`Q(`B0%D@')@<R!+(`40)9`
M5D!*(!60-9#:)DXH:)_BA$*O^#=JZW3ZMGO\[6%/W9V6HHX1%-'*KM=[9>)&
MR)#F`-!H)H;HO7BSG&L2WS4;A#Z=G_IN"&>M@$.8`$F!9$!R(',@"R`%D"60
M%9`22`5D#:2VB1,>VD,YX>D(`YT=.`Y*[<9!D]B*@R8T=OBA3C49T(IES6S>
M]#=K15PL`9(:(LM5UFILZ\@-<]Z*V'H.9`'61:NQK;T>M&Q%;+T"4H)UU6IL
MZX%;ZW4K8NO:)DX0:9%W@OB7QI@R<6.KB1U;3>S8:A)*_&=`$B`I^&2@R8',
M@2S`IV@U]J.-W4>[;$7\:%=`2K"N6HUM[:T*ZU;$UK5-G*C1&=:)VOFAI]1N
M>#2):>ZTAM6=V]2)*6:-1DUH-'(-9T`2("GX9*#)@<R!+,"G`,T2R`I("3X5
M:-9`:ILXL5!9`2<8S1"BA$WGPF3-B$U!-RX&]>EF5F"\K??$J$*9S*:,[(DR
M''A3SHQ58;.L1<$H]LZU"2LDQ"DCN5O&Z.S=<J.*Z6PBC0EZ;B^;=WK=>6-C
MP2JI1,'H;"66K-)-#D?]V!O1*U9(DTM&<K>*D:C6!E'[5!8AH&229UT[A=Q.
MHT[0=C;C_`@.](&;C@$\\AX,BNV3011X\9P85=AO"TX9B=?,H'[0M&04#/O>
M.IA@H9216&>,Q#HW**;]MM4)O!5\+@5%%6(GT$_!:DPA!?G!++OOZ#5HA05+
M1M*@BI$T:-UM[XVTVBGH1EX=U>W(J^DB'*A,<-=&UIXO]"'?Z00:Q6I'S.FL
M*/"ZX43E(6D!<.8+@Z0[SUBENW,_&@5W7JL2EDBIE)$,E8R1J'*#O*G`V[;,
MI:"TIJ,70&L**2B]P*A,:X+1\`ZZ`#R#DHVD-14C:<W:(![XWKI9.R7<V*ND
M@!W[7XQZG4-P`JZ1-00F*C>@HBO==LI(NNW,(!J'_(@25*6,1)4Q$J\<O>:H
M6C`2KX*1>"W1:X6JDI%X58S$:XU>M:-R8Z$R`.^(A4X8D!\_OX=`(W>Q#KR5
M:V)4SN#3!4/I4C.CHB[%]@D7%%7*2+IGQDA4.7K-4;5@)%X%(_%:HM<*524C
M\:H8B=<:O6I'Y8:'IC0G/)=/DZJDMZW2R%LKO7$[4:_H_(%DD$1]9E1FK1P,
MX]&=MYHE;"2E4D;2@3-&HLH-\A9+;]Z:8\$%([$O&(G]TJ`S55]AJ9*1>%>,
MQ'MMD%=U;P&IG8)NO%6:P1Z.3;SIV'IYID>]U_(#KY$W1&$_K57.$#4%93S.
MC'U?I99HN]>+HH'7@Q(CL09VRDB&1L9&XIT;%--=K74<`F_J*6-J@?8%VB\9
M_;SJ*S82[Y*15+UB(ZGZVB"OZA!XN^INX%5JP@]\$+\SRZ=>3/JQU\@9]"-O
MRS$QY9S%4Y?KT]!O8]%QE#*J@>X-43\,0^@.6A/*,$GQ?IE!Y^^7&U5,EFVM
MHA`.4^T=1=6Q@S(J&='%1958LLHTFEH<WWF-7AF-U>B2D=RO8B=)+JP-HA;R
M$EASP>8!NKU&I4;.]9I_[=]H#?CEEEIG6)Q57:-HT%9CHMXV4^>RT!31#%&"
M*$64(<H1S1$M$!6(EHA6B$I$%:(UHMI!;HQ4RN1<C"[*WP<Z\>*$R"#)'$Y8
M)?UI:A#G\(-!Y,W[,U%PCTL0I8@R1#FB.:(%H@+1$M$*48FH0K1&5#O(B1@M
M7&[$SI]/&KF[TS+(3OP:9&=^#?I%6E]4;7@0I8QDE<H8V9FAJ.>MIKFHV'Z.
M:,%([`M&KKVWXBU%Q?8K1"4CL:\8.?:AE]A9BXKM:P>Y<?6S34V*\KUK+.V/
M_#76("?<6N6$6R,[TV\*6BA!E!ID>66HRA'-$2W0JQ"5K)91S\N>+$7%3WJ%
MJ$3["E5K1+6#W*BI_(0]?_YB-.ITACU1AAK](L]O5+0WYP9.#;(S_8@21"EZ
M9:C*$<T1+="K0-42T0I1B5X5JM:(:@>YX?&3.<V@NB#O3ULC&$<:N>>4GK=>
M34Q!ZC$2*)/\L2<+W*QR09T,Z\K[LT*V_RDCN5O&Z.S=<J-RDWVA=TB>=WI!
MRI=54HF"T=E*+%G%3>['7@56K)`FEXSD;A4C4:T-XO1??.-M@6NGC-MGWI=T
MHF,)]!2-G%--%'IKV\04M(\UC.0P,C/H3-H?"Z6,9#.?,1+KW"`W'1!Z:^1<
M"LH$C,<55LD="T9RQZ5!IC%AS\_*K+!,R4B<*T;BO#:(VJ(._KT;[V'73A$W
MW"I]](X97&>;G!G<)*"D1T[4BP*5IA(T922==&:0G5!$5<I(O#)&XI6CUQQ5
M"T;B53`2KR5ZK5!5,A*OBI%XK=&K=E1N+%0&XAVQT`D+)Q8:]6D$RA$<\KVA
MR71(GYHRDCXU,XCZ%$_E":I21J+*&(E7CEYS5"T8B5?!2+R6Z+5"5<E(O"I&
MXK5&K]I1N>%1.0D[/!?G>T.=S7`BI9'W6LR;IB>FH#.03&9$.MF,57HAB8?A
M,/222`E+I%3*2#IPQDA4N4'N2AEX\\L<"RX8B7W!2.R7C'Y>]15+I%3)2+PK
M1J):&^15W9O@:Z>@&^^N!(Z27Y[O#3%Y8Y"[.@:PC](%:=[FP3<U!6GZ8#1C
MI)-=\2B"_!XKI,^GC,0Z8R36N4%]JH<UDT#<337%?L%>8E\P$OLEHY_6?,4*
ML2X9B77%2*S7!GDUA[#;-7?#_G_)"=&Q$?9%&CE#'K*]IIPSXG6YIN?Q&_2.
M#;11Z<^##N-XV/=FDX2]98RDC&0D98Q41__I[7*C&M#QK55%H7<PG;.7LQ'&
M';2INE2BX()G*[%DE6[S8!!CKI<ETN:2D=RN8B2)W;5!U$`>;C6K&B^GSZCO
M*\#28+\AN"S7V]BXV2J#K,3N!-$4T0Q1@BA%E"'*$<T1+1`5B):(5HA*1!6B
M-:+:06Z,_`S3^5P%?6W$#&#IX`,_0_=@5!0>6^5--A-1<5^:(IHA2A"EB#)$
M.:(YH@6B`M$2T0I1B:A"M$94.\B-V/NR2Q%FEPQR1H]666B*JAFB!%&**$.4
M(YHC6B`J$"T1K1"5B"I$:T2U@]Q8V*DD6CO_4GHVPK2206IJE74D\A(A$U')
M`#)I)7G#,F-[V0PD4M"V][8QJ:C8/G.0^R3L!`D]B5],(Y@?B30:Z+U/V(,/
MPXF`JS,UB/+GC&:,9!E+&#G+K?\1VY15>L\=QD'D;10R5G0L=':ZX->-QVP!
M)<K5M#H8-ID*:KQW4IF(@%LZ-8AR5HQFC&0KF#"B?M'V)-@FI4;%.9BNQIOD
M17,W-_+JW,P'P%\W7I^R[4.?6B94X]573G[_2(WW/XDE`F[IU"`G\MK&VB,F
MHCK;>%/P3.2-HB/RZMQY>>.5VMO):"21]WK=)&H%TGB-G,@;9$>^59UMO%:=
MBWSK0Q5P(T_1?D?CE=IKO$82>?_`%[4":;Q&3N0-LL=\JSK;>*,Z$_G6!QJO
MMN>71UYOYIUN;_;W,GXG]-L6ZA'IP.I'K7^K0G^?_F5[^+J=;)^?CU>/^^_J
M=RCB'HV9%NL?R7CHC^NF&_@\'M?-&N#SX&ZL/@Q`#?2O1#WZO8VFTWM7/D7!
M^)/^)0[O"NW]J$P3";@2TI7FX`!7^N,)S:Y=-8CI2F>MHP%=:3[K`6Y#NM*<
M6>#*'5WI:BG]L,BGSII18SK;0DWIU$?4Q(YV?.K3X^IZD/32F)RZ;D&O\L;J
M11T^%'HQ-U:OW?`*O68;JY=H>(5>FM%]NJX\1-%X2NLZEJ%MPEBM^'B%/J)!
MSZ798_B/F-KST-F>"5V9=%Z9TA7U$AGO0Y\1&*MWR7B%/BI`SZ#K"KWX'ZMW
MQEB&WO_3T^F*`KU0IBM=9>@]_UB](D:W:CBNNSI91:.IJXM-1V/ZBA7Z9*,Q
M?64*>3$:TU>@D%?TZ+OX=#"N.X?#</S059\)C9(N/AV.Z<M[>-]T.*:O\"'/
MAF/ZDA[RQ7!,7]5#7@S']'W)#GXWIF_D(2^'8_I>'O';MJO13^Z\;;YNEYO#
MU]WK\>IY^X6FPE[SP<.#_M$>_3\G\U&RS_L3_=@.+3VT0:<?5]K2;Q[TU+>\
MONSW)_X?=8/VYYH^_@\``/__`P!02P,$%``&``@````A`,%?]25^!P``U1T`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S`N>&ULK)G;;N,V$(;O"_0=#-^O
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M@_ZNRM=V\.]1>ZA?DZ;:_5:=2W`;UHFMP&-=/[/0;,<0)$])=MROP!_-:%?N
MBY=C]V?]FI;5TZ&#Y?9A1FQBR]WWL&RWX"C(3!R?*6WK(UP`_']TJEAI@"/%
MM_[SM=IUA]78]28SVUJX,U!Y+-LNKICD>+1]:;OZ]`\/ZF<D11PA`I\H$DS\
MF>7:,.9'15PA`I]"Q)Y/YK[O!7-V*6\,[XE,^,3AU13>R`/5?N[PB2,&$]NS
M`G;5;^0%(F^F\CYXI;#K^A'A\Z8K78@\^+SI2FVH)[Z\K+#$TKU]K5->('V]
MA457W-\U]>L(-C&40'LIV)%@+YDN5AHW2M;>CTH/:HZI/#"9U1BL@ZIJ8;]\
MO0\L_V[Z%6I\*V+6-,;6(S88P0J:R88FB$P0FR`Q06J"S`3Y`$S!%ND-%/[_
MX0V38=[@K-8(E%F.801&8$IH@L@$L0D2$Z0FR$R0#X!F!&Q>S8CKQQ#6`HM>
MC6$SR%IP7;,6>(S+#QRVU!M"0D(B0F)"$D)20C)"\B'1I@ZGSPU39]&PDT!-
MSCVP`GUQUSS(A=-(!KGN3`_:R"!9`H1$A,2$)(2DA&2$Y$.BV0$7?8,=++JW
M`R>QY@3FCF1#2$A(1$A,2$)(2DA&2#XDVD3A;J!-E)^+$W;/Z@[5]GE=P^+!
MP7%E*[AP_O%3D8GH\Q=DH>8OB'(DY,2!NX*L#R<P3HA(!J&1,2$)(2DA&2'Y
MD&B6P.G^\Y8P$=T200:6"#*PA!/7ZN\LCF5[^FZ)Y/?2#4(2HIK*&':_`E57
M5\WD]ZB:#XGF#6N\A[?1*V4![0?6!8O63>#$@1NP7'/7G>O7LQ%!ZM`,KZ0Y
M@6F."')Z\^R9%?B>44VQU,&9)F2L5,:H2R1C9=I80>#/YL90N92!H30+H=XU
M"]F.<P+6WU[;9`,W6:+N)B?.\!AVW87AI@CRY%8,91JZ$''BV;UU<]MSS*8F
M)CD)T4U)3*;I+CS;-6LO'^9H-K$F3?/I[5+KPW5W!-*+S;,,>S!J4&V(^M\N
M_0D7(>+%Y7F.YQI",8:HK`21TDX1J:@,$==V_&#A&-HYAO!?4\/>S69-W<=W
M9!]NV,3;0KV*/-*RBJA!&0DM2)1U))`H)&<6>#-C*C'-2A`I[121TLX,;<?S
M?4,[U[+T:F(MW]"F_CX'/_/>VW0V[Q6AU<%)K@4RZLK8_QN,4FL?(E)K'R$2
MA];<7P1&"QECB,I*$"GM%)&*RA#A@3A;6,0P/CN8BGE*L=Y.,^R=[<<;2\TF
MCHRZ,NX]FWX<.`#5VH>(E.610**N;/C-91E",<U*$"GM%)'2SG1MUPI<4SO7
MLO2Z8AWDL*[>L8DWG*"GJHDCHYJ,>]O&%E%JQ4-$:L4C1'S%9PX\"=%/NQ@C
M5%*"2$FGB%14AHA+^XX]-^[:.49<J276?=Y@$@LWSBB.C%HR=LJ&/3F"1*V6
M9"(:'HDH44L+R_.,'RXQZJA52A`-2XE(9[JT#=VL:Y1ICD*]MEY*K"&]P27>
MOVJE)%I:K;LR9[>Q191:[Q"16N\($5_OA>T&QGK'&*&2$D1*.D6DHC*!?#A[
M9!/HS`SY7$O4C6+=Z="H__2;Q>8]KN8?1T:5F;]81:)692)1=?*1B/*@#?SQ
M)&/4&E::T!I6&I'/,#'@'9MOP7_Z5L\QY$JEL=[TYPWD':YF($<>-'5RTJYG
MK.S&YE&.JI(0$4Q4)I*F.\*H>3]I=P[/.LUN-\8856\)(C5>BNC-\3*,$N,%
MEFW/C>XZQYA^/+U,66O[ELM?Z@N<<N\V(+Q#UFSFR(6-+-UR/>/*-K:,PJ,O
MI"BB**8HH2BE**,HUY!F#[OA$7N<.>O(;GPFVROI]PN!`J@TY9#9+FY4E'2(
MHHBBF**$HI2BC*)<0[I#M[7VL)_,VZ9`>J'X9FNOHI0-7`L2$44T*J8HH2BE
M**.(O65B5\]'Y#;PMT;\*?ZI;)[*37D\MJ-M_<+>",&&N+^3F+^N6MN+)2LY
MN&CS&\>"-UG])B7?R'=<QC=AL(2'1%0KG"WC_BFW$9_.EO#@A,;#2[0'YPI?
MP\#]F63HK!VXU&OQ[A*>WU[1]T#_JI"WA"><-&'M+^&!(/"I'!E>JEV*I_+W
MHGFJSNWH6.[!8JM_#-CPUW+\CTZ<68]U!Z_3^N/K`*]/2WBR;;&MNZ_K#O]@
M`\@7LO?_`@``__\#`%!+`P04``8`"````"$`(J<.BX@%``"S%```&0```'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6RLF-F.XC@4AN]'FG>(<M]D#R$"6L62
M!<U(HU'/S'4J&(B*8)2DMK?OXWA);-.EHGMN*L7'\6_[]_&)\?SK6WTV7E#3
M5OBR,)V);1KH4N)]=3DNS'^^)5\BTVB[XK(OSOB"%N8[:LVOR]]_F[_BYJD]
M(=09H'!I%^:IZZZQ9;7E"=5%.\%7=(%O#KBIBPX^-D>KO3:HV/>-ZK/EVG9H
MU45U,:E"W'Q&`Q\.58DVN'RNT:6C(@TZ%QV,OSU5UY:KU>5GY.JB>7J^?BEQ
M?06)Q^I<=>^]J&G499P?+[@I'L\P[S?'+TJNW7_0Y.NJ;'"+#]T$Y"PZ4'W.
M,VMF@=)ROJ]@!L1VHT&'A?G@Q#O',ZWEO#?HWPJ]MJ/_C?:$7].FVO]171"X
M#>M$5N`1XR<2FN\)@L:6UCKI5^"OQMBC0_%\[O[&KQFJCJ<.ECN`&9&)Q?OW
M#6I+<!1D)FY`E$I\A@'`7Z.N2&J`(\5;_WRM]MUI87KA))C:G@/AQB-JNZ0B
MDJ91/K<=KO^C00Z3HB(N$X$G$W&=B>\&T^@>%9^IP).I.),H"/PPFGY^*!#9
MSP>>3&0Z<7P[O&,V(9.`IQC'O8[`]NJ'`4^A<?=<9DP$GDSD_J5Q(*/H`I/4
M8HOWV06V:++TN;<INF(Y;_"K`1L:TJ&]%J0\.#'I@6<=S1&1AS]*0\@_HO)`
M9!;FU#0@PUK8.R_+8#:=6R^0[R6+6>DQCARQYA$DN8GL1@5;%20J2%60J2!7
MP6X$++!%>`.;X/_PAL@0;_BL5AP,9KF*$3R"-]FH8*N"1`6I"C(5Y"K8C8!D
MA'?#"`^2Y79IXCE!6BU,V#<B)]Q(6?$5C?%H$2)+OM;(1B-;C20:2362:237
MR&Y,)`N@E$FY\/'4233L*%`3<P]FD;S(*QKD07$206[DR4%K$21202-;C20:
M2362:237R&Y,)#N@*-]A!XGN[>"36%$BS=U7ZL5:Q/!6&XUL-9)H)-5(II%<
M([LQD:8.ZR5-G5;,"7FS=:>J?%IA6$XH*3<RQ(/*2.LE$9$=860FRL2:$?JN
M[\LA)2Z\18:,"97:L15!W+9$(ZE&,HWD&MF-B60)U/U?MX2(R)8P,K*$D9$E
ME$`Q(N\<UW9\>?]LQ??"#8VDFFHF8IBJLBMS\3U7W8V)Y`TYGH]?L#?2`DXT
M/"](M&P")2Y46['FCE8E6-!01C<WFKFA:@X+<GOS',]U`ENV+Q$R?**IUE4F
M8H81:EWE<E=VY`=*.=P)&>A*<A#277+PIS8<$9&-I<0=UV@W4AQ:LR!?[,H-
M(T,*;AD)>Q<#+YH%BHFB)V&B)IMILKDDZX=P[I5E=V-9R3!RCI,<^SCG^G#9
M&X8@Z_B0UQR-<HRC(6K+$4NI*+1]9=@)#QE:I1P-VAE'0U3.$=,.`EO=!SL>
MTK>2/2&'O/$^_*DL<NA1D?X,["OYBB$ECY1)KWG4*)$X&F420SYL!;'9W2B4
MUSWA#>7,5=Z>*8\:>LPX&GK,;_>H;DW>\$<]RDZ34^2O.TW/HI+3%/F0]R-W
M9K([:X=&N4,N;3B"&CTTU(HACXKZ?1QZ[DRI^@F/&'(RY6CH+>/HP]YR'L5Z
M<SQ',YU-Y$8NPSI\Z/`W?(7]?/,(,GK7D..I4A,9@G/9L.]IU`AM]*BMCA(=
MI3K*=)3KB-R[D*'20=!LH_<H]+=LC9HC6J/SN35*_$SN2"!CEW.!Z07.RO'X
M#8[RS2:,X7`#4U;Y-$[ZWVT*SZ8QO/#U>+@B>G!O\!6Y.KK%W1A^<^DZ*QAH
M?].D]/O@QP]@Q8T&?@QG]1L\B.$@"]P22G!E="V.Z,^B.5:7UCBC`]AE]\?7
MAEXZT0\=RZ%'W,%E49].)[@<1/`;S9[`6?>`<<<_D`[$=>/R.P```/__`P!0
M2P,$%``&``@````A`"2:<0RX`@``6P<``!D```!X;"]W;W)K<VAE971S+W-H
M965T,C(N>&ULE%7;;IPP$'VOU'^P_!X,[!)VT;+1IE':2*U45;T\>XT!*Q@C
MVYM-_KYC3"CDULT+E^'XG)GC\;"YN)<-NN/:"-7F.`I"C'C+5"':*L>_?EZ?
MK3`REK8%;53+<_S`#;[8?ORP.2I]:VK.+0*&UN2XMK;+"#&LYI*:0'6\A2^E
MTI):>-45,9WFM.@7R8;$87A.)!4M]@R9/H5#E:5@_$JQ@^2M]22:-]1"_J86
MG7EDD^P4.DGU[:$[8TIV0+$7C;`//2E&DF4W5:LTW3=0]WVTI.R1NW]Y1B\%
MT\JHT@9`1WRBSVM>DS4!INVF$%"!LQUI7N9X%V67:TRVF]Z?WX(?S>09F5H=
M/VM1?!4M![-AF]P&[)6Z==";PH5@,7FV^KK?@.\:%;RDA\;^4,<O7%2UA=U.
MH"!75U8\7''#P%"@">+$,3'50`)P15*XS@!#Z'U_/XK"UCF.TR!)PT4$<+3G
MQEX+1XD1.QBKY!\/B@8J3Q(/)'`?2!;GIY(0GU!?WQ6U=+O1ZHB@9T#2=-1U
M8)0!\<L%024.NW/@'*<80:X&-N%NFZ2K#;D#Y]B`N?08N(Z8:$00$!V50>UT
M90=VRLY:E\JE#TQEXI=E%N^1<>`<PZ$=DT_2]<CKE3UFT??+M)[E>X0<&"P'
MKHG24RL'$'3K/]`J'-.9N0EM=+J;#MRKCW8.$5`<I9;IRTKG<R5W%.)%W_?_
MZ1ZW<*XZ1*:[F*Q>:1?HNM,+=."YU!"92KU6H)O9DR/1G_4H"<"BMT^'6S<7
M'2)3T63U2I^NYZIO2SGP7&J(]!/#-X8?9OZP2ZXK_HDWC4%,'=R@BN'XCM%Q
MANYBU]9/X\MLU\]6,GZ`V=;1BG^CNA*M00TO@3(,4O!(^^GH7ZSJ($V8<,K"
M5.L?:_B)<3C!H3.T5,H^OH`P&7^+V[\```#__P,`4$L#!!0`!@`(````(0!N
MQ8H7\"```!7/```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*S=6V_;
M2)K&\?L%]CL$OI_$HB0?@B0#2^+Y@,5B=O?:G3@=HY,XL-W=,]]^GQ)/]=:_
M8H?IN9E,_UBDZ*=*I7JI`]_\_9]?/K_XX^;^X?;NZ]N3U<O3DQ<W7]_??;C]
M^NO;D__Y1_:WBY,7#X_77S]<?[[[>O/VY%\W#R=_?_>?__'FS[O[WQX^W=P\
MOM`1OCZ\/?GT^/CM]:M7#^\_W7RY?GAY]^WFJ[9\O+O_<OVH_[S_]=7#M_N;
MZP_'G;Y\?I6<GIZ]^G)]^_6D/\+K^Q\YQMW'C[?O;PYW[W__<O/UL3_(_<WG
MZT>=_\.GVV\/X]&^O/^1PWVYOO_M]V]_>W_WY9L.\<OMY]O'?QT/>O+BR_O7
MY:]?[^ZO?_FLO_N?J\WU^_'8Q__`X;_<OK^_>[C[^/A2AWO5GRC_YLM7EZ]T
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MXXY9K^:PGWG<5_W8.@[5P_7C];LW]W=_OM`$H-'S\.W:32>KU^YPXR#M1\@T
M;+\W:C5<W5&NW&'>GIR?O-"`?-!S[8]WVXOUFU=_Z.GQ?FBS8YN5;;$?6[CG
M@COL(80TA"R$/(0BA#*$*H0ZA":$-H3.@U>*=LI7(^/?D:\[C,MW3&8WPAQX
M$H0YMAAW.820AI"%D(=0A%"&4(50A]"$T(;0>6#"U%/%A!F?2<<QZ5J_/=&$
M,(W)U7DPXG9]FW4_9[HAMX<<("DD@^20`E)"*D@-:2`MI//%1*BG^(((76O-
M##J:EV'XO.X;K?7/]QOMIT;3<(2DD`R20PI(":D@-:2!M)#.%Q.K7IP6Q.I:
M'V,=P]CULNZ7`<=Q"#E`4D@&R2$%I(14D!K20%I(YXL)3*_7"P)SK6U@O:SU
MCS?H-L$4.#4:<SY`4D@&R2$%I(14D!K20%I(YXO)4"^W"S)TK8/G<G)I`]OU
M;=;^ZWC89C^UF4*%I)`,DD,*2`FI(#6D@;20SA<3JBN__`71TZ\QKK4=F+UH
M8([Q["$'2`K)(#FD@)20"E)#&D@+Z7PQ@6G=O"`PU]H&UDOP3-[:@;F?&HVI
M'B`I)(/DD`)20BI(#6D@+:3SQ63H*HD%(1Z;VQ0',C%NSH,4YT93C*24E)%R
M4D$J216I)C6DEM09LHFZ!?F//X]7_?H]6.F<V?QV0RLS/Z[.@U;[N=6<<G]X
M[3A2RE89*2<5I))4D6I20VI)G2&;LENI+TBY7]@KY3&&W:JG9\;MU&C<[S#O
M-U)*RD@YJ2"5I(I4DQI22^H,V43=RMU/U!7DZPMWA6BX:O/C-7E?!)BTA[I`
M2PIOV81I8FHU9GMP3PS-V][+6DK*2#FI()6DBE23&E)+Z@S9N-V*WH_[Z9=[
M=X4D7$1M+X)EYVYH%4P3%W8RV<^MYI2'^L*?)D`9=\Q)!:DD5:2:U)!:DBZF
M]F/D>/8V95<&+$BYKQK4:V,R.W?=U(Z_/>E`2DD9*2<5I))4D6I20VI)G2&;
MGRL!_/S<I)!L7_[$G-`7$R;:J;[PYX2@,MBOIE9CGQQ(*2DCY:2"5)(J4DUJ
M2"VI,V33=K6!G_8S<T)?2K@Y9IY3+X*K<;O55'`\T6H_MYI3GG8<*66KC)23
M"E))JD@UJ2&UI,Z03=D5%`M2[NL/,W"GDF2.E$O>J=$8WV$%2DD9*2<5I))4
MD6I20VI)G2&;J"LO%B3:5R,FT:%`T3_>4`ZN]^U74ZLY4E#*5ADI)Q6DDE21
M:E)#:DF=(1-ILJPN.S:W==E`WL)I3SJ04E)&RDD%J215I)K4D%I29\CF%U9A
M/_W"E4P%VCCH=@.9TF$5+L;V<ZMQQP,I)66DG%202E)%JDD-J25UAFS:RZJQ
MA-780"923*ESHSE1%&@I6V6DG%202E)%JDD-J25UAFRBKNSY\2DUZ:LD?TH=
M:&VGU/#RUMQJCG2HN"ZG17#*5ADI)Q6DDE21:E)#:DF=(1NIJQ(61-H7%2;2
MH<[P+K$FH`,I)66DG%202E)%JDD-J25UAFQ^RVHI=]T@N.`ZD'F2;R\P)%%Q
M'>8=QU&:DC)23BI():DBU:2&U)(Z0S;2L+QZ>L&?3#64OTH*+J+LAE;V(L!%
MT&H_MQHC/9!24D;*206I)%6DFM206E)GR*:\K*Q*IK)J3&8WD!FX?'4:ZJ5Y
M=CC,^XV'2DD9*2<5I))4D6I20VI)G2&;J"MD%DRE?=UCIM*A%+*O3N&5JF1J
M->9W(*6DC)23"E))JD@UJ2&UI,Z0C=05,@LB[>L>$VE/&U4.4PW%03HUFA,%
MI0DH(^6D@E22*E)-:D@MJ3-D$EV')=3/7]`^'LJ65P.9*6%U$5Z\FEM-<9-2
M4D;*206I)%6DFM206E)GR,8=5EQ/OY;IDT^1"]K!.UJ[H95]+;L\#2YHSZWF
ME/O#^^][L55&RDD%J215I)K4D%I29\BFO*S26K/2&D@#=PQK3SJ04E)&RDD%
MJ215I)K4D%I29\CFMZRN6K.N&L@^\2^#C_?MYU9CR@=22LI(.:D@E:2*5),:
M4DOJ#-E(E]55[N-Z05TPD!F2K*O8*B5EI)Q4D$I21:I)#:DE=89L?F%=-5^J
M>F8*986ES_&Y<"^.WP\X?I)Y/].\+%A=!N\2',96FC:GQ</J<KX`:\]X6=GB
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M(*6DC)23"E))JD@UJ2&UI,Z027N[;,UY;'Y<*_GY!2^)NZ&5N828G`:M]G.K
M*6522LI(.:D@E:2*5),:4DOJ#-F4-7.8,?WT:Y6;W8(5Z4!FX.*=AKG1G&A_
M*&_B2-DJ(^6D@E22*E)-:D@MJ3-D$UVV=MYR[3R0230YG2^_])=RYE9SI%AA
MIVR5D7)202I)%:DF-:26U!FRD8;+Z6<&*=?0VY[,-UM!![9*21DI)Q6DDE21
M:E)#:DF=(9M?N+:?+S@L_(&%+9?]`P6C-;C`M)];S:.U/Y:9`$`9=\Q)!:DD
M5:2:U)!:4F?(INW6X/XRX9G1VB_9_;7`MB<OF3WI0$I)&2DG%:225)%J4D-J
M29TAFU]8ELRC]9DD6:!L!_(N-(ZD=>MT(20YG2]U]C_Y,;;2^MIK]9W+8UNW
M"O=[W)UQOS!\YHS[Y;OI^X'\,Q[(GO%\Z68XXZ&5_O'.^#O5_M:MVOTS?N8\
M^T6^.<^!_/,<2/]X9S`7G\-Y#JW,>:Z^4[)LPR7W,^?)=?7Q".8K8WO2@922
M,E).*D@EJ2+5I(;4DCI#YKETMFP1?6QN+S@.9*?W55B7S*VFZ9V4DC)23BI(
M):DBU:2&U)(Z0S;292OF,ZZ8!S*18L4\-YH3Y8J9K3)23BI():DBU:2&U)(Z
M0S;192OF,ZZ8!S*))JNPK)M;S9%RQ<Q6&2DG%:225)%J4D-J29TA&^FR%?/9
MM&+V9NY54''LAE:V>`Y;[>=6<\K#4MO[0BE;9:2<5)!*4D6J20VI)76&;,KA
MNOKI5Z<S+IX',@.74P%6Q8=YOS'DE)21<E)!*DD5J28UI);4&;*)+EL[GW'M
M/)!)-%F%Y<C<:LSO0$I)&2DG%:225)%J4D-J29TA&VFXG'YFD'(1?=:3(AW#
MVI,.I)24D7)202I)%:DF-:26U!FR^;EUM;]4]M[+6U@]GPU+=.\;Y0,%PS6H
M1O9SJ[$'#J24E)%R4D$J216I)C6DEM09LG&[\L"/^YGA.E03?J0]F4@YITZ-
MYD1!Z1DH(^6D@E22*E)-:D@MJ3-D$PUKJ+F>7CI^65Z=]63"3E9SG=Q?JYQ;
MS6E/.XZ4LE5&RDD%J215I)K4D%I29\BD?;ZLXCHVMQ770/YT2SJ04E)&RDD%
MJ215I)K4D%I29\CFMZR\.F=Y-5`P)(/+)?NYU3C^#J24E)%R4D$J216I)C6D
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MVX)KH&"0AN\>S*W&L`ZDE)21<E)!*DD5J28UI);4&;*1+JO!+J8:;!Z121*^
M>S"TLN\>A*WV<ZLYY?[PVG&DE*TR4DXJ2"6I(M6DAM22.D,VY65EV07+LH',
MP,5+V=QHC.]`2DD9*2<5I))4D6I20VI)G2&;Z+*R[()EV4`FT20)WSV86\V1
M]L?2CB.E;)61<E)!*DD5J28UI);4&;*1+BO++F)E61)<SMX-K8*I(&BUGUN-
MD1Y(*2DCY:2"5)(J4DUJ2"VI,V137E:67;`L&\@,7$X%0UDV#]+#O-\8<DK*
M2#FI()6DBE23&E)+Z@S91,.R[)E5`4NOBYY,HDD27MF>6XWY'4@I*2/EI()4
MDBI236I(+:DS9"-=5GI=L/0:R)LD]Z0#*25EI)Q4D$I21:I)#:DE=89L?K%"
MZ^=^4_V"E=9`P7`-KWK/K>;AVA_+ZY24K3)23BI():DBU:2&U)(Z0S9N5^_X
M=>TS,T!?'OG%Z\54,<WK6LZI4Z,Y45`Z'VILE9%R4D$J216I)C6DEM09,HE>
M+JNTCLUMI360^1G*))D_H]I?SII;C6$=2"DI(^6D@E22*E)-:D@MJ3-D(UU6
M:5U.E=:8S&X@??=\I#WI0$I)&2DG%:225)%J4D-J29TAFU]80_W\U==+UE<#
M!7-J^/;!W&KL@0,I)66DG%202E)%JDD-J25UAFS<RPJL2Q98`WFO-GO2@922
M,E).*D@EJ2+5I(;4DCI#-K]EU=3E5$V-(VLWD)U!U^$;`G.K<<<#*25EI)Q4
MD$I21:I)#:DE=89LI,M*ITN63@.Y7^_X_CM:<Z,YT?Y0WLR;LE5&RDD%J215
MI)K4D%I29\@FNJQTNF3I-)#[!9PIT60=7O6?6\V1#C77Q?1BEK)51LI)!:DD
M5:2:U)!:4F?(1KJL=+IDZ320>2G"6G1N-"?:'\J;;U.VRD@YJ2"5I(I4DQI2
M2^H,V41CQ=1/W8OFDK740";L9!V^(3"WFM-F+<56&2DG%:225)%J4D-J29TA
MF[:K:'Z\EKKL"R"_EAK(1,KQB\+I,.\WAIR2,E).*D@EJ2+5I(;4DCI#)M'5
M:5A,_?3;KOVA;*$UFLD[60?OR>R]9F.\AXCI7HSN;,VWZ'0S1ICNQ@C3[1AA
MNA\C3#=DA.F.C##=DA&F>S+"=%-&WX+PEY5=JU/67:.9A#&BO59>P/W1M.=H
M"ABF@&$*&*:`80H8IH!A"ABF@&$*&*:`?0L"#NNRIR^^K$Y9?(T6+'7#]V*\
M9F.:&L+]X;3K:$H8IH1A2ABFA&%*&*:$84H8IH1A2ABFA'T+$EY6BJU.68N-
MYJU@-2/T[3Q3G##%"5.<,,4)4YPPQ0E3G##%"5.<,,4)4YR^!7&&E=E?F(Y9
MM:U.>S.31;(.W_'RFHWC5N%/NXZF\&$*'Z;P80H?IO!A"A^F\&$*'Z;P80K?
MMR#\937<ZG0JXOSZ(GAK9C<VLV\SKH-F&O']T;S/%RATF$*'*7280H<I=)A"
MARETF$*'*7280H<I=-^"T)>5>:M3UGFCF6$=>0T<JKKY]4X!PQ0P3`'#%#!,
M`<,4,$P!PQ0P3`'#%#!,`?L6!+RLZ%N=LNH;S02<K,-W=;QFXQRAA%GY14P)
MHYT2ABEAF!*&*6&8$H8I89@2ABEAWX*$PR+PN57&5.KY\T;P]H/FC:&*TP-[
MER^"9IHWIF9>Z#`-:YA"ARETF$*'*7280H<I=)A"ARETF$+W+0A]62VX.F4Q
M.)H9UI%Y@^6@M^<8N@)&.P4,4\`P!0Q3P#`%#%/`,`4,4\`P!>R;#?AX-_D?
M+[97P]WG_6I[-!-PL@[?N?":C6D>(J:;Q/NEU/%-.MTE'J;;Q,-TGWB8;A0/
MTYWB8;I5/$SWBH?I9O$PW2W>MR!A5[@L2;@O=)3P/"%L+X()8;>:;U`_-TLV
MX;5YKYD7^E!*>9]QC+13Z&BGT&$*':;080H=IM!A"AVFT&$*W;<@=%?++`F]
MKWWLL![J(;WH3C,SYPUS6_OC:-6HGO8<0]>HABE@F`*&*6"8`H8I8)@"ABE@
MF`*&*6#?@H!==>,'[$J8B\N7[HYS"[_HNW)#/?CBSVAV3MF$5_6]9F/22K\_
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M0$ZMQC`5,$P!PQ0P3`'#%#!,`<,4,$P!PQ0P3`'#%+!O0<"NJ%D2<%\$V8"'
MPDC=.$W;R087I5=3,R]AF!*&*6&8$H8I89@2ABEAF!*&*6&8$H8I8=^"A%U5
MLR3AO@JR"?N54?^!P-4*I@$+4YPPQ0E3G##%"5.<,,4)4YPPQ0E3G##%Z9N-
M\WA'>S].-Q^OML=[2CQ^NGW_V^[.0?0&$^N3=V^.Z5VMCH<)WA\<;7Z'9#^U
MVTZOCH?1W(TUO?$>7+A.O6;C>,\BED>LB%@9L2IB=<2:B+41ZZP%P;LRYM\0
M?%\-F>&=#&:"'\P$WYMNL?GNS1_O=">`8(Y1YE,++W.8,L?1E?G4;CAZ\"*L
M'IA:C$=7#\#4`SBZ>F!J-QP]6*^J/Z86X]'5'[X%_>&J'K\_GGEI3/HJR0;?
MFQOXWDC&NP'#KCJ9\<ST))AV'4WI#Y8<^V=U=GZIEX$@13T'L*?Z8[#Y$=0?
M:*<>L(^P/5LGY^'*7WV"/=4G>`3U"=JI%^PCK,_7ZTUX64/]XN\9](NKA_Q^
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M,#V58.H<F#H'ILZ!J7-@Z@J8N@*FKH"I*V`*WK<@>%>1^<$_]]K25W`*>`XS
MV>!B<#(4>BI'O)>;H)F>(U,S+W280H<I=)A"ARETF$*'*7280H<I=)A"ARET
MWX+0796V)/2^JK.CVJ_TAD(A@6G*@2E.F.*$*4Z8XH0I3ICBA"E.F.*$*4Z8
MXO0MB-.59'Z<?^'"3=*7=S;JJ>3S!W,P16LP3\V\P0Q3^C"E#U/Z,*4/4_HP
MI0]3^C"E#U/Z,*7O6Y"^J^#\])^;0?J*S\P@V_`^]KN5J[G<9R[5[?,,LL7;
M27,S+_1IU]$4.DRAPQ0Z3*'#%#I,H<,4.DRAPQ0Z3*'[9D-78;0H]&/[H`@>
MS+O0N%_1#A%+(Y9%+(]8$;$R8E7$ZH@U$6LCUED+XG3%ES^&_\(,LNX+.3.#
M#&:_$K+%FT=SLW'@*OVA+O2^%!(QI8]V2A^F]&%*'Z;T84H?IO1A2A^F]'T+
MTG<EEI_^,S/(NB_);,*]V<$,4YPP#6:8XH0I3ICBA"E.F.*$*4Z8XH0I3ICB
M]"V(TY5`?IQN,+L[MBU]&W3=UU(VY][,)?9D&USAT#PR-?-&,DS1PQ0]3-'#
M%#U,T<,4/4S1PQ0]3-'#%+UO0?2NPO&C?VXD]Q613;@WDS#+%?>CGO8K"1K;
M,`4,4\`P!0Q3P#`%#%/`,`4,4\`P!0Q3P+X%`;M*Q@_XI\=V7Q+9Y*<RR5]R
M!%>U-+:G9M[8ABEZF**'*7J8HH<I>IBBAREZF**'*7J8HO<MB-[5,W[TSXWM
MOOZQ"0\UD?]NLQOH&,DPQ0E3G##%"5.<,,4)4YPPQ0E3G##%"5.<O@5QNGK&
MC_.O+#GZVLA&/=5+_F`.+J-K,$_-O,$,4_HPI0]3^C"E#U/Z,*4/4_HPI0]3
M^C"E[UN0OJMG_/2?&\Q]_6,3]FNBH0)W*SP,9ICBA"E.F.*$*4Z8XH0I3ICB
MA"E.F.*$*4[?@CA=I;(DSKZRL7$.U8Z>,E[!%[S7I@$[-?,&+$P)PY0P3`G#
ME#!,"<.4,$P)PY0P3`G#E+!O-F'W_?PE"1_;'PL^/\W@_9[=:FCFGBE>Z$&S
MO==L#GW>=;0TTBZ+6!ZQ(F)EQ*J(U1%K(M9&K+,6A.YJE@7#>M/7.&98#^9>
M"::$N9R;6XUA'E8T!3Q44?,+J`*&*6"8`H8I8)@"ABE@F`*&*6"8`O8M"-A5
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MN.7J0@-1OXK,+3MM<3_J'=NB,]"/4\>VZ`RB1[NZ<!-(=+#H5Y*U4^SD=A?J
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M7]U[!_U_/`Z?D_SE[O'Q[LOQ(Y.?;JX_W-R[!GISY^/=W>/X'^X!_KR[_^UX
MJ>#=_PL```#__P,`4$L#!!0`!@`(````(0!4/^["-04``-D2```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;*R876^C.!2&[U?:_X"XGP`.'PE*,FH^
M^-*NM%K-[EY3XB2H`4=`F\Z_GV,;$VQG.VUW;TKS</QBOSX^V"R^OE9GXP4W
M;4GJI>E,;-/`=4'V97U<FG]]B[[,3*/M\GJ?GTF-E^9WW)I?5[_^LKB2YJD]
M8=P9H%"W2_/4=9?0LMKBA*N\G9`+KN'.@315WL'/YFBUEP;G>]:H.EO(MGVK
MRLO:Y`IA\QX-<CB4!=Z2XKG"=<=%&GS..^A_>RHOK5"KBO?(57GS]'SY4I#J
M`A*/Y;GLOC-1TZB*,#W6I,D?SS#N5\?-"Z'-?FCR55DTI"6';@)R%N^H/N:Y
M-;=`:;78ES`":KO1X,/2?'#"S$&FM5HP@_XN\;4=_6^T)W*-FW+_6UEC<!OF
MB<[`(R%/-#3=4P2-+:UUQ&;@C\;8XT/^?.[^)-<$E\=3!]/MP8CHP,+]]RUN
M"W`49";(HTH%.4,'X*]1E30UP)'\E5VOY;X[+<VI/_$">^I`N/&(VRXJJ:1I
M%,]M1ZI_>)#32W$1U(O`58B@B8N\8/81%;=7@6NOXDQFGN?ZL^#]78%(-AZX
M]B+!QT5@<3`1N'Z^)_->!*X?[HG%9XE-^C;O\M6B(5<#5A+,0WO)Z;IT0@>2
M14PWGYPA`?YM_F'BJ<H#E5F:@6G`U+:0M"\K;SY?6"^0:$4?L]9C'#EB(R)H
M5E'9K0IV*HA4$*L@44&J@FP$++!E\`:R[__PALI0;\2HU@+<S$**$2)"--FJ
M8*>"2`6Q"A(5I"K(1D`R8GK'B"DDR_V:('*"MEJ:D/)#3J"Y,M`UCYGRU4^G
M?*.1K49V&HDT$FLDT4BJD6Q,)`N@ADBY\/;0:32L*%`;QN[;MCS):QXT]4=!
M:.[*09LA:$@%C>PT$FDDUDBBD50CV9A(=D`U_(`=-)K9(0:QY@3&+LA&(UN-
M[#02:2362**15"/9F$@#A=F1!LKKXX2^0+I363RM"7^9W<F'*=1!7AVIB#S^
MGLQOX^\)?Z6RXL<)@G(_)!'RE06T&X*$D9%&8HTD&DDUDHV)9`E4^?]N"161
M+>G)R)*>C"SA!$H/?<,@VU%6RVZX/[BAD5A338:87G4JK\%TN"]4LS&1O*&[
MX/'K]$Y:P#9(Y`6-EDW@!$%MO<WYW)/[L^F#;D5S>Z^9KYK3!R%FWFP^M]6*
M%`TR8J"Q]JADB!GU4'U4^M-'98,,/$IR$-+]`P[2:-E!3M"X]*)`L6+3![G#
M\ML.S<30=YRX#K/+]:<!4@IXI+6)-=U$BTDEW1ER$5*V0=FXC>0-W:!)YGRJ
M&C$5V;0>*7GG*WDGHD:)UR.7'4A8L=L)1,O?R\IW/5=93Y'080<1UB@6Z":=
M")V;="H0ET8!FBH3FPD=?L89;^8<NLL;+\W/><?WBO!F%WFR9L)+TX5WY6C-
M!JIWO"$:I9QH2%\E8M>,U*6T$U$^L]-Q8=2^9F@O?NM5W#<;/2\12F\^+Q51
M_?,"SW8]I0!E0IP]3\Y0NH5\R^5OY`*I][.M(QQPU77=(V]<&EW-9=X.@L3T
M;&_M!-KI*-)1K*-$1ZF.Z.F<=IYW@KO#3]O\X%7AYH@W^'QNC8(\TY,TV+E:
M#)@?\]<.$N=\Y<[6#^'=#(-1>1!&[)"A\"0(X7VEQ\.'A`>VMI3X-?W`<"=^
M#1VZ&S\-8=M\1]\-'\`*_<;:#6%C>8=[(>S#@%M#C^##PB4_XM_SYEC6K7'&
M![#+9KNOAG^:X#^Z/JL>20>?%%B"G>`3$H8#A3V!?#\0THD?]`'#1ZG5#P``
M`/__`P!02P,$%``&``@````A`"4<RTS=!0``4A8``!D```!X;"]W;W)K<VAE
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MS6I?P@Q(V)6F.*S5!]U+=5O5-JL^0'^7Q6L[^5]I3_5KU)3[W\I+`=&&/)$,
M/-;U$Y$F>X)@L":-#OL,_-$H^^*0/9^[/^O7N"B/IP[2;<.,R,2\_;M?M#E$
M%&QF1G\;>7V&&X"_2E62TH"(9&_]YVNY[TYKU5S,;&=NZB!7'HNV"TMBJ2KY
M<]O5U3]4I).;&DP,9@*?:&+<;6(Q$_AD)OIL:=O68NE\_DY`V4\'/IF)<[\)
M/!N]"7S^^)VXS`0^[[X3C2:IS[F?==EFU=2O"CQ(D(;VFI''4O=TJ!7,-LW-
MD/__2C^DC+@\$)NUZJ@*9+:%FGW9V*Z]TEZ@SG*FV<H:G5?L4$$J@=CZ(@A$
M$(H@$D$L@D0$Z01H$)8A-E!\_T=LB`V)#<YJBV`,EB$$`A4XQ!=!(()0!)$(
M8A$D(D@G@`N$>2,0)A3+[9:`-4%&K54H^:$FC(7+3W1+-29]^$G*=Q+Q)1)(
M))1())%8(HE$TBGA0@`]A*N%CZ=.U/!$@=LP=]M="'.G(G,Q$1F.^$@,HJ$4
M)!)())1())%8(HE$TBGAP@'=\(YP$'4?#IS$EA)N[I;#QV<W:'"4+Y%`(J%$
M(HG$$DDDDDX)-W7(%S=UVC%G9$GI3F7^M*WIZG:C0DSHC+1?$A,^(HRX0YO8
M,4+7V+X=4F+``C"4E;$0>D<PB#!LH40BB<0222223@D7$NC[/Q\28L*'A)%)
M2!B9A(02:$9DS3'FNL4743#\/D1#(I'D&@\:YFKRKLGP.[JF4\+%AFR+IPOL
MC;*`?1'6!5'S0:#$@&X[YMP1<KYCHK&-^K>&+<3@,)'1!\_2]:6H"`<;G&@D
M72H>-),[%(T2[E*V.9?:83K8P*6X"$*YWQ%!HN8C2(DQ;<:&(V1TQT36\/CY
MPS"<>D")I??A,EUKZ2SYN@BE,9'D&TN:A//5+=LQA/RFTS%<;,B6[8[@]'(^
M.@P)!294R@Y5DPI#U+]-]%TM0$0+RG!=RQ4CA))Q5(1H](X1C:H$$?76C85C
M+P7S%#7T!6>ZE=/)'N_SCV$O%^)$=XE"&0E[W!T;:$SJ")$YE%;`$*LDPW+=
MI;#NA_*H"-'H'2,:O9/O>Z?<*+Z<R`[PCC#1#2/L<_`9V>H4">4D;'UVJ!I3
M[B,:4QX@8BE?D@8E/'`H&4=%B$;O&-&H2A"Q4C67<\$Z1<6-8B*[Q&F4?F@+
M0':'0J=B2*@Q<5^$JK$.?$3CPA@P9$%;G2P<PA,3XL`Q@Q&BT3Y&--HGB!9T
MX5W,YU+30DGOS9<9V5?^?`#I[A0N,U8?11;TR\FDA9>.G4Y5QE@A/B)8QL>!
MXB(6H&K93UJW3<>:"]D)43/66H1HO%Z,Z,/K):BBUS,LQW%TH>.DJ+E1IF0+
M^U&4O]57Z''?>XTC9S]BG;+-\5@/.Z8R1^3+*)!1**-(1K&,$AF18S%RJ_0F
M:,718RYZY%$5S;'8%>=SJ^3U,SG"@DZX60V8GJ]M=1L/V(1?_(4'>V`H-I$[
M7MB_W@L\=CS8%\IZ.,%[,&[P+3G9N\4-#U[-99^MZ<$+J\P?+.\!0B'_L+4\
M>*6[P6'&O5X;9@`G>M?L6/R>-<?RTBKGX@#AFO=O.0T]$Z1?.E9#CW4'9WE]
M.9W@[+:`5_GY#-)QJ.L.O\"%M>$T>/,O````__\#`%!+`P04``8`"````"$`
M^:+9M8D%```^%0``&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6RLF-N2
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MM)L')%_D64DKNJ\'(&?P#\5M]@S/`*7[NUT.+6"V:R793_4'T]^:IF[<WS4&
M_9V3UZKWOU8=Z>NRS'=)?B;@-O03ZX%'2I]8:+QC"`H;J'38],`?I;8C^_3Y
M5/])7R.2'XXU=/<(6L0:YN_>`U)EX"C(#*P14\KH"3X`_FI%SE(#'$G?FM_7
M?%<?I[H]'HS<H6U"N/9(JCK,F:2N9<]538M_>%#3HD[$:D7@MQ4QW0\+V&T!
MYUK`'CC6R)TTU7Y0%7Q4\[WP*ZJR!I/1R!E/7&`?E!RW)2'S1<E/UNFU)>%7
ME/QDG2;T)[>W9\TG:S6%2>R?K]8+QO)Z/^VPP1.CR;,@K=/[NY*^:C!XH>NK
M2\JF`M,W04YD&+>ZR[E_2SG(-:;RP&2F.J0%9%,%X^3E?N29=\8+Y';6QLQP
MC!(Q%Q$LD9ELH(*%"D(5+%40J2!6P4H%:Q4D*MBH8-L#!EC;^0N9\7_XRV28
MO\*9F0!7PRW9[KF($$4"%2Q4$*I@J8)(!;$*5BI8JR!1P48%VQZ0S(2A(IEY
M>QH4.<FBISI,"%U.FJZ2<3,>8_,)CZ7<')$`D04B(2)+1")$8D16B*P121#9
M(++M$\E"&.)?L)!%P\P`:IV'(T])M!D/LF$&[H(LQU&RL0OJTA&1!2(A(DM$
M(D1B1%:(K!%)$-D@LNT3R598G+Y@*XMN;!5FS#@!#P69(Q(@LD`D1&2)2(1(
MC,@*D34B"2(;1+9](AD&V2(9QM>=`5OEZV.>/<TH)!-,JC>&N`WK"U]UF(CL
M8TN\JX\MX;NC9E'AQ(+UOI>O(SE?%UV0Z)`0D24B$2(Q(BM$UH@DB&P0V?:)
M9"VLPK]N+1.1K6U)S]J6]*SEQ!XV.P!K:"JSP*)[W[F*R!*I1ET,VU>`JBWW
M5=R]%ZHK1-9(->EB6E5E6MMT[X7JMD\DQ]EQJ[^)NI&TL-\66<NB96LYL6`[
MV<O(L=S*>1MT7:J"KICXPD5+K,9_<^QZ,!$K;H6HU!(I1R@FEI5'8]MR'<6Q
M%2JU1LH)BMG(RK9KV\YD(K=]VR\E.0^#6'+^/TTC3$3N$$ZL_KIG.:[\4?,V
MR.GFFJ`EUP&Q:,F8=XCM6:YG*AT;=I6);EPBY0@IQ[*R8WFVXWGR%ZZ0\AHI
M)TAY(RM;Y@WE;5]9ZA!V)OKU'FE4Y"YID77-_SE&@4#7G?)"H$G3!_;0M8;V
M2'$J%$'-<;Q97)8"72N,!+JJQP)Q=<OSK+'E*+O,E0BZJJ\%NJHG`EW5-P*U
MZK#W&GL3)0^W(HA?)?0/'W`U\7%G_*`7</GF*MN;L!H9I3?X>4?:]*$!TI;K
M[6H"C!88A1@M,8HPBC%:8;3&*,%H@Q&[ZF$S!6\03WM^=<./U`4I#V1.3J=*
MR^@SNY8QV4S<87YG-!OYL"V"L:YRL[M,4MX$8Q]6>UPB</VP218E/G)]6`%Q
M?.+ZL(9A#K=8#]8-/F,?=(M;/AS1L,[,]N'@@?F#XS^`=?C%S/%A2PW<Z%H`
MMU>7]$`V:7G(SY5V(GNP<=CL"TM^_\4?ZC9S'VD-]U9-$A_AGI+`$6XX@$WD
MGM):/+`*NIO/^Y\```#__P,`4$L#!!0`!@`(````(0!G*G2:[P0``),1```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;*Q8VVZK.!1]'VG^`?%^0B!`
M$I3DJ`GAIAEI-)K+,R5.@@HX`MJT?S_;-G:PG3EJJO-2RF)[V7OMB^VLOK_7
ME?&&VJ[$S=JT)U/30$V!#V5S6IM__Q5]6YA&U^?-(:]P@];F!^K,[YM??UE=
M<?O2G1'J#6!HNK5Y[OM+8%E=<49UWDWP!37PY8C;.N_AM3U9W:5%^8$.JBO+
MF4Y]J\[+QF0,0?L9#GP\E@4*<?%:HZ9G)"VJ\A[6WYW+2\?9ZN(S='7>OKQ>
MOA6XO@#%<UF5_0<E-8VZ"-)3@]O\N0*_WVTW+S@W?='HZ[)H<8>/_03H++90
MW>>EM;2`:;,ZE.`!D=UHT7%M/ME!9MNFM5E1@?XIT;4;_6]T9WR-V_+P6]D@
M4!OB1"+PC/$+,4T/!(+!EC8ZHA'XHS4.Z)B_5OV?^)J@\G3N(=P>>$0<"PX?
M(>H*4!1H)HY'F`I<P0+@KU&7)#5`D?R=/J_EH3^O36<Q67B>ZR_F0/.,NCXJ
M":=I%*]=C^M_F15U2;`X`PL\!Q9[^>G![C`8GGSPXRN`M5(_X#F0S!\G@:*@
M)/#\^DK`<4H"SX=78K'HT&"'>9]O5BV^&E!!(']WR4D]VH$-2<+#S&(B`O]_
M<8>`$Y8G0K,VYZ8!$>T@6=\VWG*VLMX@P8K!9JO;V++%CEN0;"*TH0KL52!2
M@5@%$A5(52`;`1;((K2!I/L9VA`:H@WW:LN!FUB.(@2WX$-"%=BK0*0"L0HD
M*I"J0#8")"%FBA#W>P#/!6*]-B'512XXWE)V<,ML9JS82:AW&A)JR%Y#(@V)
M-231D%1#LC$BN0Z]0\J!'[M.K*&2@$WX[BU=Q7=F-(.&(HP<7RT%82120$/V
M&A)I2*PAB8:D&I*-$4D.6/0#<A!K*@=W8LL0\)TC.PT)-62O(9&&Q!J2:$BJ
M(=D8D1SU%4=97YR0K:L_E\7+%D/PH''<R8<9]#_6%0F)[/^`+&_^#\A-D9`A
M#K3Y47XH'6(OC+B0D8;$&I)H2*HAV1B1)('N+L7^2Y(0$EF2`1E),B`C21@R
MF]*=Q9G:2DGMQ7>AAH;$&FLB;,A^!:S*AI6*[YPU&R.2-N34.]Y&[Z0%G))X
M7A!K602&.+`!CV*NK&<W&-V:9GAWF"K.8.10\19SUU$[4B1HN*.Q-E4B;,8K
M5*9*I:E\Q_;G2N//!`U,)2D(Z?Z`@L1:5I`ASKCU.KXGM][=8.2*\@O%,.[Z
MGB&N3>6R/6_F*KTYTL;$&F^BV:02K^--EZX2WVP\1M*&',PD<;Y4>I1%%FV`
ME+SS%=6XU2CQ!LAUA))[#I'V][:Q/<>=+V2BB!/1FP=MD3&';MP))[IQIQP:
MN.?3Y5)99,:)V*UF?(R#6]+/4(^=$F%OYYFRI<1KTX7=<E2U<]GIW6#EC)*.
M#R2;"3\O.[Y23'MNY3-![85CJRTJXN2W5<4<NLV7<*8?SI=RJV&^J3OS;26"
MY,9)"@_*3-0ONT&R2T6-VA/:H:KJC`*_DMLAA&6S$C"[NH9^`+L,$*CX/(CH
M,5G!DWD`G5>WAROP$TT2Q7Y+KL9W[+=.`$=<G6<["^``J.-/;O`$#NL?MFX`
M1Z0[N!?`B0)P2ZP(KL27_(1^S]M3V71&A8X@RI2>(UIVJ68O/;Z`6'"UQ3W<
MA>F_9_CQ`\'1>#J!N!TQ[OD+F4#\G++Y#P``__\#`%!+`P04``8`"````"$`
MNF()]I4```"I````$````'AL+V-A;&-#:&%I;BYX;6P\CD$*`C$0!.^"?PAS
M=[-Z$)$D"PJ^0!\P9,=-()DLF2#Z>^/%2T/34-5F>N>D7E0E%K:P'T90Q+[,
MD1<+C_MM=P(E#7G&5)@L?$A@<MN-\9C\-6!DU0DL%D)KZUEK\8$RRE!6XKX\
M2\W8>JV+EK42SA*(6D[Z,(Y'G3L`G/&J6KAT5>P?0*5?:F?T7^*^````__\#
M`%!+`P04``8`"````"$`9.^:R)8#``!^#@``$``(`61O8U!R;W!S+V%P<"YX
M;6P@H@0!**```0``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````"<5U%O
MHS@0?C_I_D/$^Y:T6U6GBK!RB--:1PR+G6[[9'F)TZ"E$($W:N_7GPEM`^G@
M5?IF[&]FOIGY;&/OV_-3/MJIJL[*8N*<GXV=D2K2<I45CQ-GR>=?_G%&M9;%
M2N9EH2;.BZJ=;_[??WEQ56Y5I3-5CXR+HIXX&ZVWUZY;IQOU).LSLUR8E759
M/4EM/JM'MUROLU3-RO3WDRJT>S$>7[GJ6:MBI59?MN\.G=;C]4Y_UNFJ3!M^
M]1U_V1K"OH>VVSQ+I399^HLLK<JZ7.L1?DY5[KG=1<^P8RK]767ZQ1][;O?3
M8ZG,56`<^VN9U\IS#Q/>K9)-T6*95;7O[?3U3J6ZK$9U]I\IVX4S^BEKU="9
M.#M99;+0AE8#:S_VXWQ;Z\K_45:_ZHU2NO9<`V@G]\,NMCO.+OVKRSW"C/K(
MQD/+Q"ST.?),YZJ.UK&L-$#YZK++><^B9=P2>NNB,-H0N-"F7H(4;;>SLLO\
M/8<@HBP*R0QQ/!-3%"(:8,%N,>;L5+R(Y9]-&#>1%IAR)J*YB&)\J@GCT:DF
M`8)SX;=8!-$B1O0!=,F6BP5*'AJBC-Q0,B<!HER@((B6E(,FA-Z9W*($=AB9
MB(D(EDEB0`(Q-E3E.;DW[;``X@3'B,P$OH\Q97`1">6(WI!IB&V>^IQ"@J8D
M))Q@N&0TXIB)&#T@XQ:L@.E/\.]M%,YPP@3^OB0<K@6AIO18<'0_$"K!X5Z4
M,4H&Z4R7C%#,F&FCT2WE">+$"!HD9L(M"&^EA^BL,>&$WF`:#"7+<(B#9E]\
M7QH..`D?Q)Q0LT,("L4,#,*64V:2;MJ+&R7`5.S".A_P;!/C!6CSKD;!Y4]S
MKH"@O@!:S=GP76W:<$<2M4$_*-4&[O/M"'9O!*8(:-(6H2M-&\ZJ*`$SL4KJ
M,YW_"L>Q'EWMO?1ZB;U?!0>US)2667Z"7&P&/;V\`@65565N_IT"V4,F(/!8
M8S8>'T76)0.Z'S0Y#2W@O@X+N2$&AK";P&%Z1[;HYMPT``QC-X'#0'OL$`P,
M8S?Y3!CX&+3$.9G7Z:Q.YB3@+=T[E0Z5M>TCR`3,&`(.J/;H6CX2%.A]X)9^
M-05-[$<KW`2[S4`;K.?Q@,WQ'=^K03>=WH_^T:]]F!6_ZN66ES.IU=O;I3_I
ML8VLU,K\U;^M'R:\6_-LJ?+&2;"1Q:-:O6$^+C0OK;OV.>F?7YZ-OX[-(ZHS
MY[F'AZ/_/P```/__`P!02P,$%``&``@````A`%);1/$R`0``0`(``!$`"`%D
M;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````)R174O#,!2&[P7_0\E]FWY,&:'-0&57#@0GBG<Q.>N"31J2
M:-M_;]9U=:)77H;WS9/GG)2K7C71)U@G6UVA+$E1!)JW0NJZ0D_;=;Q$D?-,
M"]:T&BHT@$,K>GE1<D-X:^'!M@:LE^"B0-*.<%.AO?>&8.SX'A1S26CH$.Y:
MJY@/1UMCP_@[JP'G:7J-%7@FF&?X`(S-3$034O`9:3YL,P($Q]"``NT=SI(,
M?W<]6.7^O#`F9TTE_6#"3)/N.5OP8SBW>R?G8M=U25>,&L$_PR^;^\=QU%CJ
MPZXX('K83\.<WX15[B2(FX'V;[:)G-N7^'=6"C[:$6Z!>1!1>(\<[4[)<W%[
MMUTCFJ?959P6<99O\Y042[)8O);XU)KNTQFH)H%_$T\`.GK__'/Z!0``__\#
M`%!+`0(M`!0`!@`(````(0`T$38L2P(``+\F```3````````````````````
M``!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````
M3`(```L`````````````````A`0``%]R96QS+RYR96QS4$L!`BT`%``&``@`
M```A`-`:\Y2;`@``9"8``!H`````````````````J@<``'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&``@````A`-=UL+?3!```LA(```\`
M````````````````A0L``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````
M(0!]N`*HV`4``"$6```8`````````````````(40``!X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"+0`4``8`"````"$`!\-NXU48``#HK0``&0``````
M``````````"3%@``>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+`0(M`!0`
M!@`(````(0!.;+7\#PX``(17```9`````````````````!\O``!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L!`BT`%``&``@````A`+2-3FX."P``@#P`
M`!D`````````````````93T``'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"+0`4``8`"````"$`K2ETRBX=``#CN0``&0````````````````"J2```
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+`0(M`!0`!@`(````(0#:8(;G
MS00``),1```9``````````````````]F``!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L!`BT`%``&``@````A`$:0$VQC!0``-!4``!D`````````````
M````$VL``'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"+0`4``8`"```
M`"$`]6?GV8L$``":#P``&0````````````````"M<```>&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+`0(M`!0`!@`(````(0#U,3F-<@(``/,%```9````
M`````````````&]U``!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!`BT`
M%``&``@````A`,_DSJII`@``4@8``!D`````````````````&'@``'AL+W=O
M<FMS:&5E=',O<VAE970T-"YX;6Q02P$"+0`4``8`"````"$`;O'3O)L"```H
M!@``&0````````````````"X>@``>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM
M;%!+`0(M`!0`!@`(````(0#4/EZLQP(``+@'```9`````````````````(I]
M``!X;"]W;W)K<VAE971S+W-H965T-#`N>&UL4$L!`BT`%``&``@````A`$C%
M6U&:`@``KP8``!D`````````````````B(```'AL+W=O<FMS:&5E=',O<VAE
M970T,2YX;6Q02P$"+0`4``8`"````"$`+'-*2#\#```S"@``&0``````````
M``````!9@P``>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+`0(M`!0`!@`(
M````(0!&&E/O6P4``$$6```9`````````````````,^&``!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L!`BT`%``&``@````A`%>-;'FM`P``)PP``!D`
M````````````````88P``'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M+0`4``8`"````"$`RR6RFJP#```F#```&0````````````````!%D```>&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+`0(M`!0`!@`(````(0`8B@]G>@4`
M`'05```9`````````````````"B4``!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L!`BT`%``&``@````A`-M>Y7FA`P``G0L``!D`````````````````
MV9D``'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"+0`4``8`"````"$`
M^V*E;90&``"G&P``$P````````````````"QG0``>&PO=&AE;64O=&AE;64Q
M+GAM;%!+`0(M`!0`!@`(````(0!3"-#]_@P``-A_```-````````````````
M`':D``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`/\BF+,+A```:[0!
M`!0`````````````````G[$``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`
M%``&``@````A`.LNZDD%`P``OPD``!@`````````````````W#4!`'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0`<JZ'$#`4``'D3
M```8`````````````````!<Y`0!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"+0`4``8`"````"$`,+XKT4<%```"%```&0````````````````!9/@$`
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+`0(M`!0`!@`(````(0!LGC7:
MG`(``-\&```9`````````````````-=#`0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L!`BT`%``&``@````A`)$V_Q!A`P``"`H``!D`````````````
M````JD8!`'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"+0`4``8`"```
M`"$`<(7W1R`"``".!```&0````````````````!"2@$`>&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+`0(M`!0`!@`(````(0!-#L>Y+P,``&P)```9````
M`````````````)E,`0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L!`BT`
M%``&``@````A`(S+>M;8`@``+@@``!D`````````````````_T\!`'AL+W=O
M<FMS:&5E=',O<VAE970U."YX;6Q02P$"+0`4``8`"````"$`9?1?KW0(``#!
M+```&0`````````````````.4P$`>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM
M;%!+`0(M`!0`!@`(````(0!B?]6^90@``!0L```9`````````````````+E;
M`0!X;"]W;W)K<VAE971S+W-H965T-C`N>&UL4$L!`BT`%``&``@````A```&
MCS=4!```(@\``!@`````````````````560!`'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+`0(M`!0`!@`(````(0`^N"G7_`(``)$(```9````````````
M`````-]H`0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!`BT`%``&``@`
M```A`/(8?ZI;`P``#0H``!D`````````````````$FP!`'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"+0`4``8`"````"$`SL;`GU$2``#@70``&0``
M``````````````"D;P$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M
M`!0`!@`(````(0">"&:HV0<``!(@```9`````````````````"R"`0!X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A`*;O4S@Z!0``
M(AD``!D`````````````````/(H!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"+0`4``8`"````"$`)ZK58)LP```+(@$`&0````````````````"M
MCP$`>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(````(0!D
M+UK'9PL``,TX```9`````````````````'_``0!X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L!`BT`%``&``@````A`.I;1X+G`P``$P\``!D`````````
M````````'<P!`'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4``8`
M"````"$`I2ZGCED%``#,$P``&0`````````````````[T`$`>&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0"O^94](P8``%P8```9
M`````````````````,O5`0!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!
M`BT`%``&``@````A`,$HH1D[!@``CQ@``!D`````````````````)=P!`'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"+0`4``8`"````"$`K?$Z6<`(
M``#O)P``&`````````````````"7X@$`>&PO=V]R:W-H965T<R]S:&5E=#4N
M>&UL4$L!`BT`%``&``@````A`(VYRK(\"0``KR<``!@`````````````````
MC>L!`'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M`!0`!@`(````(0!7
M&IATO@(``(X'```8`````````````````/_T`0!X;"]W;W)K<VAE971S+W-H
M965T-RYX;6Q02P$"+0`4``8`"````"$`1(V76M8D```%[```&```````````
M``````#S]P$`>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`%``&``@`
M```A`$H?TG5^!0``Y!0``!@`````````````````_QP"`'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0`THOX5F@(``*`&```9````
M`````````````+,B`@!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!`BT`
M%``&``@````A``SI2D_3`@``S`<``!D`````````````````A"4"`'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"+0`4``8`"````"$`J)N4[&0-``"!
M1```&0````````````````".*`(`>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;%!+`0(M`!0`!@`(````(0!.1ZR=ZP<```4C```9`````````````````"DV
M`@!X;"]W;W)K<VAE971S+W-H965T,C`N>&UL4$L!`BT`%``&``@````A`.A"
M14"'&@``1X4``!D`````````````````2SX"`'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6Q02P$"+0`4``8`"````"$`B0O?CPT)``#/*```&0``````````
M```````)60(`>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(
M````(0#'X"U+804``&D3```9`````````````````$UB`@!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L!`BT`%``&``@````A`'"#C@._#```.$$``!D`
M````````````````Y6<"`'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M+0`4``8`"````"$`/636"EH#``!Q"@``&0````````````````#;=`(`>&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+`0(M`!0`!@`(````(0"G'9^)C`\`
M`/-)```9`````````````````&QX`@!X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L!`BT`%``&``@````A`,%?]25^!P``U1T``!D`````````````````
M+X@"`'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`
M(J<.BX@%``"S%```&0````````````````#DCP(`>&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0`DFG$,N`(``%L'```9````````
M`````````*.5`@!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`%``&
M``@````A`&[%BA?P(```%<\``!D`````````````````DI@"`'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"+0`4``8`"````"$`5#_NPC4%``#9$@``
M&0````````````````"YN0(`>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M`0(M`!0`!@`(````(0`E',M,W04``%(6```9`````````````````"6_`@!X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!`BT`%``&``@````A`/FBV;6)
M!0``/A4``!D`````````````````.<4"`'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"+0`4``8`"````"$`9RITFN\$``"3$0``&0``````````````
M``#YR@(`>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+`0(M`!0`!@`(````
M(0"Z8@GVE0```*D````0`````````````````!_0`@!X;"]C86QC0VAA:6XN
M>&UL4$L!`BT`%``&``@````A`&3OFLB6`P``?@X``!``````````````````
MXM`"`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"````"$`4EM$\3(!``!`
M`@``$0````````````````"NU0(`9&]C4')O<',O8V]R92YX;6Q02P4&````
/`$H`2@`O%```%]@"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ERWAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOptionsAbstract', window );"><strong>Number Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">75,423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOptionsAbstract', window );"><strong>Number Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">15,632,742</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">13,733,488</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">10,590,161</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,442,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,583,677</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">5,121,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(854,573)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(75,423)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(1,931,788)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(250)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(250)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Cancelled</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(427,476)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(608,750)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(46,135)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">16,792,443</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">15,632,742</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">13,733,488</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">13,276,462</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.44</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.16</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.16</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 4.71</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 3.31</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.88</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.44</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.16</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1', window );">Options outstanding, beginning</a></td>
        <td class="text">7 years 2 months 12 days<span></span></td>
        <td class="text">7 years 8 months 12 days<span></span></td>
        <td class="text">7 years 7 months 6 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2', window );">Options outstanding, ending</a></td>
        <td class="text">6 years 10 months 24 days<span></span></td>
        <td class="text">7 years 2 months 12 days<span></span></td>
        <td class="text">7 years 8 months 12 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
        <td class="text">5 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, beginning</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 58,878,132</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 26,804,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 14,067,649</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, ending</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">43,996,311</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">58,878,132</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">26,804,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 40,720,977</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AggregateIntrinsicValueAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOptionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_NumberOptionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WeightedAverageRemainingContractualLifeAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedClinicalTrialCostsCurrent', window );">Accrued clinical trial costs</a></td>
        <td class="nump"><a title="txmd_AccruedClinicalTrialCostsCurrent" onclick="toggleNextSibling(this);">$ 1,706,542</a><span style="display:none;white-space:normal;text-align:left;">txmd_AccruedClinicalTrialCostsCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="txmd_AccruedClinicalTrialCostsCurrent" onclick="toggleNextSibling(this);">$ 665,782</a><span style="display:none;white-space:normal;text-align:left;">txmd_AccruedClinicalTrialCostsCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
        <td class="nump"><a title="us-gaap_AccruedSalariesCurrent" onclick="toggleNextSibling(this);">814,205</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedSalariesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_AccruedSalariesCurrent" onclick="toggleNextSibling(this);">941,313</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedSalariesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation costs</a></td>
        <td class="nump"><a title="us-gaap_AccruedVacationCurrent" onclick="toggleNextSibling(this);">442,430</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedVacationCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_AccruedVacationCurrent" onclick="toggleNextSibling(this);">256,920</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedVacationCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
        <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">276,470</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">224,550</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">185,965</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">177,900</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
        <td class="nump"><a title="txmd_AllowanceForWholesaleDistributorFeesCurrent" onclick="toggleNextSibling(this);">160,503</a><span style="display:none;white-space:normal;text-align:left;">txmd_AllowanceForWholesaleDistributorFeesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="txmd_AllowanceForWholesaleDistributorFeesCurrent" onclick="toggleNextSibling(this);">306,303</a><span style="display:none;white-space:normal;text-align:left;">txmd_AllowanceForWholesaleDistributorFeesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
        <td class="nump"><a title="us-gaap_AccruedRoyaltiesCurrent" onclick="toggleNextSibling(this);">72,710</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedRoyaltiesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_AccruedRoyaltiesCurrent" onclick="toggleNextSibling(this);">52,188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedRoyaltiesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
        <td class="nump"><a title="txmd_SalesDiscountsReturnsAndAllowancesGoods1" onclick="toggleNextSibling(this);">90,446</a><span style="display:none;white-space:normal;text-align:left;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="txmd_SalesDiscountsReturnsAndAllowancesGoods1" onclick="toggleNextSibling(this);">126,233</a><span style="display:none;white-space:normal;text-align:left;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
        <td class="nump"><a title="us-gaap_AccruedRentCurrent" onclick="toggleNextSibling(this);">91,368</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedRentCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedFinancingCostsCurrent', window );">Accrued financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="txmd_AccruedFinancingCostsCurrent" onclick="toggleNextSibling(this);">850,000</a><span style="display:none;white-space:normal;text-align:left;">txmd_AccruedFinancingCostsCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 3,840,639</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 3,601,189</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain stockholders at both December 31, 2014 and 2013.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedClinicalTrialCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AccruedClinicalTrialCostsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedFinancingCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for financing costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AccruedFinancingCostsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 710<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CommitmentsAndContingenciesTablesAbstract', window );"><strong>Commitments And Contingencies Tables</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum rental payments</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, future minimum rental
payments under our office lease are as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Years Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: left">2015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">371,240</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="text-align: left">2016</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: left">2017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">393,848</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="text-align: left">2018</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">302,748</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: left">2019</td><td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Non-cancellable sub-lease income</font></td><td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left"></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="text-align: left; padding-bottom: 2.5pt">Net minimum lease payments</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,450,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: left; width: 66%"><font style="font: 10pt Times New Roman, Times, Serif"></font></td><td style="text-align: left; width: 1%">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CommitmentsAndContingenciesTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_CommitmentsAndContingenciesTablesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES (Details)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">34.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">35.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">35.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal tax benefit</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">5.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">5.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">5.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Adjustment in valuation allowances</a></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(50.90%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(32.40%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(18.20%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other differences</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">11.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">(8.40%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">(22.30%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision (Benefit) for Income Taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventory consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Finished product</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">874,294</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">621,679</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Raw material</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">155,341</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">250,943</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Deferred costs</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">152,478</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">170,996</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,182,113</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,043,618</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1PDO">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>May 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>May 11, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>May 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
        <td class="nump"><a title="us-gaap_WarrantsAndRightsOutstanding" onclick="toggleNextSibling(this);">$ 13,927,916</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WarrantsAndRightsOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnamortizedCostsOfWarrants', window );">Unamortized costs of warrants</a></td>
        <td class="nump"><a title="txmd_UnamortizedCostsOfWarrants" onclick="toggleNextSibling(this);">875,600</a><span style="display:none;white-space:normal;text-align:left;">txmd_UnamortizedCostsOfWarrants</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredFinanceCostsCurrentNet" onclick="toggleNextSibling(this);">260,022</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFinanceCostsCurrentNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense-long term</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseNoncurrent" onclick="toggleNextSibling(this);">1,427,263</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseNoncurrent" onclick="toggleNextSibling(this);">1,750,455</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">43,218,938</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">13,551,263</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">4,492,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LoanGuarantyCosts', window );">Loan guaranty costs</a></td>
        <td class="nump"><a title="txmd_LoanGuarantyCosts" onclick="toggleNextSibling(this);">2,944</a><span style="display:none;white-space:normal;text-align:left;">txmd_LoanGuarantyCosts</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">Sancilio and Company Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember]" onclick="toggleNextSibling(this);">$ 2.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember]" onclick="toggleNextSibling(this);">850,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights', window );">Number of shares purchased forfeit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember]" onclick="toggleNextSibling(this);">833,000</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member', window );">Sancilio &amp;amp;amp; Company Warrants 1st Installments [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member]" onclick="toggleNextSibling(this);">283,333</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jun. 30,  2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member]" onclick="toggleNextSibling(this);">405,066</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member]" onclick="toggleNextSibling(this);">45.89%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member]" onclick="toggleNextSibling(this);">1.12%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights', window );">Valuation method of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Black-Scholes Model<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpenseRecognized', window );">Non-cash compensation recongised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExpenseRecognized[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member]" onclick="toggleNextSibling(this);">405,066</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExpenseRecognized<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member', window );">Sancilio and Company Warrants 2nd Installments [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">283,333</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">462,196</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">45.84%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">1.41%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpenseRecognized', window );">Non-cash compensation recongised</a></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExpenseRecognized[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">154,068</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExpenseRecognized<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExpenseRecognized[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">77,034</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExpenseRecognized<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expense-short term</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">154,068</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense-long term</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseNoncurrent[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member]" onclick="toggleNextSibling(this);">77,026</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseNoncurrent<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants3Member', window );">Sancilio and Company Warrants 3rd Installments [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants3Member]" onclick="toggleNextSibling(this);">283,334</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_SancilioAndCompanyWarrants3Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember', window );">Modification Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember]" onclick="toggleNextSibling(this);">$ 0.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_ModificationWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember]" onclick="toggleNextSibling(this);">3,314,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_ModificationWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember]" onclick="toggleNextSibling(this);">6,124,873</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_ModificationWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember]" onclick="toggleNextSibling(this);">44.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_ModificationWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember]" onclick="toggleNextSibling(this);">89.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_ModificationWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_ModificationWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember', window );">Warrants Issued to Unaffiliated Individuals [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember]" onclick="toggleNextSibling(this);">31,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividualsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember]" onclick="toggleNextSibling(this);">44.81%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividualsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember]" onclick="toggleNextSibling(this);">1.04%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividualsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividualsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumbersOfUnaffiliatedIndividuals', window );">Number of unaffiliated individuals</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_NumbersOfUnaffiliatedIndividuals[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember]" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">txmd_NumbersOfUnaffiliatedIndividuals<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividualsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProfessionalFees[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember]" onclick="toggleNextSibling(this);">29,736</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfessionalFees<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividualsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember', window );">Warrants Issued to Unaffiliated Entity [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">$ 2.57</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">1,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">1,532,228</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">44.71%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">0.74%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization deferred financing costs</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">1,532,228</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpenseRecognized', window );">Non-cash compensation recongised</a></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExpenseRecognized[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">309,165</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExpenseRecognized<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExpenseRecognized[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">360,528</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExpenseRecognized<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExpenseRecognized[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">218,045</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExpenseRecognized<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expense-short term</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">257,796</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense-long term</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseNoncurrent[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember]" onclick="toggleNextSibling(this);">386,694</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseNoncurrent<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedEntityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember', window );">June 2012 Notes/Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember]" onclick="toggleNextSibling(this);">7,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember]" onclick="toggleNextSibling(this);">9,424,982</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember]" onclick="toggleNextSibling(this);">44.64%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember]" onclick="toggleNextSibling(this);">0.75%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization deferred financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember]" onclick="toggleNextSibling(this);">547,210</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod', window );">Fair value of warrants by relative fair value calculation method</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember]" onclick="toggleNextSibling(this);">1,649,890</a><span style="display:none;white-space:normal;text-align:left;">txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RemainingAmortizationOfFinancingCostsAndDiscounts', window );">Remaining amortization deferred financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember]" onclick="toggleNextSibling(this);">1,102,680</a><span style="display:none;white-space:normal;text-align:left;">txmd_RemainingAmortizationOfFinancingCostsAndDiscounts<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants1Member', window );">June 2012 Notes/Warrants 1st Issue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants1Member]" onclick="toggleNextSibling(this);">$ 2.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrants1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants1Member]" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrants1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants2Member', window );">June 2012 Notes/Warrants 2nd Issue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants2Member]" onclick="toggleNextSibling(this);">$ 3.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants2Member]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_June2012NotesWarrants2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member', window );">Warrants Issued to Unaffiliated Individuals [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member]" onclick="toggleNextSibling(this);">1,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member]" onclick="toggleNextSibling(this);">44.78%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member]" onclick="toggleNextSibling(this);">0.72%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumbersOfUnaffiliatedIndividuals', window );">Number of unaffiliated individuals</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_NumbersOfUnaffiliatedIndividuals[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">txmd_NumbersOfUnaffiliatedIndividuals<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProfessionalFees[us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member]" onclick="toggleNextSibling(this);">1,656</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfessionalFees<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember', window );">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">$ 3.20</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">1,250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 31,  2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 31,  2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">1,711,956</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">44.29%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">0.88%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization deferred financing costs</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">1,451,934</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">260,027</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember', window );">February 2012 Notes/ Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">$ 0.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">5,685,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">3,314,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">10,505,247</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">44.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">89.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">$ 859,647</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">$ 0.24</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 3.20</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_RangeAxis=us-gaap_WeightedAverageMember]" onclick="toggleNextSibling(this);">$ 1.82</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_RangeAxis<br>= us-gaap_WeightedAverageMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpenseRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to non cash compensation expenses of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExpenseRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the warrants or rights are expired in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to fair value of warrants or rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refer to numbers of shares forfeit during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to valuation method of warrants or rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the warrants or rights are vesting in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to fair value of awards by a calculation method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LoanGuarantyCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expense incurred for loan guaranty costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_LoanGuarantyCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumbersOfUnaffiliatedIndividuals">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to numbers of entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_NumbersOfUnaffiliatedIndividuals</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RemainingAmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to remaining amortization deferred financing costs during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_RemainingAmortizationOfFinancingCostsAndDiscounts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnamortizedCostsOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to unamortized costs associated with warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_UnamortizedCostsOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WarrantsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item provides the weighted-average contractual remaining life of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount (net of debt premium) that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28567-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of current deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 3<br><br> -Subparagraph (k)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrants2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_June2012NotesWarrantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_ModificationWarrantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants3Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrants3Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedEntityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsIssuedToUnaffiliatedIndividualsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_WeightedAverageMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">$ 28,776</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">$ 23,480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">$ 10,262</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">$ 28,776</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Development costs for corporate website [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">36 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">OPERA software patent [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">20 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents (Member)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">20 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INVENTORY (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished product</a></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoods" onclick="toggleNextSibling(this);">$ 874,294</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoods</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoods" onclick="toggleNextSibling(this);">$ 621,679</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoods</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
        <td class="nump"><a title="us-gaap_InventoryRawMaterials" onclick="toggleNextSibling(this);">155,341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryRawMaterials</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryRawMaterials" onclick="toggleNextSibling(this);">250,943</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryRawMaterials</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs</a></td>
        <td class="nump"><a title="us-gaap_DeferredCostsCurrent" onclick="toggleNextSibling(this);">152,478</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredCostsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredCostsCurrent" onclick="toggleNextSibling(this);">170,996</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredCostsCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">$ 1,182,113</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">$ 1,043,618</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E41AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) (Warrants [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSharesUnderWarrantAbstract', window );"><strong>Number of shares under warrant</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">14,293,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">12,193,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">3,057,627</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">2,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">17,332,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">(365,583)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">(8,145,486)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants expired</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Warrants cancelled</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">(51,142)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">13,927,916</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">14,293,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">12,193,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Vested and Exercisable</a></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">13,562,764</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, beginning</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 1.79</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 1.63</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 0.36</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants', window );">Warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">2.72</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">1.26</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises', window );">Warrants exercised</a></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0.5</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0.38</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures', window );">Warrants cancelled</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0.24</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, ending</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 1.82</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 1.79</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 1.63</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable', window );">Vested and Exercisable</a></td>
        <td class="nump"><a title="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">1.83</a><span style="display:none;white-space:normal;text-align:left;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding', window );">Warrants outstanding, beginning</a></td>
        <td class="text">3 years 10 months 24 days<span></span></td>
        <td class="text">4 years 9 months 18 days<span></span></td>
        <td class="text">7 years 10 months 24 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding', window );">Warrants outstanding, ending</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">3 years 10 months 24 days<span></span></td>
        <td class="text">4 years 9 months 18 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable', window );">Vested and Exercisable</a></td>
        <td class="text">2 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Warrants outstanding, beginning</a></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 48,932,777</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 17,971,994</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 3,483,691</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Warrants outstanding, ending</a></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">36,623,875</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">48,932,777</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">17,971,994</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue', window );">Vested and Exercisable</a></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 35,599,540</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AggregateIntrinsicValueAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to class of warrant or righst contractual life beginning oustanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to class of warrant or righst contractual life closing oustanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average remaining contractual life of warrants vested and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants exercised in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants cancelled or forfeited in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants granted in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants vested and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSharesUnderWarrantAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_NumberOfSharesUnderWarrantAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WeightedAverageRemainingContractualLifeAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of non-option equity instruments exercised by participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of non-option equity instruments granted to participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">63 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MonthlyBaseRentOfLeases', window );">Monthly Base rent of leases</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_MonthlyBaseRentOfLeases" onclick="toggleNextSibling(this);">$ 30,149</a><span style="display:none;white-space:normal;text-align:left;">txmd_MonthlyBaseRentOfLeases</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FutureMinimumLeasePaymentsOverLifeOfLease', window );">Future minimum lease payments over life of lease</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_FutureMinimumLeasePaymentsOverLifeOfLease" onclick="toggleNextSibling(this);">1,899,414</a><span style="display:none;white-space:normal;text-align:left;">txmd_FutureMinimumLeasePaymentsOverLifeOfLease</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental Expense</a></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">180,894</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">60,168</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">361,793</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">106,315</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Rental income</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" onclick="toggleNextSibling(this);">$ 32,963</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" onclick="toggleNextSibling(this);">$ 41,613</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total term (in months) of the company's outstanding lease obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FutureMinimumLeasePaymentsOverLifeOfLease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum rental payments for leases required over the life of lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_FutureMinimumLeasePaymentsOverLifeOfLease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MonthlyBaseRentOfLeases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Base monthly rent of operating leases, as stipulated in leasing agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_MonthlyBaseRentOfLeases</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ERHDO">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="7">0 Months Ended</th>
        <th class="th" colspan="5">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 21, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 13, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 25, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013</div>
        </th>
        <th class="th">
          <div>Apr. 25, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 19, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2012</div>
        </th>
        <th class="th">
          <div>May 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 21, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfLinesOfCredit" onclick="toggleNextSibling(this);">$ 500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLinesOfCredit</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfLinesOfCredit" onclick="toggleNextSibling(this);">$ 300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLinesOfCredit</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromLinesOfCredit" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromLinesOfCredit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromLinesOfCredit" onclick="toggleNextSibling(this);">300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromLinesOfCredit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">1,165,981</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">1,905,409</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">64,380</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromNotesPayable" onclick="toggleNextSibling(this);">8,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromNotesPayable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">4,691,847</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">1,850,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Acrued interest</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognized loss on extinguishment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_GainsLossesOnExtinguishmentOfDebt" onclick="toggleNextSibling(this);">(10,307,864)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainsLossesOnExtinguishmentOfDebt</span><span></span></td>
        <td class="num"><a title="us-gaap_GainsLossesOnExtinguishmentOfDebt" onclick="toggleNextSibling(this);">(7,390,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainsLossesOnExtinguishmentOfDebt</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">212,853</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">17,253</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">696</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_MrMilliganMember', window );">Mr. Milligan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDecreaseForgiveness1', window );">Line of credit facility decrease forgiveness</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCreditFacilityDecreaseForgiveness1[dei_LegalEntityAxis=txmd_MrMilliganMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCreditFacilityDecreaseForgiveness1<br>/ dei_LegalEntityAxis<br>= txmd_MrMilliganMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember', window );">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Stated interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Description of interest payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Interest payments were due and payable on the tenth day following the end of each calendar quarter<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from revolving credit note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromDebtNetOfIssuanceCosts[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromDebtNetOfIssuanceCosts[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of revolving credit note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfDebt[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">401,085</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Revolving credit outstanding</a></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">1,250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per unit)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">$ 3.20</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_MultipleAdvanceRevolvingCreditNoteMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember', window );">VitaMed Promissory Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Stated interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">2.35%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">3.02%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Description of interest payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Under the extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Revolving credit outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">299,220</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">299,220</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfLinesOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">100,735</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLinesOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromLinesOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromLinesOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">735</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">7,366</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">4.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of interest rate terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier
of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory
note(s) issued in an amount of not less than $1,000,000, or the Funding.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">2,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember', window );">VitaMed Promissory Notes [Member] | Reich Family Limited LP [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfLinesOfCredit[dei_LegalEntityAxis=txmd_ReichFamilyLimitedLPMember;us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">299,220</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLinesOfCredit<br>/ dei_LegalEntityAxis<br>= txmd_ReichFamilyLimitedLPMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromLinesOfCredit[dei_LegalEntityAxis=txmd_ReichFamilyLimitedLPMember;us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromLinesOfCredit<br>/ dei_LegalEntityAxis<br>= txmd_ReichFamilyLimitedLPMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_IssuanceOfPromissoryNotesMember', window );">Issuance of 6% Promissory Notes (January and February 2012) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_IssuanceOfPromissoryNotesMember]" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_IssuanceOfPromissoryNotesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes1Member', window );">February 2012 Notes Issued To Individual And Entity [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes1Member]" onclick="toggleNextSibling(this);">1,358,014</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes1Member]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes1Member]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RemainingSurrenderValueOfNotes', window );">Remaining balance of notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_RemainingSurrenderValueOfNotes[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes1Member]" onclick="toggleNextSibling(this);">1,347,128</a><span style="display:none;white-space:normal;text-align:left;">txmd_RemainingSurrenderValueOfNotes<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member', window );">February 2012 Notes Issued To Parties [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">5,685,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">1,357,110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">1,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">1,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Acrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrentAndNoncurrent[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">15,124</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrentAndNoncurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFairValue[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">1,517,741</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFairValue<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">197,383</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognized loss on extinguishment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GainsLossesOnExtinguishmentOfDebt[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">10,307,864</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainsLossesOnExtinguishmentOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RemainingSurrenderValueOfNotes', window );">Remaining balance of notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_RemainingSurrenderValueOfNotes[us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member]" onclick="toggleNextSibling(this);">1,344,719</a><span style="display:none;white-space:normal;text-align:left;">txmd_RemainingSurrenderValueOfNotes<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember', window );">February 2012 Notes/ Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">3,314,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">5,685,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per unit)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">$ 0.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">859,647</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate principal and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">3,102,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Amount of shares issued in exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">8,145,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">8,145,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RemainingSurrenderValueOfNotes', window );">Remaining balance of notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_RemainingSurrenderValueOfNotes[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">2,691,847</a><span style="display:none;white-space:normal;text-align:left;">txmd_RemainingSurrenderValueOfNotes<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes1Member', window );">June 2012 Notes Issued To Individual And Entity [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes1Member]" onclick="toggleNextSibling(this);">2,347,128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012Notes1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes2Member', window );">June 2012 Notes Issued To Parties [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes2Member]" onclick="toggleNextSibling(this);">2,344,719</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes2Member]" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012Notes2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember', window );">June 2012 Notes (secured promissory notes) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember]" onclick="toggleNextSibling(this);">7,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember]" onclick="toggleNextSibling(this);">4,882,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Acrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrentAndNoncurrent[us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember]" onclick="toggleNextSibling(this);">21,595</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrentAndNoncurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrentAndNoncurrent[us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember]" onclick="toggleNextSibling(this);">21,595</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrentAndNoncurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of interest rate terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember]" onclick="toggleNextSibling(this);">$ 21,595</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_June2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RemainingSurrenderValueOfNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to amount of remaining surrender value of notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_RemainingSurrenderValueOfNotes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13476-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount (net of debt premium) that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28567-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of interest payable on debt, including, but not limited to, trade payables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDecreaseForgiveness1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in line of credit facility from forgiveness by the holder of the line of credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDecreaseForgiveness1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effective interest rate during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_MrMilliganMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_MrMilliganMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_February2012Notes2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_IssuanceOfPromissoryNotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_IssuanceOfPromissoryNotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_June2012Notes2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_June2012NotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 3 &#150; INVENTORY&#160;</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventory consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Finished product</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">874,294</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">621,679</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Raw material</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">155,341</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">250,943</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Deferred costs</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">152,478</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">170,996</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,182,113</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,043,618</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5DAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract', window );"><strong>Future minimum rental payments, year ending December 31,</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" onclick="toggleNextSibling(this);">$ 371,240</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">382,377</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" onclick="toggleNextSibling(this);">393,848</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" onclick="toggleNextSibling(this);">302,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">1,450,213</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OperatingLeasesFutureMinimumPaymentsNetDue', window );">Net minimum lease payments</a></td>
        <td class="nump"><a title="txmd_OperatingLeasesFutureMinimumPaymentsNetDue" onclick="toggleNextSibling(this);">$ 1,450,213</a><span style="display:none;white-space:normal;text-align:left;">txmd_OperatingLeasesFutureMinimumPaymentsNetDue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OperatingLeasesFutureMinimumPaymentsNetDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to operating leases future minimum payments net due.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_OperatingLeasesFutureMinimumPaymentsNetDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>34
<FILENAME>0001387131-15-000875-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-15-000875-xbrl.zip
M4$L#!!0````(`*&$;$:_64)TFP\!`%;3#@`1`!P`='AM9"TR,#$T,3(S,2YX
M;6Q55`D``^[X`57N^`%5=7@+``$$)0X```0Y`0``[)UM<Z.XEH"_;]7^!V^J
M]MLZX<UON=U]R^TDL[F3%U\[W7VGJJNF",B.MC%X!#CQ_?4K86.##;;`!@2H
MJV;*%4`Z.GHX.CH21Y_^_C$S&@N`;&B9GR_$2^&B`4S-TJ$Y_7SQ;=SLCP?W
M]Q>-OW_YS_]HX'^?_JO9;-Q!8.C7C1M+:]Z;$^MOC2=U!JX;OP$3(-6QT-\:
MWU7#)7^Q[J`!4&-@S>8&<`"^L*KINJ%<REJCV:0H]CLP=0M]&]UOBGUSG/GU
MU=7[^_NE:2W4=PO]LB\UBZZXL>4B#6S*&E[_O+WYK3^"_P;HY\"`P'3LGR]O
MN"%SX#I0LQ]O?O[KZ^CAIR2(BBC)XD_G8Z;_27Z)RN7'!#?V1G5P0?AZZ[^E
M&T'&_Q.%%TF\%KK72I=2*$=U7'LCE/`AK/^M'O_T\8H,>$W^W\#]9=K7'S;\
M?!'0P[M\::'IE20(XM6_'A_&VAN8J4UHVHYJ:N#"?\J`YJ^HY\1>KW?E7?5O
MW;N35.[7(5^1RZ^JO2V9"'C@_CU)\%7=V3P0O+EUM;H8NA5&WMI>W0K]6W6P
M<Y\-M,NIM;C"%ZY(!S8%L2F+_NT(3&)%;E_AJ_Z-T+842>P<:M_J#O\!UVY.
M576^>6"BVJ_>S>L+$<+@*\@R@!WYC'<EXB'3,DUW%BV7[J`K9SD'5_BF)KX+
M(*AMGCO^4/@!+`/Y<[1TWI4(Z<B;LGG`";Q3,QV_KK,K_Y6Z\-\00M6U[;$[
M`I.&!^3UF]=-I*RF_\#EAZU?K"^3RC]?V)!8F(O&E5_4ZHW1+-,!'TX#8CGZ
M]O,$%R`W1:FYK7-S*W[QH;/<_'7S=ZB3*Q.(S9@G&0@IS@=L</_[Q1?OC95:
M'47^=+7[\+:ZJ\CZUK7-L=(M/4(*[_UQOFP;L*EB?66W_%!)_A_7^CBJ)*GL
M2I*R5-(=LF8^[8+H6-[O,BH,*P4Y9/CZLFV.7]+VVMYC>$#>/A32LW_EK#"N
M@?_S%K_BUA*`L6-IOY[G#O8C'L'L%:#"M+Y5))C.0("OS24="_,Q-Z`&G96L
M#1WB.U?>UGHPN.Z_JTA_P7:L_P'MBR_^GV/;^^DJLNB@6%?1<I7"^"A^?__E
MPCD1OQJ]/$065HNS'!I88WU3WS3OZS*B[\-M+[#'E1QZ7.8]SE"/Y_F.W[G(
MA(Z+`%;/'?P@O^P:=GZ\&FKRYG,.V.4@4WNP]J7E@"]]U-_[\Q&:<.;.J@'(
M^;V_)+6/5'.Z4W-(NWES%YJ2R&FF)'*64Y+XJ=^?:_4=P-:_@^-;#WS9FU&G
ML[;J!\<U.UR#VN76EM;:<ESKCBM[UC4\MRU9+#CGB=^NUU0IGX@UKZ3HOJV2
M16;-)N8>L!%:I&\UUW:LV9]CU=2@`:V^J9--'JJY_*$BA&NM2/1F8*@V;OBZ
M4<]H!*=OSJKWR8KT];'V%QJV\7HJZ[!-:SN1X&0P3,:NJ]]*X>J'@,IHK1?7
M(5)`)-:=(I$-`R/F86"Z6P/#V6"7C0@3TTUA8L3,34R[*0L<(U8Q"IL8TE=9
MFYAV4^KY)H:SP3(;NR:&]%QB$Q-$JE@3(]4=(XF;&,X&6VR4P\3X,3:.$:,8
MY167.[!&QME@E(U2K6,=QTBN.T9RW4W,@V5.7P":W9L::<("$`5A_:ID99KL
M?)0$H5<-2DAKR$>;`3`2M)Y;&@I+PVEBE"9V#,Z39?[350W2)SKYW,_;"+/1
M&-%29?F@;3HW-12FAG/$'$<Y&QEOUZ,L^+$9,0#'HVLX<&Z`OKX@N0M&8&$9
M"VA.!PCHT'FR'%`-.,B(X^`1YP:\.MN]AAXDM"HH.D@C!N(MU$$:,8=]UE)3
M4GRV\.\69ZMT;)$N3,P6Z>NLV2)[KWVV\&^9LU4ZMD@7)F:+]'4.;/6V;$E\
M3"PE6\D7+DA?9\K6H4_G!AYC``TLSPU%WI1W!.U?U6!JKUE1GP`?T0&?U=%^
MT,:A*@=4I?KL;#T*WH`)0-C<8]L/3!?4$2UO**33`[=9M#:+XU4VO-BS7CN9
M5?S56Q+=&[I(>U-MT)\B`(@F?D#G;0B0"3^"*4\?'@;5(&P$#*Q7?8C[9/F"
M5--6-8*._749O!)<XDVCI0(#I'FF:N(@51BD/',];1QS:S9W\1Q[;$V<=Q6!
M>Q/7.86O>&9MVZ`B.>#NH`D=\``70-]I'X;G4?T_"WG;3G;<=1K-5-SLI*)E
M<S>^BM\SX-Q8,Q5Z*U\5^>PP%4^QVJ@X0WOQ)6YQ2FIQBDA;P"U.M2Q.GC[.
MVEG^7PO-+!.LO+WE#7*G`]74H8Y=QB'^KS(?P]^;.I@DX<1SDFFU4_%1*B4S
MNRMR>%ZB@YF*?MEW%OH.'76&I1V[<WQI5G?2DNFHXKPIW$95RD;EZ1MQ&\5M
M5%%;O_DLKI2SN/*NQG'@R@\<>^MS%,#Q6`*3L81R@'5HZ.1@L0\6LT/D(;"J
M=R8;+E>'ADN^A1H#S470@<"^_=`,5P<ZT<AJ[//VHCQ/;E5D0G-J#_%8^(8'
MPJ_+Z`+"`!9^LELYP#LT5'+PR@]>*8?2=>X'#ATU="&-<4N7U-)QX,H+7"DM
M'#]OEX7!L92VBJ/#`CKL69V8G38<EWKDVL"VK+,=;81>4Q9*=DK2KFGNI##-
M7KNS-LV=K6DNO9[E-'J6\]'S[A!8<CVS/5ZL=Q/TYW-D+8!>EYTKB8+;WEZ"
MI!JJ_K@3]R4O9ZGL+#$^6XIQ>2L5S3F0.9>)6$S.YD8*F!N)]SLC,3@IC6F0
M<C`-/B(<C6),@I2#28@*EO'^YH&QF$]!.!H5_/PBZ1I?-<_&/C\-26IG[61N
MQLU2>F2K=.0W>\@6>>!X.9"EGH-Q*ULS*\O>/#`]LMS*UL+*E@K9@36;6::W
MM%T-,,<.UAMY_O8O%\M--J99)HEW[WT+%6XW1^90M(MC4A`F.4>^HDQ$7]<A
MV?2B&D,5ZO?F0)U#1S5JQ<%!'7#3<<AT<'P8PX<!DS("C@I-H/L[Q6L%0W3C
MN1$Y9$0X,(4#4[S9*/-N/?;>,+I4&MSK+]PXLQ>UC4_ZRW&I^9HH]_89\_;+
M:4HX1HQAQ)")X7.!PN<"Y30J')S"P<G9C!Q)3,F]U<*-1VD^`>&X%#^Y*3J7
M+?=*&?-*RVE*.$:,8<20B>$^:N$^:CF-"@>G<'!R/N5!Y!XJ<QZJ6$"_<W>"
M77>B"![X2,#22)`C`27;'Y&SDJ*SZZO&^KCZ,4`+J('[T;@:[\N]J5DS\*)^
M]%WGS4+0/_`ZG$X_MOE5]9W64S`Q,`4KY]L3FJ6(:68I8I:SE,AU/$$NN9Y3
M+G5Y[<Y:STI`S^WRYQ!4TNBYG7T.05&H5`Y!KSD,+=U&[OXLO=U(N?LS>[LA
M!>R&5'Z[(:6Q&U(.=D,*Y'B5RI_C54J3XU7*(<>K%+#/E=@UGL(^Y[%KG/JL
M%5&0I&ZWU9/+/I]B/2\2XZL6-"=8_.7".=%$E5-]#)&%%>@LAP8FI6_JFT9_
M749DG@]KY#A2221A.NU'M0"N4N(/M@%F)@D(LP`?REM3O1,]S-H=S\?LAX;4
M"9.D3K<E*"U%X?11T,>.T\D>>9OE,2^0XA\B\!TZZB/0\4`V@[9MH>63Y53E
M9.4'RYPZ`,UNP*NS'8Z]DP$.-;O0]=%0E"NC]5$OPL,!8!2`8/@M$P`D>@`V
M8](-1$!S+,2Y.)_'#@QLW/4A'AB6+WC4LE6-#'WVUV7P2GA\"W=#@9Q*67(:
M"E_*OH^$?RN<6<[LR1%D.;%31M#+V"D3@R<[>?UW;]LNT%\LHE)8@Q$YOM&%
MCL>Y)/=I[RP[QH*P%.O'@=_FHN=S;4874V-'R7U-2C6D1V*"'M8&'HHX5+7\
MI]*[+HS&DS@U;%&3<V;"`^>3>DL!0Q=I;ZH-^E,$O"\6?D#G;0B0"3]6QW$"
MUX&:_?`PJ!\PWH"52DM\-8\V3Q)GL=(LLI=NZ8!CQ5FL-(O,NVB<OZKQEY>S
M%[UR]&29_<D$&I#H[^4-HI42:PK,06U4?JDF/HPP\&`!:&"9&FX$\C9XC*!=
MD;P,>\V*VOIW1`=\V$KH0MV`"4`(Z.OO=>N(EF=SZ/3`\4JZ>7FL&L!>*_4)
M[&YAKI]%^PI,[6VFHE\[FSVCU'3>%>?2FU=FHR7)^5\;WUAM5V1MLCS\>V/`
ML>[@]"?-J<[IY_37+SK)Z>?T<\\_'?T5V5=3%?I9V/)3(\^'T\_IKZ_GP^GG
M]-?7\Y$Y_2S1+S-`?XT\'TX_I[^^G@^GG]-?7\]'X?2S1+_"`/TU\GPX_9S^
M^GH^G'Y.?UD\'SF0;;L26?I39-O.P\KLG.Y1]NSQ:4_WR#SA0=B3+_UI""E]
MQNQ/0U`"IR$HY>=927,:@I(+S]LL_4KY[;.2)DM_GF?$KGV[1]=PX-P`?7VA
M8G<"^S:6L8#F=("`#AV21J0:/MZ!7"FT*LC;K\KYZ%AOI.-@E`N,=:=E`\;V
M7#S9M\P\;2YK65-WS_R3$X\Z8CYG2N')1W=[=I?8XPRQR="ZJY+.X+T^S=1S
MD9HD#Z',N6&&F_!W]Z1S,AV(5G5(?@"3%@;_GA&`VMN=.H/&\@'.H`/TAR''
MY>3`I0[@]0.8JL:MI[1`W?$*+]C`>1@E#E$&^<XJAV4<WX_H$1H&G*HE/X0E
M'I;=%G)$8J*K4B"Z*C6E+A\/F1D/=R/'4IK(,>G3K!E2FI+B,X1_MSA#S#)$
MNBHQ0Z1/,_;%":>;.1S)-$Q"),^3NJ%SI.6%>N1>%V4:,US5L<FT?0=>D:NB
M);GB*:$BG\,>Z/^X)A?>\4JA'5^_?J]VMV_#>+@./\L^?_?9>/=WPW>DBQ*'
M[X+L9.@RQ/-2D0\(D_!2T$=Z#!L-#@$W&GOK1MM#@5J!M4<^X#`SX"1?<USW
M9=8#3CNPSLA]5"9\U'9@F3"[<\2V2\T<`080V#]#+,4"<SO[!>80+?]P35"C
MP26JN?4U%2%M5-\KC6HN-Q))C03GI$I&@M*-K/[(P,JT@[&.K_[;SDJL@E&W
MH/+]']%:[A0D=0HX)=4Q$-M/9>2F)/+N+KZ[UUV1Z7AP8,,4[_HBQP/VMD<=
M/X*5;[$K?)-4>=.U<(:89(CEI">;S^ZXT\+6R)7\([L=7R>KF4PO=+8IUA?9
MXPKT>[/O3O%?^Z8^!G/'4Q9YH/+L4.N@V%E/+_O33;<9.KS?VP&)8\(P)KM?
M-B7/2[+N[<(,3XU!8H`?1LT,AX(;E<1Q68.L98ACH+D(Z'5Q?>,:7=4H+<TR
M#@>!E:D0>XLZQP,PG!^F^&$L^+(>?$22HO4P,]7?.W*@U04./^NNR721D*+[
MJ^^V'FAU5;M_FS6O'<B:UP[,;7GXGJWP_;JKDHT@8@XY<<7`5-C[S1EBEZ$4
M4^!UGV;MQ;8#7]!Q.\0N0U(:.R1E:8<VK@RW/6QQ$W)F0D8D(U]V%8?UCXL9
M6.8"(`>^&L!3PE!=JOAWE1$(G,\2W_3",<C<IR7A_X`_PI%@#8E=SS:X7I/$
M*\DZ,!^*IP56-UZL[RHNV,5:Q"JMP;!RM.V%ANDS/'?@>)B58\$0%I4)NE8>
M'78"]3F'7'>V6O\#3":X.&`_/`S*W>GQ:9/WVUA@'\LY#!<'MM;S_N:[Y\,[
MGWN!G<\"QZ3@[<Z]I)AXW9:INR"3"=+V<ZXQ[A]@/$'-,E37[IOZP)K-57-9
M54P.M[?0D<3KEZQ'$B5@(A1N(@HV$4H:$Z%D9B*VF/0"7W]R<\&*N=C%IY?F
M4]!>#I^"MIOA\Y!Y.CK&/L5*ONJ6Z0G/6]^$T\(`+6&WI)WU]P^>4=H:#.^C
M&'^198C@`G,V-%0-D):5&P&ODW>;%%Y:B6YPT?:BE\9>]'*P%QR6XF'9G<5D
MO#3OG^?M]_H/`*=O#M#["X#4:4767T>J.=U9=(UL9X%]G>D1W9&Q3WY<=SF.
MZSY'P#1TRG<F\Q0EP)82CJMSMLK!EI*&+26'1=F=T^+X3*;XF4RFI\,%#W[9
M;CWF"#"`P/ZQ+RDV'`?)R<-@/%HZ[BY-=;"R?Z@(85(K`LS`4&W<Y'6CGM&(
M.+7!<2>VY?6U'9R&XFDHC1F1`WZLKS)_5]TW4YU,H`%QO?J]J<,%U%W5J`E+
MB911K+&1<]B"&CQEC#-31F;.<BB9G,-4J$6)UVKYE9,5U$.QAJB5@R%JQ1QW
MR$EAFY1=\]-BZTS$XU$^#EB)`&,VU,>A*A54A2Y@<5)*1`KCV_XI#N*I5ZSH
M0-.+=:*9.;Z+\\#(3)VQ](\)3$E%\O>E8J?X+'X%'`(9J8F*I/%+14'QR?QR
M&E+B4\'R(86](87-Y`0[^=<HP^DU&622::-H@Y/Y(0BQ6?LX->6AAO'T?L>#
MPD^6^4^L/]*U.I%F[%C:KWM3(VI8D)WVYDJ#F^WG(V`["&I8^]ZMWTSHV*/Q
MMVK`2-K[I,[":7KH%'2<O"2"]-]5I.\G(CNH?!ZO/I2(S.?W=C8WK"4`G@*?
MYV2G3378C4$FMKV%#K"%1J+Y=O=R;'=G+PA]G*TQ5B?V3JSMM_,U"R(<50!'
M*F$`@B^<E6CAC-G0A+C[&>E*FY5'9_,Y:;"]!?H^8D$95[G_6[#_R[B9.`6=
MS1V/T(0S=\:!.CT"$/%%?$B['-\,\%4_.+[9X1O4+L>7QDGC@W7QP:H\'#:%
MY,Z6NNL`/?F]V9#PFV7H,]4<J]I;R5>=X],.[K>QZ%@VZ8VDL6ROVS(U#QR-
MHG=0A_HX$U/0\KZU726M]7Z+VX1?8_?5!G^Y6/[;!?#GLCX-`^L=F-NH6^D3
MV_ICPDZC]P>-2*V<QYN)YS).VX4:KC4[R0S7&K),#1<'F8-,;V9WB,PHJYZW
M[:(PILXQ%F6W26G[VI*$J.55TKH!>9`4V%!3K>69>-,1V]1B7;0\$OC&+?_R
M[51\.U6EUZE78[,8F)YTN%?'O3KZZ8F8$.HU9.>#VL5ON4?TM_'-'GPSH-HN
M`E^@;2F2V+G&]_B%^9?"59#28LH?OZD(V+%5K)7@W92Z#BS?,*8>;VMTA&[)
MLT_N#"#5L2*`2Z"#71FC2@U4>@-,:P;-8]4>U\MNO5$%^]=#6J!0Z!!7<Z3+
MYOCG21U&QIG*=)=G;DB+\N^KI]B.6KD:[M;BT?04L:8K0SH"4X@]`^PX$N^E
ML38C(S`YM*/^XLO+&];G'+@.U.S'F_]I8+?F\M-57+'[U0ZP;46J<6_JX.-W
ML*2N-SC<Q986K.[&TMS9>K"BKD44FK^OR@\^'E7LT+/%MRM+35U^<#]X;&G!
MZOKXJD[NN#/4*74U$]6PP:J&4`'!D@<N0N3/T-94XP^@HJ1M:08;$E?:/@`_
M@&'\;EKOYAC#:IE`][:Z(>IJGZP@`#&E[5?[W3)<$P_&RSMH`&2GK&ZGE`B\
M5WH8@;F%'&A.QX[JN/2U_4&&@V.E[=?J23/`ZIY:B/Z5ZFL:,(AU!'K#*R%8
M=:C(J!=@U=4K<._PW^@;>?='&/Z]DN*K(V0EJXS\CJIN4Y)?V69#.51?\72?
M'%&-?4MOSO1F&3KN[=N_7*R84,WA(WLO&L34>A>(W]70@09G^%7\?"%<?&GC
M^]IR#YLOVIK.(9E"(5FK)W1Z2K>;7K(1<%2(7[Y;%9D84QN3Y<Y<@Y!U`R;$
M!4^KM697:,E26VIOA3M>V7G$HU%=4Y25CM+KRB?)U]=U2+8!X)=`A?J].5#G
MT%$-/*^96::G_;3J$^66T&T+K8!XQRL[CW@TZA.[4J\K=963Q`M<^JX:+DBM
M*T7I=3I;27;+35,OE1):;:&7H-XA`A.`QP4]59,_;'AM0N/SA8-<<-&X2EEZ
M3,..E4[:!AUBA5<'+YID5`.FA@W-&=N0L):4;0D8R?4XG9:\CBQV>MUVI/U=
M%YVN<BK\A'9/D+MBDMJ?'3P+.%_[Y;8@BMW>5H*8\D\0@T83<E<1\`B=6(R;
M]1LS`@M@GF!_VGA^TQ6VU>^4FZ):JM%?DMJB3%TK'LTL[`+;0W6IOAK@Q)Z7
M1)',YP/F/[+X]$+0:*`M2QU1ZB46PK:!D\1L'7$'5^71UY+.M3M4RY-E:B?V
M9ZLE=D*JW"DX3<4T#94Z7:';$NDKOL%S*AOB`>),+<>>5CMHPN/*/T4.*G,N
MM01!2"['/9[6FE.(<5_?"9S;#\UP=3QT_F99^CLTC-2LMUNM((,T=9U+/CJ=
M2=V3!<2.TQQ[K+<?<V#:X`Q`=5J"TFIMA8JKX!1!J+2C2!VI+><B"/T7Q@?]
MJ8X0G##F("_UYZN'_8]VNZ>DD=N:`^0LR<*R@S5&YNASXOUB;%._LJ(L=H.B
MQ%=QJCB40W1/3B?.Z@T^T4]I]11!ED/SU&"QB>ND&KO;DMR2%86RSC`M6"F>
M]WJ6UDM*I],18TU19%UG$H]N`BUW%*%SDGCW)EFWMM#RA'=&%!2Y+8:&D6VA
M22ND:KC8Q0ZT3%>A[]2.@`;@@OBU^*83P1#QU+'3DO<]YZA*3A6(R@T46]'S
M"1J!!JK]EMI`*&)/E-H!QXN41EN#1$5YB\0:TU5`96]$3&\[^!XEJ4&D\K/:
MN'<.E]\W#.N=I&NYL]"-Y;XZ$]?8[\13#1IV2`/F+%&=9Q>8CFM1[)U)X'"$
M;ZBB9T36E8#N!?N&`'E[+:A5ZV_-"`A\_W1W\46X%`0Q9),I:CV?K)%:S536
M0-PV+Z525'DF*4]19PHIPSVPJJ;O.F\6@O\&.IT:8X03A=6_N.[>K>QTT?9U
MEZ-HJQG)21H[(L^JAM-DH5;1V61Y=AVR:YK,Z+-43J":,TAU+C4=D"KPLI[U
MM?/"4F&X#U1UHE34>CJS5&=XV;Q5R':G%;T@>(CR!-+06R1O;5((^AZ4TOP`
M)#T1T/L+@-0I6.U3>YYXCP3P^ZK:4,,SM!MHN,Z.L`>V=5"HL=>1.I(4F(VE
MDRB[=D5\84'1+JG3:O<ZLLANNR+2DQQO5T]LRT([&.,Y3[/\31B^HW$R;P?<
MGJ9P&=P'<J3J\TC:V4HJ],BW?K22BE*>DLH!2>6$D@JYZO3P6WE84BE7G1Y^
MSXYPVBU.I][QM.SV_O^S=[6]C>-(^J\<YKOG^"J2!^P"F:33%R#="9*>&<Q'
MM<UTM&M;&<E.=_;7'RF_4;(MD5))=F8.B\48'5OU5+%4+!;KA3E(HR`]Y<,B
MQ:BMG@XKT[*>AJT^'AHI<Y`&K3YF`R,5#M(P>SHPTIV>AEJI8?6TO.^?LY5B
MCIZR4"LEAD6Z6_U07PJCUDAOYN-TIK_$/]970+_HN7ZJ9/GZ>GO-B8`!U!J]
M"U!JC1Z"+[7;-,_M,U>IE$NS$G<OMG`@2>?Y+_HIS?06E<X__%AD<9H9YSS.
MWFX6>E9DG9A?9NET:GYZ8W":)6^[&N7\Z^*ZA[BJTB/B$PO'0WG*PB&2847+
M%X1_5>%XZ'I9.)1C@@CE)Q&.^5:Z>JK]CGW<^FT&>2FPB#!S0C9'J76"%:Z.
M$;;)QGWC"M8$+)7`TCT0>P.S4R=NYKDQGC;[Q*C,J\X6-F]L997'B:U<L/]H
M:]FO=;Q89C"8(X$C[GIR;9#TR,WQV;73-WM;_*C'YL>38NB>1VK46;.+'2>G
M^+QKE/-;LH@_Z<F]^6*2YS8QPY-A7(E*GQ._U!GK1LN-@:[UUVQI3"'9#%3T
M8I6SB`E87C_&R3RWIESG=W-CI<V+O$SR9_O`NR=+`,9R((J$C!R];*0+`A0[
M0'T2+T:"JK(^#8.3V+X6A&X,@?G,CFJ*3V(G@+SMOSWHHAIO5R9TK8M"QT+Q
M\GQI,RLNTWQQL,HT=-LCBE7LEC=Y<.RA"LXXHA$0^(TKM-Y)CZD,R'G,BU+H
M0F*S!2FW3NH`G9900M<%*V,SD0J"<C&S->3_*1S9NZ=KX['.QW88UC%="?4Z
M2800<3/O:NAUQ1:\=$:/E1N=[Q,<R*G[U2RF?;M6WB?DD9D*6M:<PZ2Z0`HV
MD8)0UB\D@$4IDHCW3P80:\(B'E7K#O<I=0`4NB*4<7?7@@<4:O%H*:/,%T_Y
MS]9-``HZ(69.LBZ@?4HMP82?JKE$DI16"PQ,N$,<8289H>W`K'<OD$6*.%6<
MN?7\>V1:X0A^DTA$&&$<&D>PRR`C+.G!E3F&XTJ_9.81Q<9G/#QW'X18(4Y8
M5#KU':76$5CHDG&)W?7J#UCH&O*H5&$0`.Q!YSK.QL^%H_ZJIVE1+048<V24
M8*G<M():DIWQ!7N`E'-<JF+L%U_P28LI0B/2$MZC+J+-'_7<O-)3JPN363(O
M^K#9CK.`ZTP()@P)!Z@?;3C$P2NO#&>2BM,A#C;5#$4VZ;(KXH^9V6SOL[3]
MS6?E_$N-4^AF9#@$PFG79ZY5=U'LUM6UI]N8A[97X,9`^`U5VDCBJ.3QMB<=
MJGUF5U:J%"H$XOI`1L6>AKEISYWHUF=Q[:TR!J+;D)-5%355(-K5F&&U7V@.
M1+8^76IOCP.1<F/N4[4;@-N/I`O9AD2F"EF%0"Q68U925:<0S+O;F&-4I2LY
MB)@;,X:JNDR%GU;9>-W=D^W>D3^FTW:9WWM]JP26R/$I*S1:0`CW;KCYGX"$
M$.RN4"9+5>@-$![CJ<[7W:6JQ>]M71..S#';K5*I$&F'(<A%8=BUJMWIA[HJ
MA"@.3#]($Z40G"L)"2$X2"C-Z^AJ(K04/%P87CII0-`/<F4(<F^H(.@'NC0R
M`I5_J&LCW%L>$/)!+HZ$M4&AK@XN7=="T`_S>3!AH-IW8!_8#6(I_[PRB*7X
MC\XNTV+JSBI][R')_XU]L@PBI!1'/1O3(1CATO;V[-DD#\&(1`QAT+T%7K5\
M$E@8XE124$;@5<LK$\<&`C&TK056+2]&!,8,@^[9\*I%/1@A7,I2G_1S5"T?
M1C`UFJ7.7+5\&(D$5]!'$F#%8CXV2R$$NQSP>N7#AZ1(H3-7*Q\^0!V3X/"2
MI-`>7E"8B0H.NH2AX29&>,!>4<Q]+-IC7"VS9/YM->-DW8/%YK#X:I73=&-/
M0XY4T-E+;%8*232B@<%?9Z5:\$%M\V`Z/!LU10S-6>[GMB:=4O8'9Z9H#1:B
M7PV'!UR*B3<2!4$9^A8?BB6X62BG0WUD(HM/0V.DJ.3GP$3#Y3(B)]"0MG;R
MT#W$X#*N`]]>8<PY/Z*#\P)<S]2;.JT,:?''NY>B'O7##YV-D]R[C]%VB3[,
M7J;IF];.PWS-_DARQH7OAGP0;3_\UITJNO`K>"FA]8S9;6;F3'D!<GEML;MP
MYSB<"W]UJMF"SS-=16#'_USM3-VIOXN=&4Y[BYVGR[(VU8X(UGPL.`ZB%RZ"
M\_:1PIY[^'!,=#]4&"4C[X&K+CZD0E'S6W1Z'AO6R?_0>M*7J.6117AZ^>?!
M6Y<CL/0]T)S4HK=<1N_3_7DPUV$=&9,*`_)J2[1W72S632[T9-?WPFVNC'MT
MFHDP[B0NU3N%(`OFZV)FQU2`<'2HDEB$<++&TC</'38SQ+&4Y.Q8:F[HPD5W
MT+4.\&?]O?B3;W5DJ[L'Q2ES!]/Z(8+C`_C@R#C&$>7-'F!O#`&?$97D""/?
M.XB!%FC3ZDH_/9G'Z/SV]M+;&"N&L?`(Y_;)D!H1MDL[)GS#T.,B>=+3S\DX
MG<;+?#>:T3L\0P5'/EYMO\R5<ZJWVG>?):_Q0M]/X[&V-NG=V(@B49W(S16Z
M^;R]J/R83B>S>/X8CY_]K_5XQ*G'T;<W?KAM%(54P4_Q&>\6Z7'Y-==_+FTE
M[.MVC;99%>EW/=^I9<!KARF7B'@$+?IE&F.':=$WTP114<X7AN2Y\(1#MX*&
MU`LAS$(U1P3+I,'PAD:0A(PX.B'>[MZT[:!Q3NC;^]'"'-XX]3R_#<),$US.
MI.?1>A!-;QD?L`ZG.$<VNJA2A#CQL)L]<047O+'.\SERT7YMS!81V5YO)]2X
MSL[SH1@B05Y^<Y]<M?6:S\ZXM767S\\AZ=-1KG`[HG8&>K4I<2MV]^;'04UB
M])F<%S+X$&H6H\\,/4!<'<)=2@G)E!MN[!,H0#SK-$O>"?&PRH`!TC"(T0KI
M]EX/`5Q\Z]G859WE'_Y<)HLWOW?\0/,S%BG)4-6;+#V['76_SH:,4DRJ]\H`
MU+V.OI*:`TR/O(=ZCD8EJALX()CV#B!'W):*5O<H0&P/>A$G<SW93"3R`#7B
M!&-:FL,"A:K;Z:PPGSTH%=QAR[A7R)ZWJJ>M'D"V65B)N.WOV0.Z;B>[U2[3
M/ZHN63K$.!IR+^3:`\@V"XLI$\83VCOE`\`+V9(/)%R8W;AZU]`#J`X+R[%9
M6%8-M?6`L=6Z1DK9$1*]H6L@+S"6/(CZQ>1?RU63\_Q+>F19+G<C4NQ5^^_)
MXOFRY=2A#BN_-Z,'"OJ)17):IA<_9A._A]K)&]/I>DS![W&6Q>;KJ]-Y_XL_
M$I(:KPL$[2E8'YRY$'U9/V&HM2SYS\'XAF)P`!:*!2\OWT5N@V9ZGJ]*]E?#
M<.[CK+(IM$TZCXQ+M%8T7[I@8(%K/\^,E?,%VU/B<5>6@M^:1YV])F.8NW,9
M"6*[H7=#TA\_P%F>/#++%;+#G)[=]\U0/^]<#UI;?G6OTZR'X5CF4*)LA,6'
M8%=PP"\.-<=]<<3.#8']C-#UH]*ME"/$\2IN$+[&>3%2T-F5S&$X3Q9Z_5*L
M+A8?]#C]-B^>4MPQPF25447=(WG?H,]!2,%^*1:HE`OV=Q`2=%DB):6187]3
M$?Z_D`;R__^.KVQ?664GWB(^ZP7X!$."!7&S_$LTV@`(:I8_PD*ZA>C=J(>V
MRA^)R&TLT9EXX,!&R6RK!S``A_:I-G<CE&."B%NM#(YK6`!UAK6-@*`7KLY:
MM4HS`'ZI0V<?C"(J(D#B08,/1A%RQQIW)1XV]6`DJ>NU0+XW'F+'E"BP10^=
M>#"R-YJ0U(,&'HP8X8"&-&S:P8@+=^`YI#'P6'6%):0E"NK":P0E%=C;%MJ#
M=X0CBGQY]_'5P%J-4H&8JX_>Q$%1!P?;*79'I)T-:(B([#FPUE-'$BA=JRW[
MW.4EW#W]:L`,4=0?4B2^AR^DNJ)7Y@XEI_J53IR6IPXY(&`,&HM^&>?/]UGZ
MFDSTY)>W7W/;+F0[L?QBO$A>#4J8PN(1XYP@I<J^JR<`6.CAATDD(HDB=7KH
MP<<]3`05E(!(W>S_F8YS?:57_S4_LJ9N^\O;)/Z:3.'$CHV-<IO,!=!OAGXQ
M'F?FM7%^<S&?!/$3/-6;*N:^O%TQ#<%CZ)H1*3@E[XS)X'1$JDHSE/OG\4H_
MZ2S3D_44#!![C)$PUKB6C0I9$)RA&L6XD*36"/2!,OA.!3-6&IH"`-,HD6W8
ME=_';_'7*=`]K/'4<2W,"E40F,%K+HCD>&B4X9D'E)5:,P+`+-N(BSS7WKYE
MPSF&NH$[/\)P<$,5@$=<N`W'0/%>+LUK.%_`"7=DG$,B:_5UGS`4V.!$)"HC
MBIMUH1>PP>XK(ST(]F9NJ_73#,BO,Q)EJM8,.`0[HPOVHKG`7-6:?$AXX6TL
MB<"TU@L)@K>QN`]ZK)-7L'W3=BZK=4+VZ4)A#7[!S9DIJG_!^P,;W(.)R-+=
M0BNL>;ZTM2!W3T4XQ'C:FPRZZS3;Y'O>99?3.)F!O/!V+W63/H(`@*,/U8^(
M1LIM%W5:],%%!,;8<BCT%[,T6R3_69<0;1STR^<X^P9TY(\0<F^O:@EV1A=L
M*1C'BK*6\(K0\"_5W)M>LD4/DVH/*#@SDR!!:(^`PE/X(DE+@^N\`%77]^OB
M*LD+\WJ?Z5FRG(%HE=G2C4-\7*OVJ(+`#!9AA!AA76`6$=2BF#3-KM+EU\73
M<KK9K8#RQ]S2^#IR7:&U",TR18?!%EZ5R)EL!ZVL`C?S13S_9NN'X8Z*A++C
MKT:58'=XX;YC45HS%+S0I252N+E/_<,+2U7I!.]*OV3F86";*)%*EJ8#[!X?
M2CH\?"?=K)DNI(,U1##)_$@?N0>SI\V\A^O/"$6"-U_#'2`/"SP\?B`IK^3=
MG01X<.R(",(1B,3OX[<BY<-L(>;78ZTGN055Q)Z,BJ6Y?P9`TYU,Y,YZ]J$+
MA35\JZ#"C=MTP?HEO1C_N4PR;7[YHK/%V_W4G.#,6<YV:WFQ7P&)@2/E;F[^
MQ&%A!UM3)-S$TU/!#KXDC8PCU@OL/OPR+J.28]9(%`1EL"I0A=SS^C`H@_=@
M%&&$.Z`\8JBW9;"P.S.C1$FDFI-[#M"'11X\^X`JJ1ANWN)Z1QY\^&;F:"LE
MAT#^H%_6"G;W5$P/A[R(CA26S-GECA'K`BH\^%/)W>P#%'9`^71=JS9/[T=0
M]CQ&-X(RG]FFV?9OR2+^I"=&?69)GJ?9FS-'?IMT>65LSWB19EXCX89@!Y$1
MV;!C/V_9N=9?LV6<O=F_%(\A7ET$!@!=E"AAN2M7(KM17,NYW@+VJ?B4DI1Z
M-/>G,WBG,[O18<5/5\FS-_.+Y3?SK\8/>=0OBP*[_8&/U*/!-+^9BU#P0[RU
MV):Z;"U)4?;B\]:>`>Z=S(O/`+@!#+?;2LH&J6$\MN.XJO3JL-TF<VW^<YGI
M20)R]N$UP$K$.J$*OH,<!)7'#OPC3_YGGDS_\=,B6^J?_NN_.TJA(+.1@OE,
MO7;7]7<>=#)^OHYGR?3M-IDE1F5N[WW>9*4(Z5V619WK;F0,<T;&M'Z7C8L@
MW#)J;^1N>&1W?;VYM@9OS%A/K@Y<[Z_S46*=4(6ZKM77N1]4IWF]JGYL/[S1
M8D;.MHS<>+(2XO7JCASZZ"6K+O8Q8AU!>9\+L+<DSPATJ\-,3Z#I;OD1=]SJ
M5I*F`TDZVIS`5I^WH[5*)S!__[\CX/56\N&'SL9)#I13*_%17%5Z==B*I+"[
M%WO_EV]^<+#W<?!E`N."18<!'B0*@C(X<0DI?$2*_8$,CF>IXVL=C'+GX3AE
MPS!):=4Y=(UD07!V'X@[#,[.TU>#81;QXJ+>N9HU#'(72R11D2O'X_2Z(0OV
MHDE$A7#OB?M"%A[6)P*U$]F-(9[I?&'+X4$*43&1Y<3RW?-#:0>+01`HTJ%G
MF4A%4#P/%FOGE&&PA8H<?\X--3IATB]I$<SR<>BDE+V+<Q^9EW_,RR4>[:'5
MQ$9"(_H$\W(A5"]+V3YJC"/DA\Y9$PQB$3@F;B\EY_$;TD7K9QM@W?7M6'U:
MV,!^OLB6-K;TV?RKL:DPE5><13;+/HAR">XFB+3US&[F'WZ,G^/Y-VVS;<TC
M+^:3=2W\1MP@`5A<#&NN],L.07&0C6W#;<@A"RPB6!UM[>W7CAYV:@`EA,AN
M@+;7\B"99)[=SSM`"KX0X4AQF]WF"<GQ80\G-?V:ZZ?E]#9Y"NZHNWU$98/]
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MDSFDPO:7DG]%<91L`!&2(\89\Y`)P4,8@VWC`SMN:]U;J*UK:@?$N#'90\]N
M2]_+K^2$N9.X?>AO&NZ\/<3?/\4+G27F::U]<W.49J5H^(&'MT;@)X)JA#D$
M@3GK)_FSGGQ,TTEK(43$.GL'()2>WAZ#CQBD\:T4"\6PT9=5R$.[:O-9MWXK
MBKXH9%\K#U/ICNF(?)KR)XOBQ?M,O\3)9'W.[6@.")5N2>IQ`MV@>*988-D*
MR]526\OJ9`8;F]M5,,:LNYW>ZFATQ>-5/M\"3W%T7TOP\$D=9$<AD>!R$\#U
M)@<'TDM\2C'5&N,N&EC\\&:>+S/[IK<6&>/"-3?5Y[:AZY4DI)@4LIFN*Z7+
MU/QU:NO1.^H)IXAO+QZ./;PU`J^4&6M@F">"Q@CPQZPZV21$`SA'DGK$F0LJ
MW3%M`@"5&'A#'TF".1H.(VV#$4G&Y?!RO%X:Q]U&0,VOKI,?]I-7O0V5B@\O
MT99H6121`='Z.0D18JTQ78S'R]FRV#'=3BSF\U3;#_9>UFF2X]>/(."M5U1$
M#G@H.$.RZ;5(A)1ZCT/SZ=IO>X]NL^[7)\C/Z7S<T?$3A%;VB*,T.@/RNOEC
MW)Y76P/:N#E5'Z>[J"1AA.##3M5Q:G`8O?;\B`J"(#!^BN?+IWB\*.;:0$E0
MJ5W>B`<="%Q>9_.6N#9OO#W"+_1M\EIDN+C--=I?WZ\"9SI[3)\6W^.]KAW;
MZWN"G/M['R!#@"_R?.9Z<97.XF3^.9YM-^!_WM/HT_D`7N>T7;R\9*EYWO^F
MV2R=ZR_F*!Z_O%UERV^7\7R23(PMOS?_GR_R(>2>UX=V`E6D/I.+N3M7/:03
M,>"A5/4U-G)`#MN]Q?5'>>8.N3A+!L*7J"GTUQYXVS>Z_B2MA'M\!5L$QU5T
M7<*V^^M(H5*.;3CE?K#[-=_#-&)G"![>ZHY*=VCOFL^.QGDD5>0VMSP76<";
M\1%A[CWDNV:TZZ(K+)B?-3V)+/K80498,324HC<&R"`=2,7]V#H8H1J,B8XJ
MZZ^Q8&S"FZ`3K-4IS,L)UZH7WY/:'HCM^5DW_9S4_.YWG7Q[MN;FU0#]ION/
M66#VA_KD!DS;0^R;W;I<2F]VN6$7RZOWSW%M7.?]L`@;"<+R#UBVBS#DS7RB
MGXX_9)5CE\R_V;2A[\ETVA!R6;,'8I*X(()LKK9;X#PC/C??_V0OQ5^F^DL6
M3_0LSOYMBSYLI>LLF>>/RQ?SIYFO=!3=UO>=B7!8#TH0":ZV!3/OF\\>E``C
M2B,`+=AE"X8]8FA3T!;G&?'9GRDX)^'T:0K^`GSV:`K@I'/`ZP]Y,>K[`G$N
M6+GKA@<U.(Q^$W_9JH:^&\BZ&(P3>%DGXSYHZ_).=';W=)WDXWCZAXZSUOF9
M'+OS#`&0=&/./N'+]_0D[*QI`S#PG.G6N:+=6;#4NS-QG2Y/HU4;X@`LF.^>
MC@7SW;T$]<0.M9A/-MT45V5'FR(D;ZCW1\JBT,_NM54]L29HFU'J\TGW;!N&
M2\7>/J2@X/FE)[>&MRK27[64V38#@4CNWXSV:"30"4G+<I@UF0>;OQ7,)LS#
M?=95X9*[L__@DNP>XZG.-Y->\P>]6&;SW&9(3J?I=YNDGQ=U4;CMBF(2$;K)
M)_0E!H;02UZ(L:@EP*J0T[=X"E`-Q`F6!Y:P\O0.(+S&O!/A-D]M`+%Z$3=B
M,L[Z[\^ID:61IQ'G(DN^+A=I=JT[BX:BB**-/@70@\3IY2-'B'?!Z8B]T,7-
M;K9MY76;Q%^3:=).VY+)/WZZ3M/%"*$1VBO9%0J5%]X7`3#X(W)VP>.]A'VN
M*CGO'<#;+]YGZ9/.;5>X>`J@OX0PSO=?JR-4NF/R<OI$Q$173+_%X\(7["H?
M'BFRCZ7R]/88O#PC1AAMB\%L(7'6?0M0QCW#=`]#Y>GM,7BE96-&$/?%X+IB
MEU-S<#`GXR^VN!S",8PB+G;MH1J(=$;D9>`%BC@+A;01Y=V+SF);!GB;YOEE
MG&5O3VGV/<YJZ]LKUX#Q]$&_ZOE2KYL6WCP\>H7#."?EL8G'P51A?WAZTK;;
MEKZ9C].9_A+_>(@7^D$;S&-C38O7XV)QK2?F@=/'1;RPN]M;Z<OA[;3NEYD^
M<.AS)X$"X!J(U?J&.,=8Y>^1U?HV..?+JGV2]11N4_,F;[_79K##01Y_1FX%
M:1=`?3/72E??#7>MU!/Q0/V$Y.ZR:.I[,]\T`#%?6L7B?HNGR]7;L#EH`.GJ
MZ&>.5!C#`2!/((,6*CTR1HD$[C7G+806FF^$@-TKQC,00M&PY6+RKV6^**X"
M_X^]:VUNVU;:?X63<]II9QP7('A-IIYQ;*>3,_'EQ&G[YB,M03;?4J1+BD[]
M[P\`7D1)O(`@>)'E#^TXDDCL\V"Q`!;875GF&4+8#N>V('V!$=-=8+74W:'@
MB&CAL5K,(]\?FC,BKNO'9$F<KHT#7UB_FCR_W23@48I^)>#IQR8)=DQ$N^1:
MLEY?D0I:UNL%SQW:6OE6>6&0"H%6DB"OA;$6E(\K[S:D.9/-,<3C<A31`F,:
MDBQ?QTP_C3U:>DV=7PHY_=91"$F]PR?%)Y\5YXJB\A1>PJ<\FJD7UQIMV^U#
M;JX2&I:!M)*<GF/*S:,/H$>1V3*#RY?'E[#--)%>J[GE#4J4DT<3=%L%EE&G
MPKV+*<D0\,E)"^^6%@).A8&TH.KZTJ-PI:;MDLS%=MO*M'41,[M8F998^(*?
M`N^)WIE@+Z`"<L@G2;06=:";LBUN%%&ODXG60UI7=?KHS,IR..?=N4'=3J4R
M5ZB2<Y4$721-2@[GA7#7]2/;DVD/)F['LLY(MXAVCRLH5ZDZI)L0]L]H925D
M'C95I)E0M<83DJM<,]*(E';O0MKEA1,_^:?Q/?F4+`UN\>,JR=Y.'N#1`6.8
M454I>5N!U0'D);.E63"O_XD].K`@RV./Y]RJJT]#5!Y6AQ$5@LT@65;+D%[<
M+58TYRQ,:O2NL]53[!].Z`9QU-],FU=^7/\HN=M/UD,<EHRO)*=(2=@,")^`
MV_P7DG0_?PT=/W)FS`'!?DSD+WS&Z<\3P:`:J'!>T$(FR7!J8HU969*;F.SV
MG`B?WH>8Q13]Z:YHT6;?_2>)5L+QRIU%GS^?M5L8CX>X+(#\92,N4]G>$&M`
MV[`R'6"G6?6O%PMWAL/H.F32/@3>G/R+([2R!W#&I@6M$[`SFMZ'XZ!H.MA*
MJ)KJT&+V1CH"5GO6V4SW&=^SFZ9?L+N\B\,([WC[QK#I62F,:A'%0`QJIOE!
M9-UVYCD1T9BT5M5U^(4FS;B*:4O7BW6MJ3/'\_#\PW-6)#C]887U`GH1I<..
M:0.RGZ*97!P_?PEOD;`L7$B2S$-1`#DHV-WY5-6-LQ!":,\X*"Z>JSG8W5*]
M&`ZVK58E!Z@5!]H^<;"UB;HB:R8R1]![&V3W]^"&R9**NV`@V$-;`+MYYBOK
M!.Z=76QRM/)"1PAJYLN"SFT%=</2T=YAK_0(\\(VP=Z-_*WC&F%MW\\>+T*_
M#.8NV1>P&S)M5W_[.=:+!\39(YG'\W??R6?`3_Z<1N3'!"\W(7#_QH'.2<>%
MOW);+`:V3]#W@HM*4]AV9.RG26R$S[TG,EXF?NZ5`-Q3_.O-`*=EY-8(J/=)
M1T#6Z_XJN2/]Q8W^NL$A_<"YQY#7?94?US'\.-QYYP[2B@@ELQ"@5"=85Q"U
MB7D[@["'`5'C2,RNB*4QML)0;'.\_MA3*'4GD)U5JWC)96@0LOMC("AU]HIE
MS$F!7.UDD._<6\5[4SP0F7_[S'ET5X[W&3L1OK[SW/LD>.4K#I>\03PG-P:Z
M3-WE-:_;:/:2O/K!>_[@T!2!9%I9L"<$XH;*SE2@9J?B5#2S(<K'F!9=O71]
M=QDOV?<WSC.+?[I^PB'-=9T^)IS]P+)M#6:%*[F;V[DA2C\\]5EV*L=+T\A)
M(<R`IEWP")<V)"Q-?<A3V7T.`T&]+VD0O9Q4&0)6UG?`LK4>I2G,0VQ15Q\J
M`F`Q71F7,.N$%4SUZ6_37][&=QY.1P9='\K0)0T:Q4PL_(W+%;MM-R/5-OH0
M>V.P9^-<:G969$*UF-)16``1).<Q_N1__1[0YX4C#I"E(M-LAV"C87'):1K4
M;K+;R"K&CPDT+2P]38#:37B@FD+"YRUOS*,\CY-5#WF#\$2JZ4"%6:(X_O;J
M8BT^.O0P<?5\Z?Q#'_P0A&'PG9XD.8_DF]5S/X=15=<8JP)9FJ3D0<@2(>%H
M1>.5SUFE8+(F=(-YY<2$0#8Q=41;E1_$J`=;);!LL"P2*9TLQ**2J@"2$38-
MB,R7#JUT$4;_MB5!5(M)B'J%B*-9Z#[67N3LJ+$G67O*8VH_E._DW\J<F"S'
MG]-/Z75PA4BP>L`*3<7_H,R=9V41T(!E\DKV.28_#18*=F8/"IE<R3_)]/YW
M[(3DY2VX6N.53)6HOI]\)>#N'/\OQ2,"4(A)J7O%21*Z*6Y&G[-B1(0TV17Y
M&2)J\H-"S#5AT8^7Y!T1^341SE&>Z=*'_L0`E,F(\?S=B1CGY!>7-+Y4@4<*
M5=PID"<ZDDY^IPNN1#_^(9I#4T4>*7>9(8^4.\I$D4$GYT\]1OH/C!DGU<8M
M9M"Q%&I86"^>1Q0JO4E/9L_K118?QS+T58P\>B:?C3SRMRYU9MP.KVF64AHN
MNG7(<*%"].5$<'W!F9VZ7M`GJE'8:Q2JW'6+!B"P"E/`MDP\P^\<$T-";,+'
M(+QWG["/H_)=71(#JV:NA&(\[&5XZ7K4W>0+Q+[PRK2-)1M6$GTQ$!HZNWQ:
MT8:`"/59;TI$L(&N%3.9=1<!%D2`/"DQ-&2!GCGH'$EM%E<^W46L\8%W$-$P
M!I*Q+,R/YP(\4H$VD(C=`N8,I+475$XIBJ:D1X*M20G8UJ%:0DN+LAV"PF_-
M9?6WX4HF7ZC;)<.W3;F1K8!)-Z3IBRJR-TDAVC2UC?0AI>W7B_F[[R2E:/`\
MJ]QP$^*E&R\KLWQ)$-TVD86J)*\5J1<T+>X2EE5=L0W-E`+F<^#?TX.QG:5;
M^347$6D1!.KF4J?09D=Y!"T^)*N+#0;+1&(.OCQ\]Y:-0+)]8AI^O6!-]<28
M:M`2UF;J8ZP7H6=I^3)[I+DHQA>7+[]'FI6BA;CE(ZVXI65Y@^?K$^Z*K`2\
M4>@<7J_*5"IU8LD%U.HZ.(<'=BP<HCD8)MPU'!DPIM)#U/!692HU"GZN)E4[
M.:WP`5*/G^/EKBSCAZ/<O>?Z2N!CQ8N7CTH4+S.G*W5N9<9%437FX-*.>6A@
M8"1@9[9B[2#EMAO,09K^0DGL*/,?.V3/L20?W3TK<:3$CZG_>(G#>^83G5,_
M(*YP_FE%SRGSCN8NZ81A[(2>B\,?_P71>_+[G]R?V<>1^X^RI-=?Z*,N&5(1
MY9/\@'XY3U_NINXE]N*?7/)H%,\>E)6[I%+G6$(\P[2N(7OV,?53T><=^J^4
M"2:`3U#_%/W,7LRT@;Q9<9+<(.3WY&O%PU%$7D0^_S<\(HL3]I\2)+[1C[%/
MRZ#*ZNZB,4FOK%[\'3./:/:3]MK/,9JO=D,.35/7BO=:V@O:#U1F?]>^&=!^
MDBP!:QB6JDX1*\OZ5,#:?M[910M)OT)4::C'@XL*=FPKD+AY:3RN"B=_TD.2
MF]"=X=*"A8+[D>K2J*@RIUN-9%(AB0W`O0`EE&5KRK!:CZC^\;"WLZ\X$N+\
M!R\6F-8FJ\B*424K/"[6OULWV5888HK7)X6W*W>!O2MW%GA.'*U#^]L(IF[4
M-NXD&.G63%O)#Y_(8N/&<V8L]T<[B8KF<E>BI!S:?.ZN6.'`Y&+$QR#,TIGL
MUGQN/L\HZ=:3&P3.L^)K#:UMB,9RJU`7]XRF&0@2WWGQ$D>"F^_<$7`I7@63
MF@:A28M5MI%K%TO5+Z_P=_95Y6U2K8!%ZX@%VKJF6V812[-<LK!H=&^J6NF!
M)/T[GT!_"[SYTO%OG=D#=_0D5"W-M`WY6)@GJ)]N*3G$MK)LDRU$XN\1]N4U
MNW(17?Q#=NENA.<"UZTK`W@-`W"I4[D@?0"IO_5?92[IM@%)`K)MMVE5U@HM
ML@N+Y-:V?SL1J*[JN2*5R;`;+)`DF!I$./*:XJ7+K.F=&;)F`"0?DVGCS(D>
M!I`Y&9J%@R]NX3;CG,K"6,D4XJ;5>LZ)6/G7Y=&WY4$;8C<-R;-V\FP6."4D
M7S/$/W!$[TBW@J>_!58&KUT&KI/UNK@.5ZU0_6"2TF4HV<GT""T_QVT`UC8]
M&,]9D@9T8!AUX&JD&P\:S[F39JC0GA(T^?$#)B3KRLE`E'#2#HDZZFI^%#LU
M2%S9>,JJ/:F:9:()@>J85::\K)::GTE/`6+[9#%E1>95S<[+JHNBVO`%L'OP
MU)IA/TKJGM&'[MG*Z,/S^B=I--,IK;.3MW%*#Y6R%7"Z$\;ADCO?P<7RT0N>
M,2XLI=.`]#2&*G<>Z-^V?!B]R#TN0W5A^]5,9;_89LRX?/F,M=2I)'!MS=`W
M=``<E6G5*T<EAU2J779(Q;'?.`CC)$21>F@4==_AD1'W\IEBR]C<,\>U2C\,
M%:HAIF:M?S#<H`(WXGDY#X8NO4"7T`[K8)CBNF9XJ*/.**A1AYR/!\-792Z\
M]INX5\8:&9O2AN5#<TL?VK3T1^"1U]!08'K75+97I?'B-T)H^^I(OP@G0JI,
M1TPCR88%#I+D+KZ;1E(UW30.D=0NSIY&4BU5M0^1U$[>(0Y5M5Y9%3]GK695
M.U!6._N@FLG5#M,0"+BM.+C4MR\,'SJ77*?:KW3VXQSC8+B8&NB@&.[L3^,@
MUSQ4<D5<<!Q\&@>Y#)#GM>-16>M`*9;FZ&LF&12S4[^2+.(;;";9`"]H[4`+
M;GP,,2Y&JP_N003`Z,NY589O$H0.ZCT$`/1E&"9+<*^>0P![6X%-EM!>O8:$
MT$/4T!X]A@`6TU"_,MK=6TC4_N`&_2">0@"LOC8'DR6V#R]A;T<$^\AB%__@
M01(YD&<00-"7LV7*[/;O%21K_$,DMA>/(.'RX':D`WH#";T'MS8=U!,(@'%P
M2]5!O8!`5=%+(3AS.Y[3<8S]^4C[U;Z]JD5X^\LG_V[U$/D<8J]Z:+3VL5-]
M95'23O4@B1QJIWJ(W`ZQ3SU`6GO:I1XDDT/M44<D]S2IS<.:H:7/?;H>),L5
M6EN1K`FSBCVE*<3*SNFDYF_2=&BC@JN)5]B!0`I8JIK,0&."K"UB)Y8;2-=,
M%8)Q8=6D!)93KM0`0#7%,5:G3<JRQ;/$[2XMQ_<Q"!?8)>,_ZX/FA(7Y!J4X
MO59O^'CSVUH(K?/"=I6>([,AL6I.XD=9/01S[NR&'3*H?/"<V5]O;V</@8<C
MA:R:L5>;W[!)0JZLF[1FXA<\"^Y]6BJM1[>(2);#'?DD0:JQKMVR&T)=`T9M
MOK41($F9,!"P89[U>U!D->94#C(#Z/4Y\D9`UDT-31/0!<SPB&IF="E]I4(+
M:&):F,V6-R%^=-QY^KNSQA*P<@U#K12R1)5#M6ZR=/)<$K/^*$FZ^.'Y"Z9W
M?9]P_N69X\UBKS!Q]9@I$AJ:;=G9HD%0OO)BC1-;]T((5,,"V^4<A9:&R3J*
M=$3%%K.BPV1XJG9+'66#O4DH&0BD;+=W(:"6$-8C+EC@B-:8J4Y+WX.WL,04
MV";:L`2;<@G*+=W143;^=0ZY6>=\#AS_M]BA+3^SX=&^*$09<5HV#>^\7YJ_
MZ1Q'L]!EOI>6"\.LWN\GGU:K)$:PV/*-Y_@J`'9>43&@%0:I2T=9)';$\10W
M>S)25H&"TU/HZ$B9NR&>K8*0_.G,G]P(L[]\9NPCL@FF'4S+$`9Q2#YBTZGR
M_2%0'%JD\<[#]'443.C>Q2OZ+XHT8H4)9R%F`K+'0_;4@_.4?DZ6)1%EB>RA
MYCA4GJA%I]4>$]&)Z:.O6"H1/2=7@L1AQ>0*R.=A^CF3D]946,/+RR(RRJ-C
M18+SK-!Q$U"&J\#_+QE7[L+%<SHHD^(.&0%4&_+L0N3OI'0HCMQ[GQ:C#!32
MPT^L4B7Y+J=-61#60KQ*)B/E[^S]J2809"NZHOD+/Q=U)R##?<84IJA%]`D<
MTE=MZ!#]G&D8^=660AU/M(]R/P5S=)S&9)$1[BRHRU=V;49L<Y&7I-2.##]P
M%:0I<,:MV,WE?<#^$):\.)E#/_E)898>IX=F[BQ5,PQ5QJW#,FA3XDV>PE%/
MKQQ]ZY6SM/S3=;R*B%&FLVRBWG6E#RMOK'&HDFX@U=1DW+"LDGP4:KC#)#DH
M,DQ;U3095_@F11'WO4>>6FTF0IJ4P)Q)400E4@1T&T`I-VU'H.A/3/V!>'[Z
MA$/G'F?%Z1J+LO(05EN459,1IM`.SX1HW+9B53>[:VOP0AESWLNAL.+N=@V%
M^K':S[#=4PH[#^J>)HH]H5-DWJVE$\I(3+JW=(K,T?7V<GPZ<PPX?")?ETMQ
M1<NF1_2-S(WV-5@Y7O%[ZAF]"E;?\&I]@%>L,%LS;]>?\=HJW-A(#2+M9"C:
MK?M;<AL#V8=,$8\[7X<&&)^BCCZ`K,8\K<W+/N[)NY$;MR\$/#$8JQ35[X3?
MZ,OM[[R;$%VJ!V0'_6;);=&7L_\5"LZ.R^E)TAIM,"OA+0O8MC)FEWPC\A`]
MMZ&_.<<SC[QK?DDX>#CUY]^P4^?OH.("ZRTH3&&\;QW,>B0.,Z(SZ4?T=]QE
MXT]NU&\07*K:^0"6HU12B4J>WY.8BMDH.?6UDOAKF6BW-:WT[E%AY<2S)TD?
MYG=8V:II%U=Z34+($#I;^;<55J5WZ&U[6&&1H+":.H*PVYN`ED(CH)M&\1IX
M6YG%SZX"/UF:7/P=NZOG3SX9J#']-OJ-MLQ_,U!T()@(T;-+&<=P35#&):WL
M@FA+LE0H[<ARVES5)9S<X`P"5;4LW48EY/T3N>]\U_OU#6D0OU%^&0!2MJGN
M>]2\M:"F:Y8,1P$'F+&)$QDY4^M\*1J]K07(T'5+QKG@5)3@T0V=W5V]A/$S
MBCK4HMD;I:Y%L:^&.@TFB\/*&ZW23+4.H93K#5Q@QJ=N3_2Z`46O>MUM+]MH
MJZF3A?]B2NN-JTXV*H;6=4?>`@5/.%/A+&,W=I(M-*6-<WIV0QT8)0=A:D,`
M)(>4/8)M,S(K0:K'N3=F1)#9U_UW*CA&#>&$?(+V"[F3N:K!WA"=-Q#T'B;K
M&LQJ0[`EKZB=8?^1N(O]><$B=K'H-8;+0ATPE\DI>:HKGF-_HH$D?N3.=CW7
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MFFIJIL3`LQ(X(S'6UW@Q@&7*'#+38:RG*>RM9D`D(V?,<(0)W:CHE,>"WJTP
M)&9#J;Q-P=U`U&HAP1T]*\F>U?ANM>-6=<_EX9P8Q5T-8`W%Z!B]4BS!8M:?
M0.P'PPTM%VX)I'Z`@'XTI;002$8E92EP2\F_:Y;FKGD6V&HVSRY\1A-T.K-5
M['C40\,;$,G!/G5F&9=;U`X+IL=T$?Q7"CCU<SM.W;),BZP+>LD)47\V/"A+
M@J-Y-_&!;2#83[J<";$E.,GL%)^Q@`:A1#_<--D23-&R4TL*&&1U+G&2:,>6
M').YV1#L<2@"4P7VCI.W%Q1R[OTTYLRIFE\BJ;.E^4V]A.IYU\M`'=!,DDZQ
M;0RETWJE4]:6A=)I7AJ'S*8J<ZP;>3*1T>!,DD_QP3ZR[9PFG>*#?63;N4EG
M671"M"H\\]E=X`_XWO7INZ[CTHP=`M='S,U1*BI&;UB:([M.;K1O]B6T)@M!
M((+IY`:-U2]G7A!)U3"!WMF1H2<8/,HETA%#R2^H60-#:0SVZH)&%>B>NJBN
M;$,G$BW&M>,4RC.M%FY<"DDV'+SV.:#1L0JF"D^\/'!]H`B<*N`V$9>5IPV6
M.E5X'<)[X+&!I@JK0Q@0/#:;$LJ-.?I@YZKD^VAV=D;AYI[BY8Q&H+Y5\_*I
M'_%=&#OALYH5%FTW22)K3W!>!G-WX<[8%E-D_I@XU.*$F3W3KL1O]<2I-R62
M'!-X8RG@TEJ@-:N$R=HG'K"EY::KC?%TP;:(#J\9L4WY<'GAK=U5[)<5TP<P
M"_;FM\";+QW_UID]M+(SVK&Q$?J?--A&$)T:/@ARZF[CNPC_'6-_=?&$\[";
M5,RSX#OVUROKSY_/V@D+]"9A62YG9HG.XY`L')*K0LD+BZGL\\R`J'UUW0KQ
M3%6#=I:*1$"0/H"4>'%X2K;9$(V(A/>,@N=&*D!Y*7(!0?H`(M0EJ@:0K7<'
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M3LG^>J]\=^>KAW>*#7YXK_`B>K.6C@H69LV0X;\B.S8O`W@7K,B2)7GOVX6S
M=+WG=[QOIN.2O7V>O;U(78*__9LW65[-:YI+:7V;@""T/*[Z:8_T!>DRTJGF
MFSJH:1]FXGSP'&*0B%!*%'CNO+5HYWC&UHT*@D=%X=B?X6L']]'!:,@.IO/1
M*PD`HL[:?4=DN`^#V)]3"QJ$[Y3P_NXG%6A'*K*.5%W_6=8(2(VQ28UQD1T/
M+]IW2S;ID6_C!5V.A<G*E,Q[S7J12H)^Z'4(IJU`&7#_S=_<-KTA7;ZV;M"R
M[2,`P+`H!=A][<.]Z$-)ING/!W>%^YB1.]D@LJO&3CA[4,C.E>S4GK`7/-+;
M8;SFJ$?]'71(=M=8S4!'ILJAL8/B>NV?W**H9%F@PM%P37R%TQGUZ6P68EHU
MZC$U+9P69+"%[N:6NW(A.ZA:MQ%&3.T-[4C7D&`W#,K%JR+TJ@BJ26R&Z,9S
MVC:QYZ55Q@C]5^*%:]W6U^NOIY^5;0=PZ[Y0C_4Q!@5K5ID'\9V'A]E,M!1#
M;$3`(XT."D/`.J8=,:I]?%4&N<I@ZN!(T_6I*4.)C?R%'3G0C]*#M.83LNU#
MTO_&3KC"H??\T?7IK6#'^^0O@G#);G7MP;D:U`L':\KMQ>>+LZ\7_VOO79O4
M1I*%X>\GXOP'A1_/&W:$FD'<\>QL1/LVQ_MX;!^W9^;93R<$%(V.A<3JTNW>
M7__FI:HD@41#-PT":B\S-$A569E967FKS+?6?_]Q^?7;NZ\?_VF]__#I\M.;
M#Y<?"6MO+[]=6B_^^'3YQ]L/\-S+THA;AO[:QIH>,R]-<97.X0N,N%K_4BQ@
M314/6!,W<8%M(_@JAJ/7NA-N%%M(:1O_V;8)$O058(3?\F++C660+G[U9$!O
M0QF.QNTL_.8T3?SMX)$)I[OO^(PEY6-\CR3>%XEI%/K\RO(2F&*\@_/FQ8?`
M2F9A&L-^AA_$C[$`I"T$K`G3;5[6D14>'Z3:?!_#U/C"MM*+U0E\.TY)0,4)
MK4S^19]QK(RG#(H?@N)6#L7!Q*#X"5#<SJ$X.C<4;^/[3V9'Y.J5JDVWM7W\
M\:NX$4$J-H]3.Z<8XQSN),39L@?M#<(1!PY2&P)62T>[WVT9`AXO`3NV,^@9
M`AXS`5O=?AT(>!R!C"W'Y4XJBRB<>LG]2*YSIL$&?+F+\WRCA"63_K%?H@RZ
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MP`<G`0Y,4O]1$[`UW*`&@"%@?0DXV*2BA\D)-SGA3^]W<VQGDPL*)LZX7Z+T
M'$.4^A&ELX\HFB'*5F=I>W@XHM3<9#8YX7N,7_7L=M\$V6M#C&;3I(37A!A]
MN]<WMR5J0HR!W>[MH\2T20BO)Y>=79ZD(=&1+NU4UF%(5/MUG`2)3MT8-0GA
M)B'\1&FQ03C/T,+L"T.+`QBJ.TX(?WP?7Y,E;K+$'Y$EWC)9XB9+'*<V6>+U
M1;')$C=9XB9+W&2)'VN*8[]ERDX?,?D&S@;!<T.^NI+/L9MM4S7\J`G8ZM3B
MCL:.3GN3(7[$CKCV)AT(3-AQGR3I=$QV>,U(TF^9(NXU(\FP>;@2[C4WDTUF
M^!X#64[;;@WW7MO(4*."&HX]Z!IJU(0:V!_)Y(;7A!A=N]_:>VW".IJ89ZJ5
MG5W*I"'1D2[M5-9A2%3[=9P$B4[='#6YX;O,NW1,#FQ]:-$QM*@++9J&%O6A
MQ7GEAL/(HQ):CC1DE+GVMY_3^.+:=1>O9(ZO?_?>"]Q@[+G^AV`:1G,W\<+@
M&\SRV@_'W__^G_^!6/N;>NM-&%"2&#WU!3Z-[_2S<+0&"-Y7,?WUV?LHG+>:
M3N>BZ<#_DI`^.ZV+MO/L[X_%@EYPBA^^1!Z`O_#AU7!J%0"D=:=%#!03YO=0
MN?UIZ/UM)BQW#,K,P@WNO.`:D2\7+B;65-$4YH8OYB)(8@((4.6G$V$E\O44
M?D"TA2EI1C@8:4/X]^TL]/T[*[P-8,0X'<7>Q',C#^'\TTO<W^%;?/1U.'9_
MBX0(&M:E[P/LP%4XLX?)AFK,D>L#0(*!P+>2R`UB=XQ4BJV9>R.L$0QA"=^;
M`^RX!B_(K0D>:Y1Q\3I^7.;=KV(LO!O<C_&WR)V(RV#R&?`074H\9+_#.L);
MA/=]&+T-TU$R37WU%$^R-UY?O^.)MVDQEH+/RI9!Y-%K(=3##K?4BO0K3[M-
M-KK/<JA=1*C3&R'*H2X2UAB>#.=@,X0C>)58C!EXD@H+C![X)4")Z2,WXZ82
MT3QN6'\)&.C&`[#*!D8*I`%>M1'`_325>@K)-8[$Q$NLL1O!9[!1KL4%6EG\
MXR(*;[R)D)O(<A5I:=")(JL:SX8=[(UGEA>CF0,[*EV`X>,JX&C7)R`?`DQ.
MSH$(+\X\6'F$)I^E((57O>R`L/5&%C_@61Q`P)8(YV!-P;]A"8@LP@5N8@]Q
ME50B>^'&B85(Q77,PPCE$ZQOV+0F[EUL)2$(!VL"LB'X5PJBC(:]C;R$,1%.
MI[D?\PNQW&O7"V!L%&?W8$OBB)8Y\0#-*2Z>J2%N7#]E^MLD.B,1ISY+S@P_
M!(R8PNB(>\1-O!!C;XHH\:)Q.D=<C_F84JREV&4<`KWQ7V!J>_R(!FR!!`O3
M&&0Q+CH!,8E+=F.`%``$L%%6NBO[?'6)MS-XE_$C)@W2A?+9\=*&_S^M+OZ7
M-TA(ZX7M@Z@%,>M:M\#[,"40!=ACG/H@K/$9^$H`(Z#XCV%J^$<0)LPEXW$:
MP=<`?R2FB"S`-1C<8I3$OUCN!#<DG5`X)H\$^!71#8PQ=^^0]I'X5^H!+?@,
M*&3>+QT(NQ3RRP?(ERA<B"BY^P)G60(#OP.@%@CYH12A#0Z']]X/X.K+.!;G
M+.=Q9*^`%TV[):1X!T7/7N<%P4/:H244+BP73IXP3FPK$(F40>F<MOB$#SX!
MP@CT2M+'2+C3$06SH;87D'3%`?39,PE1#%@Q3(Z"$/8-2`&2)A,2+"!)4$+Y
MW@T+/2E<%RA102=TB6]9F$9BX7H1@4%3H+3`_>CRZ?-C(8)82*F81E&9@/,%
M2,_H0MZ%?65=-!M.=Y$H;*"RFB9XTF2K!`AQ>(0KA@,,C=$+.&I@R2*9A8P5
M%-HL)J4`G%2LBQ"I%\48`CT8$#@%*0$/@1J-RXKQHHEU)UPX'RHDWKYVS:;H
MJ]SC1P#ZBG#XB(<J6#],W@]SU+ND$54E+8Y@F<=&%R6?V'#-$6&=F+)61=3V
MN]K2.SH2*-K@60("%7RUFWWDD:7=62+(,\UD4^UA6>OX$(#:>(V6`I_B[P&>
M1'Q$%:Y6MN@VVXUV4+:PS%V6EFXH^M;H,(\1:5]<U."UU4:Z,4SZ_:@EFEYE
M%7&.:34@JM`/QB2:A`L49BAHR.B/R4\&HJ>P&.VZ5:X<%&I7:-&[T22V7H?P
M+]L"4_#]Y=5KN_RA-^&$-#.RZO'9RZLW]E::4[O;M#4>O>+.OO@M#">WGN^3
M"D>66$886[]@95\"!(4U`CA6F],Q-P6H8;UQ%U0HXM^`PP5QOE1+"<Z24\.=
M@]7N_5MB07E)?7%-'A#4-I562=X#.::[6/@2=7&C"/:'@,SN:$(Z\:V7S"RY
MDNV0&RJ+WE63>K%U#4HC0&VC+2XA9Y?NN&+=)0<:Z*93H0XS^>SZ4['!VE#A
M#8_,_`)`Y)BY(`]%<%<-$9SAR0S_`7LJ[S/S-.](19D0#L<_*/_S3(0%J4O.
MZ8B=&J@PXS*C)5<+^G+&[*&@"847H6\M(I<YH`ZV`_D8<!$CH3PPZ!YH@-&,
MZ'DKQF(^`NRU'=O"TQ0724#,W(G5`0S$J5Y;;+VX`A7^4P@S]E\NL4294G#O
MX;ZB#6A$?([>>O$BC%W_\_1C&%S32SQ*C?T1&?R(7(3[@@!7+HJB_#[L0;]O
M:USN`-[(DD?1\\@FY$+JCRA)V=68F>T@6WU$I4^HO&\+T981*!%RVV:&=FA,
M49>-=Q"!(2&LVD57*1BYU=LS"T=-0W3(H0`\F(:UV_I:*T6T+F(0@PRM@N<B
M"1<$D_Q3U>1H9LE0-&]E*A:\ORYO2E6[^.FAMZ-;A3<[PRTS!"1Z=46Q89O'
MRSF$P#`;XRE#O(=1#619-5_O%^2LZ#N<V(O(&XO[<M9V'&_G_S:Z7E#*-?)+
MV"("AX9SNP6/&E[:F)<>F'>R&5=A'#J,7!FZ*F6MQ>PNEE$N&;,R#'92#+9S
MMLJ=DWAH!6Z21@(/-ADB0[NBA-$P8@8/27^U83/#9NO9S)W`HF*QS&XCM-!$
M'%MP8LZU4@96O3\A_6Z<E'(?J6C*K"7+1PZO$G"`-?&E.&;_Z@@CM==H&H=1
M;%C5L.HRJVK7"9ZME`2!)GTQR@<LBT4U8\XOBSS`#QRT&*<;)^PRT1$QCOL#
M-X)%$WL\:$2)(TF4CM4DBK,-0QJ&7&9(\LT!1A:H\TUR<6'D(S>>65.P+:D>
M`=!\',Y''B8UDEO.E=E.=\AC,5JK\C$4BF@YBS&F)Y&DG8@Y,24EN:!7Q0M2
M\J7Q&\">(4:8]-#EFL`O9,(;)C9,7&3B@FPD?O/(PTH9<;[W'3.H*#$._2ST
MNV(PBUSL(X$5/">D:**G_=:#(WY"3D+,;)LN">B1F'*JG;`P'0-^]XK99B7I
M#%,9\CP)QGT:+]*':=[5)MUGH$=12ND",]N"A!SE9*'.01`10+<S@31#DN9>
M1\%BQ3-2\*1G#4B(SG30T1+!F9=T=G(H0OO\E$J'OODP7>0E4-&W2+Y![;'S
M?"^Y8T?_-Q"+-(7*OHOS/D;I6.343)H"OTPX-![>XFN^N!$^#2_S4)%&P'XL
M+I109KSXF$9$2L-$+`114^9V2G>H?AJ5"4840T"^3X\AI]QT?%ZA5BLH,M=&
M+>1_T\GU7&62*C;GA"2@5TQA,IGR-$W)PLM!P-N4U19<O`CPL,'($"?Q<'XD
MY<:BVQ/S2"?24Z_B+3G8*4,^DII\!DJXE`K%>4]+7F$/]21*K0TS;K(\>8PM
M/XVS%%RS1.%,[\_0PRF?(AJC``&0%;KD%0+YCF(]B:&4GY5YRO_+*&(64PF\
M$;&.1M-]Z.'79L+GBP8P@8I!!9S1FYDL'`KSXS!+-\Z93KP1T@1XI!CB4TM(
MQ'P11B[H`-[$)[5ABI$K.+W8WRXQPG3G5!"\IW#-P4"?3CEXQHNSMS!K&SWQ
M(6)CPEILP_HP+7'O+RU;QM1RI"*F#G")G"DL`X(D'!`"8GEO.A6@`XWQ)D5R
MBY<ILC&S[6]-0;3(:3FK3B?;+?$+[8V,JXC2V;OAE-&0@<W!0Q!?:K(^WC8)
MYR2;HM`=S]0/@U^*">E:QT+V@7,LCVPKVXZ*T3!\FQ<?6NEB.8J*%X4PTQ$R
MH02O85TA*!+3=*+F[>TL=1F1`J^D\P6?PRI$(;W0J*W0,R#S;I.9K;^G^\0$
M0<;],>A`B!1R7<?X;)!.P>9.([ZQ@RE,?/>8UVBA'"&\(WYR0!&B<DGYB)W(
M0V+;ZNK.'+>KZQ,$9%<A]#-O$6L0L[Q\GM6]<3V?A#'ZKJ*`[NSH#'_+'85I
MHG">`&=-F"5&PO=@Y_*\K'87$*;#4QE*2?"X<1CH6RG$$H`66N\?`9#`&WL+
MDJ(R5D2R,=O")6N8P3$#&\26_@\7^!_(3:)/SVU+?&"Z/N)<N>V$#.073UN9
MS0H/R66S.1&CJ(2]9=VZN#7S;Z#2I*-M9#*LG)'RQDBD9`VE=:+&!4^4!)?A
MGVU:/';B*+WS])`0\&I2&>[,;^Z/.H>*67H`D.*,T[Y>YR4E;P@Z]V'W:6_@
M/)P(WY89VG`*1!0$)NPEB#W:@5J4D^ZH[FXHKN2S!$]F[:->N1@8)VY$+WP>
M)R%R+;.KTS@83?8=H9<W:3B>GD<PWP;3IZ'.LU.:Z9W*H5'7?4B+MS2U8)0*
MA58?\)DUIF0RO(/:CL![3QA-=Y,D\D8IV^-)R/R@U8*XH!>4W!!=3HPA^NOK
M71702>7(B_*:!$*&E35B5M?^P@PB-TZCS1;,BH0(7%:RX4'VM^3U;C1W[DA+
M=G_0<B4UI'QG&0M_D-ZO-17M;]3J7AX]N$F6='NI@PFRJ0'8Q!?+)"32\-$#
M6W2#]2F[)K^;LT52-A/!BF:`>B)6Z&A8?ZJK:-F-KTRUCR8,.D"0CLNQS98%
M,RCG/Y'E00Z$4D<#H8$SN`ZWT0]ERY=G\?4[,HO/*SVG9'(C::-5K#+%2Z`B
M2EPOR$D2"PYS3\K>`,UAF6RGOT5"EU()!AP)W#<Q@.^2E/<"*88L%RR=Q,YN
M.++),YX%I$R"YN@E^I:*FHO87&W;G-_A'K"S%$(RZ>-DA=-FH$2Y#+\W"\-)
M!KIB,^G[PCQ'@;?)>97=YD\-ZTVF$4J85+1`@LKY4`0R737,\$"+8_>P$@S8
M`*P89%.6KA7BI<6&=9E4Z6BV5M+0+L-<0-`,UR/G?,[)C.='(>P9*@6`+B%R
M#H`H\TG02W',U,DCK\A2P"\+4#P4@^8QJU*CRPFE*-2V<R0JCLV6DKK>01?*
MI#06<,8J-^PM*O_*L:`/!PWOV8G%SZ`4YI&$^TV9VW3Z4!XC>BCE2?,AD`:F
M;*&$<]V`32ROO/%Q[4YYKXL[&G#JT6'[ADU,_\Z6C]'W\F'4/LMG;ZR_C%-E
M_RS;25=HUI,*_@:48!'$=/1^)E/W,IC`,.C3O!%XJ6??I2&*UA)!>L'60A[6
MI[6<:L*0N:.*W&NY]:L$^"F[:"[H$&1O:OXI4'WQ$)#Y#_F#DG+;+["NRJKO
M+'^RJVL"5>IU+@F?CZ&\8X"/(U!+_?!.:(6.+[U;[$/$R@]6S/L&W5G9:JSJ
ME2CO5;B03A,4PY''WJD$&%X[2`K?@FSST*D*@))#"-A<3N7>XJT1FY%);AQ]
MIXXJ-4G?DEJ)?&Z11G#(PE&[P'U"J?7HI[$+D$NBQ!SS8G)J*A#^@8A$#0PT
M9+0@345?@V#7=P$A<UD.PZ,K"7;^,H0V66XXEL(.//;Z:+<L+IDFH;H'\`UU
MS+NX&L]"7\07O\,I@#H(H9A\?4A1MLDM:;P5WK!^Y]]<TB[%@@TV>D$K;65:
MIS.P^3PJ..J]8)'2X3@#_/MWM'9?_.`"%"P6:8%NY,GJ'D7?MS9Y<A="&`9<
MMZX&I!]C!B&7IG43XO%)]BTAU54:%@"(95%"7']!BZN:46+YW$Y2O`2:8-@+
M,UUXR[[(^\_UUYGO_"5'8?C:28+WZX.+9<$A+4&Y=\@45W@N^/`E`^E9;%2V
MM-R!`QSYKMOLYJP="?%K+4:_N'>Z>L<G@.6=@B5O"_FE%[WDZ/K71N[GY=]R
M/X%92_GBY,G/J?TD(W*"F?<C,R2(,8*6Q$-NQ0T+;#P.X?EV^8B>M,J%1W''
M%^Y+YG,E&<G[[E$)$\(?@S>Q\45@_?&,W0<O1B_UU@)%QO>PL-#4>N&]9)=T
MCHR%T;U8;NF$4DA?>/*%/,\@U5&"H<+T+5N#BK\MY5GEV8IY*6_@%3=RX2C$
MV(7TS"\7M,%UDIKNH5LQ4G):8P,/1DG2L]OD*_ZBPO&D*E=0.,+G`$Y<=;C+
MBW8E&HJUK*%D_D*OPHOA#.A4D]Q/Y7DDE-I@+H647-'%&X)2Q.A"&)*1\VD'
M)%;`[M)*C&2QTAC'`_3N9=7]K1C5N3`/@F>]E8&_,XYOO%FZ78LA")(C0AK?
MG#:#ZJ_2SRC$1K48I)H=7.M:9U+?O24MF(+I=$YR,<%`%C+3,6)RV_OD\\9R
M5/:2YX@\5?A#%J'-S`>Y^=B#<%-VL-*;*"TU-%(`)V$"VA$L:BR$C*IFFU!K
MLFK.W+Y:5M&48*>9,M<;.QD1*.UY(7>RNL=;LN%*=LNJ+>PM%C`%[+__@E5A
M9!N)5^,]IB`F(BB8+>*X\]UP?XFL6)(/]FD>1S.%(S)FV0K(%U3Z2^2O;,8Y
MHY?L-C2R78J#R^23K0J45AP$FS#=,JM>3B@E-)9/U_1"]-854W++(MJ4<7+]
M"UW4K%14?C]D^)6<38J_YG^"Y'+U(70//^\-!_:@[]C6<\>Q^^TA;:CGO:X]
M['2L!^9_V#D7A7]7ND'N8?75(K@QS#^>P7YZB_F9(=T@?\<(J%4](6)I!2YA
M)`>P)2$^8SE>0,TD0PWYG+XR5.W!+V]MQ=[%"M">=LEGC])]L!N91ZM<C9P%
M(!]&UHCPFEFD9@^C:S>0:94QS?WFZ^?8SMRNLF0`2&Z*-JH7V<[Q,$>+?4R<
MU*L!0,.\&L([O:BL6(L[PMN^>)$C3C$;FA;A^K)D]0@4K*FG_)-H;6,.X7IK
M2\W1L&"7D?&TR#D[1EIP3'(I8^7HE#+"L9U^UVX.6BP<6G:OV;,[S2YG&DM?
MX5H!D8MI%40#8GT-<M!-JRB00Q3G$6:>`#+MU7-)Q.=S.B%R?,X3J&0*?6.0
M!(A*N*/D!UE&)X7G?790Y#!#.GCB?A?L^1S=D;MQ=316H+-PG._&L3?U6$V/
M*C;#*ICX%KEZ[3R8:!'8.G41S@&6[PB)%US,0O3\@J8RG;+M(%&/7(!^5?C9
M>O_V$MVM<S`XV`T<XMTWY+PEA.9^(1?MV..T^#%5SE%'.UCNP/T%9^T"*V!&
M_"E,PG'HLR^F.#-0ZB/A.X?B;;'&/BJ%N9SW:"(H:5;6VY2<@S^H)'@N$9R5
M2)()0B'LCHCXARM]1/KR8)Y6$C/:5X?87W@+01X&RE<(_?":F3%-,!A;9"U.
M`)>A$LI"GPK"24[L(&.YD79^\_L^`!F/W0795HL0`5>IM'(9Q+6Q*.=LC2E"
M\<2+D#5DE:.E&V&:AK:,4])'RFZ7VX"X,8R^%[!09"%&JA=0S.*:K<])E%['
M^9*L]\CW59F;V])9956.OZN#([,"YK!?"\(0A7[FE7*O([!L+RAKD:JB*_L<
MJ\1HF:1>1_^4E*^4%X4B)Y=MB!:#3B13JAH(<+#3`6F<4KPLGI$#KT,,XM`>
M4T=9ENHTHFC.)H);)60I-!$DF,1"#0NDIY9=O/I9GCIK:Z!J;J,9/E.A$/VT
MA)K"7NZD4`V+<J7'XR@5).`+)WF%L,[14=-#(R`#E_WD6$(KR"6:TWD=:L,N
M=ZM(NBZD*UJ%ZX!(UP6J8;*&VH`@RI$M&EAX+D(O#"Y!#KP:LX]5L@>YZ.6Q
M@X,!+\7$8]G<.4:7?A#UON(/&8==3?A17FQBA6O<.I$7YR[<\$!`-LHR^1Z$
MM^6=)S90I)=U[S]B\7GZ3N.Z1FKV'WQW1\-6`ZUZ[PDM]_HGLO*,O/-)E)>[
MU]VLTN(B:T^3\_%1V)??1;;[`ZN^3;`JH]R$EYB4-W9)G_[M\O(+:TT\918L
M9^TZKD@WT%'BE'8/B>SJ.R\J\TUY73E/D??$(HQDD425%LS)I)P\4+A]%W&"
M3V9TJ.+=TE'IQ6,_I$0-*AM`.)(W2$IR9?E^'G=?X!LGV<V.3#.2T8HP+D2Z
M].!C`BRD"D!A<!TB53@[6=^T*8QL5=VUX3,ST"J?OH>H[KY(0$C9TO=D5":Q
MOO^2Y8H7HF@KG2588J&XSD5QJ4,&:PD9Q?BJ3OYB&4&2U8ZKR+36_G6^;^9.
M/.3-!;(U)KG3;0!:8PP(HJR3RS%=V%-0XG'.*=2V)6LYRMLZW`0HE_P)ZU,7
M_XI7FP@;*@^[>)6(BT!,5K(G,RE<%*FK#1N\,/I"1\!7H51?KM=YJ=M.O!7Q
M./(6,E>H-B)Y&>`ZR.1#A8AD6FC!-::E44'+TN:-2N@$BO(."O5E-;2OU45L
MESM+W5.X>SLN6HF;8`9`Z@.CKN^YAL+A0,W4KM(Y?$'A_W\I&'.'BC;JIB"^
MX6_V4.1RH;4^2I2A6\6RGF/\JA9IAUO5J!C1I6IL:>N[BUB\LM0G7;$A*U^Q
M">";EJU0;75WWS(7H^4B>M*^Q!*ONEB'LWBB/LCH]UBXP:_/G.ZS=6N55%3P
M4`8>0F61EK<U;.1\DQLXOJ<&QKY(S/53\/,KBZHLCXM"]$$M+5]\0)T4]!MT
MBMA4PPF0AJV3R4^Z0??1_;-"^]&<L/D^7HIT;?6R@V_'*0FHF%L/R;]6`V`&
MQ0]"<2N'8EEER:!XMRANYU`<G1N*MP"MD\P>?5!@&1$LKQ-,+F1[ONAZ]*+5
M[-BM]L!N=;LO=W68J*I8K9^V'E'>ZHGOI[C2G[:?XP%ENG"6?;2K5F6\EJ9[
M6.?JECUH._M=X@-1:PA8+AWM?K=E"'B\!.S8SF"#WO&&@/4E8*O;KP,!=W3B
M_S7S$O$4;H$'+?6W"$O%8'#=2^Y'\A.RZ#[X<A?G>;/9W,-BML&<(8H]Z`X-
M4>I%E+;M.`-#E+H1I=W?X"RM]P'Z5";SHU?]27")7\.(][NEAZ"6M_>PF@T<
MW(883M,>#/=Q@AIJ;$*-OCUH;^!S,-38"S5Z=KNY=TE51UOS3!6SAT[V,'ZK
M[=).91V&1+5?AR%1[==Q$B0Z=7OT([EV!3<4P'LCU-6`4H_'LE.!GV+)SJ-F
MV_VH@<U&<X,HDE')]T2+?3BQ#"TVHH5C3-7ZT&(?L:G[#-4=]XS;\"J9R0DW
M.>&/S@EOFYQPDQ..4YN<\/JBV.2$FYQPDQ-N<L*/-:'1L;OM6B0T&@(^.`EP
M8)+ZCYJ`K6'7$/"8"3CH;1"3-SGA)B?\Z?UNCNUL<D'!Q!GW2Y2>8XA2/Z)T
M]A%%,T39ZBQM#P]'E)J;S"8G?(_QJY[=[IL@>VV(T6R:E/":$*-O]_KFMD1-
MB#&PV[T-W#\F(?Q$M;*SRY,T)#K2I9W*.@R):K^.DR#1J1NC)B'<)(2?*"TV
M".<96IA]86AQ`$-UQPGACVDX8K+$39;XH[/$6R9+W&2)X]0F2[R^*#99XB9+
MW&2)FRSQ8TUQ[+=,V>DC)M_`V2!X;LA75_(Y=K-MJH8?-0%;G5K<T=C1:6\R
MQ(_8$=?>I`.!"3ONDR2=CLD.KQE)^BU3Q+UF)!DV#U?"O>9FLLD,WV,@RVG;
MK>'>:QL9:E10P[$'74.-FE`#^R.9W/":$*-K]UM[KTU81Q/S3+6RLTN9-"0Z
MTJ6=RCH,B6J_CI,@T:F;HR8W?)=YEX[)@:T/+3J&%G6A1=/0HCZT.*_<<!AY
MM$3+(E5'&D;*8?O;SVE\<>VZBU=7XYF8I+[X/)5YO_[=>R]P@['G^A^":1C-
MW<0+@V^XDF\P_6L_''__^W_^!Z+S;VJ0SW"VPF/!]4?AQB)^GR9I)'[W`F^>
MSK^X=W,1)/';5,#Q&^`2OHKIK\\NX\_35M/I7#BMB[;SS$H#CW_XX^KM,VLB
MQM[<]6-,6?^[T^DV6TX[`WK#^9;!S-9Z&20>G?G>C;@2XS3R$D_$[WZ,_70B
M)N^C</XFG"_2A-;^>?K.C0*8+?XBHBM4'30B"BO"UVA%30?^EX2YU?W]Z6C_
M;28LSOP?"3^\M1:1B'']5@(_+,($/@,I_3M+K9=X,=:+AN?<Q+H-4W]BS=P;
M'$8$EA<P*N"#%::@.+G^./4)'58X5?J2%4@_?Y8Z;<%<X9C@24*M;R6`JUGH
M3T046]X40;LC,&X%O!&$"2AA&4%@&T8,/2`AG,1J26+2R#BX>/6AWE<N:.A?
MGW$&YA8W,`9G?`&C,,L![ETX^TRBO8QQ4[T58S$?P49J._:CK3-#WG7DW6N*
M-)X#9[SV]AFOO?7H?7R8W/A5U5C1"O^"0_,!E+I")<`*%ZA#+%\N6X&B<SS9
MGQL(.'VC<C?IGSV[/VS9G4[USCK,^@S1UA"M:_?:+;O?618)AUZ?(=H:HK7M
M?KMM=P:#PQ*M=A'PZO.A<)8__M#XRXTBL`VKSXN]Z1!%JZU21]@'DV\#PX,9
M?]CJV\.BJ_]^Q.]C]8;B3T)Q4"B'(.J&0T/Q,Z%XRW;J1?$Z6T?+J&@UNJLG
M7+?1V1EK;C+[OO<`36M-PG3DBP-N@VHP'GB%J6GW6TV[W=U\)T@"'$+Z&=KO
MDO:M(6@ZO>4+E8;V9T'[+M%^..C7A_;WQ9#W%O$JB7V518UW%4E=CM5^"&Y$
MD(31W5LO'OMAG!XBZKH47(</*7[X]/G;.ZMM211U`9\?/OWY[M.WSU__N82V
M5)-U*0"_.V)N&*E\]!2:((C]V(L3BEEAF'8:^GYX"U1]=<#U/6TD=F@BL8<*
MV?3W&;(Q(=B3#<69$.QQ&-I2XO8&3Q2&?.\%7@S:"U;XF*3CI)(MCB\^\OR^
MM>PH+#+HH[.P>D.90%9-"-5K.7:O7^W5,,&K74F5K^XMJ*P@OCW7KT1WG1.S
M-]AGNPB"=^WV&D_+/E9Q]D1H=9OV<$WN2+TEP?[NF#U>*+P54Q%%`A6_V(2P
M]QW>ZK;L3K\Z<<-$,T^+W'V0:L/:I"L<G=+C/$3`??O\[?)CSOEY7F&,:BU^
M+]$+QW8&+=O9(K_:!*Z.G>+-3MON.9L?:B<1KJJ,`&3QJ'71HNI;@/JM-RFH
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MHA=5D[2''7NPQJUK0DC[B.-UL-5B=:'0>HN#8PHA*<F`#0;<:#SC9E#B1OCA
M`KM(W!-:.GM.;0V'=F=HQ,5AQ87=ZO7M[IHBM?46&+77']@1%XFQ\&[0EQ5?
M1,)WL?_)PHV2.^O%IS`1EM-:[@=D>#03%)VA/1R8U)0S)<*YZ14L,1;:GV&4
MB'7GUP!CK=6&L)$-^Y`-;7O0/`0-SD*#T*EJ4^ZM%UR;I+65-3]]%I.**CM;
M1EM,WMJQ4KS5:]K--:Z4(\Q;.Y0>](@4MLH4#I/;M+?<IFZ[;W>:-:IT;"C^
MM,6M[4Z_;_>=;GTH?HAB`6O+!JS)@ZNN&E#RTF'J!IC,,9,Y=ERJI\D<.W&Z
MFLPQDSEF,L>.-"')9(X=":%,YIC)'*M=`,%DCM6`""9SS&2.'0>GFLRQ&A#!
M9(Z9S+&Z\ZC)'#MK(IR;7F$RQTSFV'$1P62.F<RQD\\C,IECYT9QDSFV,[EG
M,L>..(_(9(Z=&\5-YEA5OMCF26#+Z6-?HG`!<OKNB^_""\'DW;]2C_S$=4H;
M>^_]`$73I(N9=+%ZZ)LF7>S$Z6K2Q4RZV"'2Q?3I6\D/)OFHTAYHMVRGV[QW
M-I,E=FA"-0=VIUL=VC598COK>95&@9>DD:`DD*GW`S\;#^U^_77=MCT8;FZR
M&N_L45.[T[-[K=I0N\ZZE(F![B40W;.;G6I^-$38!Q&Z7;LY.-;.6[77<B['
MXW2><O;:1"PB,?;<Q`L#<_+M]>1[X;1:=K^[[\!D=8:B(?.3D'G8MON]?6LX
MRU0^+L5F9U'G]Q_^W[NW)MI\@-ACKVVWAJ;EUMF0V[';=>RW]91QYHUBG27!
MY_M#R!L'G=]Z\=@/XS0Z0-629PK7(_4AZ_O5S??]6A'">^OWI8&KBCT_V?PF
M-F]B\\?A;32Q^1.GJXG-F]B\B<T?6<C7Q.:/A%`F-F]B\^?CS#2Q^7.BMHG-
M/US@F;"PB<V?)!%,;-[$YD_^Y#.Q^?,@LXG-F]C\&09K36S^K,AM8O,/C'4^
M#01O<WJ=)7XL1!!CZ#>B$/"=<*/8$L$$%$`5)"-XVHYM872%_MFVR0L&GUK6
MK1M;SUL#>SCHV];S3M\>#.3/SUM]NS.`-R(1+\0X\6Z$?]>P/@1Z9#56A=9)
M8T=BDH[%A(`8W5G/'0>F:F($.\3'X)5;+YD!C[BQF(7^Q/+FBRB\$>CZCS&R
M':94!^W&"]/8O^,')_##U!L+^(%3&QH9#3;(E"C)>[BGSPO?[?\4!K*92IVN
MZZL2M(H79%9`7)(6<""6-6D!9QL^-FD!ITE7DQ9@T@(.V>$%?DVG[CA)H_M+
M(9KX<]4\@^'0;C9-HH`AE'&A+PD8T]#AH5'?MMUO57.J";/M@0B#%ISL+5.G
M?2\1MTA0(X>-2K6;0,Q3!&)Z';O;V=PC;?**CIK:K3Y(ABWMP7H+O+TJ18^(
MN7WY^N[+Y8>WUKO_]^7=IZMW)@ZSSSB,8W>0\WLF\G8^%.]WFW:G>Y8%F/TM
M+U]65F>N#-TLAWP^!(D;7'NP'GZEKK=C^_G;L1\^?;O\]-N'UQ_?'>J*++ZK
MQO%%DL"VD#&;5]9%L^$`1ZZ/G.(`>X5R]0"^Q0.8#[I\P,SBL!3=M9V&43(C
MF#"F!J_'L35VH^@.GW/G,%I"KH)\,!2^!A7@WQP,E:%,3W.9NL7K4J0N'[N@
M2"V-MOQM^U7]4%9%SAT%_3:.\CE-$^8[5$C$Z1XJSF>5!(=,L.^(`UZ_D6A]
MHT3K)8G6<T5&/J'[,G>:G"L^/HG$RL`C6$:1]3.AZJP9Y2^!)H:87%B7(./<
M:U&%IJ]B[GJ!W%F9=O(%1@HGUHN[*&X\/L.X)M>BY`IQL2MJUZN]1@\V9(KC
M"(68Q9C%U#[8(XV";FN#1)0'N4273:2M#(_/7]Y]O<01XG210W&_PWB5W\)9
M,$UNW4@`O(DJA5&P_>[)!3B5+(KA3I(HP%H8=JN#HH=)=C%D6I[F1<ON#*L;
M">]R1=4WY@QUJJ)OP[4>:;.)=K:HW=#+Z33Z!R;7T85(6TT=1?&"B<!S_<)I
M/L!-M90UAG[><1@MP@B.<^M6C&)8U,X4Q'O9^#AREX:.W5^3S&'RQ_9`@Q=/
M383J@_?L<:^">TYUQ,SLBT/1YC$V7_"SNYD!5^^3>'_9F:L'<-DQO:U/<$'7
M2R?6+(SF82#PBF3D+NZL291>9X@;N\'$F^`QS::WR?BNSOAN#VUG4)V09R33
M/DYL!^RRYA-F?)L3NWH#`.[[!REJ98B0V;G5)2KJ?9[NU+(UC/54^KC1O0T=
M#!T,'0P=3L^0?(!O]U,87+BU22\QC&L$B*&#H8.AP['2H7:6Y)YBI/]5XH6U
M5IROUHN%"'!RXX6JG*37[]K#077-:2-#3/#NK&EC-D@-B(#CF0CJ$55;_SWU
M$V\!=FT2N1,Q=Z/O=!?6NO$2&".(,5<9?IZOC9&:0BA/40C%:;;M=F_STMRF
M[LU1D_N!NH7A@I/B`K/ISXK<^]&7SKUF5D4=G1VDFWT+$]??&.^F;-).RB:U
M.RV[U:I1SQ)#\2>E^`O':=N]3G71V:<B^.8=UPR==[*S85?;W8'9V7NC^$.5
MH%V3_N$$.'`QO+)_^(=KM/-$\Y;-MMM%EVK#:\N2K6B^I@39LI?PE(I4';8$
MV>-[M!CJKJ.N*4%F2I#5`Q^F!%D%:*LER$RM,5-KS"S&+*8N/F-3:RR'8E-K
MK'PMIM;8&9'I16<XW`N13*6QAVRA3K<Z7<]LH9TM:D>5QKJ-:L>\*33VA#5-
MR@J-94AZNHIC)Y>=:FJ/'9X&+P9#N]<SE4P.@?N6W30)\H<E0;-Q"/E39^O:
M,-G.F6S+2<QF-W0P=#!T.&TZG(#U:`J9G`VW&CH8.A@Z&#K4C0YUMB3WY(XU
M-4UVQ<G=?LONMZI[`1EQ8FJ:G#5MS`:I`1%PO`=GYYQ(39,]U1Y;O:"\Z\/;
MU#O9Y36PG=Z%[P[M]A:W>DWE@Z.F]@/5#L,%)\4%9L^?$[7WHTD=8;63I_*(
MF,(G)U0>H=_MVOV.*8YP+O1^,6S:@(R]T]M4/=DKF7N]KJEYLD]Z/U05,C5/
M#E+SQ-^B)DAQ605-<:_%4C8%^"]AR>0,,2&PDIE8R=&P(L'7\Y/0FJQ<!4#G
MU<H5`"N\P=H5/6L.@,P`?)AR/+.\&(-6UB(2\3CR1C"D[TT%#:&N!Q(4;C#1
M(ZW,V+!R4%OW`<RW$_651"N-,0T%WXJ3R,5]<^%[@;#F(IF%$X8;?Q6`T#D.
M0@"EL9BF/D,;3BT7F[S^H-_].]!?K3OA1LNK5`]+"(7OBW&2NCXL/UR`9GZG
M(G6K"W*7FL@JTJP+]_'"-ER4M=&"&M;;-)+H(A#H6TL$$QAAN4))QT*J8:D2
MFR*3P`MN;`6AY<T7KA<1_2(Q#J\#9+;&D6R02M_0WD%?\D<WO6#KQ7P(>'>!
M3*="";`]@G0NX.G8DL%BR4[($#Z8CO@8`.CBC9]5B@/#"VOF3JP.\'R<`E-(
M9K2!X<=^B@.^LHX675M2?*M:3P\JZ*36?)&$"UJW_%.=SED1JVH?`+SZ,..^
MJ!BH*^D/N*Y8I6O((=L/O@'9&6X6W=(<HJXGMAZVBDWY*,PDL=Q=R<Q5AU2,
MNS!,HY6#R@O@6)S3#F3Q+\:S`(:^AG,#7L0?<P=.>!O`]AO=@6`G.0Q?N=8?
MC:L&K#;RXHDWIATOY[_UDAD\9HD?"R^B*2PZ2[P`]G5K^`L.L<[7I;2T*@7M
MD1N:_]OH=[U@D[U]T6RTNF9_G_#^SO/3/2AZK/#("&\]\#_[@+98@;&.0J]M
MI8GG>YF6FQ=Z2N:-P_G("U@`@0)Z#?HI:"-!9@0(U&<G7NBCC4!5PE@A8;F'
MU426!1]^5R7W8A9\2U(O9K'7;I$>/G-OA%*&"(P2A8B'`2-F`1H]KF4,F]"%
M45C;CS.E'+Z[C*[A(ZS2MBY37([OP<<W;N!.7-*4K7<I&@0@CO\(8'3;^EW\
M\,:A;;V.W'][ODU0_,-=($F^IG&,KU^%*4!P.8T`)%HV?_%_PTBX):KUF4ON
M.BJ75^DH%O]*L1(.G>YAF7KM6$I71[-1GMV@C$MM.V?FKMM-5O5..I`9MG_E
M_/"69*&V(8(%8D@$,9O)SUMMNS-HVM9SIVFW>BTBV?/6P.[W>^0>03FQUOJV
MI>DMC?"6K>23=P,F?9'.UF7!GB-HLG&*C@(W7UE/@:P@"@`OUA1FD+"AUHD>
M(=\/;^7-GOW1XM[:Q)LI<#3TK\^XOM@6M7D'-2[->YB"C?\$GK#>L5LASZ^'
M3WHX##[>Z4VUILYI+:/Y&E^M7=;B`W'3W4AW/<?,XNJ@X`[*<'1MIUT=\*MW
MJLIN,H&?C*--KKSAZ),5UWW#W(:Y3TI<'P*MAJ./FJ./1UQ7EYXUS&V8^Q#W
M['9=Y7:SZ3J]'8:Q]KRH1P3B'K6A'K&H+;:6(M`NXXQ[(5!I'.5O/Z?QQ;7K
M+EY]T!EIEU3EZ*T7C_TP3B/Q#:![[8?C[W__S_]`.OQ-O7(UGHE)ZHO/T^67
M+X/);V$XN?5\_QM.I8>`DR/`U7X5TU^?O8_".3IP+YH._"\)Z;/3NF@[S_[^
M6*_KUL[N;S,AW<"4/D:.5UP*>HZ3F<XTO*9&2&/5",FE_C8<QLMU!2JXH,,I
MQ3I6ZDA5Y2C1:"O=M%X]>=!@9P&-';FU-_9CFQYSAW-''[;'7.?1^H2A;FV"
M#:;'7`XTTV.N")KI,5<!VFJ/N0HTF=9SARC?:1J<F<6<WF)JZ91<<C^8UG-/
MXW@YSKY9IO5<_<GTHF5WAM79"*;YW$&ITQK:G6YU]I/91#M;U(Z:SW4:_0.3
MZPC".V5U?5:K*&[MIEKM/K=ZXWQG"N+3!Q^W#&695G/'2H,73TT$4]K[ODE,
M5>DZTN8Q-M^)%#0^\AX$ETL52@K-"#+$K90I,9NB:I).>V@[@^48G)%,^SVQ
M';#+FJ8Y[$$V`."^/S`JZT&)<)"$Z-I9MH:QGDH?-[JWH8.A@Z&#H</I&9*F
M.^S9,*ZA@Z&#H8.A0]WH4#M+<D\Q4M,2=E?LV^MW[>&@961(#62("=[5D#9F
M@]2`"#B>B:#NR_#=09JS:?OZP+WR]$T!G6;;;O=,#\@S(?<#=0O#!2?%!6;3
MGQ6Y]Z,O'6'CUYTZ.TRWUQ-J"^G8[4[+;FW1'-LTACQNBK]PG+;=ZYB&KR=.
M9P=WM6GYND^*/U0),BU?#]+R]=Z:6T_73F1EMMTNNE0;7EN6;$7S-27(EKV$
MIU2DZK`ER):SO^M0,^>4J&M*D)D29/7`ARE!5@'::@DR4VO,U!HSBS&+J8O/
MV-0:RZ'8U!HK7XNI-79&9'K1&5;W&C&5Q@Z]A3K=ZG0]LX5VMJ@=51KK-JH=
M\Z;0V!/6-"DK-)8AZ>DJCIU<=JJI/79X&KP8#.U>SU0R.03N6W;3),@?E@3-
MQB'D3YVM:\-D.V>R+2<QF]W0P=#!T.&TZ7`"UJ,I9'(VW&KH8.A@Z&#H4#<Z
MU-F2W),[UM0TV14G=_LMN]^J[@5DQ(FI:7+6M#$;I`9$P/$>G)US(C5-]E1[
M;/6"\JX/;U/O9)?7P'9Z%[X[M-M;W.HUE0^.FMH/5#L,%YP4%Y@]?T[4WH\F
M=8353I[*(V(*GYQ0>81^MVOW.Z8XPKG0^\6P:0,R]DYO4_5DKV3N];JFYLD^
MZ?U05<C4/#E(S1-_BYH@Q645-$6Z!?>WG]/XXMIU%Z^NQC,Q27WQ>?I!IT1<
M4D;$93#Y+0PGMY[O?\/%?P/`7OOA^/O?__,_D&'_MCQ$.'WO!0#"1^]&3)9'
M>Y\F:23R]Z/?_5B((!;%L:TQP`I_?!737Y^]C\)YJ^ET+IH._"\)Z;/3NF@[
MS_[^=(B^I/[EJO`%4546O^C8&.NR!#P[ISH!;OZZM^#UD!<-'PM@?&L*N+#N
MA!O%EA=;+OK8?#^\E>DF^RM<<V_!G,TJQ-#0OS[C2Z];%(P9U+A>S&&J"/P3
M>,)Z1X%1*U]DY?"6^&'P\4YOJC7%-VII8FI\M79Y01S$3=>$N[;65'=P-Z1K
M.^WS;K+Z9!QM`KB&HT]67/<-<QOF/BEQ?0BT&HX^:HX^'G%=70_%,+=A[D,D
M?^VZ],IFTW5Z#YBO'+<%/^FJBW$7_D'E>TQ^S"<YWZ6JR2@K,KYWO>A/UT_%
M%Q%=S5P8-YC@WS0NS)?.%_@IAA?=*'*#)*Z=%_+;#.N8\*HL5Q::G,*ZK!M<
MF+40P,"X-*R!@AQV*U=B>;`^?">8D!O2S99KI3'\X`7T/3EL+@"%H0^@_AY.
MA&]-T@C]4?@S^RQ%,($WEHL`=[@4,$T!'UH6@$$P`"'1_9G,U"3L51P)/[QM
MG)?'<UACC^?NSM$Z91`=QF^)V^&,UUY=Q./TU[Y<0::6^K.$(%^Z<\L1_ZH^
MA2J)+Z=[P&S;:+I[+?;G+%<]?72Z[WT3[K<XGJ'5ZAYO#*KEFZ%2;:C4K(Z4
MF7J,#UKJ5R_^?C&-A,!"&2(2<6)A9<6C=&=L:1P?(*.;X-)).O<?$(]'R6.@
M_:D(KF&)IT!RLS$87#@-J6/>B^Q'8^0G0\<GHF._!71L=@Y$QSK;)%N.\F?H
MNXGG>\F=X=5'6!?F\#@*0CX&R9U.HS6\Z'0;@Z$Y/HZ=DKW.!?QSX!SQ`5(O
MV^:;B.;6"R_@$(>I2G38P^2X0^7UER#=B]Z>)(<AY0;4.`#ZZVP"/'K5;[T;
M;R*"B77G"7]B&*_:#FU67Z`UZI]!O$'\3M7DTONB_AZ274K27O[V\]-F2U7=
M!_T\I=%>N[&8?''OL)38Y:T;3:X2>.DSCUDV3RUSL7)I5$3,)TRELNJ91F42
MJDQ"E4FH,@E5)J'*A-B/S@T"VF#_PFGT^\8A?N1T['61CH=RAQLZ[HR.SD6K
MT6J;L(8)AM>107N#1K-[,0`6-3'4XZ9DN]UH=S$:WM]7),10\HFBX4U0X"XZ
MO4;SF*/AM;5(3&!\/YI/]Z+7:'7WQ,$F*OO$]#34--2L8\A^I]9)_OK@OF+V
MQW?C:0/VWNW5I[4QSEVNK%JC-50R5#)4VH5-X>>S!LH*-.\BFJYB]1/AO7H7
M)%YR]R4=^=[XO1^Z22'4?AE_GG*HO7?1;CZSTL#C'_ZX>OO,FHBQ-W?]&$.Z
M?V\/ASVGUVWU__9SZ;BKD[X)Y_,P(-!I5?'G-(D3E\OAED#1O6BV`9`<%/Q:
M'I`/G]X_^[O3A_]VNUTG#\JZV1X/F\30_XS3&([B__D4!NYTZOD>%K/E$7^G
MD/_]P`^;':<Y[`^WA5VQRN?HV@UD]9PW0'J,PS$[!),O\"JP#/WY&0OQN,'8
M<_TK^(:;O+WUXK$?QFE4J]0+''FDMT?V:7\)$'D`4OSPZ?.W=Y9C20'5A7>_
M_=<[Z\WGW[]<?OKGDMA*#PKZO1D;3Y8N$[D+D8*B&O_^UK8^!..&;;DPYHT[
M<8&IHD48$2/:!$D86<57+%E!'7A_X09WMC5S8RNY#:W;6>C[=U9X&P@0S>DH
M]B:>&WD('O8M_%U,<+Z/']_@=&^%[]YB.HWOS3VL7P%;<D0N<P!!#@P3_<DO
M,BB8AO,Z'+N_14($]\".+^MG&]8?@2_BF."6V\8*L3/RK1<+*Q+_2KT(X5Q&
MCIH>,X`(!#TDI<"(<>+="%@SY06%<Y$0>2(Q%5$$:TI"+"HO*=WI_Q*FD5Z=
M^G;P2^Z!6U'^/;R8_P'6EOV6QHWLIX/Q\(&X.=OW+E8HP]X`K]/8"X#82UO\
MC)#RER"&=*U;8,E`,4?OE]B:"==/9M98E01;1.$D'2>**4%9&E/J7`C\'0G8
M27"HXJZ#W^<BPB/)^S=^)]^##070"-R^XL?8!\33;L`>"S1UP^)V#;CMJ.LX
M?XYY\K$^!.']J3KS`"/JT+.M6UY)'JPPP)E5]M[8]P*TN*TD@G=C*Q!C(+T;
M,1"1N$Y]-PGA3W<!,-_`@VHGYY=$(@.!PPWJ3FX`$IAMMM1!?0$G_-P=DW2`
M@10.&B@UEMJK9\7<:,L7@619!LN:B!AH)^4$2),;U$IH6?$=Z(?AG)"'^`=A
MDH[Y)TG"R(N_HZ2)L5,L(&,*"H`%6`L7+DQ]$8%X37)KF(BI-_8$8!A8B0#P
M`B`8:4VS,+&FOAO/D,O".!$A2-$P]F(2>]:-"_P&P$^B.]Q6#4NRUT0`L<.%
MI`2(T65\+:'$QA8HXYDB?>("=D2,#6Z]D,B"&+V&;T2$H[@^_A.(Z"'1YR.`
M@07[K0?+I]IYWASQ,Q$P*XY#>$!1#F0&]LG0+D#C&[MC8(*$9O?#6Q%9DS!&
MH!!:,;JS1`"J./,[?)XQ"\`1)O!U$/0('2B.@O<*2G<"!/\227Y/-*S/0/-E
M?E`[CK85\CO2R[460";@5%J(QI\8SX+0#Z_O`#C0^PDRP8>7.YG#HGBUS++R
MK9C!F8%U98V\T+UQ/5\=J`J5DNYY=#;@#+4P=4WB5H!\"=*I.R9IBD29X&S>
M*`7.'$4NI<GBU]<B`'DTAE6+>!QY9,W@'S`L8%SU*;;Q_+L5/M"7V3Z\$=$%
M+.1B'*:86$7G].=O;VS]2BZ%-C.S=JT[KR1%PS[TD$G`;!L3:$#1+S`+[I>=
M:-RCT)\\5;,A7R2`R@N9Q_O*NF@VG.XB>;:B&!,)6GGE^.J/WW^__/I/Z_-[
MZ^K#;Y\^O/_PYO+3-^ORS9O/?WSZ]N'3;]:7SQ\_O/GP[FKI."WX7^\_V0ZV
M_/MZ+>WN/"ZB^TL$`A9;>),,+_#LTRHFAS8N+'<LM0EID:\_XW-G$9]O+N^_
M6!W'2C5!H8-_K[$RI+9N%>P$T$%`_&#S&CQ\.9U3C3ER?93SL;8N0*X&,0@_
MJL<Z<V\PK1]T?8%&2D!K(/&9(V;M"J<^;MZ*O;3Y9B1W&Y?&?64%<#:Y?G%C
MO`%%XW&RI#9+VI]L><)5_,5ZR1S4,5+)QD`?4)1RFQ4.Y<1+4MX4I)'`_]C2
MG;MWJ/D+P=6,IV("JA]N3W@GC<BJ!^L>M_+S5K=I-YM-*HU<.G:#X`#EDO9=
M`-IE1%W;(E1;:5??67",QV1@LW8+>C.KGM,TF$C-X4C)4&DU/NUZ[K6KOX%^
M+JQ+)92_@GT%^C5>)4)Y>8GM\E"$$CAH<KT-TU$R37W]ROF:X8PZ?9Y%.=2!
M;LT.:>#Q$,R.:S>[NS9)A07L#+\P>^"AA&>CB.9L?$5@*`)890,C!=)`N:9H
M*O44F?&P)6$[@OD/GV=HNE]@:#I6UA=&?N59B`8IDY8&G2BRJO&D-8=]$T<8
M]+#2!1@`K@*.#N_,,9^!""_.P*((([+,%*3PJA>@'91S/"),X@<\2V8='+KA
M'.P-M/_)6&%<X%GL(:Z22F0OW#BQ$*FXCGD8H9H!ZQLVK8E[%Z,,&:$Q"[;?
MOU+02&C8V\A+&!/A=)K[,;\0R[UV47RQTV`]MB2.:)D3#+"GN'BFAKA1<2&V
M1J513PI0AA\"!BS1,$JD71XOQ!AM%FOL1>-TCK@>L[:I6$NQRSB,)O2O&Q2F
M[%10@"V08&$:@\S&12<"C<HIFFV@E(&M&N,-F&QY>I^O+O%V!N\R?L2D82T+
M/IGX\']:7?PO;Y"0.W;^2!"UH$^Y:("F,"40!=ACC,X;(46\ZNL9P]3PCR!D
M6QZF3_%F#L`?B2DB"W`-5JL8)?$O8-GBAB1%,SLLT%Z,;N3I-=+NW\D^SH\2
M6?&+58*:0_I3MS8M/P0W@.$0>:LRPG*X8ZR&IN)N`,ZC':&*Q()=(2#RQM_=
M:Q`XF1\F2).(Y&;.<\EB)%V`E<I;A%R-[JVVEK24QP.+:HI/2/>#3<L^-!)1
M*`(CJ41&WT5BH0.>W;.R*/D%/307R2R<L+L4OR!!E+F;U#M+'B4%:AR'8XK:
M9@[`B8RSR-4#-D#*OP#1-?%BD('2`_M5_@"J2W@=$`Y>TH)8,.*28CV4!`P1
M@8](PY3&\22Z[VP+_4-@Q*:`&=2#61#%4GBS:JH'5'!Y="@A!/]6XO$(>*R&
M:NDVXLE;\LF(BX\NZ$?LA%;[YVY)5'G')+3T(JL(=<#5E"4^YMJ@/T#4W<GH
M05PB$70L*W.ZD['*YF286'<BT?I)>6@(U7)W`3+3QTUJ>5/41T:@_<$>IIDI
M6(!;&=X8L<9-G9%R`3+27U!^R%^TYCH2@9AZH%]^F$HYAT.PAQX$X<8#$2!R
M,%PL+HVT&#<.,5)P![('C04OP,!U@EH9B-0+GQ@_DV)6.19)J)6@$G$C>ZA/
ME#,?3QLWPN,!XP0<#L*#1#T8Y^MLH"$?3F0$GF9F^9JBE#R4/-P=A]9&/)(<
M>^_]P%[=U+OK?`WPU1/@'6CZQ**5(O]D/+EKD@/(^TZ14MZNE%L8)Z`DBD0:
MA^F<;"]6K2:H6**0H(`A6MWD.[#(9R@",GMI3RMU<1*2P(VSJ)I_QV8>"P"0
M;&@Z^MZ-T/D!($P6G$^#,DDH*Q>46M>+<F(?S+@09(F,]K*@D>9J3I1LNFW_
MXG@N1C?SJ\RIL!AK16_=A0\"5>JP.I3)]JNT3"<5ZV*%4"V*,12Y`?;JP2!P
M,L,R$["L&#5%OMYU(%/TO-7#C^CMF(4^D_?#'+4"&:0Z8@7QV.BBY!,'!G-$
M6">FK%41M?VNMO2.C@2*-GB6E3[!^1ED]B*/F-VY3]^2ZD2JH:OP*M&W1N5Y
ME('LHB=6>]\I@($^G:,6@'6VD!\B'=&>91)-PD4B(Z\4O(DI0@N2JK`8G1%E
M9:E-UA5&9MQH$ENO0_@7I6&]O[QZ;9<_]":<D"*G4ZLOK][86RE:[6[3UGCT
MBCO[XK<PG-QZ/F<!?D8C.R.,K5^PLB\Q`3J_1@#'@AFV`:AAO<F9^@OB?*G%
M$IPEAXR;ZW]L*]\@'`G7%,E"Y50IH10%DF.ZBX4O41<OV;F8>S=&)R2IT&1_
MRY5LA]Q0169<-:D76]=8#!1=`)A$RY!SALVX8MTEYQ^HLE.5M:N>77^(<A3_
M0^$-C\(U!8`HP'9!D:;@KAHB<C;+;(-\[-/3O"/U:D(X:`M@*\PS$1:DE(R`
MZ<CH!D']&I<9+87,,"8WYD@3>[>]"&.D$64P`>I@.U"L2'M:*)*&[A^5X%Q2
M./26*3)S)U9'=7WFM<76BRO0^#^%,&/_Y6%=P0<\I@[@%OF@&02)]C$,KB^H
MW;GRE%0%KTZ>'MG.8@$A>9]"/L3@<+Z`T9W<99'YS'L`?_F(2I]0>=_6I*W(
MR3W9=IRA.1Q3<MU].Y-=`4L05NW.*_1F5F_[+.MP&F*$&P7KP;;$CBKX+MV)
M;6Y3F%<!>I&$"P)6_JFJB&8YKM4U#^#5A]4UH&%7:AH\X$ZTO_Z:</O!UZP[
MP^K!2YW+JCCR`VYVYWQG>!$53UC:'YB9@]LJ?ZM'AET7D3<6RQ"6WE_>'3_S
M?QM=+ZCPK].7L(T%#@TZ2PL>-?Q>=W[/<\4]*'K,9BIC@<-L,,QWD%='JW;9
M8G87RZ0UF8)F]IK9:\=^MN14+]2#`GF--E)9>70!<74S8&P:'I*1&+,5S%8X
M_JW@3@#)L5C>$B-YGQSOD\ZU+3(.4W]"9LTX*=TA9)DH+Y$*):@IU!4CV$+X
M8AQSA&-TE^6EQ&9+F2UUC%M*>TSE!67VY!5S`?#J]P^\J4\7!2*/;YAC-'_,
M%WF7[_C`COE7ZL6>3H5':YZN?:=C-9':A6;CF(USC!N'0@?PALR4R[)<D-?Q
M5M[4#V_5%3B^PZ^R]EQYJ88R"2F%3SZ&!PPZX`0,D,@41C?)U4R@H3#<DY*[
MG]]:3@JLT`!_H6(:9K.9S79\FZUPUM">\"A011?$?.\[7BBB>V+H5N9+KW(3
M6!2I'&'!)]``T0C2A:0F7KP(Z:+7E%!>//1&8LJWSP2VF\.=ZA4O8)4DDDUE
MLLE);+"G<9Q_F.:C"S)B`/HS)1C+&S$4<]1IT030[4P@W9"LN==1`%KQC)1[
M&4S@&QNHFR<BUH6'9%17ASF4*H]ASC!=Y"5E,5@A"Q/)(`6E?W/,]!N(<)I"
MUR/+AU5D+(5O*](4Q;LX\)J/&=A<?(FO9B*-@/U8K*D#A/'B8P(G*6(3L1!$
M35:KIC("I)]&!8T1Q1!0N$?6:O-D`1V-6JWTR2Q'M9#_32?7<W6Y4K$YIX(&
M>%F'BL%PWIW*@\\@X*W*JB`N'BO/9#5T9#XIP461'KQ:R1L1/LCUY&"7Y7MD
M:1T-2KB4A%H:9L)Z3A'=-@TS;L)K`G3D+C^M[ACI:!11.+/W,O3P+4A,^X\I
MVJ[0Q3EP@7Q'L9[$4,K/RJN[_\LH8A93=UHC8AV-IOO0PZ_-A,\E-+"$E0SG
M<QVKG*G*605^'&8W<'-F,V^$%%O@%+,EU!(2,<=*?:"O>!,JNH1V@HNG;,*5
M/A@C3'=66[`"QS7G5?AT&L,S7IR]A8G\&'P,U>T%KFXT+8EH+BU;IB?D2"6O
M3=RJ.V(RMX*$PU26/YQXTZF(L#0!("VYQ3(AV9C9]K>F(%KDM)S/K-.<E_B%
M]D;&543I[%UYHN3`YCP,$%]9*4!`<C@7?*'%'<]R%0,+=[25/DCL`V=9'ME6
MMAT5HV$F3%Y\:.60Y:BZC1>G(V1""5[#ND)0)*;I5,W[6K+;O'35+BN(JZ.R
M,J@58]8*%9R*PMMD9NOOL=PJ9^IDW!^#KL:EN+PQBJ;BY4).'I4UK6B-U-./
M\([XR0%%B,K=4\_J4-BJ*(V\I2,OPK"Y&\^\1:Q!S*ZJ\ZRR)I?/-YZC@,I?
MZ$OOECL*TT3A/`'.FC!+R/M'/"^;"`6$J8)V.91&N>M`C#UB"4`+K?>/`$C@
MC;T%25$9'B?9F&WADC7,X)BYP9)=[/MRN2P:B3X]MZTN!LFR=,JM+&1.5/&T
ME?<(X"&Y;#9]N*0>_'GKXM;,OX%*DTXP(/-FY8SD*PL/:_![8M5\[K\GA`+F
M3R43LTS!#^19*<M]/Z-<6BSC5ZQ4(U'"9UY,$7<8!RP.I3N5U)^P<[46W+ML
M0X['44IU,_FJG+P6O91UMLV0?$@M#<L;_X<4#)S:ECM51G`.2#V"1/@LC)(+
MRG>?8R!(7DVD+9Y;?_Y6N#K^8<Z/J'\2%(X^HZB.R=)1-O/@E(W&L[M][[8G
MF.W065N8''4-A]2_A=;05G7TS.]3O,>?5R^X=@N>+\A^<!QZ,6M3+E]0NI#6
M10D9Y?UY\D:!E809K(.6S&#UE)0A&%C2_`Y'$PA[8J5&+JGW6P6;6-=TGXJ*
MGWK7,\$;+R3N!`#_E89XC/&93]HGJU=\@LGT,S*%QO*X+L>2]8(8V')>RI2V
MV^69TB`<8>D0VG%>L$@3_5+[94,F$:X,J\L,\%DHK[+ERN+)*G2P^X1(ENC"
M5Y(5C2=9'1DWAQ\Z%!$:*K?)J6SQJ[H=92?L7BMS@PUV[UES'M(AQ)<5\C/I
M;&WZ'^[C-WIP6LZ@N3V\:<`U>Z1UL=7F5N(/M<)L`VX;#CK,(61VQ['MCM8!
M=@=O!VGUTI;`#1![\+X;E;-_R::AHMIT>FFE('>P*0>'=FOJS@RV)3QR!4X\
M.-02I?9&Y'3E;U!9"-/K668_1E$XTDT9"-ITA!G8B4=W,]BAA4Z(W"W+,JW[
M(<&F)]O*2VYP\I?O]V+#UA`8`7-L`J9]D.,WDP32^TR"HEHH[#D^M>5F.)!E
M=IF4N9JDEZE-SG.\&!:$>9_5DMPFV7PKMK'8#N>^.F"]\8*3G`):<'S@[<)"
MX,QC',_9]I0F5!`&%\M&+[O5\[[JM6:?+`@>R"JFY`U'2WSI+B+&]3;T:BJ(
MMW-AVC7P81[:F_F!PQ_?W!_BC-V6K_.A'O;HJT8T.I5U'DZ$S[YZ7:A0!H\2
MQ)YL\*+*B*%;1]5C53S)P3`,+>HD\)6:_:#G1?3"YW$2(L\RLSIGXF;_2Q<D
M9CLUC^#,,\J95>27"O)MT%2YS+]R:0A964D8I<+;I\_J+)U$!97@'?0\":QE
MC,:#FW!K%Y)L2<C\H..:<2&P6=*\8=E=3?37)9LKH)/172_*AT(1,GF"(0Q_
MX6UR$M0;+9A%M@A<SA*`!SFQ+9\X@/D:Y,2#GZ4@)VK(`!5+6/@CZU&4+]Z4
MQ:OSZ%$U\7+)"3*(+"@Q"(!-?+%,0B(-Q\Y@BVZP/AU<R.WF;)%TLYU@Q3P&
M]42LT-&P=-O1K(IS7*Q_"J#+!E-ET'!J!#,H1R58,\$LJ-)L*2Y&2+?YS^XL
MJJCHT._D_>$KYY0L=$'A]"I6F6)A=["67"I%JR2)M0@Y*1KV7H#Y/++P@OX6
M"5U*)1AP)$C5`?!=DO)>(,60Y:83+[$S;S/G;(QGW$]K#NA(=($S-1>QN=JV
MN<2I>\#.RDE03I+,4LUS&O:7=!E^;Q:&DPQTQ68R@0]K7F!WK8A7V6W^U+#>
M9"'M*"L`C+MSGH4AY':@\N$9'G)5*Y5@@('#X@T1E:ICA5B(O&&5:_Y%#2VG
M_J]'SOF<DQG/C\)DQEUZ,/Q"V4T@RGP92LF*$B9YY!59RL6X:)0H!LUC5I7)
M*2=4J856')M3/51E,*I%**6Q@#,VR)MMN=`H'PX:WC.A*P;0\ZBA+JDR2XC.
M'*HX,;K3Y\N'0.;%J)K=,->-1XT/L48B']+NE'>XX+:KV),/3KDWG!GCW]GR
M,?I>/HPZ9_GL)WI`%>TB:DU]P78!=NT50>SNOQ'9X82+.I2X]G"V_JP*/663
M7=!Q)^.SN:=`R45Q+Z_HY8]$JFAT09U-5]+\\F>X*@Y5I4CG2B_Q@9//8>*#
M!Q10/[P36G7CEA46ISMBWQ8KYKV"F7?9:JSJE:A$NW`A\[M0X$8>)])A1W.=
MRU7XEOJDP],`*.6N@4R34V$_YPG\0LBDQ!-=>#'",E$R#4ZM1#ZW2",X3N%0
M7?@N%LBZC"G?Q"Y`+HD2<XI^SH>3[RQ+U"AZR;A9J2I^Q5FZ!83,93,;CPI1
MV?D26-HXN>&T;XZZ<(*:SB#%)=,DU+4$OGGMN^/O%U?C6>B+^.)WD/>H;:AF
M!AXEKK+UK?IH%]ZP?N??7-(CQ8)-,WI!JV=E^J4SL/GD*>04D[.*FH0"_GWN
MK.V+'[+O`XE"6J`;>;(W3S%-5QLWN3)@#`.N6[?DTX\Q@U!DRKH)\:#DZN:(
M5%?I4@`@-C4*<?T%?:UJ1HGETY34U1!@K>KDKI!W]B*?ZIMEZ.DTWY?LLN=B
M8TE(_LUEP2%M/KEWV.>IPFX%3RHS4"[IRXTSN2/S?+K-;LZND1"_UF+TBWNG
M>^]\`EC>*5CR5H]?6MY/CJY_S2<*+?^6^XGSD)C[\PH^R8B<8.;]R`PYE=U+
MEM/<J#<NWS;P[?(1/6E_R[CH"_<E\[F2C)0H[%$#(CN7)F5S-Q!W/&-'P8O1
M2[VU0'GQ/6ZM\L)[R=FS.3(61O=BN:43JL;PPI,OY'F&4KZPJ[+LO**E)Q-Z
MZ9IMGJV8E_*F7'$C%XY"3+.62<3+[:APG:20>^A`C)2<SI+&X&"4)#V[3;[B
M&2H<3ZJ\.65.^QP^C*L.=UE>L41#L98UE,PSZ%7X*YP!G6J2^ZFYEH12F\:E
MD)+3N5@74HH872U=,G+^AA2)%;"PM!(C6>SLV$&K[&_%".Q3>4WAC(,9;Y;*
MJF*\@42)R"6OL`:L5#2Z$$#9)%+3#JYULT*I\MZ2(DQ103HJ2V)X\FZ:B'QR
M<&,_.7O)341N*?PANT^261!R_[&[X*;L;*4W46!J:*0,3L*$FW1A7]5X:1]J
M95;-F=M:RUI:UHMJE"_;RAY%!$J[6<AWK`JXGH5O0N^TDO9@Y[O="L>1ZERV
M:CCFS@QV6JMSHU?0!ZM0*Q6ZBLFP$Z6*:;`IX:$WYP>K2OJF*=V#@&,B3N%\
MN<'+C9@'.E9=.\F"RJ#FL)2\K:H.&>SCQ-H4JF1\.93Z;:H0'&MIJJV2&Y/B
M="8;!)UWG[^]D?=+LY9\,OE0!"Y**=E@,->G+\I+*[(L=6B8<._.A>XOQ1VG
M?-05T,;5)<:)QY`NJHP,`L$9A2#$U'5I(>_?W)7=Q0PKP+>J0??8;(CAU3')
MT06;+PWKB_111"K"31#@\-6CP<LZ$JO6J[,DX3CR,]>''G932&%L@F!Y_!L/
M;VMXT>0"S\@[?`Z[P&8L]!J=ZUNBA=TTFG::#-0Y$@XCX"!W+B_[<NH,9Z-F
M#W+DZ%^INN6D]KJ.VN@;W6!6IIQ5P-DZ[O_*2G3D%=9];?$EO+BZ=!4\=GVQ
M+2IU%V,\3_U0]HS$VMP$@=/.88_3=Q`;06A5PH9$4=RW,J\J%Z$!:!SL`#SX
M8://"7T6?P9-Y@+0<_&&;B!'UA>)I:43^1#MNOS5-A('`N6OK`8",9G:3JP<
M2U%`>T'*:GE)D:,>B>M1"=,X+72(+I["JT-Q0A%><&9G1I9V0*Y=VG6W`!0^
MP8X6+_ZN;JU3KA#U85RXU)95:KH*#()"^Z/39(3]^&BR!=]QG\#;`5<*F`H.
MO#)4^-/(XSOL\R*,^4&EY2S'TY<CO4"VKYWR<`WKDO>UO/C(5Z[5QE82G:6+
MDA]XA.7ZJDLG-_6Q3I7E++R;G-V,5^DY-416++&2VY!1@E&ND1M\)Y/#O0.`
MWN1:MO.208R`A/UW>;-S>9<LS@P/;"S&:T..S'>4*&D[_9>0+,,A!="AL)N\
MO`(.8JS=O`"PX*P.Q!VUCI>Q/6L1^M[X3F8UL4R]%=*%K1E)Q0$Y:RR-%#=2
M5.`-7ZD7N>[E>A_I[@@%9N41<@R+FX'6JEM$R1EMB3IM,]E+<R)3G8E>MRIU
MO^1/RGI+W(/+WHWV$-6A(/8,7-D=>A31I6^L8X&BVQM7M+DN<'M.<LM;-9,H
MQ8`@1HJ`H2/9L9MWT0+TM+D[]L0ZH:ZT]Y6IES;.RG[A4@VXY6/5F'&$^6=G
MYZ+[2XLU)<XH-0L01@)8HI/5<Q1*V?F!1X7'6?LL,V6=/\"V]P-E:C*+^;XQ
M)2QB!9X%'0NWPL?;6_R`[E2A*0?'F<<)N`WKL[1-RKEKK)(D^#!V\<JQ/]5^
MHU9'3Z)*!JG8:E9)132LW[P;>?C[<!*A^IVK/ABN@X#R:C(H9/=B.*L\LK!U
M.28=!LSA.*GN#<]EL.!=72<G4P(NR54!^,+4D%N9XEC,!9OF71WE4W#'=ZWO
M9&<+F@+H<<1^)NQB8(\('8&4$Z;ART5V-+AK%A5Q/3GNN*P$P`+HC$I#_IV8
MRW4K)E`.D!)@SW&S4I-:S!%#7T28QE)P(:*O(W>NFFJ(*:AVB<KJ4B^5A1A=
MCGPD'JE7*C-,97>PU8LEJCC>R`D:<^SUE&FL2B8`Y]RY?G(GBW](;7@)0A6'
MFPB\E,+*L^#*/HDL)9C&7)-,LB1"2*HPYLC%61$L_A+#[]Z42K?=XE&%YY*:
M<CP3H--)[5R-C,<)AR;SA=MT,C'IQ$NPY_)D5((`ET^BY7O!!!"`G=>QWM:U
MT`5%R-^&:5G*'Z?N@F-^1B"P8+`;W=G*P>[B6J($??1G>O]I59F[$IR.^E6@
M;P9C(E5-K6JBTAW.B*;4:#<`!I2I+`MV)G&&"R949\7?<QPZ#<>IY.TQIJ\H
M"S6K"<9^,"W)$]2<J-+6#S!&T5GMLR%Y"S(@=V;KVSFY"S5Y&$=W>&+C2::^
M(TJ3^TWF_B#-=1P)]7JJC8`'`.W#-WPOARO-<8]NN6@^-,7"):\"=QO"-&L%
M$IFY,B>*M9.[S-&F3BRV>^7`"^S<S6<8H"DI7NK.JI[AP"K/3`VNX=!.,NO2
M]Y?\$7Q#*5?AD+^68OB/@/22JX1TU!4E@!)/PV6\2YHS&DG`9C688]Y79REA
M9!)ISAOS7\H;0_'9LXZ7Z1;TP*'E'BO*_E1")6M3GW-Y`<?&N2S1@D]*97*@
MMX=V+P^9JQ]4EE!ZEGR:-\PW:BY].:'Z`[%*'2CC9F6,UW@Y]6KSG=\3&7XE
M=Y/;6.\!@N1R]2$,LSSO#0?VH._8UG/'L?OM(6VJY[VN/>QTMKP<K6_>V+F\
M7G_O]>=JL4EDTD,LL'88(>8M7F4/N9GG.^D:/U^17D#-)$,-Y6M_9:C:@U_>
MVCJ,P`::%.6>OL*2/<KU=V2Y;)6FSW=E5?005A"YY"*7LX?1M1O(ZLDQS?WF
MZV?TPZDK"WR'%AM#TIT\]2(K<AZ68F6EEJ*-&0"8U%H-X5T^-B+;6[M4O@>]
M.QCP]7D1K@_6-'X:B4!,/>51QTQ5CF^LNU"1U;R$O4\FY"*7*#S2\F.2JPQ;
MCDXI*AS;Z7?MYJ#%,J)E]YH]N]/LZ@`\R0BV8<OE1.[F5T%"(-;7(`>O."@*
MY!#%]NX\JZNKGDDB53(X3M()D>-SGD`E4^B&4'=L9/O:X%"-QU-XWF<70@XS
M%(I)W.\@;\%PX%C)\DBN2O/-75KSW3A&]\"$\[W+-\,JF/@679.P\V"B=J\L
M^1L6\50<([B8A7AC`A26Z;34!E#>FO=O+_&JPMR+8^D>0R\`<EX1J?E?Z'K#
MV./J]V/J-4[7+EP\0PN7'-A(D=9:$HY#7RIJ,$)Q9J#41\)W#L4/QUHNZYK=
M.BHL*;E&^:%TG!<T/3?75#Y6OJ5I&A'_4`IV+F$F/ZO$3!:[]!:",G,I+R/T
MPVMFQ#1!<['(5HP-K/,N8X)4;'XJ""<YL8/,Y4;ZX@B/X0.0\=A=<#)-B(`3
MI7@)Q+&Q*.=JC2E$+P'!N3.J+_Q2@QI-1ULZD.@CN=#E-B!N#*/O&@M%]HFE
M8XKN^EQSY!2#+1Q+X>"'E/-KY?NJS,UM:;XNJDW[)6-@#GNU(`A1X.<*?EY'
M0DPNT(7'W"&BN79+8/]K+9/4$.C8E/*5J@>@R,G5Y)BHVN=*6P/A'8DI((PK
M"B^+9D3<=8B7GU2Q87V4904!1G03:A/!K?('-)KPFO<(4[=T3IY%K2SD<SPU
MQ2WH*1E69T@`IS-UC2A+'F3(Z<J8.Q$R*D:F?U:!F01\5BUY15A+K.DG-#WT
MXC6X6G)$Z.#!<TY79*?S.M0V7JYYB,Z$H&L<N'6!0-<%BN%U9K7Y0)0C6Y!'
M@PH](_ART.Q^JQ(?N-I8,1M=;Y''#ON642@D86[N'+/GWE7\(5TKJU?BU>T/
M8@,LUHO)'T(!P6G0/!@6G,:[V-^#\/9<;D%KI?N=&Z&<CZTOP*IT1[/2-WOR
M2*'2U5Q0B`)CC!A@+=G8`;?^NR]7MI2YI9=46KU\48T2[&K7LKW<CT9MN33)
M\DME`B"UOYU22@X`H&Z(OF)/H1N#/L$/^VDB!3</Q!==QO12X0K.K<`@'(AN
M&>VP@I143W7M..8FB?,Y[7V\=XLW'.1=@>?-1K/I(&)D6%,AYPV_<,4OA'!V
M@S9'YV_.-):W:/)`2L`?`*:**TI'LIZ],/G"3SDU4Q_W_AW/B6(A6^_:04I6
M<)5*TV;;<56I?OPM:YB1W;E@IS45\J'C,]<N1U>\HABQ5$(8>ZL<JTOILUTF
MJ[;<4J>,[-#"LJ<7&NQ)JN4_IEU0EAP[GU4J[-EY*-"(8=?[2&"W0]F_*Y:5
M9E9I+Q61,38KR'3R);1+U6BBZJ`5*:OWA"9"1E6,<NJ#.K])9Z$_H4QDLL0Y
M'9OX"&,?2&9-99VD+:^.RR75\"+!9B5B:>A?GXUQ#9&N&#NBQE@7>('"7<3B
ME:4^K98CW61%2VT+*^O%<FW9AS5$Q!JK-'II-55>WT-;&2HLE]5LE<C5=7&=
M1;*C:996A>;LP@5:.<ZS=4N4M%/P4$$"A,JB&,/6L%V2),Z[6)90H4K$&O+N
MAKSM?5(7O65GO/;V&:^]]>A]C/FCV+PRF%S(S-GH>O2BU>S8K?;`;G6[+W>U
MUU5_6ZS9G<>.+Z9`%D4K_`L.S0=02FJMK%)6\H2$HO/@EKCK.6&I/GGI4G<O
MX'1Q^*7Y*-EPZPF=GMT?MNQ.IWIG'69]AFAKB-:U>^V6W>\LBX1#K\\0;0W1
MVG:_W;8[@\%AB;:+8^.OF9>(I]`+B^=#X2Q__*'QE_0Z'%Z'*%IME3K"/IA\
M&Q@>S/C#5M\>.KWM$+^/U1N*/PG%0:$<@J@;#@W%SX3B+=NI%\7K;!TMHZ+5
MZ*Z><-U&9V>LN<GL^]X#-*TU"=.1+PZX#:K!>-A.:#?M?JMIM[N;[P1)@$-(
M/T/[7=*^-01-IV>W.HZA_=G1ODNT'P[Z]:']\AFXMXYP-0EGZMR//[C)^CN5
M$71N^1Z?T^C^2RL4L>5$"\H#XQMDI45*9>T3SMST8*`%7I7)E4FD*_JZZ7;Q
M/AA2XA*;F(Q=RJ7X[?+R"^?/\I3NTC7JN*)HNTXG22F/BA+X\HWCLOPOS#)0
MG4)4X4K.$.#L*!GSS[51<JGY#N>_Y'H!V>JJ>I9^KLHQR%J/A2P6S"L''%&+
MD]+>0IP`>$,M@KBBB@8ZER<K<X0Q@2V7N:H''Q-@E$8#_[P.LWZ$.#IFF11'
MQD>Y8@#EV2W=#@ZSJ]HRD3*.T[ETM.>2E3%#P!-<X89;#G&A/I'KK56H16RK
MPNZISSCFI"!,WLO5PL9P_9SS13.*N:,P3612"+>\(D@H1R='KI7.5+I$*9<Y
M<"=8S,-=(%MC4S"J@T-KY*)SE->7I)Q72U!B8B=7M[.IC`!M1.!IQ*/.)==5
M[%7J2BQRR&9LJ!)Y21Z=%M_<GIQ5MYD#G0!?Q9B+7GS@FK.7F03[$H5!B,UA
M./?[S(X&'/F>DCH?`NLRO4YE;RB^UX6;\?WEU6M5PS>'SRM,),-:7-8?"SQM
M2,A?7OUA6Y_"!EWWN,`ZI5\X$<=5:4#OM8R_TC+^XK>0K[EBZQX^$UY<I:,D
M7'AC&*E[T6F^?$6%FC.A^X=J\\,)X20Z0#*^@[^3N_\O5_;Z4I89Q5QODJ78
M/`2+"A<F;2#H#+73E=<DY+F3OP4>9F+\=B;4I0!9KS#;Y%SXZB8[AR+7BT6^
M*3>II(F$FUA!W2/4)>I75N)F*QD75L*'P9A7HBK@X"5KO)&3M?(I/U\1<DG=
M%U@!_<;U?-V8F*6^_)EROK.LZI>X2FKJ$8>VKNS(Z\54Y0)*J5F>+HE,I=:#
M`&6P2M@2@3X#&6"=VN)TZ?903UX>0)$\UZ^I<C_%P48"]@-=]Z@8JV&]<[&@
MA3N174-DY]H%EKU-2'7*0*2NDCQMI`H^Z*FHQ$"6HEVE<*G;^C=XY&(E#<J8
M([S*0@$T/S[%97DX;5^!)RO-Y!$*I)'UA=0QE6MX&&ZD":HK!IDZL_?CJ6RV
M$Q;#(&-_!V5C2;C*;IWJTB"7`>1KNV7R]G6(=0I??(!77VK!7!2\0UMW]R)U
MY8V\^BAK3+S1Y;)>?",AVVOV7K)R'LMI<H)'WBVD&O#2"N`ROJAVZ3:T=#-E
MM1X:WT4&=H[<()Y2A4<`R,.<:+YL0BT\U167,%]^EE1=5KLRE516AE?9Y=S\
MC4\7>#O;B0HLWDWZSB,*59\M%O%#]O'DW%&472L047>2"8E7$'+ZDJ4;T.T:
M7'$@6$_'K&1J`:E[%7(YY>_RZTQ5I/LSK"\J@6!=IQ[97>JZ5OZJ$547`0:2
M4D?U)6'3:>3312I9S5GBA$AMJRE5EK?L]@BB1+4B6L5?=L&6JV<AT=RQ[JO$
MM@.GZV;]^4H?Q*,26Y)D949R+55R8.=.B>9P]918I/#H."N10@0D2T@>_TIL
M7L#3%WAK#GA-/<0WC63W0MW;15ZFY598=ME9=._QD;_=*(\&=7SD3R5B6)5<
MOW+@\)&@#QSF"+:29=V<K(:;U#H4*;&K.;<KS2-/F=.;RG[K@'+_X$XCV-?_
M2/T[>1UY1<]EM+8O'(=W?;Z;K!*:?5)+EQ5<V-Q_!+EV/O"*]5JR'&M0`'=B
M?=9%;SYB,OP;M'B!%;$)%QBAUI6L[XUOXP.R'!<V!L*O9,':_%O6.ZJ,9[UP
MN?UT$*>ZHA\M[1U(U6N<D&RC&,:)OUOO0["(7RK=7:U9WG,&3IGH6X[PLS(,
M\!'=$4^)+MVCJ*2%]6(51VD>1]29NH@C*I&I<407!L9Y'+&FJ.N@XPCX$*W$
MY2;<NJAOAB.N'@@R9PT`\8PN-HQ$=HE@75=!!B2F\FY8.4E*4K>DS3/+FGN7
M9FV[++X70362E;#[@9XYKFJ@[Q".W5BVYUN'_RV7;\F^P=(XR=H&K'"/4D^(
M>V3]*FED`4IN47<`>4=7DW)RJ9P3]3C4';QP8DSA9:D]44$">YW=P,>^?.X^
ML=^N`J:P,&]"*]->UIQ^KL3VAOKYF;B*0!)K3&,/V7)I+''L:(G\FHMP6U<S
M`?M)BN264_04*,_`Y^D4BX$C;2\S)^+'O,LWDX`.2<#<'Z!0S+C@MSR1\QS*
M1*99\L77<KWAJ#Y!Y-VXLAU0]I/V7,K6=B&!J21I)C]!9&9CZV*8J*<6KR)C
MB4TL^S86W-'2C9&/`[GR?*<6?%?*&+KSSL57O"C7D9-\M]K'P7V`JP$D$%:!
M;+!'AI2QBI:JU(L:92(5;HY0'.9KU\F;7;&H<O]2PP?R1;,-/77'^!-5VD1=
M/5)^$]6UI%2,Y>,@L#-Q?GR'I"HJ933M^C<9*_H.*YV^!9,NY_S2E2,SNZ[(
M<E7^DE4/1":VF"=(>!$4_W#AE>C.<O*]T>^7A$5`\@+-JA1FI>PI_6@Z%)#5
M93@3T;;?V;)ZDSIH0[[)E?NQQ<!&YC7:O@(>M6^G,I4D)R+E?F?!#4<J2$4$
MZ`ZVMV9G.Q]85/Z&.`M)DHV4:1U*YIY[M\*O0A7`D?V;:A##.%3#0JGF%LK.
MZ<!NH7R)KAFDSD@IW-G7Q)Q%;O*\C5+:+^AO/Z?QQ;7K+EY=9>'GS$'W!9MS
MP'GT#6!^[8?C[W__S__`7)F_J;?>N/'L,IC@O["'+UCTN(/HM3O]$KEOX(^O
M8OKKL_=1.&?CWH'_)2&[?EL7;>?9WQ^/W(IJAYO'D"A_A2L:O()=#@>V7^18
M7.H2DSYMM<2G6](^:SX^V2IDA7%=K)V*R+G+>JN7I.Q09.U4Q</1)8EFI6!?
M]51,9!8(O$.MCJE-`1[SSUO=IMUL-NF&?^G8;"7"><6A$7$C\N7+^41!L[=8
MQ$LFB:3!1.H/1TJ&+4J)9C)G(^FQ+'(^!!B##*.[PTF9G9:25>L!,5M9U>>H
M2LD>!\!YM+-*+P]+"Y[^3F739>L]`"%(DTAULBI4+:?"ECGO<^3>:D54UUBC
M1NJ8\#-1#3W\\)8+Y'#!YDB*,&P`D6NW*^OI7-!#LL>N[/<@2WEFS55TV9OR
MEB!+5>^XBS"[\N3J.;+UPN7>/6DL:[&5=&)]*:U>S*OCLH7:*RCKB6$\)=)%
MJFD<3^U:6W9$(9\=2F'E:TQF68Z8'E#!5>@FW[#NE2Q50F)9F,CEY5973ZEB
M&@Z;AL.FX;!I.&P:#IN&PZ;A<`VZ)9F&PZ;AL&DX;!H.FX;#^Y2ZIN'P3F]'
MF(;#)ZVUF(;#IN&P:3A\/)O5-!PV#8=/EK]7E3G3<-@T'#8-A_?1<#B+B]T;
M[UH.D*GF*%]$1*U1:AP>,UUR3)<<TR5'F"XYIDN.Z9)CNN2L79'IDF.ZY!CR
MUK1;BNF2<YYK-UUR3)<<TR7'$,UTR3E.HIDN.??KA:9+S@EVT#!=<LZ-XJ9+
MSKE1W'3),5URMML#)]HMPW3).5_:FRXY9TQ[TR5GJW!FEG1R3P[)<LH)@)2K
M0%/H<,!OUC@'Q?1J,+T:3*\&TZO!]&HPO1KJ*(9-KP;3J\'T:C"]&DROAD-G
M8II>#:97@^G58'HUF%X--=")3:\&TZO!]&HPO1I.3;3M=[9SZ]6013BV#5DL
MASP^(_2YTR`[0/8?Y=",,RI$-CY]_O;.&EB2D[O`!I^__=>[K]:;/[Y^???I
MF_7QP^7K#Q\_?/OP[FHIMC%Z*D[<JR7'E4:)RQ1#Y`^!W#U(TE15Z9M7^UAX
MQ11/>]]L^'3WS;:[9/2(Q+`'7`KI/^)2"$VWPXM;=<;38R[//.@BU(%@7+Y6
M\11I:1M<Q.D-2G+*^;K@>!RA$3/VO0"GMQ)2GZA4^WV)ZIV?=IG"3V,]OV_.
M\FQ\3D*T^\V>W7W8K8BM;SK4:NF]7M?N#YY@X3N[+;#-#8`"8R[<NP@.%U#6
MPB"-E=<\G,]!B4,]OIQ3MR7.0]FAG!P#S(!N=C=Z:Y/9#KN:8<>QVVNN7NZ?
MH[:1@&N9Z\;E.NVUY*).IV5WVLT3X:)6MV</6[M:S>'EDB^N7:[XFS,794'F
MNJ&^W[,[_9-AI%;'[G;KQ$B/%D?XR'(;K8WM)K8Z7<F6JB0X#AFG9/:]<%[2
M2N6?]+G0':<^M'4&77O8.Y6#T^GW[6&S3ISZ0)%7J)"IJS9CF`&LA5&:8%Q+
MB+J=G_"*W6WN2F\Y]&K:8-NT=[::6H@]=91&5#S6JQT#]5MVWSF58[/;LITU
M=\^/4Q9Q)6!=/1XK;-<,[<.FW>E4WWP^+AYR\'93^S1ED`"%J%[8'H+9W=O5
MCCWT8E1DR-GLQ5J+(,DR,N)(@<AUWM)'>:,?>(W\R:Z&;TK,C:Y[[R7F4$L,
M#KA?]%.B[]#B=?E".YJS]/ZWS]\N/]X3'][X_N0^+J7>XYY_R/U25NGM0:=I
M]]J/OBK^J"O`QXW!7M,!O?:),7C8B[3_L_P?`N%$LX1PY'*_E44Y\8&P6LWF
M0';`&?N4VJ9NBBU<#WN`8(X@76+TJ)4N=29ZWFQTFKG2PF75JC%%T<?\H5R%
M86HY@]7/J:C^E"%PFK:$@K(0,7OY.09)ND.94X9M5^C2!``(&*!ZTBKYN3"\
MFW""83[L3S<FR*2AK-X]X[^P!T8EVV(I82=+<]H@3:DTL^D-)\SDWOR&V^M`
MN4TFB<<D\9@DGHWP9))X3!*/2>(Q23PFB:?^_C>3Q&.2>$P2CTGBJ<MJ3!*/
M2>(Y"DXU23R'1;])XJFWV#-)/":)YW&RR"3QF"0>D\1S#*QCDGA.*`7%)/&8
M)!Z3Q&.2>&J`09/$8Y)X3!)/?9)X[LO(64[C>2M&R2&+$JWG1+W6K%+1,%^I
M"+^YLKY<_O/R]<=WA),]5"?:!.2,9&N)MR^@""M8G94L=V3M+^Z=*@#X>^HG
M5'K[<G*CZS]_%3>A?T-]#+@LZ*<P$4L8/ODJ:Y]!XLE*=VU=ZNZ6BGT+KNA'
M]5A5#6F"Q@^QMKBJ?,AE_K[X+M50G&"-R!!D8X)P?/SXAHI#TJ^R7/0*,:Q2
M0M![F,FV_"N!@$]P1='2EZG,]BV*1RI>/HG<6SCF;P-KFE*K!"M=<)W9YPXI
MR?A_P-8/;Y[.5:%V#+U1U6_;HEKM5+A-E@`4LM$'%><&_NK]1'(?RPS.&Q(7
MMUC<%?/?X#.5,G=YN3%7/.?:\@G0"_^F?W,5Z[(URT4E=*!@'4@`@"MY\M&@
MA[X5?/!@05TU1.`FV/<#:4,_*Z!&6.1R`HC&&HS>Q)9%UR=B%;0&UV*$63%9
M@JO7X5@$PB3EP>$7&EH6PTO@J9DU<>^R7$3Z7IZ65.`<+`2!%>RL?P$'8KE-
M76\7Z^(I5#,JI4F,,Z4!`XPY&H+L8P($)KX$XOGR\%1%&W'2C*8C6?HT3!,J
MGT?<L![Q-J#AFHMY$J_C":[`T3`J!8&+^3'GQ!HG]\[@86'G.YN66H+0]V(4
MT29M=?CP+F=^O3=HG!B+`K-FD.N>@H7480%2.W&I+FC#`CE`%,$N,WJN+H'Q
MNQO!#XA-QNGSEMPP!"ML+10&+I9FU24\2Q=)D_!@K;RH8?8#]0;T[.:@:TL.
MD.7T)RNHUE2->)E!6$94@N/>'44*U[)FU*8)5E"NVS&('PNLP]H`46>A[B\+
ME!8;`DQE"<\U-(>U7V//7R[I*B4H+(D:`5.5UQ20A86G'3"-&>>D6L:ENJ5+
M37S$#Q&-L6$.M1)@E@3=M-UHY773%U=",`J<YDM34/0D9GMP>%^K3Z_#*")!
MG=L\KU7WB(]XZE_J4Y\T+.I&$H>P24ITIT("P'EU1Y!2C@IR_^DE[N^8-K&E
M1O7>BT"B_A%X*!]>N\%WJ3X];TOQ.\+O?!@$I8&L;)]U5(*]'I-8N@8AAD)&
MY36Z\8QSZ0$<^%D?XZJ\-.@O&[[J>W-/"B_0HQ@H.D1(S9`EJNGX^1J">$VP
MA+/W;X_5Q'^$,\"3YP/^$,OA=`KB*HJ5P)+2;4&'(CZ/HPA<V'MJ/6A]E)-_
M`<4A@!=GWL+F&M[8^HL[N0"H//_O7C*>"3CU_F\$!Q[.Y_HQE?R6\UK%*;-*
M_&5(7CW[N>.4T@;;C68KIQ#"&#%7N':YJ1@^TFNB:L1X56=^J!B'CZ$60_$7
M5OB_#A./U$\7>Y-=T##`?B*@!-55?D&]K1QZ=;SBI'!6C-.$89,S#^74,)`\
M.@D(/1<FR4HA$>-'4<""JW'0:K2[/V4Z9\GRVJ0/?`IO9)\`UB]:7,$^KYW)
MPUT?9:WAT&ZU6/V0NH.'FCUF\/*$W&9`L.JW1#S`C&R#Q.I_Y5ZB]D68>!=Q
MBPY$LC[1U03+N"5=<V7[;+Q[\GN&%8=5CB<8<EQO:5\08&'ANV-!)/9%!3#5
M8@!'`G)P_[;?HT9AO^+?:KLR8W[(JZ5*F6/N@#'TFLB86!5FF6JF<%E*@\]*
MIV]U"RKC!=*=P*")^FVM-P)+Z-X;1=5?5W`7I*JZB=YYFP.#'<BT\JIVQYJ7
ME+*H-SIW[@C$+2F0Q%[`Y/Y=)>_@2V/D0%],,H-FB7YL"]*&0!,WDP#WR<R&
M]3:-E&E&%>PM7DNY4LP[%"C`*CN@G;Y^WK?;O9XMSQ'5!0$7!8C0*)>)@XI0
MU#Q1*?G`N\O//:RJ^ADILT67%WJ.I2>G:+X`R5AF%+6ULVOC^B&H1A#Q-!?>
M)RC0H9.A*T!TJ9+Z[C7H:=?4E6W)441!@"&+/9OD2N$XUR<OBEHTR-&/PQ7_
M`Q`6I"20#XUEROII\"823416*+9426,<8"3\\!9!+;A"KT22^+H=2F'ES`NV
M;!.2+9J`X(43P/-PXDT]UA663>,6O!V%Z35W#_1R'*E<$,O(/+N6:>4NZC5T
M,5N6O=,KO(9;E::5#8Z664NV0"KE<5+YO8"B=JFZ6Z%L!IOC9#K>QOMT*5('
M1@)-/E:VB90*%9NTW1W8*M1&?_9M![V3Q4.2F_>P)TBZ?^*"_X>L0R4/9+^@
MH79<K_$)P0C(;HE2!^"$G<?L(";OSQ<UPV76R(C/UA6\4V=%;%("0+.07((*
M%ZA`@K^P+5GF;@^#@ERH()',LO3=`B;PRYB"?JBEC>ZT%IZCBPI]KG*#(F:^
M@[!DG16)7B9@0:=.XTS5RYY=M@+IK:[MM#K6"]3,,OKB)'(+=?JPJ3W0KWD_
MRR\'O[S,65SES.O&>5VSJ&PC)3)'Y/.VIL.$E3LZAVS6I&WIU+V3-N:9">*_
MQ.9;39F<7;LWZ-KMPE8K;#/N>Y7S_DH6YT-S7/@N1WYI%&P(1=MN.QWDRO50
M!(+[*))38/D\KN`N;J,M4#J0)4G&$;DTJ`&5\@C>MQP*.N3ZM'LK!K1U>?7&
MZO2;%]VF7>0`#XGS>VX"QLZ['SA[ZL4S;AB)O$*/HMY#0%%3QA5DRY`1;F?5
MD#QF]WA^/"EOL*G<..&M(I<U$:,LT)!C`$TM+4+D<7`?]>DTD9;-Q'H1@V7W
ME_3T7Z*@0*>5W*U$%\`=)0,X38*>^B`#A5S/CV6WZ:GK\5F$_6U%%3U4[V1.
M$'']<>IGO7"EI6P51IBF%"\D"W,*VB2KEQ*3Y.2!;?9=),K7(ZT^3(V7&?/<
M.,YG+!:;]E'8$81KU^G;_8YC9QQ&W,)OJ/E8I`[!N!RT):ETVTV7FW^&RR15
MNX4&HO>;0+B^/>AUJCP$B,@B"DKH38U')6]XTRE0$WE:M<5CDSR*R$;-M=VN
MV//P'4R9F]?5[68G\C!=%1_&&EZ;Q4!94\-,1[1B4JXG1>6I2!LX*9UF2VDL
M14]1V?E>I;:L=D0762`.%<H2&4\P#&RGT[4[@]X:)6XC"R^7["(SV`JFG702
MYMRIM#=:=F_HV(-./\^L90M$29*W``O8KK3^\.\E:*P7Z'(34SIF:"DO61BB
ML",H2@7>N6DI]V8T96C]4C39ZV(GUDD2R+-ZU1F1.3ETNM'J[F'+*6=KK)$"
M9:9@++=:NP/&7VO`MB#^"<H<@KF]C4:AB3)5KW3KWP^YU*.DA25/Q5*)0<I6
MA3NL:/CF%^MDBY5'<)S.>5;M`+Y'^"H1LT1<&>]19NFRH8QX+C=)%;T)"!KT
MO?J!LY\V0APK8F6VOTJF*:4*6928X909;6S;R80X2L+B+#%*<Z&NM"M92!51
M2-7K5J>F94E%V.T70/'3^0(IH'*Y\BX]@B-+,KJ4642HG:)4QK,I'&$0B%7T
M+'"RLLC5)$(]DEO((EC`(7V-M--928P,RDR"5<.IZJ$R*<,W\D\TB(&8$2%D
M(N)QY(V$3`OR`C)H*,:[C5_%ZB_Y5):BT?>:6GE&NC?=R1X,@#N=826;\-Y0
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M#T$QNK/F:4(Q*:T<`62L[JJAL^MI^2P,MCD*TUDSX7/B6]3(:*&6J+.EM()A
M/1\,!O)X7U$;&@5\J)!%[Y=X95;.*4N$2D!9W?.?LXV="^?Q.BIF*3L.2I>`
M3L5AF=YS;N+C31C<@-TB/='_2'TR61P8BNW?NK@(]I[]H3"1)>5*V9#<AFP#
MBP`=M559"]I)4,"DS<;>JH+2E4*"#%JT12KL(1E85-N>;2K6712<2S:2AU%1
MLH]PFS&XG#>I;3,V30N`RNL_L&1Y7Q3L2XS,ZGCJ7$37RKS4&"H<Q0[GXB[G
M?>:S7_-WH>Q"]B<!&'":&?[N(9<JFY,,MW"J3'H,0!`;)V3[$<;6WWT@TW3!
M2P?CCW.0,:"5R"S+&/`23^^6\!1GN>[^G8J+%-$&F)H('Z'%W]D%DM(9@QZ1
M:J!4M(6134D'<@*UXN`BG^BZ>DE)IH%>T9V-+WBA`PXJX$$P8!=A++1K8HD?
MB_'FW-M9O!EH[4H_."7)AK>\'`X[Q`FY5(`9Z18)HE>'T4,*?G!"8QS",;,&
M`R\PVS$3T>CR*#Q-\Q<-:]Z0E#"P[$5GZE($Y6?,<U<6/7S6SX\+L@\GS+.1
MW'&>B%_F_3]3H.T%WE1SX4GW&D;QPY@\7]Y$8L";PY[!%&P0(0O$C2*E#MAD
M,],QM^J%C%!,*!]5=L:K^"$"N9+[G$F3$C+K.%:1>;;QG\GH'69N=#MVK].7
MLFE)WVG9_7[7[CC=>_;@\V:C/<BN&4D=GT-\+$M<:R0",?4P3I5;.1%L*OBF
M(LK.GMUW>G:WV;$HJ16#R#P`WZ^#M89SUH^WSQ9E49_%R&A+J?S7BO37EG0S
M,APK^F"[;;<8UDVR6'7(V,3N2JP>6YL\2-ZB,B-/)9,<IS0:M@96-9JU,0[U
MK/8S;I+8VE7YIA6QAZ5!\Y1:ZX/%:T=)=MF7K%@U%B?I4^8$/'6#MX43JT0^
M]9PVR(M!J70B"%A"T07.%5BKU"*K0B5BS:HXQ)J;,!WIT-+7@0J78J3R!(+'
M]_@$?N&]I*]B[P><Q'B'.J<J+6<)>'E/P0L/7N5T&+R[#<(H3P0=(Y'VXEB(
MB0PS+>FY+^!TS#+D$->:"_`\]_$V(%`FR"7\:=;2SN\_)`99ULGS5$529%J@
M5]#)*<0<"3+L[G(N?7<4WI#%MY%=8Z,R+R>BN8N$VHS7]0UG4B+S3F[K]:JA
MOA1A?_"L[?RLF6_R0U$#MTF'EI@LFV:3]/%N=H-[Y0*5;94X(VR=8?G(F9W\
M(J7:HTRB5J]G#UJM[90,Z>:5/+XNLV=E,+G'RS2XHJO%+2Q7>U=DJGX:N-.I
MYWNR/H3.+E[%;LY;T;+AQ"CU5I!XR:*O2W(U[]G!R;6?2EZ2?/T>8+^!<>@$
M?8>#`AUBJL:13!KZ=CV@]S9@>?<Z\N#]UR(*O/%W7.S$`V&!)9<ETI:3G8NI
MB>O(;!>9>2NGD+SDM:(3%Q"BG%8K^.W:[8Y3!V_0N>@B69P`.;$HL?+GD#Q9
M\F99N7;R)O=$E::2%VGM#FZIXNF<&R/G)U_KO^CDK^X6SFIM$[!)X"Q=8!W8
MF<^YX.G!`E32TM4'F,[EB#,-:BG?8`T>\BDCVC#/A.E2%HJL3%*5T%8Y#T/O
MH-UG.^UU*6J/$LND[%0/72VDSRVZL8F9:N?M5";[LJW:PVR<34W5HT@QS0K$
M5=1Z6RX)]Y6OF.`]V+MO8)+$+ADS94TAZULFSFGEZ\1]???Q\MN[M]:7RZ^Z
MQ*FI%%?I;*!J)K_Q)>N[);C.RX>P\UHE2V5*=E*AQ-+52=CUL_,*);D0L%V(
M1')`(G^-GB`HO4I_)?.8KZPAO>4TK8RPRTG-C7MH?E)J:8DLJ(,$D%7X+I7Y
M%I^U)*CV)JX8_,KLVMQOF"]DZ^0*R%$(":6,IL&R\4USJ%^7<[3669;6"_24
MY`SF8E*'<H+@3L4'\]^IEPK6M"IH6;2@5?K&BA4]%RI&2.F4H1M1X4-E7,=+
MUG69'8QOQJ7NRKQ?(9=(?9_I>R@??]WS@3(GN75?/A!^L38GZ(5B(CQI7O(!
M&48>P(H%HV4R8BX3MU#M:5WVD.;U!R0+W9,DI)9+,*SU6PT&@W*OU2Z3A`B,
MU;W@E8^VE#IH$H*6CSIU@R3F*FJ<DH":BW?.)][;[+8MWQ?$DP@%,O#8)!US
MF.HM<#5)=@)F&Q]I+II@]]KRK@KP9*O?PF\Y'(.W9&-=\8!R8*A`F:SH54@%
M8!_2BL7?@&,A`YG3#.692L`SR+F[Q34I_'Z`?;#L=/N"N/F!#L/(78@T\<9\
MQ)_;3BB46=&Y(6_"$+UY;QK2=PFB/4#?(TA0['G`X7D?1D<7$CGPV(&)W%V%
M6:X&3C_RM22!93)D?I:(;L@'A=M)J4LTMU:9X)Q:+DU-6W?FWBS?-BHGM=R<
M01C-J6)O&G%JD;)P&]8EMF=(I>,R-XI+1NB-AX7;4(QZ<'XM\!`+DDJ5SB)+
MF#J))UC*C:H$Q(F,A&XR`N-^PQ)MG7S5:RW6Z#+90I\`*)!`&7_.>N_S3K/#
MVGFQ(@V:1<K2!KP!6I)-IDNX*#/%T^7=1U1X)/(QUKP`2?6#"A+X=S![CR?7
M'Y2O^GF[.>!;>YD$+,)X=M[?+/E?EI0IPS1=&N2<-MPH$O&HKG(SZ:E`+O;F
M(V1\TAOI["'N0D\/]M/@O$@`*<&*[/E0`_X^)D\QE^19+/S\9;["R4=`T.G7
M&=K#@4-`Y&]%KN7DW!%U<,0?_-CZ2Q="BF-XBJ5E7HT[;P=F(4Y?6CV=#3-.
M^ZL.-%')&(5AC.[#,1%<Y$+[8(!$6)4?$*[N:L=9M9<W,]>#4R508Z\:_(T-
MW6!9.&.+.,5RB.,*<TU37WR>OJ=Z+K^#@3=/YU]AH[J^3+"+WX?1YP55K0FN
M/V(%PJ56.C4(?ER6ENB'LT>6J9GSNJB[IDSMU"TJ.).>$L.IS#/>F$7A1>E>
MLBU%_*J^<H5Z@%ECX?NRQ]BOSYK/Z.]XX8[5WS3TK\_&I/\\6VIX1L[P12Q>
M6>K3+Z`039+9*VO0_.D7:[M"\1JP>QK]E3;Q`P``;("TK8',HX;A_\5:W^V0
M1OXG'1WOV"[*LP8A<N?M'3<"O":=$C6LK5)8=2,ZV$/=2FP=I.]K=>^^BL9\
M?;"E.[OJG?VTO5ZWH,JI-')N#UIVN]^O$7EVO7]VM;:#4VJ(74*/HV_[%N0Y
ME;;6[6;+[M>*/+O>2-6M54TWYY)^V`]:_B%:.S]^&^/C#VYK]"T$@T#;!ZSZ
M*].`EEAH4'3\@F++%X]05CR*'3Z!,<]]-'PRJ^)T=,%,P9<)GX8ESD(B[4`.
MU4SZ9)WE5QN9?Q+).JFR"=>L&WYO3=97@;JW2?JVAMJF0SIVI]NT6TY[NR77
MZU"K1*OTMS@_/51,ZR%ZO9\>+P@?)N@V7H9",GU43>PSE^9._)(KSDY=5^?=
M#;Y?)P<FCER6O=W+9V]?_?'ZZMU___'NTS?KW9_P3Y._?6^D.@-&MOOMZLX@
MQ4APP'[@6RS\@'D4V95&>9_B37@K@GP'#(H8\[=\!5VF=E``VXWE=4]YI\7%
M>&3^PFDL;BCY6,\JHGAIKC\*/Q5"<#EH$WAR`3+2&W/1#1DW=MIV=P#2LM-;
MBFC@^"MA#=F]>GD<KFJ!\;E.H]G-EVS(VE#H0K0:<)HPCZA<!]O2Q<',[2:5
MUN#B'86XC&S"O5)KHMGNP_][R]51R[L>J'1,.;YL:T@U0W*W=O%.&%9PU_>>
M\SVX9R+#BTXL78I4=X<-!TY]WZ<>B%20U9H(S+G1#:05@ZGJ]3(E':/_<:P;
M&G#]BJPJOYY97L*)50B#E%2ZC<[@ZP<Q\B,*?9AR6Z'/6^'LHN/Y%!9Y$Z];
M4H,V=W.!`(+O9$QH@BI=G$1J.U.\",,L=/7\=3AVK:]N@L1_#WJ`-W&+M_"X
M`XL()J`4PI^X"\4/F>O1:\N+_($V0;BOMSKB^%X%P9&U-.<RZ[YN-ZB*G7B1
M_#&[<-EF`3B0]58T(+?`K]AO00#K4-H$_`&(I&O%LE,Z8TKG7=`;W+(PNY>H
MDU<91!0+%?,?C.OTO#E%HTHGJ(Z47N6:/;VCLA28<:W"[Y^CKZC3'D"YT.<Q
M=3ZY2N=S60H"V4QU$7%5%Y%\#R4OF&*J4Z$C.8;*+Q"\)?QY3W6<[S3:N7%X
MTVDNQ3<O(\_U;>N_A'\C4-D'0-T@OMA5>/.!D<'L303U8DI7C%[=A]M=QS.W
MF?N!0=M/NF3:%1_DK&BHW76N:/E+H%"!K7HI:X^]4Q7/N&+;N:,E@Y$`&D76
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M)[.@(]0.WW".]$ZDV".#'AOF)^]#]#T5##F5L^N`SMFJA*`TF;H62NANJ%QS
MS;35V3-E-F#*7:!][P)T!Y>3#`9JIA#?%T.MEFIGKQ$[+=L9MNW.L#JB4Z^%
MG)9@=QJ]ZDLGYX[XO6R`3N,P/I]C(,"3<G[?'O8=>SBL5FSJ'97<LUUD`I3K
M^0G.,5EGR^SF_>_F5J._"R7+N-1.;4$ULQ1,4-(XS^NQ,<R"ZKZ@(U0230#0
MR#"SY<V"CD[],E&_PT3]-I"')KQDPDL&`T<88'L:W?.^6-LNPADGJGPZ0`L3
M:SM@K*UO$'_0#=!><V^P7BLX+<[O#.QANV7WU]1#KW>LS=P`//SF-:X3XVDX
MIP755P4W0:Q'I#FW>UV[.WC"I"MSKVXU>[E[F*R,$Y-()[>@8U$-35C-Z(9F
MGYL%';-N:")L)L*VP<1G$5TQ&#`8J)GN>5]8;3>W)';3N>?>ICH'E-V[`2,7
M-&K;PU;?'JYIC%K1&ZANFOMN:%]K1X/3&&Q^@=V0Z>!F8[M1[1<RY*K+KFKW
M[%ZK;0_ZU1V[]TZL.AM@RRM9-<GD,UXP$=@>XL+A'A5_BAA+SF,##>G)IY84
M-=<&ZK8C*\_Q;J]E]WN;U]$P$N>`Y_C6K1@-F0YX]W9-7H\A5UUV5;MK=X=#
MN]NID=*U?(YG+3MWW?_)+[8L754';C-C/H.V"#<.H"%?[O?UT#9>:_J!8:.B
MUVXL)M@"4@2QBXVT:/C/U&XPOI1-MXKM26O0=?32BK,V8;HU6*I[.[::S2$I
M.E2=!ZG\Q7=EB\**YF&6;AP&?_E^>!N_RNAPJ'YOIH7802((M6HA)O?BN6+%
M=!![3`>QJI]-"['=D.$X6X@U30NQFK0Z<IJ@-#=MIW?@/CK'3+.]]1!;$Z0Q
M1*K9QNHWSI-8[2/:44[';O;Z=J]SX'9O-8O55^98_886OLD3K6:HKNVT'-""
M3)&^PQ3I&Y@\?)/.>ES15'/5Z<%7G1Q["!9@?_"$!8Y7+SN=V-8P"ZK[@HY%
M.327B,PE(K//S8*.6>LREX@V3D3?;7.N3L]VVIOG7SYU<ZYSO31B,&`P4#-]
M\[[@G^E]M2XGN-]NVYVG-)"-.W)-EN^:>-VY(WXO&Z#?.$1!N.,@P),ZXGOV
M`)1VQSG6>GQ[-CM,7.T^AL*25G;O(/4=CX,,3YI8WVA79P<9E]7Y+JAFIH()
MICW"`]/OVIW67LL&GMAF,`NJ^X*.4#,T0;7[Y-:3)EL9H646=`)"RW2X.N'0
M6:\YL/MKA*")G9G(D<'`\<3.3%NKFJF83M?N87>9SF$ZP!\#'9XVC-;933FH
M4T3\GL)HAO,/P?G=@3WH#VRG?0CT'XO=86)G]\;..IV6W6R:.VF'V,.=1M_$
MSHQ?YYA,!1-&>X0W9M#MV-V^B:.9G7ZZ"SH6U=`$STSPS&SL<U[0$2I9)HYV
MH#A:I]6W._W-VZ"8.)J)(AD,U#>.9II7G7[SJI[='Z)_TW13J+\GU&FLN8=H
MR%0[X[!GFEX<P:[JM.WAL&>WUQ1!/GC3BSI97:4KV6]CJKTRX$9%Q)]:GFP$
MA-.V6_V>W>F99(/#',_M:GE_[HC?RX';;507P*G7"DZ+\SM-N]]JVL.#W"[>
M1X.H[5K^E+9\>F"GII7>3Z6MH]YZ\=@/XS2J58LG''FD/J3XX=/G;^]@=-6Q
MI`LO7WW[_.;__M?GCV_??;V27W=ZOUCO_ON/#]_^23A--:7U8'MLZ:37D!&Z
M2/(#`458^1*)J8@BT+R(+Y;0=8B^5R7;85\8P0'5X+Y($M"69%.M5]9%L^$H
MR^4R4TH)*J68VM:ML&;N!&#"9"_\OQ5S&Z=P:BVAV@;3*+)NL".,];S9:#9A
M$#=-9F'D_1N>P6YD7ARGZ.^R\?7;F3>>64%8-B)!0:,"!)&@%V$,&"),DS@!
MI1K6T""$XAH/PV^;8K>2%PX'.NT($+OS,##[9)M]0L"L&'!ZGQ3(VNJ6[9H\
MUDNVS#;@+&TO@JUDBQ6`<KH]NSGLVTUGN-54V0+"-"HLHK!#T=PU6W0ST#64
M7F%;?I`4C*VW:83-S+2+(-N?WIY@JD++D\U?3<[/@?6/U+^S6L/<GJ.>9M3V
M,@F!][A9YFWD)8`W@L>]CH28PV/6K9?,K-]`383IK2MW/(NESM4>_`+\;%N6
M&U.;S4@L@-/A%=!';P1R/'ZK1P8MTPK<.4P*7T?"@[6$W)]3#LYG%TWP1^XE
MFWMT(D&78$U$8"W2D>^-83(X__`1F'5@=WM=N^TTU^R]AO4-)EY@ST`<%:'@
MD5@6!/2-'O065OB\T^CUK04(+QJU(?LQXG,`Y3Q>62^^J+%(2+_F[/C\FJW5
M]5HNJQ+-BXE[9X6DT2.,BS0:ST#KM]*%1`2Z$O%7U[<<NS7HV/UA;^V:%2NT
MFXH5UH-"@`B5:(H/>U$91#C*UL!\$@D0(!P+,8FM*5@5,(P7YY".TM%=P",_
MO+F;"/^.P'G>:34&%AA_/DP&BM(4`+4F8!J-">,%]$_`E@G3(.%6KV.8'J0M
M&D@L;I$/L_G$#[2E`-J%>T<>Q]&=E<;,*/HA-(VDE@4KN4RO8:-9'<9FXV`:
MP%[GE<(5:7XGX!06@/')JF_6ML8B2EPOD#MJ`A;I)'7]V,H8*J9CD!DJ+G#4
MH->T!\WU._BJ\NVRMY8UXPP*V-RJQZ_UPGMI]5L=VQFV]<BH@#]O=[IVO]/#
M%I=C-YX1`[WPX.EM3DNGW;-[S3ZS#X]N(]1X;B5*#A60DC-C<5I?Q#%NFALO
M)NZ_94EJ.;"CVX,J;2FO:#2L#YG@L`F2279:DIB2&DEWG0(F)9"8+_SP3J!,
M"EEFWH@XD7(87DM`P"::T&G@)7A4N`E!1),KF0B+T"R$-V`;>]<GCG\[W<JN
MWX6]T(:SL#MHK]-#B<&=@4/TE@S>6.;K#7N8UT=M/0J`[]=@VTNP[D&7W03D
M.JBUO[O`XY;#QV_[07KM/P2=[`#+QX]O'JW(9J-5*K`$!#ZK[$TZ26+7IWE`
M1^\XCMWO=1^BNUJE>JO3Z#?S>NL'%B'Z#."%/5B1+5^SY5KW*+`,1$&)[6R\
M^"5]S`H5,[18LVV3KGL).`)MM*7XHQK<317=9:5[B!>,!OTU\-K2EU#PQFG0
M!@I:6!3!$.258I@YW5`U!O-DT.@^5BV6--E4-3XWCQ>PU)58)%))Z3Y"[%S!
MF,*WK4\>'$UN6K2HYPLWN+-AGX[#:!%&0-^)_6C1Q#,2+-7&=:5<PN+U*_K@
M@^4204&RJ=7H%&03#O#P+=!N-EK;;@'-\KNS#G%_9WS25A+IW'9+3H51NJM5
MJK<2'-6F(,K<:]@^UT!E9#NNC7J?/KO,&J3<GAT--E,Q6S50+`_+I/](`T&8
M(&D>@PGOPSY^WK:=9DM:100("+=@["W@[$<1X8['4<I27Z"QJ\3Q>S&*4C>Z
MHQ$M#*K'*`+%#V#HX%H0?^)S,O:>L_'5GL"17`N$/VD@<EB2U'*[:%./>'UI
MAPQLIP.;9-"K,-X;5NFR<4DYL"S8I"$K?A/<D.,PP(Q!%IC+L)4LV:8![\%8
M,@,+[7K&D#CLH6[!;`G0"@!\#ML65*Q>IV_SV=JR^[C_G2X+C7+?A)M@4*@]
MR)TLY[;Q/Q14%47AHIH"3XQ3/`\%GX)?E,2]+"HK\]1/O`4<>5Z`WIUP8ZVA
M0!38`"YRPPTRZ<)WQS2#UAGP:]YBZJ?<:?IYG(2T$%NN1;&-TJTQ<W&RL@_:
MH)]CQYUAE1,+&:75<+H9H[!';&53Z<.(M1L8Y_G`[E*(TB&/&FR.0(QI1Q#.
MDFQ5V6+M)7,S%M$-^Q_Q"`/QX*<Q:'5+:'"O"4_ZU;Q+,)?_HZ5*`H(A=B4L
M+EIBY+"<"H:[VVTAY`WK+\$[?.%Z$\N'=?KX#"L_2MMA3R5O<4U]I<X5</T<
MAFTZ/>2,&/D%6`,>J];E2M!#P_3MP1!E5[=A?9&.43:9PU4+->-?:Y5W6:1I
MZ37U,(<8H+OV8L`082<&+5JR6G@CM!L.5B`9&/[2WF3F#,EPZ#+V?&;.3_`N
M;[,^L^?9"9O-7)BMQT4$T-@>V"VG^E#;)!Y02-T@@JZ/!3AV;^C8[>5H@#,L
M.$L?%@UH]7KVH*5'9@;;132@U6D"R-V-H@&']'\^*;L64W;^RKG&M:PH8.5I
M$WEJLE,OB1NJTW"T6IE+15'BM](@<^"<!=DW=-;%>_E8=&$B3/45DPL7)"X<
M;91;&L%Q!8(`).\<Q`/*$M^;\A'>:)),D;N#SR:I(]-9'%L`\#6^0@<+Z'VM
M#A+Y>;O1RKD6ELZE#`Y+P5$<ELXBIS%HG;$.B9H9IECQ83D7R2R<A'YXC8X/
M/E0G`L]C+Q#:JSUU/967)9E`LY3''BRZ;7)Q-08K`^#[/9P(GY7`DA^`:/]*
M/>0H\G(INRA(B7OQ,TBQ>5Y\@K'AI\BUUDV(&JKO)7=*76!12N1E7W#DQ=\O
MIJ`A9/8(>MNT(82+4R_+9>R;">H3;UEU)4B9:JEL\T.D71T%ZC8.\=[R1IJ`
M0AZ$"9_1P(UW>A,UK$H)G@;N'&URS&D<AS$Z]^,X''OH,LALDBLPTF!3A!4.
MYP;YBZ_>?"@Z&63<`E4+].;A_LCL=)2A16?;`$STWB&];<<?"5ZSM]KUW%L'
MWV5@A?_##903JIU/92E+C"!H'+MU;UB#E/P2\UZ[/.0)\57`D7.#1'H3B8F7
MD!=,QU^^P&D46I*LMO4B%@R!NL;BCL",).,"=K'`D]7U_/@E'XV%ET%1BRGW
M9E5A*>H\9>_>\.7:S*?"N8:R[#SM[+E[9XWR-A&,CXL(+<S>$5C&C36",$.X
M'&!8,J6M-+^B:E"2V.?8?0>MO)Y-!C8]2J`B_B92V<3/%'X&=8`"T_J4CKT?
MK"K^`E\63_].I]$:_O0+'?@6'?B1'*[9&`S@!UBW]&N240H"VKKSA#^A1W[2
M_E(EP>,J$:Y$(W#?\U8/.*O5IZ]@;9TNK*W=(45T@;QT`POGE49BC#=R)0CH
M6@A03&-`B03YA@Q8I+3$FSL>LWSGX0*ZXDMG@IP%U&[M!XF7LZ[.2-O]@"D$
M=U4A74*=M!]T+)</28KGOOE@LT(,5`T7UB1*K]&QE<"&GI/8&0G6FH&6*&!F
M\'T84#Q7N[_HI3$:74@@CBVB\T)$-V3HL&X+7Z0+]+Y+6<6I"U.8B.5;G([A
MX7B:^G`4AR,*N_W1N&I8[\.0KQF\Q7DN)Z"W:U>8%E/OWU[:O#=OT!](]X:B
M9<AL*U.S8:NY@%J70\MC=P%8$CE?I'`3Y=N[2?T;-R(0Y#N6FT3A8G9'T__Y
MYV6E*S67?@*HSKOUPF@J0-:B:*)+I+$R5V%3"0R1ER;%#=KM^Z2^3E.4U%,Y
M+\L.&NV1=*6@S#AE*?+/VPZ9S%&>0E3G\'D0.5*H9LDX;H4GD[5"^$"84.LK
M+J]PJ"DG[LH2V?W==+(C@U>-!XPZ*,"`\WR?_J0D!.`-WQMC!-S..\OJ*RWH
M"J^%5?QDZ8U?GS6?T=_2*4=_2RAOO4DR0S";/W%-CFU`ODC"!8$M_U3U%3)7
M5'7M#7AUFR(@60$.&G:R!'_OI^T'\RMN6\LAN]L/Z30J!RTA["^6G&DPW'ZJ
MUJ!MM]LZ*8"=NFX4J-0PV')*Q:%,93@5Q2)1AR<H4Q\HN.%=NS*U"R<C.2GY
M';\F?(_NE)Q4H5?,<G8G7NA?C/!.]I*P9&]3'$Z3:^%KN;=63H(@_`4.B%LX
M2Z*5]'`6;_DH2-G)Q/X-B0UE3N(*0;Z`6L3A5IV90DI;43U[WFEV[6:OIR&4
M8[%88(D2%(<A549[A":<(*.TIC+GSI)FIS+'E_6Z;H561T!TNHU!N6;G-)P6
M:W96E5;WE]"J%T$"B/.`<?3:83U!&%R0A[\0:G,)^;AZ5I\E!I8WD2HGX#]-
M)0'^;Z/?]8)242F_].!$P;$OFHT6/+JAZ]V(S4.)S=;!Q&9F'&X@'WHMVQEJ
M^9`%V8I20,G,K21!_A[)IM+`0DG0*9,$;.@W.LX]TF!=;$2+B>=.MP.R88`B
M8`'*.\;.9;#\(IZA5DZ`DLW7[X/]U\L]*;.,^6D_1(3@P]Z#++4-;-)EDS2W
M$&EQJ\4H<%?MTTH9^""HV=(V4M)(R<=*R?:^I61'"SAE#V67WLC6!$J2H&.-
M\H[XWR=%4=O39"4NZ8=H<1&RT9R;"7\!6R=%$1K#`L`@QC``C`<$]18N7[IP
M$TZ&!@61<K0`'M3OPO$8++R1F*(#,7^9KKN,JQION?I$;;9RRM<AA;:F3OE"
M:FBI5U[J$"K_A7T8;)<5$@VZ=F_0M=O5EU(K'*7S<.)-I1&'[ZAL=/'#8R4#
MMB?F_H<1>Z(#3E^5EL_O^;=5'@DGMRZOP%H'/0@1T";Z6\0:,O]BF;NW-.56
MN?$*O^GD%XPZ6!1Q&+YL6*]#.7+I"G6^Q9KQW"QW2M7H7$Z\)=VQ=`)KYMZ(
ME;C`<Z=I=\'^:G7Z]B8@E`_2LYU6QQ[T07=]G_VR9*"6:)T:QWFU4_G/INA.
MK(XP=*L"#,,MS=#B6I8)1-!D%,`+*9'.//?#.,9UP6X$^%,OGBFGPD2,DH=J
MFM]4\CDB`*$C&`H05E"'$F6[0TS@+D0Z+*($0*3NX9#Z[<HD'9VPD4:1(']H
MV2P</J/D>F6QJ`1R=N"SHCV1)[3*+,K'R8L@G%+VV_ICPARB=:/*A^P":\4A
MN1RZ7CE>G'O*-9#X`NZ?3D%JN5QS(4O!Q1-,1YIXUV%Z*(>@-!#D6.7`K/(!
M;B1"K?O%Y\"I<.,U.Q7R4\EE-*<*-GIK:/?;9'CG?*-2'#Q0!IX1%ZY1U.2M
M[>I,4%3.[J\:4F!"=+H"$Q3XCR-NB@LM3,YGGB_D&64,!4_#T@*9W*F6T,"5
M\X"4)$WG#L?S5"CUA?LR'U]="JV2J<8961S7I<-4QEKS0=#2(>#],+@.:1,`
MRT[3),7$#K3^\L.INZ>H10%)_LU*DIJ$9@<$IQC;AX-/FY(:"K`$H\D%*@%W
M\HJ&'C;+(]!/`Q-\%TGAJ_%,S#$0?(>_!ND4<W$C"34'=3%#-\0T??4*+<)W
MTV#,J>^+,`9^4J"Y+-D]=06,;])BBJ7O"T[TA2=!102(\??O07A[,0MO^>;*
M%)[-,M=48FDD4`_^Q7HQ6DNP>^+@.JIS*6%EP?)B_%("F9,7:A:5E#%/$7(8
M2T9BR?CGRRRPS2@Z@_^&65A5XLH!`<RX0O*08,9J.)X,\Y=*6$LZ!IX[=K?=
MLENMP28J:VEB4*O1[?^RN2SN*UE,\R_IL_TJ>:P=J265^G6&^?-6MT^EP2*!
M2&!5L-J3JDV`Y^U!S^X-.P45<OD][5/=/&,GE_BDQ5[12=IN#FVGU[4!A![8
M)BWI+FTY`[O9Z1;]I=7N4C+CY*,RE)<_6/E4XM4^0#M72?3L#*(<K5Q-IDR\
MY':XR'FC8#/@+?D&VQ:"C:J<I21=3H+O<L72!Y:XWY>OX&=\55#H.8,!+^RS
MZJTHD^=L)>-S0]0@&6GO&8R%&[G%\W=5!2Q<B[^G9.JF660:@B670O:]]H$0
M$$6?PN?E0?XJYA#;5D_#6>8]:#6:N0Q&VFE.U0N,@P33'ILK:8^K1G0)3"@:
MAW:GU;&'@]83NP=ZI<$I<I/>(T]7S._5=1$,JVMSP/`>VH-A<VULOFSLL>N/
M4S]_\V,=/AK6\VZG;[><ILP;CZW,R"9U2UZOR"GA!"TM>]7P1[%^ISP7I*UG
MJ>QDLV?U?IQ\<1]MY1,8E9:^Q`W>[>\-&#=KP3V[FS_W"*+[C5$'KQBO,0*2
M&>Z!!QBC>S%%^X.JK;HFHX2`(/6'KT6H#=CMK7B^CM\JW<_-3?+_7*7S.;K\
MI(:OW$>N<A\A.61E#,`BYMNZZCJ\EHH7="5I3\&0IP@=RXY-X]#WW44L7EGJ
MDPYL;A=57@KQWML2["'!X_7-3\>47[W]R$_;DVZKEJY``R!5\.NS]K.'S%V&
MC0TZ<WW2EQ^O6+QR'6H=MCE3M/RE[O->RON\[Y05_`6MX+-'2P8C`32*K)_Q
M=XFMBE^_ZJA)Q0-OLLO;%4]\Q(O<<+K]$T_;<Z7"I=*-*I#T`;#H!;$WMOY$
MA:8B6V-S<7U_!\==B725P-/:/JUF30OGZO:9ZK1[0`[2%AW2'C3+PWN]R>FV
M2TVJ:J#6MIO=OMUK5?=/.\SJCHADU?WM=DJI9J/=,T0ZEGW57].!V1"K'CL*
MB[VUL6+382FUBP/[+ZQ0L*M3^B'J%2Z334EV"9$':`<*W-9\N(\=]7C6<_IV
MNTV5]78^B6D;NP'Z&ZWJL_3($;_:17SW3I.2+N%/.\E3+<30X9!TJ+.INH-#
M\)TN67Z,\G<OY^`+77SZZ<3QRZ-$_U,>?YAT;XZ_LQ6[A@[UH,,I&G[O*)G,
MG'B5LE=.TG5V/XF1P,>R\PT=#!T,'<[&$'R#D4O?W\FQ^,B(=C%#J"(*O9^X
MQ%/!D+,NNPZ8EZU*"$HPN8.E[\+>W`V5:VZ$MCI[ILP&3/G(B<_W<"A%W#Y6
M9RAV'!0[8FOWO@2DZA/F[,U=!^N^M>W.L#H=HEX+.:U#UFGTV@;QA]P`G<;)
MNMKKS?E]>]AW[.&P6LFL=TI/C>U9D]VSGO?@S.,[J&;G'V#GMQK]72ADM43\
MR1@?QJ=[ZG0X8GO/9/28^*;9^T8&&SH8.M3F+*RQ/6B2?LRA:(2`$<:&#H8.
MYVT@FDR?PV3Z;'#`FI228Q,])J7$4,Q0[*0H=AJ&\'WY0+M(N3A12]@!NIE\
MH`/F`_4-X@^Z`=IK"@/5:P6GQ?F=@3ULM^Q^O[K26;WS@>IFZIHD(./S/1$E
MV/@:#1T,'8[%YWMX^\_D!SW\6'S1[G7M[N`);R68>C^K5RV[)YN*;(2N.?R.
MA`ZG:`6:U!]C!IJ=;R2PH8.A@S$#31:0R0(R&0I'G:%@*&8H9BA6_RR@FI8"
MVDVUB65ZM!K=71WZ-)0U"=.1OQ7Z=GSN[P:,7&)+VQZV^O;0J2XD7XK4_:!@
M_[2OM3_::0PV+\IHR'1P'U:[41T^,.2JRZYJ]^Q>JVT/^MWZ$.M4#/U576C9
M])?/>,%$8%/M"X<[>_\I8NRGBVW'97"8&GG77'.HV^ZM//.[O9;=[VU>1]9(
MIP.>^=4Q?T.FVFVNUIH\94.NNNRJ=M?N#H=VMU,C!6WYS/\YP2,O^TI]O\BC
M@;WG]P$R=Z-K#X#@LQ4'P7>UH;FB.MRBDV`9VB+<.("&?+%;*(N8^]\T3KSI
M'8'S;2:L6X%D1.4`="'W6EA3UXNL&VSI;BU`+XAG;B2L<$J@W+I1Y`9);'F4
M=DT*10*#N/#G?)%X81!;:0P_>`%]3U;VQ=5X%OH`ZN_A1/C6)(V`$>CG.^%&
ML25`69FL*B)\AXFFP.+&%H!!,,0B`;:)DIF:A`AKC80?WC;VB[\E(I;,R[!A
M&$9N@%^?-9_1W_'"':N_:>A?GXU!9Q/1LR6/!3"1[RYB\<I2GWZQ5`/BIFP)
MO,F*GA6VP_TJ\&[4VSSJ>'U'[7(%$@#A@%;M9^M6N+L@$Y^"Z_3RTU_[YAK;
MZ:U]V4-59U-62J5N:_L>[W]5GT*5Q)?3/6"V;12O7//U1X<B[NTH[[1^*M&Q
M'KJ^=1'H72YK`P%M:%6YQ]=9I(9*M:%2L]J?N1<JU2Y:^>BE?O7B[Q?32`A0
MY.'T%'%B16Y2+>]-"'W)TMQ.\R^8F?<?$(]'R6.@_6G5*C8LL6LD-QN#P873
MD#KFO<A^-$9^,G1\(CKV6T#'9N=`=*RS3;+E*'^&OIMXOI?<&5Y]A'5A#H^C
M(.1CD-SI-%K#BTZW,1B:X^/8*=GK7,`_!\X1'R#ULFV^B6ANO?`"#G$<Y"[X
MD7#N/@X3<Q'K:25(]Z*W)\EA2+D!-0Z`_CJ;`(]>]5OOQIN(8&+=><(_R"7S
MXV"\9F--KT&C_AG$&\3O5$U^BI2FC9)=[DU[V4E2U7[SH*+R:$0NM<GR8CBU
ML*P60I,NX)MP%(OHAO*=<N_$%OST;Q&%UCBDQ_YH7#6L;Y%PXS2Z@Q,PF,36
M[2R,!0"7I)&7W&&JE1=.<`IWL8C"1>3AY-,PXA0G,"<.E]OTI.2NAN`=?`3\
M`'9OM%>.$&3-"9.8E<;99W-0(Q*"9G2'V7;CF16FJ(&$X^\6H'(L\#WQ8R'&
M.%P26E,_'2<IHEBX\#1::?G$-,2W'OW6C28-ZS,,**H@"E3>`@$A7YQY`$"$
MND_^<?EC#K88OT-X%T+`'$'B)9Y0#%)X[A9XS%JD(]\;^W<PI>OY*`$8.)AG
MG.(T8:"@J(*7N!B9-`=B$2!8#>!9,J7X5PH/`-9*41,WK+\$9_T55TU0%%=>
M7.$D%6I42I2!!^)T.O7&'CR2AVWB)JY"4IZHDF*MIN-<8(Y4XU"L>K!Y]SY;
MBA\^RU1/(-Z7-!K/@)VL-^%\#AQU1>1A_B!PX/N%&[`[/3T`S`>BS(<`V+(Y
MM&'/6NXD7"1R>^"7UL<0N)9<1!\"3!WS;C)<B2"F/6Q]\7%B>0#0:_P-(!T.
M"+1(K*D7N,'8@QWBJ7&(*&*^\,,[@1!/O`B$7AC!1W=RX\%QA9\"S&@+XM1/
M*)N7MQ:!,&9RH?3!C%N+\E<3/,F")/)&:8)_T;8GN,9PJ!&T.$1$;\U`%/+W
M8L*[=1;Z$Z%RBD%",_A2UL[EC@Z9IP@(A"^$W]1N)WC=>)9;IL;,I91!W_3G
M3#!:8%V*)032PD&TD+3)SVRKR>#\%8!4+4A)-82?\7P'L:.7M?H-S.?ADR`W
MX>2>T^UL^6C^*_G4\BK#B!?IRE6`@!3Q&)`N-0Z9[JQ70FM&$L'_6UUL]([_
MYX1M>#U-9B`^_PVPH1:!"=LT.4XH""\-ZPN(]TB)X+F(K@&66R^967]ZB?N[
MF-A6$$JD$@0S=V*-A`A4^G<)>AO6)?%323HWS<QGF"04`N:`L=_!.X-=!;D4
M]`6!PA.RXE4RZ7G(E,^!]5Z,HM0%);+5)K2V2@2,TR(X&'%:P"S+$Z<EOW&!
MR,$%'O'>U(-!%KA)DIF;6+?`@NZ<T_.!^2[3:P"&LO)YN^E!Z$E@5H"8U2O2
MBGDKDW:D]RV1/!*)ZP6X_[-9622!^$OP[/\N[O)"+$2E@"177ISA&R+"H0K"
M#+\G40=/*44(^4E*MORN<9K+NZ:,]S;92>N9GN].T*P9X[?L7G'NDDTE\7LF
M_(T\A8<$GRAS`6B?A'YX?2>URQ!X#-5/+V",(HYRMU66!3IJNA674)A_RVZG
M1*#L>D@-?!.FQ5%AAZ1$5OR<W7210GGLIW26K=7QB1&J;$Q;WZ/1)@KL"E$<
M1BZ*(5^&X@GOW%CUO&]C;MZ8FS?FYHVY>6-NWIA<[*.+ES<;S?Z%TY!-H$SF
MU/'2L==%.AXJ;\K0<6=T="Y:C5;[0'2L7?Z;R9JN%X/V!HUF]V(`+&J2;8^;
MDNUVH]W%M.G^OE+F#"6?*&VZ"0K<1:?7:!YSVG1M+1*30;T?S:=[T6NTNGOB
M8).^^\3T--0TU*QC;O=.K9-\G9E])7<?7VF,#=A[MS4RUB;#[G)EU1JMH9*A
MDJ'2$>>8^T==2[/6.>2%W(*&I;.KE]-TJS.L+9U=C=]Q"BX\L)2H]8`\:YW-
ML56NM;7S/&N"8\M<:VO'>=:,BVUSK9=6OKK*K7*M.6TJ6,ZWEKDG$OO%7)7\
M:BDQ%/-%7:2]7U@&I['`$A0+Q-Y\(7/`...GQCDE3P/!)5!B/L>D/LPO&B>@
MD`(5E](<54H.P8(Y89SH%@F?^,X+*+N4<$O)9?`HI<3#7[X?WL:O#H;5BGDW
MR\_9."'':9J,G&U-[D<V=2S)S-AF[NVS.`BT3SH5[XK3)O^@C2*O))PK5G3]
MU$LIG66;#X$YWN-=Y'$<-UHR&`F@463]3*)78JOBYZ]B+A.5*QYXDYUR%4]\
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MR!R`U0?@_W=_2>]Z+<3L?".!#1T,'>I^$M;8+GR#H4S?W\FQ^,@0=S%E:`<%
M01Y^!#T5##ECL].SG79UQ?]'EFG9VOS<6UF84Y,\I8C;Q^H,Q0S%#,7J>N0?
MLJK'F@2EY=I8QOK-0O!MN]]NVYVG=/\>5MNO=1C469=3=.Z(W\L&Z#?ZA@"'
M2`#HV0,P#AWG$.@_<?/6Y/[<QWQV=]"V>WVS]0^Q]=N-=G6V\Y$C_F2L#^/C
M/74Z'+'!9Q)^'N&#[7?M3JNZ5+;)]CG1_6[H8.A@Z'`V1J!)_+GO('S2NQ_F
M%*SGKC=T,'0P=#AM*]"D]QPHO:?7'-C]-:>JR>\Y$GECLD4,Q0S%3HIBIV'N
MWI?JLPN_YHG:NT[7[K5;=K^SBW2H6@;?:AWU=!J=ZMZ<YX[XO6R`?L-P_B$X
MOSNP!_V![;0/@?Y3M&]-?L^]^3V=3@N;U9O]?H#]WE$M1D\0\2=C?1C/[JG3
MX30,/I/J\PA_[*#;L;M]D^MS=GO?T,'0P=#AM*U`D^!C$GS,5C<BU]#!T.%\
MS4"3ZW.@7)].JV]W^M6WUTVNSY&('I,Y8BAF*'92%#MB<_>^!)_=Y%`LTZ/5
MZ.[JI*>AK$F8CORMT+?CPWXW8.325WIV?XAQU6IO<BE2]X."_=.^UA%8I[&F
MGI,A4^T\5;U&=0<L0ZZZ[*I.VQX.>W9[3</+O1/K5*S[TE7_*6+LAHN=PV6T
ME[IP/Y%6L%=FW:@1[5/+GHV`<-IVJ]^S.SV3/'F8H[Q=?3:<.^+W<CAW&]4%
MJ^NU@M/B_$[3[K>:]O`@5=J6S]6?$SQZLJ_4]XL\*.R6O@^0N1M=>P!$LPC3
M_Z9QXDWORL!:[&O>RY*3U;;"-(+_)W$"!S%VEP\7B1<&,<$R<R>6D)E8UB+R
MQ@!!Y`;7^-PT"N?6\V;#:5I):#WO-EJ.M8"1XYD;B<9^5Y;#Z(%P>X6KOABY
ML<"^]O.%"&(7\0CHP\\"E*ZH@-I(C,/KP/LW/.\%1(1(Q*F?Q/1D,A/6G7"C
MV!+!!!XIH1M>A[))>Z(:R'K=UHOG';L];-N=;M>VGL/YWFS:O6Z7'GWNV(-V
MRV[V8!B8;R'&B7<C_+N7!),76[P"@-N]=:-);-UD2MJML.`/;^[B%T&(<$Z%
MEZ0P3L.ZO'IC]9W!!7!#)/Z5>O!E_@%DD5'^?=#R<(WPI[#"J76-.>\$`\X4
MB1M,_4/$Q.DHAO%$D"!S>2&`Y$TM=YRDKE^88.)-IX`?XDH<64T5'XX5:["Y
MDS`!/*5!CMLT#0B@4EZ-A$]$`J*E@>0`R;M,*?@;I`'R:0C(!EI.X'GKUHTM
M=[&(PA\T@7\'4L$&3&"JOFW=SKSQS`(6PUG&/#R!,,()-7@A6#:6"\R&)X68
M7+CPMWLM)/615UJ-(>^-AO4)IG=_`&<%8NHE!$`D`#DXT"05")X+VS%(O"!%
MF-TD$5&`@X0P'BPZN"80_#".B8M+KASJ+;8>F^6[?F-,$ACW81,LU):#V.2]
MC-O<8>3F]_+9R=X/048UEHH@JA1V7<1-`D>7XO@X"<$*2@,O@;./)>W7JS]L
M^`9L)1+$2&SKB^\&Q#]`S/G"#^\$":HN<3,?<C$Q$KSP)IS/@>A7-/+,O<'C
MT;6FKA=9-ZZ?XHLT]?-6NVUWF\V&]3:-\*%[Q;QB/EX3\EV$SSWO@GAO#:1(
M'P!,_5:1"6R$+0B#B[$;SU9W>HXO)0)0YN-'=XP/NL$=P@=;ATQ%>G;J!6XP
M]F`'@*Z0B#G(9-@RW^3KN8,"AV$$T<0`2`%!A&C_3JT?7[X5D;!`-L0I2_U_
MI(&@]>=X^6\_I_'%M>LN7M$PL]"'8>)W<-8D=Y_"1+SUXC'L8S@,O@&?O/;A
MF;__YW^@5OPW]>*'`-8FOKD_2IXE,0%_?!737Y^]AU,$I[]H.O"_)*3/3NNB
M[3S[^Q/N)!AYI#ZD^.'3YV_O"`.IUER+#Q2W'/UF.8XEO^XV>>M]^/3F\^_O
MK&^7_^_=%3Z'4*L5^`)EXD6\<,=`D5?6!6AT%;X]?&T5CAQL^Y,Y.UK$P0!>
M==/=8D".GGVO3H/-=,#\^33#?80'!ZAG<'*`%H6;'15*CU@?3TL$?)Q&$:I4
M\,-$@-H4B4GCZ/!4!+-6:A?(:C@&!!X"`J04B,Q`L'JK]0X+=0YK[$;1'1((
MM6T4V4LGOM/LVMW6T.XX/<N]<3V?7*0@M</I-!:)-4U1^T6RT@^*RC-`V?4,
M@&EWENFZ8\S0?[N-3OEFVQ\9Z&R$T\GW^(`;B>16B(`9GG2SE,T.O;449?`P
M2Y,0R!"AVJ4.L,+1)\"VH(.5U$UZ#A19%TT<WP]OXU?U5;G(LV%A$IV,7OSZ
MK/F,_I;2DOZF27Y]-@:A(*)G2Z%GV'F^NXC%*TM]^L6Z]2;)[)4U;/[$\81-
MUI9%$S:+9>PF3I%'(J_OJ'-G@`1`.*!5^]FZ%>XN19!`6QN$.?VU;YX5<7IK
M7PX,U3DF*:52M_73#O*OWJ\<$$KX5W*#G+_STY/FS<E9G%TL<@/1IJ9K_E0:
M9-QR0M!(JJ_MK%W9,GO-O<EDN^PG`N`G0[U'4*]KJ&>HMS/JU2Z3]=$TO4+7
MF#XH;+3[T*Q3QD;.6WV(B/!Q9%QW&]7IC8]>0;4`,7C?"N]/+M`-/=:DIAR5
MB'XJ=?_19+R<H%L%(QD8=<!8#7N/7/3JX!V%V'!GU20ONLTU><U/QI\OC<"H
M)DF[U:AVTY2,;VCR]#1Q!FL*D^Z1)J>G:W\1$?R`PAN=]B%&OV0:D%@KNO=]
MS_$^G]P^&'D;&![&Z([3V/SFQ&YN2%:+'4/BIR#QB\&:X^5>$N_MS#'$?Q+B
MMUJ-+>,@1W:ZU=9,^:)3.5Z\9N?12TKJX'PFZQO&N#>FS-:7UI[BXO3!MD0U
M&(^J#M!U-@\-2P(<P*-B6,&P@F$%PPIE!^937($Z:$J8]3G-LALI\.+&F#*'
MMJ+ON2//]Y([OG(26XM(Q(+RQ;V'I$'3$UY,H1[*+:.T,$Q%W>^:36*820PS
MB6$F,>Q($L-J8EZ]58=$9D]9EWA6R+S>??FU-Z3D[F6464R]%E-G9\;Z%,O5
M,JY;S_L),V8*MR36.#>.+^FKNJ;";G.].FV[.73L3KNZOL)A<MD,K59#)QV[
MWV_;74.K^M.J:P];37O0JXYU[854M8OF[D#R?^75M@>_O+7>@#ZV)D?2A'B>
M(L13G1Q\-C6)SX/0W4[?[FY1Z-"0^ZC)[0QZ=KNS93'_>I]=^XO5[N!@^T9U
M8[0O.KN+SR[IO9JR1Y4\MX$1LX^%G#T=G*[=QLI#G2>\F&'H</\D/=MI]NU6
M\Q#;H786QY.(ZC]7[P`8966_>68;"/VG45CJTWWH3"B]P;%B*'T2E+[_X-H/
MH8_+]-A9')/N(6^,^M/(!:MV"!]="MC3^UD,R0W)#<E/@^0;97:>9A'LOX0U
M$KXGL%`?%E+V$JS3-P\C8?G>=ZRH"%\'!$00)OS,K;!N/=^W\(MK$0BJ[A>G
MTZDW]O!N846)Q5!5FN8ZYEE=CWBYN.YJ#JJLB\MEWT>R&UX\$S([U8UA_O',
MMMRR*^G6#'X?86U#$2-E/7@1WKEVO2!.5B:4":XXJ:4*R\M2VA5514^J7OHS
MO2GV6L+4PP]_Y.N$HRXF[^[$O.0AP^4=$,(<[HM4.`!0E[%*GE[/GC;!0056
MJ0M!H1I[?AN6%C[-BDBOJP6]7#?Z:@Q;+/7%Y^D[50A4O_X5MOK70NW1;R@G
M]%@UJ"MMBJ-606!RX$T.O,F!-SGPICCJMG.8XJA/D5QHBJ,>-?7J5E[34.^8
MJ7<$`?<MQS7%44UQU//`NRF.:HJC'GLXV11'?43"@RF.6CN2F.*H]:.)*8YJ
MBJ.>0P*<*8YZ\B0VQ5'/F?BF..K!#CI3''576Z+.V7&F(J9A!<,*AA4.XM?;
M:W'4+$?M,7EGU3ELZIH(#,*W0RZ#R4=9$-43<>W2UTP=5Y/#9G+83`Z;R6&K
M:PY;32Q!4\?5+*96BZFSW\74<3V.>I.FCNOQT,K4<3T>6IDZKJ:.ZZE&HTP=
MUS,AM*GC>E;D-G5<'^%,,'5<#Y?G9^JXUH,.IHYK/>A@ZK@^M:@V=5P/K:R8
M.JYG0VE3Q_5<*&WJN!XTCFGJN!YUMMK3^UD,R0W)#<E/@^0UK>-:EIZZ54KI
M<F;JFS#`Q(N(S+6O7OR]I")C#=)0<>21^I#BAT^?O[VSG+9U8;W^X^K#IW=7
M5]:;SY_>O/OT[>OEMP^?/UTMH2_5E-7CG$J=U=)YY9=>,!$X8-,+")*_A+5(
MH_',C045P%U$X20=RZ*X4Z"M%8L;+BZ6+A:^)Z+8NO62F>4NX-$?WMQ-L)+O
MH/63;0T'\`_,!.[W?L*D71I/#AZK]R<6C1H&PKH1P22,+%4)]TZX,'BQTBB!
MH:N-XC_;/`6FRME6).(%IV+[=_LKE5N!REH1-1:^3P2X\1*0?D',I5H7D0A<
M\IM[(G&C.Z8*Y5MKTF.IY-M9Z(O8]04\&">1-\*R<@`5HMMS_>3.6LS<:.Z.
M/5'XMO@T$@JH[P76)$JO"8`8?H'U4K%G+O#L`_L0M/GY(X#.\PN3S,)X`6OQ
MX2-?H,82RUZ2HJ"*::J)%P$S8%UI/<`8\`1:>Q0W:/:OP,M!*G1I:<F,4T24
M?I32U%/*6T?6+#)ZOPL\WA]*1F\--*/G"M]&<A9\8MC'C0'_X*1X_"9[1P<O
MU!OKMH)U?-N@-AOB?1ZO-/M:W.90*VL;+W%(CGV13:BF.18SQWP815S</;&E
M=!D$=R9B09/G6"W""N$Q+($&<N/<)/+53O^72_5Q\(N=^_IU^==OLJ]I(=DO
M;[-?&M8;/=&E;;UF_GQ#+[S-+>VY8_>:0WO8;=KXN3OHV<-FFSX/P%QO.@-Z
MY3E\[+;M`5CO!6ZT\>H'8P(^((9_P5=;+?@_HA<^]QW'[CA]!N!Y"Z88V+U6
MC_D;?F_#<\ZP=<^X;5[K\U[?[@Z','!GV+2;^-KS0;L),+?D@,VE@6C:I<%:
MC3(-:Q/5:%6=FL\]*MN#6AB,@/F7(D")=ER*52?/R6\^__[[AV^_@VYU95U^
M>HN*UK</GWY[]^G-AW=79ZE=/2N@[+/.M/TH0/=9PD@M+RX]60L('S%@N1/0
M05`W<*DV>8@-'4!)6;AC;.)@O0['+A_0;A+"1._],/(F+FJ/<>J";@(GNFOU
MVB!I`]`]@S"X&&,4R:?K5KG$9IJ,I/,8=AX65YF`JFG](X6CV\D)=_%CX:$>
M`K]=B44B#X$F2P-X:M"POLT4\+">18I=)%"E`0BNI0*2S&!._`X5Y&MAC?!A
M@A!FB^@*&YP%SV%8IS.T7GC!V$]C7CZVBR"58I*#'H`2`:C*+[6NP$(I<7_8
MK(H`'E!YDUTP$*7S=&XMW#N^,!?>"#[G?&\JU+4Y7@,"`B(;1&/GD%TE#L2'
M2$MD/G1'`'+`]D#R`"8ERE67$"ZY'UI\VD?XD.(I1#P\H!<`=.W!X35L%Y2V
M:IUMX4:)1\HN,#]>F1S=T5L1EW0CWW(XY4.P`X>NPP/'Z%1)>*<P3VZR#FO3
M-3B#)C!%1Z\A]KA)"7%QE0;:+E]-<26`GY8][%6M8BW<TE3QX$V&_';FC6=R
MTTY@-\/"85?Q=I:K@J,?]EEOD%^*55A&X36E7C1[H&!T"S1<HQ^V3JH?RWW]
M/TJX>$GR,!697$H(I8"YB+A/2GEY`L!K^384ASJC#WR%=U#C*[R'N?3X3[)U
MWP6(Z@++'3Z<;&ZHY7#0*L7!@[SL($NVJ1=[7CEOU<&7QT=6VGVPNSO5-Q+.
M(='MB1BZ.A'\W!EZ+TF<[4'+;O>/-87S6*2VR1@_+),/V_;@(.GB)R^^30[^
M83F[V;+[1\O9QR*^MRF";ZXA[F+-3Y\%G$N6>B`)ZKVWZGMJX-#XRK9^JMSM
M1>5'8Q>9<J$1ZG"T#(_F7#K,N;3E)/7;/D=Q-#UJ)WW2P4".!L;IZ(+W$\<B
MZK.;S`'XQ`?@GH^]HS[L=I.YCG7%UAQBF^VTITRB7\L'3Y^MO[K8#3+HG])A
MO/OI';O3;=JM+:IV[CU9OX:WJG/UK/:ADLCI>KT'S/>8P_FAA^^3HJ>"'U41
MQJ<MS[;3M6ZQ\>4LK8<L[]$;^PG(>="J\+N>PI>)@Q_%-5B%7Z)P+`1BED_1
M)TL=/&B.">:W6HF'-7M"^C<E6V.:B!?<A/X-EXW'.TO7+M>.""9X1T"C1B;N
M8MH.'&I>@-<9QF$:<;;;*(V]0,1QP_J+1PW"1.5#^7>%.=S@#O@4,9\-STF$
M`-!(^)ZX$=9MF/H3:^;"1]?"S+W(DYDO@MH!8"HAI5R5E[6'KR<>+H/2CU.?
M<P-E[A^\8L,:K+$;SZPIYL<\29[1WMGY\W1Z\=KUT3BSKF8"=,7+*'*#:Y%I
MB*?)VY7Y4^6W"X*0X`D!72.)KIC0Y>;0Q1Q)#(CO8#IHA(ES;AP&(/J`A;WO
M@B^_T$,J]P]O6''65I%1-6_RE82,/\<SG)-RX2OXERZKQ#BR2EFMY&K?^U?J
MP9MW,*Y+]W?X'?@JI01<3K=3O\%7`-M8W1#"%:J]A@N#72OP!E%<D:"_3;+]
M<JK^>]>+L%"-^#Q]KY;](8B3**41O\"F'M_5)$.?=@T";!'$B'0-LY4#^FFW
M6)TS?C_G.9RNBDF4Z*XBB\B#<4`-D7M/7?N*\2J7\&Y0G;"S+\&N)?<2;E[X
M,DK%1',_I[2.8;=29Q-WCJ]8VPS)&=]+P^:OGN&&$$#O*1+]AH@^$F,WC76>
M=SP+H^0"]LH<MTP:P9[#G^)T/,NOWY;)M+BU"!5@#L*<'V%3LR1PN'Z>2N2D
MSBO9I#,/]G8TGNWQGMFSDSPB_D*&2<1U&'G_YJNW$NWY5CH@N3@E70E#(@(P
M8)*G">I&R&$@\)']1B[P-Y"<[DPDLTB("Q^I6TI&S,F="-@I,.KHSKJ\>F,-
M6DV;C!9/21F"@27-[W#>@!0E5FK04S_38]\JV,2Z]FZ8>>&[ZYG@C1<2=P*`
M_TI#U)/@JS&?."[=RT($?D=D8%ZVAW?YT&CG35**)>L%,;#EO.1?PMOEF=(@
M',4BHCT($RW21+_4?MF0)5U6AL5;G=%$=S!21V6FX2V=UP6ZT!;3-)[0_9`)
M4RO##VQ1AL8NI$<?2EQ7S+M94K2$3=<&WR;760%ZD80+`E;^J6S+3+6L]N;`
MJP\R;E?*C`]V:"0K;+0>-N:([4(EG:U-_\-UB$=K02N]0+N<J+X%O&G@3G`<
M>9%FJ\VMQ!_>^<@V8)757V7P'^80,KOCV'9'ZP"[@[>#NMN$6X*N1GGPOAN5
MLW_)IL$]PZ>75@IR!YNZQT2CY0<#^TMXLN\\5TE@M1='R^HFS*(PO9[)N4`]
MC*)P%+(M9ZN+7''B!O+N%^F&J0^F&6J=JDU?B=9-E[/KLI67:P0TNJIRP;X.
MW:TA,`+FV`1,^R#';R8)I'>4!$6U4&ALN2?WNQD.Y;Q+RCQWTFG7SCGMI,Q6
M@C0OMZ7W>!N+[2PO9>=Q@H80F:)>`A:K=T/U4.A0]!C'<[8]I0F%10"6C5[T
M^5];6$[%FX)D"I+U9A\>KV#-!5@,!,:DNE9HB7OS!<"%!Q=;WV!+DHL'R'D+
M1AI0/GN"X88S\=HC7PY#/$DC#B)L6<NGU*^YD6=RV9UY"88D&I^3JQGH"*_1
M]'P3SM&Q1,?Y.WGQ>D-_)N#1XX?^N'K[S)J(L3=W_1B/G;]WVL-VI]O-X-UL
MZMT!W,X!W-X`X':KV>P=$N!6#N#6!@`[`P"YYQP.X!*6^!\N5/0_G\+@OU/8
MW5-/3'`Y5TDX_OZ!*N7`%O[BN\'OQ/+_(Z'XGZ\"2X2-$0Q\]`]8=OSUZ@]^
M:BT:NNU.:U`K-CL`$IQ!L]EO/10+R8_YY-6G%&?Y/'WKWL7OP^CS@AJ6AU]D
MJ3X:*"[#0/>B">S*&.#/?;VB*[`,Q+]26/&[&_B'7*_$SYOP5@04DZ'VWQ\_
MOI$K_?N7=O/MWW[>'"RU$-\+OK^:AF$2@%'U$?ZP?M!7R=T"SBF`FP3N,_EM
M%.+I-4N2Q:N??[Z]O6W\&$5^(XRN?P91T/X9?_X9'WPFAU<3`&H+XQ*JPT@-
M.XL0.?_G/8!QT6Q>--7WOCL2/F"-O_\?>.N9]?.CAG:V&5JAY3(J3N%&8S4,
M?+P')_*)GZ=@?UZH$=7K6#5O"0@Y4<A?X\.P5YY9E&[VZS.G&LH"B"K^MPWA
MEH'+H4B#\6/NP_=H)XG@XH^K9W__$'`]$!AF0"H=;#(PPU'GP#0#UX,/JJXA
MF,PWZ*>:4%F39J/3M!9PAL<S,KZYVAO&'K&8$.YFJE;D8RM[^&,6^A,LL@;/
ML3,9W;SP!\WN4#42A`"^X;@,%G]I=X?P\-PEKWP:`&"@6Y%_?@PF%]93+`P-
MNB68:;-5[4(KK8V__5S`N=I%/Z]L(_CE;S\CDKU7^$_X\_\'4$L#!!0````(
M`*&$;$8U>[L=714``.TF`0`5`!P`='AM9"TR,#$T,3(S,5]C86PN>&UL550)
M``/N^`%5[O@!575X"P`!!"4.```$.0$``.U=6W/;.+)^WZK]#SS>VMK9!\66
MG<Q.O).S)4N4AW5D22/*F:0J55,T!=G<H4B'E]C>7[\`=0E)W!J22,!5)P^)
M(Z.A[OX:Z$:C`?S\K^=5:'U#21K$T8>3[INS$PM%?KP(HOL/)[=NI^?V'>?$
M2C,O6GAA'*$/)U%\\J___?.?+/SGY__I=*QA@,+%I36(_8X3+>-_6F-OA2ZM
M:Q2AQ,OBY)_61R_,R2?Q,`A18O7CU6.(,H1_L?[B2^OMFPO?ZG0`W7Y$T2).
M;F?.KMN'+'N\/#U]>GIZ$\7?O*<X^2-]X\>P[MPX3WRTZVMZ^<4>7/=FP7]0
M\J4?!BC*TB_S!RS((\JSP$]O!E\^7<U&7\[/NF^[YQ?=+]GS:O$[^:G[]LWS
M$@L[\#+<$?[]N[^>#\XN\%_=L_EY]_+LI\NW/P&9RKPL3W=,G3V?;?ZLR7\.
M@^B/2_+7G9<B"R,8I9?/:?#AI*2*IXLW<7)_>GYVUCW]=#-R_0>T\CI!1)#T
MT<F6BO3"HNN^?__^M/CMMBG5\ODN";??<7&Z96?7,_YM(&A?XB0-+M."O5'L
M>UEAB-*OL;@MR/\ZVV8=\E&G>]ZYZ+YY3A<G6^47&DSB$,W0TB+_8H/:?6M6
MPGNUP*:T.B5-3C%,^0I;1"]:V%$69"\$LV15L(S%*/I\2-#RPPDQBL[61,@7
M_P5"F[T\XN&5!F1TG%BG!_':CZ,T#H,%-L;%E1<23;L/"&6IC%$I82M<3KT$
M*^L!80(OW)ME9B]-\4\&+2(0IY/EY)%,?1A:)76+>VB#;S>+_3\>XG"!Y^4!
M6@9^D-E?<VRM^XHA[;`-J?I>^C`,XZ>]P:`Z."[7JT<O`FBXTNR8'+CY:N4E
M+QBMX#X*,$@>GJ=\/\[Q1!7=3[%&_`!)E:?6RS'Y=Z)O&*<XD>J0:GA,+B;D
M%_T\(5-.+TT!4RV?XIA\#8-GM(`QQ&AZ3$ZF"7KT@H7]_(BB(E`0,L-N?5R[
MP1'(?7`7(IAZ>.V;LJ)1X-T%89`!!I^$[)@<CN,,8<_ZXMV%4@Q9;8\Z<Y7<
M"\Q1\2F.:UGX1S3WGN7(,9H>DY,9"HDWPY$0Q(S8K8_)SU6>!A%*4^QJ?6RK
MP"A)3'5D;[P*LL+OXU`=?Q]Q7GA%#%`>@/2HMH]"Y&.P?LTQ6B@)7X9!A$/?
MP`OQ"M23C@,0]7&CC+L4?<VQ>FSBA0'Q!+M]^Y'/<2.@)B,A&`=S,AT?29IJ
M7XU$=3!V.<V;C?!@K,GH&HKV8,QQ"9J+_&",B6B:C`*AYB:B:B$B5#<]+G&S
M$1EPMI'0-12=0<'F$+04><"X!'?07A0"Q%ZAC_:]Y0!E7A"F8R\A8><WZ9KG
ML%ZUR7=4L1J-!X`,\]HW&Q$`F9,2-A03J!HS@+193M49;#Y^`;(F)&HR@E$%
M&4K?`L][LMHBA]T]6>RV&!NJ&H!B-^U)<!CC36<_5=4,H6V+5ZD9@XB;73DH
M1U[@'MKE6ZIKA2[:Y?S\<,[/6^5\;WY;Y7)_@VC7#O:'OUW4+_;F\Z*9R&&7
M+E`/Q:2DS7*JSF`[?`'"+BY)<_MIJO#"J)O?;U/E6ZV7EK)BJD+LT56[DAPN
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MH)QK!04BMW%@[?8,,*]\<*JM8&!<:`6#)9=QRJ_FR[%O*[)[P%D51`R#ZJU6
MJ!2T8!R":R['>)$`<X+EEL88'H1]/H49_I*606AEC.:FF59]5P5/9/:S'^;D
MH.)U'"^>@C`4S=@0:C/<JA0[%548A^,`/<9I@!>PX*F"3V&&YY7B)1/9.(RJ
MIQMXD[?F*3M^1$GV,@V]]3+X:QX\DM6A,'`34YDQ=7,G;+G`,$/2,ZOQ5@G[
MQS5Z1KM0CE<PMDN[Y-*8FM76@)7T9E,:O(:NM]<]SOD0<);0;(&-,ZT!6B+,
MX6*&\&(S1R*/7FNH>XH"(\(1T3@HBC6CRE#G$NB>=<'02$0V#B+^040:'59;
MO>OE]3`H^"HN*1$NE>G&NJ=@P2E0:IW,$]4XBR+;@W$$P81NJ7L&!@/"$](X
M-'J+14#D]L*I%RR<J.\]!ID7EO@71"X`6MT3,Q@QN"*,PW!&-GLCM+"])`JB
M^Q0'9/DJ+THX-I>9\#&$T.K.1X,QA"O".`Q+(0%>-JMX73FE;C<&E:V&YJ%1
MDL;P7$5,V54//#%_/JU+.<+_UU00P;["JE(=<0&OCK!^J/3W]U8+/2376U5D
M>BN2R9WC?V[L,99G,K0F4WO6FSNX@<;:C^LD3M-I$B]%+J'22.?2PPM1NEG"
M"O.E5$/=$QY#S?5!SY;-.+?4C]-LLB3;-:F+IRA1K%YKJ'LVEF/`D8V!04=S
MFF0]"T7WFWU0P9X'HZG.$8S"D.SV%5>LAM@I]A:K(`K2;%V46+LSBS&P@?2Z
MQSL7H/JH5]*'<9/!#*4(L_.`&1_@J2N,BYT=*8H2,MT3!10\D/3&839`CPGR
M@[4ZL<&MXB0+_E,IP67N9?.)=*_HH7@!)#<.K9ULZV,B(^S"`'-]N;$Q4R$M
M00T?EH,V<ET'%XEOFL;%%.,XBJMR2>=Q`8GN/22:-<D>$HM`]]"10L+:2N)+
M;MSD1JI[T^)<T)I1)\I0@C_A0\6GT#TGJ&(ED]U`L-8,[JX%N1/BQ&BL.TY0
MAX@KL7G3=SF:F2PWI]2B>[*D%57$":ETI_E5`8/HP#SDB%UMSM=^/R@Y1$7.
MF/S.2=.<Y%4E4"IV`\/VG3'8[J4E\\"^]H(H)0$C2B>1_4RDSX/T@0@S68KG
M5``I#-0?C0$5K`WCO&%A<E&:)<5QU'Z,O3F>>NY"=(6B8F.1;!1'F_>)ALC+
M\D186+9/;S"T_V$,VH?HS#@#^+[T&V*]K,^TYU@1WS>(KM`R3E#I>@=LX(F'
M4<%^*7EQL&:+NEM,B94>%CJ4A[\-?JGNU4X+&N6MSAGK>",3#^VK2#[&31N8
M8Y1!<F6U9KJ-G\DUM1YI'GW3T-S)LC&[M:N03I$,`MUC%XXP5UI).*N[_D/M
M_:Q*V<0[>-F$.Y_T_^^7R6A@S]R_63\,[*'3=^9_M^Q?;YWY9VV%(?136Q4!
M?X0+V.^YOUC#T>0WG74AY,X#+-$TB;\%6$57+[<I6CC1SF/V_"SX5GFJASG%
M@OOX?X>A/ITH`E3W[,SYR+3YO[QG!]N>-&*F/PP:EM#&(5--MO&>&).E'&DZ
M[5GB0]&#*<8X/`N!BY5WG`SB_"Y;YN'V(!\?33&5]@3RH5A"E&(<DB;D&!M,
M'!^*Z2%)1P.V"EY'UK'!'//AWO6H:4BC]OV(;(,@+2:H:8)60;Z">F(FJ?84
M\W&=L4`]QLWB[H.7H"LO+?:[2#9`$@/SVL,@_,E<",6*,`ZWNL6MC^'VL1#W
MHL6RA`R&XGMS402IQ3@PM[O*FX16+UK\1B[0Q=$?#@A=E'P+?!Q%)/W0"U8"
M<!6[`>86SLQ%>R^]&8>^R94978-32\>JU="^]9`@C]1]K?]U(OIJ6.$^!(`:
MB+7!N2H5+9D7/=/<;V^<%6:V)61`5`W.88'T\AK@I-\K5$&510T$U^"DEHJ6
M7@W&W\7?#V6*'HBSP8DN-4V]!J1K%\OMXWUWI$!\#4YD@?7S.D*K)$>+ZHT9
M57,M_4X1>*6>@79A<,[K6-I]!68#OKH10`H$WN!,&5@_KP#9HXS]PX>YP1FU
M/71F'.X<):P/QQU69L3L0^?^NO=2E(K-XY[_-0](F2:T9`)`:F@YD@#(^DX[
M5#WFQ:D4Z]P[SQ4@%O1A:'W3`5A+%68NZ,,XP=S[""V*JNQB"MX^G""'6TQM
M:"F4.M`0)9D',4?\W;G2`YP3LP^]Q5\[=+[OW8#N?`60&NJ<!$#296`P]1@7
M8)4Y+SB=/!8G1>QGE/A!B@07N`%(#?5$^P$K5(_1P&[V5K=,B\LU!52&^IO]
MX.0IQ6@D1^2U:CRSX"6[Z)"3@,30DMO],&2JPS@`9^AQ$^=,ED``!22&UM?"
M`92JP[Q(K\SR.,Z0?(.!3V%H?>Q^^+&481Y\Y2D#!A^?PM"*U_WF3R!\YJ#W
M/;C>UHNI+CR^TQE:^'KHJJ.N&./P+,\?FRJPJ9=D+^*3)V(J0\M?]YM4>4HQ
M;V(M9$9)$"_JFPU\($4TNA,!<GGH0[*JFS1&7AQR+,%%J;\#!&]N27DLP44C
MW<!'.5:/7L2Y:N$?5L<B9V#".,T3A/\S_\6V^I.;:6_<_.T)+D$M>9DLW>`^
M"I:!3_+]ZZ(5K-MI'`9^6;,5QG^J,^[>WMST9I^+2R&<Z[$S=/J]\=SJ]?N3
MV_'<&5];T\G(Z3NVV[A<V^I(CL[?UUEWQA_M\7PR:U[C@M*^,HO=LSJ+$VP7
M,ZM_.YO91*FN:\^;U^,P>$8+$9O=.IM#YY,]:(N]ZNOS;`[/ZQQ.9_:TYPPL
M^]/4'KMV"[;(V3BML'E!F^2\-[YVKD9V6]HLFR:K6*'"[UNQ?8Z<WI4S<N9M
M#';FJJK"[+LZL^/)W':M:>]S#^NW^5F6_X!4A<T?J1FU<K=.2S?JE*ZK8K-)
M>2QGC/V5;<U[GUI`NQ2M<XV3<DTS>U3<[#/MS5HQR:L\)9FVM!_C-6*4B9ZH
MZE+.Z.K6=<:VZY)+B?IX,&U?I6K^*J7MV2!2CKB^S^P>1=P(X)SR4=@,;ISY
M^N:DWGA`!"!^WQZWXO1=%"(?F\:O.;8-E(0OFR#1"P=>YK%%H/R7:X_L/C&5
M7V^QK=BST6?LTL8]+$%O9`UZ\Y[UP^VX=SMP<)OFGSUS\[L4?<W),R8DH.'@
M0+DX]_;*Q;,%F8AM$MBTH'M0("D,*,\I%P@/**T?MEVW@0E$U#GQ1AQ!*=^I
M(NBZX^;%W(70(DDHQ[H+I-MCE(ZH11Q3/I855[?'?"G`%G%-N=QRF-T>M]5X
M6\0PY8%K47>;=EP-OT5<,]:%M2!<CUF7HG$!^Q>2-6,I)F]/##KV%4E`NV-&
M!-RF[>Q"81'7E/\M!\3M<2N(WT3<4VY7&,6U:#G"<$XD$>U?Y4%=:U*!HH<!
M>2<[3,=D;XD\/,B6D_*^*G'$YBNLW7<8)CM;9'J)K"YRB[&34!;&.GH7/.U8
MU?L:5"&$\&G?:BO-CU<5C`S)@YT/:%&\&PM@O-9>]YX82^V,MZKXHAJW`;UC
M=^8]W7AX*L=3.`28:G/=6W8JN+`$-0Z6W9U/Y-:73:#)1X7=6O=V(@`4D9CF
M;172BUFA"Z&66>S5K`'>I+ITW!YW7HLH-3X0\5Y#*7M>+0J6N^<;ALDG6V[)
MY?)Y2((3/HND/;^Y;F^BH/;MN!$+9.ADMF'8P?PFI"Y+:DNEEKH]RQX8<64Y
M.CSB`<)^<EOB44H&!J'7[6,.&T)P#1DWI@8Y(J6.U0TW>:`@I-)]'&+_L0;1
MAG$0%M)5998"**+1?1AB?_CDFC`.O&WDNLY[H?*<(5R2R^ATGX@X8`R"-&)>
M5%_:Y8%E]JB-B.I^CX;<'2T"D_.WU!X$D_.VMZJ$+%.;#M1>E7'K)_)JG-JB
MJ4S18"!8CW&$C#+")!&]66LI6C)!]"=72VLA^XT7Y4O/S_)D^Q0W%",QI5FK
M*!`Z$%6TA@NY$XZ<RMQDJJ"@",C,6CB!$)$JP3S?7J\O`#GXMXPM8ZK20(.7
MYPC#ED%>LOQ=!FVL=]F\4UO$`MZ[VHH]8+9$;0,+RCXTV)18-K9(DBHMED@Z
M@[-"Q))LL#4VBT#G0RGK2TE=+_02B`R\]KK#-`D8]7=0A%(W[_TWW[\[SP;(
MG8I)=,=A0/7+!3$T*[-A^J/G%\J`#A.JO>[H;*]API&ZA6$2AO$3R?D,X^2W
M!RQFZH4(>X@L">YRW`EYS40R:E1ZT)VF5AE$ZIHQ=4Q-DWB)4O+,GQ>*`:U:
M)9=.=[IZKS$FT4)K+JF/6P988_.D>($1ZI8$9+H3S^JN2:J#YM'`D0D.EC>/
M)*8SE.5)1.I[=^,^+:J_NAQ4X.2Z;]I10$=5)R9.>.6'(0CKU),`D-D/WHGN
MVW>4IT)5_9B(,>%X%K]X(11/-H'NVW;V<F,\N8W%B>3FH1"5VP+7N\V]#KD?
M/+2XYN56RR?[8;DPJJ:^<M)?2_Y+)`0G.TF5=<JD:"-'29_D@D%"[66SSW3I
M.(\BE8B-SSMJDQLHDADPG;.%`IZ]HX4ZUR@46Q3Z0+Q(%(WL<^R+/@DOA$*G
M57&,B3Z")Y1`IPE=L"6@#]<));AH]30J:.9]1^VB5,^E:ME?K(O`YEQXQ8P1
M6S[V<HG(U7-H)]+,R]#ZT&T>1/>;*PE+M[[0T:1*'QH#9#:;,^3'D8]#SG6D
MFPT1'EE>Z&9>1M*.+Y7&JCI0[%SWEI.Z,=2"\B.JV+CU%40V(A)9Y8\P&R'C
M`JK][(;?J^Y-LE8,1J;45VDI_0<ONB^]I(@;K>L]/GIAO@9PFP0\S'B4ODCW
M9EXK]K2'ZE^EB:W+T1?_SM/U91J'V1'=F^[-Q5:,A:=$\Y),=$S*695161EV
M.-W5&9928_,ZB5.!!?/:&W#L9<?2.K^)V>KCA<K+,DZ>O$1TLP.X`]UAHQ@L
MSMD7H%J,FWDI_IVH>%`A3=E')!7PE?:D.]P[#&B@HLQ'''1JK=K:N"$JOVB"
M`[+QZ*@$T$<,BEL<=0K8*86T'<T13/5,,BPW2.W*U*Y(UI(>9%^;#!+H1VI/
MAG.-LA;!!%?SP:2C-F<DE_09*2-;-&JS!B::UGK_[7LS(_)R23K,,\SY31`%
MJWRU?6-YD`OF3W`'.N\.`/`X0RLOP):23)9##*$7?L8!RF%B<[K4'0@H0EZ_
M?>!071H7/@#UX43SIY@((EBO[=&5[M"B>6M@ZNX56P'^5G0T.RAUICOSVI8E
M4/I[O;8PC//D6*90ZDMW6K4E2Z"T]XH-`<>E1S.$[WUI/_71DB'4M=?\600(
M;WB1S0Y]20\J'6B+^%09/01&;=B-XZA/TAIA2.I2W1S_A3]>[X7`P!/WH"U"
M.PP]93E-W=42WYXO7)#3U8?RZ_/;*Z6LO8@$2Y\P7MRIO9#$3YELT"-_W6'@
M\2?_!5!+`P04````"`"AA&Q&:%8JWSLU``!\P@,`%0`<`'1X;60M,C`Q-#$R
M,S%?9&5F+GAM;%54"0`#[O@!5>[X`55U>`L``00E#@``!#D!``#M?6USX[:2
M[O>MNO]!=[:V]IP/DQG)GDEF]N1NR;(TT1Y94B1YDE2E2D6+D,PS%.GPQ6/M
MK[\`*<E\00,@!1*@K5-U$L<&P.Y^&D"C@>[^QW\_;>W6(_)\RW5^?M/^X?V;
M%G)6KFDYFY_?W,[?=N>]X?!-RP\,QS1LUT$_OW'<-__]__[/O[7P__[Q?]^^
M;0TL9)N?6]?NZNW06;O_U1H;6_2Y]04YR#,"U_NOUE?##LEOW(%E(Z_5<[</
M-@H0_D/\X<^MRQ\N5JVW;P6&_8H<T_5N9\/CL/=!\/#YW;OOW[__X+B/QG?7
M^^;_L'+%AIN[H;="Q[&FG__L7W_ISJS_1=Z?/=M"3N#_N;C'C#R@,+!6_LWU
MG[]?S49_=MZW+]N=B_:?P=/67)*?VI<_/*TQL]=&@`?"?__P'YWK]Q?X'^WW
MBT[[\_N?/E_^)$A48`2A?R3J_=/[_?_B[O^P+>?;9_*/.\-'+8R@XW]^\JV?
MWR1$\?WB!]?;O.N\?]]^]_O-:+ZZ1UOCK>40)%?HS:$7&876K_WITZ=WT5\/
M37,MG^X\^_"-BW<'<HXCX[^:P;%#LO&'=_$?DTTMQM`)HGWKLQ]Q,G)71A#I
M+)>B%MB"_-?;0[.WY%=OVYVW%^T?GGSSS0&G2-B>:Z,96K?(O['N';\:)%1C
M:V*MV[XC3=YA1,,M5IZN8_:=P`IV!%YO&Y&,V8C&O/?0^N<W1'_>'K2)?/C?
M1?H&NP<\$WV+3*0WK7<GT=IS'=^U+1/KK7EEV$32\WN$`I]'*+=C+51.#0\+
MZQ[A#H9=FF3J*%713^8W(A#[D_7D@:R2&-I"XF:/4`?=\\!=?;MW;1,OX==H
M;:VLH/]7B+6U+!O<`>O@JF?X]P/;_5X:C-P`<JG>/AB.@(13S612,`^W6\/;
M8;2LC6-AD`R\3JU6;H@7*F<SQ1)968@KO&*CR*1_Z#QBG%R/*\-<0YE43,@?
M>J%'EIRN[PLLM7`/F70-K"=DBA%$:2J3DJF''@S+[#\](">R*9C$T%O+U1ML
M@6RL.QN)B0=J7Y46C2SCSK*M0&#R<;K)I'#L!@COK#OCSN9B2&LK=>5*;"]B
M&Q7<0ZYFX1_1PGCB(T=I*I.2&;+);H8M(1$UHK>62<]5Z%L.\GV\U:ZPK@I:
M2>Q>DG?CK15$^SXVU?'WR.:%#\\"PA/H*E7WD8U6&*Q?0XP6\NS=P'*PZ6L9
M-CZL&MQY(-1;KI5QYZ._0BR>/MF%!>P)>OOZ+1^Y%E"5EI`8!0NR'$OB)CU6
M)5:=&+E`\VHM/#'2>/TJLO;$B`,[5&?YB1'&ZE.E%2BJ;JQ>-5B$Q54/[%RM
M12:XVG#Z562=B8(-=*C)\A"C4GB`^JP00>P+C%'_;GF-`L.R_;'A$;/SD7OF
M.6U49?Q)9:M2>T"08*A]M1:!(''<CA79!$656:!KM906)[!Z^T60-&:G*BV8
MHB"+]J^!YI*DUDAANR2)[1IMPZ(*4'"8^C@XC?"JO9]%Q2S2MRY:N6HLU+G:
MDT-ARTMXA'KIYLJZP!#U4MXYG?).K927IK=6*LLK1+UZ4![^>E&_*$WG1366
MP]%=4-P4XW:MEM+B!-9#EX#9!7:I[CZM*+QBO:N_;RM*=[%1:O**%66BQ%#U
M<G(Z`_5[^$3WW2*#5'GK6-R;)]:?1;/AK0YDTQHG"0!>M1X>UY+GK!\BNN[Q
M$-XJO$-O30MKA!\](]U_*"F7XRB6$[S#3=_MV[RC#E`]W<>/O37=K6$5)#K?
MNP:*HR^]W:+M'?(*DION6CVMAFT7HS#J4#U=CAMTBY)VZ%.K3J*U$=I!::4\
M=$_3C']M.1;9,D?X/U-THZ<`.28R#Y23`:6\0\>_)B/M0PS:K;>M0Z_DCX9C
MMN(A6LDQ]M0?Z+?=58IHFSS3=SVJM",IK0W_+A)5Z+_=&,;#.[*DOD-VX!]^
M$RVR;]^W]^_R_WW_Z^7QU2V6%!KB'X^;@FW<(3OZ]G+?F-;VG0:D+Y*OW1AD
M[]ME27[6EJYW('ZO:H+S.=;OSRML(&#]ZMO1U_`<01ORPX&RM>=NN?+<R\YE
M<I`4,";D3<OU\$'KYS?M]\^TV*Z/3+S!>B&%Y<(H^6CUP\9]?&<B*P8(_Y#%
M!?]J.4(;PXX5O/MDT70)M\HUDHH(=9_E(9`6K`N3"HJ^1B'']%SO-V2:A-,M
MI(HW;Q%D9<L0FPM0"$FU\UY;L2[;%-ID2?:PK15=6`J+/N("DOY%6>GGK?HH
MOF_L.L9Z;=D6.9+'5-SL+;6<M$D'L/V21MEILD\;CA2Y4A76%246%'']Z\8,
M;2P_\`PG(&&2+$5/MUQ^J%GHPKLDBV!(\/4O++W(CV,/L?7Y]$^T8PD^T[0!
MDJ=1K,-6>3"\%WA8NL23+;06=(Y0<--4(-\I\BP7+WLFB=MF"SK5M!$2SU,,
M+N<UBKZ+23,)>0/;V-!%GFJBM:CSE$(BOJQ1Q/N'#@/+7QGV'\CPF`H.M=9:
M\$RB(0P^U+YY_H9L^Y^.^]V9(\-W'60.?3^D&H['+0GHHC4:?,HA2#[6#LE7
MUPZ=P/!V43H2X*A/;=H`"&@40Z+_L7Y3,IZT,_3@>N1**LYTPK0HJ3T:``2#
M<`B/GVK'(U*2'N9IDPAUI\&0:M@`Z>?IA83^J7:A3\,[VUH-;-<(6")/-&N`
MP+/4LCR]=2\Z[G;K.M'#GOF]X2%_$@910BL\*YE+#Z-?`Q#AD@]"I.*<&]MQ
M\8%E@'\';`I@<ZT!85,-XJ#B//QL3PNC<&S<(`S2-(,()([%_WB780=_[%NE
ME[?\_%JIF]M.ZVWK*`G\<V\RGD]&P^ONHG_=NNJ.NN->OS7_I=]?S*N^=BZ8
M9BO%QH4X&ZV_I<;[>YUL<3)PI5BZ9+$T7^!_W?3'F)W)H#69]F?=Q1`W4,4,
M/P]7BK</XKS-%Y/>/W^9C*[[L_E_MOYVW1\,>\/%WUO]7V^'BS_.3PG.3PGT
M?DH@`:5X)I$$;:X3/<ZD/S7(LDSOINGC`S'BJ[QC*0]4AE;P2GW?'FA>\[.%
M0@)W11@`+VAD'-[4HJ/EZP?9"%;S.$(.B(EC*?B&8M\VUW2IYGS!GB4NGV8]
M%[NN:49RPR=2PS*'3L]XL`+#YJ'"[%;!])(.$9^!2CTCY0&;D8@"!YE]PW,L
M9^/SD**W7])6<<T@8E`.[DUJL8&S1=+LNFQ;?3TG;)+U7-@*.GSS*W>#W+VB
MQ(/31OVLB2Z)S>O0(]F!(M]H5/A@C+Y'?V$>D`2Z:X^=.!>@2:<CB+$>ED<Q
MT[^I,-+8@'"4\42H/([7Z"[HN<Z^&DS\4X"P@>0'7AQ%M"4YO-HPDJ(C:(]E
M(48@-&4\-JH0S5@Q8X4]!=/4.,U'-L\.A*^,ETO5;)W1WR8/T95$_PEY*\M_
MOATHMHU2A](>Y7(<04#+>"=5T?8J!VG&6$V%FL<2A+6,-UC53.HH@UFY21QU
M;2J2&0X@X&2\XZIHDI9#+M&WJ=!E66#=V>D'7J1XS[;"9'V+Q5WR-)H;IJF0
M,KC1U&O*U,W3X07&:2J^+'9`@-4ZD;KFOT(_3G:T<`'G?L06*?-H$@<T<OSH
MO<X,_15:OA6@.?(>K16*13!#*W<3PQ1I.^LJI-HO:Z]$M0@`5+NR;B\@ROLW
MDJD)<Q)/BH'K[3-/.9N>ZU-7!M*-TTM?"$6)!\5?UEL%B%]$E_;TQN3N-0<"
MIO1X>D-V&EL@F&6=54)SJ>NGI_XQM2'MDBROEW!WO:$JQ`6(C%HW4V%U.VVW
M3`VE+[HG<00B7=;/=,*"VB-OLVT[4LG).JVP)ZRKK&'U154:=R#":KU+0KS%
M'G$KRN5^%_QF!??/AX$!,H+0.]$@%OF"OCI2!:.@NI3U:0ENRBECCU[0D[,O
M,T;0%\(RC(#/)]1ZKD34D.-]%!Y"7T!+<0(BJM9;-49!G)]\Y/H,9U2JF?;(
MY*D%I9]P):F-N$O&1/4,_WY@N]^!^*Z/XC%0O>[\E]9@-/FMAOBN[8/A`%%;
M/Y+4KI9/`F3P)H3_8_%+'Y-],^V._ZB:,+'R<'2Z?\K2/;^]N>G._HC"RX9?
MQL/!L-<=+UK=7F]R.UX,QU]:4XQ$;]BO7-['(G)TRC]E*1^.OV*EF,PJEW>^
M@!R5PO;[+(43K!2S5N]V-NL3D<[G-42.)HJTT:EL9ZD<#'_'LZP>ZM)UVN@$
M=K($3F?]:7=XW>K_/NV/Y_WJ]3!=5(Q.Y45>'1?=\9?AU:A?DRR!@EQT<B_9
MNCD:=J^&H^&BAFF>+'9%I_5#EM;Q9-&?MZ;=/[I8NI6OKN`[]#25'W,K:2HZ
M=Q^36[FN'BNQT*G,[5/#,=ZE^JU%]_?JH::?B-($YC:D67\4;?O3[JP.=:27
M6Z'3FMN"KF[GPW%_/B<&2P_/H]HBS\'B)%3".[F=">O`S7`1&U7=\36AG^SU
M_7$=&SV[0`F=@]RN->^/^CVB)[_>8D7IST9_X(ULW,4,=$<M;#AV6W^['7=O
MKX>X3>5Y#;*52^@\Y#:V^>W5'*\39`'N$UNF>LD+68Y,"[*3V_C$+<C6WPY#
MUX"("*>9>M<I/G,[9A$^XX$KY_)H,K,8R6VG1\.Y-CKS%C2+X-S.2K.C:Z,]
M85"SB,YMM$FSNC9BT_8UB][<OINQLFO4X;2YS2*:<@;,&-U*5#IA?3.HO^"<
M#Q,V>&U<Y(U=%@/Y39AB\M:H.$?;ET5T;M=-6L"U$<LPV5C$YS9;IN%6G]HP
M+3@60_E=E6_'U<64D,D`%J5+L9G;<XL8#_M/M([?^+O"U$Y3SWU`7K";VD9<
M!0NO$@^"J9Y$^JI\U[JZ1V9HH\D:))27%$IX!&W218GCF7WN6E!:S4@L!?)R
MM2/5%MCII80ZJTLR510PMSAS(-1Z@DH(YR4]$NJL)D%5$4@$P<Q+1+LK^JK1
MU#FA5:6(ZYSDZD@N+T5/IJ&B!%=%YE<^_5B&?CT7U1D^I7/VPT23INYZ.2YU
M2_@2$<C-6Y5LI&:OR@N2(N@T']KM/$5EK?-.4@`/G?>%&RS+;;CE@9)JIFA/
MH&FXRZ92SR7GQG@2DGFRF:HTA@)"SY$)[K=JQ0[N7[<^6H?VR%HS/!,"G9<_
M:68K\3P0HCQ!>*I^:1R]9?<M9Y-Y_D1[4IQMVSBP`!9DV[9@Y,XC"3&9&KO(
MY4[B,D,2+3!#/L*?O<><7*-'9+L1+]U58#U:C%?[98=K#FHG<RFP==7_'+F0
M2Y_NR<\_\RKNR5?IO^]B5DW+#LD]PARM0B^"K/^TLD,LS0'6'/+..0SVL5B'
M?+%3Y$5AYSF%H2Q6TKZ@Q5W`B>P(WQC(^8XV]PJR]0R\?9")3S/N*$[D^&I'
M'X#MRZGTHQIXAZ2JD5N?Z/1T#M(I'AM;KH.>WU.-_ZH.$$74)B]#[=QDU8&O
MLT--/P71V6^7R"/)\R/EFBKRWPG/1TI:L"SY>J[:^QAN'B"I9JH<>R71R-,.
M0J'C#BJ\G,3IM"LSY^+AL?QT`E_:X4*B<`1\C_6[08YA`DQ/!R54[!@G<'1D
MU!XHP"0Y]XB='BE0%_6)4`&Q9Z*Y]^SIH`'*0]#:.:`2?IE[RDXE7*7?ZUR2
M]%R2]/QRM,+RI.?WH>?WH5JX'\[O0\_O0\_O0Y4OJH,0GXK(=3%F#YN1Y"=N
M?4VXCRHW0WF@.+QHZG8`^?WB,=.GL?LM?]0\GYH`^0(G>15NHM4JW(916I5K
M]."AE14Y)?#/-HI$ZYC=K>L%UO]&OP?Y9'B*)'U!>QV0RJB>:S)(\Q@Q-(#5
M2WM4N<2#5JQ*#UTZ;P/3]9(+PL\E;JC+W97-W"#D\[JDQ./G<CAH%0%]]B2=
M/4EG3]+9DW3V))T]26=/THOS)`V(]-$(&QEFUJ"YVMT8_W*]GFWXG->2A0;1
M>S4N(0_=`M88+#PS(/(^K?!`:E;K,I`)@\Z2F'8KN"KD=5[9:]<.G5=[3#_R
M'!3$E!*:N4YJL(NBNX2R<]45YTI/8SM^A(6\N;L.OAL>RG#/PU&HNZI[!SF@
MBK,H_3H""L1\>/!<S-0OKK=U';2(7$F[:R_<]`S'C`J%3/'_G0">AE%H8L%A
MEK1]2'\82[,*;L>*[P1!<8C$L(OTUMX?+<R$IO=-B1N0R1HJC4&Y16+VTQXU
M`?(%]D@5+WVI+GFZ)YY?PN39$W]VP)\=\"_6`7]V`57@`M+5\CB[@,XNH+,+
MZ!6[@&IQ(S3R^%F40SV7?JDNOD:[@]ALG5U`.D+WTEQ`0V<O\U/MZ\(#Z6UC
MEY2+;E>M'#:*65RE!E-C;Y>%KY`2-,KN5JT).MO?RK2E&CL<V.A/W."%=SL:
MW35L[*=,5K<DFR!TDFVT&ZS=UH.-%IYAHJWA?2/9/[]:@;&U''\>/CS$FLX&
ML-@@R\M&PUB"60C,2VU=96,4=._\P#-6C'`1L?[+]D?-[WR*\*'G91V#`TXX
M'Z^G,O1*@"*,:H(S/3T9#-H3P6O)N\I2"`-CO4C,F;SJ><1BBZ/LNOPBT3WR
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MC,-5];Z^YPP]NO8CMIE['C*M@)@-0M?ZO.Z*WCQS)@?EREZ$$=DK'@`->3!P
M@\PI9LKR?=?;148<$PY6%U5QE>(8<*D'?7"2)3_T_9!HP61=1/B<7LNVHH*_
MX@`(<0!J_T^241B@.R\TO!W^2R>BHLT4/]1\V?ZDN]S9I(,"_U2UP#O%!-XY
MOCAOG,!3I,.F4]4"+R;O`\V*XE!.$'>2<E#:LF--_B=TD.!:0FNZ[&B_@<)D
M@T*6O76F2&"O'[2FRX[VFR1,-BADV3MCB@1Q&1_>#BL*?BHIXB35X*E(2B"3
MCU8_;-S'=R:RX@,M_B%[CL6_6H[0QK#[3F`%.\#3@UOE&NGLX*'1"VISC9*.
MZ0%]!+A)ND7-WAJ&V%R`PDK=,M6(54MG2V'1U^I5F2%K=3\PMI:]&UE;*T#F
M:,I<I^$.RW;=YAVDLZXXN>"1I5UV]8#<5]Z-9=O6QH`K1T?>G4RS9;ON/5!`
MJ'0B05$JCMT=60Z:K&/WV,!8D8O1W8WQ9&W#[97K>>YWXCPS'O!?@AW#O5M@
ME.6EHG-EL=NLXBQ!$"OVU%/XB)(&(#^8&0&Z#CW,R11YEFL6`Q@:I<$`LUF2
M[3"N"6#DKSSK@1TZ4F"0EP)OEJ,J#>63ZA6L$#)]4J&<"&",@LGZX.#MN3XK
M02._;T.P%&4$M`N50CA##\8N"A2=K`GU,&#9E@V!ATXV!(;:V(ODLB"V'#8$
MA#S)$``?U*;F(G'7D_5OY+V9$TR\&0G@&8=$$I/U'*WPKDN>YO4,VT;FU6[?
MSM\W9*QV)P[<$)BE<`EIAMJP&"IK_2?DK2P?33V+7&AF^6D7U`?><$W6`C'>
M(.S+!L#(WR,)\SY_C0:[-`1##OW@84-Y_:RC*28(%-BE(4!QZ(>=9-H8.H?S
MSS5:><CPT0"/:#TBS`IK`14=H2$P%F,']M>ICB:*3K#[*K(P>)F&#<&(2C4(
MA=IC79HSK%&HNW5#5MEMJ$=#P&&3#Z*D]KB17+R3T3-BVU6R1T-08I,/HJ2/
M^2>&$M2C(2BQR0=14AZ_'*W.>UKW\71=QQR[SBK^#_Z&Q.C<$.R$.0%A_*35
MQF5Y7PT[%`Y2.W9H"%Q,ZD&GO]I35IKF6\>(\U@ADX1RDCUWZJ&M%6Z9R:$*
M#-)(*`4X`N%5>S;[@B7CCUS?QV=)I_\46,XFM/Q[PA3OBH#;M2%0"O(!`JCV
M&$;>0"[V;R`9!^A$JX;`DB<91$#MZ6L>N*MOY`H03_[$1?W\WL!;<Q3N#^/"
M[]L0M$09`3$L>Q<'OI<C/&(ZYI$9A+\1;;5[$Q=\,\?JI#L2HAR`$*@]'J>Y
M3+Z/B#*TF5BA5O@/QD;8/&2-H3N8)1D"L55[J(;9("N\<%:-7,?&HYC@`H1.
MEY.VQ7B4EVS5$%#R)(,()`[)]>=Q8B7:`9(Y_50TTPY)Z:3+ZI##[9QKI\2,
M.>?:.>?:.>?:.>?:T1$7+<._9&%7:U189!O$I^ZATPTWH4^<_W/T$$26$HEX
M948Q"??7/MM.(4YD+WHBZ)0$A<:!]M'60AQ(=XB#H>TV21/1CEZD(E,DPAWJ
MH*J(5)$X=R;MD,Q+UX0J('->?@RPA_YIIGC$0V*7GRHC3P<O8P;88]F`O!EL
MXB&QRTZ>(3NMFO;9I;C40Y(OG5]*5BUVYQ%Y`<F)G?2J\.IU,[LI2WDN!I<X
M"Z!1]+$ZLVCA?C4\RPTQ/1Z)%1&UB^C]&I`/3Y`'$`O92U>*'D+(CKU-@^T;
MD!./0SLH<]E)\?)T")\'TNT;D!:/0SOLYE"[4<Q05+,O(GCA&8YOK(A`_:M=
M\B]L1V&1,1K@/BPN$MWBUY-T\AQ7M+9JG(DEY`X#I[E[\32$='8K5H!B-8Y&
M29=AEH=6>&R>99UNASE2LY\QIHC+I1>^ZE*[W$D,"NHH\GM)"@KJL%Q?JE<\
M:=$FS0")3;Z>MY$UOTQK!I!%&=+3)BSQ>KH9\.1)!DT%C>96TDVU3R32_RN,
MTF4=F@@_"Q(9JR%@EF4,O.[1$_+X1V)O1WE#&/D`A(=H.L!T?B!<=7K`G6#B
M"CE8X"O+L)_9&2`C"#WA#5-LM*:CS64-`EYU$?&2F2":`1>5:O!*5[^\53ID
M-&L&TE*X!&^=-5J<)49@-`-9(2[`6VLM5M<"`1C-P"1/,NQ*DWL#EZ;S&#/'
M])&1CMQ^NDN^`!,@%DJ+FD=AIO>NC4GQXT./6.WI3]F(F/EBTOOG+Y/1=7\V
M_\]6_]?;X>(/S4I01WX4P8@86ENE(=%[<CAQ,-EVVH3`P++/Q3W3.*TS\.6%
MUA@"!%NBO%"=A9SZY_)"ZL6JY46PWN6%ON`M=6LX<V-USWZ$EV]8=VB(0-T;
M.I&RUP?H$39:KY&'CXFC48_]]CK7L/:7[@*R!*@$_1^2I3D/K#6RQ];*M8W0
M[SIFS]T^&,Z.*5EV)RWK7XF0#)OD>D5K-BJ`EFUGB$0%:GBE>8Z=U>]QVSEV
M5HRYNDP>.:6RVS2RM'J"S:0<W%(N)._C4\]ZQ`OMU#96D38!>P1I2V^JZ08!
M$PSJ<;6"!9<5&J6*UGJNT!C"K6R5KTZ^6J[9IV.@\P/D+,6\A\CT]LOVAYI7
M=P&-S^98APD'%_</:L\+W>^&9_(/"IEFFFX`=&(AT:M]>15EX[PR?!2=+C';
M1BP^SW`V$8?^U>ZYS31^J!MQ]LR>8V)=<\;&EFO`5O,U-<<2.KQN#?QJ>III
MOBIIN2LK5C>]MW2T1IZ'S.@..$XLW`V#>]<C:==96SNKG[*8<>$;1A'Z(<AT
M0FQJ>!,OC@V(<A)/D1<Q(XH<U+]I"++YJ/(24^[<BZ.ZB\V[N$_3$,O3KJ?G
MET;U)`S\P'!,R]D4@RK1L9EXY1B0[9"1E9-FNW6=@GL:HY/^8'&)U_/PE".;
MMP`"'1H(D,C2I[B4=Y9DH76/U:N!,`FO>&K#19BE0L;H>_0GYEM'D?[ZXU>$
M#PA)M4$%$:E18!KGZ!ZU:0`B&5HAJ9<-"(#>N!P_2PMYC%Z'/+?06(I42L$#
MC6+_%7WR12>R\FM0NKO&4!5G`\11\D5QUS0CX1AV3,O`]::AM[HW?`2Y"T@_
M7C>-L1`G'\2@[+D3?'2'U8*$.ZX"DK<-VJ/`UW="O35'I!`7(#"2+_O%3`9P
M%Q'KW01@1+D`@9%<;DYH(2V(2Z9S,V&A,@%?3.MH$\2:%?UQ\A!E;>L_(6]E
M^:S#?_&Q-,;W1)Y`N,N>0\NLCE3Z+LJLE/21-(;O)(Y`\-1F.F`M-W*F*CR4
MQE"?QA*(=5DW@[2)6LJDH8^D,7HG<02")]M;49C`CC3P.B\.O`[G0E%?+TFY
MRM;/736&LA@+('9J[^PK+DO>5/1R/(#PZ92^5TDV->TA+L\5"/JKSH;97,`Y
M/(%POZ),F,T%E\X*B&E9)Y)@`-``@9YO6E.-Y<XF&92OVM<#41(-`(-]FV,3
MC65/)Q64N;[.EOC7`]?K&?Y]N>-`:@C],2O("HBIXK<;N4QJ,T16V=@_-'^P
M+49"=('.#<%1A`D0P81G1<=4>$>S(94+[\/[DKGP6NUS-KQS-CS-L^&=4(J%
MQ$UQ2KH]-]$[&C7'BVX!)1&!O*#L5",U<9]Y05($G>9#.R=N45GK'!A9``^=
M8QEOL"RWX98'2JK9DJ9&=11'HZBXRR%34Y?XC?$D)/9DLZ6B!#\"8L^1"6J[
M6K'_ADAZ?&1VL75M\)<B:O.EHL3:?!A@<B$X+L_I^L[I^B`TSNGZ]+":SNGZ
MQ)B3;F$!;O@;S*KU8*.N^6@X*S1#CZ[]:#F;GH=,*R")[9CY^T2[+^O.^"0V
M.]R2G$#HE,X`56DRQ8XB$_?T9(H=IM6KV.REEC5B[_J,+GIO_5Q>M8O_IQ',
MVVR8G=18`GS!"P"EN4T@&RN=K0.)>-9J)\SQIFC9EON<0OU0IHV=,I[335EM
M>I%YXA;E`_;+RT[?#Y+3+@E'^\"'(EM!&AXI1D!`2IL.A0'IE`2D<^#C8\,!
M23$"`O*Q-D`N2@)R<;!)ZRYS(1N0%".P2UDR(#>N::VM591-46CK@#LH*P=8
M$`(>!Z#L2WLR`=D?/AX_HUFXMXZQ7F/E(,GRAHYI/5IF:-AL.`J-L>PT8]4J
MP10(FNP5C$5;7/:F-%[)[LN.H@=%$J'*\P.B])/LLE2A@XY>"Z%UC=%C>:'H
M5JP@%EP6P%.)[/H75$K8-C"KR_)"D9]2!@`I'D`$9+LHJ:2PC5Y6E^5%,W8.
M/@\@`G5N%(E-C#TKB@VRO&C^I@%Q!>)6>NLXEY4M4%961NC0N:QL)1[><UE9
M6/2U.F,/RUKWS@\\8T6+*$BN?H=FRTM%SCVQF"DZN9!,U5Y9'&EUS&@+$DN,
MR^I5/SA<F;L%B0<7GXJT_T!(YJE8#T]RP@O>V6>(2``3.++64(K#LL/I"]CI
M7($+F7[WA(>4'U$,Z_&/_OZOU.1P+%N2-YR^J)_.E6R3#)B_V`C?NEY`$M/W
M7#]X)A:*_X4[Z(N&"-V0O!7G?*<IT"$1P!RM0@^+%OD]P[:1>;7+ZE+!^28^
ML+Y8R^0/THFRD<K`'`16B0?+BVXK_&MLL.77"6!^EAM,7SQ/Y0G"4'*Z-RJ)
M7Y$?X*W\=/R8`S40.P%^(-PD9WJCDC<P+"_.@'42:HQA&H@9EQL(,=59\$DR
MK#M&#<%]"<&[;`G!(\-=WP^WAYQV^V39R-LRK-GJOJFOXM3$.JAEBC/1\2I5
M0H4J66Q_=6T\C$VR-N"5DJ-NU7Z\&7I7APQ`!50;8R65_YGE?QMX"`V=`'EX
MKZY1_6B??EW*!TL`5#VUKJ!*IMXUN0]$CJE@Y4M^^G6I'BP!4/749A?LQCZ=
MB.?)>F`YY*&ELXD\/%W')"F`W)"90E)T!.T5H1@C()YJ_5W7^QJG,?DH(KX7
MXM\XP1@QDG6Q^VF/G0CY(&*2*TP(>LX&KK=&5B#D<P3/E`6&U1=#>=R!$-?A
M<"1[0;1XW*#@WC5/=%CQ!FL@G((\@2#6X7$D&[CCHQE:N1L'J*_,\JBF.S<0
M)(`'$)2R[D1IU<P?#,O<$[U?\>%=CMI<7Y#X5(./%-2Z#-,4CUUG50R9YQX-
M`R=+.(B/6F<;5:.PC5L<*5K?AF$&LP"B)_D-$.5FX&HW0W:44?7XQYYAKT([
ML8$"6U/)T?1%[62F0!PE5]X\OCTZX51-!BH\CM[8E60'1$VG>@R)5S$'\O'J
MLK7"+>>X+3R(OMB6Y04$5G)1AOCXB"U<(%`"F'V\;OH"(DX]"(':N@U3SUTC
MGSQVYY5OR+;4%Q0FP2`.DAT6U\A?>5;DHV:])XF+%`A[+DX<55_,I#$'XBO9
ME]'=>`C%%7$>D1?3!(!&:ZHW$C#%H'@E/W(ZFBK[(P-D>6>:Z2U6.K602&5'
M_21MP1GR$?[6/;$!T2.RW0>"-EO6POWU!J$@&R`ZBC/U%P3PD#>YF;B)4P_"
MI?:I2]IB'Q@KA-4P9#E]H![:@\0F',3G!;X'23_%VJ?C5_HD;D^#]CI4MRA`
MK53K^*A##'&U`K5:&=-PULJ,*$"M5/O@I?*7@_6NE`P*7I=&<@4!ZJ-:%U;U
M0JAUC610<-9'L?51;5G6D>6@R3K.^P_K3+*5]KCFB05E+]G-EL[`E"SL&BD2
MY"?E==-7XN+4@Q!(=L4=W@0>J")N6/"5%KVQWN)FT0P)F99!]A0ACUS#^1(:
MY/N[Z'86D&^NG=ZB!<@%I9IPJNE8NK=S)#U5NK==MG1OYURZ]URZ]\66[IW:
MAC,VMIQ*=NE6FF8@I-(*8J&%U'D%4++MU-2GH4J4+G3-J]"4D[N6V0O+8E-K
M$D-2'8P$V0^=%68"[Z;)(R>AJ_/^_2=FSMH"(RQKMK'8JN^6YD'VD@4=&5SG
MU]"PK;6%3)+E.+*LCB02LIC`B'9757N9#TLA#L`%38-B\.R].]%$[XT[QXN\
M+)-JJL&KVJ_S@@0KO6N[4Q>5M<Y[=`$\JMF=)96`3]:JAT%)E[37MO9XGDP1
MAX<*L2=KU3/$GBIIKZC$A8#8<V1"8B]=Q$)2"@ARY;'8\6J\9YKIO<-2>=(M
M`S#W?LJ'+JB>V7-,T9->-5]3L^_3X2UX^W>"=+4S(IJO2CJ;-:K436<;:8;\
MP+/(FZ'H-'F+8?)G\UNN(<OJME14+:G2I2+W:)C#/X3WQX:FQTO$T53P9B4Q
M^K*MR!84OSZ1QB6D))KO0A!_QT0_T8.";AC<NQZ0?.5444*?>L':PV99SWNC
MTLS&3,9O588.&`EWJDQIGWG!*@2SJZ<#LS2CD_BU7Z(:4#Q[*E`AZ%,O6(W8
M+#?TE"[.;*9J4:J.32T*QB+@5:D=7Q"@CU2MK\Z.!D<F71;<B$NQ_OJK0A$^
M0+>K4B3[VP?;W2$T1]XC5CHZ'V/7>8R>?T9J["_<P+"3?R>/&,=N\`<*GO/U
M1>?*O<;#BE#+Y_77HQK%`)[K7Z8:QC;BP/7VOR+M&`4_ZJ7C%2LF0QZ0AJH-
M8#GQS#(-O=4]^1-F.?IU98?!W)?TU[)J.(;T2'(P3FGBHW\D*F@![[ZDC:^Q
M'E3`)X2^Y#B@TZ@^1OA5@OUQ]!>-?(9+T(^8D(!&431'@E.Q,YU"L3,JXV6H
M.<ER:`O6+1UI$4=#)8T34\/JHTU\C1A6(@58&QAW0^6#_=2(T479LR,!.`3P
MTSE4ATHP[RD(LY.:QT%\P0L`I?E[']E8Z?SZ1B*>.C^HV=/+>T"3:J8H$$AD
MQKALJF4O@9R$#=U58#UBXZ_KF%'2>'*+N7:];6SP[L/&@;-`H3%4/0,O9F*4
M8TOVHQ-.AH?8QW"+37YO3RL'*'['YJ`CR$N#+(G$[5O!+2K1LW8`BV,AL!EE
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M(N#LXUY9":@^S-4,N.AAK2VY5FT96N/,X%W'3!P%)")/&_XUJ`#(-Z@+DHNU
M9O@]EL_NN4[$:VC8(VM=\)S%&Z6Q1RXAQD#H)+]*IG'C!QG*KM#&<@C%DY!Q
M(PJIK\AP.DS3(KAP9JPPR^!%JN0G"D)$%CY-`2.\=#`%CDZE<\^>@E^9LQ(\
MR$M'4>Q@U*GA#$PAK<Q)B#7,RP=3[-C3J>&<FR.NW#F'-<Q+AU/T4-.IX12;
M(ZYGN[XT6R@WV$N'ELXP"'`-I]8<B2<>4X7&>^DP%SZ3=B3?)G<W&P]MC(#4
M/_0LQ[=6<8%$]AF4TZLY9TX11D`H=(E[/MXE)S/AI!FJ[$(?_J22J5L`3ZFW
M^!PQ@"JD2_#T,R/[MZ1UJ0_U<Z]+=6`10&HCN\B1!"82^U==J@-^\G6I#UL,
MH`HE#NP:1>\?GZ"DP_<OBI6^;)\#^,\!_.<`_G,`OSA^YP#^<P"_CEB=`_C/
M`?R-#N!_554B"^]%.;YT"Q:>G2M&:BMKG?>&`GCHO/:7JA@I'Y9**D:RQ%[Z
M3;O"BI&*RC0+B#U')K@`J17[,?-CU_?#;<J]Q"MFP.VZ;-.FLG:70L78@7!4
MNVC1B)]9_K>!AXB+$'G(#V;T_+@,]FDC-!]4F"L]#6&Z8CX@4GGNJVL;@65;
MP:XXNO0QFH\OBR\]+6X6%POD;<OA2GJ^'#2?N0'M1FTQO+8>+1,Y9ODYFASA
MY6":YPK"]E++JZL._>KJLMC554?EU57IV\@<[A+SD8RTN`*;K^Z1&=IHGR.B
M5%%9SHV9Q$]H<\$F3Z.R^5QDX]&,.SMJQ6I*.;!T,V7^4/DHN2P^]339R[.N
M2PUW54Y=5?79M?40-U^5=/99JU(WG1W@QWIESW7O>%Y9L(NB2]%*5PB@NAN-
M=3UWIX;<K%9M29PO8L\7L>>+6'WWH?-%[/DB]O5<Q)9VFYQ^]5?YI[&Z:VH'
MEO9%U2,R/2^;I3)?]":SAH^?U;6TT/0\\$2\W?'9ORO"/KF09*3/K>Z;+U0]
M*Y25GL>[2B:EV%5SY9]^H3I:O<@$'C=H=`%^0;\`_U#L`OSB?`%^O@`_7X"?
M+\#/%^#G"W!=;BW/%^":>.:;KTHZWQ6<+\#/%^`-N@"'4MKM"U]'9;Q&@?7`
M2V8'M5>5QDZ^S<AG4[9SF5T#/#[XBI7]3K=]69C`+#;4DH.DD,^2!Q8:/%7@
MT*=4%A:$`9;D5V(R_<(\GLFT>?[0F2+/<LTOGNM7X7R!/_8:]`EB6\`QJ4*C
MB-$Q]/T0F=>AA^=`3'9<U#-AD0B5#B\\5B/TH1Q7$-P-K>Q]Y/&8#/^@X=4M
M()2/-4)A*F(;TJB&UNK><YO(QU^]1E$^]AHT"F(;TJBR^=+UT"B1RMS2IJI&
ME;CK6Y_.Q;:;<51N>D%NB4<[EBAJ.5"S"-"A8D?!HM]U2@;43LT=.Z"+F'I2
MK$A#Y1'Q$K54LG1`3=7<;<03P[&@G6)E+43':]37X@("55:Q7TK>D2>J%)4[
M4JLQ"$XBZR4J=.7R`O6[V8ZX1!&T_6MME_Q*N<5[&EVO4,,E"`Q4<<EU[UY5
M+?9:3N2GU6O7I98>]TA'8Y-$E_BT\)^32CR=0(H.:T_)LIG*Q`6JIBXU^E+'
M.-5:69"*5ZR0920%OMC0I?!?^<G6T6>9[+QBK2PM+E`U-7!@EHD:S5\$"<JC
MBG#?\L0T5)45"PQ4YK(^SM=09;NBY\FG5.)NMO^C2-5N^5=6C:R=6XL80'5K
M]BNE[*-._%_7.=G7]Y26^OG7I8;B(@%54H-G3G+V[S33]1A9F6\V4/FJDP.H
M<0F/7?U)*(8._A$MC"?D[Q-'C$DABL!Z?(Z43F6A^)C-0C$<]R8W_=:B^WM_
M_IQ]XCB*TBP4`58#`E/.8**]4\^W5?H$?T\.+]5#IIT^^1I`V>>>TM,X;482
MA>/LZ8;!O>M9P8Z=30%JKRZM`EWXKA#5(%*:8<*+3H=[J$E6P)$W#QS-,P_(
MPT?G#`!2,-0YG#]*J^D8]@P](B=$<^0]6BLTG,UY0?V<CHI"^[G3*(L8EPD]
M5\<)WANP7>9L1J[O]["1MEN['C%B&;L6W$=5AF)AXX)#.H31>[U,<KHE_J.0
M)?[W!"LUD=NFT_N3V,FA73G%,V1C]<%'."^P1(\]G[+$S_JC[J)_W9IV9XNA
M=B>?!(N[!3[`^OCD&\N/=P[B]]0B=QY`IG^U2_U%-$]>H>&T.6.)H@QFO"LA
MQ68<S$:NL\$[]/8:W07\)'?TUAKDNBN#CRO`FIZV2996WKD`:J_FU,:4-!L4
MS4]L<G#1^;1V,G;5G-2`2_"O5F#<X+F/N;!\W_5V8S=`/GCN(GU8712=N#B3
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M[L9#D>+]9@7W4^0YUM,B<1$T&O68!YI28RT_Z0K.:2Q!`'Z2?NITNNNU95N$
MF\6]Y<4L<4Z>C#[+MJ+SOA@B`K2#3JW2)WY9VY`?>.$JB+/>VH;#,P6IS5^(
MU<<0A6Y)?G/$\FT(H(,J4X\E;`XPVIMV<K#1V\@[&3^=C;J1Y>`UI><ATZ)%
M(1Z<DXE6R_:/ZK>H`J\&\K1#4"@VK]%=,'2(`A%]'!@KU-VZH<-`!>K1-(38
M?-1T2Y8FXA@US,2!=.3V:PP:!;BITJ]]RG;T$$<W^9-U=$DR-7;LAU10C\9@
M)L2'GIZ[Z"DRWC"GAL5(DI]LU314\K3K:F)3V8LG/-:HQ.\*^\YI@S0-Q\*L
M03"K#1N_#M$`2V2"#_`KY/D3+UG(FV%EL+HU#4H!9B#P).<?C&[>!@C-D+6]
M"ST?)4\A&1N#VK8QHN=P`,G[1Z63I6<;/I[:OY%'\4XP\68DJ<R^-L5ZCE;X
MB$>>%O4,VT;FU6[?SM\W9$RG$P=N#.HRV8541&D$^E7H8]Y]O^<Z*T12"T5>
M.*&HC(_OLU$95[?SX;@_G[=ZDW&O/U[,NHOA9*Q;=$:*U9GE?\NA3]%W1A^5
M\SM+%B?D`FJO34P%'YOLS&1*H!GA$CD>KG;\J`EF)V4.?@X<'.SR?.L6))'G
M3^!%/K.3&G^^B.AY$TW_T`G9:.GLX9>*J,Z^_E[H!^X6>3GR>2\Z.!T5!6*(
MS"NW*!^U>9O7R/.0N8_#%T<D=M**=%[2M$TO6`HR`TXKR>"`:L*.X>!U6RHZ
MN14$1(@-\-`N^8442`P[NH/7#:_2S<8BQ0=LL=>%QD4Y-"X.7#1CJ1+C`T3C
MHBXT+LNA<7G@0E$$E"PT4GR`:'Q4>U=),3JOD+.ZWQK>M\+'UTS/QIYAJ1+0
M[98Y3_>!ZL+GHUQ/;8ZT="1X`-(%H?_A5AJ"#3OFRD!9YP/OW+"1OS]8C%'`
M.^92FZN*!Q:>7:X@#^"]IF9^P2G>;O`OC`TK]S.KU[*CBW%?V`6?XP("3:MY
M)3RCFH,,E7`!WU#]UY`]=[NU@NCM5]<Q29$3R]G@I4(T0]S'=O8NLC>YN1DN
M;OKCQ;S5'5^3*\G%</RE/^Y!^>(JSGO'9Y'.6:<<9Y7S,T=V5!SSU]#P`N39
MNX'E&)@=P[XV`H/)TD66I7E_U.^1?'Z_WG9GB_YL]$=K,!QW,4?=4>NZN^C6
MR%9XYZ._0@Q3_Y%@):9^ESF.;J_F_5]O,4BM_M<(*KTNP3-LYE82RBH(]E"Y
MAJ>)XF4<I+;6YO*;ATEV=6?PWHR+[RP'W$MOL(.ZB#86"&R\-+_JII#+.U@R
MNJCQ"?!$S@5(<Q^`3(QT/O5+PE'K4WZ::.XIG]9<T14V?]XP\:DG:?M+3?HE
ML/^<<WJ=<WJ=<WI)O+)TOR,G.L-O'PQGQ\MI`C6O>[6&M-45(U7/>ZPH\B5.
M(WD=!ZQ'Q0>C4G'^&'V/_L0L/";27UF-VH(G0G%F9+MD6979IYZUHKK!CQ7`
MXQ:Z2YE&KJ9G-[HB1/40RT^*='?=T2K,B^P%#LJVM`\;NC9V_L#UXO*5"_>0
M(2J>K,!D$>JK.S#%&`$W=?YUQ?[WY!^D:BC^S?\'4$L#!!0````(`*&$;$8Q
MOV.RQ7T``#4]!P`5`!P`='AM9"TR,#$T,3(S,5]L86(N>&UL550)``/N^`%5
M[O@!575X"P`!!"4.```$.0$``.V]>W/D-I(O^O^-N-\!UV?/3CM";;O;GIFU
M9_><J-;#4[-J22.I[7%X-R8H$B5AS"++?.@QG_[B0;)(XDD6B\B2=R-V;*LR
MDYG`#PD@`63^^_]]7L?H$6<Y29/_^.S=%U]]AG`2IA%)[O_CLT\W;Q<WQ\OE
M9R@O@B0*XC3!__%9DG[V?__/__O_(/I___[_O7V+S@B.H^_021J^72:K]$_H
M(ECC[]#W.,%94*39G]`/05RROZ1G),89.D[7FQ@7F/X@/OP=^N:+KT/T]JV#
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MY_:D/AT[6;&#`6W^V4VX38L@'J5\FW-VM2_PN!;?\LW?TG3FP>-:NL7953MF
M?SRG_]91'#\7=,K"4:TZDV5P</Q3W.]6LAOI:=B1&S-GF6;*%N$B5T%^Q^66
M^=O[(-A\R>:L+W%<Y/5?WK*_O/WJ7>4=_U?UY[^?TJ9.7S"^*=+PE\L-<\D?
M\?H.-Q_CEO['9P[T7_:M8)R+K#8ER$)+>U047X8IG2PVQ=M8M+Q@7V7IVDF-
MJN%2!^*_QW>-?-'25`6-(1VR#.=\,3&HH]O6N+9JI>$ZIAQLF8:3MY]N/OL_
MG`X)PAS]+&C_^]^_W,KVAZC%4Y!%M_0KBV>2:^SMT<R)'*5Z;;1T",`@1*55
M'Q6<!C$B]#,C`P*(TU]+LEG3Y;79L?2I9G4G:A4[3J1+`@88:KWZT&BH@#F+
MJRS=X*QXN:+:%HLD:O3\\&)Q(4Z<<V)H@"EM7#FP@<&:NZY]_-6<1XCSHB")
M4,-]!,]GG9590HHRP]3*,_+,_BTWNB\3PYPHM"O>!I^>&@SFK"KVH=8P<)#5
M+,#\WD>2D'6Y-D*J1S,GBI3JM8'3(0"#%956?7A4-,#P<$U5-,UVK=_GQ(&D
M5AL#S8]@^K^O4;_O^>^@YIF/P;/=#W1I9O4#*O4Z?J!-``8'*JTD/R!H)O,#
M['#@;7U4P/N8'Q?<!$E(8I+2V8N=A03)RX]!EM$ED'HYX<@S!P8&J<\PX<3@
M'2-#M)3"+A4;7UE4C*CF!#:C',=!GE^N*NTNLVMR_U`89A@#_9P>QZIVV_MH
MB;VCS%7#/L(X/4I7-:I0FB'.,]&L-=A+O1OCIMX!\E/O!CNJ=X?AJ=ZYN:I_
M#=:;/]7_+SNM=WF!ENQ\-H[95GPZ+S88:>_'(.T](*2]'XRT]X>!M/<[3(KO
MZ1]AX.OK,?CZ&A"^OAZ,KZ\/`U]?[X"OK[-Y\76>)O>W.%LO:2\F!7G$3".<
MY/PR"XMMLD-D/=(&L<^&N1%&->@;P`L#A\,5[B.2$2`F!C$YJ!&$VI)XH!O8
MGH"IQ*Z=F8Y5.B2SGI\HE.L<E+1^]XXD@U+2T0?#`:/9[Q+^(DW^6@8Q61$<
MT5_?\RL"#329$GJOY,X[FTL::D[CCUP9O4-HC+:R)WKW'HG+(%LO-*GCT:#M
M8QD79!/C1?3(;G9>X\<T?B3)_7&&(U)<I`76H\V==S:T#36G09LK(PRT#=16
M"IE6[*CB1XT`)"0@)@*]H0`LTGJ)]CFP.9#-VP6=MD_P76&Y8J`FG7-.-"G;
MGAM5=-XAYZ!<'V&,]"VC18P8X+V`XS(OTC7.CE/N;C.^U+LF^2_&$QPKUZP1
M5C<3.G%6,PL8I+GI*<5<*RZT`.:J)#.LEZ*,'+."S*YZ!V!Z<CC@LNHH`:O-
M@1C+E`Y-LS([P2N<T=F8SLTX*;&;HQK$.=NJ;)@IS9K,C<T[KH;KVL=7S8PR
MP;WWV"K;:%Q1VQ^"'"_N,XQ9R.U'4CQ<X2PAS^W'<^?GQX9XZSA!\\5@=S%T
M&Y<=(P4&+'=17?U6H1:&&FF(B4-"'FH+1%0BL)GX&L?\V5B0%2^W=%>3!R%_
M>O'AI?V+Z?[6``&S7O`:;%CG!I@SMW=8CU99ND,FR!"G@[4W2=>;DFZ>;M)5
M\11D>)D45'%R1_?[>8[-KR\<>>==0@XPI[N8=&`$`\@AVO:Q>'EU>KU`><6)
M-A28X%YXG)&$%/B</.*H9QH=<Q^#?Z09O_-B\)V#),QZUWZX:9W+]^[L8-`Z
M7&?I>CZ7\):+0%L92`A!=R^(BT'B)A0D_TJ5I8L57)RDZX#P4Q_SDQ`#_9PH
MM:K=QJ26&`P";1K*FZ1''*?B[5N8YA1B*XJN,,TV*=UF8?2$[W(*R'WOG?Z<
M9NLTP6*=^W*2E??'01*1B*IPQ=VVX3ZP.^]L.Z2AYC2;(E=&[W@;HVT?>Q4[
M*@0_BJ@`%-82JODZ1V_I+BAA:7B`3=W+),*KG:?OP5+F=8ZC3.RZS$$BO`-[
M-[W[$-]*>1MKIO2]ACOK,TFZEXOP.LA^R<_2[`=2!&N2Y#?EAOZT-GO7H1)F
M/Y0>9IIT-.W&[AV6XW76'E,7C10^YS]6<K[,MX*`>5S7+"R>LZ\X95V!FVUE
M3)858$!9)`6)2%RR"S\W."PS4A"<GSZ'<1GAZ(SVEH@K\(.$R]5ID"5T?9%?
MX>SF(<CPAQ>U`%/*EGU^<=8$,/MONDXZF?U]#LR`VK^-4JJ;%@/:<H"*%U07
MH(R.O$<SYSA0JM=&;H<`#-946O71,?F33,WB<['99"E=].ZRN1\N8[8%Z%CS
MFB7H4`'>0;:+UI*+JL2@.@I0"4),$FI$H4H6>B.D?0[#>5&'397F*R#;P5&?
M;N9#(K6:O0.A+I%WG-DTDV\2,;KJIC>LE2A+8,SW4BR=4_'")GH*=@IHPUK2
MPC/O5L9!_>ZVQL``!E@N6JIRQ!4O:$L+:C6UB"+"EH]!?!60:)D<!QNZGX^-
MSLG",^NNPT7]SK[!Q``&9RY:2A-CPX,8$R()JMB`N;9K7`0DP5&]7S%B34<\
M[VT>D\+=FSLJ2C"P,JHGX2D,RW4I;N6<X!4)";0[$.+,,HBK6YXW.'LD(5Y>
MWSB<'QNXYC]%MIH@GR5K6<"`S4U/Z1X#CNAR'IK+6B9ANL:WP?.B+![2C!@O
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MR7RN)%FL5B0FO%+3`\G$TQUCEAL3PYRI;>R*M_/9Z*FAH,:NHHR<Y&W0,*&"
M<:&->%,%:F%[$\0XKT(#%Y975!K:6<\S3.IVSC%4A-[QY**=G""0TJ+KB=]`
M[RV%PP><A`_L5N*P/`X]-L_)')1&6#(Z='C`(,U148?<#@V;0R1GG[TU?7Z7
M][/VUB/.[M*F[J*ZTQP5UJ9Z473?GI<K6I4-&R`[SVR+%E?UFW6+C0$*I(8H
M.T/FH*'H,>R,[#S^T:/;)]D8O$\?0[34PN:#-]@8DF';>?S#1I<*V\8`'#;F
M1-C;R<L;;+X9`9MOX,#FFZ&P^>8@8/.-&VQ.]@V;:TS"A[-@3>*7<[(FK+S]
ME1XP)NK9H&)7N0&)GA0&/*SZR9EL*`,2'*AB0>=7>]E!YSC\XCY]_#+"1&R>
MZ;_T]\ST3W\_Q_=!?)H4ZHL+2HHYL&)0C>%#\;-W3.AUDI*N,BHDR/;\6#>K
M@\.&Y[@2S7P/;C7J;9_4]@B\=[))*^E9[(RQ>78BP#)$7ZZ<+YQ866:#@:/R
M#2HL]#!`XJ:D=$^IXF(5R?[PO^4[*&_^$B1E0/^3E]K%=QG_#Y:5?KJTWQJ(
MU5]C'^/*&.(H>MK90&53MT&3CA`&C"S:R9<D6Y!`G=/"VQ0MDX@\DJBDLP^[
MAU#/0#/C9@!L_*/&%32@,3,4,E].7V/3%1R&\)J>UA\\=.$T'2%0@)C#9V:G
M4MV(VC=2_E(FV&7J4=/-AA"3F@TZ5$0PD&'0K(\*1@IHFNEH;O`B:CH_^-!Y
M#Q410'R8O88>'SX\AB,@_.+!!0Y@T3`(#&]RED*$PF&SW>$D[)>];V-:-^Z6
MR:*\+_.".JD;VD?\LTQ'I[N/-F8?=R'=#%+=C31SPD#;4'7[&*3[:0$^(CP1
M29"0PC?3C1P!TSE1.`9\@#`W&&J'@;"=@#4OFOY2QFPM_^Y&.%7KA*>GGG'>
MLZG<FOYTI#!08]5/]\*,,3)\O$,5Z\0/S0:@Q;BA,I![Q8M^>Z6EA8L8\V9+
MALP9R>C,Y1TXQIV6@=PK</3[+BTM7."8YR:EKTGY>F<?R)GL$O<CIGO$NQAS
M]:Z"EX#^N_$I@(5GYNO;=O5[=[?U#-Z1-T1+'?Q:O//XJL[#JA^"C*1E/NSE
MK)K)SQ,WDP'JIVXJ#E`W@%VUA?RX]B]XM<(9U=A8?$]%-=_TIU5Q.^M))-Y=
MCEDO*;A4$_)"=F\^)1'.GC)2X&S_X:2;@JQP?$'"-`[*G`*097,+$L.K2!O'
MC$47751O55<TD<.`C)..<M9QQG2$:C;TK\%Z\R=4L>X+3].LE*XR\LC2H\9!
MR+,/&I=(.N(YUT9FA=N+(C6E=YPYJ=>'6$6,-C7UOMU27SO%W4X#W6PNR*1F
MXWA41-YA8--,AX"K+0(`Y?K\$9/[AP)'"[IJ"^[-&RT-[:R9U$WJ=C*JJPB]
M8\=%.RG#>D6+*N)].Y"/:416).1/'NK+0(8[Q`;J^6X36U7>WBO6DGH'AYM^
MTEWC%L-LE[?J[]2[N$_)-L'$]@Z(`38#!<R&I%&&->`:Q`T#;V-4UM:`V.[-
MVV):MX*\`E/<1AJ'R2XO"#BJS'%"8IL1/@@5V@[%GX=K:/:)TTCNYQ*29>HT
MT,*`D5U!R^6D+^>:/Y6:NEYME>C]HL7IJFN/&#!>!EU]W0+F75X(]^,%.JZW
M7B5ZO]!QN@7;(P8,G4&W8K?0>9]$\T#'<:UG\$-#)8!8*.E-&[IPAYA/9Y3J
M$%;P4Q4.R8N,A%1)7K'I4T**_/KFDS&.9>&9MXR(@_K=:B(&!N^^<8B6<HZ$
MF@?EO/A6F4Q8743C$K]/XV@=)#=!^&!8JZNH9G-M>A4;]R63>$>"6:]^WU>$
MB%,"\S`WY5V.?RU9@:]'VSF;AG;6K*0F=3M9256$WG'CHIUTC-O0(DX,&T"W
M]'NF@GTZ:H\@ZJML@%%-"A5(/?VL4&+T^\W4<IP^X61[8<%XH4A/.U_&+XNZ
MVTQ?&D+OR'#13LY!2\GY:Z&*X8C?.-I_WG7W\+6!>,Y\ZXX!:BTE#'C8U%/E
M6&\2L^=`YIVZ,.DMNZRK<X\](B\%83L**BO`<@KOT#"J)5\NJXC0SYP,RFJD
M5NN<)'A)_]5:.;A%Z`4=DJ)*A#14\%#25\V`%$:*.*V7G(#"TUWC>T+WXD%2
M7`3KON/0D\V5'="D9)TB4$7C'1@6Q:0BT>+8<DN+&+$_6!SS3*CQ,HGP\W_B
M%ZUQ$MV\P-"HV45&CP@0--2::;!1$2-.C2BY#W2<I&&YKK96"K.Z/\^%!952
M-03:OX'H>85"_0ZO2?B&U&<O7^&,I'1)')W02<M@2X]N[GY7JMD'0(<(%!)4
MFFDA(8@1I4:,W`<Z%E21B"ES%@?W"KMZO\^%!J5:-0HZ/X+H?95&4@GVF@8Q
M(A]]?5QF&=.1Y&$0_X2#3.\,]*1S(<"F;`T&'1T(7%B4D]/0<W(DZ!%C\.H<
MQ&+E1QS'_YFD3\D-#O(TP1$_:^Z'LASHYUU.6M3N+BLUQ"!`Y**A9ID9(,;V
M]A?&AVI&<5<@\P>H']*X3(H@>SDC,<Y4">PU=/,"2*-F%S@](D"`46NF!4I#
MCCB]Q]VJ<(+7>)-F!4GN69"EU(-$1S[SWM6H=&\+JZ0%A!RC@FH`_8X5EZS(
MD:!'E1A_2.)`/J9SYWV:Z:,>/:IY<:-4L0N7#@D@E*CTTG@73HIJ6G^`N"KO
M8A*>Q6E0:,WJT,P+!H5Z72BT"``!0=9*`P-!B#BEQ_DE7:_3A%]ONWD(:'-<
MED5>!$E$79?>)1J99IYK'`SHS3@&#D!`<E!3%T[EG(BS'B'!C%K</N-N8C,G
M0CUG]&^JI8R!=N[XFU;=?@Q.(@2!))MVVEA<M>>N0G*<Q3]J6`3`#3,M2C^(
MD515XZ4A`XB6OFXVK/#XS.1(F>"&P.7JC"1!$A(Z`M*<L!?FBSMV%!GVUSW#
M6+W<(G`P1GFOP,#G'7LCE-7?/4A7J&%&-3?ZN>8'<GUED>>XR"TP[!/-"3BU
M@FUH=2G`@$BIEG3Z<'-S>GL#"0I5>,`)$1+M_,#0J"OCHT<(#"9J[70'$8+G
M.QBP.0[R!XUMXJ=9$\:VE.GDA:5_!]/E+66D'J8_P>C611BF95+DUSC$Y)%=
MN+S`105`'92-++/Z!@?E.R["0`\&-@Y*2M-+Q8*RAN<()9@O3H(X3I]XA<Q5
MFJ$H+>^*51FCH&:A)/_R_MW1NW??\GOZ__+^#T>___WOCZBH?(/#@CSB>-*8
MX7BH+A/VM(15!<4Z:'9)YH2B2KDV]-J_@X&:0BFIOFI-`@,#5QG>!"0Z?=[@
M),>+)+HL'G#6F5PUMCIQSIO8T]F4;I9/*QL8?+GKVH<=)T1AM1`*.`<,!+I@
MS2.JK/CQAY0B+8+XW'6-K`'&+1,"$AA76;K!6?%R1?5E=;9.?RW)AH4(]-.5
MF65>9V17ONN%]/2`W(]52:ER*WG&404KOH2"@:V6W[3LV)64<R+)H&H;0`HR
M,+C1ZZ:>ID#MT[MS[@7ML`'+HC:YO[60K+1^`;2E!0,?BX)RHFM.CK"@AX&B
M95)0'5GU&0%NZC%/G\.X9,>YWZ=I]$1B_:;"A77>O9F[,=T]FYT/#.H&*"OO
M\6I64`NJ$[QAQREY98_-D^G)Y\2:3>DVOG2T8#!E45`Z%&,5TMB%D$CPP8"1
M(WS\PL8%+EYAXKAYLV)$[-]2OFZ"Y&R$^D;;?"!"CP.(O6_L<TB]?4Z".Q(3
M5CN-5<1F%]<>TCC"6<[VB,6+99/ESCXG8H8:U<:4*R^8J6F@PGU(GB\7'Y;G
MR]OEZ0U:7)R@F]O+X__\\^7YR>GUS>_0Z5\_+6]_`@=5MS-[$X,G.#J<WNNI
M(4)NV#E^BQ%(D*`^,*PJDKJ=]_:)?9STJA56G?%V*<&`R*B>]EQW(ZAA@.<$
MKS#5.KK&CS@I=1FR)*IY=V%*%;N;KPX)&("H]9(NPU94*!-D,)#!PZ&RFS2%
M6574LX>K]2I+(6N9%`QRS/J93UCC+1L,*#FCR#>`W+#C&3;6_9LS;+KGK^!@
MPYXBD8*=\8EBM@E[$HN3D"JHL=S(,>N=1KOJG:N.>G(P'LFNHYPPMN&HTL:V
M>&!`;'"T`$I\8%A$X`!B`(-W_6T&NLOG+$!V9%=9M:+C.OX0Q-J%M9)RYL-:
MG:J]<]H^&1CDZ'53G,Y6*VU17>,MW8MEZ)%QH'_YZHNOOGKW)_3NJZ.OON+_
MCW+Q^#4HBX<T(__$T9]0DM9_):)*#/-KZ7Y>Q^XV<5:O?TW@D\GFGB)52O;G
MQ38-&,QI%%/-@&EB0-O[WQOA]N[W?SCZZML_'GU57>A^]\TW1]_^\0]'?_S]
M'S4`A'C7>Q%%_"%=$%\%)%HFQ\&&T(5GJPUU\14'QED#5\Z&=()85BXPL'96
M50IN-8R(WW\A"0H%+PP(7N,B(`F.3H,LH:,D7X1AN2YCEMG^!*](2'3K/1?&
M>8MEN1K2K9AEXP(#06=5%?'5FA!%@A(&]N25K?,2V/>>PFTO`2OZH=5/'?W(
M.]L(S!E@X,9V*CKR,!76.?:8\VM8>'/45HV^5LR-K^3@HG%1/ST\2[.3ZN&A
M_+K1<O@X3,:L2[LQYG56>4,$@)EMQV@M3;SF1ZDPX-L-$EP%V67&TWY$?/MV
MA3.>Z<HIPJ!G]A>XL1FDC^7H.,%`=)"ZEHC/46L+_H;N4:(TCH,L1QN<B>WW
MYQ#1*I*P+9JX@%-#R4S^T*DS0(_*/@=0-&K4M*)0"O7`A9VHACV@-6H&WW#K
M*FZ#FJ`&#;..BJX0$U%"N/#29PQUYO(--$W.4$<6T)"S9PW5X0[RF<C`U9\3
MIZ>3DR'K/@<V,&!TU]5TY'(HRSTI6Z]UK6?D\(1%EU6>@1PB]AS7=UW,`5W<
M26895W9::J_@TJ_I-*1P065<S2D!!6DI-R#SNQN+5UA95G"@<[X/4-()9>`6
M;LLD3->XR=%KN9^GI9XW1X%1Y6Y:`B4I&%B9]9.3#S!JU"KF#"QU\DT0X[QZ
MC:%/Y211S7H*JU:Q<P3;)0$#%K5>?9!4!)!2,AVG>7&Y8IDU\ILTUJ^)>E3S
M3EI*%;OS5(<$#"S4>LFS4<YSG-XS.I130AC8^#Y+\_PJ2U?:.T(=BCDQH5"M
MC8?6S[".S&7%^F#@%&C#26#`X'*#LX`]7ZA205ESM^GI9WT29U.[\RA.1PS&
ME=@TE![&U?1U1BXHC[9O<!RS9$XXH0K&BR1:1&N2$&8,N[I;F:>;9QV99UVV
M##*HLYIQX@0#P4'J2H]6V`KI"-T+YB-^YR?H\,.`YS7.,6W?!VK>"5VNQ2E/
MM6E&I85GWENR#NIW+\@:&,!`ST5+>;4M>#C4HBT7#)R=X$V&0Q+P*CUT**U9
MW=-_\O_4M(&18^;D<#;5>_GA=.1@\&7744Y=L.40SJS%`P-BTI+!=6GA>:'F
MM$"#M:[7J:?)&]=?FP'#BPAFG=.-B,W<-J47S,BJ*E&S)0.*&TE!_7H^ID1`
M`,.2;[CN"M6TLR=)<=H-J@C!S%4F[=3I48@(3K-9ZDWE<8"<_W/]+M(D[8X#
MD^4JZME1I%=9PI%,"@M)6OWZ6/I(\I#N`(,$IV5>80H&BEAUGYRGVQ`&+),"
MT[8RE5=2D\]=:LFD=+_LDHH6#)(L"BI2=?.?0:&HO>AO2JDF]RPZK\VH:V29
M]16/@_*=1SL&^GE0]:U`58+OV04WTR+)05>Y`$I%A$)&!0-@->JKN?L$W^D]
ME()RYEH#.E5[I07Z9-#`HU=1ZY1`;<J8PM>8/^[>9I4ZP_S))?N-W:9B3]!,
M;FJ@C'EC22/,ZT:7!@B`!LXQRDLYH-,@0?=ED`5)\0+)W7T?D"1G.UJ<7R:G
MSVQ]69+\050J-S@_![Y9CYI=S>@<0-N8P*S<7#6589?G*$VHLVRSL&L,$66"
M@4`^A!*Z02Z9;L<I7:32A<1=C#_@A.?)8`E>V!]SNK(XPT%1:I]"C!,UMR<=
M:VS?H0Z5`P;-.RC?!_B6@SK5F@6M!`\,?,M;=_,YI8%^3J1:U6[#44L,*Y!K
M4]-40`;4>G,;B#ZCG282EY;4J"K^G";Y![Q*,RSH;H-GG--9(PO2+*)[KNQE
M6>`UKY]#.6G3Q;P]+.&8/7YQ_LO/>VTZ^0+U7CX':VSMWU#EXN:."T4%DP=I
M;%(#*]\BIBCSN%)0SS\FM"K+>)9(H>W9S&K*KX331R)6#FES$`,(4A>XL)[V
M]FAF72JHU.LL#]H$L-R62K4^/"@-H//<.O-@_=#X0Y"3D(4B2%P6V@>35JXY
M`>-H0AM"%A8P>QLW/74(VS[]/D)WC%-<BQ.\H-^(_XC)_0-5<D'W8,$]OBC7
M=SB[7/$V:#WU<P/K6&%S8G@W@]O0'B<)#.)W4K\_$&IA*!#24,+%L8B5_`"4
M#PCQ9^,HV",*1N<D?3]K_U%O0=+HI@BRPC09&O24`R_W)&&>COJIF$6_/77`
MI(^E07:*D\;6[JD?4,.8+;@U(L7`29E1-:]X6_`$*A?XB?^B6^@Z\LZ>F=C5
M',DQV!C!>/HAVDHO2SIE*:C?WF3DD>[BT"8.0OX8F[^W98Z>G8Z!AJFP921.
M)68`0-48Y(#4'B=TJ*K5W1&KL%PK.US9GIY4ARLXVIZW+-8L[^T[P]F,&_O<
MQV9#C.H?E;GP@L'N0(6MZ,7/X0,EJ/(?@SKW-9K93D0T&JX](:!`JS1P$'0[
M$@X'P"JUA\,8EM\U+8[X;Y<;?@IR^HRSD.3:V,<(.0!6$'8S79>]2B%@H#U6
M<S.Z&:)QQ<%6%:D0`AK8PH()D&T4!`#:#H8Z+Y0/$MQVU4>A^W#<-W^!,\(A
M5'P`,"R;X>J..1-TA$J:.BPFMGA\"C)V+1<V$*O0WW`D=A@!0%%AB+/[/`@P
MRJJ.0N/AN,?M4O]R]2DAV@<.`V4`P*K9/%<7*@F`CF"CUL/F>G9]*R-AT=0T
M+IDHT)@6!NT(:JT0`*BV&.CLC0\.UV:UIP`V+*>]B/Y1BO>^^6VJJ9W+K;P+
M<OZVB5V5XW<UKUEIOYP4^`9GCR3$HOVN<9C>)UR*J6[W_C\[;U'E>1JQ6Y)Y
MO]\$,U!G,K0_M$_7FSA]P1AQV>@#$X[:TG<=O\7S.N*C\MW[:DRRO_S]QVIM
M)US369H9WZ^[L<PQ%H8HSW#L0N\=@P.4E&XI55SMR6$U[6-V#8)<!DREG3"I
M&AY*;.T@;#;4[6QP@\?1DF`@=5?U73"<5RRSN+]%WO7G_('U59!)E:,'\GIR
MB'9S-)Y1SP@#>`.UM>$LR*F#W$IXFPD1K!06F%K20X?:#JN;GAQH*UNEF4.7
MJATAWD&]J^8NCC0,\@>/*X!C=N,SCJM</-T!/'9N,<L$M1YP,7_0LL`DT#N>
MI[1"*GK18FD'I]M8C^74)AVG3@XI'-)*1L!NL?Q(B@?7Y!/3B8<V"0QIE*%S
M@XOL68<8_?1=FF/3C?R)[9HUIX7CTKRS#6ZM\HAZ)SF(W=L"W<$H[1K=P`MC
M!ABNL,-*O1?4.%R_;CHX'\`/S3-KC]&=F;V#=ZS&TA-:NI?$=5R7G\(@'C3N
M[#8]/5(;^$!^WF=HIDY1ZS7F??R^CSG'O,'\VL-SO]/$F+?"H*5TB"'>P+ZB
MYY<`^\-)7W//P#H3;FJ?7JZ.@_SA+$Z?;$4!S"SS7FBP*]\=\WIZ,#[604GI
M:D)3P);NR1D3XES@RMG2B8%IQ]/K1#CZ\/(I9\]`FBH9B[`@CX2M)"T0'"-H
MY@PX(PWMK0(&2@$#XM&J2Q&GQ<V?T=GYY8\WZ.SZ\B.ZO#J]7MPN+[Y'B^/;
MY0_+V^7I#0QP=Q:L[.(!W2C%N+-BNDVG@?]^/N5M,S-Q8VGW/1-]!\P@VZ-Q
M_6'8^A0J4I35'^/OGGFF(OI7]N_LI`.M^.Q3YN(V\[9P5M!\#DA9TW8].$TC
M=TE\5>Q38;O].QA,*I0R%>&#`8-NK8IE0A?T]RQ2N\AS[%A&1&;R5TA$9X"^
ME$B?`PR<G-24G%6+B:V(2<.&`LX'`W5-ELFS-#M)R[MB5<:+,&1O^768,[/,
MB3@7Y=MX,]&#09N#DN94H5'%1&<ZP>4I#+.G\@<S!2+=T[JZJSQ=)82]SO@>
MJP&`Z]R=K#C`P@#=N8Y9?T)R[D:N,KPFY=IICE3R^5N+&,S0+T<43&#F"%=-
M;8L2YF905+'"`&"=H+;[LD(7IM00SQK_-2K<B?PJ*<&`RJB>'.UE[\N&'6;Z
M\V(KG&74+&K@O38UGH7'I_=2JF_R7!T&,`!ST=+NL037U$];)BJS4%5=NUSQ
M\;%(HOK^"EW,UV\?+K/C."!K'0X'RIBU),,8\SJ%&H8(`(/;,5J;_&55M<?Y
M=<N>%_LS%E&$<XEDG-X'4T%QF809#EC14O'/5KB]NK9D.=T9(F#FJC`##>L5
MBG'D!@/4P2I+AY<\06'>.P3A(4A>R"$FP1V)(1V(R";7\:]K'&+R&-#MMW-K
MJ5C]`E9OC!FJ,A^T8,D`G:5U7D7(3O4J2JA@9!7K$_HU^=JY(X]?^"G4-^.N
MQ0`?<+*R<K%N00'D7:?"O[,+Q<<EW>4DA?'PSXW5\^RL-<8R+TM\\+&GU;D/
M04Z(0D$)ZCA08]3VKL8(/$K,`!"I,<@!DSW.`T&E6FLU+F'CL5XH7`4OH]:!
M#1^,16#/#+<58,4$[0FBJ\+:M=]&D$&%7AVQO,9T!:'--.;`YQ=Z&C/,T.LQ
MP8>>6F'Y&E@53LX$&53HT2&2E=3S;_?JBR3J>O;6;T/&YR"QWGWFB$:PNM0!
M,@%'A489HO#$3$@=H18!HK2S6FV%BZ`.EMW'!=@AL"/:#Q'80S$L%K'@8.K^
M&$73,D,$P'QFI,*H.S>X$MW#]%:]3W9\IP`:P"R<ED_Q;LXH"`"@'0QU`+9!
M"A@?/%IUV[NYY<4/IS<@W\W1#6J=Y2'\M209=GQ_X<`WZX5X5S,ZM^)M3-!B
M7*X*2]?DJ6"Z@N7']$VQS.".KG'3A%]C`W-\+UE(QR*=&(J7*VI001?V+`W#
MAI&X-I%!@%>`6@TS(E7+#1ZR-LTE[%*E'@*1YG]3\?+=&:X982'W+,VHB2'&
M47Y&$<`7Y2=XD^;ZJA5NK#[0ZF*,"J<F/J@(=="YC\UKO"HI$M]LA(C/&49S
M')89H1B-!"\,=+JO;'9>&D%=L^ZV5CV(39A>;\=-&*D%',HFK,FKM^LFS"@(
M`*`=#'4`MD$*]$V8777;)NQL>;&X.`:Y"6O-.]L[UZUL5[JIR\XW\ZMD-S-Z
M3Y/-3&"`Z:JIXI$RYT.LM5`>Q'PM&W(^4:ZJV9-!VHFUK!U25]B!SQ<FG:L&
M6YE`8G)(3>`N)L%6NVZ;5ST]J2TS)&DPL/B"GDYY'>KZ]"`!IU'2'6NP:OVV
M3;M("VRY::4G]P4RE=(Z@+5I08)+H:`96`EC$`\[TB`!=J>J;=DY27!.%PX9
MCH@VC*FG]X4NI=HZ>'6(0>)+I:$98'=!\@NB8L7RC?/!`]=V85H_U1RTFMTR
M^=\X]`VP[QIJ#I"`TZKIME^`-5=>XRKF28>0BS\ST,\)-*O:;8QIB:%%L&V*
MRF'KBI[A"JQ7:UO5KFS73J!E:`B9Q1?0=,KKL-:GAPPWC:Y&Q(F%6K4\@UAQ
ML&V@PT9`3^X+<;:-@(X6,M(<]@-ZE,'`E7MD>^?0.-0SB]W.*@[B$$ZOM^40
M;E,)0G<OK20_T`[BN,F\6$?_QK*FF4P,<X+4KGBG-(J6&A8(K7K*K\#%S^RX
MUU88=<^]H6OWF;/EB-(S-P5=@-A:6IL/A_UXA.[P/4D2-FK9924N%F+S0JSL
MT]9+W;B8O<AQ:=894S:6FTW,2[^P>JZB6LPR6:79FJ=MLU7R<>6>-:GC,),Z
M61[=6,$$9X;I*^4U^W1U=7[Z\?3B=G&.3I8WQ^>7-Y^N3V_0Y1EJ;AZ@Y<79
MY?7'Q>WR\@),CJ$"TY8L6"D_3<-T2>9]]R4KUWW8M?T=#(X42JD\&-V+$%&C
MF50,4`#!RI7<!L]L>V7`1(]JYN>`*A5[3_[:)(#`H=++A@_&@PK&!`,C%[2/
MJ(K;^X5)U&QSE@5>6R_=N?//NF\=:E9GV^K*#`:+0S4V3GDWQW\^/?ET?LKF
MNXO+B[=BSE-<L=MYWG,JDGV69HTM/?.MU)Y*8*M4UE2\;I-ZAY.;?K9ZULS1
M-5&.N2!2YZQULFA+[`\@?87U^*@IH20H<=+2!20NB8(GP$AS8VZ9G#Z'/'4H
MJT.#[]@CI2H]1+W2,YDZ3,[LR!ICI@2Z(4)@N:L1FFLQ6M]DXR\G<"5-%")B
MU2783:2@2BLRU8I?@V&F_[882U6KA1E2EV^A,W\[(M1N&7?>V;`ZU)P&GZZ,
M,#`Y4%MI-<;K6->><C8(3K6A*'`U*[S3KE;;)/-N"V3ENBO_[>_>H6102CIO
M:A^)MJ=8F!BYS.Z#I*J`04='GL8D$I&Y)+JB:K+`G:BH4:T]@[@IQ6W;D$XD
M>TY43MH<;3A/(AC,.)C2&BG#4DOV$>I(Y[ZV+9^=531?0-M/@"L+OU.#L>I;
M<9J7&;[%S\6'6/]6;?K/',S@,S329.-0\8W7,23UAO5'Y^V?3]'QY<>KQ<5/
M,$96E=Z5)/=7U.30H;*\@6'6,EQ6Q3LUN+348!!H55&3F9<=Y=<<X!SW#;E/
MR(J$+(^*9)_-';LRSWKV/,B@SM&S$R<8.`Y25X["?_RXN/Z)Q=UOEM]?+,^6
MQXN+6[0X/K[\=,%SC%U=GB^/P3QN;\I.;#VYM023@6/><T>KZMTS2"TY&.C9
M==26#4%;%G"^4&&6S0.:63S#S.CM3/20@6;S;"Q+XL7MY360Y5M3IY,E9:A*
MCI%_8K9D94?U=99ID7G/V;GM+'5.9$[4!-VZB3N)!(/O:>S0IN4_%KD:6X*/
M4"7ZB,<:1+9G(1ZR9Y9K`UDC!2:.63?]=M4[^W<].1C4VG648EYT6WV-CC]=
M7Y^R5>;-S>DMD(6E-I.DQ0,[\,W\^-G-C-[[9S,3&,2Y:JIX!<WYJ-MCG-SG
M-;S@O)S62O?UZ#`1(!#JN%X=P@\?M^[KV;/EWTY/@+E,OH(X%55.NFL4J]=T
M89T7EN[&=.%HYP,$0V=E90_*65'%*Z\:IW.BFGLI7>4=#HN<N6:[B^)N0G,+
MQ<[B'5W#])2`=7UZM5B>H-._79U>W)S"<&W?IVGT1.*8#I%^5GSGO?E`&7,Z
MNU'FM;W>(`'>`;J+UGVXUC*X`]Q*.8"]L]YD>W#3@7/FEUVNIO0>?-G8P&#5
M75<Y\'F[N/A^^>'\%-1JD2\66G7'G/VH"^/L@1PG0Z1XCI$+#/2<5577C&MQ
M0G:'>BN=0HHV3AB(M(<8S6P'@,EA(<?SY>+#\AQ0MG9V;WO`<8^:>-Y3')/"
MW<,9%2482!G5DX]2[@K(WJQKC,V#::G]`<GHJ32D0*%D\T@7E[>G-^AJ\=."
MKM%@P(=G>W](XPAG.8M-%B_L>K\MY8B%:=;;7DX&=&YY&3G`0,M)3>E65XOI
M=TBP(<8'SF^IS7/W9`/X_</1T=LY,P,'J;M'O+F]//[//U^>GYQ>WU"\_O73
M\A;(M9TFX\:`^X8&#B]Y3ESO&VK)P>#,KJ,B01W+?D)9(*_>%';98W(F%L\X
MLT3A]/20D6:/NQU??CQ%MXN_0=E;MO,IWV9!DK/TGVEB.YRUL\V;BMC-B&Y*
M8C,/&)@Y*BKG)A9IKCD?:C."<VTZ"]T]W2`)$)#IZ`<'L(/'J[N7O#X]7]R>
MGM#M[S6<(-PUR7_)%TGTB?9Y5@0D<2C]:>&9%8@NZG>@9V*``S8'+25X,1Y^
M-MOA`N<6CUFO)E0C-GR8TN[^T(UUUF38`XSIY`]VX`.#Q@'*]D'YX=/-\N+T
MY@8=7UX<GU[<7O,4KD!\'RLY2@J1L"")J)7L^2!.PB%'M`-ES(O-$>9U03I`
M`""T#M=:RB.ZE<$]:D<*Y.VTD_%V-SM,"#A06USO$`F'!6N;.Z;;](_+6Y9Y
M]`8M+DZ85V8OG4\OX#QS_FM)5]@XBU^:'!:M7.+.;GFPE#DQ/-+$-H@'B@"#
MXG%Z]V'<2&EE!FK)@>R@C0U@<\RNS&#`;'3$;IR'`5WK,<_I^>DQV_S_]1/=
M_9]>G_]4YWAF50\6MPOTYM/%XM/)DM)\#@.I-^5=CG\MZ81S^NB0"4Y//F_9
M#;/2W3H;:EHPB+,H*&&L(4>"'ISSZQMD/>+6T_L$E?D(6T<,%E;V1#D?;D[_
M^HG=(3QEB26`+!0[&=!XTI\7A_B1@67FN)%5^5Z\2$L/!E@.2LIOZPB=2C<Q
MW56GJVXF2"`H"_('MM^B_V#7.QZ#F`T91[BY\<Y=O,_9G'[!,RLCE)SY8Y16
ME9*!`<%K'&*J^QT=)+=9$&T?KXJ49_GV]T4<IT^L-CK+Q9Z6=\6JC&LJ8;7V
M<&O*3\Q[$CE]XW2/*J>3#\91[\$H*8DHDXMJ4K25R..IC5B>-KL6W)##&'=-
MYBTW;Z\G]Y(#S<&GZVC!X-2BH"[#'I@:O]K<%VZ(<F<'D<7$`7&NO&`0.%!A
M*7,)><91]4`:!B3[CVO/2$(*?$X><61<(3CP^7P&K37#]`A:8@(#.U=-90_8
M>Y4/!'3K34`R-FPNLQ.2;](\B"]7YVERSTT2JCK.LJ-$S0K-'8SMH'6$'#@`
M'J^\A.E&%`L1,!%ON0Q0"#^C*OX0Q"5NY=[?%B`R;[X<>>?$\"!SVJ!U8@2#
MTB':2E,[Y46<N5NAI,4/`YK-?7[7;8R.W,O+"J=MC)H6#,PL"NH?[D#9Q_`2
M:1^"G&7I7;,L5Z+,R*:J/;+DUP.I3V:K9+.O&R5IUK.>\:9V3H&&BP$#U_&Z
M*TOKO>6B4%L6#%2SI^MN/E%).7?"``=/J"`#@RJ];MJ$$X!B@=?X$2<EOL9A
M>D^W8LXGC@Y\\T;+'<WHAL`M3&`PYJJI_*B,\Z$6(PS8W3R0S494F/]SD$14
M_CU+:.^&/5?F>:?7(09U9U073C!0'*2N/&\*9GY64K.+4@8P<+F(6(U=DE=6
M.<9NK%RSUF9S,Z%3H,W,`@9[;GI*I=JV7)"@=HUS3-N1G>.?4#<=ISS\7B7;
MM1QJ.W#.._LZF]*=?ZUL8*#GKJL\!PM.[O-:O#!0>!ID"1T8^17.^*;&S>%9
MN>9$GZ,);>196,"@SDW//N)J+D39$.>#@;5/.;Y<G>8%60<%SC4F]XGF1)):
MP39PNA1@<*)4JP\+2L0BN@T9#%!<X*=6B<LL3>B_AK@5IG;S2,/%S`FLL4:V
MH3=4!AAPCE1<GD=9>"Y^0<L\+W'$IU,JFOYA$:4;ECJE79.W\QD82+_*2)I1
METS2B-H2!WG.2[SRZ&/TCS+G;R!/<!YFA(<DM3<WAHJ9]Q+-.".[EVF&R0"#
M])&**Y#>X06"WYOP`4=E3&>:!1UD$8E+%BR_P6&9\?S-I\]A7$8X.J.`8$'Q
MLB[:WE_%6.,[>_C0K+&@O354)VXT^5?`C*.]F2;%HZH/L771)BW8\4\0TQFE
M_B3*FV\BDB!J)`J#."QC\1R7<G%*.O<DN$!QFN=H0]?<.?LVHI+H8&17EHH4
MA>EZ33GR5E9-:*.ZN91:E7^\9;J[CU4;NY\1Z&:4>ER9>0&.%B>%36.@$0`-
MFXJRI,/0:1?@!Y^NAJD1:N,&B%%'E4TH37E-DE#(0`&@VW+:6]6C;\1#NPL_
M[A8\/$`ZJVH"XHK?@H<$P-XX$P/L@O9W-2$,\Y<&=H_>TFJ4P5=J><$`<Z#"
MQA5M5=\3BU,*:`CMOP6@H["NQ#=XZ>DLR=<J=*"IN@6IHQB`:!ZJNPG89/L:
M!*+S35>M9RW2BY>R8'F@UFE6D'_R;61UB#@(\]-\PL=@F+)Q5*-D"OG@AL^$
M1IG&%:Z.ANB:IB4-UOS1WC^TBL<YC1Y'WMGK_+F:(U7ZLS&"`?(0;=VW?O%6
M$@QP;J<[=?F<'X,LH_N-_#*[)O</#GFBQLOSL]`9:;9ZN3-0&!BP[VJ!:0`\
M"5[$DO0_4GF[XIX5>N=H?O>^PC(O_;XUX4?,=,31XA%GP3UN7I;5(7:ZCF/_
M+0ZY\KQ<\Y.MG#)65AH]\[X_-L<HF*?!V!#9[Y>\CY]9S#,.KNJ+*!"?1"OV
M%O*1OX5LG>LD/.93?P^5[!4021"=FM"'.`A_>4MEIBSSU\<THDTE1FT`YAY"
MRSTU#Z*N@A<6_%I012/NM,2KJ%S5P`,WY]-\Q--T-F$#:>:X";[@?>#NU2S3
M@!TX#/GI*THW("]5J%\GMIML4<WYHP?@4,&^!]VXAK`-M&%200^N4:88]U><
M?[+5Y=1CY'2UPDPUW+P\OPX*_BPN">E&4&2L'C8ZQHCT,R[&&Z\>$</E`1P+
MHXTPC8(B>$89%8.RCAQHH^$$KW"6X8@:W<34AX;$1DOS,P9&F:R&_R!1`)$_
M1G\3Z*-*'D>_.%;A6YT)@VR:8(.A`@RW0I>A?RCS;,&`P08UFWMG3N^`'*6N
MJ1S50BI')41`\[KBN.4C2<BZ7%]3U8.XVN/D9VEVN<&LG%QR?X[I`FVH#]Y)
MMA^//$%SJ/WS#H*]#XY]6&.\B,2EH[40CS(N'VVJ#T`;0>:",\-&S"!9?D;(
M"'/5(V*`((`C8+CV)L3_VE3**I.@C`B+VN;E>AUD+XALY4*#OO[:(6L`:QO:
MV/T`W,TH-:;-O`!A[*2P7`U$,!TASL;7U0TC^IFS`BEEI+7OG"1X6>"U[N&V
M"R.(*\R2(4Y7F!LN,)AT5G4@&AD[XOS0(?DIQZLR/B<KG>=TX@0!2MD4)U1N
MV>##4M)5REO17#\K.2F*R2.4_5\KB5!UNTYCOHK04_JGGJ*:C$\5%;021UH-
M]Y[>21.EHM]AA5U:NS:QIU-G!JI.8(B4YV1'6;/%L'8UMPEIC17DW:%-H;T"
MK+PZ4+TUYV6"JMU[UDX4%6V%UJ=Q`&\Y[OH\VVG3,\U'#C,!@'T#-<47O`^U
MO9IE"B.T/X.VWT'UAQ#K6-3Z%,^@).77@K6%V['M;!N]Z<3/NBZ:N%$ZJZF)
M9(,9AQ,;),V"4XTZ<%O5'1MNL68)K/;3*;7L`QITW>:8<,0)P:]EN'6L48VU
MM]M\-HP^1[@ST'`]LK9WG%M9;F`,K"8SR04N--<!S*1>:E4JE%76J6S10=N'
M&W34E:D$<FVP48>]G<SIFH^]-]8M:G3$7F"C5%@)G`XE&']F5$\N)2EHT"9+
MHS($DA>Y,>$Z>/H8%#@C06S%3I?6"W14ZBJ1TR:$!QR%=E*6Q.`)K2L:&)BI
M;^3Q*&3UV%5CJ)ITWLH[>F6[I7=D.C!X,2@G%]^IKC>&MACQ3`L#VX+@[^]G
M;>8B+8+8=2'0Z"951[^\79RCY<4/IQ>WE]<_[2D4+^<0,]T0-5'/%DZWJ]P$
MS/6DWL>=FWY]4'`&5'%,5-U4@XPKD?+H.$WR,F87ZM1NV$([&RILZC:8T!'"
M0(1%._G^@<A+%3;T,.;O2J\EU2ICIS3:`^X^V;PW"-1*=J\+=&F\H\2BF`X@
MI*;;K[=0G^495G%#F>?V)^X&]1V,G=,[ED:IJT.8]LS5NDJ<<5M18A8"O,8Q
MNQMS%60L.&C97AA99MUF."C?V6X8Z+U#;X"2ZC50AD-,'OFSEK>9X$8;ROZ"
MWK#$,.C=^\]A8(ZK6PV2ZOJ-&7$FAMGS:1D5EY)H*:G!8,VJHAIIFV:-!<>/
M53MP<?\?M[UT:SNLV>'KF'R$3,P&J((G:@XP&'-24QM068GW',F]U]!*=XC0
M!4$K?:[!`SBP00O$#%%9'9^YO/WSZ34Z_G1]?7IQBQ8W-Z>W-YZZ[0133Q6*
M]_7J$;3]?>:.<#@<4VHG#Y0M$3J%E$M3>U7[^RS-![_SJ)A`7*?O&.!TDYYS
M@/'(3FK*)VG;=/1'Z)Y1PL#9(@S+=<F7N^W!0/\]QCP%5!*UT]=JC===GYA,
M_*QW8R9NE,[UF(EDSS,>OA7C(<'W3&&3OYW8+NFNS%8\BEKRO2UI-.IK5ILF
M>GASIY.V:A>WJ%Q<@HVW!?:]S=2?XQC(X'6$24GUYG*.(YR/05*NJ"IE5E=[
MWQ;!,$0$S6QS!V)=C.B'8$T\WM<G`Q75A5W7;=9I8A1N(?Y^E-@)4R[,OD+\
M=H-T(7X])Q0'-4IK/Y%^,_KHNB+#/$>%.^@,/'-CS:I^'V):!E#^RZ:E8G68
M81ZQ=XVMSA;N4G>)C19V8$NAISJ:=75]>K58GJ#3OUV=7MR<PMCRZNNU6),6
MN+'.N54=8DP;>"Y\WEW""&4ES]"NEK/A];\]N86V)G+-+66HP,@!;[?BJ*^Q
MBT`5-#)4=K*_=7%EAN$M5`:Y^8O<UPN9<1Y#H:[JV4.!WW)NM&6?:&^]=VB:
M3@CL;$#@J#TEL/$<`@1-)P7\-W0<9-D+VX"+!X3@,=<*S[;=^?"FT0H"@DN+
MH8Y(U4@Y!.R:53>%[=ODX`&MO_9B8P("5,U!A)GC$`"HO_9"?P'E+Q?AKR41
M=W=TQO0*:5DWH+N)G/<,=7?CN^>FX^6!@?4$1O1!7].CBJ'C9EE"#LN.=\YW
MNQ%>Z0T7.17HFJ>N/6W-)3!6W+RO?W<SNOL$<9PL,/#?T0`YJ4$M#O9>;:C9
M$[4>;*!/`7!H`;"1^L^R!=0<@PU565X7CQ<SVV'9#D8VYV<C9$"!YX[Z0U]F
M*Z,K[D[5C7E>5SK$H*X#=>&$@LM16N_L+&?L.#I21G6;B@_><<\@K:$[$<..
M3&05;F^KZO<=HP^`'$0""2,Y&^\89++*`[-9F<`(?1;]0''FR1-.LQ+)+SC(
MO@,_+!3F7^-U0.@Z([M<G9$\#.*?J"4C0LS.DH$,DJ%-X7I*X"CV$(;,0%OZ
M(X?"\_>'."*82;=/Z23MU<B"B_J>N>-Q7@DZ4&1WM5=@^0\'BV7Z^>&7XRS2
M@..Y;?*.B&:B#AG3+?T5J/[CH:+ZC+;K9(TDA,'&=-O@W2#-)!TPHEOJ*P#]
M;P<+:$H[71MQ8<`!W3)X1T!3VD,&]%9]!:"_A0'H$_)((IQ$^57PPC(NG=`]
M\0D.XR##T<<T*5C2,,/6T9U]UA0T`XWJI-)PY`4#S($*2WDW*#F**ADHJAAA
M@E-$*>N"#H[MT6?R"42U`2;X=3G`@DZII@2UF@E57$<L^$;YMB4U8.*N3N.;
M1-I'B<-8?6+09(P)B2H^L'@T*-M'Y:>$NCRR9LDL:B'[JHT9AEF)HV-*2<(@
MOF4Y^6WY4^T\\]6Z=%1_6]/2PN`=/4.T5+US+5FB_(H/%8P14B;!2L.;@,[H
MUERH.N*9<_T8%.YE[E%0>L>3DWHZ(&V"%RHX/D)W:5+F..=/\,-TO29YSHZF
MX"'KAR#D>QXG9$G$'I"E45B!K!XE-&2IU=,AZ[&B!@BAJRQ=88[O(#[#CDY*
MR^0!4A8#%-#2<$"#F%E-'=1B?$\G0>:Y@C!D2WMV$0C40^*%T*O9N"11I?LY
M">Y(3.QIPP=)F!F20TWKX=.5'1)8!^JLSM455/BMH+JW'4`<IT\L>?!9FOWX
M0(W+@QB?D)RN'>]**D3O`H>SS[<O&&[4=HO@SNL=<R,5EEQE+8%?,GJJ9=#=
M9R,$K3"4*O;5<+I.7X+8R36JJ3W,S#J5%5-RG]0[U-STTTW"64V^)R]&]S4X
MIY@7KO<:%V66Y,SUULC.>27+=ZKQX\X[F_\::D[CO%P9O<-IC+9FMT6%;-)$
M[%$S(0J6OV*9[YQ<59O0AY>2%54YJ"V5=S!95=.Z);RWIU/5)\[J&@N.454-
M_=P15:/:_6BJDM@[*%PUU&$#1G4,OA=PVRQI2*$E"[2IZ5+YXGRY^+`\7]XN
M3XWE+^8LD7-7+!.Z6BY9:M);MO'3'0NI*.<MAJ-5M5N_0R+S/J3MNO7!<Q,^
MX*BD6YETA<[3Y/YM@;,U8OQH*R!'/W,9_PT12^<DP<L"KW4YN[34_C`EJ:S'
M54,*%%M]_>02,1TDH9\9`^(<0-#$%+I<'?.$N6=!R)SNR\?@F:S+]8<TR](G
M-BL&&_I+\:)IDF$BYL3=&./:8!S"#P:A(Y3NP[8B1YN,T"7.AL7'`;VV5!FX
M3*CGQGEQS:Z2\>SS(GG-@#;2B_`-69MQ-LCJ^$%#UJ*T-),7_&DDJ;A01O_S
M0."*\S`C&T/&PT$20(%5-FT05K?LAP-526=Y3=!0L&5G@]A-\+*>(-XP606Y
M$.,H9^5PV2+F`A>7JV6>ETT=24W[N##.7$G.T9!>Q24+%QA`.JLJ%]`0C(@U
M&,KP8QH_\G`&QS9*4B@.]!I70R._7#$+-0TAD\V),YV2;53U:<!@2*-8'S$-
M&?-;@`'3]M$.;MS?G&F;%,$`1*&4#(X>'M*RR(L@80E=8,#B.`YR"O`?@RP+
MDN(RNV:Y+R_*]1U+(G"#0[K(Y`''((YQ].&EHLLK0MV$M[/4.<$W41.T\;JC
M2#`0G\8.*5,1%\#\)7\LDJ,-U?DAR*&\5U):??J,LY#D^"HC(6Y^;$SMGY+O
M*,L[_EW-M:+>)@@VUAVUE](256PL6!3R0/I3Q8G>D`1%:1P'6<[?2Y4)*3[W
M=%`V:-H%ERU-J5V_)Q@1:W\Q_WIJY_92DBF4FQI=2SQS#[BNC=4Z:I?).>N-
MF/%X[Y;V+M':+5IB>`/#KJIYVSN@=_Q&#$\PU9"N&\ZH1/*(J=;:>=B=W7>L
MT&24+5"HX@7C-`8J;/;D:%5)8&_=N0AVH:V6`0.R=0BT2B:A:1:):N;$N"H5
M>ZE4VR1@X*362\YH7T620;U>Z1Z8T\%0O;QW.E]OD_N[L"`KK;^QL*4%@QZ+
M@M(%M_O[#-^S'!M#CG]G6KM<I`6NG\[8EBYM6M@K%Z6FYH4+B[;F[,R(\0!8
MZ]LZ1D<+=*7OU"/=A;YSC\P_*P]/"N+$Z6/V'I@2Q($-#/[<=97O)/,KR?51
M,@SP]:<=DOT0Q*7;O=<6M<]IOZ>R:=:O2,&`R:R?5+26_HX>&4'CR2""Z%-2
MI3['4?TLZ"K#:U*N]147!TGP!S8GT_0`-+(#!:6+SLH+M5%%[6G9\WU`DOP\
MS7.<7R:GSRQA0$GR!V:2_NS?RO3WKZ&M4-U5EA=&87J?L(Y%,2NPPLL4M/F9
MEXFH!!A.AMW\O\79VG"YI$LR:]Q,H5PG-M;Z'<Q`5RCEM,T463B<%S-[;/:;
M(@U_8=>HJ'-JW3[ER0)S_D9)U1EV+G@;T0$Z2WTH<B%N3[<)%T/[CH[WZEBP
M=2"XIZ>4HA0$5?R&+Y(C+)8ZU2:N9[43QVS/*=U4;QY4FLF]CWYW'>4)HV)"
M=T',GVQ#7H:V[_N*>^=TR(3TA^#>;7MC%N!O$>IBF'X-:N+VCLW1*FNC['!>
M&.AM8G.PV\M`!1<,''9,<`,?9SD`Q+7U='TEP%"'V"M57R_.MU$JHGR`U/X=
MWF)'J9TEG(8VE!CB2#].$VIRP=+ZUQ<53W\M^8.4YNVR$RC=!/GS!T,,U;L(
M%RE`O<8`U=4W4//6(CT4PE@.BS0#M`W7FBS^E25VY'<3=?=>!O"#@++.+"<$
M]YGA`U>C<1^O6[+J1FG_%BE'L:]KI%KK/N`$KTC(,W'7!ISA@)7Z'-2O!CGP
M(H0[6='O^!_JXP?FD5I.JD@KQ^6IRP&^F0"WK)K*(/OD-=G["4TPJ0OI)BZA
MO;?DRC1;2,G9@":J9.7P/K<,4E,?:,Z:*)/GFTW<'CH+/E*MKF)J`+-H\4SD
MB)^*",[PMZLH7V*2B='/['^-^7!\!?HO\!/_2>G%W3CA]-9(O:U/VJJ@?\1E
M\1KD&RX0QJZ"F\57G+KF:!',N2^0%>N`J_G5N_?5JB3E8&$$HU?MNZ3W;313
M9_!M_SQ?DEY9J6T>WNUOWKM7HY"I<^F2O&0G.T]T65>P]1FH/9K&O_']Q1B'
MWF4\&'^N47NT.S_B]\/VE0XWBDC!*W<(Y<_2[*I:Z:LJ)SKRS)<6UU'];6I<
M"P,,K^"HI;3B;M@JZ/!`8[USFZ9LHFXF8&.!/9,)"QS=IKI5CM(%NK+.-X,,
M,V8[N[CQP<#8,&6E[+\LG3!J`8Z5'TL3E#.IM2OC<Q6%'8Y9VII[5K5"5)?*
MV9'O%$FW3&BTKK35:Q97UGG1Z&Y,%XUV/D!H=%;6X/@.`8?=%<(0&$J<OE&H
M,<4&PAX;:`RJ=9T<@O9EGJ]@#/_QDE^)R.NL(\HK",.E',RBWL4&0Q`]%3QL
M`]==CHD<""W`^)@1E69]/=A-Z\3X]E$N1KK-FFH9H+V7@^(&W&[8.Q$&W.X>
ME6TKVA>-*W@?^3TP-/GO77V87LC!N#`'$Z2*A\YNZPCM,THQ'-O#U_8Z,8"]
MU\`UOUK&H7HOW4)LU*R+RIQGT`SRAQCG^=:YK<3E"3"X?C]-X[T'C>OW$^#:
M?WJ#'14WX+I^JW'HD_+0YUQ;IL.:=,V/N70'`?,^YNI?$&#5:5UN'0BZV9R)
M24WMY0U&!,,=&#23(JRTM_,@Y$$"-B\!JO1[SDJW*P"B^'W6%[M]M3K/=>L?
MO0-!IY&4C([]SGN=O\^MZXT#>A5A\GGBSV=I=DRQ.\)G]OAGO2`RU"S7J:O#
M#`:'0S4V/"BO%]E-2N+.&CM/8TC`?:#JT`65>,]QC=EM:;$]OMG$VOH%3IRS
M@]7-%`FF9C98`'7255$;@='5^&.4B,?=][2(JN]7+^Y8?#]4WEF6:69;/.G4
M:Q9.?0+O$#!IU>_LFNP[&#ZFT3J)Q&7[RVU=#@W0S2QS>A47Y=ONQ$3O'40#
ME-1A:LJB*C;?46OW(V;_P-&"^K#@GCWCXN@O@[BY@W].5LH;6N-ES>^+1IHK
M^ZR!@KS#<@KM);Q6W&\#P<Z><]7\K6<8,94`Z577?)5`P,6-=C-CAZ(@>[T8
MWDHQQTOA;6U0#0(3]6P.R:YRXW+TI#"<BE6_/FQ:#-1CY"*O[IX#CAK@;XBX
M&).?T!VE#'V5N6,ES0:MW4QM8#=.#`Q([J2[[.5J/A2QN(,GL/Z`<Y9;<4>@
M6J3X!:F3B6:`&D4`!J>+WM)3>L'C%95-RN$=,&F4X1>1#N:9\6@0`!B-=JW-
MJ:6G0N*$;T/O6#:!XW3-CC6X,U\P%>_YN=B'ERW)E<CUOZ`F1$TS+/*\7-<G
MY]4;!IRM=2EJ]OG!V=^N[K7AI+>P>_F:]Y$VFXF*M0NGX;GD`(W&#_8V^#"D
M#7Y(8RJ&5<]B&?=,K;_O+\\^/N=I2FF@[O>SL$;L++9*J[N&"%`.TDF;XYKD
MOYQE&+>39<[1#>KO'NS`-37CWH:MZJ.O<]`:+)4.@"DI6E':USIB:P=V0AY)
MA)-H[LFV^]V#';&F9MS[1-O^Z.L<L09+I?S+%0EZ(1C*=:&%"([S%KA<G9$D
M2$*2W//8^B)IBNCHKD.ZL\\Y?H8:U1X&KKQ@T#Q0846]C88=17B%LXQ=N*_%
MB#.3.8-\<HK'LS1;85+H\V!:0TR#9/H-`HXPWQP4'"#0.Z:GM,+Z%J%)^\F>
MES!1LQZPT&F$C[F/N'A(HUT.6>R2/!^TN)IJ.6RQB0&,7E?=5?F+A6=><T:/
M9]?L@OZV!MN0<]`^I_>S:;4IUK/H+AM@M.ETE3QBFKSESV_"UC(8990MN2<3
MI$.>9H5ZE6'V+*0RZMA88EA#.^?:TZANMZRX@M`[JERTDQ/P<MKZ&<_;_($N
M*:V'`+/U@;F:LXX67F9\JZ:V?HE3EGP1S-F,$F(NA<1=&+T/>6L9<3L7;``.
MJ"7>`^*>5BZ*>P0?7JXQ.]AXQ,V/QT$<EG%K,:::5D>+FFUMLZ.QS6)GI!SO
M\]0$RKO=*D%W+W1))$2BU98DW$JM%N?[+D4Z,E0W5LC\!4O'A.W&28`!W[%J
MZRN=!AZ#>542C\O5IR18K4A,6.G+91*QH'<9Q$I8VGEF0Z&K^@WH;`PP,.:H
MI3Y85K;X$-DR0EE#IBN<YSPYI2%K@TPV[_I0K61W-=BE\8X>BV+R$F]+-DDZ
M#XV7:=4P-5UM%N_\W:*J.XN<L0[3),:WJC3M),\[1B<TPE(K][&Z_5[EGM]_
M&'9QGV$L*N#1G9E07F6]FFZ^(@4&-;>%"11$,+!CT$Q.!5*1TD44I=V"85^[
MV7K15FVWE?L?B6:^_:=&O>W&LD<`H\,U6DE;P6;%O-^017OA?XUS3)OD@2WX
M\2..TPU#FZ'W!S#/YP^&&K1U$JZ<,(`T5%WCM8NL$L"3845;$2[HV^.ZU;D#
MG1C@O4]W4U?>;8/LK&XI2W5I3ALMO"ZR:BJ?:;)D7<%+<!>_YCNQW4O]'TE"
MUN5:TX9S*G#PMV2-#3OSNY3JZ]XG/&\F]P=W]2MZ?/6O532M$SQ['N>U`J]M
MG'<;=NYQ+K[^FQKG'9.E<2Y^_0V,<]5[GQEG<^/G#W:,.S3JK$_57O4\;C=8
M-XMGK_T!F[)IYIO"C9]_78-[ING;\.W?T.!VFKJG'=R6O*)#2O+:>6;/$^I<
MA-?&X!V$0[34YJ,5-4+V>DME>PS(3@?5SQETE#/?2-&IVKN'TB>#`06C;OH[
M)\W=NT=.OR<HG*=!\GT9L"^]\*M6*@L41+,!0*M@T_<2!93XK5$[J1H(I4/W
M%>$T=]0\KP9;MP>FGJ8[H@]B%:=HC$E6:"VYWKW='HRQW$C9T!\/?)0T;WKY
MLF!1%@]IIGA<N,?O',3XL373)(-)]Y'#'UD6RZS/Q(.&@Y<A9*M35J'PP,>>
M:`VQ1%\FROME>_K&08PY4_-,,MY4'SC\L6:PRK$TY($/JZKB::OZBK!SZH;6
M?^<@AI>MF2898KJ/'/XPLUCF4#8Z+:<J^0-NP/6JS'3JC>R_(\Q?/]#!Z=*D
M>QJRID^_QH'L8&]_>`LAVX+*O#Z.IBA.OG-5G(G2SL5<.([43:>^]3R4>=:4
M<X,,ZB2<<^($@_5!ZO:ARGG>\H3CW:0S$UVSGP:<I^M-G+Y@?(.S1SJ4U(9>
MI(F(3O.!G-^F11"W?V<!SXNT^`D7VSP\O*AG->8US3O3M^<<&K,V9WMDS?)A
M,`-S3FNE@NY,#BJ3K&%"[,'<FC\:_@T.=+'S/4NSZD^,3E>_8VXE7L70-S;P
M+#Y`J<'K=P8FL^67,HTW>.H7[YSF[22((.I5G4>4M@K_\WZB:HK/',1VTM)(
M$T93I6]`.0W?LWWNF6[W=)-BM%W\?UK5Z%2W""84/MO-C<D;I+GQ,9ED[U/5
M7LPQ52T$"?[FUN7TK=,2?2#`EQIC(M@W<E\#Z/O&Z-/8P5A=*9.RW++WN9I9
MTL0PYXK'KKBU9CNG]@XZ9Q7[4.(,;!U1L:`T0YP)_<S9_ALPPLY)@I<%7NL"
M;38F[TB3#+"BK>&`C;B^F@-0QU@1Y]T9>I8G!8NP((^D>%DD$4\HRNXSK-)L
M+5SU75YD0=C/3SQ&P.R/#089)KT\<.+V#K_1*FO>)*"@DL%S?F1""B);,7M^
MK""V?Y^2"&>51B8$NG#-_HC!;H+TH$'/`@-@SGI:]^<EXZU?/0">4UOGU$,<
M?H?-^[RJ,,(ZL[9X9L6>B)+>%$%6F.)*CCIK7URE6](C=(?O29(<_LV@BS01
MAU:GOY;4=6^S".7?,ZOW<,W<_L&#"-@Z-]PT%\]M7WLU05Q72_?\,!+LL*SO
M.LTX,%N?//"A*37>G@=G\SWO:[$9C=2.S/KNW6L>G!N2!::;2_O^Z,$/4*D!
M]SY$FR^^[D':-],P3"GI*QZD54G44DY],=='#WR0*AIPSX.T]<77/$AE,[6#
M-&2O*^/8/$P/+6@P;V)=$38X3:*=@@:Z%+OJL`&>Y#71U&?LUK4=.\92/M&;
M\;OP3^='-./N1_<#/@IG=,UMLNK""X[X.46+95^'98;'2L8S,B>^^8[&!IBQ
M/1%S8/(^HP_55'+U%2NJ>&M,8<2Y(<W0';/D,C_*R^&C!,U<&'B7(P!G4V8^
M&1A6>MYH`P^=*C-W[2+-=XGZ`2;;RM8[B((289_&##]Y!<>H7?\\&7Q;`D$C
M6#)\)Q`WT@X>QWU+]A]OGA3-N@CQ-"*!(UH9W9U"WBM`]=P!V@E1K0^I3B,2
M-*HUX=`IY!T\J@\]HCG??ND;.-&9:0P!$!`=8X`(#2V2J!48FFHTJ&6#=FZF
MYMC)RZD$PQD"^S`+4A#R&J\#PH(4QVG"0UME$)^3U9!XI%V$K]"DJW&Z**6-
M'V3`TE%I:^RRD8-:@A"3-*.3SHN>%1_JH-IEJ;E;O:,LKTYXB+E&I^LB"`9Z
M=]0>;BA6,F)8[%7+#@N@`Z*K&E[P6QNSWG#BIY*>@P.F)@FP8#<L)*IG/SSP
M@0YZ*K0='.4TRX`&PV%Q3).`0X0BX$BEI.V(T*19!BPH#@T^F@0<'A2G#B_N
M&XS'<9I/LXE12((%3*VIP^`IB3F@[8M.=Z"144G_74*ACL)@879TL--)T@$A
M%VH4<W%_G^'[H&"E5C.2Y"04M5@-44LKRVP0=%2^`9J%'@:<W)3L@Z;A0@T;
M^F&*9%Q[NQG?KC[0-575*OO]W@'=A+<WVX0WX/4?@W07=2YC881()S"T>O<_
MRZC3?.N01IRQN:8<;<H/@=I#[MG('6+`@/$#Q&,#>@LXG[$`=H83V-G:!\SB
MM`W?.R3';6VV*0>>]F.O;]C93)UG1SM-.H0FK?&"3C'KCGW&VGT.?',F)7`V
MHWVOTLKD?4<\5%/M99RZ_L<*6)9JE6'7)/_E+,-L;&':D,6U7*%@.+MO,)J,
MLF%2Q0L:F@:%I6(UE/3MBM(B4A&C;(*B`?MTCAL<TB'U0QK3F2,FQ<M`?.H$
M^$:HV3"[WU1Q@T:I465I#F^(X$/S%F?K$>T@V*#`L&V$*_@8ST%`KJ6H5-./
M_L2+R+[@((-2-]9DRPEY)!'=08YT@UUV*.A3&>6*PC8OE.C52+W[X*Q)T`O!
M,92$;N$#CLH85QG!35N[7+>W,]5%F5#^K&G:IFZ63D:VJ82#\=936R258*[D
ML_3SG+LJQ]S^!FI_!-V]=`BK#R'^)5B%8$:'5,XMQ6*F$'P0J1&EAI@D_>$Y
MN,(TDYEBJG"N&U*6$77N5N0&(GQV"3CL_:,S'[SL,Y7\8),GB'8<"M[<PP<S
M?/:58\YB=!]U-3ER"V(<&N)L>[6]?_0W@C:ER5JL19-N%777-ZL"8;P*U'E!
M-L:+FWKB^:YLVA3>7M;447I?S#FI)UW0K$NYB:);Q0-&Y[?+J_U6<!/X=2C:
MUB><NTZ;6M%^:;8N%0P<F%33%&"KB`]M"I+OW,B9E_?V$2^WEZS93_=G9A\Z
M%</K+)G6OAF8+Y,KWOC?9VD^>5S$]*6#")38FVK*8:CXC'>ONW_;=&.ONKGJ
MRV\7:?C+DM^#/2DS.NB%XMS&G/_8O9VE*<DU6,K,>:<+G%F6]N,MT'7LZ50O
M_&'XT=9S\AK>>QI#RB\=DA\U--64?E3QF5?C1_6VZ8?;:RB'55G3>C"_Y\&F
M_-(A#39#4TTYV!2?>36#36^;;K`=>TX">Z#;31_%-BS)8_=GI--F<YHW,C"<
MMJT(UQZ_<T@.VUAD:V\?>7TC;T01+>SV3@8P>%KNQE0):L_NW/3I5Q]3=#+^
M548:M5?4E,$?%WP.[:4I-0`U9TS?M(.&_G2?/YQ-P>0V]\>\0V3S@`9WD]G3
MY_@>J,1!#?%1#3SI*!^DP>L9Z&/,EB^HO*I@=RLBPK.K2<'(?0S^_>H$RA?,
MT?Q[BOX-5^AP/,4,K=!W'*\HD@AU0_JZHXY.IO_F8I&MS*#5V]B4_6D@6B?N
MM5V5.J0I;)H.F-)=[*;1Z_,AD[3'[L%6'SG`K%Y45:6*/:'?5E)LWU;UHP?\
MG&$3-//NN<1V4,+[PM6WY?-&L?<TRD4<S^L`'ZS"P8SMD8T[V;`>^'TH+ZH\
MVKZG*#6<*?H]$"?Z_H"&\2[-['.*GO>L&=(4/>B@&=S._L[>5G?V:Q^.;=6?
MTKUJ,OL>WD]32QOW>=7P[A;\VS[/SAQ&M,^UZ,D,WSND&)U3"OV]?^R57Q=S
MRN7]*JZ'#7P:2/_K1"K(--.S1,VW#VGP#FK.?3Y?57X8RD;;A]$C=MB`<09D
MD@!49V4^8W_+F[MND\RPAY,^>*!;-4W#[6E'UOL:T%&Z3UL/::-U29N,VI_<
MGZ=Y?AQDV<LJS9BQNIP@)H8YQX==\3:^]=1@`@-6%:4T1[A`:<V$8LJ%PC8;
M#("=KE:8Y>2B8R5,U_@V>&9YW:XQZV(2$S'VBC,<44-BN@TK2JK(2X=8TV"3
M2)X3LA,V11O;$X@%,PBFLZ4_6BH>E-=,J`B>`=6`<;&<&8P7=':C:L0-'=:Y
MZMU$0AL9-N.'#@F=O(,:"Q8CI/35C+P!_A%*V!2R0JMJ;+`?[G""5Z0XG$%Q
M_,#6;<OD!*]PEN&($BWR'!<Y6Y,)AQ''Z1.[5;U#0P_Z"K2A,Z*)AHZF`9\X
MJ`$VW"XI(VGTCS(OV"8"D837Q.-L**CY#FBA=ED\X&QKT"X3CRP*VJC1&3MT
M:/3E'!3^-<KW07Z%LW60,(RS76[*F%!$J/P,0T<X.RTE24GW4-4.C&[Q!S68
M6H!_-)L,LV-8Q3UOAL*T"&)3'&>PWA)HL_21Y,P7O_D@5CV?([IY1D(>X@NI
M/=V"JZ>31G4QJ9A22%M99KM;YJA\<PW,0N_='PY04BI45G&U,(,$XW<P?)ZT
M;N$.W378Y\P]I[<;:%+;U3FR>D?D.'WM`4(H,[%DUS*ASI@N%/)KG&/:V`]T
M3WN"'W&<;MBRP[5YK&*\XM312"-@+3+@(M=-<:F0T;\&Z\V?3M`Q%04E*"&9
M9DJAKB/V"D1M(G,U):QEGU%'J<HMDX:B>I8F8I9F<:Z`\0(%E'/D"EPT:F2$
M"4S4Z%L!P@3?TZV$\11Y?$#H!SD$!!2'=`'A:CTG]8JTEK)&:%$ZX`YMJZ'[
M=H/'\F'`:%OB]AK';!A=!5GQ<IL%24XW4FP__N&E\XM34>1!LOP40!YAKKK8
M\0!!8!9\NVAO*F)<\2#.A-KRCEBAU>[/H,H5:]KAW%*,V,XV)[I=C6@#V<8#
M!K..BDJ;$ATDG8O[S@G"O,C*L!`E7*@9BV>B1YZ2=EZX&=3M8DQ!"`A8>NUD
M-+5H$2-&/S-R,`!2CI'%.BV3(K]<M?XV;)2I)0#P;2;3'-R<BAT0,(?J+.VH
M6^XN$&PP@'I2XC/:O9>K%0EQEE]FO$C50QI']+]T2V\SSZS[&1?U.QL;$P,8
MP+EH*7O$$)-'MI+K/&S8TU'<.=WKQV<87V.ROBNS'"L"SB;"V8[=C(HVAVU*
M*N]PL*K6QP"G12N,4=:FAN%JCEE/L3?6S`M>D_P7TQ961SRG<S$KW/8J:DKO
M^'%23\JDVB9&C!K6!E$RQK8U-#%XA9-Q.ZBGA@LKVQ90!2UP>S_)JBN<L3\$
M]]K7<V86KQA3*&]$68L>+LYD)>U(\_5L.*#KL6O\B),2:V+M/9*9G^BZ//K6
M*"BO0#G)OFY_'0<;P@X%<)#CR[N8W(MK:BQ9BVK=9"2?;?GIH'2S"#70>A^+
MC@I*EVG2Y&W(4[.S%43[7@V3@0K*N2>T?$R3XB%^88_&KZDGN%QQK?MK!#/I
M;"BQ*-L@1$,'`QUFY?K(J*@1(Z>[E80_J>&HV)?_."M9R8&/)"'K<LUUJYXI
MYY?4"9Z3%:Y45ADW@'DVU`PVJ,&1,R<,9`U55WK%R/G16@BH?,^F$H%2*@/%
M5$B#0!@+46[1(HG88`IBEET\D;!IH9USZ6E4M[W>41)Z!YJ+=O*"A]&@B@@&
M:K8/XKDO92I6^MV4=QS=0FLI0_,8`7Y2%[@:IDYE8.,&@\3!*FO@*:[OP4!G
M*\GB=@%Y1O(PB'_"0?8Q8`=ZQ4M]E4'SLF-G:3-OR7<QN;=;'R,*#*)WT]\R
MJV<"[?6T?H1>J,@JJQ,ZP2%FM8W1U^^.8(R$WNCN+''JU8W(31KA['*U;24W
M;S%$GD<O/MQL@U-W%P8MPK*K(?VA03'W^\.!^4F)E\GM4\H,LB=0<I8##=9*
M,X?"N2/D$&&L,D`!WS\<&GSI5_$T`&Y)@@EAR=1Q(&[$'"Z,^R8H@/S'`P/R
M&6W127#<$@02QI*AHU#<2#E8$/<M4&#XWPX-P^1Q&E_<$@03PWU#QV&XEG*X
M&.Y9H,#PMP>%X=T:!"1:=X`HK)=GPY16OZU5'T7LZ>"KI_!%FE35LMF9;!U+
M%&_C5*<O@]AG._P:851S_#6`UWOL;*3"^H-X<1*?EW=O!?BF"0^[04\Y5BYP
M(7N\P=R^@.=@D@YW!E88'F^<TJJ$*L/]W1XG+)[ZX"I+5T0996_]//-=+%/L
M7*657"&#I;/><")/;7L:9*S43GZ%L[IH`PE9TA(2EP6.5.UM88%W'\Y58>EV
M/N\=G"'J<-=I@G+&?(3N&#O/`!@)`>@-25"44D^="7I.F'\.8P5+IYL<_UJR
MT\A'^C_&=^A*TEF?F1N4[=S!5-"!&?H&Y:0WX`TIXK2PKN[W##FW7-S7DWN$
MD*2T`4;GX*[L6Q2TP^E\NNOZFB7C1<D.:B]7)\%+?I9FHGS(;7I%F^&!+AZX
MQU5>XW1DG&VA.,B09HWHQ.4=3X-5E1:%G)?=N(LH-[H7M;UX(M&4RT%%BC:5
MI&H"G'E)PVU<A&%6XNB8_IV$07R;D2`^3O,B/RZS3/62T,;P]R@-9^LZ^JV2
MK;0#Q4/S(=I*SRM8'D5VKX(EYL8HR%E'%@^8KF5BMLFD'8;IJC]B>?.K7]+M
M?7&VY2QY0I[B(4O+^P?ZSZ"B9LL@NCW@>U0&AK#2#!5,-;IRHKI]@3[EC#E%
MU(_$."SX!T*A,=JD&<=/]=V8!'<D)@7!.7H3466?2/%`UU<I]6/\A@C]2/4G
M1IZDV9I^9WM1/7P)J2IDA>(TN<?9YU]X1.$926CK\EJU=@0JB4&BSZ2I/^2M
M:JU^LZ"+(L*,"F)1K9&Z^(YKEX%G80`&/C=MY4N5*TRW910'`1/`^)$HH,91
MTTQ9%`EBUO+3=W6./&K5CP^4(P]B?$)RZD7O6!V?,XSU_L.=%UB/#E;<GW=Y
MJO6CF_Y&0?9R_S?H:*9Z(P<*C'9%I9,AVD$\%,N?Q?$@T)H]DLH_KWL[3->;
M('GY72?!1Q53W>+03Q_&09Y?KGX,6$'(XC*[)O</[+HZJ8H)L"J_S<]Y];N\
M^QDG!EC/[V*#E+N2EYZB??]4T;,1G7$.1&<7A)E<GJ,7'1__]-/;CQ_?GIPP
M#[,."CA`.`M(QHM]CH6`0<`!=+Y=>_TJ8T5YJ^F(>@$9!7`ZN0X'W."07>.G
M4Q*=AU>8%!]>QG7Z`($'`(+AUBA!P3"1<%'Y=HW)!CP3A2*1#X\Y#+$HA0./
M)H'S1UP\I-%83V`5<P!0<+5![Q6V!='67`1TW\"*.5-@[K(*,(HXA$YWT'_H
M[/\H9,*9_>M4VU4J$"ESRT?^"DOJ<#<V6)T\2&=M2O**&RE2(PD!7KKQSQ1!
M=`M)=R19L'DYR<K[8[;98#O9*_K_%(B:CG1EA-65`[7N=V;%CBI^Q`2@1@*J
M1/CLSV42X15)2('/R2.KUD7WCO?D+L8B#?[I<QB7;"_Y?9I&3R2.>YF*QLJ`
MU<OC#5#=:!)97-F\&U2E!'`MH`X=TYV\^(U'?^XKL4<H#L)?&-GFX27G9QMY
M><=V\Z$($ST$C^S7@%WD^0<."[Z[JU6O8XWTNU7-82^`.D^3>Q;*6'*O19OS
M.%VSI^F\\5DV9E851.,C!O#"`M!PQ>4;0+1CF0C4R$!M(2*1-1/CTUOLFHT(
M5*>9E>QW$,]&M*Y2$]59B7I9J^A0#W)$%UZ;4F2TIZLO]@,?M/<9YBE7_:R]
M/Y8Q58MZM.B1N1.ZN$ACYDQ$(;"+M,":,>G*"*QOAVDMI:"JV%'%CQH!5>4T
MQ$1X'8F5AK=9$.%UD/W"8@8_D")8DR2_*3?TI[5A-3:,'6;?#M)=V\-;*8B*
M0;4<U!+DLY\OTN2O91"3%<'1^Z_>O>?IOILI@DT*FAYV9835MP.U5KQE0`T_
M8@(0E]":5/D\ZK%#KS*\"4C$+C@P1X(C?K6!*AYJ#EUM#+`ZT%%;[?%JM7BV
MG:^6"27,"O)/VLW\$@9?;C<?I7\3^63HC/ST0,('Q-;7=%V,PH<@NZ<$P7U`
M1WF!<'5C&]%Y/+BC4SO/^;:-DK(I7$@(MREJ*!F?SB-4;MAM;9P]DA#GS4<V
MK!!VA*,_T?4[Y122\NI$1G40JS^!/=H>P7Z!MLU8G_;ZA/!QFN3,B])9U0Q=
MB1`D9'5:[@6J8?.Q5PK58S@XK5*CY2<D#^,T+S-\BY^+#S&=%W2(-;"`Q*Y=
M7RG,V%`R.&Z$&-;M7([/[OH8).4JJ.HW.4Z.)AZ0'>:@\%[\SKK]W5?J>F#-
MDNKRW,9KNLZ<(*'MK/9>`)Y57Q>OYK;??Z58!S3-UOW>[W2[][9S@@:Z5>W?
M)M`3EE<``#QYC0JVW.&U]:XQG?N2G#JGYDYPSHYUNKF!!S'"`N=`K?O87-S3
MWKWG]Y)K!KY9(>(Z0;KZ#KTAGR-V/SEG%Y3%9]`]><0)JQ_,X,,B+<7+$;OT
M+(Z]CM!=65!`%"@F:[X_+](CAC^*IFVR=;Z!%^*BDKJY-X1^J&BNOE)0E:),
M(NO<6H/^K2849(3'VSD1.UFC^.:-0+]*]0O+O$C7[*[,FY1R,;P'"1UA$?W7
MZBK%BP!QSFYD?G[$QQ=5A>JRR2C4J;1*#RJB::.CZD?*6>"JF&,3\/]<U3Q?
MH*:3CBH-Q6E@(U-<Y`CZAM_SI_Q9=3N`CE&J-1'G@@4K6E[_Y&FP)2&)24H!
M=RRN)-?W6=YIXI16#FC#RTU=Z;ULQ8<H(ZHX4<WJ,QZI-^C]X!Y[?U@]]OZU
M]=C7@WOLZ\/JL:]?6X\-[K##ZJ\#[2Y^Z)3G)8Y.1,5QOK00K];YC^)!>W[Z
MC+.0Y#A2+!Z'RP#6J:,-T#_HKZZD$RY5M7:C2QZVL2EC<7TJ06&0/]!U'MLI
MBZ^@%6:U`#RM;IC9]5/01;V^^Y'NWFGC).197//#94'"_/S\6#>XQT@!"(Z1
M)DAN@!_0UL)0(PTQ<4C(0VV!B$KTZ1YJ%\5*`?$+US]B]@\<+>C^.;C'K5H6
M(C,_RY!&5O*KZ+&"8&%A1RODMXZ$>H@"K^M00BZNN5="WP9":CLF05U&);<I
MUE7?BO<*$.$]S]*L26.@A8!,"K.3M7KVN[&9QRMG7STS;KV'WV918'M8%BYB
MSA[13DWR(/06+I(LO:E"7/:^JRF!=UU/S>$]QX)^(7M7#JKCOD_C:!TD-T'X
MH%M6RR2PNDJK7[^/EHEXR<."0K1CBLK[%2FJ1"`NXT@$MIXR(@+)5^5=3$)T
MN5IAMO3RDW]BP_PZCD8_)!DJ`%87C]3^\!Z6S%&"%%3/#E5;BKPWST8T=<NX
M[Q7WS.E/OY;\=7]S9M,I4^IG=U1E/,51^^'"@LTF]WQ%_^%E2U*US8(NU**+
M-!%[R5-J5/&R3/(BXVU=[RU9;A2QBY0W4S-\%!;.9K18E8<DD7;S"9UVQ#GA
MJF3G@RS749`5A!\6LG>H%*8)2TPCLO=A_G5$MI_OY"PQ'H:&=&:[:U+>4/$4
MDW0`T"_`>=!<QT.NV(&0_)[W>_Y?$H['BX*%SIWM4&&N"?Z(0S:*#QRP8VGV
MK<[[]CI99&?->C#0J'^>!AV-M,,'2-^4G3!2$QXN2II\01/AI)'W&I#2-V9'
MK#0YE`X0*546F5*53'A'>8>/%-F8G9!255!A*_*LSKESL,#Y@2_:%DG46AA.
M@B"5X,.'DL&JG3!5K9W9I2"\E0P&17G1"NVS_>V`I:V&%SX6S(JKNKL^N4#U
MR<7VM*)]AM$_N0"^EI7:8=CB5<]^@!!P69Z.10'TU:JB,88M3TT"#A(++@O0
M\6B`O!Z5&F/H`M0DX`"QX+;$'(L%L"O.W0.4^>4V(+BD34"2G(0\3>H>XK_Z
MC\&"W`R6ZH\D(L+.##$+Q][AX@GCI)=^EF&.'S;&_&5+%1MFCU2RQZIZ"SM/
M;E)9R8O@;2+#K9:'BM_OQ=IM_]A5?NC5X=9D)0S,UHMU&%EV)VCRUE9V_RC6
M?NS5(=EF*0PT`PH\W(0/."IC%G7I7BML,J?7M3872=1D3UY00]?5G->$:WB]
M0WWJA[U]"1B(]VRF.=%$7GV=PZV_\&WAN:EMRD&XS6D=;/7P?LUS$?VCS`M^
M@GV;MFH&!83.5%61CZJIQ-T[[4W"T9)@06M7,_3.CR1A5I4D%\65B*BNQ'*6
M$/9*@,M&;Q97R^//JQ<$S2-0YA@;S]=V<_5=1J8"C+NFW7IG`VX+<WI8:'!3
M5K[9Z-33K*`1NW;2NZL*8_G5M7R1=PR_QCPUZ!6[(6.]5&SDA=S=+HK_%KJ^
MO5!L-<*+M=]UC+`[W:+U:^SQ.E\_M25=X]O@6>0,7]SE/'0G=;2%'E;_NBFK
M+6$@V!#E0X+Q.ZCKM&,13.4-L5W@"EB/6JZ9!,+JXXFL,>Q<\8Z+M[#U=>^K
M_MKXYMGK,CE]#A]8"("N<4[P7<&2K8CRM72+3[?LN>P$Q@B!A9H=+##436TP
MLSWQ"EOGG[CZ`E^Y1_0;(F&*^`J[B,P_XVD:N&/'/W0GR_+&'-?7DK>7K"_H
M7X/\03$?N#'"ZOZ!6JO.O3J!JVU=C.V]\#?YYZ),*B^FFI%[DO`T0+3;28[N
M<'5")KXLKJ%W'J2]J2ZBUW_XW/L3-:=3P]&7KYPDP8+1KF9,>9X**.A951VH
MWP^QO3-_7*1.K;B@@'XDRMWD6$&P4+*C%;;T>RS31%7FH7EJM0ZBJM8[_Y(^
MVU[`OT8*S">P.URGT/6S&6'5"S[2/1?]"]TDI=D+*U.A>TAI(H8%``=-^YU<
ML:`M#R_9X?5)Y,?L(XE9+69=S88^`:Q>T&@G5=9HR'RV]34FX<-9L";QR[G(
M.7A^I6EU/2FL]K?J*2^L&P94<:#S*[_53.@0%-O&V[2*!FKKE^A(8?6*54^Y
M1@ES0X(#W::HX@'5+2^Z;(U:2N"=\F+.SJCJDQ?T#E:?Z/(Q:BFA]XDY_Z*Z
M3]Y[+L:T6*U(3%A@^_:!9"*ZK:_`I*>&UC=V556UEK9,B'-5G>2QBUA@8AN%
M:!).G04A%A%)90#&R`&KJUS5U4?9ZG?U02M"RV(JC5"62+@@:[X]K@_._=02
MQ?=!?(;I1H^L[\HLYY>LI`Y44L'J-).*^H[**FK>)SRU!Y6"5MC3;87C*G6V
M5,]:MUBP,<#J(T=M%=T5X[#(ZW-(QLNB3CQR6:7BSOM)M-C)!DO?DV9HG688
MY>0^(2L2!BQ_?Y.AG'`4M%)ZB_JBO."OR&;>SK;."TL$>94MO<NUR5*60QQ1
MHW'KSSF^Y]BJ__(%RR>$,E9BG`B#UM2W9R*31Q"Q:"_]WFK%[66`3,6+Q4!I
M`"R0ZE9/-H8#`:EY+?4_(#T,D.H2>-L8#@2DYO3=_P/2PP#I-T-!^LU!@?2;
M_P'IX8#TLJZ-)6JW=W+PU>=%%[@X4;Q;<6>%!=S!>NLW&/WR]?5I5YV`L#D.
M8_"*/)64Z=G++Q:(^T!W,;XI[[CJXJ:9K8]-O*`[V4'Q`;W,DO&%6W'4E0AY
M[)H]%>BEEY=5G.%RY79X::&'U9MNRDJW8^LW"Y<K4,>89_@N*X/LA957Y\KH
M]O\Z0EB=8]'2Y;;:]H9)SC-3LF)BS?6FA,F$T5&N_700W63LI9H:,7*`0T87
MC=`1`N\+<_1!U1E>S];^4B;8ZKU41+"ZP:!AOPL8*<SFUXT$%1'@YC>/@'[S
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MNTOI)J`^SR0)7??SL'?(2T(3?J")$_;.%*W*)*+_N<;__"?]A>[KJC_DO(8L
M_P_^0JO(Z%K3ST;A+Y@W!S84`)9)8&%#JY_D5&M"WR5Y;PJRPO$%"=,X*/-M
M'7)M!683.:S.<-)5KJG,F%#-Q7==855AW6<WL8QNO(B"HF#Z]C=@'2`IUF_M
MJSJ!(KL8D=RS$U6>NH[_I>7Y@AB+\U;FK:J;%%6O^"MG?OJ\H4Z<S<^Z8N^*
MX>/$!ZP;!RFMCU2)_LR;`GC\P2^36;W_!96<B!NM,_4"/_&?<L5@=.,#V,/.
M2DM+SF:<)OBI6E`<0E_R,.OPKNRQ'41/JG7N=^1I55^2^E6^..7]MHT@VSN7
MI:V*2U9XOJYPV13"#A+ZOX25MD0;44MYN_C-F/O'M!<C=M39^QG$5N4,*YRY
MB@@6&@P:ZMTT>R53Y?+@^1A0AN^#C%<8E78S?I(!I!&_0<FLKI,IZ=(":$EA
M=9153RE50(L!-77G/2Y0NYG-;M-/2="\<%PF$7DD41G$NGX:Q`VKZ\:HWN_-
MI@.W;W;;8E!+#M0^/N67JT=T;YOQ<'I6H?703A4BP%QGL'A2`RVL7K,K:KOF
M`,&=*JUPNF_5(SZ`SAEV_ZKI'3@7L6J5G"YD]8@/H'^&7=!J^L?K^9#CK*P;
M4</88?7A*-UW69%X'8A4JW6:%>2?K+1,7K1J;$B=JB>%U8%6/?5[MW++BD+&
MR\I^I*'HLR=2//C-`*PI$<RWF=<X3.\3IKG4<6YLL#IQD,Z&F"E_<)0_\&AW
MG1^^WIG[+^325+[98O3#"T]?3QZW97&.@S@L11+JC[AX2.4>'BD'5I?O9H0A
M(-,I5A6PLE@Y>],:4&0TLM":"_-[.7<AG$^5[+Q;M82E&B5YR"ZK&N[KNDJ`
MU?-CU3<EL*GO\@8MD>Q%LZ@/L*I%5VX>1J!=G`10MZ=9<\B7<BP,L+K945NG
M$S#^&)UXNI)]@O,P([P8F'*>8GFCF[.#K3>K?I6[<4=YL'IY&F/T((BV\CM9
MM%G(/>,B_&3.OL\PC^D?IX\X$]9)':TB@M5[!@WEE.<D1Z3`:Y;U@0YA+#(Y
M!+4$ZEH?Q0F51Y?:S"'5VE%>.O4(8'6'1CO#8J>9V+;'3[P:DA@Z=P60J:X]
MTZNSJ>LZS)D35D\.5=OX8FF[HM&FAZ^SP8/H[6Y,Q>&BCXT!5M\Z:JN^^+&]
MT)-W"T32+>N:]G#[SH#'5>EVIA95,31KT3X9K(XRZNBT[NP5[?"3G#0-DN_+
M@.GQHB[7*5'`Z@:=>JJB*O4T1I*P%%LW.C1B*@#=5Q+$%NZPRIWS_ZE6PB=T
M>I8O3TTE&5;/3VV65`"07:]Y>B!\0D1XO8G3%XQ_EXN=`1O+3?%Q^CN/!;$7
M!4E*(44UR'BA'OH)GO>6^EZJ7KX2=9OXKI/0B51<M^+%>QFY*"MWA-9!]@LN
MMG\1][+HI$L!NZZ>%50_'2!6F_C;Q$AMY+XFG/:-&AB;9!%J?I7P[1T3SZZ+
M)0?FWRY%I?3O^5S9*_?>1/M:U;9N<;9672&=]_NO!(,[&2^=9+H5-2NH##XU
MIR(R4T'YGND@;K!NMR!'[#]_=Y7\E'Q,3FZ3/]-_W/P.<3=9''$A^#F@KAL?
M4:IW/_W^X[NO3WY'O[MAFYVDRH!)_S/EY?=6U65;EN;RA>Z%J`3RB!%=.A</
M+(\E>Y3U0"@I3E`4O!SF0+HLB[R@IM!F]S>:QBCQNH;4#BV@GP/$8P[AZCO'
ME,%6+W9>U::K\F-6*Q@QYNC$L57/M1@A&[>_F2'Q'L*0>/^;'Q+O_V=(N-_O
MD(J2?L#W)&%*7Y:U94XW/EP$P8+FCE;HX14RP:UH#MNJ95RX7*CUKI9/H51_
M`"XXCN,TGP`:DI@#!(;.AFE@$0KIOD%A?'G(?ZS<=%,M_6MY#APN`Q8<QAM@
MF($4+_6JI/I5K%Y0U/-,'58"]4+3T`**I=!P&8<.`X>%R$'!X#A]PLDV48,^
M#XB.$%:'6K0T.'+&R'?^=>J).`[1VFOY1L>G7EI*6%UC4U/*Y).PJ[@-B\CB
ML^$E&WG]$AZ#+ZJ\/O$+FWE)TOP7GWW3..:U2([XCSDJ>8+.ZI"THA!WM+?%
M2KR>EYX$+ZQBO'`ZM^D5[80'NE/1G'@[<0$#P0"554=[VP0E+"[7Q`KY/7S:
MMT\9H5LQ'@]D/5H%%NFOF^H#*(C$>0I=E'%O#*M:T>CBA%__/;Z+9^OFCET=
M]^NJ9[]O;8RO)>$=D'YR5U29[,[$Z?^NT+Z?G@'IPY%:ZYZ=N8F9N7?+_.U]
M$&S^OLAS7.3'/,=VIZ:NDN#O[[WWD%DO::G#J8Y01>>UD>DR+;2U\Y8&7%,K
M5-.U]I;4:X/KFQE<XUJ:U%,SGI/@CCHL-@49/(1,!:AY#<KUF[I%ZMMA\`#)
M0QK3A7<N$EFI&EZF^OLW8!K>H)R<IG)+^CM4)>Y:%$5&[LJ"ITJD^PRZ%/+7
M'RUHL.H'3KUCXX$Y2,RJ&H8,C_`(<D^=U!1+K.[N*_V_1`2H&_2Z]=N]H40U
MJ>\V%T4HS]/<W.I;,HCMKM!.W_*"&+UAY)_[6N<8GN@J5S\&>D`=XJ2FM%)J
MO\1)5ZAA0YS/4P\MDP+3YJG?$YW@.^4:2D$&J#],VDGE2BO:VC,=(4;NJ?7I
M1B3M#F[%0S8K,:">L.LHAY6V'(W/JIA\N:VMGSVC?S_FM_Q+=CU`*)HF^0>\
M2K.JLO%M\(SST^<B"U*6N3/(7I8%7O/]:'44P1M#P$X]N/;V.4#0F,-*>;"W
MYD!1X'[[8;3],KKCGZ[QQS]^A#J?1_S[(G:PU0#5*GA%*M6W&C$?<()7Q(`R
MB10<0O0::GJ7,M3.'+VI>+PM>*)_E'G!J]'?IHOFQ.DJ(-$R.0XVI`ABBL!'
M3)<"=./(IIX?2?$@_L1JAYSA@-6V5RZ.)I(-J,<G-TE:=&T_P#;IVT\@]@WV
MM*#ZRA%J?8<O"<3Q\/93J/J6OY&>X8`M;L0_E\DB%/EMKG&(R2.+0VB&O94/
M$"(&J:MP")P)O:G9/V==7$M`6Q%@.G%)X944*:M.X]9[+0;0W:;2T[&_6JQ@
M^NF2O>6L@J[ZZ+T+'^A>,ZCKV'E<0AV>1EZ/!S3F-2&2P?W8XX3?DSJ%!_7E
M-J0$K#=KOWX5O`R?_2HFT'VHTW7HO%?Q@^FXDRJSWC6FCKYT[+@>$^B.T^GJ
MV'$U.ZKX?46G<'$<Y`]7(F%7].'E4\YNAFR=2EB01WZXH@Q7.7,#ZLH12DL!
M+5P@)@/50MC;LS=,#NW:S]O>M)'EJ7^K!WILZQ7^6A(6>BFH)6P'I)\:K4R`
M>M-=5ZE67L7)-XV"%VV9_4Z$DE44:!14Q<L5-:%8)!$[Y>1YO9SZ3\L-N2/M
M2KOT:"WE"'$Y1\T9,1?EN7O/THSJ%V(<\8`I7XN=X$V:$_/`-/$![%(G=;6=
MR>Y[OZGY>8#W\VK56LN`-7<N>2'AL7.G@AM0CXY0>N#<V8CR/W=>X^H)>7ZY
MNA9),]EEZ!?=`:J)'E`?.JDIOZ6JF=BY=L7&BZ"_>#U<5>.Q.7<?-005W("Z
M;X32`X?@]M:"]R'(+>7/*_L;,%5_ZJD!]9^#DM+[&<I"UR_BF:EB/^G_50:=
MX6]$!CQ;ZM86)<RW%BH%S<\J6AP>APE[%TO_P9:VCT',//55&I/PY18_%Q_B
M-/Q%-V*LC,`&C[N^JG'$U__\7UH"Z.#B(M#/U3^9+,2%_;>W4V9^4IFK,Y7K
MJ0!UED$Y^0RW(:W/^;U%,L7!U`N=)!=W.4_RH0Y>RG2`VMZHGARBK(B/$%L:
M_%PS>,-^&);KDB\Q3UB2/U9OBZ0)_?<8\V142=2^:3DH-C*5;$!]/;E)TNC<
M?@"UO\#N55;?X&ZU_94C6)&7JGPWW<60J,ZVWTJUSZ_GJA_'#>.$LJ89KK`4
M?W&5X,U11WA%$E+@<_+(=D#=L._I<QB7+`W3]VD:/9$X5COQ83(`#?K1JLO.
MOQ;TEDN28^#LKFXE#=7BO.PYAMI,)S-I)(^0`65,[Z*ZOM>=9?E[O=!1[?LL
MS5U'MPLGJ#$]2&'%LX?NP#U"7`*$\=L<"8A9I5KCU[>0DLC\,-W.!:@7!RBK
MF7,];8%&UQ(!XA_UBDEO1ON4OMY8C\VU*U(IU8F56`2*_UDU=J;^!J"1MC?3
MI-?AC+XJOM#^%%ITTP^WZ:KO(2[Y2/R4H^:;_%B3_^8K9JBJQ=A*WJP,%UIX
M`'B"P:I*0<(ZZ>N/VZ2OG/D(M=@/S6'0R4>D8Q//XY=)7F0\F9NH"H&G=1W6
MK[T&)^)NY![<"?WX6_'U.EE%Z_MLW<<U.*@T_OKVK/*SLONM(L6@M":9XZ,`
MG-O\MBJAN^>/0TFF7M1Y@:\R$F*Y,K&HIR-A<;PH*`B;P`+EK#I*Y*&@H?YY
M&D`TT@X9$[(14\"BD7HXR-B0ZA'Z1-AHY!TV.F0SIL%'(_=0$$(WH"M,V,OC
M:1#2DG?("%&9,05"6G(/!2&B,#$[K=VNEB:!BDKP(6/&:,\4X%%]``J*I)HW
M`Y:H&E[(6+"I[-+=&AE@>W38,E//?E#].FXAJ1<#N'>'+15-`@ZLA\<M!DV"
MP/;RT.6>2<!!]?+8!9U)T&'&.-ME,I?4-)+D))RXGKK#QP`D:Y[/QNECF?J/
M'B@JJW.#_2-2^2$HOFSO]NT!B<H/'B@*6SNK_2-1^[%7A$:[C7M`I/:CGL[.
MSP*2\>\O\KQ<USIN<,CNS;-*.#B)KH-"^<[&E1?0N?9@E?L08`(0EX!:(HY0
M+0354A`3<V@7(F20RD?+>_L(()CLS[8]W'JXW&*P^>H1\G)J/%7[M<*)8EC=
MINQ/K87ECU65^H4H4M\)3^X#K;MI](J@/5%#[',<"!7%RZK:+1<I_W/GNMH1
MJE5%E:[U$&(9<JBV![52;"]Y\UX?7.-U0!)>J:&)&-SB;)V_FV[Q..[[![^>
MW-'LR9:8X_0XT/G!*4ZT]X\!P.Y\-N[387=\<O-]Y'-?-,TX7"8B/PG_KQ.Z
M(=@_6IT^_(K6(\/LW2>*A28LC:G0I?H+8NI`0O6=O;'O[/N:;@._TT)Y+U^#
MAM_]&CG;GA$&2$]7*\Q2;&T+XK!0BJINC@IT[MR`0#1"Z3XH&A&M6CX\!L6*
M/]!&Y_6M10H*VN/^,A34*9ZI>JWWO*J>5%,"ZC6+@OT>:I);LY[IO$6&TA5L
MU`OW%<?I4Y"H0RD.;)`[R:"M4X\U_*@1`*7_>JD=3'20>ZBMGE.7L/Q,Z0I0
MSS2YSL]9*L+\K&27,C[2+?BZ7-<I?,6F/,(9*Z29AT'\$PZ4@?;1P@#U\>XV
MZ.N]"I%'2`A%E=1ZQ4-_:`2+ZJ-,-&*R`8/CI*1+@=NGE*EI+MSK*N3`P*#6
M?0<04(%L:T9%\K[W7I?9:OM#AO$$W=^(.4@`R-I/``$F]#!`<$:;?7<,-%(.
M$0*R\KLC@,D\$`#0#=T$`*BE'"0`).4G``#;)Q\``';H]</KZMW[EW6OCS-;
M%P/I'N5$<5?/G17`:=-8C;4=:A6AZ,WVG\[IO]$_UW^B_\.BG?0O_S]02P,$
M%`````@`H81L1IK2;S]]30``?(0%`!4`'`!T>&UD+3(P,30Q,C,Q7W!R92YX
M;6Q55`D``^[X`57N^`%5=7@+``$$)0X```0Y`0``[7UM<^,VLN[W6W7_@V].
MW=H]'R8S]DQV-SF[]Y0LR1.=E25%TDPV55N5HB7(YH8B';YX[/WU%R`EF2]X
M:9`$T=)HJS9Q;#2([J<!-!J-[K_^]_/6NW@B8>0&_M^^N?SVW3<7Q%\%:]>_
M_]LWGQ9O>HO^:/3-110[_MKQ`I_\[1L_^.:__]___E\7]']__3]OWES<N,1;
M_W`Q"%9O1OXF^*^+B;,E/UQ\)#X)G3@(_^OBL^,E[#?!C>N1\*(?;!\]$A/Z
MA^S#/UQ\^/;]ZN+-&T"WGXF_#L)/\]&AVX<X?OSA[=LO7[Y\ZP=/SI<@_"WZ
M=A7`NEL$2;@BA[YF/_QS./C8F[O_)N$_^YY+_#CZY_*!,O)(DMA=1;>#?_[C
M>C[^Y]6[RP^75^\O_QD_;]>_LI\N/WS[O*',#IR8=D3__MW_O1J\>T__<?EN
M>77YP[N__/#A+\!!Q4Z<1(=!O7M^M_M?1OY7S_5_^X']X\Z)R`5%T(]^>([<
MOWV3$\67]]\&X?W;JW?O+M_^XW:\6#V0K?/&]1F2*_+-GHKUPJ.[_/[[[]^F
M?]TWK;1\O@N]_3?>O]T/Y]`S_:LK:9\;2>3^$*7#&P<K)TX54?F9"V$+]E]O
M]LW>L%^]N;QZ\_[RV^=H_<U>^*D$P\`C<[*Y8/^F"G7X:IS#>[NFJK1]RYJ\
MI3`E6ZH1/7\]]&,W?F&8A=MTR)2-M,^'D&S^]@U3BC=[%6$?_@\(;?SR2*=7
MY++9\<W%VT9C[0=^%'CNFBKC^MKQF*07#X3$D6J@2L).1CES0BJL!T()'*_V
MD+F]F!H_F[2$01Q--]-'MO11:+7$+>^ABW$OXF#UVT/@K>FZ/"`;=^7&P]\3
MJJUUV5!VV`57?2=ZN/&"+[7!J'30[JBWCXX/D'"A69LC6"3;K1.^4+3<>]^E
M(#ETG5JM@H0N5/[]C$IDY1*E\/1Z:7/\(_^)XA2$2AE6&K8YBBG[0S\)V9+3
MBR+`4BNF:'-<-^XS6<,&Q&G:YDAF(7ETW/7P^9'XJ:$@'0R_=;MZ0RV0>_?.
M(S#QB-J;TJ*QZ]RYGAL#)I^"K,T13H*8T)WUQ;GSE!CRVK:Z<N6V%]A&):9H
M5[/HCV3I/*N1XS1M<R1SXK'=C%I"$#7BMVYS/-=)Y/HDBNA6NZ*Z"K22Y%0M
M[\9;-T[W?6JJT^^QS8N>B`'"`Y"VJOO$(RL*UD\)18N$WLN-ZU/3UW4\>@)U
ME/,`1-VNE7$7D=\3*IXAVX4!]@2_??>63[L6D$E+"#:")5N.6^*FV)<1JPXV
M7$%SLQ8>;&@J.D/6'FQP0@)SEA]L8#(:DU8@5-UD5!U8A/JJ)R0V:Y$!5QL%
MG2'K#`JV@*`CRP,V2G`'W5DA0.PU^NA^MQR0V'&]:.*$S.Q\4IYYFO5JC;]6
MV3)J#P`'+&IOUB(`#DY):,@FT%5F`*G9D>H/T+S]`AR:E,BD!:,+,I2^@S'7
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M%F\?T\C7-ZL'USMHUB8,MKJRW0TDD'(3A-2N^MLWE^_>X0"#SC$RHC]&`$!R
M;2V#(A"N'('<\'<H7+6"0D16W]X'3V_7Q,T`H#^4Y4Y_]>N8W#M>IC^]9Y<G
M<-JJTN@8),T;]T'1.Y1P]OU!L'5<GR_>8@O+LN6)K2+8XHAW4JTK5,&V,PE\
M9[-Q/9<9W-D';\GVCH2"O4;27B72'0,?WAD0)@_^O205PZX@W;'.SLF]R_81
M/V:OFF2Z6VX)%'CK\I:LK@(=YO-H3^;]]'3FC:A%^?QW\B(3>J4I4.J7",0N
M8-.&W/=VU))VRQ=WL050RE=6I<QCRJ9P9R1T`[J\K=GC2KF42TV!XGZ/0MQ<
M-FW(O4='LV8CNO&<>[Z\2TVL[9$Z<N:R94.^NRO+&S=:.=XOQ`FEJBUN#93Z
M=U:EKF+6WF[Y,_&\O_O!%W]!G"CPR7H410G70CSL/$(2(!1_0K![*MBVA\?G
MP$NHR,*7-$^`X#0I:`J4_Y\1R%_`ID6K,9NA<_(8A,RGG.4?D!J/`@H@"G]!
M@(*<:7M@I$K1IVS<YQZJ\C`H-02*_GL$HN>R:$_BL^3.<U<W7N#P'-&'41>:
M@0]+",3-X<_B6A-LMX&?7L@O'BBCT32)T^PR=`I*5QPI'10.%(=7@`1L'K8R
M0RT[B]S0WPDV`DES*!HX#KE"?NV#P*QE,`2YQE``<!Q[!;QRQ/_7MQ5VZ`=^
M,WS;JDZ)4[AJO;IX<W'@G_[<GTX6T_%HT%L.!Q?7O7%OTA]>+'X<#I>+6O>L
M+=^633>'N_A9$+F*:]DROE)JBY>!6>RUFI%R.RRN9P`JI3M!/L=MKF%-T=B_
M=P&"4FF.QD%=%QR!`'!@Q)(<B2')_FK;>2T78\`9,28)[Y[+17.R(NX3NW2>
MD'C'C&0R2*EL^[=U$('PCP.IP]M!.D`Q,L56MCW@.DCP^,,A^>*CN9Z_3I_X
M%'@3`P(BMNTSU\%)0QHXX`,"50\2\[[SAAL[!PO*RH;0/Z['F1"$`TY'&P>Q
MXZ4M+4_"X)&$\<O,<[(`P=\3]Y')1[H<RJG0^.?U,8:(`\?TRRT/:BN;VQB-
M`U\?)@GS.-`IKN:3P%_I;6AY"MO>?IFP97M8E6L<V)1?;=.I/7Q>>0ESRGX,
M@O47U_/$.,&HK=\9P$'3$0<.``?DD2T3T6Z\@,DEIK!^FP`'2L4V#G#@H-0'
MPYC3`0X&`(2CM`>+Z6Y%H&&Z=JAKR)\*8KED&-1@K3Y_5EN'\!Z@J)N/_=-'
M75=..);3W*C!/G49#11!8SX1;1B$**)VL>\=H+NT*F#7;[D]%"]C#A.`P/FN
M7S[G.-`9[-;Y.7DB?B)YS5EI",7#F'-#&P\!KSB`2`VN*DL*3P:/``J,,7>&
M-C`*WG$`I(--$UB,>2]:WV].Q6X$Y+#GW`W+B,!7QDBQ!F?UMSTIZQCY+9CU
M5\:<(`V!.Q9C?K9?)](!IR7_I`[A:F,H4@;#+36QD?",`Y1<C*X"D6I+*!P&
MO2`UUC@>MSBPZ*W7Z5&>'NH==SWR^\ZC2S?+W*`E)R@`+10O@_X+3;S@$L&!
MX)PE3?+)>NB$/MT](WH:3+9)F@IM5Q10C""$%HJ@P7>0F@C")8(#07'9+(A1
M`4?(8(A'8_/A5&Q\E5U5WR<,Q[D+3TC#DYU4-JWJ`+)7#?RJN84G#N_A3QPN
M_ECH[S_/3QZ,V4F>%WQA,-X$X2!([N)-XE5#;M5.9[UNCOC!1!UYX=B.B^<G
M.L&F82J(=6J^STB8/BR$'B/%]$?\XD)/1!AAS1Z']I+X(0C=?[^N[BHXJW2V
MGVVT!J-()'CA2U-K:$*WI[']MJ-EV(JBP`N9_$&ZA,$Z+](Q!D4`A8(#P9S3
M0W\?!!';?C#2`$D-X:!#$[[]28F.^&T)0!A(45/M>D*"(WXEHA`"4J1`FUTK
MN5<P/AFIF8K%OL/FP',TW4P?R:X@!]]9\T'FK%DLZ;]NAY/EXF)Z<S&=#>>]
MY8@VL.BFR2JY'$:L]LP("6PZS!V/1+OH*NFKN4I#RPX5A?3+7G(^FU@6NXBN
M">RY2K0(/.EV5&IHV^^A!X*`3QP@?`R#*)J%P49VR5=H9-M;H2=\#G_'?D&T
MVU#\^]V;/<A;4C&);2^&'IQ*WG',J@7Q//84C_ATN%[/7_?66]=/4]&SJD2[
MP4MV'2"];2^&&HZ@%E^8L)Q3D=(Q/-#1#NA.Z@7IVW(EA`HRVUX+7>1`4L`!
MV(!08=)31BI*JF);ED#VWX7B6]S7IF(BVTX*7;``$L`!584QC2W,OC="%Q8A
MMR=CD62;^9B:7``@\XUM.REJ0UGE^.C!9`X.#=.2W]QV`@Q-LU+&,Y*ED@UQ
M$OA!4?,4P/`(<.2Y@$XT.=LXL&'YVJ+T$4HVNI$?$RI416XZ/@6.Y!9`=%2,
MXX`G;_\<G-#^/?/+R+(F2*EPI+T`P@01@/ZV]7VV;?GDGKF\[6]<>^7;"65`
M[J03D-/8>H(,O;DG9/?XL63<[*JQO[[PNR%IV"_[&[N\8[&!BCFLV8WU5!DZ
M^-<2T?%KQD?']2-F;Y-HZ@^?F4F0N-%#=L$HG_,`4NNI-G0T`"P*'-MPJI0^
MY2BM*M`/J.U`=Z4[CUP3/WU4PYY(L5]&5-@WQ(D366Q0O=ZLI^;0G>%U!88#
M\JKAKO2;2DBLY_'0`4_)^K'["5X]'S=43MG+^X0R^QKO<$TV04BR=DOGF41T
MC0H=BA(U0,.7M.P(2\9&*2E?7BHG];G)X$>MIR/1,_^,B_\T-)2ROA-IMFPJ
MM8M#8#TCBKYF"-D^?A-P0F*(H[G4S'JF$ZW=@\?BL<_'_6OJ?6SSM1.Y*W9:
M<;TDEL6C*@FM)T/1<S<#!8'#AON9N/</=%0]:F@Z]V22;.](.-VD`\_%8X+!
MK-N?]30J>A@W$QOZJ-;\V^M=2H32$^Q"D.MW\"#7Q7+:__N/T_%@.%_\X>*/
M@^'-J#]:_N?%\*=/H^4O.-XGUTOF!"*WFD5B-\(E>UD+X&373C4S*RIM9'IJ
MP5/))E'D*'\%A@&0<;E,HP247%MDP!342H1`;OAYBPP#"IDJ]8/M8^"S5;#W
M[$(`X9,=(S9\3G+1UC:-R^+8!L'6<27Q7H+FR%"1:5S9IN0SE(L`Q?&NZ98P
M0T@,#*>I[7#_.G`(.<9AU`M2E*G`49#9?AI0!RB0)'"`5LY*ID)+U-YVR'\=
MF.2\X\"GHRQLYM>YBKEI/OG:8UK?G8X@C.T[JBP^PS6_-JK`U7QT>\0PISQF
MS\`'24C9FZ6C2_,O3,B7]"]2`Q]$CF:U!<UJJ#@0K;C5(6=Z6Q_""KWM=U9-
M,10(!`>(+,SA-8YA%^9`UJ^1#[TM2_IV*8\%@?5@^]D5&$A=H1P)E/G4&TT`
M+?5C^X%6>[!R!80#7-G^D/YM^IC&'0R?2;AR(]D=4(VN;#_V:F4;E8H)-<J9
M7K8#L[0OVR_!VMEJCQ?H5$_34(5ZTW=':OO]5RO3M2`&U*CM3FJU8"O06G\<
MUL[\.Q[D4D5[-0FFFT^^*WO2H-F-]>=DK4Q$H7Q00YNI8G-LA?U8?X36SF1%
MCFYO_:\D>^08+0/!=4'*R)T3I6]Q6(1?BL&<_)ZXD1N3!0F?W!7)F)Z357#O
MI[THBA>9_[+U%V]@#>H*A:8Z%S]OUZDF75[M](C]YM>?G3!TZ-BS.7`3A,IG
MJ(Q,267]Q9H:/Q`?1F4/49W="+,![A1%A$J#_JR_+X/AU5ABG<RB7E2<YNE;
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M=>^L*3$<&ZQ1V\:8Q=E`ZD=C^A2,978U0X\^'BD,>!FT-EO-?,UVA']K>F(2
M#!SJED^0+U:38BO;<?Q&41'7#\`%7#&3[8B*W[]G?K!>%!%X,M\JG>T`_P[!
MA8D0!]PIMZE7LUH#7@RVG,KV$X`.H8:(#P?0*+*Z&KO,[1#R.CEACS0-W!'E
MDS5VE]RI4=!*-MHC5;;BKLED,7"C="6=A63K)ENH[<$EM?WHP9KY(1$DCHUI
MGY^O&%(H\78)VMM^#]$APG*1X8"UK(79DM2G([^7O1=6D%E_/&%Q'G,EB`/L
M?26$76*XGG^X;*=V\3YR<1KV/<>595C3[,;ZRXL.E:&6A'$H!^Y*(\:<A1T;
MCDT*E=C-(!X2AQ77R?Z=8W\7P:%V-NOT8?TY1I=KAK9LL>K$WJ5"Y47<)WGN
M5!BU]6<=-<!1H2N6TO&?#JO<LLIX/OT:/XA1**0"F?7'(@:T@".74X0_#>SK
M)R$3LNIN`D9M_46*`6402^ED=>)UGZRG%15ZZ\]93.F%0%*GJ!G[K7'FO-2U
M'@ZDUM_"&#0=2O*Q^;;!E"KL'2ES0O=)V=MP`*GU5R\&5$$@GU-4!:KU84+9
M<)T[U\M.5/ZZN#3F_J:Y:&CU;/T)C9DUI89TL1Y!6U&+%C3`9($ELU8&6K#A
M87W2B%9P']:?\K09[ZHIN6.OL";@F!VZHY9"VJ5]X7F?TCBH'2`S'.L#-8KW
MCPQ7OR<NJ_@)C8H$D$(1->:#:@!/H,OLJ9PP*ZQ2Z=%%+WZ9>8X?4SN'O;A[
M9$TT=$/2!U1)C/FFS"F)4G*GHRTW04BY71&R3DL*I^;1@#P&D31G'8P:JB'&
MO%2M:PA$6L>O&W"QM6%(P/7$F/>J-3W1E]R)&I^'1!8M&)_2OL`/=/`;GP"9
M(3$^<TO@:Q!0[O&W9.-0DT(1[?KI)02>RDL,F)SPP:J9\QU`"H6U:P]#,UB/
M(.5[?KB[`+W]2.7/J2144#"-A2P9`5,D'7PX3H*8J"\.Q110_(RY;(S@QY,*
M/NS&KD]8FA!JZ+FRH[B8!(I>U^Z99NAQY8(/OM>-?!_MK&OMO-)!@>S:A=*6
MJ5.6$`XTY^1Q=YR?;H"344("Q;!K)X<^ADJY'+]G(\]B/E6R_+&QG`JJ`%U[
M+YHI@$@ZIZ4#,#M*3`'%WEBPC1'L%7;4D>(.%U4;'BJ-["+H=4-?<L?NU4S9
M3;,-EB-(Q+HAHX'J@OD$MG`OI5H&IX"R'$\X<N9SW.HAUQ@C5$6[U4AI)$K]
M8#X1KAY6IY4$=Y$\/GJI%%AA@TP*(W\3A-L,"'7N4&@'4+S-U]6!XZTI'1PG
MYI$?$RK;F*4Q%^-6;`4%QUPQ'4U)ER-'JRQC`8,]RETZS\Q&E^-1:@B%Q%P1
MG(:0<!G'@<HD\%>4H]>;?G]]L(_3E-F`ZV]X%U`DS9<VT;CUUI50YT7Y.-#(
MZ]AIY!4T=LC3EBJH0E_7&"B*[TG:0Q$P%R[0*@*2FGK82OD<[KM'_O!Y]>#X
M]X2EG"1W+&1R]])FOXTJ<-7K"@JYN5""-B"O(SY#TY%]]#6-WR[+'_OZ/O$?
M95AP!&/T<'(H<N;B!IH@IRLF+)9)3';KRZ7,^,BW@N)D+CZ@+DY<=H1PV*H<
MLGUT_-?ZG(7Z('^^>'/!DB-Z092$A/['\L?A17]Z.^M-?K%8!F0:WCO^+O/;
M:^43I@[^>I:3T'2SP\GQ7HNBJ&W?EKJW.,T:<?`*^))JU+4GC:%L_TN6BY*T
MJENEA<`4+&@6DT6RW3KARW2S<.]]=^.NV).5+'4"72MGE-]5_F*FL-;\I;S6
M+#[=WO;FO[#B0XO1Q\GH9M3O3987O7Y_^FFR'$T^7LRFXU%_-+19D:C*':#X
MAX3&IJ]4AAE@*8#26Y[@:L3*7E(MN:"9B_L\5X*M_?OR=!M-/@\GR^G<YL9^
M&//KR"#I#25$5GVCE7$!9I&<RO+<`>!3\9.JA8!FRDBR@>7GSN6[\MR94KMX
M?M'_-)\/V0ZU6`R7-C>E0RYDEL]TEYS"_3=A-L:CXZ[W:48R%G6F6N..;=K$
M%7`AYJV,R/)D;`GELHVJ%A.:^7KC/K-"U>*)>EF>J#>C?PP']B>H\$VW>@H"
M2.T&I_-'I[4'ZO5B>1J"L:Q&J6N+"LW,VZTQPV=678'P)]]5>?+-YL-9;S2X
M&/YC-IPLAE;G7W[XQ942,@4AU&WZQ(M?!'IH&"6$T/K\@6.1=X##98)FU@CS
MO13FS?OJR6S9FWP<78^']G>NCT&P_N)Z'L6IS(V.(:G9C=UP(\'P0(<Y`+'E
M^5<+T6J`$E1(:"9CWM#EI=XKS,D/\A/?>-2['HU'2[N^R)2C'"LZ$Q)":_OP
MQAT>]!"G(K9][0#&CG=>@TD&S=3CONDIS+?ORO-M,ET.%Q>SWB\]N@U:=:W<
MQ7H>$WY[R_6&M.:/D,"Z`T2&!:<&T#',C32)QT/@4<E%[$@8\_WWEW^J7)<M
MI_V__S@=#X;SQ1\NAC]]&BUMNO*K?+!9#PBX5]#9O"#C#DUK*FET87ERP?`K
M7Y7I2@C-M,O%<_/G6R449C3I3V^'%\O>/ZP:?8>!ZUV928@P/"?0/&7)J*Q?
MF2GQ$3TM.(9YDWN:+SP\52([YL-Q;SD<4'-N;OG(E,\LL`P=/Z*PL/19ZBFD
MIK2:5H`_.*UII=6)Y5D&Q;&2:$!;3FAFWG42L;PH43_P5[3G,.U:,`,KP1[7
MGQ:CR7"QN.A/)_WA9#GO+4?3B=69Z$:_L0(8GR@W8>RX/BQ-IX+,YC/A/"YL
MF%J3#T9M>]9!,"N_,=80"YJY]EHUEK%+66`A8,07!C->52)$J*UX.UK>TJFV
MN.A-!FS>L1#&X<1R_**$,QV#4K,;J],2,%+0!-7KQ_)4K85S9>K6$1V:2;P@
M'EG1W?ZGA&[W)/1>#D'6`R=V^/.X$D"R&(Z'?6:[_O2)&J_#^?B7BYO1I$>G
M<6]\,>@M>Q=__#3I?1J,:)O_M#BOJTSFWC;KS&SMCBS.;>E8`7,:2F]Y+M?$
MMC2;]82%9Q8G=Q'Y/:&=#EEDJ6#_K<2>+#Y=+X8_?6*7=4,6YVQSSRVS`,E"
M(J*PFENE."B(^U-,8MO=J<"DDCE%P3NB^0)YDB-]FG-5B4B!/\VY^..^:YN[
MX0F]TBF\&TM']@([3DJHCNU%#D0&.-X[LQ?8S%:F_V+W(4^.QU8+.&PP<FB9
M73P`ZHC%9M:)MMRQ*T*9O/-(M`R=]6N0XZZJ].O?>YX7?&'YJEGVA2"YBS>)
M=Z@]G8I'YJ]M\RO@BKM8=,J$D'$L(H<W5.!U0TP!+E&$!585\S@@$@;S@R&#
M]P#.Y8L%0EWAX("T'--*C\EN3,;N$UFK5F(`*3A7%Q80P>)`@M[VT7'#-"E<
M2(\NCT'D>-/-.&!EMI_VC\;@ZVFMWH`8&TLZJ8]Q`Z'A@/V&CO^SXR4DET+C
M-262TH0"D@.!-9:Z4AM8+;'@0/(0!:-A](@H@'@9*XI18[&5,X\#HL4#9?[:
MB=@3Y"U[A94EKWG<9;09I1>]=.%@^[YRZM7J#`BLL<RC^KE$ZHL,!^8LC!H\
M([F-P<X*-*!)>,8!RIS0,U)"Z`DWN*=6F8YC$$`*!0R/>PDL#QSP+1[<Q\<L
MK^"/CK^F_=^SG`Y@#*'T4"#Q^'3T)(,#S=Z:9>)TH]U8X8<,)2$4/SS.&Z`L
M<``WI]*D8V".Z0%=0+P@]5'LWI>KG:\`8BB`>%PW&C+!`>+0"7W*7C0C86IK
M@6>?DA`*'AZ7#5`6.(#[%-'#Z3"*W:T3RZJ>E=M!8<'C9>%SB@.%"?F2XR<,
M?/KCBN2<!.#YI-\3%$D\;I6ZTL*!]2QT@S`KJD8M9<^)HC0\)!7W^E])E$9Z
M#DBT"MWT?"J[N]#M"8HU'I=,76D=62#0,KU`Y8<!59)@Z(0!91V?@X#:.3&N
M'L@Z\>@^TJ.#6[M>PIQ&"[)*PC0)Q/!YY25405@%;.9H2O9YI<LF`>1T:>!;
MQQ9P9$[>:):'PSV[;`6HI.4X)`W&,,%/*GOPJ\H=1KA+5I0*6FOBJGJP_D1:
M-ZNPKG#0S#).=E7)=*OD^.#E&<8P\\X)AZ4S6("ZUAQ6]V$]&X^)=,3Z0D0S
MUW/9B663O))8))^C&,/D_OJ2%3<)U\,S(5M/3(QWJA5SP<IF6R4722DI,8X)
MAS0[L9%],1L9J[&VL^"T=T5)#]:GH'YN8VT>D<W%<J"H;#9RBM"44AUCF(]?
M7<[C_/&J.%`Z]CT;=8ZAX,Y.("=R`R'BN!_8,Q!L<K'>E3#P)&:BV`9AO"ML
ME]^$-=2CG:_8?@G7IN*T*7<TNX,@Z[9DDWBOJ+:4R[V-8;,X]23<`NPT:RE)
MR(\Z$3=4.FCF8S5CJVPJ5M/A<)(.8YB%IYA]^&!/\`>Y+^4^#>?N_0,L'4?]
M+FVGZZB5G;BI!)O:98+J/J_C^IFP#Y-U[XG.UGMR>+:SOSZD9@7[[TS*491L
MTU"#B!+NAJY<B]D'#7[/MOVEIQ>&A8'1F*>Z?WB",G->4G?@%R=<IX++WJ%$
M/"[U3WOM?,=V&H*F"TV+PL:K2/FW3'G>>JO8?=J;%#651[=OVPD.6E.8>D)%
M8UCF$NK++,I*HK9\6GT,EN1)Y==_U;/A9D.8(I'#4.=.G+Z8\E?TY)(E`=2>
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M""T.''4U%QJ5FF/TX`Q&BN?URY)^N_?LU@$T3WS:B.8YS1W\,2+*!CH(MHXK
M?1T-(,:!J(;F@H/&<TR^&H(V,X3L1W9+MG<D%.-6:6C;2:6AA>5,('R><7@A
MYPX]KLL7Q5P3'!.EX=*7XR=W@6D;`]6$*#3"@4-%=WB"W@\9Q?*S\RZI9%UJ
M9GOIX>A'2=)<OG`L,+?.,TCDQ6:V(P\`(N?QA4/DPE7Q4T0VB3=V-Y(3*HC8
M^LL>Z)D-:BA5)8,#REP.OUV(N<1IPFEK>^FJC928<9L5:027872PK*))[KHB
MN\S@)_#;Q9"XW$1KK+_ZW=E>-O7A;L;O,3N`^7[?2M:)&G[?L[<769XGJ$^X
MG>_@.!Q83/.$RK_<D!F`%[J]+^#0'#/SKFQ?M"8T)'[OA@Q=O_`[D+N&C'[T
MK(WMR!&'%Y\_PHFS5;KPU90X-*6#&0A2F[QD4'C=<@'T*C<0IZGM(RQ4<<OF
MC(AI'(Z%W;,I%1ZE9K;/ES6QX#*+`X>&BT9ORXQL8QOTOGO;*6-;MJ';W7V+
M&*!Q1KPF]I3Y&RH)\'))91&X$TXJJ^QA7!,"2-_';VW]P8YNME@9TS9=N2U#
MRK+%1/2DP'+02`Y,HO:VC1PI2@)`N2SCV%4/8YP[7VZ=F(2NXT%0*3:W;>W4
M`87',`Y,BBEJLU0M8DCXK6V_+]9`1,8N#D#RS,"V(?OES^M,B1Q[M3><.(@=
MK[3=V,_AM<MM)K/O*BE7^5G,$9AZ)Y;&7'!57(5/\5!21G!:2<=5W+:S=@IP
MV8VY'_A1XK%;*_$.Q=J+FUNSY(#B"R!,8-JF=J,<T4&&+$Q`%KI4;FG-@M,#
M0SC^+E2>'V6AL-)RZ@.AMV:WU9X4<*G@F"6#A#!'U9QXU/I?SYR0N;#45K:4
MRIJQ5VOV0"2``ZN4M6)V<B52,AH@3NW71JV%DYI['"CMK9OL(3+)3WWI@4E%
M!T2K_9*I]6852`HX$),E_%=.,!`Q$+OVBZ0VL2<@\CB!@W&NX@_LB7VE_D&Q
M]@^J1_0G6P9H0*@FK+)L7;(U-=\*Z^L#Y5):9;7E&Q`L,X\[X3Y4<LES)]QY
MFAE@;$'Q)I#\%*5V."*KZLZX,C=(0H(/PQJK@WMY;7&`PE<I$0)C=`&S7TVB
M"`A.YW00YW00YW00YW00-TGHNVEQ(Y\>^9_93Y$*&QF-[1"*^C"I)8$#,2&'
M'\,@JK.#[>BLUQ@1V4C0Q:[`/PZL>JM5LDU2_W3^,$A_]D@J5W^=+RHF9$V,
M:GM?L+W`@A6@;:'J'\F_SX[!/KEG@[`?E"AD4>JWEE/97LB;KP=MA`%A\KH4
MO;M2QTNE<EBE[C(*W\M)%U[6X@8T^.,IIRQKB2^;QX[16\=/-G2D2<@B8]B]
MUVL!:'E$A)S2]L8*@`W,2SO&%2P^I1R&`44#0F][=]/#!"X1O+.+6FUT+&Z\
MBQZ$@BDALQT;KH>ADG\<)Y;BHB]%B;M-U`#(6.PX?+]2<7T"M^65`MF0*_,/
MG()AR][DX^AZ/,1Y;UZK)'A5J36[P7"W=)07?:U4<#]?^ITO_<Z7?N=+O_.E
M'\Y+/_9N."9C:AE4%OGKEUOG7T'8]YQ(D7E*JQ,<V(+FI!9?.-*72X;\.F!(
MHB?MCG#@6D.?X:#S&4<QC^E02>B3.!L4&Y[RJEA"8MLM5E.+*X^.%3+!<:S/
M\MF0<!%LXB]4.B6.53`"R6U[U=J!5$M6AERAO<?',*!L_!B$V\`GR_10_S((
MD_N^XZ_=-=U89O3_?BR>@6FB9>UN;#O5&D)8CVE,,U4L`$@R?QCUL81ZZ,@"
M!WKYP(/IIJS!DC`.!9WMS1(>G`$2P$G<QPL\JGQ':J6"M\21>O:?GOVG9__I
MV7^*P7]Z]MVT[+NQ[%<]^VZ^3M\-*@<`<I].IPZ`(W;-(??C&'?-G7TW9]]-
M:1:NR:8-@TF[(QR;*\AHTN8-QZ678MAZQE.MSG!@7%/']93`B"$E6*X;+M.M
M+\\&4^G6UN#\$MWUTBR`[99EL'STR#)TUF3KA+^Q,I*?W=C9NGZT2![IG[9*
M\'0[L99XK5T(Z\D.QQXK,3)`51:@],=_1\*3!WH,%8^8U92(CZ#J%.90P:"'
M,?=&-W\C5`M885^(CZF-H%8(#SWXTE?'*CK$A]A&H*)+GME;_9ZX6:)/T9A_
M)N[]`]/")VKKW1-(`$*S7FV;R(W`;T.@.%1#869FA=)<__YP^PBH;56W1VO9
M<W4-L:9".T[HVX/<8K+=MA!LIA"&@F/:.&SKLL*W`%A7M7H"*L9?L"M&;0'8
M5XS6KJFJAQJM-05&#SX$8M<83;Y/54_H)&B@)7QJJ(X8+,%H5$=D,COE^,M+
M?@#F!XT`S,MS!"8.3\)-DB9DS#E!]MF(FOAY`;U:]OZV$=;9AEAQG$EDKK(J
M#W/"KCTH/-/-#965X_U"'%DRTS8Z1^QTAF,-]T]J"OT8M8B-?_DE:$MO#MTA
M]EEWHRDEP1ZM;M#/UWJ'I>@0L?N[0_W("_=8->0F2%K;=E[[0^PA[TX_\J(]
M6O7(Y=QJ13W2_FP'J.!0CWPZLZIZV"_C/7:=.]=S6;U*6!JV[^1%O<>CWO5H
M/%J.AMC2L:5<Y]G5.,%":&T6,G.?W#75@VCFO+!PUX$3DP%9>72:K&\#/V:5
M9.5'#W@/EH^C<!3+%=`T981C,2^/FBXSB1_/2+AXH`.'XUFFLWU*;`U&OD!P
M@K>OG^FO(<E,8=2V#W&M`2D3SI'LG/P-\T_Z&^9YFP0^;UJMPH2L^[2ENW*\
M9>@Z'J!XO)KLZ#8Y&%N8%L?=:!<.W8$AY>)%[8]V)Y,+`!5(GYU5*D\H2)7V
M1[M+R06`"J19&&Q(%-%1.MX-@<\H(9UM_U]3T!0"00,>,V`/YJR_7\9SC$.0
MA'=BVVW7!%9=49EZ5NUYP1?'7Y&;(/SY@7(>.?1`Z=+1NW<)[40^_=*]6J<'
MVYZTFN:(OI#03$FF5?/@Q?&@TX]/8#M@N.D**A*!H6E%3:%LC.DTGY,X"?V(
M3?.])D4L&.$UJJ8TI^#DMJ-[ZTTH7?'@FDU4*N")E&]K.^"V\1RJ,FYJ5\H^
M>./Z5!GV%;-`)V$!"5#TW^,1O9HG3%.CS)]R?@@)K`<9UYXE"AF<0+6C21"3
MPZ4#Z(KMSV6/X62Z'"XN9KU?>BQ$%->U6IX]M8>0W]JFCY[<Q2.?#B0!)-[D
M-L:1"T4&0]GSSN,"2:;-XMC&ZG2;0@(<L$C42XK*&%WVS7'@W\<DW+)QJLL5
M\5L?&R9\+G!DSRR/397G2=0>!R8R[5*`8C8ETSX_36_]Q(Y8<_(4>$_,JDPK
M:+)5%Y351TUN^QY#KD^\E#U0D1@Z[K`D0;>IEW?K1E$0OJ1;H!0-.8GMDR8<
M`0CKAJ0^BJ*$H3[=Z`A>2075?F-G3;CP@1(P)/\;<A<F3OA"_W*5?O52*GAQ
M<_"5G'V)JWCN2M17>J*^TA4U@K5=Q7-7HM:3M*Z@C=TS-Q!T)W+^G\0GP)6#
MWQ0J802;I(S7+L0K7RWX3:'B1;`-RGCM0KQPZ>KFI#86T%!3N.927T9D]>U]
M\/1V3=SLX$E_*)\WZ:]^'9-[QQOZL1N_"([]M%6E$8Z3)>"TSQM\FYF>H6+.
MOB\\R-,FQ1:6!<P36T6PQ1&;.://B;MZN'&VKO<R=K=N3-;CF71YD!%`3R+M
MVQ`5:577!36GIE(<A[>NY[GWCB]W=U2:0<79_J(+$*>(*QS7@V/7IX?,S*MR
MXZS8!=G+K?/L;I/M=1"&P1?F<W$>Z5_B%XG?3ZL7RX'/"O=_V1-80T!XH4UK
MA)`HGK.'24E(QSXCH1NL]:`5]V+;P=@<6Y6$C@1;$JU"]U&>@UBK$]O1U2TC
M6Y4/#F!G8;`B9!W=4/X9RQ,23S=[;V`:92+&$T)K.]Y:#T:X-'"@-R>/SDM:
M2F"Z8>,58U5M:3MD6@\9$:<X<,A/?]CZ9S\`NOX"ATOV:3V.Z>9G%C?DQ]-P
MSE)`3Q)F^DXW"[*B>VH:@^5X'EE?O^S:1;N&DN6M<<>V(Z7U$&Y)CHB58OA,
MPI4;D5GHLINN,@>\$&R9;-3=V0[);D$!H#+#`;O^.OSKE?V0X/HK,1M]1?Y'
MFI,VO\,S'B,UD!(2Z\'#]<T;+O,XYE?>/@9B)"&QGB&X_N%`A=&1SD'>,79`
M5B%Q(O;B[=Y](I1OV4X)[\&>3[JU$[Y,-#@F[-X'L<O>)<:MTM">C[L6/`)&
M<:!09(5JSR[#CQ@.,044%R3G1A7K.`#*+^WY1P>P;:U(`04(B=6O8OWX-[6\
M;04#5TP!!==8J%!]LU(!+H)-JE9&,1"Q]4C<>IM9O2QB"#8X-_SL>`GXT5F.
MP'H$;[/MK<0X1G0^^4Z6UI6L]^_N9R'9NLE66E=2JQ/KP<%-4`0)"`>R'QW7
MC\9!%-'#J#]\CEW_/G&C!\:%ZD((0&H]\E@/1;`PCM^D84&7RUW0I>0L7F@%
M11/)@8['(HY)MXB#U6_L4IBN#[F`C317:Y0^_1=#`J&%`H7D9A8N#IOS3AAE
MR<+HZ*`7J5E%!9ONWSMKF8-C%K`H)X(":/N(#N$%T\0KLI4/KTF+R*ZIXJV8
MG._!AJ>\#RB.2$[R^N+!#BM;_\%I$CB$UA_VM`5@01`X4'L]H[J2:,YB*^LO
M@>H>PUU>..;Q5G:49>\1E'?\BV[Z'KM%'L\)?%"\4SHG\#DG\#%^$#XG\#DG
M\#&#"=H$/NFZFIVY1WXON4\B=CNP((]Q^N2+O;*5/FG3H+?]P@;^OEA;*(:>
M%1;&41.3)E`@>.H-%8&Q-_4>RT%QF48MDS7D:;V8P':<OLX#>Q7;'<I;E8A#
M0G$\.:L`C'<H<E5R#@F%[1#H9B+O9E6QE9O-7(PRKN1L+;W\"/PG$L:LB&G^
M]"F$:4>G(+,>U`6#"L9,5];/,OCLA&Z0T.^'[.D0U/P1T5F/XJEE`,FE@/!.
MK#!V-N@7^5XN:6\]FJ<F8CRNNY@OZ7?!QX1R>^M1-TVDW?(>WE;HJ)?>G+$!
M+D/'CYP5$V9T_9+_B]SII-,'#K<'W!6EPUN;R:?:053EG.*UQ8&0OEY*@&O)
M5=62J]T-R8KVK;+7RNVLOR43*U:E1C"/0QSKG86'*CBN>H_CF8J-EPPX\#F.
MAPQ8`Y1P8'BL\4D&@VW/L;9:,RKOU]@E)AG^GJ2IMO9-P)?RL+Z.*TE2?6DA
M1SO[D54]3O.02-Z?:W1A^V*G)6Q%LD$.Z37QR<9=N8[WRL`-<>(D!&^.T-Z.
M*P]3$XD=_\L6XPD+D`1KH\Y7</0IU9`$=+>?4NU(9[7U$'\D$>7G"']<:;<Z
MB/!OXXZHR-3AR9;4/\<(`736_:8:;]7`8N#,'SL/+=*WD0^!1V4896<O6+'D
M[\NO+1;+:?_O/T['@^%\\8>+X4^?1LM?D-5,SOA3/[8HM[/ZDI>NO(`7%N5V
M."Z!^`*OO,XM#AW)BXK#L"H37B+],;9W%'S]$2$P-O1ZXFLH>"27M*3642OO
M(<ZUCLP^9_A(=\BMXR^<U8,\2(S7T-I%%J`6CY@Q4V'!9$,M5GJF'(_[\FA@
M3D-KAVN`),6,&9+D(G8WQ)NXJ\!SDJCGK_O!]M'Q7Z1251&AKL,%XQC'V?1T
MWOV!;`CIDS_+$57G)W^=//GKMIKPI;$;3>S5A&>A^T1GY,QS5NFT%*PLK"V_
M*0X]EB\KXM'G`A-,2E6X2/!&AF2%$`M-+5Q4,9;EP:EB+47MH6M)^Q>K,A%S
MUVHYRSALFMX7)URKC9E2LV-8;O@CS\7.V/1$L3QUUTY$4G.7^-%.<J'CWZ<<
M1=<OKVUF611BRLDK._Z:*I8_<;9*X\?,UW#H`%=_R\XP(_PC655WET6ITS]+
M?]A+XH<@9)ED9:NKG,YR'+784UM98B'\XUAJBV.=.>$TS&)0T^2',Q*FPX=B
M)J:W'61=$SR50#""F"E<]J1,;[+M:6Q'4S>::47&\0(T3>(H=ORUZ]_KH50@
MM!U>W0@JC@APX$6WY&W@:VY?4B+;X=-@G`"L(\5(M>()"6R'/]?'!N-:5QDD
M:*&34]F.6ZZ/$-HE3IJL?$*^I'^2QB+`Z&W'J8*ATQ/(\4>BIHRE#R44A_1=
M&]OQI7`@*XR9NA@]?(CW#">]2,RWL!X1JI9@9<Q'L&*EY[+Z"U:9W'H8:-,%
MBR\/A+&\O?7:95)UO&S@-T$X2\+5@Q,1D=.!T:G)[,46:$TT*/_&PCJH^K!'
M-ZN8I9X1[7S"^`X@-10,BR=4+7[,8Z*T082[#93:^M6W!B9P:72+27&9U82D
M0@Q%Q.(95(>=(S`;,BU*_SA]3%,&#9])N'(CF0NA3E_V[H9;/0%))870NM!G
MYGV=9574D_4TF2TLL7(IH9[=Z8K4SN26=05%&:UW0RVGDYC:M2PF44_6DZ^:
MFMJ6+"G)B*Y:P^T*00I64[A='<^27*\H:)[4>FK75I9<--5`.["Q.RP$:S\B
MX3AJP'YU&8W,U7(&:\;7G<WH2-+7F2LEW5Q/SJGKZJ>N,U=ANCFNIM+6`1^@
MW!"ADY_?%"IRBPXM\>`QS93TR;E`_+LVN290L5OT*%4'C4G<,GL\^_5-$/:=
MZ*'>^:34!10NW*XAKEP0P5G(*#0G;!W-W%F+1\^5I-X!$4,A1!#R`I?%$66$
MXA?@_NY=S910=NMPGY-"G9-"G9-"21`8&TH*U:#(!'N*IRAI]-KDB&2>&S6.
M8MGI@%2/KPN-<$B[HB$\0>^'C.)MYJWKN]MDJY)UJ9GM5T8<_2A)FLL7#D/U
MUGD&B;S8S/:#(8#(>7SA$/G/A*6-)NL>-8(=]<HB:&[[79`:`BF?.*`XYZ<Z
MYZ<R`@?:_%2WB1>[CQ[IK9\<?T7H23SPGES_OA^2M1NS_$W2A%5P<MNOXN`)
MK'1%8LCUW6WF,'-WCF@RAQDLLB'?)R0D.%8GT&8AX:)I]C&#R*BV#2D1#G24
M&@<!RNPNLJ`+I>NYP6OVT7U1%'G>5269]0=N`*4JQ,,!!6$J:%'X>7DM>`"=
M]:=1K2'138%X\??EA>(!=-;#]5N#HN7J\=I0O*\)Q7M=Z\I8K%]K4+SO!(K;
M8.UNW%4J']`6(2.P'DZC*7PU\X:DOO]8=D&^##[YSF9#U8!E"AOY:_?)72>.
M)P="LP_K`2":V-02D06XAFDV^-I(%<FMQPRT"!)/,(;P^9_$)X<S*F@5DU)`
M[RN,><\U40"PWZ7@Y9:MG`0J>F->J39$WXT]R_VTW)25DT!ECV6'@`C`[OXM
MGPFZG4#Q.8;-02PD+(\5SM7`)-7`6LDU?JX&9M8'N)]_DJC!_#05!PVBRY3-
M'S:F2XG#Z/QU5H,:E,923F4MK[)4W($&!YWLR8=/E\(;^H&?CISN.8>2MV-W
M(TH45K\[:^%.$)R:L89IBG&MD?VK]O0MU.&/ATKPDE=C-;NS%FBE,2D;20IA
M!@]J2&Z#,&9)I?M!%+^R)GJ))B.P%J8%G:UJ;A'/Q_VKTP59):$;NR3J.YY'
MUM<O9873G)DZ'0,A;O]<VW2.ZDO/T-XJ6$$>W3`58C2@%EMU#1',QKJ=6<L%
M#9VIS:34)72?21333;TY;(J.K&5];@092#I=PG7CN&&6^*416-)N[.67;H05
M0#0XML<TA\N=I&+7KF#77;E@UX'#7A0EVWWRIEVJ61)N)3:MR6_:"P32V%7-
M"QV1<LG*P8FJP<GX_!QXM!N//0>F*Z%"RTQ_W%Y6;EUUZP:&$]2[N1O]=A,2
M,O)C0M&-.]0Z_J?M1=C9TCD9!">H<?LI-F!W4<1?6UCGBI^VEUK=]BK'@P"'
MQO4R[TO*Y'1SX_HL8L^_3WTQ/7_-<DD$B33C&+P'>XG<-?#7%0@.&`<[WV4V
M7I*.MI^$3"83(LFHH:*SEZ!=`S(8\UT>::NNK9L@W!`W!GD&A<=!K6[MA6TW
M.O+6$%VGOB6ZPJ<BO"7Q0[!NZ%]2=V8OBWHS)Q-43!V[=.E^3N9D%=S[@GJE
M,D]GF=A>LO.F/EN^&'!L9;.0/#KN>C?*W3HNWL$$S>TE--?8N*2L8D1C$O@K
M/4#R%/;2D]?&I,HPE@B^EB<8-6WUP>73VGNDU'3J<86`,$2`<RUP_3(G7IK*
M[_#'ON.M$B^W"PNVN]J]V7OK#]W_&@K*D'%R"#MJ</AF'=7HQUZJ;RADM86#
M8[\L9K+.1;?LQTL7GJV;;!6G<HU.[#U+U#JB:XO%T.3+SI?4*!8$[`OFFIK,
M7NIOZ-2"LHYC)LW"8$,BEOI=E0B\VM+><U`M$X3/H"'%'Y!H%;JI7UH6%Y(E
MN`;[-1KW:B\7.'3:M"0X0[#V[D-"LJH)U.#,!B'`BM_4WJM<*``R%DUEP]J;
M&[L#@LATKC0#A\?;LXD%K)G2SYP9-Z>RH!]X8.8;>2)>\,A0E8M8@QXJ>SO^
M!4UF,&W%NKCM<W2V`Y=5/X$N2D?J$RK:YS?.BE!5362>(#$%%%>K@24JAH\?
MT@["M7:)I3L.*A&,P5Y>"]O1)5)0<.P@7?"=I=RVJXS[,4"5T:I3IGM03E`9
M>4&%W:Z+TA'82SF#*<KS]-=$+M>=KHC2$=C+OH-*#3&NAF/7)]--EFU<K"K%
M5E`X[3CMN$.V;]:#LBU5"V,+_")J,GL9E713-:A8-WH5].JQ98Y<85"8J#$X
M18+E:Q\1FX9D.PX<_V/BL`^^I%>V`K%RVD$E:L^-)V2NY>4%:_')JP._A>*3
MEW6+3UZ=BT_J68[GXI.V)3\^%Y^T&!K@.?[$V2KJ915;'9'DBP/'485R/R95
M@9-R.QQBYRF,0.AFLQ:RZD3LA?W(7]%1T[TO?])D0Z"\?2_-JZK5`SCMA6&Y
MB].HUA"(J=-`X/^4.)Z[<<F:)=[-2K_OA\6&(L4%3FXM@QX8%%U1X'!DS+^>
MDL26BR7.SR6).Y*TT9+$%HNS?JTEB8UE]@>('&])XM2)OGQ1%<`M-<.QIH!6
M\-+(<10P5%YW1*+[CE=V_#7T8&#F:SAT@*N_NI=+M?A'L4G-212'+KO\3PW%
M3[X;1_/%)Z6!(">SEM?4*&!\NP,B0!Q+=>T[TEP4O8$+Z4+OZ#/\M\KM26C'
M(>M'>N_72^*'(!1D:&@J//&G;'M+S"N.2LQ'KD496]EM\L@7OH5I*D7^9ZP5
ML.A,>V3B/7+-F69!.[EZ'ME4,:`]XD_9=@R:UR"5F$].BTJU1PIE*3K1+?D`
MK-7WL*AQ$$APZ&'/2SLG:S[WRO=74'K;[D*P%N@)!`>(P^VC%[P0LB#A$]4P
M_L@G@?^41F6E.ALM@]CQ\G]G04:3(/Z%Q*]9N]*CXDZ])5$KW7S>MOL3K$*=
MPG'B&IA9@#=!N/L5:R?)U]_U.*P[D*SKI!0@',K9\#`R2\+5`_L393+]M;'C
M'N=+UDKV='SB$PH9831];5;3?^1JXPC"/%KLWUKY(+#ZM,RPT?"=9N,\O.`Q
M`GNN=WN%B#I$O2)-#N;(8ML/(RU$M%]I1;2?H]BUALQ-IJ2(:)?1X+@+!D6W
MR]A`$NG.'6)ES0`B-,86`:_6/0AB8W21\=QARJ-J)"2GA!6F8'KN`%4!-%(B
MQ$A)8F*D+*$(;=D-317*4FIF^R(9H%_\RO:=!-H?7EBN8O>)[97^.DW)S"X5
M-T&XS<0DMF0*KS1A?5B."('MI=PB]CHR,OQ,.G,&?*(V=[@;G@(D""'*J2*%
M!BX.'!XV+H>Y^S#-':=`:2WF01,(P+;#D4AM]]9CEL,@=L+XB//`30(_N\_(
MCC2OV?*BCTQN9H*SU-^T%B712.?,H_`59RP4RVA_N]^MKN:^:BW"`INV5I#`
ML3L:X?31#1W%O;SI[UJ+Z<"G=Q4T3E;S=I42$W[6*',R+GS76B@(-LWCH(%#
M\\R="'Z]LAAV8?1,\.M52Z>"H;_&=.VMW+"9GU48"]WHJE#KT]9B+>II57>"
M0:R4LDA;E7\/1&K],KV&8T]#)HAWB\*XJS5O)%&`-;N#0FTH*:`.:H"-!2H^
MVQXHO>K*4IY2;X56=6Q@AU#-,%1&I(9F-.78OK^G1;W8_[E-U<CU"=4.0\5(
M.M2.BB!/1D%D[I3ZTM)WEEP:*AW2J9+(O"''K"9RWT==>=7Q;%P:*NK1H9K(
M71='>KV`P9#5<)!<&BK)T;$IB]QQ4H>G+(%ZSU_GCN,MKCG\[J%:8ZB"1H>+
MCTR\*'6H))Q#!?-^X*>"21QO[&XT71[J7J`:8>P!26/O!U12A@*;>../XM)8
MKLF]Z[,Q3A.)?URDZ[#NP&$T7<QM,"B*::XC29L`:SLFA#U`8>S$1V4,QJ/T
M0E2XJ.-VD'4"Q;X3+Y0Q[(_5Q\!AI(Y30=X-5`4Z<3495(%C]2!46*GG,I!W
M`U6"3EQ)QI0`F7^@B1+TO2!JS;KC=`95B$Z<1L840BA%FY9=PW,ZL#\HP)VX
M<XP!##R4MXEQ[_X^)/=.S$IHAJX?N:NLQJ;\&*VD@N)E+&V'_K$9*`ELF14.
M<2SY]&M%%HS%%,D^"=4`,X4QH6"V&DFD1@!IJ$$+K._>272E>(+/@9^MG)#2
M226/T&`\L95.X[+IO1F?%+*U#OE=5`NLYZRSKM1/\DFH\IEQBME1/B4"K:L>
MLDQ*K\&+A51*[_6*`U^>DRF=DRF=DRF=DREA0^V<3.F<3,D>4N=D2C@RQ'2?
M3.GKK9&KO63E.#C7RSW7RVVM7JZQTDT<_3C7RS5;ZP@@<KSU<@_YE7M1E&P+
M?@=5:2$`Z5$ERX.SA1W`N1O]=A,2YC4B5.+QG)^$7L(POP>4]E,=/&4"P@LK
M*TK$*KM^#CPJ<L^-7_2!%?5A>]]J<:K*A(0?W"4)M_4@S2AM[X:M`YD7"'[X
M!NZ3NR;^NO[,+/9@NZQ>ZW#R!-3R_2VR6XS7F\+"+<8'O5N,J_,MAEY.M-4#
M62<>V:7:J55]77'IT>(G<!S207<D+7*-Y$JE]E5M91UL,47>&-O53.L3JJVT
M>6-TMST9K_0K<O=HJ=G7`7.):1P7/_59?67'7\\\QY\X6Z*Z,3+S-1SJPU5]
MW9E>BW\43N-#_<W7$JXJ;Z:$Q+:_Q>2T$!4N%0D.Q]'O&"^]3*_HYSNR\QW9
M^8[L?$=VLG=DM4\FS>]F.OBTY3NZ]@[?;9TG&UP8'6DZLU9%I7M+U<G'T5O2
M*+0<?'=VS'I^IQ;6G8ZPV/V4)+>?R6_:-J3,:K51H$[0LM"[@NS@T[:-SN-:
M=+^^B]'W_(O1[_0N1M^?+T;/%Z/GBU%4VU-E`3U?C)XO1L\7H^>+T?/%Z/EB
M]'PQBNIB5)0R;173`TG\DI:H&\?NHRI9FKC]R7F8%?P:Q6570#`[.RHP$;1%
M/WMJ`2(5S)&[>ZK9B(1U-)O*6/PI:]Y&-;HM&<PJ,=M.;(=#"[.L[2-_EC+U
M,0PB$\<\V<>L.1:[UD2)J)&L:,PJ&4510M:#)*03)AMI5MTV9[(<7E"N):I2
MHR]KSV.T-:&VH&HO.C$)T5RZ-9@#N2SQ^XE@;KGA?@RH9&;2;G>YW$A$C62Y
M:<A@+MF\>5WB?@RH2V8R?'>I2Q)1GX8NV33&-=*QFBGB9M4<QY)[%8<>YK*$
MFM9#SJ>`6MA^!OSN]T:!F%'F_]4ILB@O'B@@!?N0CLN)I%6<\M2V,1GSG6QN
M\@%`5:Z3FG@ZQ6X[AN@K\5()KUBXOA-#NMWF(*#ZW4G=OU;UNWVHCF3M53%^
M*()H64TUQP'5U$[*$W:JJ;4`.Q)EA1_HT]I=%5>1'?.AX;"@JMQ)D<4NC8I6
MX#P-S3X6$UC#ZW/920U(A$;PV3>4%UJNU.+N#4S`?F5=X9N."SH+.BF4V>4L
M:`?08W!90<N/RKU7ZEZ@JF2LAF<GCBQP,5=D=3^5BS^/,?;0+^(]R6Q4EZO1
M4*!:9J9.:`N5?6TBB%0I,Z^%;7W4'@4XC.]45;$F;J=49+3^I+S"LZS"3T-7
MG5P)',FRRCL@V3[BW*DE<*>^EP5*P$2RAB:#@2IQ)WY_726V*3BCU@&PY&OY
M%8R*"@JVL83NAE[#``ODXEERVEETE961V_=^U:R,?&7&(ZA9&=F\.+ZJ.W#-
MYP/TOP85J+I[NR'X/%2!S3CS["BP%C(GDGCK1%9<C5N8*S/!M\C6W!.\<FG'
MDBV*J9MC1^6;4%4U$Z';0%6-8M"ZIMI)K37RZ8]DZ3R3:)<.:\(*-<7NT^OF
M4<BM]:=R;JW1I#^]'5XL>_\8+EYS:AUZL9E;Z\#<ZX#5B;:D1%8?2M))P/14
ME3JKU`Y'\A(`%)7WCD4^L&2TV@^K<IJ50#%&EW&*JTPB!,;HTD`=U*F7Q`]!
MR%*K2?-!B=H?$1HB%G"D>:J.3I6J24R!`Q2YBBG!094[*4TZ[CO>G#P1/R$+
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MHHBK_5;QZA1(-PQ%Q)62ZGAL=1`[F-;,RN:>+O$:_@YP!]9,:QU,@GJ\H49T
MY,_"8$6B:$X%3D?W0$\"`_)$O."1;>(:T"I[LII?N"6,@>)""K8BEZ^HO=5T
MO"T!)\JMV]QNP0"LS@&WS4.KF:P)+4$..HD"\?\^P]]/8UT01#%5F)T0G;4Z
M;6TU[6U+&.?8/H'#R)QX3+UF3AB[T(B?[\OGDOEPW%L.!Q>SWGPY0A?TDV/Q
M91DZ?D3!=N65+G:D:DH41?=$P[Q^*?P%6F!/JSL<5_-0B(7E];1X1A)X)!CS
M6!V&I*;$`6LC%2]AK>892233./#O8Q)N!^0N5M>UX[<^/?CX?.((=2J/317H
M)&J/`S69_BE`:2G$2>#,^^S&SBU5%3I@-XJ"\&42Q"02!BPQ&CF)[<M5N=[D
M77@0UDT5!V-?RJJ,+(.=F2B5N8S`FOVO+7$UVUW)^^523]RO[:T5AF@N[3+3
MG0G[2E/85YK";O_Y5@O"OC(7[!B1U;?WP=/;-7&S#97^4-Y'Z:]^'9-[QQOZ
ML3APF[:J-,*Q8[9BY_#8R[FG.P,B^[[0A*%-BBTL0\`36T6PQ1&C","&:8K<
M]M?IXX1F2@WN<]<%2#!7G1%X;7%@J*^Y$N!0S<F!&Y(5[5OU!J+<SG9LE5BO
MRKYL+H.F<N&Q"H2S)%P].!'IW8<D#?7_V8T?9B3TW>=ESB,]'O>E=E?-OJQ7
ME%$CTX`[PY:QW]MLTC@[:B8^N&'&A,(ZEM+8R["KA0:(<QRW[7,2Q6&RBK/J
MGY[CJ^P%;G,<VTJ[I@&7T=P-,B;0U*:`@``'<%(E5`&#:O\?NSY5OWY(UJ[D
M4K#8RG(H(/0.J.RXY7!Z_"F!F.MCY#,-8_OGC;,BO6V0R"/*1!2V?<,U@56)
MP)"U4/SL(;^B%((L)$-)9_LMBRX00+9PF1&/6<*;:+I)G8,SYT4>+""FP'06
MTI@W*A'@`"I]K$ZWT)GC2HI,%UO9?A12$Q`>J\>_0PF$D2T*5/5RO]-V^_$[
ML7WC5GL^:@L*QQ0=).2&RF!*3Y`K$D;3,#W</P0>%;,L#EI.9OLFKZXU`A&&
M(9,DO16X(61.W.U=$D9$\+:`-1:TM7VE5\?TD+*-8XKT/2>B4_AG%AOJQ]-P
MSI)S[^IN;Q9D10^'[+:][W@>65^_[-I%NX:22=2X8VN5QYM-LY8$BB:'RG42
M48ZCJ!_X*\(RM*?N'U!L\I_>E6.3KS\M1I/A8G'1GT[ZP\ERWEN.IA-T,<IN
M]!LKFOB)<AS2<?D,,$"`LIS,YB3/8\>&J0@_%K5'XN."P%.>E0*.D$0/5X97
M664`((VQ10S+U4Z%T!A=,'!EB-<OZIA@*=$IX)3G!T<(<)4?0!RPE`@I3E7]
M4RY[[04&MX15$L7!EH25D:KN_96$MIW&`"TLHP63A3&W<>;$V25?A`.2?\ZG
M(K;M`-,`18<MH\`(U4(>BZPFLWW"T@0#*@>;GDE=".41SFHRZ"*'896#<61G
M*KVOA\-[71RP+&Q0072-PX=Z.'S0Q<&8F[`M'#Y@#''B&*#7Q%\];)WP-^U3
M4(D2J8FM>10J,=7FFX$V8=N/4OM05*%$"IM`,94`EME#<49:.!Z)=B;HA,2J
MDY&@N>T+%*@6EM,"R)A'NBS.2,A^X=S+BD+)J2R'LJD=DJJIQ)$!#K1*"@6>
M1P@]"BI0!*RV?$"R<R_5#[9;-TLTV_/769;2>[JB0!/G_.FR?#G5G][>CI:W
MP\ER<=&;#-@=U7(T^3B<]/&ET9%QKY'[4[.;5H\`SJ/+\BX1)R+3.\^]SRX6
M6>EGD?4OH["^7M;`HW`04(O#T%GLE@[VP7MA92'G=/S333H&GBW/F@M;VU\<
M&R*@D(,AZ=\D,1W7K>N[VV2;?G&VCWVDJRVKS+X;B``/#7K;P;N-$=*6%0Z#
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M32I+\ZO1I,;J8_^IIA6=::PHC:O<"'S=I?%/`K_/JK)X'HNQV;N*LH(@`F^W
M5@\(`A[:`%^;;Z/W%1`=G)"8/WTYK$@[0!"@;`A!@-Q:G;YVO*L+XI%53-8_
M)4X8D]![N7%]JK>NXPV<V)$Z6-^7':R+X7C89W5M?OK4FR^'\_$O%S>C26_2
M'_7&%X/>LH?"R5KE=.1O@G";"E7'S:K=T2E'U)B:WS71LA)E8P'7M&;>+`PV
ML@QLA4:V79KM`,KA&X?_FFI7MLF/I74<2\UL.P;;`87+.PY8AD[(,HI%,Q(N
M'JA$KIW(7;'"H*Z7Q*];)J>>N(K0MB.N'>B`\CF)L$1JC$?D]X1=@3^EYS%0
M+.*'BK7SZ7HQ_.G3<+*\&'Y.+Y5QQ1^6V50;-&(*FY9+<5"JJGS<UCA>0*@`
M*=LL7%:09,,H#6ZLSH4AID")CNQ1D9@5)%DPRKPH,V`("8X=&VQY+SC#4SWP
MDI#@1$>>[T+"#HZ77,7Q*5]R\9O;/F4I]4R.RKF^E>GEZER^ZDC*5XG>Q@1?
MB)^&ZFT?'?]%59!%W-S:2E$15-4CKF(2Q]D^39*:U><;9(422.@&Z_0<&TW(
ME_1/,N,'2&_9$ZHRN<LKNI94$"9D24<Z"]T5]X5N6@<HWP+9CBN$IS+P(YA*
MGQV/^<WKSJ0RN6UO9SLSB2\4A!-IG]EVX+Q$-T$X?61R7@;[`EK9BB"88D!:
MVTY0G<FG)0ZM5S"[O[!_W-&>Z&_^/U!+`P04````"`"AA&Q&%^029H$4``#Q
M[P``$0`<`'1X;60M,C`Q-#$R,S$N>'-D550)``/N^`%5[O@!575X"P`!!"4.
M```$.0$``.U=>V_C.)+_^PZX[Z`+<+A9'-*.G>[>[FSW+A3;27O6K[:<?@`-
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MU,7F(OQ7C7U`7#UF_K^W[NKAKYL)^;;PK7=^^]YJ#C2$!NW[\?N'-\;OOV'S
MVEN^?_,)_T36]OO\O6-\;K:QVOBR^?I.LW\-FOS@Z@N\1`H,#\O]>)80^</E
M*]N9-UH7%\W&MT%?8W1G`>'5QB36SSSRYOOW[QNL-"+E*#?WCAE5?=F@Q??(
MQ7'-4$H$],1R/63I*7K#BQF2Q&\:06&*E.22O@U(241JX`R=B_57<WO=@((&
M'2+G%\WSRV9$[KOG<X16,<L,N?>LZK`@G\6Q3>SF\K"2'";+MBQ_F2\=PW,:
MWG:%&T!T#E38(7K,5\Z49H`^T,?YO6,E.;VC,R9F\!)S:VG`M%TVHJD%IL?$
M2YB!-[:S[.`9\DU0X&\^,LF,8.-,\9`SQQX=\^X*Z;A2G='T099EPRP#XQ,^
MH<]6*P+3"![\QP<ZWJZH?*>`0J&_@,D1M4!)&C`3?=ICU3*ZED>\+9V6SI*U
M<Z80@"VDH"U#/UC;!IX1B[`.AI._J9PK$7OR5V092E"7DJCL0R-;3:)RW\7&
MR/H[^WWE8!>J84Q]>!`RAB0%3#HR==^LQ[/K2BY+^""2^2.TT+8MUS:)`8;8
MN$8F-0/:`F//#5107"R6?PN$3BTS#A70'@VU4;_74:?=CG*M]M5ANZMHG[K=
MJ782/B_=,7(`Z0(#`S)+-)&F%:OELKI:E%]2%?_EI"8F^EAZ[F@V6E&G#=K/
MF2P%=&+UO!:I1YO"_P;=(:AF=*.,QMV).NT!P4DQG,`US]9_+FS3`)<9%D.B
M$Z_[FP]&7ZRG8C:QVMY45YLV';7_^6G4[W0GVO\JOW2Z-[UV;_H7I?OYKC?]
M?E(EIY,V<A<WIOU0,L5V9&)5O:VNJK:J?5)N^J.OQSW#EBL(=2+A!W^(1?Q7
MZF]!5&7:KN]@^&/ZJ0MR'HS5X3$/<,U?+I&S!2M#YA8XY3H"QU;7;1^\46L^
MAD&M$QR.\HJT8CV\R^I!NQL,U,EW9H9ZM\,>F!YU.%74=GMT-YSVAK?*&*9"
MN]<]Y@'?L]8`R';"(;_[4RSL]UEA]X9?P)",)L<\Y$>TH.T[U(U473<.*G*>
M"Z7;O,A*=P0V9:*T[R:3+AW!FG;<<<0-V6`C*>'D`[%HFUG1WO2^P5)X]"(=
M.WB%B-'=K+!%,VE4JIEG8L&VLH(=3[ICM==1NM_&W:'6/6+9]@"--2?W)DZ.
M6>ZI6+Z7O,6=JL/;WG6_>QJ]20O;)^B>F-`JSC&_R4*QO%^+;7"_IU[W^KWI
M<7L/0]O#[AAM$8SB0-BI)V()O\E*>#B:=C5EK'Y785`?L523<7DRCL]Y+I;P
M6\XE3H7C1Q^$]RSX%4_1!L<V>?=`+%HNZNL-(>;K*E/UVU%;A`DV::YBC)R=
M`<X\$PN6"^,FW3[+5HS5R9%;VVO?)19VW;9MZ8`LE8LM*!/+FHOBKN^TWK"K
M:31/U(9E[I1R;=O+)?%8UDVU#)`NS4A@:Y>[$!$(I=_BHCPP((/>-$C(J<,.
M50)-4W2'1YZCT+")=3`@GWVP(-@QMS?$0B!A9':0A\*U44PCU@07%&K=?K=-
MC<[G.[`ZW4G_.\2)0Q44H?:5CCI5E5_NANI=IP<TQ_RF2//O7?R;#Z"Z-&\4
MI_,R3\72YR)'[>Y:`]^$NME=FE4ZZK%?*36Z3SJU6EJUQ<6=U=.JRB]1&\<]
M1ZIH8TH#IEKZ"SG$VN.BV#K:"UHX9MW%Z?"D>K(/Q1K@HMPX4WX2<%[*/"GI
MPE*QR+FP-R]]?I)^*H^>%#O_6"QO+A9.YM1/<LXFUY.BSBT12YL+D#.)]I/`
M^8Q[VGSGEHF%GO.^,Y-]/XF],`U?9-)Y$J$2+DM>BR92\B=EY&614SYF4:E8
M!7RDG)-1/DD_E5I.&Y_L8[&\N=@XF68^R5F8GTO*O9Q,K`<N"A;FZDZ**4O:
MI4Q1%4JQ>O@PMSR!=U)1M3Q#!WN(F.X0.?2EPAK7R5%PO&(U<K%RG6Q%V)82
M-W92;47U[*'1$D7R+Y[K*_*8U1>GF%(:XIZ*E9#SBCK./)UDG)-Z2@F[N%@L
M=2X\ST\^G120S#[EKS$B`K$2N'`]G9$Z+15"-11)7RSTUUQXGBOT8Q9U.MN7
MDG9^D5C@7##.90)/,N=2@?FFII1*K(F<,)U+#YZ,3KE6A,HHT4'Y!NF=#DZB
MYZ3;%,J^62)\+@`7"+]YS-(OR'_G6Z6JQ&+=<%&U(&U^,E*5=55%126:*7E1
MG:>98]9'\MN"_`DCI!#K@HN64U\CG&9&94TTRU51MIIP,729+HY[3>'?Y17D
M;,OIQ'KAPNK\MW^GJ5)+.<VJVBF9-F^X`+RB>DZS1RSW5E4%M4H45/'M.:^@
MUDE!.7(O44N),OAMYR)EG!20(^$RRU5FL/B]Y<+Y<#)3>4(NLTYE1HE_=RY4
MPLD4Y0GYLD0)ER5*X-]\"Y5P><Q*2.RA*DKF%A.(U<`%Y.GM5B?'5JB&(NF7
M"%WX*?5I`<X5=;-(UF5++A=:YX_PHUYJT]^KY]N8$AJQ$K@X.O.-^\G25/CN
M/5\O%6F%^GG+!=(%W\6?]%1U+VZ^LNHPB#7&1=8E^W-/>JNEMZKJ*M$2%W)7
MT](QZT:\.3J="*E$*M80'Y&7;Z0^:8D[!Z%HSW0)E5@W.=]R9\Y)^'/;-?J#
M7O,QP3.%70]RY4'YQS.7T"MCSL)G"P?//I[1>R3.HXL=_@707FV69D1"JQ9<
M#\(TFI5&V'!4!7)TKA;N^A*HQ%YAYB`VHLY'%7C$H^SC1#,*;0?F<N,I()OH
MOBYD8,'F,V+MT_J?%"2,OKH@,P/VF:"V=ZT\*6"8.G4!IV?;,^'MQ(TDX897
MIS1V=Z>$?V?O5_D`P&W'4RSNNA;1Y3W!M4-]6V=5"5CH7^<1WSE]=-YLG5\V
M7VU<8]?3.IW8B:%>)R*^/3J1?RM1Q>8C!MKNFUHM%EU:5-!P+@_]Y7S'7+5]
MX0U(HO9S&1O8]-SHR2-[0Z>K^T3=877MT9\*%S=5&1Q)SF'`2`?)>SHXFV\?
MV9G].E+6B_#F)^92L1O65./_?3>(2Z:V:AC,$"%SC(C1L]IH13QDMNG<-P.3
M/)I]I>X1D/=<UZ>W15%$'\^>H!X"1??4(GJ.3XTDO8GL"HPGL8TIL_&&'Z0D
MHK+[X&J;CV>Z@Z'!,R58"H+"I6V!/^=L>QY>4G:0)+B08'-]6L6M8_NKB)0`
MB4A&Z9ZJ+KW;`%LNZTLBE[6-9%&#7EK,5?09X@Q@:MA9$YU^EUI]0!15(*U4
MTIJ]L9TP3+3F;=OUW/P!D$<F+<(.OO?:MA5>51G\!N.U!QZ`PZY%&\)3Y"XB
MJ#7HI<4<J:N[P8Y.7-K[[D9?(&N.07<4H6H9JJY#MZ'(PQ!W>%E5U^257A;Q
MT,W.:Q'!X:"*)V3YE)49EVJL:3MCM&6&EG;;]WP'PA070WRR@+'7P6MLVBMV
M-Z+ND34)SA:.C/3>_*4R"8(&CQ.)@>^?42+AMV#Y`)CU#3><1R*HPR`W9GK?
ME6_2O'(^Q+QRN1%1NTGG#S:8(F`IT7.1B>CD1A@-N^R8*X1:B4%NS`-D^3.D
M@YV)'*)"M"6DDN+L66'B"/?)FBW[J<_"P#\P?7KS]ZUM&P^`88ACW/NQ2BJ'
MT.U).[\9VU1"LS>R9UYX-61BE[Y0H$=\N!,,(]2B+_94T[0?:`]<JB&ZU22`
M68->5LAQ5\%+^+JP`0]@`DB>0^Y]#SP'C#GEUF*1%G@P1-LFS$L=F5.'(%,P
ME$5TLD*D<<HN9)O@)0(,UOP&Z5A=TB&;#/?*"&4%V<=S9,*0FV"RO/<=EQ5'
MP(H*I77]PQ1*'R,7C^Y-,@]VZTRQLXPPB4EJ($M"B)X^`82!;7D+<WO-WJM8
MWFC&>AH')\7%^ROE>1>\('@:P)18^DO6VRBR&JVQTR<S'(*((-9AD'5:A3=6
M6_-`/2E($1IP4SI^C+H6AZRP8]NG,>MN8.<+,GW0%_MX,X):2B4KO$3&EG4&
M5O"Q#W$'*$Q;("?6906ZES<T[-,">CP,W>(SM8,<3X<%%4&O65=CI54GWQ.:
MR_B?"EA1_X;X@14EO-#*Y)("8Y.G,BZ>6MK57*@95CA:L<4[SC-74VHAZTLK
M>.R0-?+PV`3/D9;04&`7_.>6R;KJMTWDNO'[S)$S(?.%!^:#1!NH`<ON=6=8
M'H/=FWM?LPKU/1?H+]BER_H>@,LX)01[@TBTF->"*N:3-)63BV3H+^^Q,YII
M6`?#0]\+P.H_P\2[WM:22+UZ7MIRY8]?4"AK=("]A6W4'?T5N/>%[=$EX1FM
M'#UR;X)U>VZ1WW?;02I3RVK4<V;I]99MWB!K'!<F]BH&JHL#N[W9)34`<2"C
M+FW'([^'FWC2>5OZ\BS*<7(14`U&60=%8*A@7-]9:#8C)D%LJX-!UL3PD1EC
MKD!77<U)+,3R\!P[3Y$,LY%UZR,Z,K>IO2MY!;+J@_FX-#]D)+=8J72^S1GI
M]79'$F86U`?D&.Q'PN>(?>DGK/`1+LN4+)_";7D<FMA*/8UPDM7]Z<;3$$P:
M"[*"@PMV&?(HZ*)P`ZOP:&G6:VL_._.\SE(4B$*<I^=XP;?LKQ)/HEH-M>=@
MM*F8$MU9Q'LA$43%CY)"LI)#%408"/C.XT21KN90A4'7%VR`KY28Z(^12D%]
M=4W&,TCG\<;1'?D>[27=+-&S:!#D$OUIEK-J;4CJQS\!ZL1H>3;)BMKXLTF6
M'TQ?,9V?,#77V$%S'(=0]+-QAVZ'0B9]B9M(@+],VQ*\V?GC@;=>4.@M*82>
MM]:X7J*O],7U-9X3BV(8^1%*T5I5D?]`P+=-V]T?>A[W@0"OZZ)4K>#EX;.I
MS!RIM-6-']5UFRQ_28M9)2_R!O%R_S>(EQ+DX>OWNK4_X$<8WB<#'+GO,#D"
M_SVS:B1F4KR`T"F5_<1E#_Z7GWYW@('EC\,]_KMH)H(GI)`UXY2^NLC='5$R
MQ1OOVH21F-D1+Z:LK2?+MJ@=\J(ZGF)>Z@ML^":--]/C*\X`CD.K!P,Q?O.E
MPFQ<AGY1K#AVS2@GB>=L0`8!1J]#.VA+$Q>!*9K:J6U5F5<-Y<0O/X,U^K['
M)#8[_FJY0E;\<G>`4XG14CH$/:"&*@*SM]8,FYJY9\76K`JN>8CH6E71M0X1
MW655=)?RHNO;UIR&CCUVI"-9XV2L.H8UCAX5D<99BT4^Q$/;^@PN#)D1<-LN
MFJW`V8NPT/ZGX=:@?W%L`_K]YLK$X7>[$[RVS37-$[#=B71/<1I;=7KY]-C!
M,^Q`/Z'3V/)QZE#2"7%_II%6I98/)QMOT7JMSAW,RK\2;P%NC$4VT\2Y>?U^
M.V.3]F.63PJ?;(>ZU4%_MQW'G[=I[H.^#1_#?YR74)U>/JS1K)PZR(!`R_E)
M/;<OQ$-+8KF:OUH%#&[^7*[*)1]N=;5R[#4VZNJZ/I]\V*FB!M@8._:2N*[M
M;-D'(&F<8AKY,+'N!6D4B#B"T[RS:VLQQ0'@V39+X&PE]MKYSK;*T$CLI8.7
MIL9;Z:8+X@1':'&NG(A(/E1MW_7L)78X=R4S\,KI#@A;JR(VB4=C89\O*V*3
M.&(L[//KBMA>RXMM@HF^N`&/R=SVR1*HC?XXC4I$(1^>@3.`/I!Y-J;EG\O7
M=[KRT*!T-!,Z1:5D\B&[P?>.CYPMS2:PKF:L>7'Y`6`I@7)`2%HE4"1>?W[U
M+5PTNO++),?0$F`X%#T((,B+(!$$]"S5G\.BKEJ&AE<>ZS)%4!@UE#%(CK8J
MR`/!]JMO4MO59%]18B-W2!93'`8>SM0)2`X#$6?X!"3R(4JE$+X@:-AWRQ-!
M^83RH?L5SV;0'.;3[GDE\O5?\\@,FT.BVR;RW=UKR^PK!#&5?+@&MD%F)#@0
M/W\/@8A"/CSILX>G=L%7HVF(-9D."W77@BJWU0&GZ>7#FG(&\X>LD.1`$(DB
MD0/8YY+;7U%D<@"[6RJ:B>9>QD5B7=[:IK%$EH;T16:BY97(U_^V_8"MW6+,
M>2""\A?O^]`N,>4"`ODTT;%U]GDU_2:!=;5GS6QG&6PJ#7L;[T*I1/MXC.'.
M\J<ZVR5[84WJ<([T;<WY%J*,1=ISUP37LK*]P6Y6PS48I%/SB%[!&1Y&')PG
MGD4GHI`.3O:8.'5#"H^0"\K^8`B&=V40:-T--U#7`=-AYJL(3E0JG[6,/S+)
MC"S^N73CJ8-=W2%L`[WHC+K@6Z'B$[X>7\U+"R+>1]BVU]@).AKOQ<HO>_G/
M"^(%*/Q")GZMPS^7]6.@Y`E9^??19+#589`5=-J1*#Z4MP+=2W^@%WV+$W4U
M^)8U^Z4.5[IGMY_N++#8-@?W.VWI!X*!!R=P=6LR26?MXT,GF?;OZ-'<(:0L
MTBJ4TL'+?!J7.@F&4V4E6ND@[G<F4GRP;NS1/[H:&<X3JG""!/V6MT3UY6P'
M,0JX4P7*CQ0K9GEYUZ92?RL=&2;D.AB@E:9P"=^!@*UX_ED)W\N#5><0-\SI
M:=RITYRRYJB43#KS\P1G73%+P^YZ>YZSM(KJES4BB#Q*YFGU/;+B1DDQ@73C
M(W0>`TT4>);90NE`//:DJV`M_<-/-:O?[,L;RN@[UIZEVTL\19O\1&TIF71C
M*'/I$[L6'(Q)T"O-AQ_P.(`39Z-KL;S\34H?&JZ^@.$%O_X;4$L!`AX#%```
M``@`H81L1K]90G2;#P$`5M,.`!$`&````````0```*2!`````'1X;60M,C`Q
M-#$R,S$N>&UL550%``/N^`%5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
MH81L1C5[NQU=%0``[28!`!4`&````````0```*2!Y@\!`'1X;60M,C`Q-#$R
M,S%?8V%L+GAM;%54!0`#[O@!575X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`*&$;$9H5BK?.S4``'S"`P`5`!@```````$```"D@9(E`0!T>&UD+3(P,30Q
M,C,Q7V1E9BYX;6Q55`4``^[X`55U>`L``00E#@``!#D!``!02P$"'@,4````
M"`"AA&Q&,;]CLL5]```U/0<`%0`8```````!````I($<6P$`='AM9"TR,#$T
M,3(S,5]L86(N>&UL550%``/N^`%5=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`H81L1IK2;S]]30``?(0%`!4`&````````0```*2!,-D!`'1X;60M,C`Q
M-#$R,S%?<')E+GAM;%54!0`#[O@!575X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`*&$;$87Y!)F@10``/'O```1`!@```````$```"D@?PF`@!T>&UD+3(P
M,30Q,C,Q+GAS9%54!0`#[O@!575X"P`!!"4.```$.0$``%!+!08`````!@`&
+`!H"``#(.P(`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>35
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q
M96%F9#(T.#(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U
M-&0Q96%F9#(T.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?4U1//"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?0T%3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^5$A%7T-/35!!3ED\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y354U-05)97T]&7U-)1TY)1DE#04Y47T%#
M0T]53E0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)
M3E9%3E1/4ED\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y/5$A%4E]#55)214Y47T%34T544SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D9)6$5$7T%34T544SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E!215!!241?15A014Y313PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5$%.1TE"3$5?05-3
M1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3U1(
M15)?0U524D5.5%],24%"24Q)5$E%4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DY/5$537U!!64%"3$4\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%4E-?15%52519/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y#3TU%7U1!
M6$53/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4D5,
M051%1%]005)42453/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0E5324Y%4U-?0T].0T5.5%)!5$E/3E,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-251-14Y44U]!3D1?0T].5$E.
M1T5.0TE%4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-%3$5#5$5$7U%505)415),65]&24Y!3D-)04Q?1#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-50E-%455%3E1?159%3E13/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U5-34%265]/
M1E]324=.249)0T%.5%]!0T-/54Y4,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-534U!4EE?3T9?4TE'3DE&24-!3E1?04-#3U5.
M5#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)3E9%
M3E1/4EE?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3U1(15)?0U524D5.5%]!4U-%5%-?5&%B;&5S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1DE8141?05-315137U1A8FQE
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!215!!
M241?15A014Y315]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y)3E1!3D=)0DQ%7T%34T544U]486)L97,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/5$A%4E]#55)214Y47TQ)
M04))3$E424537U1A8FP\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y35$]#2TA/3$1%4E-?15%525197U1A8FQE<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.0T]-15]405A%4U]486)L
M97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-
M251-14Y44U]!3D1?0T].5$E.1T5.0TE%4U\\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S,N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y314Q%0U1%1%]154%25$523%E?1DE.04Y#
M24%,7T0Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4U5-34%265]/1E]324=.249)0T%.5%]!0T-/54Y4,SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-534U!4EE?3T9?4TE'3DE&24-!
M3E1?04-#3U5.5#0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,S8N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y)3E9%3E1/4EE?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D]42$527T-54E)%3E1?05-315137T1E=&%I;',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,S@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&25A%1%]!
M4U-%5%-?1&5T86EL<U].87)R871I=F4\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,SDN:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y&25A%1%]!4U-%5%-?1&5T86EL<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970T,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!215!!241?15A014Y3
M15]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#0Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^24Y404Y'24),15]!4U-%5%-?1&5T86EL<U].87)R/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#0R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y404Y'24),15]!4U-%5%-?
M1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970T,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/DE.5$%.1TE"3$5?05-315137T1E=&%I;'-?,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D]42$527T-54E)%3E1?3$E!0DE,251)
M15-?1&5T83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970T-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D]42$527T-54E)%3E1?3$E!0DE,251)15-?1&5T83$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M-#8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.3U1%4U]005E!0DQ%7T1E=&%I
M;'-?3F%R<F%T:78\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T-#<N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y.3U1%4U]005E!0DQ%7T1E=&%I;'-?3F%R<F%T:78Q/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#0X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM(3TQ$15)37T51
M54E465]$971A:6QS7TYA/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0Y+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4U1/0TM(3TQ$15)37T5154E465]$971A:6QS7TYA,3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970U,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-43T-+2$],1$52
M4U]%455)5%E?1&5T86EL<U].83(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3$N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%4E-?15%525197T1E=&%I;',\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%
M4E-?15%525197T1E=&%I;'-?,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-43T-+2$],1$524U]%455)5%E?1&5T86EL<U\R/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#4T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM(3TQ$
M15)37T5154E465]$971A:6QS7S,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-34N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y)3D-/345?5$%815-?1&5T86EL<U].87)R871I=F4\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)3D-/345?
M5$%815-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U-RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DE.0T]-15]405A%4U]$971A:6QS7S$\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3@N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y214Q!5$5$7U!!4E1)15-?1&5T86EL
M<U].87)R870\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T-3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y"55-)3D534U]#3TY#14Y44D%424].4U]$971A:6P\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M-C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-251-14Y44U]!3D1?0T].
M5$E.1T5.0TE%4U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#8Q+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0T]-34E4345.5%-?04Y$7T-/3E1)3D=%3D-)15-?,CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970V,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-%3$5#5$5$7U%505)4
M15),65]&24Y!3D-)04Q?1#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C,N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y354)315%514Y47T5614Y44U]$971A:6QS7TYA<G(\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968]
M,T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T
M/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L
M<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^
M1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^
M#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\
M<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%
M>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q
M96%F9#(T.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P
M-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE
M970P,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U9044^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;B`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,#8L(#(P,34\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E
M9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M5&AE<F%P975T:6-S340L($EN8RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P,#`R-3<T,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,3`M2SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y$96,@,S$L#0H)"3(P,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&
M;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R
M<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(&$@5V5L;"UK;F]W;B!396%S
M;VYE9"!)<W-U97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@82!6;VQU;G1A<GD@1FEL97(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='DG<R!297!O<G1I;F<@4W1A='5S($-U
M<G)E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#Y!8V-E;&5R871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%!U8FQI8R!&;&]A=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S.3DL-C$V+#4R-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S$L-S$U+#4U,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE
M;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM069F:6QI871E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M
M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDP+#0Q,"PY-SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C
M7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D
M,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T
M<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%3T%!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0W5R<F5N="!!<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-3$L,S8Q+#8P-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-30L,3DQ+#(V,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M;W5N=',@<F5C96EV86)L92P@;F5T(&]F(&%L;&]W86YC92!F;W(@9&]U8G1F
M=6P@86-C;W5N=',@;V8@)#(Q+#$Q.2!A;F0@)#(V+#4U-2P@<F5S<&5C=&EV
M96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$U-"PR,3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#8Y,"PW-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=F5N=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PQ.#(L,3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP-#,L-C$X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C=7)R96YT(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,S<L-#`W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT
M-S<L-S$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4V+#(S-2PS-#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.2PT,#,L,S0V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:7AE9"!A
M<W-E=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,L
M,CDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C$L,S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R($%S<V5T<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0R-RPR-C,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<U
M,"PT-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#(R."PU.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-C4L-3@X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396-U<FET>2!D97!O<VET
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,U+#8X
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPW.#`L.#4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPU-3$L-S(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.2PP-SDL-#@X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L,#$V
M+#,Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#=7)R96YT($QI86)I;&ET:65S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#,R-RPQ,CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#$Q-"PR,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4R,BPV,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P,BPU.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-U<G)E;G0@
M;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M.#0P+#8S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L-C`Q+#$X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#8Y,"PS.#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,Q
M-RPY.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='DZ/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:R`M('!A<B!V86QU92`D,"XP,#$[(#$P+#`P,"PP,#`@<VAA<F5S(&%U=&AO
M<FEZ960[(&YO('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:R`M('!A<B!V86QU92`D,"XP,#$[(#(U,"PP
M,#`L,#`P('-H87)E<R!A=71H;W)I>F5D.R`Q-38L,#DW+#`Q.2!A;F0@,30T
M+#DW-BPW-3<@:7-S=65D(&%N9"!O=71S=&%N9&EN9RP@<F5S<&5C=&EV96QY
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-38L,#DW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30T+#DW
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^061D:71I;VYA;"!P86ED(&EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X,BPY.#(L.#0V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,U+#`X-BPP-38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M
M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$S-"PW-#DL.#,V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#@P+#4S,BPV,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD97)S
M)R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X+#,X
M.2PQ,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-"PV.3@L-#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K
M:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4Y+#`W.2PT.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#8R+#`Q-BPS.3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C
M7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D
M,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$%!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%!A<F5N=&AE
M=&EC86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N="!O9B!&:6YA
M;F-I86P@4&]S:71I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@9F]R(&1O=6)T9G5L
M(&%C8V]U;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q
M+#$Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C8L-34U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('!A<B!V86QU92`H:6X@
M9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@
M875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES
M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E
M<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64@
M*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S
M(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES
M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34V+#`Y-RPP
M,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-#0L.3<V+#<U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-BPP.3<L,#$Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30T+#DW-BPW-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S
M9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%2E-!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY33TQ)
M1$%4140@4U1!5$5-14Y44R!/1B!/4$52051)3TY3("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DEN8V]M92!3=&%T96UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<RP@;F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U+#`R-BPR,3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L-S<U
M+#4Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,RPX,3@L,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;W-T(&]F(&=O;V1S('-O;&0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C<Q+#@P,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.34Y+#4Y-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S0X
M+#$Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=R;W-S('!R;V9I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$L,S4T+#0Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8L.#$V+#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#8Y+#DP,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/
M<&5R871I;F<@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-A;&5S+"!G96YE<F%L+"!A;F0@861M:6YI<W1R
M871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#$R-"PP
M-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.2PP,30L.#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30L,#8Y+#<P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,RPR,3@L.3,X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3,L-34Q+#(V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L-#DR+#,V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#0V-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X
M+#$T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4V+#(V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN9R!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-2PS.34L-#<W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(L-C(T+#(T-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M+#8Q."PS,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-30L,#0Q+#`V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-2PX,#@L,C0T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#$T."PT,C,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D]T:&5R(&EN8V]M92!A;F0@*&5X<&5N<V4I/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI<V-E;&QA;F5O
M=7,@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPU
M-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-"PU-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YT97)E<W0@:6YC;VUE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-RPS,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPR,S0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I
M;F%N8VEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C8P+#`R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q+#4P,RPY,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#$V-2PY.#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PY,#4L-#`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]A;B!G=6%R86YT>2!C;W-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPY-#0I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#4L,#,V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&]S<R!O;B!E>'1I;F=U:7-H;65N="!O9B!D96)T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,"PS,#<L.#8T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5N969I8VEA;"!C;VYV
M97)S:6]N(&9E871U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8L-S$V+#4P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!E>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-S8L,30Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-C$Q+#`V.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."PY-S$L
M.#$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQO<W,@8F5F;W)E('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U-"PR,3<L,C$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(X+#0Q.2PS,3,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4L,3(P+#(S-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@U-"PR,3<L,C$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,C@L-#$Y+#,Q,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,U+#$R,"PR,S4I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;&]S<R!P97(@<VAA<F4L(&)A<VEC(&%N9"!D:6QU=&5D("AI;B!D;VQL
M87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,"XS-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@P+C,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!N=6UB
M97(@;V8@<VAA<F5S(&]U='-T86YD:6YG("AI;B!S:&%R97,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#DL-S(W+#(R.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-RPU-CDL-S,Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3$L-C,P+#8Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F
M8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-0T1)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3E-/3$E$
M051%1"!35$%414U%3E13($]&(%-43T-+2$],1$524R<@*$1%1DE#250I($51
M54E462`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60@:6X@0V%P:71A
M;"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!
M8V-U;75L871E9"!$969I8VET(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E1O=&%L/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@8F%L86YC92!A="!$96,N(#,Q+"`R
M,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@R+#DW.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,34L,3DX+#(T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,38L.3DS+#`W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L-S$Q+#@U."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN
M9R!B86QA;F-E+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#(L.3<X+#@P-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E
M9"!I;B!P<FEV871E('!L86-E;65N="P@;F5T(&]F(&-O<W0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.34T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX.3$L-3,Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX.34L-#@U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R97,@:7-S=65D(&EN('!R:79A=&4@<&QA8V5M96YT+"!N970@;V8@
M8V]S="P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#DU,RPT.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U960@:6X@97AC:&%N9V4@9F]R(&1E8G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-3$L.#@R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP-30L-C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&EN(&5X8VAA;F=E(&9O<B!D96)T
M+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S<U
M+#0Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F5S(&ES<W5E9"!F;W(@97AE<F-I<V4@;V8@;W!T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#DL,#8X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DQ
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F5S(&ES<W5E9"!F;W(@97AE<F-I<V4@;V8@;W!T:6]N<RP@
M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DS,2PW
M.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E<R!I<W-U960@:6X@97AE<F-I<V4@;V8@=V%R<F%N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,30U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP.3,L.#4U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ
M,#(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R97,@:7-S=65D(&EN(&5X97)C:7-E(&]F('=A<G)A;G1S
M+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,30U
M+#0X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16UP;&]Y964@4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@S,BPP-C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@S,BPP-C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G1S(&ES<W5E9"!F;W(@9FEN86YC:6YG(&-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPP,30L-S@T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L,#$T+#<X-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N=',@:7-S=65D(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PU-C,L-C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-C,L-C(P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I
M<W-U960@87,@8V]M<&5N<V%T:6]N+7)E;&%T960@<&%R='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#(X-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#(X-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@
M:7-S=65D(&9O<B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A;F-E;&QA=&EO;B!O9B!W87)R86YT<R!I<W-U960@9F]R
M(&QO86X@9W5A<F%N='D@8V]S=',M<F5L871E9"!P87)T:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#@S,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#@S,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E;F5F:6-I
M86P@8V]N=F5R<VEO;B!F96%T=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#<Q-BPU,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV+#<Q-BPU,#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-2PQ,C`L,C,U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,U+#$R,"PR,S4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;F1I;F<@8F%L86YC92!A="!$96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY.2PW.#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PU.#`L-#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3(L,3$S+#,Q
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#0S,RPQ,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L86YC92P@<VAA<F5S(&%T($1E8RX@
M,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY+#<X
M-"PY.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E<R!I<W-U960@:6X@<')I=F%T92!P;&%C96UE;G0L(&YE
M="!O9B!C;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PQ
M,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW."PV,#4L,C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S@L-C4P+#,U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!P<FEV
M871E('!L86-E;65N="P@;F5T(&]F(&-O<W0L('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#4L,3$V+#,U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E
M9"!F;W(@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,"PX,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,"PY,3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R
M(&5X97)C:7-E(&]F(&]P=&EO;G,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S4L-#(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L-#(S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!3:&%R92!"
M87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,3<P+#DU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L,3<P+#DU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D(&9O<B!F
M:6YA;F-I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-S$Q+#DU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-S$Q+#DU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D(&9O<B!S97)V
M:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8W+#(V,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@V
M-RPR-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!A<R!C;VUP96YS871I;VXM<F5L871E
M9"!P87)T>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8L,C@T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S8L,C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.;VXM96UP;&]Y964@<VAA<F4@8F%S960@8V]M<&5N<V%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,RPQ,CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,RPQ,CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R."PT
M,3DL,S$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(X+#0Q.2PS,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L86YC92!A="!$96,N(#,Q
M+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0L.3<W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3,U+#`X-BPP-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@X,"PU,S(L-C(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#8Y."PT,#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA
M;F-E+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30T+#DW-BPW-3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0L.3<V+#<U-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S
M(&ES<W5E9"!I;B!P<FEV871E('!L86-E;65N="P@;F5T(&]F(&-O<W0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL.#4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L-S8Q+#4P,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R
M+#<W,2PS-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U960@:6X@<')I=F%T92!P;&%C96UE;G0L
M(&YE="!O9B!C;W-T+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDL.#4P+#$P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!F;W(@97AE<F-I<V4@
M;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S0T+#@Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,T-2PW-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R(&5X97)C:7-E(&]F
M(&]P=&EO;G,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#4T+#4W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!E>&5R8VES92!O9B!W87)R
M86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#8S
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U960@:6X@97AE<F-I<V4@;V8@=V%R<F%N
M=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8U
M+#4X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F5S(&ES<W5E9"!F;W(@97AE<F-I<V4@;V8@<F5S=')I8W1E
M9"!S=&]C:R!U;FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E<R!I<W-U960@9F]R(&5X97)C:7-E(&]F(')E<W1R:6-T
M960@<W1O8VL@=6YI=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!3:&%R92!"87-E9"!#;VUP96YS
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C,Y+#,U
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,C,Y+#,U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F]N+65M<&QO>65E('-H87)E(&)A<V5D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<P+#0U,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W
M,"PT-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U-"PR,3<L,C$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4T+#(Q-RPR,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L86YC92!A="!$
M96,N(#,Q+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$U-BPP.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$X,BPY.#(L.#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,S0L-S0Y+#@S-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0X+#,X.2PQ
M,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N9&EN9R!B86QA;F-E+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q-#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34V+#`Y-RPP,3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-38L
M,#DW+#`Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X
M-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5+3D%)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3E-/3$E$051%
M1"!35$%414U%3E13($]&($-!4T@@1DQ/5U,@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%3
M2"!&3$]74R!&4D]-($]015)!5$E.1R!!0U1)5DE42453/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4T+#(Q-RPR,3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R."PT
M,3DL,S$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,S4L,3(P+#(S-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@
M<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H(&9L;W=S('5S960@:6X@
M;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C@L.3@W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L.#@S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L-#@T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ
M871I;VX@;V8@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(S+#0X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#(V,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X+#<W-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O=FES:6]N(&9O
M<B!D;W5B=&9U;"!A8V-O=6YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-2PT,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,34L-#DS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0P+#4T.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!E>'1I;F=U:7-H
M;65N="!O9B!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PS,#<L.#8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"96YE9FEC:6%L(&-O;G9E<G-I;VX@9F5A='5R93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW,38L-3`T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ
M871I;VX@;V8@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PQ,#(L-C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PV,#0L,C0P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B87-E9"!C;VUP
M96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C,Y
M+#,U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,C`W+#(S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L.#8X+#,T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E9F5R
M<F5D(&9I;F%N8VEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C8P+#`R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-#4Q+#DS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@97AP96YS92!F
M;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S
M,"PY-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,S8L.3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S,X+#0U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&]A;B!G=6%R86YT>2!C;W-T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PP,S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE
M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-#4X+#`R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q+#`V."PV,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S(X+#(U,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,X+#0Y-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S$L-3DR
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PP,C<L,3,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8X,"PR.#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,X-BPS,3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L,C@Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W
M+#,P.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U-C4L-S`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PR,3(L.3$R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<R+#@U,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S,T+#@U-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PP-SDL.38W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0U-RPX,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$T-"PW-3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS
M97,@86YD(&]T:&5R(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(S.2PT-3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@W-2PS,C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,SDL,34W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=&AE<B!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,34P+#`V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@8V%S:"!F;&]W<R!U<V5D(&EN(&]P97)A=&EN
M9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T
M-2PU,C`L.3DV*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(P+#<V."PP-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-S,W+#,R-BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%3
M2"!&3$]74R!&4D]-($E.5D535$E.1R!!0U1)5DE42453/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A=&5N="!C;W-T<RP@
M;F5T(&]F(&%B86YD;VYE9"!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-3@V+#0X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@T,SDL,#,T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P-BPQ,#$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O
M9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S,"PY-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-#`L-SDP*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8V+#0P-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E9G5N9"`H<&%Y
M;65N="D@;V8@<V5C=7)I='D@9&5P;W-I=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`L-C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,3`S+#<S-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!F;&]W<R!U
M<V5D(&EN(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V,#8L-S4V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4X,RPU-C$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<R+#4P-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0T%32"!&3$]74R!&4D]-($9)3D%.0TE.1R!!0U1)5DE42453/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S
M(&9R;VT@<V%L92!O9B!C;VUM;VX@<W1O8VLL(&YE="!O9B!C;W-T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L-S<Q+#,U,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X+#8U,"PS
M-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW+#@Y-2PT.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@;W!T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0U+#<T-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#DQ
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Y,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@=V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@;F]T97,@86YD(&QO86YS('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!B
M86YK(&QI;F4@;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@=V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT
M(&]F(&)A;FL@;&EN92!O9B!C<F5D:70\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S`P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N="!O9B!N;W1E
M<R!P87EA8FQE+7)E;&%T960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297!A>6UE;G0@;V8@;F]T97,@<&%Y86)L
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PV.3$L.#0W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M.#4P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@8V%S:"!F;&]W<R!P<F]V:61E9"!B>2!F:6YA;F-I
M;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#,L,CDX+#`Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<S+#DX.2PT,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PT,S8L.#@U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A<V4@:6X@
M8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPX,CDL-C4S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4R+#8S-RPW.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#0R-RPP-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@L(&)E9VEN;FEN9R!O9B!P97)I
M;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#$Y,2PR-C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#4U,RPT-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,C8L-#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H+"!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,2PS-C$L-C`W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L,3DQ+#(V,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-34S+#0W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY355!03$5-14Y404P@1$E30TQ/4U5215,@3T8@
M0T%32"!&3$]7($E.1D]234%424]..CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R(&EN=&5R97-T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3(L.#4S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,C4S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-54%!,14U%3E1!3"!30TA%1%5,12!/1B!.3TXM0T%32"!&24Y!
M3D-)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D(&9O<B!F:6YA;F-I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S$Q+#DU-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3`Y
M+#4S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N=',@:7-S=65D(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#8R+#$Y-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3,R+#(R.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M=',@97AE<F-I<V5D(&EN(&5X8VAA;F=E(&9O<B!D96)T(&%N9"!A8V-R=65D
M(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$P
M,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E<R!I<W-U960@:6X@97AC:&%N9V4@9F]R(&1E8G0@86YD
M(&%C8W)U960@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,#4T+#8U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F]T97,@<&%Y86)L92!I<W-U960@9F]R(&%C8W)U
M960@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,34L,3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T
M-6-?-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E1(12!#3TU004Y9/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]R9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N
M(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$A%($-/35!!3ED\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^/"]B/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CX\=3Y.
M3U1%(#$@)B,Q-3`[(%1(12!#3TU004Y9)B,Q-C`[/"]U/CPO8CX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
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M9"!T;R!A<R`F(S$T-SMO=7(@8V]M<&%N>2PF(S$T.#L@)B,Q-#<[=V4L)B,Q
M-#@[("8C,30W.V]U<BPF(S$T.#L@;W(@)B,Q-#<[=7,N)B,Q-#@[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\=3Y.871U<F4@;V8@0G5S:6YE<W,\+W4^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
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M96=U;&%T;W)Y(&%P<')O=F%L(&%N9`T*8V]M;65R8VEA;&EZ871I;VX@;V8@
M;W5R(&%D=F%N8V5D(&AO<FUO;F4@=&AE<F%P>2!P:&%R;6%C975T:6-A;"!P
M<F]D=6-T<RX@5&AE(&1R=6<@8V%N9&ED871E<R!U<V5D(&EN(&]U<B!C;&EN
M:6-A;"!T<FEA;',-"F%R92!D97-I9VYE9"!T;R!A;&QE=FEA=&4@=&AE('-Y
M;7!T;VUS(&]F(&%N9"!R961U8V4@=&AE(&AE86QT:"!R:7-K<R!R97-U;'1I
M;F<@9G)O;2!M96YO<&%U<V4M<F5L871E9"!H;W)M;VYE(&1E9FEC:65N8VEE
M<RP-"FEN8VQU9&EN9R!H;W0@9FQA<VAE<RP@;W-T96]P;W)O<VES+"!A;F0@
M=F%G:6YA;"!D<GEN97-S+B!792!A<F4@9&5V96QO<&EN9R!T:&5S92!H;W)M
M;VYE('1H97)A<'D@9')U9R!C86YD:61A=&5S+"!W:&EC:`T*8V]N=&%I;B!E
M<W1R861I;VP@86YD('!R;V=E<W1E<F]N92!A;&]N92!O<B!I;B!C;VUB:6YA
M=&EO;BP@=VET:"!T:&4@86EM(&]F(&1E;6]N<W1R871I;F<@97%U:79A;&5N
M="!C;&EN:6-A;"!E9F9I8V%C>2!A=`T*;&]W97(@9&]S97,L('1H97)E8GD@
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M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T
M-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE
M971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY354U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],
M24-)15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-534U!4ED@
M3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS
M<&%C:6YG.B`M,"XQ-7!T)SX\=3Y.3U1%#0HR("8C,34P.R!354U-05)9($]&
M(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\+W4^/"]F;VYT/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQU
M/E!R:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO;CPO=3X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!A8V-O;7!A;GEI;F<@8V]N
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@;&5T=&5R+7-P86-I;F<Z
M("TP+C$U<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!N;W)M86PG/CQU/D-A<V@\+W4^/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!L971T97(M<W!A8VEN9SH@+3`N,35P
M=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&YO<FUA;"<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!L971T97(M<W!A8VEN9SH@+3`N,35P=#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA
M;"<^5V4-"FUA:6YT86EN(&-A<V@@870@9FEN86YC:6%L(&EN<W1I='5T:6]N
M<R!T:&%T(&%T('1I;65S(&UA>2!E>&-E960@=&AE(&9E9&5R86QL>2!I;G-U
M<F5D(&QI;6ET(&]F("0R-3`L,#`P('!E<B!F:6YA;F-I86P@:6YS=&ET=71I
M;VXN#0I792!H879E(&YE=F5R(&5X<&5R:65N8V5D(&%N>2!L;W-S97,@<F5L
M871E9"!T;R!T:&5S92!F=6YD<RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[(&QE='1E<BUS<&%C:6YG.B`M,"XQ-7!T.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/E1R861E($%C8V]U;G1S(%)E
M8V5I=F%B;&4@86YD($%L;&]W86YC90T*9F]R($1O=6)T9G5L($%C8V]U;G1S
M/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
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M('!A<W0@9'5E(&9O<B!M;W)E('1H86X@.3`@9&%Y<R!T;R!B92!D96QI;G%U
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M96EV960N(#QF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C4R-3(U)SY4;R!T:&4@
M97AT96YT(&1A=&$@=V4@=7-E('1O(&-A;&-U;&%T92!T:&5S92!E<W1I;6%T
M97,@9&]E<R!N;W0-"F%C8W5R871E;'D@<F5F;&5C="!B860@9&5B=',[(&%D
M:G5S=&UE;G1S('1O('1H97-E(')E<V5R=F5S(&UA>2!B92!R97%U:7)E9"X\
M+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&-O;&]R.B`C,C4R-3(U)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y
M;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/CQU/DEN=F5N=&]R:65S
M)B,Q-C`[/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P
M86-I;F<Z("TP+C$U<'0G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4]
M,T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/DEN=F5N=&]R:65S#0IR97!R
M97-E;G0@<&%C:V%G960@=FET86UI;G,L(&YU=')I=&EO;F%L('!R;V1U8W1S
M(&%N9"!S=7!P;&5M96YT<R!A;F0@<F%W(&UA=&5R:6%L<RP@=VAI8V@@87)E
M('9A;'5E9"!A="!T:&4@;&]W97(@;V8@8V]S="!O<@T*;6%R:V5T('5S:6YG
M('1H92!A=F5R86=E+6-O<W0@;65T:&]D+B!4:&4@8V]S=',@;V8@;6%N=69A
M8W1U<FEN9R!T:&4@<')E<V-R:7!T:6]N('!R;V1U8W1S(&%S<V]C:6%T960@
M=VET:"!T:&4@9&5F97)R960-"G)E=F5N=64@*&%S(&1I<V-U<W-E9"!I;B!2
M979E;G5E(%)E8V]G;FET:6]N*2!A<F4@<F5C;W)D960@87,@9&5F97)R960@
M8V]S=',@86YD(&%R92!I;F-L=61E9"!I;B!I;G9E;G1O<GDL('5N=&EL('-U
M8V@@=&EM90T*87,@=&AE(')E;&%T960@9&5F97)R960@<F5V96YU92!I<R!R
M96-O9VYI>F5D+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS
M<&%C:6YG.B`M,"XQ-7!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT
M('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SX\:3X\=3Y0<F4M
M3&%U;F-H#0I);G9E;G1O<GD\+W4^/"]I/CPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y
M;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/CQI/B8C,38P.R8C,38P
M.SPO:3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^26YV96YT;W)Y
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M(&EN8W5R<F5D+B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\=3Y&:7AE9"!!<W-E=',\+W4^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\:3X\=3Y%<75I<&UE;G0\+W4^/"]I/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M5V4@<W1A=&4@97%U:7!M96YT(&%T(&-O<W0L(&YE="!O9B!A8V-U;75L871E
M9`T*9&5P<F5C:6%T:6]N+B!792!C:&%R9V4@;6%I;G1E;F%N8V4@8V]S=',L
M('=H:6-H(&1O(&YO="!S:6=N:69I8V%N=&QY(&5X=&5N9"!T:&4@=7-E9G5L
M(&QI=F5S(&]F('1H92!R97-P96-T:79E(&%S<V5T<RP@86YD(')E<&%I<@T*
M8V]S=',@=&\@;W!E<F%T:6YG(&5X<&5N<V4@87,@:6YC=7)R960N(#QF;VYT
M('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SY792!C;VUP=71E
M(&1E<')E8VEA=&EO;B!U<VEN9R!T:&4@<W1R86EG:'0M;&EN92!M971H;V0-
M"F]V97(@=&AE(&5S=&EM871E9"!U<V5F=6P@;&EV97,@;V8@=&AE(')E;&%T
M960@87-S971S+"!W:&EC:"!R86YG92!F<F]M('1H<F5E('1O('-E=F5N('EE
M87)S+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C$U<'0G/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4]
M,T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/CQI/CQU/DQE87-E:&]L9`T*
M26UP<F]V96UE;G1S/"]U/CPO:3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF
M;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SY792!S=&%T
M90T*:6UP<F]V96UE;G1S(&%T(&-O<W0L(&YE="!O9B!A8V-U;75L871E9"!D
M97!R96-I871I;VXN(%=E(&-O;7!U=&4@9&5P<F5C:6%T:6]N('5S:6YG('1H
M92!S=')A:6=H="UL:6YE(&UE=&AO9"!O=F5R('1H92!R96UA:6YI;F<-"G1E
M<FT@;V8@=&AE(&QE87-E+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T
M=&5R+7-P86-I;F<Z("TP+C$U<'0G/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/CQU/DEN
M=&%N9VEB;&4-"CPO=3X\+V9O;G0^/'4^07-S971S/"]U/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U
M<'0G/CQI/CQU/E!A=&5N=`T*86YD(%1R861E;6%R:W,\+W4^/"]I/CPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G
M/CQI/B8C,38P.R8C,38P.SPO:3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SY792!H879E#0IA9&]P=&5D('1H
M92!P<F]V:7-I;VYS(&]F(#PO9F]N=#Y&:6YA;F-I86P@06-C;W5N=&EN9R!3
M=&%N9&%R9',@0F]A<F0L(&]R($9!4T(L($%C8V]U;G1I;F<@4W1A;F1A<F1S
M($-O9&EF:6-A=&EO;BP@;W(@05-#+"`\9F]N="!S='EL93TS1"=L971T97(M
M<W!A8VEN9SH@+3`N,35P="<^,S4P+`T*/&D^26YT86YG:6)L92U';V]D=VEL
M;"!A;F0@3W1H97(\+VD^+#QI/B`\+VD^;W(@/"]F;VYT/D%30R`S-3`\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^+B!#87!I=&%L
M:7IE9"!P871E;G0@8V]S=',L#0IN970@;V8@86-C=6UU;&%T960@86UO<G1I
M>F%T:6]N+"!I;F-L=61E(&QE9V%L(&-O<W1S(&EN8W5R<F5D(&9O<B!P871E
M;G0@87!P;&EC871I;VYS+B`\+V9O;G0^26X@86-C;W)D86YC92!W:71H($%3
M0R`S-3`L(#QF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T
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M-"!I<W-U960@<&%T96YT<R`H4V5E($YO=&4@-RDN(#PO9F]N=#X\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\=3Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S
M)B,Q-C`[/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
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M('1H92!F;VQL;W=I;F<Z)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;BUT;W`Z(#`[(&UA<F=I;BUB;W1T;VTZ(#`G/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`U)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
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M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`@,"`P(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@+3`N,C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I
M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#4E.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\<"!S='EL93TS1"=M87)G:6XM
M=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,30Y.R8C,38P.SPO<#X\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T:#H@.3(E
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/G-I9VYI9FEC86YT(&1E=&5R:6]R871I;VX@:6X@86X@87-S970F(S$T-CMS
M('!H>7-I8V%L(&-O;F1I=&EO;CL\+W1D/CPO='(^/"]T86)L93X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z("TP+C(U:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;BUT;W`Z(#`[(&UA<F=I;BUB;W1T;VTZ(#`G/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`U)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
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M<CX\+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N,C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN+71O<#H@,#L@;6%R9VEN
M+6)O='1O;3H@,"<^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#4E.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`S)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
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M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XU:6X[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`M,"XR-6EN)SXF(S$V,#L\
M+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T
M=&]M.B`P)SX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@9F]N
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M9GD[('=I9'1H.B`Y,B4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^86-C=6UU;&%T:6]N(&]F(&-O<W1S('-I9VYI9FEC
M86YT;'D@:6X@97AC97-S(&]F(&]R:6=I;F%L(&5X<&5C=&%T:6]N<R!R96QA
M=&5D('1O('1H92!A8W%U:7-I=&EO;@T*;W(@8V]N<W1R=6-T:6]N(&]F(&%N
M(&%S<V5T.SPO=&0^/"]T<CX\+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@,"`P(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@+3`N,C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#4E.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
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M93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CL@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TP+C(U:6XG/B8C,38P.SPO<#X-
M"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y
M;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;BUT;W`Z(#`[(&UA<F=I;BUB;W1T;VTZ
M(#`G/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`U)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
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M=&0^/"]T<CX\+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N
M-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N,C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
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M9V5L>2!I;F1E<&5N9&5N=`T*;V8@=&AE(&-A<V@@9FQO=W,@;V8@;W1H97(@
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M(')E8V]V97)A8FQE+"!T:&5N('=E(')E8V]R9`T*82!L;W-S(&9O<B!T:&4@
M9&EF9F5R96YC92!B971W965N('1H92!A<W-E=',F(S$T-CL@9F%I<B!V86QU
M92!A;F0@<F5S<&5C=&EV92!C87)R>6EN9R!V86QU97,N(%=E(&1E=&5R;6EN
M92!T:&4@9F%I<B!V86QU92!O9@T*=&AE(&%S<V5T<R!U<VEN9R!A;B`F(S$T
M-SMI;F-O;64@87!P<F]A8V@F(S$T.#L@8F%S960@=7!O;B!A(&9O<F5C87-T
M(&]F(&%L;"!T:&4@97AP96-T960@9&ES8V]U;G1E9"!F=71U<F4@;F5T(&-A
M<V@@9FQO=W,@87-S;V-I871E9`T*=VET:"!T:&4@<W5B:F5C="!A<W-E=',N
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M;F1S+B!792!B96QI979E(&]U<B!C=7)R96YT(&%S<W5M<'1I;VYS(&%N9`T*
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M=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S(&%N9"`R
M,#$R+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/'4^1F%I<B!686QU92!O9B!&:6YA;F-I86P@
M26YS=')U;65N=',\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/=7(@9FEN86YC
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M86ER('9A;'5E(&AI97)A<F-H>2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY792!C871E9V]R:7IE(&]U<B!A<W-E=',@86YD
M(&QI86)I;&ET:65S#0IT:&%T(&%R92!V86QU960@870@9F%I<B!V86QU92!O
M;B!A(')E8W5R<FEN9R!B87-I<R!I;G1O(&$@=&AR964M;&5V96P@9F%I<B!V
M86QU92!H:65R87)C:'D@87,@9&5F:6YE9"!B>2!!4T,@.#(P+"`\:3Y&86ER
M#0I686QU92!-96%S=7)E;65N=',N(#PO:3Y4:&4@9F%I<B!V86QU92!H:65R
M87)C:'D@9VEV97,@=&AE(&AI9VAE<W0@<')I;W)I='D@=&\@<75O=&5D('!R
M:6-E<R!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L#0IA<W-E=',@
M86YD(&QI86)I;&ET:65S("A,979E;"`Q*2!A;F0@;&]W97-T('!R:6]R:71Y
M('1O('5N;V)S97)V86)L92!I;G!U=',@*$QE=F5L(#,I+B!!<W-E=',@86YD
M(&QI86)I;&ET:65S(')E8V]R9&5D(&EN('1H90T*8V]N<V]L:61A=&5D(&)A
M;&%N8V4@<VAE970@870@9F%I<B!V86QU92!A<F4@8V%T96=O<FEZ960@8F%S
M960@;VX@82!H:65R87)C:'D@;V8@:6YP=71S+"!A<R!F;VQL;W=S.CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XM=&]P.B`P.R!M87)G
M:6XM8F]T=&]M.B`P)SX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\=&0@<W1Y;&4],T0G=VED=&@Z(#@E.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,B4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/&(^3&5V96P-"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@,3PO8CX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!W:61T:#H@.#`E.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/G5N861J=7-T960-"G%U;W1E9"!P
M<FEC97,@:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A<W-E=',@
M;W(@;&EA8FEL:71I97,[/"]T9#X\+W1R/CPO=&%B;&4^#0H-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"CQT
M86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P)SX\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\=&0@<W1Y;&4],T0G
M=VED=&@Z(#@E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^3&5V
M96P-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M,CPO8CX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!W
M:61T:#H@.#`E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/G%U;W1E9`T*<')I8V5S(&9O<B!S:6UI;&%R(&%S<V5T<R!O
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M/"]T86)L93X-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS
M<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN+71O<#H@,#L@
M;6%R9VEN+6)O='1O;3H@,"<^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,3(E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQB/DQE=F5L#0H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#,\+V(^/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=VED=&@Z(#@P)3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SYU;F]B<V5R=F%B;&4-"FEN
M<'5T<R!F;W(@=&AE(&%S<V5T(&]R(&QI86)I;&ET>2X\+W1D/CPO='(^/"]T
M86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!="!$96-E;6)E
M<B`S,2P@,C`Q-"P@86YD(#(P,3,L('=E(&AA9"!N;R!A<W-E=',-"F]R(&QI
M86)I;&ET:65S('1H870@=V5R92!V86QU960@870@9F%I<B!V86QU92!O;B!A
M(')E8W5R<FEN9R!B87-I<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!F86ER
M('9A;'5E(&]F(&EN9&5F:6YI=&4M;&EV960@87-S971S(&ES#0IM96%S=7)E
M9"!O;B!A(&YO;BUR96-U<G)I;F<@8F%S:7,@=7-I;F<@<VEG;FEF:6-A;G0@
M=6YO8G-E<G9A8FQE(&EN<'5T<R`H3&5V96P@,RD@:6X@8V]N;F5C=&EO;B!W
M:71H(&]U<B!I;7!A:7)M96YT#0IT97-T+B!4:&5R92!W87,@;F\@:6UP86ER
M;65N="!O9B!I;G1A;F=I8FQE(&%S<V5T<R!D=7)I;F<@=&AE('EE87)S(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S+"!A;F0@,C`Q,BX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q
M-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQU/DEN8V]M92!487AE<SPO=3X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/D)A<V5D('5P;VX@82!C:&%N9V4@:6X@;W5R(&)U<VEN97-S(&UO
M9&5L+`T*9&5F97)R960@:6YC;VUE('1A>&5S(&%R92!D971E<FUI;F5D(&)Y
M(&-A;&-U;&%T:6YG('1H92!L;W-S(&9R;VT@;W!E<F%T:6]N<R!O9B!O=7(@
M8V]M<&%N>2!S=&%R=&EN9R!/8W1O8F5R(#0L(#(P,3$N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
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M;"!M;W)E(&QI:V5L>2!T:&%N(&YO="!B92!R96%L:7IE9"X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/DEN(&%C8V]R9&%N8V4@=VET:"!!4T,@-S0P+"`\:3Y);F-O
M;64@5&%X97,\+VD^+`T*=V4@<F5C;V=N:7IE('1H92!E9F9E8W0@;V8@=6YC
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M=7(N($%T($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S+"!A;F0@,C`Q,B!W92!H
M860@;F\@=6YC97)T86EN(&EN8V]M92!T87@@<&]S:71I;VYS+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
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M('1O(&)E('5N8V5R=&%I;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]U<B!T87@@<F5T=7)N
M<R!A<F4@<W5B:F5C="!T;R!R979I97<@8GD@=&AE#0I);G1E<FYA;"!2979E
M;G5E(%-E<G9I8V4@=&AR964@>65A<G,@869T97(@=&AE>2!A<F4@9FEL960N
M($-U<G)E;G1L>2P@>65A<G,@9FEL960@869T97(@,C`Q,2!A<F4@<W5B:F5C
M="!T;R!R979I97<N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\=3Y3:&%R92U"87-E9"!#;VUP96YS871I;VX\+W4^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.R8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!M
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M86X@86-C97!T86)L92!M;V1E;"!I;@T*86-C;W)D86YC92!W:71H($%30R`W
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M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/D5Q=6ET>2!I;G-T<G5M96YT<R`H)B,Q-#<[
M:6YS=')U;65N=',F(S$T.#LI#0II<W-U960@=&\@;F]N+65M<&QO>65E<R!A
M<F4@<F5C;W)D960@;VX@=&AE(&)A<VES(&]F('1H92!F86ER('9A;'5E(&]F
M('1H92!I;G-T<G5M96YT<RP@87,@<F5Q=6ER960@8GD@05-#(#4P-2P@/&D^
M17%U:71Y($)A<V5D#0I087EM96YT<R!T;R!.;VXM16UP;&]Y965S/"]I/BP\
M:3X@/"]I/F]R($%30R`U,#4\:3XN(#PO:3Y!4T,@-3`U/&D^(#PO:3YD969I
M;F5S('1H92!M96%S=7)E;65N="!D871E(&%N9"!R96-O9VYI=&EO;B!P97)I
M;V0@9F]R#0IS=6-H(&EN<W1R=6UE;G1S+B!);B!G96YE<F%L+"!T:&4@;65A
M<W5R96UE;G0@9&%T92!I<R!W:&5N(&5I=&AE<B`H82D@82!P97)F;W)M86YC
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M<B!G<F%N="!A<R!D969I;F5D(&EN($%30R`U,#4N/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
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M=FEC92!P97)I;V0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y$96)T($1I<V-O
M=6YT<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D-O<W1S(&EN8W5R<F5D(&9R
M;VT@<&%R=&EE<R!T:&%T(&%R92!P<F]V:61I;F<-"FQO;F<M=&5R;2!F:6YA
M;F-I;F<L('=H:6-H(&EN8VQU9&4@=V%R<F%N=',@:7-S=65D(&EN(&-O;FYE
M8W1I;VX@=VET:"!T:&4@=6YD97)L>6EN9R!D96)T+"!A<F4@<F5F;&5C=&5D
M(&%S(&$@9&5B="!D:7-C;W5N="!B87-E9`T*;VX@=&AE(')E;&%T:79E(&9A
M:7(@=F%L=64@;V8@=&AE(&1E8G0@86YD('=A<G)A;G1S('1O('1H92!T;W1A
M;"!P<F]C965D<RX@5V4@9V5N97)A;&QY(&%M;W)T:7IE(&1I<V-O=6YT<R!O
M=F5R('1H92!L:69E(&]F('1H90T*<F5L871E9"!D96)T('5S:6YG('1H92!E
M9F9E8W1I=F4@:6YT97)E<W0@<F%T92!M971H;V0N/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M=3Y2979E;G5E(%)E8V]G;FET:6]N/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^
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M=7)E9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
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M3F]T90T*,3,N)B,Q-C`[5&AE<F4@87)E(&YO(&UA:F]R(&5X=&5R;F%L(&-U
M<W1O;65R<R!F;W(@;W5R($]40R!P<F5N871A;"!V:71A;6EN(&]R(&]T:&5R
M('!R;V1U8W1S+B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^/'4^3W9E
M<BUT:&4M0V]U;G1E<B!0<F]D=6-T<SPO=3X\+VD^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/B8C,38P.SPO
M:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^5V4@9V5N97)A=&4@3U1#(')E=F5N=64@9G)O;2!P<F]D=6-T('-A
M;&5S#0IP<FEM87)I;'D@=&\@<F5T86EL(&-O;G-U;65R<RX@5V4@<F5C;V=N
M:7IE(')E=F5N=64@9G)O;2!P<F]D=6-T('-A;&5S('5P;VX@<VAI<&UE;G0L
M('=H96X@=&AE(')I9VAT<R!O9B!O=VYE<G-H:7`@86YD(')I<VL@;V8-"FQO
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M97,@<F5L871I=F4@=&\@<V%L97,N(#QF;VYT('-T>6QE/3-$)V-O;&]R.B`C
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M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3X\=3Y0
M<F5S8W)I<'1I;VX@4')O9'5C=',\+W4^/"]I/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3XF(S$V,#LF(S$V
M,#L\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V-O;&]R.B`C,C4R-3(U)SY792!S
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M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^5V4@86-C97!T(')E='5R;G,@;V8@=6YS86QA
M8FQE('!R;V1U8W0-"F9R;VT@8W5S=&]M97)S('=I=&AI;B!A(')E='5R;B!P
M97)I;V0@;V8@<VEX(&UO;G1H<R!P<FEO<B!T;R!A;F0@=7`@=&\@='=E;'9E
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M;@T*;V8@=&AE(')I9VAT(&]F(')E='5R;BX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/E=E(&UA:6YT86EN('9A<FEO=7,@<F5B871E('!R;V=R86US(&EN(&%N(&5F
M9F]R=`T*=&\@;6%I;G1A:6X\:3X@/"]I/F$@8V]M<&5T:71I=F4@<&]S:71I
M;VX@:6X@=&AE(&UA<FME='!L86-E(&%N9"!T;R!P<F]M;W1E('-A;&5S(&%N
M9"!C=7-T;VUE<B!L;WEA;'1Y+B!4:&4@8V]N<W5M97(@<F5B871E('!R;V=R
M86T-"FES(&1E<VEG;F5D('1O(&5N86)L92!T:&4@96YD('5S97(@=&\@<F5T
M=7)N(&$@8V]U<&]N('1O('5S+B!)9B!T:&4@8V]U<&]N('%U86QI9FEE<RP@
M=V4@<V5N9"!A(')E8F%T92!C:&5C:R!T;R!T:&4@96YD('5S97(N(%=E#0IE
M<W1I;6%T92!T:&4@86QL;W=A;F-E(&9O<B!C;VYS=6UE<B!R96)A=&5S(&)A
M<V5D(&]N(&]U<B!E>'!E<FEE;F-E(&%N9"!I;F1U<W1R>2!A=F5R86=E<RP@
M=VAI8V@@:7,@<F5V:65W960L(&%N9"!A9&IU<W1E9"!I9B!N96-E<W-A<GDL
M#0IO;B!A('%U87)T97)L>2!B87-I<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI
M/CQU/E-E9VUE;G0@4F5P;W)T:6YG)B,Q-C`[/"]U/CPO:3X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^)B,Q
M-C`[/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
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M=&\@=&AE(%!R97-I9&5N="!O9B`@;W5R($-O;7!A;GDN(%=E(&1O(&YO="!O
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M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M=3Y3:&EP<&EN9R!A;F0@2&%N9&QI;F<@0V]S=',\+W4^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY792!E>'!E;G-E(&%L;"!S:&EP<&EN9R!A;F0@:&%N9&QI;F<@
M8V]S=',-"F%S(&EN8W5R<F5D+B!792!I;F-L=61E('1H97-E(&-O<W1S(&EN
M(&-O<W0@;V8@<V%L97,@;VX@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T
M960@9FEN86YC:6%L('-T871E;65N=',N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^/'4^061V
M97)T:7-I;F<-"D-O<W1S/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G
M;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/B8C,38P.R8C,38P.SPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^5V4@97AP96YS92!A9'9E<G1I<VEN9R!C;W-T<R!W:&5N(&EN8W5R<F5D
M+@T*061V97)T:7-I;F<@8V]S=',@=V5R92`D-CDX+#@W,2P@)#$Q+#<S.2!A
M;F0@)#8U+#DT-"!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$T+"`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DN/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P
M.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\=3Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS
M97,\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY297-E87)C:"!A;F0@9&5V96QO
M<&UE;G0L(&]R(%(F(S,X.T0L(&5X<&5N<V5S#0II;F-L=61E(&EN=&5R;F%L
M(%(F(S,X.T0@86-T:79I=&EE<RP@<V5R=FEC97,@;V8@97AT97)N86P@8V]N
M=')A8W0@<F5S96%R8V@@;W)G86YI>F%T:6]N<RP@;W(@0U)/<RP@8V]S=',@
M;V8@=&AE:7(@8VQI;FEC86P@<F5S96%R8V@-"G-I=&5S+"!A;F0@;W1H97(@
M86-T:79I=&EE<RX@26YT97)N86P@4B8C,S@[1"!A8W1I=FET>2!E>'!E;G-E
M<R!I;F-L=61E(&QA8F]R871O<GD@<W5P<&QI97,L('-A;&%R:65S+"!B96YE
M9FET<RP@86YD(&YO;BUC87-H('-H87)E+6)A<V5D#0IC;VUP96YS871I;VX@
M97AP96YS97,N($%D=F%N8V4@<&%Y;65N=',@=&\@8F4@97AP96YS960@:6X@
M9G5T=7)E(%(F(S,X.T0@86-T:79I=&EE<R!W97)E("0Q+#$W-2PP.#(@86YD
M("0R+#8P-BPT,#4@9F]R('1H92!Y96%R<PT*96YD960@1&5C96UB97(@,S$L
M(#(P,30@86YD(#(P,3,L(')E<W!E8W1I=F5L>2X@0U)/(&%C=&EV:71Y(&5X
M<&5N<V5S(&EN8VQU9&4@<')E8VQI;FEC86P@;&%B;W)A=&]R>2!E>'!E<FEM
M96YT<R!A;F0@8VQI;FEC86P@=')I86P-"G-T=61I97,N($]T:&5R(&%C=&EV
M:71Y(&5X<&5N<V5S(&EN8VQU9&4@<F5G=6QA=&]R>2!C;VYS=6QT:6YG(&%N
M9"!L96=A;"!C;W5N<V5L+B!4:&4@86-T:79I=&EE<R!U;F1E<G1A:V5N(&)Y
M(&]U<B!R96=U;&%T;W)Y(&-O;G-U;'1A;G1S#0IT:&%T('=E<F4@8VQA<W-I
M9FEE9"!A<R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,@:6YC
M;'5D92!A<W-I<W1I;F<L(&-O;G-U;'1I;F<@=VET:"P@86YD(&%D=FES:6YG
M(&]U<B!I;BUH;W5S92!S=&%F9B!W:71H#0IR97-P96-T('1O('9A<FEO=7,@
M1D1!('-U8FUI<W-I;VX@<')O8V5S<V5S+"!C;&EN:6-A;"!T<FEA;"!P<F]C
M97-S97,L(&%N9"!S8VEE;G1I9FEC('=R:71I;F<@;6%T=&5R<RP@:6YC;'5D
M:6YG('!R97!A<FEN9R!P<F]T;V-O;',-"F%N9"!&1$$@<W5B;6ES<VEO;G,N
M($QE9V%L(&%C=&EV:71I97,@=&AA="!W97)E(&-L87-S:69I960@87,@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S(')E;&%T960@=&\@9&5S
M:6=N:6YG(&5X<&5R:6UE;G1S#0IT;R!G96YE<F%T92!D871A(&9O<B!P871E
M;G1S(&%N9"!T;R!F=7)T:&5R('1H92!F;W)M=6QA=&EO;B!D979E;&]P;65N
M="!P<F]C97-S(&9O<B!O=7(@<&EP96QI;F4@=&5C:&YO;&]G:65S+B!/=71S
M:61E(&QE9V%L(&-O=6YS96P-"F%L<V\@<')O=FED960@<')O9F5S<VEO;F%L
M(')E<V5A<F-H(')E9V%R9&EN9R!T:&4@;&5G86P@;&%N9'-C87!E(&]F('!O
M=&5N=&EA;"!P871E;G1S+B!4:&5S92!C;VYS=6QT:6YG(&%N9"!L96=A;"!E
M>'!E;G-E<R!W97)E#0ID:7)E8W0@8V]S=',@87-S;V-I871E9"!W:71H('!R
M97!A<FEN9RP@<F5V:65W:6YG+"!A;F0@=6YD97)T86MI;F<@=V]R:R!F;W(@
M;W5R(&-L:6YI8V%L('1R:6%L<R!A;F0@:6YV97-T:6=A=&EV92!D<G5G<RX@
M5V4@8VAA<F=E#0II;G1E<FYA;"!2)B,S.#M$(&%C=&EV:71I97,@86YD(&]T
M:&5R(&%C=&EV:71Y(&5X<&5N<V5S('1O(&]P97)A=&EO;G,@87,@:6YC=7)R
M960N(%=E(&UA:V4@<&%Y;65N=',@=&\@0U)/<R!B87-E9"!O;B!A9W)E960M
M=7!O;@T*=&5R;7,L('=H:6-H(&UA>2!I;F-L=61E('!A>6UE;G1S(&EN(&%D
M=F%N8V4@;V8@82!S='5D>2!S=&%R=&EN9R!D871E+B!792!E>'!E;G-E(&YO
M;G)E9G5N9&%B;&4@861V86YC92!P87EM96YT<R!F;W(@9V]O9',@86YD#0IS
M97)V:6-E<R!T:&%T('=I;&P@8F4@=7-E9"!I;B!F=71U<F4@4B8C,S@[1"!A
M8W1I=FET:65S('=H96X@=&AE(&%C=&EV:71Y(&AA<R!B965N('!E<F9O<FUE
M9"!O<B!W:&5N('1H92!G;V]D<R!H879E(&)E96X@<F5C96EV960-"G)A=&AE
M<B!T:&%N('=H96X@=&AE('!A>6UE;G0@:7,@;6%D92X@5V4@<F5V:65W(&%N
M9"!A8V-R=64@0U)/(&5X<&5N<V5S(&%N9"!C;&EN:6-A;"!T<FEA;"!S='5D
M>2!E>'!E;G-E<R!B87-E9"!O;B!S97)V:6-E<R!P97)F;W)M960-"F%N9"!R
M96QY(&]N(&5S=&EM871E<R!O9B!T:&]S92!C;W-T<R!A<'!L:6-A8FQE('1O
M('1H92!C;VUP;&5T:6]N('-T86=E(&]F(&$@<W1U9'D@87,@<')O=FED960@
M8GD@0U)/<RX@06-C<G5E9"!#4D\@8V]S=',@87)E('-U8FIE8W0-"G1O(')E
M=FES:6]N<R!A<R!S=6-H('-T=61I97,@<')O9W)E<W,@=&\@8V]M<&QE=&EO
M;BX@5V4@8VAA<F=E(')E=FES:6]N<R!E>'!E;G-E(&EN('1H92!P97)I;V0@
M:6X@=VAI8V@@=&AE(&9A8W1S('1H870@9VEV92!R:7-E#0IT;R!T:&4@<F5V
M:7-I;VX@8F5C;VUE(&MN;W=N+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^16%R;FEN9W,@
M4&5R(%-H87)E)B,Q-C`[/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5V4@8V%L8W5L871E
M(&5A<FYI;F=S('!E<B!S:&%R92P@;W(@15!3+`T*:6X@86-C;W)D86YC92!W
M:71H($%30R`R-C`L(#QI/D5A<FYI;F=S(%!E<B!3:&%R93PO:3XL('=H:6-H
M(')E<75I<F5S('1H92!C;VUP=71A=&EO;B!A;F0@9&ES8VQO<W5R92!O9B!T
M=V\@15!3(&%M;W5N=',Z#0IB87-I8R!A;F0@9&EL=71E9"X@5V4@8V]M<'5T
M92!B87-I8R!%4%,@8F%S960@;VX@=&AE('=E:6=H=&5D+6%V97)A9V4@;G5M
M8F5R(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL('!A<B!V86QU92`D,"XP
M,#$@<&5R#0IS:&%R92P@;W(@0V]M;6]N(%-T;V-K+"!O=71S=&%N9&EN9R!D
M=7)I;F<@=&AE('!E<FEO9"X@5V4@8V]M<'5T92!D:6QU=&5D($504R!B87-E
M9"!O;B!T:&4@=V5I9VAT960M879E<F%G92!N=6UB97(@;V8@<VAA<F5S#0IO
M9B!O=7(@0V]M;6]N(%-T;V-K(&]U='-T86YD:6YG('!L=7,@86QL('!O=&5N
M=&EA;&QY(&1I;'5T:79E('-H87)E<R!O9B!O=7(@0V]M;6]N(%-T;V-K(&]U
M='-T86YD:6YG(&1U<FEN9R!T:&4@<&5R:6]D+B!3=6-H#0IP;W1E;G1I86QL
M>2!D:6QU=&EV92!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!C;VYS:7-T
M(&]F(&]P=&EO;G,@86YD('=A<G)A;G1S(&%N9"!W97)E(&5X8VQU9&5D(&9R
M;VT@=&AE(&-A;&-U;&%T:6]N(&]F#0ID:6QU=&5D(&5A<FYI;F=S('!E<B!S
M:&%R92!B96-A=7-E('1H96ER(&5F9F5C="!W;W5L9"!H879E(&)E96X@86YT
M:2UD:6QU=&EV92!D=64@=&\@=&AE(&YE="!L;W-S(')E<&]R=&5D(&)Y('5S
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
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M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@
M=VED=&@Z(#@P)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#$Q('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%S
M(&]F($1E8V5M8F5R(#,Q+#PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXR,#$S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S
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M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`U,B4[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-T;V-K(&]P=&EO
M;G,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-"4[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C$V+#<Y,BPT-#,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#0E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,3`E.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ-2PV,S(L-S0R/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T)3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,3,L-S,S+#0X.#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A;G1S
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXQ,RPY,C<L.3$V/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C$T+#(Y,RPT.3D\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M,3DS+#0Y.3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,S`L-S(P+#,U.3PO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
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M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,C4L.3(V+#DX-SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y5
M<V4@;V8@17-T:6UA=&5S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
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M8V$L(&]R($=!05`N(%1H92!P<F5P87)A=&EO;@T*;V8@=&AE<V4@9FEN86YC
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M:6UE<R!I;B!M871E<FEA;`T*86UO=6YT<RP@9G)O;2!T:&5S92!E<W1I;6%T
M97,@=6YD97(@9&EF9F5R96YT(&%S<W5M<'1I;VYS(&]R(&-O;F1I=&EO;G,N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/'4^4F5C96YT;'D@27-S=65D($%C8V]U;G1I
M;F<@4')O;F]U;F-E;65N=',\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL
M93TS1"=C;VQO<CH@(S(U,C4R-2<^26X@075G=7-T#0HR,#$T+"!T:&4@1D%3
M0B!I<W-U960@06-C;W5N=&EN9R!3=&%N9&%R9',@57!D871E+"!O<B!!4U4L
M($YO+B`R,#$T+3`U+"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E
M;65N=',M1V]I;F<@0V]N8V5R;@T**%-U8G1O<&EC(#(P-2TT,"DZ($1I<V-L
M;W-U<F4@;V8@56YC97)T86EN=&EE<R!A8F]U="!A;B!%;G1I='DF(S$T-CMS
M($%B:6QI='D@=&\@0V]N=&EN=64@87,@82!';VEN9R!#;VYC97)N+B!!4U4@
M,C`Q-"TQ-0T*<F5Q=6ER97,@;6%N86=E;65N="!T;R!E=F%L=6%T92!W:&5T
M:&5R('1H97)E(&%R92!C;VYD:71I;VYS(&%N9"!E=F5N=',@=&AA="!R86ES
M92!S=6)S=&%N=&EA;"!D;W5B="!A8F]U="`\+V9O;G0^=&AE#0IE;G1I='DF
M(S$T-CMS(&%B:6QI='D@=&\@8V]N=&EN=64@87,@82!G;VEN9R!C;VYC97)N
M('=I=&AI;B!O;F4@>65A<B!A9G1E<B!T:&4@9FEN86YC:6%L('-T871E;65N
M=',@87)E(&ES<W5E9"`H;W(@879A:6QA8FQE#0IT;R!B92!I<W-U960@=VAE
M;B!A<'!L:6-A8FQE*2!A;F0L(&EF('-O+"!D:7-C;&]S92!T:&%T(&9A8W0N
M($%352`R,#$T+3$U(&ES(&5F9F5C=&EV92!F;W(@86YN=6%L('!E<FEO9',@
M96YD:6YG#0IA9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-B!A;F0@:6YT97)I;2!P
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M;W!T:6]N(&]F('1H92!!4U4@,C`Q-"TQ-2!T;R!H879E(&$@;6%T97)I86P@
M969F96-T(&]N(&]U<B!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N
M=',@86YD#0ID:7-C;&]S=7)E<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@
M36%Y(#(P,30L('1H92!&05-"(&%N9"!T:&4@26YT97)N871I;VYA;`T*06-C
M;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@*$E!4T(I(&ES<W5E9"!!4U4L($YO
M+B`R,#$T+3`Y+"!2979E;G5E(&9R;VT@0V]N=')A8W1S('=I=&@@0W5S=&]M
M97)S("A4;W!I8R`V,#8I+B!4:&4@<W1A;F1A<F0F(S$T-CMS#0IC;W)E('!R
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M;W(@<V5R=FEC97,N($EN(&1O:6YG('-O+`T*8V]M<&%N:65S('=I;&P@;F5E
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M52`R,#$T+3`Y(&ES(&5F9F5C=&EV92!F;W(@<'5B;&EC(&)U<VEN97-S(&5N
M=&ET:65S+"!C97)T86EN#0IN;W0M9F]R+7!R;V9I="!E;G1I=&EE<R!A;F0@
M8V5R=&%I;B!E;7!L;WEE92!B96YE9FET('!L86YS+"!F;W(@86YN=6%L('!E
M<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$V+"!I;F-L
M=61I;F<@:6YT97)I;0T*<&5R:6]D<R!W:71H:6X@=&AA="!P97)I;V0N($5A
M<FQY(&%D;W!T:6]N(&ES(&YO="!P97)M:71T960@=6YD97(@1T%!4"X@5V4@
M87)E(&-U<G)E;G1L>2!E=F%L=6%T:6YG('1H92!I;7!A8W0@;V8@05-5(#(P
M,30M,#D@;VX-"F]U<B!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N
M=',@86YD(&1I<V-L;W-U<F5S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@2G5L
M>2`R,#$S+"!T:&4@1D%30B!I<W-U960@05-5(#(P,3,M,3$L#0I);F-O;64@
M5&%X97,@*%1O<&EC(#<T,"DZ(%!R97-E;G1A=&EO;B!O9B!A;B!5;G)E8V]G
M;FEZ960@5&%X($)E;F5F:70@=VAE;B!A($YE="!/<&5R871I;F<@3&]S<R!#
M87)R>69O<G=A<F0L(&$@4VEM:6QA<B!487@@3&]S<RP-"F]R(&$@5&%X($-R
M961I="!#87)R>69O<G=A<F0@17AI<W1S("AA(&-O;G-E;G-U<R!O9B!T:&4@
M1D%30B!%;65R9VEN9R!)<W-U97,@5&%S:R!&;W)C92DL(&]R($%352`R,#$S
M+3$Q+B!4:&4@86UE;F1M96YT<R!I;B!!4U4-"C(P,3,M,3$@<')O=FED92!G
M=6ED86YC92!O;B!T:&4@9FEN86YC:6%L('-T871E;65N="!P<F5S96YT871I
M;VX@;V8@86X@=6YR96-O9VYI>F5D('1A>"!B96YE9FET('=H96X@82!N970@
M;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D+`T*82!S:6UI;&%R('1A>"!L
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M($YO+B`R,#$S+3$Q(&1O(&YO="!R97%U:7)E(&YE=R!R96-U<G)I;F<@9&ES
M8VQO<W5R97,N(%1H92!A;65N9&UE;G1S(&EN($%352`R,#$S+3$Q(&%R92!E
M9F9E8W1I=F4@9F]R(&9I<V-A;`T*>65A<G,L(&%N9"!I;G1E<FEM('!E<FEO
M9',@=VET:&EN('1H;W-E('EE87)S+"!B96=I;FYI;F<@869T97(@1&5C96UB
M97(@,34L(#(P,3,N(%1H92!A;65N9&UE;G1S(&EN($%352!.;RX@,C`Q,RTQ
M,2!D:60@;F]T(&AA=F4-"F$@;6%T97)I86P@:6UP86-T(&]N(&]U<B!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY)
M;B!$96-E;6)E<B`R,#$Q+"!T:&4@1D%30B!I<W-U960@05-5($YO+B`R,#$Q
M+3$Q+`T*0F%L86YC92!3:&5E="`H5&]P:6,@,C$P*3H@1&ES8VQO<W5R97,@
M86)O=70@3V9F<V5T=&EN9R!!<W-E=',@86YD($QI86)I;&ET:65S+"!O<B!!
M4U4@,C`Q,2TQ,2X@05-5(#(P,3$M,3$@96YH86YC97,@8W5R<F5N="!D:7-C
M;&]S=7)E<PT*86)O=70@9FEN86YC:6%L(&EN<W1R=6UE;G1S(&%N9"!D97)I
M=F%T:79E(&EN<W1R=6UE;G1S('1H870@87)E(&5I=&AE<B!O9F9S970@;VX@
M=&AE('-T871E;65N="!O9B!F:6YA;F-I86P@<&]S:71I;VX@;W(@<W5B:F5C
M=`T*=&\@86X@96YF;W)C96%B;&4@;6%S=&5R(&YE='1I;F<@87)R86YG96UE
M;G0@;W(@<VEM:6QA<B!A9W)E96UE;G0L(&ER<F5S<&5C=&EV92!O9B!W:&5T
M:&5R('1H97D@87)E(&]F9G-E="!O;B!T:&4@<W1A=&5M96YT(&]F#0IF:6YA
M;F-I86P@<&]S:71I;VXN($5N=&ET:65S(&%R92!R97%U:7)E9"!T;R!P<F]V
M:61E(&)O=&@@;F5T(&%N9"!G<F]S<R!I;F9O<FUA=&EO;B!F;W(@=&AE<V4@
M87-S971S(&%N9"!L:6%B:6QI=&EE<R!I;B!O<F1E<B!T;PT*9F%C:6QI=&%T
M92!C;VUP87)A8FEL:71Y(&)E='=E96X@9FEN86YC:6%L('-T871E;65N=',@
M<')E<&%R960@:6X@8V]N9F]R;6ET>2!W:71H($=!05`@86YD(&9I;F%N8VEA
M;"!S=&%T96UE;G1S('!R97!A<F5D(&]N('1H90T*8F%S:7,@;V8@26YT97)N
M871I;VYA;"!&:6YA;F-I86P@4F5P;W)T:6YG(%-T86YD87)D<RX@05-5(#(P
M,3$M,3$@:7,@969F96-T:79E(&9O<B!A;FYU86P@<F5P;W)T:6YG('!E<FEO
M9',@8F5G:6YN:6YG(&]N(&]R(&%F=&5R#0I*86YU87)Y(#$L(#(P,3,L(&%N
M9"!I;G1E<FEM('!E<FEO9',@=VET:&EN('1H;W-E('EE87)S+B!!4U4@,C`Q
M,2TQ,2!D:60@;F]T(&AA=F4@82!M871E<FEA;"!I;7!A8W0@;VX@;W5R(&9I
M;F%N8VEA;"!P;W-I=&EO;B!O<@T*<F5S=6QT<R!O9B!O<&5R871I;VYS+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
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M8W5R<F5N="!P97)I;V0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y296-L87-S
M:69I8V%T:6]N<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D-E<G1A:6X@,C`Q
M,R!A;F0@,C`Q,B!A;6]U;G1S(&AA=F4@8F5E;B!R96-L87-S:69I960-"G1O
M(&-O;F9O<FT@=&\@8W5R<F5N="!Y96%R('!R97-E;G1A=&EO;BXF(S$V,#L\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D
M,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?
M-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970P.2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.5D5.5$]263QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G9E
M;G1O<GD@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.5D5.5$]263PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CX\
M=3Y.3U1%(#,@)B,Q-3`[($E.5D5.5$]2628C,38P.SPO=3X\+V(^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SY);G9E;G1O<GD@8V]N<VES=',@;V8@=&AE(&9O;&QO=VEN
M9SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W
M:61T:#H@.3`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-R!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E
M;6)E<B`S,2P\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C`Q-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C`Q,SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR
M-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C@E.R!T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6QE9G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&:6YI<VAE9"!P<F]D=6-T/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#0E.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.#<T
M+#(Y-#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-"4[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L
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M(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUL969T.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^4F%W(&UA=&5R:6%L/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
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M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXR-3`L.30S/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M<F=B*#(P-"PR,S@L,C4U*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUL969T.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5F97)R960@8V]S=',\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C$U,BPT-S@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3<P
M+#DY-CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H
M:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6QE9G0Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^5$]404P@24Y614Y43U)9/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
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M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXD/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#`T
M,RPV,3@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S
M9F-?.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O
M<FMS:&5E=',O4VAE970Q,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D]42$52($-54E)%3E0@05-31513/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D
M($-O<W1S+"!#87!I=&%L:7IE9"P@4')E<&%I9"P@86YD($]T:&5R($%S<V5T
M<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3U1(15(@0U524D5.5"!!4U-%5%,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/&(^/'4^3D]412`T("8C,34P.R!/5$A%4B!#55)214Y4($%34T544SPO
M=3X\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/
M=&AE<B!C=7)R96YT(&%S<V5T<R!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F<Z
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#DP)3L@9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#<@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^1&5C96UB97(@,S$L/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,30\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
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M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#8X)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T
M.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^4')E<&%I9"!C;VYS=6QT:6YG/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#0E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^-#$Q+#@V-#PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@-"4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,S`L-3DV
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`P<'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M4')E<&%I9"!I;G-U<F%N8V4\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,SDT+#@W.#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
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M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR
M-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6QE9G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY0<F5P86ED(')E<V5A<F-H(&%N9"!D979E;&]P;65N
M="!C;W-T<SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]T:&5R
M(')E8V5I=F%B;&5S+7)E;&%T960@<&%R='D@*$YO=&4@,3(I/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
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M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
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M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`P<'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3W1H97(@<')E<&%I
M9"!C;W-T<SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ.#$L,3@V/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C,L
M.#`V/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E9F5R<F5D
M(&9I;F%N8VEN9R!C;W-T<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
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M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E
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M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M5$]404P@3U1(15(@0U524D5.5"!!4U-%5%,\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L-3,W
M+#0P-SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L-#<W+#<Q
M-3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.R8C,38P.SPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?
M-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O
M5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^1DE8140@05-31513/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N
M="!A;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1DE8140@05-31513/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQB
M/CQU/DY/5$4@-2`F(S$U,#L@1DE8140@05-31513/"]U/CPO8CX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^)B,Q-C`[)B,Q-C`[/"]B/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY&
M:7AE9"!A<W-E=',@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG.CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#LF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[('=I9'1H.B`Y,"4[(&9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0W('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D1E8V5M8F5R(#,Q+#PO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
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M4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`V."4[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5Q
M=6EP;65N=#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T)3L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C$S,BPQ-3`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#0E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$P
M)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,3`X+#0U.#PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9U<FYI='5R92!A;F0@9FEX
M='5R97,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C4S+#@Y-3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
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M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,34U+#`X,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z
M(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY!8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
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M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T
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M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@
M,3!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY43U1!3"!&25A%1"!!4U-%5%,\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8S+#(Y,SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8Q+#,Q.#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY$97!R96-I871I;VX@97AP96YS92!F;W(@=&AE('EE87)S(&5N9&5D($1E
M8V5M8F5R#0HS,2P@,C`Q-"P@,C`Q,RP@86YD(#(P,3(@=V%S("0R."PY.#<L
M("0T-RPX.#,L(&%N9"`D,C<L-#@T+"!R97-P96-T:79E;'DN($EN($1E8V5M
M8F5R(#(P,3,L(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!W87,@<F5D=6-E
M9`T*8GD@)#$Q+#DX,"!A<W-O8VEA=&5D('=I=&@@;&5A<V5H;VQD(&EM<')O
M=F5M96YT<R!O9B!O=7(@<')E=FEO=7-L>2!L96%S960@;V9F:6-E('!R;W!E
M<G1Y+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?
M.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4%)%4$%)1"!%6%!%
M3E-%/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!R97!A:60@17AP96YS92!A;F0@3W1H97(@07-S971S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4%)%4$%)1"!%6%!%3E-%/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/CQB/CQU/DY/5$4@-B`F(S$U,#M04D5004E$($584$5.4T4F(S$V,#L\+W4^
M/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^4')E<&%I9"!E>'!E;G-E(&-O;G-I<W1S(&]F
M('1H92!F;VQL;W=I;F<Z)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE
M(&%L:6=N/3-$8V5N=&5R(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z
M(#DP)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#<@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C
M96UB97(@,S$L/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C(P,30\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
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M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#<P
M)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED(&UA;G5F86-T=7)I;F<@8V]S
M=',\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,R4[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXX.3DL,#`P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C@Y.2PP,#`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H
M:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E!R97!A
M:60@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C0V,RPW,C`\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXX,C0L,C(Q/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR,S@L,C4U*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY!8V-R971E9"!P<F5P86ED(&-O<W1S/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXV-"PU-#,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,C<L,C,T/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY43U1!3"!04D5004E$
M($584$5.4T4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L-#(W+#(V,SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C$L-S4P+#0U-3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO
M='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?
M-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,3,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E1!3D=)
M0DQ%($%34T544SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY';V]D=VEL;"!A;F0@26YT86YG:6)L92!!<W-E=',@
M1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DE.5$%.1TE"3$4@05-31513/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQB
M/CQU/DY/5$4@-R`F(S$U,#L@24Y404Y'24),12!!4U-%5%,\+W4^/"]B/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=L971T
M97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET92<^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O
M<G1H#0IT:&4@9W)O<W,@8V%R<GEI;F<@86UO=6YT(&%N9"!A8V-U;75L871E
M9"!A;6]R=&EZ871I;VX@;V8@;W5R(&EN=&%N9VEB;&4@87-S971S(&%S(&]F
M($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,SH\+V9O
M;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SXF(S$V,#L\+V9O;G0^)B,Q-C`[
M/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@
M,3`P)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#$U('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M8F5R
M(#,Q+"`R,#$T/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T
M('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/D=R;W-S($-A<G)Y:6YG($%M;W5N=#PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^06-C=6UU;&%T960@06UO<G1I>F%T
M:6]N/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.
M970@)B,Q-C`[(#QB<B`O/D%M;W5N=#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^5V5I9VAT960M($%V97)A9V4@)B,Q-C`[(#QB
M<B`O/E)E;6%I;FEN9R!!;6]R=&EZ871I;VX@4&5R:6]D("AY<G,N*3PO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%M;W)T:7II;F<@
M:6YT86YG:6)L92!A<W-E=',Z/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`U,B4[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M;&5F=#H@,3!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/4$5203QS=7`^)B,Q-S0[/"]S=7`^
M('-O9G1W87)E('!A=&5N=#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,Q+#DU,3PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@R+#0Y-CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
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M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@
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M(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUL969T.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E=F5L;W!M
M96YT(&-O<W1S(&]F(&-O<G!O<F%T92!W96)S:71E/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CDQ+#<T
M,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
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M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[)B,Q-C`[)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^;B]A/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3`[('!A9&1I;F<M;&5F
M=#H@,C!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY!<'!R;W9E9"!H;W)M;VYE('1H97)A<'D@9')U9R8C,38P.V-A
M;F1I9&%T92!P871E;G1S/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
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M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXH,3DL-#`Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXI/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ.#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3$P.R!P861D:6YG+6QE9G0Z(#$P
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/DYO;BUA;6]R=&EZ:6YG(&EN=&%N9VEB;&4@87-S971S.CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL
M969T.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DAO<FUO;F4@=&AE<F%P>2!D
M<G5G(&-A;F1I9&%T92!P871E;G1S("AP96YD:6YG*3PO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-C<U+#DX,CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
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M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
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M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C$P,RPS-C@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C$P,RPS-C@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
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M=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[('!A9&1I;F<M;&5F=#H@,C!P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4;W1A;#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*#$Q,RPV-#`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
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M;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*
M#0H-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\+W`^#0H-"@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/CPO
M9F]N=#X\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I
M9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,34@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C
M96UB97(@,S$L(#(P,3,\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^1W)O<W,@0V%R<GEI;F<@06UO=6YT/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
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M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/DYE="`F(S$V,#L@/&)R("\^06UO=6YT/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG:'1E9"T@079E<F%G92!296UA
M:6YI;F<@06UO<G1I>F%T:6]N(%!E<FEO9"`H>7)S+BD\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!;6]R=&EZ:6YG(&EN=&%N9VEB
M;&4@87-S971S.CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@-3(E.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P
M<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^3U!%4D$\<W5P/B8C,3<T.SPO<W5P/B!S;V9T=V%R
M92!P871E;G0\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA
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M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
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M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,Q+#0U,CPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,34N.#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`M,3`[('!A9&1I;F<M;&5F=#H@,C!P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$979E;&]P;65N="!C;W-T<R!O
M9B8C,38P.V-O<G!O<F%T92!W96)S:71E/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CDQ+#<T
M,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
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M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
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M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
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M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,#L@<&%D9&EN9RUL
M969T.B`Q,#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY.;VXM86UO<G1I>FEN9R!I;G1A;F=I8FQE(&%S<V5T<SH\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M<F=B*#(P-"PR,S@L,C4U*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,#L@<&%D9&EN9RUL969T.B`R,'!T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/DAO<FUO;F4@=&AE<F%P>2!D<G5G(&-A;F1I9&%T92!P871E;G1S("AP96YD
M:6YG*3PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
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M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[
M)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^-3<R+#<R-CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
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M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@=&5X="UI;F1E;G0Z("TQ,#L@<&%D9&EN9RUL969T.B`R
M,'!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/DUU;'1I<&QE('1R861E;6%R:W,@9F]R('9I=&%M:6YS+W-U<'!L96UE
M;G1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C4Y+#,R.#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z(#(P<'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T
M86P\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C<U-2PW-#@\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXH.3`L,38P/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C8V-2PU.#@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
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M=&4G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4G/E=E(&%M;W)T:7IE9`T*=&AE(&EN=&%N9VEB;&4@
M87-S970@<F5L871E9"!T;R!D979E;&]P;65N="!C;W-T<R!F;W(@8V]R<&]R
M871E('=E8G-I=&4@;W9E<B`S-B!M;VYT:',L('=H:6-H(&ES('1H92!P<F5S
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M97-T:6UA=&5D('5S969U;"!L:69E(&]F(&%P<')O>&EM871E;'D@,C`@>65A
M<G,N($1U<FEN9R!T:&4-"GEE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T
M(&%N9"`R,#$S+"!T:&5R92!W87,@;F\@:6UP86ER;65N="!R96-O9VYI>F5D
M+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4G/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#!I
M;B<^/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/DEN
M#0IA9&1I=&EO;B!T;R!N=6UE<F]U<R!P96YD:6YG('!A=&5N="!A<'!L:6-A
M=&EO;G,L(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!W92!H860@-"!I<W-U
M960@<&%T96YT<RP@:6YC;'5D:6YG.B`\+V9O;G0^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P:6XG/CQF;VYT('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN+71O
M<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#4E.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`S)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
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M:6]N(&1A=&4@:6X@,C`R.3L@86YD/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-S5I;CL@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TP+C(U:6XG/CQF;VYT('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S
M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN+71O<#H@,#L@;6%R9VEN+6)O='1O
M;3H@,"<^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#4E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,30Y.SPO<#X-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#H@,#L@;6%R9VEN+6)O='1O;3H@,#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W`^/"]T9#X\=&0@<W1Y
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M9F]N=#X\+W1D/CPO='(^/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`P+C<U:6X[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`M,"XR-6EN)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,&EN)SX\9F]N
M="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^4W5B<V5Q=65N
M=`T*=&\@1&5C96UB97(@,S$L(#(P,30L(#$@861D:71I;VYA;"!P871E;G0@
M=V%S(&ES<W5E9"!R96QA=&5D('1O(&]U<B!C;VUB:6YA=&EO;B!P<F]G97-T
M97)O;F4@86YD(&5S=')A9&EO;"!F;W)M=6QA=&EO;G,N/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,&EN)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET92<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^06UO<G1I>F%T:6]N#0IE>'!E;G-E
M('=A<R`D,C,L-#@P+"`D,3`L,C8R(&%N9"`D,C@L-S<V(&9O<B!T:&4@>65A
M<G,@96YD960@1&5C96UB97(@,S$L(#(P,30L(#(P,3,L(&%N9"`R,#$R+"!R
M97-P96-T:79E;'DN/"]F;VYT/B!!<R!O9B!$96-E;6)E<@T*,S$L(#(P,30L
M('1H92!E<W1I;6%T960@86UO<G1I>F%T:6]N(&5X<&5N<V4@9F]R('1H92!N
M97AT(&9I=F4@>65A<G,@:7,@87,@9F]L;&]W<SH\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*
M#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R!W:61T:#H@.#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY996%R
M($5N9&EN9R!$96-E;6)E<B`S,2P\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S
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M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@8V]L
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M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
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M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D(&-O
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M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
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M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXR,#$W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
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M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C`Q.#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
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M,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,C`Q.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
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M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`T-B4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`U)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`T-24[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T
M<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F
M8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,30N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/5$A%4B!#55)2
M14Y4($Q)04))3$E42453/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R($QI86)I;&ET:65S($1I<V-L;W-U
M<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/5$A%4B!#55)214Y4($Q)04))3$E42453/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQB
M/CQU/DY/5$4@."`F(S$U,#L@3U1(15(@0U524D5.5"!,24%"24Q)5$E%4SPO
M=3X\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.R8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY/=&AE<B!C=7)R96YT(&QI
M86)I;&ET:65S(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN9SH\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL
M93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@.3`E.R!F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$-R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^1&5C96UB97(@,S$L
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M)SXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60G/C(P,3,\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U
M*2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`V."4[('1E>'0M86QI9VXZ
M(&QE9G0G/D%C8W)U960@8VQI;FEC86P@=')I86P@8V]S=',\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@-"4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#<P-BPU
M-#(\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=&5X="UA
M;&EG;CH@<FEG:'0G/C8V-2PW.#(\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/D%C8W)U960@<&%Y<F]L;"P@8F]N=7-E<R!A;F0@8V]M;6ES<VEO;B!C
M;W-T<SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXX,30L,C`U/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CDT,2PS,3,\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/D%C8W)U960@=F%C871I;VX@8V]S=',\+W1D
M/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^-#0R+#0S,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXR-38L.3(P/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M06-C<G5E9"!L96=A;"!A;F0@86-C;W5N=&EN9R!E>'!E;G-E/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/C(W-BPT-S`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^,C(T+#4U,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H
M,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^3W1H97(@86-C<G5E9"!E>'!E;G-E<SQS=7`^
M*#$I/"]S=7`^/"]F;VYT/CPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ.#4L.38U/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$W-RPY
M,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SY!;&QO=V%N8V4@9F]R('=H;VQE<V%L92!D
M:7-T<FEB=71O<B!F965S/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$V,"PU,#,\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S`V+#,P
M,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^06-C<G5E9"!R;WEA;'1I
M97,\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^-S(L-S$P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C4R+#$X.#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/D%L;&]W86YC92!F;W(@8V]U<&]N<R!A;F0@<F5T=7)N<SPO=&0^/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXY,"PT-#8\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^,3(V+#(S,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H
M,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^06-C<G5E9"!R96YT/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CDQ+#,V.#PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U
M,3L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SY!8V-R=65D(&9I;F%N8VEN9R!C;W-T<SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B,Q-3$[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SXX-3`L,#`P/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0G/E1/5$%,($]4
M2$52($-54E)%3E0@3$E!0DE,251)15,\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C,L.#0P
M+#8S.3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXS+#8P
M,2PQ.#D\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M7U]?7U]?7U]?7U]?7U]?7U\\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQS=7`^*#$I/"]S=7`^($EN($IU
M;F4@,C`P."P@=V4@9&5C;&%R960@86YD#0IP86ED(&$@<W!E8VEA;"!D:79I
M9&5N9"!O9B`D,"XT,"!P97(@<VAA<F4@;V8@;W5R($-O;6UO;B!3=&]C:R!T
M;R!A;&P@<W1O8VMH;VQD97)S(&]F(')E8V]R9"!A<R!O9B!*=6YE(#$P+"`R
M,#`X+"!O9B!W:&EC:"`D-#$L,S4Y#0IR96UA:6YE9"!U;F-L86EM960@8GD@
M8V5R=&%I;B!S=&]C:VAO;&1E<G,@870@8F]T:"!$96-E;6)E<B`S,2P@,C`Q
M-"!A;F0@,C`Q,RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/&(^)B,Q-C`[/"]B/CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D
M-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T
M.#(O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^3D]415,@4$%904),13QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$96)T($1I<V-L
M;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.3U1%4R!005E!0DQ%/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CQB/CQU/DY/5$4@.2`F(S$U,#L@3D]415,@4$%904),13PO
M=3X\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CQB/B8C,38P.R8C,38P.SPO8CX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^27-S=6%N8V4@
M86YD(%!A>6UE;G0@;V8@375L=&EP;&4@061V86YC90T*4F5V;VQV:6YG($-R
M961I="!.;W1E/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@2F%N=6%R>2`S,2P@,C`Q
M,RP@=V4@96YT97)E9"!I;G1O(&$@8G5S:6YE<W,-"FQO86X@86=R965M96YT
M('=I=&@@4&QA=&\@86YD($%S<V]C:6%T97,L($Q,0RP@;W(@4&QA=&\L(&9O
M<B!A($UU;'1I<&QE($%D=F%N8V4@4F5V;VQV:6YG($-R961I="!.;W1E+"!O
M<B!T:&4@4F5V;VQV:6YG($-R961I=`T*3F]T92X@5&AE(%)E=F]L=FEN9R!#
M<F5D:70@3F]T92!A;&QO=V5D('5S('1O(&1R87<@9&]W;B!F=6YD:6YG('5P
M('1O(&$@)#$P+#`P,"PP,#`@;6%X:6UU;2!P<FEN8VEP86P@86UO=6YT+"!A
M="!A('-T871E9"!I;G1E<F5S=`T*<F%T92!O9B`V)2!P97(@86YN=6TN(%!L
M871O('=A<R!A8FQE('1O(&UA:V4@861V86YC97,@=&\@=7,@9G)O;2!T:6UE
M('1O('1I;64@=6YD97(@=&AE(%)E=F]L=FEN9R!#<F5D:70@3F]T92!A="!O
M=7(@<F5Q=65S="P-"G=H:6-H(&%D=F%N8V5S('=E<F4@;V8@82!R979O;'9I
M;F<@;F%T=7)E(&%N9"!W97)E(&%B;&4@=&\@8F4@;6%D92P@<F5P86ED+"!A
M;F0@;6%D92!F<F]M('1I;64@=&\@=&EM92X@26YT97)E<W0@<&%Y;65N=',@
M=V5R90T*9'5E(&%N9"!P87EA8FQE(&]N('1H92!T96YT:"!D87D@9F]L;&]W
M:6YG('1H92!E;F0@;V8@96%C:"!C86QE;F1A<B!Q=6%R=&5R(&EN('=H:6-H
M(&%N>2!I;G1E<F5S="!W87,@86-C<G5E9"!A;F0@=6YP86ED+"!C;VUM96YC
M:6YG#0IO;B!!<')I;"`Q,"P@,C`Q,RP@86YD('1H92!P<FEN8VEP86P@8F%L
M86YC92!O=71S=&%N9&EN9R!U;F1E<B!T:&4@4F5V;VQV:6YG($-R961I="!.
M;W1E+"!T;V=E=&AE<B!W:71H(&%L;"!A8V-R=65D(&EN=&5R97-T(&%N9`T*
M;W1H97(@86UO=6YT<R!P87EA8FQE('5N9&5R('1H92!2979O;'9I;F<@0W)E
M9&ET($YO=&4L(&EF(&%N>2P@=V%S(&1U92!A;F0@<&%Y86)L92!O;B!&96)R
M=6%R>2`R-"P@,C`Q-"X@5&AE(%)E=F]L=FEN9R!#<F5D:70-"DYO=&4@=V%S
M('-E8W5R960@8GD@<W5B<W1A;G1I86QL>2!A;&P@;V8@;W5R(&%S<V5T<RX@
M3VX@96%C:"!O9B!&96)R=6%R>2`R-2!A;F0@36%R8V@@,3,L(#(P,3,L("0R
M,#`L,#`P('=A<R!D<F%W;B!A9V%I;G-T('1H90T*4F5V;VQV:6YG($-R961I
M="!.;W1E+B!/;B!-87)C:"`R,2P@,C`Q,RP@=V4@<F5P86ED("0T,#$L,#@U
M+"!W:&EC:"!I;F-L=61E9"!A8V-R=65D(&EN=&5R97-T+"!A;F0@=&AE<F4@
M=V%S(&YO(&)A;&%N8V4@;W5T<W1A;F1I;F<-"G5N9&5R('1H92!2979O;'9I
M;F<@0W)E9&ET($YO=&4@87,@;V8@1&5C96UB97(@,S$L(#(P,3,@86YD($9E
M8G)U87)Y(#(T+"`R,#$T('=H96X@:70@97AP:7)E9"X@07,@861D:71I;VYA
M;"!C;VYS:61E<F%T:6]N(&9O<@T*=&AE(%)E=F]L=FEN9R!#<F5D:70@3F]T
M92P@=V4@9W)A;G1E9"!T;R!0;&%T;R!A('=A<G)A;G0@=&\@<'5R8VAA<V4@
M,2PR-3`L,#`P('-H87)E<R!O9B!O=7(@0V]M;6]N(%-T;V-K(&%T(&%N(&5X
M97)C:7-E('!R:6-E#0IO9B`D,RXR,"!P97(@<VAA<F4@*%-E92!.;W1E(#$P
M*2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/'4^0F]R<F]W
M:6YG#0IU;F1E<B!"=7-I;F5S<R!,;V%N($%G<F5E;65N="!A;F0@4')O;6ES
M<V]R>2!.;W1E/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($UA
M<F-H(#(P,3$L(%9I=&%-960@96YT97)E9"!I;G1O(&$@8G5S:6YE<W,-"FQO
M86X@86=R965M96YT('=I=&@@1FER<W0@56YI=&5D($)A;FL@9F]R(&$@)#,P
M,"PP,#`@8F%N:R!L:6YE(&]F(&-R961I="!F;W(@=VAI8V@@<&5R<V]N86P@
M9W5A<F%N=&5E<R!A;F0@8V%S:"!C;VQL871E<F%L('=E<F4-"G)E<75I<F5D
M+B!097)S;VYA;"!G=6%R86YT965S(&%N9"!C87-H(&-O;&QA=&5R86P@;&EM
M:71E9"!T;R`D,3`P+#`P,"!E86-H('=E<F4@<')O=FED960@8GD@4F]B97)T
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M86YD('=A<R!D=64@;VX@36%R8V@@,2P@,C`Q,BX-"E=E(&YE9V]T:6%T960@
M82!O;F4M>65A<B!E>'1E;G-I;VX@=VET:"!&:7)S="!5;FET960@=&\@=&AE
M(&)A;FL@;&EN92!O9B!C<F5D:70L('=H:6-H('=A<R!E>&5C=71E9"!O;B!-
M87)C:"`Q.2P@,C`Q,BX@56YD97(@=&AE#0IE>'1E;G-I;VXL(&)O<G)O=VEN
M9W,@8F]R92!I;G1E<F5S="!A="!A(')A=&4@;V8@,BXS-24@86YD('=E<F4@
M9'5E(&]N($UA<F-H(#$L(#(P,3,N($]N($YO=F5M8F5R(#$S+"`R,#$R+"!T
M:&4@;W5T<W1A;F1I;F<@8F%L86YC90T*;V8@)#(Y.2PR,C`@=V%S(')E<&%I
M9"!I;B!F=6QL+"!A;F0@=V4@86UE;F1E9"!T:&4@;&EN92!O9B!C<F5D:70@
M=&\@<F5F;&5C="!A("0Q,#`L,#`P(&)A;FL@;&EN92!O9B!C<F5D:70N($EN
M(&%C8V]R9&%N8V4@=VET:`T*=&AE(&%M96YD960@;&EN92!O9B!C<F5D:70L
M('1H92!P97)S;VYA;"!G=6%R86YT964@86YD(&-A<V@@8V]L;&%T97)A;"!L
M:6UI=&5D('1O("0Q,#`L,#`P('!R;W9I9&5D(&)Y('1H92!296EC:"!&86UI
M;'D@3&EM:71E9`T*4&%R=&YE<G-H:7`@<F5M86EN960@:6X@<&QA8V4L('=H
M:6QE('1H92!P97)S;VYA;"!G=6%R86YT965S(&%N9"!C87-H(&-O;&QA=&5R
M86P@=V5R92!R96UO=F5D(&9O<B!-<BX@1FEN:7II;R!A;F0@37(N($UI;&QI
M9V%N+@T*26X@1F5B<G5A<GD@,C`Q,RP@=V4@8F]R<F]W960@)#$P,"PP,#`@
M9G)O;2!&:7)S="!5;FET960@0F%N:R!U;F1E<B!T:&4@86UE;F1E9"!B86YK
M(&QI;F4@;V8@8W)E9&ET+B!/;B!!<')I;"`R-2P@,C`Q,RP@=V4@<F4M<&%I
M9`T*)#$P,"PW,S4L('=H:6-H(')E<')E<V5N=&5D('1H92!P<FEN8VEP86P@
M86YD(&EN=&5R97-T('1H870@=V%S(&1U92!U;F1E<B!T:&4@86UE;F1E9"!B
M86YK(&QI;F4@;V8@8W)E9&ET+B!/;B!-87D@,2P@,C`Q,RP@=&AE#0IA;65N
M9&5D(&)A;FL@;&EN92!O9B!C<F5D:70@97AP:7)E9"!A;F0@=V%S(&YO="!R
M96YE=V5D+B!!8V-O<F1I;F=L>2P@=&AE('!E<G-O;F%L(&=U87)A;G1E92!W
M87,@8V%N8V5L960L(&%N9"!T:&4@8V%S:"!C;VQL871E<F%L#0IW87,@<F5F
M=6YD960@=&\@=&AE(%)E:6-H($9A;6EL>2!,:6UI=&5D(%!A<G1N97)S:&EP
M+B!$=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N
M9"`R,#$R+"!W92!P86ED("0W,S4@86YD("0W+#,V-BP-"G)E<W!E8W1I=F5L
M>2P@;V8@:6YT97)E<W0@97AP96YS92P@=VAI8V@@87)E(&EN8VQU9&5D(&EN
M(&EN=&5R97-T(&5X<&5N<V4@;VX@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI
M9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y)
M<W-U86YC92!O9B!*86YU87)Y(&%N9"!&96)R=6%R>2`R,#$R#0I0<F]M:7-S
M;W)Y($YO=&5S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@2F%N=6%R>2!A;F0@1F5B
M<G5A<GD@,C`Q,BP@=V4@:7-S=65D#0HV)2!P<F]M:7-S;W)Y(&YO=&5S(&EN
M('1H92!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B`D.3`P+#`P,"P@
M9'5E($UA<F-H(#$L(#(P,3(L('=H:6-H('=E<F4@<W5B<V5Q=65N=&QY(&EN
M8W)E87-E9"!T;R!A;@T*86=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@;V8@
M)#$L-S`P+#`P,"X@07,@9&ES8W5S<V5D(&)E;&]W(&EN($ES<W5A;F-E(&%N
M9"!3971T;&5M96YT(&]F($9E8G)U87)Y(#(P,3(@3F]T97,L('1H97-E('!R
M;VUI<W-O<GD-"FYO=&5S('=E<F4@;6]D:69I960@;VX@1F5B<G5A<GD@,C0L
M(#(P,3(@=&AR;W5G:"!T:&4@:7-S=6%N8V4@;V8@<V5C=7)E9"!P<F]M:7-S
M;W)Y(&YO=&5S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^27-S=6%N8V4@86YD
M(%-E='1L96UE;G0@;V8@1F5B<G5A<GD@,C`Q,@T*4')O;6ES<V]R>2!.;W1E
M<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/D]N($9E8G)U87)Y(#(T+"`R,#$R+"!W90T*
M:7-S=65D('!R;VUI<W-O<GD@;F]T97,L('1H92!&96)R=6%R>2`R,#$R($YO
M=&5S+"!T;R!A;B!I;F1I=FED=6%L(&%N9"!A;B!E;G1I='DL(&)O=&@@;V8@
M=VAI8V@@=V5R92!S=&]C:VAO;&1E<G,@;V8@;W5R#0IC;VUP86YY+"!I;B!T
M:&4@<')I;F-I<&%L(&%M;W5N="!O9B`D,2PS-3@L,#$T(&%N9"`D,2PS-3<L
M,3$P+"!R97-P96-T:79E;'DL(&%N9"!G<F%N=&5D('=A<G)A;G1S('1O('!U
M<F-H87-E(&%N(&%G9W)E9V%T92!O9@T*.2PP,#`L,#`P('-H87)E<R!O9B!O
M=7(@0V]M;6]N(%-T;V-K('!U<G-U86YT('1O('1H92!T97)M<R!O9B!A($YO
M=&4@4'5R8VAA<V4@06=R965M96YT+"!D871E9"!&96)R=6%R>2`R-"P@,C`Q
M,BX@5V4@<F5C96EV960-"F%N(&%G9W)E9V%T92!O9B`D,2PP,#`L,#`P(&]F
M(&YE=R!F=6YD:6YG('5P;VX@:7-S=6%N8V4@;V8@=&AE($9E8G)U87)Y(#(P
M,3(@3F]T97,@86YD(')E;&%T960@=V%R<F%N=',@86YD('-U<G)E;F1E<B!B
M>0T*=&AE(&AO;&1E<G,@;V8@8V5R=&%I;B!P<F]M:7-S;W)Y(&YO=&5S+"!W
M:&EC:"!W92!P<F5V:6]U<VQY(&ES<W5E9"!I;B!T:&4@86=G<F5G871E(&%M
M;W5N="!O9B`D,2PW,#`L,#`P('!L=7,@=&AE#0IA9V=R96=A=&4@86-C<G5E
M9"!I;G1E<F5S="!O9B`D,34L,3(T("AC;VQL96-T:79E;'DL('1H92`F(S$T
M-SM0<FEO<B!.;W1E<R8C,30X.RDN(%5N9&5R('1H92!&96)R=6%R>2`R,#$R
M($YO=&5S+"!A<PT*86UE;F1E9"P@=V4@8F]R<F]W960@86X@861D:71I;VYA
M;"`D,RPP,#`L,#`P(&1U<FEN9R!-87)C:"P@07!R:6PL(&%N9"!-87D@,C`Q
M,BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E(&=R86YT960@=V%R<F%N=',@=&\@
M<'5R8VAA<V4@86X@86=G<F5G871E#0IO9B`U+#8X-2PS,#`@<VAA<F5S(&]F
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M<&5N<V5D("AS964@5V%R<F%N="!!8W1I=FET>2!D=7)I;F<@,C`Q,B!I;B!.
M3U1%(#$P(&9O<B!M;W)E(&1E=&%I;',I+B!4:&4@9F%I<@T*=F%L=64@;V8@
M=&AE(%!R:6]R($YO=&5S('=A<R!E<W1I;6%T960@8GD@8V%L8W5L871I;F<@
M=&AE('!R97-E;G0@=F%L=64@;V8@=&AE(&9U='5R92!C87-H(&9L;W=S(&1I
M<V-O=6YT960@870@82!M87)K970@<F%T92!O9@T*<F5T=7)N(&9O<B!C;VUP
M87)A8FQE(&1E8G0@:6YS=')U;65N=',@=&\@8F4@)#$L-3$W+#<T,2P@<F5S
M=6QT:6YG(&EN(&$@9&5B="!D:7-C;W5N="!O9B`D,3DW+#,X,R!A;F0@<F5C
M;V=N:7IE9"!A(&QO<W,@;VX@97AT:6YG=6ES:&UE;G0-"F]F(&1E8G0@;V8@
M)#$P+#,P-RPX-C0L('=H:6-H(')E<')E<V5N=&5D('1H92!F86ER('9A;'5E
M(&]F('1H92`U+#8X-2PS,#`@=V%R<F%N=',@;F5T(&]F('1H92!D:69F97)E
M;F-E(&)E='=E96X@=&AE(&-A<G)Y:6YG(&%M;W5N=`T*;V8@=&AE(%!R:6]R
M($YO=&5S(&%N9"!T:&5I<B!F86ER('9A;'5E(&%S(&]F('1H92!D871E(&]F
M('1H92!M;V1I9FEC871I;VX@;VX@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI
M9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!*
M=6YE(#$Y+"`R,#$R+"!W92!S971T;&5D(&%N(&%G9W)E9V%T92!A;6]U;G0-
M"F]F("0S+#$P,BPP,#`@;V8@<')I;F-I<&%L(&%N9"!A8V-R=65D(&EN=&5R
M97-T(&]F('1H92!&96)R=6%R>2`R,#$R($YO=&5S(&EN(&5X8VAA;F=E(&9O
M<B!T:&4@97AE<F-I<V4@;V8@=V%R<F%N=',@=&\@<'5R8VAA<V4-"C@L,30U
M+#0X-B!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:RX@07,@9&ES8W5S<V5D
M(&)E;&]W(&EN($ES<W5A;F-E(&%N9"!087EM96YT(&]F($IU;F4@,C`Q,B!.
M;W1E<RP@=&AE(')E;6%I;FEN9R!B86QA;F-E(&]F("0R+#8Y,2PX-#<-"F]F
M('1H92!&96)R=6%R>2`R,#$R($YO=&5S('=A<R!M;V1I9FEE9"!O;B!*=6YE
M(#$Y+"`R,#$R('1H<F]U9V@@=&AE(&ES<W5A;F-E(&]F('1H92!*=6YE(#(P
M,3(@3F]T97,@*&%S(&1E9FEN960@8F5L;W<I("AS964@3D]410T*,3`@9F]R
M(&UO<F4@9&5T86EL<RDN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y)<W-U86YC
M92!A;F0@4&%Y;65N="!O9B!*=6YE(#(P,3(@4')O;6ES<V]R>0T*3F]T97,\
M+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!*=6YE(#$Y+"`R,#$R+"!W92!I
M<W-U960@<V5C=7)E9"!P<F]M:7-S;W)Y#0IN;W1E<RP@;W(@=&AE($IU;F4@
M,C`Q,B!.;W1E<RP@=&\@=&AE(&AO;&1E<G,@;V8@=&AE($9E8G)U87)Y(#(P
M,3(@3F]T97,@:6X@=&AE('!R:6YC:7!A;"!A;6]U;G1S(&]F("0R+#,T-RPQ
M,C@@86YD("0R+#,T-"PW,3DL('!U<G-U86YT('1O('1H92!T97)M<R!O9B!A
M($YO=&4@4'5R8VAA<V4@06=R965M96YT+B!);B!C;VYN96-T:6]N('=I=&@@
M=&AE($IU;F4@,C`Q,B!.;W1E<RP@=&AE(&AO;&1E<G,@;V8@=&AE($9E8G)U
M87)Y(#(P,3(@3F]T97,-"G-U<G)E;F1E<F5D('1H92!R96UA:6YI;F<@8F%L
M86YC92!O9B!S=6-H(&YO=&5S(&EN('1H92!A9V=R96=A=&4@86UO=6YT(&]F
M("0Q+#,T-RPQ,C@@86YD("0Q+#,T-"PW,3DL("!W:&EC:"!S=6US#0II;F-L
M=61E9"!P<FEN8VEP86P@86YD(&%C8W)U960@:6YT97)E<W0@=&AR;W5G:"!*
M=6YE(#$Y+"`R,#$R+"!A;F0@=V4@<F5C96EV960@86X@86=G<F5G871E(&]F
M("0R+#`P,"PP,#`@;V8@;F5W(&9U;F1I;F<L(&]R('1H90T*2G5N92!&=6YD
M:6YG+"!F<F]M('1H92!H;VQD97)S(&]F('1H92!&96)R=6%R>2`R,#$R($YO
M=&5S+B!4:&4@<')I;F-I<&%L(&%M;W5N="!O9B!E86-H(&]F('1H92!*=6YE
M(#(P,3(@3F]T97,L('!L=7,@86YY(&%D9&ET:6]N86P-"F%D=F%N8V4@;6%D
M92!T;R!U<R!T:&5R96%F=&5R+"!T;V=E=&AE<B!W:71H(&%C8W)U960@:6YT
M97)E<W0@870@=&AE(&%N;G5A;"!R871E(&]F(#8E+"!W87,@9'5E(&EN(&]N
M92!L=6UP('-U;2!P87EM96YT(&]N($9E8G)U87)Y#0HR-"P@,C`Q-"X@07,@
M<V5C=7)I='D@9F]R(&]U<B!O8FQI9V%T:6]N<R!U;F1E<B!T:&4@2G5N92`R
M,#$R($YO=&5S+"!W92!E;G1E<F5D(&EN=&\@82!S96-U<FET>2!A9W)E96UE
M;G0@86YD('!L961G960@86QL(&]F(&]U<@T*87-S971S+"!T86YG:6)L92!A
M;F0@:6YT86YG:6)L92P@87,@9G5R=&AE<B!D97-C<FEB960@=&AE<F5I;BX@
M5V4@86QS;R!G<F%N=&5D('=A<G)A;G1S('1O('!U<F-H87-E(&%N(&%G9W)E
M9V%T92!O9B`W+#`P,"PP,#`@<VAA<F5S#0IO9B!O=7(@0V]M;6]N(%-T;V-K
M(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@2G5N92!&=6YD:6YG+B!/;B!-87)C
M:"`R,2P@,C`Q,RP@=V4@<F5P86ED("0T+#@X,BPP,3D@;V8@=&AE($IU;F4@
M,C`Q,B!.;W1E<RP@:6YC;'5D:6YG#0IA8V-R=65D(&EN=&5R97-T+"!L96%V
M:6YG(&$@8F%L86YC92!O9B`D,C$L-3DU(&EN(&%C8W)U960@:6YT97)E<W0@
M87,@;V8@36%R8V@@,S$L(#(P,3,N($]N($%P<FEL(#(U+"`R,#$S+"!T:&4@
M8F%L86YC92!O9B!A8V-R=65D#0II;G1E<F5S="!W87,@<&%I9"!I;B!F=6QL
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/'4^27-S=6%N8V4@86YD(%!A>6UE;G0@;V8@061D
M:71I;VYA;`T*4')O;6ES<V]R>2!.;W1E<R!I;B`R,#$R/"]U/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^26X@075G=7-T(&%N9"!397!T96UB97(@,C`Q,BP@=V4@:7-S=65D
M(#8E#0IP<F]M:7-S;W)Y(&YO=&5S(&EN('1H92!A;6]U;G0@;V8@)#$L-C`P
M+#`P,"!D=64@;VX@3V-T;V)E<B`Q+"`R,#$R+"!W:&EC:"!D=64@9&%T92!W
M87,@<W5B<V5Q=65N=&QY(&5X=&5N9&5D+B!4:&5S92!N;W1E<R!W97)E#0IP
M86ED(&EN(&9U;&P@:6X@3V-T;V)E<B`R,#$R+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@
M4V5P=&5M8F5R(#(P,3(L('=E(&ES<W5E9"!A(#8E('!R;VUI<W-O<GD-"FYO
M=&4@9F]R("0R,#`L,#`P(&1U92!O;B!/8W1O8F5R(#$U+"`R,#$R+B!4:&ES
M(&YO=&4@=V%S('!A:60@:6X@9G5L;"!I;B!/8W1O8F5R(#(P,3(N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\=3Y)<W-U86YC92!A;F0@4&%Y;65N="!O9B!!9&1I=&EO;F%L
M(%!R;VUI<W-O<GD-"DYO=&5S(&EN(#(P,3$\+W4^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY);B!$96-E;6)E<B`R,#$Q+"!W92!I<W-U960@-"4@<')O;6ES<V]R
M>2!N;W1E<PT*=&\@37(N($9I;FEZ:6\@86YD($UR+B!-:6QL:6=A;B!F;W(@
M86X@86=G<F5G871E(&]F("0Q,#`L,#`P(&1U92!-87)C:"`Q+"`R,#$R+B!4
M:&5S92!P<F]M:7-S;W)Y(&YO=&5S('=E<F4@<W5B<V5Q=65N=&QY(&5X=&5N
M9&5D#0IB>2!M=71U86P@86=R965M96YT('1O($IU;F4@,2P@,C`Q,BX@26X@
M2G5N92`R,#$R+"!W92!P86ED('1H92!P<F]M:7-S;W)Y(&YO=&4@:&5L9"!B
M>2!-<BXF(S$V,#M&:6YI>FEO(&EN(&9U;&PL(&EN8VQU9&EN9R`D.#@X#0II
M;B!A8V-R=65D(&EN=&5R97-T+B!-<BX@36EL;&EG86XF(S$T-CMS('!R;VUI
M<W-O<GD@;F]T92!W87,@97AT96YD960@=&\@3V-T;V)E<B`Q-2P@,C`Q,BX@
M3VX@3V-T;V)E<B`T+"`R,#$R+"!W92!P86ED($UR+B!-:6QL:6=A;B8C,30V
M.W,-"G!R;VUI<W-O<GD@;F]T92!I;B!F=6QL+"!I;F-L=61I;F<@)#$L-3$Y
M(&EN(&%C8W)U960@:6YT97)E<W0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y#;VYV97)S
M:6]N(&]F($IU;'D@,C`Q,2!396-U<F5D($YO=&5S/"]U/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^26X@2G5L>2`R,#$Q+"!6:71A365D(&ES<W5E9"!T=V\-"G-E;FEO<B!S
M96-U<F5D('!R;VUI<W-O<GD@;F]T97,L(&]R('1H92!396-U<F5D($YO=&5S
M+"!E86-H(&EN('1H92!A;6]U;G0@;V8@)#4P,"PP,#`@86YD(&%L<V\@96YT
M97)E9"!I;G1O(&$@<V5C=7)I='D-"F%G<F5E;65N="!U;F1E<B!W:&EC:"!6
M:71A365D('!L961G960@86QL(&]F(&ET<R!A<W-E=',@=&\@<V5C=7)E('1H
M92!O8FQI9V%T:6]N+B!4:&4@4V5C=7)E9"!.;W1E<R!W97)E(&%S<W5M960@
M8GD@=7,@=7!O;@T*=&AE(&UE<F=E<B!W:71H(%9I=&%-960@:6X@3V-T;V)E
M<B`R,#$Q(&%N9"!B;W)E(&EN=&5R97-T(&%T('1H92!R871E(&]F(#8E('!E
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M8W5R960@3F]T97,L('1H92`F(S$T-SM3:&%R92!0<FEC928C,30X.R!M96%N
M=`T*=&AE(&QO=V5R(&]F('1H92!M;W-T(')E8V5N="!P<FEC92!A="!W:&EC
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M(&1A=&4@;V8@8V]N=F5R<VEO;BX@3VX@2G5N92`Q.2P@,C`Q,BP@=V4@<F5A
M8VAE9"!A;B!A9W)E96UE;G0@=&\-"F-O;G9E<G0@=&AE(&]U='-T86YD:6YG
M(&%M;W5N="!O9B!T:&4@4V5C=7)E9"!.;W1E<RP@<F5P<F5S96YT:6YG('!R
M:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S="!T:')O=6=H($IU;F4@,3DL
M(#(P,3(L(&]F#0HD,2PP-30L-C0W(&EN=&\@86X@86=G<F5G871E(&]F(#(L
M-S<U+#0Q-2!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!A="`D,"XS."!P
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M=',N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\=3Y)<W-U86YC92P@4&%Y;65N="!A;F0@0V]N
M=F5R<VEO;B!O9B!6:71A365D#0I0<F]M:7-S;W)Y($YO=&5S/"]U/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^26X@2G5N92`R,#$Q+"!6:71A365D(&ES<W5E9"!P<F]M:7-S
M;W)Y#0IN;W1E<RP@;W(@=&AE(%9I=&%-960@3F]T97,L(&EN('1H92!A9V=R
M96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B`D-3`P+#`P,"X@26X@8V]N;F5C
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M('1H86X@)#$L,#`P+#`P,"P@;W(@=&AE($9U;F1I;F<N(%5P;VX@=&AE#0IC
M;&]S:6YG(&]F('1H92!&=6YD:6YG(&EN($IU;'D@,C`Q,2P@87,@;6]R92!F
M=6QL>2!D97-C<FEB960@86)O=F4@:6X@0V]N=F5R<VEO;B!O9B!*=6QY(#(P
M,3$@4V5C=7)E9"!.;W1E<RP@='=O(&]F('1H90T*5FET84UE9"!.;W1E<R!I
M;B!T:&4@86=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@;V8@)#(P,"PP,#`@
M=V5R92!P86ED(&EN(&9U;&PN($)Y(&UU='5A;"!A9W)E96UE;G0L('1H92!R
M96UA:6YI;F<-"E9I=&%-960@3F]T97,@:6X@=&AE(&%G9W)E9V%T92!P<FEN
M8VEP86P@86UO=6YT(&]F("0S,#`L,#`P('=E<F4@97AT96YD960N($EN($]C
M=&]B97(@,C`Q,2P@;VYE(&]F('1H92!6:71A365D($YO=&5S(&EN('1H90T*
M86=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@;V8@)#4P+#`P,"!W87,@<&%I
M9"!I;B!F=6QL+"!A;F0L(&)Y(&UU='5A;"!A9W)E96UE;G0L(&-E<G1A:6X@
M;V8@=&AE(%9I=&%-960@3F]T97,@:6X@=&AE#0IA9V=R96=A=&4@<')I;F-I
M<&%L(&%M;W5N="!O9B`D,3`P+#`P,"!W97)E(&-O;G9E<G1E9"!I;G1O(#(V
M-BPX,C(@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VL@870@)#`N,S@@<&5R
M('-H87)E+"!W:&EC:`T*<F5P<F5S96YT960@=&AE(&9A:7(@=F%L=64@;V8@
M;W5R($-O;6UO;B!3=&]C:R!O;B!T:&4@9&%T92!O9B!C;VYV97)S:6]N+B!)
M;B!*=6YE(#(P,3(L(&$@5FET84UE9"!.;W1E(&AE;&0@8GD@86X-"G5N869F
M:6QI871E9"!I;F1I=FED=6%L('=A<R!P86ED(&EN(&9U;&PL(&EN8VQU9&EN
M9R`D,BPQ-C`@:6X@86-C<G5E9"!I;G1E<F5S="X@5&AE(')E;6%I;FEN9R!6
M:71A365D($YO=&5S+"!H96QD(&)Y($UR+@T*36EL;&EG86X@86YD(&)Y($)&
M($EN=F5S=&UE;G0@16YT97)P<FES97,L($QT9"XL('=H:6-H(&ES(&]W;F5D
M(&)Y($)R:6%N($)E<FYI8VLL(&$@9&ER96-T;W(@;V8@;W5R(&-O;7!A;GDL
M(&EN('1H92!A9V=R96=A=&4-"G!R:6YC:7!A;"!A;6]U;G0@;V8@)#$P,"PP
M,#`L('=E<F4@97AT96YD960@=&\@3V-T;V)E<B`Q-2P@,C`Q,BX@3VX@3V-T
M;V)E<B`T+"`R,#$R+"!W92!R92UP86ED('1H92!O=71S=&%N9&EN9R!6:71A
M365D($YO=&5S#0II;B!F=6QL+"!I;F-L=61I;F<@)#4L,S0Q(&EN(&%C8W)U
M960@:6YT97)E<W0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@4V5P=&5M8F5R(&%N
M9"!/8W1O8F5R(#(P,3$L(%9I=&%-960-"FES<W5E9"!C;VYV97)T:6)L92!N
M;W1E<RP@;W(@=&AE(%9I=&%-960@0V]N=F5R=&EB;&4@3F]T97,L(&EN('1H
M92!A9V=R96=A=&4@86UO=6YT(&]F("0U,S0L,38P+B!4:&4@5FET84UE9"!#
M;VYV97)T:6)L90T*3F]T97,@8F]R92!I;G1E<F5S="!A="!T:&4@<F%T92!O
M9B`T)2!P97(@86YN=6T@86YD('=E<F4@9'5E($1E8V5M8F5R(#$L(#(P,3$N
M($]N($YO=F5M8F5R(#$X+"`R,#$Q+"!W92!E;G1E<F5D(&EN=&\@1&5B=`T*
M0V]N=F5R<VEO;B!!9W)E96UE;G1S('=I=&@@=&AE(&AO;&1E<G,@;V8@=&AE
M(%9I=&%-960@0V]N=F5R=&EB;&4@3F]T97,L('!U<G-U86YT('1O('=H:6-H
M('=E(&-O;G9E<G1E9"!T:&4@<')I;F-I<&%L(&%N9`T*86-C<G5E9"!I;G1E
M<F5S="!O9B!T:&4@5FET84UE9"!#;VYV97)T:6)L92!.;W1E<R!I;G1O(#$L
M-#$U+#$S-B!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!A="`D,"XS."!P
M97(@<VAA<F4L('=H:6-H#0IR97!R97-E;G1E9"!T:&4@9F%I<B!V86QU92!O
M9B!T:&4@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VL@;VX@=&AE(&1A=&4@
M;V8@8V]N=F5R<VEO;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9O<B!T:&4@>65A
M<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BP@=V4@<F5C;W)D960-"F%N(&%G
M9W)E9V%T92!O9B`D-BPS-#0@87,@:6YT97)E<W0@97AP96YS92!O;B!T:&4@
M86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R
M-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D
M-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,38N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY35$]#
M2TA/3$1%4E,G($5154E463QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2!.;W1E
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4U1/0TM(3TQ$15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/&(^/'4^3D]412`Q,"`F(S$U,#L@4U1/0TM(3TQ$15)3
M)B,Q-#8[($5154E463PO=3X\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/B8C,38P.R8C,38P.SPO8CX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/'4^4')E9F5R<F5D(%-T;V-K/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/D%T($1E
M8V5M8F5R#0HS,2P@,C`Q-"P@=V4@:&%D(#$P+#`P,"PP,#`@<VAA<F5S(&]F
M(%!R969E<G)E9"!3=&]C:RP@<&%R('9A;'5E("0P+C`P,2P@875T:&]R:7IE
M9"!F;W(@:7-S=6%N8V4L(&]F('=H:6-H(&YO('-H87)E<R!O9B!0<F5F97)R
M960-"E-T;V-K('=E<F4@:7-S=65D(&]R(&]U='-T86YD:6YG+CPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^0V]M;6]N(%-T;V-K/"]U/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C$U<'0G/D%T#0I$96-E;6)E<B`S,2P@,C`Q-"P@=V4@:&%D(#PO9F]N
M=#XR-3`L,#`P+#`P,"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K+"!P87(@=F%L
M=64@)#`N,#`Q+#QF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ
M-7!T)SX@875T:&]R:7IE9"!F;W(-"FES<W5A;F-E+"!O9B!W:&EC:"`\+V9O
M;G0^,34V+#`Y-RPP,3D\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@
M+3`N,35P="<^('-H87)E<R!O9B!O=7(@0V]M;6]N(%-T;V-K('=E<F4@:7-S
M=65D(&%N9"!O=71S=&%N9&EN9RX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQI/CQU/DES<W5A;F-E<R!$
M=7)I;F<@,C`Q-#PO=3X\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQI/B8C,38P.R8C,38P.SPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@2G5L>2`R.2P@,C`Q-"P@=V4@
M96YT97)E9"!I;G1O(&%N('5N9&5R=W)I=&EN9PT*86=R965M96YT('=I=&@@
M1V]L9&UA;B!386-H<R`F(S,X.R!#;RP@(&%S('1H92!R97!R97-E;G1A=&EV
M92!O9B!T:&4@=6YD97)W<FET97)S(&YA;65D('1H97)E:6XL(&]R('1H92!'
M;VQD;6%N#0I386-H<R!5;F1E<G=R:71E<G,L(')E;&%T:6YG('1O(&%N('5N
M9&5R=W)I='1E;B!P=6)L:6,@;V9F97)I;F<@;V8@."PU-C4L,S$P('-H87)E
M<R!O9B!O=7(@0V]M;6]N(%-T;V-K+B!4:&4@<')I8V4@=&\@=&AE('!U8FQI
M8PT*:6X@=&AE(&]F9F5R:6YG('=A<R`D-"XV-R!P97(@<VAA<F4N(%5N9&5R
M('1H92!T97)M<R!O9B!T:&4@=6YD97)W<FET:6YG(&%G<F5E;65N="P@=V4@
M9W)A;G1E9"!T:&4@1V]L9&UA;B!386-H<R!5;F1E<G=R:71E<G,@80T*,S`M
M9&%Y(&]P=&EO;B!T;R!P=7)C:&%S92!U<"!T;R!A;B!A9&1I=&EO;F%L(#$L
M,C@T+#<Y-B!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:RX@3VX@2G5L>2`S
M,"P@,C`Q-"P@=&AE($=O;&1M86X@4V%C:',@56YD97)W<FET97)S#0IE>&5R
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M97AP96YS97,@<&%Y86)L92!B>2!U<RX@5&AE(&]F9F5R:6YG(&-L;W-E9`T*
M;VX@075G=7-T(#0L(#(P,30N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@=&AE('EE
M87(@96YD960@1&5C96UB97(@,S$L(#(P,30L(&-E<G1A:6X-"FEN9&EV:61U
M86QS(&5X97)C:7-E9"!S=&]C:R!O<'1I;VYS('1O('!U<F-H87-E(#@V,"PX
M,#`@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VLN(%-T;V-K(&]P=&EO;G,@
M=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&]U<B!#;VUM;VX-"E-T;V-K('=E<F4@
M97AE<F-I<V5D(&%S(&9O;&QO=W,Z("AI*2`W,C0L,3DS(&]P=&EO;G,@9F]R
M("0S-#4L-S0V(&EN(&-A<V@@86YD("AI:2D@/&9O;G0@<W1Y;&4],T0G;&5T
M=&5R+7-P86-I;F<Z("TP+C$U<'0G/C$S-BPV,#<-"F]P=&EO;G,L('!U<G-U
M86YT('1O('1H92!S=&]C:R!O<'1I;VYS)B,Q-#8[(&-A<VAL97-S('!R;W9I
M<VEO;BP@=VAE<F5I;B`Q,S`L,S@P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@
M=V5R92!I<W-U960N($EN(&%D9&ET:6]N+`T*9'5R:6YG(#(P,30L('=E(&ES
M<W5E9"`U,"PP,#`@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!T;R!A;B!E;7!L
M;WEE92!U<&]N('1H92!V97-T:6YG(&]F(')E<W1R:6-T960@<W1O8VL@=6YI
M=',@=&AA="!W97)E#0IG<F%N=&5D(&EN($1E8V5M8F5R(#(P,3,N)B,Q-C`[
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"!C97)T
M86EN#0II;F1I=FED=6%L<R!E>&5R8VES960@=V%R<F%N=',@=&\@<'5R8VAA
M<V4@,S8U+#4X,R!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!F;W(@)#$X
M,2PP,#`@:6X@8V%S:"X\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET92<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3X\=3Y)
M<W-U86YC97,@1'5R:6YG(#(P,3,F(S$V,#L\+W4^/"]I/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3XF(S$V
M,#L\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/D]N($UA<F-H(#$T+"`R,#$S+"!W92!E;G1E<F5D(&EN=&\@
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M:&4@<'5B;&EC(&EN('1H92!O9F9E<FEN9R!W87,@)#$N-S`@<&5R('-H87)E
M+B!);@T*861D:71I;VXL('5N9&5R('1H92!T97)M<R!O9B!T:&4@=6YD97)W
M<FET:6YG(&%G<F5E;65N="P@=V4@9W)A;G1E9"!T:&4@2F5F9F5R:65S(%5N
M9&5R=W)I=&5R<R!A(#,P+61A>2!O<'1I;VX@=&\@<'5R8VAA<V4@=7`@=&\-
M"F%N(&%D9&ET:6]N86P@-"PT,3$L-S8U('-H87)E<R!O9B!O=7(@0V]M;6]N
M(%-T;V-K+B!4:&4@;V9F97)I;F<@8VQO<V5D(&]N($UA<F-H(#(P+"`R,#$S
M+B!/;B!!<')I;"`Q,BP@,C`Q,RP@=&AE($IE9F9E<FEE<R!5;F1E<G=R:71E
M<G,-"F5X97)C:7-E9"!T:&5I<B!O<'1I;VX@=&\@<'5R8VAA<V4@86X@861D
M:71I;VYA;"`Q+#DU-"PU.#<@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VLL
M('=H:6-H('=E<F4@:7-S=65D(&]N($%P<FEL(#$X+"`R,#$S+B!4:&4-"FYE
M="!P<F]C965D<R!T;R!U<R!F<F]M('1H:7,@;V9F97)I;F<@=V5R92!A<'!R
M;WAI;6%T96QY("0T."XU(&UI;&QI;VXL(&%F=&5R(&1E9'5C=&EN9R!U;F1E
M<G=R:71I;F<@9&ES8V]U;G1S(&%N9"!C;VUM:7-S:6]N<PT*86YD(&]T:&5R
M(&]F9F5R:6YG(&5X<&5N<V5S('!A>6%B;&4@8GD@=7,N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
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M92!I<W-U86YC92!A;F0@<V%L92!O9B`Q,RPW-3`L,#`P('-H87)E<R!O9B!O
M=7(@0V]M;6]N(%-T;V-K+B!4:&4@<')I8V4@=&\@=&AE('!U8FQI8R!I;B!T
M:&4@;V9F97)I;F<-"G=A<R`D,BXT,"!P97(@<VAA<F4N(%1H92!N970@<')O
M8V5E9',@=&\@=7,@9G)O;2!T:&ES(&]F9F5R:6YG('=E<F4@87!P<F]X:6UA
M=&5L>2`D,S`N,B!M:6QL:6]N+"!A9G1E<B!D961U8W1I;F<@=6YD97)W<FET
M:6YG(&1I<V-O=6YT<PT*86YD(&-O;6UI<W-I;VYS(&%N9"!O=&AE<B!O9F9E
M<FEN9R!E>'!E;G-E<R!P87EA8FQE(&)Y('5S+B!4:&4@;V9F97)I;F<@8VQO
M<V5D(&]N(%-E<'1E;6)E<B`S,"P@,C`Q,RX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D1U<FEN9R`R,#$S(&-E<G1A:6X@:6YD:79I9'5A;',@97AE<F-I<V5D#0IS
M=&]C:R!O<'1I;VYS('1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`W-2PT
M,C,@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VL@9F]R(&%P<')O>&EM871E
M;'D@)#,Q+#`P,"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/CQU/DES<W5A;F-E
M<R!$=7)I;F<@,C`Q,CPO=3X\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@2G5N
M92`R,#$R+"!W92!S971T;&5D("0S+#$P,BPP,#`@:6X-"G!R:6YC:7!A;"!A
M;F0@86-C<G5E9"!I;G1E<F5S="!O9B!T:&4@1F5B<G5A<GD@,C`Q,B!.;W1E
M<R!I;B!E>&-H86YG92!F;W(@=&AE(&AO;&1E<G,F(S$T-CL@97AE<F-I<V4@
M;V8@82!P;W)T:6]N(&]F('1H92!R96QA=&5D#0IW87)R86YT<R!F;W(@86X@
M86=G<F5G871E(&]F(#@L,30U+#0X-B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K
M+B!$=7)I;F<@2G5N92`R,#$R+"!W92!A;F0@=&AE(&AO;&1E<G,@86QS;R!A
M9W)E960@=&\@8V]N=F5R=`T*82!P;W)T:6]N(&]F('1H92!&96)R=6%R>2`R
M,#$R($YO=&5S+"!A;F0@<')I;F-I<&%L(&%N9"!A8V-R=65D(&EN=&5R97-T
M('1H<F]U9V@@2G5N92`Q.2P@,C`Q,B!T;W1A;&EN9R`D,2PP-30L-C0W+"!I
M;G1O(#(L-S<U+#0Q-0T*<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!A="`D,"XS
M."!P97(@<VAA<F4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!397!T96UB97(@
M,C`Q,BP@=V4@96YT97)E9"!I;G1O(&$@4V5C=7)I=&EE<PT*4'5R8VAA<V4@
M06=R965M96YT('=I=&@@;75L=&EP;&4@:6YV97-T;W)S+"!R96QA=&EN9R!T
M;R!T:&4@:7-S=6%N8V4@86YD('-A;&4@;V8@0V]M;6]N(%-T;V-K(&EN(&$@
M<')I=F%T92!P;&%C96UE;G0N(%1H92!P<FEV871E#0IP;&%C96UE;G0@8VQO
M<V5D(&]N($]C=&]B97(@,BP@,C`Q,BP@=&AR;W5G:"!W:&EC:"!W92!S;VQD
M(&%N(&%G9W)E9V%T92!O9B`S+#DU,RPT.#D@<VAA<F5S(&]F($-O;6UO;B!3
M=&]C:R!A="`D,BXQ-2!P97(@<VAA<F4L#0IF;W(@86X@86=G<F5G871E('!U
M<F-H87-E('!R:6-E(&]F("0X+#4P,"PP,#$N($EN(&-O;FYE8W1I;VX@=VET
M:"!T:&4@<')I=F%T92!P;&%C96UE;G0L($IE9F9E<FEE<R!,3$,@<V5R=F5D
M(&%S(&]U<B!E>&-L=7-I=F4-"G!L86-E;65N="!A9V5N="X@2F5F9F5R:65S
M)B,Q-#8[(&-O;7!E;G-A=&EO;B!F;W(@=&AE('1R86YS86-T:6]N('=A<R!A
M(&-A<V@@9F5E(&]F("0U-3(L-3`P+B!792!A;'-O('!A:60@;&5G86P@9F5E
M<R!A;F0@97AP96YS97,-"F]F('1H92!I;G9E<W1O<G,@:6X@=&AE(&%G9W)E
M9V%T92!O9B`D-3(L,#$V+"!R97-U;'1I;F<@:6X@;F5T('!R;V-E961S('1O
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M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
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M=W,Z("AI*2`Q+#8Y,2PS.3,@;W!T:6]N<R!F;W(@)#$Y,2PP,#`@:6X@8V%S
M:"!A;F0@*&EI*2`\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N
M,35P="<^,C8V+#@R,R!O<'1I;VYS+`T*<'5R<W5A;G0@=&\@=&AE('-T;V-K
M(&]P=&EO;G,F(S$T-CL@8V%S:&QE<W,@<')O=FES:6]N+"!W:&5R96EN(#(T
M,"PS.34@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!W97)E(&ES<W5E9"X@/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/'4^
M5V%R<F%N=',@=&\@4'5R8VAA<V4@0V]M;6]N(%-T;V-K(#PO=3X\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$T+"!W92!H860@=V%R<F%N=',@;W5T<W1A;F1I;F<-
M"G1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`Q,RPY,C<L.3$V('-H87)E
M<R!O9B!O=7(@0V]M;6]N(%-T;V-K('=I=&@@82!W96EG:'1E9"UA=F5R86=E
M(&-O;G1R86-T=6%L(')E;6%I;FEN9R!L:69E(&]F(#,N,"!Y96%R<RP-"F%N
M9"!E>&5R8VES92!P<FEC97,@<F%N9VEN9R!F<F]M("0P+C(T('1O("0S+C(P
M('!E<B!S:&%R92P@<F5S=6QT:6YG(&EN(&$@=V5I9VAT960@879E<F%G92!E
M>&5R8VES92!P<FEC92!O9B`D,2XX,B!P97(@<VAA<F4N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
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M('=A<G)A;G0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQI/B8C,38P.SPO:3X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^/'4^5V%R<F%N="!!
M8W1I=FET>2!$=7)I;F<@,C`Q-#PO=3X\+VD^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/B8C,38P.SPO:3X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"!W
M90T*9&ED(&YO="!I<W-U92!A;GD@=V%R<F%N=',N($%S(&]F($1E8V5M8F5R
M(#,Q+"`R,#$T+"!U;F%M;W)T:7IE9"!C;W-T<R!A<W-O8VEA=&5D('=I=&@@
M=&AE(%-A;F-I;&EO("8C,S@[($-O;7!A;GDL($EN8RXL(&]R(%-#20T*=V%R
M<F%N=',@:7-S=65D(&EN(#(P,3,@86YD(#(P,3(@=&]T86QE9"!A<'!R;WAI
M;6%T96QY("0X-S4L-C`P+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\9F]N="!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET92<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3X\=3Y7
M87)R86YT($%C=&EV:71Y($1U<FEN9R`R,#$S/"]U/CPO:3X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^)B,Q
M-C`[)B,Q-C`[/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY);B!*86YU87)Y(#(P,3,L('=E(&ES<W5E9"!W
M87)R86YT<R!T;R!P=7)C:&%S90T*,2PR-3`L,#`P('-H87)E<R!O9B!O=7(@
M0V]M;6]N(%-T;V-K(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@
M;V8@=&AE(%)E=F]L=FEN9R!#<F5D:70@3F]T92P@;W(@=&AE(%!L871O(%=A
M<G)A;G0L("AS964-"DY/5$4@,3`@86)O=F4@9F]R(&UO<F4@9&5T86EL<RDN
M(%1H92!0;&%T;R!787)R86YT(&AA<R!A;B!E>&5R8VES92!P<FEC92!O9B`D
M,RXR,"!P97(@<VAA<F4N(%1H92!0;&%T;R!787)R86YT('9E<W1E9"!O;B!/
M8W1O8F5R#0HS,2P@,C`Q,R!A;F0@;6%Y(&)E(&5X97)C:7-E9"!P<FEO<B!T
M;R!I=',@97AP:7)A=&EO;B!O;B!*86YU87)Y(#,Q+"`R,#$Y+B!4:&4@4&QA
M=&\@5V%R<F%N="P@=VET:"!A(&9A:7(@=F%L=64@;V8@87!P<F]X:6UA=&5L
M>0T*)#$L-S$Q+#DU-BP@=V%S('9A;'5E9"!O;B!T:&4@9&%T92!O9B!T:&4@
M9W)A;G0@=7-I;F<@82!T97)M(&]F('-I>"!Y96%R<SL@82!V;VQA=&EL:71Y
M(&]F(#0T+C(Y)3L@<FES:R!F<F5E(')A=&4@;V8@,"XX."4[(&%N9`T*82!D
M:79I9&5N9"!Y:65L9"!O9B`P)2X@1'5R:6YG('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@)#(V,"PP,C<@86YD("0Q+#0U
M,2PY,S0L(')E<W!E8W1I=F5L>2P@=V%S(')E8V]R9&5D#0IA<R!F:6YA;F-I
M;F<@8V]S=',@:6X@8V]N;F5C=&EO;B!W:71H('1H92!I<W-U86YC92!O9B!T
M:&4@4&QA=&\@5V%R<F%N="!O;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED
M871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/DEN($UA>2`R,#$S+"!W92!E;G1E<F5D(&EN=&\@82!C;VYS=6QT
M:6YG(&%G<F5E;65N=`T*=VET:"!30TDL('1O(&1E=F5L;W`@9')U9R!P;&%T
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M9VAT<PT*=&\@<F5C96EV92!W87)R86YT<R!T;R!P=7)C:&%S92`X,S,L,#`P
M('-H87)E<R!O9B!O=7(@0V]M;6]N(%-T;V-K('1H870@=V5R92!T;R!B92!G
M<F%N=&5D('!U<G-U86YT('1O('1H92!T97)M<R!O9B!A('!R:6]R(&-O;G-U
M;'1I;F<-"F%G<F5E;65N="!D871E9"!-87D@,3<L(#(P,3(N($%S(&-O;G-I
M9&5R871I;VX@=6YD97(@=&AE(&%G<F5E;65N="P@=V4@86=R965D('1O(&ES
M<W5E('1O(%-#22!A('=A<G)A;G0@=&\@<'5R8VAA<V4@.#4P+#`P,"!S:&%R
M97,-"F]F(&]U<B!#;VUM;VX@4W1O8VL@870@)#(N,#$@<&5R('-H87)E('1H
M870@:&%S('9E<W1E9"!O<B!W:6QL('9E<W0L(&%S(&%P<&QI8V%B;&4L(&%S
M(&9O;&QO=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P
M,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;BUT;W`Z(#`[(&UA<F=I;BUB;W1T;VTZ(#`G/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`V
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M<VAA<F5S('=E<F4@96%R;F5D(&]N($UA>2`Q,2P@,C`Q,R!U<&]N(&%C8V5P
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M(&1I9"!N;W0@=F5S="!U;G1I;"!*=6YE(#,P+"`R,#$S+B!4:&4@9F%I<B!V
M86QU92!O9B`D-#`U+#`V-B!F;W(@=&AE('-H87)E<R!V97-T960-"F]N($IU
M;F4@,S`L(#(P,3,@=V%S(&1E=&5R;6EN960@8GD@=7-I;F<@=&AE($)L86-K
M+5-C:&]L97,@36]D96P@;VX@=&AE(&1A=&4@;V8@=F5S=&EN9R!U<VEN9R!A
M('1E<FT@;V8@-2!Y96%R<SL@82!V;VQA=&EL:71Y(&]F#0HT-2XX.24[(')I
M<VL@9G)E92!R871E(&]F(#$N,3(E.R!A;F0@82!D:79I9&5N9"!Y:65L9"!O
M9B`P)2X@5V4@<F5C;W)D960@=&AE(&5N=&ER92`D-#`U+#`V-B!A<R!N;VXM
M8V%S:"!C;VUP96YS871I;VX@87,@;V8@2G5N90T*,S`L(#(P,3,[/"]T9#X\
M+W1R/CPO=&%B;&4^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW-6EN
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N,C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN+71O<#H@,#L@;6%R
M9VEN+6)O='1O;3H@,"<^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#8E.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`U)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXR+CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[('=I9'1H.B`X.24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,C@S+#,S,R!S:&%R97,@=F5S=&5D(&]N($IU
M;F4@,S`L(#(P,3,N(%1H92!F86ER('9A;'5E(&]F("0T-C(L,3DV(&9O<B!T
M:&5S92!S:&%R97,@=V%S(&1E=&5R;6EN960-"F)Y('5S:6YG('1H92!";&%C
M:RU38VAO;&5S($UO9&5L(&]N('1H92!D871E(&]F('1H92!V97-T:6YG('5S
M:6YG(&$@=&5R;2!O9B`U('EE87)S.R!A('9O;&%T:6QI='D@;V8@-#4N.#0E
M.R!R:7-K(&9R964@<F%T92!O9@T*,2XT,24[(&%N9"!A(&1I=FED96YD('EI
M96QD(&]F(#`E+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"P@=V4@<F5C;W)D
M960@)#$U-"PP-C@@87,@<')E<&%I9"!E>'!E;G-E+7-H;W)T('1E<FT@86YD
M("0W-RPP,C8@87,@<')E<&%I9`T*97AP96YS92UL;VYG('1E<FT@:6X@=&AE
M(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N
M=',N($1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$@,C`Q-"!A
M;F0@,C`Q,RP@=V4@<F5C;W)D960-"B0Q-30L,#8X(&%N9"`D-S<L,#,T+"!R
M97-P96-T:79E;'DL(&%S(&YO;BUC87-H(&-O;7!E;G-A=&EO;B!I;B!T:&4@
M86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<SL@86YD/"]T9#X\+W1R/CPO=&%B;&4^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XW-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@+3`N,C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#8E.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`U)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS+CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('=I9'1H.B`X.24[(&9O;G0M9F%M:6QY.B!4
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M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XW
M-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N,C5I
M;B<^/&D^)B,Q-C`[/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\:3X\=3Y787)R86YT($%C=&EV:71Y($1U
M<FEN9R`R,#$R/"]U/CPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^)B,Q-C`[)B,Q-C`[/"]I/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY)
M;B!&96)R=6%R>2`R,#$R+"!W92!I<W-U960@=V%R<F%N=',@9F]R('1H90T*
M<'5R8VAA<V4@;V8@86X@86=G<F5G871E(&]F(#4L-C@U+#,P,"!S:&%R97,@
M;V8@0V]M;6]N(%-T;V-K(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@;6]D:69I
M8V%T:6]N(&]F(&-E<G1A:6X@97AI<W1I;F<@<')O;6ES<V]R>0T*;F]T97,L
M(&]R('1H92!-;V1I9FEC871I;VX@5V%R<F%N=',L(&%N9"!W87)R86YT<R!F
M;W(@=&AE('!U<F-H87-E(&]F(&%N(&%G9W)E9V%T92!O9B`S+#,Q-"PW,#`@
M<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VL@:6X@8V]N;F5C=&EO;@T*=VET
M:"!T:&4@:7-S=6%N8V4@;V8@=&AE($9E8G)U87)Y(#(P,3(@3F]T97,L(&]R
M('1H92!&96)R=6%R>2`R,#$R(%=A<G)A;G1S("AS964@3D]412`Y*2X@0F]T
M:"!T:&4@36]D:69I8V%T:6]N(%=A<G)A;G1S#0IA;F0@=&AE($9E8G)U87)Y
M(#(P,3(@5V%R<F%N=',@87)E(&5X97)C:7-A8FQE(&%T("0P+C,X('!E<B!S
M:&%R92X@5&AE($UO9&EF:6-A=&EO;B!787)R86YT<R!H879E(&$@9F%I<B!V
M86QU92!O9B`D,3`L-3`U+#(T-RP-"F%N9"!T:&4@1F5B<G5A<GD@,C`Q,B!7
M87)R86YT<R!H879E(&$@9F%I<B!V86QU92!O9B`D-BPQ,C0L.#<S+B!&86ER
M('9A;'5E('=A<R!D971E<FUI;F5D(&]N('1H92!D871E(&]F('1H92!I<W-U
M86YC92!U<VEN9R!A('1E<FT-"F]F(&9I=F4@>65A<G,[(&$@=F]L871I;&ET
M>2!O9B`T-"XU)3L@<FES:R!F<F5E(')A=&4@;V8@,"XX.24[(&%N9"!A(&1I
M=FED96YD('EI96QD(&]F(#`E+B!792!R96-O<F1E9"!T:&4@9F%I<B!V86QU
M92!O9B!T:&4@36]D:69I8V%T:6]N#0I787)R86YT<R!A<R!P87)T(&]F('1H
M92!L;W-S(&]N(&5X=&EN9W5I<VAM96YT(&]F(&1E8G0@:6X@=&AE(&%C8V]M
M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N(%1H
M92!R96QA=&EV92!F86ER#0IV86QU92!O9B!T:&4@1F5B<G5A<GD@,C`Q,B!7
M87)R86YT<R!O9B`D.#4Y+#8T-R!W87,@<F5C;W)D960@87,@9&5B="!D:7-C
M;W5N="X@07,@82!R97-U;'0@;V8@=&AE('-U<G)E;F1E<B!O9B!T:&4@1F5B
M<G5A<GD@,C`Q,@T*3F]T97,@;VX@2G5N92`Q.2P@,C`Q,BP@=V4@97AP96YS
M960@=&AE(')E;6%I;FEN9R!U;F%M;W)T:7IE9"!D96)T(&1I<V-O=6YT+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CQI/CQU/E=A<G)A;G0@06-T:79I='D@1'5R:6YG
M(#(P,3(\+W4^/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@36%R8V@@,C`Q,BP@=V4@
M:7-S=65D('=A<G)A;G1S('1O('!U<F-H87-E#0IA;B!A9V=R96=A=&4@;V8@
M,S$L,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=&\@9FEV92!U;F%F9FEL
M:6%T960@:6YD:79I9'5A;',@9F]R('-E<G9I8V5S(')E;F1E<F5D+B!4:&5S
M92!W87)R86YT<R!W97)E('9A;'5E9`T*;VX@=&AE(&1A=&4@;V8@=&AE(&ES
M<W5A;F-E('5S:6YG(&$@=&5R;2!O9B!F:79E('EE87)S.R!A('9O;&%T:6QI
M='D@;V8@-#0N.#$E.R!R:7-K(&9R964@<F%T92!O9B`Q+C`T)3L@86YD(&$@
M9&EV:61E;F0@>6EE;&0-"F]F(#`E.R!W92!R96-O<F1E9"`D,CDL-S,V(&%S
M(&-O;G-U;'1I;F<@97AP96YS92!I;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O
M;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN
M($UA>2`R,#$R+"!W92!I<W-U960@=V%R<F%N=',@=&\-"G!U<F-H87-E(&%N
M(&%G9W)E9V%T92!O9B`Q+#,P,"PP,#`@<VAA<F5S(&]F($-O;6UO;B!3=&]C
M:R!T;R!A;B!U;F%F9FEL:6%T960@96YT:71Y(&9O<B!S97)V:6-E<R!T;R!B
M92!R96YD97)E9"!O=F5R#0IA<'!R;WAI;6%T96QY(&9I=F4@>65A<G,@8F5G
M:6YN:6YG(&EN($UA>2`R,#$R+B!397)V:6-E<R!P<F]V:61E9"!A<F4@=&\@
M:6YC;'5D92`H82D@<V5R=FEC97,@:6X@<W5P<&]R="!O9B!O=7(@9')U9PT*
M9&5V96QO<&UE;G0@969F;W)T<RP@:6YC;'5D:6YG('-E<G9I8V5S(&EN('-U
M<'!O<G0@;W5R(&]N9V]I;F<@86YD(&9U='5R92!D<G5G(&1E=F5L;W!M96YT
M(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!E9F9O<G1S+`T*<F5G=6QA=&]R>2!A
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M;VQA=&EL:71Y(&]F(#0T+C<Q)3L@<FES:PT*9G)E92!R871E(&]F(#`N-S0E
M.R!A;F0@82!D:79I9&5N9"!Y:65L9"!O9B`P)2X@070@1&5C96UB97(@,S$L
M(#(P,30L('=E(&AA9"`D,C4W+#<Y-B!R97!O<G1E9"!A<R!P<F5P86ED(&5X
M<&5N<V4M<VAO<G0@=&5R;0T*86YD("0S.#8L-CDT(')E8V]R9&5D(&%S('!R
M97!A:60@97AP96YS92UL;VYG('1E<FTN($1U<FEN9R!T:&4@>65A<G,@96YD
M960@1&5C96UB97(@,S$L(#(P,30L(#(P,3,@86YD(#(P,3(L('=E(')E8V]R
M9&5D#0HD,S`Y+#$V-2P@)#,V,"PU,C@@86YD("0R,3@L,#0U+"!R97-P96-T
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M82!R97-U;'0L('=E(&%R92!A;6]R=&EZ:6YG('1H92`D,2PU,S(L,C(X(&]V
M97(-"F9I=F4@>65A<G,N)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!*=6YE(#(P
M,3(L('=E(&ES<W5E9"!W87)R86YT('1O('!U<F-H87-E#0IA9V=R96=A=&4@
M;V8@-RPP,#`L,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:6X@8V]N;F5C
M=&EO;B!W:71H('1H92!I<W-U86YC92!O9B!T:&4@2G5N92`R,#$R($YO=&5S
M+"!O<B!T:&4@2G5N92`R,#$R(%=A<G)A;G1S+`T**'-E92!.3U1%(#DI+B!/
M9B!T:&4@2G5N92`R,#$R(%=A<G)A;G1S(&ES<W5E9"P@-BPP,#`L,#`P(&%R
M92!E>&5R8VES86)L92!A="`D,BXP,"!P97(@<VAA<F4@86YD(#$L,#`P+#`P
M,"!A<F4@97AE<F-I<V%B;&4-"F%T("0S+C`P('!E<B!S:&%R92X@5&AE(&9A
M:7(@=F%L=64@;V8@=&AE($IU;F4@,C`Q,B!787)R86YT<R!O9B`D.2PT,C0L
M.3@R('=A<R!D971E<FUI;F5D(&]N('1H92!D871E(&]F('1H92!I<W-U86YC
M92!U<VEN9R!A('1E<FT-"F]F(&9I=F4@>65A<G,[(&$@=F]L871I;&ET>2!O
M9B`T-"XV-"4[(')I<VL@9G)E92!R871E(&]F(#`N-S4E.R!A;F0@82!D:79I
M9&5N9"!Y:65L9"!O9B`P)2X@5&AE(')E;&%T:79E(&9A:7(@=F%L=64@;V8@
M=&AE($IU;F4-"C(P,3(@5V%R<F%N=',@;V8@)#$L-C0Y+#@Y,"!W87,@9&5T
M97)M:6YE9"!B>2!U<VEN9R!T:&4@<F5L871I=F4@9F%I<B!V86QU92!C86QC
M=6QA=&EO;B!M971H;V0@;VX@=&AE(&1A=&4@;V8@=&AE(&ES<W5A;F-E+B`D
M-30W+#(Q,`T*=V%S(&%M;W)T:7IE9"!T;R!I;G1E<F5S="!E>'!E;G-E(&EN
M(#(P,3(@86YD(&%S(&$@<F5S=6QT(&]F('1H92!R97!A>6UE;G0@;V8@=&AE
M(&%S<V]C:6%T960@9&5B="!O;B!-87)C:"`R,2P@,C`Q,RP@=&AE(')E;6%I
M;FEN9PT*=6YA;6]R=&EZ960@9&5B="!D:7-C;W5N="!O9B`D,2PQ,#(L-C@P
M('=A<R!A;6]R=&EZ960@=&\@:6YT97)E<W0@97AP96YS92X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/DEN($IU;F4@,C`Q,BP@=V4@:7-S=65D('=A<G)A;G1S('1O
M('!U<F-H87-E#0IA;B!A9V=R96=A=&4@;V8@,2PU,#`@<VAA<F5S(&]F($-O
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M)2X@02!T;W1A;"!O9B`D,2PV-38@=V%S(')E8V]R9&5D(&%S(&-O;G-U;'1I
M;F<@97AP96YS92!I;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F
M:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CQI/E-U;6UA<GD@;V8@;W5R(%=A<G)A;G0@
M86-T:79I='D@86YD(')E;&%T960@:6YF;W)M871I;VX@9F]R#0HR,#$R+3(P
M,30F(S$V,#L\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P
M.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z
M(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N
M=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/DYU;6)E<B!O
M9B!3:&%R97,@56YD97(@5V%R<F%N=',\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60G/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@
M4')I8V4\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G
M/E=E:6=H=&5D("8C,38P.R`\8G(@+SY!=F5R86=E)B,Q-C`[(#QB<B`O/E)E
M;6%I;FEN9R`F(S$V,#L@/&)R("\^0V]N=')A8W1U86PF(S$V,#L@/&)R("\^
M3&EF92!I;B!996%R<SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P
M="!S;VQI9"<^06=G<F5G871E)B,Q-C`[(#QB<B`O/DEN=')I;G-I8R!686QU
M93PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@-3(E.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D)A;&%N8V4@870@1&5C96UB97(@
M,S$L(#(P,3$\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!R:6=H="<^,RPP-3<L-C(W/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Y)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,"XS-CPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^-RXY
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ
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M<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6QE9G0Z(#$P<'0G/DES
M<W5E9#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('1E>'0M86QI9VXZ(')I9VAT)SXQ-RPS,S(L-3`P/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
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M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
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M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
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M;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I
M;F<M;&5F=#H@,3!P="<^17AE<F-I<V5D/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
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M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X
M="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@
M<FEG:'0G/C`N,S@\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P
M861D:6YG+6QE9G0Z(#$P<'0G/D5X<&ER960\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-3$[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U
M*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6QE9G0Z(#$P<'0G/D-A;F-E
M;&QE9#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
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M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!R:6=H="<^,"XR-#PO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D)A;&%N8V4@870@1&5C96UB
M97(@,S$L(#(P,3(\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,3(L,3DS+#0Y.3PO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL
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M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
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M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
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M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A
M9&1I;F<M;&5F=#H@,3!P="<^27-S=65D/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/C(L,3`P
M+#`P,#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI
M9VXZ(')I9VAT)SXR+C<R/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@<&%D9&EN9RUL969T.B`Q,'!T)SY%>&5R8VES960\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-3$[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR
M,S@L,C4U*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6QE9G0Z(#$P<'0G
M/D5X<&ER960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUL
M969T.B`Q,'!T)SY#86YC96QL960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34Q.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U
M-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^0F%L86YC92!A="!$96-E;6)E<B`S,2P@
M,C`Q,SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
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M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
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M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ
M(')I9VAT)SXS+CD\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M;&5F=#H@,3!P="<^
M27-S=65D/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
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M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M<&%D9&EN9RUL969T.B`Q,'!T)SY%>&5R8VES960\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^
M*#,V-2PU.#,\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/BD\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@<FEG:'0G/C`N-3`\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
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M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!P861D:6YG+6QE9G0Z(#$P<'0G/D5X<&ER960\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-3$[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L
M,C4U*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6QE9G0Z(#$P<'0G/D-A
M;F-E;&QE9#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^0F%L
M86YC92!A="!$96-E;6)E<B`S,2P@,C`Q-#PO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
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M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
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M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/C,N,#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N
M.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^
M,S8L-C(S+#@W-3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P.R!T97AT+6EN9&5N=#H@
M+3$P)SY697-T960@86YD($5X97)C:7-A8FQE(&%T($1E8V5M8F5R(#,Q+"`R
M,#$T/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,3,L
M-38R+#<V-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT
M+6%L:6=N.B!R:6=H="<^,2XX,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
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M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O;3H@,BXU
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@
M;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/C,U
M+#4Y.2PU-#`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L
M93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET92<^)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4
M:&4@=V5I9VAT960@879E<F%G92!F86ER('9A;'5E('!E<B!S:&%R92!O9@T*
M=V%R<F%N=',@:7-S=65D(&%N9"!T:&4@87-S=6UP=&EO;G,@=7-E9"!I;B!T
M:&4@0FQA8VLM4V-H;VQE<R!-;V1E;"!D=7)I;F<@=&AE('EE87)S(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S(&%N9"`R,#$R(&%R90T*<V5T(&9O
M<G1H(&EN('1H92!T86)L92!B96QO=RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T
M:#H@.3`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$T/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$S/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$R/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`U,B4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^5V5I9VAT960@879E<F%G92!F86ER('9A
M;'5E/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@
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M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C(N.#,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#(E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$R)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BXP-3PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5F]L871I;&ET>3PO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
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M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&5R;2`H:6X@>65A
M<G,I/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
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M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
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M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY$:79I9&5N9"!Y:65L9#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`P/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C`N,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B4\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@<FES:RUF<F5E(&EN
M=&5R97-T(')A=&4@87-S=6UP=&EO;B!I<R!B87-E9`T*=7!O;B!O8G-E<G9E
M9"!I;G1E<F5S="!R871E<R!O;B!Z97)O(&-O=7!O;B!5+E,N(%1R96%S=7)Y
M(&)O;F1S('=H;W-E(&UA='5R:71Y('!E<FEO9"!I<R!A<'!R;W!R:6%T92!F
M;W(@=&AE('1E<FTN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY%<W1I;6%T960@=F]L
M871I;&ET>2!I<R!A(&UE87-U<F4@;V8@=&AE(&%M;W5N=`T*8GD@=VAI8V@@
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M;"!D871A(&]F(&]U<B!S=&]C:R!P<FEC92!D=7)I;F<@,C`Q,2TR,#$T+B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/D]P=&EO;G,@=&\@4'5R8VAA<V4@
M0V]M;6]N(%-T;V-K(&]F('1H90T*0V]M<&%N>3PO=3X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/DEN(#(P,#DL('=E(&%D;W!T960@=&AE(#(P,#D@3&]N9R!497)M($EN8V5N
M=&EV90T*0V]M<&5N<V%T:6]N(%!L86XL(&]R('1H92`R,#`Y(%!L86XL('1O
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M(%1H92!!=V%R9',@879A:6QA8FQE('5N9&5R('1H92`R,#`Y(%!L86X@8V]N
M<VES="!O9B!S=&]C:R!O<'1I;VYS+"!S=&]C:R!A<'!R96-I871I;VX-"G)I
M9VAT<RP@<F5S=')I8W1E9"!S=&]C:RP@<F5S=')I8W1E9"!S=&]C:R!U;FET
M<RP@<&5R9F]R;6%N8V4@<W1O8VLL('!E<F9O<FUA;F-E('5N:71S+"!A;F0@
M;W1H97(@<W1O8VL@;W(@8V%S:"!A=V%R9',@87,@9&5S8W)I8F5D#0II;B!T
M:&4@,C`P.2!0;&%N+B!4:&5R92!A<F4@,C4L,#`P+#`P,"!S:&%R97,@875T
M:&]R:7IE9"!F;W(@:7-S=6%N8V4@=&AE<F5U;F1E<BX@4')I;W(@=&\@=&AE
M(&UE<F=E<B!W:71H(%9I=&%-960L(&YO($%W87)D<PT*:&%D(&)E96X@:7-S
M=65D('5N9&5R('1H92`R,#`Y(%!L86XN($%S(&]F($1E8V5M8F5R(#,Q+"`R
M,#$T+"!T:&5R92!W97)E($%W87)D<R!F;W(@,3@L,C0V+#8R-2!S:&%R97,@
M;V8@;W5R($-O;6UO;B!3=&]C:R!I<W-U960-"G5N9&5R('1H92`R,#`Y(%!L
M86XN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY/;B!&96)R=6%R>2`R,RP@,C`Q,BP@=V4@861O
M<'1E9"!T:&4@,C`Q,@T*4W1O8VL@26YC96YT:79E(%!L86XL(&]R('1H92`R
M,#$R(%!L86XL(&$@;F]N+7%U86QI9FEE9"!P;&%N('1H870@=V%S(&%M96YD
M960@:6X@075G=7-T(#(P,3,N(%1H92`R,#$R(%!L86X@=V%S(&1E<VEG;F5D
M('1O('-E<G9E#0IA<R!A;B!I;F-E;G1I=F4@9F]R(')E=&%I;FEN9R!Q=6%L
M:69I960@86YD(&-O;7!E=&5N="!K97D@96UP;&]Y965S+"!O9F9I8V5R<RP@
M9&ER96-T;W)S+"!A;F0@8V5R=&%I;B!C;VYS=6QT86YT<R!A;F0@861V:7-O
M<G,-"F]F(&]U<B!C;VUP86YY+B!4:&5R92!A<F4@,3`L,#`P+#`P,"!S:&%R
M97,@;V8@;W5R($-O;6UO;B!3=&]C:R!A=71H;W)I>F5D(&9O<B!I<W-U86YC
M92!T:&5R975N9&5R+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"P@=&AE<F4-
M"G=E<F4@87=A<F1S(&9O<B`R+#8P,"PP,#`@<VAA<F5S(&ES<W5E9"!U;F1E
M<B!T:&4@,C`Q,B!0;&%N+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
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M8F5L;W<N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#DP)3L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-#PO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q,SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q,CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`N,#<M,2XW-SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B4\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
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M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXP+C8Q+3(N,C,\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXE/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E9O;&%T:6QI='D\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
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M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
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M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
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M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY497)M("AI;B!Y96%R<RD\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-2TV+C(U/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
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M)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4R)3L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY$:79I9&5N9"!Y:65L9#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`R
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$R)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP,#PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#(E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`P/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B4\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,B4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C`N,#`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)3PO=&0^/"]T<CX-"CPO=&%B;&4^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4G/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^
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M;&EF:65D(&UE=&AO9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D$@<W5M;6%R>2!O
M9B!A8W1I=FET>2!U;F1E<B!T:&4@,C`P.2!A;F0@,C`Q,@T*4&QA;G,@86YD
M(')E;&%T960@:6YF;W)M871I;VX@9F]R(#(P,3(M,C`Q-"!F;VQL;W=S.CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M('=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SY.
M=6UB97(@;V8@4VAA<F5S(%5N9&5R($]P=&EO;G,\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0S('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/E=E:6=H=&5D($%V97)A9V4@17AE
M<F-I<V4@4')I8V4\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60G/E=E:6=H=&5D("8C,38P.R`\8G(@+SY!=F5R86=E("8C,38P.R`\
M8G(@+SY296UA:6YI;F<@)B,Q-C`[(#QB<B`O/D-O;G1R86-T=6%L)B,Q-C`[
M(#QB<B`O/DQI9F4@:6X@665A<G,\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60G/D%G9W)E9V%T928C,38P.R`\8G(@+SY);G1R:6YS
M:6,@5F%L=64\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U
M*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4P)3L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY"86QA;F-E(&%T($1E
M8V5M8F5R(#,Q+"`R,#$Q/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF
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M;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
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M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I
M9VAT)SXW+C8\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@9F]N="UF
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M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6QE9G0Z
M(#$P<'0G/D=R86YT960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
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M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G
M/C(N.#`\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
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M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
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M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('!A9&1I;F<M;&5F=#H@,3!P="<^17AE<F-I<V5D/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL
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M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@<&%D9&EN9RUL969T.B`Q,'!T)SY%>'!I<F5D/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
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M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
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M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
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M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUL
M969T.B`Q,'!T)SY#86YC96QL960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/B@T-BPQ,S4\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0G/BD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^0F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI
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M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
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M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SXW+C<\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M="<^,C8L.#`T+#$Q-SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U
M-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUL969T.B`Q,'!T)SY'<F%N
M=&5D/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
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M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUL969T.B`Q,'!T
M)SY%>&5R8VES960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^*#<U+#0R,SPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
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M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('!A9&1I;F<M;&5F=#H@,3!P="<^17AP:7)E9#PO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
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M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
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M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
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M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('!A9&1I;F<M;&5F=#H@,3!P="<^0V%N8V5L;&5D/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SXH
M-C`X+#<U,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
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M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D)A;&%N8V4@870@1&5C
M96UB97(@,S$L(#(P,3,\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,34L-C,R+#<T,CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A
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M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
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M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6QE
M9G0Z(#$P<'0G/D=R86YT960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,BPT-#(L,#`P/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
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M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
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M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('!A9&1I;F<M;&5F=#H@,3!P="<^17AE<F-I<V5D/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A
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M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
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M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
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M+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M;&5F=#H@,3!P="<^17AP:7)E9#PO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
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M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R
M,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUL969T.B`Q
M,'!T)SY#86YC96QL960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
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M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,30\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!R:6=H="<^,2XX.#PO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
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M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
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M+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@;&5F="<^5F5S=&5D(&%N9"!%>&5R8VES86)L92!A="!$
M96-E;6)E<B`S,2P@,C`Q-#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S
M;VQI9"<^,3,L,C<V+#0V,CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
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M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^-2XU/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
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M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%T($1E
M8V5M8F5R(#,Q+"`R,#$T+"!O=7(@;W5T<W1A;F1I;F<@;W!T:6]N<PT*:&%D
M(&5X97)C:7-E('!R:6-E<R!R86YG:6YG(&9R;VT@)#`N,3`@=&\@)#4N,C$@
M<&5R('-H87)E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@9F]R(&]P=&EO;G,-"G)E8V]G;FEZ960@:6X@
M;W5R(')E<W5L=',@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q-"P@,C`Q,RP@86YD(#(P,3(F(S$V,#L@*"0T+#,Y,RPT-34L("0S+#(P
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M9F5R(&9R;VT@=&AE(&5S=&EM871E<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%T($1E8V5M
M8F5R(#,Q+"`R,#$T+"!T;W1A;"!U;G)E8V]G;FEZ960@97-T:6UA=&5D#0IC
M;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O('5N=F5S=&5D(&]P=&EO
M;G,@9W)A;G1E9"!P<FEO<B!T;R!T:&%T(&1A=&4@=V%S(&%P<')O>&EM871E
M;'D@)#4L,38P+#`P,"P@=VAI8V@@:7,@97AP96-T960@=&\-"F)E(')E8V]G
M;FEZ960@;W9E<B!A('=E:6=H=&5D+6%V97)A9V4@<&5R:6]D(&]F(#(N.2!Y
M96%R<RX@3F\@=&%X(&)E;F5F:70@=V%S(')E86QI>F5D(&1U92!T;R!A(&-O
M;G1I;G5E9"!P871T97)N(&]F(&]P97)A=&EN9PT*;&]S<V5S+B!!="!$96-E
M;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@=&]T86P@=6YR96-O9VYI>F5D(&5S
M=&EM871E9"!C;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O('5N=F5S
M=&5D(&]P=&EO;G,@9W)A;G1E9"!P<FEO<@T*=&\@=&AA="!D871E('=A<R!A
M<'!R;WAI;6%T96QY("0S+#DR,2PP,#`@86YD("0T+#,Y,2PP,#`L(')E<W!E
M8W1I=F5L>2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($1E8V5M8F5R(#(P,3,L
M('=E(&=R86YT960@82!R97-T<FEC=&5D#0IS=&]C:R!U;FET+"!O<B!T:&4@
M4E-5+"!U;F1E<B!O=7(@,C`Q,B!0;&%N('1O(&%N(&5M<&QO>65E(&]F(#4P
M+#`P,"!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!H879I;F<@82!F86ER
M('9A;'5E(&]F#0HD,C,S+#4P,"X@1'5R:6YG('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@=V4@<F5C;W)D960@)#4S+#0R
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M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T
M83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T
M9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3D-/344@5$%815,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC
M;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^24Y#3TU%(%1!6$53/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/CQU/DY/5$4\+W4^/"]B/CQU/B8C
M,38P.SQB/B`Q,2`F(S$U,#L-"DE.0T]-12!405A%4SQF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SXF(S$V,#L\+V9O;G0^/"]B/CPO
M=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G
M/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4G/D9O<@T*=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$T+"`R,#$S(&%N9"`R,#$R+"!T:&5R92!W87,@;F\@<')O=FES:6]N
M(&9O<B!I;F-O;64@=&%X97,L(&-U<G)E;G0@;W(@9&5F97)R960N)B,Q-C`[
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^/"]F;VYT/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!="!$96-E;6)E<B`S,2P@,C`Q-"P@
M=V4@:&%V92!A(&9E9&5R86P@;F5T#0IO<&5R871I;F<@;&]S<R!C87)R>2!F
M;W)W87)D(&]F(&%P<')O>&EM871E;'D@)#$P-2PU,CDL-#$V(&%V86EL86)L
M92!T;R!O9F9S970@9G5T=7)E('1A>&%B;&4@:6YC;VUE('1H<F]U9V@@,C`S
M-"XF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@-2XT<'0G
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY!(')E8V]N8VEL:6%T:6]N(&)E='=E96X@=&%X97,@8V]M
M<'5T960@870-"G1H92!F961E<F%L('-T871U=&]R>2!R871E(&%N9"!T:&4@
M8V]N<V]L:61A=&5D(&5F9F5C=&EV92!T87@@<F%T92!I<R!A<R!F;VQL;W=S
M.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS
M1#`@8V5L;'-P86-I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`Y,"4[(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,30\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3,\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
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M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#4R)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&961E<F%L('-T871U=&]R>2!T87@@
M<F%T93PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T)3L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,S0N,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ(&UI9&1L93L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#0E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L:6=N.B!R:6=H=#L@
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M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,U+C`\+W1D/CQT
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M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3=&%T92!T
M87@@<F%T92P@;F5T(&]F(&9E9&5R86P@=&%X(&)E;F5F:70\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-2XX/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
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M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY!9&IU<W1M96YT(&EN('9A;'5A=&EO;B!A;&QO=V%N8V5S/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
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M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXH,S(N-#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!V97)T:6-A;"UA;&EG;CH@;6ED9&QE.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BDE/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q
M."XR/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('9E<G1I
M8V%L+6%L:6=N.B!M:61D;&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*24\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI
M=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4&5R;6%N
M96YT(&%N9"!O=&AE<B!D:69F97)E;F-E<SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
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M;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(')I9VAT.R!V97)T:6-A;"UA
M;&EG;CH@;6ED9&QE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/BDE/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,C(N,SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(')I9VAT.R!V
M97)T:6-A;"UA;&EG;CH@;6ED9&QE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/BDE/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^4')O=FES:6]N("A"96YE9FET*2!F;W(@26YC;VUE(%1A>&5S
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC
M86PM86QI9VXZ(&UI9&1L93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ(&UI9&1L93L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,34Q.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ
M(&UI9&1L93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXE/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^($]U<B!D969E<G)E9"!T87@@87-S970@86YD
M(&QI86)I;&ET>0T*87,@<')E<V5N=&5D(&EN('1H92!A8V-O;7!A;GEI;F<@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&-O;G-I<W0@;V8@
M=&AE(&9O;&QO=VEN9SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@
M.3`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$T/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$S/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$R/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5F97)R960@26YC
M;VUE(%1A>"!!<W-E=',Z/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`U,B4[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M;&5F=#H@,3!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY.970@;W!E<F%T:6YG(&QO<W-E<SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`T)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0S+#`Y,2PT,S<\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#0E.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,30L-S<S+#4S-SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@-"4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,3`E.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+#DR,"PX-C$\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^4B8C,S@[1"!#<F5D:70\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
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M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1O
M=&%L(&1E9F5R<F5D(&EN8V]M92!T87@@87-S970\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-#,L,#DQ+#0S-SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
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M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV
M+#$P-RPR,#<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E9A
M;'5A=&EO;B!A;&QO=V%N8V4\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
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M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXH,34L,S(Q+#`T.#PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*#8L,3`W+#(P-SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D1E9F5R<F5D($EN8V]M92!487@@07-S971S+"!N970\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,34Q.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,34Q.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,34Q.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE
M/@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
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M;6)E<B`S,2P@,C`Q-"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\:3Y5;G)E8V]G;FEZ960@5&%X($)E;F5F:71S)B,Y.SPO
M:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&D^)B,Q-C`[)B,Q-C`[/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!<R!O9B!T:&4@<&5R:6]D
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+`T*=V4@:&%D(&YO('5N<F5C;V=N
M:7IE9"!T87@@8F5N969I=',N)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T
M-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE
M971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY214Q!5$5$(%!!4E1)15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N
M<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y214Q!5$5$(%!!4E1)15,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&(^/'4^3D]412`Q,B`F(S$U,#L@4D5,051%1"!0
M05)42453/"]U/CPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&(^)B,Q-C`[)B,Q-C`[/"]B/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y,
M;V%N($=U87)A;G1Y)B,Q-C`[/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@36%R8V@@
M,C`Q,2P@5FET84UE9"!E;G1E<F5D(&EN=&\@82!B=7-I;F5S<PT*;&]A;B!A
M9W)E96UE;G0@=VET:"!&:7)S="!5;FET960@9F]R(&$@)#,P,"PP,#`@;&EN
M92!O9B!C<F5D:70@9F]R('=H:6-H('!E<G-O;F%L(&=U87)A;G1E97,@86YD
M(&-A<V@@8V]L;&%T97)A;"!W97)E(')E<75I<F5D+@T*4&5R<V]N86P@9W5A
M<F%N=&5E<R!A;F0@8V%S:"!C;VQL871E<F%L(&QI;6ET960@=&\@)#$P,"PP
M,#`@96%C:"!W97)E('!R;W9I9&5D(&)Y($UR+B!&:6YI>FEO+"!-<BX@36EL
M;&EG86XL(&%N9"!296EC:"!&86UI;'D-"DQI;6ET960@4&%R=&YE<G-H:7`N
M(%-E92!.3U1%4R`Y(&%N9"`Q,"`F(S$V,#MF;W(@;6]R92!D971A:6QS+B8C
M,38P.SPO<#X-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\8CXF(S$V,#L\+V(^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/DQO86YS(&9R;VT@
M069F:6QI871E<R8C,38P.SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($IU;F4@,C`Q
M,2P@5FET84UE9"!I<W-U960@=&AE(%9I=&%-960@3F]T97,-"FEN('1H92!A
M9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B`D-3`P+#`P,"P@;V8@=VAI
M8V@@)#$P,"PP,#`@=V%S('-O;&0@=&\@869F:6QI871E<RX@26X@2G5N92`R
M,#$R+"!T:&4@869F:6QI871E(&YO=&5S('=E<F4-"F5X=&5N9&5D('1O($]C
M=&]B97(@,34L(#(P,3(@*&]N92!H96QD(&)Y($UR+B!-:6QL:6=A;B!F;W(@
M)#4P+#`P,"!A;F0@;VYE(&9O<B`D-3`L,#`P(&AE;&0@8GD@0D8@26YV97-T
M;65N=',L($Q,0RP@=VAI8V@@:7,@;W=N960-"F)Y($)R:6%N($)E<FYI8VLL
M(&$@;65M8F5R(&]F('1H92!B;V%R9"!O9B!D:7)E8W1O<G,@;V8@;W5R(&-O
M;7!A;GDN($]N($]C=&]B97(@-"P@,C`Q,B!T:&5S92!6:71A365D($YO=&5S
M('=E<F4@<&%I9"!I;B!F=6QL#0II;F-L=61I;F<@)#4L,S0Q(&EN(&%C8W)U
M960@:6YT97)E<W0N)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!$96-E;6)E<B`R
M,#$Q+"!W92!I<W-U960@-"4@<')O;6ES<V]R>0T*;F]T97,@=&\@37(N($9I
M;FEZ:6\@86YD($UR+B!-:6QL:6=A;B!A;F0@9F]R(&%N(&%G9W)E9V%T92!O
M9B`D,3`P+#`P,"`H)#4P+#`P,"!E86-H*2!W:71H(&]R:6=I;F%L(&1U92!D
M871E<R!O9B!-87)C:"`Q+"`R,#$R+@T*5&AE<V4@<')O;6ES<V]R>2!N;W1E
M<R!W97)E(&5X=&5N9&5D(&)Y(&UU='5A;"!A9W)E96UE;G0@=&\@2G5N92`Q
M+"`R,#$R+B!);B!*=6YE(#(P,3(L('1H92!P<F]M:7-S;W)Y(&YO=&4@:&5L
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M960@:6YT97)E<W0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y0=7)C:&%S97,@8GD@4F5L
M871E9"!087)T:65S)B,Q-C`[/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1'5R:6YG(#(P
M,3(L('=E('-O;&0@;W5R('!R;V1U8W1S('1O($1R+B!"<FEA;@T*0F5R;FEC
M:RP@82!D:7)E8W1O<B!O9B!O=7(@8V]M<&%N>2P@:6X@=&AE(&%M;W5N="!O
M9B`D,BPV,S(L(&%N9"`D,2PR-S(@;V8@<F5C96EV86)L97,@<F5L871E9"!T
M:&5R971O(')E;6%I;F5D(&]U='-T86YD:6YG(&%T#0I$96-E;6)E<B`S,2P@
M,C`Q,BX@3F\@<')O9'5C=',@=V5R92!S;VQD('1O($1R+B!"97)N:6-K(&1U
M<FEN9R`R,#$T(&%N9"`R,#$S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^06=R965M96YT
M<R!W:71H(%!E<FYI>"!4:&5R87!E=71I8W,L($Q,0SPO=3X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/D]N($9E8G)U87)Y(#(Y+"`R,#$R+"!#;V]P97(@0RX-"D-O;&QI;G,L
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M<W5C:`T*86=R965M96YT<R!A<F4@<F5V:65W960@8GD@:6YD97!E;F1E;G0@
M9&ER96-T;W)S(&]F(&]U<B!C;VUP86YY(&]R(&$@8V]M;6ET=&5E(&-O;G-I
M<W1I;F<@;V8@:6YD97!E;F1E;G0@9&ER96-T;W)S(&]F(&]U<B!C;VUP86YY
M+@T*1'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P@
M,C`Q,RP@86YD(#(P,3(L('=E(&UA9&4@<'5R8VAA<V5S(&]F("0P+"`D,"!A
M;F0@)#0P-"PP,#`L(')E<W!E8W1I=F5L>2P@9G)O;0T*4&5R;FEX+B!!="!$
M96-E;6)E<B`S,2P@,C`Q-"P@,C`Q,RP@86YD(#(P,3(L('1H97)E('=E<F4@
M86UO=6YT<R!D=64@4&5R;FEX(&]F(&%P<')O>&EM871E;'D@)#0V+#`P,"P@
M)#0V+#`P,"P@86YD#0HD,S`X+#`P,"!O=71S=&%N9&EN9RP@<F5S<&5C=&EV
M96QY+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
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M;G0@:6X@=&AE(&%M;W5N=`T*;V8@)#(T.2PY.#$@9F]R(&5A8V@@;V8@=&AE
M('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S+B8C,38P
M.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^5V%R<F%N=',@87-S:6=N960@=&\@
M4F5L871E9"!087)T>28C,38P.SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($IU;F4@
M,C`Q,BP@82!W87)R86YT('1O('!U<F-H87-E(#$P,"PP,#`-"G-H87)E<R!O
M9B!O=7(@0V]M;6]N(%-T;V-K('=A<R!A<W-I9VYE9"!B>2!A(&YO;BUA9F9I
M;&EA=&5D('1H:7)D('!A<G1Y('1O('1H92!S;VX@;V8@=&AE($-H86ER;6%N
M(&]F(&]U<B!B;V%R9"!O9B!D:7)E8W1O<G,N/&(^)B,Q-C`[/"]B/CPO<#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S
M,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q
M96%F9#(T.#(O5V]R:W-H965T<R]3:&5E=#$Y+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^0E5324Y%4U,@0T].0T5.5%)!5$E/
M3E,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4FES:W,@86YD(%5N8V5R=&%I;G1I97,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"55-)3D53
M4R!#3TY#14Y44D%424].4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M8CX\=3Y.3U1%(#$S("T@0E5324Y%4U,@0T].0T5.5%)!5$E/3E,F(S$V,#L\
M+W4^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#!I;B<^5V4@<'5R
M8VAA<V4@;W5R('!R;V1U8W1S#0IF<F]M('-E=F5R86P@<W5P<&QI97)S('=I
M=&@@87!P<F]X:6UA=&5L>2`X,B4L(#DX)2P@86YD(#<V)2!O9B!O=7(@<'5R
M8VAA<V5S('-U<'!L:65D(&9R;VT@;VYE('9E;F1O<B!F;W(@=&AE('EE87)S
M(&5N9&5D($1E8V5M8F5R#0HS,2P@,C`Q-"P@,C`Q,RP@86YD(#(P,3(L(')E
M<W!E8W1I=F5L>2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#!I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P:6XG/E=E('-E;&P@;W5R('9I=&%M:6YS+`T*<')E;F%T
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M(&-U<W1O;65R<R!A8V-O=6YT960@9F]R(&%P<')O>&EM871E;'D@-S4E+"`W
M.24L(&%N9"`R."4@;V8@;W5R(')E8V]G;FEZ960@<F5V96YU92!A;F0@.3<E
M+"`Y-R4L#0IA;F0@.3@E(&]F(&]U<B!D969E<G)E9"!R979E;G5E(&9O<B!T
M:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,30L(#(P,3,L(&%N9"`R
M,#$R+"!R97-P96-T:79E;'DN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P:6XG/B8C,38P
M.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,&EN)SY&;W(@=&AE('EE87)S#0IE
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,BP@=V4@:&%D
M(&9O=7(@8W5S=&]M97)S('1H870@9V5N97)A=&5D(&UO<F4@=&AA;B`Q,"4@
M;V8@;W5R('-A;&5S("8C,34P.R!T:&5S90T*8W5S=&]M97)S(&%R92!D97-I
M9VYA=&5D(&%S(&-U<W1O;65R<R`F(S$T-SM!)B,Q-#@[+"`F(S$T-SM")B,Q
M-#@[+"`F(S$T-SM#)B,Q-#@[(&%N9"`F(S$T-SM$)B,Q-#@[+B!#=7-T;VUE
M<G,@02P@0BP-"D,@86YD($0@9V5N97)A=&5D("0Q+#8P.2PY-3`L("0Q+#4X
M-BPY,#,L("0Q+#@P-"PP,3@@86YD("0T+#`U,RPX,S@L(')E<W!E8W1I=F5L
M>2P@:6X@<V%L97,@:6X@,C`Q-#L@)#$L,C(Q+#(Q,BP@)#$L-S$Q+#0Q-RP-
M"B0R+#4X."PV,C8L(&%N9"`D,2PS,3(L,3DR+"!R97-P96-T:79E;'DL(&EN
M('-A;&5S(&EN(#(P,3,[(&%N9"`D-C<L-3DY+"`D-#DP+#`Y,BP@)#@S,"PY
M,#(L(&%N9"`D,"P@<F5S<&5C=&EV96QY+`T*:6X@<V%L97,@:6X@,C`Q,BX\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D
M,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?
M-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970R,"YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/34U)5$U%3E13($%.1"!#
M3TY424Y'14Y#2453/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S
M($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU-251-14Y44R!!3D0@0T].5$E.1T5.
M0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CX\=3Y.3U1%(#$T
M("8C,34P.R!#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO=3X\+V(^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\=3Y/<&5R871I;F<@3&5A<V4\+W4^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P
M.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY792!L96%S92!A9&UI;FES=')A=&EV92!O9F9I8V4@<W!A
M8V4@:6X@0F]C80T*4F%T;VXL($9L;W)I9&$@<'5R<W5A;G0@=&\@82`V,R!M
M;VYT:"!N;VXM8V%N8V5L86)L92!O<&5R871I;F<@;&5A<V4@=&AA="!C;VUM
M96YC960@;VX@2G5L>2`Q+"`R,#$S(&%N9"!E>'!I<F5S(&]N(%-E<'1E;6)E
M<B`S,"P-"C(P,3@N(%1H92!L96%S92!S=&EP=6QA=&5S+"!A;6]N9R!O=&AE
M<B!T:&EN9W,L(&%V97)A9V4@8F%S92!M;VYT:&QY(')E;G1S(&]F("0S,"PQ
M-#D@*&EN8VQU<VEV92!O9B!E<W1I;6%T960@;W!E<F%T:6YG(&5X<&5N<V5S
M*0T*86YD('-A;&5S('1A>"P@9F]R(&$@=&]T86P@9G5T=7)E(&UI;FEM=6T@
M<&%Y;65N=',@;W9E<B!T:&4@;&EF92!O9B!T:&4@;&5A<V4@;V8@)#$L.#DY
M+#0Q-"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!S=')A:6=H="!L:6YE(')E
M;G1A;"!E>'!E;G-E(')E;&%T960-"G1O(&]U<B!C=7)R96YT(&QE87-E('1O
M=&%L960F(S$V,#L@)#,V,2PW.3,@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M
M8F5R(#,Q+"`R,#$T+"!P87)T:6%L;'D@;V9F<V5T(&)Y('1H92!R96YT(&EN
M8V]M92!O9@T*)#0Q+#8Q,R!F;W(@<W5B;&5T('-P86-E+B!4:&4@<W1R86EG
M:'0@;&EN92!R96YT86P@97AP96YS92!R96QA=&5D('1O(&]U<B!C=7)R96YT
M(&QE87-E('1O=&%L960F(S$V,#L@)#$X,"PX.30@9F]R('1H92!S:7@-"FUO
M;G1H<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,RP@<&%R=&EA;&QY(&]F9G-E
M="!B>2!R96YT(&EN8V]M92!O9B`D,S(L.38S(&9O<B!S=6)L970@<W!A8V4N
M(%1H92!R96YT86P@97AP96YS92!R96QA=&5D('1O(&]U<@T*<')I;W(@;&5A
M<V4@=VAI8V@@97AP:7)E9"!*=6YE(#,P+"`R,#$S('1O=&%L960@)#8P+#$V
M."!F;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,RP@86YD
M("0Q,#8L,S$U(&9O<B!T:&4@>65A<@T*96YD960@1&5C96UB97(@,S$L(#(P
M,3(N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"P@9G5T
M=7)E(&UI;FEM=6T@<F5N=&%L#0IP87EM96YT<R!U;F1E<B!O=7(@;V9F:6-E
M(&QE87-E(&%R92!A<R!F;VQL;W=S.B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
M"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M('=I9'1H.B`X,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/EEE87)S
M($5N9&EN9R!$96-E;6)E<B`S,2P\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@8V]L<W!A
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M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,W
M,2PR-#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@8V]L<W!A
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M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,S@R+#,W-SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,C`Q-SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M<FEF)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXR,#$X/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,S`R+#<T.#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q.3PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
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M)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY4;W1A;"!M:6YI;75M(&QE87-E('!A>6UE;G1S
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G
M8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
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M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!C;VQS
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M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB
M;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#0U,"PR,3,\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#8V
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=VED=&@Z(#4E.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z
M(#(U)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^
M#0H\+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\=3Y,96=A;"!0<F]C965D:6YG<SPO
M=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9R;VT@
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M;&]W<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQU/D]F9BU"86QA;F-E(%-H965T($%R
M<F%N9V5M96YT<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S(&%N9"`R,#$R
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M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S
M7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F
M9#(T.#(O5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4T5,14-4140@455!4E1%4DQ9($9)3D%.
M0TE!3"!$051!("A53D%51$E4140I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E%U87)T97)L>2!&:6YA;F-I86P@
M26YF;W)M871I;VX@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-%3$5#5$5$(%%505)4
M15),62!&24Y!3D-)04P@1$%402`H54Y!541)5$5$*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\8CX\=3Y.3U1%(#$U("8C,34P.R!314Q%0U1%1"!1
M54%25$523%D@1DE.04Y#24%,#0I$051!("A53D%51$E4140I/"]U/CPO8CXF
M(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/E-U;6UA<FEZ960@<75A<G1E<FQY(&9I;F%N8VEA;"!D871A(&9O<B!F
M:7-C86P@>65A<G,@,C`Q-"P@,C`Q,RP-"F%N9"`R,#$R(&ES(&%S(&9O;&QO
M=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.R8C,38P.SPO
M<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#$P
M,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0Q-2!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$T
M(%%U87)T97)S/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET
M86QI8SL@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH26X@=&AO=7-A;F1S+"!E>&-E<'0@
M<&5R('-H87)E*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$\<W5P/G-T/"]S=7`^/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[
M(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C(\<W5P/FYD/"]S=7`^/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,\
M<W5P/G)D/"]S=7`^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^-'1H/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`U
M,B4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^4F5V96YU97,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L.#,Q/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,RPW-3(\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+#$X-CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[
M('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C0L,C4W/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY'<F]S<R!P<F]F:70\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C(L,#`P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L.#4Y/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C,L,3$X/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C,L,S<W/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U
M*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.970@;&]S
M<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^*#DL,3@S/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXH,3`L.#DY/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,3<L.#,R/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXH,38L,S`S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/DQO<W,@<&5R(&-O;6UO;B!S:&%R92P@8F%S
M:6,@86YD(&1I;'5T960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C`V/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXH,"XP-SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#`N
M,3(\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C$P/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X\+W1R/@T*/"]T86)L93X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@,3`P)3L@9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#$U('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3,@475A<G1E<G,\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@
M("`\=&0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/BA);B!T:&]U<V%N9',L(&5X8V5P="!P97(@<VAA<F4I/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,3QS=7`^<W0\+W-U<#X\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,CQS=7`^
M;F0\+W-U<#X\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ
M($)L86-K(#%P="!S;VQI9#L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,SQS=7`^<F0\+W-U<#X\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T
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M)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4R)3L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY2979E;G5E<SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,2PU,S<\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+#`X,3PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[
M('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C(L,CDU/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,BPX-C,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H
M:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D=R;W-S
M('!R;V9I=#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PQ-3<\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,2PV,3<\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,2PV-#8\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BPS.38\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYE="!L;W-S/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXH-BPS-S8\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@V+#`P.3PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#<L-C<S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH."PS
M-C$\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L
M,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M3&]S<R!P97(@8V]M;6]N('-H87)E+"!B87-I8R!A;F0@9&EL=71E9#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*#`N,#8\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P
M+C`U/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,"XP-CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*#`N,#8\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/BD\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,34@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q,B!1=6%R=&5R<SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^*$EN('1H;W5S86YD<RP@97AC97!T('!E<B!S:&%R92D\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXQ/'-U<#YS=#PO<W5P/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR/'-U
M<#YN9#PO<W5P/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS/'-U<#YR9#PO<W5P/CPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T
M('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C1T:#PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR
M-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-3(E.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)E=F5N=65S/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXW,C(\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX,3D\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXQ+#`S-CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C$L,C0Q/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET
M93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY'<F]S<R!P
M<F]F:70\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,X-CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXT-#<\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-S(Y/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CDP.#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^3F5T(&QO<W,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q
M,RPR.3`\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q,2PX-3`\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B@T+#(U,SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#4L-S(W/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DQO<W,@<&5R
M(&-O;6UO;B!S:&%R92P@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B@P+C$V/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,"XQ-#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#`N,#0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C`V
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T
M9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&(^)B,Q-C`[/"]B/CPO<#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F
M8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R
M:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4U5"4T51545.5"!%5D5.5%,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%
M=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y354)315%514Y4($5614Y44SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\8CX\=3Y.3U1%(#$V("8C,34P.R!354)315%514Y4
M($5614Y44SPO=3X\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQB/B8C,38P.R8C,38P.SPO8CX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@
M1F5B<G5A<GDF(S$V,#LQ,"P@,C`Q-2P@=V4-"F5N=&5R960@:6YT;R!A;B!U
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M:6-E(&]F("0T+C`U('!E<B!S:&%R92X@56YD97(@=&AE('1E<FUS(&]F('1H
M92!#;W=E;@T*06=R965M96YT+"!W92!G<F%N=&5D('1H92!#;W=E;B!5;F1E
M<G=R:71E<G,@82`S,"UD87D@;W!T:6]N('1O('!U<F-H87-E('5P('1O(&%N
M(&%G9W)E9V%T92!O9B`R+#`S-RPP,S8@861D:71I;VYA;`T*<VAA<F5S(&]F
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M-C`[,3<L(#(P,34N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!&96)R=6%R>2`Q
M."P@,C`Q-2P@=V4@96YT97)E9"!I;G1O(&%N(&%G<F5E;65N=`T*=&\@;&5A
M<V4@861M:6YI<W1R871I=F4@;V9F:6-E('-P86-E(&EN($)O8V$@4F%T;VXL
M($9L;W)I9&$L('!U<G-U86YT('1O(&%N(&%D9&5N9'5M('1O(&]U<B!E>&ES
M=&EN9R`V,R!M;VYT:"!N;VXM8V%N8V5L86)L92!O<&5R871I;F<-"FQE87-E
M(&-O;6UE;F-I;F<@;VX@2G5L>2`Q+"`R,#$S(&%N9"!E>'!I<FEN9R!O;B!3
M97!T96UB97(@,S`L(#(P,3@N(%1H:7,@861D96YD=6T@=VEL;"!B92!E9F9E
M8W1I=F4@8F5G:6YN:6YG($%P<FEL(#$L(#(P,34@86YD#0IW:6QL(&5X<&ER
M92!W:71H('1H92!O<FEG:6YA;"!L96%S92!T97)M(&]N(%-E<'1E;6)E<B`S
M,"P@,C`Q."X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D
M,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S
M,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H
M965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5+1T%%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%
M4R`H4&]L:6-I97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<FEN8VEP;&5S(&]F($-O;G-O;&ED871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/'4^4')I;F-I<&QE
M<R!O9B!#;VYS;VQI9&%T:6]N/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
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M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!L
M971T97(M<W!A8VEN9SH@+3`N,35P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;"<^/'4^0V%S:#PO
M=3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[(&QE='1E<BUS
M<&%C:6YG.B`M,"XQ-7!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[(&QE='1E<BUS<&%C:6YG.B`M,"XQ
M-7!T.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@;F]R;6%L)SY790T*;6%I;G1A:6X@8V%S:"!A="!F:6YA;F-I
M86P@:6YS=&ET=71I;VYS('1H870@870@=&EM97,@;6%Y(&5X8V5E9"!T:&4@
M9F5D97)A;&QY(&EN<W5R960@;&EM:70@;V8@)#(U,"PP,#`@<&5R(&9I;F%N
M8VEA;"!I;G-T:71U=&EO;BX-"E=E(&AA=F4@;F5V97(@97AP97)I96YC960@
M86YY(&QO<W-E<R!R96QA=&5D('1O('1H97-E(&9U;F1S+CPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@;&5T=&5R+7-P86-I;F<Z("TP+C$U
M<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M=V5I9VAT.B!N;W)M86PG/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D
M92!!8V-O=6YT<R!296-E:79A8FQE(&%N9"!!;&QO=V%N8V4@9F]R($1O=6)T
M9G5L($%C8V]U;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/E1R
M861E($%C8V]U;G1S(%)E8V5I=F%B;&4@86YD($%L;&]W86YC90T*9F]R($1O
M=6)T9G5L($%C8V]U;G1S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP
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M=6YT<R!R96-E:79A8FQE('!A<W0@9'5E(&9O<B!M;W)E('1H86X@.3`@9&%Y
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M8V]U;G1S('=H96X@<F5C96EV960N(#QF;VYT('-T>6QE/3-$)V-O;&]R.B`C
M,C4R-3(U)SY4;R!T:&4@97AT96YT(&1A=&$@=V4@=7-E('1O(&-A;&-U;&%T
M92!T:&5S92!E<W1I;6%T97,@9&]E<R!N;W0-"F%C8W5R871E;'D@<F5F;&5C
M="!B860@9&5B=',[(&%D:G5S=&UE;G1S('1O('1H97-E(')E<V5R=F5S(&UA
M>2!B92!R97%U:7)E9"X\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P
M86-I;F<Z("TP+C$U<'0G/CQU/DEN=F5N=&]R:65S)B,Q-C`[/"]U/CPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G
M/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
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M(')E;&%T960@9&5F97)R960@<F5V96YU92!I<R!R96-O9VYI>F5D+B`\+V9O
M;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1FEX960@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQU/D9I>&5D($%S<V5T<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI
M/CQU/D5Q=6EP;65N=#PO=3X\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!S=&%T92!E
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M:6]N('5S:6YG('1H92!S=')A:6=H="UL:6YE(&UE=&AO9`T*;W9E<B!T:&4@
M97-T:6UA=&5D('5S969U;"!L:79E<R!O9B!T:&4@<F5L871E9"!A<W-E=',L
M('=H:6-H(')A;F=E(&9R;VT@=&AR964@=&\@<V5V96X@>65A<G,N/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M
M<W!A8VEN9SH@+3`N,35P="<^/&D^/'4^3&5A<V5H;VQD#0I);7!R;W9E;65N
M=',\+W4^/"]I/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P
M86-I;F<Z("TP+C$U<'0G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
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M;&5A<V4N/"]F;VYT/B8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@07-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E
M<BUS<&%C:6YG.B`M,"XQ-7!T)SX\=3Y);G1A;F=I8FQE#0H\+W4^/"]F;VYT
M/CQU/D%S<V5T<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE
M/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SX\:3X\=3Y0871E;G0-"F%N
M9"!4<F%D96UA<FMS/"]U/CPO:3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SX\:3XF(S$V,#LF(S$V,#L\+VD^
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N
M,35P="<^5V4@:&%V90T*861O<'1E9"!T:&4@<')O=FES:6]N<R!O9B`\+V9O
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M86-I;F<Z("TP+C$U<'0G/BX@0V%P:71A;&EZ960@<&%T96YT(&-O<W1S+`T*
M;F5T(&]F(&%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;BP@:6YC;'5D92!L96=A
M;"!C;W-T<R!I;F-U<G)E9"!F;W(@<&%T96YT(&%P<&QI8V%T:6]N<RX@/"]F
M;VYT/DEN(&%C8V]R9&%N8V4@=VET:"!!4T,@,S4P+"`\9F]N="!S='EL93TS
M1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^;VYC90T*82!P871E;G0@:7,@
M9W)A;G1E9"P@=V4@86UO<G1I>F4@=&AE(&-A<&ET86QI>F5D('!A=&5N="!C
M;W-T<R!O=F5R('1H92!R96UA:6YI;F<@;&EF92!O9B!T:&4@<&%T96YT('5S
M:6YG('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"X-"DEF('1H92!P871E;G0@
M:7,@;F]T(&=R86YT960L('=E('=R:71E+6]F9B!A;GD@8V%P:71A;&EZ960@
M<&%T96YT(&-O<W1S(&%T('1H870@=&EM92X@5V4@<F5V:65W(&EN=&%N9VEB
M;&4@87-S971S(&9O<B!I;7!A:7)M96YT#0IA;FYU86QL>2!O<B!W:&5N(&5V
M96YT<R!O<B!C:7)C=6US=&%N8V5S(&EN9&EC871E('1H870@=&AE:7(@8V%R
M<GEI;F<@86UO=6YT(&UA>2!N;W0@8F4@<F5C;W9E<F%B;&4N($%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$T+"!W90T*:&%D(#0@:7-S=65D('!A=&5N=',@*%-E
M92!.;W1E(#<I+B`\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26UP86ER;65N="!O9B!,;VYG+4QI
M=F5D($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y);7!A
M:7)M96YT(&]F($QO;F<M3&EV960@07-S971S)B,Q-C`[/"]U/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
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M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#(E)SXF(S$T.3L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T:#H@.3,E)SYS:6=N:69I8V%N="!D
M96-L:6YE<R!I;B!A;B!A<W-E="8C,30V.W,@;6%R:V5T('!R:6-E.SPO=&0^
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N,C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P)SX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#4E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,B4G/B8C,30Y.R8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('=I9'1H.B`Y,R4G/G-I9VYI9FEC86YT(&1E
M=&5R:6]R871I;VX@:6X@86X@87-S970F(S$T-CMS('!H>7-I8V%L(&-O;F1I
M=&EO;CL\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M(#`@,"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M("TP+C(U:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#(E)SXF(S$T.3L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T:#H@.3,E)SYS:6=N:69I8V%N
M="!C:&%N9V5S(&EN('1H92!N871U<F4@;W(@97AT96YT(&]F(&%N(&%S<V5T
M)B,Q-#8[<R!U<V4@;W(@;W!E<F%T:6]N.SPO=&0^/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N,C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS
M1"=W:61T:#H@,3`P)3L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`P
M.R!M87)G:6XM8F]T=&]M.B`P)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/B8C,30Y.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('=I
M9'1H.B`Y,R4G/G-I9VYI9FEC86YT(&%D=F5R<V4@8VAA;F=E<R!I;B!T:&4@
M8G5S:6YE<W,@8VQI;6%T92!T:&%T(&-O=6QD(&EM<&%C="!A;B!A<W-E="8C
M,30V.W,@=F%L=64L(&EN8VQU9&EN9R!A9'9E<G-E(&%C=&EO;G,@;W(@87-S
M97-S;65N=',@8GD@<F5G=6QA=&]R<SL\+W1D/CPO='(^#0H\+W1A8FQE/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z("TP+C(U:6XG/B8C,38P.SPO<#X-"@T*/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M=VED=&@Z(#$P,"4[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,#L@
M;6%R9VEN+6)O='1O;3H@,"<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SXF(S$T.3L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T
M:#H@.3,E)SYA8V-U;75L871I;VX@;V8@8V]S=',@<VEG;FEF:6-A;G1L>2!I
M;B!E>&-E<W,@;V8@;W)I9VEN86P@97AP96-T871I;VYS(')E;&%T960@=&\@
M=&AE(&%C<75I<VET:6]N(&]R(&-O;G-T<G5C=&EO;B!O9B!A;B!A<W-E=#L\
M+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P
M+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TP+C(U
M:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#(E)SXF(S$T.3L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z("TP+C(U:6XG/B8C,38P.SPO<#X-"@T*/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M=VED=&@Z(#$P,"4[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,#L@
M;6%R9VEN+6)O='1O;3H@,"<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SXF(S$T.3L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T
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M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XU:6X[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`M,"XR-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^268@:6UP86ER;65N="!I;F1I8V%T;W)S(&%R92!P<F5S96YT
M+"!W92!D971E<FUI;F4-"G=H971H97(@86X@:6UP86ER;65N="!L;W-S('-H
M;W5L9"!B92!R96-O9VYI>F5D(&)Y('1E<W1I;F<@=&AE(&%P<&QI8V%B;&4@
M87-S970@;W(@87-S970@9W)O=7`F(S$T-CMS(&-A<G)Y:6YG('9A;'5E(&9O
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M;G1E9`T*9G5T=7)E(&-A<V@@9FQO=W,@97AP96-T960@=&\@8F4@9V5N97)A
M=&5D(&9R;VT@=&AE('5S92!A;F0@979E;G1U86P@9&ES<&]S86P@;V8@=&AE
M(&%S<V5T<R!A;F0@8V]M<&%R92!T:&%T(&5S=&EM871E('1O('1H92!R97-P
M96-T:79E#0IC87)R>6EN9R!V86QU97,@:6X@;W)D97(@=&\@9&5T97)M:6YE
M(&EF('-U8V@@8V%R<GEI;F<@=F%L=65S(&%R92!R96-O=F5R86)L92X@5&AI
M<R!A<W-E<W-M96YT(')E<75I<F5S('1H92!E>&5R8VES92!O9B!J=61G;65N
M=`T*:6X@87-S97-S:6YG('1H92!F=71U<F4@=7-E(&]F(&%N9"!P<F]J96-T
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M('-H87)E+`T*<')O:F5C=&5D('-E;&QI;F<@<')I8V5S+"!M86YU9F%C='5R
M:6YG(&-O<W0L(&%N9"!D:7-C;W5N="!R871E+B!792!B87-E(&5S=&EM871E
M<R!U<&]N(&AI<W1O<FEC86P@97AP97)I96YC92P@;W5R(&-O;6UE<F-I86P-
M"G)E;&%T:6]N<VAI<',L(&UA<FME="!C;VYD:71I;VYS+"!A;F0@879A:6QA
M8FQE(&5X=&5R;F%L(&EN9F]R;6%T:6]N(&%B;W5T(&9U='5R92!T<F5N9',N
M(%=E(&)E;&EE=F4@;W5R(&-U<G)E;G0@87-S=6UP=&EO;G,@86YD#0IE<W1I
M;6%T97,@87)E(')E87-O;F%B;&4@86YD(&%P<')O<')I871E+B!5;F%N=&EC
M:7!A=&5D(&5V96YT<R!A;F0@8VAA;F=E<R!I;B!M87)K970@8V]N9&ET:6]N
M<RP@:&]W979E<BP@8V]U;&0@869F96-T('-U8V@@97-T:6UA=&5S+`T*<F5S
M=6QT:6YG(&EN('1H92!N965D(&9O<B!A;B!I;7!A:7)M96YT(&-H87)G92!I
M;B!F=71U<F4@<&5R:6]D<RX@5&AE<F4@=V%S(&YO(&EM<&%I<FUE;G0@;V8@
M:6YT86YG:6)L97,@;W(@;&]N9RUL:79E9"!A<W-E=',-"F1U<FEN9R!T:&4@
M>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,30L(#(P,3,@86YD(#(P,3(N
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1F%I<B!686QU92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^1F%I<B!686QU92!O9B!&:6YA
M;F-I86P@26YS=')U;65N=',\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/=7(@
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M('1H92!F86ER('9A;'5E(&AI97)A<F-H>2X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!C871E9V]R:7IE(&]U<B!A<W-E
M=',@86YD(&QI86)I;&ET:65S#0IT:&%T(&%R92!V86QU960@870@9F%I<B!V
M86QU92!O;B!A(')E8W5R<FEN9R!B87-I<R!I;G1O(&$@=&AR964M;&5V96P@
M9F%I<B!V86QU92!H:65R87)C:'D@87,@9&5F:6YE9"!B>2!!4T,@.#(P+"`\
M:3Y&86ER#0I686QU92!-96%S=7)E;65N=',N(#PO:3Y4:&4@9F%I<B!V86QU
M92!H:65R87)C:'D@9VEV97,@=&AE(&AI9VAE<W0@<')I;W)I='D@=&\@<75O
M=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L#0IA
M<W-E=',@86YD(&QI86)I;&ET:65S("A,979E;"`Q*2!A;F0@;&]W97-T('!R
M:6]R:71Y('1O('5N;V)S97)V86)L92!I;G!U=',@*$QE=F5L(#,I+B!!<W-E
M=',@86YD(&QI86)I;&ET:65S(')E8V]R9&5D(&EN('1H90T*8V]N<V]L:61A
M=&5D(&)A;&%N8V4@<VAE970@870@9F%I<B!V86QU92!A<F4@8V%T96=O<FEZ
M960@8F%S960@;VX@82!H:65R87)C:'D@;V8@:6YP=71S+"!A<R!F;VQL;W=S
M.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XM=&]P.B`P
M.R!M87)G:6XM8F]T=&]M.B`P)SX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\=&0@<W1Y;&4],T0G=VED=&@Z(#@E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,B4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&(^3&5V96P-"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@,3PO8CX\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T:#H@.#`E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/G5N861J=7-T960-"G%U
M;W1E9"!P<FEC97,@:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A
M<W-E=',@;W(@;&EA8FEL:71I97,[/"]T9#X\+W1R/CPO=&%B;&4^#0H-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^
M#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M
M.B`P)SX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\=&0@<W1Y
M;&4],T0G=VED=&@Z(#@E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&(^3&5V96P-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@,CPO8CX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!W:61T:#H@.#`E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/G%U;W1E9`T*<')I8V5S(&9O<B!S:6UI;&%R(&%S
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M/CPO='(^/"]T86)L93X-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN+71O
M<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/'1D('-T>6QE/3-$)W=I9'1H.B`X)3L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,3(E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQB/DQE=F5L#0H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(#,\+V(^/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=VED=&@Z(#@P)3L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SYU;F]B<V5R=F%B
M;&4-"FEN<'5T<R!F;W(@=&AE(&%S<V5T(&]R(&QI86)I;&ET>2X\+W1D/CPO
M='(^/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!="!$
M96-E;6)E<B`S,2P@,C`Q-"P@86YD(#(P,3,L('=E(&AA9"!N;R!A<W-E=',-
M"F]R(&QI86)I;&ET:65S('1H870@=V5R92!V86QU960@870@9F%I<B!V86QU
M92!O;B!A(')E8W5R<FEN9R!B87-I<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H
M92!F86ER('9A;'5E(&]F(&EN9&5F:6YI=&4M;&EV960@87-S971S(&ES#0IM
M96%S=7)E9"!O;B!A(&YO;BUR96-U<G)I;F<@8F%S:7,@=7-I;F<@<VEG;FEF
M:6-A;G0@=6YO8G-E<G9A8FQE(&EN<'5T<R`H3&5V96P@,RD@:6X@8V]N;F5C
M=&EO;B!W:71H(&]U<B!I;7!A:7)M96YT#0IT97-T+B!4:&5R92!W87,@;F\@
M:6UP86ER;65N="!O9B!I;G1A;F=I8FQE(&%S<V5T<R!D=7)I;F<@=&AE('EE
M87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S+"!A;F0@,C`Q,BX\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/'4^26YC;VUE(%1A>&5S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP
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M:6YG($]C=&]B97(@-"P@,C`Q,2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E(&%C8V]U;G0@
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M92!Y96%R<R!I;B!W:&EC:`T*=&AE(')E;&%T960@=&5M<&]R87)Y(&1I9F9E
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M('1H86X@;F]T(&)E(')E86QI>F5D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@
M86-C;W)D86YC92!W:71H($%30R`W-#`L(#QI/DEN8V]M92!487AE<SPO:3XL
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M<F5A=&5R('1H86X@-3`E+B!#:&%N9V5S(&EN(')E8V]G;FET:6]N(&]R(&UE
M87-U<F5M96YT(&%R92!R969L96-T960@:6X-"G1H92!P97)I;V0@:6X@=VAI
M8V@@=&AO<V4@8VAA;F=E<R!I;B!J=61G;65N="!O8V-U<BX@070@1&5C96UB
M97(@,S$L(#(P,30L(#(P,3,L(&%N9"`R,#$R('=E(&AA9"!N;R!U;F-E<G1A
M:6X@:6YC;VUE('1A>"!P;W-I=&EO;G,N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!R96-O
M9VYI>F4@8F]T:"!I;G1E<F5S="!A;F0@<&5N86QT:65S(')E;&%T960-"G1O
M('5N8V5R=&%I;B!T87@@<&]S:71I;VYS(&%S('!A<G0@;V8@=&AE(&EN8V]M
M92!T87@@<')O=FES:6]N+B!!="!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q
M,RP@=V4@:&%D(&YO('1A>"!P;W-I=&EO;G,@<F5L871I;F<-"G1O(&]P96X@
M=&%X(')E='5R;G,@=&AA="!W97)E(&-O;G-I9&5R960@=&\@8F4@=6YC97)T
M86EN+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3W5R('1A>"!R971U<FYS(&%R92!S
M=6)J96-T('1O(')E=FEE=R!B>2!T:&4-"DEN=&5R;F%L(%)E=F5N=64@4V5R
M=FEC92!T:')E92!Y96%R<R!A9G1E<B!T:&5Y(&%R92!F:6QE9"X@0W5R<F5N
M=&QY+"!Y96%R<R!F:6QE9"!A9G1E<B`R,#$Q(&%R92!S=6)J96-T('1O(')E
M=FEE=RXF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92U"87-E9"!#;VUP96YS871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/'4^4VAA<F4M0F%S960@0V]M<&5N<V%T:6]N/"]U/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE
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M8VEA;"!S=&%T96UE;G1S(&]V97(@=&AE('!E<FEO9`T*9'5R:6YG('=H:6-H
M(&5M<&QO>65E<R!A<F4@<F5Q=6ER960@=&\@<')O=FED92!S97)V:6-E<RX@
M4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT<R!I;F-L=61E
M(&]P=&EO;G,L(')E<W1R:6-T960@<W1O8VLL#0IR97-T<FEC=&5D('-T;V-K
M('5N:71S+"!P97)F;W)M86YC92UB87-E9"!A=V%R9',L('-H87)E(&%P<')E
M8VEA=&EO;B!R:6=H=',L(&%N9"!E;7!L;WEE92!S:&%R92!P=7)C:&%S92!P
M;&%N<RX@07,@<W5C:"P@8V]M<&5N<V%T:6]N#0IC;W-T(&ES(&UE87-U<F5D
M(&]N('1H92!D871E(&]F(&=R86YT(&%T(&9A:7(@=F%L=64N(%=E(&%M;W)T
M:7IE('-U8V@@8V]M<&5N<V%T:6]N(&%M;W5N=',L(&EF(&%N>2P@;W9E<B!T
M:&4@<F5S<&5C=&EV92!V97-T:6YG#0IP97)I;V1S(&]F('1H92!A=V%R9"X@
M5V4@=7-E('1H92!";&%C:RU38VAO;&5S+4UE<G1O;B!O<'1I;VX@<')I8VEN
M9R!M;V1E;"P@;W(@=&AE($)L86-K+5-C:&]L97,@36]D96PL(&%N(&%C8V5P
M=&%B;&4@;6]D96P@:6X-"F%C8V]R9&%N8V4@=VET:"!!4T,@-S$X+"!T:&%T
M(')E<75I<F5S('1H92!I;G!U="!O9B!H:6=H;'D@8V]M<&QE>"!A;F0@<W5B
M:F5C=&EV92!V87)I86)L97,L(&EN8VQU9&EN9R!T:&4@97AP96-T960@;&EF
M92!O9B!T:&4-"F%W87)D(&%N9"!O=7(@97AP96-T960@<W1O8VL@<')I8V4@
M=F]L871I;&ET>2!O=F5R(&$@<&5R:6]D(&5Q=6%L('1O(&]R(&=R96%T97(@
M=&AA;B!T:&4@97AP96-T960@;&EF92!O9B!T:&4@87=A<F0N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P
M.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY%<75I='D@:6YS=')U;65N=',@*"8C,30W.VEN<W1R=6UE
M;G1S)B,Q-#@[*0T*:7-S=65D('1O(&YO;BUE;7!L;WEE97,@87)E(')E8V]R
M9&5D(&]N('1H92!B87-I<R!O9B!T:&4@9F%I<B!V86QU92!O9B!T:&4@:6YS
M=')U;65N=',L(&%S(')E<75I<F5D(&)Y($%30R`U,#4L(#QI/D5Q=6ET>2!"
M87-E9`T*4&%Y;65N=',@=&\@3F]N+45M<&QO>65E<SPO:3XL/&D^(#PO:3YO
M<B!!4T,@-3`U/&D^+B`\+VD^05-#(#4P-3QI/B`\+VD^9&5F:6YE<R!T:&4@
M;65A<W5R96UE;G0@9&%T92!A;F0@<F5C;V=N:71I;VX@<&5R:6]D(&9O<@T*
M<W5C:"!I;G-T<G5M96YT<RX@26X@9V5N97)A;"P@=&AE(&UE87-U<F5M96YT
M(&1A=&4@:7,@=VAE;B!E:71H97(@*&$I(&$@<&5R9F]R;6%N8V4@8V]M;6ET
M;65N="P@87,@9&5F:6YE9"P@:7,@<F5A8VAE9"!O<B`H8BD@=&AE#0IE87)L
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M87,@9&5F:6YE9"!I;B!!4T,@-3`U+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-
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M:6]D+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E8G0@1&ES8V]U;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/CQU/D1E8G0@1&ES8V]U;G1S/"]U/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M=&AO9"X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2979E;G5E(%)E8V]G;FET:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQU/E)E=F5N=64@4F5C;V=N:71I;VX\+W4^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY792!R96-O9VYI>F4@<F5V96YU92!O;B!A<G)A;F=E
M;65N=',@:6X@86-C;W)D86YC90T*=VET:"!!4T,@-C`U+"`\:3Y2979E;G5E
M(%)E8V]G;FET:6]N/"]I/BX@5V4@<F5C;V=N:7IE(')E=F5N=64@;VYL>2!W
M:&5N('1H92!P<FEC92!I<R!F:7AE9"!O<B!D971E<FUI;F%B;&4L('!E<G-U
M87-I=F4@979I9&5N8V4-"F]F(&%N(&%R<F%N9V5M96YT(&5X:7-T<RP@=&AE
M('-E<G9I8V4@:7,@<&5R9F]R;65D+"!A;F0@8V]L;&5C=&%B:6QI='D@:7,@
M<F5A<V]N86)L>2!A<W-U<F5D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
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M<F]D=6-T('9I82!T:&ER9"UP87)T>2!P87EE<G,N)B,Q-C`[0F]T:"!/5$,@
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M=&%M:6X@;W(@;W1H97(@<')O9'5C=',N)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\:3X\=3Y/=F5R+71H92U#;W5N=&5R(%!R;V1U8W1S/"]U/CPO:3X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/&D^)B,Q-C`[/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
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M:6]N86P@,S`M9&%Y(&UO;F5Y+6)A8VL@<F5T=7)N('!O;&EC>2!U;F1E<B!W
M:&EC:"!W92!A8V-E<'0@<')O9'5C="!R971U<FYS(&9R;VT@;W5R(')E=&%I
M;"!A;F0@94-O;6UE<F-E(&-U<W1O;65R<RX-"CPO9F]N=#Y792!R96-O9VYI
M>F4@;W5R(')E=F5N=64@9G)O;2!/5$,@<V%L97,L(&YE="!O9B!R971U<FYS
M+"!S86QE<R!D:7-C;W5N=',L(&%N9"!E0V]M;65R8V4@9F5E<RX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/CQI/CQU/E!R97-C<FEP=&EO;B!0<F]D=6-T<SPO=3X\+VD^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/CQI/B8C,38P.R8C,38P.SPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G8V]L;W(Z
M(",R-3(U,C4G/E=E('-E;&P@;W5R(&YA;64-"F)R86YD(&%N9"!G96YE<FEC
M('!R97-C<FEP=&EO;B!P<F]D=6-T<R`\+V9O;G0^<')I;6%R:6QY('1H<F]U
M9V@@9')U9R!W:&]L97-A;&5R<R!A;F0@<F5T86EL('!H87)M86-I97,N(%=E
M(')E8V]G;FEZ92!R979E;G5E(&9R;VT-"G!R97-C<FEP=&EO;B!P<F]D=6-T
M('-A;&5S+"!N970@;V8@<V%L97,@9&ES8V]U;G1S+"!C:&%R9V5B86-K<RP@
M86YD(')E8F%T97,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!A8V-E<'0@<F5T
M=7)N<R!O9B!U;G-A;&%B;&4@<')O9'5C=`T*9G)O;2!C=7-T;VUE<G,@=VET
M:&EN(&$@<F5T=7)N('!E<FEO9"!O9B!S:7@@;6]N=&AS('!R:6]R('1O(&%N
M9"!U<"!T;R!T=V5L=F4@;6]N=&AS(&9O;&QO=VEN9R!P<F]D=6-T(&5X<&ER
M871I;VXN($]U<@T*<')E<V-R:7!T:6]N('!R;V1U8W1S(&-U<G)E;G1L>2!H
M879E(&$@<VAE;&8@;&EF92!O9B`R-"!M;VYT:',@9G)O;2!T:&4@9&%T92!O
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M(')E='5R;B!N;R!L;VYG97(@97AI<W1S+`T*=VAI8V@@;V-C=7)S(&%T('1H
M92!E87)L:65R(&]F('1H92!T:6UE('1H92!P<F5S8W)I<'1I;VX@<')O9'5C
M=',@87)E(&1I<W!E;G-E9"!T:')O=6=H('!A=&EE;G0@<')E<V-R:7!T:6]N
M<R!O<B!E>'!I<F%T:6]N#0IO9B!T:&4@<FEG:'0@;V8@<F5T=7)N+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^5V4@;6%I;G1A:6X@=F%R:6]U<R!R96)A=&4@<')O
M9W)A;7,@:6X@86X@969F;W)T#0IT;R!M86EN=&%I;CQI/B`\+VD^82!C;VUP
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/&D^/'4^4V5G;65N="!297!O<G1I;F<F(S$V,#L\+W4^
M/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\:3XF(S$V,#L\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E(&%R92!M86YA9V5D(&%N9"!O
M<&5R871E9`T*87,@;VYE(&)U<VEN97-S+"!W:&EC:"!I<R!F;V-U<V5D(&]N
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M;VX@=VET:`T*<F5S<&5C="!T;R!S97!A<F%T92!P<F]D=6-T<RX@06QL('!R
M;V1U8W0@<V%L97,@87)E(&1E<FEV960@9G)O;2!S86QE<R!I;B!T:&4@56YI
M=&5D(%-T871E<RX@06-C;W)D:6YG;'DL('=E('9I97<@;W5R#0IB=7-I;F5S
M<R!A<R!O;F4@<F5P;W)T86)L92!O<&5R871I;F<@<V5G;65N="X\+W`^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&EP<&EN9R!A;F0@2&%N9&QI;F<@0V]S=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/'4^4VAI<'!I;F<@86YD($AA;F1L:6YG($-O<W1S/"]U/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D=F5R
M=&ES:6YG($-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT
M('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SX\=3Y!9'9E<G1I
M<VEN9PT*0V]S=',\+W4^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T
M97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY7
M92!E>'!E;G-E(&%D=F5R=&ES:6YG(&-O<W1S('=H96X@:6YC=7)R960N#0I!
M9'9E<G1I<VEN9R!C;W-T<R!W97)E("0V.3@L.#<Q+"`D,3$L-S,Y(&%N9"`D
M-C4L.30T(&1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P
M,30L(#(P,3,@86YD(#(P,3(L(')E<W!E8W1I=F5L>2X\+W`^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C
M:"!A;F0@1&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/'4^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V5S/"]U/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
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M;VXM8V%S:`T*<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V5S+B!!
M9'9A;F-E('!A>6UE;G1S('1O(&)E(&5X<&5N<V5D(&EN(&9U='5R92!2)B,S
M.#M$(&%C=&EV:71I97,@=V5R92`D,2PQ-S4L,#@R(&%N9"`D,BPV,#8L-#`U
M#0IF;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R
M,#$S+"!R97-P96-T:79E;'DN($-23R!A8W1I=FET>2!E>'!E;G-E<R!I;F-L
M=61E('!R96-L:6YI8V%L(&QA8F]R871O<GD@97AP97)I;65N=',-"F%N9"!C
M;&EN:6-A;"!T<FEA;"!S='5D:65S+B!/=&AE<B!A8W1I=FET>2!E>'!E;G-E
M<R!I;F-L=61E(')E9W5L871O<GD@8V]N<W5L=&EN9R!A;F0@;&5G86P@8V]U
M;G-E;"X@5&AE(&%C=&EV:71I97,@=6YD97)T86ME;@T*8GD@;W5R(')E9W5L
M871O<GD@8V]N<W5L=&%N=',@=&AA="!W97)E(&-L87-S:69I960@87,@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S(&EN8VQU9&4@87-S:7-T
M:6YG+"!C;VYS=6QT:6YG('=I=&@L(&%N9`T*861V:7-I;F<@;W5R(&EN+6AO
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M979E;&]P;65N=`T*97AP96YS97,@<F5L871E9"!T;R!D97-I9VYI;F<@97AP
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M92!K;F]W;BX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%87)N:6YG<R!097(@4VAA<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/'4^16%R;FEN9W,@4&5R(%-H87)E)B,Q-C`[/"]U
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^5V4@8V%L8W5L871E(&5A<FYI;F=S('!E<B!S:&%R
M92P@;W(@15!3+`T*:6X@86-C;W)D86YC92!W:71H($%30R`R-C`L(#QI/D5A
M<FYI;F=S(%!E<B!3:&%R93PO:3XL('=H:6-H(')E<75I<F5S('1H92!C;VUP
M=71A=&EO;B!A;F0@9&ES8VQO<W5R92!O9B!T=V\@15!3(&%M;W5N=',Z#0IB
M87-I8R!A;F0@9&EL=71E9"X@5V4@8V]M<'5T92!B87-I8R!%4%,@8F%S960@
M;VX@=&AE('=E:6=H=&5D+6%V97)A9V4@;G5M8F5R(&]F('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VLL('!A<B!V86QU92`D,"XP,#$@<&5R#0IS:&%R92P@;W(@
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M=&AE(&YE="!L;W-S(')E<&]R=&5D(&)Y('5S+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^5&AE('1A8FQE(&)E;&]W('!R97-E;G1S('1H92!P;W1E;G1I86QL>2!D
M:6QU=&EV90T*<V5C=7)I=&EE<R!T:&%T('=O=6QD(&AA=F4@8F5E;B!I;F-L
M=61E9"!I;B!O=7(@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@;&]S<R!P
M97(@<VAA<F4@86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@:68@
M=&AE>0T*=V5R92!N;W0@86YT:61I;'5T:79E(&9O<B!T:&4@<&5R:6]D<R!P
M<F5S96YT960N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#@P)3L@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
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M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$T
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$S
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$R
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`U,B4[('1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M;&5F=#H@,'!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E-T;V-K(&]P=&EO;G,\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@-"4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$V+#<Y,BPT-#,\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#0E.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXQ-2PV,S(L-S0R/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`T)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3,L-S,S+#0X.#PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A;G1S/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
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M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$T+#(Y,RPT.3D\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,S`L
M-S(P+#,U.3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
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M,CDL.3(V+#(T,3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\
M+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.R8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5S92!O9B!%<W1I;6%T97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^57-E(&]F($5S=&EM871E<SPO
M=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
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M87-S971S+`T*;&EA8FEL:71I97,L(')E=F5N=64L(&5X<&5N<V5S+"!A;F0@
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M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5N=&QY($ES
M<W5E9"!A;F0@3F5W;'D@061O<'1E9"!!8V-O=6YT:6YG(%!R;VYO=6YC96UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/E)E8V5N=&QY($ES
M<W5E9"!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]U/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/&9O;G0@<W1Y;&4],T0G8V]L;W(Z(",R-3(U,C4G/DEN($%U9W5S=`T*
M,C`Q-"P@=&AE($9!4T(@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P
M9&%T92P@;W(@05-5+"!.;RX@,C`Q-"TP-2P@4')E<V5N=&%T:6]N(&]F($9I
M;F%N8VEA;"!3=&%T96UE;G1S+4=O:6YG($-O;F-E<FX-"BA3=6)T;W!I8R`R
M,#4M-#`I.B!$:7-C;&]S=7)E(&]F(%5N8V5R=&%I;G1I97,@86)O=70@86X@
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M<V4@=&AA="!F86-T+B!!4U4@,C`Q-"TQ-2!I<R!E9F9E8W1I=F4@9F]R(&%N
M;G5A;"!P97)I;V1S(&5N9&EN9PT*869T97(@1&5C96UB97(@,34L(#(P,38@
M86YD(&EN=&5R:6T@<&5R:6]D<R!W:71H:6X@86YN=6%L('!E<FEO9',@8F5G
M:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$V+B!%87)L>2!A9&]P=&EO
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M8VEA;"!S=&%T96UE;G1S(&%N9`T*9&ES8VQO<W5R97,N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/DEN($UA>2`R,#$T+"!T:&4@1D%30B!A;F0@=&AE($EN=&5R
M;F%T:6]N86P-"D%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D("A)05-"*2!I
M<W-U960@05-5+"!.;RX@,C`Q-"TP.2P@4F5V96YU92!F<F]M($-O;G1R86-T
M<R!W:71H($-U<W1O;65R<R`H5&]P:6,@-C`V*2X@5&AE('-T86YD87)D)B,Q
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M;&EG871I;VYS+B!!4U4@,C`Q-"TP.2!I<R!E9F9E8W1I=F4@9F]R('!U8FQI
M8R!B=7-I;F5S<R!E;G1I=&EE<RP@8V5R=&%I;@T*;F]T+69O<BUP<F]F:70@
M96YT:71I97,@86YD(&-E<G1A:6X@96UP;&]Y964@8F5N969I="!P;&%N<RP@
M9F]R(&%N;G5A;"!P97)I;V1S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q
M-2P@,C`Q-BP@:6YC;'5D:6YG(&EN=&5R:6T-"G!E<FEO9',@=VET:&EN('1H
M870@<&5R:6]D+B!%87)L>2!A9&]P=&EO;B!I<R!N;W0@<&5R;6ET=&5D('5N
M9&5R($=!05`N(%=E(&%R92!C=7)R96YT;'D@979A;'5A=&EN9R!T:&4@:6UP
M86-T(&]F($%352`R,#$T+3`Y(&]N#0IO=7(@8V]N<V]L:61A=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&%N9"!D:7-C;&]S=7)E<RX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/DEN($IU;'D@,C`Q,RP@=&AE($9!4T(@:7-S=65D($%352`R,#$S
M+3$Q+`T*26YC;VUE(%1A>&5S("A4;W!I8R`W-#`I.B!0<F5S96YT871I;VX@
M;V8@86X@56YR96-O9VYI>F5D(%1A>"!"96YE9FET('=H96X@82!.970@3W!E
M<F%T:6YG($QO<W,@0V%R<GEF;W)W87)D+"!A(%-I;6EL87(@5&%X($QO<W,L
M#0IO<B!A(%1A>"!#<F5D:70@0V%R<GEF;W)W87)D($5X:7-T<R`H82!C;VYS
M96YS=7,@;V8@=&AE($9!4T(@16UE<F=I;F<@27-S=65S(%1A<VL@1F]R8V4I
M+"!O<B!!4U4@,C`Q,RTQ,2X@5&AE(&%M96YD;65N=',@:6X@05-5#0HR,#$S
M+3$Q('!R;W9I9&4@9W5I9&%N8V4@;VX@=&AE(&9I;F%N8VEA;"!S=&%T96UE
M;G0@<')E<V5N=&%T:6]N(&]F(&%N('5N<F5C;V=N:7IE9"!T87@@8F5N969I
M="!W:&5N(&$@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9"P-"F$@
M<VEM:6QA<B!T87@@;&]S<RP@;W(@82!T87@@8W)E9&ET(&-A<G)Y9F]R=V%R
M9"!E>&ES=',N($%N('5N<F5C;V=N:7IE9"!T87@@8F5N969I="!S:&]U;&0@
M8F4@<')E<V5N=&5D(&EN('1H92!F:6YA;F-I86P@<W1A=&5M96YT<PT*87,@
M82!R961U8W1I;VX@=&\@82!D969E<G)E9"!T87@@87-S970@9F]R(&$@;F5T
M(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9"P@82!S:6UI;&%R('1A>"!L
M;W-S+"!O<B!A('1A>"!C<F5D:70@8V%R<GEF;W)W87)D#0IW:71H(&-E<G1A
M:6X@97AC97!T:6]N<RP@:6X@=VAI8V@@8V%S92!S=6-H(&%N('5N<F5C;V=N
M:7IE9"!T87@@8F5N969I="!S:&]U;&0@8F4@<')E<V5N=&5D(&EN('1H92!F
M:6YA;F-I86P@<W1A=&5M96YT<R!A<R!A(&QI86)I;&ET>2X-"E1H92!A;65N
M9&UE;G1S(&EN($%352!.;RX@,C`Q,RTQ,2!D;R!N;W0@<F5Q=6ER92!N97<@
M<F5C=7)R:6YG(&1I<V-L;W-U<F5S+B!4:&4@86UE;F1M96YT<R!I;B!!4U4@
M,C`Q,RTQ,2!A<F4@969F96-T:79E(&9O<B!F:7-C86P-"GEE87)S+"!A;F0@
M:6YT97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!Y96%R<RP@8F5G:6YN:6YG
M(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$S+B!4:&4@86UE;F1M96YT<R!I;B!!
M4U4@3F\N(#(P,3,M,3$@9&ED(&YO="!H879E#0IA(&UA=&5R:6%L(&EM<&%C
M="!O;B!O=7(@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^26X@1&5C96UB97(@,C`Q,2P@=&AE($9!4T(@:7-S=65D
M($%352!.;RX@,C`Q,2TQ,2P-"D)A;&%N8V4@4VAE970@*%1O<&EC(#(Q,"DZ
M($1I<V-L;W-U<F5S(&%B;W5T($]F9G-E='1I;F<@07-S971S(&%N9"!,:6%B
M:6QI=&EE<RP@;W(@05-5(#(P,3$M,3$N($%352`R,#$Q+3$Q(&5N:&%N8V5S
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M9&%R9',N($%352`R,#$Q+3$Q(&ES(&5F9F5C=&EV92!F;W(@86YN=6%L(')E
M<&]R=&EN9R!P97)I;V1S(&)E9VEN;FEN9R!O;B!O<B!A9G1E<@T*2F%N=6%R
M>2`Q+"`R,#$S+"!A;F0@:6YT97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!Y
M96%R<RX@05-5(#(P,3$M,3$@9&ED(&YO="!H879E(&$@;6%T97)I86P@:6UP
M86-T(&]N(&]U<B!F:6YA;F-I86P@<&]S:71I;VX@;W(-"G)E<W5L=',@;V8@
M;W!E<F%T:6]N<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!D;R!N;W0@8F5L:65V
M92!T:&5R92!W;W5L9"!H879E(&)E96X@82!M871E<FEA;`T*969F96-T(&]N
M('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S(&AA9"!A;GD@;W1H97(@<F5C96YT;'D@:7-S=65D+"!B=70@;F]T
M('EE="!E9F9E8W1I=F4L(&%C8V]U;G1I;F<@<W1A;F1A<F1S#0IB965N(&%D
M;W!T960@:6X@=&AE(&-U<G)E;G0@<&5R:6]D+CPO<#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8VQA<W-I9FEC
M871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/E)E8VQA<W-I
M9FEC871I;VYS/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^0V5R=&%I;B`R,#$S
M(&%N9"`R,#$R(&%M;W5N=',@:&%V92!B965N(')E8VQA<W-I9FEE9`T*=&\@
M8V]N9F]R;2!T;R!C=7)R96YT('EE87(@<')E<V5N=&%T:6]N+B8C,38P.SPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P
M-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U
M-&0Q96%F9#(T.#(O5V]R:W-H965T<R]3:&5E=#(T+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U5-34%262!/1B!324=.249)
M0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A486)L97,I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I
M;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!P;W1E;G1I86QL>2!D
M:6QU=&EV92!S96-U<FET:65S(&EN(&]U<B!C86QC=6QA=&EO;B!O9B!D:6QU
M=&5D(&YE="!L;W-S('!E<B!S:&%R92!A;&QO8V%B;&4@=&\@8V]M;6]N('-T
M;V-K:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@=&%B
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M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS
M<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@.#`E.R!F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,3$@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^07,@;V8@1&5C96UB97(@,S$L/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,30\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3,\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
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M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#4R)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T
M.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^4W1O8VL@;W!T:6]N<SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,38L-SDR+#0T,SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@-"4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C$U+#8S,BPW-#(\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#0E
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,3`E.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
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M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL
M969T.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^5V%R<F%N=',\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$S+#DR-RPY,38\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
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M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS,"PW,C`L,S4Y/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
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M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
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M-C`[)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?
M-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,C4N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%3E1/
M4ED@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^26YV96YT;W)Y($1I<V-L;W-U<F4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M8VAE9'5L92!O9B!);G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^26YV96YT;W)Y(&-O;G-I<W1S
M(&]F('1H92!F;VQL;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@=VED=&@Z(#DP)3L@9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#<@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^1&5C96UB97(@,S$L/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,30\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
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M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#8X)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`P<'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1FEN
M:7-H960@<')O9'5C=#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T)3L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C@W-"PR.30\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#0E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C(Q+#8W.3PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)A=R!M871E<FEA
M;#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
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M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C4P+#DT,SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E
M9F5R<F5D(&-O<W1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
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M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C$W,"PY.38\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1/5$%,($E.5D5.5$]2
M63PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
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M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
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M/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?
M-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,C8N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/5$A%4B!#
M55)214Y4($%34T544R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!#;W-T<RP@0V%P
M:71A;&EZ960L(%!R97!A:60L(&%N9"!/=&AE<B!!<W-E=',@1&ES8VQO<W5R
M92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&]T:&5R(&-U<G)E;G0@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]T:&5R(&-U<G)E;G0@87-S971S
M(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN9SH\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P
M/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E.R!W:61T:#H@.3`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-R!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY$96-E;6)E<B`S,2P\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,C`Q-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,C`Q,SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C@E.R!T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#!P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED(&-O;G-U
M;'1I;F<\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-"4[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXT,3$L.#8T/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[
M('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C4S,"PU.38\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6QE9G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED(&EN<W5R86YC93PO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,30U+#<R,CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E!R97!A
M:60@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#(V-RPU.#@\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUL969T.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^3W1H97(@<F5C96EV86)L97,M<F5L871E
M9"!P87)T>2`H3F]T92`Q,BD\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C0Y+#DX,3PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
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M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR
M-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6QE9G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY/=&AE<B!P<F5P86ED(&-O<W1S/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C$X,2PQ.#8\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUL969T.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^1&5F97)R960@9FEN86YC:6YG(&-O<W1S/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M+#`R,CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G
M8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY43U1!3"!/5$A%4B!#55)214Y4
M($%34T544SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,2PU,S<L-#`W/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
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M)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F
M8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,C<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&25A%1"!!4U-%
M5%,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y38VAE9'5L92!O9B!F:7AE9"!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^1FEX960@87-S971S(&-O;G-I<W0@;V8@=&AE(&9O
M;&QO=VEN9SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL
M93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@.3`E.R!F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$-R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E;6)E<B`S,2P\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-#PO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q,SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@-C@E.R!T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6QE9G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY%<75I<&UE;G0\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@-"4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,3`E.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ,S(L,34P/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`T)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P."PT-3@\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#!P=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&
M=7)N:71U<F4@86YD(&9I>'1U<F5S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,RPX.34\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
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M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,3@V+#`T-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
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M97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUL969T.B`P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^06-C=6UU;&%T960@9&5P<F5C:6%T:6]N
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXH,3(R+#<U,CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M+#<V-3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6QE9G0Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^5$]404P@1DE8140@05-31513/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T
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M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
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M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L
M93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T
M,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970R."YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!215!!240@
M15A014Y312`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY0<F5P86ED($5X<&5N<V4@86YD($]T:&5R
M($%S<V5T<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F('!R97!A:60@97AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY0<F5P86ED(&5X<&5N<V4@8V]N
M<VES=',@;V8@=&AE(&9O;&QO=VEN9SHF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*
M#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R!W:61T:#H@.3`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-R!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$
M96-E;6)E<B`S,2P\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,C`Q-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,C`Q,SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S
M."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C@E.R!T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#!P=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED(&UA;G5F86-T
M=7)I;F<@8V]S=',\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-"4[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXX.3DL,#`P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`T)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@Y.2PP,#`\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#!P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED(')E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!C;W-T<SPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^.#(T+#(R,3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R
M,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M;&5F=#H@,'!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%C8W)E=&5D('!R97!A:60@8V]S=',\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C8T+#4T,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
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M<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUL969T.B`Q,'!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E1/5$%,(%!215!!240@15A014Y313PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,2PW-3`L-#4U/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-"CPO
M=&%B;&4^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^)B,Q-C`[)B,Q-C`[
M/"]B/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?
M.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T<R]3:&5E=#(Y+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%6D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y404Y'24),12!!
M4U-%5%,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1V]O9'=I;&P@86YD($EN=&%N9VEB;&4@07-S
M971S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!I;G1A;F=I8FQE
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H#0IT:&4@
M9W)O<W,@8V%R<GEI;F<@86UO=6YT(&%N9"!A8V-U;75L871E9"!A;6]R=&EZ
M871I;VX@;V8@;W5R(&EN=&%N9VEB;&4@87-S971S(&%S(&]F($1E8V5M8F5R
M(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,SH\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQF;VYT('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E)SXF(S$V,#L\+V9O;G0^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@,3`P)3L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#$U('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M8F5R(#,Q+"`R,#$T
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D=R
M;W-S($-A<G)Y:6YG($%M;W5N=#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^06-C=6UU;&%T960@06UO<G1I>F%T:6]N/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.970@)B,Q-C`[
M(#QB<B`O/D%M;W5N=#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^5V5I9VAT960M($%V97)A9V4@)B,Q-C`[(#QB<B`O/E)E;6%I
M;FEN9R!!;6]R=&EZ871I;VX@4&5R:6]D("AY<G,N*3PO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%M;W)T:7II;F<@:6YT86YG:6)L
M92!A<W-E=',Z/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`U,B4[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY/4$5203QS=7`^)B,Q-S0[/"]S=7`^('-O9G1W87)E
M('!A=&5N=#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C,Q+#DU,3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@R+#0Y-CPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR.2PT-34\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N
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M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL
M969T.B`R,'!T.R!T97AT+6EN9&5N=#H@+3$P.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E=F5L;W!M96YT(&-O<W1S
M(&]F(&-O<G!O<F%T92!W96)S:71E/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CDQ+#<T,SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
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M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^;B]A/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G
M8B@R,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M,3`[('!A9&1I;F<M;&5F=#H@,C!P=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!
M<'!R;W9E9"!H;W)M;VYE('1H97)A<'D@9')U9R8C,38P.V-A;F1I9&%T92!P
M871E;G1S/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
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M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,3DL
M-#`Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ.#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@+3$P.R!P861D:6YG+6QE9G0Z(#$P.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYO;BUA;6]R
M=&EZ:6YG(&EN=&%N9VEB;&4@87-S971S.CPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
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M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`R,'!T
M.R!T97AT+6EN9&5N=#H@+3$P.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/DAO<FUO;F4@=&AE<F%P>2!D<G5G(&-A;F1I
M9&%T92!P871E;G1S("AP96YD:6YG*3PO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
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M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C<U
M+#DX,CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
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M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
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M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C$P,RPS-C@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
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M)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P,RPS
M-C@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
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M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[('!A9&1I;F<M;&5F=#H@,C!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4;W1A;#PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E
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M9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#$Q,RPV
M-#`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
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M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*#0H-"@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\+W`^#0H-"@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/CPO9F]N=#X\+W`^
M#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`Q,#`E
M.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,34@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C96UB97(@,S$L
M(#(P,3,\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^1W)O<W,@0V%R<GEI;F<@06UO=6YT/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
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M=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYE="`F
M(S$V,#L@/&)R("\^06UO=6YT/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY796EG:'1E9"T@079E<F%G92!296UA:6YI;F<@06UO
M<G1I>F%T:6]N(%!E<FEO9"`H>7)S+BD\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY!;6]R=&EZ:6YG(&EN=&%N9VEB;&4@87-S971S
M.CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R
M9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-3(E
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M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
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M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
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M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M.24[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,Q+#0U,CPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,34N.#PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3`[('!A
M9&1I;F<M;&5F=#H@,C!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY$979E;&]P;65N="!C;W-T<R!O9B8C,38P.V-O
M<G!O<F%T92!W96)S:71E/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CDQ+#<T,SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
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M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,BPP.#(\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C,\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
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M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,#L@<&%D9&EN9RUL969T.B`Q,#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.
M;VXM86UO<G1I>FEN9R!I;G1A;F=I8FQE(&%S<V5T<SH\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR
M,S@L,C4U*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z("TQ,#L@<&%D9&EN9RUL969T.B`R,'!T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DAO<FUO;F4@
M=&AE<F%P>2!D<G5G(&-A;F1I9&%T92!P871E;G1S("AP96YD:6YG*3PO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
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M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[)B,Q-C`[)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-3<R+#<R-CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
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M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@=&5X="UI;F1E;G0Z("TQ,#L@<&%D9&EN9RUL969T.B`R,'!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DUU;'1I
M<&QE('1R861E;6%R:W,@9F]R('9I=&%M:6YS+W-U<'!L96UE;G1S/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
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M)B,Q-C`[)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4Y+#,R
M.#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SYN+V$\
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M;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z(#(P<'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C<U-2PW-#@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
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M)SXH.3`L,38P/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8V-2PU.#@\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
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M.SPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!E<W1I;6%T960@86UO<G1I>F%T
M:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^07,@;V8@
M1&5C96UB97(-"C,Q+"`R,#$T+"!T:&4@97-T:6UA=&5D(&%M;W)T:7IA=&EO
M;B!E>'!E;G-E(&9O<B!T:&4@;F5X="!F:79E('EE87)S(&ES(&%S(&9O;&QO
M=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#@P)3L@9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@8V]L<W!A;CTS1#,@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^665A<B!%;F1I;F<@1&5C96UB97(@,S$L/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
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M97)I9B<^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXR,#$U/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
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M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,C`Q-CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
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M.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
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M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
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M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@8V]L
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M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
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M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@-#8E.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO
M=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R
M-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D
M-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T,S`N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/5$A%
M4B!#55)214Y4($Q)04))3$E42453("A486)L97,I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R($QI86)I
M;&ET:65S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!O=&AE<B!C
M=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/D]T:&5R(&-U<G)E;G0@;&EA8FEL
M:71I97,@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG.CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`Y,"4[(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0W('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SY$96-E;6)E<B`S,2P\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/C(P
M,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^
M,C`Q,SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#8X)3L@=&5X="UA;&EG;CH@;&5F
M="<^06-C<G5E9"!C;&EN:6-A;"!T<FEA;"!C;W-T<SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`T)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0G/C$L-S`V+#4T,CPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#0E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE
M9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L:6=N
M.B!R:6=H="<^-C8U+#<X,CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M06-C<G5E9"!P87ER;VQL+"!B;VYU<V5S(&%N9"!C;VUM:7-S:6]N(&-O<W1S
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/C@Q-"PR,#4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^.30Q+#,Q,SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^06-C<G5E9"!V86-A=&EO;B!C;W-T<SPO=&0^/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXT-#(L-#,P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/C(U-BPY,C`\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SY!8V-R
M=65D(&QE9V%L(&%N9"!A8V-O=6YT:6YG(&5X<&5N<V4\+W1D/CQT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,C<V
M+#0W,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXR,C0L-34P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L
M,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY/=&AE<B!A8V-R=65D(&5X<&5N<V5S/'-U<#XH,2D\
M+W-U<#X\+V9O;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/C$X-2PY-C4\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,3<W+#DP,#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/D%L;&]W86YC92!F;W(@=VAO;&5S86QE(&1I<W1R
M:6)U=&]R(&9E97,\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^,38P+#4P,SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS,#8L,S`S/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SY!8V-R=65D(')O>6%L=&EE<SPO
M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXW,BPW,3`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^-3(L,3@X/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M06QL;W=A;F-E(&9O<B!C;W5P;VYS(&%N9"!R971U<FYS/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CDP
M+#0T-CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXQ,C8L,C,S/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L
M,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SY!8V-R=65D(')E;G0\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^.3$L,S8X/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,34Q.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/D%C8W)U960@9FEN86YC:6YG(&-O<W1S/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$U,3L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G
M/C@U,"PP,#`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P="<^5$]404P@3U1(15(@
M0U524D5.5"!,24%"24Q)5$E%4SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,RPX-#`L-C,Y
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C,L-C`Q+#$X
M.3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY?7U]?
M7U]?7U]?7U]?7U]?7SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/'-U<#XH,2D\+W-U<#X@26X@2G5N92`R
M,#`X+"!W92!D96-L87)E9"!A;F0-"G!A:60@82!S<&5C:6%L(&1I=FED96YD
M(&]F("0P+C0P('!E<B!S:&%R92!O9B!O=7(@0V]M;6]N(%-T;V-K('1O(&%L
M;"!S=&]C:VAO;&1E<G,@;V8@<F5C;W)D(&%S(&]F($IU;F4@,3`L(#(P,#@L
M(&]F('=H:6-H("0T,2PS-3D-"G)E;6%I;F5D('5N8VQA:6UE9"!B>2!C97)T
M86EN('-T;V-K:&]L9&5R<R!A="!B;W1H($1E8V5M8F5R(#,Q+"`R,#$T(&%N
M9"`R,#$S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\8CXF(S$V,#L\+V(^/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T
M,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7
M;W)K<VAE971S+U-H965T,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5704%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-43T-+2$],1$524R<@15%52519("A486)L97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y($YO=&4@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L
M92!O9B!W87)R86YT(&%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQI/E-U;6UA<GD@;V8@;W5R
M(%=A<G)A;G0@86-T:79I='D@86YD(')E;&%T960@:6YF;W)M871I;VX@9F]R
M#0HR,#$R+3(P,30F(S$V,#L\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@=VED=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@07)I86PL($AE;'9E=&EC82P@
M4V%N<RU397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M)SY.=6UB97(@;V8@4VAA<F5S(%5N9&5R(%=A<G)A;G1S/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,R!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SY796EG:'1E9"!!=F5R86=E
M($5X97)C:7-E(%!R:6-E/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O
M;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,7!T('-O;&ED)SY796EG:'1E9"`F(S$V,#L@/&)R("\^079E<F%G928C,38P
M.R`\8G(@+SY296UA:6YI;F<@)B,Q-C`[(#QB<B`O/D-O;G1R86-T=6%L)B,Q
M-C`[(#QB<B`O/DQI9F4@:6X@665A<G,\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60G/D%G9W)E9V%T928C,38P.R`\8G(@+SY);G1R
M:6YS:6,@5F%L=64\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L
M,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`U,B4[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^0F%L86YC92!A
M="!$96-E;6)E<B`S,2P@,C`Q,3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#DE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[('1E>'0M86QI9VXZ(')I9VAT)SXS+#`U-RPV,C<\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
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M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ
M(')I9VAT)SXW+CD\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
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M+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6QE
M9G0Z(#$P<'0G/DES<W5E9#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SXQ-RPS,S(L-3`P/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
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M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A
M9&1I;F<M;&5F=#H@,3!P="<^17AE<F-I<V5D/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
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M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@<FEG:'0G/C`N,S@\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG
M+6QE9G0Z(#$P<'0G/D5X<&ER960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M<&%D9&EN9RUL969T.B`Q,'!T)SY#86YC96QL960\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
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M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G
M/C`N,C0\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$R
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
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M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXD/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,2XV,SPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL
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M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUL969T
M.B`Q,'!T)SY)<W-U960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,BPQ,#`L,#`P/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M
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M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6QE9G0Z(#$P
M<'0G/D5X97)C:7-E9#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
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M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG
M+6QE9G0Z(#$P<'0G/D5X<&ER960\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M;&5F
M=#H@,3!P="<^0V%N8V5L;&5D/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O
M='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H
M,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY"86QA;F-E(&%T($1E
M8V5M8F5R(#,Q+"`R,#$S/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
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M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M="<^,2XW.3PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
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M;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M
M;&5F=#H@,3!P="<^27-S=65D/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34Q.SPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A
M9&1I;F<M;&5F=#H@,3!P="<^17AE<F-I<V5D/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
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M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
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M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUL
M969T.B`Q,'!T)SY%>'!I<F5D/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34Q.SPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A
M9&1I;F<M;&5F=#H@,3!P="<^0V%N8V5L;&5D/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P
M861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
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M=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^0F%L86YC92!A="!$96-E
M;6)E<B`S,2P@,C`Q-#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,BXU<'0@9&]U8FQE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SXQ,RPY,C<L.3$V/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
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M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@=&5X="UA;&EG;CH@<FEG:'0G/C,N,#PO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXD/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,S8L-C(S+#@W-3PO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUL969T.B`Q,#L@=&5X="UI;F1E;G0Z("TQ,"<^5F5S=&5D
M(&%N9"!%>&5R8VES86)L92!A="!$96-E;6)E<B`S,2P@,C`Q-#PO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
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M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
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M9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
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M<CH@=VAI=&4G/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O
M9B!W96EG:'1E9"!A=F5R86=E(&9A:7(@=F%L=64@<&5R('-H87)E(&%N9"!A
M<W-U;7!T:6]N<R!U<V5D(&EN('1H92!";&%C:RU38VAO;&5S($UO9&5L(&]F
M('=A<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T
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M<B`S,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,B!A<F4-"G-E="!F;W)T:"!I;B!T
M:&4@=&%B;&4@8F5L;W<N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#DP)3L@
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-#PO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q,SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q,CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@-3(E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E=E:6=H=&5D(&%V97)A9V4@9F%I<B!V86QU93PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,B4[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L
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M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`R
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,B4[
M('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C(N,#4\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(%=H:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
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M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C`N.#@M,2XQ,CPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B4\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,"XW,BTQ+C`T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S
M."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E9O;&%T:6QI='D\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-3$[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXE/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXT-"XR.2TT-2XX.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B4\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
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M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1E<FT@*&EN('EE87)S*3PO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+38\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L
M,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M1&EV:61E;F0@>6EE;&0\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
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M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`P
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C`N,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B4\+W1D/CPO='(^#0H\+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F(&%S<W5M<'1I;VYS('5S960@:6X@=&AE($)L86-K+5-C:&]L97,@
M36]D96P@;V8@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY4:&4@87-S=6UP=&EO;G,-"G5S960@:6X@=&AE($)L86-K+5-C:&]L
M97,@36]D96P@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q-"P@,C`Q,R!A;F0@,C`Q,B!A<F4@<V5T(&9O<G1H(&EN('1H92!T86)L
M92!B96QO=RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL
M93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@.3`E.R!F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$T/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$S/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
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M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXP+C8U+3$N-S$\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C`N-C$M,BXR,SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^5F]L871I;&ET>3PO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXV."XP-2TX,BXR.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B4\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
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M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0P+C<W+30V+C`Q
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)3PO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1E<FT@*&EN('EE87)S*3PO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C4M-BXR-3PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXU+38N,C4\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^-2TV+C(U/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H
M:71E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-3(E.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/D1I=FED96YD('EI96QD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#(E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,3(E.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`P/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B4\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,B4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`N,#`\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)3PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$R)3L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,"XP,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXE/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!O<'1I
M;VX@86-T:79I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^02!S=6UM
M87)Y(&]F(&%C=&EV:71Y('5N9&5R('1H92`R,#`Y(&%N9"`R,#$R#0I0;&%N
M<R!A;F0@<F5L871E9"!I;F9O<FUA=&EO;B!F;W(@,C`Q,BTR,#$T(&9O;&QO
M=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL
M87!S93L@=VED=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@07)I86PL($AE;'9E=&EC
M82P@4V%N<RU397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O;3H@,7!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED)SY.=6UB97(@;V8@4VAA<F5S(%5N9&5R($]P=&EO;G,\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/E=E:6=H=&5D($%V97)A
M9V4@17AE<F-I<V4@4')I8V4\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60G/E=E:6=H=&5D("8C,38P.R`\8G(@+SY!=F5R86=E("8C
M,38P.R`\8G(@+SY296UA:6YI;F<@)B,Q-C`[(#QB<B`O/D-O;G1R86-T=6%L
M)B,Q-C`[(#QB<B`O/DQI9F4@:6X@665A<G,\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0S('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60G/D%G9W)E9V%T928C,38P.R`\8G(@+SY)
M;G1R:6YS:6,@5F%L=64\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR
M,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`U,"4[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^0F%L86YC
M92!A="!$96-E;6)E<B`S,2P@,C`Q,3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#DE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SXQ,"PU.3`L,38Q/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,"XQ
M-CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!R:6=H="<^-RXV/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,R4[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Y
M)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!T97AT+6%L:6=N.B!R:6=H="<^,30L,#8W+#8T.3PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A9&1I
M;F<M;&5F=#H@,3!P="<^1W)A;G1E9#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(')I9VAT)SXU+#$R,2PR
M-3`\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@<&%D9&EN9RUL969T.B`Q,'!T)SY%>&5R8VES960\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M="<^*#$L.3,Q+#<X.#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F
M="<^*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M<&%D9&EN9RUL969T.B`Q,'!T)SY%>'!I<F5D/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,34Q.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[('!A9&1I;F<M;&5F=#H@,3!P="<^0V%N8V5L;&5D/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R
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M9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY"86QA;F-E(&%T
M($1E8V5M8F5R(#,Q+"`R,#$R/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
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M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N
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M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
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M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
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M:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@<&%D9&EN9RUL969T.B`Q,'!T)SY'<F%N=&5D/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL
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M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
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M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@<&%D9&EN9RUL969T.B`Q,'!T)SY%>&5R8VES960\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M="<^*#<U+#0R,SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^
M*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!P861D:6YG+6QE9G0Z(#$P<'0G/D5X<&ER960\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R
M:6=H="<^*#(U,#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^
M*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D
M9&EN9RUL969T.B`Q,'!T)SY#86YC96QL960\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/B@V,#@L-S4P
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!L969T)SXI/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D)A;&%N8V4@
M870@1&5C96UB97(@,S$L(#(P,3,\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^,34L-C,R+#<T
M,CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E
M>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ
M(')I9VAT)SXQ+C0T/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^-RXR/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
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M86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@<&%D
M9&EN9RUL969T.B`Q,'!T)SY'<F%N=&5D/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/C(L-#0R
M+#`P,#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
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M969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!P861D:6YG+6QE9G0Z(#$P<'0G/D5X97)C:7-E9#PO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI
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M="<^*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M<&%D9&EN9RUL969T.B`Q,'!T)SY%>'!I<F5D/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/B@R
M-3`\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[('1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M<&%D9&EN9RUL969T.B`Q,'!T)SY#86YC96QL960\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/B@T,C<L
M-#<V/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT
M+6%L:6=N.B!L969T)SXI/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY"86QA;F-E(&%T($1E8V5M
M8F5R(#,Q+"`R,#$T/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
M+C5P="!D;W5B;&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@=&5X="UA;&EG;CH@<FEG:'0G/C$V+#<Y,BPT-#,\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
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M9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
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M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T
M)SY697-T960@86YD($5X97)C:7-A8FQE(&%T($1E8V5M8F5R(#,Q+"`R,#$T
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M('1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S
M;VQI9"<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
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M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
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M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!L969T)SXD/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!T97AT+6%L:6=N.B!R:6=H="<^-#`L-S(P+#DW-SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U
M-&0Q96%F9#(T.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T
M83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O<FMS:&5E=',O
M4VAE970S,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15I&/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DE.0T]-12!405A%4R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($1I<V-L
M;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!T87@@<F%T92!R96-O;F-I;&EA
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!(')E8V]N8VEL:6%T
M:6]N(&)E='=E96X@=&%X97,@8V]M<'5T960@870-"G1H92!F961E<F%L('-T
M871U=&]R>2!R871E(&%N9"!T:&4@8V]N<V]L:61A=&5D(&5F9F5C=&EV92!T
M87@@<F%T92!I<R!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^#0H-
M"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M('=I9'1H.B`Y,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P
M,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P
M,3,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P
M,3(\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4R)3L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&
M961E<F%L('-T871U=&]R>2!T87@@<F%T93PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`T)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,S0N,#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM
M86QI9VXZ(&UI9&1L93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXE/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#0E.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E
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M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C,U+C`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!M:61D;&4[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)3PO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY3=&%T92!T87@@<F%T92P@;F5T(&]F(&9E9&5R86P@
M=&%X(&)E;F5F:70\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@
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M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
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M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
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M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!9&IU<W1M96YT(&EN('9A
M;'5A=&EO;B!A;&QO=V%N8V5S/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
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M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
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M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^4&5R;6%N96YT(&%N9"!O=&AE<B!D:69F97)E;F-E
M<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
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M=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)3PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
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M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
M9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@;6ED9&QE.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BDE/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXH,C(N,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(')I9VAT.R!V97)T:6-A;"UA;&EG;CH@;6ED9&QE.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BDE
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4')O=FES:6]N("A"96YE
M9FET*2!F;W(@26YC;VUE(%1A>&5S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X
M="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ(&UI9&1L93L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,34Q.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI
M9VXZ(&UI9&1L93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXE/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
M;&5F=#L@=F5R=&EC86PM86QI9VXZ(&UI9&1L93L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]T9#X\+W1R/@T*/"]T
M86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE
M9'5L92!O9B!D969E<G)E9"!T87@@87-S971S(&%N9"!L:6%B:6QI=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/=7(@9&5F97)R960@=&%X(&%S
M<V5T(&%N9"!L:6%B:6QI='D-"F%S('!R97-E;G1E9"!I;B!T:&4@86-C;VUP
M86YY:6YG(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!C;VYS
M:7-T(&]F('1H92!F;VQL;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.R8C,38P.SPO<#X-"@T*
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@
M=VED=&@Z(#DP)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q
M-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q
M,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q
M,CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E9F5R
M<F5D($EN8V]M92!487@@07-S971S.CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@-3(E.R!T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6QE9G0Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^3F5T(&]P97)A=&EN9R!L;W-S97,\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@-"4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT,RPP
M.3$L-#,W/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`T)3L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C$T+#<W,RPU,S<\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#0E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-2PY,C`L.#8Q/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.B`Q,'!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/E(F(S,X.T0@0W)E9&ET/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R
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M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4T-RPU,3$\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@
M,3!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY4;W1A;"!D969E<G)E9"!I;F-O;64@=&%X(&%S<V5T/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C0S+#`Y,2PT,S<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
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M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-BPQ,#<L,C`W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@
M,3!P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY686QU871I;VX@86QL;W=A;F-E/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH-#,L,#DQ+#0S
M-SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
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M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M
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M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY$969E<G)E9"!);F-O;64@5&%X($%S<V5T
M<RP@;F5T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
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M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
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M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T
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M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/"]T86)L93X-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E
M869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T
M,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T<R]3:&5E
M=#,S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,@*%1A8FQE<RD\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M
M;6ET;65N=',@06YD($-O;G1I;F=E;F-I97,@5&%B;&5S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&9U
M='5R92!M:6YI;75M(')E;G1A;"!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"P@9G5T=7)E(&UI
M;FEM=6T@<F5N=&%L#0IP87EM96YT<R!U;F1E<B!O=7(@;V9F:6-E(&QE87-E
M(&%R92!A<R!F;VQL;W=S.B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQT86)L
M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H
M.B`X,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^665A<G,@16YD
M:6YG($1E8V5M8F5R(#,Q+#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXR,#$U/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS-S$L,C0P
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^,C`Q-CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS.#(L
M,S<W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXR
M,#$W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/C,Y,RPX-#@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXR,#$X/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/C,P,BPW-#@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR,S@L,C4U*2<^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/C(P,3D\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C,34Q.R8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E1O=&%L(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3F]N+6-A;F-E;&QA8FQE('-U
M8BUL96%S92!I;F-O;64\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T)SX\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0G/DYE="!M:6YI;75M(&QE87-E('!A>6UE;G1S/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O
M=6)L92<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B
M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4G/C$L-#4P+#(Q,SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@-C8E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SXF(S$V,#L\+W1D
M/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X
M,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W
M7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T<R]3:&5E=#,T+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4T5,14-4
M140@455!4E1%4DQ9($9)3D%.0TE!3"!$051!("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E%U87)T
M97)L>2!&:6YA;F-I86P@26YF;W)M871I;VX@1&ES8VQO<W5R92!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-C:&5D=6QE(&]F('%U87)T97)L>2!U;F%U9&ET960@<W5M;6%R>2!I;F9O
M<FUA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SY3=6UM87)I>F5D('%U87)T97)L>2!F:6YA;F-I86P@
M9&%T82!F;W(@9FES8V%L('EE87)S(#(P,30L(#(P,3,L#0IA;F0@,C`Q,B!I
M<R!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V
M,#LF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M('=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,34@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C`Q-"!1=6%R=&5R<SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M+7-T>6QE.B!I=&%L:6,[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*$EN('1H;W5S86YD
M<RP@97AC97!T('!E<B!S:&%R92D\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ/'-U<#YS=#PO<W5P
M/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,7!T('-O;&ED.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXR/'-U<#YN9#PO<W5P/CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXS/'-U<#YR9#PO<W5P/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C1T:#PO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@-3(E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E)E=F5N=65S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+#@S,3PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[('1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C,L-S4R/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-"PQ.#8\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+#(U-SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^1W)O<W,@<')O9FET/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXR+#`P,#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+#@U
M.3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS+#$Q.#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXS+#,W-SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R
M,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^3F5T(&QO<W,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Y+#$X,SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#$P+#@Y.3PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#$W
M+#@S,CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^*#$V+#,P,SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,;W-S('!E<B!C;VUM;VX@
M<VAA<F4L(&)A<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXH,"XP-CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#`N,#<\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B@P+C$R/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,"XQ,#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
M,T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#$P,"4[(&9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0Q-2!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$S(%%U87)T
M97)S/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXH26X@=&AO=7-A;F1S+"!E>&-E<'0@<&5R('-H
M87)E*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C$\<W5P/G-T/"]S=7`^/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C(\<W5P/FYD/"]S=7`^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#,@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[(&9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,\<W5P/G)D
M/"]S=7`^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#,@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-'1H/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R
M,#0L,C,X+#(U-2D[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`U,B4[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4F5V
M96YU97,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[('1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C$L-3,W/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,BPP.#$\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+#(Y-3PO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C(L.#8S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY'<F]S<R!P<F]F:70\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L,34W
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L-C$W/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C$L-C0V/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L,SDV
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.970@;&]S<SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*#8L,S<V/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH
M-BPP,#D\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@W+#8W,SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*#@L,S8Q/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXI/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/DQO<W,@<&5R(&-O;6UO;B!S:&%R92P@8F%S:6,@86YD(&1I
M;'5T960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C`V/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXH,"XP-3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#`N,#8\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B@P+C`V/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXI/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*
M#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL
M93TS1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@,3`P)3L@
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#$U('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3(@475A
M<G1E<G,\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BA);B!T:&]U<V%N9',L(&5X8V5P="!P97(@
M<VAA<F4I/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P
M="!S;VQI9#L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,3QS=7`^<W0\+W-U<#X\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,CQS=7`^;F0\+W-U<#X\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,R!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,SQS=7`^
M<F0\+W-U<#X\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
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M5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4R)3L@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY2
M979E;G5E<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-S(R/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M.#$Y/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PP,S8\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXQ+#(T,3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@5VAI=&4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^1W)O<W,@<')O9FET/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS.#8\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^-#0W/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C<R.3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXY,#@\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYE="!L;W-S/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXH,3,L,CDP/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,3$L.#4P/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXH-"PR-3,\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@U
M+#<R-SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET93L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR,S@L,C4U*3L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY,;W-S('!E<B!C;VUM;VX@<VAA<F4L(&)A<VEC(&%N9"!D:6QU=&5D/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXH,"XQ-CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*#`N,30\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/BD\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C`T/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXH,"XP-CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*3PO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/B8C,38P.R8C,38P.SPO8CX\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D
M,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?
M-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970S-2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M15)*044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U5-34%262!/1B!324=.
M249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A$971A:6QS($YA<G)A=&EV
M92D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE
M;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D=F5R=&ES:6YG($-O<W1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#8Y."PX-S$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+#<S.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C4L.30T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M9'9A;F-E('!A>6UE;G1S(&9O<B!F=71U<F4@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PQ-S4L,#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+#8P-BPT,#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6EP;65N="!;365M8F5R
M72!\($UI;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N
M="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17-T:6UA=&5D('5S969U;"!L:79E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U:7!M96YT(%M-96UB
M97)=('P@36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@=7-E9G5L(&QI=F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XW('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?
M.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O<FMS
M:&5E=',O4VAE970S-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P145)044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4U5-34%262!/1B!324=.249)0T%.5"!!0T-/54Y424Y'
M(%!/3$E#2453("A$971A:6QS*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R
M:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!0
M97(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<VAA<F5S(&5X8VQU
M9&5D(&9R;VT@96%R;FEN9W,@<&5R('-H87)E(&-A;&-U;&%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PW,C`L,S4Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL.3(V+#(T
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U+#DR-BPY.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;B!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!3
M96-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN
M9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T:79E('-H87)E<R!E
M>&-L=61E9"!F<F]M(&5A<FYI;F=S('!E<B!S:&%R92!C86QC=6QA=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-SDR+#0T,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#8S
M,BPW-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,RPW,S,L-#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!3
M96-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN
M9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T:79E('-H87)E<R!E
M>&-L=61E9"!F<F]M(&5A<FYI;F=S('!E<B!S:&%R92!C86QC=6QA=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L.3(W+#DQ-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#(Y
M,RPT.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPQ.3,L-#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T
M.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U
M-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970S-RYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P131%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^24Y6
M14Y43U)9("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G9E;G1O
M<GD\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1FEN:7-H960@<')O9'5C=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`X-S0L,CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V,C$L-C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y287<@;6%T97)I86P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-2PS-#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L.30S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34R+#0W
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$W,"PY.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y43U1!3"!)3E9%3E1/4ED\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2PQ.#(L,3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`T,RPV,3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?
M-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O
M5V]R:W-H965T<R]3:&5E=#,X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6DM!0SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#$^/'-T<F]N9SY/5$A%4B!#55)214Y4($%34T544R`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@0W5R<F5N="!!<W-E=',\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M<&%I9"!C;VYS=6QT:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0Q,2PX-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#4S,"PU.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@:6YS=7)A;F-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.30L.#<X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30U+#<R,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M<&%I9"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y.2PT.3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(V-RPU.#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R
M(')E8V5I=F%B;&5S+7)E;&%T960@<&%R='D@*$YO=&4@,3(I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#DL.3@Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0Y+#DX,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M<')E<&%I9"!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@Q+#$X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(S+#@P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F97)R960@9FEN86YC:6YG(&-O<W1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C`L,#(R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5$]404P@3U1(15(@0U524D5.5"!!4U-%5%,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PU,S<L-#`W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#0W-RPW,34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D
M-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T
M.#(O5V]R:W-H965T<R]3:&5E=#,Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$)!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY&25A%1"!!4U-%5%,@*$1E=&%I;',@3F%R
M<F%T:79E*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q
M=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!%>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(X+#DX-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#<L.#@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-RPT
M.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P
M-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U
M-&0Q96%F9#(T.#(O5V]R:W-H965T<R]3:&5E=#0P+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M5E!!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY&25A%1"!!4U-%5%,@*$1E
M=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&:7AE9"!A<W-E=',L(&=R;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$X-BPP-#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U-2PP.#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3(R+#<U,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Y,RPW-C4I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:7AE9"!!<W-E=',L(&YE
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,L,CDS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L,S$X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1FEX960@87-S971S+"!G<F]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,R+#$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P."PT-3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI='5R92!A;F0@
M1FEX='5R97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1FEX960@87-S971S+"!G<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`U,RPX.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0V+#8R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T
M-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE
M971S+U-H965T-#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U14%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/E!215!!240@15A014Y312`H1&5T86EL<RD@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3W1H97(@07-S971S/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@;6%N=69A8W1U<FEN9R!C
M;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X.3DL,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`X.3DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5P86ED(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C
M;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8S+#<R,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R
M-"PR,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)E=&5D('!R97!A:60@8V]S=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8T+#4T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#(S-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1/5$%,(%!215!!240@
M15A014Y313PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0R
M-RPR-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$L-S4P+#0U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R
M-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D
M-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T-#(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5$3$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.
M5$%.1TE"3$4@05-31513("A$971A:6QS($YA<G)A=&EV92D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@97AP96YS93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R."PW-S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(S+#0X,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,C8R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M."PW-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E=F5L;W!M96YT(&-O<W1S(&9O<B!C;W)P;W)A=&4@=V5B<VET
M92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ871I;VX@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XS-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]015)!('-O9G1W87)E('!A=&5N="!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I
M;VX@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,"!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^07!P<F]V960@2&]R;6]N92!4:&5R87!Y($1R=6<@0V%N9&ED871E
M(%!A=&5N=',@*$UE;6)E<BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06UO<G1I>F%T:6]N('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,C`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E
M869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T
M,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T<R]3:&5E
M=#0S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%5U=!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY)3E1!3D=)0DQ%($%34T544R`H1&5T86EL<R`I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&
M:6YI=&4M3&EV960@26YT86YG:6)L92!!<W-E=',\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@06UO<G1I
M>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Q,RPV
M-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@Y,"PQ-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN9&5F:6YI=&4M3&EV960@26YT86YG
M:6)L92!!<W-E=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1W)O<W,@0V%R<GEI;F<@06UO=6YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#,T,BPR,C@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-34L-S0X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@06UO=6YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(R."PU.#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-C4L
M-3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y(;W)M;VYE('1H97)A<'D@9')U9R!C86YD:61A=&4@<&%T96YT<R`M
M(%!E;F1I;F<@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY);F1E9FEN:71E+4QI=F5D($EN=&%N9VEB;&4@07-S
M971S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R;W-S($-A<G)Y:6YG($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C<U+#DX,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4W,BPW,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!!;6]U;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8W-2PY.#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S(L-S(V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-=6QT:7!L
M92!T<F%D96UA<FMS(&9O<B!V:71A;6EN<R]S=7!P;&5M96YT<R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN
M9&5F:6YI=&4M3&EV960@26YT86YG:6)L92!!<W-E=',\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@0V%R<GEI;F<@
M06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#,L,S8X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3DL,S(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#,L,S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3DL,S(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/4$5202!S;V9T=V%R92!P871E;G0@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY&:6YI=&4M3&EV960@26YT86YG:6)L92!!<W-E=',\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@0V%R<GEI;F<@
M06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PY-3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,2PY-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W5M=6QA=&5D($%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,BPT.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#DY*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($%M;W5N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL-#4U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L-#4R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!!=F5R86=E($%M;W)T:7IA=&EO;B!097)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C$T('EE87)S(#D@;6]N=&AS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,34@>65A<G,@
M.2!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5V96QO<&UE;G0@8V]S=',@9F]R(&-O<G!O
M<F%T92!W96)S:71E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1FEN:71E+4QI=F5D($EN=&%N9VEB;&4@07-S
M971S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R;W-S($-A<G)Y:6YG($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3$L-S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3$L-S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!!;6]R=&EZ871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DQ+#<T,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X.2PV
M-C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#`X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!!;6]R=&EZ
M871I;VX@4&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS
M(&UO;G1H<R`Q."!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!<'!R;W9E9"!(;W)M;VYE(%1H97)A<'D@1')U
M9R!#86YD:61A=&4@4&%T96YT<R`H365M8F5R*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I;FET92U,:79E9"!);G1A;F=I
M8FQE($%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'<F]S<R!#87)R>6EN9R!!;6]U;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0S.2PQ.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D($%M;W)T:7IA
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DL-#`Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M,3DL-S@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($%M;W)T:7IA=&EO;B!097)I;V0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$X('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S
M9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R
M-#@R+U=O<FMS:&5E=',O4VAE970T-"YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M#04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^24Y404Y'24),12!!4U-%5%,@*$1E=&%I
M;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5S=&EM871E9"!A;6]R=&EZ871I
M;VX@97AP96YS92!F;W(@=&AE('EE87(Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,C4L,3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$V/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-2PQ,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(U+#$S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q.#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C4L,3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XR,#$Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(U+#$S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A
M9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S
M7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T
M-#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-1$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG
M/D]42$52($-54E)%3E0@3$E!0DE,251)15,@*$1E=&%I;',@3F%R<F%T:79E
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!,:6%B:6QI=&EE<R!$:7-C
M;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&%T92!D:79I9&5N9"!D96-L87)E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`P."TP-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F1S(%!A
M>6%B;&4L(&%M;W5N="!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y5;F-L86EM960@9&EV:61E;F1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q+#,U.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#$L,S4Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S
M9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R
M-#@R+U=O<FMS:&5E=',O4VAE970T-BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I#044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^3U1(15(@0U524D5.5"!,24%"24Q)5$E%
M4R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3W1H97(@3&EA8FEL:71I97,@1&ES8VQO<W5R92!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8VQI;FEC86P@=')I86P@8V]S
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PW,#8L-30R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V-C4L-S@R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D('!A>7)O;&PL(&)O
M;G5S97,@86YD(&-O;6UI<W-I;VX@8V]S=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@Q-"PR,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY-#$L,S$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-R=65D('9A8V%T:6]N(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-#(L-#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4V+#DR,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E
M9"!L96=A;"!A;F0@86-C;W5N=&EN9R!E>'!E;G-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-S8L-#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C(T+#4U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3@U+#DV-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<W+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@9F]R('=H;VQE
M<V%L92!D:7-T<FEB=71O<B!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-C`L-3`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S`V+#,P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E
M9"!R;WEA;'1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R
M+#<Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#$X.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;W=A;F-E(&9O<B!C;W5P
M;VYS(&%N9"!R971U<FYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY,"PT-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C8L,C,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(')E;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ+#,V.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!F:6YA;F-I;F<@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y43U1!3"!/5$A%4B!#55)214Y4($Q)
M04))3$E42453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L
M.#0P+#8S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPV,#$L
M,3@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&0@
M8V]L<W!A;CTS1#4^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P
M/ELQ73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T
M;W`^26X@2G5N92`R,#`X+"!W92!D96-L87)E9"!A;F0@<&%I9"!A('-P96-I
M86P@9&EV:61E;F0@;V8@)#`N-#`@<&5R('-H87)E(&]F(&]U<B!#;VUM;VX@
M4W1O8VL@=&\@86QL('-T;V-K:&]L9&5R<R!O9B!R96-O<F0@87,@;V8@2G5N
M92`Q,"P@,C`P."P@;V8@=VAI8V@@)#0Q+#,U.2!R96UA:6YE9"!U;F-L86EM
M960@8GD@8V5R=&%I;B!S=&]C:VAO;&1E<G,@870@8F]T:"!$96-E;6)E<B`S
M,2P@,C`Q-"!A;F0@,C`Q,RX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C
M7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T-#<N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$522$1//@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DY/5$53(%!!64%"3$4@
M*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0T/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0W/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#4^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3F]V+B`Q,RP@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#(Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,3,L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1F5B+B`R-2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,C4L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`Q.2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(X+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R-"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,C$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B
M+B`R.2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N
M=',@;V8@;&EN97,@;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@;&EN97,@;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-C4L.3@Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,#4L
M-#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C0L,S@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&YO=&5S('!A>6%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-S`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT
M<R!O9B!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#8Y,2PX-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#@U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W)U960@:6YT97)E
M<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5C;V=N:7IE9"!L;W-S(&]N(&5X=&EN9W5I<VAM96YT(&]F(&1E8G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#,P-RPX-C0I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPS
M.3`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-R=65D(&EN=&5R97-T('!A:60\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(Q,BPX-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPR-3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUR+B!-:6QL:6=A
M;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D1E8G0@26YS=')U;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EN92!O9B!C<F5D
M:70@9F%C:6QI='D@9&5C<F5A<V4@9F]R9VEV96YE<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUU;'1I<&QE($%D=F%N8V4@
M4F5V;VQV:6YG($-R961I="!.;W1E("A0;&%T;R!787)R86YT*2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E
M8G0@26YS=')U;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!P<FEN8VEP86P@86UO
M=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&%T960@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E<V-R:7!T:6]N(&]F(&EN=&5R97-T('!A>6UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DEN=&5R97-T('!A
M>6UE;G1S('=E<F4@9'5E(&%N9"!P87EA8FQE(&]N('1H92!T96YT:"!D87D@
M9F]L;&]W:6YG('1H92!E;F0@;V8@96%C:"!C86QE;F1A<B!Q=6%R=&5R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]C965D<R!F<F]M(')E=F]L=FEN9R!C<F5D:70@;F]T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N
M="!O9B!R979O;'9I;F<@8W)E9&ET(&YO=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0P,2PP.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F]L=FEN9R!C<F5D:70@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!S:&%R97,@<'5R8VAA<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E(&]F('=A<G)A;G1S
M("AI;B!D;VQL87)S('!E<B!U;FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQI;F4@;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y6:71A365D(%!R;VUI<W-O<GD@3F]T97,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E9"!I;G1E<F5S
M="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C,U)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,N
M,#(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$97-C<FEP=&EO;B!O9B!I;G1E<F5S="!P87EM96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y5;F1E<B!T:&4@97AT96YS:6]N+"!B
M;W)R;W=I;F=S(&)E87(@:6YT97)E<W0@870@82!R871E(&]F(#(N,S4E(&%N
M9"!A<F4@9'5E(&]N($UA<F-H(#$L(#(P,3,N/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^5&AE(&)A;FL@;&EN92!O9B!C
M<F5D:70@86-C<G5E9"!I;G1E<F5S="!A="!T:&4@<F%T92!O9B`S+C`R)2!P
M97(@86YN=6T@8F%S960@;VX@82!Y96%R(&]F(#,V,"!D87ES(&%N9"!W87,@
M9'5E(&]N($UA<F-H(#$L(#(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F]L=FEN9R!C<F5D:70@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y.2PR,C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,:6YE(&]F(&-R961I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CDY+#(R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N=',@;V8@;&EN97,@
M;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L
M-S,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(&QI;F5S(&]F(&-R961I=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS-C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<&%Y;65N=',@;V8@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<F%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<V-R:7!T:6]N
M(&]F(&EN=&5R97-T(')A=&4@=&5R;7,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/E1H92!6:71A365D($YO=&5S('=E<F4@87-S=6UE9"!B>2!U
M<R!U<&]N('1H92!M97)G97(@86YD(&)O<F4@:6YT97)E<W0@870@82!R871E
M(&]F(#0E('!E<B!A;FYU;2!A;F0@=V5R92!D=64@870@=&AE(&5A<FQI97(-
M"F]F("AI*2!T:&4@<VEX(&UO;G1H(&%N;FEV97)S87)Y(&]F('1H92!D871E
M(&]F(&ES<W5A;F-E(&%N9"`H:6DI('-U8V@@=&EM92!A<R!6:71A365D(')E
M8V5I=F5D('1H92!P<F]C965D<R!O9B!A('!R;VUI<W-O<GD-"FYO=&4H<RD@
M:7-S=65D(&EN(&%N(&%M;W5N="!O9B!N;W0@;&5S<R!T:&%N("0Q+#`P,"PP
M,#`L(&]R('1H92!&=6YD:6YG+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-R=65D(&EN=&5R97-T('!A:60\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,38P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6:71A365D(%!R
M;VUI<W-O<GD@3F]T97,@6TUE;6)E<ET@?"!296EC:"!&86UI;'D@3&EM:71E
M9"!,4"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1E8G0@26YS=')U;65N="!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT
M<R!O9B!L:6YE<R!O9B!C<F5D:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Y.2PR,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@;&EN97,@;V8@8W)E9&ET
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U
M86YC92!O9B`V)2!0<F]M:7-S;W)Y($YO=&5S("A*86YU87)Y(&%N9"!&96)R
M=6%R>2`R,#$R*2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1E8G0@26YS=')U;65N="!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G
M<F5G871E('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9E8G)U87)Y(#(P,3(@3F]T97,@27-S=65D
M(%1O($EN9&EV:61U86P@06YD($5N=&ET>2!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0@26YS=')U;65N
M="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S4X+#`Q-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I;FEN9R!B86QA;F-E(&]F
M(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T-RPQ
M,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9E8G)U87)Y(#(P,3(@3F]T97,@27-S=65D(%1O(%!A<G1I97,@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@
M<'5R8VAA<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#8X
M-2PS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%G9W)E9V%T92!P<FEN8VEP86P@86UO=6YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,U-RPQ,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@
M;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297!A>6UE;G1S(&]F(&YO=&5S('!A>6%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-R=65D(&EN
M=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PQ,C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9A:7(@=F%L=64@;V8@;F]T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-3$W+#<T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3DW+#,X,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;V=N:7IE9"!L;W-S(&]N
M(&5X=&EN9W5I<VAM96YT(&]F(&1E8G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#,P-RPX-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I;FEN9R!B86QA;F-E(&]F(&YO
M=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T-"PW,3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9E8G)U87)Y(#(P,3(@3F]T97,O(%=A<G)A;G1S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B="!);G-T
M<G5M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S('!U<F-H87-E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,30L-S`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV.#4L
M,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!P<FEC92!O9B!W87)R86YT<R`H:6X@9&]L;&%R<R!P
M97(@=6YI="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XS
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#4Y+#8T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=G<F5G871E('!R:6YC:7!A;"!A;F0@86-C<G5E9"!I
M;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,#(L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;6]U;G0@;V8@<VAA<F5S(&ES<W5E9"!I;B!E>&5R8VES92!O9B!W
M87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PQ-#4L
M-#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PQ-#4L-#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296UA:6YI;F<@8F%L86YC92!O9B!N;W1E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV.3$L.#0W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y*=6YE(#(P
M,3(@3F]T97,@27-S=65D(%1O($EN9&EV:61U86P@06YD($5N=&ET>2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D1E8G0@26YS=')U;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E('!R:6YC:7!A
M;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S0W
M+#$R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^2G5N92`R,#$R($YO=&5S($ES<W5E9"!4;R!087)T:65S(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&5B="!);G-T<G5M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@<')I;F-I<&%L
M(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS-#0L
M-S$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^2G5N92`R,#$R($YO=&5S
M("AS96-U<F5D('!R;VUI<W-O<GD@;F]T97,I(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B="!);G-T<G5M
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S('!U<F-H87-E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!A>6UE
M;G1S(&]F(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0L.#@R+#`Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-R=65D(&EN=&5R97-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,2PU.34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PU.34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(')A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-C
M<FEP=&EO;B!O9B!I;G1E<F5S="!R871E('1E<FUS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y!8V-R=65D(&EN=&5R97-T(&%T('1H92!A;FYU
M86P@<F%T92!O9B`V)2P@=V%S(&1U92!I;B!O;F4@;'5M<"!S=6T@<&%Y;65N
M="!O;B!&96)R=6%R>2`R-"P@,C`Q-"X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<G5E9"!I;G1E<F5S="!P86ED
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q+#4Y-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?
M,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D
M,C0X,B]7;W)K<VAE971S+U-H965T-#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$585D%-/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DY/5$53(%!!64%"3$4@*$1E=&%I;',@
M3F%R<F%T:79E(#$I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@,C`Q,CQB<CY.=6UB
M97(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,P
M+"`R,#$Q/&)R/DYU;6)E<CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D]C="X@,#0L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3V-T+B`S,2P@,C`Q,3QB<CY.=6UB97(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0@26YS
M=')U;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT<R!O9B!N;W1E<R!P87EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L-CDQ+#@T-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PX-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y686QU92!O9B!D96)T(&-O;G9E<G1E9"!T
M;R!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L-S$V
M+#4P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,38U+#DX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L.3`U+#0P.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T+#,X,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-R=65D(&EN
M=&5R97-T('!A:60\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q
M,BPX-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-RPR-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C8E($YO=&5S(&ES<W5E9"!I;B!!=6=U<W0@86YD
M(%-E<'1E;6)E<B`R,#$R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B="!);G-T<G5M96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!A>6UE;G1S(&]F(&YO=&5S
M('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^-B4@3F]T97,@:7-S=65D(&EN(%-E<'1E;6)E<B`R,#$R(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&5B="!);G-T<G5M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@<')I;F-I<&%L
M(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5P87EM96YT<R!O9B!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6:71A365D($IU;'D@,C`Q,2!3
M96-U<F5D($YO=&5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&5B="!);G-T<G5M96YT(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06=G<F5G871E('!R:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-30L-C0W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97)S(&]F('-H87)E<R!C;VYV97)T960@9F]R(&1E8G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S<U+#0Q-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P
M<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5E(&]F(&1E8G0@8V]N=F5R=&5D
M('1O('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW
M,38L-3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,RPR,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E9I=&%-960@2G5L>2`R,#$Q($9I<G-T(%-E
M8W5R960@3F]T97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G
M9W)E9V%T92!P<FEN8VEP86P@86UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y6:71A365D($IU;'D@,C`Q,2!396-O;F0@
M4V5C=7)E9"!.;W1E<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0@26YS=')U;65N="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9I=&%-960@4')O;6ES<V]R>2!.;W1E
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D1E8G0@26YS=')U;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT<R!O
M9B!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R<R!O9B!S:&%R97,@8V]N
M=F5R=&5D(&9O<B!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-C8L.#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)S:6]N('!R:6-E("AI;B!D;VQL87)S('!E<B!S
M:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XS.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5F%L=64@;V8@9&5B="!C;VYV97)T960@=&\@<VAA<F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,V-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S
M8W)I<'1I;VX@;V8@:6YT97)E<W0@<F%T92!T97)M<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
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M)#$L,#`P+#`P,"P@;W(@=&AE($9U;F1I;F<N/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W)U960@:6YT97)E<W0@
M<&%I9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ-C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9I
M=&%-960@4')O;6ES<V]R>2!.;W1E<R!;365M8F5R72!\($)R:6%N($)E<FYI
M8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N=',@
M;V8@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-R=65D(&EN=&5R97-T('!A:60\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,S0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@<F5M86EN:6YG
M('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E9I=&%-960@0V]N=F5R=&EB;&4@3F]T97,@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$
M96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!P<FEN8VEP86P@
M86UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,S0L,38P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R<R!O9B!S:&%R97,@8V]N=F5R=&5D(&9O<B!D96)T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0Q-2PQ,S8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G-I;VX@<')I8V4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C,X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E<R!)<W-U960@
M=&\@37(N($9I;FEZ:6\@06YD($UR+B!-:6QL:6=A;B!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0@26YS
M=')U;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R
M97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M,S0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.;W1E<R!)<W-U960@=&\@37(N($9I;FEZ:6\@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$96)T($EN
M<W1R=6UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C<G5E9"!I;G1E<F5S="!P86ED/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&5S($ES<W5E9"!T
M;R!-<BX@36EL;&EG86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C<G5E9"!I;G1E<F5S="!P86ED/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$L-3$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T
M.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U
M-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970T.2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%70TL^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/
M0TM(3TQ$15)3)R!%455)5%D@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0T/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`Q.2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$S/&)R/DYU;6)E<CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6PN(#(Y+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%P<BX@,C`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`R,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#(U+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E
M<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L
M=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S
M:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R
M97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-38L
M,#DW+#`Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$T-"PY-S8L-S4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O=71S
M=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34V+#`Y
M-RPP,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-#0L.3<V+#<U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960@9'5R
M:6YG('1H92!P97)I;V0L=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-#(L-S<Q+#,U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-S@L-C4P+#,U,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPX.34L-#@U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97)S(&]F(&]P=&EO;G,@=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L-#(S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.=6UB97)S(&]F('!O<G1I;VYS('-H87)E<R!I<W-U960@9F]R(&5X97)C
M:7-E(&]F(&]P=&EO;G,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S(T+#$Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-CDQ+#,Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!T;R!P=7)C:&%S
M92!S:&%R97,@;V8@8V]M;6]N('-T;V-K+"!V86QU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S0U+#<T-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#DQ,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<G,@;V8@;W!T:6]N<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K('5S:6YG(&-A<VAL97-S(&5X97)C:7-E(&9E871U<F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S-BPV,#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C8L.#(S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97)S
M(&]F(&)A;&%N8V4@<VAA<F5S(&ES<W5E9"!F;W(@97AE<F-I<V4@;V8@;W!T
M:6]N<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,S`L,S@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C0P+#,Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960@:6X@97AE
M<F-I<V4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$X,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#$P,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5E(&]F(&1E8G0@8V]N=F5R=&5D
M('1O('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPW
M,38L-3`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')I=F%T92!P;&%C96UE;G0@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U
M960@9'5R:6YG('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L.34S+#0X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4@<')I8V4@*&EN(&1O;&QA<G,@<&5R
M('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C$U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.=6UB97(@;V8@<VAA<F5S(&ES<W5E9"!D=7)I;F<@=&AE('!E<FEO9"QV
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPX.34L-#@U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4<F%N<V%C=&EO;B!C87-H(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4U,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQE9V%L(&9E97,@86YD(&5X<&5N<V5S('!A
M:60\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#`Q-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G
M<F5G871E('!U<F-H87-E('!R:6-E(&]F(&-O;6UO;B!S=&]C:R!S;VQD/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#4P,"PP,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9E8G)U
M87)Y(#(P,3(@3F]T97,O(%=A<G)A;G1S(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@:7-S=65D
M(&EN(&5X97)C:7-E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#$P,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!O9B!S:&%R97,@:7-S=65D
M(&EN(&5X97)C:7-E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+#$T-2PT.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX+#$T-2PT.#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5E(&]F(&1E8G0@
M8V]N=F5R=&5D('1O('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PP-30L-C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97)S(&]F('-H87)E<R!C;VYV97)T960@
M9F]R(&1E8G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S<U
M+#0Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N=F5R<VEO;B!P<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O;&1M
M86X@4V%C:',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960@9'5R:6YG('1H92!P97)I
M;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-38U+#,Q,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4@<')I8V4@=&\@=6YD97)W<FET=&5R<R`H:6X@9&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!S:&%R97,@:7-S=65D(&1U<FEN9R!T:&4@<&5R:6]D+'9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPW-S$L,S4S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9&1I=&EO;F%L(&-O;6UO;B!S=&]C:R!I<W-U960@=6YD97(@<VAE;&8@
M<F5G:7-T<F%T:6]N('-T871E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PR.#0L-SDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y*969F97)I97,@3$Q#("A5;F1E<G=R:71E
M<G,I(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!S:&%R97,@:7-S=65D(&1U<FEN9R!T:&4@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PT,3$L-S8U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92!P<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P97)I;V0@9F]R
M('!U<F-H87-E('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XS,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!!9&1I=&EO;F%L(&-O;6UO;B!S=&]C:R!I<W-U
M960@=6YD97(@<VAE;&8@<F5G:7-T<F%T:6]N('-T871E;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT,3$L-S8U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L
M(&-O;6UO;B!S=&]C:R!I<W-U960@=6YD97(@<VAE;&8@<F5G:7-T<F%T:6]N
M('-T871E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY
M-30L-3@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9&1I=&EO;F%L(&-O;6UO;B!S=&]C:R!I<W-U960@=6YD97(@
M<VAE;&8@<F5G:7-T<F%T:6]N('-T871E;65N="QV86QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#@L-3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1I9F5L+"!.:6-O
M;&%U<R`F86UP.R!#;VUP86YY("A5;F1E<G=R:71E<G,I(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R
M97,@:7-S=65D(&1U<FEN9R!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,RPW-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!P<FEC92`H:6X@9&]L
M;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960@9'5R:6YG('1H92!P
M97)I;V0L=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,S`L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F
M8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T-3`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4Q4$1//@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-43T-+2$],
M1$524R<@15%52519("A$971A:6QS($YA<G)A=&EV92`Q*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,"!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%Y(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%Y(#$Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D9E8BX@,CDL(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CY.=6UB97(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%Y(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,3DL(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CY.=6UB97(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(T+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E=A<G)A;G1S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q,RPY,C<L.3$V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R
M86=E(&-O;G1R86-T=6%L(')E;6%I;FEN9R!L:69E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XS('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F%M;W)T:7IE9"!C;W-T<R!O
M9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<U
M+#8P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@9FEN86YC:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C`L,#(R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED
M(&5X<&5N<V4M;&]N9R!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#0R-RPR-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<U,"PT-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,RPR,3@L.3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,L-34Q+#(V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L-#DR+#,V,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]A;B!G=6%R86YT>2!C
M;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A
M;F-I;&EO(&%N9"!#;VUP86YY(%=A<G)A;G1S(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V%R<F%N=',Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E('!R:6-E(&]F('=A<G)A;G1S("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXP,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F('-H87)E<R!P=7)C:&%S960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@<'5R8VAA<V5D(&9O
M<F9E:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S,RPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-A;F-I;&EO("9A;7`[86UP.V%M<#L@0V]M<&%N>2!787)R86YT<R`Q<W0@
M26YS=&%L;&UE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^5V%R<F%N=',Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@<'5R
M8VAA<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#,L,S,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y697-T:6YG(&1A=&4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/DIU;B`S,"P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!W
M87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`U+#`V
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AP96-T960@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5F]L871I;&ET>2!R871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-2XX.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!R871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C$R)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F0@>6EE;&0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y686QU871I
M;VX@;65T:&]D(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y";&%C:RU38VAO;&5S($UO9&5L/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!C;VUP96YS
M871I;VX@<F5C;VYG:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#`U+#`V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V%N8VEL:6\@86YD($-O;7!A;GD@5V%R<F%N=',@,FYD
M($EN<W1A;&QM96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E=A<G)A;G1S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S('!U
M<F-H87-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@S+#,S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!V86QU92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#8R+#$Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F]L871I;&ET>2!R871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2XX-"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@
M9G)E92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C0Q
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.;VXM8V%S:"!C;VUP96YS871I;VX@<F5C;VYG:7-E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34T+#`V.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W+#`S-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E<&%I9"!E>'!E;G-E+7-H;W)T('1E<FT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U-"PP-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS92UL;VYG('1E
M<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W+#`R-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%N
M8VEL:6\@86YD($-O;7!A;GD@5V%R<F%N=',@,W)D($EN<W1A;&QM96YT<R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E=A<G)A;G1S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S('!U<F-H87-E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@S+#,S-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36]D:69I8V%T:6]N
M(%=A<G)A;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^5V%R<F%N=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E(&]F('=A<G)A
M;G1S("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XS.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!P=7)C:&%S
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S$T+#<P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1F%I<B!V86QU92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPQ,C0L.#<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!T97)M/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6;VQA=&EL:71Y(')A=&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+C4P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F
M<F5E(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!)<W-U960@=&\@56YA9F9I;&EA=&5D($EN
M9&EV:61U86QS(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^5V%R<F%N=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@<'5R8VAA
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M<&5C=&5D('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E9O;&%T:6QI='D@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#0N.#$E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9R964@<F%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2XP-"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I=FED96YD('EI96QD/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('5N
M869F:6QI871E9"!I;F1I=FED=6%L<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O9F5S<VEO;F%L(&9E97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(Y+#<S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@27-S=65D('1O(%5N
M869F:6QI871E9"!%;G1I='D@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY787)R86YT<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@
M;V8@=V%R<F%N=',@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C4W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S
M('!U<F-H87-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4S,BPR,C@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI
M='D@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0N-S$E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y2:7-K(&9R964@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,"XW-"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1I=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&1E9F5R<F5D(&9I;F%N
M8VEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU
M,S(L,C(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.;VXM8V%S:"!C;VUP96YS871I;VX@<F5C;VYG:7-E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`Y+#$V-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V,"PU,C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3@L
M,#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5P86ED(&5X<&5N<V4M<VAO<G0@=&5R;3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C4W+#<Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E+6QO
M;F<@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@V+#8Y
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^2G5N92`R,#$R($YO=&5S+U=A<G)A;G1S(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V%R<F%N=',Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!S:&%R97,@<'5R8VAA<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-#(T+#DX,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T
M960@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5F]L871I;&ET>2!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-"XV-"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!R871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C<U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F0@>6EE;&0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@9&5F
M97)R960@9FEN86YC:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU-#<L,C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G1S(&)Y(')E
M;&%T:79E(&9A:7(@=F%L=64@8V%L8W5L871I;VX@;65T:&]D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8T.2PX.3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I;FEN9R!A
M;6]R=&EZ871I;VX@9&5F97)R960@9FEN86YC:6YG(&-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$P,BPV.#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DIU;F4@,C`Q,B!.
M;W1E<R]787)R86YT<R`Q<W0@27-S=64@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY787)R86YT<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@
M<')I8V4@;V8@=V%R<F%N=',@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA
M<F5S('!U<F-H87-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y*=6YE(#(P,3(@3F]T97,O5V%R<F%N=',@,FYD($ES<W5E
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^5V%R<F%N=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E(&]F('=A<G)A;G1S("AI;B!D
M;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!P=7)C:&%S960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@27-S
M=65D('1O(%5N869F:6QI871E9"!);F1I=FED=6%L<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=A<G)A;G1S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@<VAA<F5S('!U<F-H87-E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI='D@<F%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0N-S@E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9R
M964@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XW,B4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1I=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F('5N869F:6QI871E9"!I;F1I=FED=6%L<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O9F5S<VEO;F%L
M(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C4V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-
M=6QT:7!L92!!9'9A;F-E(%)E=F]L=FEN9R!#<F5D:70@3F]T92`H4&QA=&\@
M5V%R<F%N="D@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY787)R86YT<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@;V8@=V%R<F%N
M=',@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@<'5R8VAA<V5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(U,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M<&ER871I;VX@9&%T92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^2F%N(#,Q+`T*"0DR,#$Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T:6YG(&1A=&4@;V8@
M=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D]C="`S
M,2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!W87)R86YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,3$L.34V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!T97)M
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6;VQA
M=&EL:71Y(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T
M+C(Y)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4FES:R!F<F5E(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`N.#@E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!D969E<G)E9"!F
M:6YA;F-I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-#4Q+#DS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(V,"PP,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQI;F4@;V8@8W)E9&ET/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&96)R=6%R>2`R,#$R($YO=&5S+R!7
M87)R86YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E=A<G)A;G1S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!O9B!W87)R86YT
M<R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@<'5R8VAA<V5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#8X-2PS,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,Q
M-"PW,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#4P-2PR-#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI
M='D@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0N-3`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y2:7-K(&9R964@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#DN,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@.#4Y+#8T-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=A
M<G)A;G1S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!P<FEC92!O9B!W87)R86YT<R`H:6X@9&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY787)R86YT<SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@;V8@=V%R
M<F%N=',@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY7
M87)R86YT<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AE<F-I<V4@<')I8V4@;V8@=V%R<F%N=',@*&EN(&1O;&QA<G,@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D
M,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?
M-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970U,2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M15I004<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%
M455)5%D@*$1E=&%I;',@3F%R<F%T:79E(#(I("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E
M9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T+#,Y,RPT-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,C`P+#8U-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PX,S(L,#8Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!U;G)E8V]G;FEZ960@97-T:6UA=&5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$V,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#DR,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#,Y,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]G;FEZ960@=V5I9VAT960M879E<F%G
M92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(@>65A
M<G,@,3`@;6]N=&AS(#(T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N(&5X97)C:7-E('!R
M:6-E<R`H:6X@9&]L;&%R<R!P97(@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N(&5X97)C:7-E('!R
M:6-E<R`H:6X@9&]L;&%R<R!P97(@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U+C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#`Y($QO;F<@5&5R;2!);F-E;G1I
M=F4@0V]M<&5N<V%T:6]N(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@<&QA;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^5&\@<')O=FED92!F:6YA;F-I86P@
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M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!A
M=71H;W)I>F5D(&9O<B!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#(T-BPV,C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,3(@4W1O8VL@26YC96YT:79E(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@<&QA;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4&QA;B!W87,@9&5S:6=N960@
M=&\@<V5R=F4@87,@86X@:6YC96YT:79E(&9O<B!R971A:6YI;F<@<75A;&EF
M:65D(&%N9"!C;VUP971E;G0@:V5Y(&5M<&QO>65E<RP@;V9F:6-E<G,L(&1I
M<F5C=&]R<RP@86YD(&-E<G1A:6X@8V]N<W5L=&%N=',@86YD(&%D=FES;W)S
M(&]F(&]U<B!C;VUP86YY+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!A=71H;W)I>F5D
M(&9O<B!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,B!3=&]C:R!)
M;F-E;G1I=F4@4&QA;B!;365M8F5R72!\(%)E<W1R:6-T960@<W1O8VL@=6YI
M="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3,L-#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#`W,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H
M87)E<R!P=7)C:&%S960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5F5S=&EN9R!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XR,#$T+3`T+3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$X,"PP-S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C
M7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D
M,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H965T
M<R]3:&5E=#4R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%-#%!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY35$]#2TA/3$1%4E,G($5154E462`H1&5T86EL<RD@*%=A<G)A
M;G1S(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYU;6)E<B!O9B!S
M:&%R97,@=6YD97(@=V%R<F%N=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!O=71S=&%N9&EN9RP@8F5G:6YN
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PR.3,L-#DY
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(L,3DS+#0Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L,#4W+#8R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-RPS,S(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,V-2PU.#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PQ-#4L-#@V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V%R<F%N=',@97AP:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!C86YC96QL960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4Q+#$T,BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M(&]U='-T86YD:6YG+"!E;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$S+#DR-RPY,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-"PR.3,L-#DY/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,3DS+#0Y.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&5D
M(&%N9"!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,L-38R+#<V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S(&]U='-T86YD:6YG+"!B96=I;FYI;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XS-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+C<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N=',@97AE<F-I<V5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!C86YC96QL960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M(&]U='-T86YD:6YG+"!E;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XX,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2XW.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&5D(&%N9"!%>&5R8VES
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XX,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,
M:69E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G1S(&]U='-T86YD:6YG+"!B96=I;FYI;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,@,3`@;6]N=&AS(#(T(&1A>7,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT
M('EE87)S(#D@;6]N=&AS(#$X(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XW('EE87)S(#$P(&UO;G1H<R`R-"!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT<R!O=71S=&%N9&EN9RP@96YD:6YG/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XS('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<R`Q,"!M;VYT:',@
M,C0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C0@>65A<G,@.2!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&5D(&%N9"!%
M>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y
M96%R<R`Q,"!M;VYT:',@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9V=R96=A=&4@26YT
M<FEN<VEC(%9A;'5E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S(&]U='-T86YD:6YG+"!B96=I;FYI;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#@L.3,R+#<W-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<L
M.3<Q+#DY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPT.#,L-CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!O=71S=&%N9&EN9RP@96YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPV,C,L.#<U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#@L.3,R+#<W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$W+#DW,2PY.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1E9"!A;F0@17AE<F-I<V%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S4L-3DY+#4T,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P
M-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E
M869D,C0X,B]7;W)K<VAE971S+U-H965T-3,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+34%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-43T-+2$],1$524R<@15%52519
M("A$971A:6QS(#$I("A787)R86YT<R!;365M8F5R72P@55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0VQA<W,@;V8@5V%R<F%N="!O<B!2:6=H="!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@
M879E<F%G92!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#X@,BXX,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B`R+C`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y497)M("AI;B!Y96%R<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S
M<R!O9B!787)R86YT(&]R(%)I9VAT(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@:6YT
M97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XX
M."4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C<R)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#0N,CDE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#0N-C0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y497)M("AI;B!Y96%R<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;&%S<R!O9B!787)R86YT(&]R(%)I9VAT(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@
M:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2XQ,B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+C`T)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#4N.#DE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#0N.#$E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y497)M("AI;B!Y96%R<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F
M8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R
M:W-H965T<R]3:&5E=#4T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%14]!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY35$]#2TA/3$1%4E,G($5154E462`H1&5T86EL<R`R
M*2`H4W1O8VL@3W!T:6]N<R!;365M8F5R72D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`W)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N-C4E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XV,24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D(%9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8X+C`U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,S+C,U)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+C<W)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R
M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-B!M;VYT:',\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE
M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2XW-R4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C<Q)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,C,E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E
M9"!6;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,BXR.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-2XW-B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,@,R!M;VYT:',\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S(#,@
M;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^-B!Y96%R<R`S(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D
M,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S
M,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H
M965T-34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$525T%'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-43T-+2$],1$524R<@15%52519("A$971A:6QS(#,I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DYU;6)E<B!/<'1I;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2PT,C,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY.=6UB97(@3W!T:6]N<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&]U='-T86YD:6YG+"!B96=I;FYI
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#8S,BPW-#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,RPW,S,L-#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`L-3DP+#$V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!'<F%N=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0T,BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4X,RPV-S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$R
M,2PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P=&EO;G,@17AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@X-30L-3<S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#<U+#0R,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#DS,2PW.#@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS
M($5X<&ER960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($-A;F-E;&QE9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-#(W+#0W-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,#@L-S4P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0V+#$S-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@;W5T<W1A;F1I;F<L(&5N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,38L-SDR+#0T,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#8S,BPW-#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPW,S,L-#@X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y697-T960@86YD(&5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,RPR-S8L-#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D($%V97)A
M9V4@17AE<F-I<V4@4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O=71S=&%N9&EN9RP@8F5G:6YN:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-"XW,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RXS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BXX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&]U='-T86YD:6YG+"!E;F1I
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XT
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,2XQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5F5S=&5D(&%N9"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D($%V
M97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O=71S=&%N
M9&EN9RP@8F5G:6YN:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XW('EE87)S(#(@;6]N=&AS(#$R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XW('EE87)S(#@@;6]N=&AS(#$R
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XW('EE87)S(#<@;6]N=&AS(#8@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O=71S=&%N
M9&EN9RP@96YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV
M('EE87)S(#$P(&UO;G1H<R`R-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-R!Y96%R<R`R(&UO;G1H<R`Q,B!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^-R!Y96%R<R`X(&UO;G1H<R`Q,B!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T960@86YD(&5X97)C
M:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S
M(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T
M:6]N<R!O=71S=&%N9&EN9RP@8F5G:6YN:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4X+#@W."PQ,S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V+#@P-"PQ,3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T+#`V
M-RPV-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P=&EO;G,@;W5T<W1A;F1I;F<L(&5N9&EN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L.3DV+#,Q,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#@W."PQ,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPX
M,#0L,3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y697-T960@86YD(&5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0P+#<R,"PY-S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F8U\X
M-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R:W-H
M965T<R]3:&5E=#4V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q
M/CQS=')O;F<^24Y#3TU%(%1!6$53("A$971A:6QS($YA<G)A=&EV92D@*$9E
M9&5R86P@6TUE;6)E<ETL(%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R871I;F<@
M;&]S<R!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$P-2PU,CDL-#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F
M9#(T.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?
M,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970U
M-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15A,04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M24Y#3TU%(%1!6$53("A$971A:6QS*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C
M;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F5D97)A;"!S=&%T=71O<GD@=&%X(')A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1A=&4@=&%X(')A=&4L(&YE="!O9B!F961E<F%L('1A>"!B96YE9FET
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C@P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N.#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2XU
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%D:G5S=&UE;G0@:6X@=F%L=6%T:6]N(&%L;&]W86YC97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4P+CDP)2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,BXT,"4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@N,C`E
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&5R;6%N96YT(&%N9"!O=&AE<B!D:69F97)E;F-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$N,3`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."XT,"4I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(N,S`E*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;W9I<VEO;B`H0F5N969I="D@9F]R($EN8V]M92!487AE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#`T83,P-#-?,V0U-U\T
M,V9C7S@T-6-?-31D,65A9F0R-#@R+U=O<FMS:&5E=',O4VAE970U."YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14Y,04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^24Y#3TU%
M(%1!6$53("A$971A:6QS(#$I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F
M97)R960@26YC;VUE(%1A>"!!<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R871I;F<@;&]S<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0S+#`Y,2PT,S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T
M+#<W,RPU,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4L.3(P+#@V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4B9A;7`[1"!#<F5D:70\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-#<L-3$Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@V+#,T-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&1E9F5R<F5D(&EN8V]M92!T87@@87-S970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0S+#`Y,2PT,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PS,C$L,#0X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,#<L,C`W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6
M86QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T,RPP.3$L-#,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$U+#,R,2PP-#@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPQ,#<L,C`W*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R
M<F5D($EN8V]M92!487@@07-S971S+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9#`T83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C
M7S4T9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T-3DN:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4R1T%+/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)%3$%4140@4$%25$E%
M4R`H1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#,^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M3V-T+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D]C="X@,#0L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^3F]V+B`Q,RP@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I
M;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<&%Y;65N=',@;V8@;F]T97,@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#8Y,2PX-#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.#4P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-R=65D(&EN=&5R97-T('!A:60\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q,BPX-3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPR-3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)R:6%N
M($)E<FYI8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4<F%N<V%C=&EO;B!A;6]U;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#8S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5C96EV86)L97,@;W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C<R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!0=7)C
M:&%S92!!9W)E96UE;G0@5VET:"!097)N:7@@5&AE<F%P975T:6-S($Q,0R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VX@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS
M86-T:6]N(&%M;W5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5C96EV86)L97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0V+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P."PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M9V%L(&9E92!R96EM8G5R<V5M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-#DL.3@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C0Y+#DX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6%F9FEL:6%T960@=&AI<F0@
M<&%R='D@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.=6UB97(@;V8@<VAA<F5S('!U<F-H87-E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5FET84UE9"!0<F]M:7-S;W)Y($YO
M=&5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;B!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&EN92!O9B!C<F5D:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Y.2PR,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y297!A>6UE;G1S(&]F(&YO=&5S('!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C<G5E9"!I;G1E<F5S="!P86ED/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#$V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S(%M-96UB
M97)=('P@0G)I86X@0F5R;FEC:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A
M8W1I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!R96UA:6YI;F<@<')I;F-I<&%L
M(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5P87EM96YT<R!O9B!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W)U960@:6YT97)E<W0@<&%I
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS-#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&5S
M($ES<W5E9"!T;R!-<BX@1FEN:7II;R!!;F0@37(N($UI;&QI9V%N(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4F5L871E9"!087)T>2!4<F%N<V%C=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E
M('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYO=&5S($ES<W5E9"!T;R!-<BX@1FEN:7II;R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VX@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<G5E9"!I
M;G1E<F5S="!P86ED/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYO=&5S($ES<W5E9"!T;R!-<BX@36EL;&EG86X@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D
M(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W)U960@:6YT97)E<W0@
M<&%I9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4Q.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P
M-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E
M869D,C0X,B]7;W)K<VAE971S+U-H965T-C`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5/2T%+
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D)54TE.15-3($-/3D-%3E12051)
M3TY3("A$971A:6QS($YA<G)A=&EV92D@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3(^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO;B!2
M:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T+#(U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-"PQ.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-S4R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#@S,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPX-C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(L,CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R+#`X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2PU,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C0Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`S-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#$Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$U+#`R-BPR,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#@L-S<U+#4Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPX,3@L,#$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7-T;VUE<B!!
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]N8V5N=')A=&EO;B!2:7-K(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC96YT<F%T
M:6]N(%)I<VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<Y+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(X+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0W5S=&]M97(@02!;365M8F5R72!\(%-A;&5S(%)E
M=F5N=64@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;F-E
M;G1R871I;VX@4FES:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!R979E;G5E(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO;B!2
M:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VYC96YT<F%T:6]N(%)I<VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDW+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDX+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5S=&]M
M97(@02!;365M8F5R72!\(%-A;&5S(%)E=F5N=64@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T
M:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#8P.2PY-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4X-BPY,#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@P-"PP,3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U
M<W1O;65R($(@6TUE;6)E<ET@?"!386QE<R!2979E;G5E(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N
M=')A=&EO;B!2:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PP-3,L.#,X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,C$L,C$R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,3$L-#$W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#=7-T;VUE<B!#(%M-96UB97)=('P@4V%L97,@4F5V96YU92!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O
M;F-E;G1R871I;VX@4FES:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3@X+#8R-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S$R+#$Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W+#4Y
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0W5S=&]M97(@1"!;365M8F5R72!\(%-A;&5S(%)E=F5N=64@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;VYC96YT<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Y,"PP.3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@S,"PY,#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S
M,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q
M96%F9#(T.#(O5V]R:W-H965T<R]3:&5E=#8Q+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$%!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TU-251-14Y44R!!3D0@0T].
M5$E.1T5.0TE%4R`H1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$
M:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]N+6-A;F-E;&%B;&4@;W!E<F%T:6YG(&QE
M87-E('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8S(&UO
M;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36]N=&AL>2!"87-E(')E;G0@;V8@;&5A<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,P+#$T.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5T=7)E(&UI;FEM=6T@
M;&5A<V4@<&%Y;65N=',@;W9E<B!L:69E(&]F(&QE87-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@Y.2PT,30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;G1A;"!%>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L.#DT/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`L,38X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S8Q+#<Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P-BPS,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E;G1A;"!I;F-O;64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,S(L.38S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,2PV,3,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0P-&$S,#0S7S-D-3=?-#-F
M8U\X-#5C7S4T9#%E869D,C0X,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]D,#1A,S`T,U\S9#4W7S0S9F-?.#0U8U\U-&0Q96%F9#(T.#(O5V]R
M:W-H965T<R]3:&5E=#8R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-41!0SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4R`H
M1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9U='5R92!M:6YI;75M(')E
M;G1A;"!P87EM96YT<RP@>65A<B!E;F1I;F<@1&5C96UB97(@,S$L/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S<Q+#(T,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@R+#,W-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDS+#@T.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q.#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`R+#<T.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-#4P+#(Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!M:6YI;75M(&QE87-E('!A>6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#4P+#(Q
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T
M83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T
M9#%E869D,C0X,B]7;W)K<VAE971S+U-H965T-C,N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U
M4D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-%3$5#5$5$(%%505)415),
M62!&24Y!3D-)04P@1$%402`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3(^
M,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^475A<G1E<FQY($9I
M;F%N8VEA;"!);F9O<FUA=&EO;B!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PR-3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L
M,3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`S+#<U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,BPX,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(L.#8S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#(Y-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP.#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3,W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#(T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PP,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#@Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2PP,C8L,C$Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+#<W-2PU
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,L.#$X+#`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1W)O<W,@<')O9FET/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#,W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,3$X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX-3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,SDV/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#8Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,S4T+#0Q-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#$V+#`P,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#8Y
M+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,38L,S`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,3<L.#,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,3`L.#DY*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H.2PQ.#,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X+#,V,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#<L-C<S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H-BPP,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@V+#,W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4L-S(W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-"PR-3,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,2PX
M-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@Q,RPR.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@U-"PR,3<L,C$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C@L-#$Y+#,Q,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,U+#$R
M,"PR,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,;W-S('!E<B!C;VUM;VX@<VAA<F4L(&)A<VEC(&%N9"!D:6QU
M=&5D("AI;B!D;VQL87)S('!E<B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#`N,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,3(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`W*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N
M,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,"XP-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,30I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@P+C$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,"XS-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#`N,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C,X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P-#-?,V0U-U\T,V9C7S@T
M-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E869D,C0X,B]7;W)K<VAE
M971S+U-H965T-C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$526$%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-50E-%455%3E0@159%3E13("A$971A:6QS($YA<G)A=&EV
M92D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y&96(N(#$W+"`R,#$U/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,3`L(#(P,34\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%
M=F5N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960@9'5R:6YG
M('1H92!P97)I;V0L=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-#(L-S<Q+#,U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-S@L-C4P+#,U,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPX.34L-#@U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S
M97%U96YT($5V96YT(%M-96UB97)=('P@0V]W96X@86YD($-O;7!A;GDL($Q,
M0R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S
M:&%R97,@:7-S=65D(&1U<FEN9R!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#`S-RPP,S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPU.#`L,C0V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!P
M<FEC92!T;R!U;F1E<G=R:71T97)S("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"XP-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F('-H87)E<R!I<W-U960@9'5R:6YG('1H92!P97)I;V0L=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3DL,3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F(&1A>7,@9W)A;G1E9"!F;W(@;W!T:6]N('1O('!U<F-H87-E('-H
M87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,S`@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#`T83,P
M-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V0P-&$S,#0S7S-D-3=?-#-F8U\X-#5C7S4T9#%E
M869D,C0X,B]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS
M.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E
M(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970T,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970T-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#0X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T.2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3`N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#4Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970U,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4T+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970U-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4W+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U."YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T-3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#8P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970V,2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C(N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#8S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970V-"YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?9#`T
E83,P-#-?,V0U-U\T,V9C7S@T-6-?-31D,65A9F0R-#@R+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWWAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details ) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" onclick="toggleNextSibling(this);">$ (113,640)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</span><span></span></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" onclick="toggleNextSibling(this);">$ (90,160)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsGrossExcludingGoodwill" onclick="toggleNextSibling(this);">1,342,228</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsGrossExcludingGoodwill" onclick="toggleNextSibling(this);">755,748</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Amount</a></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsNetExcludingGoodwill" onclick="toggleNextSibling(this);">1,228,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsNetExcludingGoodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsNetExcludingGoodwill" onclick="toggleNextSibling(this);">665,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsNetExcludingGoodwill</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone therapy drug candidate patents - Pending [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember]" onclick="toggleNextSibling(this);">675,982</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_HormoneTherapyDrugCandidatePatentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember]" onclick="toggleNextSibling(this);">572,726</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_HormoneTherapyDrugCandidatePatentsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
        <td class="nump"><a title="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember]" onclick="toggleNextSibling(this);">675,982</a><span style="display:none;white-space:normal;text-align:left;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_HormoneTherapyDrugCandidatePatentsMember</span><span></span></td>
        <td class="nump"><a title="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember]" onclick="toggleNextSibling(this);">572,726</a><span style="display:none;white-space:normal;text-align:left;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_HormoneTherapyDrugCandidatePatentsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple trademarks for vitamins/supplements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember]" onclick="toggleNextSibling(this);">103,368</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_MultipleTrademarksForVitaminsSupplementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember]" onclick="toggleNextSibling(this);">59,328</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_MultipleTrademarksForVitaminsSupplementsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
        <td class="nump"><a title="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember]" onclick="toggleNextSibling(this);">103,368</a><span style="display:none;white-space:normal;text-align:left;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_MultipleTrademarksForVitaminsSupplementsMember</span><span></span></td>
        <td class="nump"><a title="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet[us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember]" onclick="toggleNextSibling(this);">59,328</a><span style="display:none;white-space:normal;text-align:left;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet<br>/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_MultipleTrademarksForVitaminsSupplementsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">OPERA software patent [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember]" onclick="toggleNextSibling(this);">31,951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_ComputerSoftwareIntangibleAssetMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember]" onclick="toggleNextSibling(this);">31,951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_ComputerSoftwareIntangibleAssetMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember]" onclick="toggleNextSibling(this);">(2,496)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_ComputerSoftwareIntangibleAssetMember</span><span></span></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember]" onclick="toggleNextSibling(this);">(499)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_ComputerSoftwareIntangibleAssetMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember]" onclick="toggleNextSibling(this);">29,455</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_ComputerSoftwareIntangibleAssetMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember]" onclick="toggleNextSibling(this);">31,452</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_ComputerSoftwareIntangibleAssetMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Amortization Period</a></td>
        <td class="text">14 years 9 months<span></span></td>
        <td class="text">15 years 9 months 18 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Development costs for corporate website [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember]" onclick="toggleNextSibling(this);">91,743</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_InternetDomainNamesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember]" onclick="toggleNextSibling(this);">91,743</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_InternetDomainNamesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember]" onclick="toggleNextSibling(this);">(91,743)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_InternetDomainNamesMember</span><span></span></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember]" onclick="toggleNextSibling(this);">(89,661)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_InternetDomainNamesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember]" onclick="toggleNextSibling(this);">2,082</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_InternetDomainNamesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Amortization Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 months 18 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents (Member)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember]" onclick="toggleNextSibling(this);">439,184</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember]" onclick="toggleNextSibling(this);">(19,401)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember]" onclick="toggleNextSibling(this);">$ 419,783</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Amortization Period</a></td>
        <td class="text">18 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph ((a)(1),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">The following table sets forth
the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2014 and December 31, 2013:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">&#160;</font>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Gross Carrying Amount</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Net &#160; <br />Amount</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Weighted- Average &#160; <br />Remaining Amortization Period (yrs.)</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Amortizing intangible assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">31,951</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">(2,496</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">29,455</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">14.75</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt; text-indent: -10; font-family: Times New Roman, Times, Serif">Development costs of corporate website</td><td style="font-family: Times New Roman, Times, Serif"></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">91,743</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(91,743</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Approved hormone therapy drug&#160;candidate patents</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">439,184</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(19,401</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">419,783</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">18</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 10; font-family: Times New Roman, Times, Serif">Non-amortizing intangible assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt; text-indent: -10; font-family: Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">675,982</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">675,982</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">103,368</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">103,368</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,342,228</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(113,640</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,228,588</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white"></font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31, 2013</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Gross Carrying Amount</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Net &#160; <br />Amount</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Weighted- Average Remaining Amortization Period (yrs.)</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Amortizing intangible assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">31,951</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">(499</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">31,452</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">15.8</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Development costs of&#160;corporate website</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">91,743</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(89,661</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">2,082</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">0.3</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 10; font-family: Times New Roman, Times, Serif">Non-amortizing intangible assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">572,726</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">572,726</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">59,328</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">59,328</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">755,748</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(90,160</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">665,588</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">&#160;</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December
31, 2014, the estimated amortization expense for the next five years is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Year Ending December 31,</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Estimated Amortization</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2015</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2016</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2017</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2018</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2019</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; width: 46%; font-family: Times New Roman, Times, Serif"></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PREPAID EXPENSE (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of prepaid expense</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expense consists of the following:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Prepaid manufacturing costs</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">899,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">899,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">463,720</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">824,221</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Accreted prepaid costs</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">64,543</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">27,234</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">TOTAL PREPAID EXPENSE</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,427,263</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,750,455</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) (Federal [Member], USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Federal [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards[us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember]" onclick="toggleNextSibling(this);">$ 105,529,416</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= us-gaap_InternalRevenueServiceIRSMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated amortization expense for the year:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" onclick="toggleNextSibling(this);">$ 25,138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" onclick="toggleNextSibling(this);">25,138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" onclick="toggleNextSibling(this);">25,138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" onclick="toggleNextSibling(this);">25,138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2019</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" onclick="toggleNextSibling(this);">$ 25,138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other current liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2014</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Accrued clinical trial costs</td><td style="width: 4%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,706,542</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">665,782</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued payroll, bonuses and commission costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">814,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">941,313</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued vacation costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">442,430</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,920</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,550</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses<sup>(1)</sup></font></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">185,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,900</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,303</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,188</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,446</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,233</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued rent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued financing costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">850,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840,639</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,601,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><sup>(1)</sup> In June 2008, we declared and
paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359
remained unclaimed by certain stockholders at both December 31, 2014 and 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b>&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of other current liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWAAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Summary of our Warrant activity and related information for
2012-2014&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares Under Warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted &#160; <br />Average&#160; <br />Remaining &#160; <br />Contractual&#160; <br />Life in Years</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate&#160; <br />Intrinsic Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Balance at December 31, 2011</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">3,057,627</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">0.36</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7.9</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">3,483,691</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">17,332,500</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.26</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(8,145,486</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.38</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(51,142</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.24</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2012</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">12,193,499</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.63</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">4.8</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">17,971,994</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,100,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2.72</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2013</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">14,293,499</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.79</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3.9</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">48,932,777</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(365,583</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.50</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2014</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">13,927,916</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.82</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3.0</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">36,623,875</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10; text-indent: -10">Vested and Exercisable at December 31, 2014</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">13,562,764</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.83</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2.9</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">35,599,540</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">&#160;&#160;</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock', window );">Schedule of weighted average fair value per share and assumptions used in the Black-Scholes Model of warants</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average fair value per share of
warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are
set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Weighted average fair value</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">2.83</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">2.05</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"></font>&#151;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.88-1.12</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.72-1.04</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Volatility</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">44.29-45.89</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">44.64-44.81</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Term (in years)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Dividend yield</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of stock options</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assumptions
used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.07-1.77</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.65-1.71</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.61-2.23</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Volatility</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">68.05-82.29</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33.35-45.76</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">40.77-46.01</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Term (in years)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.5-6.25</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif">Dividend yield</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of activity under the 2009 and 2012
Plans and related information for 2012-2014 follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares Under Options</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted &#160; <br />Average &#160; <br />Remaining &#160; <br />Contractual&#160; <br />Life in Years</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate&#160; <br />Intrinsic Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-family: Times New Roman, Times, Serif">Balance at December 31, 2011</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">10,590,161</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">0.16</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7.6</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 3%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">14,067,649</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">5,121,250</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2.80</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(1,931,788</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(46,135</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2012</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">13,733,488</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.16</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">7.7</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">26,804,117</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,583,677</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3.31</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(75,423</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(250</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(608,750</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2013</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">15,632,742</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.44</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">7.2</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">58,878,132</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,442,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">4.71</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(854,573</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(250</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(427,476</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2014</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">16,792,443</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.88</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">6.9</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">43,996,311</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">Vested and Exercisable at December 31, 2014</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">13,276,462</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.39</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">5.5</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">40,720,977</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of schedule of weighted average fair value per share and valuation assumptions of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>NOTE
2 &#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Principles of Consolidation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances
and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal"><u>Cash</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">We
maintain cash at financial institutions that at times may exceed the federally insured limit of $250,000 per financial institution.
We have never experienced any losses related to these funds.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Trade Accounts Receivable and Allowance
for Doubtful Accounts</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations
due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide
an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,
and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection
efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance
for doubtful accounts when received. <font style="color: #252525">To the extent data we use to calculate these estimates does not
accurately reflect bad debts; adjustments to these reserves may be required.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Inventories&#160;</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">Inventories
represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or
market using the average-cost method. The costs of manufacturing the prescription products associated with the deferred
revenue (as discussed in Revenue Recognition) are recorded as deferred costs and are included in inventory, until such time
as the related deferred revenue is recognized. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Pre-Launch
Inventory</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i>&#160;&#160;</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="letter-spacing: -0.15pt">Inventory
costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe
there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic
benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as
research and development expenses during the period the costs are incurred. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fixed Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Equipment</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We state equipment at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expense as incurred. <font style="letter-spacing: -0.15pt">We compute depreciation using the straight-line method
over the estimated useful lives of the related assets, which range from three to seven years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Leasehold
Improvements</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">We state
improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining
term of the lease.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Intangible
</u></font><u>Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Patent
and Trademarks</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i>&#160;&#160;</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">We have
adopted the provisions of </font>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <font style="letter-spacing: -0.15pt">350,
<i>Intangible-Goodwill and Other</i>,<i> </i>or </font>ASC 350<font style="letter-spacing: -0.15pt">. Capitalized patent costs,
net of accumulated amortization, include legal costs incurred for patent applications. </font>In accordance with ASC 350, <font style="letter-spacing: -0.15pt">once
a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.
If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment
annually or when events or circumstances indicate that their carrying amount may not be recoverable. As of December 31, 2014, we
had 4 issued patents (See Note 7). </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Impairment of Long-Lived Assets&#160;</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review the carrying values of property
and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their
carrying values may not be recoverable. Such events or circumstances include the following:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif">&#149;</td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif">significant declines in an asset&#146;s market price;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif">&#149;&#160;</p></td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif">significant deterioration in an asset&#146;s physical condition;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif">&#149;</td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif">significant changes in the nature or extent of an asset&#146;s use or operation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif">&#149;</td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif">significant adverse changes in the business climate that could impact an asset&#146;s value, including
adverse actions or assessments by regulators;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif">&#149;</td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif">accumulation of costs significantly in excess of original expectations related to the acquisition
or construction of an asset;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif">&#149;</td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif">current-period operating or cash flow losses combined with a history of such losses or a forecast
that demonstrates continuing losses associated with an asset&#146;s use; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif">&#149;</td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif">expectations that it is more likely than not that an asset will be sold or otherwise disposed of
significantly before the end of its previously estimated useful life.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If impairment indicators are present, we determine
whether an impairment loss should be recognized by testing the applicable asset or asset group&#146;s carrying value for recoverability.
This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent
of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted
future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective
carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment
in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.
In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected
timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record
a loss for the difference between the assets&#146; fair value and respective carrying values. We determine the fair value of
the assets using an &#147;income approach&#148; based upon a forecast of all the expected discounted future net cash flows associated
with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share,
projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial
relationships, market conditions, and available external information about future trends. We believe our current assumptions and
estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates,
resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets
during the years ended December 31, 2014, 2013 and 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and
accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level
1 assets under the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities
that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair
Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for identical
assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the
consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"><td style="width: 8%; font-family: Times New Roman, Times, Serif"></td><td style="width: 12%; font-family: Times New Roman, Times, Serif"><b>Level
                                         1</b></td><td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif">unadjusted
quoted prices in active markets for identical assets or liabilities;</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"><td style="width: 8%; font-family: Times New Roman, Times, Serif"></td><td style="width: 12%; font-family: Times New Roman, Times, Serif"><b>Level
                                         2</b></td><td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif">quoted
prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"><td style="width: 8%; font-family: Times New Roman, Times, Serif"></td><td style="width: 12%; font-family: Times New Roman, Times, Serif"><b>Level
                                         3</b></td><td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif">unobservable
inputs for the asset or liability.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, and 2013, we had no assets
or liabilities that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of indefinite-lived assets is
measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with our impairment
test. There was no impairment of intangible assets during the years ended December 31, 2014, 2013, and 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Income Taxes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon a change in our business model,
deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes</i>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur. At December 31, 2014, 2013, and 2012 we had no uncertain income tax positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize both interest and penalties related
to uncertain tax positions as part of the income tax provision. At December 31, 2014 and 2013, we had no tax positions relating
to open tax returns that were considered to be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our tax returns are subject to review by the
Internal Revenue Service three years after they are filed. Currently, years filed after 2011 are subject to review.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Share-Based Compensation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation
cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective vesting
periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in
accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the
award and our expected stock price volatility over a period equal to or greater than the expected life of the award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments (&#147;instruments&#148;)
issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, <i>Equity Based
Payments to Non-Employees</i>,<i> </i>or ASC 505<i>. </i>ASC 505<i> </i>defines the measurement date and recognition period for
such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the
earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments
is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize the compensation expense for all
share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize
the compensation expense on a straight-line basis over the employee&#146;s requisite service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Debt Discounts</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred from parties that are providing
long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based
on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the
related debt using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue Recognition</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize revenue on arrangements in accordance
with ASC 605, <i>Revenue Recognition</i>. We recognize revenue only when the price is fixed or determinable, persuasive evidence
of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our OTC and prescription
prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing.
The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our
OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay
for the product via third-party payers.&#160;Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from
major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note
13.&#160;There are no major external customers for our OTC prenatal vitamin or other products.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Over-the-Counter Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We generate OTC revenue from product sales
primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of
loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include
shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive
the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. <font style="color: #252525">We
provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.
</font>We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Prescription Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: #252525">We sell our name
brand and generic prescription products </font>primarily through drug wholesalers and retail pharmacies. We recognize revenue from
prescription product sales, net of sales discounts, chargebacks, and rebates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable product
from customers within a return period of six months prior to and up to twelve months following product expiration. Our
prescription products currently have a shelf life of 24 months from the date of manufacture. Given the limited history of our
prescription products, we currently cannot reliably estimate expected returns of the prescription products at the time of
shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists,
which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration
of the right of return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain various rebate programs in an effort
to maintain<i> </i>a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program
is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We
estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary,
on a quarterly basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Segment Reporting&#160;</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are managed and operated
as one business, which is focused on creating and commercializing products targeted exclusively for women. Our
business operations are managed by a single management team that reports to the President of  our Company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with
respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our
business as one reportable operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Shipping and Handling Costs</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Advertising
Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $698,871, $11,739 and $65,944 during the years ended December 31, 2014, 2013 and 2012, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Research and Development Expenses</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&#38;D, expenses
include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based
compensation expenses. Advance payments to be expensed in future R&#38;D activities were $1,175,082 and $2,606,405 for the years
ended December 31, 2014 and 2013, respectively. CRO activity expenses include preclinical laboratory experiments and clinical trial
studies. Other activity expenses include regulatory consulting and legal counsel. The activities undertaken by our regulatory consultants
that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff with
respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols
and FDA submissions. Legal activities that were classified as research and development expenses related to designing experiments
to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel
also provided professional research regarding the legal landscape of potential patents. These consulting and legal expenses were
direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge
internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon
terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and
services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received
rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject
to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise
to the revision become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Earnings Per Share&#160;</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculate earnings per share, or EPS,
in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts:
basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per
share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares
of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such
potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of
diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the potentially dilutive
securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they
were not antidilutive for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="11" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">As of December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Stock options</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">16,792,443</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">15,632,742</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">13,733,488</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Warrants</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">13,927,916</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">14,293,499</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">12,193,499</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">30,720,359</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">29,926,241</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">25,926,987</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recently Issued Accounting Pronouncements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: #252525">In August
2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-05, Presentation of Financial Statements-Going Concern
(Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern. ASU 2014-15
requires management to evaluate whether there are conditions and events that raise substantial doubt about </font>the
entity&#146;s ability to continue as a going concern within one year after the financial statements are issued (or available
to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending
after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is
permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do
not expect the adoption of the ASU 2014-15 to have a material effect on our consolidated financial statements and
disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB and the International
Accounting Standards Board (IASB) issued ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#146;s
core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount
that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so,
companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance
obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating
the transaction price to each separate performance obligations. ASU 2014-09 is effective for public business entities, certain
not-for-profit entities and certain employee benefit plans, for annual periods beginning after December 15, 2016, including interim
periods within that period. Early adoption is not permitted under GAAP. We are currently evaluating the impact of ASU 2014-09 on
our consolidated financial statements and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2013, the FASB issued ASU 2013-11,
Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss,
or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU
2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward,
a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements
as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward
with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability.
The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal
years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 did not have
a material impact on our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, the FASB issued ASU No. 2011-11,
Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures
about financial instruments and derivative instruments that are either offset on the statement of financial position or subject
to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of
financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to
facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the
basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after
January 1, 2013, and interim periods within those years. ASU 2011-11 did not have a material impact on our financial position or
results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe there would have been a material
effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards
been adopted in the current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Reclassifications</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain 2013 and 2012 amounts have been reclassified
to conform to current year presentation.&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of tax rate reconciliation</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation between taxes computed at
the federal statutory rate and the consolidated effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif">Federal statutory tax rate</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">34.0</td><td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">35.0</td><td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">35.0</td><td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">State tax rate, net of federal tax benefit</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5.8</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5.8</td><td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5.5</td><td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Adjustment in valuation allowances</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(50.9</td><td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(32.4</td><td style="text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(18.2</td><td style="text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Permanent and other differences</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">11.1</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(8.4</td><td style="padding-bottom: 1pt; text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(22.3</td><td style="padding-bottom: 1pt; text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Provision (Benefit) for Income Taxes</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our deferred tax asset and liability
as presented in the accompanying consolidated financial statements consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Deferred Income Tax Assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Net operating losses</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">43,091,437</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">14,773,537</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">5,920,861</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif">R&#38;D Credit</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">0</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">547,511</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">186,346</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total deferred income tax asset</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">43,091,437</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">15,321,048</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">6,107,207</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Valuation allowance</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(43,091,437</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(15,321,048</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(6,107,207</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Deferred Income Tax Assets, net</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>FIXED ASSETS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 186,045</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 155,083</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(122,752)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(93,765)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed Assets, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">63,293</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">61,318</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember]" onclick="toggleNextSibling(this);">132,150</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_EquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember]" onclick="toggleNextSibling(this);">108,458</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_EquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">$ 53,895</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_FurnitureAndFixturesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">$ 46,625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_FurnitureAndFixturesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKMAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) (Warrants [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Weighted average fair value</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExercisePrice" onclick="toggleNextSibling(this);"> 2.83</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExercisePrice" onclick="toggleNextSibling(this);"> 2.05</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">0.88%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">0.72%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">44.29%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">44.64%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1.12%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1.04%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">45.89%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">44.81%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 51,361,607</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 54,191,260</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $21,119 and $26,555, respectively</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">2,154,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">1,690,753</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">1,182,113</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">1,043,618</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">1,537,407</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">2,477,715</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">56,235,344</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">59,403,346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">63,293</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">61,318</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseNoncurrent" onclick="toggleNextSibling(this);">1,427,263</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseNoncurrent" onclick="toggleNextSibling(this);">1,750,455</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsNetExcludingGoodwill" onclick="toggleNextSibling(this);">1,228,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsNetExcludingGoodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsNetExcludingGoodwill" onclick="toggleNextSibling(this);">665,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsNetExcludingGoodwill</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsNoncurrent" onclick="toggleNextSibling(this);">125,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsNoncurrent" onclick="toggleNextSibling(this);">135,686</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsNoncurrent" onclick="toggleNextSibling(this);">2,780,851</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsNoncurrent" onclick="toggleNextSibling(this);">2,551,729</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">59,079,488</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">62,016,393</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">6,327,129</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">2,114,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue" onclick="toggleNextSibling(this);">522,613</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenue" onclick="toggleNextSibling(this);">1,602,580</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">3,840,639</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesCurrent" onclick="toggleNextSibling(this);">3,601,189</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">10,690,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">7,317,986</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 250,000,000 shares authorized; 156,097,019 and 144,976,757 issued and outstanding, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">156,097</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">144,977</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">182,982,846</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">135,086,056</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(134,749,836)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(80,532,626)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">48,389,107</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">54,698,407</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 59,079,488</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 62,016,393</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.10-17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Cash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableDateDeclaredMonthAndYear', window );">Date dividend declared</a></td>
        <td class="text">2008-06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, amount per share</a></td>
        <td class="nump"><a title="us-gaap_DividendsPayableAmountPerShare" onclick="toggleNextSibling(this);">$ 0.40</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DividendsPayableAmountPerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Unclaimed dividends</a></td>
        <td class="nump"><a title="us-gaap_DividendsPayableCurrentAndNoncurrent" onclick="toggleNextSibling(this);">$ 41,359</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DividendsPayableCurrentAndNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DividendsPayableCurrentAndNoncurrent" onclick="toggleNextSibling(this);">$ 41,359</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DividendsPayableCurrentAndNoncurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateDeclaredMonthAndYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The month and year (YYYY-MM) that the dividend to be paid was declared.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DividendsPayableDateDeclaredMonthAndYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKNAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (54,217,210)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (28,419,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (35,120,235)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">28,987</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">47,883</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">27,484</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">23,480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">10,262</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">28,776</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
        <td class="num"><a title="us-gaap_ProvisionForDoubtfulAccounts" onclick="toggleNextSibling(this);">(5,436)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProvisionForDoubtfulAccounts</span><span></span></td>
        <td class="num"><a title="us-gaap_ProvisionForDoubtfulAccounts" onclick="toggleNextSibling(this);">(15,493)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProvisionForDoubtfulAccounts</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProvisionForDoubtfulAccounts" onclick="toggleNextSibling(this);">40,548</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProvisionForDoubtfulAccounts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GainsLossesOnExtinguishmentOfDebt" onclick="toggleNextSibling(this);">10,307,864</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainsLossesOnExtinguishmentOfDebt</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" onclick="toggleNextSibling(this);">6,716,504</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDebtDiscountPremium" onclick="toggleNextSibling(this);">1,102,680</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDebtDiscountPremium</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDebtDiscountPremium" onclick="toggleNextSibling(this);">1,604,240</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDebtDiscountPremium</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">4,239,358</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">3,207,238</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">1,868,345</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred financing costs</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDeferredCharges" onclick="toggleNextSibling(this);">260,027</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDeferredCharges</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDeferredCharges" onclick="toggleNextSibling(this);">1,451,934</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDeferredCharges</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock based expense for services</a></td>
        <td class="nump"><a title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" onclick="toggleNextSibling(this);">730,954</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</span><span></span></td>
        <td class="nump"><a title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" onclick="toggleNextSibling(this);">636,917</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</span><span></span></td>
        <td class="nump"><a title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" onclick="toggleNextSibling(this);">338,457</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Loan guaranty costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" onclick="toggleNextSibling(this);">2,944</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" onclick="toggleNextSibling(this);">45,036</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(458,028)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(1,068,619)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(728,253)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(138,495)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">571,592</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(1,027,137)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherCurrentAssets" onclick="toggleNextSibling(this);">680,281</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherCurrentAssets" onclick="toggleNextSibling(this);">(1,386,319)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherCurrentAssets" onclick="toggleNextSibling(this);">42,281</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">(37,309)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">(565,706)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">4,212,912</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">472,851</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">1,334,855</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(1,079,967)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">457,828</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">1,144,752</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" onclick="toggleNextSibling(this);">239,450</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" onclick="toggleNextSibling(this);">2,875,320</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" onclick="toggleNextSibling(this);">639,157</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" onclick="toggleNextSibling(this);">(150,068)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(45,520,996)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(20,768,069)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(12,737,326)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs, net of abandoned costs</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireIntangibleAssets" onclick="toggleNextSibling(this);">(586,480)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireIntangibleAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireIntangibleAssets" onclick="toggleNextSibling(this);">(439,034)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireIntangibleAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireIntangibleAssets" onclick="toggleNextSibling(this);">(206,101)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireIntangibleAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(30,962)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(40,790)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(66,405)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherDeposits', window );">Refund (payment) of security deposit</a></td>
        <td class="nump"><a title="us-gaap_PaymentsForProceedsFromOtherDeposits" onclick="toggleNextSibling(this);">10,686</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForProceedsFromOtherDeposits</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsForProceedsFromOtherDeposits" onclick="toggleNextSibling(this);">(103,737)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForProceedsFromOtherDeposits</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(606,756)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(583,561)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(272,506)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">42,771,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">78,650,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">7,895,485</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">345,746</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">30,910</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">191,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromWarrantExercises" onclick="toggleNextSibling(this);">181,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromWarrantExercises</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes and loans payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromNotesPayable" onclick="toggleNextSibling(this);">8,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromNotesPayable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from bank line of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromLinesOfCredit" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromLinesOfCredit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfWarrants" onclick="toggleNextSibling(this);">400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfWarrants</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of bank line of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLinesOfCredit" onclick="toggleNextSibling(this);">(500,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLinesOfCredit</span><span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLinesOfCredit" onclick="toggleNextSibling(this);">(300,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLinesOfCredit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of notes payable-related party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfRelatedPartyDebt" onclick="toggleNextSibling(this);">(200,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfRelatedPartyDebt</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">(4,691,847)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">(1,850,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">43,298,099</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">73,989,416</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">14,436,885</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Increase in cash</a></td>
        <td class="num"><a title="us-gaap_CashPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(2,829,653)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">52,637,786</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">1,427,053</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">54,191,260</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">1,553,474</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">126,421</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">51,361,607</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">54,191,260</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">1,553,474</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">212,853</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">17,253</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForFinancing', window );">Warrants issued for financing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedForFinancing" onclick="toggleNextSibling(this);">1,711,956</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedForFinancing</span><span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedForFinancing" onclick="toggleNextSibling(this);">2,509,537</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedForFinancing</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForServices', window );">Warrants issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedForServices" onclick="toggleNextSibling(this);">462,196</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedForServices</span><span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedForServices" onclick="toggleNextSibling(this);">1,532,228</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedForServices</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest', window );">Warrants exercised in exchange for debt and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" onclick="toggleNextSibling(this);">3,102,000</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtConversionConvertedInstrumentNonCash', window );">Shares issued in exchange for debt and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_DebtConversionConvertedInstrumentNonCash" onclick="toggleNextSibling(this);">1,054,658</a><span style="display:none;white-space:normal;text-align:left;">txmd_DebtConversionConvertedInstrumentNonCash</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes payable issued for accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_NotesIssued1" onclick="toggleNextSibling(this);">$ 15,123</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NotesIssued1</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtConversionConvertedInstrumentNonCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_DebtConversionConvertedInstrumentNonCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to amount of warrants ecercised in exchange for debt and accrued interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForFinancing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued in the period for financing in a noncash transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WarrantsIssuedForFinancing</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued in the period for servcies in a noncash transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WarrantsIssuedForServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of amortization of deferred charges applied against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Cash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Beneficial Conversion Feature<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of notes issued in noncash investing and financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherDeposits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net cash outflow or inflow from other deposits that are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherDeposits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(f))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph f<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.5)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 5<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(f))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph f<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2GAK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2012</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">$ 4,691,847</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">$ 1,850,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable" onclick="toggleNextSibling(this);">$ 200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">212,853</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">17,253</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">696</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Brian Bernick [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transaction amounts</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionAmountsOfTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">2,632</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionAmountsOfTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOfficersOrStockholders', window );">Receivables outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DueFromOfficersOrStockholders[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">1,272</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueFromOfficersOrStockholders<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember', window );">Stock Purchase Agreement With Pernix Therapeutics LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transaction amounts</a></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionAmountsOfTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionAmountsOfTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionAmountsOfTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember]" onclick="toggleNextSibling(this);">404,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionAmountsOfTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionAmountsOfTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionAmountsOfTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOfficersOrStockholders', window );">Receivables outstanding</a></td>
        <td class="nump"><a title="us-gaap_DueFromOfficersOrStockholders[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember]" onclick="toggleNextSibling(this);">46,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueFromOfficersOrStockholders<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DueFromOfficersOrStockholders[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember]" onclick="toggleNextSibling(this);">308,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueFromOfficersOrStockholders<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DueFromOfficersOrStockholders[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember]" onclick="toggleNextSibling(this);">46,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueFromOfficersOrStockholders<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LegalFeeReimbursement', window );">Legal fee reimbursement</a></td>
        <td class="nump"><a title="txmd_LegalFeeReimbursement[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember]" onclick="toggleNextSibling(this);">249,981</a><span style="display:none;white-space:normal;text-align:left;">txmd_LegalFeeReimbursement<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_LegalFeeReimbursement[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember]" onclick="toggleNextSibling(this);">249,981</a><span style="display:none;white-space:normal;text-align:left;">txmd_LegalFeeReimbursement<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_NonAffiliatedThirdPartyMember', window );">Non-affiliated third party [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_NonAffiliatedThirdPartyMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= txmd_NonAffiliatedThirdPartyMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember', window );">VitaMed Promissory Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">299,220</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCredit[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember]" onclick="toggleNextSibling(this);">2,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember', window );">VitaMed Promissory Notes [Member] | Brian Bernick [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtInstrumentRemainingFaceAmount', window );">Aggregate remaining principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_DebtInstrumentRemainingFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">txmd_DebtInstrumentRemainingFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RepaymentsOfNotesPayable[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">5,341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_VitaMedPromissoryNotesMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToPartiesMember', window );">Notes Issued to Mr. Finizio And Mr. Milligan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToPartiesMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedToPartiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty1Member', window );">Notes Issued to Mr. Finizio [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty1Member]" onclick="toggleNextSibling(this);">888</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedToParty1Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty2Member', window );">Notes Issued to Mr. Milligan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid[us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty2Member]" onclick="toggleNextSibling(this);">$ 1,519</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_NotesIssuedToParty2Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtInstrumentRemainingFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to balance amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_DebtInstrumentRemainingFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LegalFeeReimbursement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to reimbursment of legal fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_LegalFeeReimbursement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOfficersOrStockholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, amounts due from owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 3<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DueFromOfficersOrStockholders</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transactions with related party during the financial reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToPartiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToPartiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_NotesIssuedToParty2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_VitaMedPromissoryNotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_NonAffiliatedThirdPartyMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_NonAffiliatedThirdPartyMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ERJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Costs</a></td>
        <td class="nump"><a title="us-gaap_AdvertisingExpense" onclick="toggleNextSibling(this);">$ 698,871</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdvertisingExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdvertisingExpense" onclick="toggleNextSibling(this);">$ 11,739</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdvertisingExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdvertisingExpense" onclick="toggleNextSibling(this);">$ 65,944</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdvertisingExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities', window );">Advance payments for future research and development activities</a></td>
        <td class="nump"><a title="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" onclick="toggleNextSibling(this);">$ 1,175,082</a><span style="display:none;white-space:normal;text-align:left;">txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities</span><span></span></td>
        <td class="nump"><a title="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" onclick="toggleNextSibling(this);">$ 2,606,405</a><span style="display:none;white-space:normal;text-align:left;">txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of advance payments made for future research and development activiites to be expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 35<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 16 &#150; SUBSEQUENT EVENTS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February&#160;10, 2015, we
entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the
several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246
shares of the  our Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen
Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional
shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were
approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses
payable by us. The offering closed on February&#160;17, 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 18, 2015, we entered into an agreement
to lease administrative office space in Boca Raton, Florida, pursuant to an addendum to our existing 63 month non-cancelable operating
lease commencing on July 1, 2013 and expiring on September 30, 2018. This addendum will be effective beginning April 1, 2015 and
will expire with the original lease term on September 30, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EEIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">30,720,359</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">29,926,241</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">25,926,987</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">16,792,443</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">15,632,742</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">13,733,488</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">13,927,916</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">14,293,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">12,193,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities in our calculation of diluted net loss per share allocable to common stockholders</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the potentially dilutive
securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they
were not antidilutive for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="11" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">As of December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Stock options</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">16,792,443</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">15,632,742</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">13,733,488</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Warrants</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">13,927,916</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">14,293,499</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">12,193,499</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">30,720,359</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">29,926,241</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">25,926,987</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>THE COMPANY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">THE COMPANY</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 1 &#150; THE COMPANY&#160;</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc., a Nevada corporation,
or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed,
and BocaGreenMD, Inc., a Nevada corporation, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and
BocaGreen collectively are sometimes referred to as &#147;our company,&#148; &#147;we,&#148; &#147;our,&#148; or &#147;us.&#148;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Nature of Business</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a women&#146;s health care
product company focused on creating and commercializing products targeted exclusively for women. As of the date of these
consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and
commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials
are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies,
including hot flashes, osteoporosis, and vaginal dryness. We are developing these hormone therapy drug candidates, which
contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at
lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are
created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or
in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as
over-the-counter, or OTC, vitamins.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" onclick="toggleNextSibling(this);">$ 21,119</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" onclick="toggleNextSibling(this);">$ 26,555</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">250,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">250,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">156,097,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">144,976,757</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">156,097,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">144,976,757</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE</u></b><u>&#160;<b> 11 &#150;
INCOME TAXES<font style="letter-spacing: -0.15pt">&#160;</font></b></u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">For
the years ended December 31, 2014, 2013 and 2012, there was no provision for income taxes, current or deferred.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white"></font>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, we have a federal net
operating loss carry forward of approximately $105,529,416 available to offset future taxable income through 2034.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation between taxes computed at
the federal statutory rate and the consolidated effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif">Federal statutory tax rate</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">34.0</td><td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">35.0</td><td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">35.0</td><td style="width: 1%; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">State tax rate, net of federal tax benefit</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5.8</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5.8</td><td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5.5</td><td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Adjustment in valuation allowances</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(50.9</td><td style="text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(32.4</td><td style="text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(18.2</td><td style="text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Permanent and other differences</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">11.1</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(8.4</td><td style="padding-bottom: 1pt; text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(22.3</td><td style="padding-bottom: 1pt; text-align: right; vertical-align: middle; font-family: Times New Roman, Times, Serif">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Provision (Benefit) for Income Taxes</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle; font-family: Times New Roman, Times, Serif">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our deferred tax asset and liability
as presented in the accompanying consolidated financial statements consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Deferred Income Tax Assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Net operating losses</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">43,091,437</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">14,773,537</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">5,920,861</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif">R&#38;D Credit</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">0</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">547,511</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">186,346</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total deferred income tax asset</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">43,091,437</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">15,321,048</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">6,107,207</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Valuation allowance</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(43,091,437</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(15,321,048</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(6,107,207</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Deferred Income Tax Assets, net</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that it is more likely than
not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets
on our balance sheet and as such, a valuation allowance has been established against the deferred tax
assets for the period ended December 31, 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Unrecognized Tax Benefits&#9;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the period ended December 31, 2014,
we had no unrecognized tax benefits.&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 06, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">TherapeuticsMD, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000025743<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 399,616,527</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">171,715,551</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_NonaffiliatedEntityMember', window );">Non-Affiliates</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding[dei_LegalEntityAxis=txmd_NonaffiliatedEntityMember]" onclick="toggleNextSibling(this);">90,410,979</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding<br>/ dei_LegalEntityAxis<br>= txmd_NonaffiliatedEntityMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_NonaffiliatedEntityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_NonaffiliatedEntityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 12 &#150; RELATED PARTIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Loan Guaranty&#160;</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.
Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family
Limited Partnership. See NOTES 9 and 10 &#160;for more details.&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Loans from Affiliates&#160;</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, VitaMed issued the VitaMed Notes
in the aggregate principal amount of $500,000, of which $100,000 was sold to affiliates. In June 2012, the affiliate notes were
extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments, LLC, which is owned
by Brian Bernick, a member of the board of directors of our company. On October 4, 2012 these VitaMed Notes were paid in full
including $5,341 in accrued interest.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 4% promissory
notes to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012.
These promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the promissory note held by Mr. Finizio
was paid in full, including $888 in accrued interest. Mr. Milligan&#146;s promissory note was extended to October 15, 2012. On
October 4, 2012 this promissory note was paid in full including $1,519 in accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Purchases by Related Parties&#160;</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2012, we sold our products to Dr. Brian
Bernick, a director of our company, in the amount of $2,632, and $1,272 of receivables related thereto remained outstanding at
December 31, 2012. No products were sold to Dr. Bernick during 2014 and 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Agreements with Pernix Therapeutics, LLC</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 29, 2012, Cooper C.
Collins, president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of
directors. From time to time, we have entered into agreements with Pernix in the normal course of business. All such
agreements are reviewed by independent directors of our company or a committee consisting of independent directors of our company.
During the years ended December 31, 2014, 2013, and 2012, we made purchases of $0, $0 and $404,000, respectively, from
Pernix. At December 31, 2014, 2013, and 2012, there were amounts due Pernix of approximately $46,000, $46,000, and
$308,000 outstanding, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, there were amounts due to us
from Pernix for legal fee reimbursement relating to a litigation matter pursuant to a license and supply agreement in the amount
of $249,981 for each of the years ended December 31, 2014 and 2013.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Warrants assigned to Related Party&#160;</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, a warrant to purchase 100,000
shares of our Common Stock was assigned by a non-affiliated third party to the son of the Chairman of our board of directors.<b>&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJSAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues, net</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 15,026,219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 8,775,598</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 3,818,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">3,671,803</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">1,959,597</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">1,348,113</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">11,354,416</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">6,816,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">2,469,900</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
        <td class="nump"><a title="us-gaap_SellingGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">22,124,072</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingGeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_SellingGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">19,014,837</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingGeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_SellingGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">14,069,701</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingGeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">43,218,938</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">13,551,263</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">4,492,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">52,467</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">58,145</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">56,260</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">65,395,477</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">32,624,245</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">18,618,323</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(54,041,061)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(25,808,244)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(16,148,423)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income and (expense)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">46,569</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">34,544</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">3,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">37,309</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">27,234</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Financing costs</a></td>
        <td class="num"><a title="us-gaap_AmortizationOfFinancingCosts" onclick="toggleNextSibling(this);">(260,027)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCosts</span><span></span></td>
        <td class="num"><a title="us-gaap_AmortizationOfFinancingCosts" onclick="toggleNextSibling(this);">(1,503,922)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCosts</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_InterestExpenseDebt" onclick="toggleNextSibling(this);">(1,165,981)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseDebt</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpenseDebt" onclick="toggleNextSibling(this);">(1,905,409)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseDebt</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Loan guaranty costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" onclick="toggleNextSibling(this);">(2,944)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</span><span></span></td>
        <td class="num"><a title="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" onclick="toggleNextSibling(this);">(45,036)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_GainsLossesOnExtinguishmentOfDebt" onclick="toggleNextSibling(this);">(10,307,864)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainsLossesOnExtinguishmentOfDebt</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" onclick="toggleNextSibling(this);">(6,716,504)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(176,149)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(2,611,069)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(18,971,812)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(54,217,210)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(28,419,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(35,120,235)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (54,217,210)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (28,419,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (35,120,235)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.36)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.22)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.38)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">149,727,228</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">127,569,731</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">91,630,693</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Beneficial Conversion Feature<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1,2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GrossProfit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 940<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35710027&amp;loc=d3e41242-110953<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34747878&amp;loc=d3e3636-108311<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PREPAID EXPENSE<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidExpensesDisclosureTextBlock', window );">PREPAID EXPENSE</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 6 &#150;PREPAID EXPENSE&#160;</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expense consists of the following:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table align="center" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 70%; text-align: left; font-family: Times New Roman, Times, Serif">Prepaid manufacturing costs</td>
    <td style="width: 3%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">899,000</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 3%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">899,000</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Prepaid research and development costs</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">463,720</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">824,221</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Accreted prepaid costs</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">64,543</td>
    <td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">27,234</td>
    <td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">TOTAL PREPAID EXPENSE</td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,427,263</td>
    <td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,750,455</td>
    <td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidExpensesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of prepaid expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_PrepaidExpensesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FIXED ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 5 &#150; FIXED ASSETS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Equipment</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">108,458</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Furniture and fixtures</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">53,895</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">46,625</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">186,045</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">155,083</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Accumulated depreciation</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(122,752</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(93,765</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">TOTAL FIXED ASSETS</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">63,293</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">61,318</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the years ended December
31, 2014, 2013, and 2012 was $28,987, $47,883, and $27,484, respectively. In December 2013, accumulated depreciation was reduced
by $11,980 associated with leasehold improvements of our previously leased office property.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Principles of Consolidation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances
and transactions have been eliminated in consolidation.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal"><u>Cash</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">We
maintain cash at financial institutions that at times may exceed the federally insured limit of $250,000 per financial institution.
We have never experienced any losses related to these funds.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">&#160;&#160;</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Trade Accounts Receivable and Allowance
for Doubtful Accounts</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations
due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide
an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,
and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection
efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance
for doubtful accounts when received. <font style="color: #252525">To the extent data we use to calculate these estimates does not
accurately reflect bad debts; adjustments to these reserves may be required.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Inventories&#160;</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">Inventories
represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or
market using the average-cost method. The costs of manufacturing the prescription products associated with the deferred
revenue (as discussed in Revenue Recognition) are recorded as deferred costs and are included in inventory, until such time
as the related deferred revenue is recognized. </font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fixed Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Equipment</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We state equipment at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expense as incurred. <font style="letter-spacing: -0.15pt">We compute depreciation using the straight-line method
over the estimated useful lives of the related assets, which range from three to seven years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Leasehold
Improvements</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">We state
improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining
term of the lease.</font>&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Intangible
</u></font><u>Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Patent
and Trademarks</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i>&#160;&#160;</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">We have
adopted the provisions of </font>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <font style="letter-spacing: -0.15pt">350,
<i>Intangible-Goodwill and Other</i>,<i> </i>or </font>ASC 350<font style="letter-spacing: -0.15pt">. Capitalized patent costs,
net of accumulated amortization, include legal costs incurred for patent applications. </font>In accordance with ASC 350, <font style="letter-spacing: -0.15pt">once
a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.
If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment
annually or when events or circumstances indicate that their carrying amount may not be recoverable. As of December 31, 2014, we
had 4 issued patents (See Note 7). </font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Impairment of Long-Lived Assets&#160;</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review the carrying values of property and
equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying
values may not be recoverable. Such events or circumstances include the following:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%">&#149;</td>
    <td style="text-align: justify; width: 93%">significant declines in an asset&#146;s market price;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%">&#149;&#160;</td>
    <td style="text-align: justify; width: 93%">significant deterioration in an asset&#146;s physical condition;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%">&#149;</td>
    <td style="text-align: justify; width: 93%">significant changes in the nature or extent of an asset&#146;s use or operation;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%">&#149;</td>
    <td style="text-align: justify; width: 93%">significant adverse changes in the business climate that could impact an asset&#146;s value, including adverse actions or assessments by regulators;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%">&#149;</td>
    <td style="text-align: justify; width: 93%">accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%">&#149;</td>
    <td style="text-align: justify; width: 93%">current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#146;s use; and</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 2%">&#149;</td>
    <td style="text-align: justify; width: 93%">expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If impairment indicators are present, we determine
whether an impairment loss should be recognized by testing the applicable asset or asset group&#146;s carrying value for recoverability.
This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent
of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted
future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective
carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment
in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.
In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected
timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record
a loss for the difference between the assets&#146; fair value and respective carrying values. We determine the fair value of
the assets using an &#147;income approach&#148; based upon a forecast of all the expected discounted future net cash flows associated
with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share,
projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial
relationships, market conditions, and available external information about future trends. We believe our current assumptions and
estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates,
resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets
during the years ended December 31, 2014, 2013 and 2012.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and
accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level
1 assets under the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities
that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair
Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for identical
assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the
consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"><td style="width: 8%; font-family: Times New Roman, Times, Serif"></td><td style="width: 12%; font-family: Times New Roman, Times, Serif"><b>Level
                                         1</b></td><td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif">unadjusted
quoted prices in active markets for identical assets or liabilities;</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"><td style="width: 8%; font-family: Times New Roman, Times, Serif"></td><td style="width: 12%; font-family: Times New Roman, Times, Serif"><b>Level
                                         2</b></td><td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif">quoted
prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif"><td style="width: 8%; font-family: Times New Roman, Times, Serif"></td><td style="width: 12%; font-family: Times New Roman, Times, Serif"><b>Level
                                         3</b></td><td style="text-align: justify; width: 80%; font-family: Times New Roman, Times, Serif">unobservable
inputs for the asset or liability.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, and 2013, we had no assets
or liabilities that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of indefinite-lived assets is
measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with our impairment
test. There was no impairment of intangible assets during the years ended December 31, 2014, 2013, and 2012.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Income Taxes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon a change in our business model,
deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes</i>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur. At December 31, 2014, 2013, and 2012 we had no uncertain income tax positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize both interest and penalties related
to uncertain tax positions as part of the income tax provision. At December 31, 2014 and 2013, we had no tax positions relating
to open tax returns that were considered to be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our tax returns are subject to review by the
Internal Revenue Service three years after they are filed. Currently, years filed after 2011 are subject to review.&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Share-Based Compensation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation
cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective vesting
periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in
accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the
award and our expected stock price volatility over a period equal to or greater than the expected life of the award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments (&#147;instruments&#148;)
issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, <i>Equity Based
Payments to Non-Employees</i>,<i> </i>or ASC 505<i>. </i>ASC 505<i> </i>defines the measurement date and recognition period for
such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the
earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments
is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize the compensation expense for all
share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize
the compensation expense on a straight-line basis over the employee&#146;s requisite service period.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Discounts</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Debt Discounts</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred from parties that are providing
long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based
on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the
related debt using the effective interest rate method.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue Recognition</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize revenue on arrangements in accordance
with ASC 605, <i>Revenue Recognition</i>. We recognize revenue only when the price is fixed or determinable, persuasive evidence
of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our OTC and prescription
prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing.
The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our
OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay
for the product via third-party payers.&#160;Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from
major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note
13.&#160;There are no major external customers for our OTC prenatal vitamin or other products.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Over-the-Counter Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We generate OTC revenue from product sales
primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of
loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include
shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive
the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. <font style="color: #252525">We
provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.
</font>We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Prescription Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: #252525">We sell our name
brand and generic prescription products </font>primarily through drug wholesalers and retail pharmacies. We recognize revenue from
prescription product sales, net of sales discounts, chargebacks, and rebates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable product
from customers within a return period of six months prior to and up to twelve months following product expiration. Our
prescription products currently have a shelf life of 24 months from the date of manufacture. Given the limited history of our
prescription products, we currently cannot reliably estimate expected returns of the prescription products at the time of
shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists,
which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration
of the right of return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain various rebate programs in an effort
to maintain<i> </i>a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program
is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We
estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary,
on a quarterly basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Segment Reporting&#160;</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are managed and operated
as one business, which is focused on creating and commercializing products targeted exclusively for women. Our
business operations are managed by a single management team that reports to the President of  our Company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with
respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our
business as one reportable operating segment.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Shipping and Handling Costs</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Advertising
Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $698,871, $11,739 and $65,944 during the years ended December 31, 2014, 2013 and 2012, respectively.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Research and Development Expenses</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&#38;D, expenses
include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash
share-based compensation expenses. Advance payments to be expensed in future R&#38;D activities were $1,175,082 and $2,606,405
for the years ended December 31, 2014 and 2013, respectively. CRO activity expenses include preclinical laboratory experiments
and clinical trial studies. Other activity expenses include regulatory consulting and legal counsel. The activities undertaken
by our regulatory consultants that were classified as research and development expenses include assisting, consulting with, and
advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing
matters, including preparing protocols and FDA submissions. Legal activities that were classified as research and development
expenses related to designing experiments to generate data for patents and to further the formulation development process for
our pipeline technologies. Outside legal counsel also provided professional research regarding the legal landscape of potential
patents. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for
our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as
incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date.
We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity
has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses
and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion
stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies progress to completion. We charge
revisions expense in the period in which the facts that give rise to the revision become known.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Earnings Per Share&#160;</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculate earnings per share, or EPS,
in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts:
basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per
share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares
of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such
potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of
diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the potentially dilutive
securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they
were not antidilutive for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="11" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">As of December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Stock options</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">16,792,443</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">15,632,742</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">13,733,488</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Warrants</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">13,927,916</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">14,293,499</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">12,193,499</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">30,720,359</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">29,926,241</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">25,926,987</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Newly Adopted Accounting Pronouncements</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recently Issued Accounting Pronouncements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: #252525">In August
2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-05, Presentation of Financial Statements-Going Concern
(Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern. ASU 2014-15
requires management to evaluate whether there are conditions and events that raise substantial doubt about </font>the
entity&#146;s ability to continue as a going concern within one year after the financial statements are issued (or available
to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending
after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is
permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do
not expect the adoption of the ASU 2014-15 to have a material effect on our consolidated financial statements and
disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB and the International
Accounting Standards Board (IASB) issued ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#146;s
core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount
that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so,
companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance
obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating
the transaction price to each separate performance obligations. ASU 2014-09 is effective for public business entities, certain
not-for-profit entities and certain employee benefit plans, for annual periods beginning after December 15, 2016, including interim
periods within that period. Early adoption is not permitted under GAAP. We are currently evaluating the impact of ASU 2014-09 on
our consolidated financial statements and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2013, the FASB issued ASU 2013-11,
Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss,
or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU
2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward,
a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements
as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward
with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability.
The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal
years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 did not have
a material impact on our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, the FASB issued ASU No. 2011-11,
Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures
about financial instruments and derivative instruments that are either offset on the statement of financial position or subject
to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of
financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to
facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the
basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after
January 1, 2013, and interim periods within those years. ASU 2011-11 did not have a material impact on our financial position or
results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe there would have been a material
effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards
been adopted in the current period.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Reclassifications</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain 2013 and 2012 amounts have been reclassified
to conform to current year presentation.&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32704220&amp;loc=d3e8275-108329<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6387522&amp;loc=d3e8384-108330<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5144-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408196&amp;loc=d3e61069-111654<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Handling Costs<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6514758<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915142&amp;loc=d3e60635-111653<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408413&amp;loc=d3e221937-122793<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Shipping Costs<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525344<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 13 - BUSINESS CONCENTRATIONS&#160;</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We purchase our products
from several suppliers with approximately 82%, 98%, and 76% of our purchases supplied from one vendor for the years ended December
31, 2014, 2013, and 2012, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We sell our vitamins,
prenatal dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug
stores that generally sell products to retail pharmacies, hospitals, other institutions and directly to retail customers.
Revenue generated from four customers accounted for approximately 75%, 79%, and 28% of our recognized revenue and 97%, 97%,
and 98% of our deferred revenue for the years ended December 31, 2014, 2013, and 2012, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">For the years
ended December 31, 2014, 2013 and 2012, we had four customers that generated more than 10% of our sales &#150; these
customers are designated as customers &#147;A&#148;, &#147;B&#148;, &#147;C&#148; and &#147;D&#148;. Customers A, B,
C and D generated $1,609,950, $1,586,903, $1,804,018 and $4,053,838, respectively, in sales in 2014; $1,221,212, $1,711,417,
$2,588,626, and $1,312,192, respectively, in sales in 2013; and $67,599, $490,092, $830,902, and $0, respectively,
in sales in 2012.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 9 &#150; NOTES PAYABLE</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Payment of Multiple Advance
Revolving Credit Note</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2013, we entered into a business
loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the Revolving Credit
Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal amount, at a stated interest
rate of 6% per annum. Plato was able to make advances to us from time to time under the Revolving Credit Note at our request,
which advances were of a revolving nature and were able to be made, repaid, and made from time to time. Interest payments were
due and payable on the tenth day following the end of each calendar quarter in which any interest was accrued and unpaid, commencing
on April 10, 2013, and the principal balance outstanding under the Revolving Credit Note, together with all accrued interest and
other amounts payable under the Revolving Credit Note, if any, was due and payable on February 24, 2014. The Revolving Credit
Note was secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the
Revolving Credit Note. On March 21, 2013, we repaid $401,085, which included accrued interest, and there was no balance outstanding
under the Revolving Credit Note as of December 31, 2013 and February 24, 2014 when it expired. As additional consideration for
the Revolving Credit Note, we granted to Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price
of $3.20 per share (See Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Borrowing
under Business Loan Agreement and Promissory Note</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United Bank for a $300,000 bank line of credit for which personal guarantees and cash collateral were
required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers
of our Company, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of our Company.
The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012.
We negotiated a one-year extension with First United to the bank line of credit, which was executed on March 19, 2012. Under the
extension, borrowings bore interest at a rate of 2.35% and were due on March 1, 2013. On November 13, 2012, the outstanding balance
of $299,220 was repaid in full, and we amended the line of credit to reflect a $100,000 bank line of credit. In accordance with
the amended line of credit, the personal guarantee and cash collateral limited to $100,000 provided by the Reich Family Limited
Partnership remained in place, while the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan.
In February 2013, we borrowed $100,000 from First United Bank under the amended bank line of credit. On April 25, 2013, we re-paid
$100,735, which represented the principal and interest that was due under the amended bank line of credit. On May 1, 2013, the
amended bank line of credit expired and was not renewed. Accordingly, the personal guarantee was canceled, and the cash collateral
was refunded to the Reich Family Limited Partnership. During the years ended December 31, 2013 and 2012, we paid $735 and $7,366,
respectively, of interest expense, which are included in interest expense on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance of January and February 2012
Promissory Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January and February 2012, we issued
6% promissory notes in the aggregate principal amount of $900,000, due March 1, 2012, which were subsequently increased to an
aggregate principal amount of $1,700,000. As discussed below in Issuance and Settlement of February 2012 Notes, these promissory
notes were modified on February 24, 2012 through the issuance of secured promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Settlement of February 2012
Promissory Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 24, 2012, we
issued promissory notes, the February 2012 Notes, to an individual and an entity, both of which were stockholders of our
company, in the principal amount of $1,358,014 and $1,357,110, respectively, and granted warrants to purchase an aggregate of
9,000,000 shares of our Common Stock pursuant to the terms of a Note Purchase Agreement, dated February 24, 2012. We received
an aggregate of $1,000,000 of new funding upon issuance of the February 2012 Notes and related warrants and surrender by
the holders of certain promissory notes, which we previously issued in the aggregate amount of $1,700,000 plus the
aggregate accrued interest of $15,124 (collectively, the &#147;Prior Notes&#148;). Under the February 2012 Notes, as
amended, we borrowed an additional $3,000,000 during March, April, and May 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We granted warrants to purchase an aggregate
of 5,685,300 shares of Common Stock in consideration of the modification of the Prior Notes and warrants to purchase an aggregate
of 3,314,700 shares of Common Stock in connection with the issuance of the February 2012 Notes. We determined that the resulting
modification of the Prior Notes was substantial in accordance with ASC 470-50,&#160;<i>Modifications and Extinguishments</i>. As
such the modification was accounted for as an extinguishment and restructuring of the debt, and the 5,685,300 warrants issued in
consideration of the modification were expensed (see Warrant Activity during 2012 in NOTE 10 for more details). The fair
value of the Prior Notes was estimated by calculating the present value of the future cash flows discounted at a market rate of
return for comparable debt instruments to be $1,517,741, resulting in a debt discount of $197,383 and recognized a loss on extinguishment
of debt of $10,307,864, which represented the fair value of the 5,685,300 warrants net of the difference between the carrying amount
of the Prior Notes and their fair value as of the date of the modification on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2012, we settled an aggregate amount
of $3,102,000 of principal and accrued interest of the February 2012 Notes in exchange for the exercise of warrants to purchase
8,145,486 shares of our Common Stock. As discussed below in Issuance and Payment of June 2012 Notes, the remaining balance of $2,691,847
of the February 2012 Notes was modified on June 19, 2012 through the issuance of the June 2012 Notes (as defined below) (see NOTE
10 for more details).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Payment of June 2012 Promissory
Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2012, we issued secured promissory
notes, or the June 2012 Notes, to the holders of the February 2012 Notes in the principal amounts of $2,347,128 and $2,344,719, pursuant to the terms of a Note Purchase Agreement. In connection with the June 2012 Notes, the holders of the February 2012 Notes
surrendered the remaining balance of such notes in the aggregate amount of $1,347,128 and $1,344,719,  which sums
included principal and accrued interest through June 19, 2012, and we received an aggregate of $2,000,000 of new funding, or the
June Funding, from the holders of the February 2012 Notes. The principal amount of each of the June 2012 Notes, plus any additional
advance made to us thereafter, together with accrued interest at the annual rate of 6%, was due in one lump sum payment on February
24, 2014. As security for our obligations under the June 2012 Notes, we entered into a security agreement and pledged all of our
assets, tangible and intangible, as further described therein. We also granted warrants to purchase an aggregate of 7,000,000 shares
of our Common Stock in connection with the June Funding. On March 21, 2013, we repaid $4,882,019 of the June 2012 Notes, including
accrued interest, leaving a balance of $21,595 in accrued interest as of March 31, 2013. On April 25, 2013, the balance of accrued
interest was paid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Payment of Additional
Promissory Notes in 2012</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August and September 2012, we issued 6%
promissory notes in the amount of $1,600,000 due on October 1, 2012, which due date was subsequently extended. These notes were
paid in full in October 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2012, we issued a 6% promissory
note for $200,000 due on October 15, 2012. This note was paid in full in October 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Payment of Additional Promissory
Notes in 2011</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 4% promissory notes
to Mr. Finizio and Mr. Milligan for an aggregate of $100,000 due March 1, 2012. These promissory notes were subsequently extended
by mutual agreement to June 1, 2012. In June 2012, we paid the promissory note held by Mr.&#160;Finizio in full, including $888
in accrued interest. Mr. Milligan&#146;s promissory note was extended to October 15, 2012. On October 4, 2012, we paid Mr. Milligan&#146;s
promissory note in full, including $1,519 in accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Conversion of July 2011 Secured Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2011, VitaMed issued two
senior secured promissory notes, or the Secured Notes, each in the amount of $500,000 and also entered into a security
agreement under which VitaMed pledged all of its assets to secure the obligation. The Secured Notes were assumed by us upon
the merger with VitaMed in October 2011 and bore interest at the rate of 6% per annum, were due on the one year anniversary
thereof, and were convertible into shares of our Common Stock at our option. We were permitted to satisfy the obligations
underlying the Secured Notes by delivering such number of shares of our Common Stock calculated by dividing the
then-outstanding principal balance by the Share Price. For purposes of the Secured Notes, the &#147;Share Price&#148; meant
the lower of the most recent price at which we offered and sold shares of our Common Stock (not including any shares of our
Common Stock issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities) or the
five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we reached an agreement to
convert the outstanding amount of the Secured Notes, representing principal and accrued interest through June 19, 2012, of
$1,054,647 into an aggregate of 2,775,415 shares of our Common Stock at $0.38 per share. This resulted in a beneficial
conversion feature of $6,716,504 as recorded in other income and expense on the accompanying consolidated financial
statements. For the year ended December 31, 2012 we recorded an aggregate of $33,204 as interest expense on the accompanying
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance, Payment and Conversion of VitaMed
Promissory Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, VitaMed issued promissory
notes, or the VitaMed Notes, in the aggregate principal amount of $500,000. In connection with the VitaMed Notes, VitaMed
granted warrants to purchase equity interests in VitaMed that were equivalent to an aggregate of 613,718 shares of our Common
Stock when the VitaMed Notes were assumed by us upon the merger with VitaMed. The VitaMed Notes bore interest at a rate of 4%
per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed
received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding. Upon the
closing of the Funding in July 2011, as more fully described above in Conversion of July 2011 Secured Notes, two of the
VitaMed Notes in the aggregate principal amount of $200,000 were paid in full. By mutual agreement, the remaining
VitaMed Notes in the aggregate principal amount of $300,000 were extended. In October 2011, one of the VitaMed Notes in the
aggregate principal amount of $50,000 was paid in full, and, by mutual agreement, certain of the VitaMed Notes in the
aggregate principal amount of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share, which
represented the fair value of our Common Stock on the date of conversion. In June 2012, a VitaMed Note held by an
unaffiliated individual was paid in full, including $2,160 in accrued interest. The remaining VitaMed Notes, held by Mr.
Milligan and by BF Investment Enterprises, Ltd., which is owned by Brian Bernick, a director of our company, in the aggregate
principal amount of $100,000, were extended to October 15, 2012. On October 4, 2012, we re-paid the outstanding VitaMed Notes
in full, including $5,341 in accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September and October 2011, VitaMed
issued convertible notes, or the VitaMed Convertible Notes, in the aggregate amount of $534,160. The VitaMed Convertible
Notes bore interest at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we entered into Debt
Conversion Agreements with the holders of the VitaMed Convertible Notes, pursuant to which we converted the principal and
accrued interest of the VitaMed Convertible Notes into 1,415,136 shares of our Common Stock at $0.38 per share, which
represented the fair value of the shares of our Common Stock on the date of conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December 31, 2012, we recorded
an aggregate of $6,344 as interest expense on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOKAK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="12">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 4,257</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 4,186</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 3,752</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 2,831</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 2,863</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 2,295</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 2,081</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 1,537</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 1,241</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 1,036</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 819</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 722</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 15,026,219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 8,775,598</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 3,818,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer A [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember]" onclick="toggleNextSibling(this);">75.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= us-gaap_CustomerConcentrationRiskMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember]" onclick="toggleNextSibling(this);">79.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= us-gaap_CustomerConcentrationRiskMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember]" onclick="toggleNextSibling(this);">28.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= us-gaap_CustomerConcentrationRiskMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer A [Member] | Sales Revenue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= us-gaap_CustomerConcentrationRiskMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_DeferredRevenueConcentrationRiskMember', window );">Deferred revenue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByTypeAxis=txmd_DeferredRevenueConcentrationRiskMember]" onclick="toggleNextSibling(this);">97.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_DeferredRevenueConcentrationRiskMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByTypeAxis=txmd_DeferredRevenueConcentrationRiskMember]" onclick="toggleNextSibling(this);">97.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_DeferredRevenueConcentrationRiskMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByTypeAxis=txmd_DeferredRevenueConcentrationRiskMember]" onclick="toggleNextSibling(this);">98.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_DeferredRevenueConcentrationRiskMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member', window );">Customer A [Member] | Sales Revenue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member]" onclick="toggleNextSibling(this);">1,609,950</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member]" onclick="toggleNextSibling(this);">1,586,903</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member]" onclick="toggleNextSibling(this);">1,804,018</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk1Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member', window );">Customer B [Member] | Sales Revenue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member]" onclick="toggleNextSibling(this);">4,053,838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member]" onclick="toggleNextSibling(this);">1,221,212</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member]" onclick="toggleNextSibling(this);">1,711,417</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk2Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member', window );">Customer C [Member] | Sales Revenue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member]" onclick="toggleNextSibling(this);">2,588,626</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk3Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member]" onclick="toggleNextSibling(this);">1,312,192</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk3Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member]" onclick="toggleNextSibling(this);">67,599</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk3Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member', window );">Customer D [Member] | Sales Revenue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member]" onclick="toggleNextSibling(this);">$ 490,092</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk4Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member]" onclick="toggleNextSibling(this);">$ 830,902</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk4Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember;us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueNetMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= txmd_CustomerConcentrationRisk4Member</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_DeferredRevenueConcentrationRiskMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_DeferredRevenueConcentrationRiskMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 7 &#150; INTANGIBLE ASSETS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">The following table sets forth
the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2014 and December 31, 2013:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">&#160;</font>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31, 2014</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Gross Carrying Amount</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Net &#160; <br />Amount</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Weighted- Average &#160; <br />Remaining Amortization Period (yrs.)</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Amortizing intangible assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">31,951</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">(2,496</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">29,455</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">14.75</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt; text-indent: -10; font-family: Times New Roman, Times, Serif">Development costs of corporate website</td><td style="font-family: Times New Roman, Times, Serif"></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">91,743</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(91,743</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Approved hormone therapy drug&#160;candidate patents</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">439,184</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(19,401</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">419,783</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">18</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 10; font-family: Times New Roman, Times, Serif">Non-amortizing intangible assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 20pt; text-indent: -10; font-family: Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">675,982</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">675,982</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">103,368</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">103,368</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,342,228</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(113,640</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,228,588</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white"></font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31, 2013</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Gross Carrying Amount</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Net &#160; <br />Amount</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Weighted- Average Remaining Amortization Period (yrs.)</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Amortizing intangible assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">31,951</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">(499</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">31,452</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">15.8</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Development costs of&#160;corporate website</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">91,743</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">(89,661</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">2,082</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">0.3</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 10; font-family: Times New Roman, Times, Serif">Non-amortizing intangible assets:</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">572,726</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">572,726</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">59,328</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">59,328</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">755,748</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(90,160</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">665,588</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">We amortized
the intangible asset related to development costs for corporate website over 36 months, which is the prescribed life for software
and website development costs. We amortize the intangible asset related to OPERA&#174; using the straight-line method over the estimated
useful life of approximately 20 years, which is the life of the intellectual property patents. We amortize the approved hormone
therapy drug candidate patents using straight-line method over the estimated useful life of approximately 20 years. During the
years ended December 31, 2014 and 2013, there was no impairment recognized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="background-color: white">In
addition to numerous pending patent applications, as of December 31, 2014, we had 4 issued patents, including: </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="background-color: white">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif">&#149;</td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"><font style="background-color: white">one method patent that relates to our OPERA&#174; information
technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029; and</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><font style="background-color: white">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif"></td><td style="width: 3%; font-family: Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif">&#149;</p>
                                                        <p style="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif">&#160;</p></td><td style="text-align: justify; width: 92%; font-family: Times New Roman, Times, Serif"><font style="background-color: white">3 utility patents that relate to our combination progesterone
and estradiol formulations, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending
patent applications with respect to certain of these patents in Argentina, Australia, Canada, the European Union, Mexico, Brazil,
Japan, Russia, South Africa and South Korea.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><font style="background-color: white">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="background-color: white">Subsequent
to December 31, 2014, 1 additional patent was issued related to our combination progesterone and estradiol formulations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="background-color: white">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">Amortization
expense was $23,480, $10,262 and $28,776 for the years ended December 31, 2014, 2013, and 2012, respectively.</font> As of December
31, 2014, the estimated amortization expense for the next five years is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Year Ending December 31,</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Estimated Amortization</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2015</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2016</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2017</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2018</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">2019</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">25,138</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; width: 46%; font-family: Times New Roman, Times, Serif"></td><td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 5%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"></td><td style="text-align: right; width: 45%; font-family: Times New Roman, Times, Serif"></td><td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 8 &#150; OTHER CURRENT LIABILITIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other current liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2014</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Accrued clinical trial costs</td><td style="width: 4%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,706,542</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">665,782</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued payroll, bonuses and commission costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">814,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">941,313</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued vacation costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">442,430</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,920</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,550</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses<sup>(1)</sup></font></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">185,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,900</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,303</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,188</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,446</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,233</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued rent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued financing costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">850,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840,639</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,601,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><sup>(1)</sup> In June 2008, we declared and
paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359
remained unclaimed by certain stockholders at both December 31, 2014 and 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b>&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 10 &#150; STOCKHOLDERS&#146; EQUITY</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Preferred Stock</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">At December
31, 2014, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred
Stock were issued or outstanding.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Common Stock</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">At
December 31, 2014, we had </font>250,000,000 shares of Common Stock, par value $0.001,<font style="letter-spacing: -0.15pt"> authorized for
issuance, of which </font>156,097,019<font style="letter-spacing: -0.15pt"> shares of our Common Stock were issued and outstanding.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><u>Issuances During 2014</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 29, 2014, we entered into an underwriting
agreement with Goldman Sachs &#38; Co,  as the representative of the underwriters named therein, or the Goldman
Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of our Common Stock. The price to the public
in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a
30-day option to purchase up to an additional 1,284,796 shares of our Common Stock. On July 30, 2014, the Goldman Sachs Underwriters
exercised their option to purchase the additional 1,284,796 shares of our Common Stock. Net proceeds from this offering were approximately
$42.8 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed
on August 4, 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014, certain
individuals exercised stock options to purchase 860,800 shares of our Common Stock. Stock options to purchase shares of our Common
Stock were exercised as follows: (i) 724,193 options for $345,746 in cash and (ii) <font style="letter-spacing: -0.15pt">136,607
options, pursuant to the stock options&#146; cashless provision, wherein 130,380 shares of Common Stock were issued. In addition,
during 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were
granted in December 2013.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014, certain
individuals exercised warrants to purchase 365,583 shares of our Common Stock for $181,000 in cash.<font style="background-color: white">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Issuances During 2013&#160;</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 14, 2013, we entered into an underwriting
agreement with Jefferies LLC as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to
the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share. In
addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to
an additional 4,411,765 shares of our Common Stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters
exercised their option to purchase an additional 1,954,587 shares of our Common Stock, which were issued on April 18, 2013. The
net proceeds to us from this offering were approximately $48.5 million, after deducting underwriting discounts and commissions
and other offering expenses payable by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2013, we entered into an underwriting
agreement with Stifel, Nicolaus &#38; Company, Incorporated, as the representative of the underwriters named therein, or the Stifel
Underwriters, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering
was $2.40 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts
and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2013 certain individuals exercised
stock options to purchase an aggregate of 75,423 shares of our Common Stock for approximately $31,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Issuances During 2012</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During June 2012, we settled $3,102,000 in
principal and accrued interest of the February 2012 Notes in exchange for the holders&#146; exercise of a portion of the related
warrants for an aggregate of 8,145,486 shares of Common Stock. During June 2012, we and the holders also agreed to convert
a portion of the February 2012 Notes, and principal and accrued interest through June 19, 2012 totaling $1,054,647, into 2,775,415
shares of Common Stock at $0.38 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2012, we entered into a Securities
Purchase Agreement with multiple investors, relating to the issuance and sale of Common Stock in a private placement. The private
placement closed on October 2, 2012, through which we sold an aggregate of 3,953,489 shares of Common Stock at $2.15 per share,
for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies LLC served as our exclusive
placement agent. Jefferies&#146; compensation for the transaction was a cash fee of $552,500. We also paid legal fees and expenses
of the investors in the aggregate of $52,016, resulting in net proceeds to us from the private placement of $7,895,485. Pursuant
to the terms of the Securities Purchase Agreement, we agreed to file a registration statement covering the resale of these shares,
which was filed on November 27, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2012, certain
individuals exercised stock options to purchase 1,958,216 shares of Common Stock. Stock options to purchase shares of Common Stock
were exercised as follows: (i) 1,691,393 options for $191,000 in cash and (ii) <font style="letter-spacing: -0.15pt">266,823 options,
pursuant to the stock options&#146; cashless provision, wherein 240,395 shares of Common Stock were issued. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Warrants to Purchase Common Stock </u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, we had warrants outstanding
to purchase an aggregate of 13,927,916 shares of our Common Stock with a weighted-average contractual remaining life of 3.0 years,
and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.82 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation methodology used to determine
the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,
including volatility of the stock price, the risk-free interest rate and the term of the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Warrant Activity During 2014</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014, we
did not issue any warrants. As of December 31, 2014, unamortized costs associated with the Sancilio &#38; Company, Inc., or SCI
warrants issued in 2013 and 2012 totaled approximately $875,600.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<font style="background-color: white">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Warrant Activity During 2013</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2013, we issued warrants to purchase
1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see
NOTE 10 above for more details). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October
31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately
$1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and
a dividend yield of 0%. During the years ended December 31, 2014 and 2013, $260,027 and $1,451,934, respectively, was recorded
as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2013, we entered into a consulting agreement
with SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our
efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal
capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights
to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting
agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares
of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 6%; font-family: Times New Roman, Times, Serif"></td><td style="width: 5%; font-family: Times New Roman, Times, Serif">1.</td><td style="text-align: justify; width: 89%; font-family: Times New Roman, Times, Serif">283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application
by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the
terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested
on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of
45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June
30, 2013;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 6%; font-family: Times New Roman, Times, Serif"></td><td style="width: 5%; font-family: Times New Roman, Times, Serif">2.</td><td style="text-align: justify; width: 89%; font-family: Times New Roman, Times, Serif">283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined
by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.84%; risk free rate of
1.41%; and a dividend yield of 0%. As of December 31, 2014, we recorded $154,068 as prepaid expense-short term and $77,026 as prepaid
expense-long term in the accompanying consolidated financial statements. During the years ended December 31 2014 and 2013, we recorded
$154,068 and $77,034, respectively, as non-cash compensation in the accompanying consolidated financial statements; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 6%; font-family: Times New Roman, Times, Serif"></td><td style="width: 5%; font-family: Times New Roman, Times, Serif">3.</td><td style="text-align: justify; width: 89%; font-family: Times New Roman, Times, Serif">283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that
SCI helped us design. It is anticipated that this event will not occur before December 2015.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Warrant Activity During 2012</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2012, we issued warrants for the
purchase of an aggregate of 5,685,300 shares of Common Stock in connection with the modification of certain existing promissory
notes, or the Modification Warrants, and warrants for the purchase of an aggregate of 3,314,700 shares of our Common Stock in connection
with the issuance of the February 2012 Notes, or the February 2012 Warrants (see NOTE 9). Both the Modification Warrants
and the February 2012 Warrants are exercisable at $0.38 per share. The Modification Warrants have a fair value of $10,505,247,
and the February 2012 Warrants have a fair value of $6,124,873. Fair value was determined on the date of the issuance using a term
of five years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification
Warrants as part of the loss on extinguishment of debt in the accompanying consolidated financial statements. The relative fair
value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012
Notes on June 19, 2012, we expensed the remaining unamortized debt discount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Warrant Activity During 2012</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2012, we issued warrants to purchase
an aggregate of 31,000 shares of Common Stock to five unaffiliated individuals for services rendered. These warrants were valued
on the date of the issuance using a term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield
of 0%; we recorded $29,736 as consulting expense in the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2012, we issued warrants to
purchase an aggregate of 1,300,000 shares of Common Stock to an unaffiliated entity for services to be rendered over
approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug
development efforts, including services in support our ongoing and future drug development and commercialization efforts,
regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and
controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated
therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services
as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at
$1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk
free rate of 0.74%; and a dividend yield of 0%. At December 31, 2014, we had $257,796 reported as prepaid expense-short term
and $386,694 recorded as prepaid expense-long term. During the years ended December 31, 2014, 2013 and 2012, we recorded
$309,165, $360,528 and $218,045, respectively as non-cash compensation with respect to these warrants in the
accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product.
We have determined that the process will take approximately five years. As a result, we are amortizing the $1,532,228 over
five years.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, we issued warrant to purchase
aggregate of 7,000,000 shares of Common Stock in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants,
(see NOTE 9). Of the June 2012 Warrants issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable
at $3.00 per share. The fair value of the June 2012 Warrants of $9,424,982 was determined on the date of the issuance using a term
of five years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June
2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the issuance. $547,210
was amortized to interest expense in 2012 and as a result of the repayment of the associated debt on March 21, 2013, the remaining
unamortized debt discount of $1,102,680 was amortized to interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, we issued warrants to purchase
an aggregate of 1,500 shares of Common Stock to three unaffiliated individuals for services rendered. The warrants were valued
on the date of the issuance using a term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of
0%. A total of $1,656 was recorded as consulting expense in the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Summary of our Warrant activity and related information for
2012-2014&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares Under Warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted &#160; <br />Average&#160; <br />Remaining &#160; <br />Contractual&#160; <br />Life in Years</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate&#160; <br />Intrinsic Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Balance at December 31, 2011</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">3,057,627</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">0.36</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7.9</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">3,483,691</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">17,332,500</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.26</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(8,145,486</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.38</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(51,142</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.24</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2012</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">12,193,499</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.63</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">4.8</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">17,971,994</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,100,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2.72</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2013</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">14,293,499</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.79</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3.9</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">48,932,777</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Issued</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(365,583</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.50</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2014</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">13,927,916</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.82</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3.0</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">36,623,875</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10; text-indent: -10">Vested and Exercisable at December 31, 2014</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">13,562,764</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.83</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2.9</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">35,599,540</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average fair value per share of
warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are
set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Weighted average fair value</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">2.83</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">2.05</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"></font>&#151;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.88-1.12</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.72-1.04</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Volatility</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">44.29-45.89</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">44.64-44.81</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Term (in years)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Dividend yield</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated volatility is a measure of the amount
by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average
of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation
of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical
volatility of peer entities due to the lack of sufficient historical data of our stock price during 2011-2014.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Options to Purchase Common Stock of the
Company</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2009, we adopted the 2009 Long Term Incentive
Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our
company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options
and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the merger with VitaMed, no Awards
had been issued under the 2009 Plan. As of December 31, 2014, there were Awards for 18,246,625 shares of our Common Stock issued
under the 2009 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 23, 2012, we adopted the 2012
Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve
as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors
of our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2014, there
were awards for 2,600,000 shares issued under the 2012 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions
used in the Black-Scholes Model during the years ended December 31, 2014, 2013 and 2012 are set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Risk-free interest rate</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.07-1.77</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.65-1.71</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.61-2.23</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Volatility</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">68.05-82.29</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33.35-45.76</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">40.77-46.01</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Term (in years)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.5-6.25</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; text-align: left; font-family: Times New Roman, Times, Serif">Dividend yield</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">%</td><td style="width: 2%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif">0.00</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated
volatility is a measure of the amount by which the price of Common Stock is expected to fluctuate each year during the term of
the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock
prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal
to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data
on our stock price. The average expected life is based on the contractual term of the option using the simplified method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of activity under the 2009 and 2012
Plans and related information for 2012-2014 follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares Under Options</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted &#160; <br />Average &#160; <br />Remaining &#160; <br />Contractual&#160; <br />Life in Years</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate&#160; <br />Intrinsic Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 50%; font-family: Times New Roman, Times, Serif">Balance at December 31, 2011</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">10,590,161</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">0.16</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7.6</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 3%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">14,067,649</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">5,121,250</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2.80</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(1,931,788</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(46,135</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2012</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">13,733,488</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.16</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">7.7</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">26,804,117</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,583,677</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3.31</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(75,423</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(250</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(608,750</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2013</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">15,632,742</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.44</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">7.2</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">58,878,132</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,442,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">4.71</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(854,573</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Expired</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(250</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt">Cancelled</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(427,476</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2014</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">16,792,443</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.88</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">6.9</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">43,996,311</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">Vested and Exercisable at December 31, 2014</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">13,276,462</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1.39</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">5.5</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">40,720,977</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, our outstanding options
had exercise prices ranging from $0.10 to $5.21 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Share-based compensation expense for options
recognized in our results for the years ended December 31, 2014, 2013, and 2012&#160; ($4,393,455, $3,200,655 and $1,832,061, respectively)
is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant
and revised in subsequent periods if actual forfeitures differ from the estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, total unrecognized estimated
compensation expense related to unvested options granted prior to that date was approximately $5,160,000, which is expected to
be recognized over a weighted-average period of 2.9 years. No tax benefit was realized due to a continued pattern of operating
losses. At December 31, 2013 and 2012, total unrecognized estimated compensation expense related to unvested options granted prior
to that date was approximately $3,921,000 and $4,391,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2013, we granted a restricted
stock unit, or the RSU, under our 2012 Plan to an employee of 50,000 shares of our Common Stock having a fair value of
$233,500. During the years ended December 31, 2014 and 2013, we recorded $53,428 and $180,072, respectively, of non-cash
compensation related to the RSU on the accompanying consolidated financial statements. The RSU vested and the shares
of Common Stock underlying the RSU were  issued in June 2014.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ERXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 17, 2015</div>
        </th>
        <th class="th">
          <div>Feb. 10, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 42,771,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 78,650,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 7,895,485</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Cowen and Company, LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">2,037,036</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ dei_LegalEntityAxis<br>= txmd_CowenAndCompanyLLCMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">13,580,246</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ dei_LegalEntityAxis<br>= txmd_CowenAndCompanyLLCMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SharePrice1', window );">Share price to underwritters (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_SharePrice1[dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 4.05</a><span style="display:none;white-space:normal;text-align:left;">txmd_SharePrice1<br>/ dei_LegalEntityAxis<br>= txmd_CowenAndCompanyLLCMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 59,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ dei_LegalEntityAxis<br>= txmd_CowenAndCompanyLLCMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfDaysForOptionToPurchaseShares', window );">Number of days granted for option to purchase shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">30 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfDaysForOptionToPurchaseShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of days granted to underwriter for the option to purchase additional share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_NumberOfDaysForOptionToPurchaseShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SharePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_SharePrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5RAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="12">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 4,257</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 4,186</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 3,752</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 2,831</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 2,863</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 2,295</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 2,081</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 1,537</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 1,241</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 1,036</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 819</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 722</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 15,026,219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 8,775,598</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">$ 3,818,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">3,377</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">3,118</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">2,859</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">2,396</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">1,646</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">1,617</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">1,157</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">908</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">729</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">447</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">386</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">11,354,416</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">6,816,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">2,469,900</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (16,303)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (17,832)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (10,899)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (9,183)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (8,361)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,673)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,009)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,376)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (5,727)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (4,253)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (11,850)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (13,290)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (54,217,210)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (28,419,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (35,120,235)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share, basic and diluted (in dollars per shares)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.10)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.12)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.07)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.06)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.06)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.06)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.05)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.06)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.06)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.04)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.16)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.36)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.22)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.38)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GrossProfit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly unaudited summary information</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Summarized quarterly financial data for fiscal years 2014, 2013,
and 2012 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014 Quarters</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif">(In thousands, except per share)</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1<sup>st</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2<sup>nd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3<sup>rd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">4th</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Revenues</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">2,831</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">3,752</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">4,186</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">4,257</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Gross profit</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">2,000</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">2,859</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">3,118</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">3,377</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Net loss</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(9,183</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(10,899</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(17,832</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(16,303</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Loss per common share, basic and diluted</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.07</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.12</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.10</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013 Quarters</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif">(In thousands, except per share)</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1<sup>st</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2<sup>nd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3<sup>rd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">4th</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Revenues</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">1,537</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">2,081</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">2,295</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">2,863</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Gross profit</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">1,157</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">1,617</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">1,646</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">2,396</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Net loss</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(6,376</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(6,009</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(7,673</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(8,361</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Loss per common share, basic and diluted</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.05</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012 Quarters</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif">(In thousands, except per share)</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1<sup>st</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2<sup>nd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3<sup>rd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">4th</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Revenues</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">722</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">819</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">1,036</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">1,241</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Gross profit</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">386</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">447</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">729</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">908</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Net loss</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(13,290</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(11,850</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(4,253</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(5,727</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Loss per common share, basic and diluted</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.16</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.14</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.04</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 4,393,455</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 3,200,655</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 1,832,061</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized estimated compensation expense</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" onclick="toggleNextSibling(this);">5,160,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" onclick="toggleNextSibling(this);">3,921,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" onclick="toggleNextSibling(this);">4,391,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
        <td class="text">2 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">$ 0.10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 5.21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of plan</a></td>
        <td class="text">To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards. <span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized[us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member]" onclick="toggleNextSibling(this);">25,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= txmd_LongTermIncentiveCompensationPlan2009Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod[us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member]" onclick="toggleNextSibling(this);">18,246,625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod<br>/ us-gaap_PlanNameAxis<br>= txmd_LongTermIncentiveCompensationPlan2009Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of plan</a></td>
        <td class="text">Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized[us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= txmd_NonQualified2012StockIncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod[us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember]" onclick="toggleNextSibling(this);">2,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod<br>/ us-gaap_PlanNameAxis<br>= txmd_NonQualified2012StockIncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member] | Restricted stock unit [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember;us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember]" onclick="toggleNextSibling(this);">53,428</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember<br>/ us-gaap_PlanNameAxis<br>= txmd_NonQualified2012StockIncentivePlanMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember;us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember]" onclick="toggleNextSibling(this);">180,072</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember<br>/ us-gaap_PlanNameAxis<br>= txmd_NonQualified2012StockIncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of shares purchased</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember;us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember<br>/ us-gaap_PlanNameAxis<br>= txmd_NonQualified2012StockIncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate', window );">Vesting date</a></td>
        <td class="text">2014-04-01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue', window );">Fair value</a></td>
        <td class="nump"><a title="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember;us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember]" onclick="toggleNextSibling(this);">$ 180,072</a><span style="display:none;white-space:normal;text-align:left;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember<br>/ us-gaap_PlanNameAxis<br>= txmd_NonQualified2012StockIncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to fair value of awards on equity-based plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateTimeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share instruments newly issued under a share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares purchased on the open market during the period for issuance to employees under the plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 15 &#150; SELECTED QUARTERLY FINANCIAL
DATA (UNAUDITED)</u></b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Summarized quarterly financial data for fiscal years 2014, 2013,
and 2012 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014 Quarters</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif">(In thousands, except per share)</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1<sup>st</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2<sup>nd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3<sup>rd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">4th</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Revenues</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">2,831</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">3,752</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">4,186</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">4,257</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Gross profit</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">2,000</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">2,859</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">3,118</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">3,377</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Net loss</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(9,183</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(10,899</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(17,832</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(16,303</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Loss per common share, basic and diluted</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.07</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.12</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.10</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013 Quarters</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif">(In thousands, except per share)</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1<sup>st</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2<sup>nd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3<sup>rd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">4th</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Revenues</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">1,537</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">2,081</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">2,295</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">2,863</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Gross profit</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">1,157</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">1,617</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">1,646</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">2,396</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Net loss</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(6,376</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(6,009</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(7,673</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(8,361</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Loss per common share, basic and diluted</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.05</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="15" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2012 Quarters</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="font-style: italic; text-align: left; font-family: Times New Roman, Times, Serif">(In thousands, except per share)</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1<sup>st</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2<sup>nd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">3<sup>rd</sup></font></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">4th</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 52%; font-family: Times New Roman, Times, Serif">Revenues</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">722</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">819</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">1,036</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif">1,241</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Gross profit</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">386</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">447</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">729</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">908</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Net loss</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(13,290</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(11,850</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(4,253</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(5,727</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">Loss per common share, basic and diluted</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.16</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.14</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.04</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td>
    <td style="text-align: right; font-family: Times New Roman, Times, Serif">(0.06</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other current assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Prepaid consulting</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">411,864</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">530,596</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Prepaid insurance</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">394,878</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">145,722</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">299,498</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">1,267,588</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Other receivables-related party (Note 12)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">249,981</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">249,981</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Other prepaid costs</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">181,186</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">23,806</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Deferred financing costs</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">260,022</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,537,407</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">2,477,715</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amounts of other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAWCK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="4">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Jul. 29, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 20, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 20, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 25, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">250,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">250,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">156,097,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">144,976,757</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">156,097,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">144,976,757</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 42,771,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 78,650,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 7,895,485</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Numbers of options to purchase shares of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">75,423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3', window );">Numbers of portions shares issued for exercise of options, shares</a></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" onclick="toggleNextSibling(this);">724,193</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3" onclick="toggleNextSibling(this);">1,691,393</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options to purchase shares of common stock, value</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">345,746</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">30,910</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">191,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Numbers of options to purchase shares of common stock using cashless exercise feature</a></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" onclick="toggleNextSibling(this);">136,607</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" onclick="toggleNextSibling(this);">266,823</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2', window );">Numbers of balance shares issued for exercise of options, shares</a></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" onclick="toggleNextSibling(this);">130,380</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" onclick="toggleNextSibling(this);">240,395</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Number of shares issued in exercise of warrants</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther" onclick="toggleNextSibling(this);">181,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther" onclick="toggleNextSibling(this);">3,102,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Value of debt converted to shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" onclick="toggleNextSibling(this);">(6,716,504)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember', window );">Private placement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">3,953,489</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ txmd_PrivatePlacementAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">$ 2.15</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ txmd_PrivatePlacementAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">7,895,485</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ txmd_PrivatePlacementAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrivatePlacementFees', window );">Transaction cash fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_PrivatePlacementFees[txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">552,500</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrivatePlacementFees<br>/ txmd_PrivatePlacementAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LegalFees[txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">52,016</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LegalFees<br>/ txmd_PrivatePlacementAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash', window );">Aggregate purchase price of common stock sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForCash[txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">8,500,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForCash<br>/ txmd_PrivatePlacementAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember', window );">February 2012 Notes/ Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Number of shares issued in exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">3,102,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Amount of shares issued in exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">8,145,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">8,145,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Value of debt converted to shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">1,054,647</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Numbers of shares converted for debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">2,775,415</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1[us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember]" onclick="toggleNextSibling(this);">$ 0.38</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1<br>/ us-gaap_LongtermDebtTypeAxis<br>= txmd_February2012NotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_GoldmanSachsMember', window );">Goldman Sachs [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[dei_LegalEntityAxis=txmd_GoldmanSachsMember]" onclick="toggleNextSibling(this);">8,565,310</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ dei_LegalEntityAxis<br>= txmd_GoldmanSachsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SharePrice1', window );">Share price to underwritters (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_SharePrice1[dei_LegalEntityAxis=txmd_GoldmanSachsMember]" onclick="toggleNextSibling(this);">$ 4.67</a><span style="display:none;white-space:normal;text-align:left;">txmd_SharePrice1<br>/ dei_LegalEntityAxis<br>= txmd_GoldmanSachsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[dei_LegalEntityAxis=txmd_GoldmanSachsMember]" onclick="toggleNextSibling(this);">42,771,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ dei_LegalEntityAxis<br>= txmd_GoldmanSachsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under shelf registration statement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodSharesNewIssues1[dei_LegalEntityAxis=txmd_GoldmanSachsMember]" onclick="toggleNextSibling(this);">1,284,796</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodSharesNewIssues1<br>/ dei_LegalEntityAxis<br>= txmd_GoldmanSachsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_JefferiesLLCMember', window );">Jefferies LLC (Underwriters) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[dei_LegalEntityAxis=txmd_JefferiesLLCMember]" onclick="toggleNextSibling(this);">29,411,765</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ dei_LegalEntityAxis<br>= txmd_JefferiesLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[dei_LegalEntityAxis=txmd_JefferiesLLCMember]" onclick="toggleNextSibling(this);">$ 1.70</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ dei_LegalEntityAxis<br>= txmd_JefferiesLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Additional period for purchase share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">30 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockExpectedToIssuedDuringPeriodShares', window );">Total Additional common stock issued under shelf registration statement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_StockExpectedToIssuedDuringPeriodShares[dei_LegalEntityAxis=txmd_JefferiesLLCMember]" onclick="toggleNextSibling(this);">4,411,765</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockExpectedToIssuedDuringPeriodShares<br>/ dei_LegalEntityAxis<br>= txmd_JefferiesLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under shelf registration statement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodSharesNewIssues1[dei_LegalEntityAxis=txmd_JefferiesLLCMember]" onclick="toggleNextSibling(this);">1,954,587</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodSharesNewIssues1<br>/ dei_LegalEntityAxis<br>= txmd_JefferiesLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodValueNewIssues1', window );">Additional common stock issued under shelf registration statement,value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_StockIssuedDuringPeriodValueNewIssues1[dei_LegalEntityAxis=txmd_JefferiesLLCMember]" onclick="toggleNextSibling(this);">48,500,000</a><span style="display:none;white-space:normal;text-align:left;">txmd_StockIssuedDuringPeriodValueNewIssues1<br>/ dei_LegalEntityAxis<br>= txmd_JefferiesLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember', window );">Stifel, Nicolaus &amp; Company (Underwriters) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember]" onclick="toggleNextSibling(this);">13,750,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ dei_LegalEntityAxis<br>= txmd_StifelNicolausAndCompanyMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember]" onclick="toggleNextSibling(this);">$ 2.40</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ dei_LegalEntityAxis<br>= txmd_StifelNicolausAndCompanyMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember]" onclick="toggleNextSibling(this);">$ 30,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ dei_LegalEntityAxis<br>= txmd_StifelNicolausAndCompanyMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalPeriodForPurchaseShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to additonal period for purchase of shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AdditionalPeriodForPurchaseShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrivatePlacementFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to fees and expense regarding private placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_PrivatePlacementFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SharePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_SharePrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockExpectedToIssuedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to numbers of share expected to be issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_StockExpectedToIssuedDuringPeriodShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesNewIssues1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesNewIssues1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an cashless exercise feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to stock issued during period shares stock options exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to stock issued during period shares stock options exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesStockOptionsExercised3</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodValueNewIssues1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodValueNewIssues1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LegalFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued as consideration for cash for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_GoldmanSachsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_GoldmanSachsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_JefferiesLLCMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_JefferiesLLCMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_PrivatePlacementAxis=us-gaap_PrivatePlacementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_February2012NotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>PREPAID EXPENSE (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturingCostsNoncurrent', window );">Prepaid manufacturing costs</a></td>
        <td class="nump"><a title="txmd_PrepaidManufacturingCostsNoncurrent" onclick="toggleNextSibling(this);">$ 899,000</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidManufacturingCostsNoncurrent</span><span></span></td>
        <td class="nump"><a title="txmd_PrepaidManufacturingCostsNoncurrent" onclick="toggleNextSibling(this);">$ 899,000</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidManufacturingCostsNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent', window );">Prepaid research and development costs</a></td>
        <td class="nump"><a title="txmd_PrepaidResearchDevelopmentCostsNoncurrent" onclick="toggleNextSibling(this);">463,720</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidResearchDevelopmentCostsNoncurrent</span><span></span></td>
        <td class="nump"><a title="txmd_PrepaidResearchDevelopmentCostsNoncurrent" onclick="toggleNextSibling(this);">824,221</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidResearchDevelopmentCostsNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidAccreditedCostsNoncurrent', window );">Accreted prepaid costs</a></td>
        <td class="nump"><a title="txmd_PrepaidAccreditedCostsNoncurrent" onclick="toggleNextSibling(this);">64,543</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidAccreditedCostsNoncurrent</span><span></span></td>
        <td class="nump"><a title="txmd_PrepaidAccreditedCostsNoncurrent" onclick="toggleNextSibling(this);">27,234</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidAccreditedCostsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">TOTAL PREPAID EXPENSE</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseNoncurrent" onclick="toggleNextSibling(this);">$ 1,427,263</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseNoncurrent" onclick="toggleNextSibling(this);">$ 1,750,455</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseNoncurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidAccreditedCostsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of accredited contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_PrepaidAccreditedCostsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturingCostsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_PrepaidManufacturingCostsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_PrepaidResearchDevelopmentCostsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMCDI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2011</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 82,979</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 15,198,241</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (16,993,078)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ (1,711,858)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2011</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">82,978,804</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in private placement, net of cost</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3,954</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">7,891,531</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">7,895,485</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in private placement, net of cost, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3,953,489</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Shares issued in exchange for debt</a></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentAmount1[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,775</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentAmount1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentAmount1[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,051,882</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentAmount1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentAmount1" onclick="toggleNextSibling(this);">1,054,657</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentAmount1</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued in exchange for debt, shares</a></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentSharesIssued1[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,775,415</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,932</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">189,068</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">191,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,931,788</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">8,145</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">3,093,855</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther" onclick="toggleNextSibling(this);">3,102,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in exercise of warrants, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">8,145,486</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee Share Based Compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,832,061</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">1,832,061</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForFinancingCosts', window );">Warrants issued for financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedForFinancingCosts[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">13,014,784</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedForFinancingCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedForFinancingCosts" onclick="toggleNextSibling(this);">13,014,784</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedForFinancingCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices', window );">Warrants issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,563,620</a><span style="display:none;white-space:normal;text-align:left;">txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" onclick="toggleNextSibling(this);">1,563,620</a><span style="display:none;white-space:normal;text-align:left;">txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedAsCompensationRelatedParty', window );">Warrants issued as compensation-related party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedAsCompensationRelatedParty[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">36,284</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedAsCompensationRelatedParty<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedAsCompensationRelatedParty" onclick="toggleNextSibling(this);">36,284</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedAsCompensationRelatedParty</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued for cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" onclick="toggleNextSibling(this);">400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued', window );">Cancellation of warrants issued for loan guaranty costs-related parties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(7,830)</a><span style="display:none;white-space:normal;text-align:left;">txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued" onclick="toggleNextSibling(this);">(7,830)</a><span style="display:none;white-space:normal;text-align:left;">txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">6,716,504</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" onclick="toggleNextSibling(this);">6,716,504</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(35,120,235)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(35,120,235)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2012</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">99,785</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">50,580,400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(52,113,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(1,433,128)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2012</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">99,784,982</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in private placement, net of cost</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">45,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">78,605,236</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">78,650,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in private placement, net of cost, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">45,116,352</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">30,835</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">30,910</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">75,423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">75,423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee Share Based Compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">3,170,954</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">3,170,954</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForFinancingCosts', window );">Warrants issued for financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedForFinancingCosts[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,711,956</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedForFinancingCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedForFinancingCosts" onclick="toggleNextSibling(this);">1,711,956</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedForFinancingCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices', window );">Warrants issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">867,262</a><span style="display:none;white-space:normal;text-align:left;">txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" onclick="toggleNextSibling(this);">867,262</a><span style="display:none;white-space:normal;text-align:left;">txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedAsCompensationRelatedParty', window );">Warrants issued as compensation-related party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedAsCompensationRelatedParty[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">36,284</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedAsCompensationRelatedParty<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="txmd_WarrantsIssuedAsCompensationRelatedParty" onclick="toggleNextSibling(this);">36,284</a><span style="display:none;white-space:normal;text-align:left;">txmd_WarrantsIssuedAsCompensationRelatedParty</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Non-employee share based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">83,129</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" onclick="toggleNextSibling(this);">83,129</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(28,419,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(28,419,313)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">144,977</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">135,086,056</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(80,532,626)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">54,698,407</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">144,976,757</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">144,976,757</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in private placement, net of cost</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,850</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">42,761,503</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">42,771,353</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in private placement, net of cost, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,850,106</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">855</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">344,891</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">345,746</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">854,573</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">180,635</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther" onclick="toggleNextSibling(this);">181,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in exercise of warrants, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">365,583</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Shares issued for exercise of restricted stock units</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(50)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares issued for exercise of restricted stock units, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee Share Based Compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">4,239,358</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">4,239,358</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Non-employee share based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">370,453</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" onclick="toggleNextSibling(this);">370,453</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(54,217,210)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(54,217,210)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 156,097</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 182,982,846</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (134,749,836)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 48,389,107</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">156,097,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">156,097,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in additional paid in capital (APIC) resulting from the cancellation of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AdjustmentsToAdditionalPaidInCapitalCancellationOfWarrantsIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedAsCompensationRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WarrantsIssuedAsCompensationRelatedParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_WarrantsIssuedForFinancingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 51<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32707879&amp;loc=d3e34017-109320<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other increase (decrease) in additional paid in capital (APIC).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Warrant<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 4 &#150; OTHER CURRENT ASSETS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Prepaid consulting</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">411,864</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">530,596</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Prepaid insurance</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">394,878</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">145,722</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">299,498</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">1,267,588</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Other receivables-related party (Note 12)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">249,981</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">249,981</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Other prepaid costs</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">181,186</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">23,806</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Deferred financing costs</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">260,022</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">1,537,407</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">2,477,715</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INCOME TAXES (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DeferredIncomeTaxAssetsAbstract', window );"><strong>Deferred Income Tax Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating losses</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" onclick="toggleNextSibling(this);">$ 43,091,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" onclick="toggleNextSibling(this);">$ 14,773,537</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" onclick="toggleNextSibling(this);">$ 5,920,861</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D Credit</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">547,511</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">186,346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax asset</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">43,091,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">15,321,048</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">6,107,207</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(43,091,437)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(15,321,048)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(6,107,207)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Income Tax Assets, net</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredIncomeTaxAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_DeferredIncomeTaxAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible loss carryforwards not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FIXED ASSETS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">December 31,</td></tr>
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">2013</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="width: 68%; text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Equipment</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="width: 4%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">108,458</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Furniture and fixtures</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">53,895</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">46,625</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">186,045</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">155,083</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 0pt; font-family: Times New Roman, Times, Serif">Accumulated depreciation</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(122,752</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(93,765</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif">TOTAL FIXED ASSETS</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">63,293</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">61,318</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>242</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssets</Role>
      <ShortName>FIXED ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PREPAID EXPENSE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpense</Role>
      <ShortName>PREPAID EXPENSE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://therapeuticsmd.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - FIXED ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsTables</Role>
      <ShortName>FIXED ASSETS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - PREPAID EXPENSE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseTables</Role>
      <ShortName>PREPAID EXPENSE (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - FIXED ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative</Role>
      <ShortName>FIXED ASSETS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - FIXED ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsDetails</Role>
      <ShortName>FIXED ASSETS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - PREPAID EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseDetails</Role>
      <ShortName>PREPAID EXPENSE (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - INTANGIBLE ASSETS (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details )</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>INTANGIBLE ASSETS (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://therapeuticsmd.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - NOTES PAYABLE (Details Narrative 1)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1</Role>
      <ShortName>NOTES PAYABLE (Details Narrative 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '1/1/2012 - 3/31/2012' is shorter (90 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '4/1/2012 - 6/30/2012' is shorter (90 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '7/1/2012 - 9/30/2012' is shorter (91 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '10/1/2012 - 12/31/2012' is shorter (91 days) and has only 3 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '1/1/2013 - 3/31/2013' is shorter (89 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '4/1/2013 - 6/30/2013' is shorter (90 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '7/1/2013 - 9/30/2013' is shorter (91 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '10/1/2013 - 12/31/2013' is shorter (91 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '1/1/2014 - 3/31/2014' is shorter (89 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '4/1/2014 - 6/30/2014' is shorter (90 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '7/1/2014 - 9/30/2014' is shorter (91 days) and has only 1 values, so it is being removed.</Log>
    <Log type="Info">Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 43 values. Shorter duration columns must have at least one fourth (10) as many values. Column '10/1/2014 - 12/31/2014' is shorter (91 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Process Flow-Through: 00000002 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2011'</Log>
  </Logs>
  <InputFiles>
    <File>txmd-20141231.xml</File>
    <File>txmd-20141231.xsd</File>
    <File>txmd-20141231_cal.xml</File>
    <File>txmd-20141231_def.xml</File>
    <File>txmd-20141231_lab.xml</File>
    <File>txmd-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidConsultingCurrent', window );">Prepaid consulting</a></td>
        <td class="nump"><a title="txmd_PrepaidConsultingCurrent" onclick="toggleNextSibling(this);">$ 411,864</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidConsultingCurrent</span><span></span></td>
        <td class="nump"><a title="txmd_PrepaidConsultingCurrent" onclick="toggleNextSibling(this);">$ 530,596</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidConsultingCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
        <td class="nump"><a title="us-gaap_PrepaidInsurance" onclick="toggleNextSibling(this);">394,878</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidInsurance</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidInsurance" onclick="toggleNextSibling(this);">145,722</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidInsurance</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development costs</a></td>
        <td class="nump"><a title="txmd_PrepaidResearchAndDevelopmentCostsCurrent" onclick="toggleNextSibling(this);">299,498</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidResearchAndDevelopmentCostsCurrent</span><span></span></td>
        <td class="nump"><a title="txmd_PrepaidResearchAndDevelopmentCostsCurrent" onclick="toggleNextSibling(this);">1,267,588</a><span style="display:none;white-space:normal;text-align:left;">txmd_PrepaidResearchAndDevelopmentCostsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Other receivables-related party (Note 12)</a></td>
        <td class="nump"><a title="us-gaap_DueFromRelatedPartiesCurrent" onclick="toggleNextSibling(this);">249,981</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueFromRelatedPartiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DueFromRelatedPartiesCurrent" onclick="toggleNextSibling(this);">249,981</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueFromRelatedPartiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
        <td class="nump"><a title="us-gaap_OtherPrepaidExpenseCurrent" onclick="toggleNextSibling(this);">181,186</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherPrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherPrepaidExpenseCurrent" onclick="toggleNextSibling(this);">23,806</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherPrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredFinanceCostsCurrentNet" onclick="toggleNextSibling(this);">260,022</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFinanceCostsCurrentNet</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 1,537,407</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 2,477,715</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OtherCurrentAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_OtherCurrentAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidConsultingCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_PrepaidConsultingCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">txmd_PrepaidResearchAndDevelopmentCostsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of current deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5865-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 14 &#150; COMMITMENTS AND CONTINGENCIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Operating Lease</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We lease administrative office space in Boca
Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30,
2018. The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses)
and sales tax, for a total future minimum payments over the life of the lease of $1,899,414.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The straight line rental expense related
to our current lease totaled&#160; $361,793 for the year ended December 31, 2014, partially offset by the rent income of
$41,613 for sublet space. The straight line rental expense related to our current lease totaled&#160; $180,894 for the six
months ended December 31, 2013, partially offset by rent income of $32,963 for sublet space. The rental expense related to our
prior lease which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013, and $106,315 for the year
ended December 31, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, future minimum rental
payments under our office lease are as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Years Ending December 31,</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="text-align: center; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif">2015</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">371,240</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif">2016</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">382,377</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif">2017</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">393,848</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif">2018</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">302,748</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif">2019</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">&#151;&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: left; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Non-cancellable sub-lease income</font></td><td style="text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif">&#151;</td><td style="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"></td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Net minimum lease payments</td><td style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">1,450,213</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; width: 66%; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"></font></td><td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2.5pt; width: 5%; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font-family: Times New Roman, Times, Serif"></td><td style="text-align: right; width: 25%; font-family: Times New Roman, Times, Serif"></td><td style="padding-bottom: 2.5pt; text-align: left; width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Legal Proceedings</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we are involved in litigation and proceedings
in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material
effect on our consolidated financial condition, results of operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Off-Balance Sheet Arrangements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, 2013 and 2012, we had no
off-balance sheet arrangements that have had or are reasonably likely to have current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or
capital resources that are material to investors.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
